Effects	O
of	O
triflusal	S-chemical
and	O
aspirin	S-chemical
in	O
a	O
rat	O
model	O
of	O
cerebral	O
ischemia	O
.	O
BACKGROUND	O
AND	O
PURPOSE	O
:	O
Neuroinflammation	O
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
cerebral	O
ischemia	O
.	O
Triflusal	S-chemical
,	O
a	O
selective	O
cyclooxygenase-2	S-GP
,	O
and	O
its	O
active	O
metabolite	O
3-hydroxy-4-trifluoromethylbenzoic	B-chemical
acid	E-chemical
may	O
inhibit	O
apoptosis	O
and	O
inflammation	O
after	O
cerebral	O
ischemia	O
.	O
An	O
in	O
vivo	O
model	O
of	O
cerebral	O
ischemia	O
was	O
used	O
to	O
investigate	O
the	O
effects	O
of	O
triflusal	S-chemical
and	O
aspirin	S-chemical
treatment	O
on	O
infarct	O
volume	O
,	O
and	O
inflammation	O
after	O
cerebral	O
ischemia	O
in	O
the	O
rat	O
.	O
METHODS	O
:	O
Male	O
Wistar	O
rats	O
were	O
subjected	O
to	O
a	O
permanent	O
right-sided	O
middle	O
cerebral	O
artery	O
occlusion	O
.	O
Rats	O
received	O
oral	O
administration	O
of	O
either	O
triflusal	S-chemical
or	O
aspirin	S-chemical
.	O
After	O
3	O
days	O
after	O
surgery	O
,	O
immunostaining	O
was	O
used	O
to	O
detect	O
neuroinflammatory	O
cells	O
and	O
molecules	O
,	O
and	O
infarct	O
volumes	O
were	O
measured	O
.	O
RESULTS	O
:	O
Both	O
triflusal	S-chemical
and	O
aspirin	S-chemical
at	O
a	O
dose	O
of	O
30	O
mg/kg	O
but	O
not	O
10	O
mg/kg	O
significantly	O
reduced	O
infarct	O
volume	O
compared	O
with	O
vehicle	O
treatment	O
.	O
Middle	O
cerebral	O
artery	O
occlusion	O
resulted	O
in	O
increased	O
astrocyte	O
and	O
heat	B-GP
shock	I-GP
protein-27	E-GP
(	O
Hsp27	S-GP
)	O
immunostaining	O
in	O
the	O
ipsilateral	O
cortex	O
.	O
Triflusal	S-chemical
(	O
30	O
mg/kg	O
)	O
or	O
aspirin	S-chemical
treatment	O
(	O
30	O
mg/kg	O
)	O
did	O
not	O
reduce	O
the	O
levels	O
of	O
GFAP	S-GP
or	O
Hsp27	S-GP
immunostaining	O
.	O
Triflusal	S-chemical
(	O
30	O
mg/kg	O
)	O
also	O
significantly	O
decreased	O
the	O
protein	O
levels	O
of	O
IL-Ibeta	S-GP
but	O
not	O
nuclear	B-GP
factor	I-GP
kappa	I-GP
B	E-GP
or	O
tumor	B-GP
necrosis	I-GP
factor-alpha	E-GP
in	O
the	O
cortex	O
ipsilateral	O
to	O
the	O
middle	O
cerebral	O
artery	O
occlusion	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
suggest	O
that	O
triflusal	S-chemical
and	O
aspirin	S-chemical
appear	O
to	O
be	O
equally	O
neuroprotective	O
against	O
middle	O
cerebral	O
artery	O
occlusion-induced	O
cerebral	O
ischemia	O
.	O
Therefore	O
,	O
strong	O
rationale	O
exists	O
to	O
continue	O
the	O
neuroprotective	O
examination	O
of	O
triflusal	S-chemical
in	O
brain	O
injury	O
.	O

Troglitazone	S-chemical
reduces	O
plasminogen	B-GP
activator	I-GP
inhibitor-1	E-GP
expression	O
and	O
secretion	O
in	O
cultured	O
human	O
adipocytes	O
.	O
AIMS/HYPOTHESIS	O
:	O
Increased	O
plasma	B-GP
plasminogen	I-GP
activator	I-GP
inhibitor-1	E-GP
(	O
PAI-1	S-GP
)	O
concentrations	O
are	O
characteristic	O
for	O
subjects	O
with	O
insulin	S-GP
resistance	O
and	O
could	O
contribute	O
to	O
the	O
increased	O
cardiovascular	O
risk	O
in	O
this	O
state	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
troglitazone	S-chemical
,	O
a	O
ligand	O
of	O
the	O
nuclear	B-GP
receptor	E-GP
peroxisome	B-GP
proliferator	I-GP
activated	I-GP
receptor-gamma	E-GP
,	O
on	O
PAI-1	S-GP
expression	O
and	O
secretion	O
in	O
human	O
adipocytes	O
.	O
METHODS	O
:	O
We	O
used	O
two	O
models	O
:	O
in	O
vitro	O
differentiated	O
subcutaneous	O
and	O
omental	O
adipocytes	O
cultured	O
under	O
serum-free	O
conditions	O
and	O
isolated	O
subcutaneous	O
and	O
omental	O
fat	O
cells	O
kept	O
in	O
suspension	O
culture	O
.	O
Plasminogen	B-GP
activator	I-GP
inhibitor-1	E-GP
protein	O
was	O
measured	O
by	O
ELISA	O
,	O
PAI-1	S-GP
mRNA	O
by	O
a	O
semiquantitative	O
RT-PCR	O
technique	O
.	O
RESULTS	O
:	O
Exposure	O
of	O
in	O
vitro	O
differentiated	O
subcutaneous	O
adipocytes	O
from	O
young	O
normal-weight	O
females	O
to	O
1	O
microgram/ml	O
troglitazone	S-chemical
for	O
72	O
h	O
caused	O
a	O
reduction	O
of	O
both	O
PAI-1	S-GP
secretion	O
(	O
by	O
29	O
+/-	O
5	O
%	O
;	O
p	O
<	O
0.01	O
)	O
and	O
PAI-1	S-GP
mRNA	O
expression	O
(	O
by	O
26	O
+/-	O
3	O
%	O
;	O
p	O
<	O
0.05	O
)	O
.	O
In	O
cultures	O
from	O
severely	O
obese	O
subjects	O
,	O
troglitazone	S-chemical
induced	O
a	O
decrease	O
of	O
PAI-1	S-GP
antigen	O
secretion	O
from	O
newly	O
differentiated	O
omental	O
adipocytes	O
by	O
49	O
+/-	O
8	O
%	O
(	O
p	O
<	O
0.01	O
)	O
and	O
from	O
subcutaneous	O
adipocytes	O
by	O
30	O
+/-	O
7	O
%	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Exposure	O
of	O
freshly	O
isolated	O
subcutaneous	O
and	O
omental	O
adipocytes	O
in	O
suspension	O
culture	O
to	O
troglitazone	S-chemical
induced	O
a	O
similar	O
reduction	O
of	O
PAI-1	S-GP
concentration	O
in	O
the	O
culture	O
medium	O
(	O
by	O
35	O
+/-	O
11	O
%	O
,	O
p	O
<	O
0.05	O
,	O
and	O
33	O
+/-	O
8	O
%	O
,	O
p	O
<	O
0.05	O
compared	O
with	O
control	O
,	O
respectively	O
)	O
.	O
CONCLUSION/INTERPRETATION	O
:	O
This	O
study	O
provides	O
evidence	O
that	O
troglitazone	S-chemical
reduces	O
PAI-1	S-GP
production	O
in	O
human	O
adipocytes	O
,	O
probably	O
at	O
the	O
transcriptional	O
level	O
.	O
This	O
observation	O
could	O
point	O
to	O
a	O
new	O
beneficial	O
effect	O
of	O
troglitazone	S-chemical
,	O
particularly	O
in	O
obese	O
subjects	O
,	O
which	O
could	O
be	O
associated	O
with	O
a	O
reduced	O
cardiovascular	O
risk	O
.	O

Environmental	O
pesticide	O
exposure	O
modulates	O
cytokines	S-GP
,	O
arginase	S-GP
and	O
ornithine	B-GP
decarboxylase	E-GP
expression	O
in	O
human	O
placenta	O
.	O
To	O
evaluate	O
the	O
cytokine	S-GP
balance	O
and	O
enzymatic	O
alterations	O
induced	O
by	O
environmental	O
pesticide	O
exposure	O
during	O
pregnancy	O
,	O
this	O
transversal	O
study	O
explored	O
placentas	O
derived	O
from	O
non-exposed	O
women	O
(	O
control	O
group-CG	O
)	O
,	O
and	O
from	O
women	O
living	O
in	O
a	O
rural	O
area	O
(	O
rural	O
group-RG	O
)	O
,	O
collected	O
during	O
intensive	O
organophosphate	S-chemical
(	O
OP	O
)	O
pesticide	O
spraying	O
season	O
(	O
RG-SS	O
)	O
and	O
during	O
non-spraying	O
season	O
(	O
RG-NSS	O
)	O
.	O
The	O
exposure	O
biomarkers	O
blood	O
cholinesterase	S-GP
and	O
placental	O
carboxylesterase	S-GP
(	O
CaE	S-GP
)	O
were	O
significantly	O
decreased	O
in	O
RG-SS	O
.	O
Among	O
the	O
cytokines	S-GP
studied	O
IL-8	S-GP
,	O
IL-6	S-GP
,	O
TNFα	S-GP
,	O
IL-10	S-GP
,	O
TGFβ	S-GP
and	O
IL-13	S-GP
,	O
the	O
expression	O
frequency	O
of	O
IL-13	S-GP
increased	O
in	O
RG-SS	O
.	O
Arginase	S-GP
and	O
ornithine	B-GP
decarboxylase	E-GP
(	O
ODC	S-GP
)	O
enzymes	O
were	O
induced	O
in	O
syncytiotrophoblast	O
and	O
endothelial	O
cells	O
.	O
Interestingly	O
,	O
the	O
decrease	O
in	O
CaE	S-GP
activity	O
was	O
associated	O
with	O
arginase	O
and	O
ODC	S-GP
activity	O
induction	O
.	O
These	O
findings	O
suggest	O
that	O
environmental	O
pesticide	O
exposure	O
impacts	O
the	O
placenta	O
by	O
increasing	O
the	O
expression	O
frequency	O
of	O
the	O
anti-inflammatory	O
cytokine	S-GP
IL-13	S-GP
,	O
which	O
may	O
be	O
related	O
to	O
the	O
up-regulation	O
of	O
enzymes	O
implicated	O
in	O
tissue	O
repair	O
.	O

Nonalcoholic	O
fatty	O
liver	O
disease	O
:	O
current	O
issues	O
and	O
novel	O
treatment	O
approaches	O
.	O
Nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
is	O
considered	O
the	O
most	O
common	O
liver	O
disorder	O
in	O
the	O
Western	O
world	O
.	O
It	O
is	O
commonly	O
associated	O
with	O
insulin	S-GP
resistance	O
,	O
obesity	O
,	O
dyslipidaemia	O
,	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
and	O
cardiovascular	O
disease	O
.	O
Nonalcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
is	O
characterized	O
by	O
steatosis	O
with	O
necroinflammation	O
and	O
eventual	O
fibrosis	O
,	O
which	O
can	O
lead	O
to	O
end-stage	O
liver	O
disease	O
and	O
hepatocellular	O
carcinoma	O
.	O
Its	O
pathogenesis	O
is	O
complex	O
,	O
and	O
involves	O
a	O
state	O
of	O
'lipotoxicity	O
'	O
in	O
which	O
insulin	S-GP
resistance	O
,	O
with	O
increased	O
free	B-chemical
fatty	I-chemical
acid	E-chemical
release	O
from	O
adipose	O
tissue	O
to	O
the	O
liver	O
,	O
play	O
a	O
key	O
role	O
in	O
the	O
onset	O
of	O
a	O
'lipotoxic	O
liver	O
disease	O
'	O
and	O
its	O
progression	O
to	O
NASH	O
.	O
The	O
diagnosis	O
of	O
NASH	O
is	O
challenging	O
,	O
as	O
most	O
affected	O
patients	O
are	O
symptom	O
free	O
and	O
the	O
role	O
of	O
routine	O
screening	O
is	O
not	O
clearly	O
established	O
.	O
A	O
complete	O
medical	O
history	O
is	O
important	O
to	O
rule	O
out	O
other	O
causes	O
of	O
fatty	O
liver	O
disease	O
(	O
alcohol	S-chemical
abuse	O
,	O
medications	O
,	O
other	O
)	O
.	O
Plasma	B-GP
aminotransferase	E-GP
levels	O
and	O
liver	O
ultrasound	O
are	O
helpful	O
in	O
the	O
diagnosis	O
of	O
NAFLD/NASH	O
,	O
but	O
a	O
liver	O
biopsy	O
is	O
often	O
required	O
for	O
a	O
definitive	O
diagnosis	O
.	O
However	O
,	O
there	O
is	O
an	O
active	O
search	O
for	O
plasma	O
biomarkers	O
and	O
imaging	O
techniques	O
that	O
may	O
non-invasively	O
aid	O
in	O
the	O
diagnosis	O
.	O
The	O
treatment	O
of	O
NASH	O
requires	O
a	O
multifaceted	O
approach	O
.	O
The	O
goal	O
is	O
to	O
reverse	O
obesity-associated	O
lipotoxicity	O
and	O
insulin	S-GP
resistance	O
via	O
lifestyle	O
intervention	O
.	O
Although	O
there	O
is	O
no	O
pharmacological	O
agent	O
approved	O
for	O
the	O
treatment	O
of	O
NAFLD	O
,	O
vitamin	B-chemical
E	E-chemical
(	O
in	O
patients	O
without	O
T2DM	O
)	O
and	O
the	O
thiazolidinedione	O
pioglitazone	S-chemical
(	O
in	O
patients	O
with	O
and	O
without	O
T2DM	O
)	O
have	O
shown	O
the	O
most	O
consistent	O
results	O
in	O
randomized	O
controlled	O
trials	O
.	O
This	O
review	O
concentrates	O
on	O
our	O
current	O
understanding	O
of	O
the	O
disease	O
,	O
with	O
a	O
focus	O
on	O
the	O
existing	O
therapeutic	O
approaches	O
and	O
potential	O
future	O
pharmacological	O
developments	O
for	O
NAFLD	O
and	O
NASH	O
.	O

Pharmacodynamic	O
characteristics	O
of	O
lixisenatide	O
once	O
daily	O
versus	O
liraglutide	O
once	O
daily	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
insufficiently	O
controlled	O
on	O
metformin	S-chemical
.	O
AIM	O
:	O
Assess	O
the	O
pharmacodynamics	O
of	O
lixisenatide	O
once	O
daily	O
(	O
QD	O
)	O
versus	O
liraglutide	O
QD	O
in	O
type	O
2	O
diabetes	O
insufficiently	O
controlled	O
on	O
metformin	S-chemical
.	O
METHODS	O
:	O
In	O
this	O
28-day	O
,	O
randomized	O
,	O
open-label	O
,	O
parallel-group	O
,	O
multicentre	O
study	O
(	O
NCT01175473	O
)	O
,	O
patients	O
(	O
mean	O
HbA1c	S-GP
7.3	O
%	O
)	O
received	O
subcutaneous	O
lixisenatide	O
QD	O
(	O
10	O
µg	O
weeks	O
1-2	O
,	O
then	O
20	O
µg	O
;	O
n	O
=	O
77	O
)	O
or	O
liraglutide	O
QD	O
(	O
0.6	O
mg	O
week	O
1	O
,	O
1.2	O
mg	O
week	O
2	O
,	O
then	O
1.8	O
mg	O
;	O
n	O
=	O
71	O
)	O
30	O
min	O
before	O
breakfast	O
.	O
Primary	O
endpoint	O
was	O
change	O
in	O
postprandial	O
plasma	O
glucose	S-chemical
(	O
PPG	O
)	O
exposure	O
from	O
baseline	O
to	O
day	O
28	O
during	O
a	O
breakfast	O
test	O
meal	O
.	O
RESULTS	O
:	O
Lixisenatide	O
reduced	O
PPG	O
significantly	O
more	O
than	O
liraglutide	O
[	O
mean	O
change	O
in	O
AUC	O
(	O
0	O
)	O
(	O
:30-4:30h	O
)	O
:	O
-12.6	O
vs.	O
-4.0	O
h/mmol/l	O
,	O
respectively	O
;	O
p	O
<	O
0.0001	O
(	O
0:30	O
h	O
=	O
start	O
of	O
meal	O
)	O
]	O
.	O
Change	O
in	O
maximum	O
PPG	O
excursion	O
was	O
-3.9	O
mmol/l	O
vs.	O
-1.4	O
mmol/l	O
,	O
respectively	O
(	O
p	O
<	O
0.0001	O
)	O
.	O
More	O
lixisenatide-treated	O
patients	O
achieved	O
2-h	O
PPG	O
<	O
7.8	O
mmol/l	O
(	O
69	O
%	O
vs.	O
29	O
%	O
)	O
.	O
Changes	O
in	O
fasting	O
plasma	O
glucose	O
were	O
greater	O
with	O
liraglutide	O
(	O
-0.3	O
vs.	O
-1.3	O
mmol/l	O
,	O
p	O
<	O
0.0001	O
)	O
.	O
Lixisenatide	O
provided	O
greater	O
decreases	O
in	O
postprandial	O
glucagon	S-GP
(	O
p	O
<	O
0.05	O
)	O
,	O
insulin	S-GP
(	O
p	O
<	O
0.0001	O
)	O
and	O
C-peptide	S-GP
(	O
p	O
<	O
0.0001	O
)	O
.	O
Mean	O
HbA1c	S-GP
decreased	O
in	O
both	O
treatment	O
groups	O
(	O
from	O
7.2	O
%	O
to	O
6.9	O
%	O
with	O
lixisenatide	O
vs.	O
7.4	O
%	O
to	O
6.9	O
%	O
with	O
liraglutide	O
)	O
as	O
did	O
body	O
weight	O
(	O
-1.6	O
kg	O
vs.	O
-2.4	O
kg	O
,	O
respectively	O
)	O
.	O
Overall	O
incidence	O
of	O
adverse	O
events	O
was	O
lower	O
with	O
lixisenatide	O
(	O
55	O
%	O
)	O
versus	O
liraglutide	O
(	O
65	O
%	O
)	O
,	O
with	O
no	O
serious	O
events	O
or	O
hypoglycaemia	O
reported	O
.	O
CONCLUSIONS	O
:	O
Once	O
daily	O
prebreakfast	O
lixisenatide	O
provided	O
a	O
significantly	O
greater	O
reduction	O
in	O
PPG	O
(	O
AUC	O
)	O
during	O
a	O
morning	O
test	O
meal	O
versus	O
prebreakfast	O
liraglutide	O
.	O
Lixisenatide	O
provided	O
significant	O
decreases	O
in	O
postprandial	O
insulin	S-GP
,	O
C-peptide	S-GP
(	O
vs.	O
an	O
increase	O
with	O
liraglutide	O
)	O
and	O
glucagon	S-GP
,	O
and	O
better	O
gastrointestinal	O
tolerability	O
than	O
liraglutide	O
.	O

D-myo-inositol	B-chemical
1-phosphate	E-chemical
as	O
a	O
surrogate	O
of	O
D-myo-inositol	B-chemical
1,4,5-tris	I-chemical
phosphate	E-chemical
to	O
monitor	O
G	B-GP
protein-coupled	I-GP
receptor	E-GP
activation	O
.	O
Phospholipase	B-GP
C	I-GP
beta	E-GP
(	O
PLC-beta	S-GP
)	O
-coupled	O
G	B-GP
protein-coupled	I-GP
receptor	E-GP
(	O
GPCR	S-GP
)	O
activities	O
traditionally	O
are	O
assessed	O
by	O
measuring	O
Ca2+	S-chemical
triggered	O
by	O
D-myo-inositol	B-chemical
1,4,5-trisphosphate	E-chemical
(	O
IP3	S-chemical
)	O
,	O
a	O
PLC-beta	S-GP
hydrolysis	O
product	O
,	O
or	O
by	O
measuring	O
the	O
production	O
of	O
inositol	B-chemical
phosphate	E-chemical
using	O
cumbersome	O
radioactive	O
assays	O
.	O
A	O
specific	O
detection	O
of	O
IP3	S-chemical
production	O
was	O
also	O
established	O
using	O
IP3	S-chemical
binding	O
proteins	O
.	O
The	O
short	O
lifetime	O
of	O
IP3	S-chemical
makes	O
this	O
detection	O
very	O
challenging	O
in	O
measuring	O
GPCR	S-GP
responses	O
.	O
Indeed	O
,	O
this	O
IP3	S-chemical
rapidly	O
enters	O
the	O
metabolic	O
inositol	B-chemical
phosphate	E-chemical
cascade	O
.	O
It	O
has	O
been	O
known	O
for	O
decades	O
that	O
lithium	B-chemical
chloride	E-chemical
(	O
LiCl	S-chemical
)	O
leads	O
to	O
D-myo-inositol	B-chemical
1-phosphate	E-chemical
accumulation	O
on	O
GPCR	S-GP
activation	O
by	O
inhibiting	O
inositol	B-GP
monophosphatase	E-GP
,	O
the	O
final	O
enzyme	O
of	O
the	O
IP3	S-chemical
metabolic	O
cascade	O
.	O
We	O
show	O
here	O
that	O
IP1	S-chemical
can	O
be	O
used	O
as	O
a	O
surrogate	O
of	O
IP3	S-chemical
to	O
monitor	O
GPCR	S-GP
activation	O
.	O
We	O
developed	O
a	O
novel	O
homogeneous	O
time-resolved	O
fluorescence	O
(	O
HTRF	O
)	O
assay	O
that	O
correlates	O
perfectly	O
with	O
existing	O
methods	O
and	O
is	O
easily	O
amenable	O
to	O
high-throughput	O
screening	O
.	O
The	O
IP-One	O
assay	O
was	O
validated	O
on	O
various	O
GPCR	S-GP
models	O
.	O
It	O
has	O
the	O
advantage	O
over	O
the	O
traditional	O
Ca2+	S-chemical
assay	O
of	O
allowing	O
the	O
measurement	O
of	O
inverse	O
agonist	O
activity	O
as	O
well	O
as	O
the	O
analysis	O
of	O
PLC-beta	S-GP
activity	O
in	O
any	O
nontransfected	O
primary	O
cultures	O
.	O
Finally	O
,	O
the	O
high	O
assay	O
specificity	O
for	O
D-myo-inositol	B-chemical
1	I-chemical
monophosphate	E-chemical
(	O
IP1	S-chemical
(	O
1	O
)	O
)	O
opens	O
new	O
possibilities	O
in	O
developing	O
selective	O
assays	O
to	O
study	O
the	O
functional	O
roles	O
of	O
the	O
various	O
isoforms	O
of	O
inositol	B-chemical
phosphates	E-chemical
.	O

Manganese	S-chemical
-exposed	O
developing	O
rats	O
display	O
motor	O
deficits	O
and	O
striatal	O
oxidative	O
stress	O
that	O
are	O
reversed	O
by	O
Trolox	S-chemical
.	O
While	O
manganese	S-chemical
(	O
Mn	S-chemical
)	O
is	O
essential	O
for	O
proper	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
development	O
,	O
excessive	O
Mn	S-chemical
exposure	O
may	O
lead	O
to	O
neurotoxicity	O
.	O
Mn	S-chemical
preferentially	O
accumulates	O
in	O
the	O
basal	O
ganglia	O
,	O
and	O
in	O
adults	O
it	O
may	O
cause	O
Parkinson	O
's	O
disease-like	O
disorder	O
.	O
Compared	O
to	O
adults	O
,	O
younger	O
individuals	O
accumulate	O
greater	O
Mn	S-chemical
levels	O
in	O
the	O
CNS	O
and	O
are	O
more	O
vulnerable	O
to	O
its	O
toxicity	O
.	O
Moreover	O
,	O
the	O
mechanisms	O
mediating	O
developmental	O
Mn	S-chemical
-induced	O
neurotoxicity	O
are	O
not	O
completely	O
understood	O
.	O
The	O
present	O
study	O
investigated	O
the	O
developmental	O
neurotoxicity	O
elicited	O
by	O
Mn	S-chemical
exposure	O
(	O
5	O
,	O
10	O
and	O
20	O
mg/kg	O
;	O
i.p	O
.	O
)	O
from	O
postnatal	O
day	O
8	O
to	O
PN27	O
in	O
rats	O
.	O
Neurochemical	O
analyses	O
were	O
carried	O
out	O
on	O
PN29	O
,	O
with	O
a	O
particular	O
focus	O
on	O
striatal	O
alterations	O
in	O
intracellular	O
signaling	O
pathways	O
(	O
MAPKs	S-GP
,	O
Akt	S-GP
and	O
DARPP-32	S-GP
)	O
,	O
oxidative	O
stress	O
generation	O
and	O
cell	O
death	O
.	O
Motor	O
alterations	O
were	O
evaluated	O
later	O
in	O
life	O
at	O
3	O
,	O
4	O
or	O
5	O
weeks	O
of	O
age	O
.	O
Mn	S-chemical
exposure	O
(	O
20	O
mg/kg	O
)	O
increased	O
p38	S-GP
(	O
MAPK	S-GP
)	O
and	O
Akt	S-GP
phosphorylation	O
,	O
but	O
decreased	O
DARPP-32	S-GP
-Thr-34	O
phosphorylation	O
.	O
Mn	S-chemical
(	O
10	O
and	O
20	O
mg/kg	O
)	O
increased	O
caspase	S-GP
activity	O
and	O
F	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
-isoprostane	E-chemical
production	O
(	O
a	O
biological	O
marker	O
of	O
lipid	O
peroxidation	O
)	O
.	O
Paralleling	O
the	O
changes	O
in	O
striatal	O
biochemical	O
parameters	O
,	O
Mn	S-chemical
(	O
20	O
mg/kg	O
)	O
also	O
caused	O
motor	O
impairment	O
,	O
evidenced	O
by	O
increased	O
falling	O
latency	O
in	O
the	O
rotarod	O
test	O
,	O
decreased	O
distance	O
traveled	O
and	O
motor	O
speed	O
in	O
the	O
open-field	O
test	O
.	O
Notably	O
,	O
the	O
antioxidant	O
Trolox	S-chemical
™	O
reversed	O
the	O
Mn	S-chemical
(	O
20	O
mg/kg	O
)	O
-dependent	O
augmentation	O
in	O
p38	S-GP
(	O
MAPK	S-GP
)	O
phosphorylation	O
and	O
reduced	O
the	O
Mn	S-chemical
(	O
20	O
mg/kg	O
)	O
-induced	O
caspase	S-GP
activity	O
and	O
F	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
-isoprostane	E-chemical
production	O
.	O
Trolox	S-chemical
™	O
also	O
reversed	O
the	O
Mn	S-chemical
-induced	O
motor	O
coordination	O
deficits	O
.	O
These	O
findings	O
are	O
the	O
first	O
to	O
show	O
that	O
long-term	O
exposure	O
to	O
Mn	S-chemical
during	O
a	O
critical	O
period	O
of	O
neurodevelopment	O
causes	O
motor	O
coordination	O
dysfunction	O
with	O
parallel	O
increment	O
in	O
oxidative	O
stress	O
markers	O
,	O
p38	S-GP
(	O
MAPK	S-GP
)	O
phosphorylation	O
and	O
caspase	S-GP
activity	O
in	O
the	O
striatum	O
.	O
Moreover	O
,	O
we	O
establish	O
Trolox	S-chemical
™	O
as	O
a	O
potential	O
neuroprotective	O
agent	O
given	O
its	O
efficacy	O
in	O
reversing	O
the	O
Mn	S-chemical
-induced	O
neurodevelopmental	O
effects	O
.	O

Metformin	S-chemical
and	O
phenformin	S-chemical
activate	O
AMP-activated	B-GP
protein	I-GP
kinase	E-GP
in	O
the	O
heart	O
by	O
increasing	O
cytosolic	O
AMP	S-chemical
concentration	O
.	O
AMP-activated	B-GP
protein	I-GP
kinase	E-GP
(	O
AMPK	S-GP
)	O
acts	O
as	O
a	O
cellular	O
energy	O
sensor	O
:	O
it	O
responds	O
to	O
an	O
increase	O
in	O
AMP	S-chemical
concentration	O
(	O
[	O
AMP	S-chemical
]	O
)	O
or	O
the	O
AMP	S-chemical
-to-	O
ATP	S-chemical
ratio	O
(	O
AMP	S-chemical
/	O
ATP	S-chemical
)	O
.	O
Metformin	S-chemical
and	O
phenformin	S-chemical
,	O
which	O
are	O
biguanides	S-chemical
,	O
have	O
been	O
reported	O
to	O
increase	O
AMPK	S-GP
activity	O
without	O
increasing	O
AMP	S-chemical
/	O
ATP	S-chemical
.	O
This	O
study	O
tests	O
the	O
hypothesis	O
that	O
these	O
biguanides	S-chemical
increase	O
AMPK	S-GP
activity	O
in	O
the	O
heart	O
by	O
increasing	O
cytosolic	O
[	O
AMP	S-chemical
]	O
.	O
Groups	O
of	O
isolated	O
rat	O
hearts	O
(	O
n	O
=	O
5-7	O
each	O
)	O
were	O
perfused	O
with	O
Krebs-Henseleit	O
buffer	O
with	O
or	O
without	O
0.2	O
mM	O
phenformin	S-chemical
or	O
10	O
mM	O
metformin	S-chemical
,	O
and	O
(	B-chemical
31	I-chemical
)	I-chemical
P	E-chemical
-NMR-measured	O
phosphocreatine	S-chemical
,	O
ATP	S-chemical
,	O
and	O
intracellular	O
pH	O
were	O
used	O
to	O
calculate	O
cytosolic	O
[	O
AMP	S-chemical
]	O
.	O
At	O
various	O
times	O
,	O
hearts	O
were	O
freeze-clamped	O
and	O
assayed	O
for	O
AMPK	S-GP
activity	O
,	O
phosphorylation	O
of	O
Thr	O
(	O
172	O
)	O
on	O
AMPK-alpha	S-GP
,	O
and	O
phosphorylation	O
of	O
Ser	O
(	O
79	O
)	O
on	O
acetyl-CoA	B-GP
carboxylase	E-GP
,	O
an	O
AMPK	S-GP
target	O
.	O
In	O
hearts	O
treated	O
with	O
phenformin	S-chemical
for	O
18	O
min	O
and	O
then	O
perfused	O
for	O
20	O
min	O
with	O
Krebs-Henseleit	O
buffer	O
,	O
[	O
AMP	S-chemical
]	O
began	O
to	O
increase	O
at	O
26	O
min	O
and	O
AMPK	S-GP
activity	O
was	O
elevated	O
at	O
36	O
min	O
.	O
In	O
hearts	O
treated	O
with	O
metformin	S-chemical
,	O
[	O
AMP	S-chemical
]	O
was	O
increased	O
at	O
50	O
min	O
and	O
AMPK	S-GP
activity	O
,	O
phosphorylated	O
AMPK	S-GP
,	O
and	O
phosphorylated	B-GP
acetyl-CoA	I-GP
carboxylase	E-GP
were	O
elevated	O
at	O
61	O
min	O
.	O
In	O
metformin	S-chemical
-treated	O
hearts	O
,	O
HPLC-measured	O
total	O
AMP	S-chemical
content	O
and	O
total	O
AMP	S-chemical
/	O
ATP	S-chemical
did	O
not	O
increase	O
.	O
In	O
summary	O
,	O
phenformin	S-chemical
and	O
metformin	S-chemical
increase	O
AMPK	S-GP
activity	O
and	O
phosphorylation	O
in	O
the	O
isolated	O
heart	O
.	O
The	O
increase	O
in	O
AMPK	S-GP
activity	O
was	O
always	O
preceded	O
by	O
and	O
correlated	O
with	O
increased	O
cytosolic	O
[	O
AMP	S-chemical
]	O
.	O
Total	O
AMP	S-chemical
content	O
and	O
total	O
AMP	S-chemical
/	O
ATP	S-chemical
did	O
not	O
change	O
.	O
Cytosolic	O
[	O
AMP	S-chemical
]	O
reported	O
metabolically	O
active	O
AMP	S-chemical
,	O
which	O
triggered	O
increased	O
AMPK	S-GP
activity	O
,	O
but	O
measures	O
of	O
total	O
AMP	S-chemical
did	O
not	O
.	O

Bevantolol	S-chemical
:	O
a	O
beta-1	B-GP
adrenoceptor	E-GP
antagonist	O
with	O
unique	O
additional	O
actions	O
.	O
UNLABELLED	O
:	O
Bevantolol	S-chemical
is	O
a	O
beta-1	B-GP
adrenoceptor	E-GP
antagonist	O
that	O
has	O
been	O
shown	O
to	O
be	O
as	O
effective	O
as	O
other	O
beta	O
blockers	O
for	O
the	O
treatment	O
of	O
angina	O
pectoris	O
and	O
hypertension	O
.	O
Some	O
interesting	O
additional	O
properties	O
,	O
such	O
as	O
the	O
absence	O
of	O
the	O
side	O
effect	O
of	O
cold	O
extremities	O
,	O
required	O
investigation	O
,	O
and	O
a	O
great	O
deal	O
of	O
new	O
evidence	O
has	O
been	O
accumulated	O
during	O
the	O
last	O
three	O
years	O
.	O
This	O
new	O
data	O
is	O
consistent	O
with	O
the	O
proposal	O
put	O
forward	O
a	O
couple	O
of	O
years	O
ago	O
that	O
bevantolol	O
interacts	O
with	O
alpha-adrenoceptors	S-GP
.	O
All	O
the	O
available	O
evidence	O
,	O
published	O
and	O
unpublished	O
,	O
has	O
been	O
reviewed	O
and	O
fits	O
into	O
a	O
coherent	O
pattern	O
,	O
here	O
arranged	O
into	O
five	O
sections	O
.	O
Chemistry	O
:	O
affinity	O
for	O
alpha-adrenoceptors	S-GP
.	O
Animal	O
experiments	O
confirm	O
both	O
agonist	O
and	O
antagonist	O
effects	O
on	O
alpha-receptors	O
,	O
in	O
addition	O
to	O
antagonist	O
activity	O
at	O
beta-1	B-GP
receptors	E-GP
.	O
In	O
addition	O
,	O
bevantolol	S-chemical
has	O
electrophysiologic	O
effects	O
,	O
including	O
bradycardia	O
by	O
a	O
direct	O
action	O
on	O
the	O
sinus	O
node	O
and	O
a	O
class	O
1	O
antiarrhythmic	O
action	O
.	O
Investigations	O
in	O
humans	O
have	O
shown	O
that	O
although	O
bevantolol	S-chemical
has	O
a	O
short	O
half-life	O
,	O
good	O
control	O
of	O
hypertension	O
can	O
be	O
achieved	O
on	O
once-a-day	O
dosing	O
.	O
SAFETY	O
:	O
bevantolol	S-chemical
has	O
remarkably	O
few	O
side	O
effects	O
,	O
does	O
not	O
cause	O
cold	O
extremities	O
,	O
and	O
does	O
not	O
significantly	O
affect	O
glomerular	O
filtration	O
rate	O
in	O
patients	O
with	O
renal	O
impairment	O
.	O
Evidence	O
has	O
been	O
obtained	O
in	O
man	O
for	O
interaction	O
with	O
alpha-adrenoceptors	S-GP
in	O
the	O
brain	O
;	O
and	O
in	O
the	O
peripheral	O
circulation	O
bevantolol	S-chemical
does	O
not	O
,	O
as	O
do	O
other	O
beta	O
blockers	O
,	O
increase	O
peripheral	O
vascular	O
resistance	O
,	O
but	O
reduces	O
it	O
.	O
It	O
is	O
suggested	O
that	O
all	O
the	O
additional	O
actions	O
of	O
bevantolol	S-chemical
can	O
be	O
attributed	O
to	O
a	O
partial	O
agonist	O
action	O
on	O
alpha-adrenoceptors	S-GP
.	O

Neuroprotective	O
Effects	O
of	O
Puerarin	S-chemical
on	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	S-chemical
induced	O
Parkinson	O
's	O
Disease	O
Model	O
in	O
Mice	O
.	O
Puerarin	S-chemical
,	O
an	O
active	O
component	O
of	O
Pueraria	O
montana	O
var	O
.	O
lobata	O
(	O
Willd	O
.	O
)	O
Sanjappa	O
&	O
Pradeep	O
is	O
well-known	O
for	O
its	O
anti-oxidative	O
and	O
neuroprotective	O
activities	O
.	O
Although	O
anti-Parkinson	O
's	O
disease	O
activity	O
of	O
puerarin	S-chemical
was	O
reported	O
in	O
both	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
model	O
,	O
detailed	O
mechanisms	O
are	O
not	O
clarified	O
.	O
In	O
this	O
study	O
,	O
we	O
addressed	O
that	O
puerarin	S-chemical
attenuated	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	S-chemical
(	O
MPTP	S-chemical
)	O
-induced	O
behavioral	O
deficits	O
,	O
dopamine	S-chemical
rgic	O
neuronal	O
degeneration	O
and	O
dopamine	O
depletion	O
.	O
Puerarin	S-chemical
administration	O
enhanced	O
glutathione	S-chemical
(	O
GSH	S-chemical
)	O
activity	O
,	O
glial	B-GP
cell	I-GP
line-derived	I-GP
neurotrophic	I-GP
factor	E-GP
(	O
GDNF	S-GP
)	O
expression	O
and	O
PI3K	S-GP
/	O
Akt	S-GP
pathway	O
activation	O
,	O
which	O
might	O
ameliorate	O
MPTP	S-chemical
injection-induced	O
progressive	O
elevation	O
of	O
reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
formation	O
in	O
mice	O
.	O
In	O
addition	O
to	O
the	O
effect	O
on	O
ROS	O
,	O
puerarin	S-chemical
ameliorated	O
MPTP	S-chemical
-reduced	O
lysosome-associated	B-GP
membrane	I-GP
protein	I-GP
type	I-GP
2A	E-GP
(	O
Lamp	B-GP
2A	E-GP
)	O
expression	O
.	O
Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
puerarin	S-chemical
attenuates	O
MPTP	S-chemical
-induced	O
dopaminergic	O
neuronal	O
degeneration	O
via	O
modulating	O
GDNF	S-GP
expression	O
,	O
PI3K	S-GP
/	O
Akt	S-GP
pathway	O
and	O
GSH	S-chemical
activation	O
,	O
which	O
subsequently	O
ameliorate	O
MPTP	S-chemical
-induced	O
ROS	O
formation	O
and	O
decrease	O
of	O
Lamp	B-GP
2A	E-GP
expression	O
.	O
Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

A	O
novel	O
retinoic	B-GP
acid-responsive	I-GP
element	E-GP
regulates	O
retinoic	B-chemical
acid	E-chemical
-induced	O
BLR1	S-GP
expression	O
.	O
The	O
mechanism	O
of	O
action	O
of	O
retinoic	B-chemical
acid	E-chemical
(	O
RA	S-chemical
)	O
is	O
of	O
broad	O
relevance	O
to	O
cell	O
and	O
developmental	O
biology	O
,	O
nutrition	O
,	O
and	O
cancer	O
chemotherapy	O
.	O
RA	S-chemical
is	O
known	O
to	O
induce	O
expression	O
of	O
the	O
Burkitt	B-GP
's	I-GP
lymphoma	I-GP
receptor	I-GP
1	E-GP
(	O
BLR1	S-GP
)	O
gene	O
which	O
propels	O
RA	S-chemical
-induced	O
cell	O
cycle	O
arrest	O
and	O
differentiation	O
of	O
HL-60	O
human	O
myeloblastic	O
leukemia	O
cells	O
,	O
motivating	O
the	O
present	O
analysis	O
of	O
transcriptional	O
regulation	O
of	O
blr1	S-GP
expression	O
by	O
RA	S-chemical
.	O
The	O
RA	S-chemical
-treated	O
HL-60	O
cells	O
used	O
here	O
expressed	O
all	O
RA	B-GP
receptor	E-GP
(	O
RAR	S-GP
)	O
and	O
retinoid	B-GP
X	I-GP
receptor	E-GP
(	O
RXR	S-GP
)	O
subtypes	O
(	O
as	O
detected	O
by	O
Northern	O
analysis	O
)	O
except	O
RXRgamma	S-GP
.	O
Treatment	O
with	O
RAR	S-GP
-	O
and	O
RXR	S-GP
-selective	O
ligands	O
showed	O
that	O
RARalpha	S-GP
synergized	O
with	O
RXRalpha	S-GP
to	O
transcriptionally	O
activate	O
blr1	S-GP
expression	O
.	O
A	O
5'-flanking	O
region	O
capable	O
of	O
supporting	O
RA	S-chemical
-induced	O
blr1	S-GP
activation	O
in	O
HL-60	O
cells	O
was	O
found	O
to	O
contain	O
a	O
205-bp	O
sequence	O
in	O
the	O
distal	O
portion	O
that	O
was	O
necessary	O
for	O
transcriptional	O
activation	O
by	O
RA	S-chemical
.	O
Within	O
this	O
sequence	O
DNase	B-GP
I	E-GP
footprinting	O
revealed	O
that	O
RA	S-chemical
induced	O
binding	O
of	O
a	O
nuclear	B-GP
protein	I-GP
complex	E-GP
to	O
an	O
element	O
containing	O
two	O
GT	B-GP
boxes	E-GP
.	O
Electromobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
and	O
supershift	O
assays	O
showed	O
that	O
this	O
element	O
bound	O
recombinant	O
RARalpha	S-GP
and	O
RXRalpha	S-GP
.	O
Without	O
RA	S-chemical
there	O
was	O
neither	O
complex	O
binding	O
nor	O
transcriptional	O
activation	O
.	O
Both	O
GT	B-GP
boxes	E-GP
were	O
needed	O
for	O
binding	O
the	O
complex	O
,	O
and	O
mutation	O
of	O
either	O
GT	B-GP
box	E-GP
caused	O
the	O
loss	O
of	O
transcriptional	O
activation	O
by	O
RA	S-chemical
.	O
The	O
ability	O
of	O
this	O
cis-acting	O
RAR-RXR	B-GP
binding	I-GP
element	E-GP
to	O
activate	O
transcription	O
in	O
response	O
to	O
RA	S-chemical
also	O
depended	O
on	O
downstream	O
sequences	O
where	O
an	O
octamer	B-GP
transcription	I-GP
factor	I-GP
1	E-GP
(	O
Oct1	S-GP
)	O
site	O
and	O
a	O
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cells	E-GP
(	O
NFATc	S-GP
)	O
site	O
between	O
this	O
element	O
and	O
the	O
transcriptional	O
start	O
,	O
as	O
well	O
as	O
a	O
cyclic	B-GP
AMP	I-GP
response	I-GP
element	I-GP
binding	I-GP
factor	E-GP
(	O
CREB	S-GP
)	O
site	O
between	O
the	O
transcriptional	O
start	O
and	O
first	O
exon	O
of	O
the	O
blr1	S-GP
gene	O
,	O
were	O
necessary	O
.	O
Each	O
of	O
these	O
sites	O
bound	O
its	O
corresponding	O
transcription	O
factor	O
.	O
A	O
transcription	O
factor-transcription	O
factor	O
binding	O
array	O
analysis	O
of	O
nuclear	O
lysate	O
from	O
RA	S-chemical
-treated	O
cells	O
indicated	O
several	O
prominent	O
RARalpha	S-GP
binding	O
partners	O
;	O
among	O
these	O
,	O
Oct1	S-GP
,	O
NFATc3	S-GP
,	O
and	O
CREB2	S-GP
were	O
identified	O
by	O
competition	O
EMSA	O
and	O
supershift	O
and	O
chromatin	O
immunoprecipitation	O
assays	O
as	O
components	O
of	O
the	O
complex	O
.	O
RA	S-chemical
upregulated	O
expression	O
of	O
these	O
three	O
factors	O
.	O
In	O
sum	O
the	O
results	O
of	O
the	O
present	O
study	O
indicate	O
that	O
RA	S-chemical
-induced	O
expression	O
of	O
blr1	S-GP
expression	O
depends	O
on	O
a	O
novel	O
RA	B-GP
response	I-GP
element	E-GP
.	O
This	O
cis-acting	O
element	O
approximately	O
1	O
kb	O
upstream	O
of	O
the	O
transcriptional	O
start	O
consists	O
of	O
two	O
GT	B-GP
boxes	E-GP
that	O
bind	O
RAR	S-GP
and	O
RXR	S-GP
in	O
a	O
nuclear	B-GP
protein	I-GP
complex	E-GP
that	O
also	O
contains	O
Oct1	S-GP
,	O
NFATc3	S-GP
,	O
and	O
CREB2	S-GP
bound	O
to	O
their	O
cognate	O
downstream	O
consensus	O
binding	O
sites	O
.	O

Protection	O
of	O
glycyrrhizic	B-chemical
acid	E-chemical
against	O
AGEs-induced	O
endothelial	O
dysfunction	O
through	O
inhibiting	O
RAGE	S-GP
/	O
NF-κB	S-GP
pathway	O
activation	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O
ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Licorice	O
(	O
Glycyrrhiza	O
uralensis	O
roots	O
)	O
is	O
used	O
as	O
a	O
traditional	O
medicine	O
for	O
the	O
treatment	O
of	O
diabetes	O
mellitus	O
and	O
its	O
vascular	O
complications	O
.	O
Glycyrrhizic	B-chemical
acid	E-chemical
(	O
GA	O
,	O
also	O
known	O
as	O
Glycyrrhizin	S-chemical
)	O
,	O
a	O
triterpenoid	B-chemical
saponin	I-chemical
glycoside	E-chemical
,	O
is	O
considered	O
to	O
be	O
a	O
bioactive	O
component	O
in	O
Licorice	O
and	O
is	O
beneficial	O
to	O
diabetic	O
vascular	O
complications	O
.	O
AIM	O
OF	O
STUDY	O
:	O
The	O
present	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
potential	O
protective	O
activities	O
on	O
AGEs-induced	O
endothelial	O
dysfunction	O
,	O
including	O
anti-apoptosis	O
,	O
antioxidant	O
stress	O
and	O
anti-proinflammatory	O
responses	O
,	O
and	O
explore	O
the	O
underlying	O
mechanism	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
were	O
incubated	O
and	O
pre-treated	O
with	O
GA	O
(	O
10	O
(	O
-9	O
)	O
-10	O
(	O
-6	O
)	O
M	O
)	O
or	O
RAGE	S-GP
-Ab	O
(	O
5μg/ml	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
200μg/ml	O
AGEs	O
.	O
AO/EB	O
fluorescence	O
staining	O
assay	O
was	O
performed	O
to	O
evaluate	O
anti-apoptosis	O
activity	O
.	O
The	O
superoxide	B-GP
dismutase	E-GP
(	O
SOD	S-GP
)	O
activity	O
and	O
malondialdehyde	S-chemical
(	O
MDA	S-chemical
)	O
level	O
in	O
cell	O
supernatant	O
were	O
detected	O
by	O
kits	O
while	O
the	O
intracellular	O
reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
generation	O
was	O
determined	O
by	O
2,7-dichlorodihydrofluorescin	B-chemical
diacetate	E-chemical
(	O
DCFH-DA	S-chemical
)	O
kit	O
.	O
Immunocytochemistry	O
analysis	O
was	O
designed	O
to	O
determine	O
transforming	B-GP
growth	I-GP
factor	I-GP
beta1	E-GP
(	O
TGF-β1	S-GP
)	O
protein	O
expression	O
while	O
immunofluorescence	O
analysis	O
for	O
RAGE	S-GP
and	O
NF-kB	S-GP
.	O
The	O
protein	O
expressions	O
of	O
TGF-β1	S-GP
,	O
RAGE	S-GP
and	O
NF-kB	S-GP
were	O
analyzed	O
by	O
Western	O
blot	O
analysis	O
.	O
RESULTS	O
:	O
Pretreatment	O
with	O
GA	O
at	O
a	O
concentration	O
of	O
10	O
(	O
-8	O
)	O
-10	O
(	O
-6	O
)	O
M	O
significantly	O
reduced	O
the	O
AGEs-induced	O
apoptosis	O
in	O
HUVECs	O
.	O
GA	O
significantly	O
increased	O
antioxidant	O
enzyme	O
SOD	S-GP
activity	O
and	O
decreased	O
peroxide	O
degradation	O
product	O
MDA	S-chemical
level	O
in	O
a	O
dose-dependent	O
manner	O
.	O
Furthermore	O
,	O
GA	O
also	O
remarkably	O
inhibited	O
the	O
overgeneration	O
of	O
AGEs-induced	O
ROS	O
.	O
Both	O
immunocytochemistry	O
analysis	O
and	O
western	O
blot	O
analysis	O
showed	O
that	O
GA	O
significantly	O
decreased	O
the	O
protein	O
expression	O
of	O
poinflammatory	O
cytokine	S-GP
TGF-β1	S-GP
in	O
a	O
similar	O
manner	O
which	O
RAGE	S-GP
-Ab	O
did	O
.	O
Additionally	O
,	O
AGEs-induced	O
RAGE	S-GP
and	O
NF-kB	S-GP
protein	O
expressions	O
were	O
down-regulated	O
significantly	O
by	O
the	O
pretreatment	O
with	O
GA	O
or	O
RAGE	S-GP
-Ab	O
.	O
CONCLUSION	O
:	O
These	O
findings	O
provide	O
evidences	O
that	O
GA	O
possesses	O
protective	O
activity	O
on	O
AGEs-induced	O
endothelial	O
dysfunction	O
,	O
including	O
anti-apoptosis	O
,	O
anti-inflammation	O
and	O
antioxidant	O
stress	O
,	O
via	O
inhibiting	O
RAGE	S-GP
/	O
NF-kB	S-GP
pathway	O
.	O
GA	O
might	O
be	O
an	O
alternative	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
diabetic	O
vascular	O
complications	O
in	O
an	O
appropriate	O
dosage	O
.	O

Studies	O
on	O
the	O
antioxidant	O
potential	O
of	O
flavones	S-chemical
of	O
Allium	O
vineale	O
isolated	O
from	O
its	O
water-soluble	O
fraction	O
.	O
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
examine	O
the	O
chemical	O
constituents	O
and	O
antioxidant	O
potential	O
of	O
water-soluble	O
fractions	O
from	O
the	O
commonly	O
consumed	O
vegetable	O
,	O
Allium	O
vineale	O
.	O
The	O
water-soluble	O
fraction	O
,	O
containing	O
phenolic	O
compounds	O
,	O
was	O
extracted	O
with	O
ethyl	B-chemical
acetate	E-chemical
to	O
obtain	O
flavonoids	S-chemical
which	O
were	O
separated	O
and	O
purified	O
by	O
repeated	O
column	O
chromatography	O
over	O
Sephadex	O
LH-20	O
,	O
RP	O
C18	O
and	O
silica	B-chemical
gel	E-chemical
.	O
The	O
isolated	O
compounds	O
were	O
identified	O
according	O
to	O
their	O
physicochemical	O
properties	O
and	O
spectral	O
data	O
(	O
UV	O
,	O
HPLC-TOF/MS	O
,	O
(	B-chemical
1	I-chemical
)	I-chemical
H	E-chemical
NMR	O
,	O
(	B-chemical
13	I-chemical
)	I-chemical
C	E-chemical
NMR	O
and	O
2D	O
NMR	O
)	O
.	O
Three	O
flavonoids	O
were	O
isolated	O
and	O
identified	O
as	O
chrysoeriol-7-O-	B-chemical
[	I-chemical
2″-O-E-feruloyl	I-chemical
]	I-chemical
-β-d-glucoside	E-chemical
(	O
1	O
)	O
,	O
chrysoeriol	S-chemical
(	O
2	O
)	O
,	O
and	O
isorhamnetin-3-β-d-glucoside	S-chemical
(	O
3	O
)	O
.	O
Antioxidant	O
studies	O
of	O
the	O
aqueous	O
extract	O
and	O
three	O
isolated	O
compounds	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
were	O
undertaken	O
and	O
they	O
were	O
found	O
to	O
have	O
significant	O
antioxidant	O
activity	O
.	O
Antioxidant	O
activities	O
were	O
evaluated	O
for	O
total	O
antioxidant	O
activity	O
by	O
the	O
ferric	B-chemical
thiocyanate	E-chemical
method	O
,	O
ferric	S-chemical
ion	O
(	O
Fe	B-chemical
(	I-chemical
3+	I-chemical
)	E-chemical
)	O
reducing	O
antioxidant	O
power	O
assay	O
(	O
FRAP	O
)	O
,	O
ferrous	S-chemical
ion	O
(	O
Fe	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
)	O
metal	O
chelating	O
activity	O
,	O
and	O
DPPH	S-chemical
free	O
radical-scavenging	O
activity	O
.	O
The	O
water-soluble	O
ethyl	B-chemical
acetate	E-chemical
and	O
methanol	S-chemical
extraction	O
methods	O
were	O
also	O
compared	O
using	O
HPLC-TOF/MS	O
.	O

Agonist	O
and	O
antagonist	O
actions	O
of	O
yohimbine	S-chemical
as	O
compared	O
to	O
fluparoxan	S-chemical
at	O
alpha	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenergic	I-GP
receptors	E-GP
(	B-GP
AR	I-GP
)	I-GP
s	E-GP
,	O
serotonin	S-chemical
(	B-GP
5-HT	I-GP
)	I-GP
(	I-GP
1A	I-GP
)	E-GP
,	O
5-HT	B-GP
(	I-GP
1B	I-GP
)	E-GP
,	O
5-HT	B-GP
(	I-GP
1D	I-GP
)	E-GP
and	O
dopamine	B-GP
D	I-GP
(	I-GP
2	I-GP
)	I-GP
and	I-GP
D	I-GP
(	I-GP
3	I-GP
)	I-GP
receptors	E-GP
.	O
Significance	O
for	O
the	O
modulation	O
of	O
frontocortical	O
monoaminergic	O
transmission	O
and	O
depressive	O
states	O
.	O
Herein	O
,	O
we	O
evaluate	O
the	O
interaction	O
of	O
the	O
alpha	B-GP
(	I-GP
2	I-GP
)	I-GP
-AR	I-GP
antagonist	E-GP
,	O
yohimbine	S-chemical
,	O
as	O
compared	O
to	O
fluparoxan	S-chemical
,	O
at	O
multiple	O
monoaminergic	B-GP
receptors	E-GP
and	O
examine	O
their	O
roles	O
in	O
the	O
modulation	O
of	O
adrenergic	O
,	O
dopaminergic	O
and	O
serotonergic	O
transmission	O
in	O
freely-moving	O
rats	O
.	O
Yohimbine	S-chemical
displays	O
marked	O
affinity	O
at	O
human	B-GP
(	I-GP
h	I-GP
)	I-GP
alpha	I-GP
(	I-GP
2A	I-GP
)	I-GP
-	I-GP
,	I-GP
halpha	I-GP
(	I-GP
2B	I-GP
)	I-GP
-	I-GP
and	I-GP
halpha	I-GP
(	I-GP
2C	I-GP
)	I-GP
-ARs	E-GP
,	O
significant	O
affinity	O
for	O
h5-HT	B-GP
(	I-GP
1A	I-GP
)	E-GP
,	O
h5-HT	B-GP
(	I-GP
1B	I-GP
)	E-GP
,	O
h5-HT	B-GP
(	I-GP
1D	I-GP
)	E-GP
,	O
and	O
hD	B-GP
(	I-GP
2	I-GP
)	I-GP
receptors	E-GP
and	O
weak	O
affinity	O
for	O
hD	B-GP
(	I-GP
3	I-GP
)	I-GP
receptors	E-GP
.	O
In	O
[	O
(	B-chemical
35	I-chemical
)	I-chemical
S	E-chemical
]	O
GTPgammaS	O
binding	O
protocols	O
,	O
yohimbine	S-chemical
exerts	O
antagonist	O
actions	O
at	O
halpha	B-GP
(	I-GP
2A	I-GP
)	I-GP
-AR	E-GP
,	O
h5-HT	B-GP
(	I-GP
1B	I-GP
)	E-GP
,	O
h5-HT	B-GP
(	I-GP
1D	I-GP
)	E-GP
,	O
and	O
hD	B-GP
(	I-GP
2	I-GP
)	E-GP
sites	O
,	O
yet	O
partial	O
agonist	O
actions	O
at	O
h5-HT	B-GP
(	I-GP
1A	I-GP
)	E-GP
sites	O
.	O
In	O
vivo	O
,	O
agonist	O
actions	O
of	O
yohimbine	S-chemical
at	O
5-HT	B-GP
(	I-GP
1A	I-GP
)	E-GP
sites	O
are	O
revealed	O
by	O
WAY100,635	S-chemical
-reversible	O
induction	O
of	O
hypothermia	O
in	O
the	O
rat	O
.	O
In	O
guinea	O
pigs	O
,	O
antagonist	O
actions	O
of	O
yohimbine	S-chemical
at	O
5-HT	B-GP
(	I-GP
1B	I-GP
)	E-GP
receptors	O
are	O
revealed	O
by	O
blockade	O
of	O
hypothermia	O
evoked	O
by	O
the	O
5-HT	B-GP
(	I-GP
1B	I-GP
)	E-GP
agonist	O
,	O
GR46,611	S-chemical
.	O
In	O
distinction	O
to	O
yohimbine	S-chemical
,	O
fluparoxan	S-chemical
shows	O
only	O
modest	O
partial	O
agonist	O
actions	O
at	O
h5-HT	B-GP
(	I-GP
1A	I-GP
)	E-GP
sites	O
versus	O
marked	O
antagonist	O
actions	O
at	O
halpha	B-GP
(	I-GP
2	I-GP
)	I-GP
-ARs	E-GP
.	O
While	O
fluparoxan	S-chemical
selectively	O
enhances	O
hippocampal	O
noradrenaline	S-chemical
(	O
NAD	S-chemical
)	O
turnover	O
,	O
yohimbine	S-chemical
also	O
enhances	O
striatal	O
dopamine	S-chemical
(	O
DA	S-chemical
)	O
turnover	O
and	O
suppresses	O
striatal	O
turnover	O
of	O
5-HT	S-chemical
.	O
Further	O
,	O
yohimbine	S-chemical
decreases	O
firing	O
of	O
serotonergic	O
neurones	O
in	O
raphe	O
nuclei	O
,	O
an	O
action	O
reversed	O
by	O
WAY100,635	S-chemical
.	O
Fluparoxan	S-chemical
increases	O
extracellular	O
levels	O
of	O
DA	S-chemical
and	O
NAD	S-chemical
,	O
but	O
not	O
5-HT	S-chemical
,	O
in	O
frontal	O
cortex	O
.	O
In	O
analogy	O
,	O
yohimbine	S-chemical
enhances	O
FCX	O
levels	O
of	O
DA	S-chemical
and	O
NAD	S-chemical
,	O
yet	O
suppresses	O
those	O
of	O
5-HT	S-chemical
,	O
the	O
latter	O
effect	O
being	O
antagonized	O
by	O
WAY100,635	S-chemical
.	O
The	O
induction	O
by	O
fluoxetine	O
of	O
FCX	O
levels	O
of	O
5-HT	S-chemical
,	O
DA	S-chemical
,	O
and	O
NAD	S-chemical
is	O
potentiated	O
by	O
fluparoxan	S-chemical
.	O
Yohimbine	S-chemical
likewise	O
facilitates	O
the	O
influence	O
of	O
fluoxetine	S-chemical
upon	O
DA	S-chemical
and	O
NAD	S-chemical
levels	O
,	O
but	O
not	O
those	O
of	O
5-HT	S-chemical
.	O
In	O
conclusion	O
,	O
the	O
alpha	B-GP
(	I-GP
2	I-GP
)	I-GP
-AR	E-GP
antagonist	O
properties	O
of	O
yohimbine	S-chemical
increase	O
DA	S-chemical
and	O
NAD	S-chemical
levels	O
both	O
alone	O
and	O
in	O
association	O
with	O
fluoxetine	O
.	O
However	O
,	O
in	O
contrast	O
to	O
the	O
selective	O
alpha	B-GP
(	I-GP
2	I-GP
)	I-GP
-AR	E-GP
antagonist	O
,	O
fluparoxan	S-chemical
,	O
the	O
5-HT	B-GP
(	I-GP
1A	I-GP
)	E-GP
agonist	O
actions	O
of	O
yohimbine	S-chemical
suppress	O
5-HT	S-chemical
levels	O
alone	O
and	O
underlie	O
its	O
inability	O
to	O
augment	O
the	O
influence	O
of	O
fluoxetine	S-chemical
upon	O
5-HT	S-chemical
levels	O
.	O

Low	O
molecular	O
weight	O
dual	O
inhibitors	O
of	O
factor	B-GP
Xa	E-GP
and	O
fibrinogen	S-GP
binding	O
to	O
GPIIb/IIIa	S-GP
with	O
highly	O
overlapped	O
pharmacophores	O
.	O
Dual	O
antithrombotic	O
agents	O
acting	O
as	O
anticoagulants	O
and	O
aggregation	O
inhibitors	O
could	O
have	O
substantial	O
advantages	O
over	O
currently	O
prescribed	O
combinations	O
of	O
antithrombotic	O
drugs	O
.	O
Herein	O
,	O
we	O
report	O
compounds	O
with	O
moderate	O
inhibitory	O
activity	O
for	O
factor	B-GP
Xa	E-GP
and	O
fibrinogen	S-GP
GPIIb/IIIa	S-GP
binding	O
(	O
both	O
in	O
the	O
micromolar	O
range	O
)	O
.	O
These	O
compounds	O
resulted	O
from	O
our	O
efforts	O
to	O
merge	O
the	O
pharmacophores	O
of	O
selective	O
factor	B-GP
Xa	E-GP
inhibitor	O
rivaroxaban	S-chemical
with	O
a	O
mimic	O
of	O
the	O
Arg-Gly-Asp	S-chemical
(	O
RGD	S-GP
)	O
sequence	O
of	O
fibrinogen	S-GP
to	O
obtain	O
designed	O
multiple	O
ligands	O
with	O
potential	O
antithrombotic	O
activity	O
.	O
Resulting	O
from	O
this	O
study	O
,	O
a	O
structurally	O
novel	O
class	O
of	O
submicromolar	O
fibrinogen	O
GPIIb/IIIa	S-GP
binding	O
inhibitor	O
bearing	O
1,2,4-oxadiazol-5	B-chemical
(	I-chemical
4H	I-chemical
)	I-chemical
-one	E-chemical
moiety	O
is	O
also	O
described	O
.	O

Differential	O
gene	O
expression	O
in	O
ERα	S-GP
-positive	O
and	O
ERα	S-GP
-negative	O
breast	O
cancer	O
cells	O
upon	O
leptin	S-GP
stimulation	O
.	O
In	O
postmenopausal	O
women	O
,	O
adipositas	O
represents	O
a	O
serious	O
risk	O
factor	O
for	O
cancer	O
development	O
and	O
progression	O
.	O
White	O
adipose	O
tissue	O
secretes	O
the	O
16	O
kDa	O
hormone	O
leptin	S-GP
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
regulation	O
of	O
appetite	O
and	O
metabolism	O
.	O
An	O
increasing	O
number	O
of	O
reports	O
indicate	O
that	O
leptin	S-GP
also	O
interferes	O
with	O
signal	O
transduction	O
pathways	O
implicated	O
in	O
the	O
development	O
of	O
breast	O
cancer	O
.	O
In	O
our	O
previous	O
study	O
,	O
we	O
identified	O
the	O
estrogen	B-GP
receptor	I-GP
alpha	E-GP
(	O
ERα	S-GP
)	O
as	O
a	O
relevant	O
enhancer	O
of	O
leptin	S-GP
-induced	O
signal	O
transduction	O
leading	O
to	O
transactivation	O
of	O
signal	B-GP
transducer	I-GP
and	I-GP
activator	I-GP
of	I-GP
transcription	I-GP
3	E-GP
(	O
Stat3	S-GP
)	O
.	O
The	O
purpose	O
of	O
this	O
study	O
is	O
the	O
investigation	O
of	O
specific	O
target	O
gene	O
expression	O
in	O
response	O
to	O
leptin	S-GP
-mediated	O
Stat3	S-GP
signaling	O
.	O
We	O
performed	O
a	O
comprehensive	O
microarray	O
analysis	O
of	O
ERα	S-GP
-positive	O
and	O
ERα	S-GP
-negative	O
MDA-MB-231	O
cells	O
upon	O
leptin	S-GP
treatment	O
and	O
identified	O
49	O
genes	O
which	O
showed	O
a	O
significant	O
ERα	S-GP
-dependent	O
regulation	O
in	O
leptin	S-GP
-treated	O
MDA-MB-231	O
cells	O
.	O
There	O
was	O
no	O
intersection	O
with	O
genes	O
which	O
were	O
merely	O
up-	O
or	O
downregulated	O
by	O
ERα	S-GP
expression	O
and	O
only	O
9	O
and	O
11	O
genes	O
overlapping	O
targets	O
which	O
were	O
regulated	O
by	O
leptin	S-GP
stimulation	O
either	O
in	O
ERα	S-GP
-expressing	O
or	O
ERα	S-GP
-negative	O
MDA-MB-231	O
cells	O
,	O
respectively	O
.	O
To	O
demonstrate	O
the	O
specificity	O
,	O
expression	O
of	O
three	O
target	O
genes	O
was	O
validated	O
by	O
quantitative	O
real-time	O
PCR	O
.	O
In	O
conclusion	O
,	O
these	O
data	O
imply	O
that	O
leptin	S-GP
can	O
induce	O
a	O
different	O
set	O
of	O
target	O
genes	O
dependent	O
on	O
ERα	S-GP
expression	O
,	O
which	O
might	O
contribute	O
to	O
the	O
development	O
and	O
progression	O
of	O
cancer	O
diseases	O
.	O

Immunoregulatory	O
effects	O
of	O
Glycyrrhizic	B-chemical
acid	E-chemical
exerts	O
anti-asthmatic	O
effects	O
via	O
modulation	O
of	O
Th1/Th2	O
cytokines	S-GP
and	O
enhancement	O
of	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
Foxp3	O
(	O
+	O
)	O
regulatory	O
T	O
cells	O
in	O
ovalbumin	S-GP
-sensitized	O
mice	O
.	O
ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Glycyrrhizic	B-chemical
acid	E-chemical
(	O
GA	O
)	O
is	O
the	O
main	O
bioactive	O
ingredient	O
of	O
licorice	O
(	O
Glycyrrhiza	O
glabra	O
)	O
,	O
and	O
has	O
been	O
found	O
to	O
be	O
associated	O
with	O
multiple	O
therapeutic	O
properties	O
.	O
AIM	O
OF	O
THE	O
STUDY	O
:	O
In	O
this	O
study	O
,	O
we	O
investigated	O
immunoregulatory	O
effects	O
of	O
glycyrrhizic	B-chemical
acid	E-chemical
on	O
anti-asthmatic	O
effects	O
and	O
underlying	O
mechanisms	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Asthma	O
model	O
was	O
established	O
by	O
ovalbumin	S-GP
-induced	O
.	O
A	O
total	O
of	O
60	O
mice	O
were	O
randomly	O
assigned	O
to	O
six	O
experimental	O
groups	O
:	O
control	O
,	O
model	O
,	O
dexamethasone	S-chemical
(	O
2mg/kg	O
)	O
and	O
GA	O
(	O
10mg/kg	O
,	O
20mg/kg	O
,	O
40mg/kg	O
)	O
.	O
Airway	O
resistance	O
(	O
Raw	O
)	O
were	O
measured	O
by	O
the	O
forced	O
oscillation	O
technique	O
,	O
histological	O
studies	O
were	O
evaluated	O
by	O
The	O
hematoxylin	S-chemical
and	O
eosin	S-chemical
(	O
HE	O
)	O
staining	O
,	O
Th1/Th2	O
and	O
Th17	O
cytokines	S-GP
were	O
evaluated	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
and	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
Foxp3	O
(	O
+	O
)	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
was	O
evaluated	O
by	O
Flow	O
Cytometry	O
(	O
FCM	O
)	O
,	O
the	O
forkhead/winged	B-GP
helix	I-GP
transcription	I-GP
factor	E-GP
(	O
Foxp3	S-GP
)	O
was	O
evaluated	O
by	O
western	O
blotting	O
.	O
RESULTS	O
:	O
Our	O
study	O
demonstrated	O
that	O
,	O
compared	O
with	O
model	O
group	O
,	O
GA	O
inhibited	O
OVA	S-GP
-induced	O
increases	O
in	O
Raw	O
and	O
eosinophil	O
count	O
;	O
interleukin	B-GP
(	I-GP
IL	I-GP
)	I-GP
-4	E-GP
,	O
IL-5	S-GP
,	O
IL-13	S-GP
levels	O
were	O
recovered	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
compared	O
;	O
increased	O
IFN-γ	S-GP
level	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
;	O
histological	O
studies	O
demonstrated	O
that	O
GA	O
substantially	O
inhibited	O
OVA	S-GP
-induced	O
eosinophilia	O
in	O
lung	O
tissue	O
and	O
airway	O
tissue	O
compared	O
with	O
model	O
group	O
.	O
Flow	O
cytometry	O
studies	O
demonstrated	O
that	O
GA	O
substantially	O
enhanced	O
Tregs	O
compared	O
with	O
model	O
group	O
.	O
CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
GA	O
may	O
effectively	O
ameliorate	O
the	O
progression	O
of	O
asthma	O
and	O
could	O
be	O
used	O
as	O
a	O
therapy	O
for	O
patients	O
with	O
allergic	O
asthma	O
.	O

Effect	O
of	O
cyproheptadine	S-chemical
on	O
serum	O
leptin	S-GP
levels	O
.	O
Leptin	S-GP
is	O
a	O
167	O
amino	B-chemical
acid	E-chemical
protein	O
encoded	O
by	O
the	O
obesity	O
gene	O
that	O
is	O
synthesized	O
in	O
adipose	O
tissue	O
and	O
interacts	O
with	O
receptors	O
in	O
the	O
hypothalamus	O
linked	O
to	O
the	O
regulation	O
of	O
appetite	O
and	O
metabolism	O
.	O
It	O
is	O
known	O
to	O
suppress	O
appetite	O
and	O
increase	O
energy	O
expenditure	O
.	O
Cyproheptadine	S-chemical
is	O
a	O
piperidine	S-chemical
antihistamine	S-chemical
that	O
increases	O
appetite	O
through	O
its	O
antiserotonergic	O
effect	O
on	O
5-HT2	S-GP
receptors	O
in	O
the	O
brain	O
.	O
Although	O
both	O
leptin	S-GP
and	O
cyproheptadine	S-chemical
are	O
effective	O
in	O
controlling	O
appetite	O
,	O
their	O
interaction	O
has	O
not	O
been	O
addressed	O
in	O
clinical	O
studies	O
.	O
This	O
study	O
evaluated	O
serum	O
leptin	O
concentrations	O
in	O
patients	O
who	O
received	O
cyproheptadine	S-chemical
to	O
treat	O
a	O
variety	O
of	O
disorders	O
.	O
Sixteen	O
patients	O
aged	O
7	O
to	O
71	O
years	O
(	O
mean	O
,	O
26.25	O
years	O
)	O
were	O
given	O
cyproheptadine	S-chemical
2	O
to	O
6	O
mg/day	O
for	O
a	O
minimum	O
of	O
7	O
days	O
.	O
Body	O
weight	O
was	O
measured	O
and	O
blood	O
samples	O
were	O
obtained	O
at	O
baseline	O
and	O
after	O
1	O
week	O
of	O
treatment	O
.	O
Serum	O
leptin	S-GP
levels	O
were	O
determined	O
by	O
leptin	S-GP
radioimmunoassay	O
.	O
The	O
mean	O
body	O
weight	O
at	O
baseline	O
(	O
52.59	O
kg	O
)	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
at	O
1	O
week	O
after	O
treatment	O
(	O
52.84	O
kg	O
;	O
P	O
>	O
.05	O
)	O
,	O
but	O
the	O
mean	O
leptin	S-GP
level	O
after	O
1	O
week	O
of	O
treatment	O
with	O
cyproheptadine	S-chemical
(	O
3.14	O
ng/mL	O
)	O
was	O
14.2	O
%	O
higher	O
than	O
that	O
at	O
baseline	O
(	O
2.75	O
ng/mL	O
;	O
P	O
<	O
.05	O
)	O
.	O
This	O
increase	O
may	O
suggest	O
that	O
both	O
leptin	S-GP
and	O
cyproheptadine	S-chemical
may	O
affect	O
appetite	O
via	O
similar	O
receptors	O
and	O
that	O
cyproheptadine	S-chemical
does	O
not	O
impair	O
leptin	O
activity	O
through	O
these	O
receptors	O
.	O
Further	O
study	O
will	O
be	O
necessary	O
to	O
clarify	O
this	O
relationship	O
.	O

Identification	O
of	O
amino	B-chemical
acids	E-chemical
in	O
the	O
factor	B-GP
XI	I-GP
apple	I-GP
3	I-GP
domain	E-GP
required	O
for	O
activation	O
of	O
factor	B-GP
IX	E-GP
.	O
Activated	B-GP
coagulation	I-GP
factor	I-GP
XI	E-GP
(	O
factor	B-GP
XIa	E-GP
)	O
proteolytically	O
cleaves	O
its	O
substrate	O
,	O
factor	B-GP
IX	E-GP
,	O
in	O
an	O
interaction	O
requiring	O
the	O
factor	B-GP
XI	I-GP
A3	I-GP
domain	E-GP
(	O
Sun	O
,	O
Y.	O
,	O
and	O
Gailani	O
,	O
D.	O
(	O
1996	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
271	O
,	O
29023-29028	O
)	O
.	O
To	O
identify	O
key	O
amino	B-chemical
acids	E-chemical
involved	O
in	O
factor	B-GP
IX	E-GP
activation	O
,	O
recombinant	O
factor	B-GP
XIa	E-GP
proteins	O
containing	O
alanine	S-chemical
substitutions	O
for	O
wild-type	O
sequence	O
were	O
expressed	O
in	O
293	O
fibroblasts	O
and	O
tested	O
in	O
a	O
plasma	O
clotting	O
assay	O
.	O
Substitutions	O
for	O
Ile	O
(	O
183	O
)	O
-Val	O
(	O
191	O
)	O
and	O
Ser	O
(	O
195	O
)	O
-Ile	O
(	O
197	O
)	O
at	O
the	O
N	S-chemical
terminus	O
and	O
for	O
Ser	O
(	O
258	O
)	O
-Ser	O
(	O
264	O
)	O
at	O
the	O
C	S-chemical
terminus	O
of	O
the	O
A3	B-GP
domain	E-GP
markedly	O
decreased	O
factor	B-GP
XI	E-GP
coagulant	O
activity	O
.	O
The	O
plasma	B-GP
protease	E-GP
prekallikrein	S-GP
is	O
structurally	O
homologous	O
to	O
factor	B-GP
XI	E-GP
,	O
but	O
activated	O
factor	B-GP
IX	E-GP
poorly	O
.	O
A	O
chimeric	O
factor	B-GP
XIa	E-GP
molecule	O
with	O
the	O
A3	B-GP
domain	E-GP
replaced	O
with	O
A3	O
from	O
prekallikrein	S-GP
(	O
FXI	S-GP
/	O
PKA3	S-GP
)	O
activated	B-GP
factor	I-GP
IX	E-GP
with	O
a	O
K	O
(	O
m	O
)	O
35-fold	O
greater	O
than	O
that	O
of	O
wild-type	O
factor	B-GP
XI	E-GP
.	O
FXI	S-GP
/	O
PKA3	S-GP
was	O
used	O
as	O
a	O
template	O
for	O
a	O
series	O
of	O
proteins	O
in	O
which	O
prekallikrein	S-GP
A3	O
sequence	O
was	O
replaced	O
with	O
factor	B-GP
XI	E-GP
sequence	O
to	O
restore	O
factor	B-GP
IX	E-GP
activation	O
.	O
Clotting	O
and	O
kinetics	O
studies	O
using	O
these	O
chimeras	O
confirmed	O
the	O
results	O
obtained	O
with	O
alanine	S-chemical
mutants	O
.	O
Amino	B-chemical
acids	E-chemical
between	O
Ile	O
(	O
183	O
)	O
and	O
Val	O
(	O
191	O
)	O
are	O
necessary	O
for	O
proper	O
factor	B-GP
IX	E-GP
activation	O
,	O
but	O
additional	O
sequence	O
between	O
Ser	O
(	O
195	O
)	O
and	O
Ile	O
(	O
197	O
)	O
or	O
between	O
Phe	O
(	O
260	O
)	O
and	O
Ser	O
(	O
265	O
)	O
is	O
required	O
for	O
complete	O
restoration	O
of	O
activation	O
.	O

The	O
dynamics	O
of	O
cobalamin	S-chemical
utilization	O
in	O
L-1210	O
mouse	O
leukemia	O
cells	O
:	O
a	O
model	O
of	O
cellular	O
cobalamin	S-chemical
metabolism	O
.	O
The	O
uptake	O
and	O
metabolism	O
of	O
cobalamin	S-chemical
(	O
Cbl	S-chemical
)	O
has	O
been	O
studied	O
in	O
L-1210	O
murine	O
leukemia	O
cells	O
propagating	O
in	O
vitro	O
.	O
Extracellular	O
Cbl	S-chemical
(	O
protein	O
bound	O
and	O
free	O
)	O
and	O
intracellular	O
Cbl	S-chemical
(	O
protein	O
bound	O
and	O
free	O
)	O
were	O
determined	O
after	O
culturing	O
L-1210	O
cells	O
in	O
the	O
presence	O
of	O
[	B-chemical
57Co	I-chemical
]	I-chemical
cyanocobalamin	E-chemical
(	O
CN-Cbl	S-chemical
)	O
bound	O
to	O
transcobalamin	B-GP
II	E-GP
(	O
transcobalamin	S-GP
,	O
TC	S-GP
)	O
.	O
The	O
intracellular	O
pool	O
of	O
free	O
[	B-chemical
57Co	I-chemical
]	I-chemical
Cbl	E-chemical
increased	O
during	O
the	O
first	O
24	O
h	O
of	O
culture	O
and	O
a	O
substantial	O
fraction	O
of	O
this	O
free	O
pool	O
was	O
effluxed	O
from	O
the	O
cell	O
to	O
the	O
medium	O
.	O
Upon	O
depletion	O
of	O
extracellular	O
TC-	B-chemical
[	I-chemical
57Co	I-chemical
]	I-chemical
CN-Cbl	E-chemical
,	O
the	O
intracellular	O
concentration	O
of	O
free	O
Cbl	S-chemical
decreased	O
as	O
did	O
the	O
efflux	O
of	O
Cbl	S-chemical
to	O
the	O
medium	O
.	O
Internalized	O
[	B-chemical
57Co	I-chemical
]	I-chemical
CN-Cbl	E-chemical
was	O
converted	O
to	O
hydroxocobalamin	S-chemical
(	O
OH-Cbl	S-chemical
)	O
,	O
methylcobalamin	S-chemical
(	O
Me-Cbl	S-chemical
)	O
and	O
5'-deoxyadenosylcobalamin	S-chemical
.	O
These	O
Cbl	S-chemical
forms	O
were	O
found	O
in	O
both	O
soluble	O
(	O
cytoplasmic	O
)	O
and	O
insoluble	O
(	O
membrane	O
)	O
fractions	O
.	O
Intracellular	O
protein-bound	O
[	B-chemical
57Co	I-chemical
]	I-chemical
Cbl	E-chemical
fractionated	O
with	O
methionine	B-GP
synthase	E-GP
(	O
MS	S-GP
)	O
and	O
methylmalonyl-CoA	B-GP
mutase	E-GP
(	O
MU	S-GP
)	O
activity	O
.	O
The	O
major	O
form	O
of	O
Cbl	S-chemical
associated	O
with	O
the	O
two	O
enzymes	O
was	O
OH-Cbl	S-chemical
.	O
Cells	O
propagated	O
in	O
medium	O
containing	O
N5-methyltetrahydrofolate	S-chemical
and	O
homocysteine	S-chemical
showed	O
a	O
substantial	O
increase	O
in	O
MS	S-GP
activity	O
which	O
paralleled	O
the	O
increase	O
in	O
the	O
intracellular	O
concentration	O
of	O
Me-Cbl	S-chemical
and	O
the	O
Cbl	S-chemical
bound	O
to	O
the	O
enzyme	O
.	O

Sophocarpine	S-chemical
alleviates	O
hepatocyte	O
steatosis	O
through	O
activating	O
AMPK	S-GP
signaling	O
pathway	O
.	O
Sophocarpine	S-chemical
,	O
an	O
effective	O
compound	O
derived	O
from	O
foxtail-like	O
sophora	O
herb	O
and	O
seed	O
,	O
has	O
been	O
reported	O
that	O
it	O
can	O
alleviate	O
non-alcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
in	O
rats	O
and	O
affect	O
adipocytokine	S-GP
synthesis	O
.	O
Meanwhile	O
,	O
adipocytokines	S-GP
could	O
adjust	O
hepatic	O
lipid	O
metabolism	O
through	O
AMPK	S-GP
signaling	O
pathway	O
.	O
In	O
the	O
work	O
presented	O
here	O
,	O
primary	O
hepatocytes	O
were	O
isolated	O
from	O
specific	O
pathogen-free	O
male	O
SD	O
rats	O
and	O
incubated	O
with	O
200	O
μmol/L	O
oleic	B-chemical
acid	E-chemical
for	O
24h	O
to	O
induce	O
steatotic	O
model	O
,	O
then	O
treated	O
with	O
sophocarpine	S-chemical
for	O
72	O
h.	O
Oil	O
red	O
staining	O
was	O
performed	O
to	O
evaluate	O
steatosis	O
,	O
total	O
RNA	O
and	O
protein	O
of	O
primary	O
hepatocytes	O
were	O
extracted	O
for	O
real-time	O
RT-PCR	O
and	O
western	O
blot	O
analysis	O
.	O
A	O
cluster	O
of	O
aberrances	O
were	O
observed	O
in	O
the	O
model	O
group	O
,	O
including	O
hepatocyte	O
steatosis	O
,	O
increased	O
leptin	S-GP
and	O
decreased	O
adiponectin	S-GP
mRNA	O
expressions	O
.	O
While	O
sophocarpine	S-chemical
treatment	O
resulted	O
in	O
:	O
significant	O
improvement	O
of	O
steatosis	O
(	O
>	O
50	O
%	O
decrease	O
)	O
,	O
decrease	O
of	O
leptin	S-GP
expression	O
(	O
<	O
0.57-fold	O
)	O
and	O
increase	O
of	O
adiponectin	S-GP
expression	O
(	O
>	O
1.48-fold	O
)	O
.	O
Moreover	O
,	O
compared	O
with	O
the	O
model	O
group	O
,	O
sophocarpine	S-chemical
could	O
significantly	O
increase	O
P-AMPKα	S-GP
(	O
>	O
5.82-fold	O
)	O
,	O
AMPKα	S-GP
(	O
>	O
1.29-fold	O
)	O
and	O
ACC	S-GP
(	O
>	O
3.27-fold	O
)	O
protein	O
expressions	O
,	O
and	O
reduce	O
P-ACC	S-GP
(	O
<	O
0.30-fold	O
)	O
and	O
HNF-4α	S-GP
(	O
<	O
0.20-fold	O
)	O
protein	O
expression	O
.	O
The	O
mRNA	O
expression	O
of	O
Srebp-1c	S-GP
was	O
downregulated	O
significantly	O
simultaneously	O
(	O
<	O
0.68-fold	O
)	O
.	O
We	O
concluded	O
that	O
sophocarpine	S-chemical
could	O
alleviate	O
hepatocyte	O
steatosis	O
and	O
the	O
potential	O
mechanism	O
might	O
be	O
the	O
activated	O
signaling	O
pathway	O
of	O
AMPK	S-GP
.	O

Synthesis	O
of	O
pyrazolo	B-chemical
[	I-chemical
1,5-a	I-chemical
]	I-chemical
pyrimidine	E-chemical
linked	O
aminobenzothiazole	S-chemical
conjugates	O
as	O
potential	O
anticancer	O
agents	O
.	O
A	O
series	O
of	O
pyrazolo	B-chemical
[	I-chemical
1,5-a	I-chemical
]	I-chemical
pyrimidine	E-chemical
linked	O
2-aminobenzothizole	S-chemical
conjugates	O
(	O
6a-t	O
)	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anticancer	O
activity	O
against	O
five	O
human	O
cancer	O
cell	O
lines	O
.	O
Among	O
them	O
two	O
compounds	O
6p	O
and	O
6m	O
showed	O
significant	O
anticancer	O
activity	O
with	O
IC50	O
values	O
ranging	O
from	O
2.01	O
to	O
7.07	O
and	O
1.94-3.46μM	O
,	O
respectively	O
.	O
Moreover	O
,	O
cell	O
cycle	O
arrest	O
in	O
G2/M	O
and	O
reduction	O
in	O
Cdk1	S-GP
expression	O
level	O
were	O
observed	O
upon	O
treatment	O
of	O
these	O
compounds	O
and	O
they	O
also	O
induced	O
caspase-3	S-GP
dependent	O
apoptosis	O
.	O
This	O
was	O
further	O
confirmed	O
by	O
staining	O
as	O
well	O
as	O
DNA	O
fragmentation	O
analysis	O
.	O

Study	O
of	O
the	O
nematode	O
putative	O
GABA	B-GP
type-A	I-GP
receptor	E-GP
subunits	O
:	O
evidence	O
for	O
modulation	O
by	O
ivermectin	S-chemical
.	O
Two	O
alleles	O
of	O
the	O
HG1	S-GP
gene	O
,	O
which	O
encodes	O
a	O
putative	O
GABA	B-GP
receptor	I-GP
alpha/gamma	E-GP
subunit	O
,	O
were	O
isolated	O
from	O
Haemonchus	O
contortus	O
.	O
These	O
two	O
alleles	O
were	O
shown	O
previously	O
to	O
be	O
associated	O
with	O
ivermectin	S-chemical
susceptibility	O
(	O
HG1A	S-GP
)	O
and	O
resistance	O
(	O
HG1E	S-GP
)	O
,	O
respectively	O
.	O
Sequence	O
analysis	O
indicates	O
that	O
they	O
differ	O
in	O
four	O
amino	B-chemical
acids	E-chemical
.	O
To	O
explore	O
the	O
functional	O
properties	O
of	O
the	O
two	O
alleles	O
,	O
a	O
full-length	O
cDNA	O
encoding	O
the	O
beta	O
subunit	O
,	O
a	O
key	O
functional	O
component	O
of	O
the	O
GABA	B-GP
receptor	E-GP
,	O
was	O
isolated	O
from	O
Caenorhabditis	O
elegans	O
(	O
gab-1	S-GP
,	O
corresponding	O
to	O
the	O
GenBank	B-GP
locus	I-GP
ZC482.1	E-GP
)	O
and	O
coexpressed	O
in	O
Xenopus	O
oocytes	O
with	O
the	O
HG1	S-GP
alleles	O
.	O
When	O
gab-1	S-GP
was	O
coexpressed	O
with	O
either	O
the	O
HG1A	S-GP
allele	O
or	O
the	O
HG1E	S-GP
allele	O
in	O
Xenopus	O
oocytes	O
,	O
gamma-aminobutyric	B-GP
acid	I-GP
(	I-GP
GABA	I-GP
)	I-GP
-responsive	I-GP
channels	E-GP
with	O
different	O
sensitivity	O
to	O
the	O
agonist	O
were	O
formed	O
.	O
The	O
effects	O
of	O
ivermectin	S-chemical
on	O
the	O
hetero-oligomeric	O
receptors	O
were	O
determined	O
.	O
Application	O
of	O
ivermectin	S-chemical
alone	O
had	O
no	O
effect	O
on	O
the	O
receptors	O
.	O
However	O
,	O
when	O
coapplied	O
with	O
10	O
micro	O
m	O
GABA	S-chemical
,	O
ivermectin	S-chemical
potentiated	O
the	O
GABA	S-chemical
-evoked	O
current	O
of	O
the	O
GAB-1	S-GP
/	O
HG1A	S-GP
receptor	O
,	O
but	O
attenuated	O
the	O
GABA	S-chemical
response	O
of	O
the	O
GAB-1	S-GP
/	O
HG1E	S-GP
receptor	O
.	O
We	O
demonstrated	O
that	O
the	O
coexpressed	O
HG1	S-GP
and	O
GAB-1	S-GP
receptors	O
are	O
GABA	S-chemical
-responsive	O
,	O
and	O
provide	O
evidence	O
for	O
the	O
possible	O
involvement	O
of	O
GABA	B-GP
receptors	E-GP
in	O
the	O
mechanism	O
of	O
ivermectin	S-chemical
resistance	O
.	O

Dendritic	O
cell	O
migration	O
assay	O
:	O
a	O
potential	O
prediction	O
model	O
for	O
identification	O
of	O
contact	O
allergens	O
.	O
This	O
manuscript	O
describes	O
methodology	O
and	O
a	O
prediction	O
model	O
for	O
the	O
MUTZ-LC	O
migration	O
assay	O
.	O
The	O
assay	O
represents	O
the	O
physiological	O
change	O
in	O
Langerhans	O
cell	O
(	O
LC	O
)	O
behavior	O
after	O
exposure	O
to	O
a	O
sensitizing	O
chemical	O
,	O
resulting	O
in	O
LC	O
migration	O
from	O
the	O
epidermis	O
to	O
the	O
dermis	O
.	O
MUTZ-LC	O
are	O
derived	O
from	O
the	O
commercially	O
available	O
MUTZ-3	O
cell	O
line	O
.	O
Upon	O
exposure	O
to	O
a	O
sensitizer	O
MUTZ-LC	O
migrate	O
preferentially	O
towards	O
CXCL12	S-GP
whereas	O
upon	O
exposure	O
to	O
a	O
non-sensitizer	O
MUTZ-LC	O
migrate	O
towards	O
CCL5	S-GP
.	O
A	O
CXCL12	S-GP
/	O
CCL5	S-GP
ratio	O
>	O
1.10	O
in	O
2/3	O
independent	O
experiments	O
is	O
indicative	O
of	O
a	O
sensitizer	O
,	O
whereas	O
a	O
CXCL12	S-GP
/	O
CCL5	S-GP
ratio	O
≤1.10	O
is	O
indicative	O
of	O
a	O
non-sensitizer	O
.	O
At	O
non	O
cytotoxic	O
chemical	O
concentrations	O
9	O
sensitizers	O
(	O
2,4-dinitrochlorobenzene	S-chemical
,	O
paraphenylendiamine	S-chemical
,	O
cinnamaldehyde	S-chemical
,	O
isoeugenol	S-chemical
,	O
nickel-sulfate	S-chemical
,	O
tetramethylthiuram	B-chemical
disulfide	E-chemical
,	O
eugenol	S-chemical
,	O
cinnamic-alcohol	S-chemical
,	O
ammonium-hexachloroplatinate	S-chemical
)	O
were	O
distinguished	O
from	O
4	O
non	O
sensitizers	O
(	O
sodium	B-chemical
lauryl	I-chemical
sulfate	E-chemical
,	O
salicylic	B-chemical
acid	E-chemical
,	O
phenol	S-chemical
,	O
octanoic	B-chemical
acid	E-chemical
)	O
.	O
Critical	O
points	O
in	O
assay	O
performance	O
are	O
(	O
i	O
)	O
MUTZ-3	O
passage	O
number	O
after	O
thawing	O
(	O
p6-p40	O
)	O
;	O
(	O
ii	O
)	O
cell	O
viability	O
(	O
>	O
80	O
%	O
)	O
;	O
(	O
iii	O
)	O
standard	O
curve	O
to	O
optimize	O
correlation	O
of	O
fluorescence	O
with	O
cell	O
number	O
;	O
and	O
(	O
iv	O
)	O
optimization	O
of	O
the	O
concentration	O
of	O
rhCXCL12	S-GP
and	O
rhCCL5	S-GP
in	O
transwell	O
.	O
The	O
protocol	O
has	O
been	O
tested	O
in	O
three	O
European	O
laboratories	O
and	O
results	O
suggest	O
that	O
it	O
may	O
provide	O
working	O
conditions	O
for	O
performing	O
the	O
DC	O
migration	O
assay	O
which	O
is	O
aimed	O
at	O
distinguishing	O
sensitizers	O
from	O
non	O
sensitizers	O
.	O

Evidence	O
for	O
genetic	O
heterogeneity	O
of	O
pseudohypoaldosteronism	O
type	O
1	O
:	O
identification	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
human	B-GP
mineralocorticoid	I-GP
receptor	E-GP
in	O
one	O
sporadic	O
case	O
and	O
no	O
mutations	O
in	O
two	O
autosomal	O
dominant	O
kindreds	O
.	O
Pseudohypoaldosteronism	O
type	O
1	O
(	O
PHA1	O
)	O
is	O
characterized	O
by	O
neonatal	O
salt	O
wasting	O
resistant	O
to	O
mineralocorticoids	O
.	O
There	O
are	O
2	O
forms	O
of	O
PHA1	O
:	O
the	O
autosomal	O
recessive	O
form	O
with	O
symptoms	O
persisting	O
into	O
adulthood	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
amiloride-sensitive	B-GP
luminal	I-GP
sodium	I-GP
channel	E-GP
,	O
and	O
the	O
autosomal	O
dominant	O
or	O
sporadic	O
form	O
,	O
which	O
shows	O
milder	O
symptoms	O
that	O
remit	O
with	O
age	O
.	O
Mutations	O
in	O
the	O
gene	O
encoding	O
the	O
human	B-GP
mineralocorticoid	I-GP
receptor	E-GP
(	O
hMR	S-GP
)	O
are	O
,	O
at	O
least	O
in	O
some	O
patients	O
,	O
responsible	O
for	O
the	O
latter	O
form	O
of	O
PHA1	O
.	O
We	O
here	O
report	O
the	O
results	O
of	O
a	O
genetic	O
study	O
in	O
a	O
sporadic	O
case	O
and	O
in	O
5	O
affected	O
patients	O
from	O
2	O
families	O
with	O
autosomal	O
dominant	O
PHA1	O
.	O
In	O
the	O
sporadic	O
case	O
we	O
identified	O
a	O
new	O
frameshift	O
mutation	O
,	O
Ins2871C	S-GP
,	O
in	O
exon	O
9	O
of	O
the	O
hMR	S-GP
gene	O
.	O
Family	O
members	O
were	O
asymptomatic	O
and	O
had	O
no	O
mutation	O
.	O
This	O
mutation	O
is	O
the	O
first	O
described	O
in	O
exon	O
9	O
and	O
impairs	O
the	O
last	O
27	O
amino	B-chemical
acids	E-chemical
of	O
the	O
hormone-binding	B-GP
domain	E-GP
.	O
In	O
2	O
kindreds	O
with	O
autosomal	O
dominant	O
PHA1	O
we	O
found	O
no	O
mutation	O
of	O
the	O
hMR	S-GP
gene	O
.	O
Our	O
results	O
confirm	O
the	O
hypothesis	O
that	O
autosomal	O
dominant	O
or	O
sporadic	O
PHA1	O
is	O
a	O
genetically	O
heterogeneous	O
disease	O
involving	O
other	O
,	O
as	O
yet	O
unidentified	O
,	O
genes	O
.	O

NMDA	B-GP
receptors	E-GP
are	O
not	O
alone	O
:	O
dynamic	O
regulation	O
of	O
NMDA	B-GP
receptor	E-GP
structure	O
and	O
function	O
by	O
neuregulins	S-GP
and	O
transient	B-GP
cholesterol-rich	I-GP
membrane	I-GP
domains	E-GP
leads	O
to	O
disease-specific	O
nuances	O
of	O
glutamate	S-chemical
-signalling	O
.	O
Glutamate	B-GP
receptors	E-GP
of	O
the	O
N-methyl-D-asparate	S-chemical
(	O
NMDA	S-chemical
-	O
)	O
subtype	O
are	O
tetrameric	O
allosteric	O
and	O
ligand-gated	B-GP
calcium	I-GP
channels	E-GP
.	O
They	O
are	O
modulated	O
by	O
a	O
variety	O
of	O
endogenous	O
ligands	O
and	O
ions	O
and	O
play	O
a	O
pivotal	O
role	O
in	O
memory-related	O
signal	O
transduction	O
due	O
to	O
a	O
voltage-dependent	O
block	O
by	O
magnesium	S-chemical
,	O
which	O
makes	O
them	O
Hebbian	O
coincidence	O
detectors	O
.	O
On	O
the	O
structural	O
level	O
NMDA	B-GP
receptors	E-GP
have	O
an	O
enormous	O
flexibility	O
due	O
to	O
seven	O
genes	O
(	O
NR1	S-GP
,	O
NR2A-D	S-GP
and	O
NR3A-B	S-GP
)	O
,	O
alternative	O
splicing	O
,	O
RNA-editing	O
and	O
extensive	O
posttranslational	O
modifications	O
,	O
like	O
phosphorylation	O
and	O
glycosylation	O
.	O
NMDA	B-GP
receptors	E-GP
are	O
thought	O
to	O
be	O
responsible	O
for	O
excitotoxicity	O
and	O
subsequent	O
downstream	O
events	O
like	O
neuroinflammation	O
and	O
apoptosis	O
and	O
thus	O
have	O
been	O
implicated	O
in	O
many	O
important	O
human	O
pathologies	O
,	O
ranging	O
from	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
Alzheimer	O
's	O
and	O
Parkinson	O
'	O
disease	O
,	O
depression	O
,	O
epilepsy	O
,	O
trauma	O
and	O
stroke	O
to	O
schizophrenia	O
.	O
This	O
fundamental	O
significance	O
of	O
NMDA	B-GP
receptor	E-GP
-related	O
excitotoxicity	O
is	O
discussed	O
in	O
the	O
context	O
of	O
the	O
developing	O
clinical	O
success	O
of	O
Memantine	S-chemical
,	O
but	O
moreover	O
set	O
into	O
relation	O
to	O
various	O
proteomic	O
and	O
genetic	O
markers	O
of	O
said	O
diseases	O
.	O
The	O
very	O
complex	O
localisational	O
and	O
functional	O
regulation	O
of	O
NMDA	B-GP
receptors	E-GP
appears	O
to	O
be	O
dependent	O
on	O
neuregulins	S-GP
and	O
receptor	B-GP
tyrosine	I-GP
kinases	E-GP
in	O
cholesterol	S-chemical
-rich	O
membrane	O
domains	O
(	O
lipid	O
rafts	O
)	O
,	O
calcium	S-chemical
-related	O
mitochondrial	O
feedback-loops	O
and	O
subsynaptic	O
structural	O
elements	O
like	O
PSD-95	S-GP
(	O
post-synaptic	B-GP
density	I-GP
protein	I-GP
of	I-GP
95	I-GP
kD	E-GP
)	O
.	O
The	O
flexibility	O
and	O
multitude	O
of	O
interaction	O
partners	O
and	O
possibilities	O
of	O
these	O
highly	O
dynamic	O
molecular	O
systems	O
are	O
discussed	O
in	O
terms	O
of	O
drug	O
development	O
strategies	O
,	O
in	O
particular	O
comparing	O
high	O
affinity	O
and	O
sub-type	O
specific	O
ligands	O
to	O
currently	O
successful	O
or	O
promising	O
therapies	O
.	O

Lipid	O
specific	O
activation	O
of	O
the	O
murine	B-GP
P4-ATPase	E-GP
Atp8a1	S-GP
(	O
ATPase	B-GP
II	E-GP
)	O
.	O
The	O
asymmetric	O
transbilayer	O
distribution	O
of	O
phosphatidylserine	S-chemical
(	O
PS	S-chemical
)	O
in	O
the	O
mammalian	O
plasma	O
membrane	O
and	O
secretory	O
vesicles	O
is	O
maintained	O
,	O
in	O
part	O
,	O
by	O
an	O
ATP	S-chemical
-dependent	O
transporter	O
.	O
This	O
aminophospholipid	O
``	O
flippase	S-GP
``	O
selectively	O
transports	O
PS	S-chemical
to	O
the	O
cytosolic	O
leaflet	O
of	O
the	O
bilayer	O
and	O
is	O
sensitive	O
to	O
vanadate	S-chemical
,	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
,	O
and	O
modification	O
by	O
sulfhydryl	S-chemical
reagents	O
.	O
Although	O
the	O
flippase	S-GP
has	O
not	O
been	O
positively	O
identified	O
,	O
a	O
subfamily	O
of	O
P-type	B-GP
ATPases	E-GP
has	O
been	O
proposed	O
to	O
function	O
as	O
transporters	O
of	O
amphipaths	O
,	O
including	O
PS	O
and	O
other	O
phospholipids	O
.	O
A	O
candidate	O
PS	B-GP
flippase	I-GP
ATP8A1	E-GP
(	O
ATPase	B-GP
II	E-GP
)	O
,	O
originally	O
isolated	O
from	O
bovine	O
secretory	O
vesicles	O
,	O
is	O
a	O
member	O
of	O
this	O
subfamily	O
based	O
on	O
sequence	O
homology	O
to	O
the	O
founding	O
member	O
of	O
the	O
subfamily	O
,	O
the	O
yeast	B-GP
protein	I-GP
Drs2	E-GP
,	O
which	O
has	O
been	O
linked	O
to	O
ribosomal	O
assembly	O
,	O
the	O
formation	O
of	O
Golgi-coated	O
vesicles	O
,	O
and	O
the	O
maintenance	O
of	O
PS	O
asymmetry	O
.	O
To	O
determine	O
if	O
ATP8A1	S-GP
has	O
biochemical	O
characteristics	O
consistent	O
with	O
a	O
PS	B-GP
flippase	E-GP
,	O
a	O
murine	O
homologue	O
of	O
this	O
enzyme	O
was	O
expressed	O
in	O
insect	O
cells	O
and	O
purified	O
.	O
The	O
purified	O
Atp8a1	S-GP
is	O
inactive	O
in	O
detergent	O
micelles	O
or	O
in	O
micelles	O
containing	O
phosphatidylcholine	S-chemical
,	O
phosphatidic	B-chemical
acid	E-chemical
,	O
or	O
phosphatidylinositol	S-chemical
,	O
is	O
minimally	O
activated	O
by	O
phosphatidylglycerol	S-chemical
or	O
phosphatidylethanolamine	S-chemical
(	O
PE	S-chemical
)	O
,	O
and	O
is	O
maximally	O
activated	O
by	O
PS	S-chemical
.	O
The	O
selectivity	O
for	O
PS	S-chemical
is	O
dependent	O
upon	O
multiple	O
elements	O
of	O
the	O
lipid	O
structure	O
.	O
Similar	O
to	O
the	O
plasma	B-GP
membrane	I-GP
PS	I-GP
transporter	E-GP
,	O
Atp8a1	S-GP
is	O
activated	O
only	O
by	O
the	O
naturally	O
occurring	O
sn-1,2-glycerol	S-chemical
isomer	O
of	O
PS	O
and	O
not	O
the	O
sn-2,3-glycerol	S-chemical
stereoisomer	O
.	O
Both	O
flippase	S-GP
and	O
Atp8a1	S-GP
activities	O
are	O
insensitive	O
to	O
the	O
stereochemistry	O
of	O
the	O
serine	O
headgroup	O
.	O
Most	O
modifications	O
of	O
the	O
PS	S-chemical
headgroup	O
structure	O
decrease	O
recognition	O
by	O
the	O
plasma	O
membrane	O
PS	B-GP
flippase	E-GP
.	O
Activation	O
of	O
Atp8a1	S-GP
is	O
also	O
reduced	O
by	O
these	O
modifications	O
;	O
phosphatidylserine-O-methyl	B-chemical
ester	E-chemical
,	O
lysophosphatidylserine	S-chemical
,	O
glycerophosphoserine	S-chemical
,	O
and	O
phosphoserine	S-chemical
,	O
which	O
are	O
not	O
transported	O
by	O
the	O
plasma	O
membrane	O
flippase	O
,	O
do	O
not	O
activate	O
Atp8a1	S-GP
.	O
Weakly	O
translocated	O
lipids	O
(	O
PE	S-chemical
,	O
phosphatidylhydroxypropionate	S-chemical
,	O
and	O
phosphatidylhomoserine	S-chemical
)	O
are	O
also	O
weak	O
Atp8a1	S-GP
activators	O
.	O
However	O
,	O
N-methyl-phosphatidylserine	S-chemical
,	O
which	O
is	O
transported	O
by	O
the	O
plasma	O
membrane	O
flippase	S-GP
at	O
a	O
rate	O
equivalent	O
to	O
PS	S-chemical
,	O
is	O
incapable	O
of	O
activating	O
Atp8a1	S-GP
activity	O
.	O
These	O
results	O
indicate	O
that	O
the	O
ATPase	S-GP
activity	O
of	O
the	O
secretory	O
granule	O
Atp8a1	S-GP
is	O
activated	O
by	O
phospholipids	O
binding	O
to	O
a	O
specific	O
site	O
whose	O
properties	O
(	O
PS	S-chemical
selectivity	O
,	O
dependence	O
upon	O
glycerol	S-chemical
but	O
not	O
serine	S-chemical
,	O
stereochemistry	O
,	O
and	O
vanadate	O
sensitivity	O
)	O
are	O
similar	O
to	O
,	O
but	O
distinct	O
from	O
,	O
the	O
properties	O
of	O
the	O
substrate	O
binding	O
site	O
of	O
the	O
plasma	O
membrane	O
flippase	S-GP
.	O

Inhibition	O
of	O
ghrelin	B-GP
O-acyltransferase	E-GP
attenuates	O
food	O
deprivation-induced	O
increases	O
in	O
ingestive	O
behavior	O
.	O
Ghrelin	S-GP
is	O
an	O
orexigenic	B-GP
hormone	E-GP
produced	O
by	O
the	O
stomach	O
in	O
direct	O
proportion	O
to	O
the	O
time	O
since	O
the	O
last	O
meal	O
and	O
has	O
therefore	O
been	O
called	O
a	O
'hunger	O
signal	O
'	O
.	O
The	O
octanoylation	O
of	O
ghrelin	S-GP
is	O
critical	O
for	O
its	O
orexigenic	O
functions	O
and	O
is	O
dependent	O
upon	O
ghrelin	B-GP
O-acyltransferase	E-GP
(	O
GOAT	S-GP
)	O
catalyzation	O
.	O
The	O
GOAT	S-GP
inhibitor	O
,	O
GO-CoA-Tat	O
,	O
decreases	O
the	O
circulating	O
concentrations	O
of	O
octanoylated	B-GP
ghrelin	E-GP
and	O
attenuates	O
weight	O
gain	O
on	O
a	O
high	O
fat	O
diet	O
in	O
mice	O
.	O
Unlike	O
rats	O
and	O
mice	O
,	O
Siberian	O
hamsters	O
and	O
humans	O
do	O
not	O
increase	O
food	O
intake	O
after	O
food	O
deprivation	O
,	O
but	O
increase	O
food	O
hoarding	O
after	O
food	O
deprivation	O
.	O
In	O
Siberian	O
hamsters	O
,	O
exogenous	O
ghrelin	S-GP
increases	O
ingestive	O
behaviors	O
similarly	O
to	O
48-56h	O
food	O
deprivation	O
.	O
Therefore	O
,	O
we	O
tested	O
the	O
necessity	O
of	O
increased	O
ghrelin	S-GP
in	O
food-deprived	O
Siberian	O
hamsters	O
to	O
stimulate	O
ingestive	O
behaviors	O
.	O
To	O
do	O
so	O
we	O
used	O
our	O
simulated	O
natural	O
housing	O
system	O
that	O
allows	O
hamsters	O
to	O
forage	O
for	O
and	O
hoard	O
food	O
.	O
Animals	O
were	O
given	O
an	O
injection	O
of	O
GO-CoA-Tat	O
(	O
i.p.	O
,	O
11μmol/kg	O
)	O
every	O
6h	O
because	O
that	O
is	O
the	O
duration	O
of	O
its	O
effective	O
inhibition	O
of	O
octanoylated	B-GP
ghrelin	E-GP
concentrations	O
during	O
a	O
48h	O
food	O
deprivation	O
.	O
We	O
found	O
that	O
GO-CoA-Tat	O
attenuated	O
food	O
foraging	O
(	O
0-1h	O
)	O
,	O
food	O
intake	O
(	O
0-1	O
and	O
2-4h	O
)	O
,	O
and	O
food	O
hoarding	O
(	O
0-1h	O
and	O
2	O
and	O
3days	O
)	O
post-refeeding	O
compared	O
with	O
saline	O
treated	O
animals	O
.	O
This	O
suggests	O
that	O
increased	O
octanoylated	B-GP
ghrelin	E-GP
concentrations	O
play	O
a	O
role	O
in	O
the	O
food	O
deprivation-induced	O
increases	O
in	O
ingestive	O
behavior	O
.	O
Therefore	O
,	O
ghrelin	S-GP
is	O
a	O
critical	O
aspect	O
of	O
the	O
multi-faceted	O
mechanisms	O
that	O
stimulate	O
ingestive	O
behaviors	O
,	O
and	O
might	O
be	O
a	O
critical	O
point	O
for	O
a	O
successful	O
clinical	O
intervention	O
scheme	O
in	O
humans	O
.	O

Effect	O
of	O
amrinone	S-chemical
on	O
tumor	B-GP
necrosis	I-GP
factor	E-GP
production	O
in	O
endotoxic	O
shock	O
.	O
Tumor	B-GP
necrosis	I-GP
factor	E-GP
(	O
TNF	S-GP
)	O
is	O
a	O
macrophage-derived	O
mediator	O
responsible	O
for	O
many	O
of	O
the	O
pathophysiologic	O
manifestations	O
of	O
endotoxic	O
shock	O
.	O
We	O
now	O
demonstrate	O
that	O
amrinone	S-chemical
,	O
a	O
noncatechol	O
inotrope	O
,	O
strongly	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
TNF	S-GP
production	O
at	O
concentrations	O
readily	O
achieved	O
in	O
vivo	O
.	O
This	O
inhibition	O
is	O
apparent	O
in	O
murine	O
macrophages	O
,	O
in	O
macrophage	O
cell	O
lines	O
,	O
in	O
vivo	O
,	O
and	O
in	O
cell	O
lines	O
containing	O
a	O
reporter	O
gene	O
construct	O
that	O
substitutes	O
the	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
coding	O
sequence	O
for	O
the	O
TNF	S-GP
coding	O
sequence	O
and	O
introns	O
.	O
Inhibition	O
by	O
amrinone	S-chemical
(	O
like	O
inhibition	O
by	O
pentoxifylline	S-chemical
)	O
is	O
manifested	O
at	O
the	O
level	O
of	O
mRNA	O
accumulation	O
,	O
in	O
contrast	O
to	O
inhibition	O
caused	O
by	O
dexamethasone	S-chemical
.	O
Combined	O
application	O
of	O
dexamethasone	S-chemical
and	O
amrinone	S-chemical
caused	O
additive	O
inhibition	O
of	O
TNF	S-GP
biosynthesis	O
in	O
vitro	O
.	O
Furthermore	O
,	O
treatment	O
of	O
mice	O
with	O
amrinone	S-chemical
immediately	O
prior	O
to	O
endotoxin	O
challenge	O
led	O
to	O
significantly	O
improved	O
survival	O
.	O
These	O
findings	O
suggest	O
that	O
amrinone	S-chemical
possesses	O
antiinflammatory	O
as	O
well	O
as	O
inotropic	O
properties	O
that	O
may	O
make	O
it	O
an	O
appropriate	O
agent	O
for	O
use	O
in	O
septic	O
shock	O
or	O
other	O
serious	O
bacterial	O
infections	O
.	O
Abrupt	O
removal	O
of	O
amrinone	S-chemical
or	O
pentoxifylline	S-chemical
from	O
the	O
culture	O
medium	O
prior	O
to	O
LPS	O
stimulation	O
,	O
however	O
,	O
caused	O
significantly	O
augmented	O
TNF	S-GP
production	O
.	O
Therefore	O
,	O
amrinone	S-chemical
and	O
other	O
phosphodiesterase	S-GP
inhibitors	O
may	O
also	O
enhance	O
sensitivity	O
to	O
LPS	O
during	O
a	O
period	O
of	O
time	O
following	O
discontinuation	O
of	O
therapy	O
.	O

Effect	O
of	O
chronic	O
renal	O
failure	O
on	O
arginase	S-GP
and	O
argininosuccinate	B-GP
synthetase	E-GP
expression	O
.	O
BACKGROUND	O
:	O
L-arginine	S-chemical
(	O
L-arg	S-chemical
)	O
participates	O
in	O
numerous	O
biological	O
functions	O
including	O
urea	S-chemical
and	O
nitric	B-chemical
oxide	E-chemical
synthesis	O
.	O
Sources	O
of	O
L-arg	S-chemical
include	O
dietary	O
proteins	O
and	O
endogenous	O
synthesis	O
by	O
argininosuccinate	B-GP
synthetase	E-GP
and	O
argininosuccinate	B-GP
lyase	E-GP
.	O
L-arg	S-chemical
is	O
converted	O
to	O
urea	S-chemical
by	O
arginase	B-GP
I	E-GP
in	O
the	O
liver	O
and	O
arginase	B-GP
II	E-GP
in	O
the	O
kidney	O
.	O
Normally	O
,	O
the	O
liver	O
fully	O
consumes	O
L-arg	S-chemical
for	O
urea	S-chemical
generation	O
and	O
does	O
not	O
contribute	O
to	O
its	O
circulating	O
pool	O
.	O
Instead	O
,	O
much	O
of	O
the	O
circulating	O
L-arg	S-chemical
is	O
produced	O
by	O
the	O
kidney	O
.	O
If	O
true	O
,	O
plasma	O
L-arg	S-chemical
should	O
be	O
severely	O
reduced	O
in	O
chronic	O
renal	O
failure	O
(	O
CRF	O
)	O
;	O
however	O
,	O
plasma	O
L-arg	S-chemical
is	O
frequently	O
unchanged	O
in	O
CRF	O
.	O
We	O
hypothesized	O
that	O
preservation	O
of	O
plasma	O
L-arg	S-chemical
in	O
CRF	O
may	O
be	O
,	O
partly	O
,	O
due	O
to	O
downregulation/inhibition	O
of	O
arginase	S-GP
.	O
METHODS	O
:	O
Argininosuccinate	B-GP
synthetase	E-GP
,	O
arginase	B-GP
I	I-GP
and	I-GP
II	E-GP
protein	O
abundance	O
and	O
activity	O
were	O
measured	O
in	O
the	O
liver	O
and	O
kidneys	O
of	O
rats	O
6	O
weeks	O
after	O
5/6	O
nephrectomy	O
or	O
sham	O
operation	O
.	O
In	O
addition	O
,	O
arginase	S-GP
activity	O
was	O
measured	O
in	O
the	O
presence	O
of	O
different	O
urea	S-chemical
concentrations	O
to	O
simulate	O
azotemia	O
in	O
vitro	O
.	O
RESULTS	O
:	O
Arginases	B-GP
I	I-GP
and	I-GP
II	E-GP
protein	O
abundance	O
as	O
well	O
as	O
arginase	S-GP
activity	O
in	O
the	O
liver	O
,	O
measured	O
in	O
the	O
physiological	O
buffer	O
,	O
were	O
similar	O
among	O
the	O
CRF	O
and	O
control	O
groups	O
.	O
However	O
,	O
in	O
vitro	O
experiments	O
simulating	O
a	O
uremic	O
milieu	O
revealed	O
a	O
marked	O
concentration-dependent	O
inhibition	O
of	O
arginase	S-GP
activity	O
by	O
urea	S-chemical
in	O
the	O
tissue	O
lysates	O
.	O
CRF	O
had	O
no	O
significant	O
effect	O
on	O
argininosuccinate	B-GP
synthetase	E-GP
abundance	O
in	O
the	O
kidney	O
,	O
liver	O
,	O
spleen	O
or	O
intestine	O
.	O
CONCLUSIONS	O
:	O
Although	O
CRF	O
does	O
not	O
change	O
the	O
abundance	O
or	O
intrinsic	O
properties	O
of	O
arginase	S-GP
,	O
the	O
inherent	O
rise	O
in	O
urea	S-chemical
concentration	O
inhibits	O
its	O
enzymatic	O
activity	O
.	O
The	O
latter	O
,	O
in	O
turn	O
,	O
attenuates	O
L-arg	S-chemical
catabolism	O
and	O
urea	O
production	O
and	O
,	O
thereby	O
,	O
mitigates	O
the	O
fall	O
in	O
plasma	O
L-arg	S-chemical
.	O

Increased	O
Cat3	S-GP
-mediated	O
cationic	O
amino	B-chemical
acid	E-chemical
transport	O
functionally	O
compensates	O
in	O
Cat1	S-GP
knockout	O
cell	O
lines	O
.	O
Arginine	S-chemical
transport	O
is	O
important	O
for	O
a	O
number	O
of	O
biological	O
processes	O
in	O
vertebrates	O
,	O
and	O
its	O
transport	O
may	O
be	O
rate-limiting	O
for	O
the	O
production	O
of	O
nitric	B-chemical
oxide	E-chemical
.	O
The	O
majority	O
of	O
L-Arg	S-chemical
transport	O
is	O
mediated	O
by	O
System	B-GP
y+	E-GP
,	O
although	O
several	O
other	O
carriers	O
have	O
been	O
kinetically	O
defined	O
.	O
System	B-GP
y+	E-GP
cationic	O
amino	B-chemical
acid	E-chemical
transport	O
is	O
mediated	O
by	O
proteins	O
encoded	O
by	O
a	O
family	O
of	O
genes	O
,	O
Cat1	S-GP
,	O
Cat2	S-GP
,	O
and	O
Cat3	S-GP
.	O
High	O
affinity	O
L-arginine	S-chemical
transport	O
was	O
investigated	O
in	O
embryonic	O
fibroblast	O
cells	O
derived	O
from	O
Cat1	S-GP
knockout	O
mice	O
that	O
lack	O
functional	O
Cat1	S-GP
.	O
Both	O
wild	O
type	O
and	O
knockout	O
cells	O
transport	O
arginine	S-chemical
with	O
comparable	O
Km	O
and	O
Vmax	O
.	O
However	O
,	O
the	O
apparent	O
affinity	O
for	O
lysine	S-chemical
transport	O
was	O
2.4	O
times	O
lower	O
in	O
Cat1	S-GP
(	O
-/-	O
)	O
cells	O
when	O
compared	O
with	O
wild	O
type	O
cells	O
,	O
a	O
property	O
characteristic	O
of	O
Cat3	S-GP
-mediated	O
transport	O
.	O
Northern	O
analysis-documented	O
Cat2	S-GP
mRNA	O
increased	O
2-fold	O
,	O
whereas	O
Cat3	S-GP
mRNA	O
levels	O
increased	O
11-fold	O
in	O
Cat1	S-GP
(	O
-/-	O
)	O
relative	O
to	O
Cat1	S-GP
(	O
+/+	O
)	O
cells	O
.	O
The	O
low	O
affinity	O
Cat2a	S-GP
mRNA	O
was	O
not	O
detectably	O
expressed	O
in	O
these	O
cells	O
.	O
Even	O
though	O
Cat3	S-GP
expression	O
is	O
normally	O
limited	O
to	O
adult	O
brain	O
,	O
there	O
was	O
a	O
large	O
increase	O
in	O
the	O
amount	O
of	O
Cat3	S-GP
protein	O
present	O
at	O
the	O
plasma	O
membrane	O
of	O
Cat1	S-GP
(	O
-/-	O
)	O
embryonic	O
fibroblast	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
Cat3	S-GP
compensates	O
for	O
the	O
loss	O
of	O
functional	O
Cat1	S-GP
in	O
cells	O
derived	O
from	O
Cat1	S-GP
knockout	O
mice	O
and	O
mediates	O
the	O
majority	O
of	O
high	O
affinity	O
arginine	S-chemical
transport	O
.	O

Desipramine	S-chemical
administration	O
in	O
the	O
olfactory	O
bulbectomized	O
rat	O
:	O
changes	O
in	O
brain	O
beta-adrenoceptor	S-GP
and	O
5-HT2A	S-GP
binding	O
sites	O
and	O
their	O
relationship	O
to	O
behaviour	O
.	O
1	O
.	O
The	O
effects	O
of	O
repeated	O
administration	O
of	O
the	O
tricyclic	S-chemical
antidepressant	O
drug	O
,	O
desipramine	S-chemical
(	O
DMI	S-chemical
)	O
,	O
on	O
behaviour	O
(	O
locomotor	O
activity	O
and	O
rearing	O
)	O
and	O
the	O
number	O
and	O
affinity	O
of	O
brain	O
beta-adrenoceptor	S-GP
and	O
5-HT2A	S-GP
receptor	O
binding	O
sites	O
were	O
examined	O
in	O
olfactory	O
bulbectomized	O
(	O
OB	O
)	O
and	O
sham-operated	O
control	O
rats	O
.	O
2	O
.	O
Locomotor	O
activity	O
and	O
rearing	O
were	O
increased	O
in	O
OB	O
rats	O
compared	O
to	O
sham-operated	O
controls	O
.	O
The	O
effect	O
of	O
various	O
doses	O
of	O
DMI	S-chemical
(	O
administered	O
orally	O
twice	O
daily	O
for	O
21	O
days	O
)	O
on	O
these	O
behavioural	O
measures	O
was	O
examined	O
.	O
A	O
dose	O
of	O
7.5	O
mg	O
kg-1	O
provided	O
optimal	O
reversal	O
of	O
hyperlocomotion	O
and	O
increased	O
rearing	O
in	O
OB	O
rats	O
,	O
without	O
changing	O
these	O
measures	O
in	O
sham-operated	O
controls	O
.	O
3	O
.	O
The	O
time	O
course	O
of	O
DMI	S-chemical
(	O
7.5	O
mg	O
kg-1	O
)	O
on	O
behavioural	O
and	O
neurochemical	O
measures	O
was	O
examined	O
.	O
locomotion	O
and	O
rearing	O
in	O
OB	O
rats	O
were	O
not	O
significantly	O
altered	O
after	O
7	O
days	O
,	O
were	O
significantly	O
attenuated	O
after	O
14	O
days	O
and	O
were	O
normalized	O
after	O
21	O
days	O
.	O
4	O
.	O
After	O
7	O
days	O
of	O
DMI	S-chemical
administration	O
the	O
number	O
of	O
beta-adrenoceptors	S-GP
was	O
lower	O
in	O
frontal	O
and	O
occipital	O
cortex	O
and	O
hippocampus	O
.	O
This	O
reduction	O
was	O
largely	O
restricted	O
to	O
the	O
beta	B-GP
1-adrenoceptor	E-GP
subtype	O
.	O
Administration	O
of	O
DMI	S-chemical
for	O
14	O
or	O
21	O
days	O
did	O
not	O
further	O
reduce	O
the	O
number	O
of	O
beta-adrenoceptors	S-GP
.	O
The	O
DMI	S-chemical
induced	O
reduction	O
in	O
beta-adrenoceptors	S-GP
did	O
not	O
differ	O
in	O
OB	O
and	O
sham-operated	O
control	O
rats	O
.	O
5	O
.	O
DMI	S-chemical
administration	O
for	O
up	O
to	O
21	O
days	O
produced	O
a	O
progressive	O
reduction	O
in	O
the	O
number	O
of	O
5-HT2A	S-GP
receptors	O
in	O
frontal	O
cortex	O
,	O
without	O
significant	O
alterations	O
in	O
occipital	O
cortex	O
.	O
6	O
.	O
The	O
time	O
course	O
of	O
the	O
reduction	O
in	O
the	O
number	O
of	O
5-HT2A	S-GP
receptors	O
was	O
similar	O
to	O
that	O
of	O
the	O
DMI	S-chemical
-induced	O
behavioural	O
changes	O
whereas	O
that	O
for	O
the	O
reduction	O
in	O
beta-adrenoceptors	S-GP
was	O
clearly	O
different	O
.	O
7	O
.	O
The	O
present	O
results	O
suggest	O
that	O
the	O
action	O
of	O
DMI	S-chemical
in	O
this	O
animal	O
model	O
is	O
unlikely	O
to	O
be	O
directly	O
related	O
to	O
a	O
reduction	O
in	O
beta-adrenoceptors	S-GP
but	O
may	O
be	O
related	O
to	O
a	O
reduction	O
in	O
frontal	O
cortical	O
5-HT2A	S-GP
receptors	O
.	O

Plasmacytoid	O
dendritic	O
cells	O
produce	O
cytokines	S-GP
and	O
mature	O
in	O
response	O
to	O
the	O
TLR7	S-GP
agonists	O
,	O
imiquimod	S-chemical
and	O
resiquimod	S-chemical
.	O
The	O
immune	O
response	O
modifiers	O
,	O
imiquimod	S-chemical
and	O
resiquimod	S-chemical
,	O
are	O
TLR7	S-GP
agonists	O
that	O
induce	O
type	B-GP
I	I-GP
interferon	E-GP
in	O
numerous	O
species	O
,	O
including	O
humans	O
.	O
Recently	O
,	O
it	O
was	O
shown	O
that	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDC	O
)	O
are	O
the	O
primary	O
interferon	S-GP
-producing	O
cells	O
in	O
the	O
blood	O
in	O
response	O
to	O
viral	O
infections	O
.	O
Here	O
,	O
we	O
characterize	O
the	O
activation	O
of	O
human	O
pDC	O
with	O
the	O
TLR7	S-GP
agonists	O
imiquimod	S-chemical
and	O
resiquimod	S-chemical
.	O
Results	O
indicate	O
that	O
imiquimod	S-chemical
and	O
resiquimod	S-chemical
induce	O
IFN-alpha	S-GP
and	O
IFN-omega	S-GP
from	O
purified	O
pDC	O
,	O
and	O
pDC	O
are	O
the	O
principle	O
IFN	S-GP
-producing	O
cells	O
in	O
the	O
blood	O
.	O
Resiquimod	S-chemical
-stimulated	O
pDC	O
also	O
produce	O
a	O
number	O
of	O
other	O
cytokines	S-GP
including	O
TNF-alpha	S-GP
and	O
IP-10	S-GP
.	O
Resiquimod	S-chemical
enhances	O
co-stimulatory	O
marker	O
expression	O
,	O
CCR7	S-GP
expression	O
,	O
and	O
pDC	O
viability	O
.	O
Resiquimod	S-chemical
was	O
compared	O
throughout	O
the	O
study	O
to	O
the	O
pDC	O
survival	O
factors	O
,	O
IL-3	S-GP
and	O
IFN-alpha	S-GP
;	O
resiquimod	S-chemical
more	O
effectively	O
matures	O
pDC	O
than	O
either	O
IL-3	S-GP
or	O
IFN-alpha	S-GP
alone	O
.	O
These	O
results	O
demonstrate	O
that	O
imidazoquinoline	S-chemical
molecules	O
directly	O
induce	O
pDC	O
maturation	O
as	O
determined	O
by	O
cytokine	S-GP
induction	O
,	O
CCR7	S-GP
and	O
co-stimulatory	O
marker	O
expression	O
and	O
prolonging	O
viability	O
.	O

Glucocorticoids	O
stimulate	O
ENaC	S-GP
upregulation	O
in	O
bovine	O
mammary	O
epithelium	O
.	O
Mammary	O
epithelia	O
produce	O
an	O
isotonic	O
,	O
low-	O
Na	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
fluid	O
that	O
is	O
rich	O
in	O
nutrients	O
.	O
Mechanisms	O
that	O
account	O
for	O
the	O
low	O
electrolyte	O
concentration	O
have	O
not	O
been	O
elucidated	O
,	O
although	O
amiloride	S-chemical
-sensitive	O
ion	O
transport	O
has	O
been	O
reported	O
in	O
some	O
situations	O
.	O
We	O
hypothesized	O
that	O
corticosteroid	O
exposure	O
modulates	O
epithelial	B-GP
Na	I-GP
(	I-GP
+	I-GP
)	I-GP
channel	E-GP
(	O
ENaC	S-GP
)	O
expression	O
and/or	O
activity	O
in	O
bovine	O
mammary	O
epithelial	O
cells	O
.	O
BME-UV	O
cells	O
were	O
grown	O
to	O
confluent	O
monolayers	O
on	O
permeable	O
supports	O
with	O
a	O
standard	O
basolateral	O
medium	O
and	O
apical	O
medium	O
of	O
low-electrolyte	O
,	O
high-	O
lactose	S-chemical
composition	O
that	O
resembles	O
the	O
ionic	O
composition	O
of	O
milk	O
.	O
Ion	O
transport	O
was	O
assessed	O
in	O
modified	O
Ussing	O
flux	O
chambers	O
.	O
Exposure	O
to	O
glucocorticoids	O
(	O
dexamethasone	S-chemical
,	O
cortisol	S-chemical
,	O
or	O
prednisolone	S-chemical
)	O
,	O
but	O
not	O
aldosterone	S-chemical
,	O
increased	O
short-circuit	O
current	O
(	O
I	O
(	O
sc	O
)	O
)	O
,	O
a	O
sensitive	O
measure	O
of	O
net	O
ion	O
transport	O
,	O
whereas	O
apical	O
exposure	O
to	O
amiloride	S-chemical
or	O
benzamil	S-chemical
reduced	O
corticosteroid-induced	O
I	O
(	O
sc	O
)	O
close	O
to	O
basal	O
levels	O
.	O
Quantitative	O
RT-PCR	O
indicated	O
a	O
glucocorticoid-induced	O
increase	O
in	O
mRNA	O
for	O
beta-	B-GP
and	I-GP
gamma-ENaC	E-GP
,	O
whereas	O
alpha-ENaC	S-GP
mRNA	O
expression	O
was	O
only	O
mildly	O
affected	O
.	O
Exposure	O
to	O
mifepristone	S-chemical
(	O
a	O
glucocorticoid	B-GP
receptor	E-GP
antagonist	O
)	O
,	O
but	O
not	O
spironolactone	S-chemical
(	O
a	O
mineralocorticoid	B-GP
receptor	E-GP
antagonist	O
)	O
,	O
precluded	O
both	O
the	O
corticosteroid-induced	O
elevation	O
in	O
amiloride	S-chemical
-sensitive	O
I	O
(	O
sc	O
)	O
and	O
the	O
induced	O
changes	O
in	O
beta-	B-GP
and	I-GP
gamma-ENaC	E-GP
mRNA	O
.	O
We	O
conclude	O
that	O
Na	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
movement	O
across	O
mammary	O
epithelia	O
is	O
modulated	O
by	O
corticosteroids	O
via	O
a	O
glucocorticoid	B-GP
receptor	E-GP
-mediated	O
mechanism	O
that	O
regulates	O
the	O
expression	O
of	O
the	O
beta-	B-GP
and	I-GP
gamma-subunits	I-GP
of	I-GP
ENaC	E-GP
.	O
ENaC	S-GP
expression	O
and	O
activity	O
could	O
account	O
for	O
the	O
low	O
Na	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
concentration	O
that	O
is	O
typical	O
of	O
milk	O
.	O

Effects	O
of	O
folic	B-chemical
acid	E-chemical
deficiency	O
and	O
MTHFR	S-GP
C677T	S-GP
polymorphism	O
on	O
spontaneous	O
and	O
radiation-induced	O
micronuclei	O
in	O
human	O
lymphocytes	O
.	O
Folic	B-chemical
acid	E-chemical
plays	O
a	O
key	O
role	O
in	O
the	O
maintenance	O
of	O
genomic	O
stability	O
,	O
providing	O
methyl	O
groups	O
for	O
the	O
conversion	O
of	O
uracil	S-chemical
to	O
thymine	S-chemical
and	O
for	O
DNA	O
methylation	O
.	O
Besides	O
dietary	O
habits	O
,	O
folic	B-chemical
acid	E-chemical
metabolism	O
is	O
influenced	O
by	O
genetic	O
polymorphism	O
.	O
The	O
C677T	S-GP
polymorphism	O
of	O
the	O
methylene-tetrahydrofolate	B-GP
reductase	E-GP
(	O
MTHFR	S-GP
)	O
gene	O
is	O
associated	O
with	O
a	O
reduction	O
of	O
catalytic	O
activity	O
and	O
is	O
suggested	O
to	O
modify	O
cancer	O
risk	O
differently	O
depending	O
on	O
folate	S-chemical
status	O
.	O
In	O
this	O
work	O
the	O
effect	O
of	O
folic	B-chemical
acid	E-chemical
deficiency	O
on	O
genome	O
stability	O
and	O
radiosensitivity	O
has	O
been	O
investigated	O
in	O
cultured	O
lymphocytes	O
of	O
12	O
subjects	O
with	O
different	O
MTHFR	S-GP
genotype	O
(	O
four	O
for	O
each	O
genotype	O
)	O
.	O
Cells	O
were	O
grown	O
for	O
9	O
days	O
with	O
12	O
,	O
24	O
and	O
120	O
nM	O
folic	B-chemical
acid	E-chemical
and	O
analyzed	O
in	O
a	O
comprehensive	O
micronucleus	O
test	O
coupled	O
with	O
centromere	O
characterization	O
by	O
CREST	O
immunostaining	O
.	O
In	O
other	O
experiments	O
,	O
cells	O
were	O
grown	O
with	O
various	O
folic	B-chemical
acid	E-chemical
concentrations	O
,	O
irradiated	O
with	O
0.5	O
Gy	O
of	O
gamma	O
rays	O
and	O
analyzed	O
in	O
the	O
micronucleus	O
test	O
.	O
The	O
results	O
obtained	O
indicate	O
that	O
folic	B-chemical
acid	E-chemical
deficiency	O
induces	O
to	O
a	O
comparable	O
extent	O
chromosome	O
loss	O
and	O
breakage	O
,	O
irrespective	O
of	O
the	O
MTHFR	S-GP
genotype	O
.	O
The	O
effect	O
of	O
folic	B-chemical
acid	E-chemical
was	O
highly	O
significant	O
(	O
P	O
<	O
0.001	O
)	O
and	O
explained	O
>	O
50	O
%	O
of	O
variance	O
of	O
both	O
types	O
of	O
micronuclei	O
.	O
Also	O
nucleoplasmic	O
bridges	O
and	O
buds	O
were	O
significantly	O
increased	O
under	O
low	O
folate	S-chemical
supply	O
;	O
the	O
increase	O
in	O
bridges	O
was	O
mainly	O
observed	O
in	O
TT	O
cells	O
,	O
highlighting	O
a	O
significant	O
effect	O
of	O
the	O
MTHFR	S-GP
genotype	O
(	O
P	O
=	O
0.006	O
)	O
on	O
this	O
biomarker	O
.	O
Folic	B-chemical
acid	E-chemical
concentration	O
significantly	O
affected	O
radiation-induced	O
micronuclei	O
(	O
P	O
<	O
0.001	O
)	O
:	O
the	O
increased	O
incidence	O
of	O
radiation-induced	O
micronuclei	O
with	O
low	O
folic	B-chemical
acid	E-chemical
was	O
mainly	O
accounted	O
for	O
by	O
carriers	O
of	O
the	O
variant	O
MTHFR	S-GP
allele	O
(	O
both	O
homozygotes	O
and	O
heterozygotes	O
)	O
,	O
but	O
the	O
overall	O
effect	O
of	O
genotype	O
did	O
not	O
attain	O
statistical	O
significance	O
.	O
Treatment	O
with	O
ionizing	O
radiations	O
also	O
increased	O
the	O
frequency	O
of	O
nucleoplasmic	O
bridges	O
.	O
The	O
effect	O
of	O
folic	B-chemical
acid	E-chemical
level	O
on	O
this	O
end-point	O
was	O
modulated	O
by	O
the	O
MTHFR	S-GP
genotype	O
(	O
P	O
for	O
interaction	O
=	O
0.02	O
)	O
,	O
with	O
TT	O
cells	O
grown	O
at	O
low	O
folic	B-chemical
acid	E-chemical
concentration	O
apparently	O
resistant	O
to	O
the	O
induction	O
of	O
radiation-induced	O
bridges	O
.	O
Finally	O
,	O
the	O
effect	O
of	O
in	O
vitro	O
folate	S-chemical
deprivation	O
on	O
global	O
DNA	O
methylation	O
was	O
evaluated	O
in	O
lymphocytes	O
of	O
six	O
homozygous	O
subjects	O
(	O
three	O
CC	O
and	O
three	O
TT	O
)	O
.	O
The	O
results	O
obtained	O
suggest	O
that	O
,	O
under	O
the	O
conditions	O
of	O
this	O
work	O
,	O
folic	B-chemical
acid	E-chemical
deprivation	O
is	O
associated	O
with	O
global	O
DNA	O
hypermethylation	O
.	O

Thiocolchicoside	S-chemical
suppresses	O
osteoclastogenesis	O
induced	O
by	O
RANKL	S-GP
and	O
cancer	O
cells	O
through	O
inhibition	O
of	O
inflammatory	O
pathways	O
:	O
a	O
new	O
use	O
for	O
an	O
old	O
drug	O
.	O
BACKGROUND	O
AND	O
PURPOSE	O
:	O
Most	O
patients	O
with	O
cancer	O
die	O
not	O
because	O
of	O
the	O
tumour	O
in	O
the	O
primary	O
site	O
,	O
but	O
because	O
it	O
has	O
spread	O
to	O
other	O
sites	O
.	O
Common	O
tumours	O
,	O
such	O
as	O
breast	O
,	O
multiple	O
myeloma	O
,	O
and	O
prostate	O
tumours	O
,	O
frequently	O
metastasize	O
to	O
the	O
bone	O
.	O
To	O
search	O
for	O
an	O
inhibitor	O
of	O
cancer-induced	O
bone	O
loss	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
thiocolchicoside	S-chemical
,	O
a	O
semi-synthetic	O
colchicoside	S-chemical
derived	O
from	O
the	O
plant	O
Gloriosa	O
superba	O
and	O
clinically	O
used	O
as	O
a	O
muscle	O
relaxant	O
,	O
on	O
osteoclastogenesis	O
induced	O
by	O
receptor	B-GP
activator	I-GP
of	I-GP
NF-kappaB	I-GP
ligand	E-GP
(	O
RANKL	S-GP
)	O
and	O
tumour	O
cells	O
.	O
EXPERIMENTAL	O
APPROACH	O
:	O
We	O
used	O
RAW	O
264.7	O
(	O
murine	O
macrophage	O
)	O
cells	O
,	O
a	O
well-established	O
system	O
for	O
osteoclastogenesis	O
,	O
and	O
evaluated	O
the	O
effect	O
of	O
thiocolchicoside	S-chemical
on	O
RANKL	S-GP
-induced	O
NF-kappaB	S-GP
signalling	O
and	O
osteoclastogenesis	O
as	O
well	O
as	O
on	O
osteoclastogenesis	O
induced	O
by	O
tumour	O
cells	O
.	O
KEY	O
RESULTS	O
:	O
Thiocolchicoside	S-chemical
suppressed	O
osteoclastogenesis	O
induced	O
by	O
RANKL	S-GP
,	O
and	O
by	O
breast	O
cancer	O
and	O
multiple	O
myeloma	O
cells	O
.	O
Inhibition	O
of	O
the	O
NF-kappaB	S-GP
pathway	O
was	O
responsible	O
for	O
this	O
effect	O
since	O
the	O
colchicoside	S-chemical
inhibited	O
RANKL	S-GP
-induced	O
NF-kappaB	S-GP
activation	O
,	O
activation	O
of	O
IkappaB	B-GP
kinase	E-GP
(	O
IKK	S-GP
)	O
and	O
suppressed	O
inhibitor	O
of	O
NF-kappaBalpha	S-GP
(	O
IkappaBalpha	S-GP
)	O
phosphorylation	O
and	O
degradation	O
,	O
an	O
inhibitor	O
of	O
NF-kappaB	S-GP
.	O
Furthermore	O
,	O
an	O
inhibitor	O
of	O
the	O
IkappaBalpha	S-GP
kinase	S-GP
gamma	O
or	O
NF-kappaB	S-GP
essential	O
modulator	O
,	O
the	O
regulatory	O
component	O
of	O
the	O
IKK	S-GP
complex	O
,	O
demonstrated	O
that	O
the	O
NF-kappaB	S-GP
signalling	O
pathway	O
is	O
mandatory	O
for	O
osteoclastogenesis	O
induced	O
by	O
RANKL	S-GP
.	O
CONCLUSIONS	O
AND	O
IMPLICATIONS	O
:	O
Together	O
,	O
these	O
data	O
suggest	O
that	O
thiocolchicoside	S-chemical
significantly	O
suppressed	O
osteoclastogenesis	O
induced	O
by	O
RANKL	S-GP
and	O
tumour	O
cells	O
via	O
the	O
NF-kappaB	S-GP
signalling	O
pathway	O
.	O
Thus	O
,	O
thiocolchicoside	S-chemical
,	O
a	O
drug	O
that	O
has	O
been	O
used	O
for	O
almost	O
half	O
a	O
century	O
to	O
treat	O
muscle	O
pain	O
,	O
may	O
also	O
be	O
considered	O
as	O
a	O
new	O
treatment	O
for	O
bone	O
loss	O
.	O

Novel	O
agents	O
that	O
potentially	O
inhibit	O
irinotecan	S-chemical
-induced	O
diarrhea	O
.	O
Irinotecan	S-chemical
(	O
CPT-11	S-chemical
,	O
7-ethyl-10-	B-chemical
[	I-chemical
4-	I-chemical
(	I-chemical
1-piperidino	I-chemical
)	I-chemical
-1-piperidino	I-chemical
]	I-chemical
carbonyloxycamptothecin	E-chemical
)	O
has	O
exhibited	O
clinical	O
activities	O
against	O
a	O
broad	O
spectrum	O
of	O
carcinomas	O
by	O
inhibiting	O
DNA	B-GP
topoisomerase	I-GP
I	E-GP
(	O
Topo	B-GP
I	E-GP
)	O
.	O
However	O
,	O
severe	O
and	O
unpredictable	O
dosing-limiting	O
toxicities	O
(	O
mainly	O
myelosuppression	O
and	O
severe	O
diarrhea	O
)	O
hinder	O
its	O
clinical	O
use	O
.	O
The	O
latter	O
consists	O
of	O
early	O
and	O
late-onset	O
diarrhea	O
,	O
occurring	O
within	O
24	O
hr	O
or	O
>	O
or	O
=	O
24	O
hr	O
after	O
CPT-11	S-chemical
administration	O
,	O
respectively	O
.	O
This	O
review	O
highlights	O
novel	O
agents	O
potentially	O
inhibiting	O
CPT-11	S-chemical
-induced	O
diarrhea	O
,	O
which	O
are	O
designed	O
and	O
tested	O
under	O
guidance	O
of	O
disposition	O
pathways	O
and	O
potential	O
toxicity	O
mechanisms	O
.	O
Early-onset	O
diarrhea	O
is	O
observed	O
immediately	O
after	O
CPT-11	S-chemical
infusion	O
and	O
probably	O
due	O
to	O
the	O
inhibition	O
of	O
acetylcholinesterase	S-GP
activity	O
,	O
which	O
can	O
be	O
eliminated	O
by	O
administration	O
of	O
atropine	S-chemical
.	O
Late-onset	O
diarrhea	O
appears	O
to	O
be	O
associated	O
with	O
intestinal	O
exposure	O
to	O
SN-38	S-chemical
(	O
7-ethyl-10-hydroxycamptothecin	S-chemical
)	O
,	O
the	O
major	O
active	O
metabolite	O
of	O
CPT-11	S-chemical
,	O
which	O
may	O
bind	O
to	O
Topo	B-GP
I	E-GP
and	O
induce	O
apoptosis	O
of	O
intestinal	O
epithelia	O
,	O
leading	O
to	O
the	O
disturbance	O
in	O
the	O
absorptive	O
and	O
secretory	O
functions	O
of	O
mucosa	O
.	O
CPT-11	S-chemical
and	O
SN-38	S-chemical
may	O
also	O
stimulate	O
the	O
production	O
of	O
pro-inflammatory	O
cytokines	S-GP
and	O
prostaglandins	S-chemical
(	O
PGs	S-chemical
)	O
,	O
thus	O
inducing	O
the	O
secretion	O
of	O
Na	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
and	O
Cl	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
.	O
Early	O
treatment	O
of	O
severe	O
late-onset	O
diarrhea	O
with	O
oral	O
high-dose	O
loperamide	S-chemical
has	O
decreased	O
patient	O
morbidity	O
.	O
Extensive	O
studies	O
have	O
been	O
conducted	O
to	O
identify	O
other	O
potential	O
agents	O
to	O
ameliorate	O
diarrhea	O
in	O
preclinical	O
and	O
clinical	O
models	O
.	O
These	O
include	O
intestinal	O
alkalizing	O
agents	O
,	O
oral	O
antibiotics	O
,	O
enzyme	O
inducers	O
,	O
P-glycoprotein	S-GP
(	O
PgP	S-GP
)	O
inhibitors	O
,	O
cyclooxygenase-2	S-GP
(	O
COX-2	S-GP
)	O
inhibitors	O
,	O
tumor	B-GP
necrosis	I-GP
factor-alpha	E-GP
(	O
TNF-alpha	S-GP
)	O
inhibitors	O
,	O
or	O
blockers	O
of	O
biliary	O
excretion	O
of	O
SN-38	S-chemical
.	O
Further	O
studies	O
are	O
needed	O
to	O
identify	O
the	O
molecular	O
targets	O
associated	O
with	O
CPT-11	S-chemical
toxicity	O
and	O
safe	O
and	O
effective	O
agents	O
for	O
alleviating	O
CPT-11	S-chemical
-induced	O
diarrhea	O
.	O

COX-2	S-GP
-specific	O
inhibition	O
:	O
implications	O
for	O
clinical	O
practice	O
.	O
Although	O
conventional	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
have	O
long	O
been	O
a	O
major	O
therapeutic	O
choice	O
for	O
the	O
management	O
of	O
arthritic	O
conditions	O
,	O
the	O
potential	O
adverse	O
effects	O
of	O
these	O
agents	O
sometimes	O
compromise	O
their	O
clinical	O
utility	O
.	O
New	O
modes	O
of	O
therapy	O
have	O
recently	O
been	O
introduced	O
,	O
and	O
data	O
on	O
the	O
cyclooxygenase-2	S-GP
(	O
COX-2	S-GP
)	O
-specific	O
inhibitors	O
celecoxib	S-chemical
and	O
rofecoxib	S-chemical
suggest	O
that	O
these	O
agents	O
will	O
meet	O
the	O
need	O
for	O
safe	O
and	O
effective	O
therapeutic	O
alternatives	O
to	O
conventional	O
NSAIDs	O
.	O

Aspirin	S-chemical
and	O
sodium	B-chemical
salicylate	E-chemical
inhibit	O
endothelin	O
ETA	B-GP
receptors	E-GP
by	O
an	O
allosteric	O
type	O
of	O
mechanism	O
.	O
Aspirin	S-chemical
is	O
a	O
commonly	O
used	O
drug	O
with	O
a	O
wide	O
pharmacological	O
spectrum	O
including	O
antiplatelet	O
,	O
anti-inflammatory	O
,	O
and	O
neuroprotective	O
actions	O
.	O
This	O
study	O
shows	O
that	O
aspirin	S-chemical
and	O
sodium	B-chemical
salicylate	E-chemical
,	O
its	O
major	O
blood	O
metabolite	O
,	O
reverse	O
contractile	O
actions	O
of	O
endothelin-1	S-GP
(	O
ET-1	S-GP
)	O
in	O
isolated	O
rat	O
aorta	O
and	O
human	O
mammary	O
arteries	O
.	O
They	O
also	O
prevent	O
the	O
intracellular	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
mobilizing	O
action	O
of	O
ET-1	S-GP
in	O
cultured	O
endothelial	O
cells	O
but	O
not	O
those	O
of	O
neuromedin	B-GP
B	E-GP
or	O
UTP	O
.	O
Inhibition	O
of	O
the	O
actions	O
of	O
ET-1	S-GP
by	O
salicylates	S-chemical
is	O
apparently	O
competitive	O
.	O
Salicylates	S-chemical
inhibit	O
(	B-chemical
125	I-chemical
)	I-chemical
I	E-chemical
-	O
ET-1	S-GP
binding	O
to	O
recombinant	O
rat	B-GP
ETA	I-GP
receptors	E-GP
.	O
Salicylic	B-chemical
acid	E-chemical
promotes	O
dissociation	O
of	O
(	B-chemical
125	I-chemical
)	I-chemical
I	E-chemical
-	O
ET-1	S-GP
ETA	B-GP
receptor	E-GP
complexes	O
both	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
unlabeled	O
ET-1	S-GP
.	O
It	O
has	O
no	O
influence	O
on	O
the	O
rate	O
of	O
association	O
of	O
(	B-chemical
125	I-chemical
)	I-chemical
I	E-chemical
-	O
ET-1	S-GP
to	O
ETA	B-GP
receptors	E-GP
.	O
Salicylates	S-chemical
do	O
not	O
promote	O
dissociation	O
of	O
(	B-chemical
125	I-chemical
)	I-chemical
I	E-chemical
-	O
ET-1	S-GP
ETB	B-GP
receptor	E-GP
complexes	O
.	O
Salicylates	S-chemical
potentiate	O
relaxing	O
actions	O
of	O
receptor	O
antagonists	O
such	O
as	O
bosentan	S-chemical
.	O
It	O
is	O
concluded	O
that	O
salicylates	S-chemical
are	O
allosteric	O
inhibitors	O
of	O
ETA	B-GP
receptors	E-GP
.	O
The	O
results	O
also	O
suggest	O
that	O
:	O
1	O
)	O
irreversible	O
ET-1	S-GP
binding	O
probably	O
limits	O
actions	O
of	O
receptor	O
antagonists	O
in	O
vivo	O
,	O
and	O
2	O
)	O
an	O
association	O
of	O
salicylates	S-chemical
and	O
ETA	B-GP
receptor	E-GP
antagonists	O
should	O
be	O
used	O
to	O
evaluate	O
the	O
physiopathological	O
role	O
of	O
ET-1	S-GP
and	O
may	O
be	O
of	O
therapeutic	O
interest	O
in	O
the	O
treatment	O
of	O
ischemic	O
heart	O
disease	O
.	O

3-Hydroxypyridin-2-thione	S-chemical
as	O
Novel	O
Zinc	S-chemical
Binding	O
Group	O
for	O
Selective	O
Histone	B-GP
Deacetylase	E-GP
Inhibition	O
.	O
Small	O
molecules	O
bearing	O
hydroxamic	O
acid	O
as	O
the	O
zinc	S-chemical
binding	O
group	O
(	O
ZBG	O
)	O
have	O
been	O
the	O
most	O
effective	O
histone	B-GP
deacetylase	E-GP
inhibitors	O
(	O
HDAC	S-GP
i	O
)	O
to	O
date	O
.	O
However	O
,	O
concerns	O
about	O
the	O
pharmacokinetic	O
liabilities	O
of	O
the	O
hydroxamic	B-chemical
acid	E-chemical
moiety	O
have	O
stimulated	O
research	O
efforts	O
aimed	O
at	O
finding	O
alternative	O
nonhydroxamate	O
ZBGs	O
.	O
We	O
have	O
identified	O
3-hydroxypyridin-2-thione	S-chemical
(	O
3-HPT	S-chemical
)	O
as	O
a	O
novel	O
ZBG	O
that	O
is	O
compatible	O
with	O
HDAC	S-GP
inhibition	O
.	O
3-HPT	S-chemical
inhibits	O
HDAC	B-GP
6	E-GP
and	O
HDAC	B-GP
8	E-GP
with	O
an	O
IC50	O
of	O
681	O
and	O
3675	O
nM	O
,	O
respectively	O
.	O
Remarkably	O
,	O
3-HPT	S-chemical
gives	O
no	O
inhibition	O
of	O
HDAC	B-GP
1	E-GP
.	O
Subsequent	O
optimization	O
led	O
to	O
several	O
novel	O
3HPT	S-chemical
-based	O
HDAC	S-GP
i	O
that	O
are	O
selective	O
for	O
HDAC	B-GP
6	E-GP
and	O
HDAC	B-GP
8	E-GP
.	O
Furthermore	O
,	O
a	O
subset	O
of	O
these	O
inhibitors	O
induces	O
apoptosis	O
in	O
various	O
cancer	O
cell	O
lines	O
.	O

Efficient	O
induction	O
of	O
apoptosis	O
in	O
HeLa	O
cells	O
by	O
a	O
novel	O
cationic	O
porphycene	S-chemical
photosensitizer	O
.	O
In	O
the	O
present	O
study	O
we	O
analyze	O
the	O
photobiological	O
properties	O
of	O
2,7,12-tris	B-chemical
(	I-chemical
α-pyridinio-p-tolyl	I-chemical
)	I-chemical
-17-	I-chemical
(	I-chemical
p-	I-chemical
(	I-chemical
methoxymethyl	I-chemical
)	I-chemical
phenyl	I-chemical
)	I-chemical
porphycene	E-chemical
(	O
Py3MeO-TBPo	S-chemical
)	O
in	O
Hela	O
cells	O
,	O
in	O
order	O
to	O
assess	O
its	O
potential	O
as	O
a	O
new	O
photosensitizer	O
for	O
photodynamic	O
therapy	O
of	O
cultured	O
tumor	O
cells	O
.	O
Using	O
0.5	O
μM	O
Py3MeO-TBPo	S-chemical
,	O
flow	O
cytometry	O
studies	O
demonstrated	O
an	O
increase	O
of	O
intracellular	O
drug	O
levels	O
related	O
to	O
the	O
incubation	O
time	O
,	O
reaching	O
a	O
maximum	O
at	O
18	O
h.	O
LysoTracker	O
(	O
®	O
)	O
Green	O
(	O
LTG	O
)	O
and	O
MitoTracker	O
(	O
®	O
)	O
Green	O
(	O
MTG	O
)	O
probes	O
were	O
used	O
to	O
identify	O
the	O
subcellular	O
localization	O
.	O
Upon	O
exposure	O
to	O
ultraviolet	O
excitation	O
,	O
red	O
porphycene	S-chemical
fluorescence	O
was	O
detected	O
as	O
red	O
granules	O
in	O
the	O
cytoplasm	O
that	O
colocalized	O
with	O
LTG	O
.	O
No	O
significant	O
toxic	O
effects	O
were	O
detected	O
for	O
Py3MeO-TBPo	S-chemical
in	O
the	O
dark	O
at	O
concentrations	O
below	O
1	O
μM	O
.	O
In	O
contrast	O
,	O
Py3MeO-TBPo	S-chemical
combined	O
with	O
red-light	O
irradiation	O
induced	O
concentration-	O
and	O
fluence-dependent	O
HeLa	O
cells	O
inactivation	O
.	O
Besides	O
,	O
all	O
photodynamic	O
protocols	O
assayed	O
induced	O
a	O
clear	O
effect	O
of	O
cell	O
detachment	O
inhibition	O
after	O
trypsin	S-GP
treatment	O
.	O
Both	O
apoptotic	O
and	O
necrotic	O
cell	O
death	O
mechanisms	O
can	O
occur	O
in	O
HeLa	O
cells	O
depending	O
on	O
the	O
experimental	O
protocol	O
.	O
After	O
18	O
h	O
incubation	O
with	O
0.5	O
μM	O
Py3MeO-TBPo	S-chemical
and	O
subsequent	O
red	O
light	O
irradiation	O
(	O
3.6	O
J/cm	O
(	O
2	O
)	O
)	O
,	O
a	O
high	O
number	O
of	O
cells	O
die	O
by	O
apoptosis	O
,	O
as	O
evaluated	O
by	O
morphological	O
alterations	O
,	O
immunofluorescent	O
relocalization	O
of	O
Bax	S-GP
from	O
cytosol	O
to	O
mitochondria	O
,	O
and	O
TUNEL	O
assay	O
.	O
Likewise	O
,	O
immunofluorescence	O
techniques	O
showed	O
that	O
cytochrome	B-GP
c	E-GP
is	O
released	O
from	O
mitochondria	O
into	O
cytosol	O
in	O
cells	O
undergoing	O
apoptosis	O
,	O
which	O
occurs	O
immediately	O
after	O
relocation	O
of	O
Bax	S-GP
in	O
mitochondria	O
.	O
The	O
highest	O
amount	O
of	O
apoptosis	O
appeared	O
24	O
h	O
after	O
treatment	O
(	O
70	O
%	O
)	O
and	O
this	O
cell	O
death	O
occurred	O
without	O
cell	O
detachment	O
to	O
the	O
substrate	O
.	O
In	O
contrast	O
,	O
with	O
0.75	O
μM	O
Py3MeO-TBPo	S-chemical
and	O
3.6	O
J/cm	O
(	O
2	O
)	O
irradiation	O
,	O
morphological	O
changes	O
showed	O
a	O
preferential	O
necrotic	O
cell	O
death	O
.	O
Singlet	O
oxygen	S-chemical
was	O
identified	O
as	O
the	O
cytotoxic	O
agent	O
involved	O
in	O
cell	O
photoinactivation	O
.	O
Moreover	O
,	O
cell	O
cultures	O
pre-exposed	O
to	O
the	O
singlet	O
oxygen	S-chemical
scavenger	O
sodium	B-chemical
azide	E-chemical
showed	O
pronounced	O
protection	O
against	O
the	O
loss	O
of	O
viability	O
induced	O
by	O
Py3MeO-TBPo	S-chemical
and	O
light	O
.	O
Different	O
changes	O
in	O
distribution	O
and	O
organization	O
of	O
cytoskeletal	O
elements	O
(	O
microtubules	S-GP
and	O
actin	S-GP
microfilaments	O
)	O
as	O
well	O
as	O
the	O
protein	O
vinculin	S-GP
,	O
after	O
apoptotic	O
and	O
necrotic	O
photodynamic	O
treatments	O
have	O
been	O
analyzed	O
.	O
Neither	O
of	O
these	O
two	O
cell	O
death	O
mechanisms	O
(	O
apoptosis	O
or	O
necrosis	O
)	O
induced	O
cell	O
detachment	O
.	O
In	O
summary	O
,	O
Py3MeO-TBPo	S-chemical
appears	O
to	O
meet	O
the	O
requirements	O
for	O
further	O
scrutiny	O
as	O
a	O
very	O
good	O
photosensitizer	O
for	O
photodynamic	O
therapy	O
:	O
it	O
is	O
water	O
soluble	O
,	O
has	O
a	O
high	O
absorption	O
in	O
the	O
red	O
spectral	O
region	O
(	O
where	O
light	O
penetration	O
in	O
tissue	O
is	O
higher	O
)	O
,	O
and	O
is	O
able	O
to	O
induce	O
effective	O
high	O
apoptotic	O
rate	O
(	O
70	O
%	O
)	O
related	O
to	O
the	O
more	O
widely	O
studied	O
photosensitizers	O
.	O

Kinetics	O
of	O
inhibition	O
of	O
human	B-GP
and	I-GP
rat	I-GP
dihydroorotate	I-GP
dehydrogenase	E-GP
by	O
atovaquone	S-chemical
,	O
lawsone	S-chemical
derivatives	O
,	O
brequinar	B-chemical
sodium	E-chemical
and	O
polyporic	B-chemical
acid	E-chemical
.	O
Mitochondrially-bound	O
dihydroorotate	B-GP
dehydrogenase	E-GP
(	O
EC	B-GP
1.3.99.11	E-GP
)	O
catalyzes	O
the	O
fourth	O
sequential	O
step	O
in	O
the	O
de	O
novo	O
synthesis	O
of	O
uridine	B-chemical
monophosphate	E-chemical
.	O
The	O
enzyme	O
has	O
been	O
identified	O
as	O
or	O
surmised	O
to	O
be	O
the	O
pharmacological	O
target	O
for	O
isoxazol	S-chemical
,	O
triazine	S-chemical
,	O
cinchoninic	B-chemical
acid	E-chemical
and	O
(	B-chemical
naphtho	I-chemical
)	I-chemical
quinone	E-chemical
derivatives	O
,	O
which	O
exerted	O
antiproliferative	O
,	O
immunosuppressive	O
,	O
and	O
antiparasitic	O
effects	O
.	O
Despite	O
this	O
broad	O
spectrum	O
of	O
biological	O
and	O
clinical	O
relevance	O
,	O
there	O
have	O
been	O
no	O
comparative	O
studies	O
on	O
drug-	O
dihydroorotate	B-GP
dehydrogenase	E-GP
interactions	O
.	O
Here	O
,	O
we	O
describe	O
a	O
study	O
of	O
the	O
inhibition	O
of	O
the	O
purified	O
recombinant	O
human	B-GP
and	I-GP
rat	I-GP
dihydroorotate	I-GP
dehydrogenase	E-GP
by	O
ten	O
compounds	O
.	O
1,4-Naphthoquinone	S-chemical
,	O
5,8-hydroxy-naphthoquinone	S-chemical
and	O
the	O
natural	O
compounds	O
juglon	S-chemical
,	O
plumbagin	S-chemical
and	O
polyporic	B-chemical
acid	E-chemical
(	O
quinone	S-chemical
derivative	O
)	O
were	O
found	O
to	O
function	O
as	O
alternative	O
electron	O
acceptors	O
with	O
10-30	O
%	O
of	O
control	O
enzyme	O
activity	O
.	O
The	O
human	O
and	O
rat	O
enzyme	O
activity	O
was	O
decreased	O
by	O
50	O
%	O
by	O
the	O
natural	O
compound	O
lawsone	S-chemical
(	O
>	O
500	O
and	O
49	O
microM	O
,	O
respectively	O
)	O
and	O
by	O
the	O
derivatives	O
dichloroally-lawsone	S-chemical
(	O
67	O
and	O
10	O
nM	O
)	O
,	O
lapachol	S-chemical
(	O
618	O
and	O
61	O
nM	O
)	O
and	O
atovaquone	S-chemical
(	O
15	O
microM	O
and	O
698	O
nM	O
)	O
.	O
With	O
respect	O
to	O
the	O
quinone	S-chemical
co-substrate	O
of	O
the	O
dihydroorotate	B-GP
dehydrogenase	E-GP
,	O
atovaquone	S-chemical
(	O
Kic	O
=	O
2.7	O
microM	O
)	O
and	O
dichloroally-lawsone	S-chemical
(	O
Kic	O
=	O
9.8	O
nM	O
)	O
were	O
shown	O
to	O
be	O
competitive	O
inhibitors	O
of	O
human	B-GP
dihydroorotate	I-GP
dehydrogenase	E-GP
.	O
Atovaquone	S-chemical
(	O
Kic	O
=	O
60	O
nM	O
)	O
was	O
also	O
acompetitive	O
inhibitor	O
of	O
the	O
rat	O
enzyme	O
.	O
Dichloroally	B-chemical
]	I-chemical
-lawsone	E-chemical
was	O
found	O
to	O
be	O
a	O
time-dependent	O
inhibitor	O
of	O
the	O
rat	O
enzyme	O
,	O
with	O
the	O
lowest	O
inhibition	O
constant	O
(	O
Ki*	O
=	O
0.77	O
nM	O
)	O
determined	O
so	O
far	O
for	O
mammalian	B-GP
dihydroorotate	I-GP
dehydrogenases	E-GP
.	O
Another	O
inhibitor	O
,	O
brequinar	S-chemical
was	O
previously	O
reported	O
to	O
be	O
a	O
slow-binding	O
inhibitor	O
of	O
the	O
human	B-GP
dihydroorotate	I-GP
dehydrogenase	E-GP
[	O
W.	O
Knecht	O
,	O
M.	O
Loffler	O
,	O
Species-related	O
inhibition	O
of	O
human	B-GP
and	I-GP
rat	I-GP
dihyroorotate	I-GP
dehydrogenase	E-GP
by	O
immunosuppressive	O
isoxazol	S-chemical
and	O
cinchoninic	B-chemical
acid	E-chemical
derivatives	O
,	O
Biochem	O
.	O
Pharmacol	O
.	O
56	O
(	O
1998	O
)	O
1259-1264	O
]	O
.	O
The	O
slow	O
binding	O
features	O
of	O
this	O
potent	O
inhibitor	O
(	O
Ki*	O
=	O
1.8	O
nM	O
)	O
with	O
the	O
human	O
enzyme	O
,	O
were	O
verified	O
and	O
seen	O
to	O
be	O
one	O
of	O
the	O
reasons	O
for	O
the	O
narrow	O
therapeutic	O
window	O
(	O
efficacy	O
versus	O
toxicity	O
)	O
reported	O
from	O
clinical	O
trials	O
on	O
its	O
antiproliferative	O
and	O
immunosuppressive	O
action	O
.	O
With	O
respect	O
to	O
the	O
substrate	O
dihydroorotate	S-chemical
,	O
atovaquone	S-chemical
was	O
an	O
uncompetitive	O
inhibitor	O
of	O
human	B-GP
dihydroorotate	I-GP
dehydrogenase	E-GP
(	O
Kiu	O
=	O
11.6	O
microM	O
)	O
and	O
a	O
non-competitive	O
inhibitor	O
of	O
the	O
rat	O
enzyme	O
(	O
Kiu	O
=	O
905/	O
Kic	O
=	O
1,012	O
nM	O
)	O
.	O
1.5	O
mM	O
polyporic	B-chemical
acid	E-chemical
,	O
a	O
natural	O
quinone	S-chemical
from	O
fungi	O
,	O
influenced	O
the	O
activity	O
of	O
the	O
human	O
enzyme	O
only	O
slightly	O
;	O
the	O
activity	O
of	O
the	O
rat	O
enzyme	O
was	O
decreased	O
by	O
30	O
%	O
.	O

Designing	O
,	O
structural	O
elucidation	O
,	O
comparison	O
of	O
DNA	O
binding	O
,	O
cleavage	O
,	O
radical	O
scavenging	O
activity	O
and	O
anticancer	O
activity	O
of	O
copper	B-chemical
(	I-chemical
I	I-chemical
)	E-chemical
complex	O
with	O
5-dimethyl-2-phenyl-4-	B-chemical
[	I-chemical
(	I-chemical
pyridin-2-ylmethylene	I-chemical
)	I-chemical
-amino	I-chemical
]	I-chemical
-1,2-dihydro-pyrazol-3-one	E-chemical
Schiff	B-chemical
base	E-chemical
ligand	O
.	O
A	O
novel	O
copper	B-chemical
(	I-chemical
I	I-chemical
)	I-chemical
Schiff	I-chemical
base	E-chemical
complex	O
has	O
been	O
synthesized	O
and	O
fully	O
characterized	O
by	O
spectral	O
,	O
analytical	O
and	O
structural	O
modes	O
.	O
Single	O
crystal	O
X-ray	O
diffraction	O
studies	O
revealed	O
that	O
the	O
copper	B-chemical
(	I-chemical
I	I-chemical
)	E-chemical
complex	O
[	B-chemical
CuCl	I-chemical
(	I-chemical
PPh3	I-chemical
)	I-chemical
L	I-chemical
]	E-chemical
has	O
a	O
distorted	O
tetrahedral	O
geometry	O
around	O
the	O
central	O
copper	B-chemical
(	I-chemical
I	I-chemical
)	E-chemical
ion	O
.	O
The	O
interaction	O
of	O
the	O
ligand	O
and	O
the	O
complex	O
with	O
CT-DNA	O
has	O
been	O
explored	O
by	O
absorption	O
titration	O
method	O
which	O
revealed	O
that	O
the	O
compounds	O
could	O
interact	O
with	O
CT-DNA	O
through	O
intercalation	O
.	O
A	O
gel	O
electrophoresis	O
assay	O
demonstrated	O
the	O
ability	O
of	O
the	O
complex	O
to	O
cleave	O
the	O
pBR322	O
DNA	O
.	O
The	O
antioxidative	O
properties	O
showed	O
that	O
the	O
copper	B-chemical
(	I-chemical
I	I-chemical
)	E-chemical
complex	O
has	O
a	O
strong	O
radical-scavenging	O
potency	O
than	O
ligands	O
.	O
Further	O
the	O
cytotoxic	O
effect	O
of	O
the	O
compounds	O
examined	O
on	O
cancerous	O
cell	O
lines	O
showed	O
that	O
the	O
complex	O
exhibited	O
substantial	O
anticancer	O
activity	O
.	O

Comparative	O
pharmacology	O
of	O
human	B-GP
beta-adrenergic	I-GP
receptor	E-GP
subtypes	O
--	O
characterization	O
of	O
stably	O
transfected	O
receptors	O
in	O
CHO	O
cells	O
.	O
Although	O
many	O
beta1-receptor	S-GP
antagonists	O
and	O
beta2-receptor	S-GP
agonists	O
have	O
been	O
used	O
in	O
pharmacotherapy	O
for	O
many	O
years	O
their	O
pharmacological	O
properties	O
at	O
all	O
three	O
known	O
subtypes	O
of	O
beta-adrenergic	B-GP
receptors	E-GP
are	O
not	O
always	O
well	O
characterized	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
,	O
therefore	O
,	O
to	O
provide	O
comparative	O
binding	O
characteristics	O
of	O
agonists	O
(	O
epinephrine	S-chemical
,	O
norepinephrine	S-chemical
,	O
isoproterenol	S-chemical
,	O
fenoterol	S-chemical
,	O
salbutamol	S-chemical
,	O
salmeterol	S-chemical
,	O
terbutalin	S-chemical
,	O
formoterol	S-chemical
,	O
broxaterol	S-chemical
)	O
and	O
antagonists	O
(	O
propranolol	S-chemical
,	O
alprenolol	S-chemical
,	O
atenolol	S-chemical
,	O
metoprolol	S-chemical
,	O
bisoprolol	S-chemical
,	O
carvedilol	S-chemical
,	O
pindolol	S-chemical
,	O
BRL	B-chemical
37344	E-chemical
,	O
CGP	B-chemical
20712	E-chemical
,	O
SR	B-chemical
59230A	E-chemical
,	O
CGP	B-chemical
12177	E-chemical
,	O
ICI	B-chemical
118551	E-chemical
)	O
at	O
all	O
three	O
subtypes	O
of	O
human	B-GP
beta-adrenergic	I-GP
receptors	E-GP
in	O
an	O
identical	O
cellular	O
background	O
.	O
We	O
generated	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
stably	O
expressing	O
the	O
three	O
beta-adrenergic	B-GP
receptor	E-GP
subtypes	O
at	O
comparable	O
levels	O
.	O
We	O
characterized	O
these	O
receptor	O
subtypes	O
and	O
analyzed	O
the	O
affinity	O
of	O
routinely	O
used	O
drugs	O
as	O
well	O
as	O
experimental	O
compounds	O
in	O
competition	O
binding	O
studies	O
,	O
using	O
the	O
non-selective	O
antagonist	O
125I-cyanopindolol	S-chemical
as	O
a	O
radioligand	O
.	O
Furthermore	O
,	O
we	O
analyzed	O
the	O
beta-receptor	S-GP
-mediated	O
adenylyl	B-GP
cyclase	E-GP
activity	O
in	O
isolated	O
membranes	O
from	O
these	O
cell	O
lines	O
.	O
The	O
results	O
from	O
our	O
experiments	O
show	O
that	O
all	O
compounds	O
exhibit	O
distinct	O
patterns	O
of	O
selectivity	O
and	O
activity	O
at	O
the	O
three	O
beta-receptor	S-GP
subtypes	O
.	O
In	O
particular	O
,	O
a	O
number	O
of	O
beta2-	B-GP
or	I-GP
beta3-receptor	E-GP
agonists	O
that	O
are	O
inverse	O
agonists	O
at	O
the	O
other	O
subtypes	O
were	O
identified	O
.	O
In	O
addition	O
,	O
beta1-receptor	S-GP
antagonists	O
with	O
agonistic	O
activity	O
at	O
beta2-	B-GP
and	I-GP
beta3-receptors	E-GP
were	O
found	O
.	O
These	O
specific	O
mixtures	O
of	O
agonism	O
,	O
antagonism	O
,	O
and	O
inverse	O
agonism	O
at	O
different	O
subtypes	O
may	O
have	O
important	O
implications	O
for	O
the	O
therapeutic	O
use	O
of	O
the	O
respective	O
compounds	O
.	O

Combination	O
chemotherapy	O
with	O
a	O
substance	B-chemical
P	E-chemical

Synthesis	O
,	O
DNA	O
binding	O
and	O
antitumor	O
evaluation	O
of	O
styelsamine	S-chemical
and	O
cystodytin	S-chemical
analogues	O
.	O
A	O
series	O
of	O
N-14	O
sidechain	O
substituted	O
analogues	O
of	O
styelsamine	S-chemical
(	O
pyrido	B-chemical
[	I-chemical
4,3,2-mn	I-chemical
]	I-chemical
acridine	E-chemical
)	O
and	O
cystodytin	S-chemical
(	O
pyrido	B-chemical
[	I-chemical
4,3,2-mn	I-chemical
]	I-chemical
acridin-4-one	E-chemical
)	O
alkaloids	O
have	O
been	O
prepared	O
and	O
evaluated	O
for	O
their	O
DNA	O
binding	O
affinity	O
and	O
antiproliferative	O
activity	O
towards	O
a	O
panel	O
of	O
human	O
tumor	O
cell	O
lines	O
.	O
Overall	O
it	O
was	O
found	O
that	O
styelsamine	S-chemical
analogues	O
were	O
stronger	O
DNA	O
binders	O
,	O
with	O
the	O
natural	O
products	O
styelsamines	B-chemical
B	I-chemical
and	I-chemical
D	E-chemical
having	O
particularly	O
high	O
affinity	O
(	O
K	O
(	O
app	O
)	O
5.33	O
×	O
10	O
(	O
6	O
)	O
and	O
3.64	O
×	O
10	O
(	O
6	O
)	O
M	O
(	O
-1	O
)	O
,	O
respectively	O
)	O
.	O
In	O
comparison	O
,	O
the	O
cystodytin	B-chemical
iminoquinone	I-chemical
alkaloids	E-chemical
showed	O
lower	O
affinity	O
for	O
DNA	O
,	O
but	O
were	O
typically	O
just	O
as	O
active	O
as	O
styelsamine	S-chemical
analogues	O
at	O
inhibiting	O
proliferation	O
of	O
tumor	O
cells	O
in	O
vitro	O
.	O
Sub-panel	O
selectivity	O
towards	O
non-small	O
cell	O
lung	O
,	O
melanoma	O
and	O
renal	O
cancer	O
cell	O
lines	O
were	O
observed	O
for	O
a	O
number	O
of	O
the	O
analogues	O
.	O
Correlation	O
was	O
observed	O
between	O
whole	O
cell	O
activity	O
and	O
clogP	O
,	O
with	O
the	O
most	O
potent	O
antiproliferative	O
activity	O
being	O
observed	O
for	O
3-phenylpropanamide	S-chemical
analogues	O
37	O
and	O
41	O
(	O
NCI	O
panel	O
average	O
GI	O
(	O
50	O
)	O
0.4	O
μM	O
and	O
0.32	O
μM	O
,	O
respectively	O
)	O
with	O
clogP	O
~4.0-4.5	O
.	O

Effects	O
of	O
beta-adrenoceptor	S-GP
antagonist	O
administration	O
on	O
beta	B-GP
2-adrenoceptor	E-GP
density	O
in	O
human	O
lymphocytes	O
.	O
The	O
role	O
of	O
the	O
``	O
intrinsic	O
sympathomimetic	O
activity	O
''	O
.	O
Abrupt	O
withdrawal	O
of	O
beta-adrenoceptor	S-GP
antagonists	O
may	O
lead	O
to	O
``	O
rebound-effects	O
''	O
.	O
To	O
study	O
the	O
mechanism	O
underlying	O
this	O
phenomenon	O
,	O
the	O
effects	O
of	O
the	O
nonselective	O
beta-adrenoceptor	S-GP
antagonists	O
propranolol	S-chemical
[	O
no	O
intrinsic	O
sympathomimetic	O
activity	O
(	O
ISA	O
)	O
]	O
,	O
alprenolol	S-chemical
(	O
weak	O
ISA	O
)	O
and	O
mepindolol	S-chemical
(	O
strong	O
ISA	O
)	O
on	O
lymphocyte	O
beta	B-GP
2-adrenoceptor	E-GP
density	O
--	O
assessed	O
by	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-	I-chemical
[	I-chemical
125I	I-chemical
]	I-chemical
-iodocyanopindolol	E-chemical
(	O
ICYP	S-chemical
)	O
binding	O
--	O
and	O
plasma	O
renin	S-GP
activity	O
(	O
PRA	O
)	O
were	O
investigated	O
in	O
male	O
healthy	O
volunteers	O
aged	O
23-35	O
years	O
.	O
Propranolol	S-chemical
treatment	O
(	O
4	O
X	O
40	O
mg/day	O
)	O
increased	O
the	O
density	O
of	O
beta	B-GP
2-adrenoceptors	E-GP
by	O
25	O
%	O
after	O
2	O
days	O
;	O
concomitantly	O
PRA	O
and	O
heart	O
rate	O
were	O
reduced	O
.	O
During	O
treatment	O
beta	B-GP
2-adrenoceptor	E-GP
density	O
remained	O
elevated	O
.	O
After	O
withdrawal	O
of	O
propranolol	S-chemical
PRA	O
reached	O
pre-drug	O
levels	O
rapidly	O
,	O
while	O
heart	O
rate	O
was	O
significantly	O
enhanced	O
.	O
Beta	B-GP
2-Adrenoceptor	E-GP
density	O
,	O
however	O
,	O
declined	O
slowly	O
being	O
still	O
significantly	O
increased	O
after	O
3	O
days	O
,	O
although	O
propranolol	S-chemical
was	O
not	O
detectable	O
in	O
plasma	O
after	O
24	O
h.	O
The	O
affinity	O
of	O
ICYP	S-chemical
to	O
beta	B-GP
2-adrenoceptors	E-GP
was	O
not	O
changed	O
during	O
or	O
after	O
treatment	O
.	O
Mepindolol	S-chemical
treatment	O
(	O
2	O
X	O
5	O
mg/day	O
)	O
caused	O
a	O
30	O
%	O
decrease	O
of	O
beta	B-GP
2-adrenoceptor	E-GP
density	O
and	O
PRA	O
after	O
2	O
days	O
;	O
both	O
parameters	O
remained	O
reduced	O
during	O
treatment	O
.	O
After	O
withdrawal	O
,	O
PRA	O
reached	O
rapidly	O
pre-drug	O
levels	O
,	O
whereas	O
beta	B-GP
2-adrenoceptor	E-GP
density	O
was	O
still	O
after	O
4	O
days	O
significantly	O
diminished	O
.	O
The	O
KD-values	O
for	O
ICYP	S-chemical
,	O
however	O
,	O
were	O
not	O
changed	O
.	O
During	O
and	O
after	O
treatment	O
heart	O
rate	O
was	O
not	O
affected	O
.	O
Alprenolol	S-chemical
treatment	O
(	O
4	O
X	O
100	O
mg/day	O
)	O
led	O
to	O
a	O
rapid	O
fall	O
in	O
PRA	O
,	O
but	O
did	O
not	O
significantly	O
affect	O
beta	B-GP
2-adrenoceptor	E-GP
density	O
.	O
It	O
is	O
concluded	O
,	O
that	O
the	O
ISA	O
may	O
play	O
an	O
important	O
role	O
in	O
modulating	O
beta	B-GP
2-adrenoceptor	E-GP
density	O
and	O
hence	O
tissue	O
responsiveness	O
to	O
beta-adrenoceptor	S-GP
stimulation	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Molecular	O
recognition	O
of	O
histidine	S-chemical
tRNA	O
by	O
histidyl-tRNA	B-GP
synthetase	E-GP
from	O
hyperthermophilic	O
archaeon	O
,	O
Aeropyrum	O
pernix	O
K1	O
.	O
To	O
investigate	O
the	O
recognition	O
sites	O
of	O
histidine	S-chemical
tRNA	O
for	O
histidyl-tRNA	B-GP
synthetase	E-GP
from	O
an	O
extreme	O
hyperthermophilic	O
archaeon	O
,	O
Aeropyrum	O
pernix	O
K1	O
,	O
we	O
examined	O
histidylation	O
activities	O
by	O
using	O
overexpressed	O
histidyl-tRNA	B-GP
synthetase	E-GP
and	O
various	O
histidine	S-chemical
tRNA	O
transcripts	O
that	O
were	O
prepared	O
by	O
in	O
vitro	O
transcription	O
system	O
.	O
Results	O
indicated	O
that	O
anticodon	O
was	O
not	O
recognized	O
by	O
the	O
histidyl-tRNA	B-GP
synthetase	E-GP
similar	O
to	O
that	O
of	O
Escherichia	O
coli	O
histidine	S-chemical
tRNA	O
recognition	O
system	O
.	O
Discriminator	O
base	O
C73	O
was	O
weekly	O
recognized	O
and	O
an	O
additional	O
G	O
residue	O
was	O
specifically	O
recognized	O
by	O
the	O
enzyme	O
.	O

Antitumor	O
and	O
immunomodulatory	O
activity	O
of	O
a	O
water-soluble	O
low	O
molecular	O
weight	O
polysaccharide	O
from	O
Schisandra	O
chinensis	O
(	O
Turcz	O
.	O
)	O
Baill	O
.	O
A	O
water-soluble	O
low	O
molecular	O
weight	O
polysaccharide	O
(	O
SCPP11	O
)	O
was	O
extracted	O
and	O
purified	O
using	O
DEAE-cellulose	O
and	O
Sephadex	O
G-100	O
column	O
from	O
Schisandra	O
chinensis	O
(	O
Turcz	O
.	O
)	O
Baill	O
.	O
Its	O
in	O
vivo	O
and	O
in	O
vitro	O
antitumor	O
and	O
immunomodulatory	O
activity	O
were	O
investigated	O
.	O
The	O
results	O
showed	O
that	O
SCPP11	O
with	O
a	O
molecular	O
weight	O
of	O
3.4×10	O
(	O
3	O
)	O
Da	O
exhibited	O
indirect	O
cyctotoxic	O
activity	O
against	O
tumor	O
cells	O
in	O
vitro	O
,	O
but	O
could	O
significantly	O
inhibit	O
the	O
growth	O
of	O
Heps	O
cells	O
in	O
vivo	O
at	O
dose	O
of	O
50mg/kg	O
,	O
and	O
its	O
inhibition	O
rate	O
is	O
higher	O
than	O
that	O
in	O
the	O
positive	O
group	O
.	O
Moreover	O
,	O
SCPP11	O
could	O
ameliorate	O
the	O
hematological	O
and	O
biochemical	O
parameters	O
to	O
almost	O
normal	O
and	O
no	O
significant	O
changes	O
in	O
organ	O
weight	O
,	O
and	O
could	O
increase	O
the	O
body	O
weight	O
.	O
In	O
addition	O
,	O
SCPP11	O
(	O
at	O
50mg/kg	O
)	O
could	O
also	O
increased	O
in	O
thymus	O
indexes	O
as	O
well	O
as	O
IL-2	S-GP
and	O
TNF-α	S-GP
levels	O
in	O
serum	O
in	O
vivo	O
and	O
significantly	O
enhance	O
the	O
phagocytosis	O
activity	O
and	O
the	O
productions	O
of	O
NO	S-chemical
of	O
RAW264.7	O
in	O
vitro	O
.	O
The	O
results	O
indicated	O
that	O
antitumor	O
properties	O
of	O
SCPP11	O
might	O
be	O
achieved	O
by	O
improving	O
immune	O
response	O
.	O
It	O
could	O
be	O
explored	O
as	O
a	O
potential	O
adjuvant	O
against	O
cancer	O
used	O
in	O
the	O
health	O
food	O
and	O
pharmaceutical	O
therapy	O
.	O

Cell	O
cycle	O
arrest	O
,	O
extracellular	O
matrix	O
changes	O
and	O
intrinsic	O
apoptosis	O
in	O
human	O
melanoma	O
cells	O
are	O
induced	O
by	O
Boron	S-chemical
Neutron	O
Capture	O
Therapy	O
.	O
Boron	S-chemical
Neutron	O
Capture	O
Therapy	O
(	O
BNCT	O
)	O
involves	O
the	O
selective	O
accumulation	O
of	O
boron	O
carriers	O
in	O
tumor	O
tissue	O
followed	O
by	O
irradiation	O
with	O
a	O
thermal	O
or	O
epithermal	O
neutron	O
beam	O
.	O
This	O
therapy	O
is	O
therefore	O
a	O
cellular	O
irradiation	O
suited	O
to	O
treat	O
tumors	O
that	O
have	O
infiltrated	O
into	O
healthy	O
tissues	O
.	O
BNCT	O
has	O
been	O
used	O
clinically	O
to	O
treat	O
patients	O
with	O
cutaneous	O
melanomas	O
which	O
have	O
a	O
high	O
mortality	O
.	O
Human	O
normal	O
melanocytes	O
and	O
melanoma	O
cells	O
were	O
treated	O
with	O
BNCT	O
at	O
different	O
boronophenylalanine	S-chemical
concentrations	O
for	O
signaling	O
pathways	O
analysis	O
.	O
BNCT	O
induced	O
few	O
morphological	O
alterations	O
in	O
normal	O
melanocytes	O
,	O
with	O
a	O
negligible	O
increase	O
in	O
free	O
radical	O
production	O
.	O
Melanoma	O
cells	O
treated	O
with	O
BNCT	O
showed	O
significant	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
changes	O
and	O
a	O
significant	O
cyclin	B-GP
D1	E-GP
decrease	O
,	O
suggesting	O
cell	O
death	O
by	O
necrosis	O
and	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
,	O
respectively	O
.	O
BNCT	O
also	O
induced	O
a	O
significant	O
increase	O
in	O
cleaved	O
caspase-3	S-GP
and	O
a	O
decrease	O
in	O
the	O
mitochondrial	O
electrical	O
potential	O
with	O
selectivity	O
for	O
melanoma	O
cells	O
.	O
Normal	O
melanocytes	O
had	O
no	O
significant	O
differences	O
due	O
to	O
BNCT	O
treatment	O
,	O
confirming	O
the	O
data	O
from	O
the	O
literature	O
regarding	O
the	O
selectivity	O
of	O
BNCT	O
.	O
The	O
results	O
from	O
this	O
study	O
suggest	O
that	O
some	O
signaling	O
pathways	O
are	O
involved	O
in	O
human	O
melanoma	O
treatment	O
by	O
BNCT	O
,	O
such	O
as	O
cell	O
cycle	O
arrest	O
,	O
ECM	O
changes	O
and	O
intrinsic	O
apoptosis	O
.	O

Membrane-initiated	O
estradiol	S-chemical
signaling	O
in	O
immortalized	O
hypothalamic	O
N-38	O
neurons	O
.	O
Regulation	O
of	O
sexual	O
reproduction	O
by	O
estradiol	S-chemical
involves	O
the	O
activation	O
of	O
estrogen	B-GP
receptors	E-GP
(	O
ERs	S-GP
)	O
in	O
the	O
hypothalamus	O
.	O
Of	O
the	O
two	O
classical	O
ERs	S-GP
involved	O
in	O
reproduction	O
,	O
ERα	S-GP
appears	O
to	O
be	O
the	O
critical	O
isoform	O
.	O
The	O
role	O
of	O
ERα	S-GP
in	O
reproduction	O
has	O
been	O
found	O
to	O
involve	O
a	O
nuclear	O
ERα	S-GP
that	O
induces	O
a	O
genomic	O
mechanism	O
of	O
action	O
.	O
More	O
recently	O
,	O
a	O
plasma	O
membrane	O
ERα	S-GP
has	O
been	O
shown	O
to	O
trigger	O
signaling	O
pathways	O
involved	O
in	O
reproduction	O
.	O
Mechanisms	O
underlying	O
membrane-initiated	O
estradiol	O
signaling	O
are	O
emerging	O
,	O
including	O
evidence	O
that	O
activation	O
of	O
plasma	O
membrane	O
ERα	S-GP
involves	O
receptor	O
trafficking	O
.	O
The	O
present	O
study	O
examined	O
the	O
insertion	O
of	O
ERα	S-GP
into	O
the	O
plasma	O
membrane	O
of	O
N-38	O
neurons	O
,	O
an	O
immortalized	O
murine	O
hypothalamic	O
cell	O
line	O
.	O
We	O
identified	O
,	O
using	O
western	O
blotting	O
and	O
PCR	O
that	O
N-38	O
neurons	O
express	O
full-length	O
66kDa	O
ERα	S-GP
and	O
a	O
52kDa	O
ERα	S-GP
spliced	O
variant	O
missing	O
the	O
fourth	O
exon	O
-	O
ERαΔ4	S-GP
.	O
Using	O
surface	O
biotinylation	O
,	O
we	O
observed	O
that	O
treatment	O
of	O
N-38	O
neurons	O
with	O
estradiol	S-chemical
or	O
with	O
a	O
membrane	O
impermeant	O
estradiol	S-chemical
elevated	O
plasma	O
membrane	O
ERα	S-GP
protein	O
levels	O
,	O
indicating	O
that	O
membrane	O
signaling	O
increased	O
receptor	O
insertion	O
into	O
the	O
cell	O
membrane	O
.	O
Insertion	O
of	O
ERα	S-GP
was	O
blocked	O
by	O
the	O
ER	S-GP
antagonist	O
ICI	B-chemical
182,780	E-chemical
or	O
with	O
the	O
protein	B-GP
kinase	I-GP
C	E-GP
(	O
PKC	S-GP
)	O
pathway	O
inhibitor	O
bisindolylmaleimide	S-chemical
(	O
BIS	S-chemical
)	O
.	O
Downstream	O
membrane-initiated	O
signaling	O
was	O
confirmed	O
by	O
estradiol	S-chemical
activation	O
of	O
PKC-theta	S-GP
(	O
PKCθ	S-GP
)	O
and	O
the	O
release	O
of	O
intracellular	O
calcium	O
.	O
These	O
results	O
indicate	O
that	O
membrane	O
ERα	S-GP
levels	O
in	O
N-38	O
neurons	O
are	O
dynamically	O
autoregulated	O
by	O
estradiol	S-chemical
.	O

Disrupted	O
cytoskeletal	O
homeostasis	O
,	O
astrogliosis	O
and	O
apoptotic	O
cell	O
death	O
in	O
the	O
cerebellum	O
of	O
preweaning	O
rats	O
injected	O
with	O
diphenyl	B-chemical
ditelluride	E-chemical
.	O
In	O
the	O
present	O
report	O
15	O
day-old	O
rats	O
were	O
injected	O
with	O
0.3μmol	O
of	O
diphenyl	B-chemical
ditelluride	E-chemical
(	B-chemical
PhTe	I-chemical
)	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
/kg	O
body	O
weight	O
and	O
parameters	O
of	O
neurodegeneration	O
were	O
analyzed	O
in	O
slices	O
from	O
cerebellum	O
3	O
and	O
6	O
days	O
afterwards	O
.	O
The	O
earlier	O
responses	O
,	O
at	O
day	O
3	O
after	O
injection	O
,	O
included	O
hyperphosphorylation	O
of	O
intermediate	O
filament	O
(	O
IF	O
)	O
proteins	O
from	O
astrocyte	O
(	O
glial	B-GP
fibrillary	I-GP
acidic	I-GP
protein	E-GP
-	O
GFAP	S-GP
-	O
and	O
vimentin	S-GP
)	O
and	O
neuron	O
(	O
low-	B-GP
,	I-GP
medium-	I-GP
and	I-GP
high	I-GP
molecular	I-GP
weight	I-GP
neurofilament	I-GP
subunits	E-GP
:	O
NF-L	S-GP
,	O
NF-M	S-GP
and	O
NF-H	S-GP
)	O
;	O
increased	O
mitogen-activated	B-GP
protein	I-GP
kinase	E-GP
(	O
MAPK	S-GP
)	O
(	O
Erk	S-GP
and	O
p38MAPK	S-GP
)	O
and	O
cAMP-dependent	B-GP
protein	I-GP
kinase	E-GP
(	O
PKA	S-GP
)	O
activities	O
.	O
Also	O
,	O
reactive	O
astrogliosis	O
takes	O
part	O
of	O
the	O
early	O
responses	O
to	O
the	O
insult	O
with	O
(	B-chemical
PhTe	I-chemical
)	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
,	O
evidenced	O
by	O
upregulated	O
GFAP	S-GP
in	O
Western	O
blot	O
,	O
PCR	O
and	O
immunofluorescence	O
analysis	O
.	O
Six	O
days	O
after	O
(	B-chemical
PhTe	I-chemical
)	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
injection	O
we	O
found	O
persistent	O
astrogliosis	O
,	O
increased	O
propidium	B-chemical
iodide	E-chemical
(	O
PI	O
)	O
positive	O
cells	O
in	O
NeuN	S-GP
positive	O
population	O
evidenced	O
by	O
flow	O
cytometry	O
and	O
reduced	O
immunofluorescence	O
for	O
NeuN	S-GP
,	O
suggesting	O
that	O
the	O
in	O
vivo	O
exposure	O
to	O
(	B-chemical
PhTe	I-chemical
)	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
progressed	O
to	O
neuronal	O
death	O
.	O
Moreover	O
,	O
activated	O
caspase	B-GP
3	E-GP
suggested	O
apoptotic	O
neuronal	O
death	O
.	O
Neurodegeneration	O
was	O
related	O
with	O
decreased	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
glutamate	E-chemical
uptake	O
and	O
decreased	O
Akt	S-GP
immunoreactivity	O
,	O
however	O
phospho-GSK-3-β	S-GP
(	O
Ser	S-chemical
9	O
)	O
was	O
not	O
altered	O
in	O
(	B-chemical
PhTe	I-chemical
)	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
injected	O
rat	O
.	O
Therefore	O
,	O
the	O
present	O
results	O
show	O
that	O
the	O
earlier	O
cerebellar	O
responses	O
to	O
(	B-chemical
PhTe	I-chemical
)	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
include	O
disruption	O
of	O
cytoskeletal	O
homeostasis	O
that	O
could	O
be	O
related	O
with	O
MAPK	S-GP
and	O
PKA	S-GP
activation	O
and	O
reactive	O
astrogliosis	O
.	O
Akt	S-GP
inhibition	O
observed	O
at	O
this	O
time	O
could	O
also	O
play	O
a	O
role	O
in	O
the	O
neuronal	O
death	O
evidenced	O
afterwards	O
.	O
The	O
later	O
events	O
of	O
the	O
neurodegenerative	O
process	O
are	O
characterized	O
by	O
persistent	O
astrogliosis	O
and	O
activation	O
of	O
apoptotic	O
neuronal	O
death	O
through	O
caspase	B-GP
3	E-GP
mediated	O
mechanisms	O
,	O
which	O
could	O
be	O
related	O
with	O
glutamate	S-chemical
excitotoxicity	O
.	O
The	O
progression	O
of	O
these	O
responses	O
are	O
therefore	O
likely	O
to	O
be	O
critical	O
for	O
the	O
outcome	O
of	O
the	O
neurodegeneration	O
provoked	O
by	O
(	B-chemical
PhTe	I-chemical
)	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
in	O
rat	O
cerebellum	O
.	O

Rofecoxib	S-chemical
:	O
a	O
review	O
of	O
its	O
use	O
in	O
the	O
management	O
of	O
osteoarthritis	O
,	O
acute	O
pain	O
and	O
rheumatoid	O
arthritis	O
.	O
Rofecoxib	S-chemical
is	O
a	O
selective	O
cyclo-oxygenase	B-GP
(	I-GP
COX	I-GP
)	I-GP
-2	E-GP
inhibitor	O
which	O
has	O
little	O
or	O
no	O
effect	O
on	O
the	O
COX-1	S-GP
isoenzyme	O
at	O
doses	O
up	O
to	O
1000	O
mg/day	O
.	O
Rofecoxib	S-chemical
has	O
greater	O
selectivity	O
for	O
COX-2	S-GP
than	O
celecoxib	S-chemical
,	O
meloxicam	S-chemical
,	O
diclofenac	S-chemical
and	O
indomethacin	S-chemical
.	O
In	O
well-controlled	O
clinical	O
trials	O
,	O
rofecoxib	S-chemical
12.5	O
to	O
500	O
mg/day	O
has	O
been	O
evaluated	O
for	O
its	O
efficacy	O
in	O
the	O
treatment	O
of	O
osteoarthritis	O
,	O
acute	O
pain	O
and	O
rheumatoid	O
arthritis	O
[	O
lower	O
dosages	O
(	O
5	O
to	O
125	O
mg/day	O
)	O
were	O
generally	O
used	O
in	O
the	O
chronic	O
pain	O
indications	O
]	O
.	O
In	O
the	O
treatment	O
of	O
patients	O
with	O
osteoarthritis	O
,	O
rofecoxib	S-chemical
was	O
more	O
effective	O
in	O
providing	O
symptomatic	O
relief	O
than	O
placebo	O
,	O
paracetamol	S-chemical
(	O
acetaminophen	S-chemical
)	O
and	O
celecoxib	S-chemical
and	O
was	O
similar	O
in	O
efficacy	O
to	O
ibuprofen	S-chemical
,	O
diclofenac	S-chemical
,	O
naproxen	S-chemical
and	O
nabumetone	S-chemical
.	O
Overall	O
,	O
both	O
the	O
physician	O
's	O
assessment	O
of	O
disease	O
status	O
and	O
the	O
patient	O
's	O
assessment	O
of	O
response	O
to	O
therapy	O
tended	O
to	O
favour	O
rofecoxib	S-chemical
.	O
In	O
patients	O
with	O
postsurgical	O
dental	O
pain	O
,	O
pain	O
after	O
spinal	O
fusion	O
or	O
orthopaedic	O
surgery	O
,	O
or	O
primary	O
dysmenorrhoea	O
,	O
rofecoxib	S-chemical
provided	O
more	O
rapid	O
and	O
more	O
sustained	O
pain	O
relief	O
and	O
reduced	O
requirements	O
for	O
supplemental	O
morphine	O
use	O
after	O
surgery	O
than	O
placebo	O
.	O
Rofecoxib	S-chemical
was	O
more	O
efficacious	O
than	O
celecoxib	S-chemical
in	O
patients	O
with	O
acute	O
dental	O
pain	O
and	O
pain	O
after	O
spinal	O
fusion	O
surgery	O
,	O
although	O
celecoxib	S-chemical
may	O
have	O
been	O
used	O
at	O
a	O
subtherapeutic	O
dose	O
.	O
In	O
comparison	O
with	O
traditional	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
ibuprofen	S-chemical
,	O
diclofenac	S-chemical
and	O
naproxen	B-chemical
sodium	E-chemical
,	O
rofecoxib	S-chemical
was	O
similar	O
in	O
efficacy	O
in	O
the	O
treatment	O
of	O
acute	O
pain	O
.	O
Although	O
naproxen	B-chemical
sodium	E-chemical
provided	O
more	O
rapid	O
pain	O
relief	O
than	O
rofecoxib	S-chemical
in	O
patients	O
with	O
primary	O
dysmenorrhoea	O
,	O
the	O
reverse	O
was	O
true	O
after	O
orthopaedic	O
surgery	O
:	O
rofecoxib	S-chemical
provided	O
more	O
rapid	O
pain	O
relief	O
and	O
less	O
supplemental	O
morphine	S-chemical
was	O
needed	O
.	O
Rofecoxib	S-chemical
was	O
as	O
effective	O
as	O
naproxen	S-chemical
in	O
providing	O
symptomatic	O
relief	O
for	O
over	O
8700	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O
Compared	O
with	O
traditional	O
NSAID	O
therapy	O
,	O
rofecoxib	S-chemical
had	O
a	O
significantly	O
lower	O
incidence	O
of	O
endoscopically	O
confirmed	O
gastroduodenal	O
ulceration	O
and	O
,	O
in	O
approximately	O
13,000	O
patients	O
with	O
osteoarthritis	O
and	O
rheumatoid	O
arthritis	O
,	O
a	O
lower	O
incidence	O
of	O
gastrointestinal	O
(	O
GI	O
)	O
adverse	O
events	O
.	O
Rofecoxib	S-chemical
was	O
generally	O
well	O
tolerated	O
in	O
all	O
indications	O
with	O
an	O
overall	O
tolerability	O
profile	O
similar	O
to	O
traditional	O
NSAIDs	O
.	O
The	O
most	O
common	O
adverse	O
events	O
in	O
rofecoxib	S-chemical
recipients	O
were	O
nausea	O
,	O
dizziness	O
and	O
headache	O
.	O
In	O
conclusion	O
,	O
rofecoxib	S-chemical
is	O
at	O
least	O
as	O
effective	O
as	O
traditional	O
NSAID	O
therapy	O
in	O
providing	O
pain	O
relief	O
for	O
both	O
chronic	O
and	O
acute	O
pain	O
conditions	O
.	O
Rofecoxib	S-chemical
provides	O
an	O
alternative	O
treatment	O
option	O
to	O
traditional	O
NSAID	O
therapy	O
in	O
the	O
management	O
of	O
symptomatic	O
pain	O
relief	O
in	O
patients	O
with	O
osteoarthritis	O
.	O
Initial	O
data	O
from	O
patients	O
with	O
primary	O
dysmenorrhoea	O
and	O
postoperative	O
pain	O
are	O
promising	O
and	O
further	O
trials	O
may	O
confirm	O
its	O
place	O
in	O
the	O
treatment	O
of	O
these	O
indications	O
.	O
Rofecoxib	S-chemical
has	O
also	O
shown	O
promising	O
results	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
and	O
is	O
likely	O
to	O
become	O
a	O
valuable	O
addition	O
to	O
current	O
drug	O
therapy	O
for	O
this	O
patient	O
population	O
.	O
Importantly	O
,	O
rofecoxib	S-chemical
is	O
associated	O
with	O
a	O
lower	O
incidence	O
of	O
GI	O
adverse	O
events	O
than	O
traditional	O
NSAIDs	O
making	O
it	O
a	O
primary	O
treatment	O
option	O
in	O
patients	O
at	O
risk	O
of	O
developing	O
GI	O
complications	O
or	O
patients	O
with	O
chronic	O
conditions	O
requiring	O
long	O
term	O
treatment	O
.	O

Dimethylfumarate	S-chemical
attenuates	O
renal	O
fibrosis	O
via	O
NF-E2-related	B-GP
factor	I-GP
2	E-GP
-mediated	O
inhibition	O
of	O
transforming	B-GP
growth	I-GP
factor-beta	E-GP
/	O
Smad	S-GP
signaling	O
.	O
TGF-beta	S-GP
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
renal	O
fibrosis	O
.	O
Suppressing	O
the	O
TGF-beta	S-GP
signaling	O
pathway	O
is	O
a	O
possible	O
therapeutic	O
approach	O
for	O
preventing	O
this	O
disease	O
,	O
and	O
reports	O
have	O
suggested	O
that	O
Nrf2	S-GP
protects	O
against	O
renal	O
fibrosis	O
by	O
inhibiting	O
TGF-beta	S-GP
signaling	O
.	O
This	O
study	O
examines	O
whether	O
dimethylfumarate	S-chemical
(	O
DMF	S-chemical
)	O
,	O
which	O
stimulates	O
Nrf2	S-GP
,	O
prevents	O
renal	O
fibrosis	O
via	O
the	O
Nrf2	S-GP
-mediated	O
suppression	O
of	O
TGF-beta	S-GP
signaling	O
.	O
Results	O
showed	O
that	O
DMF	S-chemical
increased	O
nuclear	O
levels	O
of	O
Nrf2	S-GP
,	O
and	O
both	O
DMF	S-chemical
and	O
adenovirus-mediated	O
overexpression	O
of	O
Nrf2	S-GP
(	O
Ad-	O
Nrf2	S-GP
)	O
decreased	O
PAI-1	S-GP
,	O
alpha-smooth	B-GP
muscle	I-GP
actin	E-GP
(	O
alpha-SMA	S-GP
)	O
,	O
fibronectin	S-GP
and	O
type	B-GP
1	I-GP
collagen	E-GP
expression	O
in	O
TGF-beta	S-GP
-treated	O
rat	O
mesangial	O
cells	O
(	O
RMCs	O
)	O
and	O
renal	O
fibroblast	O
cells	O
(	O
NRK-49F	O
)	O
.	O
Additionally	O
,	O
DMF	S-chemical
and	O
Ad-	O
Nrf2	S-GP
repressed	O
TGF-beta	S-GP
-stimulated	O
Smad3	S-GP
activity	O
by	O
inhibiting	O
Smad3	S-GP
phosphorylation	O
,	O
which	O
was	O
restored	O
by	O
siRNA-mediated	O
knockdown	O
of	O
Nrf2	S-GP
expression	O
.	O
However	O
,	O
downregulation	O
of	O
the	O
antioxidant	B-GP
response	I-GP
element	E-GP
(	O
ARE	S-GP
)	O
-driven	O
Nrf2	S-GP
target	O
genes	O
such	O
as	O
NQO1	S-GP
,	O
HO-1	S-GP
and	O
glutathione	B-GP
S-transferase	E-GP
(	O
GST	S-GP
)	O
did	O
not	O
reverse	O
the	O
inhibitory	O
effect	O
of	O
DMF	S-chemical
on	O
TGF-beta	S-GP
-induced	O
upregulation	O
of	O
profibrotic	O
genes	O
or	O
extracellular	O
matrix	O
proteins	O
,	O
suggesting	O
an	O
ARE	S-GP
-independent	O
anti-fibrotic	O
activity	O
of	O
DMF	S-chemical
.	O
Finally	O
,	O
DMF	S-chemical
suppressed	O
unilateral	O
ureteral	O
obstruction	O
(	O
UUO	O
)	O
-induced	O
renal	O
fibrosis	O
and	O
alpha-SMA	S-GP
,	O
fibronectin	S-GP
and	O
type	B-GP
1	I-GP
collagen	E-GP
expression	O
in	O
the	O
obstructed	O
kidneys	O
from	O
UUO	O
mice	O
,	O
along	O
with	O
increased	O
and	O
decreased	O
expression	O
of	O
Nrf2	S-GP
and	O
phospho-Smad3	S-GP
,	O
respectively	O
.	O
In	O
summary	O
,	O
DMF	S-chemical
attenuated	O
renal	O
fibrosis	O
via	O
the	O
Nrf2	S-GP
-mediated	O
inhibition	O
of	O
TGF-beta	S-GP
/	O
Smad3	S-GP
signaling	O
in	O
an	O
ARE	S-GP
-independent	O
manner	O
,	O
suggesting	O
that	O
DMF	S-chemical
could	O
be	O
used	O
to	O
treat	O
renal	O
fibrosis	O
.	O

Suppression	O
of	O
NF-kappaB	S-GP
activity	O
by	O
sulfasalazine	S-chemical
is	O
mediated	O
by	O
direct	O
inhibition	O
of	O
IkappaB	B-GP
kinases	I-GP
alpha	I-GP
and	I-GP
beta	E-GP
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
Activation	O
of	O
NF-kappaB	S-GP
/	O
Rel	S-GP
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O
Various	O
drugs	O
used	O
in	O
the	O
treatment	O
of	O
IBD	O
,	O
such	O
as	O
glucocorticoids	O
,	O
5-aminosalicylic	B-chemical
acid	E-chemical
,	O
and	O
sulfasalazine	S-chemical
,	O
interfere	O
with	O
NF-kappaB	S-GP
/	O
Rel	S-GP
signaling	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
define	O
the	O
molecular	O
mechanism	O
by	O
which	O
sulfasalazine	S-chemical
inhibits	O
NF-kappaB	S-GP
activation	O
.	O
METHODS	O
:	O
The	O
effects	O
of	O
sulfasalazine	S-chemical
and	O
its	O
moieties	O
on	O
NF-kappaB	S-GP
signaling	O
were	O
evaluated	O
using	O
electromobility	O
shift	O
,	O
transfection	O
,	O
and	O
immune	O
complex	O
kinase	O
assays	O
.	O
The	O
direct	O
effect	O
of	O
sulfasalazine	S-chemical
on	O
IkappaB	B-GP
kinase	E-GP
(	O
IKK	S-GP
)	O
activity	O
was	O
investigated	O
using	O
purified	O
recombinant	O
IKK-alpha	B-GP
and	I-GP
-beta	E-GP
proteins	O
.	O
RESULTS	O
:	O
NF-kappaB	S-GP
/	O
Rel	S-GP
activity	O
induced	O
by	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
alpha	E-GP
,	O
12-O-tetradecanoylphorbol-13-acetate	S-chemical
,	O
or	O
overexpression	O
of	O
NF-kappaB-inducing	B-GP
kinase	E-GP
,	O
IKK-alpha	S-GP
,	O
IKK-beta	S-GP
,	O
or	O
constitutively	O
active	O
IKK-alpha	S-GP
and	O
IKK-beta	S-GP
mutants	O
was	O
inhibited	O
dose	O
dependently	O
by	O
sulfasalazine	S-chemical
.	O
Sulfasalazine	S-chemical
inhibited	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
alpha	E-GP
-induced	O
activation	O
of	O
endogenous	O
IKK	S-GP
in	O
Jurkat	O
T	O
cells	O
and	O
SW620	O
colon	O
cells	O
,	O
as	O
well	O
as	O
the	O
catalytic	O
activity	O
of	O
purified	O
IKK-alpha	S-GP
and	O
IKK-beta	S-GP
in	O
vitro	O
.	O
In	O
contrast	O
,	O
the	O
moieties	O
of	O
sulfasalazine	S-chemical
,	O
5-aminosalicylic	B-chemical
acid	E-chemical
,	O
and	O
sulfapyridine	S-chemical
or	O
4-aminosalicylic	B-chemical
acid	E-chemical
had	O
no	O
effect	O
.	O
Activation	O
of	O
extracellular	B-GP
signal-related	I-GP
kinase	I-GP
(	I-GP
ERK	I-GP
)	I-GP
1	I-GP
and	I-GP
2	E-GP
,	O
c-Jun-N-terminal	B-GP
kinase	I-GP
(	I-GP
JNK	I-GP
)	I-GP
1	E-GP
,	O
and	O
p38	S-GP
was	O
unaffected	O
by	O
sulfasalazine	S-chemical
.	O
The	O
decrease	O
in	O
substrate	O
phosphorylation	O
by	O
IKK-alpha	B-GP
and	I-GP
-beta	E-GP
is	O
associated	O
with	O
a	O
decrease	O
in	O
autophosphorylation	O
of	O
IKKs	S-GP
and	O
can	O
be	O
antagonized	O
by	O
excess	O
adenosine	B-chemical
triphosphate	E-chemical
.	O
CONCLUSIONS	O
:	O
These	O
data	O
identify	O
sulfasalazine	S-chemical
as	O
a	O
direct	O
inhibitor	O
of	O
IKK-alpha	B-GP
and	I-GP
-beta	E-GP
by	O
antagonizing	O
adenosine	B-chemical
triphosphate	E-chemical
binding	O
.	O
The	O
suppression	O
of	O
NF-kappaB	S-GP
activation	O
by	O
inhibition	O
of	O
the	O
IKKs	S-GP
contributes	O
to	O
the	O
well-known	O
anti-inflammatory	O
and	O
immunosuppressive	O
effects	O
of	O
sulfasalazine	S-chemical
.	O

Association	O
of	O
estrogen	B-GP
receptor-alpha	E-GP
and	O
progesterone	B-GP
receptor	E-GP
A	O
expression	O
with	O
hormonal	O
mammary	O
carcinogenesis	O
:	O
role	O
of	O
the	O
host	O
microenvironment	O
.	O
INTRODUCTION	O
:	O
Medroxyprogesterone	B-chemical
acetate	E-chemical
(	O
MPA	S-chemical
)	O
induces	O
estrogen	B-GP
receptor	E-GP
(	O
ER	S-GP
)	O
-positive	O
and	O
progesterone	B-GP
receptor	E-GP
(	O
PR	S-GP
)	O
-positive	O
ductal	O
invasive	O
mammary	O
carcinomas	O
in	O
BALB/c	O
mice	O
.	O
We	O
sought	O
to	O
reproduce	O
this	O
MPA	S-chemical
cancer	O
model	O
in	O
C57BL/6	O
mice	O
because	O
of	O
their	O
widespread	O
use	O
in	O
genetic	O
engineering	O
.	O
Within	O
this	O
experimental	O
setting	O
,	O
we	O
studied	O
the	O
carcinogenic	O
effects	O
of	O
MPA	S-chemical
,	O
the	O
morphologic	O
changes	O
in	O
mammary	O
glands	O
that	O
are	O
induced	O
by	O
MPA	S-chemical
and	O
progesterone	S-chemical
,	O
and	O
the	O
levels	O
of	O
ER	S-GP
and	O
PR	S-GP
expression	O
in	O
MPA	S-chemical
-treated	O
and	O
progesterone	S-chemical
-treated	O
mammary	O
glands	O
.	O
Finally	O
,	O
we	O
evaluated	O
whether	O
the	O
differences	O
found	O
between	O
BALB/c	O
and	O
C57BL/6	O
mouse	O
strains	O
were	O
due	O
to	O
intrinsic	O
differences	O
in	O
epithelial	O
cells	O
.	O
METHODS	O
:	O
The	O
carcinogenic	O
effect	O
of	O
MPA	S-chemical
was	O
evaluated	O
in	O
C57BL/6	O
mice	O
using	O
protocols	O
proven	O
to	O
be	O
carcinogenic	O
in	O
BALB/c	O
mice	O
.	O
In	O
addition	O
,	O
BALB/c	O
and	O
C57BL/6	O
females	O
were	O
treated	O
with	O
progesterone	S-chemical
or	O
MPA	S-chemical
for	O
1	O
or	O
2	O
months	O
,	O
and	O
mammary	O
glands	O
were	O
excised	O
for	O
histologic	O
studies	O
and	O
for	O
immunohistochemical	O
and	O
Western	O
blot	O
evaluation	O
of	O
ER	S-GP
and	O
PR	S-GP
.	O
Hormone	O
levels	O
were	O
determined	O
by	O
radioimmunoassay	O
.	O
Isolated	O
mammary	O
epithelial	O
cells	O
were	O
transplanted	O
into	O
cleared	O
fat	O
pads	O
of	O
21-day-old	O
female	O
Swiss	O
nu/nu	O
mice	O
or	O
control	O
congenic	O
animals	O
.	O
RESULTS	O
:	O
MPA	S-chemical
failed	O
to	O
induce	O
mammary	O
carcinomas	O
or	O
significant	O
morphologic	O
changes	O
in	O
the	O
mammary	O
glands	O
of	O
C57BL/6	O
mice	O
.	O
The	O
expression	O
of	O
ER-alpha	S-GP
and	O
PR	B-GP
isoform	I-GP
A	E-GP
in	O
virgin	O
mice	O
was	O
surprisingly	O
much	O
higher	O
in	O
BALB/c	O
than	O
in	O
C57BL/6	O
mammary	O
glands	O
,	O
and	O
both	O
receptors	O
were	O
downregulated	O
in	O
progestin	S-chemical
-treated	O
BALB/c	O
mice	O
(	O
P	O
<	O
0.05	O
)	O
.	O
PR	B-GP
isoform	I-GP
B	E-GP
levels	O
were	O
low	O
in	O
virgin	O
control	O
mice	O
and	O
increased	O
after	O
progestin	S-chemical
treatment	O
in	O
both	O
strains	O
.	O
ER-beta	S-GP
expression	O
followed	O
a	O
similar	O
trend	O
.	O
No	O
differences	O
in	O
hormone	O
levels	O
were	O
found	O
between	O
strains	O
.	O
Surprisingly	O
,	O
the	O
transplantation	O
of	O
the	O
epithelial	O
mammary	O
gland	O
cells	O
of	O
both	O
strains	O
into	O
the	O
cleared	O
fat	O
pads	O
of	O
Swiss	O
(	O
nu/nu	O
)	O
mice	O
abolished	O
the	O
mammary	O
gland	O
morphologic	O
differences	O
and	O
the	O
ER	S-GP
and	O
PR	S-GP
differences	O
between	O
strains	O
.	O
CONCLUSION	O
:	O
C57BL/6	O
mammary	O
glands	O
are	O
resistant	O
to	O
MPA	S-chemical
-induced	O
carcinogenesis	O
and	O
to	O
hormone	O
action	O
.	O
MPA	S-chemical
and	O
progesterone	S-chemical
have	O
different	O
effects	O
on	O
mammary	O
glands	O
.	O
Low	O
ER-alpha	S-GP
and	O
PR-A	S-GP
levels	O
in	O
untreated	O
mammary	O
glands	O
may	O
be	O
associated	O
with	O
a	O
low-risk	O
breast	O
cancer	O
profile	O
.	O
Although	O
we	O
can	O
not	O
at	O
this	O
time	O
rule	O
out	O
the	O
participation	O
of	O
other	O
,	O
untested	O
factors	O
,	O
our	O
findings	O
implicate	O
the	O
stroma	O
as	O
playing	O
a	O
crucial	O
role	O
in	O
the	O
strain-specific	O
differential	O
hormone	B-GP
receptor	E-GP
expression	O
and	O
hormone	O
responsiveness	O
.	O

GABA	B-GP
(	I-GP
A	I-GP
)	I-GP
receptors	E-GP
as	O
molecular	O
targets	O
of	O
general	O
anesthetics	O
:	O
identification	O
of	O
binding	O
sites	O
provides	O
clues	O
to	O
allosteric	O
modulation	O
.	O
PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
summarize	O
current	O
knowledge	O
of	O
detailed	O
biochemical	O
evidence	O
for	O
the	O
role	O
of	O
gamma-aminobutyric	B-GP
acid	I-GP
type	I-GP
A	I-GP
receptors	E-GP
(	O
GABA	B-GP
(	I-GP
A	I-GP
)	I-GP
-Rs	E-GP
)	O
in	O
the	O
mechanisms	O
of	O
general	O
anesthesia	O
.	O
PRINCIPAL	O
FINDINGS	O
:	O
With	O
the	O
knowledge	O
that	O
all	O
general	O
anesthetics	O
positively	O
modulate	O
GABA	B-GP
(	I-GP
A	I-GP
)	I-GP
-R	E-GP
-mediated	O
inhibitory	O
transmission	O
,	O
site-directed	O
mutagenesis	O
comparing	O
sequences	O
of	O
GABA	B-GP
(	I-GP
A	I-GP
)	I-GP
-R	E-GP
subunits	O
of	O
varying	O
sensitivity	O
led	O
to	O
identification	O
of	O
amino	B-chemical
acid	E-chemical
residues	O
in	O
the	O
transmembrane	O
domain	O
that	O
are	O
critical	O
for	O
the	O
drug	O
actions	O
in	O
vitro	O
.	O
Using	O
a	O
photo	O
incorporable	O
analogue	O
of	O
the	O
general	O
anesthetic	O
,	O
R	B-chemical
(	I-chemical
+	I-chemical
)	I-chemical
etomidate	E-chemical
,	O
we	O
identified	O
two	O
transmembrane	O
amino	B-chemical
acids	E-chemical
that	O
were	O
affinity	O
labelled	O
in	O
purified	O
bovine	B-GP
brain	I-GP
GABA	I-GP
(	I-GP
A	I-GP
)	I-GP
-R	E-GP
.	O
Homology	O
protein	O
structural	O
modelling	O
positions	O
these	O
two	O
residues	O
,	O
alphaM1-11	O
'	O
and	O
betaM3-4	O
'	O
,	O
close	O
to	O
each	O
other	O
in	O
a	O
single	O
type	O
of	O
intersubunit	B-GP
etomidate	I-GP
binding	I-GP
pocket	E-GP
at	O
the	O
beta/alpha	B-GP
interface	E-GP
.	O
This	O
position	O
would	O
be	O
appropriate	O
for	O
modulation	O
of	O
agonist	O
channel	O
gating	O
.	O
Overall	O
,	O
available	O
information	O
suggests	O
that	O
these	O
two	O
etomidate	S-chemical
binding	O
residues	O
are	O
allosterically	O
coupled	O
to	O
sites	O
of	O
action	O
of	O
steroids	S-chemical
,	O
barbiturates	S-chemical
,	O
volatile	O
agents	O
,	O
and	O
propofol	S-chemical
,	O
but	O
not	O
alcohols	S-chemical
.	O
Residue	O
alpha/betaM2-15	O
'	O
is	O
probably	O
not	O
a	O
binding	O
site	O
but	O
allosterically	O
coupled	O
to	O
action	O
of	O
volatile	O
agents	O
,	O
alcohols	S-chemical
,	O
and	O
intravenous	O
agents	O
,	O
and	O
alpha/betaM1-	O
(	O
-2	O
'	O
)	O
is	O
coupled	O
to	O
action	O
of	O
intravenous	O
agents	O
.	O
CONCLUSIONS	O
:	O
Establishment	O
of	O
a	O
coherent	O
and	O
consistent	O
structural	O
model	O
of	O
the	O
GABA	B-GP
(	I-GP
A	I-GP
)	I-GP
-R	E-GP
lends	O
support	O
to	O
the	O
conclusion	O
that	O
general	O
anesthetics	O
can	O
modulate	O
function	O
by	O
binding	O
to	O
appropriate	O
domains	O
on	O
the	O
protein	O
.	O
Genetic	O
engineering	O
of	O
mice	O
with	O
mutation	O
in	O
some	O
of	O
these	O
GABA	B-GP
(	I-GP
A	I-GP
)	I-GP
-R	E-GP
residues	O
are	O
insensitive	O
to	O
general	O
anesthetics	O
in	O
vivo	O
,	O
suggesting	O
that	O
further	O
analysis	O
of	O
these	O
domains	O
could	O
lead	O
to	O
development	O
of	O
more	O
potent	O
and	O
specific	O
drugs	O
.	O

Repeated	O
Low	O
Dose	O
Administration	O
of	O
the	O
Monoacylglycerol	S-chemical

Evaluation	O
of	O
histamine	B-GP
H1-	I-GP
,	I-GP
H2-	I-GP
,	I-GP
and	I-GP
H3-receptor	E-GP
ligands	O
at	O
the	O
human	B-GP
histamine	I-GP
H4	I-GP
receptor	E-GP
:	O
identification	O
of	O
4-methylhistamine	S-chemical
as	O
the	O
first	O
potent	O
and	O
selective	O
H4	B-GP
receptor	E-GP
agonist	O
.	O
The	O
histamine	B-GP
H	I-GP
(	I-GP
4	I-GP
)	I-GP
receptor	E-GP
(	O
H	B-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
)	O
is	O
involved	O
in	O
the	O
chemotaxis	O
of	O
leukocytes	O
and	O
mast	O
cells	O
to	O
sites	O
of	O
inflammation	O
and	O
is	O
suggested	O
to	O
be	O
a	O
potential	O
drug	O
target	O
for	O
asthma	O
and	O
allergy	O
.	O
So	O
far	O
,	O
selective	O
H	B-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
agonists	O
have	O
not	O
been	O
identified	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
therefore	O
evaluated	O
the	O
human	B-GP
H	I-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
(	O
hH	B-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
)	O
for	O
its	O
interaction	O
with	O
various	O
known	O
histaminergic	O
ligands	O
.	O
Almost	O
all	O
of	O
the	O
tested	O
H	B-GP
(	I-GP
1	I-GP
)	I-GP
R	E-GP
and	O
H	B-GP
(	I-GP
2	I-GP
)	I-GP
R	E-GP
antagonists	O
,	O
including	O
several	O
important	O
therapeutics	O
,	O
displaced	O
less	O
than	O
30	O
%	O
of	O
specific	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
histamine	E-chemical
binding	O
to	O
the	O
hH	B-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
at	O
concentrations	O
up	O
to	O
10	O
microM	O
.	O
Most	O
of	O
the	O
tested	O
H	B-GP
(	I-GP
2	I-GP
)	I-GP
R	E-GP
agonists	O
and	O
imidazole	S-chemical
-based	O
H	B-GP
(	I-GP
3	I-GP
)	I-GP
R	E-GP
ligands	O
show	O
micromolar-to-nanomolar	O
range	O
hH	B-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
affinity	O
,	O
and	O
these	O
ligands	O
exert	O
different	O
intrinsic	O
hH	B-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
activities	O
,	O
ranging	O
from	O
full	O
agonists	O
to	O
inverse	O
agonists	O
.	O
Interestingly	O
,	O
we	O
identified	O
4-methylhistamine	S-chemical
as	O
a	O
high-affinity	O
H	B-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
ligand	O
(	O
K	O
(	O
i	O
)	O
=	O
50	O
nM	O
)	O
that	O
has	O
a	O
>	O
100-fold	O
selectivity	O
for	O
the	O
hH	B-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
over	O
the	O
other	O
histamine	B-GP
receptor	E-GP
subtypes	O
.	O
Moreover	O
,	O
4-methylhistamine	S-chemical
potently	O
activated	O
the	O
hH	B-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
(	O
pEC	O
(	O
50	O
)	O
=	O
7.4	O
+/-	O
0.1	O
;	O
alpha	O
=	O
1	O
)	O
,	O
and	O
this	O
response	O
was	O
competitively	O
antagonized	O
by	O
the	O
selective	O
H	B-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
antagonist	O
JNJ	B-chemical
7777120	E-chemical
[	O
1-	B-chemical
[	I-chemical
(	I-chemical
5-chloro-1H-indol-2-yl	I-chemical
)	I-chemical
-carbonyl	I-chemical
]	I-chemical
-4-methylpiperazine	E-chemical
]	O
(	O
pA	O
(	O
2	O
)	O
=	O
7.8	O
)	O
.	O
The	O
identification	O
of	O
4-methylhistamine	S-chemical
as	O
a	O
potent	O
H	B-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
agonist	O
is	O
of	O
major	O
importance	O
for	O
future	O
studies	O
to	O
unravel	O
the	O
physiological	O
roles	O
of	O
the	O
H	B-GP
(	I-GP
4	I-GP
)	I-GP
R	E-GP
.	O

Toosendanin	S-chemical
induces	O
apoptosis	O
through	O
suppression	O
of	O
JNK	S-GP
signaling	O
pathway	O
in	O
HL-60	O
cells	O
.	O
Toosendanin	S-chemical
(	O
TSN	S-chemical
)	O
,	O
a	O
triterpenoid	S-chemical
isolated	O
from	O
Melia	O
toosendan	O
Sieb	O
.	O
et	O
Zucc.	O
,	O
has	O
been	O
found	O
to	O
suppress	O
proliferation	O
and	O
induce	O
apoptosis	O
in	O
a	O
variety	O
of	O
human	O
cancer	O
cells	O
.	O
However	O
,	O
the	O
mechanism	O
how	O
TSN	S-chemical
induces	O
apoptosis	O
remains	O
poorly	O
understood	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
TSN	S-chemical
on	O
the	O
growth	O
,	O
cell	O
cycle	O
arrest	O
,	O
induction	O
of	O
apoptosis	O
and	O
the	O
involved	O
signaling	O
pathway	O
in	O
human	O
promyelocytic	O
leukemia	O
HL-60	O
cells	O
.	O
Proliferation	O
of	O
HL-60	O
cells	O
was	O
inhibited	O
in	O
a	O
dose-dependent	O
manner	O
with	O
the	O
IC	O
(	O
50	O
(	O
48	O
h	O
)	O
)	O
of	O
28	O
ng/mL	O
.	O
The	O
growth	O
inhibition	O
was	O
due	O
primarily	O
to	O
the	O
S	O
phase	O
arrest	O
and	O
cell	O
apoptosis	O
.	O
Cell	O
apoptosis	O
induced	O
by	O
TSN	S-chemical
was	O
confirmed	O
by	O
Annexin	O
V-	O
FITC	S-chemical
/	O
propidium	B-chemical
iodide	E-chemical
staining	O
.	O
The	O
increase	O
of	O
the	O
pro-apoptotic	O
protein	O
Bax	S-GP
,	O
cleaved	O
PARP	S-GP
and	O
caspase-3	S-GP
,	O
and	O
the	O
decrease	O
of	O
anti-apoptotic	O
protein	O
Bcl-2	S-GP
were	O
observed	O
.	O
Western	O
blot	O
analysis	O
indicated	O
that	O
TSN	S-chemical
inhibits	O
the	O
CDC42	S-GP
/	O
MEKK1	S-GP
/	O
JNK	S-GP
pathway	O
.	O
Taken	O
together	O
,	O
our	O
study	O
suggested	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
the	O
pro-apoptotic	O
effects	O
of	O
TSN	S-chemical
on	O
HL-60	O
cells	O
were	O
mediated	O
through	O
JNK	S-GP
signaling	O
pathway	O
.	O

Guidance	O
on	O
the	O
use	O
of	O
miglustat	S-chemical
for	O
treating	O
patients	O
with	O
type	O
1	O
Gaucher	O
disease	O
.	O
Type	O
1	O
Gaucher	O
disease	O
(	O
GD	O
)	O
is	O
a	O
progressive	O
lysosomal	O
storage	O
disorder	O
due	O
to	O
an	O
autosomal	O
recessive	O
deficiency	O
of	O
glucocerebrosidase	S-GP
.	O
Clinical	O
manifestations	O
include	O
anemia	O
,	O
thrombocytopenia	O
,	O
hepatosplenomegaly	O
,	O
and	O
bone	O
and	O
pulmonary	O
disease	O
.	O
Intravenous	O
enzyme	O
replacement	O
(	O
ERT	O
)	O
with	O
imiglucerase	O
is	O
the	O
accepted	O
standard	O
for	O
treatment	O
of	O
symptomatic	O
patients	O
.	O
More	O
than	O
3,500	O
patients	O
worldwide	O
have	O
received	O
ERT	O
with	O
well-documented	O
beneficial	O
effects	O
on	O
the	O
hematological	O
,	O
visceral	O
,	O
skeletal	O
,	O
and	O
pulmonary	O
manifestations	O
,	O
and	O
with	O
resultant	O
improvement	O
in	O
health-related	O
quality	O
of	O
life	O
.	O
Miglustat	S-chemical
,	O
an	O
imino	B-chemical
sugar	E-chemical
that	O
reversibly	O
inhibits	O
glucosylceramide	B-GP
synthase	E-GP
and	O
reduces	O
intracellular	O
substrate	O
burden	O
,	O
is	O
an	O
oral	O
treatment	O
for	O
patients	O
with	O
type	O
1	O
GD	O
that	O
was	O
recently	O
approved	O
in	O
the	O
United	O
States	O
for	O
symptomatic	O
patients	O
with	O
mild	O
to	O
moderate	O
clinical	O
manifestations	O
for	O
whom	O
ERT	O
is	O
not	O
an	O
option	O
.	O
Because	O
responses	O
to	O
miglustat	S-chemical
are	O
slower	O
and	O
less	O
robust	O
than	O
those	O
observed	O
with	O
ERT	O
,	O
and	O
because	O
miglustat	S-chemical
is	O
associated	O
with	O
significant	O
side	O
effects	O
,	O
clinicians	O
who	O
care	O
for	O
patients	O
with	O
GD	O
should	O
become	O
familiar	O
with	O
the	O
limited	O
indications	O
for	O
miglustat	S-chemical
use	O
and	O
the	O
circumstances	O
when	O
it	O
may	O
be	O
prescribed	O
appropriately	O
.	O
This	O
review	O
article	O
and	O
position	O
statement	O
represents	O
the	O
current	O
opinion	O
of	O
American	O
physicians	O
with	O
extensive	O
expertise	O
in	O
GD	O
regarding	O
patient	O
management	O
in	O
the	O
context	O
of	O
the	O
availability	O
of	O
standard	O
imiglucerase	O
treatment	O
and	O
the	O
recent	O
introduction	O
of	O
miglustat	S-chemical
.	O

Inhibitory	O
effects	O
of	O
lysine	S-chemical
analogues	O
on	O
t-PA	S-GP
induced	O
whole	O
blood	O
clot	O
lysis	O
.	O
The	O
lysine	S-chemical
analogues	O
epsilon-aminocaproic	B-chemical
acid	E-chemical
(	O
EACA	S-chemical
)	O
and	O
trans-4-amino-methyl	B-chemical
cyclohexane	I-chemical
carboxylic	I-chemical
acid	E-chemical
(	O
AMCA	S-chemical
)	O
are	O
used	O
to	O
prevent	O
excessive	O
bleeding	O
in	O
patients	O
with	O
coagulopathies	O
,	O
such	O
as	O
hemophilia	O
and	O
thrombocytopenia	O
,	O
or	O
in	O
those	O
who	O
have	O
received	O
tissue	B-GP
plasminogen	I-GP
activator	E-GP
(	O
t-PA	S-GP
)	O
.	O
However	O
,	O
their	O
relative	O
efficacy	O
in	O
inhibiting	O
lysis	O
of	O
clots	O
that	O
have	O
been	O
formed	O
in	O
the	O
presence	O
of	O
exogenous	O
t-PA	S-GP
or	O
that	O
have	O
been	O
formed	O
and	O
then	O
exposed	O
to	O
exogenous	O
t-PA	S-GP
has	O
not	O
been	O
well	O
characterized	O
.	O
The	O
present	O
study	O
utilized	O
blood	O
from	O
normal	O
volunteers	O
and	O
125I	S-chemical
-	O
fibrinogen	S-GP
in	O
a	O
dilute	O
whole	O
blood	O
clot	O
assay	O
to	O
determine	O
the	O
relative	O
concentrations	O
of	O
lysine	S-chemical
analogues	O
required	O
for	O
inhibition	O
of	O
clot	O
lysis	O
induced	O
by	O
exogenous	O
t-PA	S-GP
.	O
AMCA	S-chemical
(	O
0.06	O
mM	O
)	O
and	O
EACA	S-chemical
(	O
0.6	O
mM	O
)	O
were	O
effective	O
in	O
prolonging	O
clot	O
lysis	O
if	O
(	O
1	O
)	O
whole	O
blood	O
clots	O
were	O
formed	O
and	O
then	O
exposed	O
to	O
a	O
lysine	S-chemical
analogue	O
and	O
exogenous	O
t-PA	S-GP
or	O
if	O
(	O
2	O
)	O
whole	O
blood	O
clots	O
were	O
formed	O
in	O
the	O
presence	O
of	O
exogenous	O
t-PA	S-GP
and	O
a	O
lysine	S-chemical
analogue	O
.	O
However	O
,	O
their	O
inhibitory	O
effect	O
was	O
markedly	O
reduced	O
if	O
clots	O
were	O
formed	O
in	O
the	O
presence	O
of	O
t-PA	S-GP
and	O
then	O
exposed	O
to	O
either	O
of	O
the	O
lysine	S-chemical
analogues	O
.	O
The	O
analogues	O
did	O
not	O
inhibit	O
the	O
initial	O
binding	O
of	O
t-PA	S-GP
to	O
fibrin	S-GP
.	O
They	O
did	O
inhibit	O
binding	O
of	O
plasminogen	S-GP
to	O
fibrin	S-GP
as	O
well	O
as	O
the	O
activation	O
of	O
plasminogen	S-GP
by	O
t-PA	S-GP
in	O
the	O
absence	O
of	O
fibrin	S-GP
.	O
The	O
data	O
suggest	O
that	O
lysine	S-chemical
analogues	O
,	O
even	O
at	O
low	O
concentrations	O
,	O
reduce	O
the	O
rate	O
of	O
t-PA	S-GP
induced	O
whole	O
blood	O
clot	O
lysis	O
by	O
several	O
mechanisms	O
.	O

Striatal	O
dopamine	S-chemical
,	O
dopamine	B-GP
transporter	E-GP
,	O
and	O
vesicular	B-GP
monoamine	I-GP
transporter	E-GP
in	O
chronic	O
cocaine	S-chemical
users	O
.	O
Depletion	O
of	O
striatal	O
dopamine	S-chemical
(	O
DA	S-chemical
)	O
has	O
been	O
hypothesized	O
to	O
explain	O
some	O
of	O
the	O
neurological	O
and	O
psychiatric	O
complications	O
of	O
chronic	O
use	O
of	O
cocaine	S-chemical
,	O
including	O
increased	O
risk	O
for	O
neuroleptic-precipitated	O
movement	O
disorders	O
.	O
We	O
measured	O
levels	O
of	O
DA	S-chemical
,	O
as	O
well	O
as	O
two	O
DA	S-chemical
nerve	O
terminal	O
indices	O
,	O
namely	O
,	O
the	O
DA	B-GP
transporter	E-GP
(	O
DAT	S-GP
)	O
and	O
the	O
vesicular	B-GP
monoamine	I-GP
transporter	E-GP
(	O
VMAT2	S-GP
)	O
in	O
autopsied	O
brain	O
of	O
12	O
chronic	O
cocaine	S-chemical
users	O
.	O
Mean	O
DA	S-chemical
levels	O
were	O
normal	O
in	O
the	O
putamen	O
,	O
the	O
motor	O
component	O
of	O
the	O
striatum	O
;	O
however	O
4	O
of	O
the	O
12	O
subjects	O
had	O
DA	S-chemical
values	O
below	O
the	O
lower	O
limit	O
of	O
the	O
control	O
range	O
.	O
DA	S-chemical
concentrations	O
were	O
significantly	O
reduced	O
in	O
the	O
caudate	O
head	O
(	O
head	O
,	O
-33	O
%	O
;	O
tail	O
,	O
-39	O
%	O
)	O
with	O
a	O
trend	O
for	O
reduction	O
in	O
nucleus	O
accumbens	O
(	O
-27	O
%	O
)	O
.	O
Striatal	O
DAT	S-GP
protein	O
(	O
-25	O
to	O
-46	O
%	O
)	O
and	O
VMAT2	S-GP
(	O
-17	O
to	O
-22	O
%	O
)	O
were	O
reduced	O
,	O
whereas	O
DAT	S-GP
determined	O
by	O
[	B-chemical
3H	I-chemical
]	I-chemical
WIN	I-chemical
35,428	E-chemical
binding	O
was	O
normal	O
.	O
In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
chronic	O
cocaine	S-chemical
use	O
is	O
associated	O
with	O
modestly	O
reduced	O
levels	O
of	O
striatal	O
DA	S-chemical
and	O
the	O
DA	B-GP
transporter	E-GP
in	O
some	O
subjects	O
and	O
that	O
these	O
changes	O
might	O
contribute	O
to	O
the	O
neurological	O
and	O
psychiatric	O
effects	O
of	O
the	O
drug	O
.	O

Annexin	B-GP
1	E-GP
regulation	O
in	O
human	O
epidermal	O
cells	O
.	O
Annexin	B-GP
1	E-GP
(	O
named	O
p35	S-GP
,	O
lipocortin	B-GP
I	E-GP
or	O
calpactin	B-GP
II	E-GP
)	O
,	O
initially	O
described	O
as	O
a	O
glucocorticoid	O
induced	O
protein	O
,	O
belongs	O
to	O
a	O
new	O
characterized	O
family	O
of	O
intracellular	O
proteins	O
.	O
In	O
the	O
skin	O
,	O
the	O
role	O
of	O
annexins	S-GP
has	O
still	O
not	O
been	O
elucidated	O
.	O
In	O
a	O
previous	O
study	O
,	O
we	O
reported	O
the	O
localization	O
of	O
annexin	B-GP
1	E-GP
in	O
both	O
freshly	O
isolated	O
human	O
epidermal	O
cells	O
and	O
in	O
cultured	O
keratinocytes	O
using	O
immunofluorescence	O
,	O
FACS	O
analysis	O
and	O
immunoblotting	O
techniques	O
.	O
The	O
protein	O
was	O
characterized	O
by	O
Western	O
blot	O
and	O
immunoprecipitation	O
as	O
a	O
35	O
kDa	O
protein	O
.	O
Results	O
from	O
in	O
vivo	O
studies	O
confirmed	O
the	O
presence	O
of	O
annexin	B-GP
1	E-GP
in	O
basal	O
and	O
suprabasal	O
layers	O
of	O
normal	O
human	O
skin	O
with	O
modified	O
reactivity	O
patterns	O
in	O
hyperproliferative	O
lesions	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
glucocorticoids	O
in	O
annexin	B-GP
1	E-GP
regulation	O
was	O
investigated	O
in	O
epidermal	O
cells	O
by	O
Western	O
blot	O
and	O
immunoprecipation	O
assays	O
.	O
In	O
contrast	O
to	O
other	O
studies	O
,	O
we	O
found	O
that	O
glucocorticoid	O
treatment	O
of	O
epidermal	O
cells	O
led	O
to	O
a	O
decrease	O
in	O
annexin	B-GP
1	E-GP
content	O
in	O
the	O
cytoplasm	O
and	O
the	O
membranes	O
of	O
cells	O
.	O
As	O
annexin	B-GP
1	E-GP
was	O
not	O
detected	O
in	O
the	O
nucleus	O
of	O
cells	O
,	O
we	O
conclude	O
that	O
there	O
was	O
a	O
down	O
regulation	O
of	O
annexin	B-GP
1	E-GP
after	O
glucocorticoid	O
treatments	O
rather	O
than	O
a	O
translocation	O
of	O
the	O
protein	O
to	O
the	O
nucleus	O
.	O
Despite	O
the	O
absence	O
of	O
the	O
signal	O
peptide	O
sequence	O
necessary	O
for	O
protein	O
secretion	O
,	O
annexin	B-GP
1	E-GP
was	O
released	O
in	O
the	O
keratinocyte	O
culture	O
medium	O
.	O
We	O
found	O
that	O
the	O
protein	O
was	O
secreted	O
only	O
in	O
low	O
Ca2+	S-chemical
medium	O
(	O
0.15	O
mM	O
)	O
,	O
this	O
process	O
required	O
an	O
active	O
metabolism	O
.	O

Amino	B-chemical
acid	E-chemical
residues	O
at	O
the	O
N-	O
and	O
C-termini	O
are	O
essential	O
for	O
the	O
folding	O
of	O
active	O
human	B-GP
butyrylcholinesterase	E-GP
polypeptide	O
.	O
Human	B-GP
serum	I-GP
butyrylcholinesterase	E-GP
(	O
HuBChE	S-GP
)	O
is	O
currently	O
the	O
most	O
suitable	O
bioscavenger	O
for	O
the	O
prophylaxis	O
of	O
highly	O
toxic	O
organophosphate	S-chemical
(	O
OP	O
)	O
nerve	O
agents	O
.	O
A	O
dose	O
of	O
200mg	O
of	O
HuBChE	S-GP
is	O
envisioned	O
as	O
a	O
prophylactic	O
treatment	O
that	O
can	O
protect	O
humans	O
from	O
an	O
exposure	O
of	O
up	O
to	O
2×LD50	O
of	O
soman	O
.	O
The	O
limited	O
availability	O
and	O
administration	O
of	O
multiple	O
doses	O
of	O
this	O
stoichiometric	O
bioscavenger	O
make	O
this	O
pretreatment	O
difficult	O
.	O
Thus	O
,	O
the	O
goal	O
of	O
this	O
study	O
was	O
to	O
produce	O
a	O
smaller	O
enzymatically	O
active	O
HuBChE	S-GP
polypeptide	O
(	O
HBP	O
)	O
that	O
could	O
bind	O
to	O
nerve	O
agents	O
with	O
high	O
affinity	O
thereby	O
reducing	O
the	O
dose	O
of	O
enzyme	O
.	O
Studies	O
have	O
indicated	O
that	O
the	O
three-dimensional	O
structure	O
and	O
the	O
domains	O
of	O
HuBChE	S-GP
(	O
acyl	S-chemical
pocket	O
,	O
lip	O
of	O
the	O
active	O
center	O
gorge	O
,	O
and	O
the	O
anionic	O
substrate-binding	O
domain	O
)	O
that	O
are	O
critical	O
for	O
the	O
binding	O
of	O
substrate	O
are	O
also	O
essential	O
for	O
the	O
selectivity	O
and	O
binding	O
of	O
inhibitors	O
including	O
OPs	O
.	O
Therefore	O
,	O
we	O
designed	O
three	O
HBPs	O
by	O
deleting	O
some	O
N-	O
and	O
C-terminal	O
residues	O
of	O
HuBChE	S-GP
by	O
maintaining	O
the	O
folds	O
of	O
the	O
active	O
site	O
core	O
that	O
includes	O
the	O
three	O
active	O
site	O
residues	O
(	O
S198	O
,	O
E325	O
,	O
and	O
H438	O
)	O
.	O
HBP-4	S-GP
that	O
lacks	O
45	O
residues	O
from	O
C-terminus	O
but	O
known	O
to	O
have	O
BChE	S-GP
activity	O
was	O
used	O
as	O
a	O
control	O
.	O
The	O
cDNAs	O
for	O
the	O
HBPs	O
containing	O
signal	O
sequences	O
were	O
synthesized	O
,	O
cloned	O
into	O
different	O
mammalian	O
expression	O
vectors	O
,	O
and	O
recombinant	O
polypeptides	O
were	O
transiently	O
expressed	O
in	O
different	O
cell	O
lines	O
.	O
No	O
BChE	S-GP
activity	O
was	O
detected	O
in	O
the	O
culture	O
media	O
of	O
cells	O
transfected	O
with	O
any	O
of	O
the	O
newly	O
designed	O
HBPs	O
,	O
and	O
the	O
inactive	O
polypeptides	O
remained	O
inside	O
the	O
cells	O
.	O
Only	O
enzymatically	O
active	O
HBP-4	S-GP
was	O
secreted	O
into	O
the	O
culture	O
medium	O
.	O
These	O
results	O
suggest	O
that	O
residues	O
at	O
the	O
N-	O
and	O
C-termini	O
are	O
required	O
for	O
the	O
folding	O
and/or	O
maintenance	O
of	O
HBP	O
into	O
an	O
active	O
stable	O
,	O
conformation	O
.	O

Characterization	O
of	O
binding	O
sites	O
of	O
a	O
new	O
neurotensin	B-GP
receptor	E-GP
antagonist	O
,	O
[	B-chemical
3H	I-chemical
]	I-chemical
SR	I-chemical
142948A	E-chemical
,	O
in	O
the	O
rat	O
brain	O
.	O
The	O
present	O
study	O
describes	O
the	O
characterization	O
of	O
the	O
binding	O
properties	O
and	O
autoradiographic	O
distribution	O
of	O
a	O
new	O
nonpeptide	O
antagonist	O
of	O
neurotensin	B-GP
receptors	E-GP
,	O
[	B-chemical
3H	I-chemical
]	I-chemical
SR	I-chemical
142948A	E-chemical
(	O
2-	B-chemical
[	I-chemical
[	I-chemical
5-	I-chemical
(	I-chemical
2,6-dimethoxyphenyl	I-chemical
)	I-chemical
-1-	I-chemical
(	I-chemical
4-	I-chemical
(	I-chemical
N-	I-chemical
(	I-chemical
3-dimethylaminopropyl	I-chemical
)	I-chemical
-N-methyl	I-chemical
carbamoyl	I-chemical
)	I-chemical
-2-isopropylphenyl	I-chemical
)	I-chemical
-1H-pyrazole-3-carbonyl	I-chemical
]	I-chemical
-amino	I-chemical
]	I-chemical
-ad	I-chemical
amantane-2-carboxylic	I-chemical
acid	I-chemical
,	I-chemical
hydrochloride	E-chemical
)	O
,	O
in	O
the	O
rat	O
brain	O
.	O
The	O
binding	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
SR	I-chemical
142948A	E-chemical
in	O
brain	O
membrane	O
homogenates	O
was	O
specific	O
,	O
time-dependent	O
,	O
reversible	O
and	O
saturable	O
.	O
[	B-chemical
3H	I-chemical
]	I-chemical
SR	I-chemical
142948A	E-chemical
bound	O
to	O
an	O
apparently	O
homogeneous	O
population	O
of	O
sites	O
,	O
with	O
a	O
Kd	O
of	O
3.5	O
nM	O
and	O
a	O
Bmax	O
value	O
of	O
508	O
fmol/mg	O
of	O
protein	O
,	O
which	O
was	O
80	O
%	O
higher	O
than	O
that	O
observed	O
in	O
saturation	O
experiments	O
with	O
[	B-chemical
3H	I-chemical
]	I-chemical
neurotensin	E-chemical
.	O
[	B-chemical
3H	I-chemical
]	I-chemical
SR	I-chemical
142948A	E-chemical
binding	O
was	O
inhibited	O
by	O
SR	B-chemical
142948A	E-chemical
,	O
the	O
related	O
nonpeptide	O
receptor	O
antagonist	O
,	O
SR	B-chemical
48692	E-chemical
(	O
2-	B-chemical
[	I-chemical
[	I-chemical
1-	I-chemical
(	I-chemical
7-chloroquinolin-4-yl	I-chemical
)	I-chemical
-5-	I-chemical
(	I-chemical
2,6-dimethoxyphenyl	I-chemical
)	I-chemical
-1H-pyrazole	I-chemical
-3-carbonyl	I-chemical
]	I-chemical
amino	I-chemical
]	I-chemical
-adamantane-2-carboxylic	I-chemical
acid	E-chemical
)	O
and	O
neurotensin	S-chemical
.	O
Saturation	O
and	O
competition	O
studies	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
histamine	B-GP
H1	I-GP
receptor	E-GP
antagonist	O
,	O
levocabastine	S-chemical
,	O
revealed	O
that	O
[	B-chemical
3H	I-chemical
]	I-chemical
SR	I-chemical
142948A	E-chemical
bound	O
with	O
similar	O
affinities	O
to	O
both	O
the	O
levocabastine	S-chemical
-insensitive	O
neurotensin	B-GP
NT1	I-GP
receptors	E-GP
(	O
20	O
%	O
of	O
the	O
total	O
binding	O
population	O
)	O
and	O
the	O
recently	O
cloned	O
levocabastine	S-chemical
-sensitive	O
neurotensin	B-GP
NT2	I-GP
receptors	E-GP
(	O
80	O
%	O
of	O
the	O
receptors	O
)	O
(	O
Kd	O
=	O
6.8	O
and	O
4.8	O
nM	O
,	O
respectively	O
)	O
.	O
The	O
regional	O
distribution	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
SR	I-chemical
142948A	E-chemical
binding	O
in	O
the	O
rat	O
brain	O
closely	O
matched	O
the	O
distribution	O
of	O
[	B-chemical
125I	I-chemical
]	I-chemical
neurotensin	E-chemical
binding	O
.	O
In	O
conclusion	O
,	O
these	O
findings	O
indicate	O
that	O
[	B-chemical
3H	I-chemical
]	I-chemical
SR	I-chemical
142948A	E-chemical
is	O
a	O
new	O
potent	O
antagonist	O
radioligand	O
which	O
recognizes	O
with	O
high	O
affinity	O
both	O
neurotensin	B-GP
NT1	E-GP
and	O
NT2	B-GP
receptors	E-GP
and	O
represents	O
thus	O
an	O
excellent	O
tool	O
to	O
study	O
neurotensin	B-GP
receptors	E-GP
in	O
the	O
rat	O
brain	O
.	O

Extracellular	B-GP
loop	I-GP
II	E-GP
modulates	O
GTP	S-chemical
sensitivity	O
of	O
the	O
prostaglandin	B-GP
EP3	I-GP
receptor	E-GP
.	O
Unlike	O
the	O
majority	O
of	O
G	B-GP
protein-coupled	I-GP
receptors	E-GP
,	O
the	O
prostaglandin	B-GP
E	I-GP
(	I-GP
2	I-GP
)	I-GP
(	I-GP
PGE	I-GP
(	I-GP
2	I-GP
)	I-GP
)	I-GP
E-prostanoid	I-GP
3	I-GP
(	I-GP
EP3	I-GP
)	I-GP
receptor	E-GP
binds	O
agonist	O
with	O
high	O
affinity	O
that	O
is	O
insensitive	O
to	O
the	O
presence	O
of	O
guanosine	B-chemical
5	I-chemical
[	I-chemical
prime	I-chemical
]	I-chemical
-O-	I-chemical
(	I-chemical
3-thio	I-chemical
)	I-chemical
triphosphate	E-chemical
(	O
GTPγS	S-chemical
)	O
.	O
We	O
report	O
the	O
identification	O
of	O
mutations	O
that	O
confer	O
GTPγS	S-chemical
sensitivity	O
to	O
agonist	O
binding	O
.	O
Seven	O
point	O
mutations	O
were	O
introduced	O
into	O
the	O
conserved	O
motif	O
in	O
the	O
second	B-GP
extracellular	I-GP
loop	E-GP
(	O
ECII	S-GP
)	O
of	O
EP3	S-GP
,	O
resulting	O
in	O
acquisition	O
of	O
GTP	S-chemical
-sensitive	O
agonist	O
binding	O
.	O
One	O
receptor	O
mutation	O
W203A	S-GP
was	O
studied	O
in	O
detail	O
.	O
Loss	O
of	O
agonist	O
binding	O
was	O
observed	O
on	O
intact	O
human	O
embryonic	O
kidney	O
293	O
cells	O
expressing	O
the	O
W203A	S-GP
receptor	O
,	O
conditions	O
where	O
high	O
GTP	S-chemical
levels	O
are	O
present	O
;	O
however	O
,	O
high	O
affinity	O
binding	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
PGE	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
was	O
observed	O
in	O
broken	O
cell	O
preparations	O
washed	O
free	O
of	O
GTP	S-chemical
.	O
The	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
PGE	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
binding	O
of	O
W203A	S-GP
in	O
broken	O
cell	O
membrane	O
fractions	O
was	O
inhibited	O
by	O
addition	O
of	O
GTPγS	S-chemical
(	O
IC	O
(	O
50	O
)	O
21	O
±	O
1.8	O
nM	O
)	O
.	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
wild-type	O
EP3	S-GP
receptor	O
displays	O
unusual	O
characteristics	O
of	O
the	O
complex	O
coupled	O
equilibria	O
between	O
agonist-receptor	O
and	O
receptor-	O
G	B-GP
protein	E-GP
interaction	O
.	O
Moreover	O
,	O
mutation	O
of	O
ECII	S-GP
can	O
alter	O
this	O
coupled	O
equilibrium	O
from	O
GTP	S-chemical
-insensitive	O
agonist	O
binding	O
to	O
more	O
conventional	O
GTP	S-chemical
-sensitive	O
binding	O
.	O
This	O
suggests	O
that	O
for	O
the	O
mutant	O
receptors	O
,	O
ECII	S-GP
plays	O
a	O
critical	O
role	O
in	O
linking	O
the	O
agonist	O
bound	O
receptor	O
conformation	O
to	O
the	O
G	B-GP
protein	E-GP
nucleotide	S-chemical
bound	O
state	O
.	O

Nocapyrones	B-chemical
H-J	E-chemical
,	O
3,6-Disubstituted	B-chemical
α-Pyrones	E-chemical
from	O
the	O
Marine	O
Actinomycete	O
Nocardiopsis	O
sp	O
.	O
KMF-001	O
.	O
Three	O
new	O
3,6-disubstituted	B-chemical
α-pyrones	E-chemical
,	O
nocapyrones	B-chemical
H-J	E-chemical
(	O
1-3	O
)	O
,	O
were	O
isolated	O
from	O
the	O
marine	O
actinomycete	O
Nocardiopsis	O
sp	O
.	O
KMF-001	O
.	O
Their	O
structures	O
were	O
assigned	O
to	O
be	O
3-alkylated	B-chemical
6-	I-chemical
(	I-chemical
1-methyl-1-propenyl	I-chemical
)	I-chemical
-2H-pyran-2-ones	E-chemical
on	O
the	O
basis	O
of	O
UV	O
,	O
MS	O
,	O
NMR	O
,	O
and	O
high	O
resolution	O
(	O
HR	O
)	O
-FAB-MS	O
analyses	O
.	O
Nocapyrone	B-chemical
H	E-chemical
(	O
1	O
)	O
reduced	O
the	O
pro-inflammatory	O
factor	O
such	O
as	O
nitric	B-chemical
oxide	E-chemical
(	O
NO	S-chemical
)	O
,	O
prostaglandin	B-chemical
E2	E-chemical
(	O
PGE2	S-chemical
)	O
and	O
interleukin-1β	S-GP
(	O
IL-1β	S-GP
)	O
.	O
Moreover	O
,	O
nocapyrone	B-chemical
H	E-chemical
showed	O
5.82	O
%	O
stronger	O
inhibitory	O
effect	O
on	O
NO	S-chemical
production	O
than	O
chrysin	O
at	O
a	O
concentration	O
of	O
10	O
µm	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
BV-2	O
microglial	O
cells	O
.	O

Strain-dependent	O
dysregulation	O
of	O
one-	O
carbon	S-chemical
metabolism	O
in	O
male	O
mice	O
is	O
associated	O
with	O
choline	S-chemical
-	O
and	O
folate	S-chemical
-deficient	O
diet-induced	O
liver	O
injury	O
.	O
Dysregulation	O
of	O
one-	O
carbon	S-chemical
metabolism-related	O
metabolic	O
processes	O
is	O
a	O
major	O
contributor	O
to	O
the	O
pathogenesis	O
of	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
.	O
It	O
is	O
well	O
established	O
that	O
genetic	O
and	O
gender-specific	O
variations	O
in	O
one-	O
carbon	S-chemical
metabolism	O
contribute	O
to	O
the	O
vulnerability	O
to	O
NAFLD	O
in	O
humans	O
.	O
To	O
examine	O
the	O
role	O
of	O
one-	O
carbon	S-chemical
metabolism	O
dysregulation	O
in	O
the	O
pathogenesis	O
and	O
individual	O
susceptibility	O
to	O
NAFLD	O
,	O
we	O
used	O
a	O
``	O
population-based	O
''	O
mouse	O
model	O
where	O
male	O
mice	O
from	O
7	O
inbred	O
were	O
fed	O
a	O
choline	S-chemical
-	O
and	O
folate	S-chemical
-deficient	O
(	O
CFD	O
)	O
diet	O
for	O
12	O
wk	O
.	O
Strain-dependent	O
down-regulation	O
of	O
several	O
key	O
one-	O
carbon	S-chemical
metabolism	O
genes	O
,	O
including	O
methionine	B-GP
adenosyltransferase	I-GP
1α	E-GP
(	O
Mat1a	S-GP
)	O
,	O
cystathionine-β-synthase	S-GP
(	O
Cbs	S-GP
)	O
,	O
methylenetetrahydrofolate	B-GP
reductase	E-GP
(	O
Mthfr	S-GP
)	O
,	O
adenosyl-homocysteinase	S-GP
(	O
Ahcy	S-GP
)	O
,	O
and	O
methylenetetrahydrofolate	B-GP
dehydrogenase	I-GP
1	E-GP
(	O
Mthfd1	S-GP
)	O
,	O
was	O
observed	O
.	O
These	O
changes	O
were	O
strongly	O
associated	O
with	O
interstrain	O
variability	O
in	O
liver	O
injury	O
(	O
steatosis	O
,	O
necrosis	O
,	O
inflammation	O
,	O
and	O
activation	O
of	O
fibrogenesis	O
)	O
and	O
hyperhomocysteinemia	O
.	O
Mechanistically	O
,	O
the	O
decreased	O
expression	O
of	O
Mat1a	S-GP
,	O
Ahcy	S-GP
,	O
and	O
Mthfd1	S-GP
was	O
linked	O
to	O
a	O
reduced	O
level	O
and	O
promoter	O
binding	O
of	O
transcription	O
factor	O
CCAAT/enhancer	B-GP
binding	I-GP
protein	I-GP
β	E-GP
(	O
CEBPβ	S-GP
)	O
,	O
which	O
directly	O
regulates	O
their	O
transcription	O
.	O
The	O
strain	O
specificity	O
of	O
diet-induced	O
dysregulation	O
of	O
one-	O
carbon	S-chemical
metabolism	O
suggests	O
that	O
interstrain	O
variation	O
in	O
the	O
regulation	O
of	O
one-	O
carbon	S-chemical
metabolism	O
may	O
contribute	O
to	O
the	O
differential	O
vulnerability	O
to	O
NFLD	O
and	O
that	O
correcting	O
the	O
imbalance	O
may	O
be	O
considered	O
as	O
preventive	O
and	O
treatment	O
strategies	O
for	O
NAFLD.-Pogribny	O
,	O
I.	O
P.	O
,	O
Kutanzi	O
,	O
K.	O
,	O
Melnyk	O
,	O
S.	O
,	O
de	O
Conti	O
,	O
A.	O
,	O
Tryndyak	O
,	O
V.	O
,	O
Montgomery	O
,	O
B.	O
,	O
Pogribna	O
,	O
M.	O
,	O
Muskhelishvili	O
,	O
L.	O
,	O
Latendresse	O
,	O
J.	O
R.	O
,	O
James	O
,	O
S.	O
J.	O
,	O
Beland	O
,	O
F.	O
A.	O
,	O
Rusyn	O
,	O
I.	O
Strain-dependent	O
dysregulation	O
of	O
one-	O
carbon	S-chemical
metabolism	O
in	O
male	O
mice	O
is	O
associated	O
with	O
choline	S-chemical
-	O
and	O
folate	S-chemical
-deficient	O
diet-induced	O
liver	O
injury	O
.	O

TRP	B-GP
and	I-GP
ASIC	I-GP
channels	E-GP
mediate	O
the	O
antinociceptive	O
effect	O
of	O
citronellyl	B-chemical
acetate	E-chemical
.	O
Background	O
Citronellyl	B-chemical
acetate	E-chemical
(	O
CAT	S-chemical
)	O
,	O
a	O
monoterpene	S-chemical
product	O
of	O
the	O
secondary	O
metabolism	O
of	O
plants	O
,	O
has	O
been	O
shown	O
in	O
the	O
literature	O
to	O
possess	O
several	O
different	O
biological	O
activities	O
.	O
However	O
,	O
no	O
antinociceptive	O
abilities	O
have	O
yet	O
been	O
discussed	O
.	O
Here	O
,	O
we	O
used	O
acute	O
pain	O
animal	O
models	O
to	O
describe	O
the	O
antinociceptive	O
action	O
of	O
CAT	S-chemical
.	O
Methods	O
The	O
acetic	B-chemical
acid	E-chemical
-induced	O
writhing	O
test	O
and	O
the	O
paw-licking	O
test	O
,	O
in	O
which	O
paw	O
licking	O
was	O
induced	O
by	O
glutamate	S-chemical
and	O
formalin	S-chemical
,	O
were	O
performed	O
to	O
evaluate	O
the	O
antinociceptive	O
action	O
of	O
CAT	S-chemical
and	O
to	O
determine	O
the	O
involvement	O
of	O
PKC	S-GP
,	O
PKA	S-GP
,	O
TRPV1	S-GP
,	O
TRPA1	S-GP
,	O
TRPM8	S-GP
and	O
ASIC	S-GP
in	O
its	O
antinociceptive	O
mechanism	O
.	O
To	O
do	O
so	O
,	O
we	O
induced	O
paw-linking	O
using	O
agonists	O
.	O
Results	O
CAT	S-chemical
was	O
administered	O
intragastrically	O
(	O
25	O
,	O
50	O
,	O
75	O
,	O
100	O
and	O
200mg/kg	O
)	O
,	O
and	O
the	O
two	O
higher	O
doses	O
caused	O
antinociceptive	O
effects	O
in	O
the	O
acetic	B-chemical
acid	E-chemical
model	O
;	O
the	O
highest	O
dose	O
reduced	O
pain	O
for	O
4h	O
after	O
it	O
was	O
administered	O
(	O
200mg/kg	O
)	O
.	O
In	O
the	O
formalin	S-chemical
test	O
,	O
two	O
doses	O
of	O
CAT	S-chemical
promoted	O
antinociception	O
in	O
both	O
the	O
early	O
and	O
later	O
phases	O
of	O
the	O
test	O
.	O
The	O
glutamate	S-chemical
test	O
showed	O
that	O
its	O
receptors	O
are	O
involved	O
in	O
the	O
antinociceptive	O
mechanism	O
of	O
CAT	S-chemical
.	O
Pretreatment	O
with	O
CAT	S-chemical
did	O
not	O
alter	O
locomotor	O
activity	O
or	O
motor	O
coordination	O
.	O
In	O
an	O
investigation	O
into	O
the	O
participation	O
of	O
TRP	B-GP
channels	E-GP
and	O
ASICs	S-GP
in	O
CAT	S-chemical
's	O
antinociceptive	O
mechanism	O
,	O
we	O
used	O
capsaicin	S-chemical
(	O
2.2μg/paw	O
)	O
,	O
cinnamaldehyde	S-chemical
(	O
10mmol/paw	O
)	O
,	O
menthol	S-chemical
(	O
1.2mmol/paw	O
)	O
and	O
acidified	O
saline	O
(	O
2	O
%	O
acetic	B-chemical
acid	E-chemical
,	O
pH	O
1.98	O
)	O
.	O
The	O
results	O
showed	O
that	O
TRPV1	S-GP
,	O
TRPM8	S-GP
and	O
ASIC	S-GP
,	O
but	O
not	O
TRPA1	S-GP
,	O
are	O
involved	O
in	O
the	O
antinociceptive	O
mechanism	O
.	O
Finally	O
,	O
the	O
involvement	O
of	O
PKC	S-GP
and	O
PKA	S-GP
was	O
also	O
studied	O
,	O
and	O
we	O
showed	O
that	O
both	O
play	O
a	O
role	O
in	O
the	O
antinociceptive	O
mechanism	O
of	O
CAT	S-chemical
.	O
Conclusion	O
The	O
results	O
of	O
this	O
work	O
contribute	O
information	O
regarding	O
the	O
antinociceptive	O
properties	O
of	O
CAT	S-chemical
on	O
acute	O
pain	O
and	O
show	O
that	O
,	O
at	O
least	O
in	O
part	O
,	O
TRPV1	S-GP
,	O
TRPM8	S-GP
,	O
ASIC	S-GP
,	O
glutamate	B-GP
receptors	E-GP
,	O
PKC	S-GP
and	O
PKA	S-GP
participate	O
in	O
CAT	S-chemical
's	O
antinociceptive	O
mechanism	O
.	O

The	O
effect	O
of	O
CCL3	S-GP
and	O
CCR1	S-GP
in	O
bone	O
remodeling	O
induced	O
by	O
mechanical	O
loading	O
during	O
orthodontic	O
tooth	O
movement	O
in	O
mice	O
.	O
Bone	O
remodeling	O
is	O
affected	O
by	O
mechanical	O
loading	O
and	O
inflammatory	O
mediators	O
,	O
including	O
chemokines	S-GP
.	O
The	O
chemokine	B-GP
(	I-GP
C-C	I-GP
motif	I-GP
)	I-GP
ligand	I-GP
3	E-GP
(	O
CCL3	S-GP
)	O
is	O
involved	O
in	O
bone	O
remodeling	O
by	O
binding	O
to	O
C-C	B-GP
chemokine	I-GP
receptors	I-GP
1	I-GP
and	I-GP
5	E-GP
(	O
CCR1	S-GP
and	O
CCR5	S-GP
)	O
expressed	O
on	O
osteoclasts	O
and	O
osteoblasts	O
.	O
Our	O
group	O
has	O
previously	O
demonstrated	O
that	O
CCR5	S-GP
down-regulates	O
mechanical	O
loading-induced	O
bone	O
resorption	O
.	O
Thus	O
,	O
the	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
role	O
of	O
CCR1	S-GP
and	O
CCL3	S-GP
in	O
bone	O
remodeling	O
induced	O
by	O
mechanical	O
loading	O
during	O
orthodontic	O
tooth	O
movement	O
in	O
mice	O
.	O
Our	O
results	O
showed	O
that	O
bone	O
remodeling	O
was	O
significantly	O
decreased	O
in	O
CCL3	S-GP
(	O
-/-	O
)	O
and	O
CCR1	S-GP
(	O
-/-	O
)	O
mice	O
and	O
in	O
animals	O
treated	O
with	O
Met	S-chemical
-RANTES	O
(	O
an	O
antagonist	O
of	O
CCR5	S-GP
and	O
CCR1	S-GP
)	O
.	O
mRNA	O
levels	O
of	O
receptor	B-GP
activator	I-GP
of	I-GP
nuclear	I-GP
factor	I-GP
kappa-B	E-GP
(	O
RANK	S-GP
)	O
,	O
its	O
ligand	O
RANKL	S-GP
,	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
alpha	E-GP
(	O
TNF-α	S-GP
)	O
and	O
RANKL	S-GP
/	O
osteoprotegerin	S-GP
(	O
OPG	S-GP
)	O
ratio	O
were	O
diminished	O
in	O
the	O
periodontium	O
of	O
CCL3	S-GP
(	O
-/-	O
)	O
mice	O
and	O
in	O
the	O
group	O
treated	O
with	O
Met	S-chemical
-RANTES	O
.	O
Met	S-chemical
-RANTES	O
treatment	O
also	O
reduced	O
the	O
levels	O
of	O
cathepsin	B-GP
K	E-GP
and	O
metalloproteinase	B-GP
13	E-GP
(	O
MMP13	S-GP
)	O
.	O
The	O
expression	O
of	O
the	O
osteoblast	O
markers	O
runt-related	B-GP
transcription	I-GP
factor	I-GP
2	E-GP
(	O
RUNX2	S-GP
)	O
and	O
periostin	S-GP
was	O
decreased	O
,	O
while	O
osteocalcin	S-GP
(	O
OCN	S-GP
)	O
was	O
augmented	O
in	O
CCL3	S-GP
(	O
-/-	O
)	O
and	O
Met	S-chemical
-RANTES-treated	O
mice	O
.	O
Altogether	O
,	O
these	O
findings	O
show	O
that	O
CCR1	S-GP
is	O
pivotal	O
for	O
bone	O
remodeling	O
induced	O
by	O
mechanical	O
loading	O
during	O
orthodontic	O
tooth	O
movement	O
and	O
these	O
actions	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
CCL3	S-GP
.	O

Adhesion	O
of	O
osteoblasts	O
to	O
a	O
vertically	O
aligned	O
TiO2	S-chemical
nanotube	O
surface	O
.	O
The	O
adhesion	O
of	O
cells	O
to	O
vertically	O
aligned	O
TiO2	S-chemical
nanotubes	O
is	O
reviewed	O
.	O
The	O
attraction	O
between	O
a	O
negatively	O
charged	O
nanotube	O
surface	O
and	O
a	O
negatively	O
charged	O
osteoblast	O
is	O
facilitated	O
by	O
charged	O
protein-mediators	O
like	O
proteins	O
with	O
a	O
quadrupolar	O
internal	O
charge	O
distribution	O
,	O
fibronectin	S-GP
and	O
vitronectin	S-GP
.	O
It	O
is	O
shown	O
that	O
adhesion	O
and	O
spreading	O
of	O
osteoblasts	O
on	O
vertically	O
aligned	O
TiO2	S-chemical
nanotube	O
surfaces	O
depend	O
on	O
the	O
diameter	O
of	O
the	O
nanotubes	O
.	O
Apparently	O
,	O
a	O
small	O
diameter	O
nanotube	O
surface	O
has	O
on	O
average	O
more	O
sharp	O
convex	O
edges	O
per	O
unit	O
area	O
than	O
a	O
large	O
one	O
,	O
leading	O
to	O
stronger	O
binding	O
affinity	O
on	O
its	O
surface	O
.	O

Gastric	B-GP
mucin	E-GP
secretion	O
in	O
response	O
to	O
beta-adrenergic	B-GP
G	I-GP
protein-coupled	I-GP
receptor	E-GP
activation	O
is	O
mediated	O
by	O
SRC	S-GP
kinase	S-GP
-dependent	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
transactivation	O
.	O
In	O
many	O
systems	O
,	O
the	O
integration	O
of	O
converging	O
regulatory	O
signals	O
that	O
relay	O
on	O
G	B-GP
protein-coupled	I-GP
receptor	E-GP
(	O
GPCR	S-GP
)	O
activation	O
into	O
functional	O
cellular	O
pathways	O
requires	O
the	O
involvement	O
of	O
receptor	B-GP
tyrosine	I-GP
kinase	E-GP
.	O
In	O
this	O
report	O
,	O
we	O
provide	O
evidence	O
that	O
activation	O
of	O
GPCR	S-GP
by	O
beta-adrenergic	O
agonist	O
leading	O
to	O
stimulation	O
in	O
gastric	B-GP
mucin	E-GP
secretion	O
requires	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
(	O
EGFR	S-GP
)	O
participation	O
.	O
Using	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
glucosamine	E-chemical
-labeled	O
gastric	O
mucosal	O
cells	O
,	O
we	O
show	O
that	O
stimulatory	O
effect	O
of	O
beta-adrenergic	O
agonist	O
,	O
isoproterenol	O
,	O
on	O
mucin	S-GP
secretion	O
was	O
inhibited	O
by	O
EGFR	S-GP
kinase	S-GP
inhibitor	O
,	O
PD153035	S-chemical
,	O
as	O
well	O
as	O
wortmannin	S-chemical
,	O
a	O
specific	O
inhibitor	O
of	O
PI3K	S-GP
.	O
Both	O
inhibitors	O
,	O
moreover	O
,	O
blunted	O
the	O
mucin	S-GP
secretory	O
responses	O
to	O
beta-adrenergic	O
agonist-generated	O
second	O
messenger	O
,	O
cAMP	S-chemical
as	O
well	O
as	O
adenylate	B-GP
cyclase	E-GP
activator	O
,	O
forskolin	S-chemical
.	O
The	O
gastric	B-GP
mucin	E-GP
secretory	O
responses	O
to	O
isoproterenol	S-chemical
,	O
furthermore	O
,	O
were	O
inhibited	O
by	O
PP2	S-chemical
,	O
a	O
selective	O
inhibitor	O
of	O
tyrosine	B-GP
kinase	E-GP
Src	S-GP
responsible	O
for	O
ligand-independent	O
EGFR	S-GP
autophosphorylation	O
,	O
but	O
not	O
by	O
ERK	S-GP
inhibitor	O
,	O
PD98059	S-chemical
.	O
The	O
inhibition	O
of	O
ERK	S-GP
,	O
moreover	O
,	O
did	O
not	O
cause	O
attenuation	O
in	O
mucin	S-GP
secretion	O
in	O
response	O
to	O
cAMP	S-chemical
and	O
forskolin	S-chemical
.	O
The	O
findings	O
underline	O
the	O
role	O
of	O
EGFR	S-GP
as	O
a	O
convergence	O
point	O
in	O
gastric	B-GP
mucin	E-GP
secretion	O
triggered	O
by	O
beta-adrenergic	B-GP
GPCR	E-GP
activation	O
,	O
and	O
demonstrate	O
the	O
requirement	O
for	O
Src	S-GP
kinase	S-GP
in	O
EGFR	S-GP
transactivation	O
.	O

Cholinergic	O
modulation	O
by	O
opioid	B-GP
receptor	E-GP
ligands	O
:	O
potential	O
application	O
to	O
Alzheimer	O
's	O
disease	O
.	O
Morphinans	S-chemical
have	O
a	O
storied	O
history	O
in	O
medicinal	O
chemistry	O
as	O
pain	O
management	O
drugs	O
but	O
have	O
received	O
attention	O
as	O
modulators	O
of	O
cholinergic	O
signaling	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
Disease	O
(	O
AD	O
)	O
.	O
Galantamine	S-chemical
is	O
a	O
reversible	O
,	O
competitive	O
acetylcholinesterase	S-GP
(	O
AChE	S-GP
)	O
inhibitor	O
and	O
allosteric	O
potentiating	O
ligand	O
of	O
nicotinic	B-GP
acetylcholine	I-GP
receptors	E-GP
(	O
nAChR	S-GP
-APL	O
)	O
that	O
shares	O
many	O
common	O
structural	O
elements	O
with	O
morphinan	S-chemical
-based	O
opioids	O
.	O
The	O
structurally	O
diverse	O
opioids	O
codeine	S-chemical
and	O
eseroline	S-chemical
,	O
like	O
galantamine	S-chemical
,	O
are	O
also	O
nAChR	S-GP
-APL	O
that	O
have	O
greatly	O
diminished	O
affinity	O
for	O
AChE	S-GP
,	O
representing	O
potential	O
lead	O
compounds	O
for	O
selective	O
nAChR	S-GP
-APL	O
development	O
.	O
In	O
accordance	O
with	O
the	O
emerging	O
repurposing	O
trend	O
of	O
evaluating	O
known	O
compounds	O
for	O
novel	O
pharmacological	O
activity	O
,	O
ongoing	O
research	O
on	O
augmentation	O
of	O
cholinergic	O
signaling	O
that	O
has	O
been	O
aided	O
by	O
the	O
use	O
of	O
opioids	O
will	O
be	O
reviewed	O
.	O

Breakdown	O
of	O
Th	O
cell	O
immune	O
responses	O
and	O
steroidogenic	O
CYP11A1	S-GP
expression	O
in	O
CD4+	O
T	O
cells	O
in	O
a	O
murine	O
model	O
implanted	O
with	O
B16	O
melanoma	O
.	O
The	O
association	O
between	O
the	O
balance	O
of	O
Th1/Th2	O
cell	O
responses	O
and	O
CYP11A1	S-GP
expression	O
in	O
CD4+	O
T	O
cells	O
was	O
investigated	O
in	O
a	O
murine	O
model	O
implanted	O
with	O
highly	O
metastatic	O
B16F10	O
melanoma	O
cells	O
(	O
B16F10	O
mice	O
)	O
.	O
When	O
2	O
x	O
10	O
(	O
5	O
)	O
cells/mouse	O
of	O
B16F10	O
cells	O
were	O
inoculated	O
into	O
C57BL/6	O
mice	O
,	O
Th2	O
cell	O
responses	O
and	O
pulmonary	O
metastasis	O
were	O
increased	O
.	O
In	O
addition	O
,	O
corticosterone	S-chemical
levels	O
in	O
splenic	O
tissue	O
or	O
serum	O
and	O
CYP11A1	S-GP
mRNA	O
expression	O
(	O
mRNA	O
encoding	O
cholesterol	B-GP
side-chain	I-GP
cleavage	I-GP
p450	I-GP
enzyme	E-GP
)	O
in	O
CD4+	O
T	O
cells	O
were	O
increased	O
in	O
these	O
mice	O
.	O
When	O
the	O
anti-corticosterone	O
drug	O
aminoglutethimide	S-chemical
(	O
CYP11A1	S-GP
inhibitor	O
)	O
was	O
administered	O
to	O
B16F10	O
mice	O
,	O
corticosterone	S-chemical
levels	O
in	O
splenic	O
tissue	O
or	O
serum	O
and	O
CYP11A1	S-GP
mRNA	O
expression	O
were	O
decreased	O
at	O
14	O
days	O
after	O
tumor	O
inoculation	O
.	O
In	O
addition	O
,	O
Th1	O
cell	O
responses	O
were	O
restored	O
and	O
pulmonary	O
metastasis	O
was	O
reduced	O
by	O
aminoglutethimide	S-chemical
.	O
These	O
results	O
indicated	O
that	O
the	O
breakdown	O
of	O
Th	O
cell	O
responses	O
and	O
increase	O
of	O
pulmonary	O
metastasis	O
were	O
due	O
to	O
an	O
increase	O
in	O
steroidogenic	O
CYP11A1	S-GP
mRNA	O
expression	O
in	O
CD4+	O
T	O
cells	O
.	O
Moreover	O
,	O
it	O
was	O
suggested	O
that	O
promotion	O
of	O
CYP11A1	S-GP
mRNA	O
expression	O
in	O
Th2	O
cells	O
was	O
partially	O
involved	O
due	O
to	O
an	O
increase	O
in	O
level	O
of	O
corticosterone	S-chemical
in	O
splenic	O
tissue	O
and	O
the	O
breakdown	O
of	O
Th	O
cell	O
responses	O
locally	O
in	O
the	O
splenic	O
tissue	O
,	O
which	O
then	O
affected	O
the	O
maintenance	O
of	O
Th2	O
cell	O
functions	O
in	O
the	O
microenvironment	O
of	O
tumor-bearing	O
mice	O
.	O

Stimulatory	O
effect	O
of	O
insulin	S-GP
on	O
theca-interstitial	O
cell	O
proliferation	O
and	O
cell	O
cycle	O
regulatory	O
proteins	O
through	O
MTORC1	S-GP
dependent	O
pathway	O
.	O
The	O
present	O
study	O
examined	O
the	O
effect	O
of	O
insulin	S-GP
-mediated	O
activation	O
of	O
the	O
mammalian	B-GP
target	I-GP
of	I-GP
rapamycin	I-GP
complex	I-GP
1	E-GP
(	O
MTORC1	S-GP
)	O
signaling	O
network	O
on	O
the	O
proliferation	O
of	O
primary	O
culture	O
of	O
theca-interstitial	O
(	O
T-I	O
)	O
cells	O
.	O
Our	O
results	O
show	O
that	O
insulin	O
treatment	O
increased	O
proliferation	O
of	O
the	O
T-I	O
cells	O
through	O
the	O
MTORC1	S-GP
-dependent	O
signaling	O
pathway	O
by	O
increasing	O
cell	O
cycle	O
regulatory	O
proteins	O
.	O
Inhibition	O
of	O
ERK1/2	S-GP
signaling	O
caused	O
partial	O
reduction	O
of	O
insulin	S-GP
-induced	O
phosphorylation	O
of	O
RPS6KB1	S-GP
and	O
RPS6	S-GP
whereas	O
inhibition	O
of	O
PI3-kinase	S-GP
signaling	O
completely	O
blocked	O
the	O
insulin	S-GP
response	O
.	O
Pharmacological	O
inhibition	O
of	O
MTORC1	S-GP
with	O
rapamycin	S-chemical
abrogated	O
the	O
insulin	S-GP
-induced	O
phosphorylation	O
of	O
EIF4EBP1	S-GP
,	O
RPS6KB1	S-GP
and	O
its	O
downstream	O
effector	O
,	O
RPS6	S-GP
.	O
These	O
results	O
were	O
further	O
confirmed	O
by	O
demonstrating	O
that	O
knockdown	O
of	O
Mtor	S-GP
using	O
siRNA	O
reduced	O
the	O
insulin	S-GP
-stimulated	O
MTORC1	S-GP
signaling	O
.	O
Furthermore	O
,	O
insulin	S-GP
-stimulated	O
T-I	O
cell	O
proliferation	O
and	O
the	O
expression	O
of	O
cell	B-GP
cycle	I-GP
regulatory	I-GP
proteins	E-GP
CDK4	S-GP
,	O
CCND3	S-GP
and	O
PCNA	S-GP
were	O
also	O
blocked	O
by	O
rapamycin	S-chemical
.	O
Taken	O
together	O
,	O
the	O
present	O
studies	O
show	O
that	O
insulin	O
stimulates	O
cell	O
proliferation	O
and	O
cell	O
cycle	O
regulatory	O
proteins	O
in	O
T-I	O
cells	O
via	O
activation	O
of	O
the	O
MTORC1	S-GP
signaling	O
pathway	O
.	O

Protective	O
role	O
of	O
L-carnitine	S-chemical
and	O
vitamin	B-chemical
E	E-chemical
on	O
the	O
testis	O
of	O
atherosclerotic	O
rats	O
.	O
Atherosclerosis	O
is	O
a	O
condition	O
caused	O
by	O
lipid	O
build-up	O
and	O
inflammation	O
in	O
the	O
arteries	O
,	O
so	O
hyperlipidemia	O
is	O
the	O
major	O
reason	O
for	O
atherosclerosis	O
.	O
Testis	O
was	O
found	O
to	O
be	O
negatively	O
affected	O
by	O
hyperlipidemia	O
which	O
leads	O
to	O
its	O
impaired	O
functions	O
.	O
Vitamin	B-chemical
E	E-chemical
and	O
<	B-chemical
sc	I-chemical
>	I-chemical
l	I-chemical
<	I-chemical
/sc	I-chemical
>	I-chemical
-carnitine	E-chemical
have	O
well-known	O
lipid-lowering	O
and	O
antioxidative	O
activities	O
.	O
Triton	B-chemical
WR	I-chemical
1339	E-chemical
is	O
a	O
non-ionic	O
detergent	O
,	O
which	O
induces	O
severe	O
hyperlipidemia	O
by	O
inhibition	O
of	O
lipoprotein	O
lipase	O
.	O
The	O
present	O
study	O
evaluates	O
the	O
protective	O
role	O
of	O
vitamin	B-chemical
E	E-chemical
and	O
<	B-chemical
sc	I-chemical
>	I-chemical
l	I-chemical
<	I-chemical
/sc	I-chemical
>	I-chemical
-carnitine	E-chemical
on	O
the	O
testis	O
in	O
atherosclerosis	O
and	O
detects	O
the	O
most	O
effective	O
choice	O
for	O
protection	O
against	O
atherosclerosis	O
;	O
vitamin	B-chemical
E	E-chemical
,	O
<	B-chemical
sc	I-chemical
>	I-chemical
l	I-chemical
<	I-chemical
/sc	I-chemical
>	I-chemical
-carnitine	E-chemical
or	O
a	O
combination	O
of	O
both	O
.	O
A	O
total	O
of	O
80	O
albino	O
male	O
rats	O
were	O
divided	O
into	O
eight	O
groups	O
(	O
10	O
rats	O
for	O
each	O
group	O
)	O
:	O
control	O
(	O
G	O
(	O
1	O
)	O
)	O
,	O
triton	S-chemical
(	O
G	O
(	O
2	O
)	O
)	O
,	O
<	B-chemical
sc	I-chemical
>	I-chemical
l	I-chemical
<	I-chemical
/sc	I-chemical
>	I-chemical
-carnitine	E-chemical
(	O
G	O
(	O
3	O
)	O
)	O
,	O
triton	S-chemical
+	O
<	B-chemical
sc	I-chemical
>	I-chemical
l	I-chemical
<	I-chemical
/sc	I-chemical
>	I-chemical
-carnitine	E-chemical
(	O
G	O
(	O
4	O
)	O
)	O
,	O
vitamin	B-chemical
E	E-chemical
(	O
G	O
(	O
5	O
)	O
)	O
,	O
triton	S-chemical
+	O
vitamin	B-chemical
E	E-chemical
(	O
G	O
(	O
6	O
)	O
)	O
,	O
<	B-chemical
sc	I-chemical
>	I-chemical
l	I-chemical
<	I-chemical
/sc	I-chemical
>	I-chemical
-carnitine	E-chemical
+	O
vitamin	B-chemical
E	E-chemical
(	O
G	O
(	O
7	O
)	O
)	O
and	O
triton	S-chemical
+	O
<	B-chemical
sc	I-chemical
>	I-chemical
l	I-chemical
<	I-chemical
/sc	I-chemical
>	I-chemical
-carnitine	E-chemical
+	O
vitamin	B-chemical
E	E-chemical
(	O
G	O
(	O
8	O
)	O
)	O
.	O
Data	O
showed	O
a	O
significant	O
increase	O
in	O
the	O
levels	O
of	O
total	O
cholesterol	S-chemical
(	O
TC	O
)	O
,	O
triglycerides	S-chemical
(	O
TGs	O
)	O
,	O
low-density	O
lipoprotein	O
cholesterol	S-chemical
(	O
LDL-C	O
)	O
,	O
17	B-chemical
beta	I-chemical
hydroxysteroid	E-chemical
dehydrogenase	O
(	O
17	O
β	O
HSD	O
)	O
,	O
testicular	O
catalase	O
and	O
malondialdehyde	S-chemical
(	O
MDA	S-chemical
)	O
in	O
G	O
(	O
2	O
)	O
when	O
compared	O
with	O
G	O
(	O
1	O
)	O
,	O
whereas	O
high-density	O
lipoprotein	O
cholesterol	S-chemical
(	O
HDL-C	O
)	O
,	O
serum	O
testosterone	S-chemical
,	O
testicular	O
17	O
ketosteroid	S-chemical
reductase	O
(	O
17	O
KSR	O
)	O
,	O
total	O
thiol	S-chemical
and	O
glutathione	S-chemical
-	O
S	S-chemical
-transferase	O
(	O
GST	O
)	O
data	O
showed	O
a	O
significant	O
decrease	O
in	O
G	O
(	O
2	O
)	O
when	O
compared	O
with	O
G	O
(	O
1	O
)	O
.	O
Treatment	O
with	O
<	B-chemical
sc	I-chemical
>	I-chemical
l	I-chemical
<	I-chemical
/sc	I-chemical
>	I-chemical
-carnitine	E-chemical
or/and	O
vitamin	B-chemical
E	E-chemical
helps	O
in	O
improving	O
the	O
adverse	O
effect	O
of	O
triton	S-chemical
;	O
also	O
the	O
histological	O
changes	O
confirm	O
this	O
finding	O
.	O
So	O
the	O
present	O
study	O
recommends	O
all	O
people	O
to	O
include	O
<	B-chemical
sc	I-chemical
>	I-chemical
l	I-chemical
<	I-chemical
/sc	I-chemical
>	I-chemical
-carnitine	E-chemical
and	O
vitamin	B-chemical
E	E-chemical
in	O
their	O
diet	O
to	O
be	O
protected	O
against	O
atherosclerosis	O
.	O

Interactions	O
of	O
2,3-benzodiazepines	S-chemical
and	O
cyclothiazide	S-chemical
at	O
AMPA	B-GP
receptors	E-GP
:	O
patch	O
clamp	O
recordings	O
in	O
cultured	O
neurones	O
and	O
area	O
CA1	O
in	O
hippocampal	O
slices	O
.	O
1	O
.	O
The	O
2,3-benzodiazepines	S-chemical
GYKI	B-chemical
52466	E-chemical
,	O
GYKI	B-chemical
53405	E-chemical
and	O
GYKI	B-chemical
53655	E-chemical
antagonized	O
AMPA	S-chemical
-induced	O
currents	O
in	O
cultured	O
superior	O
colliculus	O
neurones	O
in	O
a	O
non	O
use-dependent	O
manner	O
(	O
steady	O
state	O
IC50s	O
:	O
GYKI	B-chemical
52466	E-chemical
9.8	O
+/-	O
0.6	O
microM	O
;	O
GYKI	B-chemical
53405	E-chemical
3.1	O
+/-	O
0.6	O
microM	O
;	O
GYKI	B-chemical
53655	E-chemical
0.8	O
+/-	O
0.1	O
microM	O
)	O
.	O
2	O
.	O
Higher	O
concentrations	O
of	O
all	O
three	O
antagonists	O
slowed	O
the	O
onset	O
kinetics	O
and	O
quickened	O
the	O
offset	O
kinetics	O
of	O
AMPA	S-chemical
-induced	O
currents	O
indicative	O
of	O
an	O
allosteric	O
interaction	O
with	O
the	O
AMPA	S-chemical
recognition	O
site	O
.	O
3	O
.	O
Cyclothiazide	S-chemical
(	O
3-300	O
microM	O
)	O
dramatically	O
slowed	O
desensitization	O
of	O
AMPA	S-chemical
-induced	O
currents	O
and	O
potentiated	O
steady	O
state	O
currents	O
(	O
EC50	O
10.0	O
+/-	O
2.5	O
microM	O
)	O
to	O
a	O
much	O
greater	O
degree	O
than	O
peak	O
currents	O
.	O
Both	O
tau	O
on	O
and	O
tau	O
off	O
were	O
also	O
increased	O
by	O
cyclothiazide	S-chemical
in	O
a	O
concentration-dependent	O
manner	O
(	O
EC50	O
:	O
tau	O
on	O
42.1	O
+/-	O
4.5	O
microM	O
;	O
tau	O
off	O
31.6	O
+/-	O
6.6	O
microM	O
)	O
.	O
4	O
.	O
Cyclothiazide	S-chemical
(	O
10-100	O
microM	O
)	O
shifted	O
the	O
concentration-response	O
curves	O
of	O
the	O
2,3-benzodiazepines	S-chemical
to	O
the	O
right	O
.	O
For	O
example	O
,	O
with	O
10	O
microM	O
cyclothiazide	S-chemical
the	O
IC50s	O
of	O
GYKI	B-chemical
52466	E-chemical
and	O
GYKI	B-chemical
53405	E-chemical
on	O
steady-state	O
AMPA	S-chemical
-induced	O
currents	O
were	O
57.9	O
+/-	O
9.5	O
and	O
41.6	O
+/-	O
1.5	O
microM	O
,	O
respectively	O
.	O
5	O
.	O
GYKI	B-chemical
53405	E-chemical
and	O
GYKI	B-chemical
52466	E-chemical
concentration-dependently	O
reversed	O
the	O
effects	O
of	O
cyclothiazide	S-chemical
(	O
100	O
microM	O
)	O
on	O
offset	O
kinetics	O
(	O
GYKI	B-chemical
53405	E-chemical
IC50	O
16.6	O
+/-	O
4.2	O
microM	O
)	O
.	O
However	O
,	O
the	O
2,3-benzodiazepines	S-chemical
were	O
unable	O
to	O
reintroduce	O
desensitization	O
in	O
the	O
presence	O
of	O
cyclothiazide	S-chemical
and	O
even	O
concentration-dependently	O
slowed	O
the	O
onset	O
kinetics	O
of	O
AMPA	S-chemical
responses	O
further	O
(	O
GYKI	B-chemical
53405	E-chemical
EC50	O
8.0	O
+/-	O
2.8	O
microM	O
)	O
.	O
6	O
.	O
GYKI	B-chemical
52466	E-chemical
decreased	O
the	O
peak	O
amplitude	O
of	O
hippocampal	O
area	O
CA1	O
AMPA	B-GP
receptor	E-GP
-mediated	O
excitatory	O
postsynaptic	O
currents	O
(	O
e.p.s.cs	O
)	O
(	O
IC50	O
10.8	O
+/-	O
0.8	O
microM	O
)	O
with	O
no	O
apparent	O
effect	O
on	O
response	O
kinetics	O
.	O
Cyclothiazide	S-chemical
prolonged	O
the	O
decay	O
time	O
constant	O
of	O
AMPA	B-GP
receptor	E-GP
-mediated	O
e.p.s.cs	O
(	O
EC50	O
35.7	O
+/-	O
6.5	O
microM	O
)	O
with	O
less	O
pronounced	O
effects	O
in	O
slowing	O
e.p.s.c	O
.	O
onset	O
kinetics	O
and	O
increasing	O
e.p.s.c	O
.	O
amplitude	O
.	O
7	O
.	O
Cyclothiazide	S-chemical
(	O
330	O
microM	O
)	O
shifted	O
the	O
concentration-response	O
curve	O
for	O
the	O
effects	O
of	O
GYKI	B-chemical
52466	E-chemical
on	O
AMPA	B-GP
receptor	E-GP
-mediated	O
e.p.s.c	O
.	O
peak	O
amplitude	O
to	O
the	O
right	O
(	O
GYKI	B-chemical
52466	E-chemical
IC50	O
26.9	O
+/-	O
9.4	O
microM	O
)	O
.	O
Likewise	O
,	O
GYKI	B-chemical
52466	E-chemical
(	O
30-100	O
microM	O
)	O
)	O
shifted	O
the	O
concentration-response	O
curve	O
for	O
the	O
effects	O
of	O
cyclothiazide	S-chemical
on	O
AMPA	B-GP
receptor	E-GP
-mediated	O
e.p.s.c	O
.	O
decay	O
time	O
constants	O
to	O
the	O
right	O
.	O
8	O
.	O
In	O
conclusion	O
,	O
cyclothiazide	S-chemical
and	O
the	O
2,3-benzodiazepines	S-chemical
seem	O
to	O
bind	O
to	O
different	O
sites	O
on	O
AMPA	B-GP
receptors	E-GP
but	O
exert	O
strong	O
allosteric	O
interactions	O
with	O
one	O
another	O
and	O
with	O
other	O
domains	O
such	O
as	O
the	O
agonist	O
recognition	O
site	O
.	O
The	O
interactions	O
of	O
GYKI	B-chemical
52466	E-chemical
and	O
cyclothiazide	S-chemical
on	O
AMPA	B-GP
receptor	E-GP
-mediated	O
e.p.s.cs	O
in	O
area	O
CA1	O
of	O
hippocampal	O
slices	O
provide	O
evidence	O
that	O
the	O
decay	O
time	O
constant	O
of	O
these	O
synaptic	O
events	O
are	O
not	O
governed	O
by	O
desensitization	O
.	O

Studies	O
on	O
the	O
mechanism	O
of	O
arterial	O
vasodilation	O
produced	O
by	O
the	O
novel	O
antihypertensive	O
agent	O
,	O
carvedilol	S-chemical
.	O
The	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
arterial	O
vasodilation	O
observed	O
following	O
acute	O
administration	O
of	O
racemic	B-chemical
carvedilol	E-chemical
,	O
a	O
novel	O
vasodilator/	O
beta	B-GP
adrenoceptor	E-GP
antagonist	O
,	O
has	O
been	O
investigated	O
in	O
rats	O
.	O
In	O
conscious	O
spontaneously	O
hypertensive	O
rats	O
,	O
carvedilol	S-chemical
(	O
0.03-3.0	O
mg/kg	O
,	O
iv	O
)	O
produced	O
a	O
dose-dependent	O
reduction	O
in	O
blood	O
pressure	O
with	O
no	O
significant	O
effect	O
on	O
heart	O
rate	O
.	O
Because	O
cardiac	O
output	O
was	O
relatively	O
unaffected	O
,	O
the	O
antihypertensive	O
response	O
of	O
carvedilol	S-chemical
was	O
associated	O
with	O
a	O
dose-dependent	O
reduction	O
in	O
total	O
peripheral	O
vascular	O
resistance	O
.	O
Submaximal	O
antihypertensive	O
doses	O
of	O
carvedilol	S-chemical
were	O
chosen	O
for	O
mechanism	O
of	O
action	O
studies	O
in	O
pithed	O
rats	O
.	O
Carvedilol	S-chemical
(	O
0.3	O
mg/kg	O
,	O
iv	O
)	O
produced	O
a	O
significant	O
inhibition	O
of	O
the	O
beta	B-GP
1	I-GP
adrenoceptor	E-GP
mediated	O
positive	O
chronotropic	O
response	O
to	O
isoproterenol	S-chemical
.	O
This	O
same	O
dose	O
of	O
carvedilol	S-chemical
also	O
inhibited	O
,	O
but	O
to	O
a	O
lesser	O
degree	O
,	O
the	O
beta	B-GP
2	I-GP
adrenoceptor	E-GP
mediated	O
vasodepressor	O
response	O
to	O
salbutamol	S-chemical
in	O
pithed	O
rats	O
whose	O
blood	O
pressure	O
was	O
elevated	O
by	O
a	O
constant	O
intravenous	O
infusion	O
of	O
angiotensin	B-GP
II	E-GP
.	O
Thus	O
,	O
carvedilol	S-chemical
blocks	O
both	O
beta	B-GP
1	I-GP
and	I-GP
beta	I-GP
2	I-GP
adrenoceptors	E-GP
at	O
antihypertensive	O
doses	O
,	O
with	O
modest	O
selectivity	O
being	O
observed	O
for	O
the	O
beta	B-GP
1	I-GP
adrenoceptor	E-GP
subtype	O
.	O
Carvedilol	S-chemical
produced	O
significant	O
inhibition	O
of	O
the	O
alpha	B-GP
1	I-GP
adrenoceptor	E-GP
mediated	O
pressor	O
response	O
to	O
cirazoline	S-chemical
in	O
the	O
pithed	O
rat	O
,	O
but	O
had	O
no	O
effect	O
on	O
the	O
alpha	B-GP
2	I-GP
adrenoceptor	E-GP
mediated	O
pressor	O
response	O
to	O
B-HT	B-chemical
933	E-chemical
,	O
suggesting	O
that	O
carvedilol	S-chemical
is	O
also	O
an	O
alpha	B-GP
1	I-GP
adrenoceptor	E-GP
antagonist	O
at	O
antihypertensive	O
doses	O
.	O
Carvedilol	S-chemical
had	O
no	O
effect	O
on	O
the	O
pressor	O
response	O
elicited	O
by	O
angiotensin	B-GP
II	E-GP
,	O
indicating	O
a	O
lack	O
of	O
nonspecific	O
vasodilator	O
activity	O
.	O
The	O
vasopressor	O
response	O
to	O
the	O
calcium	B-GP
channel	E-GP
activator	O
,	O
BAY-K-8644	S-chemical
,	O
which	O
is	O
mediated	O
through	O
the	O
opening	O
of	O
voltage	B-GP
dependent	I-GP
calcium	I-GP
channels	E-GP
and	O
the	O
subsequent	O
translocation	O
of	O
extracellular	O
calcium	S-chemical
,	O
was	O
significantly	O
inhibited	O
by	O
carvedilol	S-chemical
(	O
1	O
mg/kg	O
,	O
iv	O
)	O
,	O
suggesting	O
that	O
carvedilol	S-chemical
is	O
also	O
a	O
calcium	B-GP
channel	E-GP
antagonist	O
,	O
consistent	O
with	O
our	O
previous	O
in	O
vitro	O
studies	O
.	O
In	O
anesthetized	O
spontaneously	O
hypertensive	O
rats	O
,	O
the	O
antihypertensive	O
activity	O
of	O
carvedilol	S-chemical
was	O
nearly	O
abolished	O
by	O
combined	O
pretreatment	O
of	O
the	O
rats	O
with	O
high	O
doses	O
of	O
the	O
alpha	B-GP
1	I-GP
adrenoceptor	E-GP
antagonist	O
,	O
prazosin	S-chemical
(	O
1	O
mg/kg	O
,	O
iv	O
)	O
,	O
and	O
the	O
nonselective	O
beta	B-GP
adrenoceptor	E-GP
antagonist	O
,	O
propranolol	S-chemical
(	O
3	O
mg/kg	O
,	O
iv	O
)	O
,	O
suggesting	O
that	O
the	O
majority	O
of	O
the	O
antihypertensive	O
response	O
produced	O
by	O
carvedilol	S-chemical
may	O
be	O
accounted	O
for	O
by	O
blockade	O
of	O
beta	B-GP
and	I-GP
alpha	I-GP
1	I-GP
adrenoceptors	E-GP
.	O
We	O
therefore	O
conclude	O
that	O
carvedilol	S-chemical
,	O
at	O
antihypertensive	O
doses	O
,	O
is	O
an	O
antagonist	O
of	O
beta	B-GP
1	I-GP
,	I-GP
beta	I-GP
2	I-GP
,	I-GP
and	I-GP
alpha	I-GP
1	I-GP
adrenoceptors	E-GP
,	O
and	O
also	O
of	O
calcium	B-GP
channels	E-GP
in	O
vascular	O
smooth	O
muscle	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

NMDA	B-GP
receptor	E-GP
blockade	O
impairs	O
the	O
muscarinic	O
conversion	O
of	O
sub-threshold	O
transient	O
depression	O
into	O
long-lasting	O
LTD	O
in	O
the	O
hippocampus-prefrontal	O
cortex	O
pathway	O
in	O
vivo	O
:	O
correlation	O
with	O
gamma	O
oscillations	O
.	O
Cholinergic	O
fibers	O
from	O
the	O
brainstem	O
and	O
basal	O
forebrain	O
innervate	O
the	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
modulating	O
neuronal	O
activity	O
and	O
synaptic	O
plasticity	O
responses	O
to	O
hippocampal	O
inputs	O
.	O
Here	O
,	O
we	O
investigated	O
the	O
muscarinic	O
and	O
glutamatergic	O
modulation	O
of	O
long-term	O
depression	O
(	O
LTD	O
)	O
in	O
the	O
intact	O
projections	O
from	O
CA1	O
to	O
mPFC	O
in	O
vivo	O
.	O
Cortical-evoked	O
responses	O
were	O
recorded	O
in	O
urethane	S-chemical
-anesthetized	O
rats	O
for	O
30	O
min	O
during	O
baseline	O
and	O
4	O
h	O
following	O
LTD	O
.	O
In	O
order	O
to	O
test	O
the	O
potentiating	O
effects	O
of	O
pilocarpine	S-chemical
(	O
PILO	S-chemical
)	O
,	O
independent	O
groups	O
of	O
rats	O
received	O
either	O
a	O
microinjection	O
of	O
PILO	S-chemical
(	O
40	O
nmol	O
;	O
i.c.v	O
.	O
)	O
or	O
vehicle	O
,	O
immediately	O
before	O
or	O
20	O
min	O
after	O
a	O
sub-threshold	O
LTD	O
protocol	O
(	O
600	O
pulses	O
,	O
1	O
Hz	O
;	O
LFS600	O
)	O
.	O
Other	O
groups	O
received	O
either	O
an	O
infusion	O
of	O
the	O
selective	O
NMDA	B-GP
receptor	E-GP
antagonist	O
(	O
AP7	S-chemical
;	O
10	O
nmol	O
;	O
intra-mPFC	O
)	O
or	O
vehicle	O
,	O
10	O
min	O
prior	O
to	O
PILO	S-chemical
preceding	O
LFS600	O
,	O
or	O
prior	O
to	O
a	O
supra-threshold	O
LTD	O
protocol	O
(	O
900	O
pulses	O
,	O
1	O
Hz	O
;	O
LFS900	O
)	O
.	O
Our	O
results	O
show	O
that	O
PILO	S-chemical
converts	O
a	O
transient	O
cortical	O
depression	O
induced	O
by	O
LFS600	O
into	O
a	O
robust	O
LTD	O
,	O
stable	O
for	O
at	O
least	O
4	O
h.	O
When	O
applied	O
after	O
LFS600	O
,	O
PILO	S-chemical
does	O
not	O
change	O
either	O
mPFC	O
basal	O
neurotransmission	O
or	O
late	O
LTD.	O
Our	O
data	O
also	O
indicate	O
that	O
NMDA	B-GP
receptor	E-GP
pre-activation	O
is	O
essential	O
to	O
the	O
muscarinic	O
enhancement	O
of	O
mPFC	O
synaptic	O
depression	O
,	O
since	O
AP7	S-chemical
microinjection	O
into	O
the	O
mPFC	O
blocked	O
the	O
conversion	O
of	O
transient	O
depression	O
into	O
long-lasting	O
LTD	O
produced	O
by	O
PILO	S-chemical
.	O
In	O
addition	O
,	O
AP7	S-chemical
effectively	O
blocked	O
the	O
long-lasting	O
LTD	O
induced	O
by	O
LFS900	O
.	O
Therefore	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
glutamatergic	O
co-activation	O
of	O
prefrontal	O
neurons	O
is	O
important	O
for	O
the	O
effects	O
of	O
PILO	S-chemical
on	O
mPFC	O
synaptic	O
depression	O
,	O
which	O
could	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
executive	O
and	O
emotional	O
functions	O
.	O

Binary	O
diffusion	O
coefficients	O
for	O
mixtures	O
of	O
ionic	O
liquids	O
[	B-chemical
EMIM	I-chemical
]	I-chemical
[	I-chemical
N	I-chemical
(	I-chemical
CN	I-chemical
)	I-chemical
2	I-chemical
]	E-chemical
,	O
[	B-chemical
EMIM	I-chemical
]	I-chemical
[	I-chemical
NTf2	I-chemical
]	E-chemical
,	O
and	O
[	B-chemical
HMIM	I-chemical
]	I-chemical
[	I-chemical
NTf2	I-chemical
]	E-chemical
with	O
acetone	S-chemical
and	O
ethanol	S-chemical
by	O
dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
.	O
Mutual	O
diffusivities	O
for	O
binary	O
mixtures	O
of	O
the	O
ionic	O
liquids	O
(	O
ILs	O
)	O
[	B-chemical
EMIM	I-chemical
]	I-chemical
[	I-chemical
N	I-chemical
(	I-chemical
CN	I-chemical
)	I-chemical
2	I-chemical
]	E-chemical
(	O
1-ethyl-3-methylimidazolium	B-chemical
dicyanimide	E-chemical
)	O
,	O
[	B-chemical
EMIM	I-chemical
]	I-chemical
[	I-chemical
NTf2	I-chemical
]	E-chemical
(	O
1-ethyl-3-methylimidazolium	B-chemical
bis	I-chemical
(	I-chemical
trifluoromethylsulfonyl	I-chemical
)	I-chemical
imide	E-chemical
)	O
,	O
and	O
[	B-chemical
HMIM	I-chemical
]	I-chemical
[	I-chemical
NTf2	I-chemical
]	E-chemical
(	O
1-hexyl-3-methylimidazolium	B-chemical
bis	I-chemical
(	I-chemical
trifluoromethylsulfonyl	I-chemical
)	I-chemical
imide	E-chemical
)	O
with	O
acetone	S-chemical
and	O
ethanol	S-chemical
were	O
studied	O
in	O
dependence	O
on	O
composition	O
in	O
the	O
temperature	O
range	O
from	O
283.15	O
to	O
323.15	O
K	O
,	O
applying	O
dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
.	O
The	O
influence	O
of	O
experimental	O
parameters	O
on	O
the	O
achievable	O
uncertainties	O
was	O
analyzed	O
to	O
ensure	O
the	O
acquisition	O
of	O
accurate	O
data	O
in	O
adequate	O
measurement	O
times	O
.	O
For	O
all	O
probed	O
systems	O
,	O
increasing	O
binary	O
diffusion	O
coefficients	O
were	O
found	O
for	O
increasing	O
temperatures	O
.	O
The	O
systematic	O
variation	O
of	O
anion	O
and	O
cation	O
of	O
the	O
investigated	O
ILs	O
as	O
well	O
as	O
a	O
comparison	O
with	O
the	O
literature	O
data	O
demonstrates	O
the	O
considerable	O
influence	O
of	O
different	O
ions	O
on	O
the	O
resulting	O
binary	O
diffusion	O
coefficients	O
.	O
Mutual	O
diffusivities	O
were	O
found	O
to	O
be	O
lower	O
for	O
the	O
mixtures	O
with	O
ethanol	S-chemical
than	O
for	O
those	O
with	O
acetone	S-chemical
,	O
which	O
could	O
be	O
related	O
to	O
the	O
formation	O
of	O
hydrogen	S-chemical
bonds	O
between	O
ethanol	S-chemical
and	O
the	O
ions	O
.	O
Most	O
of	O
the	O
investigated	O
IL	O
solvent	O
mixtures	O
show	O
increasing	O
binary	O
diffusion	O
coefficients	O
with	O
increasing	O
solvent	O
concentration	O
.	O
For	O
the	O
mixtures	O
of	O
[	B-chemical
EMIM	I-chemical
]	I-chemical
[	I-chemical
NTf2	I-chemical
]	E-chemical
with	O
ethanol	S-chemical
,	O
however	O
,	O
a	O
minimum	O
of	O
the	O
mutual	O
diffusivities	O
was	O
found	O
in	O
the	O
ethanol	S-chemical
mole	O
fraction	O
range	O
from	O
0.7	O
to	O
0.8	O
,	O
which	O
may	O
hint	O
at	O
the	O
vicinity	O
of	O
a	O
critical	O
demixing	O
point	O
.	O
The	O
viscosity	O
of	O
the	O
pure	O
ILs	O
turned	O
out	O
to	O
be	O
no	O
reliable	O
indicator	O
for	O
the	O
mutual	O
diffusivity	O
in	O
mixtures	O
with	O
the	O
same	O
solvent	O
.	O

A	O
multivalent	O
peptide	O
as	O
an	O
activator	O
of	O
hypoxia	B-GP
inducible	I-GP
factor-1α	E-GP
.	O
Hypoxia	B-GP
inducible	I-GP
factor-1α	E-GP
(	O
HIF-1α	S-GP
)	O
is	O
a	O
transcription	O
factor	O
found	O
in	O
mammalian	O
cells	O
under	O
hypoxia	O
.	O
While	O
HIF-1α	S-GP
in	O
hypoxia	O
translocates	O
to	O
the	O
nucleus	O
where	O
it	O
transcribes	O
the	O
target	O
genes	O
including	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	E-GP
(	O
VEGF	S-GP
)	O
mRNA	O
,	O
HIF-1α	S-GP
is	O
degraded	O
under	O
normoxia	O
,	O
which	O
involves	O
its	O
proline	S-chemical
hydroxylation	O
and	O
subsequent	O
binding	O
to	O
the	O
von	B-GP
Hippel-Lindau	I-GP
protein	E-GP
-	O
Elongin	B-GP
B	E-GP
-	O
Elogin	B-GP
C	E-GP
(	O
VBC	S-GP
)	O
complex	O
.	O
Previously	O
,	O
peptide	O
inhibitors	O
against	O
this	O
interaction	O
between	O
hydroxylated	O
HIF-1α	S-GP
and	O
VBC	S-GP
have	O
been	O
developed	O
to	O
stabilize	O
the	O
transcriptional	O
activity	O
of	O
HIF-1α	S-GP
by	O
preventing	O
the	O
degradation	O
of	O
the	O
protein	O
even	O
under	O
normoxia	O
.	O
Despite	O
the	O
specific	O
inhibition	O
by	O
these	O
peptides	O
,	O
their	O
poor	O
inhibition	O
potency	O
needs	O
to	O
be	O
improved	O
for	O
further	O
clinical	O
application	O
.	O
In	O
this	O
work	O
,	O
we	O
have	O
designed	O
and	O
prepared	O
a	O
streptavidin-based	O
multivalent	O
peptide	O
inhibitor	O
against	O
the	O
HIF-1α	S-GP
-	O
VBC	S-GP
complexation	O
.	O
We	O
have	O
evaluated	O
the	O
potency	O
of	O
the	O
multivalent	O
peptide	O
in	O
terms	O
of	O
stabilization	O
of	O
HIF-1α	S-GP
and	O
the	O
downstream	O
effect	O
.	O
As	O
the	O
result	O
,	O
we	O
have	O
found	O
that	O
the	O
inhibitor	O
showed	O
about	O
13-fold	O
lowered	O
IC50	O
value	O
compared	O
with	O
that	O
of	O
the	O
corresponding	O
monovalent	O
peptide	O
,	O
thereby	O
activating	O
HIF-1α	S-GP
and	O
leading	O
to	O
up-regulation	O
of	O
VEGF	S-GP
protein	O
at	O
the	O
cellular	O
level	O
.	O

Comparison	O
of	O
the	O
pharmacological	O
effects	O
of	O
paricalcitol	S-chemical
and	O
doxercalciferol	S-chemical
on	O
the	O
factors	O
involved	O
in	O
mineral	O
homeostasis	O
.	O
Vitamin	B-GP
D	I-GP
receptor	E-GP
agonists	O
(	O
VDRAs	O
)	O
directly	O
suppress	O
parathyroid	B-GP
hormone	E-GP
(	O
PTH	S-GP
)	O
mRNA	O
expression	O
.	O
Different	O
VDRAs	O
are	O
known	O
to	O
have	O
differential	O
effects	O
on	O
serum	O
calcium	S-chemical
(	O
Ca	S-chemical
)	O
,	O
which	O
may	O
also	O
affect	O
serum	O
PTH	S-GP
levels	O
since	O
serum	O
Ca	S-chemical
regulates	O
PTH	S-GP
secretion	O
mediated	O
by	O
the	O
Ca-sensing	B-GP
receptor	E-GP
(	O
CaSR	S-GP
)	O
.	O
In	O
this	O
study	O
,	O
we	O
compared	O
the	O
effects	O
of	O
paricalcitol	S-chemical
and	O
doxercalciferol	S-chemical
on	O
regulating	O
serum	O
Ca	S-chemical
and	O
PTH	S-GP
,	O
and	O
also	O
the	O
expression	O
of	O
PTH	S-GP
,	O
VDR	S-GP
,	O
and	O
CaSR	S-GP
mRNA	O
.	O
The	O
5/6	O
nephrectomized	O
(	O
NX	O
)	O
Sprague-Dawley	O
rats	O
on	O
a	O
normal	O
or	O
hyperphosphatemia-inducing	O
diet	O
were	O
treated	O
with	O
vehicle	O
,	O
paricalcitol	S-chemical
,	O
or	O
doxercalciferol	S-chemical
for	O
two	O
weeks	O
.	O
Both	O
drugs	O
at	O
the	O
tested	O
doses	O
(	O
0.042-0.33	O
mug/kg	O
)	O
suppressed	O
PTH	S-GP
mRNA	O
expression	O
and	O
serum	O
PTH	S-GP
effectively	O
in	O
the	O
5/6	O
NX	O
rats	O
,	O
but	O
paricalcitol	S-chemical
was	O
less	O
potent	O
in	O
raising	O
serum	O
Ca	S-chemical
than	O
doxercalciferol	S-chemical
.	O
In	O
pig	O
parathyroid	O
cells	O
,	O
paricalcitol	S-chemical
and	O
the	O
active	O
form	O
of	O
doxercalciferol	S-chemical
induced	O
VDR	S-GP
translocation	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
,	O
suppressed	O
PTH	S-GP
mRNA	O
expression	O
and	O
inhibited	O
cell	O
proliferation	O
in	O
a	O
similar	O
manner	O
,	O
although	O
paricalcitol	S-chemical
induced	O
the	O
expression	O
of	O
CaSR	S-GP
mRNA	O
more	O
effectively	O
.	O
The	O
multiple	O
effects	O
of	O
VDRAs	O
on	O
modulating	O
serum	O
Ca	S-chemical
,	O
parathyroid	O
cell	O
proliferation	O
,	O
and	O
the	O
expression	O
of	O
CaSR	S-GP
and	O
PTH	S-GP
mRNA	O
reflect	O
the	O
complex	O
involvement	O
of	O
the	O
vitamin	B-chemical
D	E-chemical
axis	O
in	O
regulating	O
the	O
mineral	O
homeostasis	O
system	O
.	O

Salicylate	S-chemical
-based	O
anti-inflammatory	O
drugs	O
inhibit	O
the	O
early	O
lesion	O
of	O
diabetic	O
retinopathy	O
.	O
It	O
has	O
been	O
previously	O
reported	O
that	O
aspirin	S-chemical
inhibited	O
the	O
development	O
of	O
diabetic	O
retinopathy	O
in	O
diabetic	O
animals	O
,	O
raising	O
the	O
possibility	O
that	O
anti-inflammatory	O
drugs	O
may	O
have	O
beneficial	O
effects	O
on	O
diabetic	O
retinopathy	O
.	O
To	O
further	O
explore	O
this	O
,	O
we	O
compared	O
effects	O
of	O
oral	O
consumption	O
of	O
three	O
different	O
salicylate	S-chemical
-based	O
drugs	O
(	O
aspirin	S-chemical
,	O
sodium	B-chemical
salicylate	E-chemical
,	O
and	O
sulfasalazine	S-chemical
)	O
on	O
the	O
development	O
of	O
early	O
stages	O
of	O
diabetic	O
retinopathy	O
in	O
rats	O
.	O
These	O
three	O
drugs	O
differ	O
in	O
their	O
ability	O
to	O
inhibit	O
cyclooxygenase	S-GP
but	O
share	O
an	O
ability	O
to	O
inhibit	O
nuclear	B-GP
factor-kappaB	E-GP
(	O
NF-kappaB	S-GP
)	O
.	O
Diabetes	O
of	O
9-10	O
months	O
duration	O
significantly	O
increased	O
the	O
number	O
of	O
TUNEL	O
(	O
transferase-mediated	O
dUTP	O
nick-end	O
labeling	O
)	O
-positive	O
capillary	O
cells	O
and	O
acellular	O
(	O
degenerate	O
)	O
capillaries	O
in	O
the	O
retinal	O
vasculature	O
,	O
and	O
all	O
three	O
salicylate	S-chemical
-based	O
drugs	O
inhibited	O
this	O
cell	O
death	O
and	O
formation	O
of	O
acellular	O
capillaries	O
without	O
altering	O
the	O
severity	O
of	O
hyperglycemia	O
.	O
In	O
short-term	O
diabetes	O
(	O
2-4	O
months	O
)	O
,	O
all	O
three	O
salicylates	S-chemical
inhibited	O
the	O
diabetes-induced	O
loss	O
of	O
neuronal	O
cells	O
from	O
the	O
ganglion	O
cell	O
layer	O
.	O
Oral	O
aspirin	S-chemical
(	O
as	O
a	O
representative	O
of	O
the	O
salicylate	S-chemical
family	O
)	O
inhibited	O
diabetes-induced	O
increase	O
in	O
NF-kappaB	S-GP
DNA-binding	O
affinity	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
transcription	O
factor	O
array	O
in	O
nuclear	O
extract	O
isolated	O
from	O
whole	O
retina	O
.	O
All	O
three	O
salicylates	S-chemical
inhibited	O
the	O
diabetes-induced	O
translocation	O
of	O
p50	S-GP
(	O
a	O
subunit	O
of	O
NF-kappaB	S-GP
)	O
into	O
nuclei	O
of	O
retinal	O
vascular	O
endothelial	O
cells	O
of	O
the	O
isolated	O
retinal	O
vasculature	O
,	O
as	O
well	O
as	O
of	O
p50	S-GP
and	O
p65	S-GP
into	O
nuclei	O
of	O
cells	O
in	O
the	O
ganglion	O
cell	O
layer	O
and	O
inner	O
nuclear	O
layer	O
on	O
whole-retinal	O
sections	O
.	O
Sulfasalazine	S-chemical
(	O
also	O
as	O
a	O
representative	O
of	O
the	O
salicylates	S-chemical
)	O
inhibited	O
the	O
diabetes-induced	O
upregulation	O
of	O
several	O
inflammatory	O
gene	O
products	O
,	O
which	O
are	O
regulated	O
by	O
NF-kappaB	S-GP
,	O
including	O
vascular	O
cell	O
adhesion	O
molecule	O
,	O
intracellular	B-GP
adhesion	I-GP
molecule-1	E-GP
,	O
inducible	B-GP
nitric	I-GP
oxide	I-GP
synthase	E-GP
,	O
and	O
cyclooxygenase-2	S-GP
in	O
whole-retinal	O
lysate	O
.	O
Salicylates	S-chemical
,	O
in	O
doses	O
administrated	O
in	O
our	O
experiments	O
,	O
inhibited	O
NF-kappa	S-GP
B	O
and	O
perhaps	O
other	O
transcription	O
factors	O
in	O
the	O
retina	O
,	O
were	O
well	O
tolerated	O
,	O
and	O
offered	O
new	O
tools	O
to	O
investigate	O
and	O
inhibit	O
the	O
development	O
of	O
diabetic	O
retinopathy	O
.	O

Hyperthyroidism	O
causes	O
cardiac	O
dysfunction	O
by	O
mitochondrial	O
impairment	O
and	O
energy	O
depletion	O
.	O
This	O
study	O
elucidates	O
the	O
role	O
of	O
metabolic	O
remodeling	O
in	O
cardiac	O
dysfunction	O
induced	O
by	O
hyperthyroidism	O
.	O
Cardiac	O
hypertrophy	O
,	O
structural	O
remodeling	O
,	O
and	O
expression	O
of	O
the	O
genes	O
associated	O
with	O
fatty	B-chemical
acid	E-chemical
metabolism	O
were	O
examined	O
in	O
rats	O
treated	O
with	O
triiodothyronine	S-chemical
(	O
T3	O
)	O
alone	O
(	O
8	O
μg/100	O
g	O
body	O
weight	O
(	O
BW	O
)	O
,	O
i.p	O
.	O
)	O
for	O
15	O
days	O
or	O
along	O
with	O
a	O
peroxisome	B-GP
proliferator-activated	I-GP
receptor	I-GP
alpha	E-GP
agonist	O
bezafibrate	S-chemical
(	O
Bzf	S-chemical
;	O
30	O
μg/100	O
g	O
BW	O
,	O
oral	O
)	O
and	O
were	O
found	O
to	O
improve	O
in	O
the	O
Bzf	S-chemical
co-treated	O
condition	O
.	O
Ultrastructure	O
of	O
mitochondria	O
was	O
damaged	O
in	O
T3-treated	O
rat	O
heart	O
,	O
which	O
was	O
prevented	O
by	O
Bzf	S-chemical
co-administration	O
.	O
Hyperthyroidism-induced	O
oxidative	O
stress	O
,	O
reduction	O
in	O
cytochrome	B-GP
c	I-GP
oxidase	E-GP
activity	O
,	O
and	O
myocardial	O
ATP	S-chemical
concentration	O
were	O
also	O
significantly	O
checked	O
by	O
Bzf	S-chemical
.	O
Heart	O
function	O
studied	O
at	O
different	O
time	O
points	O
during	O
the	O
course	O
of	O
T3	O
treatment	O
shows	O
an	O
initial	O
improvement	O
and	O
then	O
a	O
gradual	O
but	O
progressive	O
decline	O
with	O
time	O
,	O
which	O
is	O
prevented	O
by	O
Bzf	S-chemical
co-treatment	O
.	O
In	O
summary	O
,	O
the	O
results	O
demonstrate	O
that	O
hyperthyroidism	O
inflicts	O
structural	O
and	O
functional	O
damage	O
to	O
mitochondria	O
,	O
leading	O
to	O
energy	O
depletion	O
and	O
cardiac	O
dysfunction	O
.	O

The	O
preventive	O
effect	O
of	O
uncarboxylated	O
osteocalcin	S-GP
against	O
free	B-chemical
fatty	I-chemical
acid	E-chemical
-induced	O
endothelial	O
apoptosis	O
through	O
the	O
activation	O
of	O
phosphatidylinositol	B-GP
3-kinase	E-GP
/	O
Akt	S-GP
signaling	O
pathway	O
:	O
Uncarboxylated	B-GP
osteocalcin	E-GP
and	O
endothelial	O
apoptosis	O
.	O
OBJECTIVE	O
:	O
Increasing	O
evidence	O
suggests	O
that	O
osteocalcin	S-GP
(	O
OC	S-GP
)	O
,	O
one	O
of	O
the	O
osteoblast-specific	B-GP
proteins	E-GP
,	O
has	O
been	O
associated	O
with	O
atherosclerosis	O
,	O
but	O
results	O
are	O
conflicting	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
independent	O
effect	O
of	O
uncarboxylated	B-GP
osteocalcin	E-GP
(	O
ucOC	S-GP
)	O
,	O
an	O
active	O
form	O
of	O
osteocalcin	S-GP
which	O
has	O
been	O
suggested	O
to	O
have	O
an	O
insulin	S-GP
sensitizing	O
effect	O
,	O
on	O
vascular	O
endothelial	O
cells	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
We	O
used	O
human	O
aortic	O
endothelial	O
cells	O
and	O
treated	O
them	O
with	O
ucOC	S-GP
.	O
Linoleic	B-chemical
acid	E-chemical
(	O
LA	O
)	O
was	O
used	O
as	O
a	O
representative	O
free	B-chemical
fatty	I-chemical
acid	E-chemical
.	O
Apoptosis	O
was	O
evaluated	O
using	O
various	O
methods	O
including	O
a	O
terminal	O
deoxyribonucleotide	B-GP
transferase	E-GP
-mediated	O
deoxyuridine	B-chemical
triphosphate	E-chemical
nick-end	O
labeling	O
analysis	O
kit	O
and	O
Western	O
blotting	O
for	O
cleaved	O
caspase	B-GP
3	E-GP
,	O
cleaved	O
poly	B-GP
(	I-GP
ADP-ribose	I-GP
)	I-GP
polymerase	E-GP
and	O
Bcl-xL	S-GP
.	O
The	O
phosphorylations	O
of	O
Akt	S-GP
and	O
endothelial	B-GP
nitric	I-GP
oxide	I-GP
synthase	E-GP
(	O
eNOS	S-GP
)	O
as	O
well	O
as	O
the	O
level	O
of	O
NO	S-chemical
were	O
measured	O
to	O
confirm	O
the	O
effect	O
of	O
ucOC	S-GP
on	O
insulin	S-GP
signaling	O
pathway	O
.	O
RESULTS	O
:	O
Pretreatment	O
of	O
ucOC	S-GP
(	O
30ng/ml	O
)	O
prevented	O
LA-induced	O
apoptosis	O
in	O
insulin	S-GP
-stimulated	O
endothelial	O
cells	O
;	O
effects	O
were	O
abolished	O
by	O
pretreatment	O
with	O
the	O
phosphatidylinositol	B-GP
3-kinase	E-GP
(	O
PI3-kinase	S-GP
)	O
inhibitor	O
,	O
wortmannin	S-chemical
.	O
Treatment	O
of	O
ucOC	S-GP
(	O
ranged	O
from	O
0.3	O
to	O
30ng/ml	O
)	O
significantly	O
increased	O
the	O
phosphorylation	O
of	O
Akt	S-GP
and	O
eNOS	S-GP
and	O
nitric	B-chemical
oxide	E-chemical
secretion	O
from	O
endothelial	O
cells	O
in	O
a	O
PI3-kinase	S-GP
dependent	O
manner	O
.	O
CONCLUSIONS	O
:	O
Our	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
independent	O
effect	O
of	O
ucOC	S-GP
on	O
vascular	O
endothelial	O
cells	O
.	O
Our	O
results	O
further	O
suggest	O
that	O
ucOC	S-GP
could	O
have	O
beneficial	O
effects	O
on	O
atherosclerosis	O
.	O

The	O
Intermediate-conductance	B-GP
Calcium-activated	I-GP
Potassium	I-GP
Channel	I-GP
KCa3.1	E-GP
Regulates	O
Vascular	O
Smooth	O
Muscle	O
Cell	O
Proliferation	O
via	O
Controlling	O
Calcium	S-chemical
-dependent	O
Signaling	O
.	O
The	O
intermediate-conductance	B-GP
calcium-activated	I-GP
potassium	I-GP
channel	I-GP
KCa3.1	E-GP
contributes	O
to	O
a	O
variety	O
of	O
cell	O
activation	O
processes	O
in	O
pathologies	O
such	O
as	O
inflammation	O
,	O
carcinogenesis	O
and	O
vascular	O
remodeling	O
.	O
We	O
examined	O
the	O
electrophysiological	O
and	O
transcriptional	O
mechanisms	O
by	O
which	O
KCa3.1	S-GP
regulates	O
vascular	O
smooth	O
muscle	O
cell	O
(	O
VSMC	O
)	O
proliferation	O
.	O
Platelet-derived	B-GP
growth	I-GP
factor-BB	E-GP
(	O
PDGF	S-GP
)	O
-induced	O
proliferation	O
of	O
human	O
coronary	O
artery	O
VSMCs	O
was	O
attenuated	O
by	O
lowering	O
intracellular	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
concentration	O
(	O
[	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
]	O
i	O
)	O
and	O
was	O
enhanced	O
by	O
elevating	O
[	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
]	O
i	O
.	O
KCa3.1	S-GP
blockade	O
or	O
knockdown	O
inhibited	O
proliferation	O
by	O
suppressing	O
the	O
rise	O
in	O
[	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
]	O
i	O
and	O
attenuating	O
the	O
expression	O
of	O
phosphorylated	B-GP
cAMP	I-GP
response	I-GP
element	I-GP
binding	I-GP
protein	E-GP
(	O
CREB	S-GP
)	O
,	O
c-fos	S-GP
and	O
neuron-derived	B-GP
orphan	I-GP
receptor-1	E-GP
(	O
NOR-1	S-GP
)	O
.	O
This	O
anti-proliferative	O
effect	O
was	O
abolished	O
by	O
elevating	O
[	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
]	O
i	O
.	O
KCa3.1	S-GP
overexpression	O
induced	O
VSMC	O
proliferation	O
,	O
and	O
potentiated	O
PDGF	S-GP
-induced	O
proliferation	O
,	O
by	O
inducing	O
CREB	S-GP
phosphorylation	O
,	O
c-fos	S-GP
and	O
NOR-1	S-GP
.	O
Pharmacological	O
stimulation	O
of	O
KCa3.1	S-GP
unexpectedly	O
suppressed	O
proliferation	O
by	O
inhibiting	O
the	O
rise	O
in	O
[	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
]	O
i	O
and	O
abolishing	O
the	O
expression	O
and	O
activity	O
of	O
KCa3.1	S-GP
and	O
PDGF	B-GP
β-receptors	E-GP
.	O
The	O
stimulation	O
also	O
attenuated	O
the	O
levels	O
of	O
phosphorylated	B-GP
CREB	E-GP
,	O
c-fos	S-GP
and	O
cyclins	S-GP
expression	O
.	O
After	O
KCa3.1	S-GP
blockade	O
,	O
the	O
characteristic	O
round	O
shape	O
of	O
VSMCs	O
expressing	O
high	O
l-caldesmon	S-GP
and	O
low	O
calponin-1	S-GP
(	O
dedifferentiation	O
state	O
)	O
was	O
maintained	O
,	O
whereas	O
KCa3.1	S-GP
stimulation	O
induced	O
a	O
spindle-shape	O
cellular	O
appearance	O
,	O
with	O
low	O
l-caldesmon	S-GP
and	O
high	O
calponin-1	S-GP
.	O
In	O
conclusion	O
,	O
KCa3.1	S-GP
plays	O
an	O
important	O
role	O
in	O
VSMC	O
proliferation	O
via	O
controlling	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
-dependent	O
signaling	O
pathways	O
and	O
its	O
modulation	O
may	O
therefore	O
constitute	O
a	O
new	O
therapeutic	O
target	O
for	O
cell	O
proliferative	O
diseases	O
such	O
as	O
atherosclerosis	O
.	O

Vitamin	B-chemical
E	E-chemical
deficiency	O
impairs	O
the	O
somatostatinergic	B-GP
receptor	E-GP
-effector	O
system	O
and	O
leads	O
to	O
phosphotyrosine	B-GP
phosphatase	E-GP
overactivation	O
and	O
cell	O
death	O
in	O
the	O
rat	O
hippocampus	O
.	O
Vitamin	B-chemical
E	E-chemical
plays	O
an	O
essential	O
role	O
in	O
maintaining	O
the	O
structure	O
and	O
function	O
of	O
the	O
nervous	O
system	O
,	O
and	O
its	O
deficiency	O
,	O
commonly	O
associated	O
with	O
fat	O
malabsorption	O
diseases	O
,	O
may	O
reduce	O
neuronal	O
survival	O
.	O
We	O
previously	O
demonstrated	O
that	O
the	O
somatostatinergic	O
system	O
,	O
implicated	O
in	O
neuronal	O
survival	O
control	O
,	O
can	O
be	O
modulated	O
by	O
α-tocopherol	S-chemical
in	O
the	O
rat	O
dentate	O
gyrus	O
,	O
increasing	O
cyclic	B-GP
adenosine	I-GP
monophosphate	I-GP
response	I-GP
element	I-GP
binding	I-GP
protein	E-GP
phosphorylation	O
.	O
To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
actions	O
of	O
tocopherols	S-chemical
and	O
examine	O
the	O
link	O
among	O
vitamin	B-chemical
E	E-chemical
,	O
somatostatin	S-chemical
and	O
neuronal	O
survival	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
a	O
deficiency	O
and	O
subsequent	O
administration	O
of	O
tocopherol	S-chemical
on	O
the	O
somatostatin	S-chemical
signaling	O
pathway	O
and	O
neuronal	O
survival	O
in	O
the	O
rat	O
hippocampus	O
.	O
No	O
changes	O
in	O
somatostatin	S-chemical
expression	O
were	O
detected	O
in	O
vitamin-E	S-chemical
-deficient	O
rats	O
.	O
These	O
rats	O
,	O
however	O
,	O
showed	O
a	O
significant	O
increase	O
in	O
the	O
somatostatin	B-GP
receptor	E-GP
density	O
and	O
dissociation	O
constant	O
,	O
which	O
correlated	O
with	O
a	O
significant	O
increase	O
in	O
the	O
protein	O
levels	O
of	O
somatostatin	B-GP
receptors	E-GP
.	O
Nevertheless	O
,	O
vitamin	B-chemical
E	E-chemical
deficiency	O
impaired	O
the	O
ability	O
of	O
the	O
somatostatin	B-GP
receptors	E-GP
to	O
couple	O
to	O
the	O
effectors	O
adenylyl	S-chemical
cyclase	O
and	O
phosphotyrosine	B-GP
phosphatase	E-GP
by	O
diminishing	O
Gi	B-GP
protein	E-GP
functionality	O
.	O
Furthermore	O
,	O
vitamin	B-chemical
E	E-chemical
deficiency	O
significantly	O
increased	O
phosphotyrosine	B-GP
phosphatase	E-GP
activity	O
and	O
PTPη	S-GP
expression	O
,	O
as	O
well	O
as	O
PKCδ	S-GP
activation	O
,	O
and	O
decreased	O
extracellular-signal-regulated	B-GP
kinase	E-GP
phosphorylation	O
.	O
All	O
these	O
changes	O
were	O
accompanied	O
by	O
an	O
increase	O
in	O
neuronal	O
cell	O
death	O
.	O
Subsequent	O
α-tocopherol	S-chemical
administration	O
partially	O
or	O
completely	O
reversed	O
all	O
these	O
values	O
to	O
control	O
levels	O
.	O
Altogether	O
,	O
our	O
results	O
prove	O
the	O
importance	O
of	O
vitamin	B-chemical
E	E-chemical
homeostasis	O
in	O
the	O
somatostatin	B-GP
receptor	E-GP
-effector	O
system	O
and	O
suggest	O
a	O
possible	O
mechanism	O
by	O
which	O
this	O
vitamin	O
may	O
regulate	O
the	O
neuronal	O
cell	O
survival	O
in	O
the	O
adult	O
hippocampus	O
.	O

A	O
novel	O
mutation	O
of	O
the	O
erythroid-specific	B-GP
gamma-Aminolevulinate	I-GP
synthase	E-GP
gene	O
in	O
a	O
patient	O
with	O
non-inherited	O
pyridoxine	S-chemical
-responsive	O
sideroblastic	O
anemia	O
.	O
A	O
novel	O
missense	O
mutation	O
,	O
G663A	S-GP
,	O
in	O
exon	O
5	O
of	O
the	O
erythroid-specific	B-GP
delta-aminolevulinate	I-GP
synthase	E-GP
gene	O
(	O
ALAS2	S-GP
)	O
was	O
identified	O
in	O
a	O
Japanese	O
male	O
with	O
pyridoxine	S-chemical
-responsive	O
sideroblastic	O
anemia	O
.	O
Activity	O
of	O
the	O
mutant	O
delta-aminolevulinate	B-GP
synthase	E-GP
protein	O
expressed	O
in	O
vitro	O
was	O
15.1	O
%	O
compared	O
with	O
the	O
normal	O
control	O
,	O
but	O
was	O
increased	O
up	O
to	O
34.5	O
%	O
by	O
the	O
addition	O
of	O
pyridoxal	B-chemical
5'-phosphate	E-chemical
,	O
consistent	O
with	O
the	O
clinical	O
response	O
of	O
the	O
patient	O
to	O
pyridoxine	S-chemical
treatment	O
.	O
The	O
same	O
mutation	O
was	O
also	O
detected	O
in	O
genomic	O
DNa	O
from	O
the	O
oral	O
mucosal	O
membrane	O
of	O
the	O
patiet	O
;	O
however	O
,	O
it	O
was	O
not	O
detected	O
in	O
other	O
family	O
member	O
.	O
These	O
findings	O
suggest	O
that	O
this	O
G663A	S-GP
mutation	O
is	O
responsible	O
for	O
sideroblastic	O
anemia	O
in	O
the	O
proband	O
,	O
and	O
may	O
be	O
an	O
index	O
mutation	O
in	O
this	O
pedigree	O
.	O

Effects	O
of	O
the	O
histamine	B-GP
H1	E-GP
antagonist	O
chlorcyclizine	S-chemical
on	O
rat	O
fetal	O
palate	O
development	O
.	O
BACKGROUND	O
:	O
The	O
effects	O
of	O
histamine	B-GP
H1	E-GP
antagonist	O
chlorcyclizine	S-chemical
on	O
rat	O
palate	O
development	O
were	O
characterized	O
following	O
in	O
utero	O
exposure	O
.	O
METHODS	O
:	O
To	O
identify	O
the	O
optimum	O
dose	O
for	O
inducing	O
cleft	O
palate	O
,	O
pregnant	O
rats	O
were	O
administered	O
30	O
,	O
60	O
,	O
or	O
90	O
mg/kg	O
chlorcyclizine	S-chemical
on	O
Gestation	O
Days	O
11	O
to	O
14	O
.	O
Fetal	O
palate	O
gene	O
expression	O
was	O
also	O
assessed	O
after	O
90	O
mg/kg	O
chlorcyclizine	S-chemical
at	O
8	O
,	O
15	O
and	O
30	O
hours	O
post-dose	O
on	O
Gestation	O
Day	O
14	O
using	O
microarray	O
and	O
qRT-PCR	O
.	O
RESULTS	O
:	O
Rats	O
in	O
the	O
60-	O
and	O
90-mg/kg	O
groups	O
exhibited	O
adverse	O
clinical	O
signs	O
and	O
body	O
weight	O
loss	O
.	O
Rats	O
in	O
the	O
90-mg/kg	O
group	O
also	O
demonstrated	O
increases	O
in	O
late	O
resorptions	O
and	O
decreases	O
in	O
fetal	O
weight	O
.	O
Effects	O
in	O
the	O
low-dose	O
group	O
were	O
limited	O
to	O
decreases	O
in	O
body	O
weight	O
gain	O
.	O
Fetal	O
assessment	O
on	O
Gestation	O
Day	O
21	O
revealed	O
that	O
findings	O
were	O
limited	O
to	O
the	O
60-	O
and	O
90-mg/kg	O
groups	O
,	O
and	O
included	O
cleft	O
palate	O
(	O
80	O
%	O
of	O
litters	O
for	O
both	O
groups	O
)	O
,	O
high	O
arched	O
palate	O
,	O
small	O
nose	O
,	O
micrognathia	O
,	O
high	O
domed	O
head	O
,	O
digits	O
shortened/absent	O
and	O
small	O
limb	O
.	O
The	O
fetal	O
incidence	O
of	O
cleft	O
palate	O
was	O
higher	O
at	O
90	O
mg/kg	O
,	O
thus	O
this	O
dose	O
was	O
selected	O
to	O
assess	O
palate	O
gene	O
expression	O
.	O
The	O
altered	O
genes	O
associated	O
with	O
chlorcyclizine	S-chemical
-induced	O
cleft	O
palate	O
included	O
Wnt5a	S-GP
,	O
Bmp2	S-GP
,	O
Bmp4	S-GP
,	O
Fgf10	S-GP
,	O
Fgfr2	S-GP
,	O
Msx1	S-GP
,	O
and	O
Insig1	S-GP
but	O
the	O
magnitude	O
of	O
the	O
change	O
was	O
relatively	O
small	O
(	O
1.5-	O
to	O
2-fold	O
)	O
.	O
CONCLUSIONS	O
:	O
Expression	O
of	O
several	O
genes	O
involved	O
in	O
palate	O
,	O
limb	O
and	O
digit	O
development	O
was	O
altered	O
in	O
the	O
fetal	O
palate	O
following	O
in	O
utero	O
exposure	O
to	O
chlorcyclizine	S-chemical
.	O
The	O
subtle	O
perturbation	O
and	O
interplay	O
of	O
these	O
genes	O
may	O
have	O
profound	O
effects	O
on	O
the	O
dynamics	O
of	O
fetal	O
palate	O
development	O
.	O

Encapsulation	O
of	O
Nod1	S-GP
and	O
Nod2	S-GP
receptor	O
ligands	O
into	O
poly	B-chemical
(	I-chemical
lactic	I-chemical
acid	I-chemical
)	E-chemical
nanoparticles	O
potentiates	O
their	O
immune	O
properties	O
.	O
Most	O
successful	O
vaccines	O
are	O
able	O
to	O
induce	O
persistent	O
antibody	O
responses	O
that	O
can	O
last	O
a	O
lifetime	O
.	O
Emerging	O
evidences	O
indicate	O
that	O
activation	O
of	O
immune	O
cells	O
through	O
pattern	B-GP
recognition	I-GP
receptors	E-GP
(	O
PRRs	S-GP
)	O
such	O
as	O
Toll-like	B-GP
receptors	E-GP
(	O
TLRs	S-GP
)	O
or	O
Nod-like	B-GP
receptors	E-GP
(	O
NLRs	S-GP
)	O
may	O
be	O
critical	O
mechanisms	O
.	O
Among	O
PRRs	S-GP
,	O
the	O
use	O
of	O
TLR	S-GP
ligands	O
as	O
adjuvants	O
is	O
already	O
largely	O
described	O
whereas	O
the	O
use	O
of	O
NLRs	S-GP
ligands	O
remains	O
largely	O
unexplored	O
.	O
As	O
activation	O
of	O
intracytoplasmic	O
NLRs	S-GP
is	O
able	O
to	O
induce	O
proinflammatory	O
molecules	O
,	O
the	O
added	O
value	O
of	O
encapsulation	O
of	O
Nod1	S-GP
and	O
Nod2	S-GP
receptor	O
ligands	O
into	O
Poly	B-chemical
(	I-chemical
Lactic	I-chemical
Acid	I-chemical
)	E-chemical
(	O
PLA	S-chemical
)	O
biodegradable	O
nanocarriers	O
to	O
modulate	O
their	O
immune	O
properties	O
on	O
human	O
dendritic	O
cells	O
(	O
DCs	O
)	O
maturation	O
has	O
been	O
evaluated	O
.	O
Their	O
ability	O
to	O
induce	O
systemic	O
immune	O
responses	O
in	O
mice	O
was	O
also	O
measured	O
and	O
compared	O
to	O
free	O
ligands	O
and	O
the	O
Alum	O
adjuvant	O
.	O
Nod	S-GP
ligands	O
encapsulated	O
into	O
PLA	S-chemical
NPs	O
were	O
efficiently	O
taken	O
up	O
by	O
DCs	O
and	O
subsequently	O
induced	O
a	O
strong	O
up-regulation	O
of	O
maturation	O
markers	O
and	O
the	O
enhancement	O
of	O
proinflammatory	O
cytokine	S-GP
secretion	O
by	O
DCs	O
.	O
Furthermore	O
,	O
co-injection	O
of	O
encapsulated	O
Nod	S-GP
-ligands	O
with	O
PLA	S-chemical
particles	O
carrying	O
Gag	B-GP
p24	E-GP
HIV-1	O
antigen	O
allowed	O
a	O
100	O
fold	O
increase	O
in	O
antibody	O
responses	O
in	O
comparison	O
to	O
Alum	O
.	O
These	O
results	O
suggest	O
that	O
encapsulation	O
of	O
Nod	S-GP
ligands	O
into	O
PLA	S-chemical
-NPs	O
could	O
be	O
an	O
effective	O
way	O
to	O
improve	O
vaccine	O
efficiency	O
.	O

Clinical	O
manifestations	O
of	O
genetic	O
defects	O
affecting	O
gonadotrophins	S-GP
and	O
their	O
receptors	O
.	O
Raised	O
activity	O
of	O
the	O
LH	S-GP
axis	O
caused	O
by	O
activating	O
mutations	O
of	O
LH	B-GP
receptor	E-GP
gene	O
presents	O
with	O
precocious	O
puberty	O
in	O
boys	O
,	O
analogous	O
to	O
the	O
presentation	O
of	O
LH	S-GP
secreting	O
pituitary	O
adenomas	O
(	O
Faggiano	O
et	O
al.	O
,	O
1983	O
;	O
Ambrosi	O
et	O
al.	O
,	O
1990	O
)	O
.	O
LH	S-GP
``	O
hyperactivity	O
'	O
in	O
females	O
appears	O
to	O
have	O
no	O
effect	O
.	O
Hyperactivity	O
of	O
the	O
FSH	S-GP
axis	O
caused	O
by	O
activating	O
mutations	O
of	O
the	O
FSH	B-GP
receptor	E-GP
gene	O
might	O
parallel	O
the	O
presentation	O
of	O
FSH	S-GP
secreting	O
pituitary	O
adenomas	O
with	O
Sertoli	O
cell	O
hypertrophy	O
in	O
men	O
(	O
Heseltine	O
et	O
al.	O
,	O
1989	O
)	O
or	O
reversible	O
premature	O
ovarian	O
failure	O
in	O
women	O
(	O
Moses	O
et	O
al.	O
,	O
1986	O
;	O
Okuda	O
et	O
al.	O
,	O
1989	O
)	O
.	O
Indeed	O
the	O
first	O
such	O
case	O
to	O
be	O
described	O
is	O
a	O
male	O
who	O
maintained	O
testicular	O
volume	O
and	O
fertility	O
in	O
the	O
absence	O
of	O
gonadotrophins	S-GP
(	O
Gromoll	O
et	O
al.	O
,	O
1996	O
)	O
.	O
Female	O
precocious	O
puberty	O
may	O
require	O
hyperactivity	O
of	O
both	O
gonadotrophin	S-GP
axes	O
because	O
of	O
the	O
``	O
two-cell	O
'	O
arrangement	O
required	O
for	O
ovarian	O
oestrogen	S-chemical
production	O
.	O
Mutations	O
of	O
the	O
Gs	B-GP
alpha	E-GP
-subunit	O
gene	O
can	O
mimic	O
this	O
situation	O
in	O
some	O
women	O
with	O
the	O
McCune-Albright	O
syndrome	O
(	O
Malchoff	O
et	O
al.	O
,	O
1994	O
)	O
.	O
Lack	O
of	O
LH	S-GP
activity	O
caused	O
by	O
defects	O
in	O
the	O
LH	B-GP
beta	E-GP
molecule	O
causes	O
infertility	O
in	O
men	O
and	O
that	O
resulting	O
from	O
inactivating	O
mutations	O
of	O
the	O
LH	B-GP
receptor	E-GP
gene	O
causes	O
Leydig	O
cell	O
agenesis	O
in	O
men	O
while	O
ovarian	O
development	O
in	O
females	O
is	O
relatively	O
normal	O
.	O
Lack	O
of	O
FSH	S-GP
activity	O
caused	O
by	O
defects	O
in	O
the	O
FSH	B-GP
beta	E-GP
caused	O
infertility	O
in	O
a	O
female	O
,	O
and	O
that	O
caused	O
by	O
inactivating	O
mutations	O
of	O
the	O
FSH	B-GP
receptor	E-GP
gene	O
causes	O
ovarian	O
dysgenesis	O
in	O
women	O
but	O
only	O
variable	O
depression	O
of	O
spermatogenesis	O
in	O
men	O
.	O
Incidentally	O
,	O
this	O
categorization	O
of	O
reproductive	O
disorders	O
may	O
also	O
be	O
applied	O
to	O
the	O
TSH	S-GP
axis	O
.	O
Pituitary	O
adenomas	O
and	O
activating	O
mutations	O
of	O
the	O
TSH	B-GP
receptor	E-GP
gene	O
(	O
Parma	O
et	O
al.	O
,	O
1993	O
)	O
cause	O
hyperthyroidism	O
and	O
TSH	B-GP
beta	E-GP
gene	O
defects	O
(	O
Hayashizaki	O
et	O
al.	O
,	O
1989	O
)	O
and	O
inactivating	O
mutations	O
of	O
the	O
TSH	B-GP
receptor	E-GP
gene	O
(	O
Sunthornthepvarakul	O
et	O
al.	O
,	O
1995	O
)	O
cause	O
hypothyroidism	O
.	O
To	O
complete	O
the	O
analogy	O
with	O
thyroid	O
disorders	O
,	O
it	O
is	O
curious	O
that	O
despite	O
structural	O
similarities	O
with	O
the	O
TSH	B-GP
receptor	E-GP
,	O
neither	O
LH	B-GP
nor	I-GP
FSH	I-GP
receptor	E-GP
autoantibodies	O
have	O
a	O
prominent	O
role	O
in	O
ovarian	O
pathophysiology	O
(	O
Moncayo	O
et	O
al.	O
,	O
1989	O
;	O
Van	O
Weissenbruch	O
et	O
al.	O
,	O
1991	O
;	O
Simoni	O
et	O
al.	O
,	O
1993	O
)	O
.	O
Complete	O
gonadotrophin	S-GP
resistance	O
is	O
likely	O
to	O
be	O
very	O
rare	O
,	O
however	O
,	O
so	O
what	O
are	O
we	O
likely	O
to	O
find	O
in	O
partial	O
gonadotrophin	S-GP
resistance	O
?	O
Might	O
the	O
``	O
resistant	O
ovary	O
syndrome	O
'	O
come	O
right	O
in	O
the	O
end	O
,	O
with	O
corresponding	O
minor	O
FSH	B-GP
receptor	E-GP
mutations	O
?	O
Experience	O
with	O
insulin	S-GP
and	O
androgen	O
resistance	O
syndromes	O
suggests	O
that	O
such	O
a	O
scenario	O
is	O
unlikely	O
.	O
Insulin	B-GP
receptor	E-GP
gene	O
mutations	O
are	O
found	O
in	O
extreme	O
Type	O
A	O
insulin	S-GP
resistance	O
but	O
not	O
in	O
moderate	O
forms	O
of	O
insulin	S-GP
resistance	O
(	O
O'Rahilly	O
et	O
al.	O
,	O
1991	O
)	O
.	O
Androgen	B-GP
receptor	E-GP
gene	O
mutations	O
are	O
found	O
in	O
nearly	O
all	O
cases	O
of	O
complete	O
androgen	O
insensitivity	O
but	O
rarely	O
in	O
partial	O
forms	O
(	O
Patterson	O
et	O
al.	O
,	O
1994	O
)	O
.	O
Mild	O
resistance	O
to	O
hormone	O
action	O
is	O
rarely	O
detectable	O
in	O
relatives	O
who	O
are	O
heterozygous	O
for	O
receptor	O
mutations	O
which	O
are	O
inherited	O
in	O
a	O
recessive	O
pattern	O
.	O
It	O
seems	O
unlikely	O
therefore	O
,	O
that	O
individuals	O
heterozygous	O
for	O
inactivating	O
receptor	O
mutations	O
will	O
manifest	O
symptoms	O
of	O
reproductive	O
disorders	O
and	O
account	O
for	O
common	O
conditions	O
.	O
Thus	O
,	O
while	O
mutation	O
analysis	O
provides	O
new	O
insights	O
into	O
the	O
gender	O
specific	O
role	O
of	O
the	O
gonadotrophins	S-GP
the	O
cause	O
of	O
early	O
gonadal	O
failure	O
in	O
the	O
majority	O
of	O
individuals	O
remains	O
a	O
mystery	O
.	O

Oxidation	O
of	O
tertiary	B-chemical
amine	E-chemical
-derivatized	O
surfaces	O
to	O
control	O
protein	O
adhesion	O
.	O
Selective	O
oxidation	O
of	O
ω-tertiary	B-chemical
amine	E-chemical
self-assembled	O
thiol	S-chemical
monolayers	O
to	O
tertiary	B-chemical
amine	I-chemical
N-oxides	E-chemical
is	O
shown	O
to	O
transform	O
the	O
adhesion	O
of	O
model	O
proteins	O
lysozyme	S-GP
and	O
fibrinogen	S-GP
upon	O
them	O
.	O
Efficient	O
preparation	O
of	O
both	O
secondary	B-chemical
and	I-chemical
tertiary	I-chemical
linker	I-chemical
amides	E-chemical
as	O
judged	O
by	O
X-ray	O
photoelectron	O
spectroscopy	O
(	O
XPS	O
)	O
and	O
water	O
droplet	O
contact	O
angle	O
was	O
achieved	O
with	O
an	O
improved	O
amide	S-chemical
bond	O
formation	O
on	O
gold	O
quartz	S-chemical
crystal	O
microbalance	O
(	O
QCM	O
)	O
sensors	O
using	O
2-	B-chemical
(	I-chemical
1H-7-azabenzotriazol-1-yl	I-chemical
)	I-chemical
-1,1,3,3-tetramethyl	I-chemical
hexafluorophosphate	I-chemical
methanaminium	I-chemical
uronium	E-chemical
(	O
HATU	S-chemical
)	O
.	O
Oxidation	O
with	O
hydrogen	B-chemical
peroxide	E-chemical
was	O
similarly	O
assessed	O
,	O
and	O
adhesion	O
of	O
lysozyme	S-GP
and	O
fibrinogen	S-GP
from	O
phosphate	S-chemical
buffered	O
saline	O
was	O
then	O
assayed	O
by	O
QCM	O
and	O
imaged	O
by	O
AFM	O
.	O
Tertiary	B-chemical
amine	E-chemical
-functionalized	O
sensors	O
adsorbed	O
multilayers	O
of	O
aggregated	O
lysozyme	S-GP
,	O
whereas	O
tertiary	B-chemical
amine	I-chemical
N-oxides	E-chemical
and	O
triethylene	B-chemical
glycol	E-chemical
-terminated	O
monolayers	O
are	O
consistent	O
with	O
small	O
protein	O
aggregates	O
.	O
The	O
surface	O
containing	O
a	O
dimethylamine	B-chemical
N-oxide	E-chemical
headgroup	O
and	O
ethyl	B-chemical
secondary	I-chemical
amide	E-chemical
linker	O
showed	O
the	O
largest	O
difference	O
in	O
adsorption	O
of	O
both	O
proteins	O
.	O
Oxidation	O
of	O
tertiary	B-chemical
amine	E-chemical
decorated	O
surfaces	O
therefore	O
holds	O
the	O
potential	O
for	O
selective	O
deposition	O
of	O
proteins	O
and	O
cells	O
through	O
masking	O
and	O
other	O
patterning	O
techniques	O
.	O

Nuclear	B-GP
receptors	E-GP
in	O
bile	B-chemical
acid	E-chemical
metabolism	O
.	O
Bile	B-chemical
acids	E-chemical
are	O
signaling	O
molecules	O
that	O
activate	O
nuclear	B-GP
receptors	E-GP
,	O
such	O
as	O
farnesoid	B-GP
X	I-GP
receptor	E-GP
,	O
pregnane	B-GP
X	I-GP
receptor	E-GP
,	O
constitutive	B-GP
androstane	I-GP
receptor	E-GP
,	O
and	O
vitamin	B-GP
D	I-GP
receptor	E-GP
,	O
and	O
play	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
lipid	O
,	O
glucose	S-chemical
,	O
energy	O
,	O
and	O
drug	O
metabolism	O
.	O
These	O
xenobiotic/endobiotic-sensing	B-GP
nuclear	I-GP
receptors	E-GP
regulate	O
phase	O
I	O
oxidation	O
,	O
phase	O
II	O
conjugation	O
,	O
and	O
phase	O
III	O
transport	O
in	O
bile	B-chemical
acid	E-chemical
and	O
drug	O
metabolism	O
in	O
the	O
digestive	O
system	O
.	O
Integration	O
of	O
bile	B-chemical
acid	E-chemical
metabolism	O
with	O
drug	O
metabolism	O
controls	O
absorption	O
,	O
transport	O
,	O
and	O
metabolism	O
of	O
nutrients	O
and	O
drugs	O
to	O
maintain	O
metabolic	O
homeostasis	O
and	O
also	O
protects	O
against	O
liver	O
injury	O
,	O
inflammation	O
,	O
and	O
related	O
metabolic	O
diseases	O
,	O
such	O
as	O
nonalcoholic	O
fatty	O
liver	O
disease	O
,	O
diabetes	O
,	O
and	O
obesity	O
.	O
Bile-acid	S-chemical
-based	O
drugs	O
targeting	O
nuclear	O
receptors	O
are	O
in	O
clinical	O
trials	O
for	O
treating	O
cholestatic	O
liver	O
diseases	O
and	O
fatty	O
liver	O
disease	O
.	O

Transaldolase	S-GP
deficiency	O
:	O
report	O
of	O
12	O
new	O
cases	O
and	O
further	O
delineation	O
of	O
the	O
phenotype	O
.	O
PURPOSE	O
:	O
Transaldolase	S-GP
deficiency	O
is	O
a	O
recently	O
described	O
inborn	O
error	O
of	O
pentose	B-chemical
phosphate	E-chemical
pathway	O
.	O
We	O
conducted	O
this	O
study	O
to	O
further	O
delineate	O
the	O
associated	O
phenotype	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
We	O
report	O
on	O
12	O
new	O
cases	O
representing	O
six	O
families	O
with	O
this	O
metabolic	O
defect	O
that	O
were	O
observed	O
over	O
an	O
8	O
year	O
span	O
.	O
None	O
of	O
these	O
cases	O
received	O
the	O
correct	O
diagnosis	O
initially	O
because	O
of	O
significant	O
overlap	O
in	O
the	O
presenting	O
symptoms	O
(	O
growth	O
retardation	O
,	O
dysmorphic	O
features	O
,	O
cutis	O
laxa	O
,	O
congenital	O
heart	O
disease	O
,	O
hepatosplenomegaly	O
,	O
pancytopenia	O
,	O
and	O
bleeding	O
tendency	O
)	O
with	O
a	O
wide	O
range	O
of	O
genetic	O
disorders	O
.	O
However	O
,	O
the	O
consanguineous	O
nature	O
of	O
these	O
families	O
allowed	O
us	O
to	O
pursue	O
autozygome	O
analysis	O
,	O
which	O
highlighted	O
TALDO	S-GP
as	O
the	O
likely	O
candidate	O
gene	O
and	O
sequencing	O
confirmed	O
segregation	O
of	O
a	O
novel	O
homozygous	O
mutation	O
with	O
the	O
disease	O
in	O
all	O
the	O
studied	O
families	O
.	O
Biochemical	O
analysis	O
was	O
also	O
consistent	O
with	O
transaldolase	S-GP
deficiency	O
.	O
CONCLUSION	O
:	O
This	O
study	O
expands	O
the	O
clinical	O
definition	O
of	O
transaldolase	S-GP
deficiency	O
,	O
and	O
adds	O
to	O
its	O
allelic	O
heterogeneity	O
.	O
In	O
addition	O
,	O
we	O
emphasize	O
the	O
diagnostic	O
challenge	O
posed	O
by	O
this	O
rare	O
and	O
pleiotropic	O
metabolic	O
disorder	O
.	O

Biology	O
of	O
incretins	S-GP
:	O
GLP-1	S-GP
and	O
GIP	S-GP
.	O
This	O
review	O
focuses	O
on	O
the	O
mechanisms	O
regulating	O
the	O
synthesis	O
,	O
secretion	O
,	O
biological	O
actions	O
,	O
and	O
therapeutic	O
relevance	O
of	O
the	O
incretin	S-GP
peptides	O
glucose-dependent	B-GP
insulinotropic	I-GP
polypeptide	E-GP
(	O
GIP	S-GP
)	O
and	O
glucagon-like	B-GP
peptide-1	E-GP
(	O
GLP-1	S-GP
)	O
.	O
The	O
published	O
literature	O
was	O
reviewed	O
,	O
with	O
emphasis	O
on	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
biology	O
of	O
GIP	S-GP
and	O
GLP-1	S-GP
.	O
GIP	S-GP
and	O
GLP-1	S-GP
are	O
both	O
secreted	O
within	O
minutes	O
of	O
nutrient	O
ingestion	O
and	O
facilitate	O
the	O
rapid	O
disposal	O
of	O
ingested	O
nutrients	O
.	O
Both	O
peptides	O
share	O
common	O
actions	O
on	O
islet	O
beta-cells	O
acting	O
through	O
structurally	O
distinct	O
yet	O
related	O
receptors	O
.	O
Incretin-receptor	S-GP
activation	O
leads	O
to	O
glucose	S-chemical
-dependent	O
insulin	S-GP
secretion	O
,	O
induction	O
of	O
beta-cell	O
proliferation	O
,	O
and	O
enhanced	O
resistance	O
to	O
apoptosis	O
.	O
GIP	S-GP
also	O
promotes	O
energy	O
storage	O
via	O
direct	O
actions	O
on	O
adipose	O
tissue	O
,	O
and	O
enhances	O
bone	O
formation	O
via	O
stimulation	O
of	O
osteoblast	O
proliferation	O
and	O
inhibition	O
of	O
apoptosis	O
.	O
In	O
contrast	O
,	O
GLP-1	S-GP
exerts	O
glucoregulatory	O
actions	O
via	O
slowing	O
of	O
gastric	O
emptying	O
and	O
glucose	S-chemical
-dependent	O
inhibition	O
of	O
glucagon	S-GP
secretion	O
.	O
GLP-1	S-GP
also	O
promotes	O
satiety	O
and	O
sustained	O
GLP-1-receptor	S-GP
activation	O
is	O
associated	O
with	O
weight	O
loss	O
in	O
both	O
preclinical	O
and	O
clinical	O
studies	O
.	O
The	O
rapid	O
degradation	O
of	O
both	O
GIP	S-GP
and	O
GLP-1	S-GP
by	O
the	O
enzyme	O
dipeptidyl	B-GP
peptidase-4	E-GP
has	O
led	O
to	O
the	O
development	O
of	O
degradation-resistant	O
GLP-1-receptor	S-GP
agonists	O
and	O
dipeptidyl	B-GP
peptidase-4	E-GP
inhibitors	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
.	O
These	O
agents	O
decrease	O
hemoglobin	B-GP
A1c	E-GP
(	O
HbA1c	S-GP
)	O
safely	O
without	O
weight	O
gain	O
in	O
subjects	O
with	O
type	O
2	O
diabetes	O
.	O
GLP-1	S-GP
and	O
GIP	S-GP
integrate	O
nutrient-derived	O
signals	O
to	O
control	O
food	O
intake	O
,	O
energy	O
absorption	O
,	O
and	O
assimilation	O
.	O
Recently	O
approved	O
therapeutic	O
agents	O
based	O
on	O
potentiation	O
of	O
incretin	S-GP
action	O
provide	O
new	O
physiologically	O
based	O
approaches	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
.	O

Evaluation	O
of	O
food-drug	O
interaction	O
of	O
guava	O
leaf	O
tea	O
.	O
Guava	O
leaf	O
tea	O
(	O
GLT	O
)	O
contains	O
guava	O
leaf	O
polyphenol	S-chemical
(	O
Gvpp	O
)	O
,	O
which	O
regulates	O
the	O
absorption	O
of	O
dietary	O
carbohydrate	S-chemical
from	O
the	O
intestines	O
.	O
Borderline	O
diabetics	O
,	O
who	O
are	O
at	O
high	O
risk	O
of	O
development	O
of	O
diabetes	O
,	O
take	O
GLT	O
to	O
suppress	O
a	O
rapid	O
increase	O
of	O
blood	O
sugar	S-chemical
level	O
after	O
meals	O
.	O
However	O
,	O
patients	O
with	O
diabetes	O
in	O
whom	O
diabetic	O
drugs	O
or	O
warfarin	S-chemical
as	O
a	O
blood	O
thinner	O
are	O
prescribed	O
also	O
take	O
GLT	O
with	O
the	O
expectation	O
of	O
glycemic	O
control	O
.	O
Therefore	O
,	O
we	O
studied	O
whether	O
GLT	O
had	O
potential	O
for	O
inhibition	O
or	O
induction	O
of	O
cytochrome	B-GP
P450	E-GP
(	O
CYP	S-GP
)	O
and	O
an	O
influence	O
on	O
the	O
action	O
of	O
warfarin	S-chemical
.	O
Extract	O
of	O
guava	O
leaf	O
(	O
GvEx	O
)	O
consists	O
of	O
carbohydrate	S-chemical
and	O
polyphenols	S-chemical
,	O
which	O
are	O
Gvpp	O
,	O
quercetin	S-chemical
,	O
and	O
ellagic	B-chemical
acid	E-chemical
.	O
These	O
polyphenols	S-chemical
,	O
but	O
not	O
GvEx	O
,	O
showed	O
a	O
certain	O
level	O
of	O
inhibition	O
of	O
human-cDNA-expressed	O
CYPs	S-GP
.	O
In	O
a	O
comparison	O
of	O
GLT	O
and	O
grapefruit	O
juice	O
,	O
GLT	O
showed	O
weaker	O
inhibition	O
of	O
CYP	S-GP
activities	O
and	O
of	O
midazolam	S-chemical
1'-hydroxylation	O
than	O
grapefruit	O
juice	O
.	O
Furthermore	O
,	O
neither	O
liver	O
weight	O
nor	O
CYP3A	S-GP
expression	O
in	O
the	O
liver	O
was	O
changed	O
in	O
rats	O
that	O
received	O
GvEx	O
for	O
90	O
days	O
compared	O
with	O
the	O
control	O
group	O
.	O
When	O
rats	O
were	O
concomitantly	O
treated	O
with	O
GLT	O
and	O
warfarin	S-chemical
,	O
the	O
prolongation	O
of	O
clotting	O
time	O
of	O
blood	O
by	O
warfarin	S-chemical
was	O
not	O
influenced	O
.	O
These	O
data	O
suggest	O
that	O
GLT	O
is	O
unlikely	O
to	O
interact	O
with	O
drugs	O
.	O

Neonatal	O
epileptic	O
encephalopathy	O
caused	O
by	O
mutations	O
in	O
the	O
PNPO	S-GP
gene	O
encoding	O
pyridox	B-GP
(	I-GP
am	I-GP
)	I-GP
ine	I-GP
5'-phosphate	I-GP
oxidase	E-GP
.	O
In	O
the	O
mouse	O
,	O
neurotransmitter	O
metabolism	O
can	O
be	O
regulated	O
by	O
modulation	O
of	O
the	O
synthesis	O
of	O
pyridoxal	B-chemical
5'-phosphate	E-chemical
and	O
failure	O
to	O
maintain	O
pyridoxal	B-chemical
phosphate	E-chemical
(	O
PLP	S-chemical
)	O
levels	O
results	O
in	O
epilepsy	O
.	O
This	O
study	O
of	O
five	O
patients	O
with	O
neonatal	O
epileptic	O
encephalopathy	O
suggests	O
that	O
the	O
same	O
is	O
true	O
in	O
man	O
.	O
Cerebrospinal	O
fluid	O
and	O
urine	O
analyses	O
indicated	O
reduced	O
activity	O
of	O
aromatic	B-GP
L-amino	I-GP
acid	I-GP
decarboxylase	E-GP
and	O
other	O
PLP	S-chemical
-dependent	O
enzymes	O
.	O
Seizures	O
ceased	O
with	O
the	O
administration	O
of	O
PLP	S-chemical
,	O
having	O
been	O
resistant	O
to	O
treatment	O
with	O
pyridoxine	O
,	O
suggesting	O
a	O
defect	O
of	O
pyridox	B-GP
(	I-GP
am	I-GP
)	I-GP
ine	I-GP
5'-phosphate	I-GP
oxidase	E-GP
(	O
PNPO	S-GP
)	O
.	O
Sequencing	O
of	O
the	O
PNPO	S-GP
gene	O
identified	O
homozygous	O
missense	O
,	O
splice	O
site	O
and	O
stop	O
codon	O
mutations	O
.	O
Expression	O
studies	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
showed	O
that	O
the	O
splice	O
site	O
(	O
IVS3-1	O
g	B-GP
>	I-GP
a	E-GP
)	O
and	O
stop	O
codon	O
(	O
X262Q	O
)	O
mutations	O
were	O
null	O
activity	O
mutations	O
and	O
that	O
the	O
missense	O
mutation	O
(	O
R229W	S-GP
)	O
markedly	O
reduced	O
pyridox	B-GP
(	I-GP
am	I-GP
)	I-GP
ine	I-GP
phosphate	I-GP
oxidase	E-GP
activity	O
.	O
Maintenance	O
of	O
optimal	O
PLP	S-chemical
levels	O
in	O
the	O
brain	O
may	O
be	O
important	O
in	O
many	O
neurological	O
disorders	O
in	O
which	O
neurotransmitter	O
metabolism	O
is	O
disturbed	O
(	O
either	O
as	O
a	O
primary	O
or	O
as	O
a	O
secondary	O
phenomenon	O
)	O
.	O

Use	O
of	O
(	O
Gyro	O
)	O
Gy	O
and	O
spermine	B-GP
synthase	E-GP
transgenic	O
mice	O
to	O
study	O
functions	O
of	O
spermine	S-chemical
.	O
The	O
polyamines	S-chemical
putrescine	S-chemical
,	O
spermidine	S-chemical
,	O
and	O
spermine	S-chemical
are	O
essential	O
for	O
mammalian	O
cell	O
growth	O
,	O
-differentiation	O
,	O
and	O
cell	O
death	O
and	O
have	O
important	O
physiological	O
roles	O
in	O
all	O
tissues	O
.	O
Many	O
of	O
the	O
properties	O
of	O
polyamines	S-chemical
that	O
can	O
be	O
demonstrated	O
in	O
vitro	O
are	O
common	O
to	O
all	O
three	O
molecules	O
with	O
differences	O
only	O
in	O
potency	O
.	O
Loss	O
of	O
any	O
of	O
the	O
enzymes	O
needed	O
to	O
make	O
either	O
putrescine	S-chemical
or	O
spermidine	S-chemical
(	O
which	O
also	O
-prevent	O
the	O
production	O
of	O
spermine	S-chemical
)	O
is	O
lethal	O
,	O
but	O
male	O
mice	O
lacking	O
spermine	B-GP
synthase	E-GP
(	O
SpmS	S-GP
)	O
due	O
to	O
a	O
deletion	O
of	O
part	O
of	O
the	O
X	O
chromosome	O
are	O
viable	O
on	O
the	O
B6C3H	O
background	O
.	O
These	O
mice	O
are	O
termed	O
Gyro	O
(	O
Gy	O
)	O
due	O
to	O
their	O
circling	O
behavior	O
.	O
They	O
have	O
a	O
variety	O
of	O
abnormalities	O
including	O
deafness	O
,	O
neurological	O
problems	O
,	O
small	O
size	O
,	O
and	O
a	O
tendency	O
to	O
early	O
death	O
.	O
They	O
can	O
therefore	O
be	O
used	O
to	O
evaluate	O
the	O
physiological	O
function	O
(	O
s	O
)	O
uniquely	O
provided	O
by	O
spermine	S-chemical
.	O
They	O
also	O
provide	O
a	O
potential	O
animal	O
model	O
for	O
Snyder-Robinson	O
syndrome	O
(	O
SRS	O
)	O
,	O
a	O
rare	O
human	O
inherited	O
disease	O
due	O
to	O
a	O
loss	O
of	O
SpmS	S-GP
activity	O
.	O
An	O
essential	O
control	O
in	O
experiments	O
using	O
Gy	O
mice	O
is	O
to	O
demonstrate	O
that	O
the	O
abnormal	O
phenotypes	O
exhibited	O
by	O
these	O
mice	O
are	O
abolished	O
by	O
providing	O
replacement	O
spermine	S-chemical
and	O
this	O
can	O
be	O
accomplished	O
by	O
breeding	O
with	O
CAG-	O
SMS	S-GP
mice	O
that	O
express	O
SpmS	S-GP
from	O
a	O
ubiquitous	O
promoter	O
.	O
Techniques	O
for	O
identifying	O
,	O
characterizing	O
,	O
and	O
using	O
these	O
mouse	O
strains	O
and	O
limitations	O
of	O
this	O
approach	O
are	O
described	O
in	O
this	O
chapter	O
.	O

Characterization	O
of	O
cytosolic	B-GP
glutathione	I-GP
peroxidase	E-GP
and	O
phospholipid-hydroperoxide	B-GP
glutathione	I-GP
peroxidase	E-GP
genes	O
in	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
and	O
their	O
modulation	O
by	O
in	O
vitro	O
selenium	S-chemical
exposure	O
.	O
Selenium	S-chemical
(	O
Se	S-chemical
)	O
is	O
an	O
oligonutrient	O
with	O
both	O
essential	O
biological	O
functions	O
and	O
recognized	O
harmful	O
effects	O
.	O
As	O
the	O
selenocysteine	S-chemical
(	O
SeCys	S-chemical
)	O
amino	B-chemical
acid	E-chemical
,	O
selenium	S-chemical
is	O
integrated	O
in	O
several	O
Se	S-chemical
-containing	O
proteins	O
(	O
selenoproteins	O
)	O
,	O
many	O
of	O
which	O
are	O
fundamental	O
for	O
cell	O
homeostasis	O
.	O
Nevertheless	O
,	O
selenium	O
may	O
exert	O
toxic	O
effects	O
at	O
levels	O
marginally	O
above	O
those	O
required	O
,	O
mainly	O
through	O
the	O
generation	O
of	O
reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
.	O
The	O
selenium	S-chemical
chemical	O
speciation	O
can	O
strongly	O
affect	O
the	O
bioavailability	O
of	O
this	O
metal	O
and	O
its	O
impact	O
on	O
metabolism	O
,	O
dictating	O
the	O
levels	O
that	O
can	O
be	O
beneficial	O
or	O
detrimental	O
towards	O
an	O
organism	O
.	O
Glutathione	B-GP
peroxidase	E-GP
(	O
GPxs	S-GP
)	O
is	O
the	O
largest	O
and	O
the	O
most	O
studied	O
selenoprotein	S-GP
family	O
.	O
Cytosolic	B-GP
glutathione	I-GP
peroxidase	E-GP
(	O
cGPx	S-GP
,	O
GPx1	S-GP
)	O
and	O
phospholipid	B-GP
hydroperoxide	I-GP
glutathione	I-GP
peroxidase	E-GP
(	O
PHGPx	S-GP
,	O
GPx4	S-GP
)	O
are	O
widely	O
distributed	O
throughout	O
tissues	O
,	O
and	O
play	O
a	O
pivotal	O
role	O
in	O
regulating	O
the	O
oxidative	O
status	O
in	O
the	O
cell	O
.	O
In	O
this	O
study	O
we	O
have	O
cloned	O
GPx1	S-GP
and	O
GPx4	S-GP
genes	O
in	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
.	O
The	O
constitutive	O
mRNA	O
expression	O
of	O
these	O
GPx	S-GP
genes	O
was	O
examined	O
in	O
18	O
trout	O
tissues	O
and	O
their	O
responsiveness	O
to	O
Se	O
availability	O
was	O
analysed	O
using	O
a	O
rainbow	O
trout	O
liver	O
cell	O
line	O
(	O
RTL	O
)	O
.	O
An	O
inorganic	O
(	O
sodium	B-chemical
selenite	E-chemical
,	O
Na2SeO3	S-chemical
)	O
and	O
organic	O
(	O
selenocysteine	S-chemical
,	O
Cys-Se-Se-Cys	S-chemical
)	O
selenocompound	O
have	O
been	O
used	O
as	O
Se	S-chemical
sources	O
.	O
GPx1	S-GP
activity	O
was	O
also	O
tested	O
to	O
verify	O
the	O
impact	O
of	O
transcript	O
changes	O
on	O
the	O
enzymatic	O
function	O
of	O
these	O
molecules	O
.	O
To	O
understand	O
if	O
the	O
results	O
obtained	O
from	O
the	O
transcript	O
expression	O
analysis	O
were	O
due	O
to	O
Se	S-chemical
bioavailability	O
or	O
generation	O
of	O
ROS	O
,	O
the	O
cytoxicity	O
of	O
the	O
two	O
selenocompounds	O
was	O
tested	O
by	O
measuring	O
the	O
impact	O
of	O
Se	S-chemical
on	O
cell	O
membrane	O
integrity	O
.	O
Lastly	O
,	O
Se	S-chemical
availability	O
was	O
quantified	O
by	O
mass	O
spectrophotometry	O
to	O
determine	O
the	O
amount	O
of	O
Se	S-chemical
in	O
the	O
cell	O
culture	O
media	O
,	O
the	O
Se	S-chemical
background	O
due	O
to	O
the	O
foetal	O
calf	O
serum	O
supplement	O
and	O
the	O
contribution	O
from	O
the	O
two	O
selenocompounds	O
used	O
in	O
the	O
treatments	O
.	O
Three	O
isoforms	O
of	O
genes	O
for	O
both	O
GPx1	S-GP
(	O
GPx1a	B-GP
,	I-GP
1b1	I-GP
and	I-GP
1b2	E-GP
)	O
and	O
GPx4	S-GP
(	O
GPx4a1	B-GP
,	I-GP
a2	I-GP
and	I-GP
b	E-GP
)	O
have	O
been	O
identified	O
.	O
The	O
discovery	O
of	O
a	O
third	O
gene	O
encoding	O
for	O
GPx1	S-GP
and	O
GPx4	S-GP
hints	O
that	O
salmonids	O
may	O
have	O
the	O
biggest	O
selenoproteome	O
amongst	O
all	O
vertebrates	O
.	O
Transcripts	O
of	O
GPx4	S-GP
genes	O
were	O
more	O
highly	O
expressed	O
in	O
most	O
tissues	O
examined	O
in	O
vivo	O
(	O
except	O
blood	O
,	O
head	O
kidney	O
and	O
spleen	O
)	O
,	O
whereas	O
those	O
of	O
the	O
GPx1	S-GP
genes	O
were	O
more	O
responsive	O
to	O
selenium	S-chemical
exposure	O
in	O
vitro	O
,	O
especially	O
to	O
the	O
organic	O
form	O
.	O
Interestingly	O
,	O
GPx1a	S-GP
was	O
the	O
most	O
sensitive	O
to	O
selenium	S-chemical
availability	O
in	O
non	O
stressful	O
conditions	O
,	O
whereas	O
GPx1b1	S-GP
and	O
GPx1b2	S-GP
were	O
highly	O
induced	O
by	O
exposure	O
to	O
selenium	S-chemical
levels	O
that	O
had	O
some	O
toxic	O
effects	O
on	O
the	O
cells	O
.	O
Although	O
the	O
different	O
concentrations	O
tested	O
of	O
the	O
two	O
selenocompounds	O
modulate	O
GPx1	S-GP
transcript	O
expression	O
to	O
various	O
degrees	O
,	O
no	O
significant	O
change	O
of	O
GPx1	S-GP
enzymatic	O
activity	O
was	O
detectable	O
.	O
Our	O
results	O
lead	O
us	O
to	O
conclude	O
that	O
trout	O
GPx1	S-GP
transcripts	O
expression	O
level	O
may	O
represent	O
a	O
sensitive	O
biomarker	O
for	O
selenium	S-chemical
intake	O
,	O
helping	O
to	O
evaluate	O
if	O
selenium	S-chemical
concentration	O
and	O
chemical	O
speciation	O
impact	O
on	O
cell	O
homeostasis	O
.	O

Resistance	O
to	O
thyroid	O
hormone	O
due	O
to	O
a	O
novel	O
thyroid	B-GP
hormone	I-GP
receptor	E-GP
mutant	O
in	O
a	O
patient	O
with	O
hypothyroidism	O
secondary	O
to	O
lingual	O
thyroid	O
and	O
functional	O
characterization	O
of	O
the	O
mutant	O
receptor	O
.	O
BACKGROUND	O
:	O
We	O
describe	O
a	O
rare	O
case	O
of	O
congenital	O
hypothyroidism	O
and	O
an	O
extremely	O
high	O
serum	O
thyrotropin	S-GP
(	O
TSH	S-GP
)	O
level	O
caused	O
by	O
a	O
combination	O
of	O
resistance	O
to	O
thyroid	O
hormone	O
(	O
RTH	O
)	O
and	O
a	O
lingual	O
thyroid	O
.	O
As	O
the	O
RTH	O
mutant	O
,	O
R316C	S-GP
,	O
was	O
new	O
,	O
the	O
optimum	O
dose	O
of	O
levothyroxine	S-chemical
was	O
unclear	O
.	O
To	O
aid	O
in	O
assessment	O
of	O
the	O
therapy	O
,	O
we	O
characterized	O
the	O
mutant	O
R316C	S-GP
thyroid	B-GP
hormone	I-GP
receptor	E-GP
(	O
TR	S-GP
)	O
and	O
compared	O
it	O
with	O
a	O
common	O
mutant	O
,	O
R316H	S-GP
,	O
using	O
in	O
vitro	O
studies	O
.	O
SUMMARY	O
:	O
The	O
patient	O
was	O
a	O
newborn	O
female	O
having	O
severe	O
hypothyroidism	O
with	O
a	O
free	O
thyroxine	S-chemical
level	O
of	O
0.36	O
ng/dL	O
and	O
a	O
serum	O
TSH	S-GP
level	O
of	O
177	O
microU/mL	O
.	O
A	O
scintiscan	O
showed	O
ectopic	O
lingual	O
thyroid	O
tissue	O
without	O
a	O
normal	O
thyroid	O
gland	O
.	O
Supplementation	O
with	O
levothyroxine	S-chemical
at	O
a	O
dose	O
of	O
>	O
350	O
microg/day	O
did	O
not	O
normalize	O
the	O
serum	O
TSH	S-GP
level	O
;	O
however	O
,	O
the	O
patient	O
showed	O
normal	O
growth	O
and	O
intelligence	O
at	O
14	O
years	O
of	O
age	O
.	O
Consistent	O
with	O
the	O
results	O
of	O
a	O
computer	O
analysis	O
,	O
the	O
binding	O
of	O
R316C	S-GP
to	O
triiodothyronine	S-chemical
(	O
T3	S-chemical
)	O
was	O
significantly	O
decreased	O
to	O
38	O
%	O
that	O
of	O
the	O
wild	O
type	O
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
demonstrated	O
that	O
like	O
R316H	S-GP
,	O
R316C	S-GP
did	O
not	O
form	O
a	O
homodimer	O
,	O
but	O
formed	O
a	O
heterodimer	O
with	O
RXR	S-GP
.	O
However	O
,	O
a	O
glutathione	S-chemical
-	O
S	S-chemical
-transferase	O
pull-down	O
assay	O
showed	O
reduced	O
binding	O
of	O
R316C	S-GP
with	O
NCoR	S-GP
in	O
the	O
absence	O
of	O
T3	S-chemical
and	O
impaired	O
release	O
in	O
the	O
presence	O
of	O
T3	S-chemical
.	O
In	O
addition	O
,	O
transient	O
transfection	O
experiments	O
demonstrated	O
that	O
unlike	O
R316H	S-GP
,	O
R316C	S-GP
had	O
severe	O
impairment	O
of	O
transcriptional	O
activity	O
on	O
genes	O
both	O
positively	O
and	O
negatively	O
regulated	O
by	O
thyroid	O
hormone	O
.	O
It	O
also	O
had	O
a	O
clear	O
dominant	O
negative	O
effect	O
on	O
genes	O
negatively	O
,	O
but	O
not	O
positively	O
,	O
regulated	O
by	O
thyroid	O
hormone	O
,	O
including	O
the	O
TSH-releasing	B-GP
hormone	E-GP
and	O
TSHbeta	S-GP
genes	O
.	O
CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
a	O
R316C	S-GP
TR	S-GP
mutation	O
.	O
The	O
characteristics	O
of	O
the	O
R316C	S-GP
mutant	O
differed	O
from	O
those	O
of	O
the	O
R316H	S-GP
mutant	O
.	O
Our	O
findings	O
suggest	O
that	O
R316C	S-GP
causes	O
reduced	O
association	O
with	O
and	O
impaired	O
release	O
of	O
NCoR	S-GP
,	O
resulting	O
in	O
RTH	O
predominantly	O
at	O
the	O
pituitary	O
level	O
,	O
and	O
that	O
slightly	O
elevated	O
serum	O
TSH	S-GP
level	O
with	O
high	O
dose	O
of	O
levothyroxine	S-chemical
might	O
be	O
optimum	O
for	O
normal	O
growth	O
.	O

Non-enzymatic	O
interactions	O
of	O
glyoxylate	S-chemical
with	O
lysine	S-chemical
,	O
arginine	S-chemical
,	O
and	O
glucosamine	S-chemical
:	O
a	O
study	O
of	O
advanced	O
non-enzymatic	O
glycation	O
like	O
compounds	O
.	O
Glyoxylate	S-chemical
is	O
a	O
2	O
carbon	B-chemical
aldo	I-chemical
acid	E-chemical
that	O
is	O
formed	O
in	O
hepatic	O
tissue	O
from	O
glycolate	S-chemical
.	O
Once	O
formed	O
,	O
the	O
molecule	O
can	O
be	O
converted	O
to	O
glycine	S-chemical
by	O
alanine-glyoxylate	B-GP
aminotransferase	E-GP
(	O
AGAT	S-GP
)	O
.	O
In	O
defects	O
of	O
AGAT	S-GP
,	O
glyoxylate	S-chemical
is	O
transformed	O
to	O
oxalate	S-chemical
,	O
resulting	O
in	O
high	O
levels	O
of	O
oxalate	S-chemical
in	O
the	O
body	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
2-fold	O
.	O
First	O
,	O
it	O
was	O
to	O
determine	O
,	O
if	O
akin	O
to	O
D-glucose	S-chemical
,	O
D-fructose	S-chemical
or	O
DL-glyceraldehyde	S-chemical
,	O
glyoxylate	S-chemical
was	O
susceptible	O
to	O
non-enzymatic	O
attack	O
by	O
amino	S-chemical
containing	O
molecules	O
such	O
as	O
lysine	S-chemical
,	O
arginine	S-chemical
or	O
glucosamine	S-chemical
.	O
Second	O
,	O
if	O
by	O
virtue	O
of	O
its	O
molecular	O
structure	O
and	O
size	O
,	O
glyoxylate	S-chemical
was	O
as	O
reactive	O
a	O
reagent	O
in	O
non-enzymatic	O
reactions	O
as	O
DL-glyceraldehyde	S-chemical
;	O
i.e.	O
,	O
a	O
glycose	S-chemical
that	O
we	O
previously	O
demonstrated	O
to	O
be	O
a	O
more	O
effective	O
glycating	O
agent	O
than	O
D-glucose	S-chemical
or	O
D-fructose	S-chemical
.	O
Using	O
capillary	O
electrophoresis	O
(	O
CE	O
)	O
,	O
high	O
performance	O
liquid	O
chromatography	O
and	O
UV	O
and	O
fluorescence	O
spectroscopy	O
,	O
glyoxylate	S-chemical
was	O
found	O
to	O
be	O
a	O
highly	O
reactive	O
precursor	O
of	O
advanced	O
glycation	O
like	O
end	O
products	O
(	O
AGLEs	O
)	O
and	O
a	O
more	O
effective	O
promoter	O
of	O
non-enzymatic	O
end	O
products	O
than	O
D-glucose	S-chemical
,	O
D-fructose	S-chemical
or	O
DL-glyceraldehyde	S-chemical
.	O

Effects	O
of	O
High	O
Iron	S-chemical
and	O
Glucose	S-chemical
Concentrations	O
over	O
the	O
Relative	O
Expression	O
of	O
Bcl2	S-GP
,	O
Bax	S-GP
,	O
and	O
Mfn2	S-GP
in	O
MIN6	O
Cells	O
.	O
Type	O
2	O
diabetes	O
is	O
characterized	O
by	O
hyperglycemia	O
and	O
oxidative	O
stress	O
.	O
Hyperglycemia	O
is	O
linked	O
to	O
mitochondrial	O
dysfunction	O
and	O
reduced	O
β-cell	O
mass	O
due	O
to	O
the	O
reduced	O
expression	O
of	O
genes	O
such	O
as	O
Mfn2	S-GP
as	O
well	O
as	O
the	O
participation	O
of	O
the	O
Bcl2	S-GP
gene	O
family	O
,	O
responsible	O
for	O
increased	O
apoptosis	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
effect	O
of	O
different	O
iron	S-chemical
and/or	O
glucose	S-chemical
concentrations	O
over	O
Mfn2	S-GP
,	O
Bax	S-GP
,	O
and	O
Bcl2	S-GP
expressions	O
in	O
a	O
β-pancreatic	O
cell	O
line	O
(	O
MIN6	O
cells	O
)	O
.	O
MIN6	O
cells	O
were	O
pre-incubated	O
with	O
different	O
iron	S-chemical
and/or	O
glucose	S-chemical
concentrations	O
,	O
and	O
the	O
relative	O
mRNA	O
abundance	O
of	O
the	O
Bcl2	S-GP
/	O
Bax	S-GP
ratio	O
and	O
of	O
Mfn2	S-GP
genes	O
was	O
measured	O
by	O
qRT-PCR	O
.	O
Heme	B-GP
oxygenase	E-GP
(	O
HO	S-GP
)	O
activity	O
,	O
iron	S-chemical
uptake	O
,	O
superoxide	B-GP
dismutase	E-GP
activity	O
,	O
and	O
glutathione	S-chemical
content	O
were	O
also	O
determined	O
.	O
The	O
Bcl2	S-GP
/	O
Bax	S-GP
ratio	O
increased	O
and	O
Mfn2	S-GP
expression	O
decreased	O
in	O
MIN6	O
cells	O
after	O
glucose	S-chemical
stimulation	O
.	O
These	O
effects	O
were	O
higher	O
when	O
glucose	S-chemical
and	O
iron	S-chemical
were	O
incubated	O
together	O
.	O
Additionally	O
,	O
treatment	O
with	O
glucose	S-chemical
/	O
iron	S-chemical
showed	O
a	O
higher	O
HO	S-GP
activity	O
.	O
Our	O
study	O
revealed	O
that	O
high	O
glucose	S-chemical
/	O
Fe	S-chemical
concentrations	O
in	O
MIN6	O
cells	O
induced	O
an	O
increase	O
of	O
the	O
Bcl2	S-GP
/	O
Bax	S-GP
ratio	O
,	O
an	O
indicator	O
of	O
increased	O
cell	O
apoptosis	O
.	O

Rat	O
hepatic	O
stellate	O
cells	O
become	O
retinoid	S-chemical
unresponsive	O
during	O
activation	O
.	O
Hepatic	O
stellate	O
cells	O
(	O
HSC	O
)	O
play	O
an	O
essential	O
role	O
in	O
fibrogenesis	O
.	O
Many	O
stimuli	O
cause	O
HSC	O
to	O
activate	O
,	O
lose	O
their	O
Vitamin	B-chemical
A	E-chemical
and	O
produce	O
collagen	S-GP
.	O
It	O
is	O
unclear	O
whether	O
Vitamin	B-chemical
A	E-chemical
loss	O
causes	O
activation	O
,	O
potentiates	O
it	O
or	O
is	O
simply	O
an	O
event	O
in	O
the	O
cascade	O
of	O
activation	O
changes	O
.	O
We	O
determine	O
if	O
exogenous	O
retinoids	S-chemical
prevent	O
the	O
activation	O
of	O
freshly	O
isolated	O
rat	O
HSC	O
activated	O
by	O
plating	O
on	O
plastic	O
.	O
We	O
also	O
determine	O
if	O
retinoids	S-chemical
:	O
(	O
1	O
)	O
reverse	O
HSC	O
activation	O
;	O
(	O
2	O
)	O
maintain/restore	O
HSC	O
intracellular	O
retinoid	S-chemical
levels	O
;	O
(	O
3	O
)	O
maintain	O
expression	O
of	O
HSC	O
nuclear	B-GP
receptors	I-GP
for	I-GP
retinoic	I-GP
acid	E-GP
(	O
RAR	S-GP
)	O
in	O
HSC	O
that	O
are	O
becoming	O
activated	O
or	O
are	O
chronically	O
activated	O
.	O
Markers	O
of	O
activation	O
in	O
freshly	O
isolated	O
HSC	O
were	O
decreased	O
by	O
either	O
retinol	S-chemical
or	O
retinoic	B-chemical
acid	E-chemical
without	O
increases	O
in	O
HSC	O
retinoid	S-chemical
concentration	O
.	O
mRNA	O
levels	O
for	O
RAR-alpha	S-GP
,	O
RAR-beta	S-GP
and	O
RAR-gamma	S-GP
,	O
the	O
nuclear	B-GP
receptors	E-GP
for	O
retinoic	B-chemical
acid	E-chemical
,	O
decreased	O
during	O
activation	O
of	O
freshly	O
isolated	O
HSC	O
even	O
with	O
retinoid	S-chemical
supplementation	O
.	O
RAR-alpha	S-GP
,	O
RAR-beta	S-GP
and	O
RAR-gamma	S-GP
mRNA	O
and	O
RAR-beta	S-GP
protein	O
was	O
undetectable	O
in	O
chronically	O
activated	O
HSC	O
and	O
remained	O
absent	O
after	O
retinoic	B-chemical
acid	E-chemical
supplementation	O
.	O
Activation	O
markers	O
in	O
chronically	O
activated	O
HSC	O
were	O
only	O
slightly	O
decreased	O
after	O
retinoid	S-chemical
exposure	O
.	O
We	O
conclude	O
that	O
exposure	O
of	O
HSC	O
to	O
extracellular	O
retinoids	S-chemical
diminishes	O
some	O
markers	O
of	O
activation	O
but	O
does	O
not	O
prevent	O
HSC	O
activation	O
.	O

Corticosteroids	S-chemical
and	O
human	B-GP
recombinant	I-GP
activated	I-GP
protein	I-GP
C	E-GP
for	O
septic	O
shock	O
.	O
This	O
article	O
summarizes	O
the	O
current	O
knowledge	O
on	O
the	O
benefit/risk	O
profile	O
from	O
the	O
use	O
of	O
low-dose	O
corticosteroids	S-chemical
and	O
activated	B-GP
protein	I-GP
C	E-GP
in	O
treating	O
septic	O
shock	O
.	O
Physicians	O
should	O
consider	O
using	O
low-dose	O
corticosteroids	S-chemical
and	O
drotrecogin	B-GP
alpha	E-GP
activated	O
in	O
the	O
treatment	O
of	O
patients	O
who	O
have	O
vasopressor-dependent	O
septic	O
shock	O
with	O
persistent	O
signs	O
of	O
hypoperfusion	O
,	O
organ	O
dysfunction	O
,	O
or	O
hypotension	O
.	O
The	O
optimal	O
timing	O
for	O
initiating	O
these	O
treatments	O
is	O
from	O
6	O
to	O
24	O
hours	O
from	O
onset	O
of	O
shock	O
.	O
When	O
patients	O
are	O
receiving	O
these	O
drugs	O
,	O
physicians	O
should	O
systematically	O
screen	O
for	O
superinfection	O
and	O
serious	O
bleeding	O
events	O
.	O

Jaceosidin	S-chemical
,	O
isolated	O
from	O
dietary	O
mugwort	O
(	O
Artemisia	O
princeps	O
)	O
,	O
induces	O
G2/M	O
cell	O
cycle	O
arrest	O
by	O
inactivating	O
cdc25C	S-GP
-	O
cdc2	S-GP
via	O
ATM	S-GP
-	O
Chk1/2	S-GP
activation	O
.	O
Jaceosidin	S-chemical
,	O
a	O
flavonoid	S-chemical
derived	O
from	O
Artemisia	O
princeps	O
(	O
Japanese	O
mugwort	O
)	O
,	O
has	O
been	O
shown	O
to	O
inhibit	O
the	O
growth	O
of	O
several	O
human	O
cancer	O
cells	O
,	O
However	O
,	O
the	O
exact	O
mechanism	O
for	O
the	O
cytotoxic	O
effect	O
of	O
jaceosidin	S-chemical
is	O
not	O
completely	O
understood	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
molecular	O
mechanism	O
involved	O
in	O
the	O
antiproliferative	O
effect	O
of	O
jaceosidin	S-chemical
in	O
human	O
endometrial	O
cancer	O
cells	O
.	O
We	O
demonstrated	O
that	O
jaceosidin	S-chemical
is	O
a	O
more	O
potent	O
inhibitor	O
of	O
cell	O
growth	O
than	O
cisplatin	S-chemical
in	O
human	O
endometrial	O
cancer	O
cells	O
.	O
In	O
contrast	O
,	O
jaceosidin	S-chemical
-induced	O
cytotoxicity	O
in	O
normal	O
endometrial	O
cells	O
was	O
lower	O
than	O
that	O
observed	O
for	O
cisplatin	S-chemical
.	O
Jaceosidin	S-chemical
induced	O
G2/M	O
phase	O
cell	O
cycle	O
arrest	O
and	O
modulated	O
the	O
levels	O
of	O
cyclin	B-GP
B	E-GP
and	O
p-Cdc2	S-GP
in	O
Hec1A	O
cells	O
.	O
Knockdown	O
of	O
p21	S-GP
using	O
specific	O
siRNAs	O
partially	O
abrogated	O
jaceosidin	S-chemical
-induced	O
cell	O
growth	O
inhibition	O
.	O
Additional	O
mechanistic	O
studies	O
revealed	O
that	O
jaceosidin	S-chemical
treatment	O
resulted	O
in	O
an	O
increase	O
in	O
phosphorylation	O
of	O
Cdc25C	S-GP
and	O
ATM	S-GP
-	O
Chk1/2	S-GP
.	O
Ku55933	O
,	O
an	O
ATM	S-GP
inhibitor	O
,	O
reversed	O
jaceosidin	S-chemical
-induced	O
cell	O
growth	O
inhibition	O
,	O
in	O
part	O
.	O
Moreover	O
,	O
jaceosidin	S-chemical
treatment	O
resulted	O
in	O
phosphorylation	O
of	O
ERK	S-GP
,	O
and	O
pretreatment	O
with	O
the	O
ERK	S-GP
inhibitor	O
,	O
PD98059	S-chemical
,	O
attenuated	O
cell	O
growth	O
inhibition	O
by	O
jaceosidin	S-chemical
.	O
These	O
data	O
suggest	O
that	O
jaceosidin	S-chemical
,	O
isolated	O
from	O
Japanese	O
mugwort	O
,	O
modulates	O
the	O
ERK	S-GP
/	O
ATM	S-GP
/	O
Chk1/2	S-GP
pathway	O
,	O
leading	O
to	O
inactivation	O
of	O
the	O
Cdc2	S-GP
-	O
cyclin	B-GP
B1	E-GP
complex	O
,	O
followed	O
by	O
G2/M	O
cell	O
cycle	O
arrest	O
in	O
endometrial	O
cancer	O
cells	O
.	O

Coming	O
full	O
circle	O
:	O
contributions	O
of	O
central	O
and	O
peripheral	O
oxytocin	S-GP
actions	O
to	O
energy	O
balance	O
.	O
The	O
neuropeptide	O
oxytocin	S-chemical
has	O
emerged	O
as	O
an	O
important	O
anorexigen	S-chemical
in	O
the	O
regulation	O
of	O
energy	O
balance	O
.	O
Its	O
effects	O
on	O
food	O
intake	O
have	O
largely	O
been	O
attributed	O
to	O
limiting	O
meal	O
size	O
through	O
interactions	O
in	O
key	O
regulatory	O
brain	O
regions	O
such	O
as	O
the	O
hypothalamus	O
and	O
hindbrain	O
.	O
Pharmacologic	O
and	O
pair-feeding	O
studies	O
indicate	O
that	O
its	O
ability	O
to	O
reduce	O
body	O
mass	O
extends	O
beyond	O
that	O
of	O
food	O
intake	O
,	O
affecting	O
multiple	O
factors	O
that	O
determine	O
energy	O
balance	O
such	O
as	O
energy	O
expenditure	O
,	O
lipolysis	O
,	O
and	O
glucose	S-chemical
regulation	O
.	O
Systemic	O
administration	O
of	O
oxytocin	S-chemical
recapitulates	O
many	O
of	O
its	O
effects	O
when	O
administered	O
centrally	O
,	O
raising	O
the	O
questions	O
of	O
whether	O
and	O
to	O
what	O
extent	O
circulating	O
oxytocin	S-GP
contributes	O
to	O
energy	O
regulation	O
.	O
Its	O
therapeutic	O
potential	O
to	O
treat	O
metabolic	O
conditions	O
remains	O
to	O
be	O
determined	O
,	O
but	O
data	O
from	O
diet-induced	O
and	O
genetically	O
obese	O
rodent	O
models	O
as	O
well	O
as	O
application	O
of	O
oxytocin	S-GP
in	O
humans	O
in	O
other	O
areas	O
of	O
research	O
have	O
revealed	O
promising	O
results	O
thus	O
far	O
.	O

Isoform-specific	O
inhibition	O
of	O
L-type	B-GP
calcium	I-GP
channels	E-GP
by	O
dihydropyridines	S-chemical
is	O
independent	O
of	O
isoform-specific	O
gating	O
properties	O
.	O
Dihydropyridines	S-chemical
(	O
DHPs	S-chemical
)	O
block	O
L-type	B-GP
Ca2+	I-GP
channels	E-GP
more	O
potently	O
at	O
depolarized	O
membrane	O
potentials	O
,	O
consistent	O
with	O
high	O
affinity	O
binding	O
to	O
the	O
inactivated	O
state	O
.	O
Nisoldipine	S-chemical
(	O
a	O
DHP	S-chemical
antagonist	O
)	O
blocks	O
the	O
smooth	B-GP
muscle	I-GP
channel	E-GP
more	O
potently	O
than	O
the	O
cardiac	O
one	O
,	O
a	O
phenomenon	O
observed	O
not	O
only	O
in	O
native	O
channels	O
but	O
also	O
in	O
expressed	O
channels	O
.	O
We	O
examined	O
whether	O
this	O
tissue	O
specificity	O
was	O
attributable	O
to	O
differences	O
of	O
inactivation	O
in	O
the	O
two	O
channel	O
types	O
.	O
We	O
expressed	O
cardiac	O
or	O
smooth	B-GP
muscle	I-GP
alpha1C	E-GP
subunits	O
in	O
combination	O
with	O
beta2a	O
and	O
alpha2/delta	O
subunits	O
in	O
human	O
embryonic	O
kidney	O
cells	O
,	O
and	O
used	O
2	O
mM	O
Ca2+	S-chemical
as	O
the	O
permeant	O
ion	O
.	O
This	O
system	O
thus	O
reproduces	O
the	O
in	O
vivo	O
topology	O
and	O
charge	O
carrier	O
of	O
the	O
channels	O
while	O
facilitating	O
comparison	O
of	O
the	O
two	O
alpha1C	O
splice	O
variants	O
.	O
Both	O
voltage-dependent	O
and	O
isoform-specific	O
sensitivity	O
of	O
10	O
nM	O
nisoldipine	S-chemical
inhibition	O
of	O
the	O
channel	O
were	O
demonstrated	O
,	O
with	O
the	O
use	O
of	O
-100	O
mV	O
as	O
the	O
holding	O
potential	O
for	O
fully	O
reprimed	O
channels	O
and	O
-65	O
mV	O
to	O
populate	O
the	O
inactivated	O
state	O
.	O
Under	O
drug-free	O
conditions	O
,	O
we	O
characterized	O
fast	O
inactivation	O
(	O
1-sec	O
prepulses	O
)	O
and	O
slow	O
inactivation	O
(	O
3	O
min	O
prepulses	O
)	O
in	O
the	O
two	O
isoforms	O
.	O
Inactivation	O
parameters	O
were	O
not	O
statistically	O
different	O
in	O
the	O
two	O
channel	O
isoforms	O
;	O
if	O
anything	O
,	O
cardiac	B-GP
channels	E-GP
tended	O
to	O
inactivate	O
more	O
than	O
the	O
smooth	B-GP
muscle	I-GP
channels	E-GP
at	O
relevant	O
voltages	O
.	O
Likewise	O
,	O
the	O
voltage-dependent	O
activation	O
was	O
identical	O
in	O
the	O
two	O
isoforms	O
.	O
We	O
thus	O
conclude	O
that	O
the	O
more	O
potent	O
nisoldipine	S-chemical
inhibition	O
of	O
smooth	O
muscle	O
versus	O
cardiac	B-GP
L-type	I-GP
Ca2+	I-GP
channels	E-GP
is	O
not	O
attributable	O
to	O
differences	O
in	O
channel	O
inactivation	O
or	O
activation	O
.	O
Intrinsic	O
,	O
gating-independent	O
DHP	B-GP
receptor	E-GP
binding	O
affinity	O
differences	O
must	O
be	O
invoked	O
to	O
explain	O
the	O
isoform-specific	O
sensitivity	O
of	O
the	O
DHP	S-chemical
block	O
.	O

Diels-Alder	O
mediated	O
controlled	O
release	O
from	O
a	O
poly	B-chemical
(	I-chemical
ethylene	I-chemical
glycol	I-chemical
)	E-chemical
based	O
hydrogel	O
.	O
A	O
synthetic	O
amino	B-chemical
acid	E-chemical
bearing	O
a	O
furan	S-chemical
functionality	O
was	O
developed	O
and	O
incorporated	O
into	O
peptide	O
sequences	O
using	O
solid	O
phase	O
synthesis	O
.	O
Peptides	O
expressing	O
the	O
furan	S-chemical
moiety	O
were	O
attached	O
to	O
poly	B-chemical
(	I-chemical
ethylene	I-chemical
glycol	I-chemical
)	E-chemical
(	O
PEG	S-chemical
)	O
hydrogels	O
through	O
a	O
thermally	O
reversible	O
covalent	O
bond	O
formed	O
by	O
a	O
Diels-Alder	O
reaction	O
.	O
Reactions	O
of	O
thiol	S-chemical
and	O
maleimide	B-chemical
PEG	E-chemical
macromers	O
in	O
an	O
off-stoichiometric	O
Michael	O
addition	O
were	O
performed	O
,	O
such	O
that	O
the	O
maleimide	S-chemical
moiety	O
was	O
in	O
excess	O
,	O
to	O
create	O
hydrogel	O
networks	O
with	O
pendant	O
Diels-Alder	O
compatible	O
tethering	O
sites	O
,	O
that	O
is	O
,	O
the	O
maleimide	S-chemical
.	O
By	O
making	O
use	O
of	O
the	O
Diels-Alder	O
reaction	O
,	O
it	O
was	O
possible	O
to	O
control	O
the	O
release	O
rate	O
of	O
reversibly	O
bound	O
moieties	O
from	O
the	O
hydrogel	O
by	O
changing	O
the	O
temperature	O
;	O
higher	O
temperatures	O
favor	O
a	O
faster	O
retro-Diels-Alder	O
reaction	O
and	O
,	O
therefore	O
,	O
a	O
faster	O
release	O
from	O
the	O
polymer	O
network	O
.	O
This	O
concept	O
was	O
demonstrated	O
by	O
incorporating	O
a	O
fluorescently	O
labeled	O
furan	S-chemical
-RGDS	O
sequence	O
into	O
a	O
hydrogel	O
possessing	O
excess	O
maleimide	S-chemical
functionalities	O
and	O
monitoring	O
the	O
subsequent	O
liberation	O
of	O
RGDS	O
at	O
various	O
temperatures	O
,	O
illustrating	O
a	O
Diels-Alder	O
mediated	O
release	O
mechanism	O
.	O
The	O
release	O
profile	O
was	O
quantified	O
at	O
temperatures	O
ranging	O
from	O
physiological	O
(	O
37	O
°C	O
)	O
to	O
80	O
°C	O
.	O
By	O
changing	O
the	O
temperature	O
,	O
varying	O
extents	O
of	O
release	O
were	O
attained	O
over	O
the	O
time	O
course	O
of	O
several	O
days	O
,	O
ranging	O
from	O
40	O
%	O
release	O
for	O
lower	O
temperatures	O
to	O
complete	O
release	O
for	O
the	O
highest	O
temperature	O
considered	O
.	O
Further	O
confirmation	O
of	O
a	O
reaction-diffusion	O
controlled	O
release	O
mechanism	O
was	O
obtained	O
through	O
comparison	O
of	O
experimental	O
release	O
data	O
to	O
a	O
reaction-diffusion	O
model	O
of	O
the	O
release	O
.	O
In	O
addition	O
to	O
thermal	O
modulation	O
,	O
tuning	O
of	O
the	O
release	O
rate	O
was	O
accomplished	O
by	O
altering	O
the	O
number	O
of	O
possible	O
Diels-Alder	O
tethering	O
sites	O
present	O
in	O
the	O
hydrogel	O
.	O
Increasing	O
the	O
amount	O
of	O
free	O
maleimide	S-chemical
and	O
,	O
therefore	O
,	O
the	O
number	O
of	O
potential	O
Diels-Alder	O
reaction	O
sites	O
,	O
effectively	O
slowed	O
the	O
release	O
of	O
peptide	O
from	O
the	O
polymer	O
.	O
For	O
instance	O
,	O
doubling	O
the	O
amount	O
of	O
maleimide	S-chemical
sites	O
present	O
in	O
the	O
hydrogel	O
system	O
decreased	O
the	O
amount	O
of	O
peptide	O
released	O
from	O
approximately	O
60	O
%	O
to	O
about	O
40	O
%	O
in	O
the	O
same	O
span	O
of	O
time	O
.	O

Investigating	O
the	O
enteroenteric	O
recirculation	O
of	O
apixaban	S-chemical
,	O
a	O
factor	B-GP
Xa	E-GP
inhibitor	O
:	O
administration	O
of	O
activated	O
charcoal	O
to	O
bile	O
duct-cannulated	O
rats	O
and	O
dogs	O
receiving	O
an	O
intravenous	O
dose	O
and	O
use	O
of	O
drug	O
transporter	O
knockout	O
rats	O
.	O
The	O
study	O
described	O
here	O
investigated	O
the	O
impact	O
of	O
intestinal	O
excretion	O
(	O
IE	O
;	O
excretion	O
of	O
drug	O
directly	O
from	O
circulation	O
to	O
intestinal	O
lumen	O
)	O
,	O
enteroenteric	O
recirculation	O
(	O
EER	O
)	O
,	O
and	O
renal	O
tubule	O
recirculation	O
(	O
RTR	O
)	O
on	O
apixaban	S-chemical
pharmacokinetics	O
and	O
disposition	O
.	O
The	O
experimental	O
approaches	O
involve	O
integrating	O
apixaban	S-chemical
elimination	O
pathways	O
with	O
pharmacokinetic	O
profiles	O
obtained	O
from	O
bile	O
duct-cannulated	O
(	O
BDC	O
)	O
rats	O
and	O
dogs	O
receiving	O
i.v	O
.	O
doses	O
together	O
with	O
oral	O
administration	O
of	O
activated	O
charcoal	S-chemical
(	O
AC	O
)	O
.	O
Additionally	O
,	O
the	O
role	O
of	O
P-gp	S-GP
(	O
P-glycoprotein	S-GP
;	O
abcb1	S-GP
)	O
and	O
BCRP	S-GP
(	O
breast	B-GP
cancer	I-GP
resistance	I-GP
protein	E-GP
;	O
abcg2	S-GP
)	O
in	O
apixaban	S-chemical
disposition	O
was	O
evaluated	O
in	O
experiments	O
using	O
transporter	O
inhibitors	O
and	O
transporter	O
knockout	O
(	O
KO	O
)	O
rats	O
.	O
Approximately	O
20-50	O
%	O
of	O
an	O
apixaban	S-chemical
i.v	O
.	O
dose	O
was	O
found	O
in	O
feces	O
of	O
BDC	O
rats	O
and	O
dogs	O
,	O
suggesting	O
IE	O
leading	O
to	O
fecal	O
elimination	O
and	O
intestinal	O
clearance	O
(	O
IC	O
)	O
.	O
The	O
fecal	O
elimination	O
,	O
IC	O
,	O
and	O
systemic	O
clearance	O
of	O
apixaban	S-chemical
were	O
increased	O
upon	O
AC	O
administration	O
in	O
both	O
BDC	O
rats	O
and	O
dogs	O
and	O
were	O
decreased	O
in	O
BDC	O
rats	O
dosed	O
with	O
GF-120918	S-chemical
,	O
a	O
dual	O
BCRP	S-GP
and	O
P-gp	S-GP
inhibitor	O
)	O
.	O
BCRP	S-GP
appeared	O
to	O
play	O
a	O
more	O
important	O
role	O
for	O
absorption	O
and	O
intestinal	O
and	O
renal	O
elimination	O
of	O
apixaban	S-chemical
than	O
P-gp	S-GP
in	O
transporter-KO	O
rats	O
after	O
oral	O
and	O
i.v	O
.	O
dosing	O
,	O
which	O
led	O
to	O
a	O
higher	O
level	O
of	O
active	O
renal	O
excretion	O
in	O
rat	O
than	O
other	O
species	O
.	O
These	O
data	O
demonstrate	O
that	O
apixaban	S-chemical
undergoes	O
IE	O
,	O
EER	O
,	O
and	O
RTR	O
that	O
are	O
facilitated	O
by	O
efflux	O
transporters	O
.	O
Intestinal	O
reabsorption	O
of	O
apixaban	S-chemical
could	O
be	O
interrupted	O
by	O
AC	O
even	O
at	O
3	O
hours	O
post-drug	O
dose	O
in	O
dogs	O
(	O
late	O
charcoal	S-chemical
effect	O
)	O
.	O
This	O
study	O
demonstrates	O
that	O
the	O
intestine	O
is	O
an	O
organ	O
for	O
direct	O
clearance	O
and	O
redistribution	O
of	O
apixaban	S-chemical
.	O
The	O
IE	O
,	O
EER	O
,	O
and	O
RTR	O
contribute	O
to	O
overall	O
pharmacokinetic	O
profiles	O
of	O
apixaban	S-chemical
.	O
IE	O
as	O
a	O
clearance	O
pathway	O
,	O
balanced	O
with	O
metabolism	O
and	O
renal	O
excretion	O
,	O
helps	O
decrease	O
the	O
impacts	O
of	O
intrinsic	O
(	O
renal	O
or	O
hepatic	O
impairment	O
)	O
and	O
extrinsic	O
(	O
drug-drug	O
interactions	O
)	O
factors	O
on	O
apixaban	S-chemical
disposition	O
.	O

Studies	O
on	O
an	O
(	B-chemical
S	I-chemical
)	I-chemical
-2-amino-3-	I-chemical
(	I-chemical
3-hydroxy-5-methyl-4-isoxazolyl	I-chemical
)	I-chemical
propionic	I-chemical
acid	E-chemical
(	B-GP
AMPA	I-GP
)	I-GP
receptor	E-GP
antagonist	O
IKM-159	S-chemical
:	O
asymmetric	O
synthesis	O
,	O
neuroactivity	O
,	O
and	O
structural	O
characterization	O
.	O
IKM-159	S-chemical
was	O
developed	O
and	O
identified	O
as	O
a	O
member	O
of	O
a	O
new	O
class	O
of	O
heterotricyclic	O
glutamate	S-chemical
analogues	O
that	O
act	O
as	O
AMPA	B-GP
receptor	E-GP
-selective	O
antagonists	O
.	O
However	O
,	O
it	O
was	O
not	O
known	O
which	O
enantiomer	O
of	O
IKM-159	S-chemical
was	O
responsible	O
for	O
its	O
pharmacological	O
activities	O
.	O
Here	O
,	O
we	O
report	O
in	O
vivo	O
and	O
in	O
vitro	O
neuronal	O
activities	O
of	O
both	O
enantiomers	O
of	O
IKM-159	S-chemical
prepared	O
by	O
enantioselective	O
asymmetric	O
synthesis	O
.	O
By	O
employment	O
of	O
(	B-chemical
R	I-chemical
)	I-chemical
-2-amino-2-	I-chemical
(	I-chemical
4-methoxyphenyl	I-chemical
)	I-chemical
ethanol	E-chemical
as	O
a	O
chiral	O
auxiliary	O
,	O
(	B-chemical
2R	I-chemical
)	I-chemical
-IKM-159	E-chemical
and	O
the	O
(	O
2S	O
)	O
-counterpart	O
were	O
successfully	O
synthesized	O
in	O
0.70	O
%	O
and	O
1.5	O
%	O
yields	O
,	O
respectively	O
,	O
over	O
a	O
total	O
of	O
18	O
steps	O
.	O
Both	O
behavioral	O
and	O
electrophysiological	O
assays	O
showed	O
that	O
the	O
biological	O
activity	O
observed	O
for	O
the	O
racemic	O
mixture	O
was	O
reproduced	O
only	O
with	O
(	B-chemical
2R	I-chemical
)	I-chemical
-IKM-159	E-chemical
,	O
whereas	O
the	O
(	O
2S	O
)	O
-counterpart	O
was	O
inactive	O
in	O
both	O
assays	O
.	O
Racemic	B-chemical
IKM-159	E-chemical
was	O
crystallized	O
with	O
the	O
ligand-binding	O
domain	O
of	O
GluA2	S-GP
,	O
and	O
the	O
structure	O
revealed	O
a	O
complex	O
containing	O
(	B-chemical
2R	I-chemical
)	I-chemical
-IKM-159	E-chemical
at	O
the	O
glutamate	O
binding	O
site	O
.	O
(	B-chemical
2R	I-chemical
)	I-chemical
-IKM-159	E-chemical
locks	O
the	O
GluA2	S-GP
in	O
an	O
open	O
form	O
,	O
consistent	O
with	O
a	O
pharmacological	O
action	O
as	O
competitive	O
antagonist	O
of	O
AMPA	B-GP
receptors	E-GP
.	O

Verrucarin	B-chemical
A	E-chemical
sensitizes	O
TRAIL	S-GP
-induced	O
apoptosis	O
via	O
the	O
upregulation	O
of	O
DR5	S-GP
in	O
an	O
eIF2α	S-GP
/	O
CHOP	S-GP
-dependent	O
manner	O
.	O
Tumor	B-GP
necrosis	I-GP
factor-related	I-GP
apoptosis-inducing	I-GP
ligand	E-GP
(	O
TRAIL	S-GP
)	O
is	O
one	O
of	O
the	O
most	O
promising	O
candidates	O
for	O
new	O
cancer	O
therapeutics	O
.	O
However	O
,	O
resistance	O
to	O
TRAIL	S-GP
in	O
some	O
cancers	O
remains	O
a	O
current	O
problem	O
in	O
recent	O
.	O
The	O
protein-folding	O
compartment	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
is	O
particularly	O
sensitive	O
to	O
disturbances	O
,	O
which	O
,	O
if	O
severe	O
,	O
may	O
trigger	O
apoptosis	O
.	O
Therefore	O
,	O
we	O
examined	O
whether	O
verrucarin	B-chemical
A	E-chemical
(	O
VA	O
)	O
sensitize	O
TRAIL	S-GP
-induced	O
apoptosis	O
in	O
cancer	O
cells	O
by	O
induction	O
of	O
ER	O
stress	O
.	O
We	O
first	O
found	O
that	O
VA	O
induces	O
a	O
major	O
molecule	O
of	O
ER	O
stress	O
,	O
CCAAT/enhancer	B-GP
binding	I-GP
protein	I-GP
homologous	I-GP
protein	E-GP
(	O
CHOP	S-GP
)	O
-dependent	O
DR5	S-GP
induction	O
and	O
subsequently	O
increases	O
TRAIL	S-GP
-induced	O
cleavage	O
of	O
caspases	S-GP
and	O
PARP	S-GP
in	O
TRAIL	S-GP
-resistant	O
Hep3B	O
cells	O
.	O
Importantly	O
,	O
the	O
transient	O
knockdown	O
using	O
siRNA	O
for	O
CHOP	S-GP
abrogated	O
VA-induced	O
DR5	S-GP
expression	O
and	O
attenuated	O
TRAIL	S-GP
-induced	O
apoptosis	O
.	O
Treatment	O
with	O
VA	O
also	O
increased	O
the	O
levels	O
of	O
phosphorylation	O
of	O
eukaryotic	B-GP
translation	I-GP
initiation	I-GP
factor-2α	E-GP
(	O
eIF2α	S-GP
)	O
,	O
which	O
is	O
a	O
common	O
cellular	O
response	O
of	O
ER	O
stress	O
.	O
Furthermore	O
,	O
salubrinal	S-chemical
,	O
a	O
specific	O
eIF2α	S-GP
phosphorylation-inducing	O
agent	O
,	O
increased	O
CHOP	S-GP
and	O
DR5	S-GP
expression	O
in	O
the	O
presence	O
of	O
VA	O
.	O
In	O
contrast	O
,	O
transfection	O
of	O
mutant-	O
eIF2α	S-GP
significantly	O
reversed	O
VA-induced	O
apoptosis	O
with	O
downregulation	O
of	O
CHOP	S-GP
-dependent	O
DR5	S-GP
expression	O
.	O
Therefore	O
,	O
VA-induced	O
eIF2α	S-GP
phosphorylation	O
seemed	O
to	O
be	O
important	O
for	O
CHOP	S-GP
and	O
DR5	S-GP
upregulation	O
and	O
TRAIL	S-GP
-induced	O
apoptosis	O
.	O
In	O
addition	O
,	O
generation	O
of	O
reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
is	O
an	O
effector	O
molecular	O
in	O
sensitization	O
of	O
VA-induced	O
ER	O
stress	O
.	O
We	O
concluded	O
that	O
VA	O
triggers	O
TRAIL	S-GP
-induced	O
apoptosis	O
by	O
eIF2α	S-GP
/	O
CHOP	S-GP
-dependent	O
DR5	S-GP
induction	O
via	O
ROS	O
generation	O
.	O

Nano-	O
graphene	S-chemical
in	O
biomedicine	O
:	O
theranostic	O
applications	O
.	O
Owing	O
to	O
their	O
unique	O
physical	O
and	O
chemical	O
properties	O
,	O
graphene	S-chemical
and	O
its	O
derivatives	O
such	O
as	O
graphene	B-chemical
oxide	E-chemical
(	O
GO	O
)	O
,	O
reduced	B-chemical
graphene	I-chemical
oxide	E-chemical
(	O
RGO	S-chemical
)	O
and	O
GO-nanocomposites	O
have	O
attracted	O
tremendous	O
interest	O
in	O
many	O
different	O
fields	O
including	O
biomedicine	O
in	O
recent	O
years	O
.	O
With	O
every	O
atom	O
exposed	O
on	O
its	O
surface	O
,	O
single-layered	O
graphene	S-chemical
shows	O
ultra-high	O
surface	O
area	O
available	O
for	O
efficient	O
molecular	O
loading	O
and	O
bioconjugation	O
,	O
and	O
has	O
been	O
widely	O
explored	O
as	O
novel	O
nano-carriers	O
for	O
drug	O
and	O
gene	O
delivery	O
.	O
Utilizing	O
the	O
intrinsic	O
near-infrared	O
(	O
NIR	O
)	O
optical	O
absorbance	O
,	O
in	O
vivo	O
graphene	S-chemical
-based	O
photothermal	O
therapy	O
has	O
been	O
realized	O
,	O
achieving	O
excellent	O
anti-tumor	O
therapeutic	O
efficacy	O
in	O
animal	O
experiments	O
.	O
A	O
variety	O
of	O
inorganic	O
nanoparticles	O
can	O
be	O
grown	O
on	O
the	O
surface	O
of	O
nano-	O
graphene	S-chemical
,	O
obtaining	O
functional	O
graphene	S-chemical
-based	O
nanocomposites	O
with	O
interesting	O
optical	O
and	O
magnetic	O
properties	O
useful	O
for	O
multi-modal	O
imaging	O
and	O
imaging-guided	O
cancer	O
therapy	O
.	O
Moreover	O
,	O
significant	O
efforts	O
have	O
also	O
been	O
devoted	O
to	O
study	O
the	O
behaviors	O
and	O
toxicology	O
of	O
functionalized	O
nano-	O
graphene	S-chemical
in	O
animals	O
.	O
It	O
has	O
been	O
uncovered	O
that	O
both	O
surface	O
chemistry	O
and	O
sizes	O
play	O
key	O
roles	O
in	O
controlling	O
the	O
biodistribution	O
,	O
excretion	O
,	O
and	O
toxicity	O
of	O
nano-	O
graphene	S-chemical
.	O
Biocompatibly	O
coated	O
nano-	O
graphene	S-chemical
with	O
ultra-small	O
sizes	O
can	O
be	O
cleared	O
out	O
from	O
body	O
after	O
systemic	O
administration	O
,	O
without	O
rendering	O
noticeable	O
toxicity	O
to	O
the	O
treated	O
mice	O
.	O
In	O
this	O
review	O
article	O
,	O
we	O
will	O
summarize	O
the	O
latest	O
progress	O
in	O
this	O
rapidly	O
growing	O
field	O
,	O
and	O
discuss	O
future	O
prospects	O
and	O
challenges	O
of	O
using	O
graphene	S-chemical
-based	O
materials	O
for	O
theranostic	O
applications	O
.	O

Genetic	O
Insights	O
into	O
Pyralomicin	S-chemical
Biosynthesis	O
in	O
Nonomuraea	O
spiralis	O
IMC	O
A-0156	O
.	O
The	O
biosynthetic	O
gene	O
cluster	O
for	O
the	O
pyralomicin	S-chemical
antibiotics	O
has	O
been	O
cloned	O
and	O
sequenced	O
from	O
Nonomuraea	O
spiralis	O
IMC	O
A-0156	O
.	O
The	O
41	O
kb	O
gene	O
cluster	O
contains	O
27	O
ORFs	O
predicted	O
to	O
encode	O
all	O
of	O
the	O
functions	O
for	O
pyralomicin	S-chemical
biosynthesis	O
.	O
This	O
includes	O
nonribosomal	B-GP
peptide	I-GP
synthetases	E-GP
(	O
NRPS	S-GP
)	O
and	O
polyketide	B-GP
synthases	E-GP
(	O
PKS	S-GP
)	O
required	O
for	O
the	O
formation	O
of	O
the	O
benzopyranopyrrole	S-chemical
core	O
unit	O
,	O
as	O
well	O
as	O
a	O
suite	O
of	O
tailoring	O
enzymes	O
(	O
e.g.	O
,	O
four	O
halogenases	S-GP
,	O
an	O
O-methyltransferase	S-GP
,	O
and	O
an	O
N-glycosyltransferase	S-GP
)	O
necessary	O
for	O
further	O
modifications	O
of	O
the	O
core	O
structure	O
.	O
The	O
N-glycosyltransferase	S-GP
is	O
predicted	O
to	O
transfer	O
either	O
glucose	S-chemical
or	O
a	O
pseudosugar	O
(	O
cyclitol	S-chemical
)	O
to	O
the	O
aglycone	O
.	O
A	O
gene	O
cassette	O
encoding	O
C7	S-chemical
-	O
cyclitol	S-chemical
biosynthetic	O
enzymes	O
was	O
identified	O
upstream	O
of	O
the	O
benzopyranopyrrole	S-chemical
-specific	O
ORFs	O
.	O
Targeted	O
disruption	O
of	O
the	O
gene	O
encoding	O
the	O
N-glycosyltransferase	S-GP
,	O
prlH	S-GP
,	O
abolished	O
pyralomicin	S-chemical
production	O
,	O
and	O
recombinant	O
expression	O
of	O
PrlA	S-GP
confirms	O
the	O
activity	O
of	O
this	O
enzyme	O
as	O
a	O
sugar	B-GP
phosphate	I-GP
cyclase	E-GP
involved	O
in	O
the	O
formation	O
of	O
the	O
C7	S-chemical
-	O
cyclitol	S-chemical
moiety	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
some	O
novel	O
resveratrol	B-chemical
amide	E-chemical
derivatives	O
as	O
potential	O
anti-tumor	O
agents	O
.	O
Three	O
series	O
of	O
novel	O
resveratrol	B-chemical
amide	E-chemical
derivatives	O
(	O
1a-q	O
,	O
2a-h	O
,	O
3a-l	O
)	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
biological	O
activities	O
.	O
All	O
compounds	O
were	O
characterized	O
by	O
(	B-chemical
1	I-chemical
)	I-chemical
H	E-chemical
NMR	O
,	O
(	B-chemical
13	I-chemical
)	I-chemical
C	E-chemical
NMR	O
,	O
MS	O
and	O
elemental	O
analysis	O
.	O
Furthermore	O
,	O
compound	O
3e	O
was	O
also	O
characterized	O
by	O
X-ray	O
crystallography	O
.	O
All	O
the	O
compounds	O
were	O
evaluated	O
for	O
their	O
anti-tumor	O
activity	O
against	O
MCF-7	O
,	O
A549	O
and	O
B16-F10	O
tumor	O
cell	O
lines	O
as	O
well	O
as	O
cyclooxygenase-2	S-GP
(	O
COX-2	S-GP
)	O
-derived	O
prostaglandin	B-chemical
E2	E-chemical
(	O
PGE2	S-chemical
)	O
inhibitory	O
activity	O
of	O
murine	O
macrophage	O
RAW	O
264.7	O
cell	O
line	O
.	O
Among	O
them	O
,	O
compounds	O
1c	O
,	O
1g	O
and	O
3e	O
displayed	O
the	O
most	O
potent	O
COX-2	S-GP
inhibitory	O
activity	O
with	O
the	O
IC50	O
values	O
of	O
1.02	O
,	O
1.27	O
and	O
1.98	O
μM	O
,	O
respectively	O
.	O
Molecular	O
docking	O
studies	O
were	O
performed	O
to	O
position	O
compounds	O
1c	O
and	O
3e	O
into	O
the	O
active	O
site	O
of	O
COX-2	S-GP
to	O
determine	O
the	O
probable	O
binding	O
modes	O
.	O

The	O
effect	O
of	O
estramustine	S-chemical
derivatives	O
on	O
microtubule	O
assembly	O
in	O
vitro	O
depends	O
on	O
the	O
charge	O
of	O
the	O
substituent	O
.	O
Estramustine	S-chemical
,	O
and	O
derivatives	O
of	O
estramustine	S-chemical
with	O
a	O
charged	O
substituent	O
at	O
position	O
17	O
on	O
the	O
estrogen	S-chemical
moiety	O
,	O
have	O
been	O
investigated	O
for	O
their	O
effects	O
on	O
bovine	O
brain	O
microtubules	O
in	O
vitro	O
.	O
The	O
negatively	O
charged	O
estramustine	B-chemical
phosphate	E-chemical
has	O
been	O
found	O
previously	O
to	O
be	O
a	O
microtubule-associated	B-GP
protein	E-GP
(	O
MAP	S-GP
)	O
-dependent	O
microtubule	O
inhibitor	O
[	O
Wallin	O
M	O
,	O
Deinum	O
J	O
and	O
Friden	O
B	O
,	O
FEBS	O
Lett	O
179	O
:	O
289-293	O
,	O
1985	O
]	O
.	O
In	O
the	O
present	O
study	O
the	O
binding	O
of	O
estramustine	B-chemical
phosphate	E-chemical
to	O
MAP2	S-GP
and	O
tau	S-GP
was	O
investigated	O
.	O
Both	O
these	O
MAPs	S-GP
were	O
found	O
to	O
have	O
two	O
to	O
three	O
binding	O
sites	O
for	O
estramustine	B-chemical
phosphate	E-chemical
which	O
is	O
compatible	O
with	O
the	O
reported	O
number	O
of	O
basic	O
amino	B-chemical
acid	E-chemical
repeats	O
of	O
these	O
MAPs	S-GP
,	O
considered	O
to	O
be	O
the	O
ultimate	O
tubulin	S-GP
binding	O
domains	O
.	O
The	O
Kd	O
for	O
the	O
binding	O
of	O
estramustine	B-chemical
phosphate	E-chemical
to	O
MAP2	S-GP
was	O
estimated	O
to	O
be	O
20	O
microM	O
at	O
4	O
degrees	O
,	O
and	O
for	O
the	O
binding	O
of	O
tau	O
,	O
200	O
microM	O
.	O
The	O
rate	O
of	O
dissociation	O
was	O
very	O
low	O
(	O
T1/2	O
greater	O
than	O
2	O
hr	O
)	O
,	O
which	O
indicates	O
that	O
the	O
binding	O
of	O
estramustine	B-chemical
phosphate	E-chemical
may	O
stabilize	O
the	O
protein-drug	O
complex	O
by	O
changing	O
the	O
protein	O
conformation	O
.	O
Two	O
new	O
negatively	O
charged	O
estramustine	S-chemical
derivatives	O
,	O
estramustine	B-chemical
sulphate	E-chemical
and	O
estramustine	B-chemical
glucuronide	E-chemical
,	O
were	O
found	O
to	O
be	O
similar	O
MAP	S-GP
-dependent	O
microtubule	O
inhibitors	O
.	O
The	O
concentration	O
for	O
50	O
%	O
inhibition	O
of	O
assembly	O
was	O
100	O
microM	O
for	O
the	O
sulphate	S-chemical
derivative	O
,	O
the	O
same	O
as	O
found	O
previously	O
for	O
estramustine	B-chemical
phosphate	E-chemical
,	O
and	O
250	O
microM	O
for	O
the	O
more	O
bulky	O
estramustine	B-chemical
glucuronide	E-chemical
.	O
A	O
positively	O
charged	O
derivative	O
,	O
estramustine	B-chemical
sarcosinate	E-chemical
,	O
did	O
not	O
inhibit	O
microtubule	O
assembly	O
or	O
alter	O
the	O
composition	O
of	O
the	O
coassembled	O
MAPs	S-GP
.	O
The	O
morphology	O
of	O
the	O
microtubules	O
was	O
,	O
however	O
,	O
affected	O
.	O
The	O
uncharged	O
estramustine	S-chemical
bound	O
to	O
both	O
tubulin	S-GP
and	O
MAPs	S-GP
,	O
but	O
no	O
effects	O
were	O
seen	O
on	O
microtubule	O
assembly	O
,	O
the	O
composition	O
of	O
coassembled	O
MAPs	S-GP
or	O
the	O
microtubule	O
morphology	O
.	O
Our	O
results	O
suggest	O
that	O
only	O
negatively	O
charged	O
estramustine	S-chemical
derivatives	O
have	O
a	O
MAP	S-GP
-dependent	O
microtubule	O
inhibitory	O
effect	O
.	O
The	O
two	O
new	O
negatively	O
charged	O
derivatives	O
could	O
therefore	O
be	O
valuable	O
tools	O
in	O
the	O
study	O
of	O
tubulin	S-GP
-	O
MAP	S-GP
interactions	O
.	O
The	O
results	O
also	O
confirm	O
that	O
these	O
interactions	O
between	O
tubulin	S-GP
and	O
MAPs	S-GP
are	O
mainly	O
electrostatic	O
.	O

Tumor	B-GP
necrosis	I-GP
factor-alpha	E-GP
potentiates	O
the	O
cytotoxicity	O
of	O
amiodarone	S-chemical
in	O
Hepa1c1c7	O
cells	O
:	O
roles	O
of	O
caspase	S-GP
activation	O
and	O
oxidative	O
stress	O
.	O
Amiodarone	S-chemical
(	O
AMD	S-chemical
)	O
,	O
a	O
class	O
III	O
antiarrhythmic	O
drug	O
,	O
causes	O
idiosyncratic	O
hepatotoxicity	O
in	O
human	O
patients	O
.	O
We	O
demonstrated	O
previously	O
that	O
tumor	B-GP
necrosis	I-GP
factor-alpha	E-GP
(	O
TNF-α	S-GP
)	O
plays	O
an	O
important	O
role	O
in	O
a	O
rat	O
model	O
of	O
AMD	S-chemical
-induced	O
hepatotoxicity	O
under	O
inflammatory	O
stress	O
.	O
In	O
this	O
study	O
,	O
we	O
developed	O
a	O
model	O
in	O
vitro	O
to	O
study	O
the	O
roles	O
of	O
caspase	S-GP
activation	O
and	O
oxidative	O
stress	O
in	O
TNF	S-GP
potentiation	O
of	O
AMD	S-chemical
cytotoxicity	O
.	O
AMD	S-chemical
caused	O
cell	O
death	O
in	O
Hepa1c1c7	O
cells	O
,	O
and	O
TNF	S-GP
cotreatment	O
potentiated	O
its	O
toxicity	O
.	O
Activation	O
of	O
caspases	B-GP
9	I-GP
and	I-GP
3/7	E-GP
was	O
observed	O
in	O
AMD	S-chemical
/	O
TNF	S-GP
-cotreated	O
cells	O
,	O
and	O
caspase	O
inhibitors	O
provided	O
minor	O
protection	O
from	O
cytotoxicity	O
.	O
Intracellular	O
reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
generation	O
and	O
lipid	O
peroxidation	O
were	O
observed	O
after	O
treatment	O
with	O
AMD	S-chemical
and	O
were	O
further	O
elevated	O
by	O
TNF	S-GP
cotreatment	O
.	O
Adding	O
water-soluble	O
antioxidants	O
(	O
trolox	S-chemical
,	O
N-acetylcysteine	S-chemical
,	O
glutathione	S-chemical
,	O
or	O
ascorbate	S-chemical
)	O
produced	O
only	O
minor	O
attenuation	O
of	O
AMD	S-chemical
/	O
TNF	S-GP
-induced	O
cytotoxicity	O
and	O
did	O
not	O
influence	O
the	O
effect	O
of	O
AMD	S-chemical
alone	O
.	O
On	O
the	O
other	O
hand	O
,	O
α-tocopherol	S-chemical
(	O
TOCO	S-chemical
)	O
,	O
which	O
reduced	O
lipid	O
peroxidation	O
and	O
ROS	O
generation	O
,	O
prevented	O
AMD	S-chemical
toxicity	O
and	O
caused	O
pronounced	O
reduction	O
in	O
cytotoxicity	O
from	O
AMD	S-chemical
/	O
TNF	S-GP
cotreatment	O
.	O
α-TOCO	S-chemical
plus	O
a	O
pancaspase	S-GP
inhibitor	O
completely	O
abolished	O
AMD	S-chemical
/	O
TNF	S-GP
-induced	O
cytotoxicity	O
.	O
In	O
summary	O
,	O
activation	O
of	O
caspases	S-GP
and	O
oxidative	O
stress	O
were	O
observed	O
after	O
AMD	S-chemical
/	O
TNF	S-GP
cotreatment	O
,	O
and	O
caspase	S-GP
inhibitors	O
and	O
a	O
lipid-soluble	O
free-radical	O
scavenger	O
attenuated	O
AMD	S-chemical
/	O
TNF	S-GP
-induced	O
cytotoxicity	O
.	O

Functional	O
characteristics	O
of	O
H+	S-chemical
-dependent	O
nicotinate	S-chemical
transport	O
in	O
primary	O
cultures	O
of	O
astrocytes	O
from	O
rat	O
cerebral	O
cortex	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
characteristics	O
of	O
H	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-coupled	O
nicotinate	S-chemical
transport	O
in	O
primary	O
cultures	O
of	O
astrocytes	O
from	O
rat	O
cerebral	O
cortex	O
.	O
The	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
nicotinate	E-chemical
transport	O
in	O
rat	O
astrocytes	O
increased	O
up	O
to	O
a	O
pH	O
5.5	O
.	O
The	O
nicotinic	B-chemical
acid	E-chemical
uptake	O
at	O
pH	O
6.0	O
was	O
both	O
energy-dependent	O
and	O
saturable	O
with	O
a	O
Michaelis	O
constant	O
(	O
K	O
(	O
t	O
)	O
)	O
of	O
2.8+/-0.4	O
mM	O
and	O
the	O
maximal	O
uptake	O
rate	O
(	O
V	O
(	O
max	O
)	O
)	O
of	O
31+/-3.2	O
nmol/mg	O
protein/10	O
min	O
.	O
This	O
process	O
was	O
reduced	O
by	O
a	O
protonophore	O
,	O
carbonylcyanide	B-chemical
p-trifluoromethoxyphenylhydrazone	E-chemical
,	O
and	O
a	O
typical	O
monocarboxylate	B-GP
transporter	E-GP
(	O
MCT	S-GP
)	O
inhibitor	O
,	O
alpha-cyano-4-hydroxycinnamic	B-chemical
acid	E-chemical
,	O
suggesting	O
that	O
nicotinate	S-chemical
uptake	O
by	O
rat	O
astrocytes	O
is	O
mediated	O
by	O
H	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-coupled	O
monocarboxylate	B-GP
transport	I-GP
system	E-GP
.	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
Nicotinate	E-chemical
transport	O
in	O
rat	O
astrocytes	O
was	O
significantly	O
inhibited	O
by	O
various	O
monocarboxylic	B-chemical
acids	E-chemical
such	O
as	O
l-lactic	B-chemical
acid	E-chemical
and	O
pyruvic	B-chemical
acid	E-chemical
with	O
a	O
relatively	O
low	O
affinity	O
(	O
K	O
(	O
i	O
)	O
>	O
10	O
mM	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
uptake	O
process	O
of	O
l-lactic	B-chemical
acid	E-chemical
was	O
also	O
saturable	O
with	O
a	O
high-affinity	O
component	O
(	O
K	O
(	O
t	O
)	O
=0.27	O
mM	O
)	O
and	O
a	O
low-affinity	O
component	O
(	O
K	O
(	O
t	O
)	O
=35.9	O
mM	O
)	O
.	O
Reverse	O
transcription-PCR	O
and	O
Western	O
blot	O
analyses	O
revealed	O
that	O
three	O
MCT	S-GP
subtypes	O
,	O
MCT1	S-GP
/	O
Slc16a1	S-GP
,	O
MCT2	S-GP
/	O
Slc16a7	S-GP
,	O
and	O
MCT4	S-GP
/	O
Slc16a3	S-GP
,	O
were	O
expressed	O
in	O
these	O
cells	O
.	O
Because	O
l-lactate	S-chemical
reduced	O
to	O
67	O
%	O
of	O
the	O
nicotinate	S-chemical
uptake	O
even	O
at	O
10mM	O
,	O
it	O
is	O
unlikely	O
that	O
nicotinate	S-chemical
uptake	O
in	O
rat	O
astrocytes	O
is	O
mediated	O
by	O
MCT1	S-GP
and/or	O
MCT2	S-GP
.	O
These	O
results	O
provide	O
biochemical	O
evidence	O
of	O
a	O
H	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-coupled	O
and	O
saturable	O
transport	O
system	O
,	O
presumed	O
to	O
be	O
a	O
low-affinity	B-GP
monocarboxylate	I-GP
transporter	E-GP
MCT4	S-GP
or	O
other	O
unknown	O
H	B-GP
(	I-GP
+	I-GP
)	I-GP
-coupled	I-GP
monocarboxylate	I-GP
transport	I-GP
system	E-GP
,	O
for	O
nicotinate	S-chemical
in	O
rat	O
cerebrocortical	O
astrocytes	O
.	O

4-Hydroxytamoxifen	S-chemical
-stimulated	O
processing	O
of	O
cyclin	B-GP
E	E-GP
is	O
mediated	O
via	O
G	B-GP
protein-coupled	I-GP
receptor	I-GP
30	E-GP
(	O
GPR30	B-GP
)	E-GP
and	O
accompanied	O
by	O
enhanced	O
migration	O
in	O
MCF-7	O
breast	O
cancer	O
cells	O
.	O
Over-expression	O
of	O
cleaved	O
cyclin	B-GP
E	E-GP
in	O
breast	O
tumors	O
is	O
closely	O
associated	O
with	O
tumor	O
progression	O
and	O
resistance	O
to	O
antiestrogens	O
.	O
17β-Estradiol	S-chemical
(	O
E2	O
)	O
has	O
been	O
recently	O
shown	O
to	O
induce	O
cyclin	B-GP
E	E-GP
processing	O
in	O
breast	O
cancer	O
cells	O
.	O
Tamoxifen	S-chemical
has	O
been	O
used	O
in	O
patients	O
with	O
estrogen	S-chemical
-sensitive	O
breast	O
cancer	O
,	O
yet	O
resistance	O
to	O
antiestrogens	O
and	O
recurrence	O
will	O
appear	O
in	O
some	O
of	O
the	O
patients	O
after	O
its	O
continued	O
use	O
.	O
We	O
therefore	O
addressed	O
possible	O
effects	O
of	O
tamoxifen	S-chemical
on	O
the	O
generation	O
of	O
cleaved	O
cyclin	B-GP
E	E-GP
and	O
its	O
signal	O
mechanism	O
(	O
s	O
)	O
in	O
estrogen	S-chemical
-responsive	O
MCF-7	O
breast	O
cancer	O
cells	O
that	O
express	O
both	O
G	B-GP
protein-coupled	I-GP
protein	I-GP
(	I-GP
GPR	I-GP
)	I-GP
30	E-GP
and	O
estrogen	B-GP
receptor	I-GP
α	E-GP
(	O
ERα	S-GP
)	O
.	O
4-Hydroxytamoxifen	S-chemical
(	O
OHT	S-chemical
,	O
tamoxifen	S-chemical
's	O
active	O
form	O
)	O
failed	O
to	O
prevent	O
E2-induced	O
proteolysis	O
of	O
cyclin	B-GP
E	E-GP
and	O
migration	O
,	O
but	O
rather	O
triggered	O
cyclin	B-GP
E	E-GP
cleavage	O
coincident	O
with	O
augmented	O
migration	O
.	O
OHT	S-chemical
-induced	O
cyclin	B-GP
E	E-GP
truncation	O
also	O
occurred	O
in	O
SK-BR-3	O
cells	O
that	O
express	O
GPR30	S-GP
and	O
lack	O
ERα	S-GP
,	O
but	O
not	O
in	O
MDA-MB-231	O
cells	O
that	O
express	O
neither	O
GPR30	S-GP
nor	O
ERα	S-GP
.	O
G1	O
,	O
a	O
specific	O
GPR	B-GP
30	E-GP
agonist	O
,	O
caused	O
dramatic	O
proteolysis	O
of	O
cyclin	B-GP
E	E-GP
and	O
enhanced	O
migration	O
.	O
Furthermore	O
,	O
OHT	S-chemical
-stimulated	O
cleavage	O
of	O
cyclin	B-GP
E	E-GP
and	O
migration	O
were	O
tremendously	O
attenuated	O
by	O
G15	O
,	O
a	O
GPR30	S-GP
antagonist	O
,	O
or	O
siRNA	O
against	O
GPR30	S-GP
.	O
In	O
addition	O
,	O
inhibitors	O
for	O
EGFR	S-GP
or	O
ERK1/2	S-GP
remarkably	O
suppressed	O
OHT	S-chemical
-induced	O
truncation	O
of	O
cyclin	B-GP
E	E-GP
,	O
suggesting	O
involvement	O
of	O
EGFR	S-GP
signaling	O
.	O
Collectively	O
,	O
our	O
data	O
indicate	O
that	O
OHT	S-chemical
contributes	O
to	O
the	O
production	O
of	O
proteolyzed	O
cyclin	B-GP
E	E-GP
via	O
GPR30	S-GP
with	O
augmented	O
migration	O
in	O
MCF-7	O
cells	O
.	O

Vitamin	B-chemical
A	E-chemical
and	O
retinoid	S-chemical
signaling	O
:	O
genomic	O
and	O
non-genomic	O
effects	O
.	O
Vitamin	B-chemical
A	E-chemical
or	O
retinol	S-chemical
is	O
arguably	O
the	O
most	O
multifunctional	O
vitamin	S-chemical
in	O
the	O
human	O
body	O
as	O
it	O
is	O
essential	O
from	O
embryogenesis	O
to	O
adulthood	O
.	O
The	O
pleiotropic	O
effects	O
of	O
vitamin	B-chemical
A	E-chemical
are	O
exerted	O
mainly	O
by	O
one	O
active	O
metabolite	O
,	O
all-trans	B-chemical
retinoic	I-chemical
acid	E-chemical
(	O
atRA	S-chemical
)	O
,	O
which	O
regulates	O
the	O
expression	O
of	O
a	O
battery	O
of	O
target	O
genes	O
through	O
several	O
families	O
of	O
nuclear	B-GP
receptors	E-GP
(	O
RARs	S-GP
,	O
RXRs	S-GP
and	O
PPARβ/δ	S-GP
)	O
,	O
polymorphic	B-GP
retinoic	I-GP
acid	I-GP
(	I-GP
RA	I-GP
)	I-GP
response	I-GP
elements	E-GP
and	O
multiple	O
coregulators	O
.	O
It	O
also	O
involves	O
extra	O
nuclear	O
and	O
non-transcriptional	O
effects	O
such	O
as	O
the	O
activation	O
of	O
kinase	S-GP
cascades	O
,	O
which	O
are	O
integrated	O
in	O
the	O
nucleus	O
via	O
the	O
phosphorylation	O
of	O
several	O
actors	O
of	O
RA	O
signaling	O
.	O
However	O
,	O
vitamin	B-chemical
A	E-chemical
itself	O
proved	O
recently	O
to	O
be	O
active	O
and	O
RARs	S-GP
to	O
be	O
present	O
in	O
the	O
cytosol	O
to	O
regulate	O
translation	O
and	O
cell	O
plasticity	O
.	O
All	O
these	O
new	O
concepts	O
expand	O
the	O
scope	O
of	O
the	O
biologic	O
functions	O
of	O
vitamin	B-chemical
A	E-chemical
and	O
RA	O
.	O

Pneumocystis	O
jiroveci	O
pneumonia	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
as	O
a	O
complication	O
of	O
treatment	O
with	O
infliximab	O
,	O
anti-	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
alpha	E-GP
neutralizing	O
antibody	O
.	O
We	O
report	O
that	O
a-63-year-old	O
woman	O
developed	O
Pneumocystis	O
jiroveci	O
pneumonia	O
(	O
PCP	O
)	O
as	O
a	O
complication	O
from	O
treatment	O
with	O
infliximab	O
for	O
rheumatoid	O
arthritis	O
.	O
Although	O
there	O
was	O
neither	O
symptoms	O
of	O
dyspnea	O
nor	O
typical	O
observations	O
on	O
a	O
chest	O
X-ray	O
examination	O
,	O
low	O
levels	O
of	O
oxygen	S-chemical
saturation	O
and	O
findings	O
of	O
high-resolution	O
chest	O
computed	O
tomographic	O
scanning	O
suggested	O
a	O
possibility	O
of	O
interstitial	O
pneumonia	O
.	O
A	O
polymerase	O
chain	O
reaction-based	O
detection	O
of	O
Pneumocystis	O
jiroveci	O
in	O
induced	O
sputum	O
allowed	O
an	O
early	O
diagnosis	O
of	O
PCP	O
and	O
subsequent	O
effective	O
treatment	O
.	O

4-Hydroxypyridazin-3	B-chemical
(	I-chemical
2H	I-chemical
)	I-chemical
-one	E-chemical
Derivatives	O
as	O
Novel	O
d-Amino	B-GP
Acid	I-GP
Oxidase	E-GP
Inhibitors	O
.	O
d-Amino	B-GP
acid	I-GP
oxidase	E-GP
(	O
DAAO	S-GP
)	O
catalyzes	O
the	O
oxidation	O
of	O
d-amino	B-chemical
acids	E-chemical
including	O
d-serine	S-chemical
,	O
a	O
coagonist	O
of	O
the	O
N-methyl-d-aspartate	B-GP
receptor	E-GP
.	O
We	O
identified	O
a	O
series	O
of	O
4-hydroxypyridazin-3	B-chemical
(	I-chemical
2H	I-chemical
)	I-chemical
-one	E-chemical
derivatives	O
as	O
novel	O
DAAO	S-GP
inhibitors	O
with	O
high	O
potency	O
and	O
substantial	O
cell	O
permeability	O
using	O
fragment-based	O
drug	O
design	O
.	O
Comparisons	O
of	O
complex	O
structures	O
deposited	O
in	O
the	O
Protein	O
Data	O
Bank	O
as	O
well	O
as	O
those	O
determined	O
with	O
in-house	O
fragment	O
hits	O
revealed	O
that	O
a	O
hydrophobic	O
subpocket	O
was	O
formed	O
perpendicular	O
to	O
the	O
flavin	O
ring	O
by	O
flipping	O
Tyr	S-chemical
224	O
in	O
a	O
ligand-dependent	O
manner	O
.	O
We	O
investigated	O
the	O
ability	O
of	O
the	O
initial	O
fragment	O
hit	O
,	O
3-hydroxy-pyridine-2	B-chemical
(	I-chemical
1H	I-chemical
)	I-chemical
-one	E-chemical
,	O
to	O
fill	O
this	O
subpocket	O
with	O
the	O
aid	O
of	O
complex	O
structure	O
information	O
.	O
3-Hydroxy-5-	B-chemical
(	I-chemical
2-phenylethyl	I-chemical
)	I-chemical
pyridine-2	I-chemical
(	I-chemical
1H	I-chemical
)	I-chemical
-one	E-chemical
exhibited	O
the	O
predicted	O
binding	O
mode	O
and	O
demonstrated	O
high	O
inhibitory	O
activity	O
for	O
human	B-GP
DAAO	E-GP
in	O
enzyme-	O
and	O
cell-based	O
assays	O
.	O
We	O
further	O
designed	O
and	O
synthesized	O
4-hydroxypyridazin-3	B-chemical
(	I-chemical
2H	I-chemical
)	I-chemical
-one	E-chemical
derivatives	O
,	O
which	O
are	O
equivalent	O
to	O
the	O
3-hydroxy-pyridine-2	B-chemical
(	I-chemical
1H	I-chemical
)	I-chemical
-one	E-chemical
series	O
but	O
lack	O
cell	O
toxicity	O
.	O
6-	B-chemical
[	I-chemical
2-	I-chemical
(	I-chemical
3,5-Difluorophenyl	I-chemical
)	I-chemical
ethyl	I-chemical
]	I-chemical
-4-hydroxypyridazin-3	I-chemical
(	I-chemical
2H	I-chemical
)	I-chemical
-one	E-chemical
was	O
found	O
to	O
be	O
effective	O
against	O
MK-801	S-chemical
-induced	O
cognitive	O
deficit	O
in	O
the	O
Y-maze	O
.	O

Cereblon	S-GP
is	O
a	O
direct	O
protein	O
target	O
for	O
immunomodulatory	O
and	O
antiproliferative	O
activities	O
of	O
lenalidomide	S-chemical
and	O
pomalidomide	S-chemical
.	O
Thalidomide	S-chemical
and	O
the	O
immunomodulatory	O
drug	O
,	O
lenalidomide	S-chemical
,	O
are	O
therapeutically	O
active	O
in	O
hematological	O
malignancies	O
.	O
The	O
ubiquitously	O
expressed	O
E3	O
ligase	O
protein	O
cereblon	S-GP
(	O
CRBN	S-GP
)	O
has	O
been	O
identified	O
as	O
the	O
primary	O
teratogenic	O
target	O
of	O
thalidomide	S-chemical
.	O
Our	O
studies	O
demonstrate	O
that	O
thalidomide	S-chemical
,	O
lenalidomide	S-chemical
and	O
another	O
immunomodulatory	O
drug	O
,	O
pomalidomide	S-chemical
,	O
bound	O
endogenous	O
CRBN	S-GP
and	O
recombinant	O
CRBN	S-GP
-	O
DNA	B-GP
damage	I-GP
binding	I-GP
protein-1	E-GP
(	O
DDB1	S-GP
)	O
complexes	O
.	O
CRBN	S-GP
mediated	O
antiproliferative	O
activities	O
of	O
lenalidomide	S-chemical
and	O
pomalidomide	S-chemical
in	O
myeloma	O
cells	O
,	O
as	O
well	O
as	O
lenalidomide	S-chemical
-	O
and	O
pomalidomide	S-chemical
-induced	O
cytokine	S-GP
production	O
in	O
T	O
cells	O
.	O
Lenalidomide	S-chemical
and	O
pomalidomide	S-chemical
inhibited	O
autoubiquitination	O
of	O
CRBN	S-GP
in	O
HEK293T	O
cells	O
expressing	O
thalidomide	S-chemical
-binding	O
competent	O
wild-type	O
CRBN	S-GP
,	O
but	O
not	O
thalidomide	S-chemical
-binding	O
defective	O
CRBN	S-GP
(	O
YW/AA	O
)	O
.	O
Overexpression	O
of	O
CRBN	S-GP
wild-type	O
protein	O
,	O
but	O
not	O
CRBN	S-GP
(	O
YW/AA	O
)	O
mutant	O
protein	O
,	O
in	O
KMS12	O
myeloma	O
cells	O
,	O
amplified	O
pomalidomide	S-chemical
-mediated	O
reductions	O
in	O
c-myc	S-GP
and	O
IRF4	S-GP
expression	O
and	O
increases	O
in	O
p21	S-GP
(	O
WAF-1	S-GP
)	O
expression	O
.	O
Long-term	O
selection	O
for	O
lenalidomide	S-chemical
resistance	O
in	O
H929	O
myeloma	O
cell	O
lines	O
was	O
accompanied	O
by	O
a	O
reduction	O
in	O
CRBN	S-GP
,	O
while	O
in	O
DF15R	O
myeloma	O
cells	O
resistant	O
to	O
both	O
pomalidomide	S-chemical
and	O
lenalidomide	S-chemical
,	O
CRBN	S-GP
protein	O
was	O
undetectable	O
.	O
Our	O
biophysical	O
,	O
biochemical	O
and	O
gene	O
silencing	O
studies	O
show	O
that	O
CRBN	S-GP
is	O
a	O
proximate	O
,	O
therapeutically	O
important	O
molecular	O
target	O
of	O
lenalidomide	S-chemical
and	O
pomalidomide	S-chemical
.	O

Acrolein	S-chemical
induces	O
Alzheimer	O
's	O
disease-like	O
pathologies	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
The	O
pathologic	O
mechanisms	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
have	O
not	O
been	O
fully	O
uncovered	O
.	O
Acrolein	S-chemical
,	O
a	O
ubiquitous	O
dietary	O
pollutant	O
and	O
by-product	O
of	O
oxidative	O
stress	O
,	O
can	O
induce	O
cytotoxicity	O
in	O
neurons	O
,	O
which	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
AD	O
.	O
Here	O
,	O
we	O
examined	O
the	O
effects	O
of	O
Acrolein	S-chemical
on	O
the	O
AD	O
pathologies	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
We	O
found	O
Acrolein	S-chemical
induced	O
HT22	O
cells	O
death	O
in	O
concentration-	O
and	O
time-dependent	O
manners	O
.	O
Interestingly	O
,	O
Acrolein	S-chemical
increased	O
proteins	O
'	O
levels	O
of	O
amyloid	B-GP
precursor	I-GP
protein	E-GP
(	O
APP	S-GP
)	O
,	O
β-secretase	S-GP
(	O
BACE-1	S-GP
)	O
and	O
the	O
amyloid	B-GP
β-peptide	I-GP
transporter	E-GP
receptor	B-GP
for	I-GP
advanced	I-GP
glycation	I-GP
end	I-GP
products	E-GP
,	O
and	O
decreased	O
A-disintegrin	B-GP
and	I-GP
metalloprotease	I-GP
(	I-GP
ADAM	I-GP
)	I-GP
10	E-GP
levels	O
.	O
In	O
vivo	O
,	O
chronic	O
oral	O
exposure	O
to	O
Acrolein	S-chemical
(	O
2.5	O
mg/kg/day	O
by	O
intragastric	O
gavage	O
for	O
8	O
weeks	O
)	O
induced	O
mild	O
cognitive	O
declination	O
and	O
pyknosis/atrophy	O
of	O
hippocampal	O
neurons	O
.	O
The	O
activity	O
of	O
superoxide	B-GP
dismutase	E-GP
was	O
down-regulated	O
while	O
the	O
level	O
of	O
malondialdehyde	S-chemical
was	O
up-regulated	O
in	O
rat	O
brain	O
.	O
Moreover	O
,	O
Acrolein	S-chemical
resulted	O
in	O
activation	O
of	O
astrocytes	O
,	O
up-regulation	O
of	O
BACE-1	S-GP
in	O
cortex	O
and	O
down-regulation	O
of	O
ADAM-10	S-GP
in	O
hippocampus	O
and	O
cortex	O
.	O
Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
exposure	O
to	O
Acrolein	S-chemical
induces	O
AD-like	O
pathology	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Scavenging	O
Acrolein	S-chemical
might	O
be	O
beneficial	O
for	O
the	O
therapy	O
of	O
AD	O
.	O

Inhibition	O
of	O
the	O
leukotriene	B-GP
synthetase	E-GP
of	O
rat	O
basophil	O
leukemia	O
cells	O
by	O
diethylcarbamazine	S-chemical
,	O
and	O
synergism	O
between	O
diethylcarbamazine	S-chemical
and	O
piriprost	S-chemical
,	O
a	O
5-lipoxygenase	S-GP
inhibitor	O
.	O
Diethylcarbamazine	S-chemical
inhibited	O
the	O
formation	O
of	O
sulfidopeptide	B-chemical
leukotrienes	E-chemical
in	O
rat	O
basophil	O
leukemia	O
(	O
RBL	O
)	O
cells	O
(	O
50	O
%	O
inhibitory	O
concentration	O
,	O
EC50	O
,	O
3	O
mM	O
)	O
.	O
Similar	O
concentrations	O
also	O
inhibited	O
the	O
formation	O
of	O
leukotriene	B-chemical
C4	E-chemical
(	O
LTC4	S-chemical
)	O
by	O
LTC	B-GP
synthetase	E-GP
,	O
a	O
detergent-solubilized	O
cell	O
free	O
particulate	O
enzyme	O
from	O
RBL	O
cells	O
which	O
is	O
capable	O
of	O
coupling	O
LTA4	S-chemical
to	O
glutathione	S-chemical
.	O
By	O
contrast	O
,	O
the	O
conversion	O
of	O
LTA4	S-chemical
to	O
LTC4	S-chemical
using	O
enzymes	O
from	O
rat	O
liver	O
was	O
at	O
least	O
ten	O
times	O
less	O
sensitive	O
to	O
this	O
inhibitor	O
.	O
The	O
EC50	O
for	O
inhibition	O
of	O
the	O
leukotriene	B-GP
C	I-GP
synthetase	E-GP
of	O
RBL	O
cells	O
was	O
directly	O
proportional	O
to	O
the	O
LTA4	S-chemical
concentration	O
in	O
the	O
incubations	O
,	O
ranging	O
from	O
1.5	O
mM	O
at	O
10	O
microM	O
LTA4	S-chemical
to	O
over	O
40	O
mM	O
at	O
500	O
microM	O
LTA4	S-chemical
.	O
Kinetic	O
analysis	O
revealed	O
that	O
the	O
inhibition	O
of	O
the	O
leukotriene	B-GP
C	I-GP
synthetase	E-GP
reaction	O
by	O
diethylcarbamazine	S-chemical
was	O
competitive	O
with	O
respect	O
to	O
LTA4	S-chemical
.	O
In	O
contrast	O
to	O
diethylcarbamazine	S-chemical
,	O
piriprost	S-chemical
(	O
U-60,257	S-chemical
;	O
6,9-deepoxy-6,9-	B-chemical
(	I-chemical
phenylimino	I-chemical
)	I-chemical
-delta	I-chemical
6,8-prostaglandin	I-chemical
I1	E-chemical
)	O
,	O
which	O
inhibits	O
the	O
formation	O
of	O
sulfidopeptide	B-chemical
leuktrienes	E-chemical
in	O
RBL	O
cells	O
at	O
the	O
5-lipoxygenase	S-GP
step	O
(	O
EC50	O
5	O
microM	O
)	O
,	O
did	O
not	O
inhibit	O
the	O
leukotriene	B-GP
synthetase	E-GP
of	O
these	O
cells	O
.	O
On	O
the	O
other	O
hand	O
,	O
low	O
concentrations	O
of	O
piriprost	S-chemical
,	O
which	O
had	O
no	O
demonstrable	O
inhibitory	O
activity	O
on	O
leukotriene	S-chemical
formation	O
by	O
themselves	O
,	O
markedly	O
synergized	O
the	O
inhibitory	O
activity	O
of	O
diethylcarbamazine	S-chemical
.	O
These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
both	O
piriprost	S-chemical
and	O
diethylcarbamazine	S-chemical
inhibit	O
leukotriene	S-chemical
formation	O
but	O
that	O
they	O
act	O
on	O
sequential	O
steps	O
in	O
the	O
biosynthetic	O
pathway	O
in	O
such	O
a	O
manner	O
as	O
to	O
synergistically	O
interfere	O
with	O
the	O
availability	O
or	O
utilization	O
of	O
LTA4	S-chemical
in	O
the	O
leukotriene	B-GP
C	I-GP
synthetase	E-GP
reaction	O
.	O

Aspirin	S-chemical
and	O
salicylate	S-chemical
bind	O
to	O
immunoglobulin	B-GP
heavy	I-GP
chain	I-GP
binding	I-GP
protein	E-GP
(	O
BiP	S-GP
)	O
and	O
inhibit	O
its	O
ATPase	S-GP
activity	O
in	O
human	O
fibroblasts	O
.	O
Salicylic	B-chemical
acid	E-chemical
(	O
SA	S-chemical
)	O
,	O
an	O
endogenous	O
signaling	O
molecule	O
of	O
plants	O
,	O
possesses	O
anti-inflammatory	O
and	O
anti-neoplastic	O
actions	O
in	O
human	O
.	O
Its	O
derivative	O
,	O
aspirin	O
,	O
is	O
the	O
most	O
commonly	O
used	O
anti-inflammatory	O
and	O
analgesic	O
drug	O
.	O
Aspirin	S-chemical
and	O
sodium	B-chemical
salicylate	E-chemical
(	O
salicylates	S-chemical
)	O
have	O
been	O
reported	O
to	O
have	O
multiple	O
pharmacological	O
actions	O
.	O
However	O
,	O
it	O
is	O
unclear	O
whether	O
they	O
bind	O
to	O
a	O
cellular	O
protein	O
.	O
Here	O
,	O
we	O
report	O
for	O
the	O
first	O
time	O
the	O
purification	O
from	O
human	O
fibroblasts	O
of	O
a	O
approximately	O
78	O
kDa	O
salicylate	B-GP
binding	I-GP
protein	E-GP
with	O
sequence	O
identity	O
to	O
immunoglobulin	B-GP
heavy	I-GP
chain	I-GP
binding	I-GP
protein	E-GP
(	O
BiP	S-GP
)	O
.	O
The	O
Kd	O
values	O
of	O
SA	S-chemical
binding	O
to	O
crude	O
extract	O
and	O
to	O
recombinant	O
BiP	S-GP
were	O
45.2	O
and	O
54.6	O
microM	O
,	O
respectively	O
.	O
BiP	S-GP
is	O
a	O
chaperone	B-GP
protein	E-GP
containing	O
a	O
polypeptide	O
binding	O
site	O
recognizing	O
specific	O
heptapeptide	B-GP
sequence	E-GP
and	O
an	O
ATP	B-GP
binding	I-GP
site	E-GP
.	O
A	O
heptapeptide	O
with	O
the	O
specific	O
sequence	O
displaced	O
SA	S-chemical
binding	O
in	O
a	O
concentration-dependent	O
manner	O
whereas	O
a	O
control	O
heptapeptide	O
did	O
not	O
.	O
Salicylates	S-chemical
inhibited	O
ATPase	S-GP
activity	O
stimulated	O
by	O
this	O
specific	O
heptapeptide	O
but	O
did	O
not	O
block	O
ATP	S-chemical
binding	O
or	O
induce	O
BiP	S-GP
expression	O
.	O
These	O
results	O
indicate	O
that	O
salicylates	S-chemical
bind	O
specifically	O
to	O
the	O
polypeptide	O
binding	O
site	O
of	O
BiP	S-GP
in	O
human	O
cells	O
that	O
may	O
interfere	O
with	O
folding	O
and	O
transport	O
of	O
proteins	O
important	O
in	O
inflammation	O
.	O

Inhibition	O
of	O
testicular	O
LDH-X	S-GP
from	O
laboratory	O
animals	O
and	O
man	O
by	O
gossypol	S-chemical
and	O
its	O
isomers	O
.	O
The	O
inhibitory	O
effect	O
of	O
(	B-chemical
+	I-chemical
)	I-chemical
-	I-chemical
,	I-chemical
(	I-chemical
-	I-chemical
)	I-chemical
-	I-chemical
,	I-chemical
(	I-chemical
+/-	I-chemical
)	I-chemical
-gossypol	E-chemical
and	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-gossypol	I-chemical
acetic	I-chemical
acid	E-chemical
upon	O
testicular	O
cytosolic	O
LDH-X	S-GP
was	O
measured	O
in	O
vitro	O
.	O
Gossypol	B-chemical
acetic	I-chemical
acid	E-chemical
(	O
0-100	O
mumol/l	O
)	O
inhibited	O
LDH-X	S-GP
prepared	O
from	O
the	O
testes	O
of	O
the	O
mouse	O
greater	O
than	O
rabbit	O
greater	O
than	O
human	O
greater	O
than	O
rat	O
greater	O
than	O
hamster	O
.	O
There	O
was	O
no	O
relationship	O
between	O
inhibition	O
and	O
in-vivo	O
antifertility	O
activity	O
.	O
LDH	S-GP
activity	O
measured	O
in	O
vitro	O
in	O
serum	O
of	O
men	O
and	O
hamsters	O
was	O
unaffected	O
by	O
gossypol	S-chemical
.	O
Gossypol	S-chemical
and	O
its	O
isomers	O
were	O
non-competitive	O
inhibitors	O
of	O
human	B-GP
and	I-GP
hamster	I-GP
LDH-X	E-GP
with	O
respect	O
to	O
the	O
coenzyme	O
NADH	S-chemical
,	O
competitive	O
inhibitors	O
of	O
human	B-GP
LDH-X	E-GP
and	O
noncompetitive-competitive	O
inhibitors	O
of	O
hamster	B-GP
LDH-X	E-GP
with	O
respect	O
to	O
the	O
substrate	O
alpha-ketobutyrate	S-chemical
.	O
Co-incubation	O
with	O
human	B-GP
serum	I-GP
albumin	E-GP
or	O
poly-L-lysine	S-chemical
but	O
not	O
lysine	S-chemical
protected	O
human	B-GP
and	I-GP
hamster	I-GP
LDH-X	E-GP
from	O
gossypol	S-chemical
.	O

Human	B-GP
prohormone	I-GP
convertase	I-GP
3	E-GP
gene	O
:	O
exon-intron	O
organization	O
and	O
molecular	O
scanning	O
for	O
mutations	O
in	O
Japanese	O
subjects	O
with	O
NIDDM	O
.	O
Proinsulin	S-GP
is	O
converted	O
to	O
insulin	S-GP
by	O
the	O
concerted	O
action	O
of	O
two	O
sequence-specific	O
subtilisin-like	B-GP
proteases	E-GP
termed	O
prohormone	B-GP
convertase	I-GP
2	E-GP
(	O
PC2	S-GP
)	O
and	O
prohormone	B-GP
convertase	I-GP
3	E-GP
(	O
PC3	S-GP
)	O
.	O
PC3	S-GP
is	O
a	O
type	B-GP
I	I-GP
proinsulin-processing	I-GP
enzyme	E-GP
that	O
initiates	O
the	O
sequential	O
processing	O
of	O
proinsulin	S-GP
to	O
insulin	S-GP
by	O
cleaving	O
the	O
proinsulin	S-GP
molecule	O
on	O
the	O
COOH	S-chemical
-terminal	O
side	O
of	O
the	O
dibasic	O
peptide	O
,	O
Arg31-Arg32	O
,	O
joining	O
the	O
B-chain	O
and	O
C	S-chemical
-peptide	O
.	O
Thus	O
,	O
PC3	S-GP
plays	O
a	O
key	O
role	O
in	O
regulating	O
insulin	S-GP
biosynthesis	O
.	O
Expressions	O
of	O
insulin	S-GP
and	O
PC3	S-GP
,	O
but	O
not	O
PC2	S-GP
,	O
are	O
coordinately	O
regulated	O
by	O
glucose	S-chemical
,	O
consistent	O
with	O
the	O
important	O
role	O
of	O
PC3	S-GP
in	O
regulating	O
proinsulin	S-GP
processing	O
.	O
NIDDM	O
is	O
associated	O
with	O
increased	O
secretion	O
of	O
proinsulin	S-GP
and	O
proinsulin	S-GP
-like	O
molecules	O
,	O
suggesting	O
that	O
mutations	O
in	O
the	O
PC3	S-GP
gene	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
this	O
disorder	O
.	O
To	O
examine	O
this	O
hypothesis	O
,	O
we	O
have	O
isolated	O
and	O
characterized	O
the	O
human	B-GP
PC3	E-GP
gene	O
and	O
screened	O
it	O
for	O
mutations	O
in	O
a	O
group	O
of	O
Japanese	O
subjects	O
with	O
NIDDM	O
.	O
The	O
PC3	S-GP
gene	O
consists	O
of	O
14	O
exons	O
spanning	O
more	O
than	O
35	O
kb	O
.	O
The	O
exon-intron	O
organization	O
of	O
PC2	S-GP
and	O
PC3	S-GP
genes	O
are	O
conserved	O
,	O
consistent	O
with	O
a	O
common	O
evolutionary	O
origin	O
for	O
the	O
prohormone	B-GP
convertase	E-GP
gene	O
family	O
.	O
Single-strand	O
conformational	O
analysis	O
and	O
nucleotide	S-chemical
sequencing	O
of	O
the	O
entire	O
coding	O
region	O
of	O
the	O
PC3	S-GP
gene	O
in	O
102	O
Japanese	O
subjects	O
with	O
NIDDM	O
revealed	O
missense	O
mutations	O
in	O
exons	O
2	O
(	O
Arg/Gln53	S-GP
)	O
and	O
14	O
(	O
Gln/Glu638	S-GP
)	O
,	O
neither	O
of	O
which	O
was	O
associated	O
with	O
NIDDM	O
in	O
this	O
population	O
.	O
These	O
data	O
suggest	O
that	O
genetic	O
variation	O
in	O
the	O
PC3	S-GP
gene	O
is	O
unlikely	O
to	O
be	O
a	O
major	O
contributor	O
to	O
NIDDM	O
susceptibility	O
in	O
Japanese	O
.	O

Characterization	O
of	O
5-hydroxytryptamine1B	S-GP
receptors	O
in	O
rat	O
spinal	O
cord	O
via	O
[	B-chemical
125I	I-chemical
]	I-chemical
iodocyanopindolol	E-chemical
binding	O
and	O
inhibition	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-5-hydroxytryptamine	E-chemical
release	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
in	O
rat	O
spinal	O
cord	O
synaptosomes	O
was	O
to	O
compare	O
the	O
pharmacological	O
characteristics	O
of	O
the	O
serotonin	B-GP
(	I-GP
5-HT	I-GP
)	I-GP
1B	I-GP
receptor	E-GP
defined	O
by	O
[	B-chemical
125I	I-chemical
]	I-chemical
iodocyanopindolol	E-chemical
[	B-chemical
(	I-chemical
125I	I-chemical
]	I-chemical
ICYP	I-chemical
)	E-chemical
binding	O
and	O
the	O
5-HT	B-GP
autoreceptor	E-GP
defined	O
by	O
inhibition	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-5-HT	E-chemical
release	O
.	O
In	O
Percoll	O
gradient	O
Fractions	O
3	O
and	O
4	O
of	O
spinal	O
cord	O
synaptosomes	O
,	O
a	O
single	O
saturable	O
binding	O
site	O
for	O
[	B-chemical
125I	I-chemical
]	I-chemical
ICYP	E-chemical
with	O
a	O
maximum	O
binding	O
of	O
70	O
and	O
134	O
fmol/mg	O
,	O
respectively	O
,	O
was	O
demonstrated	O
in	O
the	O
presence	O
of	O
30	O
microM	O
isoproterenol	S-chemical
.	O
The	O
Kd	O
of	O
0.16	O
nM	O
did	O
not	O
vary	O
between	O
fractions	O
.	O
Competition	O
for	O
[	B-chemical
125I	I-chemical
]	I-chemical
ICYP	E-chemical
binding	O
by	O
various	O
5-HT	S-chemical
agonists	O
and	O
antagonists	O
also	O
indicated	O
a	O
single	O
site	O
model	O
based	O
on	O
a	O
Hill	O
coefficient	O
of	O
approximately	O
1.0	O
.	O
The	O
most	O
potent	O
compounds	O
at	O
displacing	O
[	B-chemical
125I	I-chemical
]	I-chemical
ICYP	E-chemical
binding	O
were	O
RU	B-chemical
24969	E-chemical
(	O
5-methoxy-3-	B-chemical
[	I-chemical
1,2,3,6-tetrahydropyridin-4-yl	I-chemical
]	I-chemical
-1H-indole	E-chemical
)	O
,	O
5-carboxyamidotryptamine	B-chemical
HCl	E-chemical
,	O
5-methoxytryptamine	S-chemical
,	O
5-HT	S-chemical
and	O
CGS	B-chemical
12066B	E-chemical
(	O
7-trifluoromethyl-4	B-chemical
(	I-chemical
4	I-chemical
methyl-1-pyrolo	I-chemical
[	I-chemical
1,2-a	I-chemical
]	I-chemical
-quinoxaline	I-chemical
malate	E-chemical
)	O
.	O
[	B-chemical
125I	I-chemical
]	I-chemical
ICYP	E-chemical
binding	O
was	O
not	O
altered	O
by	O
compounds	O
with	O
activity	O
at	O
5-HT1A	S-GP
,	O
5-HT1C	S-GP
,	O
5-HT2	S-GP
,	O
5-HT3	S-GP
or	O
alpha-2	O
receptor	O
sites	O
.	O
Similar	O
to	O
the	O
pharmacological	O
characteristics	O
of	O
the	O
5HT1B	S-GP
site	O
defined	O
by	O
[	B-chemical
125I	I-chemical
]	I-chemical
ICYP	E-chemical
,	O
compounds	O
most	O
active	O
at	O
inhibiting	O
15	O
mM	O
K	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-stimulated	O
release	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-5-HT	E-chemical
were	O
RU24969	S-chemical
=	O
5-carboxyamidotryptamine	S-chemical
HCl	S-chemical
=	O
CGS	B-chemical
12066B	E-chemical
greater	O
than	O
5-methoxytryptamine	S-chemical
greater	O
than	O
5-HT	S-chemical
.	O
Compounds	O
with	O
activity	O
at	O
5-HT1A	S-GP
,	O
5-HT1C	S-GP
,	O
5-HT2	S-GP
or	O
5-HT3	S-GP
sites	O
were	O
inactive	O
.	O
A	O
correlation	O
analysis	O
of	O
selective	O
5-HT1B	S-GP
compounds	O
comparing	O
the	O
pKD	O
for	O
displacement	O
of	O
[	B-chemical
125I	I-chemical
]	I-chemical
ICYP	E-chemical
vs.	O
the	O
IC50	O
for	O
inhibition	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-5-HT	E-chemical
release	O
demonstrated	O
the	O
pharmacological	O
similarity	O
of	O
the	O
presynaptic	O
inhibitory	O
5-HT	B-GP
autoreceptor	E-GP
and	O
the	O
5-HT	B-GP
receptor	E-GP
site	O
defined	O
by	O
[	B-chemical
125I	I-chemical
]	I-chemical
ICYP	E-chemical
binding	O
in	O
spinal	O
cord	O
synaptosomes	O
(	O
r	O
=	O
0.791	O
,	O
P	O
=	O
.0193	O
)	O
.	O
Although	O
[	B-chemical
125I	I-chemical
]	I-chemical
ICYP	E-chemical
binding	O
was	O
unaltered	O
,	O
alpha-2	O
agonists	O
such	O
as	O
clonidine	S-chemical
,	O
norepinephrine	S-chemical
and	O
UK	B-chemical
14304	E-chemical
[	B-chemical
5-bromo-6-	I-chemical
[	I-chemical
2-imidazolin-2-ylamino	I-chemical
]	I-chemical
-quinoxaline	E-chemical
)	O
as	O
well	O
as	O
the	O
alpha-2	O
antagonists	O
rauwolscine	S-chemical
and	O
yohimbine	S-chemical
also	O
decreased	O
the	O
K	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-stimulated	O
release	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-5-HT	E-chemical
and	O
phentolamine	S-chemical
,	O
an	O
alpha-2	O
antagonist	O
increased	O
release	O
.	O
The	O
action	O
of	O
these	O
alpha-2	O
compounds	O
to	O
alter	O
[	B-chemical
3H	I-chemical
]	I-chemical
-5-HT	E-chemical
release	O
suggests	O
the	O
presence	O
of	O
heteroreceptors	O
localized	O
on	O
5-HT	S-chemical
terminals	O
in	O
the	O
spinal	O
cord	O
.	O
These	O
results	O
point	O
out	O
that	O
[	B-chemical
125I	I-chemical
]	I-chemical
ICYP	E-chemical
identifies	O
the	O
5-HT1B	S-GP
receptor	O
,	O
and	O
affinity	O
of	O
compounds	O
for	O
this	O
site	O
predicts	O
action	O
at	O
the	O
5-HT1B	S-GP
autoreceptor	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Chemical	O
genetic	O
analyses	O
of	O
quantitative	O
changes	O
in	O
Cdk1	S-GP
activity	O
during	O
the	O
human	O
cell	O
cycle	O
.	O
Cyclin-dependent	B-GP
kinase	I-GP
1	E-GP
(	O
Cdk1	S-GP
)	O
controls	O
cell	O
proliferation	O
and	O
is	O
inhibited	O
by	O
promising	O
anticancer	O
agents	O
,	O
but	O
its	O
mode	O
of	O
action	O
and	O
the	O
consequences	O
of	O
its	O
inhibition	O
are	O
incompletely	O
understood	O
.	O
Cdk1	S-GP
promotes	O
S-	O
and	O
M-phases	O
during	O
the	O
cell-cycle	O
but	O
also	O
suppresses	O
endoreduplication	O
,	O
which	O
is	O
associated	O
with	O
polyploidy	O
and	O
genome	O
instability	O
.	O
The	O
complexity	O
of	O
Cdk1	S-GP
regulation	O
has	O
made	O
it	O
difficult	O
to	O
determine	O
whether	O
these	O
different	O
roles	O
require	O
different	O
thresholds	O
of	O
kinase	S-GP
activity	O
and	O
whether	O
the	O
surge	O
of	O
activity	O
as	O
inhibitory	O
phosphates	S-chemical
are	O
removed	O
at	O
mitotic	O
onset	O
is	O
essential	O
for	O
cell	O
proliferation	O
.	O
Here	O
,	O
we	O
have	O
used	O
chemical	O
genetics	O
in	O
a	O
human	O
cell	O
line	O
to	O
address	O
these	O
issues	O
.	O
We	O
rescued	O
cells	O
lethally	O
depleted	O
of	O
endogenous	O
Cdk1	S-GP
with	O
an	O
exogenous	O
Cdk1	S-GP
conferring	O
sensitivity	O
to	O
one	O
ATP	S-chemical
analogue	O
inhibitor	O
(	O
1NMPP1	S-chemical
)	O
and	O
resistance	O
to	O
another	O
(	O
RO3306	S-chemical
)	O
.	O
At	O
no	O
1NMPP1	S-chemical
concentration	O
was	O
mitosis	O
in	O
rescued	O
clones	O
prevented	O
without	O
also	O
inducing	O
endoreduplication	O
,	O
suggesting	O
that	O
these	O
two	O
key	O
roles	O
for	O
Cdk1	S-GP
are	O
not	O
simply	O
controlled	O
by	O
different	O
Cdk1	S-GP
activity	O
thresholds	O
.	O
We	O
also	O
rescued	O
RO3306	S-chemical
-resistant	O
clones	O
using	O
exogenous	O
Cdk1	S-GP
without	O
inhibitory	O
phosphorylation	O
sites	O
,	O
indicating	O
that	O
the	O
mitotic	O
surge	O
of	O
Cdk1	S-GP
activity	O
is	O
dispensable	O
for	O
cell	O
proliferation	O
.	O
These	O
results	O
suggest	O
that	O
the	O
basic	O
mammalian	O
cycle	O
requires	O
at	O
least	O
some	O
qualitative	O
changes	O
in	O
Cdk1	S-GP
activity	O
and	O
that	O
quantitative	O
increases	O
in	O
activity	O
need	O
not	O
be	O
rapid	O
.	O
Furthermore	O
,	O
the	O
viability	O
of	O
cells	O
that	O
are	O
unable	O
to	O
undergo	O
rapid	O
Cdk1	S-GP
activation	O
,	O
and	O
the	O
strong	O
association	O
between	O
endoreduplication	O
and	O
impaired	O
proliferation	O
,	O
may	O
place	O
restrictions	O
on	O
the	O
therapeutic	O
use	O
of	O
a	O
Cdk1	S-GP
inhibitors	O
.	O

A	O
potent	O
Chk1	S-GP
inhibitor	O
is	O
selectively	O
cytotoxic	O
in	O
melanomas	O
with	O
high	O
levels	O
of	O
replicative	O
stress	O
.	O
There	O
are	O
few	O
effective	O
treatments	O
for	O
metastatic	O
melanoma	O
.	O
Checkpoint	B-GP
kinase	I-GP
1	E-GP
(	O
Chk1	S-GP
)	O
inhibitors	O
are	O
being	O
trialled	O
for	O
their	O
efficacy	O
in	O
enhancing	O
conventional	O
chemotherapeutic	O
agents	O
,	O
but	O
their	O
effectiveness	O
as	O
single	O
agents	O
is	O
not	O
known	O
.	O
We	O
have	O
examined	O
the	O
effectiveness	O
of	O
two	O
novel	O
Chk1	S-GP
selective	O
inhibitors	O
,	O
AR323	S-chemical
and	O
AR678	S-chemical
,	O
in	O
a	O
panel	O
of	O
melanoma	O
cell	O
lines	O
and	O
normal	O
cell	O
types	O
.	O
We	O
demonstrate	O
that	O
these	O
drugs	O
display	O
single-agent	O
activity	O
,	O
with	O
IC50s	O
in	O
the	O
low	O
nanomolar	O
range	O
.	O
The	O
drugs	O
produce	O
cytotoxic	O
effects	O
in	O
cell	O
lines	O
that	O
are	O
most	O
sensitive	O
to	O
these	O
drugs	O
,	O
whereas	O
normal	O
cells	O
are	O
only	O
sensitive	O
to	O
these	O
drugs	O
at	O
the	O
higher	O
concentrations	O
where	O
they	O
have	O
cytostatic	O
activity	O
.	O
The	O
cytotoxic	O
effect	O
is	O
the	O
consequence	O
of	O
inhibition	O
of	O
S-phase	O
Chk1	S-GP
,	O
which	O
drives	O
cells	O
prematurely	O
from	O
late	O
S	O
phase	O
into	O
an	O
aberrant	O
mitosis	O
and	O
results	O
in	O
either	O
failure	O
of	O
cytokinesis	O
or	O
cell	O
death	O
through	O
an	O
apoptotic	O
mechanism	O
.	O
The	O
sensitivity	O
to	O
the	O
Chk1	S-GP
inhibitors	O
was	O
correlated	O
with	O
the	O
level	O
of	O
endogenous	O
DNA	O
damage	O
indicating	O
replicative	O
stress	O
.	O
Chk1	S-GP
inhibitors	O
are	O
viable	O
single-agent	O
therapies	O
that	O
target	O
melanoma	O
cells	O
with	O
high	O
levels	O
of	O
endogenous	O
DNA	O
damage	O
.	O
This	O
sensitivity	O
suggests	O
that	O
Chk1	S-GP
is	O
a	O
critical	O
component	O
of	O
an	O
adaptation	O
to	O
replicative	O
stress	O
in	O
these	O
cells	O
.	O
It	O
also	O
suggests	O
that	O
markers	O
of	O
DNA	O
damage	O
may	O
be	O
useful	O
in	O
identifying	O
the	O
melanomas	O
and	O
potentially	O
other	O
tumour	O
types	O
that	O
are	O
more	O
likely	O
to	O
be	O
sensitive	O
to	O
Chk1	S-GP
inhibitors	O
as	O
single	O
agents	O
.	O

Novel	O
racemic	O
tetrahydrocurcuminoid	B-chemical
dihydropyrimidinone	E-chemical
analogues	O
as	O
potent	O
acetylcholinesterase	S-GP
inhibitors	O
.	O
The	O
synthesis	O
of	O
racemic	O
tetrahydrocurcumin	S-chemical
-	O
(	O
THC	S-chemical
-	O
)	O
,	O
tetrahydrodemethoxycurcumin	S-chemical
-	O
(	O
THDC	S-chemical
-	O
)	O
and	O
tetrahydrobisdemethoxycurcumin	S-chemical
-	O
(	O
THBDC	S-chemical
-	O
)	O
dihydropyrimidinone	S-chemical
(	O
DHPM	S-chemical
)	O
analogues	O
was	O
achieved	O
by	O
utilizing	O
the	O
multi-component	O
Biginelli	O
reaction	O
in	O
the	O
presence	O
of	O
copper	B-chemical
sulphate	E-chemical
as	O
a	O
catalyst	O
.	O
The	O
evaluation	O
of	O
acetylcholinesterase	S-GP
inhibitors	O
for	O
Alzheimer	O
's	O
disease	O
of	O
these	O
compounds	O
showed	O
that	O
they	O
exhibited	O
higher	O
inhibitory	O
activity	O
than	O
their	O
parent	O
analogues	O
.	O
THBDC-DHPM	S-chemical
demonstrated	O
the	O
most	O
potent	O
inhibitory	O
activity	O
with	O
an	O
IC50	O
value	O
of	O
1.34±0.03μM	O
which	O
was	O
more	O
active	O
than	O
the	O
approved	O
drug	O
galanthamine	S-chemical
(	O
IC50=1.45±0.04μM	O
)	O
.	O

Anti-apoptotic	O
cardioprotective	O
effects	O
of	O
SHP-1	S-GP
gene	O
silencing	O
against	O
ischemia-reperfusion	O
injury	O
:	O
Use	O
of	O
deoxycholic	B-chemical
acid	E-chemical
-modified	O
low	O
molecular	O
weight	O
polyethyleneimine	S-chemical
as	O
a	O
cardiac	O
siRNA-carrier	O
.	O
The	O
cardiomyocyte	O
apoptosis	O
plays	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
myocardial	O
injury	O
after	O
ischemia	O
and	O
reperfusion	O
.	O
Thus	O
,	O
alteration	O
of	O
the	O
major	O
apoptosis-regulatory	O
factors	O
during	O
myocardial	O
ischemia-reperfusion	O
is	O
expected	O
to	O
have	O
favorable	O
cardioprotective	O
effects	O
.	O
Herein	O
,	O
we	O
report	O
ischemic-reperfused	O
myocardial	O
infarction	O
(	O
MI	O
)	O
repair	O
with	O
siRNA	O
against	O
Src	B-GP
homology	I-GP
region	I-GP
2	I-GP
domain-containing	I-GP
tyrosine	I-GP
phosphatase-1	E-GP
(	O
SHP-1	S-GP
)	O
,	O
which	O
is	O
known	O
as	O
a	O
key	O
factor	O
involved	O
in	O
regulating	O
the	O
progress	O
of	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O
A	O
low	O
molecular	O
weight	O
polyethyleneimine	S-chemical
modified	O
with	O
deoxycholic	B-chemical
acid	E-chemical
(	O
PEI1.8-DA	O
)	O
-based	O
delivery	O
strategy	O
was	O
suggested	O
for	O
the	O
cardiac	O
application	O
of	O
SHP-1	S-GP
siRNA	O
to	O
overcome	O
the	O
poor	O
gene	O
delivery	O
efficiency	O
to	O
myocardium	O
due	O
to	O
the	O
highly	O
charged	O
structures	O
of	O
the	O
compact	O
cardiac	O
muscles	O
.	O
The	O
PEI1.8-DA	O
conjugates	O
formed	O
stable	O
nanocomplexes	O
with	O
SHP-1	S-GP
siRNA	O
via	O
electrostatic	O
and	O
hydrophobic	O
interactions	O
.	O
The	O
PEI1.8-DA/	O
SHP-1	S-GP
siRNA	O
polyplexes	O
effectively	O
silenced	O
SHP-1	S-GP
gene	O
expression	O
in	O
cardiomyocytes	O
,	O
leading	O
to	O
a	O
significant	O
inhibition	O
of	O
cardiomyocyte	O
apoptosis	O
under	O
hypoxia	O
.	O
In	O
comparison	O
to	O
conventional	O
gene	O
carriers	O
,	O
relatively	O
large	O
amounts	O
of	O
siRNA	O
molecules	O
remained	O
after	O
treatment	O
with	O
the	O
PEI1.8-DA/	O
SHP-1	S-GP
siRNA	O
polyplexes	O
.	O
Cardiac	O
administration	O
of	O
the	O
PEI1.8-DA/	O
SHP-1	S-GP
siRNA	O
polyplexes	O
resulted	O
in	O
substantial	O
improvement	O
in	O
SHP-1	S-GP
gene	O
silencing	O
,	O
which	O
can	O
be	O
explained	O
by	O
the	O
enhancement	O
of	O
cardiac	O
delivery	O
efficiency	O
of	O
the	O
PEI1.8-DA	O
conjugates	O
.	O
In	O
addition	O
,	O
in	O
vivo	O
treatment	O
with	O
the	O
PEI1.8-DA/	O
SHP-1	S-GP
siRNA	O
polyplexes	O
induced	O
a	O
highly	O
significant	O
reduction	O
in	O
myocardial	O
apoptosis	O
and	O
infarct	O
size	O
in	O
rat	O
MI	O
models	O
.	O
These	O
results	O
demonstrate	O
that	O
the	O
PEI1.8-DA/	O
SHP-1	S-GP
siRNA	O
polyplex	O
formulation	O
is	O
a	O
useful	O
system	O
for	O
efficient	O
gene	O
delivery	O
into	O
the	O
compact	O
myocardium	O
that	O
provides	O
a	O
fundamental	O
advantage	O
in	O
treating	O
ischemic-reperfused	O
MI	O
.	O

Phosphorylation	O
and	O
up-regulation	O
of	O
diacylglycerol	B-GP
kinase	I-GP
gamma	E-GP
via	O
its	O
interaction	O
with	O
protein	B-GP
kinase	I-GP
C	I-GP
gamma	E-GP
.	O
Diacylglycerol	S-chemical
(	O
DAG	S-chemical
)	O
acts	O
as	O
an	O
allosteric	O
activator	O
of	O
protein	B-GP
kinase	I-GP
C	E-GP
(	O
PKC	S-GP
)	O
and	O
is	O
converted	O
to	O
phosphatidic	B-chemical
acid	E-chemical
by	O
DAG	B-GP
kinase	E-GP
(	O
DGK	S-GP
)	O
.	O
Therefore	O
,	O
DGK	S-GP
is	O
thought	O
to	O
be	O
a	O
negative	O
regulator	O
of	O
PKC	S-GP
activation	O
.	O
Here	O
we	O
show	O
molecular	O
mechanisms	O
of	O
functional	O
coupling	O
of	O
the	O
two	O
kinases	S-GP
.	O
gammaPKC	S-GP
directly	O
associated	O
with	O
DGKgamma	S-GP
through	O
its	O
accessory	O
domain	O
(	O
AD	O
)	O
,	O
depending	O
on	O
Ca2+	S-chemical
as	O
well	O
as	O
phosphatidylserine	S-chemical
/	O
diolein	S-chemical
in	O
vitro	O
.	O
Mass	O
spectrometric	O
analysis	O
and	O
mutation	O
studies	O
revealed	O
that	O
gammaPKC	S-GP
phosphorylated	B-chemical
Ser	E-chemical
-776	O
and	O
Ser	S-chemical
-779	O
in	O
the	O
AD	O
of	O
DGKgamma	S-GP
.	O
The	O
phosphorylation	O
by	O
gammaPKC	S-GP
resulted	O
in	O
activation	O
of	O
DGKgamma	S-GP
because	O
a	O
DGKgamma	S-GP
mutant	O
in	O
which	O
Ser	S-chemical
-776	O
and	O
Ser	S-chemical
-779	O
were	O
substituted	O
with	O
glutamic	B-chemical
acid	E-chemical
to	O
mimic	O
phosphorylation	O
exhibited	O
significantly	O
higher	O
activity	O
compared	O
with	O
wild	O
type	O
DGKgamma	S-GP
and	O
an	O
unphosphorylatable	O
DGKgamma	S-GP
mutant	O
.	O
Importantly	O
,	O
the	O
interaction	O
of	O
the	O
two	O
kinases	S-GP
and	O
the	O
phosphorylation	O
of	O
DGKgamma	S-GP
by	O
gammaPKC	S-GP
could	O
be	O
confirmed	O
in	O
vivo	O
,	O
and	O
overexpression	O
of	O
the	O
AD	O
of	O
DGKgamma	S-GP
inhibited	O
re-translocation	O
of	O
gammaPKC	S-GP
.	O
These	O
results	O
demonstrate	O
that	O
localization	O
and	O
activation	O
of	O
the	O
functionally	O
correlated	O
kinases	S-GP
,	O
gammaPKC	S-GP
and	O
DGKgamma	S-GP
,	O
are	O
spatio-temporally	O
orchestrated	O
by	O
their	O
direct	O
association	O
and	O
phosphorylation	O
,	O
contributing	O
to	O
subtype-specific	O
regulation	O
of	O
DGKgamma	S-GP
and	O
DAG	O
signaling	O
.	O

Retigabine	S-chemical
,	O
a	O
novel	O
anti-convulsant	O
,	O
enhances	O
activation	O
of	O
KCNQ2/Q3	S-GP
potassium	B-GP
channels	E-GP
.	O
Retigabine	S-chemical
[	O
N-	B-chemical
(	I-chemical
2-amino-4-	I-chemical
[	I-chemical
fluorobenzylamino	I-chemical
]	I-chemical
-phenyl	I-chemical
)	I-chemical
carbamic	I-chemical
acid	E-chemical
;	O
D-23129	S-chemical
]	O
is	O
a	O
novel	O
anticonvulsant	O
,	O
unrelated	O
to	O
currently	O
available	O
antiepileptic	O
agents	O
,	O
with	O
activity	O
in	O
a	O
broad	O
range	O
of	O
seizure	O
models	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
retigabine	O
could	O
enhance	O
current	O
through	O
M-like	O
currents	O
in	O
PC12	O
cells	O
and	O
KCNQ2/Q3	S-GP
K	B-GP
(	I-GP
+	I-GP
)	I-GP
channels	E-GP
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
(	O
CHO-	O
KCNQ2/Q3	S-GP
)	O
.	O
In	O
differentiated	O
PC12	O
cells	O
,	O
retigabine	O
enhanced	O
a	O
linopirdine	S-chemical
-sensitive	O
current	O
.	O
The	O
effect	O
of	O
retigabine	S-chemical
was	O
associated	O
with	O
a	O
slowing	O
of	O
M-like	O
tail	O
current	O
deactivation	O
in	O
these	O
cells	O
.	O
Retigabine	S-chemical
(	O
0.1	O
to	O
10	O
microM	O
)	O
induced	O
a	O
potassium	S-chemical
current	O
and	O
hyperpolarized	O
CHO	O
cells	O
expressing	O
KCNQ2/Q3	S-GP
cells	O
but	O
not	O
in	O
wild-type	O
cells	O
.	O
Retigabine	S-chemical
-induced	O
currents	O
in	O
CHO-	O
KCNQ2/Q3	S-GP
cells	O
were	O
inhibited	O
by	O
60.6	O
+/-	O
11	O
%	O
(	O
n	O
=	O
4	O
)	O
by	O
the	O
KCNQ2/Q3	S-GP
blocker	O
,	O
linopirdine	S-chemical
(	O
10	O
microM	O
)	O
,	O
and	O
82.7	O
+/-	O
5.4	O
%	O
(	O
n	O
=	O
4	O
)	O
by	O
BaCl	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
(	O
10	O
mM	O
)	O
.	O
The	O
mechanism	O
by	O
which	O
retigabine	S-chemical
enhanced	O
KCNQ2/Q3	S-GP
currents	O
involved	O
large	O
,	O
drug-induced	O
,	O
leftward	O
shifts	O
in	O
the	O
voltage	O
dependence	O
of	O
channel	O
activation	O
(	O
-33.1	O
+/-	O
2.6	O
mV	O
,	O
n	O
=	O
4	O
,	O
by	O
10	O
microM	O
retigabine	S-chemical
)	O
.	O
Retigabine	S-chemical
shifted	O
the	O
voltage	O
dependence	O
of	O
channel	O
activation	O
with	O
an	O
EC	O
(	O
50	O
)	O
value	O
of	O
1.6	O
+/-	O
0.3	O
microM	O
(	O
slope	O
factor	O
was	O
1.2	O
+/-	O
0.1	O
,	O
n	O
=	O
4	O
to	O
5	O
cells	O
per	O
concentration	O
)	O
.	O
Retigabine	S-chemical
(	O
0.1	O
to	O
10	O
microM	O
)	O
also	O
slowed	O
the	O
rate	O
of	O
channel	O
deactivation	O
,	O
predominantly	O
by	O
increasing	O
the	O
contribution	O
of	O
a	O
slowly	O
deactivating	O
tail	O
current	O
component	O
.	O
Our	O
findings	O
identify	O
KCNQ2/Q3	S-GP
channels	O
as	O
a	O
molecular	O
target	O
for	O
retigabine	S-chemical
and	O
suggest	O
that	O
activation	O
of	O
KCNQ2/Q3	S-GP
channels	O
may	O
be	O
responsible	O
for	O
at	O
least	O
some	O
of	O
the	O
anticonvulsant	O
activity	O
of	O
this	O
agent	O
.	O

The	O
use	O
of	O
antioxidant	O
enzymes	O
in	O
freshwater	O
biofilms	O
:	O
Temporal	O
variability	O
vs.	O
toxicological	O
responses	O
.	O
This	O
study	O
aims	O
to	O
investigate	O
the	O
potential	O
of	O
antioxidant	O
enzyme	O
activities	O
(	O
AEA	O
)	O
as	O
biomarkers	O
of	O
oxidative	O
stress	O
in	O
freshwater	O
biofilms	O
.	O
Therefore	O
,	O
biofilms	O
were	O
grown	O
in	O
channels	O
for	O
38	O
days	O
and	O
then	O
exposed	O
to	O
different	O
concentrations	O
(	O
0-150μgL	O
(	O
-1	O
)	O
)	O
of	O
the	O
herbicide	O
oxyfluorfen	S-chemical
for	O
5	O
more	O
weeks	O
.	O
Under	O
control	O
conditions	O
,	O
the	O
AEA	O
of	O
biofilms	O
were	O
found	O
to	O
change	O
throughout	O
time	O
with	O
a	O
significant	O
increase	O
in	O
ascorbate	B-GP
peroxidase	E-GP
(	O
APX	S-GP
)	O
activity	O
during	O
the	O
exponential	O
growth	O
and	O
a	O
more	O
important	O
role	O
of	O
catalase	S-GP
(	O
CAT	S-GP
)	O
and	O
glutathione	B-GP
reductase	E-GP
(	O
GR	S-GP
)	O
activities	O
during	O
the	O
slow	O
growth	O
phase	O
.	O
Chronic	O
exposure	O
to	O
oxyfluorfen	S-chemical
led	O
to	O
slight	O
variations	O
in	O
AEA	O
,	O
however	O
,	O
the	O
ranges	O
of	O
variability	O
of	O
AEA	O
in	O
controls	O
and	O
exposed	O
communities	O
were	O
similar	O
,	O
highlighting	O
the	O
difficulty	O
of	O
a	O
direct	O
interpretation	O
of	O
AEA	O
values	O
.	O
After	O
5	O
weeks	O
of	O
exposure	O
to	O
oxyfluorfen	S-chemical
,	O
no	O
clear	O
effects	O
were	O
observed	O
on	O
chl-a	S-chemical
concentration	O
or	O
on	O
the	O
composition	O
of	O
other	O
pigments	O
suggesting	O
that	O
algal	O
group	O
composition	O
was	O
not	O
affected	O
.	O
Eukaryotic	O
communities	O
were	O
structured	O
clearly	O
by	O
toxicant	O
concentration	O
and	O
both	O
eukaryotic	O
and	O
bacterial	O
richness	O
were	O
reduced	O
in	O
communities	O
exposed	O
to	O
the	O
highest	O
concentration	O
.	O
In	O
addition	O
,	O
during	O
acute	O
exposure	O
tests	O
performed	O
at	O
the	O
end	O
of	O
the	O
chronic	O
exposure	O
,	O
biofilms	O
chronically	O
exposed	O
to	O
75	O
and	O
150μgL	O
(	O
-1	O
)	O
oxyfluorfen	S-chemical
showed	O
a	O
higher	O
CAT	S-GP
activity	O
than	O
controls	O
.	O
Chronic	O
exposure	O
to	O
oxyfluorfen	S-chemical
provoked	O
then	O
structural	O
changes	O
but	O
also	O
functional	O
changes	O
in	O
the	O
capacity	O
of	O
biofilm	O
CAT	S-GP
activity	O
to	O
respond	O
to	O
a	O
sudden	O
increase	O
in	O
concentration	O
,	O
suggesting	O
a	O
selection	O
of	O
species	O
with	O
higher	O
antioxidant	O
capacity	O
.	O
This	O
study	O
highlighted	O
the	O
difficulty	O
of	O
interpretation	O
of	O
AEA	O
values	O
due	O
to	O
their	O
temporal	O
variation	O
and	O
to	O
the	O
absence	O
of	O
absolute	O
threshold	O
value	O
indicative	O
of	O
oxidative	O
stress	O
induced	O
by	O
contaminants	O
.	O
Nevertheless	O
,	O
the	O
determination	O
of	O
AEA	O
pattern	O
throughout	O
acute	O
exposure	O
test	O
is	O
of	O
high	O
interest	O
to	O
compare	O
oxidative	O
stress	O
levels	O
undergone	O
by	O
different	O
biofilm	O
communities	O
and	O
thus	O
determine	O
their	O
antioxidant	O
capacity	O
.	O

Quercetin	S-chemical
-loaded	O
microcapsules	O
ameliorate	O
experimental	O
colitis	O
in	O
mice	O
by	O
anti-inflammatory	O
and	O
antioxidant	O
mechanisms	O
.	O
Quercetin	S-chemical
(	O
1	O
)	O
is	O
an	O
anti-inflammatory	O
and	O
antioxidant	O
flavonoid	S-chemical
.	O
However	O
,	O
the	O
oral	O
administration	O
of	O
1	O
did	O
not	O
lead	O
to	O
beneficial	O
effects	O
in	O
experimental	O
animal	O
colitis	O
models	O
,	O
which	O
involve	O
cytokines	S-GP
and	O
oxidative	O
stress	O
.	O
A	O
possible	O
explanation	O
is	O
that	O
the	O
absorption	O
profile	O
of	O
1	O
prevents	O
its	O
activity	O
.	O
Therefore	O
,	O
it	O
was	O
reasoned	O
that	O
the	O
controlled	O
release	O
of	O
1	O
would	O
improve	O
its	O
therapeutic	O
effect	O
.	O
Thus	O
,	O
the	O
therapeutic	O
effect	O
and	O
mechanisms	O
of	O
1-loaded	O
microcapsules	O
in	O
acetic	B-chemical
acid	E-chemical
-induced	O
colitis	O
in	O
mice	O
were	O
evaluated	O
.	O
Microcapsules	O
were	O
prepared	O
using	O
pectin/	O
casein	S-GP
polymer	O
and	O
1	O
.	O
The	O
oral	O
administration	O
of	O
1-loaded	O
microcapsules	O
decreased	O
neutrophil	O
recruitment	O
,	O
attenuated	O
histological	O
alterations	O
,	O
and	O
reduced	O
macroscopical	O
damage	O
,	O
edema	O
,	O
and	O
IL-1β	S-GP
and	O
IL-33	S-GP
production	O
in	O
the	O
colon	O
samples	O
.	O
Microcapsules	O
loaded	O
with	O
1	O
also	O
prevented	O
the	O
reduction	O
of	O
anti-inflammatory	O
cytokine	S-GP
IL-10	S-GP
and	O
the	O
antioxidant	O
capacity	O
of	O
the	O
colon	O
.	O
These	O
preclinical	O
data	O
indicate	O
that	O
pectin/	O
casein	S-GP
polymer	O
microcapsules	O
loaded	O
with	O
1	O
improved	O
the	O
anti-inflammatory	O
and	O
antioxidant	O
effects	O
of	O
1	O
compared	O
to	O
the	O
nonencapsulated	O
drug	O
.	O
Therefore	O
,	O
quercetin	S-chemical
seems	O
to	O
be	O
a	O
promising	O
active	O
molecule	O
in	O
inflammatory	O
bowel	O
disease	O
if	O
provided	O
with	O
adequate	O
controlled	O
release	O
.	O

The	O
pre-clinical	O
absorption	O
,	O
distribution	O
,	O
metabolism	O
and	O
excretion	O
properties	O
of	O
IPI-926	S-chemical
,	O
an	O
orally	O
bioavailable	O
antagonist	O
of	O
the	O
hedgehog	O
signal	O
transduction	O
pathway	O
.	O
Abstract	O
1	O
.	O
IPI-926	S-chemical
is	O
a	O
novel	O
semisynthetic	O
cyclopamine	S-chemical
derivative	O
that	O
is	O
a	O
potent	O
and	O
selective	O
Smoothened	O
inhibitor	O
that	O
blocks	O
the	O
hedgehog	O
signal	O
transduction	O
pathway	O
.	O
2	O
.	O
The	O
in	O
vivo	O
clearance	O
of	O
IPI-926	S-chemical
is	O
low	O
in	O
mouse	O
and	O
dog	O
and	O
moderate	O
in	O
monkey	O
.	O
The	O
volume	O
of	O
distribution	O
is	O
high	O
across	O
species	O
.	O
Oral	O
bioavailability	O
ranges	O
from	O
moderate	O
in	O
monkey	O
to	O
high	O
in	O
mouse	O
and	O
dog	O
.	O
Predicted	O
human	O
clearance	O
using	O
simple	O
allometry	O
is	O
low	O
(	O
24	O
L	O
h	O
(	O
-1	O
)	O
)	O
,	O
predicted	O
volume	O
of	O
distribution	O
is	O
high	O
(	O
469	O
L	O
)	O
and	O
predicted	O
half-life	O
is	O
long	O
(	O
20	O
h	O
)	O
.	O
3	O
.	O
IPI-926	S-chemical
is	O
highly	O
bound	O
to	O
plasma	O
proteins	O
and	O
has	O
minimal	O
interaction	O
with	O
human	B-GP
α-1-acid	I-GP
glycoprotein	E-GP
.	O
4	O
.	O
In	O
vitro	O
metabolic	O
stability	O
ranges	O
from	O
stable	O
to	O
moderately	O
stable	O
.	O
Twelve	O
oxidative	O
metabolites	O
were	O
detected	O
in	O
mouse	O
,	O
rat	O
,	O
dog	O
,	O
monkey	O
and	O
human	O
liver	O
microsome	O
incubations	O
and	O
none	O
were	O
unique	O
to	O
human	O
.	O
5	O
.	O
IPI-926	S-chemical
is	O
not	O
a	O
potent	O
reversible	O
inhibitor	O
of	O
CYP1A2	B-GP
,	I-GP
2C8	I-GP
,	I-GP
2C9	I-GP
or	I-GP
3A4	E-GP
(	O
testosterone	S-chemical
)	O
.	O
IPI-926	S-chemical
is	O
a	O
moderate	O
inhibitor	O
of	O
CYP2C19	B-GP
,	I-GP
2D6	I-GP
and	I-GP
3A4	E-GP
(	O
midazolam	S-chemical
)	O
with	O
KI	O
values	O
of	O
19	O
,	O
16	O
and	O
4.5	O
µM	O
,	O
respectively	O
.	O
IPI-926	S-chemical
is	O
both	O
a	O
substrate	O
and	O
inhibitor	O
(	O
IC50	O
=	O
1.9	O
µM	O
)	O
of	O
P-glycoprotein	S-GP
.	O
6	O
.	O
In	O
summary	O
,	O
IPI-926	S-chemical
has	O
desirable	O
pre-clinical	O
absorption	O
,	O
distribution	O
,	O
metabolism	O
and	O
excretion	O
properties	O
.	O

What	O
are	O
the	O
physiological	O
estrogens	S-chemical
?	O
Estradiol	S-chemical
(	O
E2	O
)	O
is	O
the	O
principal	O
physiological	O
estrogen	O
in	O
mammals	O
.	O
E2	O
and	O
its	O
active	O
metabolites	O
,	O
estrone	S-chemical
and	O
estriol	S-chemical
have	O
a	O
characteristic	O
phenolic	O
A	O
ring	O
,	O
unlike	O
progesterone	S-chemical
,	O
testosterone	S-chemical
,	O
cortisol	S-chemical
and	O
aldosterone	S-chemical
,	O
which	O
have	O
an	O
A	O
ring	O
containing	O
a	O
C3-	O
ketone	S-chemical
,	O
a	O
Δ	O
(	O
4	O
)	O
bond	O
and	O
a	O
C19	O
methyl	S-chemical
group	O
.	O
Crystal	O
structures	O
of	O
E2	O
in	O
the	O
estrogen	B-GP
receptor	E-GP
(	O
ER	S-GP
)	O
confirm	O
the	O
importance	O
of	O
the	O
A	O
ring	O
in	O
stabilizing	O
E2	O
in	O
the	O
ER	S-GP
.	O
However	O
,	O
other	O
steroids	S-chemical
,	O
including	O
Δ	B-chemical
(	I-chemical
5	I-chemical
)	I-chemical
-androstenediol	E-chemical
,	O
5α-androstanediol	S-chemical
and	O
27-hydroxycholesterol	S-chemical
,	O
which	O
have	O
a	O
saturated	O
A	O
ring	O
containing	O
a	O
3β-hydroxyl	S-chemical
and	O
a	O
C19	O
methyl	S-chemical
group	O
,	O
also	O
mediate	O
physiological	O
responses	O
through	O
binding	O
to	O
estrogen	B-GP
receptor-α	E-GP
(	O
ERα	S-GP
)	O
and	O
ERβ	S-GP
.	O
Moreover	O
,	O
selective	O
estrogen	S-chemical
response	O
modulators	O
(	O
SERMs	O
)	O
with	O
diverse	O
structures	O
also	O
regulate	O
transcription	O
of	O
ERα	S-GP
and	O
ERβ	S-GP
.	O
Our	O
understanding	O
of	O
the	O
physiological	O
responses	O
mediated	O
by	O
these	O
``	O
alternative	O
''	O
estrogens	S-chemical
is	O
in	O
its	O
infancy	O
.	O
Further	O
studies	O
of	O
the	O
role	O
of	O
these	O
steroids	S-chemical
and	O
SERMs	O
in	O
regulating	O
responses	O
mediated	O
by	O
ERα	S-GP
and	O
ERβ	S-GP
a	O
variety	O
of	O
tissues	O
,	O
during	O
different	O
stages	O
of	O
development	O
,	O
are	O
likely	O
to	O
uncover	O
additional	O
estrogenic	O
activities	O
.	O

The	O
conserved	O
PHD1-PHD2	B-GP
domain	E-GP
of	O
ZFP-1	S-GP
/	O
AF10	S-GP
is	O
a	O
discrete	O
functional	O
module	O
essential	O
for	O
viability	O
in	O
Caenorhabditis	O
elegans	O
.	O
Plant	B-GP
homeodomain	I-GP
(	I-GP
PHD	I-GP
)	I-GP
-type	I-GP
zinc	I-GP
fingers	E-GP
play	O
an	O
important	O
role	O
in	O
recognizing	O
chromatin	O
modifications	O
and	O
recruiting	O
regulatory	O
proteins	O
to	O
specific	O
genes	O
.	O
A	O
specific	O
module	O
containing	O
a	O
conventional	O
PHD	B-GP
finger	E-GP
followed	O
by	O
an	O
extended	O
PHD	B-GP
finger	E-GP
exists	O
in	O
the	O
mammalian	O
AF10	S-GP
protein	O
,	O
among	O
a	O
few	O
others	O
.	O
AF10	S-GP
has	O
mostly	O
been	O
studied	O
in	O
the	O
context	O
of	O
the	O
leukemic	O
MLL	S-GP
-	O
AF10	S-GP
fusion	O
protein	O
,	O
which	O
lacks	O
the	O
N-terminal	B-GP
PHD	I-GP
fingers	E-GP
of	O
AF10	S-GP
.	O
Although	O
this	O
domain	O
of	O
AF10	S-GP
is	O
the	O
most	O
conserved	O
region	O
of	O
the	O
protein	O
,	O
its	O
biological	O
significance	O
has	O
not	O
been	O
elucidated	O
.	O
In	O
this	O
study	O
,	O
we	O
used	O
genetic	O
and	O
biochemical	O
approaches	O
to	O
examine	O
the	O
PHD1-PHD2	S-GP
region	O
of	O
the	O
Caenorhabditis	O
elegans	O
ortholog	O
of	O
AF10	S-GP
,	O
zinc	B-GP
finger	I-GP
protein	I-GP
1	E-GP
(	O
ZFP-1	S-GP
)	O
.	O
We	O
demonstrate	O
that	O
the	O
PHD1-PHD2	S-GP
region	O
is	O
essential	O
for	O
viability	O
and	O
that	O
the	O
first	O
PHD	B-GP
finger	E-GP
contributes	O
to	O
the	O
preferred	O
binding	O
of	O
PHD1-PHD2	S-GP
to	O
lysine	S-chemical
4-methylated	O
histone	O
H3	O
tails	O
.	O
Moreover	O
,	O
we	O
show	O
that	O
ZFP-1	S-GP
localization	O
peaks	O
overlap	O
with	O
H3K4	O
methylation-enriched	O
promoters	O
of	O
actively	O
expressed	O
genes	O
genomewide	O
and	O
that	O
H3K4	O
methylation	O
is	O
important	O
for	O
ZFP-1	S-GP
localization	O
to	O
promoters	O
in	O
the	O
embryo	O
.	O
We	O
predict	O
that	O
the	O
essential	O
biological	O
role	O
of	O
the	O
PHD1-PHD2	S-GP
module	O
of	O
ZFP-1	S-GP
/	O
AF10	S-GP
is	O
connected	O
to	O
the	O
regulation	O
of	O
actively	O
expressed	O
genes	O
during	O
early	O
development	O
.	O

Localization	O
of	O
the	O
ammonium	B-GP
transporter	I-GP
proteins	E-GP
RhBG	S-GP
and	O
RhCG	S-GP
in	O
mouse	O
kidney	O
.	O
Ammonia	S-chemical
is	O
both	O
produced	O
and	O
transported	O
by	O
renal	O
epithelial	O
cells	O
,	O
and	O
it	O
regulates	O
renal	O
ion	O
transport	O
.	O
Recent	O
studies	O
have	O
identified	O
a	O
family	O
of	O
putative	O
ammonium	B-GP
transporters	E-GP
;	O
mRNA	O
for	O
two	O
members	O
of	O
this	O
family	O
,	O
Rh	B-GP
B-glycoprotein	E-GP
(	O
RhBG	S-GP
)	O
and	O
Rh	B-GP
C-glycoprotein	E-GP
(	O
RhCG	S-GP
)	O
,	O
is	O
expressed	O
in	O
the	O
kidney	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
cellular	O
location	O
of	O
RhBG	S-GP
and	O
RhCG	S-GP
protein	O
in	O
the	O
mouse	O
kidney	O
.	O
We	O
generated	O
RhBG	S-GP
-	O
and	O
RhCG	S-GP
-specific	O
anti-peptide	O
antibodies	O
.	O
Immunoblot	O
analysis	O
confirmed	O
that	O
both	O
proteins	O
were	O
expressed	O
in	O
the	O
mouse	O
kidney	O
.	O
RhBG	S-GP
localization	O
with	O
immunohistochemistry	O
revealed	O
discrete	O
basolateral	O
labeling	O
in	O
the	O
connecting	O
segment	O
(	O
CNT	O
)	O
and	O
in	O
the	O
majority	O
of	O
initial	O
collecting	O
tubule	O
(	O
ICT	O
)	O
and	O
cortical	O
collecting	O
duct	O
(	O
CCD	O
)	O
cells	O
.	O
In	O
the	O
outer	O
medullary	O
collecting	O
duct	O
(	O
OMCD	O
)	O
and	O
inner	O
medullary	O
collecting	O
duct	O
(	O
IMCD	O
)	O
only	O
a	O
subpopulation	O
of	O
cells	O
exhibited	O
basolateral	O
immunoreactivity	O
.	O
Colocalization	O
of	O
RhBG	S-GP
with	O
carbonic	B-GP
anhydrase	I-GP
II	E-GP
,	O
the	O
thiazide	S-chemical
-sensitive	O
transporter	O
,	O
and	O
the	O
anion	B-GP
exchangers	E-GP
AE1	S-GP
and	O
pendrin	S-GP
demonstrated	O
RhBG	S-GP
immunoreactivity	O
in	O
all	O
CNT	O
cells	O
and	O
all	O
CCD	O
and	O
ICT	O
principal	O
cells	O
.	O
In	O
the	O
ICT	O
and	O
CCD	O
,	O
basolateral	O
RhBG	S-GP
immunoreactivity	O
is	O
also	O
present	O
in	O
A-type	O
intercalated	O
cells	O
but	O
not	O
in	O
pendrin	S-GP
-positive	O
CCD	O
intercalated	O
cells	O
.	O
In	O
the	O
OMCD	O
and	O
IMCD	O
,	O
only	O
intercalated	O
cells	O
exhibit	O
RhBG	S-GP
immunoreactivity	O
.	O
Immunoreactivity	O
for	O
a	O
second	O
putative	O
ammonium	B-GP
transporter	E-GP
,	O
RhCG	S-GP
,	O
was	O
present	O
in	O
the	O
apical	O
region	O
of	O
cells	O
with	O
almost	O
the	O
same	O
distribution	O
as	O
RhBG	S-GP
.	O
However	O
,	O
RhCG	S-GP
immunoreactivity	O
was	O
present	O
in	O
all	O
CCD	O
cells	O
,	O
and	O
it	O
was	O
present	O
in	O
outer	O
stripe	O
OMCD	O
principal	O
cells	O
,	O
in	O
addition	O
to	O
OMCD	O
and	O
IMCD	O
intercalated	O
cells	O
.	O
Thus	O
the	O
majority	O
of	O
RhBG	S-GP
and	O
RhCG	S-GP
protein	O
expression	O
is	O
present	O
in	O
the	O
same	O
epithelial	O
cell	O
types	O
in	O
the	O
CNT	O
and	O
collecting	O
duct	O
but	O
with	O
opposite	O
polarity	O
.	O
These	O
findings	O
suggest	O
that	O
RhBG	S-GP
and	O
RhCG	S-GP
may	O
play	O
important	O
and	O
cell-specific	O
roles	O
in	O
ammonium	S-chemical
transport	O
and	O
signaling	O
in	O
these	O
regions	O
of	O
the	O
kidney	O
.	O

Identification	O
of	O
the	O
RLBP1	B-GP
gene	I-GP
promoter	E-GP
.	O
PURPOSE	O
:	O
Cellular	B-GP
retinaldehyde-binding	I-GP
protein	E-GP
(	O
CRALBP	S-GP
)	O
,	O
transcribed	O
from	O
the	O
RLBP1	S-GP
gene	O
,	O
is	O
a	O
36-kDa	B-GP
water-soluble	I-GP
protein	E-GP
with	O
316	O
amino	B-chemical
acids	E-chemical
found	O
in	O
the	O
retinal	S-chemical
pigment	O
epithelium	O
(	O
RPE	O
)	O
and	O
in	O
retinal	S-chemical
Muller	O
cells	O
.	O
It	O
is	O
thought	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
visual	O
cycle	O
by	O
functioning	O
as	O
an	O
acceptor	O
of	O
11-cis-retinol	S-chemical
from	O
the	O
isomerohydrolase	S-GP
reaction	O
.	O
The	O
goal	O
here	O
was	O
to	O
evaluate	O
the	O
functional	O
promoter	O
of	O
this	O
gene	O
.	O
METHODS	O
:	O
5	O
'	O
RACE	O
analysis	O
,	O
promoter-reporter	O
assays	O
,	O
and	O
semiquantitative	O
PCR	O
with	O
exon-specific	O
primers	O
were	O
performed	O
using	O
human-derived	O
RPE	O
cells	O
(	O
ARPE-19	O
and	O
D407	O
)	O
in	O
culture	O
to	O
evaluate	O
the	O
5	O
'	O
sequence	O
flanking	O
the	O
RLBP1	S-GP
gene	O
.	O
In	O
addition	O
,	O
the	O
murine	B-GP
,	I-GP
bovine	I-GP
,	I-GP
and	I-GP
porcine	I-GP
RLBP1	E-GP
genes	O
were	O
evaluated	O
in	O
silico	O
to	O
identify	O
likely	O
proximal	O
promoter/exon	O
1	O
sequences	O
similar	O
to	O
the	O
human	O
gene	O
.	O
RESULTS	O
:	O
5	O
'	O
RACE	O
analysis	O
revealed	O
the	O
presence	O
of	O
a	O
previously	O
undescribed	O
exon	O
in	O
the	O
RLBP1	S-GP
gene	O
.	O
This	O
was	O
confirmed	O
by	O
analysis	O
of	O
the	O
GenBank	O
Human	O
EST	O
database	O
,	O
which	O
revealed	O
the	O
presence	O
of	O
18	O
sequences	O
matching	O
exon	O
1	O
.	O
Exon-specific	O
PCR	O
revealed	O
that	O
most	O
CRALBP	S-GP
transcripts	O
expressed	O
in	O
ARPE-19	O
cells	O
contain	O
both	O
exon	O
1	O
and	O
the	O
final	O
exon	O
,	O
suggesting	O
that	O
the	O
primary	O
promoter	O
of	O
CRALBP	S-GP
exists	O
5	O
'	O
of	O
the	O
newly	O
identified	O
exon	O
1	O
.	O
Highly	O
homologous	O
sequences	O
in	O
the	O
murine	O
,	O
bovine	O
,	O
and	O
porcine	O
genes	O
were	O
also	O
identified	O
.	O
Finally	O
,	O
promoter-reporter	O
constructs	O
revealed	O
a	O
minimal	O
sequence	O
necessary	O
for	O
promoter	O
function	O
and	O
indicated	O
significantly	O
greater	O
promoter	O
activity	O
compared	O
with	O
previously	O
described	O
RLBP1	B-GP
promoters	E-GP
.	O
CONCLUSIONS	O
:	O
The	O
findings	O
presented	O
here	O
suggest	O
that	O
CRALBP	S-GP
transcripts	O
in	O
RPE	O
cells	O
contain	O
a	O
noncoding	O
exon	O
in	O
addition	O
to	O
a	O
newly	O
described	O
promoter	O
and	O
,	O
by	O
definition	O
,	O
an	O
additional	O
intron	O
.	O
This	O
finding	O
sets	O
the	O
stage	O
for	O
a	O
mechanistic	O
understanding	O
of	O
the	O
high	O
degree	O
of	O
cell	O
type-specific	O
expression	O
of	O
RLBP1	S-GP
.	O

Alteration	O
of	O
gastric	O
functions	O
and	O
candidate	O
genes	O
associated	O
with	O
weight	O
reduction	O
in	O
response	O
to	O
sibutramine	S-chemical
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
It	O
is	O
unclear	O
whether	O
weight	O
loss	O
with	O
the	O
noradrenergic	O
(	O
norepinephrine	S-chemical
)	O
and	O
serotonergic	O
(	O
5-hydroxytryptamine	S-chemical
)	O
reuptake	O
inhibitor	O
,	O
sibutramine	S-chemical
,	O
is	O
associated	O
with	O
altered	O
stomach	O
functions	O
and	O
whether	O
genetics	O
influence	O
treatment	O
response	O
.	O
METHODS	O
:	O
Forty-eight	O
overweight	O
and	O
obese	O
but	O
otherwise	O
healthy	O
participants	O
were	O
randomized	O
to	O
placebo	O
or	O
sibutramine	S-chemical
(	O
15	O
mg/day	O
for	O
12	O
weeks	O
)	O
.	O
At	O
baseline	O
and	O
posttreatment	O
we	O
measured	O
the	O
following	O
:	O
gastric	O
emptying	O
for	O
solids	O
and	O
liquids	O
by	O
scintigraphy	O
,	O
gastric	O
volumes	O
by	O
single-photon	O
emission	O
computed	O
tomography	O
,	O
maximum	O
tolerated	O
volume	O
and	O
30-minute	O
postnutrient	O
challenge	O
symptoms	O
,	O
and	O
selected	O
gastrointestinal	O
hormones	O
.	O
All	O
participants	O
received	O
structured	O
behavior	O
therapy	O
for	O
weight	O
management	O
.	O
The	O
influence	O
of	O
candidate	O
gene	O
polymorphisms	O
involved	O
in	O
norepinephrine	S-chemical
and	O
5-hydroxytryptamine	S-chemical
or	O
receptor	O
function	O
(	O
phenylethanolamine	S-chemical
N	S-chemical
-methyltransferase	O
,	O
guanine	B-GP
nucleotide	I-GP
binding	I-GP
protein	I-GP
beta	I-GP
polypeptide	I-GP
3	E-GP
,	O
alpha2A	B-GP
adrenoreceptor	E-GP
,	O
and	O
solute	B-GP
carrier	I-GP
family	I-GP
6	I-GP
[	I-GP
neurotransmitter	I-GP
transporter	I-GP
,	I-GP
serotonin	I-GP
]	I-GP
member	I-GP
4	E-GP
[	O
homo	O
sapiens	O
]	O
[	O
SLC6A4	S-GP
]	O
)	O
on	O
weight	O
loss	O
and	O
gastric	O
functions	O
was	O
evaluated	O
.	O
RESULTS	O
:	O
The	O
overall	O
average	O
weight	O
loss	O
posttreatment	O
was	O
5.4	O
+/-	O
0.8	O
(	O
SEM	O
)	O
kg	O
with	O
sibutramine	S-chemical
and	O
0.9	O
+/-	O
0.9	O
kg	O
with	O
placebo	O
(	O
P	O
<	O
.001	O
)	O
.	O
The	O
sibutramine	S-chemical
group	O
showed	O
significant	O
retardation	O
in	O
gastric	O
emptying	O
of	O
solids	O
(	O
P	O
=	O
.03	O
)	O
,	O
reduced	O
maximum	O
tolerated	O
volume	O
(	O
P	O
=	O
.03	O
)	O
,	O
and	O
increased	O
postprandial	O
peptide	B-GP
YY	E-GP
compared	O
with	O
the	O
placebo	O
group	O
.	O
Obese	O
females	O
showed	O
greater	O
effects	O
of	O
sibutramine	S-chemical
on	O
weight	O
loss	O
and	O
gastric	O
emptying	O
of	O
solids	O
and	O
liquids	O
.	O
Gastric	O
volumes	O
and	O
postchallenge	O
symptoms	O
were	O
not	O
significantly	O
different	O
in	O
the	O
2	O
treatment	O
groups	O
.	O
The	O
LS/SS	O
genotype	O
of	O
the	O
promoter	O
for	O
SLC6A4	S-GP
was	O
associated	O
with	O
enhanced	O
weight	O
loss	O
with	O
sibutramine	S-chemical
.	O
CONCLUSIONS	O
:	O
Weight	O
reduction	O
with	O
sibutramine	S-chemical
is	O
associated	O
with	O
altered	O
gastric	O
functions	O
and	O
increased	O
peptide	B-GP
YY	E-GP
and	O
is	O
significantly	O
associated	O
with	O
SLC6A4	S-GP
genotype	O
.	O
The	O
role	O
of	O
genetic	O
variation	O
in	O
SLC6A4	S-GP
on	O
weight	O
loss	O
in	O
response	O
to	O
sibutramine	S-chemical
deserves	O
further	O
study	O
.	O

Doxorubicin	S-chemical
decreases	O
paraquat	S-chemical
accumulation	O
and	O
toxicity	O
in	O
Caco-2	O
cells	O
.	O
P-glycoprotein	S-GP
(	O
P-gp	S-GP
)	O
is	O
an	O
efflux	B-GP
pump	E-GP
belonging	O
to	O
the	O
ATP-binding	B-GP
cassette	I-GP
transporter	E-GP
superfamily	O
expressed	O
in	O
several	O
organs	O
.	O
Considering	O
its	O
potential	O
protective	O
effects	O
,	O
the	O
induction	O
of	O
de	O
novo	O
synthesis	O
of	O
P-gp	S-GP
could	O
be	O
used	O
therapeutically	O
in	O
the	O
treatment	O
of	O
intoxications	O
by	O
its	O
substrates	O
.	O
The	O
herbicide	O
paraquat	S-chemical
(	O
PQ	O
)	O
is	O
a	O
P-gp	S-GP
substrate	O
responsible	O
for	O
thousands	O
of	O
fatal	O
intoxications	O
worldwide	O
that	O
still	O
lacks	O
an	O
effective	O
antidote	O
.	O
The	O
aim	O
of	O
the	O
present	O
work	O
was	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
such	O
an	O
antidote	O
by	O
testing	O
whether	O
doxorubicin	S-chemical
(	O
DOX	S-chemical
)	O
,	O
a	O
known	O
P-gp	S-GP
inducer	O
,	O
could	O
efficiently	O
protect	O
Caco-2	O
cells	O
against	O
PQ	O
cytotoxicity	O
,	O
6	O
h	O
after	O
the	O
incubation	O
with	O
the	O
herbicide	O
,	O
reflecting	O
a	O
real-life	O
intoxication	O
scenario	O
.	O
Cytotoxicity	O
was	O
evaluated	O
by	O
the	O
MTT	S-chemical
assay	O
and	O
PQ	O
intracellular	O
concentrations	O
were	O
measured	O
by	O
gas	O
chromatography-ion	O
trap-mass	O
spectrometry	O
(	O
GC-IT-MS	O
)	O
.	O
Also	O
,	O
the	O
DOX	S-chemical
modulatory	O
effect	O
on	O
choline	S-chemical
uptake	O
transport	O
system	O
was	O
assessed	O
by	O
measuring	O
the	O
uptake	O
of	O
[	B-chemical
³H	I-chemical
]	I-chemical
-choline	E-chemical
.	O
The	O
results	O
show	O
that	O
DOX	S-chemical
exerts	O
protective	O
effects	O
against	O
PQ	O
cytotoxicity	O
,	O
preventing	O
the	O
intracellular	O
accumulation	O
of	O
the	O
herbicide	O
.	O
These	O
protective	O
effects	O
were	O
not	O
completely	O
prevented	O
by	O
the	O
incubation	O
with	O
the	O
UIC2	O
antibody	O
,	O
a	O
specific	O
P-gp	S-GP
inhibitor	O
,	O
suggesting	O
the	O
involvement	O
of	O
alternative	O
protection	O
mechanisms	O
.	O
In	O
fact	O
,	O
DOX	S-chemical
also	O
efficiently	O
inhibited	O
the	O
choline	S-chemical
transport	O
system	O
that	O
influences	O
PQ	O
cellular	O
uptake	O
.	O
In	O
conclusion	O
,	O
in	O
this	O
cellular	O
model	O
,	O
DOX	S-chemical
effectively	O
protects	O
against	O
PQ	O
toxicity	O
by	O
inducing	O
P-gp	S-GP
and	O
through	O
the	O
interaction	O
with	O
the	O
choline	B-GP
transporter	E-GP
,	O
suggesting	O
that	O
compounds	O
presenting	O
this	O
double	O
feature	O
of	O
promoting	O
the	O
efflux	O
and	O
limiting	O
the	O
uptake	O
of	O
PQ	O
could	O
be	O
used	O
as	O
effective	O
antidotes	O
to	O
treat	O
intoxications	O
.	O

Comparative	O
study	O
on	O
transcriptional	O
activity	O
of	O
17	O
parabens	S-chemical
mediated	O
by	O
estrogen	B-GP
receptor	I-GP
α	I-GP
and	I-GP
β	E-GP
and	O
androgen	B-GP
receptor	E-GP
.	O
The	O
structure-activity	O
relationships	O
of	O
parabens	S-chemical
which	O
are	O
widely	O
used	O
as	O
preservatives	O
for	O
transcriptional	O
activities	O
mediated	O
by	O
human	B-GP
estrogen	I-GP
receptor	I-GP
α	E-GP
(	O
hERα	S-GP
)	O
,	O
hERβ	S-GP
and	O
androgen	B-GP
receptor	E-GP
(	O
hAR	S-GP
)	O
were	O
investigated	O
.	O
Fourteen	O
of	O
17	O
parabens	S-chemical
exhibited	O
hERα	S-GP
and/or	O
hERβ	S-GP
agonistic	O
activity	O
at	O
concentrations	O
of	O
⩽1×10	O
(	O
-5	O
)	O
M	O
,	O
whereas	O
none	O
of	O
the	O
17	O
parabens	S-chemical
showed	O
AR	S-GP
agonistic	O
or	O
antagonistic	O
activity	O
.	O
Among	O
12	O
parabens	S-chemical
with	O
linear	O
alkyl	S-chemical
chains	O
ranging	O
in	O
length	O
from	O
C1	O
to	O
C12	O
,	O
heptylparaben	S-chemical
(	O
C7	O
)	O
and	O
pentylparaben	S-chemical
(	O
C5	O
)	O
showed	O
the	O
most	O
potent	O
ERα	S-GP
and	O
ERβ	S-GP
agonistic	O
activity	O
in	O
the	O
order	O
of	O
10	O
(	O
-7	O
)	O
M	O
and	O
10	O
(	O
-8	O
)	O
M	O
,	O
respectively	O
,	O
and	O
the	O
activities	O
decreased	O
in	O
a	O
stepwise	O
manner	O
as	O
the	O
alkyl	O
chain	O
was	O
shortened	O
to	O
C1	O
or	O
lengthened	O
to	O
C12	O
.	O
Most	O
parabens	S-chemical
showing	O
estrogenic	O
activity	O
exhibited	O
ERβ	S-GP
-agonistic	O
activity	O
at	O
lower	O
concentrations	O
than	O
those	O
inducing	O
ERα	S-GP
-agonistic	O
activity	O
.	O
The	O
estrogenic	O
activity	O
of	O
butylparaben	S-chemical
was	O
markedly	O
decreased	O
by	O
incubation	O
with	O
rat	O
liver	O
microsomes	O
,	O
and	O
the	O
decrease	O
of	O
activity	O
was	O
blocked	O
by	O
a	O
carboxylesterase	S-GP
inhibitor	O
.	O
These	O
results	O
indicate	O
that	O
parabens	S-chemical
are	O
selective	O
agonists	O
for	O
ERβ	S-GP
over	O
ERα	S-GP
;	O
their	O
interactions	O
with	O
ERα/β	S-GP
are	O
dependent	O
on	O
the	O
size	O
and	O
bulkiness	O
of	O
the	O
alkyl	S-chemical
groups	O
;	O
and	O
they	O
are	O
metabolized	O
by	O
carboxylesterases	S-GP
,	O
leading	O
to	O
attenuation	O
of	O
their	O
estrogenic	O
activity	O
.	O

Activation	O
of	O
the	O
anti-cancer	O
agent	O
upamostat	S-chemical
by	O
the	O
mARC	S-GP
enzyme	O
system	O
.	O
Abstract	O
1	O
.	O
Upamostat	S-chemical
(	O
Mesupron	S-chemical
®	O
)	O
is	O
a	O
new	O
small	O
molecule	O
serine	B-GP
protease	E-GP
inhibitor	O
.	O
The	O
drug	O
candidate	O
was	O
developed	O
to	O
inhibit	O
the	O
urokinase-type	B-GP
plasminogen	I-GP
activator	E-GP
(	O
uPA	S-GP
)	O
system	O
,	O
which	O
plays	O
a	O
major	O
role	O
in	O
tumor	O
invasion	O
and	O
metastasis	O
.	O
Upamostat	S-chemical
is	O
currently	O
in	O
clinical	O
development	O
as	O
an	O
anti-metastatic	O
and	O
non-cytotoxic	O
agent	O
against	O
pancreatic	O
and	O
breast	O
cancer	O
.	O
2	O
.	O
Upamostat	S-chemical
is	O
the	O
orally	O
available	O
amidoxime	S-chemical
-	O
(	O
i.e	O
.	O
hydroxyamidine	S-chemical
-	O
)	O
prodrug	O
of	O
the	O
pharmacologically	O
active	O
form	O
,	O
WX-UK1	S-chemical
.	O
In	O
this	O
study	O
,	O
the	O
reductive	O
enzymatic	O
activation	O
of	O
upamostat	S-chemical
to	O
its	O
corresponding	O
amidine	O
WX-UK1	S-chemical
was	O
analyzed	O
.	O
3	O
.	O
The	O
recently	O
discovered	O
molybdenum	S-chemical
enzyme	O
``	O
mitochondrial	B-GP
Amidoxime	I-GP
Reducing	I-GP
Component	E-GP
``	O
(	O
mARC	S-GP
)	O
catalyses	O
together	O
with	O
its	O
electron	B-GP
transport	I-GP
proteins	E-GP
cytochrome	B-GP
b	I-GP
(	I-GP
5	I-GP
)	E-GP
and	O
NADH	B-GP
cytochrome	I-GP
b	I-GP
(	I-GP
5	I-GP
)	I-GP
reductase	E-GP
the	O
reduction	O
of	O
N	S-chemical
-hydroxylated	O
prodrugs	O
.	O
In	O
vitro	O
biotransformation	O
assays	O
with	O
porcine	O
subcellular	O
fractions	O
and	O
the	O
reconstituted	O
human	O
enzymes	O
demonstrate	O
an	O
mARC	S-GP
-dependent	O
N	S-chemical
-reduction	O
of	O
upamostat	S-chemical
.	O

Galangin	S-chemical
attenuates	O
mast	O
cell-mediated	O
allergic	O
inflammation	O
.	O
A	O
great	O
number	O
of	O
people	O
are	O
suffering	O
from	O
allergic	O
inflammatory	O
disease	O
such	O
as	O
asthma	O
,	O
atopic	O
dermatitis	O
,	O
and	O
sinusitis	O
.	O
Therefore	O
discovery	O
of	O
drugs	O
for	O
the	O
treatment	O
of	O
these	O
diseases	O
is	O
an	O
important	O
subject	O
in	O
human	O
health	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
anti-allergic	O
inflammatory	O
effect	O
of	O
galangin	S-chemical
and	O
underlying	O
mechanisms	O
of	O
action	O
using	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
.	O
Galangin	S-chemical
inhibited	O
histamine	S-chemical
release	O
by	O
the	O
reduction	O
of	O
intracellular	O
calcium	S-chemical
in	O
phorbol	B-chemical
12-mystate	I-chemical
13-acetate	E-chemical
plus	O
calcium	S-chemical
ionophore	O
A23187-stimulated	O
human	O
mast	O
cells	O
(	O
HMC-1	O
)	O
.	O
Galangin	S-chemical
decreased	O
expression	O
of	O
pro-inflammatory	O
cytokines	S-GP
,	O
such	O
as	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
(	I-GP
TNF	I-GP
)	I-GP
-α	E-GP
,	O
interleukin	S-GP
(	B-GP
IL	I-GP
)	I-GP
-6	E-GP
,	O
IL-1β	S-GP
,	O
and	O
IL-8	S-GP
.	O
The	O
inhibitory	O
effect	O
of	O
galangin	S-chemical
on	O
theses	O
pro-inflammatory	O
cytokines	S-GP
was	O
related	O
with	O
c-Jun	S-GP
N-terminal	B-GP
kinases	E-GP
,	O
and	O
p38	S-GP
mitogen-activated	B-GP
protein	I-GP
kinase	E-GP
,	O
nuclear	B-GP
factor-κB	E-GP
,	O
and	O
caspase-1	S-GP
.	O
Furthermore	O
,	O
galangin	S-chemical
attenuated	O
IgE	S-GP
-mediated	O
passive	O
cutaneous	O
anaphylaxis	O
and	O
the	O
expression	O
of	O
histamine	B-GP
receptor	I-GP
1	E-GP
at	O
the	O
inflamed	O
tissue	O
.	O
The	O
inhibitory	O
effects	O
of	O
galangin	S-chemical
were	O
more	O
potent	O
than	O
cromolyn	S-chemical
,	O
a	O
known	O
anti-allergic	O
drug	O
.	O
Our	O
results	O
showed	O
that	O
galangin	S-chemical
down-regulates	O
mast	O
cell-derived	O
allergic	O
inflammatory	O
reactions	O
by	O
blocking	O
histamine	S-chemical
release	O
and	O
expression	O
of	O
pro-inflammatory	O
cytokines	S-GP
.	O
In	O
light	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
anti-allergic	O
inflammatory	O
effects	O
,	O
galangin	S-chemical
could	O
be	O
a	O
beneficial	O
anti-allergic	O
inflammatory	O
agent	O
.	O

Tethered	O
dimers	O
as	O
NAD	B-GP
synthetase	E-GP
inhibitors	O
with	O
antibacterial	O
activity	O
.	O
The	O
solution-phase	O
parallel	O
synthesis	O
of	O
tethered	O
dimers	O
was	O
employed	O
to	O
identify	O
lead	O
inhibitors	O
of	O
bacterial	B-GP
NAD	I-GP
synthetase	E-GP
.	O
Active	O
dimers	O
contained	O
two	O
aromatic	O
end	O
groups	O
joined	O
by	O
a	O
polymethylene	O
linker	O
,	O
with	O
one	O
end	O
group	O
containing	O
a	O
permanent	O
positive	O
charge	O
.	O
Effective	O
inhibitors	O
of	O
NAD	B-GP
synthetase	E-GP
also	O
inhibited	O
the	O
growth	O
of	O
Gram-positive	O
(	O
but	O
not	O
Gram-negative	O
)	O
bacteria	O
,	O
including	O
antibiotic-resistant	O
strains	O
.	O
The	O
desmethyl	O
precursors	O
of	O
active	O
inhibitors	O
lacked	O
a	O
permanent	O
positive	O
charge	O
and	O
were	O
inactive	O
as	O
either	O
enzyme	O
inhibitors	O
or	O
antibacterial	O
agents	O
.	O
Similarly	O
,	O
a	O
close	O
structural	O
analogue	O
of	O
the	O
most	O
active	O
inhibitors	O
contained	O
two	O
additional	O
ether	O
oxygens	S-chemical
in	O
the	O
tether	O
and	O
was	O
inactive	O
in	O
both	O
assays	O
.	O
These	O
results	O
are	O
consistent	O
with	O
the	O
premise	O
that	O
NAD	B-GP
synthetase	E-GP
inhibition	O
is	O
responsible	O
for	O
the	O
antibacterial	O
actions	O
and	O
support	O
further	O
studies	O
on	O
NAD	B-GP
synthetase	E-GP
as	O
a	O
new	O
target	O
for	O
antibacterial	O
agents	O
.	O

Lorcaserin	S-chemical
:	O
a	O
review	O
of	O
its	O
use	O
in	O
chronic	O
weight	O
management	O
.	O
Oral	O
lorcaserin	S-chemical
(	O
BELVIQ	S-chemical
(	O
®	O
)	O
)	O
,	O
a	O
selective	O
serotonin	S-chemical
5-HT2C	S-GP
receptor	O
agonist	O
,	O
is	O
indicated	O
in	O
the	O
US	O
as	O
an	O
adjunct	O
to	O
diet	O
and	O
exercise	O
in	O
the	O
chronic	O
weight	O
management	O
of	O
obese	O
adults	O
,	O
or	O
overweight	O
adults	O
with	O
at	O
least	O
one	O
weight-related	O
comorbidity	O
(	O
e.g	O
.	O
dyslipidaemia	O
,	O
hypertension	O
,	O
type	O
2	O
diabetes	O
)	O
.	O
This	O
article	O
reviews	O
the	O
pharmacological	O
properties	O
,	O
therapeutic	O
efficacy	O
and	O
tolerability	O
of	O
oral	O
lorcaserin	S-chemical
in	O
this	O
patient	O
population	O
.	O
In	O
three	O
large	O
randomized	O
,	O
double-blind	O
,	O
multicentre	O
studies	O
,	O
oral	O
lorcaserin	S-chemical
was	O
more	O
effective	O
than	O
placebo	O
in	O
the	O
management	O
of	O
obese	O
and	O
overweight	O
adults	O
with	O
or	O
without	O
type	O
2	O
diabetes	O
mellitus	O
.	O
Following	O
12	O
months	O
'	O
therapy	O
,	O
significantly	O
higher	O
proportions	O
of	O
lorcaserin	S-chemical
than	O
placebo	O
recipients	O
achieved	O
a	O
≥5	O
and	O
≥10	O
%	O
reduction	O
from	O
baseline	O
in	O
their	O
bodyweight	O
and	O
a	O
significant	O
between-group	O
difference	O
favouring	O
lorcaserin	S-chemical
over	O
placebo	O
was	O
observed	O
for	O
the	O
change	O
from	O
baseline	O
in	O
bodyweight	O
.	O
Moreover	O
,	O
among	O
patients	O
who	O
had	O
achieved	O
a	O
≥5	O
%	O
reduction	O
in	O
their	O
bodyweight	O
after	O
12	O
months	O
'	O
therapy	O
with	O
lorcaserin	S-chemical
,	O
a	O
significantly	O
higher	O
proportion	O
who	O
received	O
lorcaserin	S-chemical
for	O
a	O
further	O
12	O
months	O
than	O
those	O
who	O
switched	O
to	O
placebo	O
maintained	O
≥5	O
%	O
weight	O
loss	O
at	O
24	O
months	O
.	O
In	O
general	O
,	O
oral	O
lorcaserin	S-chemical
was	O
well	O
tolerated	O
in	O
clinical	O
studies	O
,	O
with	O
hypoglycaemia	O
and	O
headache	O
the	O
most	O
frequently	O
reported	O
adverse	O
events	O
in	O
those	O
with	O
or	O
without	O
type	O
2	O
diabetes	O
,	O
respectively	O
.	O
According	O
to	O
a	O
pooled	O
analysis	O
,	O
the	O
risk	O
of	O
US-FDA-defined	O
valvulopathy	O
with	O
lorcaserin	S-chemical
is	O
generally	O
low	O
and	O
not	O
statistically	O
significantly	O
different	O
from	O
placebo	O
.	O
From	O
these	O
and	O
other	O
data	O
,	O
the	O
FDA	O
has	O
concluded	O
that	O
lorcaserin	S-chemical
is	O
unlikely	O
to	O
elevate	O
the	O
risk	O
of	O
valvulopathy	O
.	O

The	O
influence	O
of	O
chronic	O
fluorosis	O
on	O
mitochondrial	O
dynamics	O
morphology	O
and	O
distribution	O
in	O
cortical	O
neurons	O
of	O
the	O
rat	O
brain	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effects	O
of	O
chronic	O
fluorosis	O
on	O
the	O
dynamics	O
(	O
including	O
fusion	O
and	O
fission	O
proteins	O
)	O
,	O
fragmentation	O
,	O
and	O
distribution	O
of	O
mitochondria	O
in	O
the	O
cortical	O
neurons	O
of	O
the	O
rat	O
brain	O
in	O
an	O
attempt	O
to	O
elucidate	O
molecular	O
mechanisms	O
underlying	O
the	O
brain	O
damage	O
associated	O
with	O
excess	O
accumulation	O
of	O
fluoride	S-chemical
.	O
Sixty	O
Sprague-Dawley	O
rats	O
were	O
divided	O
randomly	O
into	O
three	O
groups	O
of	O
20	O
each	O
,	O
that	O
is	O
,	O
the	O
untreated	O
control	O
group	O
(	O
drinking	O
water	O
naturally	O
containing	O
<	O
0.5	O
mg	O
fluoride	S-chemical
/l	O
,	O
NaF	S-chemical
)	O
,	O
the	O
low-	O
fluoride	S-chemical
group	O
(	O
whose	O
drinking	O
water	O
was	O
supplemented	O
with	O
10	O
mg	O
fluoride	S-chemical
/l	O
)	O
and	O
the	O
high-	O
fluoride	S-chemical
group	O
(	O
50	O
mg	O
fluoride	S-chemical
/l	O
)	O
.	O
After	O
6	O
months	O
of	O
exposure	O
,	O
the	O
expression	O
of	O
mitofusin-1	S-GP
(	O
Mfn1	S-GP
)	O
,	O
fission-1	S-GP
(	O
Fis1	S-GP
)	O
,	O
and	O
dynamin-related	B-GP
protein-1	E-GP
(	O
Drp1	S-GP
)	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
were	O
detected	O
by	O
Western	O
blotting	O
,	O
immunohistochemistry	O
,	O
and	O
real-time	O
PCR	O
,	O
respectively	O
.	O
Moreover	O
,	O
mitochondrial	O
morphology	O
and	O
distribution	O
in	O
neurons	O
were	O
observed	O
by	O
transmission	O
electron	O
or	O
fluorescence	O
microscopy	O
.	O
In	O
the	O
cortices	O
of	O
the	O
brains	O
of	O
rats	O
with	O
chronic	O
fluorosis	O
,	O
the	O
level	O
of	O
Mfn1	S-GP
protein	O
was	O
clearly	O
reduced	O
,	O
whereas	O
the	O
levels	O
of	O
Fis1	S-GP
and	O
Drp1	S-GP
were	O
elevated	O
.	O
The	O
alternations	O
of	O
expression	O
of	O
the	O
mRNAs	O
encoding	O
all	O
three	O
of	O
these	O
proteins	O
were	O
almost	O
the	O
same	O
as	O
the	O
corresponding	O
changes	O
at	O
the	O
protein	O
levels	O
.	O
The	O
mitochondria	O
were	O
fragmented	O
and	O
the	O
redistributed	O
away	O
from	O
the	O
axons	O
of	O
the	O
cortical	O
neurons	O
.	O
These	O
findings	O
indicate	O
that	O
chronic	O
fluorosis	O
induces	O
abnormal	O
mitochondrial	O
dynamics	O
,	O
which	O
might	O
in	O
turn	O
result	O
in	O
a	O
high	O
level	O
of	O
oxidative	O
stress	O
.	O

Characterization	O
of	O
the	O
substrate	O
mimic	O
bound	O
to	O
engineered	O
prostacyclin	B-GP
synthase	E-GP
in	O
solution	O
using	O
high-resolution	O
NMR	O
spectroscopy	O
and	O
mutagenesis	O
:	O
implication	O
of	O
the	O
molecular	O
mechanism	O
in	O
biosynthesis	O
of	O
prostacyclin	S-chemical
.	O
High-resolution	O
NMR	O
spectroscopy	O
was	O
used	O
to	O
determine	O
the	O
docking	O
of	O
a	O
substrate	O
(	O
prostaglandin	B-chemical
H2	E-chemical
)	O
mimic	O
(	O
U46619	S-chemical
)	O
to	O
the	O
engineered	O
prostacyclin	B-GP
(	I-GP
PGI2	I-GP
)	I-GP
synthase	E-GP
(	O
PGIS	S-GP
)	O
in	O
solution	O
.	O
The	O
binding	O
of	O
U46619	S-chemical
to	O
the	O
PGIS	S-GP
protein	O
was	O
demonstrated	O
by	O
1D	O
NMR	O
titration	O
,	O
and	O
the	O
significant	O
perturbation	O
of	O
the	O
chemical	O
shifts	O
of	O
protons	O
at	O
C-11	S-chemical
,	O
H2C	S-chemical
,	O
and	O
H20	S-chemical
of	O
U46619	S-chemical
were	O
observed	O
upon	O
U46619	S-chemical
binding	O
to	O
the	O
engineered	O
PGIS	S-GP
in	O
a	O
concentration-dependent	O
manner	O
.	O
The	O
detailed	O
conformational	O
change	O
and	O
3D	O
structure	O
of	O
the	O
PGIS	S-GP
-bound	O
U46619	S-chemical
were	O
further	O
demonstrated	O
by	O
2D	O
1H	S-chemical
NMR	O
experiments	O
using	O
the	O
transferred	O
NOE	O
technique	O
.	O
The	O
distances	O
between	O
the	O
protons	O
H20	S-chemical
and	O
H2	S-chemical
,	O
H18	S-chemical
and	O
H2	S-chemical
,	O
and	O
H18	S-chemical
and	O
H4	S-chemical
are	O
shorter	O
following	O
their	O
binding	O
to	O
the	O
PGIS	S-GP
in	O
solution-down	O
to	O
within	O
5	O
A	O
.	O
These	O
shorter	O
distances	O
resulted	O
in	O
a	O
widely	O
open	O
conformation	O
,	O
where	O
the	O
triangle	O
shape	O
of	O
the	O
unbound	O
U46619	S-chemical
changed	O
to	O
a	O
more	O
compact	O
conformation	O
with	O
an	O
oval	O
shape	O
.	O
The	O
bound	O
conformation	O
of	O
U46619	S-chemical
fits	O
the	O
crystal	O
structure	O
of	O
the	O
PGIS	S-GP
substrate	O
binding	O
pocket	O
considerably	O
better	O
than	O
that	O
of	O
the	O
unbound	O
U46619	S-chemical
.	O
The	O
residues	O
important	O
to	O
the	O
substrate	O
binding	O
in	O
the	O
active	O
site	O
pocket	O
of	O
PGIS	S-GP
were	O
also	O
predicted	O
.	O
For	O
example	O
,	O
Trp282	O
could	O
be	O
one	O
of	O
the	O
most	O
important	O
residues	O
and	O
is	O
suspected	O
to	O
play	O
a	O
role	O
in	O
the	O
determination	O
of	O
specific	O
catalytic	O
function	O
,	O
which	O
has	O
been	O
established	O
by	O
the	O
docking	O
studies	O
using	O
the	O
NMR	O
structure	O
of	O
the	O
PGIS	S-GP
-bound	O
form	O
of	O
U46619	S-chemical
and	O
the	O
PGIS	S-GP
crystal	O
structure	O
.	O
These	O
studies	O
have	O
provided	O
the	O
structural	O
information	O
for	O
the	O
interaction	O
of	O
the	O
PGIS	S-GP
with	O
its	O
substrate	O
mimic	O
.	O
The	O
noted	O
conformational	O
changes	O
where	O
the	O
C-6	S-chemical
position	O
is	O
closer	O
to	O
the	O
C-9	S-chemical
position	O
of	O
U46619	S-chemical
provided	O
the	O
first	O
experimental	O
data	O
for	O
understanding	O
the	O
molecular	O
mechanism	O
of	O
the	O
catalytic	O
function	O
of	O
PGIS	S-GP
in	O
the	O
isomerization	O
of	O
PGH2	S-chemical
to	O
prostacyclin	S-chemical
.	O

Cell	O
penetrating	O
peptide	O
tethered	O
bi-ligand	O
liposomes	O
for	O
delivery	O
to	O
brain	O
in	O
vivo	O
:	O
Biodistribution	O
and	O
transfection	O
.	O
Targeted	O
nano-particulate	O
systems	O
hold	O
extraordinary	O
potential	O
for	O
delivery	O
of	O
therapeutics	O
across	O
blood	O
brain	O
barrier	O
(	O
BBB	O
)	O
.	O
In	O
this	O
work	O
,	O
we	O
investigated	O
the	O
potential	O
of	O
novel	O
bi-ligand	O
(	O
transferrin-	O
poly-l-arginine	S-chemical
)	O
liposomal	O
vector	O
for	O
delivery	O
of	O
desired	O
gene	O
to	O
brain	O
,	O
in	O
vivo	O
.	O
The	O
in	O
vivo	O
evaluation	O
of	O
the	O
delivery	O
vectors	O
is	O
essential	O
for	O
clinical	O
translation	O
.	O
We	O
followed	O
an	O
innovative	O
approach	O
of	O
combining	O
transferrin	O
receptor	O
targeting	O
with	O
enhanced	O
cell	O
penetration	O
to	O
design	O
liposomal	O
vectors	O
for	O
improving	O
the	O
transport	O
of	O
molecules	O
into	O
brain	O
.	O
The	O
biodistribution	O
profile	O
of	O
1	B-chemical
,	I-chemical
1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine	I-chemical
iodide	E-chemical
(	O
DiR	S-chemical
)	O
-labeled	O
liposomes	O
was	O
evaluated	O
in	O
adult	O
rats	O
after	O
single	O
intravenous	O
injection	O
at	O
dose	O
of	O
15.2μmoles	O
of	O
phospholipids/kg	O
body	O
weight	O
.	O
We	O
demonstrated	O
that	O
bi-ligand	O
liposomes	O
accumulated	O
in	O
rat	O
brain	O
at	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
higher	O
concentrations	O
as	O
compared	O
to	O
the	O
single-ligand	O
(	O
transferrin	S-GP
)	O
or	O
plain	O
liposomes	O
.	O
In	O
addition	O
,	O
the	O
bi-ligand	O
liposomes	O
resulted	O
in	O
increased	O
expression	O
of	O
β-galactosidase	S-GP
(	O
β-gal	S-GP
)	O
plasmid	O
in	O
rat	O
brain	O
tissue	O
in	O
comparison	O
to	O
the	O
single-ligand	O
liposomes	O
.	O
Histological	O
examination	O
of	O
the	O
transfected	O
tissues	O
did	O
not	O
show	O
any	O
signs	O
of	O
tissue	O
necrosis	O
or	O
inflammation	O
.	O
Hemolysis	O
assay	O
further	O
authenticated	O
the	O
biocompatibility	O
of	O
bi-ligand	O
liposomes	O
in	O
blood	O
up	O
to	O
600	O
nmoles	O
of	O
phospholipids/1.4×10	O
(	O
7	O
)	O
erythrocytes	O
.	O
The	O
findings	O
of	O
this	O
study	O
provide	O
important	O
and	O
detailed	O
information	O
regarding	O
the	O
distribution	O
of	O
bi-ligand	O
liposomes	O
in	O
vivo	O
and	O
accentuate	O
their	O
ability	O
to	O
demonstrate	O
improved	O
brain	O
penetration	O
and	O
transfection	O
potential	O
over	O
single-ligand	O
liposomes	O
.	O

Effect	O
of	O
JTH-601	O
,	O
a	O
novel	O
alpha	B-GP
(	I-GP
1	I-GP
)	I-GP
-adrenoceptor	E-GP
antagonist	O
,	O
on	O
prostate	O
function	O
in	O
dogs	O
.	O
We	O
examined	O
the	O
effect	O
of	O
JTH-601	S-chemical
(	O
3-	O
inverted	O
question	O
mark	O
N-	B-chemical
[	I-chemical
2-	I-chemical
(	I-chemical
4-hydroxy-2-isopropyl-5-methylphenoxy	I-chemical
)	I-chemical
ethyl	I-chemical
]	I-chemical
-N-methylaminom	E-chemical
ethyl	S-chemical
inverted	O
question	O
mark-	O
4-methoxy-2,5,6-trimethylphenol	B-chemical
hemifumarate	E-chemical
)	O
,	O
a	O
new	O
alpha	B-GP
(	I-GP
1L	I-GP
)	I-GP
-adrenoceptor	E-GP
antagonist	O
,	O
on	O
prostatic	O
function	O
in	O
isolated	O
canine	O
prostate	O
and	O
in	O
anesthetized	O
dogs	O
.	O
In	O
the	O
contraction	O
study	O
,	O
phenylephrine	S-chemical
and	O
noradrenaline	S-chemical
produced	O
concentration-dependent	O
contractions	O
in	O
canine	O
prostate	O
and	O
carotid	O
artery	O
,	O
respectively	O
.	O
In	O
these	O
tissues	O
,	O
JTH-601	S-chemical
,	O
prazosin	S-chemical
(	O
a	O
non-selective	O
alpha	B-GP
(	I-GP
1	I-GP
)	I-GP
-adrenoceptor	E-GP
antagonist	O
)	O
,	O
and	O
tamsulosin	S-chemical
(	O
an	O
alpha	B-GP
(	I-GP
1A	I-GP
)	I-GP
-adrenoceptor	E-GP
antagonist	O
)	O
competitively	O
antagonized	O
contraction	O
in	O
a	O
concentration-dependent	O
manner	O
.	O
The	O
pA	O
(	O
2	O
)	O
(	O
pK	O
(	O
B	O
)	O
)	O
values	O
with	O
prostate	O
were	O
8.49+/-0.07	O
for	O
JTH-601	O
,	O
7.94+/-0.04	O
for	O
prazosin	S-chemical
and	O
9.42+/-0.22	O
for	O
tamsulosin	S-chemical
.	O
The	O
ratio	O
of	O
pA	O
(	O
2	O
)	O
(	O
carotid	O
artery/prostate	O
)	O
,	O
i.e	O
.	O
prostatic	O
selectivity	O
,	O
was	O
10.471	O
for	O
JTH-601	S-chemical
,	O
0.008	O
for	O
prazosin	S-chemical
and	O
0.371	O
for	O
tamsulosin	S-chemical
,	O
respectively	O
.	O
In	O
anesthetized	O
dogs	O
,	O
JTH-601	S-chemical
(	O
1	O
mg/kg	O
,	O
i.d	O
.	O
)	O
significantly	O
decreased	O
urethral	O
pressure	O
by	O
15	O
%	O
without	O
affecting	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O
Tamsulosin	S-chemical
(	O
0.1	O
mg/kg	O
,	O
i.d	O
.	O
)	O
decreased	O
urethral	O
pressure	O
to	O
the	O
same	O
extent	O
as	O
did	O
JTH-601	S-chemical
,	O
but	O
with	O
a	O
significant	O
effect	O
on	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O
JTH-601	S-chemical
showed	O
higher	O
selectivity	O
for	O
canine	O
prostate	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
In	O
prostate	O
,	O
an	O
important	O
role	O
of	O
the	O
alpha	B-GP
(	I-GP
1L	I-GP
)	I-GP
-adrenoceptor	E-GP
is	O
suggested	O
in	O
the	O
smooth	O
muscle	O
contraction	O
mediated	O
by	O
alpha	B-GP
(	I-GP
1	I-GP
)	I-GP
-adrenoceptors	E-GP
.	O
JTH-601	S-chemical
is	O
expected	O
to	O
be	O
an	O
effective	O
alpha	B-GP
(	I-GP
1	I-GP
)	I-GP
-adrenoceptor	E-GP
antagonist	O
for	O
the	O
treatment	O
of	O
urinary	O
outlet	O
obstruction	O
by	O
benign	O
prostatic	O
hypertrophy	O
with	O
a	O
minimum	O
effect	O
on	O
the	O
cardiovascular	O
system	O
.	O

A	O
high-confidence	O
interaction	O
map	O
identifies	O
SIRT1	S-GP
as	O
a	O
mediator	O
of	O
acetylation	O
of	O
USP22	S-GP
and	O
the	O
SAGA	S-GP
coactivator	O
complex	O
.	O
Although	O
many	O
functions	O
and	O
targets	O
have	O
been	O
attributed	O
to	O
the	O
histone	S-GP
and	O
protein	B-GP
deacetylase	E-GP
SIRT1	S-GP
,	O
a	O
comprehensive	O
analysis	O
of	O
SIRT1	S-GP
binding	O
proteins	O
yielding	O
a	O
high-confidence	O
interaction	O
map	O
has	O
not	O
been	O
established	O
.	O
Using	O
a	O
comparative	O
statistical	O
analysis	O
of	O
binding	O
partners	O
,	O
we	O
have	O
assembled	O
a	O
high-confidence	O
SIRT1	S-GP
interactome	O
.	O
Employing	O
this	O
method	O
,	O
we	O
identified	O
the	O
deubiquitinating	O
enzyme	O
ubiquitin-specific	B-GP
protease	I-GP
22	E-GP
(	O
USP22	S-GP
)	O
,	O
a	O
component	O
of	O
the	O
deubiquitinating	O
module	O
(	O
DUBm	O
)	O
of	O
the	O
SAGA	S-GP
transcriptional	O
coactivating	O
complex	O
,	O
as	O
a	O
SIRT1	S-GP
-interacting	O
partner	O
.	O
We	O
found	O
that	O
this	O
interaction	O
is	O
highly	O
specific	O
,	O
requires	O
the	O
ZnF-UBP	B-GP
domain	E-GP
of	O
USP22	S-GP
,	O
and	O
is	O
disrupted	O
by	O
the	O
inactivating	O
H363Y	S-GP
mutation	O
within	O
SIRT1	S-GP
.	O
Moreover	O
,	O
we	O
show	O
that	O
USP22	S-GP
is	O
acetylated	O
on	O
multiple	O
lysine	S-chemical
residues	O
and	O
that	O
alteration	O
of	O
a	O
single	O
lysine	S-chemical
(	O
K129	O
)	O
within	O
the	O
ZnF-UBP	B-GP
domain	E-GP
is	O
sufficient	O
to	O
alter	O
interaction	O
of	O
the	O
DUBm	S-GP
with	O
the	O
core	O
SAGA	S-GP
complex	O
.	O
Furthermore	O
,	O
USP22	S-GP
-mediated	O
recruitment	O
of	O
SIRT1	S-GP
activity	O
promotes	O
the	O
deacetylation	O
of	O
individual	O
SAGA	S-GP
complex	O
components	O
.	O
Our	O
results	O
indicate	O
an	O
important	O
role	O
of	O
SIRT1	S-GP
-mediated	O
deacetylation	O
in	O
regulating	O
the	O
formation	O
of	O
DUBm	S-GP
subcomplexes	O
within	O
the	O
larger	O
SAGA	S-GP
complex	O
.	O

Pharmacology	O
and	O
chemistry	O
of	O
adapalene	S-chemical
.	O
BACKGROUND	O
:	O
Retinoid	S-chemical
research	O
in	O
the	O
field	O
of	O
dermatology	O
has	O
been	O
influenced	O
by	O
the	O
clinical	O
success	O
of	O
topical	O
tretinoin	S-chemical
and	O
oral	O
isotretinoin	S-chemical
in	O
the	O
treatment	O
of	O
acne	O
,	O
and	O
by	O
the	O
discovery	O
of	O
high-affinity	O
binding	O
proteins	O
for	O
retinoic	B-chemical
acid	E-chemical
mediating	O
its	O
action	O
and	O
interaction	O
with	O
other	O
vitamins	S-chemical
and	O
hormones	O
.	O
OBJECTIVE	O
:	O
We	O
sought	O
molecules	O
with	O
an	O
optimal	O
balance	O
between	O
stability	O
,	O
efficacy	O
,	O
and	O
local	O
tolerance	O
for	O
topical	O
acne	O
therapy	O
.	O
METHODS	O
:	O
In	O
vitro	O
and	O
in	O
vivo	O
bioassay	O
systems	O
were	O
used	O
to	O
test	O
the	O
ability	O
of	O
retinoids	S-chemical
to	O
modulate	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
In	O
addition	O
,	O
antiinflammatory	O
properties	O
were	O
assessed	O
.	O
Binding	O
and	O
transactivation	O
assays	O
were	O
used	O
to	O
compare	O
affinities	O
and	O
transcriptional	O
activities	O
of	O
adapalene	S-chemical
and	O
tretinoin	S-chemical
for	O
the	O
nuclear	B-GP
transcription	I-GP
factors	E-GP
,	O
retinoic	B-GP
acid	I-GP
receptors	E-GP
(	O
RARs	S-GP
)	O
.	O
RESULTS	O
AND	O
CONCLUSION	O
:	O
Adapalene	S-chemical
is	O
a	O
stable	O
naphthoic	B-chemical
acid	E-chemical
derivative	O
with	O
potent	O
retinoid	S-chemical
pharmacology	O
,	O
controlling	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
In	O
addition	O
it	O
has	O
significant	O
antiinflammatory	O
action	O
.	O
The	O
nuclear	B-GP
gene	I-GP
transcription	I-GP
factors	E-GP
RAR	B-GP
beta	E-GP
and	O
RAR	B-GP
gamma	E-GP
mediate	O
the	O
retinoid	S-chemical
activity	O
of	O
adapalene	S-chemical
.	O

The	O
fidelity	O
of	O
transcription	O
:	O
RPB1	S-GP
(	O
RPO21	S-GP
)	O
mutations	O
that	O
increase	O
transcriptional	O
slippage	O
in	O
S.	O
cerevisiae	O
.	O
The	O
fidelity	O
of	O
RNA	O
synthesis	O
depends	O
on	O
both	O
accurate	O
template-mediated	O
nucleotide	S-chemical
selection	O
and	O
proper	O
maintenance	O
of	O
register	O
between	O
template	O
and	O
RNA	O
.	O
Loss	O
of	O
register	O
,	O
or	O
transcriptional	O
slippage	O
,	O
is	O
particularly	O
likely	O
on	O
homopolymeric	O
runs	O
in	O
the	O
template	O
.	O
Transcriptional	O
slippage	O
can	O
alter	O
the	O
coding	O
capacity	O
of	O
mRNAs	O
and	O
is	O
used	O
as	O
a	O
regulatory	O
mechanism	O
.	O
Here	O
we	O
describe	O
mutations	O
in	O
the	O
largest	O
subunit	O
of	O
Saccharomyces	B-GP
cerevisiae	I-GP
RNA	I-GP
polymerase	I-GP
II	E-GP
that	O
substantially	O
increase	O
the	O
level	O
of	O
transcriptional	O
slippage	O
.	O
Alleles	O
of	O
RPB1	S-GP
(	O
RPO21	S-GP
)	O
with	O
elevated	O
slippage	O
rates	O
were	O
identified	O
among	O
6-azauracil	S-chemical
-sensitive	O
mutants	O
and	O
were	O
also	O
isolated	O
using	O
a	O
slippage-dependent	O
reporter	O
gene	O
.	O
Biochemical	O
characterization	O
of	O
polymerase	B-GP
II	E-GP
isolated	O
from	O
these	O
mutants	O
confirms	O
elevated	O
levels	O
of	O
transcriptional	O
slippage	O
.	O

The	O
role	O
of	O
trastuzumab	O
in	O
early	O
stage	O
breast	O
cancer	O
:	O
current	O
data	O
and	O
treatment	O
recommendations	O
.	O
OPINION	O
STATEMENT	O
:	O
Treatment	O
of	O
early	O
stage	O
breast	O
cancer	O
requires	O
a	O
multimodality	O
approach	O
in	O
order	O
to	O
eradicate	O
residual	O
cancer	O
and	O
prevent	O
recurrent	O
disease	O
.	O
Targeting	O
the	O
pathways	O
that	O
promote	O
or	O
sustain	O
cancer	O
cell	O
growth	O
and	O
invasion	O
is	O
critical	O
to	O
the	O
effective	O
treatment	O
of	O
breast	O
and	O
other	O
cancers	O
.	O
Overexpression	O
of	O
the	O
family	O
of	O
HER	S-GP
receptors	O
have	O
been	O
associated	O
with	O
a	O
variety	O
of	O
malignancies	O
;	O
the	O
first	O
and	O
best	O
studied	O
is	O
the	O
association	O
of	O
overexpression	O
of	O
the	O
HER2	S-GP
/	O
neu	B-GP
receptor	E-GP
with	O
a	O
more	O
aggressive	O
breast	O
cancer	O
phenotype	O
and	O
poorer	O
survival	O
.	O
A	O
humanized	O
antibody	O
to	O
HER2	S-GP
/	O
neu	S-GP
,	O
trastuzumab	O
,	O
is	O
now	O
FDA	O
approved	O
for	O
the	O
treatment	O
of	O
early	O
stage	O
,	O
HER2	S-GP
/	O
neu	S-GP
overexpressing	O
breast	O
cancer	O
sequenced	O
with	O
chemotherapy	O
including	O
doxorubicin	S-chemical
,	O
cyclophosphamide	S-chemical
,	O
and	O
paclitaxel	S-chemical
.	O
Additional	O
international	O
and	O
national	O
studies	O
support	O
the	O
significant	O
impact	O
of	O
trastuzumab	O
on	O
both	O
disease	O
free	O
and	O
overall	O
survival	O
in	O
women	O
with	O
this	O
aggressive	O
form	O
of	O
breast	O
cancer	O
.	O
Toxicity	O
includes	O
a	O
low	O
but	O
clear	O
risk	O
of	O
congestive	O
heart	O
failure	O
,	O
and	O
the	O
large	O
phase	O
III	O
trials	O
have	O
helped	O
to	O
determine	O
which	O
patients	O
are	O
at	O
higher	O
risk	O
for	O
this	O
complication	O
.	O
Non-	O
anthracycline	S-chemical
containing	O
regimens	O
are	O
an	O
alternative	O
therapy	O
associated	O
with	O
reduced	O
cardiac	O
toxicity	O
.	O
Trastuzumab	O
therapy	O
is	O
now	O
the	O
standard	O
of	O
care	O
for	O
the	O
treatment	O
of	O
early	O
stage	O
,	O
HER2	S-GP
/	O
neu	S-GP
positive	O
breast	O
cancer	O
given	O
in	O
combination	O
with	O
one	O
of	O
several	O
chemotherapy	O
regimens	O
.	O
Ongoing	O
questions	O
include	O
the	O
appropriate	O
duration	O
of	O
trastuzumab	O
treatment	O
as	O
well	O
as	O
the	O
optimal	O
chemotherapy	O
regimen	O
and	O
sequence	O
.	O
The	O
next	O
large	O
phase	O
III	O
adjuvant	O
trial	O
for	O
this	O
subset	O
of	O
breast	O
cancer	O
is	O
an	O
international	O
collaboration	O
designed	O
to	O
evaluate	O
the	O
added	O
or	O
alternative	O
benefit	O
of	O
an	O
oral	O
tyrosine	S-chemical
kinase	O
inhibitor	O
targeting	O
HER2	S-GP
/	O
neu	S-GP
as	O
well	O
as	O
the	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
(	O
EGFR	S-GP
)	O
,	O
lapatinib	S-chemical
.	O
Other	O
trials	O
are	O
investigating	O
differences	O
in	O
duration	O
.	O
Studies	O
in	O
the	O
neoadjuvant	O
setting	O
should	O
help	O
to	O
define	O
markers	O
of	O
trastuzumab	O
and	O
lapatinib	S-chemical
sensitivity	O
and	O
resistance	O
.	O
Preliminary	O
data	O
combining	O
trastuzumab	O
with	O
the	O
antiangiogenic	O
antibody	O
bevacizumab	O
is	O
encouraging	O
;	O
this	O
combination	O
will	O
be	O
tested	O
in	O
both	O
early	O
stage	O
and	O
late	O
stage	O
disease	O
.	O

Berberine	S-chemical
inhibits	O
myofibroblast	O
differentiation	O
in	O
nasal	O
polyp-derived	O
fibroblasts	O
via	O
the	O
p38	S-GP
pathway	O
.	O
The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
determine	O
whether	O
berberine	S-chemical
has	O
any	O
effect	O
on	O
phenotype	O
changes	O
and	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
production	O
in	O
nasal	O
polyp-derived	O
fibroblasts	O
(	O
NPDFs	O
)	O
and	O
to	O
investigate	O
the	O
underlying	O
molecular	O
mechanism	O
.	O
NPDFs	O
were	O
pre-treated	O
with	O
berberine	S-chemical
prior	O
to	O
induction	O
by	O
transforming	B-GP
growth	I-GP
factor	I-GP
(	I-GP
TGF	I-GP
)	I-GP
-β1	E-GP
.	O
The	O
expression	O
of	O
α-smooth	B-GP
muscle	I-GP
actin	E-GP
(	O
SMA	S-GP
)	O
and	O
collagen	B-GP
type	I-GP
I	E-GP
mRNA	O
was	O
determined	O
by	O
a	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
,	O
and	O
the	O
expression	O
of	O
α-SMA	S-GP
protein	O
and	O
collagen	B-GP
type	I-GP
I	E-GP
was	O
determined	O
by	O
western	O
blotting	O
and/or	O
immunofluorescent	O
staining	O
.	O
The	O
total	O
soluble	O
collagen	S-GP
production	O
was	O
analysed	O
by	O
the	O
SirCol	O
collagen	O
assay	O
.	O
The	O
expression	O
of	O
several	O
signaling	O
molecules	O
of	O
the	O
TGF-β1	S-GP
pathway	O
was	O
evaluated	O
by	O
western	O
blot	O
analysis	O
.	O
In	O
TGF-β1	S-GP
-induced	O
NPDFs	O
,	O
berberine	S-chemical
significantly	O
inhibited	O
the	O
expression	O
of	O
α-SMA	S-GP
and	O
collagen	B-GP
type	I-GP
I	E-GP
mRNA	O
and	O
reduced	O
α-SMA	S-GP
and	O
collagen	S-GP
protein	O
levels	O
.	O
Berberine	S-chemical
only	O
suppressed	O
the	O
expression	O
of	O
pp38	S-GP
among	O
the	O
evaluated	O
signaling	O
molecules	O
.	O
SB203580	S-chemical
(	O
a	O
specific	O
inhibitor	O
of	O
p38	S-GP
kinase	S-GP
)	O
markedly	O
suppressed	O
the	O
increased	O
expression	O
of	O
collagen	B-GP
type	I-GP
I	E-GP
and	O
α-SMA	S-GP
in	O
TGF-β1	S-GP
-induced	O
NPDFs	O
.	O
Berberine	S-chemical
exerts	O
suppressive	O
effects	O
on	O
phenotype	O
changes	O
and	O
ECM	O
production	O
in	O
NPDFs	O
via	O
p38	S-GP
signaling	O
pathway	O
interference	O
.	O
The	O
findings	O
provide	O
new	O
therapeutic	O
options	O
for	O
ECM	O
production	O
in	O
nasal	O
polyps	O
.	O

Agonistic	O
activity	O
of	O
ICI	B-chemical
182	I-chemical
780	E-chemical
on	O
activation	O
of	O
GSK	B-GP
3β	E-GP
/	O
AKT	S-GP
pathway	O
in	O
the	O
rat	O
uterus	O
during	O
the	O
estrous	O
cycle	O
.	O
We	O
examined	O
the	O
ability	O
of	O
ICI	B-chemical
182,780	E-chemical
(	O
ICI	S-chemical
)	O
to	O
block	O
uterine	O
cell	O
proliferation	O
via	O
protein	B-GP
kinase	I-GP
b	E-GP
/	O
AKT	S-GP
pathway	O
in	O
the	O
uterus	O
of	O
the	O
rat	O
during	O
the	O
estrous	O
cycle	O
.	O
Intact	O
rats	O
,	O
with	O
regular	O
estrous	O
cycles	O
,	O
received	O
a	O
subcutaneous	O
(	O
s.c.	O
)	O
injection	O
of	O
either	O
vehicle	O
or	O
ICI	S-chemical
at	O
08:00h	O
on	O
the	O
day	O
of	O
proestrus	O
or	O
at	O
00:00h	O
on	O
the	O
day	O
of	O
estrus	O
and	O
sacrificed	O
at	O
13:00h	O
of	O
metaestrus	O
.	O
Estradiol	S-chemical
(	O
E2	O
)	O
and	O
progesterone	S-chemical
(	O
P4	O
)	O
plasma	O
levels	O
were	O
measured	O
by	O
radioimmunoassay	O
.	O
Both	O
ICI	S-chemical
treatments	O
,	O
induced	O
a	O
significant	O
decrease	O
(	O
p	O
<	O
0.01	O
)	O
in	O
uterine	O
estrogen	B-GP
receptor	I-GP
alpha	E-GP
(	O
ERα	S-GP
)	O
content	O
,	O
had	O
no	O
effect	O
on	O
uterine	O
progesterone	B-GP
receptor	E-GP
(	O
PR	S-GP
)	O
protein	O
expression	O
and	O
caused	O
marked	O
nuclear	O
localization	O
of	O
cyclin	B-GP
D1	E-GP
,	O
in	O
both	O
luminal	O
and	O
glandular	O
uterine	O
epithelium	O
,	O
as	O
compared	O
to	O
vehicle-treated	O
animals	O
.	O
Furthermore	O
,	O
we	O
detected	O
that	O
ICI	S-chemical
treatment	O
induced	O
glycogen	B-GP
synthase	I-GP
kinase	E-GP
(	O
Gsk3-β	S-GP
)	O
Ser	O
9	O
phosphorylation	O
,	O
which	O
correlates	O
with	O
cyclin	B-GP
D1	E-GP
nuclear	O
localization	O
.	O
However	O
,	O
some	O
differences	O
were	O
observed	O
between	O
the	O
two	O
different	O
time	O
schedules	O
of	O
administration	O
.	O
We	O
observed	O
that	O
the	O
administration	O
of	O
ICI	S-chemical
at	O
08:00h	O
on	O
proestrus	O
day	O
produced	O
a	O
15	O
%	O
inhibition	O
of	O
luminal	O
epithelial	O
cell	O
proliferation	O
,	O
reduced	O
uterine	O
wet	O
weight	O
by	O
21	O
%	O
and	O
caused	O
reduction	O
of	O
Akt	S-GP
phosphorylation	O
at	O
Ser	S-chemical
473	O
as	O
compared	O
to	O
vehicle-treated	O
animals	O
,	O
whereas	O
ICI	S-chemical
treatment	O
at	O
00:00h	O
on	O
estrus	O
day	O
had	O
no	O
effect	O
on	O
these	O
parameters	O
.	O
The	O
overall	O
results	O
indicate	O
that	O
ICI	S-chemical
may	O
exert	O
agonistic	O
and	O
antagonistic	O
effects	O
on	O
uterine	O
cell	O
proliferation	O
through	O
differential	O
activation	O
of	O
the	O
Akt	S-GP
pathway	O
depending	O
on	O
the	O
administration	O
period	O
during	O
the	O
estrous	O
cycle	O
,	O
and	O
indicates	O
that	O
the	O
mechanism	O
of	O
cell	O
proliferation	O
during	O
the	O
physiological	O
conditions	O
of	O
the	O
estrous	O
cycle	O
,	O
is	O
under	O
a	O
different	O
and	O
more	O
complex	O
regulation	O
than	O
in	O
the	O
ovariectomized	O
+E2	O
animal	O
model	O
.	O

Serotonin	B-GP
transporter	E-GP
gene	O
regulatory	O
region	O
polymorphism	O
(	O
5-HTTLPR	S-GP
)	O
,	O
[	B-chemical
3H	I-chemical
]	I-chemical
paroxetine	E-chemical
binding	O
in	O
healthy	O
control	O
subjects	O
and	O
alcohol-dependent	O
patients	O
and	O
their	O
relationships	O
to	O
impulsivity	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
[	B-chemical
3H	I-chemical
]	I-chemical
paroxetine	E-chemical
binding	O
and	O
impulsivity	O
in	O
alcohol	S-chemical
-dependent	O
and	O
age-matched	O
control	O
subjects	O
in	O
relation	O
to	O
a	O
5'-promoter	O
region	O
serotonin	B-GP
transporter	E-GP
(	O
5-HTT	S-GP
)	O
polymorphism	O
(	O
5-HTTLPR	S-GP
)	O
.	O
Alcohol-dependent	O
subjects	O
were	O
hypothesized	O
to	O
show	O
a	O
decreased	O
number	O
of	O
bindings	O
sites	O
and	O
a	O
lower	O
dissociation	O
constant	O
.	O
5-HTTLPR	S-GP
S-genotype	O
carriers	O
in	O
both	O
alcohol	S-chemical
-dependent	O
and	O
control	O
subjects	O
were	O
expected	O
to	O
show	O
significantly	O
fewer	O
binding	O
sites	O
and	O
a	O
lower	O
dissociation	O
constant	O
.	O
Influences	O
of	O
impulsive	O
traits	O
,	O
chronic	O
daily	O
alcohol	S-chemical
intake	O
,	O
duration	O
of	O
alcohol	S-chemical
dependence	O
,	O
age	O
of	O
onset	O
and	O
age	O
on	O
[	B-chemical
3H	I-chemical
]	I-chemical
paroxetine	E-chemical
binding	O
were	O
also	O
investigated	O
.	O
Inpatients	O
meeting	O
DSM	O
IV	O
alcohol	S-chemical
dependence	O
criteria	O
and	O
of	O
German	O
descent	O
were	O
recruited	O
to	O
avoid	O
ethnic	O
stratification	O
effects	O
.	O
One	O
hundred	O
and	O
seventeen	O
control	O
subjects	O
of	O
similar	O
social	O
status	O
were	O
recruited	O
from	O
a	O
town	O
community	O
.	O
Blood	O
samples	O
were	O
taken	O
from	O
both	O
alcohol	S-chemical
-dependent	O
and	O
control	O
subjects	O
to	O
determine	O
5-HTTLPR	S-GP
genotypes	O
using	O
PCR	O
of	O
lymphocyte	O
DNA	O
,	O
and	O
to	O
perform	O
platelet	O
[	B-chemical
3H	I-chemical
]	I-chemical
paroxetine	E-chemical
binding	O
(	O
binding	O
capacity	O
:	O
B	O
(	O
max	O
)	O
;	O
and	O
dissociation	O
constant	O
:	O
K	O
(	O
D	O
)	O
)	O
.	O
Impulsivity	O
was	O
assessed	O
using	O
the	O
Barratt	O
impulsiveness	O
scale	O
version	O
5	O
(	O
BIS-5	O
)	O
in	O
alcohol	S-chemical
-dependent	O
subjects	O
only	O
.	O
Alcohol	S-chemical
-dependent	O
subjects	O
were	O
subdivided	O
into	O
low	O
or	O
high	O
impulsivity	O
groups	O
using	O
a	O
median-split	O
of	O
the	O
BIS-5	O
scale	O
.	O
The	O
control	O
group	O
was	O
slightly	O
older	O
than	O
the	O
alcohol-dependent	O
group	O
(	O
not	O
statistically	O
significant	O
)	O
.	O
[	B-chemical
3H	I-chemical
]	I-chemical
paroxetine	E-chemical
binding	O
was	O
investigated	O
in	O
72	O
control	O
subjects	O
and	O
72	O
patients	O
,	O
of	O
which	O
five	O
patients	O
met	O
type	O
2	O
alcohol	S-chemical
dependence	O
criteria	O
.	O
Genotyping	O
was	O
carried	O
out	O
in	O
all	O
patients	O
and	O
control	O
subjects	O
.	O
A	O
significant	O
influence	O
of	O
duration	O
of	O
alcohol	S-chemical
dependence	O
was	O
found	O
on	O
the	O
[	B-chemical
3H	I-chemical
]	I-chemical
paroxetine	E-chemical
binding	O
K	O
(	O
D	O
)	O
but	O
not	O
B	O
(	O
max	O
.	O
)	O
Neither	O
alcohol	S-chemical
-dependent	O
nor	O
control	O
subjects	O
showed	O
any	O
differences	O
in	O
B	O
(	O
max	O
)	O
or	O
K	O
(	O
D	O
)	O
.	O
S-allele	O
carriers	O
did	O
not	O
show	O
a	O
decreased	O
binding	O
or	O
lower	O
dissociation	O
constant	O
.	O
Furthermore	O
,	O
no	O
significant	O
interaction	O
between	O
B	O
(	O
max	O
)	O
and	O
K	O
(	O
D	O
)	O
with	O
either	O
5-HTTLPR	S-GP
genotype	O
or	O
impulsivity	O
was	O
revealed	O
.	O
This	O
was	O
the	O
first	O
study	O
to	O
investigate	O
platelet	O
[	B-chemical
3H	I-chemical
]	I-chemical
paroxetine	E-chemical
binding	O
in	O
alcohol	S-chemical
-dependent	O
and	O
age-matched	O
control	O
subjects	O
in	O
relation	O
to	O
the	O
5-HTTLPR	S-GP
genotype	O
.	O
No	O
differences	O
concerning	O
5-HTTLPR	S-GP
-alleles	O
were	O
found	O
in	O
these	O
groups	O
Furthermore	O
,	O
no	O
significant	O
interaction	O
between	O
these	O
parameters	O
and	O
impulsivity	O
was	O
shown	O
in	O
alcohol	S-chemical
-dependent	O
subjects	O
.	O
These	O
results	O
do	O
not	O
support	O
previous	O
results	O
of	O
altered	O
[	B-chemical
3H	I-chemical
]	I-chemical
paroxetine	E-chemical
binding	O
sites	O
in	O
alcohol-dependent	O
subjects	O
or	O
5-HTTLPR	S-GP
S-allele	O
carriers	O
.	O
K	O
(	O
D	O
)	O
might	O
be	O
influenced	O
by	O
duration	O
of	O
alcohol	S-chemical
dependence	O
,	O
but	O
not	O
sufficiently	O
to	O
yield	O
differences	O
between	O
alcohol	S-chemical
-dependent	O
and	O
control	O
subjects	O
.	O

tert-Butylhydroquinone	S-chemical
reduces	O
lipid	O
accumulation	O
in	O
C57BL/6	O
mice	O
with	O
lower	O
body	O
weight	O
gain	O
.	O
tert-Butylhydroquinone	S-chemical
(	O
tBHQ	S-chemical
)	O
is	O
a	O
commonly	O
used	O
antioxidant	O
additive	O
that	O
is	O
approved	O
for	O
human	O
use	O
by	O
both	O
the	O
Food	O
and	O
Agriculture	O
Organization	O
and	O
the	O
World	O
Health	O
Organization	O
(	O
FAO/WHO	O
)	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
tBHQ	S-chemical
on	O
body	O
weight	O
gain	O
and	O
found	O
that	O
food	O
supplementation	O
with	O
0.001	O
%	O
(	O
w/w	O
)	O
tBHQ	S-chemical
inhibited	O
61.4	O
%	O
(	O
P	O
<	O
0.01	O
)	O
of	O
body	O
weight	O
gain	O
in	O
high-fat	O
diet	O
(	O
HFD	O
)	O
-induced	O
C57BL/6	O
mice	O
,	O
and	O
the	O
oral	O
administration	O
of	O
tBHQ	S-chemical
(	O
1.5	O
mg/kg	O
)	O
reduced	O
47.5	O
%	O
(	O
P	O
<	O
0.05	O
)	O
of	O
body	O
weight	O
gain	O
in	O
normal	O
diet	O
fed	O
db/db	O
mice	O
.	O
The	O
HFD	O
increased	O
lipid	O
deposit	O
in	O
adipocytes	O
,	O
but	O
these	O
were	O
reduced	O
significantly	O
by	O
tBHQ	S-chemical
treatment	O
in	O
C57BL/6	O
mice	O
.	O
tBHQ	S-chemical
supplementation	O
significantly	O
lowered	O
the	O
plasma	O
triglyceride	S-chemical
and	O
total	O
cholesterol	S-chemical
,	O
with	O
reduced	O
size	O
of	O
accumulated	O
fat	O
mass	O
.	O
The	O
rate	O
limiting	O
enzyme	O
of	O
beta-oxidation	O
(	O
ACOX1	S-GP
)	O
was	O
significantly	O
over-expressed	O
in	O
the	O
liver	O
with	O
tBHQ	S-chemical
treatment	O
.	O
These	O
results	O
indicate	O
that	O
tBHQ	S-chemical
suppresses	O
body	O
weight	O
gain	O
in	O
mice	O
,	O
possibly	O
at	O
least	O
related	O
to	O
the	O
up-regulation	O
of	O
ACOX1	S-GP
gene	O
expression	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
novel	O
pyrrolidine-2,5-dione	S-chemical
derivatives	O
as	O
potential	O
antidepressant	O
agents	O
.	O
Part	O
1	O
.	O
A	O
series	O
of	O
3-	B-chemical
(	I-chemical
1H-indol-3-yl	I-chemical
)	I-chemical
pyrrolidine-2,5-dione	E-chemical
derivatives	O
was	O
synthesized	O
and	O
their	O
biological	O
activity	O
was	O
evaluated	O
.	O
The	O
chemical	O
structures	O
of	O
the	O
newly	O
prepared	O
compounds	O
were	O
confirmed	O
by	O
(	B-chemical
1	I-chemical
)	I-chemical
H	E-chemical
NMR	O
,	O
(	B-chemical
13	I-chemical
)	I-chemical
C	E-chemical
NMR	O
and	O
ESI-HRMS	O
spectra	O
data	O
.	O
All	O
tested	O
compounds	O
proved	O
to	O
be	O
potent	O
5-HT1A	S-GP
receptor	O
and	O
serotonin	B-GP
transporter	I-GP
protein	E-GP
(	O
SERT	S-GP
)	O
ligands	O
.	O
Among	O
them	O
,	O
compounds	O
15	O
,	O
18	O
,	O
19	O
and	O
30	O
showed	O
significant	O
affinity	O
for	O
5-HT1A	S-GP
and	O
SERT	S-GP
.	O
Computer	O
docking	O
simulations	O
carried	O
out	O
for	O
compounds	O
15	O
,	O
31	O
and	O
32	O
to	O
models	O
of	O
5-HT1A	S-GP
receptor	O
and	O
SERT	S-GP
confirm	O
the	O
results	O
of	O
biological	O
tests	O
.	O
Due	O
to	O
high	O
affinity	O
for	O
the	O
5-HT1A	S-GP
receptor	O
and	O
moderate	O
affinity	O
for	O
SERT	S-GP
,	O
compounds	O
31	O
,	O
32	O
,	O
35	O
,	O
and	O
37	O
were	O
evaluated	O
for	O
their	O
affinity	O
for	O
D2L	S-GP
,	O
5-HT6	S-GP
,	O
5-HT7	S-GP
and	O
5-HT2A	S-GP
receptors	O
.	O
In	O
vivo	O
tests	O
,	O
in	O
turn	O
,	O
resulted	O
in	O
determining	O
the	O
functional	O
activity	O
of	O
compounds	O
15	O
,	O
18	O
,	O
19	O
and	O
30	O
to	O
the	O
5-HT1A	S-GP
receptor	O
.	O
The	O
results	O
of	O
these	O
tests	O
indicate	O
that	O
all	O
of	O
the	O
ligands	O
possess	O
properties	O
characteristic	O
of	O
5-HT1A	S-GP
receptor	O
agonists	O
.	O

Marked	O
decline	O
in	O
beta	O
cell	O
function	O
during	O
pregnancy	O
leads	O
to	O
the	O
development	O
of	O
glucose	S-chemical
intolerance	O
in	O
Japanese	O
women	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
glucose	S-chemical
metabolism	O
longitudinally	O
during	O
pregnancy	O
to	O
explore	O
mechanisms	O
underlying	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
.	O
We	O
reviewed	O
a	O
total	O
of	O
62	O
pregnant	O
Japanese	O
women	O
who	O
underwent	O
a	O
75g	O
oral	O
glucose	S-chemical
tolerance	O
test	O
(	O
OGTT	O
)	O
twice	O
during	O
pregnancy	O
(	O
median	O
:	O
early	O
,	O
13	O
;	O
late	O
,	O
28	O
weeks	O
'	O
gestation	O
)	O
because	O
of	O
positive	O
GDM	O
screening	O
.	O
All	O
showed	O
normal	O
OGTT	O
results	O
in	O
early	O
pregnancy	O
.	O
Based	O
on	O
late	O
OGTT	O
,	O
15	O
had	O
GDM	O
(	O
late-onset	O
GDM	O
)	O
and	O
47	O
normal	O
glucose	S-chemical
tolerance	O
(	O
NGT	O
)	O
.	O
In	O
early	O
pregnancy	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
insulin	S-GP
sensitivity	O
(	O
insulin	S-GP
sensitivity	O
index	O
derived	O
from	O
OGTT	O
[	O
ISOGTT	O
]	O
and	O
homeostasis	O
model	O
assessment	O
for	O
insulin	S-GP
resistance	O
[	O
HOMA-IR	O
]	O
)	O
and	O
insulin	S-GP
secretion	O
(	O
a	O
ratio	O
of	O
the	O
total	O
area-under-the-	O
insulin	S-GP
-curve	O
to	O
the	O
total	O
area-under-the-	O
glucose	S-chemical
-curve	O
[	O
AUCins/glu	O
]	O
and	O
insulin	S-GP
ogenic	O
index	O
[	O
IGI	O
]	O
)	O
between	O
the	O
NGT	O
and	O
late-onset	O
GDM	O
groups	O
.	O
In	O
each	O
group	O
,	O
insulin	S-GP
sensitivity	O
significantly	O
decreased	O
from	O
early	O
to	O
late	O
pregnancy	O
,	O
most	O
in	O
the	O
late-onset	O
GDM	O
group	O
(	O
each	O
p	O
<	O
0.05	O
)	O
.	O
The	O
insulin	O
secretion	O
showed	O
no	O
significant	O
changes	O
with	O
advancing	O
pregnancy	O
in	O
both	O
of	O
the	O
groups	O
,	O
although	O
late-onset	O
GDM	O
showed	O
significantly	O
lower	O
IGI	O
compared	O
with	O
NGT	O
in	O
late	O
OGTT	O
(	O
p	O
<	O
0.05	O
)	O
.	O
When	O
assessed	O
beta	O
cell	O
function	O
by	O
OGTT-derived	O
disposition	O
index	O
(	O
i.e	O
.	O
Insulin	S-GP
Secretion-Sensitivity	O
Index-2	O
and	O
IGI/fasting	O
insulin	S-GP
)	O
,	O
the	O
indices	O
significantly	O
decreased	O
from	O
early	O
to	O
late	O
pregnancy	O
in	O
the	O
both	O
groups	O
(	O
each	O
p	O
<	O
0.05	O
)	O
.	O
Women	O
with	O
late-onset	O
GDM	O
showed	O
significantly	O
lower	O
indices	O
compared	O
with	O
NGT	O
(	O
each	O
p	O
<	O
0.05	O
)	O
.	O
The	O
failure	O
of	O
beta	O
cell	O
to	O
compensate	O
for	O
decreased	O
insulin	S-GP
sensitivity	O
could	O
contribute	O
to	O
the	O
development	O
of	O
the	O
late-onset	O
GDM	O
.	O

Brugada	O
syndrome	O
without	O
mutation	O
of	O
the	O
cardiac	B-GP
sodium	I-GP
channel	E-GP
gene	O
in	O
a	O
Taiwanese	O
patient	O
.	O
We	O
describe	O
a	O
45-year-old	O
Taiwanese	O
man	O
with	O
specific	O
features	O
of	O
Brugada	O
syndrome	O
but	O
no	O
clinical	O
features	O
of	O
structural	O
heart	O
disease	O
.	O
He	O
was	O
successfully	O
treated	O
with	O
an	O
implantable	O
cardioverter-defibrillator	O
.	O
His	O
electrocardiogram	O
(	O
ECG	O
)	O
patterns	O
changed	O
intermittently	O
.	O
Alpha-adrenoceptor	S-GP
stimulation	O
and	O
beta-adrenoceptor	S-GP
blockade	O
augmented	O
the	O
characteristic	O
ST-segment	O
elevation	O
,	O
whereas	O
alpha-adrenoceptor	S-GP
blockade	O
and	O
beta-adrenoceptor	S-GP
stimulation	O
mitigated	O
the	O
ST-segment	O
elevation	O
.	O
Intravenous	O
procainamide	S-chemical
administration	O
did	O
not	O
aggravate	O
ST-segment	O
elevation	O
when	O
ECG	O
had	O
shown	O
coved	O
ST	O
elevation	O
in	O
the	O
right	O
precordial	O
leads	O
.	O
Molecular	O
study	O
did	O
not	O
reveal	O
the	O
same	O
mutations	O
in	O
the	O
cardiac	B-GP
sodium	I-GP
channel	E-GP
gene	O
(	O
SCN5A	S-GP
)	O
as	O
previously	O
reported	O
in	O
Brugada	O
syndrome	O
.	O
This	O
case	O
demonstrates	O
the	O
genetic	O
heterogeneity	O
of	O
SCN5A	S-GP
in	O
Brugada	O
syndrome	O
.	O

Cooperative	O
effects	O
for	O
CYP2E1	S-GP
differ	O
between	O
styrene	S-chemical
and	O
its	O
metabolites	O
.	O
Abstract	O
1	O
.	O
Cooperative	O
interactions	O
are	O
frequently	O
observed	O
in	O
the	O
metabolism	O
of	O
drugs	O
and	O
pollutants	O
by	O
cytochrome	B-GP
P450s	E-GP
;	O
nevertheless	O
,	O
the	O
molecular	O
determinants	O
for	O
cooperativity	O
remain	O
elusive	O
.	O
Previously	O
,	O
we	O
demonstrated	O
that	O
steady-state	O
styrene	O
metabolism	O
by	O
CYP2E1	S-GP
exhibits	O
positive	O
cooperativity	O
.	O
2	O
.	O
We	O
hypothesized	O
that	O
styrene	S-chemical
metabolites	O
have	O
lower	O
affinity	O
than	O
styrene	S-chemical
toward	O
CYP2E1	S-GP
and	O
limited	O
ability	O
to	O
induce	O
cooperative	O
effects	O
during	O
metabolism	O
.	O
To	O
test	O
the	O
hypothesis	O
,	O
we	O
determined	O
the	O
potency	O
and	O
mechanism	O
of	O
inhibition	O
for	O
styrene	S-chemical
and	O
its	O
metabolites	O
toward	O
oxidation	O
of	O
4-nitrophenol	S-chemical
using	O
CYP2E1	S-GP
Supersomes®	O
and	O
human	O
liver	O
microsomes	O
.	O
3	O
.	O
Styrene	S-chemical
inhibited	O
the	O
reaction	O
through	O
a	O
mixed	O
cooperative	O
mechanism	O
with	O
high	O
affinity	O
for	O
the	O
catalytic	O
site	O
(	O
67	O
µM	O
)	O
and	O
lower	O
affinity	O
for	O
the	O
cooperative	O
site	O
(	O
1100	O
µM	O
)	O
,	O
while	O
increasing	O
substrate	O
turnover	O
at	O
high	O
concentrations	O
.	O
Styrene	B-chemical
oxide	E-chemical
and	O
4-vinylphenol	S-chemical
possessed	O
similar	O
affinity	O
for	O
CYP2E1	S-GP
.	O
Styrene	B-chemical
oxide	E-chemical
behaved	O
cooperatively	O
like	O
styrene	S-chemical
,	O
but	O
4-vinylphenol	S-chemical
decreased	O
turnover	O
at	O
high	O
concentrations	O
.	O
Styrene	B-chemical
glycol	E-chemical
was	O
a	O
very	O
poor	O
competitive	O
inhibitor	O
.	O
Among	O
all	O
compounds	O
,	O
there	O
was	O
a	O
positive	O
correlation	O
with	O
binding	O
and	O
hydrophobicity	O
.	O
4	O
.	O
Taken	O
together	O
,	O
these	O
findings	O
for	O
CYP2E1	S-GP
further	O
validate	O
contributions	O
of	O
cooperative	O
mechanisms	O
to	O
metabolic	O
processes	O
,	O
demonstrate	O
the	O
role	O
of	O
molecular	O
structure	O
on	O
those	O
mechanisms	O
and	O
underscore	O
the	O
potential	O
for	O
heterotropic	O
cooperative	O
effects	O
between	O
different	O
compounds	O
.	O

Cinitapride	S-chemical
protects	O
against	O
ethanol	S-chemical
-induced	O
gastric	O
mucosal	O
injury	O
in	O
rats	O
:	O
role	O
of	O
5-hydroxytryptamine	S-chemical
,	O
prostaglandins	S-chemical
and	O
sulfhydryl	S-chemical
compounds	O
.	O
This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
gastroprotective	O
properties	O
of	O
cinitapride	S-chemical
(	O
CNT	S-chemical
)	O
,	O
a	O
novel	O
prokinetic	O
benzamide	S-chemical
derivative	O
agonist	O
of	O
5-HT4	S-GP
and	O
5-HT1	S-GP
receptors	O
and	O
5-HT2	S-GP
antagonist	O
,	O
on	O
mucosal	O
injury	O
produced	O
by	O
50	O
%	O
(	O
v/v	O
)	O
ethanol	S-chemical
.	O
Results	O
were	O
compared	O
with	O
those	O
for	O
5-hydroxytryptamine	S-chemical
(	O
5-HT	S-chemical
:	O
10	O
mg	O
kg-1	O
)	O
.	O
The	O
possible	O
involvements	O
of	O
gastric	O
mucus	O
secretion	O
,	O
endogenous	O
prostaglandins	S-chemical
(	O
PGs	S-chemical
)	O
and	O
sulfhydryl	S-chemical
compounds	O
(	O
SH	S-chemical
)	O
in	O
the	O
protection	O
mediated	O
by	O
CNT	S-chemical
were	O
also	O
examined	O
.	O
Intraperitoneal	O
administration	O
of	O
CNT	S-chemical
(	O
0.50	O
and	O
1	O
mg	O
kg-1	O
)	O
,	O
30	O
min	O
before	O
ethanol	S-chemical
,	O
significantly	O
prevented	O
gastric	O
ulceration	O
and	O
increased	O
the	O
hexosamine	S-chemical
content	O
of	O
gastric	O
mucus	O
.	O
CNT	S-chemical
(	O
1	O
mg	O
kg-1	O
)	O
also	O
produced	O
a	O
significant	O
increase	O
in	O
gastric	O
mucosal	O
levels	O
of	O
PGE2	S-chemical
,	O
but	O
did	O
not	O
induce	O
any	O
significant	O
changes	O
in	O
SH	S-chemical
values	O
.	O
On	O
the	O
contrary	O
,	O
pretreatment	O
with	O
5-HT	S-chemical
worsened	O
ethanol	S-chemical
-induced	O
erosions	O
,	O
however	O
,	O
did	O
not	O
affect	O
gastric	O
mucus	O
secretion	O
,	O
glycoprotein	S-GP
content	O
or	O
PGE2	S-chemical
levels	O
,	O
although	O
the	O
non-protein	O
SH	S-chemical
fraction	O
was	O
significantly	O
decreased	O
.	O
The	O
present	O
results	O
demonstrate	O
that	O
the	O
gastroprotective	O
effects	O
of	O
CNT	S-chemical
could	O
be	O
partly	O
explained	O
by	O
a	O
complex	O
PG	S-chemical
dependent	O
mechanism	O
.	O
We	O
suggest	O
that	O
5-HT	S-chemical
dependent	O
mechanisms	O
through	O
5-HT2	S-GP
receptor	O
blockade	O
and	O
5-HT1	S-GP
receptor	O
activation	O
could	O
be	O
also	O
involved	O
.	O

Overview	O
of	O
monoclonal	O
antibodies	O
and	O
small	O
molecules	O
targeting	O
the	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
pathway	O
in	O
colorectal	O
cancer	O
.	O
The	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
(	O
EGFR	S-GP
)	O
provides	O
survival	O
signals	O
and	O
is	O
overexpressed	O
in	O
the	O
majority	O
of	O
colorectal	O
cancers	O
.	O
As	O
more	O
is	O
learned	O
about	O
the	O
molecular	O
details	O
of	O
EGFR	S-GP
signaling	O
,	O
antibodies	O
can	O
be	O
designed	O
to	O
interfere	O
with	O
specific	O
domains	O
of	O
the	O
EGFR	S-GP
molecule	O
.	O
In	O
this	O
review	O
,	O
we	O
analyze	O
preclinical	O
and	O
current	O
clinical	O
data	O
on	O
EGFR	S-GP
-targeting	O
molecules	O
and	O
their	O
potential	O
role	O
in	O
the	O
treatment	O
of	O
colorectal	O
cancer	O
.	O
Cetuximab	O
binds	O
to	O
domain	O
III	O
of	O
EGFR	S-GP
and	O
hinders	O
ligand	O
binding	O
.	O
It	O
is	O
now	O
approved	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
for	O
metastatic	O
colorectal	O
cancer	O
treatment	O
.	O
Panitumumab	O
is	O
another	O
widely	O
studied	O
anti-	O
EGFR	S-GP
antibody	O
with	O
similar	O
properties	O
.	O
Bispecific	O
antibodies	O
are	O
modified	O
immunoglobulin	S-GP
molecules	O
containing	O
2	O
different	O
binding	O
specificities	O
.	O
These	O
antibodies	O
can	O
redirect	O
the	O
immune	O
response	O
against	O
tumor	O
cells	O
by	O
tethering	O
effector	O
cells	O
such	O
as	O
CD3e	S-GP
-expressing	O
T	O
cells	O
or	O
CD16	S-GP
-expressing	O
natural	O
killer	O
cells	O
and	O
granulocytes	O
to	O
the	O
surface	O
of	O
cancer	O
cells	O
.	O
Tyrosine	B-GP
kinase	E-GP
inhibitors	O
are	O
quinazoline	S-chemical
-derived	O
,	O
low	O
molecular	O
weight	O
synthetic	O
molecules	O
that	O
can	O
block	O
the	O
intracellular	O
tyrosine	B-GP
kinase	I-GP
domain	E-GP
of	O
several	O
receptors	O
,	O
including	O
EGFR	S-GP
,	O
Erb2	S-GP
,	O
and	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	I-GP
receptor	E-GP
,	O
and	O
thereby	O
inhibit	O
ligand-induced	O
receptor	O
phosphorylation	O
and	O
abrogate	O
the	O
biologic	O
effect	O
of	O
EGFR	S-GP
signaling	O
.	O
The	O
presence	O
of	O
skin	O
rash	O
and	O
EGFR	S-GP
gene	O
amplification	O
have	O
been	O
advanced	O
as	O
possible	O
predictors	O
of	O
clinical	O
effectiveness	O
of	O
targeted	O
anti-	O
EGFR	S-GP
therapies	O
.	O

Evidence	O
that	O
an	O
alpha	B-GP
2A-adrenoceptor	E-GP
subtype	O
mediates	O
antinociception	O
in	O
mice	O
.	O
In	O
the	O
hot-plate	O
test	O
in	O
mice	O
,	O
the	O
antinociceptive	O
action	O
of	O
the	O
alpha	B-GP
2-adrenoceptor	E-GP
agonist	O
,	O
UK	B-chemical
14,304	E-chemical
,	O
was	O
abolished	O
by	O
the	O
alpha	B-GP
2-adrenoceptor	E-GP
antagonist	O
,	O
idazoxan	S-chemical
,	O
the	O
potent	O
alpha	B-GP
2A-adrenoceptor	E-GP
antagonist	O
,	O
RX	B-chemical
821002	E-chemical
and	O
the	O
preferential	O
alpha	B-GP
2A-adrenoceptor	E-GP
antagonist	O
,	O
BRL	B-chemical
44408	E-chemical
.	O
In	O
contrast	O
,	O
the	O
preferential	O
alpha	B-GP
2B-	I-GP
(	I-GP
and	I-GP
alpha	I-GP
2C	I-GP
)	I-GP
-adrenoceptor	E-GP
ligands	O
(	O
'antagonists	O
'	O
)	O
,	O
ARC-239	S-chemical
,	O
BRL	B-chemical
41992	E-chemical
and	O
prazosin	S-chemical
were	O
inactive	O
.	O
The	O
preferential	O
alpha	B-GP
2A-adrenoceptor	E-GP
partial	O
agonist	O
,	O
guanfacine	S-chemical
,	O
partially	O
inhibited	O
UK	B-chemical
14,304	E-chemical
-induced	O
antinociception	O
.	O
Further	O
,	O
guanfacine	S-chemical
BRL	B-chemical
44408	E-chemical
reversibly	O
elicited	O
submaximal	O
antinociception	O
.	O
It	O
is	O
concluded	O
that	O
alpha	B-GP
2A-adrenoceptors	E-GP
mediate	O
antinociception	O
in	O
mice	O
.	O

An	O
analysis	O
of	O
skeletal	O
development	O
in	O
osteoblast-	O
and	O
chondrocyte-specific	O
Runx2	S-GP
knockout	O
mice	O
.	O
Global	O
gene	O
deletion	O
studies	O
in	O
mice	O
and	O
humans	O
have	O
established	O
the	O
pivotal	O
role	O
of	O
runt	B-GP
related	I-GP
transcription	I-GP
factor-2	E-GP
(	O
Runx2	S-GP
)	O
in	O
both	O
intramembranous	O
and	O
endochondral	O
ossification	O
processes	O
during	O
skeletogenesis	O
.	O
In	O
this	O
study	O
,	O
we	O
for	O
the	O
first	O
time	O
generated	O
mice	O
carrying	O
a	O
conditional	O
Runx2	S-GP
allele	O
with	O
exon	O
4	O
,	O
which	O
encodes	O
the	O
Runt	B-GP
domain	E-GP
,	O
flanked	O
by	O
loxP	B-GP
sites	E-GP
.	O
These	O
mice	O
were	O
crossed	O
with	O
α1	B-GP
(	I-GP
I	I-GP
)	I-GP
-collagen	E-GP
-Cre	O
or	O
α1	B-GP
(	I-GP
II	I-GP
)	I-GP
-collagen	E-GP
-Cre	O
transgenic	O
mice	O
to	O
obtain	O
osteoblast-	O
or	O
chondrocyte-specific	O
Runx2	S-GP
deficient	O
mice	O
,	O
respectively	O
.	O
As	O
seen	O
in	O
Runx2	S-GP
(	O
-/-	O
)	O
mice	O
,	O
perinatal	O
lethality	O
was	O
observed	O
in	O
α1	B-GP
(	I-GP
II	I-GP
)	E-GP
-Cre	O
;	O
Runx2	S-GP
(	O
flox/flox	O
)	O
mice	O
,	O
but	O
this	O
was	O
not	O
the	O
case	O
in	O
animals	O
in	O
which	O
α1	B-GP
(	I-GP
I	I-GP
)	I-GP
-collagen	E-GP
-Cre	O
was	O
used	O
to	O
delete	O
Runx2	S-GP
.	O
When	O
using	O
double	O
staining	O
with	O
Alizarin	B-chemical
red	E-chemical
for	O
mineralized	O
matrix	O
and	O
Alcian	B-chemical
blue	E-chemical
for	O
cartilaginous	O
matrix	O
,	O
we	O
observed	O
previously	O
that	O
mineralization	O
was	O
totally	O
absent	O
at	O
embryonic	O
day	O
15.5	O
throughout	O
the	O
body	O
in	O
Runx2	S-GP
(	O
-/-	O
)	O
mice	O
,	O
but	O
was	O
found	O
in	O
areas	O
undergoing	O
intramembranous	O
ossification	O
such	O
as	O
skull	O
and	O
clavicles	O
in	O
α1	B-GP
(	I-GP
II	I-GP
)	E-GP
-Cre	O
;	O
Runx2	S-GP
(	O
flox/flox	O
)	O
mice	O
.	O
In	O
newborn	O
α1	B-GP
(	I-GP
II	I-GP
)	E-GP
-Cre	O
;	O
Runx2	S-GP
(	O
flox/flox	O
)	O
mice	O
,	O
mineralization	O
impairment	O
was	O
restricted	O
to	O
skeletal	O
areas	O
undergoing	O
endochondral	O
ossification	O
including	O
long	O
bones	O
and	O
vertebrae	O
.	O
In	O
contrast	O
,	O
no	O
apparent	O
skeletal	O
abnormalities	O
were	O
seen	O
in	O
mutant	O
embryo	O
,	O
newborn	O
,	O
and	O
3-	O
to	O
6-week	O
old-mice	O
in	O
which	O
Runx2	S-GP
had	O
been	O
deleted	O
with	O
the	O
α1	B-GP
(	I-GP
I	I-GP
)	I-GP
-collagen	E-GP
-Cre	O
driver	O
.	O
These	O
results	O
suggest	O
that	O
Runx2	S-GP
is	O
absolutely	O
required	O
for	O
endochondral	O
ossification	O
during	O
embryonic	O
and	O
postnatal	O
skeletogenesis	O
,	O
but	O
that	O
disrupting	O
its	O
expression	O
in	O
already	O
committed	O
osteoblasts	O
as	O
achieved	O
here	O
with	O
the	O
α1	B-GP
(	I-GP
I	I-GP
)	I-GP
-collagen	E-GP
-Cre	O
driver	O
does	O
not	O
affect	O
overtly	O
intramembranous	O
and	O
endochondral	O
ossification	O
.	O
The	O
Runx2	S-GP
floxed	O
allele	O
established	O
here	O
is	O
undoubtedly	O
useful	O
for	O
investigating	O
the	O
role	O
of	O
Runx2	S-GP
in	O
particular	O
cells	O
.	O
©	O
2013	O
American	O
Society	O
for	O
Bone	O
and	O
Mineral	O
Research	O
.	O

Oxytocin	B-GP
receptor	E-GP
binding	O
and	O
uterotonic	O
activity	O
of	O
carbetocin	S-chemical
and	O
its	O
metabolites	O
following	O
enzymatic	O
degradation	O
.	O
Metabolites	O
of	O
the	O
analogue	O
1-deamino-1-carba-2-tyrosine	B-chemical
(	I-chemical
O-methyl	I-chemical
)	I-chemical
-oxytocin	E-chemical
(	O
carbetocin	S-chemical
)	O
following	O
incubation	O
with	O
a	O
rat	O
kidney	O
homogenate	O
were	O
isolated	O
and	O
their	O
pharmacodynamic	O
properties	O
investigated	O
.	O
Apart	O
from	O
the	O
parent	O
compound	O
two	O
metabolites	O
were	O
identified	O
namely	O
desGlyNH2	S-chemical
-	O
carbetocin	S-chemical
(	O
carbetocin	S-chemical
metabolite	O
I	O
)	O
and	O
desLeuGlyNH2	S-chemical
-	O
carbetocin	S-chemical
(	O
carbetocin	S-chemical
metabolite	O
II	O
)	O
.	O
Both	O
carbetocin	S-chemical
,	O
carbetocin	S-chemical
metabolite	O
I	O
and	O
carbetocin	S-chemical
metabolite	O
II	O
displayed	O
binding	O
affinities	O
to	O
the	O
myometrial	O
oxytocin	B-GP
receptor	E-GP
of	O
a	O
similar	O
magnitude	O
as	O
oxytocin	S-chemical
.	O
Carbetocin	S-chemical
was	O
found	O
to	O
have	O
agonistic	O
properties	O
on	O
isolated	O
myometrial	O
strips	O
and	O
it	O
was	O
found	O
to	O
exert	O
this	O
effect	O
through	O
generation	O
of	O
inositol	B-chemical
phosphates	E-chemical
,	O
as	O
is	O
the	O
case	O
for	O
oxytocin	S-chemical
.	O
However	O
,	O
maximal	O
contractile	O
effect	O
of	O
carbetocin	S-chemical
was	O
approximately	O
50	O
%	O
lower	O
than	O
that	O
of	O
oxytocin	S-chemical
(	O
2.70	O
+/-	O
0.12	O
g	O
compared	O
to	O
5.22	O
+/-	O
0.26	O
g	O
)	O
and	O
EC50	O
was	O
approximately	O
ten	O
times	O
higher	O
(	O
48.0	O
+/-	O
8.20	O
nM	O
compared	O
to	O
5.62	O
+/-	O
1.22	O
nM	O
)	O
.	O
Neither	O
carbetocin	S-chemical
metabolite	O
I	O
nor	O
carbetocin	S-chemical
metabolite	O
II	O
were	O
able	O
to	O
contract	O
isolated	O
myometrial	O
tissue	O
.	O
All	O
three	O
compounds	O
displayed	O
antagonistic	O
properties	O
against	O
oxytocin	S-chemical
in	O
vitro	O
,	O
with	O
carbetocin	S-chemical
being	O
the	O
strongest	O
inhibitor	O
(	O
pA2	O
=	O
8.21	O
)	O
and	O
carbetocin	S-chemical
metabolite	O
II	O
(	O
pA2	O
=	O
8.01	O
)	O
being	O
stronger	O
than	O
carbetocin	S-chemical
metabolite	O
I	O
(	O
pA2	O
=	O
7.81	O
)	O
.	O
These	O
results	O
indicate	O
that	O
carbetocin	S-chemical
is	O
a	O
partial	O
agonist/antagonist	O
to	O
the	O
oxytocin	B-GP
receptor	E-GP
while	O
the	O
two	O
metabolites	O
carbetocin	S-chemical
metabolite	O
I	O
and	O
carbetocin	S-chemical
metabolite	O
II	O
are	O
pure	O
antagonists	O
.	O
All	O
three	O
analogues	O
bound	O
to	O
the	O
myometrial	O
vasopressin	B-GP
V1	I-GP
receptor	E-GP
,	O
albeit	O
with	O
much	O
lower	O
affinities	O
than	O
to	O
the	O
oxytocin	B-GP
receptor	E-GP
.	O
Carbetocin	S-chemical
metabolite	O
II	O
showed	O
the	O
weakest	O
binding	O
affinity	O
of	O
33.7	O
+/-	O
7.34	O
nM	O
compared	O
to	O
7.24	O
+/-	O
0.29	O
nM	O
for	O
carbetocin	S-chemical
and	O
9.89	O
+	O
2.80	O
nM	O
for	O
carbetocin	S-chemical
metabolite	O
I	O
.	O
Only	O
carbetocin	S-chemical
bound	O
to	O
the	O
renal	O
vasopressin	B-GP
V2	I-GP
receptor	E-GP
though	O
the	O
binding	O
affinity	O
was	O
very	O
low	O
(	O
61.3	O
+/-	O
14.6	O
nM	O
)	O
.	O

Exposure	O
to	O
DEHP	S-chemical
decreased	O
four	O
fatty	B-chemical
acid	E-chemical
levels	O
in	O
plasma	O
of	O
prepartum	O
mice	O
.	O
Maternal	O
exposure	O
to	O
di	B-chemical
(	I-chemical
2-ethylhexyl	I-chemical
)	I-chemical
phthalate	E-chemical
(	O
DEHP	S-chemical
)	O
decreased	O
the	O
plasma	O
triglyceride	S-chemical
in	O
prepartum	O
mice	O
.	O
To	O
identify	O
the	O
fatty	B-chemical
acid	E-chemical
(	O
FA	O
)	O
species	O
involved	O
and	O
to	O
understand	O
the	O
underlying	O
mechanisms	O
,	O
pregnant	O
Sv/129	O
wild-type	O
(	O
mPPARα	S-GP
)	O
,	O
peroxisome	B-GP
proliferator-activated	I-GP
receptor	I-GP
α	E-GP
-null	O
(	O
Pparα	S-GP
-null	O
)	O
and	O
humanized	B-GP
PPARα	E-GP
(	O
hPPARα	S-GP
)	O
mice	O
were	O
treated	O
with	O
diets	O
containing	O
0	O
%	O
,	O
0.01	O
%	O
,	O
0.05	O
%	O
or	O
0.1	O
%	O
DEHP	S-chemical
.	O
Dams	O
were	O
dissected	O
on	O
gestational	O
day	O
18	O
together	O
with	O
fetuses	O
,	O
and	O
on	O
postnatal	O
day	O
2	O
together	O
with	O
newborns	O
.	O
n-3/n-6	B-chemical
polyunsaturated	I-chemical
,	I-chemical
saturated	I-chemical
,	I-chemical
and	I-chemical
monounsaturated	I-chemical
FAs	E-chemical
in	O
maternal	O
plasma	O
and	O
in	O
liver	O
of	O
wild-type	O
offspring	O
,	O
and	O
representative	O
enzymes	O
for	O
FA	O
desaturation	O
and	O
elongation	O
in	O
maternal	O
liver	O
,	O
were	O
measured	O
.	O
The	O
plasma	O
levels	O
of	O
linoleic	B-chemical
acid	E-chemical
,	O
α-linolenic	B-chemical
acid	E-chemical
,	O
palmitic	B-chemical
acid	E-chemical
and	O
oleic	B-chemical
acid	E-chemical
were	O
higher	O
in	O
the	O
pregnant	O
control	O
mPPARa	S-GP
mice	O
than	O
in	O
Ppara	S-GP
-null	O
and	O
hPPARa	S-GP
mice	O
.	O
DEHP	S-chemical
exposure	O
significantly	O
decreased	O
the	O
levels	O
of	O
these	O
four	O
FAs	O
only	O
in	O
pregnant	O
mPPARα	S-GP
mice	O
.	O
Plasma	O
levels	O
of	O
many	O
FAs	O
were	O
higher	O
in	O
pregnant	O
mice	O
than	O
in	O
postpartum	O
ones	O
in	O
a	O
genotype-independent	O
manner	O
,	O
while	O
it	O
was	O
lower	O
in	O
the	O
livers	O
of	O
fetuses	O
than	O
pups	O
.	O
DEHP	S-chemical
exposure	O
slightly	O
increased	O
hepatic	O
arachidonic	B-chemical
acid	E-chemical
,	O
α-linolenic	B-chemical
acid	E-chemical
,	O
palmitoleic	B-chemical
acid	E-chemical
and	O
oleic	B-chemical
acid	E-chemical
in	O
fetuses	O
,	O
but	O
not	O
in	O
pups	O
.	O
However	O
,	O
DEHP	S-chemical
exposure	O
did	O
not	O
clearly	O
influence	O
FA	B-GP
desaturase	I-GP
1	I-GP
and	I-GP
2	E-GP
nor	O
elongase	B-GP
2	I-GP
and	I-GP
5	E-GP
expressions	O
in	O
the	O
liver	O
of	O
all	O
maternal	O
mice	O
.	O
Taken	O
together	O
,	O
the	O
levels	O
of	O
plasma	O
four	O
FAs	O
with	O
shorter	O
carbon	S-chemical
chains	O
were	O
higher	O
in	O
pregnant	O
mPPARα	S-GP
mice	O
than	O
in	O
other	O
genotypes	O
,	O
and	O
DEHP	S-chemical
exposure	O
decreased	O
these	O
specific	O
FA	O
concentrations	O
only	O
in	O
mPPARα	S-GP
mice	O
,	O
similarly	O
to	O
triglyceride	S-chemical
levels	O
.	O

Amino	B-chemical
acid	E-chemical
composition	O
,	O
antinutrients	O
and	O
allergens	O
in	O
the	O
peanut	O
protein	O
fraction	O
obtained	O
by	O
an	O
aqueous	O
enzymatic	O
process	O
.	O
Enzyme-assisted	O
aqueous	O
extraction	O
(	O
EAE	O
)	O
of	O
peanut	O
kernel	O
was	O
used	O
to	O
extract	O
oil	O
and	O
protein	O
.	O
The	O
aqueous	O
fraction	O
(	O
AF	O
)	O
obtained	O
by	O
EAE	O
had	O
a	O
better	O
essential	O
amino	B-chemical
acid	E-chemical
profile	O
than	O
the	O
residues	O
obtained	O
by	O
solvent	O
extraction	O
(	O
Rs	O
)	O
and	O
cold	O
pressing	O
(	O
Rc	O
)	O
.	O
No	O
major	O
difference	O
in	O
the	O
trypsin	S-GP
inhibitor	O
activity	O
among	O
AF	O
,	O
Rs	O
and	O
Rc	O
was	O
observed	O
;	O
however	O
,	O
the	O
trypsin	S-GP
inhibitor	O
activity	O
was	O
drastically	O
reduced	O
in	O
the	O
residue	O
obtained	O
after	O
EAE	O
.	O
AF	O
was	O
subjected	O
to	O
MALDI-TOF/MS	O
,	O
revealing	O
it	O
to	O
be	O
rich	O
in	O
peptides	O
(	O
107	O
)	O
with	O
molecular	O
masses	O
from	O
m/z	O
700	O
to	O
2369Da	O
.	O
AF	O
had	O
an	O
extremely	O
low	O
phytate	S-chemical
content	O
and	O
was	O
rich	O
in	O
peptides	O
,	O
which	O
could	O
be	O
used	O
as	O
a	O
food	O
supplement	O
.	O
ESI-MS/MS	O
data	O
were	O
used	O
for	O
the	O
identification	O
of	O
major	O
peanut	B-GP
allergens	E-GP
,	O
viz.	O
,	O
Ara	B-GP
h1	I-GP
,	I-GP
h3	I-GP
,	I-GP
h6-8	E-GP
.	O
Their	O
allergenic	O
potential	O
needs	O
to	O
be	O
established	O
.	O

Exploring	O
the	O
effect	O
of	O
N	S-chemical
-substitution	O
in	O
nor-lobelane	S-chemical
on	O
the	O
interaction	O
with	O
VMAT2	S-GP
:	O
discovery	O
of	O
a	O
potential	O
clinical	O
candidate	O
for	O
treatment	O
of	O
methamphetamine	S-chemical
abuse	O
.	O
A	O
series	O
of	O
N	S-chemical
-substituted	O
lobelane	S-chemical
analogues	O
was	O
synthesized	O
and	O
evaluated	O
for	O
their	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
dihydrotetrabenazine	E-chemical
binding	O
affinity	O
at	O
the	O
vesicular	B-GP
monoamine	I-GP
transporter	E-GP
and	O
for	O
their	O
inhibition	O
of	O
vesicular	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
dopamine	E-chemical
uptake	O
.	O
Compound	O
19a	O
,	O
which	O
contains	O
an	O
N-1,2	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
-dihydroxypropyl	E-chemical
group	O
,	O
had	O
been	O
identified	O
as	O
a	O
potential	O
clinical	O
candidate	O
for	O
the	O
treatment	O
of	O
methamphetamine	S-chemical
abuse	O
.	O

Epithelioid	O
gastrointestinal	O
stromal	O
tumor	O
with	O
PDGFRA	S-GP
activating	O
mutation	O
and	O
immunoreactivity	O
.	O
The	O
authors	O
report	O
a	O
unique	O
case	O
of	O
an	O
intra-abdominal	O
,	O
epithelioid	O
mesenchymal	O
tumor	O
that	O
had	O
an	O
activating	O
mutation	O
of	O
PDGFRA	S-GP
and	O
a	O
strong	O
PDGFRA	S-GP
immunoreactivity	O
but	O
lacked	O
both	O
c-kit	S-GP
mutation	O
and	O
c-kit	S-GP
protein	O
(	O
CD117	S-GP
)	O
expression	O
.	O
IHC	O
study	O
showed	O
that	O
the	O
tumor	O
cells	O
were	O
diffusely	O
and	O
strongly	O
positive	O
for	O
PDGFRA	S-GP
,	O
vimentin	S-GP
,	O
CD34	S-GP
,	O
and	O
Bcl-2	S-GP
but	O
completely	O
negative	O
for	O
CD117	S-GP
as	O
well	O
as	O
for	O
muscle	O
,	O
epithelial	O
,	O
endothelial	O
,	O
endocrine	O
,	O
mesothelial	O
,	O
neural	O
,	O
and	O
melanocytic	O
cell	O
markers	O
.	O
Molecular	O
study	O
revealed	O
a	O
mutation	O
at	O
the	O
juxtamembrane	O
domain	O
of	O
exon	O
12	O
in	O
PDGFRA	S-GP
gene	O
with	O
GTC	B-GP
to	I-GP
GAC	E-GP
transition	O
at	O
codon	O
561	O
(	O
V561D	S-GP
)	O
,	O
as	O
shown	O
in	O
the	O
previous	O
mutational	O
studies	O
on	O
gastrointestinal	O
stromal	O
tumor	O
(	O
GIST	O
)	O
.	O
This	O
case	O
likely	O
represents	O
an	O
example	O
of	O
GIST	O
with	O
PDGFRA	S-GP
activating	O
mutation	O
and	O
PDGFRA	S-GP
immunoreactivity	O
without	O
CD117	S-GP
positivity	O
,	O
which	O
has	O
not	O
been	O
documented	O
in	O
the	O
literature	O
.	O
STI	B-chemical
571	E-chemical
(	O
imatinib	B-chemical
mesylate	E-chemical
[	O
Gleevec	S-chemical
]	O
)	O
might	O
be	O
an	O
effective	O
therapy	O
in	O
this	O
case	O
,	O
since	O
Gleevec	S-chemical
targets	O
both	O
PDGFRA	S-GP
and	O
c-kit	S-GP
oncoproteins	O
.	O

Transgenic	O
expression	O
of	O
the	O
human	B-GP
Vitamin	I-GP
D	I-GP
receptor	E-GP
(	O
hVDR	S-GP
)	O
in	O
the	O
duodenum	O
of	O
VDR	S-GP
-null	O
mice	O
attenuates	O
the	O
age-dependent	O
decline	O
in	O
calcium	S-chemical
absorption	O
.	O
1,25	B-chemical
(	I-chemical
OH	I-chemical
)	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
D	I-chemical
(	I-chemical
3	I-chemical
)	E-chemical
regulates	O
calcium	S-chemical
homeostasis	O
through	O
its	O
actions	O
in	O
the	O
intestine	O
,	O
bone	O
,	O
and	O
kidney	O
.	O
These	O
actions	O
are	O
mediated	O
through	O
the	O
VDR	S-GP
.	O
To	O
determine	O
if	O
VDR	S-GP
's	O
actions	O
in	O
the	O
proximal	O
small	O
intestine	O
can	O
sufficiently	O
restore	O
calcium	S-chemical
homeostasis	O
,	O
we	O
generated	O
transgenic	O
mice	O
expressing	O
hVDR	S-GP
exclusively	O
in	O
the	O
duodenum	O
of	O
mVDR	S-GP
-null	O
mice	O
by	O
using	O
the	O
adenosine	B-GP
deaminase	I-GP
enhancer	E-GP
(	O
hVDR	S-GP
+/	O
mVDR	S-GP
-null	O
)	O
.	O
Unlike	O
wild-type	O
mice	O
,	O
hVDR	S-GP
+/	O
mVDR	S-GP
-null	O
mice	O
express	O
hVDR	S-GP
and	O
VDR	S-GP
target	O
genes	O
only	O
in	O
the	O
proximal	O
small	O
intestine	O
.	O
Despite	O
having	O
functional	O
hVDR	S-GP
in	O
the	O
proximal	O
small	O
intestine	O
,	O
hVDR	S-GP
+/	O
mVDR	S-GP
-null	O
mice	O
were	O
hypocalcaemic	O
when	O
fed	O
a	O
normal	O
rodent	O
diet	O
at	O
weaning	O
,	O
like	O
mVDR	S-GP
-null	O
mice	O
fed	O
the	O
same	O
diet	O
.	O
The	O
hypocalcemia	O
in	O
these	O
mice	O
is	O
prevented	O
if	O
they	O
are	O
given	O
the	O
rescue	O
diet	O
before	O
weaning	O
.	O
However	O
,	O
when	O
90-day-old	O
rachitic	O
mice	O
were	O
fed	O
a	O
rescue	O
diet	O
,	O
serum	O
calcium	S-chemical
improved	O
in	O
hVDR	S-GP
+/	O
mVDR	S-GP
-null	O
mice	O
,	O
but	O
not	O
in	O
mVDR	S-GP
-null	O
mice	O
.	O
In	O
conclusion	O
,	O
transgenic	O
hVDR	S-GP
in	O
the	O
proximal	O
small	O
intestine	O
of	O
hVDR	S-GP
+/	O
mVDR	S-GP
-null	O
mice	O
was	O
transcriptionally	O
active	O
and	O
regulated	O
calcium	S-chemical
absorption	O
,	O
but	O
VDR	S-GP
actions	O
elsewhere	O
in	O
the	O
intestine	O
are	O
probably	O
necessary	O
to	O
support	O
adequate	O
calcium	S-chemical
homeostasis	O
.	O
In	O
addition	O
,	O
hVDR	S-GP
+/	O
mVDR	S-GP
-null	O
mice	O
responded	O
better	O
to	O
the	O
late	O
rescue	O
diet	O
suggesting	O
that	O
expression	O
of	O
VDR	S-GP
in	O
the	O
proximal	O
small	O
intestine	O
protected	O
the	O
calcium	S-chemical
absorbing	O
machinery	O
from	O
age-dependent	O
decline	O
.	O

Fluorescence	O
lifetime	O
analysis	O
and	O
effect	O
of	O
magnesium	S-chemical
ions	O
on	O
binding	O
of	O
NADH	S-chemical
to	O
human	B-GP
aldehyde	I-GP
dehydrogenase	I-GP
1	E-GP
.	O
Aldehyde	B-GP
dehydrogenase	I-GP
1	E-GP
(	O
ALDH1A1	S-GP
)	O
catalyzes	O
the	O
oxidation	O
of	O
toxic	O
aldehydes	S-chemical
to	O
carboxylic	B-chemical
acids	E-chemical
.	O
Physiologic	O
levels	O
of	O
Mg	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
ions	O
decrease	O
ALDH1	S-GP
activity	O
in	O
part	O
by	O
increasing	O
NADH	S-chemical
binding	O
affinity	O
to	O
the	O
enzyme	O
.	O
By	O
using	O
time-resolved	O
fluorescence	O
spectroscopy	O
,	O
we	O
have	O
resolved	O
the	O
fluorescent	O
lifetimes	O
(	O
τ	O
)	O
of	O
free	O
NADH	S-chemical
in	O
solution	O
(	O
τ=0.4	O
ns	O
)	O
and	O
two	O
enzyme-bound	O
NADH	S-chemical
states	O
(	O
τ=2.0	O
ns	O
and	O
τ=7.7	O
ns	O
)	O
.	O
We	O
used	O
this	O
technique	O
to	O
investigate	O
the	O
effects	O
of	O
Mg	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
ions	O
on	O
the	O
ALDH1A1	S-GP
-	O
NADH	S-chemical
binding	O
characteristics	O
and	O
enzyme	O
catalysis	O
.	O
From	O
the	O
resolved	O
free	O
and	O
bound	O
NADH	S-chemical
fluorescence	O
signatures	O
,	O
the	O
KD	O
values	O
for	O
both	O
NADH	S-chemical
conformations	O
in	O
ALDH1A1	S-GP
ranged	O
from	O
about	O
24	O
μM	O
to	O
1	O
μM	O
for	O
Mg	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
ion	O
concentrations	O
of	O
0-6000	O
μM	O
,	O
respectively	O
.	O
The	O
rate	O
constants	O
for	O
dissociation	O
of	O
the	O
enzyme-	O
NADH	S-chemical
complex	O
ranged	O
from	O
0.03	O
s	O
(	O
-1	O
)	O
(	O
6000	O
μM	O
Mg	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
)	O
to	O
0.30s	O
(	O
-1	O
)	O
(	O
0	O
μM	O
Mg	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
)	O
as	O
determined	O
by	O
addition	O
of	O
excess	O
NAD	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
to	O
prevent	O
re-association	O
of	O
NADH	S-chemical
and	O
resolving	O
the	O
real-time	O
NADH	S-chemical
fluorescence	O
signal	O
.	O
During	O
the	O
initial	O
reaction	O
of	O
enzyme	O
with	O
NAD	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
and	O
butyraldehyde	S-chemical
,	O
there	O
was	O
an	O
immediate	O
rise	O
in	O
the	O
NADH	S-chemical
fluorescence	O
,	O
due	O
to	O
the	O
formation	O
of	O
bound	O
NADH	S-chemical
complexes	O
,	O
with	O
a	O
constant	O
steady-state	O
rate	O
of	O
production	O
of	O
free	O
NADH	S-chemical
.	O
As	O
the	O
Mg	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
ion	O
concentration	O
was	O
increased	O
,	O
there	O
was	O
a	O
consistent	O
decrease	O
of	O
the	O
enzyme	O
catalytic	O
turnover	O
from	O
0.31	O
s	O
(	O
-1	O
)	O
(	O
0	O
μM	O
Mg	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
)	O
to	O
0.050	O
s	O
(	O
-1	O
)	O
(	O
6000	O
μM	O
Mg	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
)	O
and	O
a	O
distinct	O
shift	O
in	O
steady-state	O
conformational	O
population	O
from	O
one	O
that	O
favors	O
the	O
ALDH1	S-GP
-	O
NADH	S-chemical
complex	O
with	O
the	O
shorter	O
fluorescence	O
lifetime	O
(	O
33	O
%	O
excess	O
)	O
in	O
the	O
absence	O
of	O
magnesium	S-chemical
ion	O
to	O
one	O
that	O
favors	O
the	O
ALDH1	S-GP
-	O
NADH	S-chemical
complex	O
with	O
the	O
longer	O
fluorescence	O
lifetime	O
(	O
13	O
%	O
excess	O
)	O
at	O
6000	O
μM	O
Mg	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
.	O
This	O
shift	O
in	O
conformational	O
population	O
at	O
higher	O
Mg	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
ion	O
concentrations	O
and	O
to	O
lower	O
enzyme	O
activity	O
may	O
be	O
due	O
to	O
longer	O
residence	O
time	O
of	O
the	O
NADH	S-chemical
in	O
the	O
ALDH1	S-GP
pocket	O
.	O
The	O
results	O
from	O
monitoring	O
enzyme	O
catalysis	O
in	O
the	O
absence	O
of	O
magnesium	S-chemical
suggests	O
that	O
the	O
ALDH1	S-GP
-	O
NADH	S-chemical
complex	O
with	O
the	O
shorter	O
fluorescence	O
lifetime	O
is	O
the	O
form	O
initially	O
produced	O
,	O
and	O
the	O
complex	O
with	O
the	O
longer	O
fluorescence	O
lifetime	O
is	O
produced	O
through	O
isomerization	O
.	O

Ablation	O
of	O
Egr2	S-GP
-positive	O
cells	O
in	O
male	O
mouse	O
anterior	O
pituitary	O
leads	O
to	O
atypical	O
isolated	O
GH	O
deficiency	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
expression	O
and	O
function	O
of	O
the	O
transcription	O
factor	O
early	B-GP
growth	I-GP
response	I-GP
factor	I-GP
2	E-GP
(	O
Egr2	S-GP
)	O
/	O
Krox20	S-GP
in	O
the	O
developing	O
anterior	O
pituitary	O
.	O
Egr2	S-GP
is	O
initially	O
expressed	O
in	O
all	O
differentiating	O
hormonal	O
cells	O
types	O
,	O
but	O
its	O
expression	O
is	O
mostly	O
restricted	O
to	O
the	O
somatotroph	O
lineage	O
after	O
birth	O
.	O
Egr2	S-GP
knockout	O
results	O
in	O
anterior	O
pituitary	O
hypoplasia	O
.	O
However	O
,	O
the	O
analysis	O
of	O
a	O
conditional	O
mutant	O
demonstrates	O
that	O
this	O
phenotype	O
does	O
not	O
originate	O
from	O
a	O
lack	O
of	O
Egr2	S-GP
expression	O
in	O
the	O
pituitary	O
.	O
Using	O
an	O
Egr2	S-GP
allele	O
driving	O
a	O
Cre-activable	O
toxin	O
gene	O
,	O
we	O
performed	O
a	O
genetic	O
ablation	O
of	O
Egr2	S-GP
-positive	O
cells	O
in	O
the	O
pituitary	O
.	O
During	O
the	O
postnatal	O
period	O
,	O
this	O
ablation	O
leads	O
to	O
specific	O
and	O
progressive	O
depletion	O
of	O
the	O
somatotroph	O
population	O
,	O
creating	O
a	O
novel	O
model	O
of	O
early-onset	O
isolated	O
GH	O
deficiency	O
(	O
GHD	O
)	O
.	O
Mutant	O
animals	O
were	O
subjected	O
to	O
a	O
complete	O
metabolic	O
analysis	O
,	O
revealing	O
atypical	O
and	O
expected	O
features	O
.	O
Consistent	O
with	O
an	O
adult-onset	O
isolated	O
GHD	O
model	O
,	O
mutant	O
animals	O
are	O
hypoglycemic	O
and	O
display	O
increased	O
insulin	S-GP
sensitivity	O
and	O
glucose	S-chemical
clearance	O
.	O
This	O
latter	O
phenotype	O
is	O
in	O
contrast	O
to	O
the	O
glucose	S-chemical
intolerance	O
observed	O
in	O
another	O
early-onset	O
GHD	O
model	O
.	O
Surprisingly	O
,	O
increased	O
insulin	O
sensitivity	O
is	O
not	O
accompanied	O
by	O
a	O
modified	O
balance	O
between	O
fat	O
and	O
lean	O
tissues	O
,	O
but	O
by	O
reduced	O
metabolic	O
adaptability	O
between	O
glucose	S-chemical
and	O
lipid	O
oxidation	O
conditions	O
.	O
This	O
suggests	O
that	O
the	O
relationship	O
between	O
these	O
metabolic	O
features	O
and	O
insulin	O
sensitivity	O
should	O
be	O
reconsidered	O
.	O
In	O
conclusion	O
,	O
our	O
mutant	O
may	O
be	O
a	O
valuable	O
genetic	O
model	O
with	O
which	O
to	O
study	O
the	O
effects	O
of	O
long-term	O
GH	O
deficiency	O
,	O
in	O
conditions	O
of	O
normal	O
pancreatic	O
function	O
and	O
unaffected	O
balance	O
between	O
fat	O
and	O
glucose	S-chemical
metabolism	O
.	O

Clinical	O
,	O
biochemical	O
and	O
molecular	O
diagnosis	O
of	O
a	O
compound	O
homozygote	O
for	O
the	O
254	O
bp	O
deletion-8	O
bp	O
insertion	O
of	O
the	O
APRT	S-GP
gene	O
suffering	O
from	O
severe	O
renal	O
failure	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
type	O
of	O
mutation	O
in	O
a	O
patient	O
with	O
clinical	O
diagnosis	O
of	O
suspected	O
APRT	S-GP
deficiency	O
.	O
DESIGN	O
AND	O
METHODS	O
:	O
A	O
51-year-old	O
male	O
patient	O
,	O
with	O
a	O
clinical	O
history	O
of	O
two	O
prior	O
episodes	O
of	O
renal	O
colic	O
with	O
urinary	O
stone	O
excretion	O
(	O
reported	O
as	O
uric	B-chemical
acid	E-chemical
stones	O
in	O
the	O
first	O
episode	O
and	O
as	O
calcium	B-chemical
oxalate	E-chemical
stones	O
in	O
the	O
second	O
)	O
,	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
severe	O
non-oliguric	O
renal	O
failure	O
(	O
1.06	O
mmol/L	O
serum	O
creatinine	S-chemical
)	O
,	O
severe	O
hyponatremia	O
(	O
114	O
mmol/L	O
Na	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
)	O
,	O
metabolic	O
acidosis	O
(	O
14	O
mmol/L	O
HCO	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
(	I-chemical
-	I-chemical
)	E-chemical
)	O
and	O
uricemia	O
in	O
the	O
normal	O
range	O
.	O
Abnormalities	O
at	O
renal	O
scan	O
and	O
persistency	O
of	O
severe	O
renal	O
failure	O
required	O
to	O
start	O
haemodialysis	O
.	O
Results	O
of	O
renal	O
biopsy	O
prompted	O
us	O
to	O
undertake	O
a	O
biochemical	O
and	O
molecular	O
biological	O
evaluation	O
of	O
the	O
patient	O
for	O
suspected	O
adenine	B-GP
phosphoribosyltransferase	E-GP
(	O
APRT	S-GP
)	O
deficiency	O
.	O
RESULTS	O
:	O
HPLC	O
analysis	O
of	O
serum	O
and	O
urine	O
,	O
for	O
determining	O
purine	S-chemical
derivative	O
profile	O
,	O
showed	O
the	O
pathological	O
presence	O
of	O
adenine	S-chemical
in	O
both	O
biological	O
fluids	O
(	O
3.57	O
micromol/L	O
and	O
7.11	O
micromol/mmol	O
creatinine	S-chemical
in	O
serum	O
and	O
urine	O
,	O
respectively	O
;	O
not	O
detectable	O
in	O
both	O
fluids	O
in	O
healthy	O
controls	O
)	O
.	O
APRT	S-GP
assay	O
in	O
a	O
sample	O
of	O
patient	O
hemolysate	O
showed	O
no	O
detectable	O
activity	O
of	O
the	O
enzyme	O
(	O
25.56+/-9.55	O
U/L	O
red	O
blood	O
cells	O
in	O
control	O
healthy	O
subjects	O
)	O
.	O
Molecular	O
biological	O
analysis	O
of	O
the	O
amplified	O
APRT	S-GP
gene	O
revealed	O
that	O
the	O
patient	O
harboured	O
in	O
exon	O
3	O
a	O
homozygous	O
254	O
bp	O
deletion-8	O
bp	O
insertion	O
,	O
previously	O
described	O
only	O
once	O
in	O
a	O
compound	O
heterozygote	O
.	O
Analysis	O
of	O
the	O
patient	O
family	O
showed	O
that	O
heterozygotes	O
for	O
this	O
APRT	S-GP
gene	O
mutation	O
,	O
in	O
spite	O
of	O
a	O
69	O
%	O
lower	O
APRT	S-GP
enzymatic	O
activity	O
than	O
that	O
of	O
healthy	O
subjects	O
,	O
had	O
no	O
detectable	O
adenine	S-chemical
concentrations	O
in	O
both	O
serum	O
and	O
urine	O
.	O
CONCLUSIONS	O
:	O
Results	O
of	O
the	O
first	O
patient	O
harbouring	O
the	O
homozygous	O
254	O
bp	O
deletion-8	O
bp	O
insertion	O
of	O
the	O
APRT	S-GP
gene	O
strongly	O
indicated	O
that	O
definitive	O
diagnosis	O
of	O
APRT	S-GP
deficiency	O
(	O
often	O
under	O
or	O
misdiagnosed	O
)	O
would	O
require	O
a	O
combined	O
clinical	O
,	O
biochemical	O
and	O
molecular	O
biological	O
evaluation	O
.	O

Mifepristone	S-chemical
alters	O
expression	O
of	O
endometrial	O
steroid	B-GP
receptors	E-GP
and	O
their	O
cofactors	O
in	O
new	O
users	O
of	O
medroxyprogesterone	B-chemical
acetate	E-chemical
.	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
mifepristone	O
on	O
the	O
expression	O
of	O
endometrial	O
steroid	B-GP
receptors	E-GP
and	O
their	O
co-factors	O
in	O
depot	O
medroxyprogesterone	B-chemical
acetate	E-chemical
(	O
DMPA	O
)	O
users	O
.	O
DESIGN	O
:	O
A	O
prospective	O
,	O
randomized	O
,	O
placebo-controlled	O
trial	O
.	O
SETTING	O
:	O
Reproductive	O
research	O
center	O
.	O
PATIENT	O
(	O
S	O
)	O
:	O
Fifty	O
healthy	O
women	O
with	O
regular	O
menstrual	O
cycle	O
.	O
INTERVENTION	O
(	O
S	O
)	O
:	O
One	O
hundred	O
fifty	O
milligrams	O
of	O
DMPA	O
were	O
given	O
every	O
3	O
months	O
.	O
Two	O
pills	O
(	O
25	O
mg	O
each	O
)	O
of	O
placebo	O
or	O
mifepristone	S-chemical
were	O
administered	O
every	O
14	O
days	O
during	O
the	O
DMPA	O
therapy	O
.	O
Four	O
endometrial	O
biopsy	O
specimens	O
were	O
obtained	O
from	O
each	O
patient	O
.	O
MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
:	O
The	O
expression	O
of	O
estrogen	B-GP
receptor	I-GP
subtypes	I-GP
alpha	I-GP
and	I-GP
beta	E-GP
(	O
ERalpha	S-GP
and	O
ERbeta	S-GP
)	O
,	O
progesterone	B-GP
receptors	I-GP
A	I-GP
and	I-GP
B	E-GP
(	O
PRAB	S-GP
and	O
PRB	S-GP
)	O
,	O
and	O
androgen	B-GP
receptor	E-GP
messenger	O
RNA	O
and	O
protein	O
was	O
detected	O
by	O
real-time	O
polymerase	O
chain	O
reaction	O
and	O
immunohistochemistry	O
,	O
respectively	O
.	O
Steroid	B-GP
receptor	I-GP
coactivator	I-GP
1	E-GP
(	O
SRC-1	S-GP
)	O
,	O
silencing	O
mediator	O
for	O
retinoid	B-GP
and	I-GP
thyroid-hormone	I-GP
receptors	E-GP
,	O
and	O
cell	O
proliferation	O
were	O
evaluated	O
by	O
immunohistochemistry	O
.	O
RESULT	O
(	O
S	O
)	O
:	O
The	O
expression	O
of	O
endometrial	O
ERalpha	S-GP
,	O
PRAB	S-GP
,	O
PRB	S-GP
,	O
and	O
SRC-1	S-GP
was	O
increased	O
significantly	O
after	O
1	O
week	O
of	O
mifepristone	S-chemical
,	O
but	O
the	O
increase	O
was	O
no	O
longer	O
seen	O
after	O
10	O
weeks	O
.	O
A	O
positive	O
correlation	O
between	O
endometrial	O
ERalpha	S-GP
,	O
PRAB	S-GP
,	O
PRB	S-GP
,	O
and	O
SRC-1	S-GP
production	O
and	O
proliferation	O
was	O
demonstrated	O
.	O
CONCLUSION	O
(	O
S	O
)	O
:	O
Short-term	O
exposure	O
of	O
mifepristone	S-chemical
in	O
new	O
starters	O
of	O
DMPA	O
increases	O
the	O
expression	O
of	O
endometrial	O
ERalpha	S-GP
,	O
PRAB	S-GP
,	O
PRB	S-GP
,	O
and	O
SRC-1	S-GP
and	O
promotes	O
cell	O
proliferation	O
.	O
Prolonged	O
exposure	O
to	O
mifepristone	S-chemical
does	O
not	O
alter	O
the	O
suppression	O
of	O
these	O
receptors	O
that	O
are	O
caused	O
by	O
DMPA	O
and	O
continues	O
to	O
result	O
in	O
endometrial	O
atrophy	O
.	O

Epratuzumab	O
,	O
a	O
CD22	S-GP
-targeting	O
recombinant	O
humanized	O
antibody	O
with	O
a	O
different	O
mode	O
of	O
action	O
from	O
rituximab	O
.	O
Epratuzumab	O
is	O
a	O
humanized	O
anti-	O
CD22	S-GP
monoclonal	O
antibody	O
currently	O
in	O
clinical	O
trials	O
for	O
treatment	O
of	O
non-Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
and	O
certain	O
autoimmune	O
diseases	O
.	O
Here	O
we	O
report	O
the	O
results	O
of	O
investigations	O
of	O
epratuzumab	O
's	O
mode	O
of	O
action	O
in	O
comparison	O
to	O
and	O
in	O
combination	O
with	O
the	O
anti-	O
CD20	S-GP
mAb	O
,	O
rituximab	O
.	O
In	O
vitro	O
cell	O
growth	O
inhibition	O
,	O
induction	O
of	O
apoptosis	O
,	O
and	O
the	O
ability	O
of	O
the	O
mAbs	O
to	O
mediate	O
complement	S-GP
-dependent	O
cytotoxicity	O
(	O
CDC	O
)	O
and	O
antibody-dependent	O
cellular	O
cytotoxicity	O
(	O
ADCC	O
)	O
were	O
evaluated	O
.	O
We	O
also	O
investigated	O
the	O
potential	O
activity	O
of	O
epratuzumab	O
in	O
the	O
regulation	O
of	O
B-cell	B-GP
antigen	I-GP
receptor	E-GP
(	O
BCR	S-GP
)	O
activation	O
.	O
Epratuzumab	O
and	O
rituximab	O
displayed	O
very	O
distinct	O
modes	O
of	O
action	O
;	O
epratuzumab	O
acts	O
as	O
an	O
immunomodulatory	O
agent	O
,	O
while	O
rituximab	O
is	O
an	O
acutely	O
cytotoxic	O
therapeutic	O
antibody	O
.	O
Epratuzumab	O
has	O
distinct	O
effects	O
on	O
cell	O
growth	O
from	O
rituximab	O
.	O
For	O
example	O
,	O
rituximab+anti-human	O
IgG	B-GP
Fcgamma	E-GP
yielded	O
marked	O
inhibition	O
of	O
proliferation	O
in	O
human	O
NHL	O
cell	O
lines	O
,	O
while	O
epratuzumab	O
had	O
little	O
or	O
no	O
effect	O
in	O
this	O
assay	O
.	O
However	O
,	O
when	O
cells	O
were	O
immobilized	O
and	O
stimulated	O
with	O
anti-	O
IgM	S-GP
,	O
epratuzumab	O
,	O
but	O
not	O
rituximab	O
,	O
caused	O
a	O
significant	O
antiproliferative	O
effect	O
.	O
Unlike	O
rituximab	O
,	O
no	O
CDC	O
could	O
be	O
detected	O
,	O
and	O
ADCC	O
was	O
modest	O
but	O
significant	O
with	O
epratuzumab	O
.	O
Importantly	O
,	O
combining	O
rituximab	O
and	O
epratuzumab	O
did	O
not	O
decrease	O
rituximab	O
's	O
ability	O
to	O
induce	O
apoptosis	O
,	O
CDC	O
,	O
and	O
ADCC	O
.	O
In	O
fact	O
,	O
the	O
combination	O
is	O
more	O
effective	O
than	O
rituximab	O
alone	O
in	O
inhibiting	O
proliferation	O
of	O
Daudi	O
Burkitt	O
lymphoma	O
cells	O
in	O
the	O
presence	O
of	O
second	O
antibody	O
,	O
and	O
at	O
least	O
equally	O
effective	O
to	O
rituximab	O
in	O
the	O
absence	O
of	O
crosslinking	O
.	O
These	O
observations	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
enhance	O
clinical	O
efficacy	O
by	O
combination	O
therapy	O
comprised	O
of	O
anti-	O
CD20	S-GP
and	O
anti-	O
CD22	S-GP
mAbs	O
.	O

The	O
genetic	O
interaction	O
between	O
VKORC1	S-GP
c1173t	S-GP
and	O
calumenin	S-GP
a29809g	S-GP
modulates	O
the	O
anticoagulant	O
response	O
of	O
acenocoumarol	O
.	O
BACKGROUND	O
:	O
The	O
efficacy	O
of	O
oral	O
anticoagulant	O
therapy	O
is	O
largely	O
conditioned	O
by	O
both	O
environmental	O
and	O
genetic	O
factors	O
.	O
OBJECTIVES	O
:	O
To	O
attempt	O
to	O
define	O
the	O
genetic	O
profile	O
involved	O
in	O
the	O
response	O
to	O
this	O
treatment	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
We	O
selected	O
100	O
men	O
younger	O
than	O
75	O
years	O
,	O
with	O
non-valvular	O
atrial	O
fibrillation	O
,	O
who	O
started	O
anticoagulation	O
with	O
acenocoumarol	O
following	O
the	O
same	O
protocol	O
:	O
3	O
mg	O
for	O
three	O
consecutive	O
days	O
.	O
Then	O
,	O
doses	O
were	O
individually	O
adjusted	O
to	O
achieve	O
a	O
steady	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
.	O
The	O
basal	O
plasma	O
level	O
and	O
the	O
level	O
after	O
3	O
days	O
were	O
obtained	O
,	O
and	O
the	O
INR	O
was	O
determined	O
.	O
We	O
studied	O
five	O
functional	O
polymorphisms	O
:	O
FVII	S-GP
-323	O
Del/Ins	O
,	O
CYP2C*9	S-GP
,	O
VKORC1	S-GP
c1173t	S-GP
,	O
calumenin	S-GP
(	O
CALU	S-GP
)	O
R4Q	S-GP
and	O
CALU	S-GP
a29809g	S-GP
.	O
The	O
dose	O
required	O
for	O
a	O
steady	O
INR	O
was	O
also	O
recorded	O
.	O
RESULTS	O
:	O
Only	O
the	O
VKORC1	S-GP
genotype	O
had	O
significant	O
impact	O
on	O
the	O
efficacy	O
of	O
therapy	O
.	O
Carriers	O
of	O
the	O
1173t	O
allele	O
were	O
significantly	O
more	O
sensitive	O
to	O
therapy	O
for	O
3	O
days	O
[	O
INR	O
2.07	O
(	O
1.59-2.87	O
)	O
vs.	O
1.74	O
(	O
1.30-2.09	O
)	O
;	O
P	O
=	O
0.015	O
]	O
and	O
they	O
needed	O
lower	O
acenocoumarol	O
doses	O
to	O
stabilize	O
their	O
INR	O
(	O
15.8	O
+/-	O
5.6	O
vs.	O
19.5	O
+/-	O
6.0	O
mg	O
week	O
(	O
-1	O
)	O
;	O
P	O
=	O
0.004	O
)	O
.	O
Its	O
effect	O
was	O
exacerbated	O
by	O
combination	O
with	O
the	O
CALU	S-GP
a29809g	S-GP
polymorphism	O
.	O
Carriers	O
of	O
both	O
variants	O
(	O
27	O
%	O
of	O
the	O
sample	O
)	O
achieved	O
the	O
highest	O
INR	O
[	O
2.26	O
(	O
1.70-3.32	O
)	O
]	O
and	O
required	O
the	O
lowest	O
dose	O
(	O
14.1	O
+/-	O
5.1	O
mg	O
week	O
(	O
-1	O
)	O
)	O
.	O
This	O
genetic	O
profile	O
was	O
particularly	O
relevant	O
in	O
patients	O
with	O
INR	O
>	O
or=	O
3.5	O
at	O
the	O
start	O
of	O
therapy	O
(	O
P	O
=	O
0.005	O
;	O
odds	O
ratio	O
=	O
6.67	O
,	O
95	O
%	O
confidence	O
interval	O
=	O
1.32-37.43	O
)	O
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
CALU	S-GP
a29809g	S-GP
might	O
be	O
a	O
new	O
genetic	O
factor	O
involved	O
in	O
the	O
pharmacogenetics	O
of	O
anticoagulant	O
therapy	O
,	O
and	O
confirm	O
that	O
specific	O
genetic	O
profiles	O
defined	O
by	O
different	O
polymorphisms	O
will	O
determine	O
the	O
initial	O
response	O
and	O
dose	O
required	O
to	O
achieve	O
a	O
stable	O
and	O
safe	O
INR	O
.	O

Beta	O
2-	O
but	O
not	O
beta	B-GP
1-adrenoceptors	E-GP
are	O
involved	O
in	O
desipramine	S-chemical
enhancement	O
of	O
aggressive	O
behavior	O
in	O
long-term	O
isolated	O
mice	O
.	O
The	O
effects	O
of	O
several	O
beta-adrenoceptor	S-GP
antagonists	O
on	O
the	O
desipramine	S-chemical
-induced	O
increase	O
in	O
aggressive	O
behavior	O
in	O
long-term	O
isolated	O
mice	O
were	O
examined	O
.	O
Desipramine	B-chemical
HCl	E-chemical
(	O
10	O
mg/kg	O
,	O
IP	O
)	O
significantly	O
increased	O
the	O
duration	O
of	O
aggressive	O
behavior	O
in	O
isolated	O
mice	O
but	O
did	O
not	O
significantly	O
change	O
the	O
latency	O
to	O
the	O
first	O
attack	O
consistent	O
with	O
our	O
previous	O
reports	O
.	O
Intraperitoneal	O
administration	O
of	O
(	B-chemical
+/-	I-chemical
)	I-chemical
propranolol	I-chemical
HCl	E-chemical
(	O
2.5-10	O
mg/kg	O
)	O
,	O
a	O
nonselective	O
beta-adrenoceptor	S-GP
antagonist	O
,	O
dose	O
dependently	O
attenuated	O
the	O
desipramine	S-chemical
-induced	O
enhancement	O
of	O
aggressive	O
behavior	O
without	O
significantly	O
affecting	O
the	O
basal	O
aggressive	O
responses	O
.	O
ICI118,551	B-chemical
HCl	E-chemical
(	O
1.25-5	O
mg/kg	O
,	O
IP	O
)	O
,	O
a	O
selective	O
beta	B-GP
2-adrenoceptor	E-GP
antagonist	O
,	O
also	O
blocked	O
the	O
desipramine-induced	O
enhancement	O
of	O
aggressive	O
behavior	O
in	O
a	O
dose-dependent	O
manner	O
,	O
whereas	O
metoprolol	B-chemical
tartrate	E-chemical
(	O
5-20	O
mg/kg	O
,	O
IP	O
)	O
,	O
a	O
selective	O
beta	B-GP
1-adrenoceptor	E-GP
antagonist	O
,	O
did	O
not	O
affect	O
it	O
.	O
Moreover	O
,	O
clenbuterol	B-chemical
HCl	E-chemical
(	O
0.1-0.5	O
mg/kg	O
,	O
IP	O
)	O
,	O
a	O
lipophilic	O
beta	B-GP
2-adrenoceptor	E-GP
agonist	O
,	O
significantly	O
increased	O
the	O
duration	O
of	O
basal	O
aggressive	O
behavior	O
.	O
Taken	O
together	O
with	O
our	O
previous	O
finding	O
that	O
the	O
desipramine	S-chemical
-induced	O
enhancement	O
of	O
aggressive	O
behavior	O
can	O
be	O
blocked	O
by	O
yohimbine	S-chemical
,	O
an	O
alpha	B-GP
2-adrenoceptor	E-GP
antagonist	O
,	O
the	O
present	O
results	O
indicate	O
that	O
not	O
only	O
alpha	O
2-	O
but	O
also	O
beta	B-GP
2-adrenoceptor	E-GP
stimulation	O
plays	O
important	O
roles	O
in	O
modulation	O
of	O
aggressive	O
behavior	O
in	O
long-term	O
isolated	O
mice	O
.	O

Bioactives	O
and	O
nutraceutical	O
phytochemicals	O
naturally	O
occurring	O
in	O
virgin	O
olive	O
oil	O
.	O
The	O
case	O
study	O
of	O
the	O
Nocellara	O
del	O
Belice	O
Italian	O
olive	O
cultivar	O
.	O
This	O
work	O
reports	O
on	O
the	O
composition	O
and	O
bionutritional	O
value	O
of	O
organic	O
virgin	O
olive	O
oil	O
from	O
the	O
Nocellara	O
del	O
Belice	O
variety	O
,	O
one	O
cultivated	O
in	O
the	O
olive	O
areas	O
of	O
the	O
Sicily	O
region	O
,	O
Italy	O
.	O
Destoned	O
oils	O
obtained	O
by	O
processing	O
olives	O
with	O
a	O
destoning-based	O
procedure	O
were	O
compared	O
with	O
conventional	O
oils	O
.	O
This	O
innovative	O
technique	O
,	O
consisting	O
in	O
removing	O
the	O
stone	O
from	O
fruits	O
prior	O
to	O
processing	O
,	O
strongly	O
enhanced	O
the	O
already	O
high-quality	O
level	O
of	O
the	O
conventional	O
product	O
.	O
An	O
in-depth	O
analytical	O
investigation	O
from	O
2008	O
to	O
2010	O
showed	O
how	O
this	O
innovative	O
olive	O
extraction	O
process	O
led	O
to	O
an	O
excellent	O
peculiar	O
final	O
product	O
,	O
mainly	O
attributable	O
to	O
the	O
improved	O
biophenol	O
and	O
volatile	O
composition	O
,	O
as	O
well	O
as	O
higher	O
concentrations	O
of	O
the	O
lipophilic	O
and	O
vitamin	O
antioxidants	O
(	O
tocopherols	S-chemical
and	O
tocotrienols	S-chemical
)	O
.	O
It	O
had	O
higher	O
levels	O
of	O
oleocanthal	S-chemical
(	O
p-HPEA-EDA	S-chemical
)	O
,	O
a	O
nutraceutical	O
compound	O
exerting	O
actions	O
against	O
COX1	S-GP
and	O
COX2	S-GP
(	O
cycloxygenases	S-GP
)	O
.	O
Its	O
head-space	O
aroma	O
displayed	O
new	O
volatile	O
phytomolecules	O
and	O
also	O
had	O
higher	O
levels	O
of	O
green	O
volatiles	O
from	O
the	O
lipoxygenase	S-GP
(	O
LOX	S-GP
)	O
-pathway	O
(	O
one	O
having	O
as	O
precursors	O
the	O
polyunsaturated	B-chemical
fatty	I-chemical
acids	E-chemical
containing	O
a	O
cis-cis-1,4-pentadiene	S-chemical
system	O
)	O
.	O
Among	O
the	O
other	O
bioactives	O
,	O
we	O
highlight	O
its	O
significant	O
levels	O
of	O
trans-β-carotene	S-chemical
and	O
xanthophylls	S-chemical
(	O
lutein	S-chemical
,	O
violaxanthin	S-chemical
,	O
neoxanthin	S-chemical
and	O
other	O
carotenoids	O
)	O
.	O
Its	O
enhanced	O
nutritional	O
value	O
was	O
also	O
attributable	O
to	O
the	O
increased	O
intensity	O
of	O
valuable	O
tasting	O
notes	O
.	O

Ellagic	B-chemical
acid	E-chemical
attenuates	O
bleomycin	S-chemical
and	O
cyclophosphamide	S-chemical
-induced	O
pulmonary	O
toxicity	O
in	O
Wistar	O
rats	O
.	O
Use	O
of	O
bleomycin	S-chemical
(	O
BLM	S-chemical
)	O
and	O
cyclophosphamide	S-chemical
(	O
CP	O
)	O
as	O
chemotherapeutic	O
drugs	O
is	O
associated	O
with	O
side	O
effects	O
including	O
toxicity	O
to	O
respiratory	O
system	O
.	O
Their	O
co-administration	O
may	O
enhance	O
lung	O
toxicity	O
which	O
may	O
subsequently	O
progress	O
to	O
the	O
lung	O
fibrosis	O
.	O
Natural	O
compounds	O
have	O
shown	O
mitigating	O
effects	O
against	O
toxicity	O
of	O
anticancer	O
drugs	O
.	O
Ellagic	B-chemical
acid	E-chemical
(	O
EA	O
)	O
,	O
a	O
polyphenolic	O
compound	O
present	O
in	O
many	O
fruits	O
and	O
nuts	O
in	O
addition	O
to	O
walnut	O
has	O
shown	O
promising	O
protective	O
effect	O
against	O
toxicity	O
of	O
drugs	O
and	O
chemicals	O
.	O
We	O
studied	O
the	O
ameliorative	O
effect	O
of	O
EA	O
on	O
lung	O
toxicity	O
in	O
rats	O
exposed	O
to	O
CP	O
(	O
150mg/kgb.w.	O
,	O
i.p	O
.	O
)	O
and	O
BLM	S-chemical
(	O
10U/kgb.w.	O
,	O
i.t.	O
)	O
.	O
EA	O
(	O
15mg/kgb.w.	O
,	O
p.o.×14days	O
)	O
treatment	O
modulated	O
enhanced	O
hydroxyproline	S-chemical
level	O
,	O
lipid	O
peroxidation	O
,	O
myeloperoxidase	S-GP
activity	O
,	O
nitric	B-chemical
oxide	E-chemical
production	O
and	O
protein	O
carbonyl	S-chemical
formation	O
in	O
lungs	O
of	O
rats	O
exposed	O
to	O
toxic	O
anticancer	O
drugs	O
.	O
There	O
was	O
a	O
marked	O
decrease	O
in	O
GSH	S-chemical
content	O
and	O
activities	O
of	O
antioxidant	O
enzymes	O
as	O
a	O
result	O
of	O
BLM	S-chemical
and	O
CP	O
treatment	O
.	O
Bronchoalveolar	O
lavage	O
fluid	O
showed	O
increased	O
level	O
of	O
cytotoxicity	O
markers	O
in	O
drug	O
treated	O
animals	O
.	O
Treatment	O
with	O
EA	O
attenuated	O
these	O
changes	O
.	O
Histopathological	O
findings	O
also	O
showed	O
protective	O
effects	O
of	O
EA	O
.	O
In	O
conclusion	O
,	O
EA	O
emerged	O
as	O
a	O
natural	O
protectant	O
with	O
an	O
ability	O
to	O
protect	O
lungs	O
from	O
onslaught	O
of	O
pulmonary	O
toxicity	O
of	O
anticancer	O
drugs	O
.	O

Proteolytic	O
processing	O
of	O
osteopontin	S-GP
by	O
PHEX	S-GP
and	O
accumulation	O
of	O
osteopontin	S-GP
fragments	O
in	O
Hyp	O
mouse	O
bone	O
,	O
the	O
murine	O
model	O
of	O
X-linked	O
hypo	O
phosphate	S-chemical
mia	O
.	O
X-linked	O
hypophosphatemia	O
(	O
XLH/HYP	O
)	O
-with	O
renal	O
phosphate	O
wasting	O
,	O
hypophosphatemia	O
,	O
osteomalacia	O
,	O
and	O
tooth	O
abscesses-is	O
caused	O
by	O
mutations	O
in	O
the	O
zinc-metallopeptidase	S-GP
PHEX	S-GP
gene	O
(	O
phosphate	S-chemical
-regulating	O
gene	O
with	O
homologies	O
to	O
endopeptidase	S-GP
on	O
the	O
X	O
chromosome	O
)	O
.	O
PHEX	S-GP
is	O
highly	O
expressed	O
by	O
mineralized	O
tissue	O
cells	O
.	O
Inactivating	O
mutations	O
in	O
PHEX	S-GP
lead	O
to	O
distal	O
renal	O
effects	O
(	O
implying	O
accumulation	O
of	O
a	O
secreted	O
,	O
circulating	O
phosphaturic	O
factor	O
)	O
and	O
accumulation	O
in	O
bone	O
and	O
teeth	O
of	O
mineralization-inhibiting	O
,	O
acidic	B-GP
serine-	I-GP
and	I-GP
aspartate-rich	I-GP
motif	E-GP
(	O
ASARM	S-GP
)	O
-containing	O
peptides	O
,	O
which	O
are	O
proteolytically	O
derived	O
from	O
the	O
mineral-binding	O
matrix	O
proteins	O
of	O
the	O
SIBLING	S-GP
family	O
(	O
small	B-GP
,	I-GP
integrin-binding	I-GP
ligand	I-GP
N-linked	I-GP
glycoproteins	E-GP
)	O
.	O
Although	O
the	O
latter	O
observation	O
suggests	O
a	O
local	O
,	O
direct	O
matrix	O
effect	O
for	O
PHEX	S-GP
,	O
its	O
physiologically	O
relevant	O
substrate	O
protein	O
(	O
s	O
)	O
have	O
not	O
been	O
identified	O
.	O
Here	O
,	O
we	O
investigated	O
two	O
SIBLING	S-GP
proteins	O
containing	O
the	O
ASARM	B-GP
motif	E-GP
-	O
osteopontin	S-GP
(	O
OPN	S-GP
)	O
and	O
bone	B-GP
sialoprotein	E-GP
(	O
BSP	S-GP
)	O
-as	O
potential	O
substrates	O
for	O
PHEX	S-GP
.	O
Using	O
cleavage	O
assays	O
,	O
gel	O
electrophoresis	O
,	O
and	O
mass	O
spectrometry	O
,	O
we	O
report	O
that	O
OPN	S-GP
is	O
a	O
full-length	O
protein	O
substrate	O
for	O
PHEX	S-GP
.	O
Degradation	O
of	O
OPN	S-GP
was	O
essentially	O
complete	O
,	O
including	O
hydrolysis	O
of	O
the	O
ASARM	B-GP
motif	E-GP
,	O
resulting	O
in	O
only	O
very	O
small	O
residual	O
fragments	O
.	O
Western	O
blotting	O
of	O
Hyp	S-GP
(	O
the	O
murine	O
homolog	O
of	O
human	B-GP
XLH	E-GP
)	O
mouse	O
bone	O
extracts	O
having	O
no	O
PHEX	S-GP
activity	O
clearly	O
showed	O
accumulation	O
of	O
an	O
∼35	O
kDa	O
OPN	S-GP
fragment	O
that	O
was	O
not	O
present	O
in	O
wild-type	O
mouse	O
bone	O
.	O
Immunohistochemistry	O
and	O
immunogold	O
labeling	O
(	O
electron	O
microscopy	O
)	O
for	O
OPN	S-GP
in	O
Hyp	O
bone	O
likewise	O
showed	O
an	O
accumulation	O
of	O
OPN	S-GP
and/or	O
its	O
fragments	O
compared	O
with	O
normal	O
wild-type	O
bone	O
.	O
Incubation	O
of	O
Hyp	O
mouse	O
bone	O
extracts	O
with	O
PHEX	S-GP
resulted	O
in	O
the	O
complete	O
degradation	O
of	O
these	O
fragments	O
.	O
In	O
conclusion	O
,	O
these	O
results	O
identify	O
full-length	O
OPN	S-GP
and	O
its	O
fragments	O
as	O
novel	O
,	O
physiologically	O
relevant	O
substrates	O
for	O
PHEX	S-GP
,	O
suggesting	O
that	O
accumulation	O
of	O
mineralization-inhibiting	O
OPN	S-GP
fragments	O
may	O
contribute	O
to	O
the	O
mineralization	O
defect	O
seen	O
in	O
the	O
osteomalacic	O
bone	O
characteristic	O
of	O
XLH/HYP	O
.	O

Distinct	O
patterns	O
of	O
mutations	O
occurring	O
in	O
de	O
novo	O
AML	O
versus	O
AML	O
arising	O
in	O
the	O
setting	O
of	O
severe	O
congenital	O
neutropenia	O
.	O
Severe	O
congenital	O
neutropenia	O
(	O
SCN	O
)	O
is	O
an	O
inborn	O
disorder	O
of	O
granulopoiesis	O
.	O
Like	O
most	O
other	O
bone	O
marrow	O
failure	O
syndromes	O
,	O
it	O
is	O
associated	O
with	O
a	O
marked	O
propensity	O
to	O
transform	O
into	O
a	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
or	O
acute	O
leukemia	O
,	O
with	O
a	O
cumulative	O
rate	O
of	O
transformation	O
to	O
MDS/leukemia	O
that	O
exceeds	O
20	O
%	O
.	O
The	O
genetic	O
(	O
and/or	O
epigenetic	O
)	O
changes	O
that	O
contribute	O
to	O
malignant	O
transformation	O
in	O
SCN	O
are	O
largely	O
unknown	O
.	O
In	O
this	O
study	O
,	O
we	O
performed	O
mutational	O
profiling	O
of	O
14	O
genes	O
previously	O
implicated	O
in	O
leukemogenesis	O
using	O
14	O
MDS/leukemia	O
samples	O
from	O
patients	O
with	O
SCN	O
.	O
We	O
used	O
high-throughput	O
exon-based	O
resequencing	O
of	O
whole-genome-amplified	O
genomic	O
DNA	O
with	O
a	O
semiautomated	O
method	O
to	O
detect	O
mutations	O
.	O
The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
sequencing	O
pipeline	O
was	O
validated	O
by	O
determining	O
the	O
frequency	O
of	O
mutations	O
in	O
these	O
14	O
genes	O
using	O
188	O
de	O
novo	O
AML	O
samples	O
.	O
As	O
expected	O
,	O
mutations	O
of	O
tyrosine	B-GP
kinase	E-GP
genes	O
(	O
FLT3	S-GP
,	O
KIT	S-GP
,	O
and	O
JAK2	S-GP
)	O
were	O
common	O
in	O
de	O
novo	O
AML	O
,	O
with	O
a	O
cumulative	O
frequency	O
of	O
30	O
%	O
.	O
In	O
contrast	O
,	O
no	O
mutations	O
in	O
these	O
genes	O
were	O
detected	O
in	O
the	O
SCN	O
samples	O
;	O
instead	O
,	O
mutations	O
of	O
CSF3R	S-GP
,	O
encoding	O
the	O
G-CSF	B-GP
receptor	E-GP
,	O
were	O
common	O
.	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
mutations	O
of	O
CSF3R	S-GP
may	O
provide	O
the	O
``	O
activated	O
tyrosine	B-GP
kinase	E-GP
signal	O
''	O
that	O
is	O
thought	O
to	O
be	O
important	O
for	O
leukemogenesis	O
.	O

Preferential	O
cerebrospinal	O
fluid	O
acetylcholinesterase	S-GP
inhibition	O
by	O
rivastigmine	S-chemical
in	O
humans	O
.	O
This	O
study	O
sought	O
to	O
examine	O
the	O
feasibility	O
of	O
prolonged	O
assessment	O
of	O
acetylcholinesterase	S-GP
(	O
AChE	S-GP
)	O
activity	O
in	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
of	O
volunteers	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
rivastigmine	S-chemical
(	O
ENA-713	S-chemical
;	O
Exelon	S-chemical
,	O
Novartis	O
Pharma	O
AG	O
,	O
Basel	O
,	O
Switzerland	O
)	O
selectively	O
inhibits	O
AChE	S-GP
in	O
CSF	O
in	O
humans	O
at	O
a	O
dose	O
producing	O
minimal	O
inhibition	O
of	O
the	O
peripheral	O
enzyme	O
.	O
Lumbar	O
CSF	O
samples	O
were	O
collected	O
continuously	O
(	O
0.1	O
mL	O
x	O
min	O
(	O
-1	O
)	O
)	O
for	O
49	O
hours	O
from	O
eight	O
healthy	O
volunteers	O
who	O
took	O
either	O
placebo	O
or	O
a	O
single	O
oral	O
dose	O
of	O
rivastigmine	S-chemical
(	O
3	O
mg	O
)	O
.	O
CSF	O
specimens	O
and	O
samples	O
of	O
blood	O
cells	O
and	O
blood	O
plasma	O
were	O
analyzed	O
at	O
intervals	O
for	O
rivastigmine	S-chemical
and	O
its	O
metabolite	O
NAP	B-chemical
226-90	E-chemical
(	O
[	B-chemical
-	I-chemical
]	I-chemical
[	I-chemical
3-	I-chemical
(	I-chemical
[	I-chemical
1-dimethylaminolethyl	I-chemical
)	I-chemical
-phenol	I-chemical
]	E-chemical
)	O
,	O
erythrocyte	O
AChE	S-GP
activity	O
,	O
CSF	O
AChE	S-GP
activity	O
,	O
and	O
plasma	O
and	O
CSF	O
butyrylcholinesterase	S-GP
(	O
BuChE	S-GP
)	O
activity	O
.	O
Safety	O
evaluations	O
were	O
performed	O
23	O
hours	O
after	O
drug	O
dosing	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O
Evaluable	O
data	O
were	O
obtained	O
from	O
six	O
subjects	O
.	O
The	O
mean	O
time	O
to	O
maximal	O
rivastigmine	S-chemical
plasma	O
concentration	O
(	O
tmax	O
)	O
was	O
0.83	O
+/-	O
0.26	O
hours	O
,	O
the	O
mean	O
maximal	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
was	O
4.88	O
+/-	O
3.82	O
ng	O
x	O
mL	O
(	O
-1	O
)	O
,	O
the	O
mean	O
plasma	O
area	O
under	O
the	O
concentration	O
versus	O
time	O
curve	O
(	O
AUC0-infinity	O
)	O
was	O
7.43	O
+/-	O
4.74	O
ng	O
x	O
hr	O
x	O
mL	O
(	O
-1	O
)	O
,	O
and	O
the	O
mean	O
plasma	O
t1/2	O
was	O
0.85	O
+/-	O
0.115	O
hours	O
.	O
The	O
concentration	O
of	O
rivastigmine	S-chemical
in	O
CSF	O
was	O
lower	O
than	O
the	O
quantification	O
limit	O
for	O
assay	O
(	O
0.65	O
ng	O
x	O
mL	O
(	O
-1	O
)	O
)	O
,	O
but	O
NAP	B-chemical
226-90	E-chemical
reached	O
a	O
mean	O
Cmax	O
of	O
3.14	O
+/-	O
0.57	O
ng	O
x	O
mL	O
(	O
-1	O
)	O
.	O
Only	O
minimal	O
inhibition	O
of	O
erythrocyte	O
AChE	S-GP
activity	O
(	O
approximately	O
3	O
%	O
)	O
was	O
observed	O
.	O
Inhibition	O
of	O
AChE	S-GP
in	O
the	O
CSF	O
after	O
rivastigmine	S-chemical
administration	O
was	O
significantly	O
greater	O
than	O
after	O
placebo	O
for	O
up	O
to	O
8.4	O
hours	O
after	O
the	O
dose	O
and	O
was	O
maximal	O
(	O
40	O
%	O
)	O
at	O
2.4	O
hours	O
.	O
Plasma	O
BuChE	S-GP
activity	O
was	O
significantly	O
lower	O
after	O
rivastigmine	S-chemical
than	O
after	O
placebo	O
,	O
but	O
this	O
was	O
not	O
clinically	O
relevant	O
.	O
BuChE	S-GP
activity	O
in	O
CSF	O
was	O
significantly	O
lower	O
after	O
rivastigmine	S-chemical
than	O
after	O
placebo	O
for	O
up	O
to	O
3.6	O
hours	O
after	O
dosing	O
,	O
but	O
this	O
difference	O
was	O
not	O
sustained	O
.	O
This	O
study	O
confirms	O
the	O
feasibility	O
of	O
using	O
continuous	O
measurement	O
of	O
AChE	S-GP
activity	O
in	O
CSF	O
over	O
prolonged	O
periods	O
,	O
that	O
rivastigmine	S-chemical
markedly	O
inhibits	O
CSF	O
AChE	S-GP
after	O
a	O
single	O
oral	O
dose	O
of	O
3	O
mg	O
,	O
and	O
that	O
the	O
inhibition	O
of	O
central	O
AChE	S-GP
is	O
substantially	O
greater	O
than	O
that	O
of	O
peripheral	O
AChE	S-GP
or	O
BuChE	S-GP
.	O

The	O
dextromethorphan	S-chemical
analog	O
dimemorfan	S-chemical
attenuates	O
kainate-induced	O
seizures	O
via	O
sigma1	B-GP
receptor	E-GP
activation	O
:	O
comparison	O
with	O
the	O
effects	O
of	O
dextromethorphan	S-chemical
.	O
In	O
a	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
a	O
dextromethorphan	S-chemical
analog	O
,	O
dimemorfan	S-chemical
,	O
has	O
neuroprotective	O
effects	O
.	O
Dextromethorphan	S-chemical
and	O
dimemorfan	S-chemical
are	O
high-affinity	O
ligands	O
at	O
sigma1	B-GP
receptors	E-GP
.	O
Dextromethorphan	S-chemical
has	O
moderate	O
affinities	O
for	O
phencyclidine	S-chemical
sites	O
,	O
while	O
dimemorfan	S-chemical
has	O
very	O
low	O
affinities	O
for	O
such	O
sites	O
,	O
suggesting	O
that	O
these	O
sites	O
are	O
not	O
essential	O
for	O
the	O
anticonvulsant	O
actions	O
of	O
dimemorfan	S-chemical
.	O
Kainate	S-chemical
(	O
KA	S-chemical
)	O
administration	O
(	O
10	O
mg	O
kg	O
(	O
-1	O
)	O
,	O
i.p	O
.	O
)	O
produced	O
robust	O
convulsions	O
lasting	O
4-6	O
h	O
in	O
rats	O
.	O
Pre-treatment	O
with	O
dimemorfan	S-chemical
(	O
12	O
or	O
24	O
mg	O
kg	O
(	O
-1	O
)	O
)	O
reduced	O
seizures	O
in	O
a	O
dose-dependent	O
manner	O
.	O
Dimemorfan	S-chemical
pre-treatment	O
also	O
attenuated	O
the	O
KA	S-chemical
-induced	O
increases	O
in	O
c-fos	S-GP
/	O
c-jun	S-GP
expression	O
,	O
activator	B-GP
protein	I-GP
(	I-GP
AP	I-GP
)	I-GP
-1	E-GP
DNA-binding	O
activity	O
,	O
and	O
loss	O
of	O
cells	O
in	O
the	O
CA1	O
and	O
CA3	O
fields	O
of	O
the	O
hippocampus	O
.	O
These	O
effects	O
of	O
dimemorfan	S-chemical
were	O
comparable	O
to	O
those	O
of	O
dextromethorphan	S-chemical
.	O
The	O
anticonvulsant	O
action	O
of	O
dextromethorphan	S-chemical
or	O
dimemorfan	S-chemical
was	O
significantly	O
counteracted	O
by	O
a	O
selective	O
sigma1	B-GP
receptor	E-GP
antagonist	O
BD	B-chemical
1047	E-chemical
,	O
suggesting	O
that	O
the	O
anticonvulsant	O
action	O
of	O
dextromethorphan	S-chemical
or	O
dimemorfan	S-chemical
is	O
,	O
at	O
least	O
in	O
part	O
,	O
related	O
to	O
sigma1	B-GP
receptor	E-GP
-activated	O
modulation	O
of	O
AP-1	S-GP
transcription	O
factors	O
.	O
We	O
asked	O
whether	O
dimemorfan	S-chemical
produces	O
the	O
behavioral	O
side	O
effects	O
seen	O
with	O
dextromethorphan	S-chemical
or	O
dextrorphan	S-chemical
(	O
a	O
phencyclidine	S-chemical
-like	O
metabolite	O
of	O
dextromethorphan	S-chemical
)	O
.	O
Conditioned	O
place	O
preference	O
and	O
circling	O
behaviors	O
were	O
significantly	O
increased	O
in	O
mice	O
treated	O
with	O
phencyclidine	S-chemical
,	O
dextrorphan	S-chemical
or	O
dextromethorphan	S-chemical
,	O
while	O
mice	O
treated	O
with	O
dimemorfan	S-chemical
showed	O
no	O
behavioral	O
side	O
effects	O
.	O
Our	O
results	O
suggest	O
that	O
dimemorfan	O
is	O
equipotent	O
to	O
dextromethorphan	S-chemical
in	O
preventing	O
KA	S-chemical
-induced	O
seizures	O
,	O
while	O
it	O
may	O
lack	O
behavioral	O
effects	O
,	O
such	O
as	O
psychotomimetic	O
reactions	O
.	O

Benzodiazepine	B-GP
receptor	E-GP
binding	O
of	O
triazolobenzodiazepines	S-chemical
in	O
vivo	O
:	O
increased	O
receptor	O
number	O
with	O
low-dose	O
alprazolam	S-chemical
.	O
Triazolobenzodiazepines	S-chemical
are	O
in	O
clinical	O
use	O
as	O
hypnotics	O
and	O
anxiolytics	O
.	O
We	O
analyzed	O
in	O
vivo	O
receptor	O
binding	O
and	O
brain	O
concentrations	O
of	O
alprazolam	S-chemical
,	O
triazolam	S-chemical
,	O
and	O
estazolam	S-chemical
.	O
Drug	O
concentrations	O
measured	O
in	O
the	O
cerebral	O
cortex	O
1	O
h	O
after	O
administration	O
were	O
directly	O
proportional	O
to	O
dose	O
for	O
all	O
three	O
compounds	O
.	O
In	O
vivo	O
receptor	O
binding	O
,	O
as	O
defined	O
by	O
the	O
specific	O
uptake	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
Ro15-1788	E-chemical
,	O
decreased	O
with	O
increasing	O
doses	O
of	O
estazolam	S-chemical
and	O
triazolam	S-chemical
,	O
a	O
finding	O
indicating	O
dose-related	O
increases	O
in	O
receptor	O
occupancy	O
due	O
to	O
these	O
compounds	O
.	O
Triazolam	S-chemical
was	O
substantially	O
more	O
potent	O
,	O
with	O
an	O
IC50	O
value	O
of	O
16	O
ng/g	O
,	O
compared	O
with	O
117	O
ng/g	O
for	O
estazolam	S-chemical
.	O
At	O
higher	O
doses	O
of	O
alprazolam	S-chemical
(	O
greater	O
than	O
0.2	O
mg/kg	O
)	O
,	O
receptor	O
binding	O
by	O
[	B-chemical
3H	I-chemical
]	I-chemical
Ro15-1788	E-chemical
,	O
likewise	O
decreased	O
with	O
increasing	O
dose	O
of	O
the	O
former	O
drug	O
.	O
However	O
,	O
at	O
lower	O
doses	O
of	O
alprazolam	S-chemical
(	O
0.02-0.05	O
mg/kg	O
)	O
,	O
which	O
resulted	O
in	O
cortex	O
concentrations	O
of	O
2-7	O
ng/g	O
,	O
receptor	O
binding	O
was	O
increased	O
above	O
control	O
values	O
in	O
cortex	O
,	O
hypothalamus	O
,	O
and	O
hippocampus	O
but	O
not	O
in	O
several	O
other	O
brain	O
regions	O
.	O
Binding	O
returned	O
to	O
control	O
values	O
at	O
doses	O
of	O
greater	O
than	O
or	O
equal	O
to	O
0.01	O
mg/kg	O
.	O
Similar	O
results	O
were	O
obtained	O
in	O
time	O
course	O
studies	O
.	O
At	O
8	O
and	O
10	O
h	O
after	O
a	O
dose	O
of	O
1	O
mg/kg	O
i.p.	O
,	O
corresponding	O
to	O
cortex	O
concentrations	O
of	O
2.7-7	O
ng/g	O
,	O
receptor	O
binding	O
was	O
increased	O
compared	O
with	O
controls	O
.	O
Similarly	O
,	O
at	O
1	O
,	O
2	O
,	O
and	O
3	O
h	O
after	O
a	O
single	O
dose	O
of	O
0.05	O
mg/kg	O
,	O
corresponding	O
to	O
cortex	O
concentrations	O
of	O
3.7-5.8	O
ng/g	O
,	O
receptor	O
binding	O
was	O
also	O
increased	O
.	O
The	O
apparent	O
affinity	O
of	O
benzodiazepine	B-GP
receptors	E-GP
for	O
clonazepam	S-chemical
in	O
mice	O
receiving	O
alprazolam	S-chemical
(	O
0.05	O
mg/kg	O
)	O
was	O
unchanged	O
from	O
that	O
in	O
untreated	O
control	O
mice	O
,	O
an	O
observation	O
suggesting	O
that	O
low	O
doses	O
of	O
alprazolam	S-chemical
increased	O
receptor	O
number	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Leukotrienes	S-chemical
in	O
the	O
pathogenesis	O
of	O
pulmonary	O
blast	O
injury	O
.	O
Our	O
previous	O
studies	O
demonstrate	O
a	O
significant	O
increase	O
of	O
sulfidopeptide	O
leukotriene	S-chemical
concentrations	O
in	O
animals	O
exposed	O
to	O
a	O
free	O
air	O
blast	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
role	O
of	O
leukotrienes	S-chemical
in	O
the	O
local	O
response	O
of	O
lung	O
tissue	O
as	O
well	O
as	O
in	O
the	O
general	O
response	O
of	O
organisms	O
to	O
blast	O
overpressure	O
.	O
The	O
study	O
was	O
conducted	O
on	O
adult	O
rabbits	O
exposed	O
to	O
moderate	O
blast	O
overpressure	O
(	O
four	O
pulmonary	O
contusions	O
characterized	O
as	O
confluent	O
ecchymoses	O
involving	O
30	O
to	O
60	O
%	O
of	O
the	O
lungs	O
)	O
,	O
generated	O
in	O
laboratory	O
conditions	O
.	O
One	O
group	O
of	O
experimental	O
animals	O
was	O
treated	O
with	O
5-lipoxygenase	S-GP
(	O
5-LO	S-GP
)	O
inhibitor	O
,	O
diethylcarbamazine	S-chemical
(	O
DEC	S-chemical
,	O
Sigma	O
,	O
St.	O
Louis	O
,	O
Missouri	O
)	O
(	O
50	O
mg/kg	O
,	O
i.v	O
.	O
)	O
,	O
immediately	O
before	O
blast	O
.	O
The	O
early	O
posttraumatic	O
period	O
was	O
observed	O
(	O
30	O
minutes	O
after	O
blast	O
)	O
.	O
Hemodynamic	O
parameters	O
(	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
blood	O
gases	O
)	O
as	O
well	O
as	O
arterial	O
plasma	O
levels	O
of	O
conjugated	O
dienes	O
were	O
observed	O
.	O
The	O
myeloperoxidase	S-GP
activity	O
,	O
lipid	O
peroxidation	O
products	O
levels	O
,	O
and	O
water	O
contents	O
were	O
measured	O
in	O
the	O
lung	O
tissue	O
of	O
injured	O
rabbits	O
.	O
We	O
observed	O
that	O
5-LO	S-GP
inhibition	O
reduced	O
edema	O
formation	O
,	O
accumulation	O
of	O
neutrophils	O
,	O
and	O
generation	O
of	O
lipid	O
peroxidation	O
products	O
in	O
injured	O
lungs	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
treatment	O
with	O
DEC	S-chemical
inhibits	O
the	O
increased	O
systemic	O
generation	O
of	O
conjugated	O
dienes	O
after	O
blast	O
injury	O
.	O
Although	O
DEC	S-chemical
exerts	O
local	O
antioxidant	O
activity	O
with	O
beneficial	O
effects	O
on	O
lung	O
tissue	O
,	O
this	O
5-LO	S-GP
inhibitor	O
intensifies	O
the	O
blast	O
overpressure	O
caused	O
hemodynamic	O
insufficiency	O
.	O

Adapalene	S-chemical
,	O
a	O
new	O
chemical	O
entity	O
with	O
retinoid	S-chemical
activity	O
.	O
Adapalene	S-chemical
is	O
a	O
novel	O
chemical	O
entity	O
which	O
,	O
in	O
terms	O
of	O
pharmacology	O
,	O
behaves	O
similar	O
to	O
tretinoin	S-chemical
,	O
but	O
is	O
chemically	O
and	O
photochemically	O
stable	O
.	O
It	O
has	O
a	O
particular	O
selectivity	O
profile	O
for	O
the	O
known	O
nuclear	O
retinoic	B-GP
acid	I-GP
receptors	E-GP
with	O
low	O
affinity	O
for	O
RAR	B-GP
alpha	E-GP
and	O
no	O
transactivating	O
potential	O
for	O
RXR	B-GP
alpha	E-GP
.	O
This	O
receptor	O
profile	O
could	O
imply	O
that	O
adapalene	S-chemical
,	O
in	O
contrast	O
to	O
tretinoin	S-chemical
,	O
affects	O
the	O
terminal	O
differentiation	O
pathway	O
of	O
epidermal	O
cells	O
rather	O
than	O
their	O
proliferation	O
.	O
Furthermore	O
,	O
adapalene	S-chemical
does	O
not	O
bind	O
to	O
members	O
of	O
the	O
cellular	O
retinoic	B-GP
acid	I-GP
binding	I-GP
protein	E-GP
family	O
.	O
Adapalene	S-chemical
has	O
comedolytic	O
activity	O
in	O
the	O
topical	O
rhino	O
mouse	O
model	O
.	O
It	O
exerts	O
a	O
moderate-to-potent	O
anti-inflammatory	O
effect	O
in	O
a	O
series	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
.	O
In	O
comparative	O
clinical	O
studies	O
involving	O
72	O
acne	O
patients	O
,	O
the	O
efficacy	O
of	O
adapalene	S-chemical
was	O
comparable	O
,	O
if	O
not	O
superior	O
,	O
to	O
tretinoin	S-chemical
,	O
but	O
adapalene	S-chemical
was	O
better	O
tolerated	O
.	O
The	O
data	O
reviewed	O
in	O
this	O
paper	O
indicate	O
that	O
adapalene	S-chemical
should	O
be	O
particularly	O
beneficial	O
in	O
the	O
treatment	O
of	O
acne	O
.	O

Serotonin	B-GP
receptors	E-GP
of	O
type	O
6	O
(	O
5-HT6	S-GP
)	O
:	O
from	O
neuroscience	O
to	O
clinical	O
pharmacology	O
.	O
The	O
serotonin	B-GP
(	I-GP
5-HT	I-GP
)	I-GP
receptors	E-GP
of	O
type	O
6	O
(	O
5-HT6	S-GP
)	O
are	O
quite	O
different	O
from	O
all	O
other	O
5-HT	B-GP
receptors	E-GP
,	O
as	O
they	O
include	O
a	O
short	O
third	O
cytoplasmatic	O
loop	O
and	O
a	O
long	O
C	S-chemical
-terminal	O
tail	O
,	O
and	O
one	O
intron	O
located	O
in	O
the	O
middle	O
of	O
the	O
third	O
cytoplasmatic	O
loop	O
.	O
A	O
lot	O
of	O
controversies	O
still	O
exist	O
regarding	O
their	O
binding	O
affinity	O
,	O
effects	O
of	O
5-HT6	S-GP
ligands	O
on	O
brain	O
catecholamines	S-chemical
,	O
behavioral	O
syndromes	O
regulated	O
by	O
them	O
,	O
and	O
brain	O
distribution	O
.	O
In	O
spite	O
of	O
the	O
lack	O
of	O
information	O
on	O
metabolic	O
pattern	O
of	O
the	O
various	O
compounds	O
,	O
some	O
of	O
5-HT6	S-GP
receptor	O
ligands	O
entered	O
the	O
clinical	O
development	O
as	O
potential	O
anti-dementia	O
,	O
antipsychotic	O
,	O
antidepressant	O
and	O
anti-obese	O
drugs	O
.	O
The	O
present	O
paper	O
is	O
a	O
comprehensive	O
review	O
on	O
the	O
state	O
of	O
art	O
of	O
the	O
5-HT6	S-GP
receptors	O
,	O
while	O
highlighting	O
the	O
potential	O
clinical	O
applications	O
of	O
5-HT6	S-GP
receptor	O
agonists/antagonists	O
.	O

Evaluation	O
of	O
in	O
vivo	O
binding	O
properties	O
of	O
3H-NMPB	S-chemical
and	O
3H-QNB	S-chemical
in	O
mouse	O
brain	O
.	O
UNLABELLED	O
:	O
Apparent	O
muscarinic	B-GP
acetylcholine	I-GP
(	I-GP
mAch	I-GP
)	I-GP
receptor	E-GP
occupancy	O
in	O
mouse	O
cerebral	O
cortex	O
,	O
hippocampus	O
,	O
and	O
striatum	O
by	O
scopolamine	S-chemical
,	O
an	O
antagonist	O
,	O
and	O
biperiden	S-chemical
,	O
a	O
relatively	O
selective	O
M1	S-GP
antagonist	O
,	O
was	O
estimated	O
with	O
competitive	O
binding	O
studies	O
using	O
two	O
different	O
radioligands	O
:	O
3H-N-methyl	B-chemical
piperidyl	I-chemical
benzilate	E-chemical
(	O
3H-NMPB	S-chemical
)	O
and	O
3H-quinuclidinyl	B-chemical
benzilate	E-chemical
(	O
3H-QNB	S-chemical
)	O
.	O
Both	O
radioligands	O
labeled	O
mAch	B-GP
receptors	E-GP
in	O
these	O
brain	O
regions	O
,	O
and	O
the	O
relative	O
regional	O
distributions	O
of	O
the	O
specific	O
binding	O
of	O
3H-NMPB	S-chemical
in	O
vivo	O
paralleled	O
the	O
distribution	O
of	O
mAch	B-GP
receptors	E-GP
.	O
3H-NMPB	S-chemical
binding	O
in	O
vivo	O
was	O
much	O
more	O
sensitive	O
to	O
direct	O
competitive	O
inhibition	O
by	O
scopolamine	S-chemical
than	O
was	O
3H-QNB	S-chemical
.	O
A	O
similar	O
discrepancy	O
in	O
sensitivity	O
to	O
competitors	O
between	O
3H-NMPB	S-chemical
and	O
3H-QNB	S-chemical
was	O
also	O
observed	O
when	O
biperiden	S-chemical
was	O
used	O
as	O
a	O
competitor	O
,	O
indicating	O
that	O
binding	O
to	O
different	O
subtypes	O
of	O
the	O
mAch	B-GP
receptor	E-GP
could	O
not	O
account	O
for	O
the	O
observed	O
differences	O
in	O
sensitivity	O
to	O
competition	O
.	O
An	O
in	O
vivo	O
saturation	O
study	O
suggested	O
that	O
the	O
apparent	O
association	O
rate	O
constant	O
(	O
k	O
on	O
)	O
of	O
3H-QNB	S-chemical
binding	O
might	O
be	O
changed	O
by	O
ligand	O
concentration	O
.	O
The	O
heterogeneity	O
of	O
the	O
free	O
ligand	O
concentration	O
in	O
intact	O
brain	O
was	O
assessed	O
in	O
relation	O
to	O
the	O
ligand	O
concentration	O
dependency	O
of	O
the	O
apparent	O
association	O
rate	O
constant	O
(	O
k	O
on	O
)	O
of	O
3H-QNB	S-chemical
binding	O
.	O
This	O
finding	O
,	O
together	O
with	O
the	O
more	O
favorable	O
accumulation	O
of	O
3H-NMPB	S-chemical
in	O
cerebral	O
cortex	O
,	O
hippocampus	O
,	O
and	O
striatum	O
,	O
leads	O
us	O
to	O
conclude	O
that	O
3H-NMPB	S-chemical
,	O
or	O
its	O
positron	O
emitting	O
counterpart	O
,	O
should	O
be	O
the	O
more	O
favorable	O
radiotracer	O
for	O
the	O
estimation	O
of	O
mAch	B-GP
receptor	E-GP
occupancy	O
by	O
cholinergic	O
drugs	O
in	O
the	O
brain	O
.	O
KEYWORDS	O
:	O
mAch	B-GP
receptor	E-GP
,	O
QNB	S-chemical
,	O
NMPB	S-chemical
,	O
in	O
vivo	O
,	O
mouse	O
.	O

Glaucogenin	B-chemical
E	E-chemical
,	O
a	O
new	O
C21	S-chemical
steroid	S-chemical
from	O
Cynanchum	O
stauntonii	O
.	O
Glaucogenin	B-chemical
E	E-chemical
(	O
1	O
)	O
,	O
a	O
new	O
C	B-chemical
(	I-chemical
21	I-chemical
)	E-chemical
steroid	S-chemical
sapogenin	O
,	O
along	O
with	O
three	O
known	O
ones	O
(	O
2-4	O
)	O
were	O
isolated	O
from	O
the	O
rhizomes	O
of	O
Cynanchum	O
stauntonii	O
(	O
Decne	O
.	O
)	O
Schltr	O
.	O
ex	O
Levl	O
.	O
Their	O
structures	O
were	O
established	O
mainly	O
by	O
the	O
spectroscopic	O
analysis	O
,	O
including	O
2D	O
NMR	O
.	O
All	O
the	O
isolated	O
compounds	O
were	O
evaluated	O
for	O
their	O
cytotoxicity	O
against	O
human	O
cancer	O
cell	O
lines	O
HeLa	O
,	O
Bel-7402	O
,	O
SGC-7901	O
and	O
BGC-823	O
.	O

Nicotine	S-chemical
-induced	O
contraction	O
in	O
the	O
rat	O
coronary	O
artery	O
:	O
possible	O
involvement	O
of	O
the	O
endothelium	O
,	O
reactive	O
oxygen	S-chemical
species	O
and	O
COX-1	S-GP
metabolites	O
.	O
Nicotine	S-chemical
caused	O
a	O
contraction	O
of	O
the	O
rat	O
coronary	O
artery	O
in	O
the	O
presence	O
of	O
Nomega-nitro-L-arginine	B-chemical
methyl	I-chemical
ester	E-chemical
(	O
L-NAME	S-chemical
)	O
and	O
arachidonic	B-chemical
acid	E-chemical
,	O
and	O
did	O
not	O
in	O
the	O
absence	O
of	O
these	O
agents	O
.	O
The	O
present	O
experiments	O
were	O
undertaken	O
to	O
pharmacologically	O
characterize	O
the	O
nicotine	S-chemical
-induced	O
contraction	O
in	O
ring	O
preparations	O
of	O
the	O
rat	O
coronary	O
artery	O
.	O
The	O
contraction	O
was	O
abolished	O
by	O
chemical	O
removal	O
of	O
endothelium	O
saponin	S-chemical
.	O
Oxygen	S-chemical
radical	O
scavengers	O
,	O
superoxide	B-GP
dismutase	E-GP
and	O
catalase	S-GP
,	O
significantly	O
attenuated	O
the	O
contraction	O
.	O
Cyclooxygenase-1	S-GP
(	O
COX-1	S-GP
)	O
inhibitors	O
(	O
flurbiprofen	S-chemical
,	O
ketoprofen	S-chemical
and	O
ketrolack	S-chemical
)	O
attenuated	O
the	O
nicotine	S-chemical
-induced	O
contraction	O
in	O
a	O
concentration-dependent	O
manner	O
,	O
and	O
cyclooxygenase-2	S-GP
(	O
COX-2	S-GP
)	O
inhibitors	O
at	O
high	O
concentrations	O
(	O
nimesulide	S-chemical
and	O
NS-389	S-chemical
)	O
slightly	O
attenuated	O
the	O
contraction	O
.	O
A	O
TXA2	B-GP
synthetase	E-GP
inhibitor	O
(	O
OKY-046	S-chemical
)	O
attenuated	O
the	O
contraction	O
to	O
a	O
small	O
extent	O
only	O
at	O
high	O
concentrations	O
.	O
A	O
TXA2	B-GP
receptor	E-GP
antagonist	O
(	O
S-1452	S-chemical
)	O
attenuated	O
the	O
contraction	O
in	O
a	O
concentration-dependent	O
manner	O
.	O
A	O
nicotinic	B-GP
receptor	E-GP
antagonist	O
(	O
hexamethonium	S-chemical
)	O
attenuated	O
the	O
contraction	O
in	O
part	O
and	O
an	O
alpha-adrenoceptor	S-GP
antagonist	O
(	O
prazosin	S-chemical
)	O
nearly	O
abolished	O
the	O
contraction	O
.	O
From	O
these	O
results	O
,	O
it	O
was	O
suggested	O
that	O
the	O
contraction	O
induced	O
by	O
nicotine	S-chemical
in	O
the	O
rat	O
coronary	O
artery	O
in	O
the	O
presence	O
of	O
L-NAME	S-chemical
and	O
arachidonic	B-chemical
acid	E-chemical
is	O
endothelium	O
dependent	O
,	O
and	O
involves	O
reactive	O
oxygen	S-chemical
species	O
and	O
endothelial	O
COX-1	S-GP
metabolites	O
of	O
arachidonic	B-chemical
acid	E-chemical
.	O
Part	O
of	O
the	O
contraction	O
is	O
probably	O
due	O
to	O
release	O
of	O
norepinephrine	S-chemical
.	O

Mesalamine	S-chemical
modulates	O
intercellular	O
adhesion	O
through	O
inhibition	O
of	O
p-21	B-GP
activated	I-GP
kinase-1	E-GP
.	O
Mesalamine	S-chemical
(	O
5-ASA	S-chemical
)	O
is	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
ulcerative	O
colitis	O
,	O
a	O
remitting	O
condition	O
characterized	O
by	O
chronic	O
inflammation	O
of	O
the	O
colon	O
.	O
Knowledge	O
about	O
the	O
molecular	O
and	O
cellular	O
targets	O
of	O
5-ASA	S-chemical
is	O
limited	O
and	O
a	O
clear	O
understanding	O
of	O
its	O
activity	O
in	O
intestinal	O
homeostasis	O
and	O
interference	O
with	O
neoplastic	O
progression	O
is	O
lacking	O
.	O
We	O
sought	O
to	O
identify	O
molecular	O
pathways	O
interfered	O
by	O
5-ASA	S-chemical
,	O
using	O
CRC	O
cell	O
lines	O
with	O
different	O
genetic	O
background	O
.	O
Microarray	O
was	O
performed	O
for	O
gene	O
expression	O
profile	O
of	O
5-ASA	S-chemical
-treated	O
and	O
untreated	O
cells	O
(	O
HCT116	O
and	O
HT29	O
)	O
.	O
Filtering	O
and	O
analysis	O
of	O
data	O
identified	O
three	O
oncogenic	O
pathways	O
interfered	O
by	O
5-ASA	S-chemical
:	O
MAPK	S-GP
/	O
ERK	S-GP
pathway	O
,	O
cell	O
adhesion	O
and	O
β-catenin	S-GP
/	O
Wnt	S-GP
signaling	O
.	O
PAK1	S-GP
emerged	O
as	O
a	O
consensus	O
target	O
of	O
5-ASA	S-chemical
,	O
orchestrating	O
these	O
pathways	O
.	O
We	O
further	O
investigated	O
the	O
effect	O
of	O
5-ASA	S-chemical
on	O
cell	O
adhesion	O
.	O
5-ASA	S-chemical
increased	O
cell	O
adhesion	O
which	O
was	O
measured	O
by	O
cell	O
adhesion	O
assay	O
and	O
transcellular-resistance	O
measurement	O
.	O
Moreover	O
,	O
5-ASA	S-chemical
treatment	O
restored	O
membranous	O
expression	O
of	O
adhesion	O
molecules	O
E-cadherin	S-GP
and	O
β-catenin	S-GP
.	O
Role	O
of	O
PAK1	S-GP
as	O
a	O
mediator	O
of	O
mesalamine	O
activity	O
was	O
validated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Inhibition	O
of	O
PAK1	S-GP
by	O
RNA	O
interference	O
also	O
increased	O
cell	O
adhesion	O
.	O
PAK1	S-GP
expression	O
was	O
elevated	O
in	O
APC	O
(	O
min	O
)	O
polyps	O
and	O
5-ASA	S-chemical
treatment	O
reduced	O
its	O
expression	O
.	O
Our	O
data	O
demonstrates	O
novel	O
pharmacological	O
mechanism	O
of	O
mesalamine	S-chemical
in	O
modulation	O
of	O
cell	O
adhesion	O
and	O
role	O
of	O
PAK1	S-GP
in	O
APC	O
(	O
min	O
)	O
polyposis	O
.	O
We	O
propose	O
that	O
inhibition	O
of	O
PAK1	S-GP
expression	O
by	O
5-ASA	S-chemical
can	O
impede	O
with	O
neoplastic	O
progression	O
in	O
colorectal	O
carcinogenesis	O
.	O
The	O
mechanism	O
of	O
PAK1	S-GP
inhibition	O
and	O
induction	O
of	O
membranous	O
translocation	O
of	O
adhesion	O
proteins	O
by	O
5-ASA	S-chemical
might	O
be	O
independent	O
of	O
its	O
known	O
anti-inflammatory	O
action	O
.	O

Desipramine	S-chemical
treatment	O
decreases	O
3H-nisoxetine	S-chemical
binding	O
and	O
norepinephrine	B-GP
transporter	E-GP
mRNA	O
in	O
SK-N-SHSY5Y	O
cells	O
.	O
The	O
antidepressant	O
desipramine	S-chemical
has	O
been	O
shown	O
to	O
decrease	O
synaptic	O
membrane	O
concentrations	O
of	O
the	O
norepinephrine	B-GP
re-uptake	I-GP
transporter	E-GP
(	O
NET	S-GP
)	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
on	O
both	O
an	O
acute	O
and	O
a	O
chronic	O
basis	O
.	O
The	O
possible	O
contribution	O
of	O
decreased	O
NET	S-GP
synthesis	O
to	O
the	O
chronic	O
downregulation	O
of	O
the	O
NETs	S-GP
has	O
not	O
been	O
definitively	O
established	O
.	O
In	O
this	O
study	O
,	O
we	O
treated	O
SK-N-SHSY5Y	O
cells	O
with	O
100	O
nM	O
desipramine	S-chemical
for	O
24	O
or	O
72	O
h	O
,	O
and	O
measured	O
3H-nisoxetine	S-chemical
binding	O
(	O
as	O
an	O
estimate	O
of	O
NETs	S-GP
)	O
and	O
NET	S-GP
mRNA	O
by	O
quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O
Similar	O
to	O
what	O
has	O
been	O
reported	O
previously	O
,	O
membrane	O
3H-nisoxetine	S-chemical
binding	O
was	O
significantly	O
decreased	O
at	O
both	O
24	O
and	O
72	O
h	O
(	O
approximately	O
50	O
%	O
at	O
both	O
time	O
points	O
)	O
.	O
However	O
,	O
a	O
significant	O
decrease	O
(	O
64	O
+/-	O
8	O
%	O
of	O
paired	O
control	O
)	O
of	O
NET	S-GP
mRNA	O
was	O
observed	O
only	O
at	O
the	O
72-h	O
time	O
point	O
.	O
We	O
conclude	O
that	O
decreased	O
NET	S-GP
synthesis	O
may	O
contribute	O
to	O
the	O
chronic	O
,	O
but	O
not	O
acute	O
,	O
effect	O
of	O
desipramine	S-chemical
to	O
downregulate	O
the	O
NET	S-GP
.	O

A	O
review	O
of	O
the	O
structural	O
and	O
functional	O
features	O
of	O
olmesartan	B-chemical
medoxomil	E-chemical
,	O
an	O
angiotensin	B-GP
receptor	E-GP
blocker	O
.	O
The	O
angiotensin	B-GP
II	I-GP
(	I-GP
A-II	I-GP
)	I-GP
type	I-GP
1	I-GP
(	I-GP
AT1	I-GP
)	I-GP
receptor	E-GP
-mediated	O
effects	O
of	O
A-II	S-GP
play	O
a	O
key	O
role	O
in	O
the	O
pathophysiology	O
of	O
hypertension	O
.	O
Effective	O
inhibition	O
of	O
A-II	S-GP
is	O
provided	O
by	O
the	O
latest	O
class	O
of	O
antihypertensive	O
medications	O
,	O
the	O
AT1	S-GP
receptor	O
blockers	O
(	O
ARBs	O
)	O
.	O
These	O
orally	O
available	O
agents	O
were	O
developed	O
around	O
a	O
common	O
imidazole-based	O
structural	O
core	O
.	O
The	O
most	O
recent	O
member	O
of	O
this	O
drug	O
class	O
to	O
be	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
,	O
olmesartan	B-chemical
medoxomil	E-chemical
,	O
contains	O
unique	O
features	O
that	O
may	O
explain	O
its	O
clinical	O
efficacy	O
.	O
Key	O
structural	O
elements	O
of	O
olmesartan	B-chemical
medoxomil	E-chemical
include	O
a	O
hydroxyalkyl	O
substituent	O
at	O
the	O
imidazole	O
4-position	O
and	O
a	O
hydrolyzable	O
ester	O
group	O
at	O
the	O
imidazole	O
5-position	O
.	O
Inter-	O
and	O
intramolecular	O
hydrogen	O
bonding	O
involving	O
these	O
groups	O
may	O
contribute	O
to	O
the	O
potentiation	O
of	O
antagonist	O
activity	O
.	O
After	O
oral	O
administration	O
,	O
olmesartan	B-chemical
medoxomil	E-chemical
is	O
deesterified	O
in	O
the	O
intestinal	O
tract	O
to	O
produce	O
the	O
active	O
metabolite	O
olmesartan	O
,	O
which	O
undergoes	O
no	O
additional	O
metabolic	O
change	O
.	O
The	O
marked	O
antihypertensive	O
efficacy	O
of	O
olmesartan	B-chemical
medoxomil	E-chemical
may	O
result	O
from	O
a	O
unique	O
pharmacological	O
interaction	O
of	O
the	O
drug	O
with	O
the	O
AT1	S-GP
receptor	O
,	O
resulting	O
in	O
a	O
potent	O
,	O
long-lasting	O
,	O
dose-dependent	O
blockade	O
of	O
A-II	S-GP
.	O
This	O
review	O
article	O
characterizes	O
the	O
structural	O
features	O
of	O
olmesartan	O
that	O
may	O
be	O
responsible	O
for	O
its	O
clinical	O
efficacy	O
.	O
Inferential	O
pharmacological	O
studies	O
compare	O
and	O
contrast	O
the	O
effects	O
of	O
olmesartan	O
to	O
those	O
of	O
other	O
ARBs	O
in	O
comparable	O
preclinical	O
animal	O
models	O
.	O

Inhibitory	O
effects	O
of	O
in	O
vivo	O
oxidized	B-GP
high-density	I-GP
lipoproteins	E-GP
on	O
platelet	O
aggregation	O
:	O
evidence	O
from	O
patients	O
with	O
abetalipoproteinemia	O
.	O
There	O
is	O
evidence	O
that	O
high-density	B-GP
lipoproteins	E-GP
(	O
HDLs	S-GP
)	O
may	O
regulate	O
platelet	O
function	O
,	O
but	O
disparate	O
results	O
exist	O
regarding	O
the	O
effects	O
of	O
oxidized	O
HDLs	S-GP
on	O
platelets	O
.	O
The	O
objective	O
of	O
our	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
in	O
vivo	O
oxidized	B-GP
HDLs	E-GP
on	O
platelet	O
aggregation	O
.	O
Platelet	O
aggregation	O
and	O
redox	O
status	O
were	O
investigated	O
in	O
5	O
patients	O
with	O
abetalipoproteinemia	O
(	O
ABLP	O
)	O
or	O
homozygous	O
hypobetalipoproteinemia	O
,	O
two	O
rare	O
metabolic	O
diseases	O
characterized	O
by	O
the	O
absence	O
of	O
apolipoprotein	B-GP
B	E-GP
-containing	O
lipoproteins	S-GP
,	O
compared	O
to	O
5	O
control	O
subjects	O
.	O
Platelets	O
isolated	O
from	O
plasma	O
of	O
patients	O
with	O
ABLP	O
aggregated	O
4	O
to	O
10	O
times	O
more	O
than	O
control	O
platelets	O
,	O
depending	O
on	O
the	O
agonist	O
.	O
By	O
contrast	O
,	O
no	O
differences	O
in	O
the	O
extent	O
of	O
platelet	O
aggregation	O
were	O
observed	O
between	O
ABLP	O
platelet-rich	O
plasma	O
(	O
PRP	O
)	O
and	O
control	O
PRP	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
protective	O
factor	O
in	O
ABLP	O
plasma	O
.	O
ABLP	O
HDLs	S-GP
inhibited	O
agonist-induced	O
platelet	O
aggregation	O
by	O
binding	O
to	O
SR-BI	S-GP
,	O
while	O
control	O
HDLs	S-GP
had	O
no	O
effect	O
.	O
On	O
the	O
other	O
hand	O
,	O
lipoprotein	S-GP
-deficient	O
plasma	O
from	O
patients	O
with	O
ABLP	O
did	O
not	O
inhibit	O
platelet	O
aggregation	O
.	O
Severe	O
oxidative	O
stress	O
was	O
evidenced	O
in	O
patients	O
with	O
ABLP	O
.	O
Compared	O
to	O
control	O
HDLs	S-GP
,	O
ABLP	O
HDLs	S-GP
showed	O
a	O
40	O
%	O
decrease	O
of	O
α-tocopherol	S-chemical
and	O
an	O
11-fold	O
increased	O
malondialdehyde	S-chemical
concentration	O
.	O
These	O
results	O
demonstrate	O
that	O
in	O
vivo	O
oxidized	B-GP
HDLs	E-GP
do	O
not	O
lose	O
their	O
antiaggregatory	O
properties	O
despite	O
oxidation.-Calzada	O
,	O
C.	O
,	O
Véricel	O
,	O
E.	O
,	O
Colas	O
,	O
R.	O
,	O
Guillot	O
,	O
N.	O
,	O
El	O
Khoury	O
,	O
G.	O
,	O
Drai	O
,	O
J.	O
,	O
Sassolas	O
,	O
A.	O
,	O
Peretti	O
,	O
N.	O
,	O
Ponsin	O
,	O
G.	O
,	O
Lagarde	O
,	O
M.	O
,	O
Moulin	O
,	O
P.	O
Inhibitory	O
effects	O
of	O
in	O
vivo	O
oxidized	B-GP
high-density	I-GP
lipoproteins	E-GP
on	O
platelet	O
aggregation	O
:	O
evidence	O
from	O
patients	O
with	O
abetalipoproteinemia	O
.	O

Carnitine	S-chemical
biosynthesis	O
.	O
Purification	O
of	O
gamma-butyrobetaine	B-GP
hydroxylase	E-GP
from	O
rat	O
liver	O
.	O
gamma-Butyrobetaine	B-GP
hydroxylase	E-GP
catalyse	O
the	O
last	O
step	O
in	O
carnitine	S-chemical
biosynthesis	O
,	O
the	O
formation	O
of	O
L-carnitine	S-chemical
from	O
gamma-butyrobetaine	S-chemical
,	O
a	O
reaction	O
dependent	O
on	O
Fe2+	S-chemical
,	O
alpha-ketoglutarate	S-chemical
,	O
ascorbate	S-chemical
and	O
oxygen	S-chemical
.	O
Initial	O
attempts	O
to	O
purify	O
the	O
protein	O
from	O
rat	O
liver	O
showed	O
that	O
gamma-butyrobetaine	B-GP
hydroxylase	E-GP
is	O
unstable	O
.	O
We	O
,	O
therefore	O
,	O
determined	O
the	O
influence	O
of	O
various	O
compounds	O
on	O
the	O
stability	O
of	O
gamma-butyrobetaine	B-GP
hydroxylase	E-GP
at	O
different	O
storage	O
temperatures	O
.	O
The	O
enzyme	O
activity	O
was	O
best	O
conserved	O
by	O
storing	O
the	O
protein	O
at	O
4	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
200	O
g/l	O
glycerol	S-chemical
and	O
10	O
mM	O
DTT	S-chemical
.	O
We	O
subsequently	O
purified	O
the	O
enzyme	O
from	O
rat	O
liver	O
to	O
apparent	O
homogeneity	O
by	O
liquid	O
chromatography	O
.	O

The	O
ATP	S-chemical
required	O
for	O
potentiation	O
of	O
skeletal	O
muscle	O
contraction	O
is	O
released	O
via	O
pannexin	S-GP
hemichannels	O
.	O
During	O
repetitive	O
stimulation	O
of	O
skeletal	O
muscle	O
,	O
extracellular	O
ATP	S-chemical
levels	O
raise	O
,	O
activating	O
purinergic	B-GP
receptors	E-GP
,	O
increasing	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
influx	O
,	O
and	O
enhancing	O
contractile	O
force	O
,	O
a	O
response	O
called	O
potentiation	O
.	O
We	O
found	O
that	O
ATP	S-chemical
appears	O
to	O
be	O
released	O
through	O
pannexin1	S-GP
hemichannels	O
(	O
Panx1	S-GP
HCs	O
)	O
.	O
Immunocytochemical	O
analyses	O
and	O
function	O
were	O
consistent	O
with	O
pannexin1	S-GP
localization	O
to	O
T-tubules	O
intercalated	O
with	O
dihydropyridine	S-chemical
and	O
ryanodine	B-GP
receptors	E-GP
in	O
slow	O
(	O
soleus	O
)	O
and	O
fast	O
(	O
extensor	O
digitorum	O
longus	O
,	O
EDL	O
)	O
muscles	O
.	O
Isolated	O
myofibers	O
took	O
up	O
ethidium	S-chemical
(	O
Etd	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
)	O
and	O
released	O
small	O
molecules	O
(	O
as	O
ATP	S-chemical
)	O
during	O
electrical	O
stimulation	O
.	O
Consistent	O
with	O
two	O
glucose	S-chemical
uptake	O
pathways	O
,	O
induced	O
uptake	O
of	O
2-NBDG	S-chemical
,	O
a	O
fluorescent	O
glucose	S-chemical
derivative	O
,	O
was	O
decreased	O
by	O
inhibition	O
of	O
HCs	O
or	O
glucose	B-GP
transporter	E-GP
(	O
GLUT4	S-GP
)	O
,	O
and	O
blocked	O
by	O
dual	O
blockade	O
.	O
Adult	O
skeletal	O
muscles	O
apparently	O
do	O
not	O
express	O
connexins	S-GP
,	O
making	O
it	O
unlikely	O
that	O
connexin	S-GP
hemichannels	O
contribute	O
to	O
the	O
uptake	O
and	O
release	O
of	O
small	O
molecules	O
.	O
ATP	S-chemical
release	O
,	O
Etd	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
uptake	O
,	O
and	O
potentiation	O
induced	O
by	O
repetitive	O
electrical	O
stimulation	O
were	O
blocked	O
by	O
HC	O
blockers	O
and	O
did	O
not	O
occur	O
in	O
muscles	O
of	O
pannexin1	S-GP
knockout	O
mice	O
.	O
MRS2179	O
,	O
a	O
P2Y1R	S-GP
blocker	O
,	O
prevented	O
potentiation	O
in	O
EDL	O
,	O
but	O
not	O
soleus	O
muscles	O
,	O
suggesting	O
that	O
in	O
fast	O
muscles	O
ATP	S-chemical
activates	O
P2Y1	S-GP
but	O
not	O
P2X	B-GP
receptors	E-GP
.	O
Phosphorylation	O
on	O
Ser	S-chemical
and	O
Thr	S-chemical
residues	O
of	O
pannexin1	S-GP
was	O
increased	O
during	O
potentiation	O
,	O
possibly	O
mediating	O
HC	O
opening	O
.	O
Opening	O
of	O
Panx1	S-GP
HCs	O
during	O
repetitive	O
activation	O
allows	O
efflux	O
of	O
ATP	S-chemical
,	O
influx	O
of	O
glucose	S-chemical
and	O
possibly	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
too	O
,	O
which	O
are	O
required	O
for	O
potentiation	O
of	O
contraction	O
.	O
This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Connexin	S-GP
based	O
channels	O
'	O
.	O

Cysteinyl	B-GP
leukotriene	I-GP
receptor	I-GP
1	E-GP
is	O
involved	O
in	O
N-methyl-D-aspartate	S-chemical
-mediated	O
neuronal	O
injury	O
in	O
mice	O
.	O
AIM	O
:	O
To	O
determine	O
whether	O
cysteinyl	B-GP
leukotriene	I-GP
receptor	I-GP
1	E-GP
(	O
CysLT1	B-GP
receptor	E-GP
)	O
is	O
involved	O
in	O
N-methyl-D-aspartate	S-chemical
(	O
NMDA	S-chemical
)	O
-induced	O
excitotoxic	O
injury	O
in	O
the	O
mouse	O
brain	O
.	O
METHODS	O
:	O
Brain	O
injury	O
was	O
induced	O
by	O
NMDA	S-chemical
microinjection	O
(	O
50-150	O
nmol	O
in	O
0.5	O
microL	O
)	O
into	O
the	O
cerebral	O
cortex	O
.	O
The	O
changes	O
in	O
CysLT1	B-GP
receptor	E-GP
expression	O
24	O
h	O
after	O
NMDA	S-chemical
injection	O
and	O
the	O
effects	O
of	O
a	O
CysLT1	B-GP
receptor	E-GP
antagonist	O
,	O
pranlukast	S-chemical
(	O
0.01	O
and	O
0.1	O
mg/kg	O
)	O
,	O
an	O
NMDA	B-GP
receptor	E-GP
antagonist	O
,	O
ketamine	S-chemical
(	O
30	O
mg/kg	O
)	O
,	O
and	O
an	O
antioxidant	O
,	O
edaravone	S-chemical
(	O
9	O
mg/kg	O
)	O
were	O
observed	O
.	O
RESULTS	O
:	O
In	O
the	O
NMDA	S-chemical
-injured	O
brain	O
,	O
the	O
CysLT1	B-GP
receptor	E-GP
mRNA	O
,	O
and	O
protein	O
expression	O
were	O
upregulated	O
,	O
and	O
the	O
receptor	O
was	O
mainly	O
localized	O
in	O
the	O
neurons	O
and	O
not	O
in	O
the	O
astrocytes	O
.	O
Pranlukast	S-chemical
,	O
ketamine	S-chemical
and	O
edaravone	S-chemical
decreased	O
NMDA	S-chemical
-induced	O
injury	O
;	O
pranlukast	S-chemical
(	O
0.1	O
mg/kg	O
)	O
and	O
ketamine	S-chemical
inhibited	O
the	O
upregulated	O
expression	O
of	O
the	O
CysLT1	B-GP
receptor	E-GP
.	O
CONCLUSION	O
:	O
CysLT1	B-GP
receptor	E-GP
expression	O
in	O
neurons	O
is	O
upregulated	O
after	O
NMDA	S-chemical
injection	O
,	O
and	O
NMDA	S-chemical
-induced	O
responses	O
are	O
inhibited	O
by	O
CysLT1	B-GP
receptor	E-GP
antagonists	O
,	O
indicating	O
that	O
the	O
increased	O
CysLT1	B-GP
receptor	E-GP
is	O
involved	O
in	O
NMDA	S-chemical
excitotoxicity	O
.	O

Oncogenic	O
K-ras	S-GP
expression	O
is	O
associated	O
with	O
derangement	O
of	O
the	O
cAMP	S-chemical
/	O
PKA	S-GP
pathway	O
and	O
forskolin	S-chemical
-reversible	O
alterations	O
of	O
mitochondrial	O
dynamics	O
and	O
respiration	O
.	O
The	O
Warburg	O
effect	O
in	O
cancer	O
cells	O
has	O
been	O
proposed	O
to	O
involve	O
several	O
mechanisms	O
,	O
including	O
adaptation	O
to	O
hypoxia	O
,	O
oncogenes	O
activation	O
or	O
loss	O
of	O
oncosuppressors	O
and	O
impaired	O
mitochondrial	O
function	O
.	O
In	O
previous	O
papers	O
,	O
it	O
has	O
been	O
shown	O
that	O
K-ras	S-GP
transformed	O
mouse	O
cells	O
are	O
much	O
more	O
sensitive	O
as	O
compared	O
with	O
normal	O
cells	O
to	O
glucose	S-chemical
withdrawal	O
(	O
undergoing	O
apoptosis	O
)	O
and	O
present	O
a	O
high	O
glycolytic	O
rate	O
and	O
a	O
strong	O
reduction	O
of	O
mitochondrial	B-GP
complex	I-GP
I	E-GP
.	O
Recent	O
observations	O
suggest	O
that	O
transformed	O
cells	O
have	O
a	O
derangement	O
in	O
the	O
cyclic	B-chemical
adenosine	I-chemical
monophosphate	E-chemical
/	O
cAMP-dependent	B-GP
protein	I-GP
kinase	E-GP
(	O
cAMP	S-chemical
/	O
PKA	S-GP
)	O
pathway	O
,	O
which	O
is	O
known	O
to	O
regulate	O
several	O
mitochondrial	O
functions	O
.	O
Herein	O
,	O
the	O
derangement	O
of	O
the	O
cAMP	S-chemical
/	O
PKA	S-GP
pathway	O
and	O
its	O
impact	O
on	O
transformation-linked	O
changes	O
of	O
mitochondrial	O
functions	O
is	O
investigated	O
.	O
Exogenous	O
stimulation	O
of	O
PKA	S-GP
activity	O
,	O
achieved	O
by	O
forskolin	S-chemical
treatment	O
,	O
protected	O
K-ras	S-GP
-transformed	O
cells	O
from	O
apoptosis	O
induced	O
by	O
glucose	S-chemical
deprivation	O
,	O
enhanced	O
complex	B-GP
I	E-GP
activity	O
,	O
intracellular	O
adenosine	B-chemical
triphosphate	E-chemical
(	O
ATP	S-chemical
)	O
levels	O
,	O
mitochondrial	O
fusion	O
and	O
decreased	O
intracellular	O
reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
levels	O
.	O
Several	O
of	O
these	O
effects	O
were	O
almost	O
completely	O
prevented	O
by	O
inhibiting	O
the	O
PKA	S-GP
activity	O
.	O
Short-time	O
treatment	O
with	O
compounds	O
favoring	O
mitochondrial	O
fusion	O
strongly	O
decreased	O
the	O
cellular	O
ROS	O
levels	O
especially	O
in	O
transformed	O
cells	O
.	O
These	O
findings	O
support	O
the	O
notion	O
that	O
glucose	S-chemical
shortage-induced	O
apoptosis	O
,	O
specific	O
of	O
K-ras	S-GP
-transformed	O
cells	O
,	O
is	O
associated	O
to	O
a	O
derangement	O
of	O
PKA	S-GP
signaling	O
that	O
leads	O
to	O
mitochondrial	B-GP
complex	I-GP
I	E-GP
decrease	O
,	O
reduction	O
of	O
ATP	S-chemical
formation	O
,	O
prevalence	O
of	O
mitochondrial	O
fission	O
over	O
fusion	O
,	O
and	O
thereby	O
opening	O
new	O
approaches	O
for	O
development	O
of	O
anticancer	O
drugs	O
.	O

New	O
triterpenoids	S-chemical
from	O
the	O
stem	O
bark	O
of	O
Hypodaphnis	O
zenkeri	O
.	O
A	O
new	O
pentacyclic	B-chemical
triterpenoid	E-chemical
and	O
three	O
new	O
derivatives	O
based	O
on	O
the	O
taraxer-14-ene	S-chemical
skeleton	O
with	O
a	O
C-28	O
attached	O
a	O
carboxylic	B-chemical
acid	E-chemical
group	O
have	O
been	O
isolated	O
from	O
the	O
stem	O
bark	O
of	O
Hypodaphnis	O
zenkeri	O
,	O
together	O
with	O
six	O
known	O
compounds	O
.	O
The	O
new	O
product	O
was	O
identified	O
as	O
2α,3α-dihydroxytaraxer-14-en-28-oic	B-chemical
acid	E-chemical
(	O
1	O
)	O
.	O
Its	O
derivatives	O
,	O
2α,3α-diacetyltaraxer-14-en-28-oic	B-chemical
acid	E-chemical
(	O
2	O
)	O
,	O
2α,3α-di-O-carbonyl-2α,3α-dihydroxytaraxer-14-en-28-oic	B-chemical
acid	E-chemical
(	O
3	O
)	O
and	O
2α,3α-dipropionyltaraxer-14-en-28-oic	B-chemical
acid	E-chemical
(	O
4	O
)	O
were	O
obtained	O
by	O
semisynthesis	O
.	O
The	O
known	O
compounds	O
were	O
identified	O
as	O
3β-hydroxytaraxer-14-en-28-oic	B-chemical
acid	E-chemical
or	O
aleuritolic	B-chemical
acid	E-chemical
(	O
5	O
)	O
(	O
McPhail	O
,	O
A.T.	O
,	O
McPhail	O
,	O
D.R.	O
,	O
Wani	O
,	O
M.C.	O
,	O
Wall	O
,	O
M.E	O
.	O
&	O
A.W.	O
,	O
Nicholas	O
,	O
A.W	O
.	O
(	O
1989	O
)	O
.	O
Identity	O
of	O
maprounic	B-chemical
acid	E-chemical
with	O
aleuritolic	B-chemical
acid	E-chemical
.	O
Revision	O
of	O
the	O
structure	O
of	O
maprounic	B-chemical
acid	E-chemical
:	O
X-ray	O
crystal	O
structure	O
of	O
p-bromobenzyl	B-chemical
acetylmaprounate	E-chemical
.	O
Journal	O
Natural	O
Products	O
,	O
52	O
,	O
212	O
)	O
,	O
3α-hydroxytaraxer-14-en-28-oic	B-chemical
acid	E-chemical
or	O
isoaleuritolic	B-chemical
acid	E-chemical
(	O
6	O
)	O
,	O
3α-acetyltaraxer-14-en-28-oic	B-chemical
acid	I-chemical
acetate	E-chemical
or	O
aleuritolic	B-chemical
acid	I-chemical
acetate	E-chemical
(	O
7	O
)	O
(	O
Chaudhuri	O
,	O
S.K.	O
,	O
Fullas	O
,	O
F.	O
,	O
Brown	O
,	O
D.M.	O
,	O
Wani	O
,	O
M.C.	O
,	O
Wall	O
,	O
M.E.	O
,	O
Cai	O
,	O
L.	O
,	O
…	O
Kinghorn	O
,	O
A.D.	O
(	O
1995	O
)	O
.	O
Isolation	O
and	O
structural	O
elucidation	O
of	O
pentacyclic	O
triterpenoids	O
from	O
Maprounea	O
africana	O
.	O
Journal	O
of	O
Natural	O
Products	O
,	O
58	O
,	O
1-9	O
)	O
,	O
3-oxo-taraxer-14-ene	S-chemical
or	O
taraxerone	S-chemical
(	O
8	O
)	O
β-sitosterol	S-chemical
(	O
9	O
)	O
and	O
stigmasterol	S-chemical
(	O
10	O
)	O
(	O
Kamboj	O
&	O
Saluja	O
,	O
2011	O
)	O
,	O
together	O
with	O
fatty	O
acids	O
.	O
Their	O
structures	O
were	O
established	O
on	O
the	O
basis	O
of	O
spectroscopic	O
studies	O
and	O
chemical	O
transformations	O
.	O

Evaluation	O
of	O
in	O
vivo	O
anti-hyperglycemic	O
and	O
antioxidant	O
potentials	O
of	O
α-santalol	S-chemical
and	O
sandalwood	O
oil	O
.	O
Sandalwood	O
finds	O
numerous	O
mentions	O
across	O
diverse	O
traditional	O
medicinal	O
systems	O
in	O
use	O
worldwide	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
in	O
vivo	O
anti-hyperglycemic	O
and	O
antioxidant	O
potential	O
of	O
sandalwood	O
oil	O
and	O
its	O
major	O
constituent	O
α-santalol	S-chemical
.	O
The	O
in	O
vivo	O
anti-hyperglycemic	O
experiment	O
was	O
conducted	O
in	O
alloxan	S-chemical
-induced	O
diabetic	O
male	O
Swiss	O
albino	O
mice	O
models	O
.	O
The	O
in	O
vivo	O
antioxidant	O
experiment	O
was	O
performed	O
in	O
d-galactose	S-chemical
mediated	O
oxidative	O
stress	O
induced	O
male	O
Swiss	O
albino	O
mice	O
models	O
.	O
Intraperitoneal	O
administration	O
of	O
α-santalol	S-chemical
(	O
100mg/kg	O
BW	O
)	O
and	O
sandalwood	O
oil	O
(	O
1g/kg	O
BW	O
)	O
for	O
an	O
week	O
modulated	O
parameters	O
such	O
as	O
body	O
weight	O
,	O
blood	O
glucose	S-chemical
,	O
serum	O
bilirubin	S-chemical
,	O
liver	O
glycogen	O
,	O
and	O
lipid	O
peroxides	S-chemical
contents	O
to	O
normoglycemic	O
levels	O
in	O
the	O
alloxan	S-chemical
-induced	O
diabetic	O
mice	O
.	O
Similarly	O
,	O
intraperitoneal	O
administration	O
of	O
α-santalol	S-chemical
(	O
100mg/kg	O
BW	O
)	O
and	O
sandalwood	O
oil	O
(	O
1g/kg	O
BW	O
)	O
for	O
two	O
weeks	O
modulated	O
parameters	O
such	O
as	O
serum	O
aminotransferases	S-GP
,	O
alkaline	B-GP
phosphatase	E-GP
,	O
bilirubin	S-chemical
,	O
superoxide	B-GP
dismutase	E-GP
,	O
catalase	S-GP
,	O
free	O
sulfhydryl	S-chemical
,	O
protein	O
carbonyl	S-chemical
,	O
nitric	B-chemical
oxide	E-chemical
,	O
liver	O
lipid	O
peroxide	S-chemical
contents	O
,	O
and	O
antioxidant	O
capacity	O
in	O
d-galactose	S-chemical
mediated	O
oxidative	O
stress	O
induced	O
mice	O
.	O
Besides	O
,	O
it	O
was	O
observed	O
that	O
the	O
beneficial	O
effects	O
of	O
α-santalol	S-chemical
were	O
well	O
complimented	O
,	O
differentially	O
by	O
other	O
constituents	O
present	O
in	O
sandalwood	O
oil	O
,	O
thus	O
indicating	O
synergism	O
in	O
biological	O
activity	O
of	O
this	O
traditionally	O
used	O
bioresource	O
.	O

Genetic	O
polymorphisms	O
in	O
the	O
cyclooxygenase-2	S-GP
gene	O
,	O
use	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
and	O
breast	O
cancer	O
risk	O
.	O
INTRODUCTION	O
:	O
The	O
association	O
between	O
use	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
and	O
breast	O
cancer	O
risk	O
remains	O
unclear	O
.	O
Inconsistencies	O
in	O
previously	O
reported	O
findings	O
may	O
be	O
partly	O
due	O
to	O
differences	O
in	O
expression	O
of	O
cyclooxygenase	B-GP
(	I-GP
COX	I-GP
)	I-GP
-2	E-GP
.	O
We	O
hypothesized	O
that	O
genetic	O
polymorphisms	O
(	O
COX-2	S-GP
.926	O
,	O
COX-2	S-GP
.5209	O
,	O
and	O
COX-2	S-GP
.8473	O
)	O
may	O
reduce	O
overall	O
breast	O
cancer	O
risk	O
or	O
risk	O
for	O
subtypes	O
of	O
breast	O
cancer	O
by	O
modulating	O
the	O
inflammatory	O
response	O
and	O
may	O
interact	O
with	O
aspirin	O
or	O
any	O
NSAID	O
use	O
.	O
METHODS	O
:	O
We	O
conducted	O
a	O
population-based	O
,	O
case-control	O
study	O
in	O
which	O
we	O
genotyped	O
1,067	O
breast	O
cancer	O
cases	O
and	O
1,110	O
control	O
individuals	O
included	O
in	O
the	O
Long	O
Island	O
Breast	O
Cancer	O
Study	O
Project	O
.	O
RESULTS	O
:	O
No	O
major	O
effects	O
of	O
the	O
three	O
COX-2	S-GP
variant	O
alleles	O
on	O
breast	O
cancer	O
risk	O
were	O
found	O
.	O
A	O
total	O
of	O
eight	O
distinct	O
haplotypes	O
and	O
18	O
diplotypes	O
were	O
observed	O
in	O
the	O
population	O
.	O
Overall	O
,	O
no	O
significant	O
associations	O
between	O
COX-2	S-GP
haplotypes/diplotypes	O
and	O
breast	O
cancer	O
risk	O
were	O
observed	O
.	O
Among	O
women	O
who	O
used	O
aspirin	O
or	O
any	O
NSAID	O
there	O
was	O
little	O
evidence	O
for	O
an	O
interaction	O
with	O
the	O
at-risk	O
COX-2	S-GP
genotypes	O
,	O
with	O
one	O
exception	O
.	O
Among	O
women	O
with	O
hormone	O
receptor	O
positive	O
breast	O
cancer	O
,	O
the	O
reduced	O
risk	O
for	O
any	O
NSAID	O
use	O
was	O
only	O
evident	O
among	O
those	O
who	O
had	O
at	O
least	O
one	O
variant	O
C	O
allele	O
of	O
COX-2	S-GP
.8473	O
(	O
odds	O
ratio	O
=	O
0.7	O
,	O
95	O
%	O
confidence	O
interval	O
=	O
0.5	O
to	O
1.0	O
;	O
P	O
for	O
the	O
interaction	O
=	O
0.02	O
)	O
.	O
There	O
was	O
no	O
corresponding	O
interaction	O
for	O
aspirin	O
use	O
,	O
possibly	O
because	O
of	O
limited	O
power	O
.	O
CONCLUSION	O
:	O
These	O
data	O
provide	O
modest	O
evidence	O
that	O
the	O
C	O
allele	O
of	O
COX-2	S-GP
.8473	O
may	O
interact	O
with	O
NSAIDs	O
to	O
reduce	O
risk	O
for	O
hormone	O
receptor	O
positive	O
breast	O
cancer	O
.	O

Metabolic	O
derangement	O
of	O
methionine	S-chemical
and	O
folate	S-chemical
metabolism	O
in	O
mice	O
deficient	O
in	O
methionine	B-GP
synthase	I-GP
reductase	E-GP
.	O
Hyperhomocyst	O
(	O
e	O
)	O
inemia	O
is	O
a	O
metabolic	O
derangement	O
that	O
is	O
linked	O
to	O
the	O
distribution	O
of	O
folate	S-chemical
pools	O
,	O
which	O
provide	O
one-	O
carbon	S-chemical
units	O
for	O
biosynthesis	O
of	O
purines	S-chemical
and	O
thymidylate	S-chemical
and	O
for	O
remethylation	O
of	O
homocysteine	S-chemical
to	O
form	O
methionine	S-chemical
.	O
In	O
humans	O
,	O
methionine	B-GP
synthase	E-GP
deficiency	O
results	O
in	O
the	O
accumulation	O
of	O
methyltetrahydrofolate	S-chemical
at	O
the	O
expense	O
of	O
folate	S-chemical
derivatives	O
required	O
for	O
purine	S-chemical
and	O
thymidylate	S-chemical
biosynthesis	O
.	O
Complete	O
ablation	O
of	O
methionine	B-GP
synthase	E-GP
activity	O
in	O
mice	O
results	O
in	O
embryonic	O
lethality	O
.	O
Other	O
mouse	O
models	O
for	O
hyperhomocyst	O
(	O
e	O
)	O
inemia	O
have	O
normal	O
or	O
reduced	O
levels	O
of	O
methyltetrahydrofolate	S-chemical
and	O
are	O
not	O
embryonic	O
lethal	O
,	O
although	O
they	O
have	O
decreased	O
ratios	O
of	O
AdoMet	S-chemical
/	O
AdoHcy	S-chemical
and	O
impaired	O
methylation	O
.	O
We	O
have	O
constructed	O
a	O
mouse	O
model	O
with	O
a	O
gene	O
trap	O
insertion	O
in	O
the	O
Mtrr	S-GP
gene	O
specifying	O
methionine	B-GP
synthase	I-GP
reductase	E-GP
,	O
an	O
enzyme	O
essential	O
for	O
the	O
activity	O
of	O
methionine	B-GP
synthase	E-GP
.	O
This	O
model	O
is	O
a	O
hypomorph	O
,	O
with	O
reduced	O
methionine	B-GP
synthase	I-GP
reductase	E-GP
activity	O
,	O
thus	O
avoiding	O
the	O
lethality	O
associated	O
with	O
the	O
absence	O
of	O
methionine	B-GP
synthase	E-GP
activity	O
.	O
Mtrr	S-GP
(	O
gt/gt	O
)	O
mice	O
have	O
increased	O
plasma	O
homocyst	B-chemical
(	I-chemical
e	I-chemical
)	I-chemical
ine	E-chemical
,	O
decreased	O
plasma	O
methionine	S-chemical
,	O
and	O
increased	O
tissue	O
methyltetrahydrofolate	S-chemical
.	O
Unexpectedly	O
,	O
Mtrr	S-GP
(	O
gt/gt	O
)	O
mice	O
do	O
not	O
show	O
decreases	O
in	O
the	O
AdoMet	S-chemical
/	O
AdoHcy	S-chemical
ratio	O
in	O
most	O
tissues	O
.	O
The	O
different	O
metabolite	O
profiles	O
in	O
the	O
various	O
genetic	O
mouse	O
models	O
for	O
hyper	O
homocyst	B-chemical
(	I-chemical
e	I-chemical
)	I-chemical
ine	E-chemical
mia	O
may	O
be	O
useful	O
in	O
understanding	O
biological	O
effects	O
of	O
elevated	O
homocyst	O
(	O
e	O
)	O
ine	O
.	O

N-acetylgalactosamine	S-chemical
functionalized	O
mixed	O
micellar	O
nanoparticles	O
for	O
targeted	O
delivery	O
of	O
siRNA	O
to	O
liver	O
.	O
Due	O
to	O
its	O
efficient	O
and	O
specific	O
gene	O
silencing	O
ability	O
,	O
RNA	O
interference	O
has	O
shown	O
great	O
potential	O
in	O
the	O
treatment	O
of	O
liver	O
diseases	O
.	O
However	O
,	O
achieving	O
in	O
vivo	O
delivery	O
of	O
siRNA	O
to	O
critical	O
liver	O
cells	O
remains	O
the	O
biggest	O
obstacle	O
for	O
this	O
technique	O
to	O
be	O
a	O
real	O
clinic	O
therapeutic	O
modality	O
.	O
Here	O
,	O
we	O
describe	O
a	O
promising	O
liver	O
targeting	O
siRNA	O
delivery	O
system	O
based	O
on	O
N-acetylgalactosamine	S-chemical
functionalized	O
mixed	O
micellar	O
nanoparticles	O
(	O
Gal-MNP	O
)	O
,	O
which	O
can	O
efficiently	O
deliver	O
siRNA	O
to	O
hepatocytes	O
and	O
silence	O
the	O
target	O
gene	O
expression	O
after	O
systemic	O
administration	O
.	O
The	O
Gal-MNP	O
were	O
assembled	O
in	O
aqueous	O
solution	O
from	O
mixed	O
N-acetylgalactosamine	S-chemical
functionalized	O
poly	B-chemical
(	I-chemical
ethylene	I-chemical
glycol	I-chemical
)	I-chemical
-b-poly	I-chemical
(	I-chemical
ε-caprolactone	I-chemical
)	E-chemical
and	O
cationic	O
poly	B-chemical
(	I-chemical
ε-caprolactone	I-chemical
)	I-chemical
-b-poly	I-chemical
(	I-chemical
2-aminoethyl	I-chemical
ethylene	I-chemical
phosphate	I-chemical
)	E-chemical
(	O
PCL-b-PPEEA	S-chemical
)	O
;	O
the	O
properties	O
of	O
nanoparticles	O
,	O
including	O
particle	O
size	O
,	O
zeta	O
potential	O
and	O
the	O
density	O
of	O
poly	B-chemical
(	I-chemical
ethylene	I-chemical
glycol	I-chemical
)	E-chemical
could	O
be	O
easily	O
regulated	O
.	O
The	O
hepatocyte-targeting	O
effect	O
of	O
Gal-MNP	O
was	O
demonstrated	O
by	O
significant	O
enriching	O
of	O
fluorescent	O
siRNA	O
in	O
primary	O
hepatocytes	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Successful	O
down-regulation	O
of	O
liver-specific	O
apolipoprotein	B-GP
B	E-GP
(	O
apoB	S-GP
)	O
expression	O
was	O
achieved	O
in	O
mouse	O
liver	O
,	O
at	O
both	O
the	O
transcriptional	O
and	O
protein	O
level	O
,	O
following	O
intravenous	O
injection	O
of	O
Gal-MNP/si	O
apoB	S-GP
to	O
BALB/c	O
mice	O
.	O
Systemic	O
delivery	O
of	O
Gal-MNP/siRNA	O
did	O
not	O
induce	O
the	O
innate	O
immune	O
response	O
or	O
positive	O
hepatotoxicity	O
.	O
The	O
results	O
of	O
this	O
study	O
suggested	O
therapeutic	O
potential	O
for	O
the	O
Gal-MNP/siRNA	O
system	O
in	O
liver	O
disease	O
.	O

Comparative	O
analysis	O
of	O
nutritional	O
compositions	O
of	O
transgenic	O
high	O
iron	S-chemical
rice	O
with	O
its	O
non-transgenic	O
counterpart	O
.	O
Iron	S-chemical
is	O
an	O
essential	O
micronutrient	O
for	O
human	O
nutrition	O
and	O
polished	O
rice	O
contains	O
very	O
low	O
amount	O
of	O
iron	S-chemical
.	O
Rice	O
with	O
high	O
iron	S-chemical
content	O
in	O
seed	O
endosperm	O
has	O
been	O
developed	O
by	O
insertion	O
of	O
soybean	B-GP
ferritin	E-GP
gene	O
under	O
the	O
control	O
of	O
the	O
endosperm	O
specific	O
glutelin	B-GP
promoter	E-GP
into	O
the	O
genome	O
of	O
indica	O
rice	O
line	O
IR68144	O
.	O
The	O
nutritional	O
composition	O
of	O
the	O
brown	O
and	O
milled	O
rice	O
grain	O
has	O
been	O
compared	O
with	O
that	O
of	O
the	O
non-transgenic	O
rice	O
of	O
the	O
same	O
variety	O
.	O
In	O
this	O
study	O
,	O
the	O
nutritional	O
components	O
,	O
as	O
well	O
as	O
the	O
anti-nutrient	O
levels	O
,	O
were	O
measured	O
.	O
Our	O
studies	O
established	O
that	O
apart	O
from	O
the	O
increased	O
level	O
of	O
iron	S-chemical
and	O
zinc	S-chemical
in	O
transgenic	O
seeds	O
,	O
the	O
nutritional	O
quality	O
of	O
both	O
the	O
brown	O
and	O
milled	O
rice	O
grains	O
from	O
the	O
transgenic	O
line	O
was	O
substantially	O
equivalent	O
to	O
that	O
of	O
the	O
non-transgenic	O
rice	O
plants	O
.	O
The	O
result	O
clearly	O
shows	O
that	O
the	O
measured	O
amounts	O
of	O
the	O
nutritional	O
components	O
are	O
well	O
within	O
the	O
range	O
of	O
values	O
reported	O
for	O
other	O
commercial	O
lines	O
.	O

Loss	O
of	O
alpha	B-GP
2-macroglobulin	E-GP
and	O
epidermal	B-GP
growth	I-GP
factor	E-GP
surface	O
binding	O
induced	O
by	O
phenothiazines	S-chemical
and	O
naphthalene	B-chemical
sulfonamides	E-chemical
.	O
We	O
have	O
found	O
that	O
certain	O
naphthalenesulfonamides	S-chemical
[	O
e.g.	O
,	O
N-6	B-chemical
(	I-chemical
-aminohexyl	I-chemical
)	I-chemical
-5-chloro-1-naphthalenesulfonamide	E-chemical
(	O
W-7	S-chemical
)	O
]	O
and	O
phenothiazines	S-chemical
[	O
e.g.	O
,	O
trifluoperazine	S-chemical
(	O
TFP	S-chemical
)	O
]	O
induce	O
a	O
loss	O
of	O
cell-surface	O
receptors	O
for	O
alpha	B-GP
2-macroglobulin	E-GP
,	O
and	O
epidermal	B-GP
growth	I-GP
factor	E-GP
(	O
EGF	S-GP
)	O
in	O
fibroblasts	O
.	O
The	O
loss	O
of	O
alpha	B-GP
2-macroglobulin	I-GP
receptors	E-GP
is	O
independent	O
of	O
receptor	O
occupancy	O
and	O
is	O
rapidly	O
reversed	O
upon	O
removal	O
of	O
these	O
agents	O
from	O
the	O
culture	O
medium	O
.	O
The	O
extent	O
of	O
EGF	B-GP
receptor	E-GP
loss	O
is	O
less	O
than	O
for	O
alpha	B-GP
2-macroglobulin	E-GP
,	O
and	O
the	O
EGF	B-GP
receptors	E-GP
do	O
not	O
reappear	O
at	O
the	O
surface	O
when	O
W-7	S-chemical
is	O
removed	O
.	O
Receptor	O
loss	O
was	O
measured	O
as	O
a	O
change	O
in	O
the	O
capacity	O
for	O
binding	O
iodinated	O
ligands	O
;	O
no	O
change	O
in	O
affinity	O
of	O
binding	O
was	O
observed	O
.	O
This	O
receptor	O
loss	O
could	O
reflect	O
inactivation	O
of	O
receptors	O
or	O
internalization	O
.	O
W-7	S-chemical
did	O
not	O
induce	O
a	O
loss	O
of	O
cell	O
surface	O
beta	B-GP
2-microglobulin	E-GP
,	O
a	O
membrane	O
protein	O
which	O
is	O
excluded	O
from	O
coated	O
pits	O
and	O
which	O
is	O
not	O
internalized	O
,	O
indicating	O
that	O
the	O
effect	O
of	O
W-7	S-chemical
was	O
specific	O
for	O
membrane	O
receptors	O
and	O
not	O
a	O
result	O
of	O
bulk	O
depletion	O
of	O
plasma	O
membrane	O
.	O
The	O
loss	O
of	O
alpha	B-GP
2-macroglobulin	E-GP
and	O
EGF	B-GP
receptors	E-GP
occurs	O
at	O
concentrations	O
which	O
do	O
not	O
cause	O
an	O
increase	O
in	O
the	O
pH	O
of	O
endocytic	O
vesicles	O
or	O
the	O
cytoplasm	O
,	O
indicating	O
that	O
these	O
agents	O
act	O
by	O
a	O
mechanism	O
distinct	O
from	O
the	O
effect	O
of	O
other	O
weak	O
bases	O
.	O
Since	O
both	O
TFP	S-chemical
and	O
W-7	S-chemical
are	O
potent	O
inhibitors	O
of	O
calmodulin	S-GP
,	O
we	O
investigated	O
the	O
possibility	O
that	O
inhibition	O
of	O
calmodulin	S-GP
was	O
responsible	O
for	O
the	O
loss	O
of	O
receptors	O
.	O
Three	O
lines	O
of	O
evidence	O
suggest	O
that	O
calmodulin	S-GP
inhibition	O
is	O
not	O
responsible	O
for	O
the	O
inhibition	O
of	O
binding	O
and	O
endocytosis	O
:	O
1	O
)	O
Promethazine	S-chemical
,	O
a	O
phenothiazine	S-chemical
that	O
is	O
a	O
poor	O
inhibitor	O
of	O
calmodulin	O
,	O
is	O
nearly	O
as	O
effective	O
as	O
TFP	S-chemical
at	O
inhibiting	O
endocytosis	O
;	O
calmidazolium	O
,	O
a	O
potent	O
inhibitor	O
of	O
several	O
calmodulin	S-GP
functions	O
,	O
did	O
not	O
cause	O
a	O
loss	O
of	O
binding	O
;	O
2	O
)	O
the	O
microinjection	O
of	O
calmodulin	S-GP
into	O
cells	O
did	O
not	O
reverse	O
the	O
effects	O
of	O
W-7	S-chemical
;	O
using	O
pressure	O
microinjection	O
,	O
we	O
introduced	O
up	O
to	O
a	O
100-fold	O
excess	O
of	O
calmodulin	S-GP
over	O
native	O
levels	O
into	O
individual	O
gerbil	O
fibroma	O
cells	O
;	O
using	O
rhodamine	S-chemical
-labeled	O
alpha	B-GP
2-macroglobulin	E-GP
,	O
we	O
saw	O
that	O
the	O
W-7	S-chemical
induced	O
inhibition	O
of	O
receptor-mediated	O
endocytosis	O
was	O
the	O
same	O
in	O
injected	O
and	O
uninjected	O
cells	O
;	O
3	O
)	O
we	O
injected	O
calcineurin	S-GP
,	O
a	O
calmodulin-binding	B-GP
protein	E-GP
,	O
into	O
cells	O
(	O
1-3	O
pg/cell	O
)	O
and	O
observed	O
no	O
effect	O
on	O
the	O
receptor-mediated	O
endocytosis	O
of	O
rhodamine	S-chemical
-labeled	O
alpha	B-GP
2-macroglobulin	E-GP
.	O
These	O
data	O
indicated	O
that	O
cell	O
surface	O
receptor	O
numbers	O
can	O
be	O
regulated	O
by	O
a	O
cellular	O
component	O
that	O
is	O
not	O
cytoplasmic	B-GP
calmodulin	E-GP
but	O
that	O
shares	O
some	O
drug	O
sensitivities	O
with	O
calmodulin	S-GP
.	O

Barrel	O
rotation	O
in	O
rats	O
induced	O
by	O
SMS	B-chemical
201-995	E-chemical
:	O
suppression	O
by	O
ceruletide	S-chemical
.	O
Intracerebroventricular	O
administration	O
of	O
SMS	B-chemical
201-995	E-chemical
(	O
5	O
micrograms/rat	O
)	O
,	O
a	O
somatostatin	S-chemical
analogue	O
,	O
induced	O
barrel	O
rotation	O
in	O
rats	O
.	O
Pretreatment	O
with	O
ceruletide	S-chemical
(	O
40	O
micrograms/100	O
g	O
b	O
.	O
wt.	O
,	O
IP	O
)	O
3	O
days	O
or	O
7	O
days	O
prior	O
to	O
the	O
injection	O
of	O
SMS	B-chemical
201-995	E-chemical
significantly	O
inhibited	O
the	O
response	O
rate	O
of	O
barrel	O
rotation	O
induced	O
by	O
SMS	B-chemical
201-995	E-chemical
,	O
but	O
not	O
that	O
induced	O
by	O
arginine-vasopressin	S-GP
(	O
1	O
microgram/rat	O
,	O
ICV	O
)	O
.	O
The	O
suppressive	O
effect	O
of	O
ceruletide	S-chemical
on	O
barrel	O
rotation	O
could	O
be	O
partially	O
countered	O
by	O
MK-329	S-chemical
,	O
a	O
selective	O
peripheral	O
CCK	S-GP
(	B-GP
CCK-A	I-GP
)	I-GP
receptor	E-GP
antagonist	O
.	O
Desulfated	O
cerulein	O
did	O
not	O
affect	O
the	O
barrel	O
rotation	O
induced	O
by	O
SMS	B-chemical
201-995	E-chemical
.	O
These	O
findings	O
suggest	O
that	O
ceruletide	S-chemical
specifically	O
suppresses	O
the	O
barrel	O
rotation	O
evoked	O
by	O
SMS	B-chemical
201-995	E-chemical
in	O
a	O
long-lasting	O
manner	O
possibly	O
acting	O
through	O
CCK-A	B-GP
receptor	E-GP
.	O

Oxysterol	S-chemical
generation	O
and	O
liver	B-GP
X	I-GP
receptor	E-GP
-dependent	O
reverse	O
cholesterol	S-chemical
transport	O
:	O
not	O
all	O
roads	O
lead	O
to	O
Rome	O
.	O
Cell	O
cholesterol	S-chemical
metabolism	O
is	O
a	O
tightly	O
regulated	O
process	O
,	O
dependent	O
in	O
part	O
on	O
activation	O
of	O
nuclear	B-GP
liver	I-GP
X	I-GP
receptors	E-GP
(	O
LXRs	S-GP
)	O
to	O
increase	O
expression	O
of	O
genes	O
mediating	O
removal	O
of	O
excess	O
cholesterol	S-chemical
from	O
cells	O
in	O
the	O
reverse	O
cholesterol	S-chemical
transport	O
pathway	O
.	O
LXRs	S-GP
are	O
thought	O
to	O
be	O
activated	O
predominantly	O
by	O
oxysterols	S-chemical
generated	O
enzymatically	O
from	O
cholesterol	S-chemical
in	O
different	O
cell	O
organelles	O
.	O
Defects	O
resulting	O
in	O
slowed	O
release	O
of	O
cholesterol	S-chemical
from	O
late	O
endosomes	O
and	O
lysosomes	O
or	O
reduction	O
in	O
sterol-27-hydroxylase	S-GP
activity	O
lead	O
to	O
specific	O
blocks	O
in	O
oxysterol	S-chemical
production	O
and	O
impaired	O
LXR	S-GP
-dependent	O
gene	O
activation	O
.	O
This	O
block	O
does	O
not	O
appear	O
to	O
be	O
compensated	O
by	O
oxysterol	S-chemical
production	O
in	O
other	O
cell	O
compartments	O
.	O
The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
summarize	O
current	O
knowledge	O
about	O
oxysterol	S-chemical
-dependent	O
activation	O
by	O
LXR	S-GP
of	O
genes	O
involved	O
in	O
reverse	O
cholesterol	S-chemical
transport	O
,	O
and	O
what	O
these	O
defects	O
of	O
cell	O
cholesterol	S-chemical
homeostasis	O
can	O
teach	O
us	O
about	O
the	O
critical	O
pathways	O
of	O
oxysterol	S-chemical
generation	O
for	O
expression	O
of	O
LXR	S-GP
-dependent	O
genes	O
.	O

The	O
presence	O
of	O
D-fagomine	S-chemical
in	O
the	O
human	O
diet	O
from	O
buckwheat-based	O
foodstuffs	O
.	O
Buckwheat	O
(	O
Fagopyrum	O
esculentum	O
Moench	O
)	O
groats	O
contain	O
the	O
iminosugar	O
D-fagomine	S-chemical
as	O
a	O
minor	O
component	O
that	O
might	O
contribute	O
to	O
the	O
alleged	O
health	O
benefits	O
of	O
this	O
pseudo-cereal	O
.	O
This	O
study	O
presents	O
analysis	O
of	O
D-fagomine	S-chemical
in	O
buckwheat-based	O
foodstuffs	O
by	O
liquid	O
chromatography	O
coupled	O
to	O
mass	O
spectrometry	O
and	O
an	O
estimation	O
of	O
its	O
presence	O
in	O
the	O
human	O
diet	O
based	O
on	O
a	O
published	O
population-based	O
cross-sectional	O
nutrition	O
survey	O
.	O
D-fagomine	S-chemical
is	O
present	O
in	O
common	O
buckwheat-based	O
foodstuffs	O
in	O
amounts	O
ranging	O
from	O
1	O
to	O
25	O
mg/kg	O
or	O
mg/L	O
,	O
it	O
is	O
stable	O
during	O
boiling	O
,	O
baking	O
,	O
frying	O
and	O
fermentation	O
,	O
and	O
it	O
is	O
biosynthesised	O
upon	O
sprouting	O
.	O
The	O
estimated	O
total	O
intake	O
of	O
D-fagomine	S-chemical
resulting	O
from	O
a	O
diet	O
that	O
includes	O
such	O
foodstuffs	O
would	O
be	O
between	O
3	O
and	O
17	O
mg	O
per	O
day	O
(	O
mean	O
for	O
both	O
genders	O
;	O
range	O
from	O
P5	O
to	O
P95	O
)	O
.	O
A	O
diet	O
rich	O
in	O
buckwheat	O
products	O
would	O
provide	O
a	O
daily	O
amount	O
of	O
D-fagomine	S-chemical
that	O
may	O
in	O
part	O
explain	O
the	O
beneficial	O
properties	O
traditionally	O
attributed	O
to	O
buckwheat	O
consumption	O
.	O

Impaired	O
expression	O
of	O
the	O
uncoupling	B-GP
protein-3	E-GP
gene	O
in	O
skeletal	O
muscle	O
during	O
lactation	O
:	O
fibrates	O
and	O
troglitazone	S-chemical
reverse	O
lactation-induced	O
downregulation	O
of	O
the	O
uncoupling	B-GP
protein-3	E-GP
gene	O
.	O
The	O
expression	O
of	O
uncoupling	B-GP
protein	I-GP
(	I-GP
UCP	I-GP
)	I-GP
-3	E-GP
mRNA	O
in	O
skeletal	O
muscle	O
is	O
dramatically	O
reduced	O
during	O
lactation	O
in	O
mice	O
.	O
The	O
reduction	O
in	O
UCP-3	S-GP
mRNA	O
levels	O
lowers	O
the	O
amount	O
of	O
the	O
UCP-3	S-GP
protein	O
in	O
skeletal	O
muscle	O
mitochondria	O
during	O
lactation	O
.	O
Spontaneous	O
or	O
abrupt	O
weaning	O
reverses	O
the	O
downregulation	O
of	O
the	O
UCP-3	S-GP
mRNA	O
but	O
not	O
the	O
reduction	O
in	O
UCP-3	S-GP
protein	O
levels	O
.	O
In	O
lactating	O
and	O
virgin	O
mice	O
,	O
however	O
,	O
fasting	O
increases	O
UCP-3	S-GP
mRNA	O
levels	O
.	O
Changes	O
in	O
UCP-3	S-GP
mRNA	O
occur	O
in	O
parallel	O
with	O
modifications	O
in	O
the	O
levels	O
of	O
free	O
fatty	B-chemical
acids	E-chemical
,	O
which	O
are	O
reduced	O
in	O
lactation	O
and	O
are	O
upregulated	O
due	O
to	O
weaning	O
or	O
fasting	O
.	O
Modifications	O
in	O
the	O
energy	O
nutritional	O
stress	O
of	O
lactating	O
dams	O
achieved	O
by	O
manipulating	O
litter	O
sizes	O
do	O
not	O
influence	O
UCP-3	S-GP
mRNA	O
levels	O
in	O
skeletal	O
muscle	O
.	O
Conversely	O
,	O
when	O
mice	O
are	O
fed	O
a	O
high-fat	O
diet	O
after	O
parturition	O
,	O
the	O
downregulation	O
of	O
UCP-3	S-GP
mRNA	O
and	O
UCP-3	S-GP
protein	O
levels	O
due	O
to	O
lactation	O
is	O
partially	O
reversed	O
,	O
as	O
is	O
the	O
reduction	O
in	O
serum	O
free	O
fatty	B-chemical
acid	E-chemical
levels	O
.	O
Treatment	O
of	O
lactating	O
mice	O
with	O
a	O
single	O
injection	O
of	O
bezafibrate	S-chemical
,	O
an	O
activator	O
of	O
the	O
peroxisome	B-GP
proliferator-activated	I-GP
receptor	E-GP
(	O
PPAR	S-GP
)	O
,	O
raises	O
UCP-3	S-GP
mRNA	O
in	O
skeletal	O
muscle	O
to	O
levels	O
similar	O
to	O
those	O
in	O
virgin	O
mice	O
.	O
4-chloro-6-	B-chemical
[	I-chemical
(	I-chemical
2,3-xylidine	I-chemical
)	I-chemical
-pirimidinylthio	I-chemical
]	I-chemical
acetic	I-chemical
acid	E-chemical
(	O
WY-14,643	S-chemical
)	O
,	O
a	O
specific	O
ligand	O
of	O
the	O
PPAR-alpha	S-GP
subtype	O
,	O
causes	O
the	O
most	O
dramatic	O
increase	O
in	O
UCP-3	S-GP
mRNA	O
,	O
whereas	O
troglitazone	S-chemical
,	O
a	O
specific	O
activator	O
of	O
PPAR-gamma	S-GP
,	O
also	O
significantly	O
increases	O
UCP-3	S-GP
mRNA	O
abundance	O
in	O
skeletal	O
muscle	O
of	O
lactating	O
mice	O
.	O
However	O
,	O
in	O
virgin	O
mice	O
,	O
bezafibrate	S-chemical
and	O
WY-14,643	S-chemical
do	O
not	O
significantly	O
affect	O
UCP-3	S-GP
mRNA	O
expression	O
,	O
whereas	O
troglitazone	S-chemical
is	O
at	O
least	O
as	O
effective	O
as	O
it	O
is	O
in	O
lactating	O
dams	O
.	O
It	O
is	O
proposed	O
that	O
the	O
UCP-3	S-GP
gene	O
is	O
regulated	O
in	O
skeletal	O
muscle	O
during	O
lactation	O
in	O
response	O
to	O
changes	O
in	O
circulating	O
free	O
fatty	B-chemical
acids	E-chemical
by	O
mechanisms	O
involving	O
activation	O
of	O
PPARs	S-GP
.	O
The	O
impaired	O
expression	O
of	O
the	O
UCP-3	S-GP
gene	O
is	O
consistent	O
with	O
the	O
involvement	O
of	O
UCP-3	S-GP
gene	O
regulation	O
in	O
the	O
reduction	O
of	O
the	O
use	O
of	O
fatty	B-chemical
acids	E-chemical
as	O
fuel	O
by	O
the	O
skeletal	O
muscle	O
and	O
in	O
impaired	O
adaptative	O
thermogenesis	O
,	O
both	O
of	O
which	O
are	O
major	O
metabolic	O
adaptations	O
that	O
occur	O
during	O
lactation	O
.	O

A	O
Mineral	O
Extract	O
from	O
red	O
Algae	O
Ameliorates	O
Chronic	O
Spontaneous	O
Colitis	O
in	O
IL-10	S-GP
Deficient	O
Mice	O
in	O
a	O
Mouse	O
Strain	O
Dependent	O
Manner	O
.	O
Inflammatory	O
bowel	O
disease	O
is	O
an	O
urgent	O
public	O
health	O
problem	O
with	O
a	O
high	O
incidence	O
in	O
developed	O
countries	O
.	O
Alterations	O
of	O
lifestyle	O
or	O
dietary	O
interventions	O
may	O
attenuate	O
the	O
disease	O
progression	O
and	O
increase	O
the	O
efficacy	O
of	O
current	O
therapies	O
.	O
Here	O
we	O
tested	O
the	O
effect	O
of	O
chronic	O
supplementation	O
with	O
a	O
mineral	O
extract	O
from	O
red	O
marine	O
algae	O
-	O
rich	O
in	O
calcium	S-chemical
(	O
34	O
%	O
)	O
,	O
magnesium	S-chemical
,	O
phosphorus	S-chemical
,	O
selenium	S-chemical
and	O
other	O
trace	O
minerals	O
-	O
in	O
a	O
clinically	O
relevant	O
model	O
of	O
spontaneous	O
enterocolitis	O
,	O
interleukin	B-GP
(	I-GP
IL	I-GP
)	I-GP
-10	E-GP
(	O
-/-	O
)	O
mice	O
.	O
The	O
mineral	O
extract	O
was	O
administered	O
in	O
the	O
drinking	O
water	O
of	O
Il10	S-GP
(	O
-/-	O
)	O
mice	O
on	O
C57BL/6	O
J	O
and	O
BALB/c	O
strain	O
backgrounds	O
for	O
25	O
weeks	O
commencing	O
from	O
3	O
to	O
4	O
weeks	O
of	O
age	O
.	O
The	O
mineral	O
extract	O
ameliorated	O
the	O
spontaneous	O
development	O
of	O
colitis	O
and	O
severity	O
of	O
disease	O
in	O
Il10	S-GP
(	O
-/-	O
)	O
mice	O
on	O
a	O
C57BL/6	O
J	O
background	O
.	O
Mineral	O
extract-treated	O
Il10	S-GP
(	O
-/-	O
)	O
C57BL/6	O
J	O
strain	O
mice	O
had	O
significantly	O
reduced	O
mortality	O
,	O
circulating	O
levels	O
of	O
serum	B-GP
Amyloid	I-GP
A	E-GP
and	O
reduced	O
colonic	O
tissue	O
damage	O
.	O
In	O
contrast	O
,	O
comparable	O
treatment	O
of	O
Il10	S-GP
(	O
-/-	O
)	O
mice	O
on	O
a	O
BALB/c	O
background	O
with	O
the	O
mineral	O
extract	O
did	O
not	O
alter	O
the	O
course	O
of	O
colitis	O
.	O
These	O
data	O
demonstrate	O
that	O
chronic	O
supplementation	O
with	O
a	O
natural	O
mineral	O
extract	O
selectively	O
ameliorates	O
spontaneous	O
mild-moderate	O
colitis	O
in	O
Il10	S-GP
(	O
-/-	O
)	O
mice	O
on	O
a	O
C57BL/6	O
J	O
,	O
but	O
does	O
not	O
attenuate	O
more	O
moderate-severe	O
colitis	O
in	O
BALB/c	O
strain	O
animals	O
.	O
Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Involvement	O
of	O
Src	S-GP
and	O
the	O
actin	S-GP
cytoskeleton	O
in	O
the	O
antitumorigenic	O
action	O
of	O
adenosine	B-chemical
dialdehyde	E-chemical
.	O
Trans	O
methyl	S-chemical
ation	O
is	O
an	O
important	O
reaction	O
that	O
transfers	O
a	O
methyl	O
group	O
in	O
S-adenosylmethionine	S-chemical
(	O
SAM	S-chemical
)	O
to	O
substrates	O
such	O
as	O
DNA	O
,	O
RNA	O
,	O
and	O
proteins	O
.	O
It	O
is	O
known	O
that	O
transmethylation	O
plays	O
critical	O
roles	O
in	O
various	O
cellular	O
responses	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
transmethylation	O
on	O
tumorigenic	O
responses	O
and	O
its	O
regulatory	O
mechanism	O
using	O
an	O
upregulation	O
strategy	O
of	O
adenosylhomocysteine	S-chemical
(	O
SAH	S-chemical
)	O
acting	O
as	O
a	O
negative	O
feedback	O
inhibitor	O
.	O
Treatment	O
with	O
adenosine	B-chemical
dialdehyde	E-chemical
(	O
AdOx	S-chemical
)	O
,	O
an	O
inhibitor	O
of	O
transmethylation-suppressive	O
adenosylhomocysteine	B-GP
(	I-GP
SAH	I-GP
)	I-GP
hydrolase	E-GP
(	O
SAHH	S-GP
)	O
,	O
enhanced	O
the	O
level	O
of	O
SAH	S-chemical
and	O
effectively	O
blocked	O
the	O
proliferation	O
,	O
migration	O
,	O
and	O
invasion	O
of	O
cancer	O
cells	O
;	O
the	O
treatment	O
also	O
induced	O
the	O
differentiation	O
of	O
C6	O
glioma	O
cells	O
and	O
suppressed	O
the	O
neovascular	O
genesis	O
of	O
eggs	O
in	O
a	O
dose-dependent	O
manner	O
.	O
Through	O
immunoblotting	O
analysis	O
,	O
it	O
was	O
found	O
that	O
AdOx	S-chemical
was	O
capable	O
of	O
indirectly	O
diminishing	O
the	O
phosphorylation	O
of	O
oncogenic	O
Src	S-GP
and	O
its	O
kinase	S-GP
activity	O
.	O
Interestingly	O
,	O
AdOx	S-chemical
disrupted	O
actin	S-GP
cytoskeleton	O
structures	O
,	O
leading	O
to	O
morphological	O
changes	O
,	O
and	O
suppressed	O
the	O
formation	O
of	O
a	O
signaling	O
complex	O
composed	O
of	O
Src	S-GP
and	O
p85	S-GP
/	O
PI3K	S-GP
,	O
which	O
is	O
linked	O
to	O
various	O
tumorigenic	O
responses	O
.	O
In	O
agreement	O
with	O
these	O
data	O
,	O
the	O
exogenous	O
treatment	O
of	O
SAH	S-chemical
or	O
inhibition	O
of	O
SAHH	S-GP
by	O
specific	O
siRNA	O
or	O
another	O
type	O
of	O
inhibitor	O
,	O
3-deazaadenosine	S-chemical
(	O
DAZA	S-chemical
)	O
,	O
similarly	O
resulted	O
in	O
antitumorigenic	O
responses	O
,	O
suppressive	O
activity	O
on	O
Src	S-GP
,	O
the	O
alteration	O
of	O
actin	S-GP
cytoskeleton	O
,	O
and	O
a	O
change	O
of	O
the	O
colocalization	O
pattern	O
between	O
actin	S-GP
and	O
Src	S-GP
.	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
SAH	S-chemical
/	O
SAHH	S-GP
-mediated	O
transmethylation	O
could	O
be	O
linked	O
to	O
the	O
tumorigenic	O
processes	O
through	O
cross-regulation	O
between	O
the	O
actin	S-GP
cytoskeleton	O
and	O
Src	S-GP
kinase	S-GP
activity	O
.	O

Fragment-based	O
drug	O
design	O
and	O
identification	O
of	O
HJC0123	S-chemical
,	O
a	O
novel	O
orally	O
bioavailable	O
STAT3	S-GP
inhibitor	O
for	O
cancer	O
therapy	O
.	O
Fragment-based	O
drug	O
design	O
(	O
FBDD	O
)	O
is	O
a	O
promising	O
approach	O
for	O
the	O
generation	O
of	O
lead	O
molecules	O
with	O
enhanced	O
activity	O
and	O
especially	O
drug-like	O
properties	O
against	O
therapeutic	O
targets	O
.	O
Herein	O
,	O
we	O
report	O
the	O
fragment-based	O
drug	O
design	O
,	O
systematic	O
chemical	O
synthesis	O
and	O
pharmacological	O
evaluation	O
of	O
novel	O
scaffolds	O
as	O
potent	O
anticancer	O
agents	O
by	O
utilizing	O
six	O
privileged	O
fragments	O
from	O
known	O
STAT3	S-GP
inhibitors	O
.	O
Several	O
new	O
molecules	O
such	O
as	O
compounds	O
5	O
,	O
12	O
,	O
and	O
19	O
that	O
may	O
act	O
as	O
advanced	O
chemical	O
leads	O
have	O
been	O
identified	O
.	O
The	O
most	O
potent	O
compound	O
5	O
(	O
HJC0123	S-chemical
)	O
has	O
demonstrated	O
to	O
inhibit	O
STAT3	B-GP
promoter	E-GP
activity	O
,	O
downregulate	O
phosphorylation	O
of	O
STAT3	S-GP
,	O
increase	O
the	O
expression	O
of	O
cleaved	O
caspase-3	S-GP
,	O
inhibit	O
cell	O
cycle	O
progression	O
and	O
promote	O
apoptosis	O
in	O
breast	O
and	O
pancreatic	O
cancer	O
cells	O
with	O
low	O
micromolar	O
to	O
nanomolar	O
IC50	O
values	O
.	O
Furthermore	O
,	O
compound	O
5	O
significantly	O
suppressed	O
estrogen	B-GP
receptor	E-GP
(	O
ER	S-GP
)	O
-negative	O
breast	O
cancer	O
MDA-MB-231	O
xenograft	O
tumor	O
growth	O
in	O
vivo	O
(	O
p.o	O
.	O
)	O
,	O
indicating	O
its	O
great	O
potential	O
as	O
an	O
efficacious	O
and	O
orally	O
bioavailable	O
drug	O
candidate	O
for	O
human	O
cancer	O
therapy	O
.	O

Potential	O
diagnostic	O
applications	O
of	O
side	O
chain	O
oxysterols	S-chemical
analysis	O
in	O
plasma	O
and	O
cerebrospinal	O
fluid	O
.	O
The	O
neurospecific	O
cholesterol	S-chemical
24-hydroxylase	O
converts	O
excess	O
brain	O
cholesterol	S-chemical
into	O
24S-hydroxycholesterol	S-chemical
(	O
24OHC	S-chemical
)	O
which	O
,	O
via	O
the	O
liver	B-GP
X	I-GP
receptor	E-GP
(	O
LXR	S-GP
)	O
,	O
can	O
increase	O
the	O
expression	O
and	O
synthesis	O
of	O
astrocyte	O
ApoE	S-GP
.	O
24OHC	S-chemical
effluxes	O
directly	O
from	O
brain	O
into	O
plasma	O
where	O
it	O
is	O
considered	O
an	O
indicator	O
of	O
brain	O
cholesterol	S-chemical
turnover	O
.	O
It	O
is	O
reduced	O
in	O
neurodegenerative	O
disease	O
states	O
proportionally	O
to	O
the	O
severity	O
of	O
disease	O
and	O
the	O
degree	O
of	O
brain	O
atrophy	O
.	O
In	O
the	O
early	O
phases	O
of	O
active	O
disease	O
,	O
a	O
higher	O
rate	O
of	O
turnover	O
may	O
result	O
in	O
transitory	O
increases	O
in	O
plasma	O
24OHC	S-chemical
.	O
Less	O
than	O
1	O
%	O
of	O
the	O
total	O
brain	O
excretion	O
of	O
24OHC	S-chemical
occurs	O
via	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
whereas	O
almost	O
all	O
27-hydroxycholesterol	S-chemical
(	O
27OHC	S-chemical
)	O
excretion	O
is	O
dependent	O
on	O
the	O
function	O
of	O
the	O
blood-cerebrospinal	O
fluid	O
barrier	O
.	O
Iincreased	O
CSF	O
oxysterols	S-chemical
were	O
found	O
in	O
patients	O
with	O
neurodegenerative	O
and	O
neuroinflammatory	O
diseases	O
in	O
the	O
presence	O
of	O
barrier	O
dysfunction	O
.	O
In	O
neurodegeneration	O
,	O
free	O
cholesterol	S-chemical
released	O
from	O
dying	O
cells	O
may	O
engulf	O
neurons	O
.	O
Cholesterol	S-chemical
also	O
increases	O
Amyloid	B-GP
β	E-GP
(	O
Aβ	S-GP
)	O
deposition	O
and	O
tau	S-GP
pathology	O
.	O
ApoE	S-GP
,	O
24OHC	S-chemical
,	O
tau	S-GP
and	O
soluble	B-GP
APP	E-GP
were	O
correlated	O
in	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
samples	O
.	O
Excess	O
of	O
cholesterol	S-chemical
converted	O
into	O
24OHC	S-chemical
may	O
up-regulate	O
ApoE	S-GP
synthesis	O
which	O
is	O
a	O
scavenger	O
for	O
Aβ	S-GP
and	O
Tau	S-GP
.	O
In	O
AD	O
this	O
protective	O
mechanism	O
seems	O
to	O
be	O
inefficient	O
,	O
probably	O
due	O
to	O
the	O
presence	O
of	O
high	O
concentrations	O
of	O
27OHC	S-chemical
,	O
microvascular	O
dysfunction	O
and	O
the	O
decreased	O
efficiency	O
of	O
ApoE4	S-GP
as	O
lipid	O
transporter	O
and	O
Aβ	S-GP
scavenger	O
.	O
24OHC	S-chemical
itself	O
was	O
cytotoxic	O
.	O
Analysis	O
of	O
side	O
chain	O
oxysterols	S-chemical
in	O
the	O
CSF	O
is	O
likely	O
to	O
provided	O
useful	O
information	O
about	O
cholesterol	S-chemical
metabolism	O
and	O
ApoE	S-GP
function	O
in	O
the	O
pathogenesis	O
of	O
AD	O
.	O

Benzodiazepines	S-chemical
,	O
but	O
not	O
beta	B-chemical
carbolines	E-chemical
,	O
limit	O
high	O
frequency	O
repetitive	O
firing	O
of	O
action	O
potentials	O
of	O
spinal	O
cord	O
neurons	O
in	O
cell	O
culture	O
.	O
Effects	O
of	O
benzodiazepines	S-chemical
(	O
BDZs	S-chemical
)	O
and	O
beta	B-chemical
carbolines	E-chemical
(	O
beta	B-chemical
CCs	E-chemical
)	O
on	O
sustained	O
repetitive	O
firing	O
at	O
high	O
frequency	O
(	O
SRF	O
)	O
of	O
action	O
potentials	O
of	O
mouse	O
spinal	O
cord	O
neurons	O
in	O
cell	O
culture	O
were	O
examined	O
using	O
intracellular	O
recording	O
techniques	O
.	O
In	O
control	O
medium	O
neurons	O
responded	O
to	O
depolarizing	O
current	O
pulses	O
with	O
SRF	O
.	O
Limitation	O
of	O
SRF	O
was	O
produced	O
by	O
the	O
anticonvulsant	O
BDZs	S-chemical
(	O
diazepam	S-chemical
,	O
clonazepam	S-chemical
,	O
nitrazepam	S-chemical
and	O
lorazepam	S-chemical
)	O
at	O
low	O
to	O
mid	O
nanomolar	O
concentrations	O
,	O
by	O
a	O
convulsant	O
BDZ	S-chemical
which	O
does	O
not	O
bind	O
to	O
high	O
affinity	O
BDZ	B-GP
receptors	E-GP
(	O
Ro	B-chemical
5-4864	E-chemical
)	O
at	O
high	O
nanomolar	O
concentrations	O
and	O
by	O
a	O
BDZ	B-GP
receptor	E-GP
weak	O
partial	O
agonist	O
(	O
Ro	B-chemical
15-1788	E-chemical
)	O
at	O
micromolar	O
concentrations	O
.	O
The	O
limitation	O
of	O
SRF	O
was	O
accompanied	O
by	O
use-	O
and	O
voltage-dependent	O
reduction	O
of	O
maximal	O
rate	O
of	O
rise	O
(	O
Vmax	O
)	O
of	O
sodium	S-chemical
-dependent	O
action	O
potentials	O
.	O
Partial	O
agonist	O
and	O
inverse	O
agonist	O
beta	O
CCs	O
did	O
not	O
limit	O
SRF	O
at	O
concentrations	O
up	O
to	O
200	O
nM	O
.	O
The	O
limitation	O
of	O
SRF	O
by	O
diazepam	S-chemical
was	O
not	O
prevented	O
by	O
inverse	O
or	O
partial	O
agonists	O
at	O
the	O
BDZ	B-GP
receptor	E-GP
,	O
including	O
Ro	B-chemical
15-1788	E-chemical
and	O
the	O
beta	B-chemical
CCs	E-chemical
.	O
These	O
findings	O
suggest	O
that	O
limitation	O
of	O
SRF	O
was	O
produced	O
by	O
binding	O
of	O
BDZs	S-chemical
,	O
but	O
not	O
beta	B-chemical
CCs	E-chemical
,	O
to	O
voltage-dependent	B-GP
sodium	I-GP
channels	E-GP
and	O
not	O
to	O
high	O
affinity	O
central	O
BDZ	B-GP
receptors	E-GP
,	O
and	O
that	O
BDZs	S-chemical
limit	O
SRF	O
by	O
slowing	O
recovery	O
of	O
sodium	B-GP
channels	E-GP
from	O
inactivation	O
.	O
We	O
propose	O
that	O
the	O
limitation	O
of	O
SRF	O
may	O
contribute	O
to	O
the	O
efficacy	O
of	O
BDZs	S-chemical
against	O
generalized	O
tonic-clonic	O
seizures	O
and	O
status	O
epilepticus	O
.	O

β-catenin	S-GP
regulates	O
GnRH	S-chemical
-induced	O
FSHβ	S-GP
gene	O
expression	O
.	O
The	O
regulation	O
of	O
gonadotropin	S-GP
synthesis	O
by	O
GnRH	S-GP
plays	O
an	O
essential	O
role	O
in	O
the	O
neuroendocrine	O
control	O
of	O
reproduction	O
.	O
The	O
known	O
signaling	O
mechanisms	O
involved	O
in	O
gonadotropin	S-GP
synthesis	O
have	O
been	O
expanding	O
.	O
For	O
example	O
,	O
involvement	O
of	O
β-catenin	S-GP
in	O
LHβ	O
induction	O
by	O
GnRH	S-GP
has	O
been	O
discovered	O
.	O
We	O
examined	O
the	O
role	O
of	O
β-catenin	S-GP
in	O
FSHβ	S-GP
gene	O
expression	O
in	O
LβT2	O
gonadotrope	O
cells	O
.	O
GnRH	S-GP
caused	O
a	O
sustained	O
increase	O
in	O
nuclear	O
β-catenin	S-GP
levels	O
,	O
which	O
was	O
significantly	O
reduced	O
by	O
c-Jun	B-GP
N-terminal	I-GP
kinase	E-GP
(	O
JNK	S-GP
)	O
inhibition	O
.	O
Small	O
interfering	O
RNA-mediated	O
knockdown	O
of	O
β-catenin	S-GP
mRNA	O
demonstrated	O
that	O
induction	O
of	O
FSHβ	S-GP
mRNA	O
by	O
GnRH	S-GP
depended	O
on	O
β-catenin	S-GP
and	O
that	O
regulation	O
of	O
FSHβ	S-GP
by	O
β-catenin	S-GP
occurred	O
independently	O
of	O
the	O
JNK	S-GP
-	O
c-jun	S-GP
pathway	O
.	O
β-Catenin	S-GP
depletion	O
had	O
no	O
impact	O
on	O
FSHβ	S-GP
mRNA	O
stability	O
.	O
In	O
LβT2	O
cells	O
transfected	O
with	O
FSHβ	B-GP
promoter	E-GP
luciferase	O
fusion	O
constructs	O
,	O
GnRH	S-GP
responsiveness	O
was	O
conferred	O
by	O
the	O
proximal	O
promoter	O
(	O
-944/-1	O
)	O
and	O
was	O
markedly	O
decreased	O
by	O
β-catenin	S-GP
knockdown	O
.	O
However	O
,	O
none	O
of	O
the	O
T-cell	B-GP
factor/lymphoid	I-GP
enhancer	I-GP
factor	I-GP
binding	I-GP
sites	E-GP
in	O
that	O
region	O
were	O
required	O
for	O
promoter	O
activation	O
by	O
GnRH	S-GP
.	O
Chromatin	O
immunoprecipitation	O
further	O
corroborated	O
the	O
absence	O
of	O
direct	O
interaction	O
between	O
β-catenin	S-GP
and	O
the	O
1.8-kb	O
FSHβ	B-GP
promoter	E-GP
.	O
To	O
elucidate	O
the	O
mechanism	O
for	O
the	O
β-catenin	S-GP
effect	O
,	O
we	O
analyzed	O
approximately	O
1	O
billion	O
reads	O
of	O
next-generation	O
RNA	O
sequencing	O
β-catenin	S-GP
knockdown	O
assays	O
and	O
selected	O
the	O
nuclear	O
cofactor	O
breast	B-GP
cancer	I-GP
metastasis-suppressor	I-GP
1-like	E-GP
(	O
Brms1L	S-GP
)	O
as	O
one	O
candidate	O
for	O
further	O
study	O
.	O
Subsequent	O
experiments	O
confirmed	O
that	O
Brms1L	S-GP
mRNA	O
expression	O
was	O
decreased	O
by	O
β-catenin	S-GP
knockdown	O
as	O
well	O
as	O
by	O
JNK	S-GP
inhibition	O
.	O
Furthermore	O
,	O
knockdown	O
of	O
Brms1L	S-GP
significantly	O
attenuated	O
GnRH	S-GP
-induced	O
FSHβ	S-GP
expression	O
.	O
Thus	O
,	O
our	O
findings	O
indicate	O
that	O
the	O
expression	O
of	O
Brms1L	S-GP
depends	O
on	O
β-catenin	S-GP
activity	O
and	O
contributes	O
to	O
FSHβ	S-GP
induction	O
by	O
GnRH	S-GP
.	O

Discovery	O
of	O
acetyl-coenzyme	B-GP
A	I-GP
carboxylase	I-GP
2	E-GP
inhibitors	O
:	O
comparison	O
of	O
a	O
fluorescence	O
intensity-based	O
phosphate	S-chemical
assay	O
and	O
a	O
fluorescence	O
polarization-based	O
ADP	S-chemical
Assay	O
for	O
high-throughput	O
screening	O
.	O
Acetyl-coenzyme	B-GP
A	I-GP
carboxylase	E-GP
(	O
ACC	S-GP
)	O
enzymes	O
exist	O
as	O
two	O
isoforms	O
,	O
ACC1	S-GP
and	O
ACC2	S-GP
,	O
which	O
play	O
critical	O
roles	O
in	O
fatty	B-chemical
acid	E-chemical
biosynthesis	O
and	O
oxidation	O
.	O
Though	O
each	O
isoform	O
differs	O
in	O
tissue	O
and	O
subcellular	O
localization	O
,	O
both	O
catalyze	O
the	O
biotin	S-chemical
-	O
and	O
ATP	S-chemical
-dependent	O
carboxylation	O
of	O
acetyl-coenzyme	B-chemical
A	E-chemical
to	O
generate	O
malonyl-coenzyme	B-chemical
A	E-chemical
,	O
a	O
key	O
metabolite	O
in	O
the	O
control	O
of	O
fatty	B-chemical
acid	E-chemical
synthesis	O
and	O
oxidation	O
.	O
The	O
cytosolic	O
ACC1	S-GP
is	O
expressed	O
primarily	O
in	O
liver	O
and	O
adipose	O
tissue	O
,	O
and	O
uses	O
malonyl-coenzyme	B-chemical
A	E-chemical
as	O
a	O
key	O
building	O
block	O
in	O
fatty	B-chemical
acid	E-chemical
biosynthesis	O
.	O
The	O
mitochondrial	O
ACC2	S-GP
is	O
primarily	O
expressed	O
in	O
heart	O
and	O
skeletal	O
muscle	O
,	O
where	O
it	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
fatty	B-chemical
acid	E-chemical
oxidation	O
.	O
Inhibitors	O
of	O
ACC	S-GP
enzymes	O
may	O
therefore	O
be	O
useful	O
therapeutics	O
for	O
diabetes	O
,	O
obesity	O
,	O
and	O
metabolic	O
syndrome	O
.	O
Two	O
assay	O
formats	O
for	O
these	O
ATP	S-chemical
-utilizing	O
enzymes	O
amenable	O
to	O
high-throughput	O
screening	O
are	O
compared	O
:	O
a	O
fluorescence	O
intensity-based	O
assay	O
to	O
detect	O
inorganic	B-chemical
phosphate	E-chemical
and	O
a	O
fluorescence	O
polarization-based	O
assay	O
to	O
detect	O
ADP	S-chemical
.	O
Acetyl-coenzyme	B-GP
A	I-GP
carboxylase	E-GP
inhibitors	O
were	O
identified	O
by	O
these	O
high-throughput	O
screening	O
methods	O
and	O
were	O
confirmed	O
in	O
a	O
radiometric	O
high	O
performance	O
liquid	O
chromatography	O
assay	O
of	O
malonyl-coenzyme	B-chemical
A	E-chemical
production	O
.	O

Quantitative	O
analysis	O
of	O
the	O
interaction	O
of	O
constitutive	B-GP
androstane	I-GP
receptor	E-GP
with	O
chemicals	O
and	O
steroid	B-GP
receptor	I-GP
coactivator	I-GP
1	E-GP
using	O
surface	O
plasmon	O
resonance	O
biosensor	O
systems	O
:	O
a	O
case	O
study	O
of	O
the	O
Baikal	O
seal	O
(	O
Pusa	O
sibirica	O
)	O
and	O
the	O
mouse	O
.	O
The	O
constitutive	B-GP
androstane	I-GP
receptor	E-GP
(	O
CAR	S-GP
)	O
not	O
only	O
displays	O
a	O
high	O
basal	O
transcriptional	O
activity	O
but	O
also	O
acts	O
as	O
a	O
ligand-dependent	O
transcriptional	O
factor	O
.	O
It	O
is	O
known	O
that	O
CAR	S-GP
exhibits	O
different	O
ligand	O
profiles	O
across	O
species	O
.	O
However	O
,	O
the	O
mechanisms	O
underlying	O
CAR	S-GP
activation	O
by	O
chemicals	O
and	O
the	O
species-specific	O
responses	O
are	O
not	O
fully	O
understood	O
.	O
The	O
objectives	O
of	O
this	O
study	O
are	O
to	O
establish	O
a	O
high-throughput	O
tool	O
to	O
screen	O
CAR	S-GP
ligands	O
and	O
to	O
clarify	O
how	O
CAR	S-GP
proteins	O
from	O
the	O
Baikal	O
seal	O
(	O
bsCAR	S-GP
)	O
and	O
the	O
mouse	O
(	O
mCAR	S-GP
)	O
interact	O
with	O
chemicals	O
and	O
steroid	B-GP
receptor	I-GP
coactivator	I-GP
1	E-GP
(	O
SRC1	S-GP
)	O
.	O
We	O
developed	O
the	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
system	O
to	O
assess	O
quantitatively	O
the	O
interaction	O
of	O
CAR	S-GP
with	O
potential	O
ligands	O
and	O
SRC1	S-GP
.	O
The	O
ligand-binding	O
domain	O
(	O
LBD	O
)	O
of	O
bsCAR	S-GP
and	O
mCAR	S-GP
was	O
synthesized	O
in	O
a	O
wheat	O
germ	O
cell-free	O
system	O
.	O
The	O
purified	O
CAR	B-GP
LBD	E-GP
was	O
then	O
immobilized	O
on	O
the	O
sensor	O
chip	O
for	O
the	O
SPR	O
assay	O
,	O
and	O
the	O
kinetics	O
of	O
direct	O
interaction	O
of	O
CARs	S-GP
with	O
ligand	O
candidates	O
was	O
measured	O
.	O
Androstanol	S-chemical
and	O
androstenol	S-chemical
,	O
estrone	S-chemical
,	O
17β-estradiol	S-chemical
,	O
TCPOBOP	S-chemical
,	O
and	O
CITCO	S-chemical
showed	O
compound-specific	O
but	O
similar	O
affinities	O
for	O
both	O
CARs	S-GP
.	O
The	O
CAR	S-GP
-	O
SRC1	S-GP
interaction	O
was	O
ligand	O
dependent	O
but	O
exhibited	O
a	O
different	O
ligand	O
profile	O
between	O
the	O
seal	O
and	O
the	O
mouse	O
.	O
The	O
results	O
of	O
SRC1	S-GP
interaction	O
assay	O
accounted	O
for	O
those	O
of	O
our	O
previous	O
in	O
vitro	O
CAR	S-GP
-mediated	O
transactivation	O
assay	O
.	O
In	O
silico	O
analyses	O
also	O
supported	O
the	O
results	O
of	O
CAR	S-GP
-	O
SRC1	S-GP
interaction	O
;	O
there	O
is	O
little	O
structural	O
difference	O
in	O
the	O
ligand-binding	O
pocket	O
of	O
bsCAR	S-GP
and	O
mCAR	S-GP
,	O
but	O
there	O
is	O
a	O
distinct	O
discrimination	O
in	O
the	O
helix	O
11	O
and	O
12	O
of	O
these	O
receptors	O
,	O
suggesting	O
that	O
the	O
interaction	O
of	O
ligand-bound	O
CAR	S-GP
and	O
SRC1	S-GP
is	O
critical	O
for	O
determining	O
species-specific	O
and	O
ligand-dependent	O
transactivation	O
over	O
the	O
basal	O
activity	O
.	O
The	O
SPR	O
assays	O
demonstrated	O
a	O
potential	O
as	O
a	O
high-throughput	O
screening	O
tool	O
of	O
CAR	S-GP
ligands	O
.	O

Inhibition	O
of	O
cytokine	S-GP
-primed	O
eosinophil	O
chemotaxis	O
by	O
nedocromil	B-chemical
sodium	E-chemical
.	O
BACKGROUND	O
:	O
Eosinophil	O
influx	O
into	O
the	O
lung	O
tissue	O
is	O
considered	O
to	O
be	O
relevant	O
for	O
the	O
pathogenesis	O
of	O
asthma	O
.	O
Various	O
chemotactic	O
factors	O
may	O
be	O
responsible	O
for	O
this	O
influx	O
.	O
Recently	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
cytokines	S-GP
granulocyte-macrophage	B-GP
colony-stimulating	I-GP
factor	E-GP
(	O
GM-CSF	S-GP
)	O
,	O
interleukin-3	S-GP
(	O
IL-3	S-GP
)	O
,	O
and	O
interleukin-5	S-GP
(	O
IL-5	S-GP
)	O
are	O
present	O
in	O
the	O
circulation	O
of	O
individuals	O
with	O
allergic	O
asthma	O
.	O
These	O
cytokines	S-GP
have	O
the	O
capacity	O
to	O
modulate	O
chemotactic	O
responses	O
of	O
eosinophils	O
toward	O
platelet-activating	O
factor	O
,	O
formyl-methionyl-leucyl-phenylalanine	S-chemical
,	O
(	O
FMLP	S-chemical
)	O
and	O
neutrophil-activating	B-GP
factor	E-GP
(	O
NAF	S-GP
)	O
/	O
IL-8	S-GP
,	O
but	O
not	O
toward	O
complement	B-GP
fragment	I-GP
C5a	E-GP
(	O
C5a	S-GP
)	O
.	O
Here	O
the	O
effect	O
of	O
nedocromil	B-chemical
sodium	E-chemical
on	O
the	O
chemotactic	O
response	O
of	O
eosinophils	O
from	O
allergic	O
asthmatic	O
individuals	O
and	O
from	O
normal	O
donors	O
preincubated	O
with	O
GM-CSF	S-GP
or	O
IL-3	S-GP
toward	O
FMLP	O
,	O
NAF	S-GP
/	O
IL-8	S-GP
was	O
evaluated	O
.	O
RESULTS	O
:	O
Nedocromil	B-chemical
sodium	E-chemical
inhibited	O
the	O
chemotactic	O
response	O
toward	O
FMLP	S-chemical
and	O
NAF	S-GP
/	O
IL-8	S-GP
of	O
GM-CSF	S-GP
primed	O
eosinophils	O
approximately	O
60	O
%	O
(	O
inhibitory	O
concentration	O
of	O
50	O
%	O
[	O
IC50	O
]	O
approximately	O
1	O
to	O
10	O
nmol/L	O
)	O
,	O
whereas	O
these	O
responses	O
of	O
IL-3	S-GP
primed	O
eosinophils	O
was	O
completely	O
inhibited	O
(	O
IC50	O
approximately	O
1	O
nmol/L	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
chemotactic	O
responses	O
toward	O
C5a	S-GP
were	O
inhibited	O
by	O
nedocromil	B-chemical
sodium	E-chemical
at	O
higher	O
concentrations	O
than	O
were	O
required	O
in	O
the	O
priming	O
studies	O
(	O
IC50	O
approximately	O
10	O
to	O
100	O
nmol/L	O
)	O
.	O
Nedocromil	B-chemical
sodium	E-chemical
(	O
0.1	O
mumol/L	O
)	O
was	O
also	O
effective	O
in	O
inhibiting	O
the	O
chemotactic	O
response	O
toward	O
FMLP	S-chemical
(	O
10	O
nmol/L	O
)	O
of	O
eosinophils	O
isolated	O
from	O
the	O
circulation	O
of	O
patients	O
with	O
allergic	O
asthma	O
3	O
hours	O
after	O
allergen	O
challenge	O
.	O
These	O
findings	O
might	O
explain	O
in	O
part	O
the	O
antiinflammatory	O
action	O
of	O
nedocromil	B-chemical
sodium	E-chemical
.	O

Urokinase	B-GP
plasminogen	I-GP
activator	E-GP
and	O
plasmin	S-GP
efficiently	O
convert	O
hemofiltrate	B-GP
CC	I-GP
chemokine	I-GP
1	E-GP
into	O
its	O
active	O
.	O
We	O
have	O
previously	O
isolated	O
from	O
human	O
hemofiltrate	O
an	O
N	S-chemical
-terminally	O
truncated	O
form	O
of	O
the	O
hemofiltrate	B-GP
CC	I-GP
chemokine	I-GP
1	E-GP
(	O
HCC-1	S-GP
)	O
,	O
and	O
characterized	O
HCC-1	B-GP
[	I-GP
9-74	I-GP
]	E-GP
as	O
a	O
strong	O
agonist	O
of	O
CCR1	S-GP
,	O
CCR5	S-GP
,	O
and	O
to	O
a	O
lower	O
extent	O
CCR3	S-GP
.	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
conditioned	O
media	O
from	O
human	O
tumor	O
cell	O
lines	O
PC-3	O
and	O
143B	O
contain	O
proteolytic	O
activities	O
that	O
convert	O
HCC-1	S-GP
into	O
the	O
[	O
9-74	O
]	O
form	O
.	O
This	O
activity	O
was	O
fully	O
inhibited	O
by	O
inhibitors	O
of	O
urokinase-type	B-GP
plasminogen	I-GP
activator	E-GP
(	O
uPA	S-GP
)	O
,	O
including	O
PA	B-GP
inhibitor-1	E-GP
,	O
an	O
anti-	O
uPA	S-GP
mAb	O
,	O
and	O
amiloride	O
.	O
Pure	O
preparations	O
of	O
uPA	S-GP
processed	O
HCC-1	S-GP
with	O
high	O
efficiency	O
,	O
without	O
further	O
degrading	O
HCC-1	B-GP
[	I-GP
9-74	I-GP
]	E-GP
.	O
Plasmin	S-GP
could	O
also	O
generate	O
HCC-1	B-GP
[	I-GP
9-74	I-GP
]	E-GP
,	O
but	O
degraded	O
the	O
active	O
product	O
as	O
well	O
.	O
The	O
kinetics	O
of	O
HCC-1	S-GP
cleavage	O
by	O
uPA	S-GP
and	O
plasmin	S-GP
(	O
Michaelis	O
constant	O
,	O
K	O
(	O
m	O
)	O
,	O
of	O
0.76	O
+/-	O
0.4	O
microM	O
for	O
uPA	S-GP
,	O
and	O
0.096	O
+/-	O
0.05	O
microM	O
for	O
plasmin	S-GP
;	O
catalytic	O
rate	O
constant	O
,	O
k	O
(	O
cat	O
)	O
:	O
3.36	O
+/-	O
0.96	O
s	O
(	O
-1	O
)	O
for	O
uPA	S-GP
and	O
6	O
+/-	O
3.6	O
s	O
(	O
-1	O
)	O
for	O
plasmin	S-GP
)	O
are	O
fully	O
compatible	O
with	O
a	O
role	O
in	O
vivo	O
.	O
The	O
activation	O
of	O
an	O
abundant	O
inactive	O
precursor	O
into	O
a	O
broad-spectrum	O
chemokine	O
by	O
uPA	S-GP
and	O
plasmin	S-GP
directly	O
links	O
the	O
production	O
of	O
uPA	S-GP
by	O
numerous	O
tumors	O
and	O
their	O
ability	O
to	O
recruit	O
mononuclear	O
leukocytes	O
,	O
without	O
the	O
need	O
for	O
the	O
transcriptional	O
activation	O
of	O
chemokine	S-GP
genes	O
.	O

Pharmacological	O
and	O
clinical	O
studies	O
of	O
the	O
antiandrogen	O
Anandron	S-chemical
.	O
This	O
paper	O
summarizes	O
the	O
animal	O
and	O
human	O
studies	O
with	O
Anandron	S-chemical
available	O
at	O
the	O
time	O
of	O
the	O
meeting	O
.	O
The	O
following	O
was	O
demonstrated	O
in	O
the	O
rat	O
and	O
confirmed	O
in	O
man	O
:	O
interaction	O
of	O
Anandron	S-chemical
with	O
the	O
prostatic	B-GP
androgen	I-GP
receptor	E-GP
,	O
antiandrogen	O
activity	O
against	O
testosterone	S-chemical
(	O
in	O
particular	O
against	O
the	O
early	O
transient	O
rise	O
induced	O
by	O
LHRH	S-GP
analogs	O
)	O
and	O
adrenal	O
androgens	S-chemical
.	O
Thus	O
,	O
as	O
shown	O
in	O
4	O
different	O
double	O
blind	O
studies	O
performed	O
in	O
stage	O
D2	O
prostrate	O
cancer	O
patients	O
,	O
the	O
combination	O
of	O
Anandron	S-chemical
with	O
surgical	O
or	O
chemical	O
castration	O
enhanced	O
the	O
beneficial	O
effects	O
of	O
castration	O
alone	O
and	O
thus	O
seems	O
a	O
step	O
forward	O
in	O
the	O
hormonal	O
treatment	O
of	O
prostatic	O
carcinoma	O
.	O

Androgen	S-chemical
antagonistic	O
effect	O
of	O
estramustine	B-chemical
phosphate	E-chemical
(	O
EMP	S-chemical
)	O
metabolites	O
on	O
wild-type	O
and	O
mutated	O
androgen	B-GP
receptor	E-GP
.	O
Estramustine	B-chemical
phosphate	E-chemical
is	O
used	O
frequently	O
,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
antitumor	O
agents	O
,	O
for	O
the	O
treatment	O
of	O
hormone-refractory	O
prostate	O
cancer	O
.	O
Estramustine	B-chemical
phosphate	E-chemical
is	O
metabolically	O
activated	O
in	O
vivo	O
,	O
and	O
its	O
metabolites	O
,	O
estramustine	S-chemical
,	O
estromustine	S-chemical
,	O
estrone	S-chemical
,	O
and	O
beta-estradiol	S-chemical
inhibit	O
the	O
assembly	O
of	O
microtubules	O
[	O
for	O
review	O
see	O
:	O
Kreis	O
W	O
,	O
In	O
:	O
Concepts	O
,	O
Mechanisms	O
,	O
and	O
New	O
Targets	O
for	O
Chemotherapy	O
(	O
Ed	O
.	O
Muggia	O
FM	O
)	O
,	O
pp	O
.	O
163-184	O
.	O
Kluwer	O
Academic	O
Publishers	O
,	O
Boston	O
,	O
1995	O
]	O
.	O
We	O
investigated	O
,	O
by	O
displacement	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
methyltrienolone	E-chemical
in	O
the	O
presence	O
of	O
2.5	O
mM	O
of	O
triamcinolone	B-chemical
acetonide	E-chemical
,	O
the	O
binding	O
of	O
estramustine	B-chemical
phosphate	E-chemical
and	O
its	O
metabolites	O
,	O
estramustine	S-chemical
,	O
estromustine	S-chemical
,	O
estrone	S-chemical
,	O
and	O
beta-estradiol	S-chemical
,	O
as	O
well	O
as	O
other	O
antiandrogen	O
agents	O
including	O
alpha-estradiol	S-chemical
,	O
bicalutamide	S-chemical
,	O
and	O
hydroxyflutamide	S-chemical
,	O
to	O
the	O
mutated	O
androgen	B-GP
receptor	E-GP
(	O
m-	O
AR	S-GP
)	O
in	O
LNCaP	O
cells	O
and	O
to	O
the	O
wild-type	O
androgen	B-GP
receptor	E-GP
in	O
wild-type	O
AR	S-GP
cDNA	O
expression	O
plasmid	O
(	O
w-pAR0	O
)	O
cDNA-transfected	O
HeLa	O
cells	O
.	O
Analogous	O
to	O
the	O
antiandrogens	O
,	O
bicalutamide	S-chemical
and	O
hydroxyflutamide	S-chemical
,	O
binding	O
of	O
estramustine	B-chemical
phosphate	E-chemical
metabolites	O
to	O
the	O
androgen	B-GP
receptor	E-GP
was	O
observed	O
.	O
The	O
EC50	O
values	O
(	O
in	O
microM	O
)	O
were	O
:	O
estramustine	B-chemical
phosphate	E-chemical
,	O
>	O
10	O
;	O
estramustine	S-chemical
,	O
3.129	O
+/-	O
0.312	O
;	O
estromustine	S-chemical
;	O
2.612	O
+/-	O
0.584	O
;	O
estrone	S-chemical
,	O
0.800	O
+/-	O
0.090	O
;	O
alpha-estradiol	S-chemical
,	O
1.051	O
+/-	O
0.096	O
;	O
beta-estradiol	S-chemical
,	O
0.523	O
+/-	O
0.028	O
;	O
bicalutamide	S-chemical
,	O
4.920	O
+/-	O
0.361	O
;	O
and	O
hydroxyflutamide	S-chemical
,	O
0.254	O
+/-	O
0.012	O
.	O
The	O
transactivation	O
assay	O
demonstrated	O
that	O
,	O
analogous	O
to	O
bicalutamide	S-chemical
,	O
estramustine	S-chemical
could	O
not	O
induce	O
luciferase	O
activity	O
in	O
either	O
w-pAR0	O
or	O
m-pARL	O
transfected	O
HeLa	O
cells	O
.	O
In	O
contrast	O
,	O
a	O
strong	O
induction	O
of	O
the	O
reporter	O
activity	O
by	O
dihydrotestosterone	S-chemical
was	O
observed	O
.	O
Down-regulation	O
of	O
prostate-specific	B-GP
antigen	E-GP
(	O
PSA	S-GP
)	O
expression	O
,	O
an	O
AR	S-GP
-target	O
gene	O
,	O
by	O
estramustine	S-chemical
and	O
bicalutamide	S-chemical
was	O
accompanied	O
by	O
the	O
blockade	O
of	O
the	O
mutated	O
androgen	B-GP
receptor	E-GP
.	O
Exposure	O
of	O
LNCaP	O
cells	O
to	O
estramustine	S-chemical
for	O
24	O
hr	O
caused	O
transcriptional	O
inhibition	O
of	O
PSA	S-GP
in	O
a	O
concentration-dependent	O
manner	O
.	O
The	O
levels	O
of	O
PSA	S-GP
mRNA	O
decreased	O
56	O
and	O
90	O
%	O
when	O
LNCaP	O
cells	O
were	O
treated	O
with	O
5	O
and	O
10	O
microM	O
of	O
estramustine	S-chemical
,	O
respectively	O
(	O
IC50	O
=	O
10.97	O
+/-	O
1.68	O
microM	O
)	O
.	O
Binding	O
of	O
hydroxyflutamide	S-chemical
to	O
m-	O
AR	S-GP
in	O
LNCaP	O
cells	O
resulted	O
in	O
a	O
concentration-dependent	O
stimulation	O
of	O
PSA	S-GP
expression	O
,	O
suggesting	O
that	O
hydroxyflutamide	S-chemical
acted	O
as	O
an	O
agonist	O
of	O
the	O
m-	O
AR	S-GP
.	O
Our	O
data	O
indicate	O
that	O
estramustine	B-chemical
phosphate	E-chemical
metabolites	O
perform	O
as	O
androgen	S-chemical
antagonists	O
of	O
AR	S-GP
,	O
an	O
additional	O
mechanism	O
involved	O
in	O
the	O
therapeutic	O
effect	O
of	O
estramustine	B-chemical
phosphate	E-chemical
in	O
patients	O
with	O
prostate	O
cancer	O
.	O

Cholestatic	O
effect	O
of	O
epigallocatechin	B-chemical
gallate	E-chemical
in	O
rats	O
is	O
mediated	O
via	O
decreased	O
expression	O
of	O
Mrp2	S-GP
.	O
Epigallocatechin	B-chemical
gallate	E-chemical
(	O
EGCG	S-chemical
)	O
has	O
been	O
shown	O
to	O
be	O
protective	O
in	O
various	O
experimental	O
models	O
of	O
liver	O
injury	O
,	O
although	O
opposite	O
effects	O
have	O
also	O
been	O
reported	O
.	O
Since	O
its	O
effect	O
on	O
biliary	O
physiology	O
has	O
not	O
been	O
thoroughly	O
investigated	O
,	O
the	O
present	O
study	O
evaluated	O
effect	O
of	O
EGCG	S-chemical
on	O
bile	O
flow	O
and	O
bile	B-chemical
acid	E-chemical
homeostasis	O
in	O
rats	O
.	O
Compared	O
to	O
controls	O
,	O
EGCG	S-chemical
treatment	O
decreased	O
bile	O
flow	O
by	O
23	O
%	O
.	O
Hepatic	O
paracellular	O
permeability	O
and	O
biliary	O
bile	B-chemical
acid	E-chemical
excretion	O
were	O
not	O
altered	O
by	O
EGCG	S-chemical
administration	O
,	O
but	O
biliary	O
glutathione	S-chemical
excretion	O
was	O
reduced	O
by	O
70	O
%	O
.	O
Accordingly	O
,	O
the	O
main	O
glutathione	B-GP
transporter	E-GP
on	O
the	O
hepatocyte	O
canalicular	O
membrane	O
,	O
multidrug	B-GP
resistance-associated	I-GP
protein	I-GP
2	E-GP
(	O
Mrp2	S-GP
)	O
,	O
was	O
significantly	O
decreased	O
at	O
the	O
protein	O
level	O
.	O
EGCG	S-chemical
administration	O
also	O
doubled	O
plasma	O
bile	B-chemical
acid	E-chemical
levels	O
compared	O
to	O
controls	O
.	O
While	O
protein	O
levels	O
of	O
the	O
main	O
hepatic	B-GP
bile	I-GP
acid	I-GP
transporters	E-GP
were	O
unchanged	O
,	O
the	O
rate-limiting	O
enzyme	O
in	O
the	O
bile	B-chemical
acid	E-chemical
synthesis	O
,	O
Cyp7a1	S-GP
,	O
was	O
significantly	O
increased	O
by	O
EGCG	S-chemical
.	O
Enhanced	O
bile	B-chemical
acid	E-chemical
synthesis	O
in	O
these	O
animals	O
was	O
also	O
confirmed	O
by	O
a	O
2-fold	O
increase	O
in	O
plasma	O
marker	O
7α-hydroxy-4-cholesten-3-one	S-chemical
.	O
In	O
contrast	O
,	O
EGCG	S-chemical
markedly	O
downregulated	O
major	O
bile	B-GP
acid	I-GP
transporters	E-GP
(	O
Asbt	S-GP
and	O
Ostα	S-GP
)	O
and	O
regulatory	O
molecules	O
(	O
Shp	S-GP
and	O
Fgf15	S-GP
)	O
in	O
the	O
ileum	O
.	O
When	O
EGCG	S-chemical
was	O
coadministered	O
with	O
ethinylestradiol	S-chemical
,	O
a	O
potent	O
cholestatic	O
agent	O
,	O
it	O
did	O
not	O
show	O
any	O
additional	O
effect	O
on	O
the	O
induced	O
cholestasis	O
.	O
This	O
study	O
shows	O
ability	O
of	O
EGCG	S-chemical
to	O
raise	O
plasma	O
bile	B-chemical
acid	E-chemical
concentrations	O
,	O
mainly	O
through	O
Cyp7a1	S-GP
upregulation	O
,	O
and	O
to	O
decrease	O
bile	O
production	O
through	O
reduction	O
in	O
Mrp2	S-GP
-mediated	O
bile	B-chemical
acid	E-chemical
-independent	O
bile	O
flow	O
.	O
In	O
conclusion	O
,	O
our	O
data	O
demonstrate	O
that	O
under	O
certain	O
conditions	O
EGCG	S-chemical
may	O
induce	O
cholestasis	O
.	O

Anti-adipogenic	O
diarylheptanoids	S-chemical
from	O
Alnus	O
hirsuta	O
f.	O
sibirica	O
on	O
3T3-L1	O
cells	O
.	O
A	O
new	O
diarylheptanoid	S-chemical
,	O
(	B-chemical
5S	I-chemical
)	I-chemical
-hydroxy-1-	I-chemical
(	I-chemical
3,4-dihydroxyphenyl	I-chemical
)	I-chemical
-7-	I-chemical
(	I-chemical
4-hydroxyphenyl	I-chemical
)	I-chemical
-hepta-1E-en-3-one	E-chemical
(	O
1	O
)	O
,	O
was	O
isolated	O
along	O
with	O
seventeen	O
known	O
diarylheptanoids	S-chemical
(	O
2-18	O
)	O
from	O
the	O
methanol	S-chemical
extract	O
of	O
Alnus	O
hirsuta	O
f.	O
sibirica	O
leaves	O
using	O
bioactivity-guided	O
fractionation	O
.	O
Among	O
the	O
isolated	O
compounds	O
,	O
compounds	O
1	O
and	O
2	O
and	O
4-12	O
reduced	O
lipid	O
accumulation	O
dose-dependently	O
in	O
3T3-L1	O
preadipocytes	O
.	O
Of	O
the	O
compounds	O
active	O
in	O
the	O
present	O
assay	O
system	O
,	O
the	O
most	O
potent	O
compound	O
7	O
,	O
platyphyllonol-5-O-β-d-xylopyranoside	S-chemical
,	O
significantly	O
suppressed	O
the	O
induction	O
of	O
peroxisome	B-GP
proliferator	I-GP
activated	I-GP
receptor	I-GP
γ	E-GP
(	O
PPARγ	S-GP
and	O
CCAAT/enhancer	B-GP
binding	I-GP
protein	I-GP
α	E-GP
(	O
C/EBPα	S-GP
)	O
protein	O
expression	O
,	O
and	O
inhibited	O
adipocyte	O
differentiation	O
induced	O
by	O
troglitazone	S-chemical
,	O
a	O
PPARγ	S-GP
agonist	O
.	O
It	O
was	O
demonstrated	O
that	O
compound	O
7	O
has	O
anti-adipogenic	O
activity	O
mediated	O
by	O
the	O
regulation	O
of	O
PPARγ	S-GP
dependent	O
pathways	O
.	O

A	O
selective	O
retinoid	B-GP
X	I-GP
receptor	E-GP
agonist	O
bexarotene	S-chemical
(	O
LGD1069	S-chemical
,	O
targretin	S-chemical
)	O
inhibits	O
angiogenesis	O
and	O
metastasis	O
in	O
solid	O
tumours	O
.	O
The	O
present	O
study	O
determined	O
the	O
influence	O
of	O
a	O
retinoid	B-GP
X	I-GP
receptor	E-GP
agonist	O
bexarotene	S-chemical
on	O
angiogenesis	O
and	O
metastasis	O
in	O
solid	O
tumours	O
.	O
In	O
the	O
experimental	O
lung	O
metastasis	O
xenograft	O
models	O
,	O
treatment	O
with	O
bexarotene	S-chemical
inhibited	O
the	O
development	O
of	O
the	O
lung	O
tumour	O
nodule	O
formation	O
compared	O
to	O
control	O
.	O
In	O
vivo	O
angiogenesis	O
assay	O
utilising	O
gelfoam	O
sponges	O
,	O
bexarotene	S-chemical
reduced	O
angiogenesis	O
in	O
sponges	O
containing	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	E-GP
,	O
epidermal	B-GP
growth	I-GP
factor	E-GP
and	O
basic	O
fibroblast	B-GP
growth	I-GP
factor	E-GP
to	O
various	O
extent	O
.	O
To	O
determine	O
the	O
basis	O
of	O
these	O
observations	O
,	O
human	O
breast	O
and	O
non-small-cell	O
lung	O
cancer	O
cells	O
were	O
subjected	O
to	O
migration	O
and	O
invasion	O
assays	O
in	O
the	O
presence	O
of	O
bexarotene	S-chemical
.	O
Our	O
data	O
showed	O
that	O
bexarotene	S-chemical
decrease	O
migration	O
and	O
invasiveness	O
of	O
tumour	O
cells	O
in	O
a	O
dose-dependent	O
manner	O
.	O
Furthermore	O
,	O
bexarotene	S-chemical
inhibited	O
angiogenesis	O
by	O
directly	O
inhibiting	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
growth	O
and	O
indirectly	O
inhibiting	O
tumour	O
cell-mediated	O
migration	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
through	O
Matrigel	O
matrix	O
.	O
Analysis	O
of	O
tumour-conditioned	O
medium	O
indicated	O
that	O
bexarotene	S-chemical
decreased	O
the	O
secretion	O
of	O
angiogenic	O
factors	O
and	O
matrix	B-GP
metalloproteinases	E-GP
and	O
increased	O
the	O
tissue	O
inhibitor	O
of	O
matrix	B-GP
metalloproteinases	E-GP
.	O
The	O
ability	O
of	O
bexarotene	S-chemical
to	O
inhibit	O
angiogenesis	O
and	O
metastasis	O
was	O
dependent	O
on	O
activation	O
of	O
its	O
heterodimerisation	O
partner	O
peroxisome	B-GP
proliferator-activated	I-GP
receptor	I-GP
gamma	E-GP
.	O
Collectively	O
,	O
our	O
results	O
suggest	O
a	O
role	O
of	O
bexarotene	S-chemical
in	O
treatment	O
of	O
angiogenesis	O
and	O
metastasis	O
in	O
solid	O
tumours	O
.	O

Site	O
dependent	O
intestinal	O
absorption	O
of	O
darunavir	S-chemical
and	O
its	O
interaction	O
with	O
ketoconazole	S-chemical
.	O
The	O
expression	O
of	O
P-gp	S-GP
increases	O
from	O
proximal	O
to	O
distal	O
parts	O
of	O
the	O
small	O
intestine	O
,	O
whereas	O
for	O
P450	B-GP
enzymes	E-GP
the	O
expression	O
is	O
reported	O
to	O
be	O
highest	O
in	O
duodenum	O
and	O
jejunum	O
,	O
decreasing	O
to	O
more	O
distal	O
sites	O
.	O
To	O
evaluate	O
to	O
what	O
extent	O
the	O
regional	O
differences	O
in	O
expression	O
of	O
P-gp	S-GP
and	O
P450	B-GP
enzymes	E-GP
affect	O
the	O
absorption	O
of	O
a	O
dual	O
substrate	O
,	O
we	O
investigated	O
the	O
transport	O
of	O
darunavir	S-chemical
across	O
different	O
small	O
intestinal	O
segments	O
(	O
duodenum	O
,	O
proximal	O
jejunum	O
and	O
ileum	O
)	O
.	O
Moreover	O
,	O
the	O
effect	O
of	O
ketoconazole	S-chemical
on	O
the	O
intestinal	O
absorption	O
of	O
darunavir	S-chemical
was	O
explored	O
,	O
since	O
these	O
drugs	O
are	O
commonly	O
co-administered	O
.	O
Performing	O
the	O
rat	O
in	O
situ	O
intestinal	O
perfusion	O
technique	O
with	O
mesenteric	O
blood	O
sampling	O
,	O
we	O
found	O
no	O
significant	O
differences	O
in	O
the	O
transport	O
of	O
darunavir	S-chemical
at	O
the	O
different	O
intestinal	O
segments	O
.	O
The	O
involvement	O
of	O
P-gp	S-GP
in	O
the	O
absorption	O
of	O
darunavir	S-chemical
was	O
clearly	O
shown	O
by	O
coperfusion	O
of	O
darunavir	S-chemical
with	O
the	O
P-gp	S-GP
inhibitor	O
zosuquidar	S-chemical
.	O
In	O
presence	O
of	O
zosuquidar	S-chemical
,	O
a	O
2.2-	O
,	O
4.2-	O
and	O
5.7-fold	O
increase	O
in	O
Papp	O
values	O
were	O
measured	O
for	O
duodenum	O
,	O
proximal	O
jejunum	O
and	O
ileum	O
,	O
respectively	O
.	O
Involvement	O
of	O
P450	S-GP
mediated	O
metabolism	O
in	O
the	O
absorption	O
of	O
darunavir	S-chemical
could	O
not	O
be	O
demonstrated	O
in	O
this	O
rat	O
model	O
.	O
Upon	O
studying	O
the	O
drug-drug	O
interaction	O
of	O
darunavir	S-chemical
with	O
ketoconazole	S-chemical
,	O
data	O
were	O
indicative	O
for	O
an	O
inhibitory	O
effect	O
of	O
ketoconazole	S-chemical
on	O
P-gp	S-GP
as	O
the	O
main	O
mechanism	O
for	O
the	O
increased	O
transport	O
of	O
darunavir	S-chemical
across	O
the	O
small	O
intestine	O
.	O

[	B-chemical
3H	I-chemical
]	I-chemical
dofetilide	E-chemical
binding	O
to	O
HERG	S-GP
transfected	O
membranes	O
:	O
a	O
potential	O
high	O
throughput	O
preclinical	O
screen	O
.	O
The	O
pharmacological	O
characteristics	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
dofetilide	E-chemical
binding	O
were	O
examined	O
in	O
membranes	O
prepared	O
from	O
human	O
embryonic	O
kidney	O
(	O
HEK293	O
)	O
cells	O
stably	O
expressing	O
human	B-GP
ether-a-go-go	I-GP
related	I-GP
gene	I-GP
(	I-GP
HERG	I-GP
)	I-GP
K+	I-GP
channels	E-GP
.	O
The	O
classIII	O
antiarrhythmic	O
compounds	O
dofetilide	S-chemical
,	O
clofilium	S-chemical
,	O
4'-	B-chemical
[	I-chemical
[	I-chemical
1-	I-chemical
[	I-chemical
2-	I-chemical
(	I-chemical
6-methyl-2-pyridyl	I-chemical
)	I-chemical
ethyl	I-chemical
]	I-chemical
-4-piperidyl	I-chemical
]	I-chemical
carbonyl	I-chemical
]	I-chemical
methanesulfonanilide	E-chemical
(	O
E-4031	S-chemical
)	O
,	O
N-methyl-N-	B-chemical
[	I-chemical
2-	I-chemical
[	I-chemical
methyl-	I-chemical
(	I-chemical
1-methyl-1H-benzimidazol-2-yl	I-chemical
)	I-chemical
amino	I-chemical
]	I-chemical
ethyl	I-chemical
]	I-chemical
-4-	I-chemical
[	I-chemical
(	I-chemical
methylsulfo	I-chemical
nyl	I-chemical
)	I-chemical
amino	I-chemical
]	I-chemical
benzene-sulfonamide	E-chemical
(	O
WAY-123,398	S-chemical
)	O
and	O
d-sotalol	S-chemical
all	O
inhibited	O
[	B-chemical
3H	I-chemical
]	I-chemical
dofetilide	E-chemical
binding	O
.	O
In	O
addition	O
,	O
the	O
structurally	O
unrelated	O
compounds	O
pimozide	S-chemical
,	O
terfenadine	S-chemical
and	O
haloperidol	S-chemical
,	O
all	O
of	O
which	O
prolong	O
the	O
QT	O
interval	O
in	O
man	O
,	O
also	O
inhibited	O
binding	O
.	O
These	O
data	O
indicate	O
that	O
a	O
[	B-chemical
3H	I-chemical
]	I-chemical
dofetilide	E-chemical
binding	O
assay	O
using	O
HERG	S-GP
membranes	O
may	O
help	O
identify	O
compounds	O
that	O
prolong	O
the	O
QT	O
interval	O
.	O

Efficacy	O
and	O
safety	O
of	O
the	O
factor	B-GP
VIII	E-GP
/	O
von	B-GP
Willebrand	I-GP
factor	E-GP
concentrate	O
,	O
haemate-P/humate-P	O
:	O
ristocetin	S-chemical
cofactor	O
unit	O
dosing	O
in	O
patients	O
with	O
von	O
Willebrand	O
disease	O
.	O
The	O
present	O
study	O
was	O
initiated	O
to	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
Haemate-P	O
(	O
Humate-P	O
in	O
North	O
America	O
)	O
(	O
anti-hemophilic	O
FVIII	S-GP
/	O
VWF	S-GP
complex	O
[	O
human	O
]	O
dried	O
,	O
pasteurized	O
)	O
dosed	O
in	O
ristocetin	S-chemical
cofactor	O
units	O
(	O
VWF	O
:	O
RCo	O
)	O
in	O
the	O
treatment	O
of	O
von	O
Willebrand	O
disease	O
(	O
VWD	O
)	O
patients	O
in	O
Canada	O
.	O
This	O
retrospective	O
data	O
collection	O
reviewed	O
the	O
medical	O
records	O
of	O
VWD	O
patients	O
treated	O
under	O
the	O
Canadian	O
Emergency	O
Drug	O
Release	O
Program	O
from	O
November	O
22	O
,	O
1991	O
,	O
to	O
April	O
30	O
,	O
1996	O
.	O
Data	O
collection	O
was	O
accomplished	O
by	O
on-site	O
retrieval	O
from	O
source	O
data	O
for	O
97	O
patients	O
.	O
Dosing	O
was	O
based	O
on	O
the	O
German	O
package	O
insert	O
,	O
which	O
lists	O
only	O
Factor	B-GP
VIII	I-GP
:	I-GP
C	E-GP
(	O
FVIII	B-GP
:	I-GP
C	E-GP
)	O
units	O
,	O
which	O
were	O
converted	O
in	O
the	O
study	O
analysis	O
to	O
VWF	O
:	O
RCo	O
units	O
based	O
on	O
the	O
analysis	O
of	O
the	O
individual	O
manufactured	O
lots	O
of	O
product	O
used	O
in	O
these	O
patients	O
(	O
average	O
ratio	O
of	O
2.6	O
IU	O
VWF	O
:	O
RCo	O
per	O
IU	O
FVIII	B-GP
:	I-GP
C	E-GP
)	O
.	O
Twenty	O
five	O
different	O
lots	O
of	O
Haemate-P/Humate-P	O
were	O
used	O
to	O
treat	O
437	O
different	O
events	O
in	O
the	O
97	O
study	O
patients	O
(	O
344	O
hemorrhagic	O
events	O
,	O
73	O
surgical	O
interventions	O
and	O
20	O
prophylactic	O
infusion	O
cycles	O
)	O
.	O
Overall	O
,	O
the	O
median	O
dose	O
of	O
concentrate	O
per	O
infusion	O
used	O
to	O
treat	O
surgical	O
events	O
was	O
69.1	O
IU	O
VWF	S-GP
:	O
RCo/kg	O
(	O
range	O
11.9-222.8	O
)	O
;	O
bleeding	O
events	O
55.3	O
IU	O
VWF	O
:	O
RCo/kg	O
(	O
range	O
17.1-227.5	O
)	O
and	O
prophylaxis	O
41.6	O
IU	O
VWF	O
:	O
RCo/kg	O
(	O
range	O
34.6-81.0	O
)	O
.	O
Treatment	O
periods	O
varied	O
,	O
with	O
the	O
majority	O
of	O
events	O
treated	O
for	O
<	O
or	O
=	O
10	O
days	O
(	O
91	O
%	O
)	O
.	O
Fifty	O
percent	O
of	O
events	O
that	O
were	O
treated	O
longer	O
than	O
10	O
days	O
were	O
given	O
for	O
prophylactic	O
reasons	O
.	O
Efficacy	O
was	O
determined	O
in	O
a	O
standardized	O
manner	O
by	O
the	O
physician	O
,	O
based	O
on	O
dosing	O
in	O
VWF	O
:	O
RCo	O
activity	O
.	O
An	O
overall	O
clinical	O
result	O
of	O
``	O
excellent	O
''	O
or	O
``	O
good	O
''	O
was	O
reported	O
in	O
97	O
%	O
(	O
424/437	O
)	O
of	O
treatment	O
events	O
.	O
A	O
pediatric	O
sub-population	O
analysis	O
of	O
the	O
patient	O
population	O
reported	O
``	O
excellent/good	O
''	O
efficacy	O
in	O
100	O
%	O
(	O
17/17	O
)	O
of	O
treatment	O
events	O
in	O
infants	O
,	O
95	O
%	O
(	O
155/164	O
)	O
in	O
children	O
,	O
and	O
94	O
%	O
(	O
76/81	O
)	O
in	O
adolescent	O
patients	O
.	O
Related	O
adverse	O
events	O
(	O
AEs	O
)	O
were	O
observed	O
in	O
only	O
4	O
(	O
4	O
%	O
)	O
patients	O
and	O
were	O
not	O
deemed	O
to	O
be	O
serious	O
.	O
The	O
findings	O
in	O
this	O
study	O
confirm	O
the	O
safety	O
and	O
efficacy	O
of	O
Haemate-P/Humate-P	O
using	O
VWF	O
:	O
RCo	O
dosing	O
in	O
pediatric	O
and	O
adult	O
patients	O
with	O
various	O
types	O
of	O
VWD	O
.	O

[	O
Characteristics	O
of	O
A-interferon	S-GP
-generated	O
dendritic	O
cells	O
in	O
patients	O
with	O
pulmonary	O
tuberculosis	O
]	O
.	O
The	O
phenotype	O
of	O
the	O
dendritic	O
cells	O
(	O
DC	O
)	O
generated	O
from	O
the	O
adhesion	O
fraction	O
of	O
mononuclear	O
cells	O
in	O
the	O
presence	O
of	O
GM-CSF	O
and	O
alpha-interferon	S-GP
was	O
studied	O
in	O
patients	O
with	O
pulmonary	O
tuberculosis	O
.	O
Despite	O
the	O
absence	O
of	O
significant	O
differences	O
in	O
the	O
count	O
of	O
mature	O
CD83+DCs	O
in	O
the	O
groups	O
of	O
patients	O
(	O
n	O
=	O
38	O
)	O
and	O
healthy	O
donors	O
(	O
n	O
=	O
30	O
)	O
,	O
elevated	O
CD14	O
(	O
+	O
)	O
-monocyte	O
levels	O
and	O
few	O
activated	O
CD25	O
(	O
+	O
)	O
-DCs	O
were	O
indicative	O
of	O
the	O
impaired	O
process	O
of	O
DC	O
maturation/generation	O
in	O
patients	O
with	O
pulmonary	O
tuberculosis	O
,	O
particularly	O
in	O
a	O
subgroup	O
of	O
patients	O
with	O
a	O
low	O
T-cell	O
proliferative	O
response	O
against	O
PPD	O
(	O
PPD-anergy	O
,	O
n	O
=	O
10	O
)	O
.	O
The	O
patients	O
with	O
tuberculosis	O
showed	O
the	O
lower	O
relative	O
levels	O
of	O
CD11c	O
(	O
-	O
)	O
-CD123	O
(	O
+	O
)	O
-DC	O
and	O
the	O
normal	O
levels	O
of	O
myeloid	O
CD11c	O
(	O
+	O
)	O
D123	O
(	O
-	O
)	O
DCs	O
.	O
However	O
,	O
in	O
patients	O
with	O
PPD-anergy	O
,	O
the	O
content	O
of	O
myeloid	O
CD11c	O
(	O
+	O
)	O
CD123	O
(	O
-	O
)	O
-DCs	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
PPD-reactive	O
patients	O
.	O
Moreover	O
,	O
the	O
patients	O
with	O
PPD-anergy	O
were	O
characterized	O
by	O
the	O
elevated	O
peripheral	O
blood	O
levels	O
of	O
CD14+CD16	O
(	O
+	O
)	O
-monocytes	O
,	O
which	O
was	O
associated	O
with	O
the	O
high	O
suppressive	O
activity	O
of	O
monocytes	O
(	O
r	O
(	O
s	O
)	O
=	O
0.53	O
;	O
p	O
<	O
0.05	O
)	O
.	O
The	O
impaired	O
process	O
of	O
DC	O
generation/maturation	O
in	O
patients	O
with	O
pulmonary	O
tuberculosis	O
is	O
believed	O
to	O
be	O
associated	O
with	O
the	O
changes	O
in	O
the	O
phenotypic	O
and	O
functional	O
properties	O
of	O
monocytes	O
and	O
to	O
be	O
a	O
cause	O
of	O
an	O
inadequate	O
antigen-specific	O
response	O
in	O
tuberculous	O
infection	O
.	O

The	O
role	O
of	O
long	O
chain	O
omega-3	B-chemical
polyunsaturated	I-chemical
fatty	I-chemical
acids	E-chemical
in	O
reducing	O
lipid	O
peroxidation	O
among	O
elderly	O
patients	O
with	O
mild	O
cognitive	O
impairment	O
:	O
a	O
case-control	O
study	O
.	O
The	O
present	O
work	O
explores	O
the	O
effect	O
of	O
dietary	O
omega-3	B-chemical
polyunsaturated	I-chemical
fatty	I-chemical
acids	E-chemical
(	O
PUFAs	S-chemical
)	O
intake	O
on	O
lipid	O
peroxidation	O
among	O
mild	O
cognitive	O
impairment	O
(	O
MCI	O
)	O
patients	O
.	O
The	O
plasma	O
lipid	O
hydroperoxide	S-chemical
(	O
LPO	O
)	O
levels	O
in	O
67	O
MCI	O
patients	O
were	O
compared	O
to	O
those	O
of	O
134	O
healthy	O
elderly	O
controls	O
.	O
Omega-3	B-chemical
PUFA	E-chemical
intake	O
was	O
assessed	O
using	O
an	O
interviewer-administered	O
food	O
frequency	O
questionnaire	O
.	O
Apolipoprotein	B-GP
E	E-GP
genotyping	O
was	O
performed	O
using	O
polymerase	O
chain	O
reaction	O
and	O
restriction	O
enzyme	O
digestion	O
.	O
The	O
association	O
between	O
various	O
confounders	O
and	O
lipid	O
peroxidation	O
was	O
evaluated	O
using	O
regression	O
analysis	O
.	O
The	O
influence	O
of	O
docosahexaenoic	B-chemical
acid	E-chemical
(	O
DHA	S-chemical
)	O
and	O
eicosapentaenoic	B-chemical
acid	E-chemical
(	O
EPA	S-chemical
)	O
intake	O
on	O
LPO	O
level	O
was	O
investigated	O
.	O
The	O
results	O
revealed	O
that	O
LPO	O
levels	O
were	O
significantly	O
higher	O
in	O
the	O
MCI	O
group	O
than	O
in	O
the	O
control	O
group	O
.	O
Inverse	O
correlations	O
were	O
found	O
between	O
DHA	S-chemical
and	O
EPA	S-chemical
intake	O
and	O
LPO	O
level	O
among	O
the	O
MCI	O
group	O
.	O
LPO	O
levels	O
decreased	O
significantly	O
with	O
increasing	O
DHA	S-chemical
and	O
EPA	S-chemical
intake	O
.	O
In	O
summary	O
,	O
the	O
findings	O
revealed	O
that	O
DHA	S-chemical
and	O
EPA	S-chemical
can	O
play	O
a	O
role	O
in	O
alleviating	O
oxidative	O
stress	O
and	O
reducing	O
the	O
risk	O
of	O
neurodegenerative	O
diseases	O
.	O

Design	O
,	O
synthesis	O
,	O
and	O
in-vivo	O
evaluation	O
of	O
4,5-diaryloxazole	S-chemical
as	O
novel	O
nonsteroidal	O
anti-inflammatory	O
drug	O
.	O
A	O
series	O
of	O
4,5-diaryloxazole	S-chemical
analogs	O
were	O
designed	O
and	O
the	O
interaction	O
between	O
oxaprozin	S-chemical
and	O
cyclooxygenase-2	S-GP
studied	O
by	O
the	O
docking	O
method	O
to	O
improve	O
the	O
biological	O
activity	O
and	O
reduce	O
the	O
gastrointestinal	O
side	O
effects	O
of	O
oxaprozin	S-chemical
.	O
Finally	O
,	O
3-	B-chemical
(	I-chemical
4-	I-chemical
(	I-chemical
4-fluorophenyl	I-chemical
)	I-chemical
-5-	I-chemical
(	I-chemical
4-aminosulfonyl-3-fluorophenyl	I-chemical
)	I-chemical
-oxazole-2-yl	I-chemical
)	I-chemical
propanoic	I-chemical
acid	E-chemical
(	O
NC-2142	S-chemical
)	O
,	O
the	O
best	O
candidate	O
,	O
was	O
selected	O
for	O
synthesis	O
and	O
bioassay	O
based	O
on	O
the	O
screening	O
result	O
.	O
NC-2142	S-chemical
could	O
lower	O
the	O
tumefaction	O
rates	O
of	O
back	O
metatarsus	O
in	O
rats	O
,	O
as	O
well	O
as	O
reduce	O
the	O
writhing	O
times	O
in	O
mice	O
.	O
NC-2142	S-chemical
produced	O
fewer	O
gastric	O
lesions	O
than	O
oxaprozin	S-chemical
.	O
After	O
the	O
aminosulfonyl	S-chemical
group	O
was	O
introduced	O
into	O
the	O
benzene	S-chemical
ring	O
of	O
oxaprozin	S-chemical
,	O
its	O
analgesic	O
and	O
anti-inflammatory	O
activities	O
remained	O
unchanged	O
,	O
and	O
it	O
reduced	O
the	O
number	O
of	O
gastric	O
lesions	O
.	O
This	O
provided	O
a	O
feasible	O
method	O
for	O
further	O
structure	O
modification	O
and	O
optimization	O
of	O
oxaprozin	S-chemical
.	O

A	O
molecular	O
mechanism	O
for	O
ibuprofen	S-chemical
-mediated	O
RhoA	S-GP
inhibition	O
in	O
neurons	O
.	O
Ibuprofen	S-chemical
is	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
widely	O
used	O
to	O
relieve	O
pain	O
and	O
inflammation	O
in	O
many	O
disorders	O
via	O
inhibition	O
of	O
cyclooxygenases	S-GP
.	O
Recently	O
,	O
we	O
have	O
demonstrated	O
that	O
ibuprofen	S-chemical
inhibits	O
intracellular	O
signaling	O
of	O
RhoA	S-GP
and	O
promotes	O
significant	O
axonal	O
growth	O
and	O
functional	O
recovery	O
following	O
spinal	O
cord	O
lesions	O
in	O
rodents	O
.	O
In	O
addition	O
,	O
another	O
study	O
suggests	O
that	O
ibuprofen	S-chemical
reduces	O
generation	O
of	O
amyloid-beta42	S-GP
peptide	O
via	O
inactivation	O
of	O
RhoA	S-GP
signaling	O
,	O
although	O
it	O
may	O
also	O
regulate	O
amyloid-beta42	S-GP
formation	O
by	O
direct	O
inhibition	O
of	O
the	O
gamma-secretase	B-GP
complex	E-GP
.	O
The	O
molecular	O
mechanisms	O
by	O
which	O
ibuprofen	S-chemical
inhibits	O
the	O
RhoA	S-GP
signal	O
in	O
neurons	O
,	O
however	O
,	O
remain	O
unclear	O
.	O
Here	O
,	O
we	O
report	O
that	O
the	O
transcription	O
factor	O
peroxisome	B-GP
proliferator-activated	I-GP
receptor	I-GP
gamma	E-GP
(	O
PPARgamma	S-GP
)	O
is	O
essential	O
for	O
coupling	O
ibuprofen	S-chemical
to	O
RhoA	S-GP
inhibition	O
and	O
subsequent	O
neurite	O
growth	O
promotion	O
in	O
neurons	O
.	O
Ibuprofen	S-chemical
activates	O
PPARgamma	S-GP
in	O
neuron-like	O
PC12	O
and	O
B104	O
cells	O
.	O
Activation	O
of	O
PPARgamma	S-GP
with	O
traditional	O
agonists	O
mimics	O
the	O
RhoA	S-GP
-inhibiting	O
properties	O
of	O
ibuprofen	S-chemical
in	O
PC12	O
cells	O
and	O
,	O
like	O
ibuprofen	S-chemical
,	O
promotes	O
neurite	O
elongation	O
in	O
primary	O
cultured	O
neurons	O
exposed	O
to	O
axonal	O
growth	O
inhibitors	O
.	O
Protein	O
knockdown	O
with	O
small	O
interfering	O
RNA	O
specific	O
for	O
PPARgamma	S-GP
blocks	O
RhoA	S-GP
suppression	O
of	O
PPARgamma	S-GP
agonists	O
in	O
PC12	O
cells	O
.	O
Moreover	O
,	O
the	O
effect	O
of	O
ibuprofen	S-chemical
on	O
RhoA	S-GP
activity	O
and	O
neurite	O
growth	O
in	O
neuronal	O
cultures	O
is	O
prevented	O
by	O
selective	O
PPARgamma	S-GP
inhibition	O
.	O
These	O
findings	O
support	O
that	O
PPARgamma	S-GP
plays	O
an	O
essential	O
role	O
in	O
mediating	O
the	O
RhoA	S-GP
-inhibiting	O
effect	O
of	O
ibuprofen	S-chemical
.	O
Elucidation	O
of	O
the	O
novel	O
molecular	O
mechanisms	O
linking	O
ibuprofen	S-chemical
to	O
RhoA	S-GP
inhibition	O
may	O
provide	O
additional	O
therapeutic	O
targets	O
to	O
the	O
disorders	O
characterized	O
by	O
RhoA	S-GP
activation	O
,	O
including	O
spinal	O
cord	O
injuries	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Imiquimod	S-chemical
,	O
a	O
Toll-like	B-GP
receptor-7	E-GP
agonist	O
,	O
induces	O
perforin	S-GP
in	O
cytotoxic	O
T	O
lymphocytes	O
in	O
vitro	O
.	O
Imiquimod	S-chemical
(	O
IMQ	S-chemical
)	O
,	O
an	O
activator	O
of	O
Toll-like	B-GP
receptor-7	E-GP
(	O
TLR-7	S-GP
)	O
,	O
induces	O
by	O
several	O
routes	O
a	O
profound	O
anti-viral	O
and	O
anti-tumor	O
effect	O
in	O
vivo	O
.	O
Physiologically	O
,	O
the	O
immune	O
system	O
is	O
using	O
perforin	S-GP
-containing	O
granules	O
of	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTL	O
)	O
towards	O
the	O
same	O
biological	O
purpose	O
.	O
This	O
functional	O
synergism	O
prompted	O
our	O
current	O
experiments	O
addressing	O
the	O
question	O
whether	O
IMQ	S-chemical
may	O
influence	O
perforin	S-GP
-release	O
and/or	O
induce	O
perforin	S-GP
in	O
CTLs	O
in	O
vitro	O
.	O
In	O
peripheral	O
lymphocytes	O
of	O
healthy	O
and	O
diseased	O
subjects	O
,	O
IMQ	S-chemical
induced	O
a	O
significant	O
increase	O
of	O
perforin	S-GP
(	O
+	O
)	O
CTLs	O
within	O
12h	O
in	O
all	O
experiments	O
performed	O
.	O
This	O
effect	O
was	O
most	O
pronounced	O
in	O
CTLs	O
of	O
patients	O
suffering	O
from	O
atopic	O
dermatitis	O
,	O
a	O
model	O
disorder	O
for	O
subnormal	O
perforin	S-GP
expression	O
:	O
as	O
compared	O
to	O
perforin	S-GP
(	O
+	O
)	O
CTLs	O
detected	O
at	O
time	O
point	O
zero	O
(	O
100	O
%	O
)	O
,	O
up	O
to	O
270	O
%	O
of	O
perforin	S-GP
(	O
+	O
)	O
CTLs	O
were	O
induced	O
by	O
2.5	O
microg/ml	O
[	O
corrected	O
]	O
IMQ	S-chemical
.	O
Perforin	S-GP
release	O
from	O
peripheral	O
blood	O
CTLs	O
after	O
PMA/ionomycin-stimulation	O
was	O
not	O
influenced	O
significantly	O
by	O
IMQ	S-chemical
.	O
Thus	O
,	O
the	O
biological	O
activity	O
of	O
IMQ	S-chemical
appears	O
to	O
exceed	O
its	O
previously	O
known	O
functions	O
,	O
inasmuch	O
as	O
it	O
boosts	O
up	O
significantly	O
the	O
perforin	S-GP
-granule	O
system	O
.	O

Evaluation	O
of	O
suppressive	O
and	O
pro-resolving	O
effects	O
of	O
EPA	S-chemical
and	O
DHA	S-chemical
in	O
human	O
primary	O
monocytes	O
and	O
T-helper	O
cells	O
.	O
Despite	O
their	O
beneficial	O
anti-inflammatory	O
properties	O
,	O
eicosapentaenoic	B-chemical
acid	E-chemical
(	O
EPA	S-chemical
)	O
and	O
docosahexaenoic	B-chemical
acid	E-chemical
(	O
DHA	S-chemical
)	O
may	O
increase	O
the	O
infection	O
risk	O
at	O
high	O
doses	O
,	O
likely	O
by	O
generating	O
an	O
immune-depressed	O
state	O
.	O
To	O
assess	O
the	O
contribution	O
of	O
different	O
immune	O
cell	O
populations	O
to	O
the	O
immunomodulatory	O
fatty	B-chemical
acid	E-chemical
effect	O
,	O
we	O
comparatively	O
investigated	O
several	O
aspects	O
of	O
inflammation	O
in	O
human	O
T-helper	O
(	O
Th	O
)	O
cells	O
and	O
monocytes	O
.	O
Both	O
fatty	B-chemical
acids	E-chemical
,	O
but	O
DHA	S-chemical
to	O
a	O
lesser	O
extent	O
compared	O
with	O
EPA	S-chemical
,	O
selectively	O
and	O
dose-dependently	O
reduced	O
the	O
percentage	O
of	O
cytokine	S-GP
-expressing	O
Th	O
cells	O
in	O
a	O
peroxisome	B-GP
proliferator-activated	I-GP
receptor	I-GP
(	I-GP
PPAR	I-GP
)	I-GP
γ	E-GP
-dependent	O
fashion	O
,	O
whereas	O
the	O
expression	O
of	O
the	O
cell	O
surface	O
marker	O
CD69	S-GP
was	O
unaltered	O
on	O
activated	O
T	O
cells	O
.	O
In	O
monocytes	O
,	O
both	O
EPA	S-chemical
and	O
DHA	S-chemical
increased	O
interleukin	B-GP
(	I-GP
IL	I-GP
)	I-GP
-10	E-GP
without	O
affecting	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
(	I-GP
TNF	I-GP
)	I-GP
-α	E-GP
and	O
IL-6	S-GP
.	O
Cellular	O
incorporation	O
of	O
EPA	S-chemical
and	O
DHA	S-chemical
occurred	O
mainly	O
at	O
the	O
expense	O
of	O
arachidonic	B-chemical
acid	E-chemical
.	O
Concomitantly	O
,	O
thromboxane	B-chemical
B	E-chemical
(	B-chemical
TXB	I-chemical
)	I-chemical
2	E-chemical
and	O
leukotriene	B-chemical
B	E-chemical
(	B-chemical
LTB	I-chemical
)	I-chemical
4	E-chemical
in	O
supernatants	O
decreased	O
,	O
while	O
levels	O
of	O
TXB3	S-chemical
and	O
LTB5	S-chemical
increased	O
.	O
This	O
increase	O
was	O
independent	O
of	O
activation	O
and	O
in	O
accordance	O
with	O
cyclooxygenase	S-GP
expression	O
patterns	O
in	O
monocytes	O
.	O
Moreover	O
,	O
EPA	S-chemical
and	O
DHA	S-chemical
gave	O
rise	O
to	O
a	O
variety	O
of	O
mono-	B-chemical
and	I-chemical
trihydroxy	E-chemical
derivatives	O
of	O
highly	O
anti-inflammatory	O
potential	O
,	O
such	O
as	O
resolvins	S-chemical
and	O
their	O
precursors	O
.	O
Our	O
results	O
suggest	O
that	O
EPA	S-chemical
and	O
DHA	S-chemical
do	O
not	O
generally	O
affect	O
immune	O
cell	O
functions	O
in	O
an	O
inhibitory	O
manner	O
but	O
rather	O
promote	O
pro-resolving	O
responses	O
.	O

Ventricular	O
tachyarrhythmias	O
in	O
a	O
canine	O
model	O
of	O
LQT3	O
:	O
arrhythmogenic	O
effects	O
of	O
sympathetic	O
activity	O
and	O
therapeutic	O
effects	O
of	O
mexiletine	S-chemical
.	O
The	O
ventricular	O
tachyarrhythmias	O
associated	O
with	O
the	O
LQT3	O
syndrome	O
are	O
typically	O
bradycardia-dependent	O
.	O
However	O
,	O
some	O
episodes	O
can	O
be	O
associated	O
with	O
exercise	O
or	O
emotional	O
stress	O
,	O
suggesting	O
a	O
different	O
arrhythmogenic	O
mechanism	O
when	O
sympathetic	O
activity	O
predominates	O
.	O
This	O
study	O
examined	O
the	O
potential	O
arrhythmogenic	O
mechanisms	O
during	O
periods	O
of	O
autonomically	O
mediated	O
transient	O
heart	O
rate	O
acceleration	O
in	O
a	O
canine	O
anthopleurin-A	S-GP
model	O
of	O
LQT3	O
syndrome	O
.	O
Using	O
plunge	O
needle	O
electrodes	O
,	O
transmural	O
unipolar	O
electrograms	O
of	O
the	O
left	O
ventricle	O
were	O
recorded	O
from	O
endocardial	O
(	O
Endo	O
)	O
,	O
mid-myocardial	O
(	O
Mid	O
)	O
and	O
epicardial	O
(	O
Epi	O
)	O
sites	O
.	O
The	O
activation-recovery	O
interval	O
(	O
ARI	O
)	O
was	O
measured	O
to	O
estimate	O
local	O
refractoriness	O
.	O
The	O
cardiac	O
cycle	O
length	O
was	O
gradually	O
shortened	O
by	O
cessation	O
of	O
vagal	O
stimulation	O
(	O
vagal	O
stimulation	O
protocol	O
(	O
VSP	O
)	O
)	O
,	O
and	O
intramural	O
electrograms	O
and	O
onset	O
mode	O
of	O
ventricular	O
tachyarrhythmias	O
were	O
analyzed	O
in	O
7	O
experiments	O
.	O
The	O
VSP	O
was	O
performed	O
8	O
times	O
before	O
and	O
5	O
times	O
after	O
administration	O
of	O
mexiletine	S-chemical
in	O
each	O
experiment	O
.	O
Before	O
mexiletine	S-chemical
,	O
vagal	O
stimulation	O
slowed	O
the	O
heart	O
rate	O
and	O
created	O
large	O
transmural	O
ARI	O
dispersion	O
because	O
of	O
a	O
greater	O
ARI	O
prolongation	O
at	O
Mid	O
rather	O
than	O
Epi/Endo	O
sites	O
.	O
After	O
cessation	O
of	O
vagal	O
stimulation	O
,	O
unipolar	O
electrograms	O
started	O
to	O
show	O
ARI	O
alternans	O
and	O
ventricular	O
premature	O
beats	O
developed	O
sporadically	O
.	O
Sustained	O
ventricular	O
tachyarrhythmias	O
were	O
induced	O
in	O
12	O
of	O
the	O
56	O
trials	O
of	O
the	O
VSP	O
.	O
Initiation	O
of	O
ventricular	O
tachyarrhythmias	O
was	O
associated	O
with	O
delayed	O
conduction	O
at	O
Mid/Endo	O
sites	O
.	O
Mexiletine	S-chemical
attenuated	O
transmural	O
ARI	O
dispersion	O
,	O
and	O
neither	O
ARI	O
alternans	O
nor	O
ventricular	O
tachyarrhythmias	O
was	O
observed	O
during	O
all	O
35	O
trials	O
of	O
the	O
VSP	O
after	O
mexiletine	S-chemical
administration	O
.	O
Heart	O
rate	O
acceleration	O
induced	O
by	O
an	O
abrupt	O
shift	O
to	O
a	O
state	O
of	O
predominant	O
sympathetic	O
activity	O
enhances	O
arrhythmias	O
in	O
this	O
LQT3	O
model	O
.	O
Mexiletine	S-chemical
homogenizes	O
ventricular	O
repolarization	O
,	O
suppresses	O
premature	O
complexes	O
and	O
was	O
antiarrhythmic	O
during	O
ventricular	O
tachyarrhythmias	O
induced	O
by	O
the	O
VSP	O
.	O

Cytotoxic	O
mechanism	O
of	O
Piper	O
gaudichaudianum	O
Kunth	O
essential	O
oil	O
and	O
its	O
major	O
compound	O
nerolidol	S-chemical
.	O
Piper	O
gaudichaudianum	O
Kunth	O
is	O
used	O
in	O
popular	O
medicine	O
as	O
anti-inflamatory	O
and	O
against	O
liver	O
disorders	O
.	O
One	O
of	O
the	O
most	O
studied	O
components	O
of	O
the	O
plant	O
is	O
the	O
essential	O
oil	O
for	O
which	O
chemical	O
analysis	O
revealed	O
(	B-chemical
E	I-chemical
)	I-chemical
-nerolidol	E-chemical
as	O
major	O
compound	O
.	O
Recently	O
,	O
we	O
have	O
shown	O
that	O
P.	O
gaudichaudianum	O
essential	O
oil	O
possesses	O
strong	O
cytotoxic	O
effects	O
in	O
mammalian	O
V79	O
cells	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
cytotoxicity	O
and	O
mutagenicity	O
of	O
P.	O
gaudichaudianum	O
essential	O
oil	O
and	O
nerolidol	S-chemical
using	O
Saccharomyces	O
cerevisiae	O
as	O
model	O
study	O
.	O
Treatment	O
of	O
the	O
XV185-14c	O
and	O
N123	O
strains	O
with	O
essential	O
oil	O
and	O
nerolidol	S-chemical
led	O
to	O
cytotoxicity	O
but	O
did	O
not	O
induce	O
mutagenicity	O
.	O
Our	O
results	O
revealed	O
an	O
important	O
role	O
of	O
base	O
excision	O
repair	O
(	O
BER	O
)	O
as	O
the	O
ntg1	S-GP
,	O
ntg2	S-GP
,	O
apn1	S-GP
and	O
apn2	S-GP
mutants	O
showed	O
pronounced	O
sensitivity	O
to	O
essential	O
oil	O
and	O
nerolidol	S-chemical
.	O
In	O
the	O
absence	O
of	O
superoxide	B-GP
dismutase	E-GP
(	O
in	O
sod1	S-GP
Δ	O
mutant	O
strain	O
)	O
sensitivity	O
to	O
the	O
essential	O
oil	O
and	O
nerolidol	S-chemical
increased	O
indicating	O
that	O
this	O
oil	O
and	O
nerolidol	S-chemical
are	O
generating	O
reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
.	O
The	O
ROS	O
production	O
was	O
confirmed	O
by	O
DCF-DA	S-chemical
probing	O
assay	O
in	O
Sod	S-GP
-deficient	O
strains	O
.	O
From	O
this	O
,	O
we	O
conclude	O
that	O
the	O
observed	O
cytotoxicity	O
to	O
P.	O
gaudichaudianum	O
essential	O
oil	O
and	O
nerolidol	S-chemical
is	O
mainly	O
related	O
to	O
ROS	O
and	O
DNA	O
single	O
strand	O
breaks	O
generated	O
by	O
the	O
presence	O
of	O
oxidative	O
lesions	O
.	O

Aripiprazole	O
acts	O
as	O
a	O
selective	O
dopamine	B-GP
D2	I-GP
receptor	E-GP
partial	O
agonist	O
.	O
Aripiprazole	S-chemical
has	O
made	O
a	O
significant	O
contribution	O
to	O
the	O
treatment	O
of	O
schizophrenia	O
and	O
related	O
disorders	O
with	O
an	O
improved	O
safety	O
and	O
tolerability	O
profile	O
,	O
which	O
has	O
been	O
attributed	O
to	O
its	O
unique	O
pharmacological	O
profile	O
.	O
It	O
has	O
been	O
claimed	O
that	O
partial	O
agonism	O
of	O
the	O
dopamine	B-GP
D	I-GP
(	I-GP
2	I-GP
)	I-GP
and	I-GP
5-HT	I-GP
(	I-GP
1A	I-GP
)	I-GP
receptors	E-GP
and	O
antagonism	O
of	O
the	O
5-HT	B-GP
(	I-GP
2	I-GP
)	E-GP
receptor	O
contribute	O
to	O
the	O
clinical	O
profile	O
of	O
aripiprazole	S-chemical
,	O
a	O
so-called	O
dopamine	S-chemical
-	O
and	O
5-HT	S-chemical
stabiliser	O
.	O
However	O
,	O
recent	O
studies	O
have	O
questioned	O
the	O
role	O
of	O
the	O
5-HT	S-chemical
-mediated	O
systems	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
aripiprazole	S-chemical
.	O
This	O
report	O
reviews	O
published	O
and	O
unpublished	O
data	O
that	O
suggest	O
that	O
aripiprazole	S-chemical
acts	O
as	O
a	O
selective	O
partial	O
agonist	O
at	O
the	O
dopamine	B-GP
D	I-GP
(	I-GP
2	I-GP
)	I-GP
receptor	E-GP
and	O
does	O
not	O
affect	O
5-HT	B-GP
receptors	E-GP
at	O
therapeutic	O
doses	O
.	O

Association	O
of	O
DRD2	S-GP
polymorphisms	O
and	O
chlorpromazine	S-chemical
-induced	O
extrapyramidal	O
syndrome	O
in	O
Chinese	O
schizophrenic	O
patients	O
.	O
AIM	O
:	O
Extrapyramidal	O
syndrome	O
(	O
EPS	O
)	O
is	O
most	O
commonly	O
affected	O
by	O
typical	O
antipsychotic	O
drugs	O
that	O
have	O
a	O
high	O
affinity	O
with	O
the	O
D2	B-GP
receptor	E-GP
.	O
Recently	O
,	O
many	O
research	O
groups	O
have	O
reported	O
on	O
the	O
positive	O
relationship	O
between	O
the	O
genetic	O
variations	O
in	O
the	O
DRD2	S-GP
gene	O
and	O
the	O
therapeutic	O
response	O
in	O
schizophrenia	O
patients	O
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variations	O
in	O
the	O
receptor	O
in	O
modulating	O
receptor	O
expression	O
.	O
In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
role	O
DRD2	S-GP
plays	O
in	O
chlorpromazine	S-chemical
-induced	O
EPS	O
in	O
schizophrenic	O
patients	O
.	O
METHODS	O
:	O
We	O
identified	O
seven	O
SNP	O
(	O
single	O
nucleotide	S-chemical
polymorphism	O
)	O
(	O
-141Cins	O
>	O
del	O
,	O
TaqIB	O
,	O
TaqID	O
,	O
Ser311Cys	S-GP
,	O
rs6275	O
,	O
rs6277	O
and	O
TaqIA	O
)	O
in	O
the	O
DRD2	S-GP
gene	O
in	O
146	O
schizophrenic	O
inpatients	O
(	O
59	O
with	O
EPS	O
and	O
87	O
without	O
EPS	O
according	O
to	O
the	O
Simpson-Angus	O
Scale	O
)	O
treated	O
with	O
chlorpromazine	S-chemical
after	O
8	O
weeks	O
.	O
The	O
alleles	O
of	O
all	O
loci	O
were	O
determined	O
by	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
.	O
RESULTS	O
:	O
Polymorphisms	O
TaqID	O
,	O
Ser311Cys	S-GP
and	O
rs6277	O
were	O
not	O
polymorphic	O
in	O
the	O
population	O
recruited	O
in	O
the	O
present	O
study	O
.	O
No	O
statistical	O
significance	O
was	O
found	O
in	O
the	O
allele	O
distribution	O
of	O
-141Cins	O
>	O
del	O
,	O
TaqIB	O
,	O
rs6275	O
and	O
TaqIA	O
or	O
in	O
the	O
estimated	O
haplotypes	O
(	O
constituted	O
by	O
TaqIB	O
,	O
rs6275	O
and	O
TaqIA	O
)	O
in	O
linkage	O
disequilibrium	O
between	O
the	O
two	O
groups	O
.	O
CONCLUSION	O
:	O
Our	O
results	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
genetic	O
variation	O
of	O
the	O
DRD2	S-GP
gene	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
variable	O
adverse	O
effect	O
induced	O
by	O
chlorpromazine	S-chemical
,	O
at	O
least	O
in	O
Chinese	O
patients	O
with	O
schizophrenia	O
.	O
Our	O
results	O
confirmed	O
a	O
previous	O
study	O
on	O
the	O
relationship	O
between	O
DRD2	S-GP
and	O
EPS	O
in	O
Caucasians	O
.	O

A	O
phase	O
1	O
study	O
of	O
tazarotene	S-chemical
in	O
adults	O
with	O
advanced	O
cancer	O
.	O
Tazarotene	S-chemical
is	O
an	O
acetylenic	B-chemical
retinoid	E-chemical
which	O
is	O
metabolised	O
to	O
tazarotenic	B-chemical
acid	E-chemical
and	O
which	O
binds	O
selectively	O
to	O
the	O
retinoid	B-GP
receptors	E-GP
RARbeta	S-GP
and	O
RARgamma	S-GP
.	O
The	O
safety	O
,	O
toxicity	O
and	O
pharmacokinetics	O
of	O
oral	O
tazarotene	S-chemical
were	O
determined	O
over	O
12	O
weeks	O
of	O
treatment	O
in	O
34	O
patients	O
with	O
advanced	O
cancer	O
.	O
Commonly	O
seen	O
toxicities	O
were	O
mucocutaneous	O
symptoms	O
,	O
musculoskeletal	O
pain	O
and	O
headache	O
.	O
Dose-limiting	O
toxicities	O
were	O
hypercalcaemia	O
,	O
hypertriglyceridaemia	O
and	O
musculoskeletal	O
pain	O
.	O
The	O
maximum	O
tolerated	O
dose	O
of	O
tazarotene	S-chemical
in	O
this	O
schedule	O
is	O
25.2	O
mg	O
day	O
(	O
-1	O
)	O
.	O
Plasma	O
concentrations	O
of	O
tazarotenic	B-chemical
acid	E-chemical
were	O
found	O
to	O
peak	O
rapidly	O
within	O
1-3	O
h	O
of	O
dosing	O
and	O
thereafter	O
declined	O
quickly	O
.	O
The	O
C	O
(	O
max	O
)	O
and	O
AUC	O
values	O
on	O
day	O
0	O
,	O
and	O
weeks	O
2	O
and	O
4	O
were	O
similar	O
indicating	O
no	O
drug	O
accumulation	O
.	O
The	O
dose-normalised	O
C	O
(	O
max	O
)	O
and	O
AUC	O
values	O
at	O
different	O
dose	O
levels	O
and	O
different	O
study	O
days	O
appeared	O
to	O
be	O
similar	O
indicating	O
linear	O
pharmacokinetics	O
.	O
No	O
objective	O
responses	O
were	O
seen	O
,	O
although	O
stable	O
disease	O
was	O
seen	O
in	O
six	O
out	O
of	O
eight	O
evaluable	O
patients	O
receiving	O
the	O
three	O
highest	O
dose	O
levels	O
of	O
tazarotene	S-chemical
(	O
16.8	O
,	O
25.2	O
or	O
33.4	O
mg	O
day	O
(	O
-1	O
)	O
)	O
.	O
We	O
conclude	O
that	O
oral	O
tazarotene	S-chemical
is	O
well	O
tolerated	O
when	O
administered	O
daily	O
for	O
12	O
weeks	O
,	O
has	O
a	O
favourable	O
toxicity	O
profile	O
compared	O
with	O
other	O
retinoids	S-chemical
and	O
merits	O
further	O
investigation	O
as	O
an	O
anticancer	O
therapy	O
.	O

Arachidonic	B-chemical
acid	E-chemical
and	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
induce	O
conformational	O
changes	O
in	O
the	O
human	B-GP
prostaglandin	I-GP
endoperoxide	I-GP
H2	I-GP
synthase-2	E-GP
(	O
cyclooxygenase-2	S-GP
)	O
.	O
By	O
using	O
the	O
technique	O
of	O
site-directed	O
spin	O
labeling	O
combined	O
with	O
EPR	O
spectroscopy	O
,	O
we	O
have	O
observed	O
that	O
binding	O
of	O
arachidonic	B-chemical
acid	E-chemical
and	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
induces	O
conformational	O
changes	O
in	O
the	O
human	B-GP
prostaglandin	I-GP
endoperoxide	I-GP
H	I-GP
(	I-GP
2	I-GP
)	I-GP
synthase	I-GP
enzyme	E-GP
(	O
PGHS-2	S-GP
)	O
.	O
Line	O
shape	O
broadening	O
resulting	O
from	O
spin-spin	O
coupling	O
of	O
nitroxide	S-chemical
pairs	O
introduced	O
into	O
the	O
membrane-binding	O
helices	O
of	O
PGHS-2	S-GP
was	O
used	O
to	O
calculate	O
the	O
inter-helical	O
distances	O
and	O
changes	O
in	O
these	O
distances	O
that	O
occur	O
in	O
response	O
to	O
binding	O
various	O
ligands	O
.	O
The	O
inter-residue	O
distances	O
determined	O
for	O
the	O
PGHS-2	S-GP
holoenzyme	O
using	O
EPR	O
were	O
1-7.9	O
A	O
shorter	O
than	O
those	O
of	O
the	O
crystal	O
structure	O
of	O
the	O
PGHS-2	S-GP
holoenzyme	O
.	O
However	O
,	O
inter-helical	O
distances	O
calculated	O
and	O
determined	O
by	O
EPR	O
for	O
PGHS-2	S-GP
complexed	O
with	O
arachidonic	B-chemical
acid	E-chemical
,	O
flurbiprofen	S-chemical
,	O
and	O
SC-58125	S-chemical
were	O
in	O
close	O
agreement	O
with	O
those	O
obtained	O
from	O
the	O
cognate	O
crystal	O
structures	O
.	O
These	O
results	O
indicate	O
that	O
the	O
structure	O
of	O
the	O
solubilized	O
PGHS-2	S-GP
holoenzyme	O
measured	O
in	O
solution	O
differs	O
from	O
the	O
crystal	O
structure	O
of	O
PGHS-2	S-GP
holoenzyme	O
obtained	O
by	O
x-ray	O
analysis	O
.	O
Furthermore	O
,	O
binding	O
of	O
ligands	O
induces	O
a	O
conformational	O
change	O
in	O
the	O
holo-	O
PGHS-2	S-GP
,	O
converting	O
it	O
to	O
a	O
structure	O
similar	O
to	O
those	O
obtained	O
by	O
x-ray	O
analysis	O
.	O
Proteolysis	O
protection	O
assays	O
had	O
previously	O
provided	O
circumstantial	O
evidence	O
that	O
binding	O
of	O
heme	O
and	O
non-	O
steroidal	S-chemical
anti-inflammatory	O
drugs	O
alters	O
the	O
conformation	O
of	O
PGHS	S-GP
,	O
but	O
the	O
present	O
experiments	O
are	O
the	O
first	O
to	O
directly	O
measure	O
such	O
changes	O
.	O
The	O
finding	O
that	O
arachidonate	S-chemical
can	O
also	O
induce	O
a	O
conformational	O
change	O
in	O
PGHS-2	S-GP
was	O
unexpected	O
,	O
and	O
the	O
magnitude	O
of	O
changes	O
suggests	O
this	O
structural	O
flexibility	O
may	O
be	O
integral	O
to	O
the	O
cyclooxygenase	S-GP
catalytic	O
mechanism	O
.	O

PICK1	S-GP
Deficiency	O
Impairs	O
Secretory	O
Vesicle	O
Biogenesis	O
and	O
Leads	O
to	O
Growth	O
Retardation	O
and	O
Decreased	O
Glucose	S-chemical
Tolerance	O
.	O
Secretory	O
vesicles	O
in	O
endocrine	O
cells	O
store	O
hormones	O
such	O
as	O
growth	B-GP
hormone	E-GP
(	O
GH	S-GP
)	O
and	O
insulin	S-GP
before	O
their	O
release	O
into	O
the	O
bloodstream	O
.	O
The	O
molecular	O
mechanisms	O
governing	O
budding	O
of	O
immature	O
secretory	O
vesicles	O
from	O
the	O
trans-Golgi	O
network	O
(	O
TGN	O
)	O
and	O
their	O
subsequent	O
maturation	O
remain	O
unclear	O
.	O
Here	O
,	O
we	O
identify	O
the	O
lipid	B-GP
binding	I-GP
BAR	I-GP
(	I-GP
Bin/amphiphysin/Rvs	I-GP
)	I-GP
domain	I-GP
protein	E-GP
PICK1	S-GP
(	O
protein	B-GP
interacting	I-GP
with	I-GP
C	I-GP
kinase	I-GP
1	E-GP
)	O
as	O
a	O
key	O
component	O
early	O
in	O
the	O
biogenesis	O
of	O
secretory	O
vesicles	O
in	O
GH	S-GP
-producing	O
cells	O
.	O
Both	O
PICK1	S-GP
-deficient	O
Drosophila	O
and	O
mice	O
displayed	O
somatic	O
growth	O
retardation	O
.	O
Growth	O
retardation	O
was	O
rescued	O
in	O
flies	O
by	O
reintroducing	O
PICK1	S-GP
in	O
neurosecretory	O
cells	O
producing	O
somatotropic	O
peptides	O
.	O
PICK1	S-GP
-deficient	O
mice	O
were	O
characterized	O
by	O
decreased	O
body	O
weight	O
and	O
length	O
,	O
increased	O
fat	O
accumulation	O
,	O
impaired	O
GH	S-GP
secretion	O
,	O
and	O
decreased	O
storage	O
of	O
GH	S-GP
in	O
the	O
pituitary	O
.	O
Decreased	O
GH	S-GP
storage	O
was	O
supported	O
by	O
electron	O
microscopy	O
showing	O
prominent	O
reduction	O
in	O
secretory	O
vesicle	O
number	O
.	O
Evidence	O
was	O
also	O
obtained	O
for	O
impaired	O
insulin	O
secretion	O
associated	O
with	O
decreased	O
glucose	S-chemical
tolerance	O
.	O
PICK1	S-GP
localized	O
in	O
cells	O
to	O
immature	O
secretory	O
vesicles	O
,	O
and	O
the	O
PICK1	B-GP
BAR	I-GP
domain	E-GP
was	O
shown	O
by	O
live	O
imaging	O
to	O
associate	O
with	O
vesicles	O
budding	O
from	O
the	O
TGN	O
and	O
to	O
possess	O
membrane-sculpting	O
properties	O
in	O
vitro	O
.	O
In	O
mouse	O
pituitary	O
,	O
PICK1	S-GP
co-localized	O
with	O
the	O
BAR	B-GP
domain	I-GP
protein	E-GP
ICA69	S-GP
,	O
and	O
PICK1	S-GP
deficiency	O
abolished	O
ICA69	S-GP
protein	O
expression	O
.	O
In	O
the	O
Drosophila	O
brain	O
,	O
PICK1	S-GP
and	O
ICA69	S-GP
co-immunoprecipitated	O
and	O
showed	O
mutually	O
dependent	O
expression	O
.	O
Finally	O
,	O
both	O
in	O
a	O
Drosophila	O
model	O
of	O
type	O
2	O
diabetes	O
and	O
in	O
high-fat-diet-induced	O
obese	O
mice	O
,	O
we	O
observed	O
up-regulation	O
of	O
PICK1	S-GP
mRNA	O
expression	O
.	O
Our	O
findings	O
suggest	O
that	O
PICK1	S-GP
,	O
together	O
with	O
ICA69	S-GP
,	O
is	O
critical	O
during	O
budding	O
of	O
immature	O
secretory	O
vesicles	O
from	O
the	O
TGN	O
and	O
thus	O
for	O
vesicular	O
storage	O
of	O
GH	S-GP
and	O
possibly	O
other	O
hormones	O
.	O
The	O
data	O
link	O
two	O
BAR	B-GP
domain	I-GP
proteins	E-GP
to	O
membrane	O
remodeling	O
processes	O
in	O
the	O
secretory	O
pathway	O
of	O
peptidergic	O
endocrine	O
cells	O
and	O
support	O
an	O
important	O
role	O
of	O
PICK1	S-GP
/	O
ICA69	S-GP
in	O
maintenance	O
of	O
metabolic	O
homeostasis	O
.	O

Trimethylamine-N-oxide	S-chemical
,	O
a	O
metabolite	O
associated	O
with	O
atherosclerosis	O
,	O
exhibits	O
complex	O
genetic	O
and	O
dietary	O
regulation	O
.	O
Circulating	O
trimethylamine-N-oxide	S-chemical
(	O
TMAO	S-chemical
)	O
levels	O
are	O
strongly	O
associated	O
with	O
atherosclerosis	O
.	O
We	O
now	O
examine	O
genetic	O
,	O
dietary	O
,	O
and	O
hormonal	O
factors	O
regulating	O
TMAO	S-chemical
levels	O
.	O
We	O
demonstrate	O
that	O
two	O
flavin	B-GP
mono-oxygenase	E-GP
family	O
members	O
,	O
FMO1	S-GP
and	O
FMO3	S-GP
,	O
oxidize	O
trimethylamine	S-chemical
(	O
TMA	S-chemical
)	O
,	O
derived	O
from	O
gut	O
flora	O
metabolism	O
of	O
choline	S-chemical
,	O
to	O
TMAO	S-chemical
.	O
Further	O
,	O
we	O
show	O
that	O
FMO3	S-GP
exhibits	O
10-fold	O
higher	O
specific	O
activity	O
than	O
FMO1	S-GP
.	O
FMO3	S-GP
overexpression	O
in	O
mice	O
significantly	O
increases	O
plasma	O
TMAO	S-chemical
levels	O
while	O
silencing	O
FMO3	S-GP
decreases	O
TMAO	S-chemical
levels	O
.	O
In	O
both	O
humans	O
and	O
mice	O
,	O
hepatic	O
FMO3	S-GP
expression	O
is	O
reduced	O
in	O
males	O
compared	O
to	O
females	O
.	O
In	O
mice	O
,	O
this	O
reduction	O
in	O
FMO3	S-GP
expression	O
is	O
due	O
primarily	O
to	O
downregulation	O
by	O
androgens	S-chemical
.	O
FMO3	S-GP
expression	O
is	O
induced	O
by	O
dietary	O
bile	B-chemical
acids	E-chemical
by	O
a	O
mechanism	O
that	O
involves	O
the	O
farnesoid	B-GP
X	I-GP
receptor	E-GP
(	O
FXR	S-GP
)	O
,	O
a	O
bile	B-chemical
acid	E-chemical
-activated	O
nuclear	O
receptor	O
.	O
Analysis	O
of	O
natural	O
genetic	O
variation	O
among	O
inbred	O
strains	O
of	O
mice	O
indicates	O
that	O
FMO3	S-GP
and	O
TMAO	S-chemical
are	O
significantly	O
correlated	O
,	O
and	O
TMAO	S-chemical
levels	O
explain	O
11	O
%	O
of	O
the	O
variation	O
in	O
atherosclerosis	O
.	O

Carvedilol	S-chemical
prevents	O
cardiac	O
hypertrophy	O
and	O
overexpression	O
of	O
hypoxia-inducible	B-GP
factor-1alpha	E-GP
and	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	E-GP
in	O
pressure-overloaded	O
rat	O
heart	O
.	O
The	O
use	O
of	O
beta-blockers	O
has	O
emerged	O
as	O
a	O
beneficial	O
treatment	O
for	O
cardiac	O
hypertrophy	O
.	O
Hypoxia-inducible	B-GP
factor-1alpha	E-GP
(	O
HIF-1alpha	S-GP
)	O
is	O
tightly	O
regulated	O
in	O
the	O
ventricular	O
myocardium	O
.	O
However	O
,	O
the	O
expression	O
of	O
HIF-1alpha	S-GP
in	O
cardiac	O
hypertrophy	O
due	O
to	O
pressure	O
overload	O
and	O
after	O
treatment	O
with	O
beta-blocker	O
is	O
little	O
known	O
.	O
To	O
evaluate	O
the	O
effect	O
of	O
carvedilol	S-chemical
on	O
both	O
myocardial	O
HIF-1alpha	S-GP
expression	O
and	O
cardiac	O
hypertrophy	O
,	O
infra-renal	O
aortic	O
banding	O
was	O
performed	O
for	O
4	O
weeks	O
in	O
adult	O
Sprague-Dawley	O
rats	O
to	O
induce	O
cardiac	O
hypertrophy	O
.	O
Carvedilol	S-chemical
at	O
50	O
mg/kg	O
body	O
weight	O
per	O
day	O
after	O
surgery	O
was	O
given	O
.	O
Heart	O
weight	O
and	O
the	O
ratio	O
of	O
heart	O
weight	O
and	O
body	O
weight	O
increased	O
significantly	O
after	O
aortic	O
banding	O
for	O
4	O
weeks	O
in	O
the	O
absence	O
of	O
drug	O
treatment	O
.	O
Mean	O
arterial	O
pressure	O
increased	O
from	O
80	O
+/-	O
9	O
mmHg	O
in	O
the	O
sham	O
group	O
to	O
94	O
+/-5	O
mmHg	O
(	O
p	O
<	O
0.001	O
)	O
in	O
the	O
banding	O
group	O
.	O
Echocardiography	O
showed	O
concentric	O
hypertrophy	O
after	O
aortic	O
banding	O
.	O
Mean	O
arterial	O
pressure	O
decreased	O
after	O
treatment	O
with	O
carvedilol	S-chemical
.	O
The	O
increased	O
wall	O
thickness	O
and	O
heart	O
weight	O
was	O
reversed	O
to	O
normal	O
by	O
carvedilol	S-chemical
.	O
Western	O
blot	O
showed	O
that	O
HIF-1alpha	S-GP
,	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	E-GP
(	O
VEGF	S-GP
)	O
and	O
brain	B-GP
natriuretic	I-GP
peptide	E-GP
(	O
BNP	S-GP
)	O
proteins	O
were	O
up-regulated	O
and	O
nerve	B-GP
growth	I-GP
factor-beta	E-GP
(	O
NGF-beta	S-GP
)	O
down-regulated	O
in	O
the	O
banding	O
group	O
.	O
Treatment	O
with	O
valsartan	S-chemical
,	O
doxazosin	S-chemical
,	O
or	O
N-acetylcysteine	S-chemical
did	O
not	O
significantly	O
affect	O
HIF-1alpha	S-GP
and	O
VEGF	S-GP
proteins	O
expression	O
in	O
the	O
banding	O
groups	O
.	O
Real-time	O
polymerase	O
chain	O
reaction	O
showed	O
that	O
mRNA	O
of	O
HIF-1alpha	S-GP
,	O
VEGF	S-GP
and	O
BNP	S-GP
increased	O
and	O
mRNA	O
of	O
NGF-beta	S-GP
decreased	O
in	O
the	O
banding	O
group	O
.	O
Treatment	O
with	O
carvedilol	S-chemical
reversed	O
both	O
protein	O
and	O
mRNA	O
of	O
HIF-1alpha	S-GP
,	O
VEGF	S-GP
,	O
BNP	S-GP
,	O
and	O
NGF-beta	S-GP
to	O
the	O
baseline	O
values	O
.	O
Increased	O
immunohistochemical	O
labeling	O
of	O
HIF-1alpha	S-GP
,	O
VEGF	S-GP
,	O
and	O
BNP	S-GP
in	O
the	O
ventricular	O
myocardium	O
was	O
observed	O
in	O
the	O
banding	O
group	O
and	O
carvedilol	S-chemical
again	O
normalized	O
the	O
labeling	O
.	O
In	O
conclusion	O
,	O
HIF-1alpha	S-GP
,	O
VEGF	S-GP
,	O
and	O
BNP	S-GP
mRNA	O
and	O
protein	O
expression	O
were	O
up-regulated	O
,	O
while	O
NGF-beta	S-GP
mRNA	O
and	O
protein	O
was	O
downregulated	O
in	O
the	O
rat	O
model	O
of	O
pressure-overloaded	O
cardiac	O
hypertrophy	O
.	O
Treatment	O
with	O
carvedilol	S-chemical
is	O
associated	O
with	O
a	O
reversal	O
of	O
abnormal	O
regulation	O
of	O
HIF-1alpha	S-GP
,	O
VEGF	S-GP
,	O
BNP	S-GP
,	O
and	O
NGF-beta	S-GP
in	O
the	O
hypertrophic	O
myocardium	O
.	O

Use	O
of	O
tranexamic	B-chemical
acid	E-chemical
for	O
an	O
effective	O
blood	O
conservation	O
strategy	O
after	O
total	O
knee	O
arthroplasty	O
.	O
We	O
have	O
investigated	O
the	O
effect	O
of	O
treatment	O
with	O
tranexamic	B-chemical
acid	E-chemical
,	O
an	O
inhibitor	O
of	O
fibrinolysis	O
,	O
on	O
blood	O
loss	O
,	O
blood	O
transfusion	O
requirements	O
and	O
blood	O
coagulation	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
of	O
42	O
patients	O
after	O
total	O
knee	O
arthroplasty	O
.	O
Tranexamic	B-chemical
acid	E-chemical
15	O
mg	O
kg-1	O
(	O
n	O
=	O
21	O
)	O
or	O
an	O
equivalent	O
volume	O
of	O
normal	O
saline	O
(	O
n	O
=	O
21	O
)	O
was	O
given	O
30	O
min	O
before	O
surgery	O
and	O
subsequently	O
every	O
8	O
h	O
for	O
3	O
days	O
.	O
Coagulation	O
and	O
fibrinolysis	O
values	O
,	O
blood	O
loss	O
and	O
blood	O
units	O
administered	O
were	O
measured	O
before	O
administration	O
of	O
tranexamic	B-chemical
acid	E-chemical
,	O
8	O
h	O
after	O
the	O
end	O
of	O
surgery	O
and	O
at	O
24	O
and	O
72	O
h	O
after	O
operation	O
.	O
Coagulation	O
profile	O
was	O
examined	O
(	O
bleeding	O
time	O
,	O
platelet	O
count	O
,	O
prothrombin	S-GP
time	O
(	O
PT	O
)	O
,	O
activated	O
partial	O
thromboplastin	S-GP
time	O
(	O
aPTT	O
)	O
,	O
plasminogen	S-GP
,	O
beta-thromboglobulin	S-GP
and	O
fibrinogen	S-GP
)	O
.	O
Fibrinolysis	O
was	O
evaluated	O
by	O
measurement	O
of	O
concentrations	O
of	O
D-dimer	O
and	O
fibrinogen	B-GP
degradation	I-GP
products	E-GP
(	O
FDP	S-GP
)	O
.	O
Total	O
blood	O
loss	O
in	O
the	O
tranexamic	B-chemical
acid	E-chemical
group	O
was	O
678	O
(	O
SD	O
352	O
)	O
ml	O
compared	O
with	O
1419	O
(	O
607	O
)	O
ml	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
occurred	O
primarily	O
during	O
the	O
first	O
24	O
h	O
after	O
surgery	O
.	O
Thirteen	O
patients	O
received	O
1-5	O
u.	O
of	O
packed	O
red	O
blood	O
cells	O
in	O
the	O
control	O
group	O
compared	O
with	O
two	O
patients	O
in	O
the	O
tranexamic	B-chemical
acid	E-chemical
group	O
,	O
who	O
received	O
3	O
u	O
.	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Postoperative	O
packed	O
cell	O
volume	O
values	O
were	O
higher	O
in	O
the	O
tranexamic	B-chemical
acid	E-chemical
group	O
despite	O
fewer	O
blood	O
transfusions	O
.	O
Postoperative	O
concentrations	O
of	O
plasminogen	S-GP
were	O
decreased	O
significantly	O
in	O
the	O
tranexamic	B-chemical
acid	E-chemical
group	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Platelet	O
count	O
,	O
PT	O
,	O
aPTT	O
,	O
bleeding	O
time	O
,	O
beta-thromboglobulin	S-GP
,	O
fibrinogen	S-GP
and	O
FDP	S-GP
concentrations	O
did	O
not	O
differ	O
between	O
groups	O
,	O
but	O
D-dimer	O
concentrations	O
were	O
increased	O
in	O
the	O
control	O
group	O
.	O
Thromboembolic	O
complications	O
occurred	O
in	O
two	O
patients	O
in	O
the	O
control	O
group	O
compared	O
with	O
none	O
in	O
the	O
tranexamic	B-chemical
acid	E-chemical
group	O
.	O

Phosphodiesterase	B-GP
type	I-GP
5	E-GP
as	O
a	O
pharmacologic	O
target	O
in	O
erectile	O
dysfunction	O
.	O
The	O
scientific	O
rationale	O
of	O
pharmacologically	O
inhibiting	O
phosphodiesterase	B-GP
type	I-GP
5	E-GP
(	O
PDE5	S-GP
)	O
in	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
(	O
ED	O
)	O
is	O
reviewed	O
.	O
Published	O
literature	O
on	O
the	O
nitric	B-chemical
oxide	E-chemical
-	O
cyclic	B-chemical
guanosine	I-chemical
monophosphate	E-chemical
(	O
cGMP	S-chemical
)	O
pathway	O
for	O
penile	O
erection	O
and	O
on	O
PDE5	S-GP
inhibition	O
using	O
sildenafil	O
as	O
the	O
model	O
for	O
pharmacologic	O
PDE5	S-GP
inhibition	O
are	O
assessed	O
.	O
The	O
key	O
second	O
messenger	O
in	O
the	O
mediation	O
of	O
penile	O
erection	O
is	O
cGMP	O
.	O
PDE5	S-GP
is	O
the	O
predominant	O
PDE	S-GP
in	O
the	O
corpus	O
cavernosum	O
,	O
and	O
cGMP	S-chemical
is	O
its	O
primary	O
substrate	O
.	O
Therefore	O
,	O
in	O
men	O
with	O
ED	O
,	O
elevation	O
of	O
cGMP	S-chemical
in	O
corpus	O
cavernosal	O
tissue	O
via	O
selective	O
inhibition	O
of	O
cGMP	S-chemical
-specific	O
PDE5	S-GP
is	O
a	O
means	O
of	O
improving	O
erectile	O
function	O
at	O
minimal	O
risk	O
of	O
adverse	O
events	O
.	O
This	O
approach	O
is	O
validated	O
by	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
sildenafil	S-chemical
,	O
the	O
pioneering	O
drug	O
for	O
selective	O
PDE5	S-GP
inhibitor	O
therapy	O
for	O
ED	O
.	O
Sildenafil	S-chemical
exhibits	O
inhibitory	O
potency	O
against	O
PDE5	S-GP
and	O
a	O
10-fold	O
lower	O
dose-related	O
inhibitory	O
potency	O
against	O
rod	O
outer	O
segment	O
PDE6	S-GP
,	O
the	O
predominant	O
PDE	S-GP
in	O
the	O
phototransduction	O
cascade	O
in	O
rods	O
.	O
Thus	O
,	O
its	O
pharmacologic	O
profile	O
is	O
predictable	O
,	O
with	O
close	O
correlation	O
between	O
pharmacodynamic	O
and	O
pharmacokinetic	O
properties	O
.	O
Clinically	O
,	O
sildenafil	S-chemical
improves	O
erectile	O
function	O
in	O
a	O
large	O
percentage	O
of	O
men	O
with	O
ED	O
.	O
The	O
most	O
common	O
adverse	O
events	O
are	O
due	O
to	O
PDE5	S-GP
inhibition	O
in	O
vascular	O
and	O
visceral	O
smooth	O
muscle	O
;	O
similar	O
adverse	O
events	O
are	O
expected	O
during	O
therapeutic	O
use	O
of	O
all	O
PDE5	S-GP
inhibitors	O
.	O
As	O
free	O
sildenafil	S-chemical
plasma	O
concentrations	O
approach	O
concentrations	O
sufficient	O
to	O
inhibit	O
retinal	O
PDE6	S-GP
,	O
usually	O
at	O
higher	O
therapeutic	O
doses	O
,	O
transient	O
,	O
reversible	O
visual	O
adverse	O
events	O
can	O
occur	O
,	O
albeit	O
infrequently	O
.	O
Selective	O
inhibition	O
of	O
PDE5	S-GP
is	O
a	O
rational	O
therapeutic	O
approach	O
in	O
ED	O
,	O
as	O
proved	O
by	O
the	O
clinical	O
success	O
of	O
sildenafil	S-chemical
.	O

Proteomic	O
and	O
metabolomic	O
responses	O
to	O
connexin43	S-GP
silencing	O
in	O
primary	O
hepatocyte	O
cultures	O
.	O
Freshly	O
established	O
cultures	O
of	O
primary	O
hepatocytes	O
progressively	O
adopt	O
a	O
foetal-like	O
phenotype	O
and	O
display	O
increased	O
production	O
of	O
connexin43	S-GP
.	O
The	O
latter	O
is	O
a	O
multifaceted	O
cellular	O
entity	O
with	O
variable	O
subcellular	O
locations	O
,	O
including	O
the	O
mitochondrial	O
compartment	O
.	O
Cx43	S-GP
forms	O
hemichannels	S-GP
and	O
gap	O
junctions	O
that	O
are	O
involved	O
in	O
a	O
plethora	O
of	O
physiological	O
and	O
pathological	O
processes	O
,	O
such	O
as	O
apoptosis	O
.	O
The	O
present	O
study	O
was	O
conducted	O
with	O
the	O
goal	O
of	O
shedding	O
more	O
light	O
onto	O
the	O
role	O
of	O
connexin43	S-GP
in	O
primary	O
hepatocyte	O
cultures	O
.	O
Connexin43	S-GP
expression	O
was	O
suppressed	O
by	O
means	O
of	O
RNA	O
interference	O
technology	O
,	O
and	O
the	O
overall	O
outcome	O
of	O
this	O
treatment	O
on	O
the	O
hepatocellular	O
proteome	O
and	O
metabolome	O
was	O
investigated	O
using	O
tandem	O
mass	O
tag-based	O
differential	O
protein	O
profiling	O
and	O
(	B-chemical
1	I-chemical
)	I-chemical
H	E-chemical
NMR	O
spectroscopy	O
,	O
respectively	O
.	O
Global	O
protein	O
profiling	O
revealed	O
a	O
number	O
of	O
targets	O
of	O
the	O
connexin43	S-GP
knock-down	O
procedure	O
,	O
including	O
mitochondrial	O
proteins	O
(	O
heat	B-GP
shock	I-GP
protein	I-GP
60	E-GP
,	O
glucose-regulated	B-GP
protein	I-GP
75	E-GP
,	O
thiosulphate	B-GP
sulphurtransferase	E-GP
and	O
adenosine	B-GP
triphosphate	I-GP
synthase	E-GP
)	O
and	O
detoxifying	O
enzymes	O
(	O
glutathione	B-GP
S-transferase	I-GP
μ	I-GP
2	E-GP
and	O
cytochrome	B-GP
P450	I-GP
2C70	E-GP
)	O
.	O
At	O
the	O
metabolomic	O
level	O
,	O
connexin43	S-GP
silencing	O
caused	O
no	O
overt	O
changes	O
,	O
though	O
there	O
was	O
some	O
evidence	O
for	O
a	O
subtle	O
increase	O
in	O
intracellular	O
glycine	S-chemical
quantities	O
.	O
Collectively	O
,	O
these	O
data	O
could	O
further	O
substantiate	O
the	O
established	O
existence	O
of	O
a	O
mitochondrial	O
connexin	S-GP
pool	O
and	O
could	O
be	O
reconciled	O
with	O
the	O
previously	O
reported	O
involvement	O
of	O
connexin43	S-GP
signalling	O
in	O
spontaneously	O
occurring	O
apoptosis	O
in	O
primary	O
hepatocyte	O
cultures	O
.	O

GH	S-GP
improves	O
spatial	O
memory	O
and	O
reverses	O
certain	O
anabolic	O
androgenic	O
steroid-induced	O
effects	O
in	O
intact	O
rats	O
.	O
GH	S-GP
has	O
previously	O
been	O
shown	O
to	O
promote	O
cognitive	O
functions	O
in	O
GH	S-GP
-deficient	O
rodents	O
.	O
In	O
this	O
study	O
we	O
report	O
the	O
effects	O
of	O
GH	S-GP
on	O
learning	O
and	O
memory	O
in	O
intact	O
rats	O
pretreated	O
with	O
the	O
anabolic	O
androgenic	O
steroid	S-chemical
nandrolone	S-chemical
.	O
Male	O
Wistar	O
rats	O
received	O
nandrolone	B-chemical
decanoate	E-chemical
(	O
15	O
mg/kg	O
)	O
or	O
peanut	O
oil	O
every	O
third	O
day	O
for	O
3	O
weeks	O
and	O
were	O
subsequently	O
treated	O
with	O
recombinant	O
human	B-GP
GH	E-GP
(	O
1.0	O
IU/kg	O
)	O
or	O
saline	O
for	O
10	O
consecutive	O
days	O
.	O
During	O
the	O
GH	S-GP
/saline	O
treatment	O
spatial	O
learning	O
and	O
memory	O
were	O
tested	O
in	O
the	O
Morris	O
water	O
maze	O
(	O
MWM	O
)	O
.	O
Also	O
,	O
plasma	O
levels	O
of	O
IGF1	S-GP
were	O
assessed	O
and	O
the	O
gene	O
expression	O
of	O
the	O
GH	B-GP
receptors	E-GP
(	O
Ghr	S-GP
)	O
,	O
Igf1	S-GP
and	O
Igf2	S-GP
,	O
in	O
hippocampus	O
and	O
frontal	O
cortex	O
was	O
analyzed	O
.	O
The	O
results	O
demonstrated	O
a	O
significant	O
positive	O
effect	O
of	O
GH	S-GP
on	O
memory	O
functions	O
and	O
increased	O
gene	O
expression	O
of	O
Igf1	S-GP
in	O
the	O
hippocampus	O
was	O
found	O
in	O
the	O
animals	O
treated	O
with	O
GH	S-GP
.	O
In	O
addition	O
,	O
GH	S-GP
was	O
demonstrated	O
to	O
increase	O
the	O
body	O
weight	O
gain	O
and	O
was	O
able	O
to	O
attenuate	O
the	O
reduced	O
body	O
weight	O
seen	O
in	O
nandrolone	S-chemical
-treated	O
animals	O
.	O
In	O
general	O
,	O
the	O
rats	O
treated	O
with	O
nandrolone	S-chemical
alone	O
did	O
not	O
exhibit	O
any	O
pronounced	O
alteration	O
in	O
memory	O
compared	O
with	O
controls	O
in	O
the	O
MWM	O
,	O
and	O
in	O
many	O
cases	O
GH	S-GP
did	O
not	O
induce	O
any	O
alteration	O
.	O
Regarding	O
target	O
zone	O
crossings	O
,	O
considered	O
to	O
be	O
associated	O
with	O
spatial	O
memory	O
,	O
the	O
difference	O
between	O
GH	S-GP
-	O
and	O
steroid-treated	O
animals	O
was	O
significant	O
and	O
administration	O
of	O
GH	S-GP
improved	O
this	O
parameter	O
in	O
the	O
latter	O
group	O
.	O
In	O
conclusion	O
,	O
GH	S-GP
improves	O
spatial	O
memory	O
in	O
intact	O
rats	O
and	O
can	O
reverse	O
certain	O
effects	O
induced	O
by	O
anabolic	O
androgenic	O
steroid	S-chemical
.	O

Monoamine	B-GP
transporter	E-GP
and	O
sodium	B-GP
channel	E-GP
mechanisms	O
in	O
the	O
rapid	O
pressor	O
response	O
to	O
cocaine	S-chemical
.	O
Intravenous	O
(	O
I.V	O
.	O
)	O
cocaine	S-chemical
(	O
0.03-3	O
mg/kg	O
)	O
produced	O
dose-dependent	O
,	O
rapid	O
,	O
and	O
brief	O
increases	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
in	O
conscious	O
rats	O
pretreated	O
with	O
the	O
dopamine	B-GP
receptor	E-GP
antagonist	O
,	O
SCH	B-chemical
23390	E-chemical
.	O
Monoamine	S-chemical
uptake	O
inhibitors	O
structurally	O
analogous	O
to	O
cocaine	S-chemical
(	O
cocaethylene	S-chemical
,	O
CFT	S-chemical
,	O
betaCIT	S-chemical
,	O
CPT	S-chemical
,	O
(	B-chemical
+	I-chemical
)	I-chemical
-cocaine	E-chemical
,	O
norcocaine	S-chemical
,	O
and	O
benztropine	S-chemical
)	O
also	O
produced	O
this	O
rapid	O
pressor	O
response	O
,	O
whereas	O
structurally	O
unrelated	O
uptake	O
inhibitors	O
with	O
diverse	O
monoamine	B-GP
transporter	E-GP
selectivities	O
(	O
BTCP	S-chemical
,	O
indatraline	S-chemical
,	O
GBR	B-chemical
12935	E-chemical
,	O
mazindol	S-chemical
,	O
nomifensine	S-chemical
,	O
and	O
zimeldine	S-chemical
)	O
either	O
did	O
not	O
produce	O
a	O
rapid	O
pressor	O
response	O
or	O
produced	O
only	O
a	O
small	O
pressor	O
response	O
.	O
At	O
nonconvulsant	O
doses	O
,	O
the	O
sodium	B-GP
channel	E-GP
blockers	O
acetylprocainamide	S-chemical
,	O
dibucaine	S-chemical
,	O
dyclonine	S-chemical
,	O
prilocaine	S-chemical
,	O
proparacaine	S-chemical
,	O
quinidine	S-chemical
,	O
and	O
tetracaine	S-chemical
produced	O
a	O
small	O
pressor	O
response	O
or	O
no	O
increase	O
in	O
BP	O
.	O
In	O
rats	O
implanted	O
with	O
telemetric	O
devices	O
,	O
cocaine	S-chemical
and	O
its	O
analog	O
,	O
CFT	S-chemical
,	O
produced	O
a	O
biphasic	O
pharmacological	O
response	O
that	O
consisted	O
of	O
an	O
initial	O
brief	O
and	O
abrupt	O
behavioral	O
arousal	O
associated	O
with	O
a	O
rapid	O
,	O
large	O
increase	O
in	O
BP	O
followed	O
by	O
prolonged	O
,	O
parallel	O
increases	O
in	O
BP	O
and	O
locomotor	O
activity	O
.	O
Pretreatment	O
with	O
SCH	B-chemical
23390	E-chemical
prevented	O
the	O
prolonged	O
but	O
not	O
the	O
initial	O
rapid	O
and	O
brief	O
pressor	O
and	O
activity	O
responses	O
to	O
both	O
cocaine	S-chemical
and	O
CFT	S-chemical
administration	O
.	O
The	O
present	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
dopamine	B-GP
,	I-GP
norepinephrine	I-GP
,	I-GP
or	I-GP
serotonin	I-GP
transporter	E-GP
functions	O
,	O
either	O
alone	O
or	O
in	O
combination	O
,	O
does	O
not	O
mediate	O
the	O
rapid	O
pressor	O
response	O
to	O
cocaine	S-chemical
.	O
The	O
sodium	B-GP
channel	E-GP
-blocking	O
action	O
of	O
cocaine	S-chemical
per	O
se	O
does	O
not	O
appear	O
to	O
be	O
involved	O
in	O
the	O
rapid	O
pressor	O
response	O
to	O
cocaine	S-chemical
.	O
Finally	O
,	O
the	O
present	O
results	O
confirm	O
previous	O
findings	O
that	O
dopaminergic	O
mechanisms	O
mediate	O
the	O
prolonged	O
increases	O
in	O
BP	O
and	O
locomotor	O
activity	O
produced	O
by	O
cocaine	S-chemical
.	O

The	O
effects	O
of	O
the	O
phosphodiesterase	B-GP
type	I-GP
5	E-GP
inhibitor	O
vardenafil	S-chemical
on	O
cognitive	O
performance	O
in	O
healthy	O
adults	O
:	O
a	O
behavioral-	O
electroencephalography	O
study	O
.	O
Phosphodiesterase	B-GP
type	I-GP
5	E-GP
inhibitors	O
(	O
PDE5	S-GP
-Is	O
)	O
improve	O
cognitive	O
performance	O
of	O
rodents	O
,	O
but	O
the	O
few	O
human	O
studies	O
investigating	O
their	O
effects	O
did	O
not	O
systematically	O
investigate	O
cognitive	O
effects	O
and	O
the	O
results	O
have	O
been	O
quite	O
contradictory	O
.	O
Therefore	O
,	O
we	O
examined	O
whether	O
the	O
PDE5	S-GP
-I	O
vardenafil	S-chemical
improves	O
memory	O
and	O
executive	O
functioning	O
and	O
affect	O
electroencephalography	O
(	O
EEG	O
)	O
in	O
healthy	O
young	O
adults	O
.	O
Participants	O
were	O
selected	O
out	O
of	O
a	O
group	O
of	O
volunteers	O
,	O
based	O
on	O
their	O
performance	O
on	O
a	O
memory	O
screening	O
and	O
they	O
were	O
orally	O
treated	O
with	O
vardenafil	S-chemical
(	O
10-20	O
mg	O
or	O
placebo	O
)	O
.	O
Memory	O
and	O
executive	O
functioning	O
were	O
tested	O
while	O
EEG	O
activity	O
was	O
recorded	O
.	O
Additionally	O
,	O
a	O
simple	O
reaction	O
time	O
task	O
and	O
questionnaires	O
addressing	O
various	O
complaints	O
were	O
presented	O
.	O
No	O
prominent	O
effects	O
of	O
vardenafil	S-chemical
on	O
cognition	O
were	O
found	O
:	O
participants	O
only	O
made	O
more	O
mistakes	O
on	O
a	O
reaction	O
time	O
task	O
after	O
20	O
mg	O
vardenafil	S-chemical
.	O
During	O
encoding	O
of	O
words	O
,	O
the	O
P300	O
was	O
generally	O
smaller	O
after	O
vardenafil	S-chemical
treatment	O
.	O
Furthermore	O
,	O
the	O
N400	O
was	O
larger	O
after	O
vardenafil	S-chemical
10	O
mg	O
than	O
placebo	O
treatment	O
in	O
a	O
spatial	O
memory	O
task	O
at	O
Fz	O
.	O
Finally	O
,	O
headache	O
and	O
feeling	O
weak	O
were	O
reported	O
more	O
after	O
vardenafil	S-chemical
treatment	O
.	O
Vardenafil	S-chemical
did	O
not	O
affect	O
cognitive	O
performance	O
of	O
healthy	O
adults	O
and	O
showed	O
only	O
some	O
incidental	O
effects	O
on	O
ERPs	O
.	O
These	O
findings	O
in	O
humans	O
do	O
not	O
corroborate	O
the	O
cognition-enhancing	O
effects	O
of	O
PDE5	S-GP
-Is	O
in	O
healthy	O
animals	O
.	O

Microtubule	O
network	O
is	O
required	O
for	O
insulin	S-GP
-induced	O
signal	O
transduction	O
and	O
actin	S-GP
remodeling	O
.	O
Both	O
microtubule	O
and	O
actin	O
are	O
required	O
for	O
insulin	S-GP
-induced	O
glucose	S-chemical
uptake	O
.	O
However	O
,	O
the	O
roles	O
of	O
these	O
two	O
cytoskeletons	O
and	O
their	O
relationship	O
in	O
insulin	S-GP
action	O
still	O
remain	O
unclear	O
.	O
In	O
this	O
work	O
,	O
we	O
examined	O
the	O
morphological	O
change	O
of	O
microtubule/	O
actin	S-GP
and	O
their	O
involvement	O
in	O
insulin	S-GP
signal	O
transduction	O
using	O
rat	O
skeletal	O
muscle	O
cells	O
.	O
Insulin	S-GP
rapidly	O
led	O
to	O
microtubule	O
clustering	O
from	O
ventral	O
to	O
dorsal	O
surface	O
of	O
the	O
cell	O
.	O
Microtubule	O
filaments	O
were	O
rearranged	O
to	O
create	O
space	O
where	O
new	O
actin	S-GP
structures	O
formed	O
.	O
Disruption	O
of	O
microtubule	O
prevented	O
insulin	S-GP
-induced	O
actin	S-GP
remodeling	O
and	O
distal	O
insulin	S-GP
signal	O
transduction	O
,	O
with	O
reduction	O
in	O
surface	O
glucose	B-GP
transporter	I-GP
isoform	I-GP
4	E-GP
(	O
GLUT4	S-GP
)	O
and	O
glucose	S-chemical
uptake	O
.	O
Though	O
microtubule	O
mediated	O
actin	S-GP
remodeling	O
through	O
PKCζ	S-GP
,	O
reorganization	O
of	O
microtubule	O
depended	O
on	O
tyrosine	S-chemical
phosphorylation	O
of	O
insulin	B-GP
receptor	E-GP
,	O
the	O
mechanism	O
is	O
different	O
from	O
insulin	S-GP
-induced	O
actin	S-GP
remodeling	O
,	O
which	O
relied	O
on	O
the	O
activity	O
of	O
PI3-kinase	S-GP
and	O
PKCζ	S-GP
.	O
We	O
propose	O
that	O
microtubule	O
network	O
is	O
required	O
for	O
insulin	S-GP
-induced	O
signal	O
transduction	O
and	O
actin	S-GP
remodeling	O
in	O
skeletal	O
muscle	O
cells	O
.	O

Elevation	O
of	O
4-hydroxynonenal	S-chemical
and	O
malondialdehyde	S-chemical
modified	O
protein	O
levels	O
in	O
cerebral	O
cortex	O
with	O
cognitive	O
dysfunction	O
in	O
rats	O
exposed	O
to	O
1-bromopropane	S-chemical
.	O
1-Bromopropane	S-chemical
(	O
1-BP	S-chemical
)	O
,	O
an	O
alternative	O
to	O
ozone	S-chemical
-depleting	O
solvents	O
(	O
ODS	O
)	O
,	O
exhibits	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
toxicity	O
in	O
animals	O
and	O
humans	O
.	O
This	O
study	O
was	O
designed	O
to	O
relate	O
CNS	O
damage	O
by	O
Morris	O
water	O
maze	O
(	O
MWM	O
)	O
test	O
and	O
oxidative	O
stress	O
to	O
1-BP	S-chemical
exposure	O
in	O
the	O
rat	O
.	O
Male	O
Wistar	O
rats	O
were	O
randomly	O
divided	O
into	O
4	O
groups	O
(	O
n=10	O
)	O
,	O
and	O
treated	O
with	O
0	O
,	O
200	O
,	O
400	O
and	O
800mg/kgbw	O
1-BP	S-chemical
for	O
consecutive	O
12	O
days	O
,	O
respectively	O
.	O
From	O
day	O
8	O
to	O
day	O
12	O
of	O
the	O
experiment	O
,	O
MWM	O
test	O
was	O
employed	O
to	O
assess	O
the	O
cognitive	O
function	O
of	O
rats	O
.	O
The	O
cerebral	O
cortex	O
of	O
rats	O
was	O
obtained	O
immediately	O
following	O
the	O
24h	O
after	O
MWM	O
test	O
conclusion	O
.	O
Glutathione	S-chemical
(	O
GSH	S-chemical
)	O
,	O
oxidized	B-chemical
glutathione	E-chemical
(	O
GSSG	S-chemical
)	O
and	O
total	O
thiol	S-chemical
(	O
total-	O
SH	S-chemical
)	O
content	O
,	O
GSH	B-GP
reductase	E-GP
(	O
GR	S-GP
)	O
and	O
GSH	B-GP
peroxidase	E-GP
(	O
GSH-Px	S-GP
)	O
activities	O
,	O
malondialdehyde	S-chemical
(	O
MDA	S-chemical
)	O
level	O
,	O
as	O
well	O
as	O
4-hydroxynonenal	S-chemical
(	O
4-HNE	S-chemical
)	O
and	O
MDA	S-chemical
modified	O
proteins	O
in	O
homogenates	O
of	O
cerebral	O
cortex	O
were	O
measured	O
.	O
The	O
obtained	O
results	O
showed	O
that	O
1-BP	S-chemical
led	O
to	O
cognitive	O
dysfunction	O
of	O
rats	O
,	O
which	O
was	O
evidenced	O
by	O
delayed	O
escape	O
latency	O
time	O
and	O
swimming	O
distances	O
in	O
MWM	O
performance	O
.	O
GSH	S-chemical
and	O
total-	O
SH	S-chemical
content	O
,	O
GSH	S-chemical
/	O
GSSG	S-chemical
ratio	O
,	O
GR	S-GP
activity	O
significantly	O
decreased	O
in	O
cerebral	O
cortex	O
of	O
rats	O
,	O
coupling	O
with	O
the	O
increase	O
of	O
MDA	S-chemical
level	O
.	O
4-HNE	S-chemical
and	O
MDA	S-chemical
modified	O
protein	O
levels	O
obviously	O
elevated	O
after	O
1-BP	S-chemical
exposure	O
.	O
GSH-Px	S-GP
activities	O
in	O
cerebral	O
cortex	O
of	O
rats	O
also	O
increased	O
.	O
These	O
data	O
suggested	O
that	O
1-BP	S-chemical
resulted	O
in	O
enhanced	O
lipid	O
peroxidation	O
of	O
brain	O
,	O
which	O
might	O
play	O
an	O
important	O
role	O
in	O
CNS	O
damage	O
induced	O
by	O
1-BP	S-chemical
.	O

The	O
Hsp90	S-GP
-specific	O
inhibitor	O
geldanamycin	S-chemical
selectively	O
disrupts	O
kinase	S-GP
-mediated	O
signaling	O
events	O
of	O
T-lymphocyte	O
activation	O
.	O
The	O
90-kDa	B-GP
heat	I-GP
shock	I-GP
protein	E-GP
(	O
Hsp90	S-GP
)	O
is	O
the	O
most	O
abundant	O
molecular	B-GP
chaperone	E-GP
of	O
eukaryotic	O
cells	O
.	O
Its	O
chaperone	O
function	O
in	O
folding	O
nascent	O
proteins	O
seems	O
to	O
be	O
restricted	O
to	O
a	O
subset	O
of	O
proteins	O
including	O
major	O
components	O
of	O
signal	O
transduction	O
pathways	O
(	O
eg	O
,	O
nuclear	B-GP
hormone	I-GP
receptors	E-GP
,	O
transcription	O
factors	O
,	O
and	O
protein	B-GP
kinases	E-GP
)	O
.	O
Improper	O
function	O
of	O
these	O
proteins	O
can	O
be	O
induced	O
by	O
selective	O
disruption	O
of	O
their	O
complexes	O
with	O
Hsp90	S-GP
using	O
the	O
benzoquinonoid	B-chemical
ansamycin	E-chemical
geldanamycin	S-chemical
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
geldanamycin	S-chemical
treatment	O
blocks	O
interleukin	B-GP
(	I-GP
IL	I-GP
)	I-GP
-2	E-GP
secretion	O
,	O
IL-2	B-GP
receptor	E-GP
expression	O
,	O
and	O
proliferation	O
of	O
stimulated	O
T-lymphocytes	O
.	O
Moreover	O
,	O
geldanamycin	S-chemical
decreases	O
the	O
amount	O
and	O
phosphorylation	O
of	O
Lck	S-GP
and	O
Raf-1	S-GP
kinases	S-GP
and	O
prevents	O
activation	O
of	O
the	O
extracellular	B-GP
signal	I-GP
regulated	I-GP
kinase	I-GP
(	I-GP
ERK	I-GP
)	I-GP
-2	E-GP
kinase	S-GP
.	O
Geldanamycin	S-chemical
also	O
disrupts	O
the	O
T-cell	B-GP
receptor	E-GP
-mediated	O
activation	O
of	O
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T-cells	E-GP
(	O
NF-AT	S-GP
)	O
.	O
Treatment	O
with	O
geldanamycin	S-chemical
,	O
however	O
,	O
does	O
not	O
affect	O
the	O
activation	O
of	O
lysophosphatide	B-GP
acyltransferase	E-GP
,	O
which	O
is	O
a	O
plasma	O
membrane	O
enzyme	O
coupled	O
to	O
the	O
T-cell	B-GP
receptor	E-GP
after	O
T-cell	O
stimulation	O
.	O
Through	O
demonstrating	O
the	O
selective	O
inhibition	O
of	O
kinase	S-GP
-related	O
T-lymphocyte	O
responses	O
by	O
geldanamycin	S-chemical
,	O
our	O
results	O
emphasize	O
the	O
substantial	O
role	O
of	O
Hsp90	S-GP
-	O
kinase	S-GP
complexes	O
in	O
T-cell	O
activation	O
.	O

Preclinical	O
and	O
clinical	O
development	O
of	O
the	O
oral	O
multikinase	O
inhibitor	O
sorafenib	S-chemical
in	O
cancer	O
treatment	O
.	O
Tumor	O
survival	O
,	O
growth	O
and	O
metastasis	O
depend	O
on	O
efficient	O
tumor	O
cell	O
proliferation	O
and	O
tumor	O
angiogenesis	O
,	O
and	O
targeting	O
both	O
of	O
these	O
processes	O
simultaneously	O
could	O
prove	O
to	O
be	O
therapeutically	O
relevant	O
.	O
The	O
RAS	S-GP
/	O
RAF	S-GP
signaling	O
pathway	O
is	O
an	O
important	O
mediator	O
of	O
tumor	O
cell	O
proliferation	O
,	O
and	O
angiogenesis	O
and	O
is	O
often	O
aberrantly	O
activated	O
in	O
human	O
tumors	O
due	O
to	O
the	O
presence	O
of	O
activated	O
Ras	S-GP
or	O
mutant	O
B-Raf	S-GP
,	O
or	O
elevation	O
of	O
growth	B-GP
factor	I-GP
receptors	E-GP
.	O
Sorafenib	S-chemical
,	O
which	O
belongs	O
chemically	O
to	O
a	O
class	O
that	O
can	O
be	O
described	O
as	O
bis-aryl	B-chemical
ureas	E-chemical
,	O
was	O
selected	O
for	O
further	O
pharmacologic	O
characterization	O
based	O
on	O
potent	O
inhibition	O
of	O
Raf-1	S-GP
and	O
its	O
favorable	O
kinase	S-GP
selectivity	O
profile	O
.	O
Further	O
characterization	O
showed	O
that	O
sorafenib	S-chemical
suppresses	O
both	O
wild-type	O
and	O
V599E	S-GP
mutant	O
B-Raf	S-GP
activity	O
in	O
vitro	O
.	O
In	O
addition	O
,	O
sorafenib	S-chemical
demonstrated	O
significant	O
activity	O
against	O
several	O
receptor	B-GP
tyrosine	I-GP
kinases	E-GP
involved	O
in	O
neovascularization	O
and	O
tumor	O
progression	O
,	O
including	O
vascular-endothelial	B-GP
growth	I-GP
factor	I-GP
(	I-GP
VEGFR	I-GP
)	I-GP
-2	E-GP
,	O
VEGFR-3	S-GP
,	O
platelet-derived	B-GP
growth	I-GP
factor	I-GP
(	I-GP
PDGFR	I-GP
)	I-GP
-beta	E-GP
Flt-3	S-GP
,	O
and	O
c-KIT	S-GP
.	O
Preclinically	O
,	O
sorafenib	S-chemical
showed	O
broad-spectrum	O
antitumor	O
activity	O
in	O
colon	O
,	O
breast	O
and	O
non-small-cell	O
lung	O
cancer	O
xenograft	O
models	O
.	O
A	O
total	O
of	O
four	O
phase	O
I	O
studies	O
using	O
oral	O
sorafenib	S-chemical
as	O
a	O
single	O
agent	O
have	O
been	O
completed	O
,	O
and	O
the	O
compound	O
showed	O
a	O
favorable	O
safety	O
profile	O
with	O
mild	O
to	O
moderate	O
diarrhea	O
being	O
the	O
most	O
common	O
treatment-related	O
adverse	O
event	O
.	O
The	O
maximum	O
tolerated	O
dose	O
was	O
400	O
mg	O
b.i.d	O
.	O
continuous	O
.	O
Single-agent	O
phase	O
II	O
trials	O
reported	O
so	O
far	O
demonstrated	O
antitumor	O
activity	O
of	O
sorafenib	S-chemical
in	O
patients	O
with	O
hepatocellular	O
carcinoma	O
,	O
sarcoma	O
and	O
renal	O
cell	O
cancer	O
(	O
RCC	O
)	O
.	O
Based	O
on	O
phase	O
II	O
results	O
in	O
RCC	O
patients	O
,	O
a	O
placebo-controlled	O
phase	O
III	O
study	O
was	O
performed	O
,	O
which	O
randomized	O
a	O
total	O
of	O
905	O
patients	O
,	O
most	O
of	O
whom	O
were	O
treated	O
previously	O
.	O
The	O
partial	O
response	O
rate	O
was	O
2	O
%	O
for	O
sorafenib	S-chemical
and	O
0	O
%	O
for	O
placebo	O
.	O
Stable	O
disease	O
was	O
observed	O
in	O
78	O
%	O
and	O
55	O
%	O
of	O
patients	O
on	O
sorafenib	S-chemical
and	O
placebo	O
,	O
respectively	O
.	O
Sorafenib	S-chemical
significantly	O
prolonged	O
median	O
progression-free	O
survival	O
(	O
24	O
weeks	O
)	O
compared	O
with	O
placebo	O
(	O
12	O
weeks	O
)	O
in	O
all	O
subsets	O
of	O
patients	O
evaluated	O
.	O
Approval	O
of	O
sorafenib	S-chemical
by	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
for	O
this	O
indication	O
is	O
pending	O
.	O
A	O
first-line	O
phase	O
III	O
study	O
in	O
RCC	O
as	O
well	O
as	O
phase	O
III	O
studies	O
in	O
hepatocellular	O
carcinoma	O
and	O
metastatic	O
melanoma	O
have	O
been	O
initiated	O
.	O

Peroxisome	B-GP
proliferator-activated	I-GP
receptor	E-GP
subtype-specific	O
regulation	O
of	O
hepatic	O
and	O
peripheral	O
gene	O
expression	O
in	O
the	O
Zucker	O
diabetic	O
fatty	O
rat	O
.	O
Fibrates	S-chemical
and	O
thiazolidinediones	S-chemical
are	O
used	O
clinically	O
to	O
treat	O
hypertriglyceridemia	O
and	O
hyperglycemia	O
,	O
respectively	O
.	O
Fibrates	S-chemical
bind	O
to	O
the	O
peroxisome	B-GP
proliferator-activated	I-GP
receptor	I-GP
(	I-GP
PPAR	I-GP
)	I-GP
-alpha	E-GP
,	O
and	O
thiazolidinediones	S-chemical
are	O
ligands	O
of	O
PPAR-gamma	S-GP
.	O
These	O
intracellular	O
receptors	O
form	O
heterodimers	O
with	O
retinoid	B-GP
X	I-GP
receptor	E-GP
to	O
modulate	O
gene	O
transcription	O
.	O
To	O
elucidate	O
the	O
target	O
genes	O
regulated	O
by	O
these	O
compounds	O
,	O
we	O
treated	O
Zucker	O
diabetic	O
fatty	O
rats	O
(	O
ZDF	O
)	O
for	O
15	O
days	O
with	O
a	O
PPAR-alpha	S-GP
-specific	O
compound	O
,	O
fenofibrate	S-chemical
,	O
a	O
PPAR-gamma	S-GP
-specific	O
ligand	O
,	O
rosiglitazone	S-chemical
,	O
and	O
a	O
PPAR-alpha/-gamma	S-GP
coagonist	O
,	O
GW2331	S-chemical
,	O
and	O
measured	O
the	O
levels	O
of	O
several	O
messenger	O
RNAs	O
(	O
mRNAs	O
)	O
in	O
liver	O
by	O
real-time	O
polymerase	O
chain	O
reaction	O
.	O
All	O
3	O
compounds	O
decreased	O
serum	O
glucose	S-chemical
and	O
triglyceride	S-chemical
levels	O
.	O
Fenofibrate	S-chemical
and	O
GW2331	S-chemical
induced	O
expression	O
of	O
acyl-coenzyme	B-GP
A	I-GP
(	I-GP
CoA	I-GP
)	I-GP
oxidase	E-GP
and	O
enoyl-CoA	B-GP
hydratase	E-GP
and	O
reduced	O
apolipoprotein	B-GP
C-III	E-GP
and	O
phosphoenolpyruvate	B-GP
carboxykinase	E-GP
mRNAs	O
.	O
Rosiglitazone	S-chemical
modestly	O
increased	O
apolipoprotein	B-GP
C-III	E-GP
mRNA	O
and	O
had	O
no	O
effect	O
on	O
expression	O
of	O
the	O
other	O
2	O
genes	O
in	O
the	O
liver	O
but	O
increased	O
the	O
expression	O
of	O
glucose	B-GP
transporter	I-GP
4	E-GP
and	O
phosphoenolpyruvate	B-GP
carboxykinase	E-GP
in	O
adipose	O
tissue	O
.	O
We	O
identified	O
a	O
novel	O
target	O
in	O
liver	O
,	O
mitogen-activated	B-GP
phosphokinase	I-GP
phosphatase	I-GP
1	E-GP
,	O
whose	O
down-regulation	O
by	O
PPAR-alpha	S-GP
agonists	O
may	O
improve	O
insulin	S-GP
sensitivity	O
in	O
that	O
tissue	O
by	O
prolonging	O
insulin	S-GP
responses	O
.	O
The	O
results	O
of	O
these	O
studies	O
suggest	O
that	O
activation	O
of	O
PPAR-alpha	S-GP
as	O
well	O
as	O
PPAR-gamma	S-GP
in	O
therapy	O
for	O
type	O
2	O
diabetes	O
will	O
enhance	O
glucose	S-chemical
and	O
triglyceride	S-chemical
control	O
by	O
combining	O
actions	O
in	O
hepatic	O
and	O
peripheral	O
tissues	O
.	O

Synaptotagmin	B-GP
1	E-GP
is	O
required	O
for	O
vesicular	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
/	O
H	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-antiport	O
activity	O
.	O
A	O
low-affinity	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
/	O
H	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-antiport	O
was	O
described	O
in	O
the	O
membrane	O
of	O
mammalian	O
brain	O
synaptic	O
vesicles	O
.	O
Electrophysiological	O
studies	O
showed	O
that	O
this	O
antiport	O
contributes	O
to	O
the	O
extreme	O
brevity	O
of	O
excitation-release	O
coupling	O
in	O
rapid	O
synapses	O
.	O
Synaptotagmin-1	S-GP
,	O
a	O
vesicular	O
protein	O
interacting	O
with	O
membranes	O
upon	O
low-affinity	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
-binding	O
,	O
plays	O
a	O
major	O
role	O
in	O
excitation-release	O
coupling	O
,	O
by	O
synchronizing	O
calcium	S-chemical
entry	O
with	O
fast	O
neurotransmitter	O
release	O
.	O
Here	O
,	O
we	O
report	O
that	O
synaptotagmin-1	S-GP
is	O
necessary	O
for	O
expression	O
of	O
the	O
vesicular	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
/	O
H	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-antiport	O
.	O
We	O
measured	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
/	O
H	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-antiport	O
activity	O
in	O
vesicles	O
and	O
granules	O
of	O
pheochromocytoma	O
PC12	O
cells	O
by	O
three	O
methods	O
:	O
(	O
1	O
)	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
-induced	O
dissipation	O
of	O
the	O
vesicular	O
H	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-gradient	O
;	O
(	O
2	O
)	O
bafilomycin	S-chemical
-sensitive	O
calcium	S-chemical
accumulation	O
and	O
(	O
3	O
)	O
pH-jump-induced	O
calcium	S-chemical
accumulation	O
.	O
The	O
results	O
were	O
congruent	O
and	O
highly	O
significant	O
:	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
/	O
H	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-antiport	O
activity	O
is	O
detectable	O
only	O
in	O
acidic	O
organelles	O
expressing	O
functional	O
synaptotagmin-1	S-GP
.	O
In	O
contrast	O
,	O
synaptotagmin-1	S-GP
-deficient	O
cells	O
-	O
and	O
cells	O
where	O
transgenically	O
encoded	O
synaptotagmin-1	S-GP
was	O
acutely	O
photo-inactivated	O
-	O
were	O
devoid	O
of	O
any	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
/	O
H	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-antiport	O
activity	O
.	O
Therefore	O
,	O
in	O
addition	O
to	O
its	O
previously	O
described	O
functions	O
,	O
synaptotagmin-1	S-GP
is	O
involved	O
in	O
a	O
rapid	O
vesicular	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
sequestration	O
through	O
a	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
/	O
H	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
antiport	O
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O

Allosteric	O
interaction	O
of	O
the	O
neuromuscular	O
blockers	O
vecuronium	S-chemical
and	O
pancuronium	S-chemical
with	O
recombinant	O
human	B-GP
muscarinic	I-GP
M2	I-GP
receptors	E-GP
.	O
Neuromuscular	O
blocking	O
drugs	O
produce	O
muscle	O
weakness	O
by	O
interaction	O
with	O
nicotinic-acetylcholine	B-GP
receptors	E-GP
.	O
Cardiovascular	O
side	O
effects	O
have	O
been	O
reported	O
.	O
In	O
this	O
study	O
the	O
neuromuscular	O
blocking	O
drug	O
vecuronium	S-chemical
and	O
the	O
controls	O
gallamine	S-chemical
and	O
pancuronium	S-chemical
slowed	O
the	O
rate	O
of	O
atropine	S-chemical
induced	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
N-methylscopolamine	E-chemical
dissociation	O
from	O
Chinese	O
hamster	O
ovary	O
cells	O
expressing	O
recombinant	O
human	B-GP
muscarinic	I-GP
M2	I-GP
receptors	E-GP
K	O
(	O
off	O
)	O
values	O
min	O
(	O
-1	O
)	O
;	O
vecuronium	S-chemical
(	O
125	O
nM	O
)	O
,	O
atropine	S-chemical
0.45+/-0.07+blocker	O
0.04+/-0.02	O
;	O
gallamine	S-chemical
(	O
21	O
nM	O
)	O
,	O
atropine	S-chemical
0.42+/-0.05+blocker	O
0.15+/-0.04	O
;	O
pancuronium	S-chemical
(	O
21	O
nM	O
)	O
,	O
atropine	S-chemical
0.36+/-0.03+blocker	O
0.03+/-0.01	O
)	O
.	O
These	O
data	O
indicate	O
that	O
vecuronium	S-chemical
,	O
gallamine	S-chemical
and	O
pancuronium	S-chemical
interact	O
with	O
an	O
allosteric	O
site	O
on	O
the	O
muscarinic	B-GP
M2	I-GP
receptor	E-GP
(	O
located	O
on	O
the	O
heart	O
)	O
and	O
this	O
may	O
explain	O
some	O
of	O
their	O
cardiac	O
side	O
effects	O
.	O

Drug-drug	O
interactions	O
between	O
HMG-CoA	S-chemical
reductase	O
inhibitors	O
(	O
statins	O
)	O
and	O
antiviral	O
protease	O
inhibitors	O
.	O
The	O
HMG-CoA	B-GP
reductase	E-GP
inhibitors	O
are	O
a	O
class	O
of	O
drugs	O
also	O
known	O
as	O
statins	O
.	O
These	O
drugs	O
are	O
effective	O
and	O
widely	O
prescribed	O
for	O
the	O
treatment	O
of	O
hypercholesterolemia	O
and	O
prevention	O
of	O
cardiovascular	O
morbidity	O
and	O
mortality	O
.	O
Seven	O
statins	O
are	O
currently	O
available	O
:	O
atorvastatin	O
,	O
fluvastatin	O
,	O
lovastatin	O
,	O
pitavastatin	O
,	O
pravastatin	O
,	O
rosuvastatin	O
and	O
simvastatin	O
.	O
Although	O
these	O
drugs	O
are	O
generally	O
well	O
tolerated	O
,	O
skeletal	O
muscle	O
abnormalities	O
from	O
myalgia	O
to	O
severe	O
lethal	O
rhabdomyolysis	O
can	O
occur	O
.	O
Factors	O
that	O
increase	O
statin	O
concentrations	O
such	O
as	O
drug-drug	O
interactions	O
can	O
increase	O
the	O
risk	O
of	O
these	O
adverse	O
events	O
.	O
Drug-drug	O
interactions	O
are	O
dependent	O
on	O
statins	O
'	O
pharmacokinetic	O
profile	O
:	O
simvastatin	O
,	O
lovastatin	O
and	O
atorvastatin	O
are	O
metabolized	O
through	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
3A	O
,	O
while	O
the	O
metabolism	O
of	O
the	O
other	O
statins	O
is	O
independent	O
of	O
this	O
CYP	O
.	O
All	O
statins	O
are	O
substrate	O
of	O
organic	O
anion	O
transporter	O
polypeptide	O
1B1	O
,	O
an	O
uptake	O
transporter	O
expressed	O
in	O
hepatocyte	O
membrane	O
that	O
may	O
also	O
explain	O
some	O
drug-drug	O
interactions	O
.	O
Many	O
HIV-infected	O
patients	O
have	O
dyslipidemia	O
and	O
comorbidities	O
that	O
may	O
require	O
statin	O
treatment	O
.	O
HIV-	O
protease	S-GP

Genetic	O
correlate	O
of	O
cognitive	O
training	O
response	O
in	O
schizophrenia	O
.	O
Intensive	O
computerized	O
auditory	O
training	O
results	O
in	O
improved	O
cognition	O
for	O
schizophrenia	O
patients	O
,	O
but	O
participants	O
show	O
variation	O
in	O
their	O
cognitive	O
gains	O
and	O
the	O
biological	O
factors	O
that	O
affect	O
the	O
response	O
to	O
training	O
are	O
unknown	O
.	O
Single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
catechol-O-methyltransferase	S-GP
(	O
COMT	S-GP
)	O
gene	O
have	O
been	O
related	O
to	O
cognitive	O
function	O
.	O
Here	O
we	O
asked	O
if	O
functional	O
variation	O
in	O
this	O
gene	O
has	O
an	O
impact	O
on	O
the	O
response	O
of	O
schizophrenia	O
patients	O
to	O
cognitive	O
training	O
.	O
We	O
genotyped	O
48	O
schizophrenia	O
patients	O
who	O
completed	O
50	O
h	O
of	O
computerized	O
cognitive	O
training	O
and	O
analyzed	O
the	O
association	O
between	O
DNA	O
variants	O
in	O
the	O
COMT	S-GP
gene	O
and	O
the	O
improvement	O
in	O
global	O
cognition	O
.	O
Although	O
conventional	O
analyses	O
did	O
not	O
reveal	O
any	O
significant	O
associations	O
,	O
a	O
set-based	O
analysis	O
examining	O
the	O
aggregate	O
effect	O
of	O
common	O
variation	O
in	O
the	O
COMT	S-GP
gene	O
(	O
42	O
SNPs	O
)	O
suggested	O
association	O
with	O
improvement	O
in	O
global	O
cognition	O
.	O
Eight	O
SNPs	O
,	O
mostly	O
located	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
COMT	S-GP
gene	O
,	O
were	O
nominally	O
associated	O
with	O
improvement	O
in	O
cognition	O
.	O
These	O
data	O
suggest	O
that	O
genotype	O
influences	O
the	O
response	O
to	O
intensive	O
cognitive	O
training	O
in	O
schizophrenia	O
,	O
and	O
may	O
indicate	O
that	O
cognitive	O
training	O
regimens	O
need	O
to	O
be	O
personalized	O
to	O
the	O
underlying	O
biosignatures	O
of	O
each	O
individual	O
patient	O
.	O
This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'Cognitive	O
Enhancers	O
'	O
.	O

Study	O
of	O
endothelial	O
cell	O
apoptosis	O
using	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
biosensor	O
cell	O
line	O
with	O
hemodynamic	O
microfluidic	O
chip	O
system	O
.	O
To	O
better	O
understand	O
how	O
hyperglycemia	O
induces	O
endothelial	O
cell	O
dysfunction	O
under	O
the	O
diabetic	O
conditions	O
,	O
a	O
hemodynamic	O
microfluidic	O
chip	O
system	O
was	O
developed	O
.	O
The	O
system	O
combines	O
a	O
caspase-3	S-GP
-based	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
biosensor	O
cell	O
line	O
which	O
can	O
detect	O
endothelial	O
cell	O
apoptosis	O
in	O
real-time	O
,	O
post-treatment	O
effect	O
and	O
with	O
a	O
limited	O
cell	O
sample	O
,	O
by	O
using	O
a	O
microfluidic	O
chip	O
which	O
can	O
mimic	O
the	O
physiological	O
pulsatile	O
flow	O
profile	O
in	O
the	O
blood	O
vessel	O
.	O
The	O
caspase-3	S-GP
-based	O
FRET	O
biosensor	O
endothelial	O
cell	O
line	O
(	O
HUVEC-C3	O
)	O
can	O
produce	O
a	O
FRET-based	O
sensor	O
protein	O
capable	O
of	O
probing	O
caspase-3	S-GP
activation	O
.	O
When	O
the	O
endothelial	O
cells	O
undergo	O
apoptosis	O
,	O
the	O
color	O
of	O
the	O
sensor	O
cells	O
changes	O
from	O
green	O
to	O
blue	O
,	O
thus	O
sensing	O
apoptosis	O
.	O
A	O
double-labeling	O
fluorescent	O
technique	O
(	O
yo	B-chemical
pro-1	E-chemical
and	O
propidium	B-chemical
iodide	E-chemical
)	O
was	O
used	O
to	O
validate	O
the	O
findings	O
revealed	O
by	O
the	O
FRET-based	O
caspase	S-GP
sensor	O
.	O
The	O
results	O
show	O
high	O
rates	O
of	O
apoptosis	O
and	O
necrosis	O
of	O
endothelial	O
cells	O
when	O
high	O
glucose	S-chemical
concentration	O
was	O
applied	O
in	O
our	O
hemodynamic	O
microfluidic	O
chip	O
combined	O
with	O
an	O
exhaustive	O
pulsatile	O
flow	O
profile	O
.	O
The	O
two	O
apoptosis	O
detection	O
techniques	O
(	O
fluorescent	O
method	O
and	O
FRET	O
biosensor	O
)	O
are	O
comparable	O
;	O
but	O
FRET	O
biosensor	O
offers	O
more	O
advantages	O
such	O
as	O
real-time	O
observation	O
and	O
a	O
convenient	O
operating	O
process	O
to	O
generate	O
more	O
accurate	O
and	O
reliable	O
data	O
.	O
Furthermore	O
,	O
the	O
activation	O
of	O
the	O
FRET	O
biosensor	O
also	O
confirms	O
the	O
endothelial	O
cell	O
apoptosis	O
induced	O
by	O
the	O
abnormal	O
pulsatile	O
shear	O
stress	O
and	O
high	O
glucose	S-chemical
concentration	O
is	O
through	O
caspase-3	S-GP
pathway	O
.	O
A	O
12	O
%	O
apoptotic	O
rate	O
(	O
nearly	O
a	O
4-fold	O
increase	O
compared	O
to	O
the	O
static	O
condition	O
)	O
was	O
observed	O
when	O
the	O
endothelial	O
cells	O
were	O
exposed	O
to	O
a	O
high	O
glucose	S-chemical
concentration	O
of	O
20	O
mM	O
under	O
2	O
h	O
exhaustive	O
pulsatile	O
shear	O
stress	O
of	O
30	O
dyne	O
cm	O
(	O
-2	O
)	O
and	O
followed	O
with	O
another	O
10	O
h	O
normal	O
pulsatile	O
shear	O
stress	O
of	O
15	O
dyne	O
cm	O
(	O
-2	O
)	O
.	O
Therefore	O
,	O
the	O
most	O
important	O
finding	O
of	O
this	O
study	O
is	O
to	O
develop	O
a	O
novel	O
endothelial	O
cell	O
apoptosis	O
detection	O
method	O
,	O
which	O
combines	O
the	O
microfluidic	O
chip	O
system	O
and	O
FRET	O
biosensor	O
.	O
This	O
finding	O
may	O
provide	O
new	O
insight	O
into	O
how	O
glucose	S-chemical
causes	O
endothelial	O
cell	O
dysfunction	O
,	O
which	O
is	O
the	O
major	O
cause	O
of	O
diabetes-derived	O
complications	O
.	O

Oestrogen	S-chemical
action	O
on	O
thyroid	O
progenitor	O
cells	O
:	O
relevant	O
for	O
the	O
pathogenesis	O
of	O
thyroid	O
nodules	O
?	O
Benign	O
and	O
malignant	O
thyroid	O
nodules	O
are	O
more	O
prevalent	O
in	O
females	O
than	O
in	O
men	O
.	O
Experimental	O
data	O
suggest	O
that	O
the	O
proliferative	O
effect	O
of	O
oestrogen	S-chemical
rather	O
than	O
polymorphisms	O
is	O
responsible	O
for	O
this	O
gender	O
difference	O
.	O
This	O
study	O
analysed	O
whether	O
both	O
differentiated	O
thyroid	O
cells	O
and	O
thyroid	O
stem	O
and	O
progenitor	O
cells	O
are	O
a	O
target	O
of	O
oestrogen	S-chemical
action	O
.	O
In	O
thyroid	O
stem/progenitor	O
cells	O
derived	O
from	O
nodular	O
goitres	O
the	O
ability	O
of	O
17beta-oestradiol	S-chemical
to	O
induce	O
thyrosphere	O
formation	O
,	O
the	O
expression	O
of	O
oestrogen	B-GP
receptors	E-GP
and	O
the	O
effect	O
of	O
17beta-oestradiol	S-chemical
on	O
growth	O
,	O
expression	O
of	O
marker	O
of	O
stem	O
cells	O
and	O
thyroid	O
differentiation	O
(	O
TSH	B-GP
receptor	E-GP
,	O
thyroperoxidase	S-GP
,	O
thyroglobulin	S-GP
,	O
sodium	B-GP
iodide	I-GP
symporter	E-GP
expression	O
)	O
were	O
analysed	O
.	O
17beta-oestradiol	S-chemical
induced	O
thyrosphere	O
formation	O
,	O
albeit	O
to	O
lower	O
extent	O
than	O
other	O
growth	O
factors	O
.	O
Thyroid	O
stem	O
and	O
progenitor	O
cells	O
expressed	O
oestrogen	B-GP
receptor	I-GP
alpha	I-GP
and	I-GP
beta	E-GP
with	O
an	O
8	O
time	O
higher	O
expression	O
level	O
of	O
oestrogen	B-GP
receptor	I-GP
alpha	E-GP
mRNA	O
compared	O
to	O
differentiated	O
thyrocytes	O
.	O
17beta-oestradiol	S-chemical
was	O
a	O
potent	O
stimulator	O
of	O
thyroid	O
stem/	O
progenitor	O
cell	O
growth	O
.	O
In	O
contrast	O
,	O
TSH-induced	O
differentiation	O
of	O
progenitor	O
cells	O
,	O
in	O
particular	O
the	O
expression	O
of	O
the	O
sodium	B-GP
iodide	I-GP
symporter	E-GP
,	O
was	O
significantly	O
inhibited	O
by	O
17beta-oestradiol	S-chemical
.In	O
conclusion	O
,	O
oestrogen	S-chemical
stimulated	O
growth	O
and	O
simultaneously	O
inhibited	O
differentiation	O
of	O
thyroid	O
nodules	O
derived	O
stem/progenitor	O
cells	O
.	O
From	O
these	O
data	O
and	O
based	O
on	O
the	O
concept	O
of	O
cellular	O
heterogeneity	O
,	O
we	O
hypothesize	O
a	O
supportive	O
role	O
of	O
oestrogen	S-chemical
in	O
the	O
propagation	O
of	O
thyroid	O
stem/progenitor	O
cells	O
leading	O
to	O
a	O
selection	O
of	O
a	O
progeny	O
of	O
growth-prone	O
cells	O
with	O
a	O
decreased	O
differentiation	O
.	O
These	O
cells	O
may	O
be	O
the	O
origin	O
of	O
hypo-	O
or	O
non-functioning	O
thyroid	O
nodules	O
in	O
females	O
.	O

Sorafenib	S-chemical
:	O
recent	O
update	O
on	O
activity	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
interferon-alpha2	S-GP
in	O
patients	O
with	O
advanced-stage	O
renal	O
cell	O
carcinoma	O
.	O
Metastatic	O
renal	O
cell	O
carcinoma	O
does	O
not	O
respond	O
favorably	O
to	O
conventional	O
treatment	O
strategies	O
and	O
is	O
not	O
very	O
responsive	O
to	O
cytokine	O
therapy	O
.	O
Therefore	O
,	O
novel	O
targeted	O
treatment	O
approaches	O
have	O
been	O
explored	O
for	O
patients	O
with	O
renal	O
cancer	O
who	O
have	O
chemotherapy-refractory	O
disease	O
.	O
Sorafenib	S-chemical
(	O
BAY	B-chemical
43-9006	E-chemical
)	O
is	O
a	O
small-molecule	O
inhibitor	O
that	O
has	O
been	O
shown	O
to	O
target	O
members	O
of	O
multiple	O
classes	O
of	O
tyrosine	B-GP
kinases	E-GP
that	O
are	O
known	O
to	O
be	O
involved	O
in	O
tumor	O
cell	O
proliferation	O
and	O
tumor	O
angiogenesis	O
.	O
These	O
kinases	S-GP
include	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	I-GP
receptor	I-GP
(	I-GP
VEGFR	I-GP
)	I-GP
-1	E-GP
,	O
VEGFR-2	S-GP
,	O
VEGFR-3	S-GP
,	O
platelet-derived	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
,	O
Flt-3	S-GP
,	O
c-kit	S-GP
,	O
and	O
Raf	S-GP
kinases	S-GP
.	O
Based	O
on	O
the	O
significant	O
improvement	O
in	O
progression-free	O
survival	O
,	O
sorafenib	S-chemical
received	O
Food	O
and	O
Drug	O
Administration	O
approval	O
in	O
December	O
2005	O
for	O
the	O
treatment	O
of	O
renal	O
cell	O
carcinoma	O
.	O
In	O
combination	O
studies	O
,	O
sorafenib	S-chemical
with	O
other	O
antitumor	O
agents	O
has	O
demonstrated	O
significant	O
clinical	O
activity	O
in	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
.	O
As	O
discussed	O
in	O
this	O
mini-review	O
,	O
the	O
clinical	O
potency	O
of	O
sorafenib	S-chemical
as	O
a	O
single	O
agent	O
or	O
in	O
combination	O
with	O
other	O
antitumor	O
agents	O
is	O
being	O
evaluated	O
in	O
several	O
ongoing	O
clinical	O
trials	O
in	O
patients	O
with	O
renal	O
carcinoma	O
.	O

DRD2	B-GP
promoter	E-GP
region	O
variation	O
as	O
a	O
predictor	O
of	O
sustained	O
response	O
to	O
antipsychotic	O
medication	O
in	O
first-episode	O
schizophrenia	O
patients	O
.	O
OBJECTIVE	O
:	O
All	O
antipsychotics	O
act	O
on	O
the	O
dopamine	B-GP
D	I-GP
(	I-GP
2	I-GP
)	I-GP
receptor	E-GP
.	O
The	O
present	O
study	O
extends	O
prior	O
pharmacogenetic	O
investigations	O
of	O
the	O
D	B-GP
(	I-GP
2	I-GP
)	I-GP
receptor	E-GP
gene	O
(	O
DRD2	S-GP
)	O
by	O
examining	O
,	O
in	O
first-episode	O
schizophrenia	O
patients	O
,	O
promoter	O
region	O
variation	O
as	O
a	O
predictor	O
of	O
response	O
time	O
to	O
two	O
first-line	O
atypical	O
antipsychotics	O
.	O
METHOD	O
:	O
Patients	O
experiencing	O
their	O
first	O
episode	O
of	O
schizophrenia	O
(	O
N=61	O
)	O
were	O
genotyped	O
for	O
two	O
DRD2	B-GP
promoter	E-GP
region	O
polymorphisms	O
(	O
A-241G	S-GP
and	O
-141C	O
Ins/Del	O
)	O
and	O
were	O
randomly	O
assigned	O
to	O
receive	O
16	O
weeks	O
of	O
treatment	O
with	O
either	O
risperidone	S-chemical
or	O
olanzapine	S-chemical
.	O
Time	O
until	O
sustained	O
response	O
(	O
two	O
consecutive	O
ratings	O
without	O
significant	O
positive	O
symptoms	O
)	O
for	O
rare	O
allele	O
carriers	O
versus	O
wild	O
types	O
was	O
examined	O
by	O
using	O
Kaplan-Meier	O
curves	O
.	O
RESULTS	O
:	O
Relative	O
to	O
wild	O
type	O
homozygotes	O
,	O
G	O
carriers	O
(	O
A-241G	S-GP
)	O
exhibited	O
a	O
significantly	O
faster	O
time	O
until	O
response	O
,	O
whereas	O
-141C	O
Del	O
carriers	O
took	O
a	O
significantly	O
longer	O
time	O
to	O
respond	O
.	O
Diplotype	O
analysis	O
revealed	O
similar	O
results	O
.	O
CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
variation	O
in	O
the	O
D	B-GP
(	I-GP
2	I-GP
)	I-GP
receptor	E-GP
gene	O
can	O
,	O
in	O
part	O
,	O
explain	O
variation	O
in	O
the	O
timing	O
of	O
clinical	O
response	O
to	O
antipsychotics	O
in	O
patients	O
with	O
first-episode	O
schizophrenia	O
.	O

Polymer-based	O
protein	O
engineering	O
can	O
rationally	O
tune	O
enzyme	O
activity	O
,	O
pH-dependence	O
,	O
and	O
stability	O
.	O
The	O
attachment	O
of	O
inert	O
polymers	O
,	O
such	O
as	O
polyethyleneglycol	S-chemical
,	O
to	O
proteins	O
has	O
driven	O
the	O
emergence	O
of	O
a	O
multibillion	O
dollar	O
biotechnology	O
industry	O
.	O
In	O
all	O
cases	O
,	O
proteins	O
have	O
been	O
stabilized	O
or	O
altered	O
by	O
covalently	O
coupling	O
the	O
pre-existing	O
polymer	O
to	O
the	O
surface	O
of	O
the	O
protein	O
.	O
This	O
approach	O
is	O
inherently	O
limited	O
by	O
a	O
lack	O
of	O
exquisite	O
control	O
of	O
polymer	O
architecture	O
,	O
chain	O
length	O
,	O
site	O
and	O
density	O
of	O
attachment	O
.	O
Using	O
a	O
novel	O
water-soluble	O
atom	O
transfer	O
radical	O
polymerization	O
initiator	O
,	O
we	O
have	O
grown	O
temperature-	O
and	O
pH-responsive	O
polymers	O
from	O
the	O
surface	O
of	O
a	O
model	O
protein	O
,	O
the	O
enzyme	O
chymotrypsin	S-GP
.	O
Poly	B-chemical
(	I-chemical
2-	I-chemical
(	I-chemical
dimethylamino	I-chemical
)	I-chemical
ethyl	I-chemical
methacrylate	I-chemical
)	E-chemical
changes	O
in	O
conformation	O
with	O
altered	O
temperature	O
and	O
pH	O
.	O
Growing	O
the	O
polymer	O
from	O
the	O
surface	O
of	O
chymotrypsin	S-GP
we	O
were	O
able	O
to	O
demonstrate	O
that	O
changes	O
in	O
temperature	O
or	O
pH	O
can	O
change	O
predictably	O
the	O
conformation	O
of	O
the	O
polymer	O
surrounding	O
the	O
enzyme	O
,	O
which	O
in	O
turn	O
enabled	O
the	O
rational	O
tailoring	O
of	O
enzyme	O
activity	O
and	O
stability	O
.	O
Using	O
what	O
we	O
now	O
term	O
``	O
Polymer-Based	O
Protein	O
Engineering	O
''	O
we	O
have	O
increased	O
the	O
activity	O
and	O
stability	O
of	O
chymotrypsin	S-GP
by	O
an	O
order	O
of	O
magnitude	O
at	O
pH	O
's	O
where	O
the	O
enzyme	O
is	O
usually	O
inactive	O
or	O
unstable	O
.	O

Synthesis	O
,	O
structure-activity	O
relationships	O
,	O
and	O
in	O
vivo	O
efficacy	O
of	O
the	O
novel	O
potent	O
and	O
selective	O
anaplastic	B-GP
lymphoma	I-GP
kinase	E-GP
(	O
ALK	S-GP
)	O
inhibitor	O
5-chloro-N2-	B-chemical
(	I-chemical
2-isopropoxy-5-methyl-4-	I-chemical
(	I-chemical
piperidin-4-yl	I-chemical
)	I-chemical
phenyl	I-chemical
)	I-chemical
-N4-	I-chemical
(	I-chemical
2-	I-chemical
(	I-chemical
isopropylsulf	I-chemical
onyl	I-chemical
)	I-chemical
phenyl	I-chemical
)	I-chemical
pyrimidine-2,4-diamine	E-chemical
(	O
LDK378	S-chemical
)	O
currently	O
in	O
phase	O
1	O
and	O
phase	O
2	O
clinical	O
trials	O
.	O
The	O
synthesis	O
,	O
preclinical	O
profile	O
,	O
and	O
in	O
vivo	O
efficacy	O
in	O
rat	O
xenograft	O
models	O
of	O
the	O
novel	O
and	O
selective	O
anaplastic	B-GP
lymphoma	I-GP
kinase	E-GP
inhibitor	O
15b	O
(	O
LDK378	S-chemical
)	O
are	O
described	O
.	O
In	O
this	O
initial	O
report	O
,	O
preliminary	O
structure-activity	O
relationships	O
(	O
SARs	O
)	O
are	O
described	O
as	O
well	O
as	O
the	O
rational	O
design	O
strategy	O
employed	O
to	O
overcome	O
the	O
development	O
deficiencies	O
of	O
the	O
first	O
generation	O
ALK	S-GP
inhibitor	O
4	O
(	O
TAE684	S-chemical
)	O
.	O
Compound	O
15b	O
is	O
currently	O
in	O
phase	O
1	O
and	O
phase	O
2	O
clinical	O
trials	O
with	O
substantial	O
antitumor	O
activity	O
being	O
observed	O
in	O
ALK	S-GP
-positive	O
cancer	O
patients	O
.	O

A	O
Novel	O
CUG	O
(	O
exp	O
)	O
·	O
MBNL1	S-GP
Inhibitor	O
with	O
Therapeutic	O
Potential	O
for	O
Myotonic	O
Dystrophy	O
Type	O
1	O
.	O
Myotonic	O
dystrophy	O
type	O
1	O
(	O
DM1	O
)	O
is	O
caused	O
by	O
an	O
expanded	O
CUG	O
repeat	O
(	O
CUG	O
(	O
exp	O
)	O
)	O
that	O
sequesters	O
muscleblind-like	B-GP
1	I-GP
protein	E-GP
(	O
MBNL1	S-GP
)	O
,	O
a	O
protein	O
that	O
regulates	O
alternative	O
splicing	O
.	O
CUG	O
(	O
exp	O
)	O
RNA	O
is	O
a	O
validated	O
drug	O
target	O
for	O
this	O
currently	O
untreatable	O
disease	O
.	O
Herein	O
,	O
we	O
develop	O
a	O
bioactive	O
small	O
molecule	O
(	O
1	O
)	O
that	O
targets	O
CUG	O
(	O
exp	O
)	O
RNA	O
and	O
is	O
able	O
to	O
inhibit	O
the	O
CUG	O
(	O
exp	O
)	O
·	O
MBNL1	S-GP
interaction	O
in	O
cells	O
that	O
model	O
DM1	O
.	O
The	O
core	O
of	O
this	O
small	O
molecule	O
is	O
based	O
on	O
ligand	O
2	O
,	O
which	O
was	O
previously	O
reported	O
to	O
be	O
active	O
in	O
an	O
in	O
vitro	O
assay	O
.	O
A	O
polyamine	S-chemical
-derivative	O
side	O
chain	O
was	O
conjugated	O
to	O
this	O
core	O
to	O
make	O
it	O
aqueous-soluble	O
and	O
cell-penetrable	O
.	O
In	O
a	O
DM1	O
cell	O
model	O
this	O
conjugate	O
was	O
found	O
to	O
disperse	O
CUG	O
(	O
exp	O
)	O
ribonuclear	O
foci	O
,	O
release	O
MBNL1	S-GP
,	O
and	O
partially	O
reverse	O
the	O
mis-splicing	O
of	O
the	O
insulin	B-GP
receptor	E-GP
pre-mRNA	O
.	O
Direct	O
evidence	O
for	O
ribonuclear	O
foci	O
dispersion	O
by	O
this	O
ligand	O
was	O
obtained	O
in	O
a	O
live	O
DM1	O
cell	O
model	O
using	O
time-lapse	O
confocal	O
microscopy	O
.	O

Comprehensive	O
review	O
of	O
rasagiline	S-chemical
,	O
a	O
second-generation	O
monoamine	B-GP
oxidase	E-GP
inhibitor	O
,	O
for	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O
BACKGROUND	O
:	O
Inhibitors	O
of	O
monoamine	B-GP
oxidase	E-GP
(	O
MAO	S-GP
)	O
with	O
selectivity	O
and	O
specificity	O
for	O
MAO	B-GP
type	I-GP
B	E-GP
(	O
MAO-B	S-GP
)	O
prolong	O
the	O
duration	O
of	O
action	O
of	O
both	O
endogenously	O
and	O
exogenously	O
derived	O
dopamine	S-chemical
.	O
Rasagiline	S-chemical
[	O
N-propargyl-l	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
-aminoindan	E-chemical
]	O
is	O
a	O
second-generation	O
propargylamine	S-chemical
pharmacophore	O
that	O
selectively	O
and	O
irreversibly	O
inhibits	O
brain	O
MAO-B	S-GP
and	O
is	O
specifically	O
designed	O
for	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O
OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
review	O
the	O
pharmacology	O
,	O
tolerability	O
,	O
and	O
clinical	O
efficacy	O
of	O
rasagiline	S-chemical
in	O
the	O
treatment	O
of	O
PD	O
.	O
METHODS	O
:	O
MEDLINE	O
(	O
1966-April	O
2007	O
)	O
,	O
the	O
Cochrane	O
Database	O
of	O
Systematic	O
Reviews	O
,	O
and	O
International	O
Pharmaceutical	O
Abstracts	O
(	O
1970-April	O
2007	O
)	O
were	O
searched	O
for	O
original	O
research	O
and	O
review	O
articles	O
published	O
in	O
English	O
.	O
The	O
search	O
terms	O
were	O
monoamine	B-GP
oxidase	E-GP
,	O
neuroprotection	O
,	O
Parkinson	O
disease	O
,	O
propargylamine	S-chemical
,	O
rasagiline	S-chemical
,	O
and	O
selegiline	S-chemical
.	O
The	O
reference	O
lists	O
of	O
articles	O
were	O
also	O
consulted	O
,	O
as	O
was	O
information	O
provided	O
by	O
the	O
manufacturer	O
of	O
rasagiline	S-chemical
.	O
RESULTS	O
:	O
Data	O
from	O
63	O
clinical	O
and	O
laboratory	O
studies	O
were	O
analyzed	O
.	O
Based	O
on	O
the	O
results	O
from	O
those	O
studies	O
,	O
we	O
concluded	O
that	O
rasagiline	S-chemical
PO	O
QD	O
,	O
at	O
the	O
therapeutic	O
dosage	O
range	O
of	O
0.5	O
to	O
1	O
rag/d	O
,	O
is	O
effective	O
and	O
well	O
tolerated	O
and	O
completely	O
,	O
selectively	O
,	O
and	O
specifically	O
inhibited	O
MAO-B	S-GP
.	O
Pharmacologically	O
,	O
rasagiline	S-chemical
was	O
found	O
to	O
be	O
<	O
or	O
=10-fold	O
more	O
potent	O
than	O
selegiline	S-chemical
and	O
was	O
not	O
metabolized	O
to	O
amphetamine	S-chemical
derivatives	O
.	O
Rasagiline	S-chemical
was	O
effective	O
both	O
as	O
monotherapy	O
in	O
early	O
PD	O
and	O
as	O
adjunctive	O
treatment	O
in	O
patients	O
with	O
advancing	O
PD	O
and	O
motor	O
fluctuations	O
.	O
As	O
monotherapy	O
,	O
rasagiline	S-chemical
provided	O
modest	O
yet	O
clinically	O
meaningful	O
benefit	O
.	O
A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
found	O
that	O
,	O
after	O
26	O
weeks	O
of	O
treatment	O
,	O
the	O
adjusted	O
effect	O
size	O
for	O
total	O
Unified	O
Parkinson	O
's	O
Disease	O
Rating	O
Scale	O
score	O
was	O
-4.20	O
(	O
95	O
%	O
CI	O
,	O
-5.66	O
to	O
-2.73	O
)	O
for	O
rasagiline	S-chemical
1	O
mg/d	O
versus	O
placebo	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Preliminary	O
long-term	O
data	O
from	O
an	O
open-label	O
study	O
suggest	O
a	O
sustained	O
therapeutic	O
advantage	O
when	O
rasagiline	O
is	O
initiated	O
early	O
(	O
before	O
the	O
need	O
for	O
dopaminergic	O
agents	O
)	O
rather	O
than	O
later	O
.	O
In	O
patients	O
with	O
more	O
advanced	O
disease	O
who	O
received	O
treatment	O
with	O
dopaminergic	O
agents	O
,	O
rasagiline	O
and	O
entacapone	S-chemical
were	O
associated	O
with	O
reductions	O
of	O
``	O
off	O
''	O
time	O
significantly	O
greater	O
than	O
placebo	O
(	O
-1.18	O
and	O
-1.2	O
vs	O
0.4	O
hour	O
;	O
both	O
,	O
P	O
<	O
or	O
=	O
0.001	O
)	O
.	O
Rasagiline	S-chemical
was	O
well	O
tolerated	O
in	O
younger	O
(	O
aged	O
<	O
;	O
70	O
years	O
)	O
and	O
older	O
(	O
aged	O
>	O
or	O
=70	O
years	O
)	O
patients	O
with	O
early	O
or	O
advanced	O
PD	O
.	O
Pharmacologically	O
,	O
rasagiline	O
has	O
the	O
potential	O
to	O
augment	O
the	O
vasopressor	O
effects	O
of	O
diet-derived	O
tyramine	S-chemical
(	O
ie	O
,	O
the	O
``	O
cheese	O
reaction	O
''	O
)	O
.	O
However	O
,	O
clinical	O
challenge	O
studies	O
of	O
tyramine	S-chemical
have	O
found	O
this	O
unlikely	O
to	O
occur	O
even	O
with	O
ingestion	O
of	O
supraphysiologic	O
amounts	O
of	O
tyramine	S-chemical
.	O
In	O
experimental	O
models	O
,	O
rasagiline	S-chemical
has	O
been	O
found	O
to	O
have	O
neuroprotective	O
properties	O
that	O
may	O
be	O
independent	O
of	O
MAO-B	S-GP
inhibition	O
.	O
CONCLUSIONS	O
:	O
Based	O
on	O
this	O
review	O
,	O
rasagiline	S-chemical
has	O
been	O
found	O
to	O
be	O
well	O
tolerated	O
and	O
effective	O
in	O
the	O
treatment	O
of	O
early	O
PD	O
and	O
as	O
adjunctive	O
treatment	O
in	O
motor	O
fluctuations	O
.	O
Whether	O
rasagiline	O
is	O
associated	O
with	O
clinically	O
significant	O
neuroprotection	O
(	O
ie	O
,	O
disease	O
modification	O
)	O
in	O
PD	O
is	O
the	O
subject	O
of	O
ongoing	O
clinical	O
trials	O
.	O

Demonstration	O
of	O
histamine	B-GP
receptors	E-GP
on	O
human	O
platelets	O
by	O
flow	O
cytometry	O
.	O
Fluoresceinated	B-GP
human	I-GP
albumin	E-GP
conjugated	O
with	O
histamine	S-chemical
(	O
FHA	S-GP
-HIS	O
)	O
has	O
been	O
used	O
for	O
the	O
demonstration	O
of	O
histamine	B-GP
receptors	E-GP
on	O
human	O
platelets	O
.	O
Such	O
receptors	O
were	O
demonstrated	O
on	O
40-63	O
%	O
of	O
peripheral	O
blood	O
platelets	O
in	O
4	O
healthy	O
donors	O
.	O
The	O
binding	O
of	O
FHA	S-GP
-HIS	O
was	O
inhibited	O
on	O
35-79	O
%	O
of	O
the	O
platelets	O
by	O
the	O
histamine	B-GP
H1	I-GP
receptor	E-GP
antagonists	O
diphenhydramine	S-chemical
and	O
clemastine	S-chemical
.	O
The	O
histamine	B-GP
H2	I-GP
receptor	E-GP
antagonist	O
cimetidine	S-chemical
blocked	O
the	O
FHA	S-GP
-HIS	O
binding	O
on	O
14-37	O
%	O
of	O
the	O
platelets	O
.	O
It	O
is	O
concluded	O
that	O
histamine	B-GP
H1	E-GP
as	O
well	O
as	O
H2	B-GP
receptors	E-GP
occur	O
on	O
human	O
platelets	O
but	O
the	O
receptors	O
are	O
not	O
equally	O
distributed	O
in	O
the	O
platelet	O
population	O
.	O

LPA1	S-GP
-induced	O
cytoskeleton	O
reorganization	O
drives	O
fibrosis	O
through	O
CTGF	S-GP
-dependent	O
fibroblast	O
proliferation	O
.	O
There	O
has	O
been	O
much	O
recent	O
interest	O
in	O
lysophosphatidic	B-chemical
acid	E-chemical
(	O
LPA	S-chemical
)	O
signaling	O
through	O
one	O
of	O
its	O
receptors	O
,	O
LPA1	S-GP
,	O
in	O
fibrotic	O
diseases	O
,	O
but	O
the	O
mechanisms	O
by	O
which	O
LPA	S-chemical
-	O
LPA1	S-GP
signaling	O
promotes	O
pathological	O
fibrosis	O
remain	O
to	O
be	O
fully	O
elucidated	O
.	O
Using	O
a	O
mouse	O
peritoneal	O
fibrosis	O
model	O
,	O
we	O
demonstrate	O
central	O
roles	O
for	O
LPA	S-chemical
and	O
LPA1	S-GP
in	O
fibroblast	O
proliferation	O
.	O
Genetic	O
deletion	O
or	O
pharmacological	O
antagonism	O
of	O
LPA1	S-GP
protected	O
mice	O
from	O
peritoneal	O
fibrosis	O
,	O
blunting	O
the	O
increases	O
in	O
peritoneal	O
collagen	S-GP
by	O
65.4	O
and	O
52.9	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
control	O
animals	O
and	O
demonstrated	O
that	O
peritoneal	O
fibroblast	O
proliferation	O
was	O
highly	O
LPA1	S-GP
dependent	O
.	O
Activation	O
of	O
LPA1	S-GP
on	O
mesothelial	O
cells	O
induced	O
these	O
cells	O
to	O
express	O
connective	B-GP
tissue	I-GP
growth	I-GP
factor	E-GP
(	O
CTGF	S-GP
)	O
,	O
driving	O
fibroblast	O
proliferation	O
in	O
a	O
paracrine	O
fashion	O
.	O
Activation	O
of	O
mesothelial	O
cell	O
LPA1	S-GP
induced	O
CTGF	S-GP
expression	O
by	O
inducing	O
cytoskeleton	O
reorganization	O
in	O
these	O
cells	O
,	O
causing	O
nuclear	O
translocation	O
of	O
myocardin-related	B-GP
transcription	I-GP
factor	I-GP
(	I-GP
MRTF	I-GP
)	I-GP
-A	E-GP
and	O
MRTF-B	S-GP
.	O
Pharmacological	O
inhibition	O
of	O
MRTF	S-GP
-induced	O
transcription	O
also	O
diminished	O
CTGF	S-GP
expression	O
and	O
fibrosis	O
in	O
the	O
peritoneal	O
fibrosis	O
model	O
,	O
mitigating	O
the	O
increase	O
in	O
peritoneal	O
collagen	S-GP
content	O
by	O
57.9	O
%	O
compared	O
to	O
controls	O
.	O
LPA1	S-GP
-induced	O
cytoskeleton	O
reorganization	O
therefore	O
makes	O
a	O
previously	O
unrecognized	O
but	O
critically	O
important	O
contribution	O
to	O
the	O
profibrotic	O
activities	O
of	O
LPA	S-chemical
by	O
driving	O
MRTF	S-GP
-dependent	O
CTGF	S-GP
expression	O
,	O
which	O
,	O
in	O
turn	O
,	O
drives	O
fibroblast	O
proliferation.-Sakai	O
,	O
N.	O
,	O
Chun	O
,	O
J.	O
,	O
Duffield	O
,	O
J.	O
S.	O
,	O
Wada	O
,	O
T.	O
,	O
Luster	O
,	O
A.	O
D.	O
,	O
Tager	O
,	O
A.	O
M	O
.	O
LPA1	S-GP
-induced	O
cytoskeleton	O
reorganization	O
drives	O
fibrosis	O
through	O
CTGF	S-GP
-dependent	O
fibroblast	O
proliferation	O
.	O

Modification	O
of	O
the	O
Catalytic	O
Function	O
of	O
Human	B-GP
Hydroxysteroid	I-GP
Sulfotransferase	I-GP
hSULT2A1	E-GP
by	O
Formation	O
of	O
Disulfide	S-chemical
Bonds	O
.	O
The	O
human	B-GP
cytosolic	I-GP
sulfotransferase	I-GP
hSULT2A1	E-GP
catalyzes	O
the	O
sulfation	O
of	O
a	O
broad	O
range	O
of	O
xenobiotics	O
,	O
as	O
well	O
as	O
endogenous	O
hydroxysteroids	S-chemical
and	O
bile	B-chemical
acids	E-chemical
.	O
Reversible	O
modulation	O
of	O
the	O
catalytic	O
activity	O
of	O
this	O
enzyme	O
could	O
play	O
important	O
roles	O
in	O
its	O
physiologic	O
functions	O
.	O
Whereas	O
other	O
mammalian	B-GP
sulfotransferases	E-GP
are	O
known	O
to	O
be	O
reversibly	O
altered	O
by	O
changes	O
in	O
their	O
redox	O
environment	O
,	O
this	O
has	O
not	O
been	O
previously	O
shown	O
for	O
hSULT2A1	S-GP
.	O
We	O
have	O
examined	O
the	O
hypothesis	O
that	O
the	O
formation	O
of	O
disulfide	S-chemical
bonds	O
in	O
hSULT2A1	S-GP
can	O
reversibly	O
regulate	O
the	O
catalytic	O
function	O
of	O
the	O
enzyme	O
.	O
Three	O
thiol	S-chemical
oxidants	O
were	O
used	O
as	O
model	O
compounds	O
to	O
investigate	O
their	O
effects	O
on	O
homogeneous	O
preparations	O
of	O
hSULT2A1	S-GP
:	O
glutathione	B-chemical
disulfide	E-chemical
,	O
5,5'-dithiobis	B-chemical
(	I-chemical
2-nitrobenzoic	I-chemical
acid	I-chemical
)	E-chemical
,	O
and	O
1,1'-azobis	B-chemical
(	I-chemical
N	I-chemical
,	I-chemical
N-dimethylformamide	E-chemical
)	O
(	O
diamide	S-chemical
)	O
.	O
Examination	O
of	O
the	O
effects	O
of	O
disulfide	S-chemical
bond	O
formation	O
with	O
these	O
agents	O
indicated	O
that	O
the	O
activity	O
of	O
the	O
enzyme	O
is	O
reversibly	O
altered	O
.	O
Studies	O
on	O
the	O
kinetics	O
of	O
the	O
hSULT2A1	S-GP
-catalyzed	O
sulfation	O
of	O
dehydroepiandrosterone	S-chemical
(	O
DHEA	S-chemical
)	O
showed	O
the	O
effects	O
of	O
disulfide	S-chemical
bond	O
formation	O
on	O
the	O
substrate	O
inhibition	O
characteristics	O
of	O
the	O
enzyme	O
.	O
The	O
effects	O
of	O
these	O
agents	O
on	O
the	O
binding	O
of	O
substrates	O
and	O
products	O
,	O
liquid	O
chromatography-mass	O
spectrometry	O
identification	O
of	O
the	O
disulfides	S-chemical
formed	O
,	O
and	O
structural	O
modeling	O
of	O
the	O
modified	O
enzyme	O
were	O
examined	O
.	O
Our	O
results	O
indicate	O
that	O
conformational	O
changes	O
at	O
cysteines	S-chemical
near	O
the	O
nucleotide	S-chemical
binding	O
site	O
affect	O
the	O
binding	O
of	O
both	O
the	O
nucleotide	S-chemical
and	O
DHEA	S-chemical
to	O
the	O
enzyme	O
,	O
with	O
the	O
specific	O
effects	O
dependent	O
on	O
the	O
structure	O
of	O
the	O
resulting	O
disulfide	S-chemical
.	O
Thus	O
,	O
the	O
formation	O
of	O
disulfide	S-chemical
bonds	O
in	O
hSULT2A1	S-GP
is	O
a	O
potentially	O
important	O
reversible	O
mechanism	O
for	O
alterations	O
in	O
the	O
rates	O
of	O
sulfation	O
of	O
both	O
endogenous	O
and	O
xenobiotic	O
substrates	O
.	O

RANKL	S-GP
targeted	O
peptides	O
inhibit	O
osteoclastogenesis	O
and	O
attenuate	O
adjuvant	O
induced	O
arthritis	O
by	O
inhibiting	O
NF-κB	S-GP
activation	O
and	O
down	O
regulating	O
inflammatory	O
cytokines	S-GP
.	O
Peptides	O
designed	O
from	O
osteoprotegerin	O
(	O
OPG	O
)	O
have	O
previously	O
been	O
shown	O
to	O
inhibit	O
receptor	B-GP
activator	I-GP
of	I-GP
NF-κB	I-GP
ligand	E-GP
(	O
RANKL	S-GP
)	O
and	O
prevent	O
bone	O
loss	O
without	O
significantly	O
inhibiting	O
inflammation	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
novel	O
peptide	O
with	O
dual	O
inhibitory	O
activity	O
against	O
bone	O
loss	O
and	O
inflammation	O
using	O
site-directed	O
mutagenesis	O
.	O
Out	O
of	O
the	O
three	O
putative	O
sites	O
(	O
i.e.	O
,	O
Tyr	S-chemical
70-	O
Asp	S-chemical
78	O
,	O
Tyr	S-chemical
82-	O
Glu	S-chemical
96	O
,	O
and	O
Leu	S-chemical
113-	O
Arg	S-chemical
122	O
)	O
available	O
on	O
OPG	O
for	O
RANKL	S-GP
binding	O
,	O
Leu	S-chemical
113-	O
Arg	S-chemical
122	O
was	O
used	O
as	O
a	O
template	O
for	O
peptide	O
synthesis	O
.	O
Peptide	O
mutants	O
of	O
the	O
template	O
sequence	O
(	O
112YLEIEFCLKHR122	O
)	O
were	O
synthesized	O
and	O
initially	O
screened	O
for	O
their	O
inhibitory	O
effect	O
on	O
RANK	S-GP
-	O
RANKL	S-GP
binding	O
by	O
competitive	O
ELISA	O
.	O
The	O
most	O
active	O
peptide	O
was	O
further	O
evaluated	O
in	O
vitro	O
for	O
RANKL	S-GP
induced	O
osteoclastogenesis	O
in	O
mouse	O
macrophage	O
cells	O
,	O
and	O
in	O
vivo	O
for	O
Freund	O
's	O
complete	O
adjuvant	O
induced	O
arthritis	O
(	O
AIA	O
)	O
in	O
Lewis	O
rats	O
.	O
The	O
efficacy	O
of	O
the	O
candidate	O
peptide	O
was	O
compared	O
with	O
that	O
of	O
the	O
standard	O
drug	O
celecoxib	S-chemical
.	O
The	O
peptide	O
YR-11	S-chemical
(	O
YLEIEFSLKHR	O
)	O
,	O
obtained	O
by	O
direct	O
substitution	O
of	O
cysteine	S-chemical
with	O
a	O
serine	S-chemical
residue	O
in	O
the	O
template	O
sequence	O
,	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
inhibited	O
RANK	S-GP
-	O
RANKL	S-GP
binding	O
,	O
and	O
RANKL	S-GP
induced	O
TRAP	S-GP
activity	O
and	O
formation	O
of	O
multinucleated	O
osteoclasts	O
without	O
any	O
cytotoxicity	O
.	O
Administration	O
of	O
YR-11	S-chemical
peptide	O
at	O
the	O
dose	O
of	O
30mg/kg	O
(	O
i.p	O
.	O
)	O
ameliorated	O
both	O
bone	O
loss	O
and	O
inflammation	O
in	O
AIA	O
rats	O
.	O
To	O
elucidate	O
the	O
mechanism	O
for	O
inhibition	O
of	O
inflammation	O
in	O
arthritic	O
rats	O
,	O
serum	O
and	O
tissue	O
cytokines	S-GP
(	O
TNF-α	S-GP
,	O
IL-1β	S-GP
,	O
and	O
IL-6	S-GP
)	O
were	O
analyzed	O
by	O
ELISA	O
and	O
RT-PCR	O
methods	O
.	O
Results	O
confirmed	O
that	O
YR-11	S-chemical
peptide	O
inhibited	O
pro-inflammatory	O
cytokines	S-GP
in	O
the	O
sera	O
and	O
hind	O
paw	O
tissues	O
of	O
AIA	O
rats	O
through	O
its	O
suppressive	O
effect	O
on	O
RANKL	S-GP
induced	O
nuclear	O
translocation	O
of	O
NF-κB	S-GP
.	O
The	O
results	O
obtained	O
in	O
this	O
study	O
substantiate	O
the	O
therapeutic	O
benefit	O
of	O
this	O
novel	O
peptide	O
in	O
the	O
prevention	O
of	O
bone	O
loss	O
and	O
inflammation	O
in	O
rheumatoid	O
arthritis	O
with	O
reduced	O
side	O
effects	O
.	O

Antioxidants	O
and	O
mucolytics	O
in	O
COPD	O
management	O
:	O
when	O
(	O
if	O
ever	O
)	O
and	O
in	O
whom	O
?	O
Chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O
Oxidative	O
stress	O
is	O
an	O
important	O
mechanism	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
.	O
The	O
oxidant/	O
antioxidant	O
imbalance	O
occurring	O
in	O
smokers	O
and	O
patients	O
with	O
COPD	O
is	O
well	O
established	O
.	O
Thus	O
,	O
therapeutic	O
strategies	O
targeting	O
oxidative	O
stress	O
with	O
pharmacological	O
antioxidant	O
agents	O
or	O
boosting	O
the	O
endogenous	O
levels	O
of	O
antioxidants	O
is	O
likely	O
to	O
be	O
beneficial	O
as	O
an	O
adjunctive	O
tool	O
in	O
the	O
treatment	O
of	O
COPD	O
patients	O
.	O
Thiol	S-chemical
compounts	O
such	O
as	O
N-acetyl-L-cysteine	S-chemical
(	O
NAC	S-chemical
)	O
,	O
carbocysteine	S-chemical
,	O
erdosteine	S-chemical
,	O
and	O
fudosteine	S-chemical
have	O
been	O
extensively	O
studied	O
.	O
Although	O
some	O
results	O
remain	O
controversial	O
,	O
NAC	S-chemical
and	O
carbocysteine	S-chemical
seem	O
to	O
have	O
beneficial	O
effect	O
in	O
patients	O
not	O
receiving	O
inhaled	O
corticosteroids	S-chemical
who	O
suffer	O
from	O
frequent	O
exacerbations	O
.	O
In	O
addition	O
,	O
other	O
antioxidants	O
like	O
superoxide	B-GP
dismutase	E-GP
(	O
SOD	S-GP
)	O
mimetics	O
and	O
nuclear	B-GP
factor-erythroid	I-GP
2	I-GP
related	I-GP
factor	I-GP
2	E-GP
(	O
Nrf2	S-GP
)	O
are	O
shown	O
to	O
decrease	O
markers	O
of	O
oxidative	O
stress	O
in	O
patients	O
with	O
emphysema	O
,	O
while	O
others	O
like	O
glutathione	B-GP
peroxidase	E-GP
(	O
GPx	S-GP
)	O
mimetics	O
and	O
NO	B-GP
synthase	E-GP
(	O
iNOS	S-GP
)	O
can	O
prevent	O
both	O
inflammation	O
and	O
oxidative	O
stress	O
in	O
clinical	O
trials	O
in	O
vivo	O
(	O
or	O
in	O
mouse	O
models	O
)	O
.	O
In	O
this	O
article	O
we	O
review	O
the	O
effectiveness	O
of	O
various	O
antioxidant	O
factors	O
in	O
COPD	O
and	O
their	O
potential	O
beneficial	O
effect	O
in	O
the	O
treatment	O
of	O
the	O
disease	O
.	O

Synthesis	O
and	O
evaluation	O
of	O
3-	B-chemical
(	I-chemical
benzylthio	I-chemical
)	I-chemical
-5-	I-chemical
(	I-chemical
1H-indol-3-yl	I-chemical
)	I-chemical
-1,2,4-triazol-4-amines	E-chemical
as	O
Bcl-2	S-GP
inhibitory	O
anticancer	O
agents	O
.	O
A	O
series	O
of	O
substituted	O
3-	B-chemical
(	I-chemical
benzylthio	I-chemical
)	I-chemical
-5-	I-chemical
(	I-chemical
1H-indol-3-yl	I-chemical
)	I-chemical
-4H-1,2,4-triazol-4-amines	E-chemical
has	O
been	O
synthesised	O
and	O
tested	O
in	O
vitro	O
as	O
potential	O
pro-apoptotic	O
Bcl-2	S-GP
-inhibitory	O
anticancer	O
agents	O
.	O
Synthesis	O
of	O
the	O
target	O
compounds	O
was	O
readily	O
accomplished	O
in	O
good	O
yields	O
through	O
a	O
cyclisation	O
reaction	O
between	O
indole-3-carboxylic	B-chemical
acid	I-chemical
hydrazide	E-chemical
and	O
carbon	B-chemical
disulfide	E-chemical
under	O
basic	O
conditions	O
,	O
followed	O
by	O
S	S-chemical
-benzylation	O
.	O
Active	O
compounds	O
,	O
such	O
as	O
the	O
nitrobenzyl	S-chemical
analogue	O
6c	O
,	O
were	O
found	O
to	O
exhibit	O
sub-micromolar	O
IC50	O
values	O
in	O
Bcl-2	S-GP
expressing	O
human	O
cancer	O
cell	O
lines	O
.	O
Molecular	O
modelling	O
and	O
ELISA	O
studies	O
further	O
implicated	O
anti-apoptotic	O
Bcl-2	S-GP
as	O
a	O
candidate	O
molecular	O
target	O
underpinning	O
anticancer	O
activity	O
.	O

Steroid	S-chemical
toxicity	O
and	O
detoxification	O
in	O
ascomycetous	O
fungi	O
.	O
In	O
the	O
last	O
couple	O
of	O
decades	O
fungal	O
infections	O
have	O
become	O
a	O
significant	O
clinical	O
problem	O
.	O
A	O
major	O
interest	O
into	O
fungal	O
steroid	S-chemical
action	O
has	O
been	O
provoked	O
since	O
research	O
has	O
proven	O
that	O
steroid	S-chemical
hormones	O
are	O
toxic	O
to	O
fungi	O
and	O
affect	O
the	O
host/fungus	O
relationship	O
.	O
Steroid	S-chemical
hormones	O
were	O
found	O
to	O
differ	O
in	O
their	O
antifungal	O
activity	O
in	O
ascomycetous	O
fungi	O
Hortaea	O
werneckii	O
,	O
Saccharomyces	O
cerevisiae	O
and	O
Aspergillus	O
oryzae	O
.	O
Dehydroepiandrosterone	O
was	O
shown	O
to	O
be	O
the	O
strongest	O
inhibitor	O
of	O
growth	O
in	O
all	O
three	O
varieties	O
of	O
fungi	O
followed	O
by	O
androstenedione	S-chemical
and	O
testosterone	S-chemical
.	O
For	O
their	O
protection	O
,	O
fungi	O
use	O
several	O
mechanisms	O
to	O
lower	O
the	O
toxic	O
effects	O
of	O
steroids	S-chemical
.	O
The	O
efficiency	O
of	O
biotransformation	O
in	O
detoxification	O
depended	O
on	O
the	O
microorganism	O
and	O
steroid	S-chemical
substrate	O
used	O
.	O
Biotransformation	O
was	O
a	O
relatively	O
slow	O
process	O
as	O
it	O
also	O
depended	O
on	O
the	O
growth	O
phase	O
of	O
the	O
fungus	O
.	O
In	O
addition	O
to	O
biotransformation	O
,	O
steroid	S-chemical
extrusion	O
out	O
of	O
the	O
cells	O
contributed	O
to	O
the	O
lowering	O
of	O
the	O
active	O
intracellular	O
steroid	S-chemical
concentration	O
.	O
Plasma	O
membrane	O
Pdr5	S-GP
transporter	O
was	O
found	O
to	O
be	O
the	O
most	O
effective	O
,	O
followed	O
by	O
Snq2	S-GP
transporter	O
and	O
vacuolar	O
transporters	O
Ybt1	S-GP
and	O
Ycf1	S-GP
.	O
Proteins	O
Aus1	S-GP
and	O
Dan1	S-GP
were	O
not	O
found	O
to	O
be	O
involved	O
in	O
steroid	S-chemical
import	O
.	O
The	O
research	O
of	O
possible	O
targets	O
of	O
steroid	S-chemical
hormone	O
action	O
in	O
fungi	O
suggests	O
that	O
steroid	S-chemical
hormones	O
inhibit	O
ergosterol	S-chemical
biosynthesis	O
in	O
S.	O
cerevisiae	O
and	O
H.	O
werneckii	O
.	O
Results	O
of	O
this	O
inhibition	O
caused	O
changes	O
in	O
the	O
sterol	S-chemical
content	O
of	O
the	O
cellular	O
membrane	O
.	O
The	O
presence	O
of	O
steroid	S-chemical
hormones	O
most	O
probably	O
causes	O
the	O
degradation	O
of	O
the	O
Tat2	S-GP
permease	O
and	O
impairment	O
of	O
tryptophan	S-chemical
import	O
.	O

UPLC-Q-TOF/HSMS/MS	O
(	O
E	O
)	O
-based	O
metabonomics	O
for	O
adenine	S-chemical
-induced	O
changes	O
in	O
metabolic	O
profiles	O
of	O
rat	O
faeces	O
and	O
intervention	O
effects	O
of	O
ergosta-4,6,8	B-chemical
(	I-chemical
14	I-chemical
)	I-chemical
,22-tetraen-3-one	E-chemical
.	O
Ergosta-4,6,8	B-chemical
(	I-chemical
14	I-chemical
)	I-chemical
,22-tetraen-3-one	E-chemical
(	O
ergone	S-chemical
)	O
,	O
isolated	O
from	O
the	O
medicinal	O
fungus	O
Polyporus	O
umbellatus	O
,	O
has	O
been	O
proven	O
to	O
prevent	O
the	O
progression	O
of	O
renal	O
injury	O
and	O
the	O
subsequent	O
renal	O
fibrosis	O
.	O
Ultra	O
performance	O
liquid	O
chromatography	O
coupled	O
with	O
quadrupole	O
time-of-flight	O
high-sensitivity	O
mass	O
spectrometry	O
and	O
a	O
novel	O
mass	O
spectrometry	O
(	O
Elevated	O
Energy	O
)	O
(	O
MS	O
(	O
E	O
)	O
)	O
data	O
collection	O
technique	O
was	O
employed	O
to	O
investigate	O
metabonomic	O
characters	O
of	O
chronic	O
renal	O
failure	O
(	O
CRF	O
)	O
induced	O
adenine	S-chemical
and	O
the	O
protective	O
effects	O
of	O
ergosta-4,6,8	B-chemical
(	I-chemical
14	I-chemical
)	I-chemical
,22-tetraen-3-one	E-chemical
(	O
ergone	S-chemical
)	O
.	O
Coupled	O
with	O
blood	O
biochemistry	O
and	O
kidney	O
histopathology	O
results	O
,	O
the	O
significant	O
difference	O
in	O
metabolic	O
profiling	O
between	O
adenine	S-chemical
-induced	O
CRF	O
group	O
and	O
ergone	S-chemical
-treated	O
CRF	O
group	O
by	O
using	O
pattern	O
recognition	O
analysis	O
indicated	O
that	O
changes	O
in	O
global	O
faecal	O
metabolites	O
were	O
occurred	O
.	O
Seven	O
endogenous	O
metabolites	O
were	O
identified	O
by	O
using	O
metabonomic	O
method	O
combined	O
with	O
multivariate	O
data	O
analysis	O
,	O
the	O
accurate	O
mass	O
,	O
isotopic	O
pattern	O
,	O
MS	O
(	O
E	O
)	O
fragments	O
information	O
and	O
MassLynx	O
i-FIT	O
algorithm	O
.	O
These	O
biochemical	O
changes	O
in	O
faecal	O
metabolites	O
are	O
related	O
to	O
the	O
perturbations	O
of	O
bile	B-chemical
acid	E-chemical
metabolism	O
and	O
phospholipid	O
metabolism	O
,	O
which	O
may	O
be	O
helpful	O
to	O
further	O
understand	O
the	O
CRF	O
and	O
therapeutic	O
mechanisms	O
of	O
ergone	S-chemical
.	O
This	O
research	O
proved	O
that	O
MS	O
(	O
E	O
)	O
can	O
simultaneous	O
acquire	O
precursor	O
ion	O
information	O
and	O
fragment	O
ion	O
data	O
at	O
high	O
and	O
low	O
collision	O
energy	O
in	O
one	O
analytical	O
run	O
,	O
which	O
facilitated	O
the	O
fast	O
structural	O
characterization	O
of	O
metabolites	O
.	O

Pharmacogenomics	O
of	O
gemcitabine	S-chemical
metabolism	O
:	O
functional	O
analysis	O
of	O
genetic	O
variants	O
in	O
cytidine	B-GP
deaminase	E-GP
and	O
deoxycytidine	B-GP
kinase	E-GP
.	O
Gemcitabine	S-chemical
(	O
dFdC	S-chemical
,	O
2',2'-difluorodeoxycytidine	S-chemical
)	O
is	O
metabolized	O
by	O
cytidine	B-GP
deaminase	E-GP
(	O
CDA	S-GP
)	O
and	O
deoxycytidine	B-GP
kinase	E-GP
(	O
DCK	S-GP
)	O
,	O
but	O
the	O
contribution	O
of	O
genetic	O
variation	O
in	O
these	O
enzymes	O
to	O
the	O
variability	O
in	O
systemic	O
exposure	O
and	O
response	O
observed	O
in	O
cancer	O
patients	O
is	O
unclear	O
.	O
Wild-type	O
enzymes	O
and	O
variants	O
of	O
CDA	S-GP
(	O
Lys27Gln	S-GP
and	O
Ala70Thr	S-GP
)	O
and	O
DCK	S-GP
(	O
Ile24Val	S-GP
,	O
Ala119Gly	S-GP
,	O
and	O
Pro122Ser	S-GP
)	O
were	O
expressed	O
in	O
and	O
purified	O
from	O
Escherichia	O
coli	O
,	O
and	O
enzyme	O
kinetic	O
parameters	O
were	O
estimated	O
for	O
cytarabine	S-chemical
(	O
Ara-C	S-chemical
)	O
,	O
dFdC	S-chemical
,	O
and	O
its	O
metabolite	O
2',2'-difluorodeoxyuridine	S-chemical
(	O
dFdU	S-chemical
)	O
as	O
substrates	O
.	O
All	O
three	O
CDA	S-GP
proteins	O
showed	O
similar	O
K	O
(	O
m	O
)	O
and	O
V	O
(	O
max	O
)	O
for	O
Ara-C	S-chemical
and	O
dFdC	S-chemical
deamination	O
,	O
except	O
for	O
CDA	S-GP
70Thr	O
,	O
which	O
had	O
a	O
2.5-fold	O
lower	O
K	O
(	O
m	O
)	O
and	O
6-fold	O
lower	O
V	O
(	O
max	O
)	O
for	O
Ara-C	S-chemical
deamination	O
.	O
All	O
four	O
DCK	S-GP
proteins	O
yielded	O
comparable	O
metabolic	O
activity	O
for	O
Ara-C	S-chemical
and	O
dFdC	S-chemical
monophosphorylation	O
,	O
except	O
for	O
DCK	S-GP
24Val	O
,	O
which	O
demonstrated	O
an	O
approximately	O
2-fold	O
increase	O
(	O
P	O
<	O
0.05	O
)	O
in	O
the	O
intrinsic	O
clearance	O
of	O
dFdC	S-chemical
monophosphorylation	O
due	O
to	O
a	O
40	O
%	O
decrease	O
in	O
K	O
(	O
m	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O
DCK	S-GP
did	O
not	O
significantly	O
contribute	O
to	O
dFdU	S-chemical
monophosphorylation	O
.	O
In	O
conclusion	O
,	O
the	O
Lys27Gln	S-GP
substitution	O
does	O
not	O
significantly	O
modulate	O
CDA	S-GP
activity	O
toward	O
dFdC	S-chemical
,	O
and	O
therefore	O
would	O
not	O
contribute	O
to	O
interindividual	O
variability	O
in	O
response	O
to	O
gemcitabine	S-chemical
.	O
The	O
higher	O
in	O
vitro	O
catalytic	O
efficiency	O
of	O
DCK	S-GP
24Val	O
toward	O
dFdC	S-chemical
monophosphorylation	O
may	O
be	O
relevant	O
to	O
dFdC	S-chemical
clinical	O
response	O
.	O
The	O
substrate-dependent	O
alterations	O
in	O
activities	O
of	O
CDA	S-GP
70Thr	O
and	O
DCK	S-GP
24Val	O
in	O
vitro	O
were	O
observed	O
for	O
the	O
first	O
time	O
,	O
and	O
demonstrate	O
that	O
the	O
in	O
vivo	O
consequences	O
of	O
these	O
genetic	O
variations	O
should	O
not	O
be	O
extrapolated	O
from	O
one	O
substrate	O
of	O
these	O
enzymes	O
to	O
another	O
.	O

Novel	O
limonene	S-chemical
and	O
citral	S-chemical
based	O
2,5-disubstituted-1,3,4-oxadiazoles	S-chemical
:	O
a	O
natural	O
product	O
coupled	O
approach	O
to	O
semicarbazones	S-chemical
for	O
antiepileptic	O
activity	O
.	O
Two	O
novel	O
series	O
of	O
N	B-chemical
(	I-chemical
4	I-chemical
)	I-chemical
-	I-chemical
(	I-chemical
5-	I-chemical
(	I-chemical
2/3/4-substituted-phenyl	I-chemical
)	I-chemical
-1,3,4-oxadiazol-2-yl	I-chemical
)	I-chemical
-N	I-chemical
(	I-chemical
1	I-chemical
)	I-chemical
-	I-chemical
(	I-chemical
2-methyl-5-	I-chemical
(	I-chemical
prop-1-en-2-yl	I-chemical
)	I-chemical
cyclohex-2-enylidene	I-chemical
)	I-chemical
semicarbazide	E-chemical
and	O
N	B-chemical
(	I-chemical
4	I-chemical
)	I-chemical
-	I-chemical
(	I-chemical
5-	I-chemical
(	I-chemical
2/3/4-substituted-phenyl	I-chemical
)	I-chemical
-1,3,4-oxadiazol-2-yl	I-chemical
)	I-chemical
-N	I-chemical
(	I-chemical
1	I-chemical
)	I-chemical
-	I-chemical
(	I-chemical
3,7-dimethylocta-3,6-dienylidene	I-chemical
)	I-chemical
-semicarbazide	E-chemical
were	O
synthesized	O
to	O
meet	O
structural	O
prerequisite	O
indispensable	O
for	O
anticonvulsant	O
activity	O
.	O
The	O
anticonvulsant	O
activities	O
of	O
the	O
compounds	O
were	O
investigated	O
using	O
maximal	O
electroshock	O
seizure	O
(	O
MES	O
)	O
,	O
subcutaneous	O
pentylenetrtrazole	S-chemical
(	O
scPTZ	O
)	O
and	O
subcutaneous	O
strychnine	S-chemical
(	O
scSTY	O
)	O
models	O
.	O
The	O
rotorod	O
test	O
was	O
conducted	O
to	O
evaluate	O
neurotoxicity	O
.	O
Some	O
of	O
the	O
selected	O
active	O
compounds	O
were	O
subjected	O
to	O
GABA	S-chemical
assay	O
to	O
confirm	O
their	O
mode	O
of	O
action	O
.	O
The	O
outcome	O
of	O
the	O
present	O
investigations	O
proved	O
that	O
the	O
four	O
binding	O
sites	O
pharmacophore	O
model	O
is	O
vital	O
for	O
anticonvulsant	O
activity	O
.	O
The	O
efforts	O
were	O
also	O
made	O
to	O
establish	O
structure-activity	O
relationships	O
among	O
test	O
compounds	O
.	O

ARF	O
represses	O
androgen	B-GP
receptor	E-GP
transactivation	O
in	O
prostate	O
cancer	O
.	O
Androgen	B-GP
receptor	E-GP
(	O
AR	S-GP
)	O
signaling	O
is	O
essential	O
for	O
prostate	O
cancer	O
(	O
PCa	O
)	O
development	O
in	O
humans	O
.	O
The	O
initiation	O
of	O
prostate	O
malignancy	O
and	O
progression	O
to	O
a	O
castration-resistant	O
stage	O
are	O
largely	O
contributed	O
by	O
the	O
modulation	O
of	O
AR	S-GP
activity	O
through	O
its	O
coregulatory	O
proteins	O
.	O
We	O
and	O
others	O
previously	O
reported	O
that	O
p14	B-GP
alternative	I-GP
reading	I-GP
frame	E-GP
(	O
ARF	S-GP
)	O
expression	O
is	O
positively	O
correlated	O
with	O
the	O
disease	O
progression	O
and	O
severity	O
of	O
PCa	O
.	O
Here	O
,	O
we	O
provide	O
evidence	O
that	O
p14ARF	S-GP
physically	O
interacts	O
with	O
AR	S-GP
and	O
functions	O
as	O
an	O
AR	S-GP
corespressor	O
in	O
both	O
an	O
androgen	S-chemical
-dependent	O
and	O
androgen	S-chemical
-independent	O
manner	O
.	O
Endogenous	O
ARF	S-GP
(	O
p14ARF	S-GP
in	O
human	O
and	O
p19ARF	S-GP
in	O
mouse	O
)	O
and	O
AR	S-GP
colocalize	O
in	O
both	O
human	O
PCa	O
cells	O
in	O
vitro	O
and	O
PCa	O
tissues	O
of	O
mouse	O
and	O
human	O
in	O
vivo	O
.	O
Overexpression	O
of	O
p14ARF	S-GP
in	O
PCa	O
cells	O
significantly	O
attenuates	O
the	O
activities	O
of	O
androgen	B-GP
response	I-GP
region	E-GP
(	O
ARR2	S-GP
)	O
-	O
probasin	B-GP
and	I-GP
prostate-specific	I-GP
antigen	I-GP
(	I-GP
PSA	I-GP
)	I-GP
promoters	E-GP
.	O
The	O
forced	O
expression	O
of	O
p14ARF	S-GP
in	O
cells	O
resulted	O
in	O
a	O
suppression	O
of	O
PSA	S-GP
and	O
NK	B-GP
transcription	I-GP
factor	I-GP
locus	I-GP
1	E-GP
(	O
NKX3.1	S-GP
)	O
expression	O
.	O
Conversely	O
,	O
knockdown	O
of	O
endogenous	O
p14ARF	S-GP
in	O
human	O
PCa	O
cells	O
with	O
short	O
hairpin	O
RNA	O
enhanced	O
AR	S-GP
transactivation	O
activities	O
in	O
a	O
dose-dependent	O
and	O
p53	S-GP
-independent	O
manner	O
.	O
Furthermore	O
,	O
we	O
demonstrated	O
that	O
p14ARF	S-GP
binds	O
to	O
both	O
the	O
N	S-chemical
-terminal	O
domain	O
and	O
the	O
ligand-binding	O
domain	O
of	O
AR	S-GP
,	O
and	O
the	O
human	B-GP
double	I-GP
minute	I-GP
2	I-GP
(	I-GP
HDM2	I-GP
)	I-GP
-binding	I-GP
motif	E-GP
of	O
p14ARF	S-GP
is	O
required	O
for	O
the	O
interaction	O
of	O
p14ARF	S-GP
and	O
AR	S-GP
proteins	O
.	O
p14ARF	S-GP
perturbs	O
the	O
androgen	S-chemical
-induced	O
interaction	O
between	O
the	O
N	S-chemical
terminus	O
and	O
C	S-chemical
terminus	O
of	O
AR	S-GP
.	O
Most	O
importantly	O
,	O
we	O
observed	O
that	O
the	O
expression	O
of	O
PSA	S-GP
is	O
reversely	O
correlated	O
with	O
p14ARF	S-GP
in	O
human	O
prostate	O
tissues	O
.	O
Taken	O
together	O
,	O
our	O
results	O
reveal	O
a	O
novel	O
function	O
of	O
ARF	S-GP
in	O
modulation	O
of	O
AR	S-GP
transactivation	O
in	O
PCa	O
.	O

Histological	O
,	O
ultrastructural	O
and	O
immunohistochemical	O
studies	O
on	O
the	O
protective	O
effect	O
of	O
ginger	O
extract	O
against	O
cisplatin	S-chemical
-induced	O
nephrotoxicity	O
in	O
male	O
rats	O
.	O
Cisplatin	S-chemical
(	O
CP	O
)	O
is	O
a	O
widely	O
used	O
anticancer	O
drug	O
;	O
however	O
,	O
it	O
has	O
several	O
side	O
effects	O
such	O
as	O
nephrotoxicity	O
.	O
Ginger	O
,	O
the	O
rhizome	O
of	O
Zingiber	O
officinale	O
,	O
consumed	O
since	O
ancient	O
times	O
has	O
numerous	O
health	O
benefits	O
.	O
The	O
objective	O
of	O
this	O
work	O
was	O
to	O
evaluate	O
the	O
protective	O
effect	O
of	O
ginger	O
extract	O
(	O
GE	O
)	O
against	O
CP-induced	O
nephrotoxicity	O
.	O
CP	O
group	O
displayed	O
a	O
marked	O
renal	O
failure	O
characterized	O
by	O
a	O
significant	O
increase	O
in	O
serum	O
creatinine	S-chemical
and	O
blood	O
urea	S-chemical
nitrogen	S-chemical
(	O
BUN	O
)	O
levels	O
in	O
addition	O
to	O
severe	O
histopathological	O
and	O
ultrastructural	O
renal	O
alterations	O
.	O
Also	O
,	O
CP	O
group	O
showed	O
an	O
increase	O
in	O
the	O
immunohistochemical	O
expression	O
of	O
Bax	S-GP
proapoptotic	O
protein	O
.	O
In	O
contrast	O
,	O
GE+CP	O
group	O
showed	O
significant	O
decrease	O
in	O
the	O
elevated	O
serum	O
creatinine	S-chemical
and	O
BUN	O
levels	O
and	O
an	O
improvement	O
in	O
the	O
histopathological	O
and	O
ultrastructural	O
renal	O
injury	O
induced	O
by	O
CP	O
.	O
The	O
overexpression	O
of	O
Bax	S-GP
proapoptotic	O
protein	O
was	O
significantly	O
decreased	O
in	O
the	O
GE+CP	O
group	O
.	O
Hence	O
,	O
the	O
present	O
results	O
indicated	O
that	O
GE	O
has	O
a	O
protective	O
effect	O
against	O
CP-induced	O
renal	O
damage	O
in	O
rats	O
.	O
Thereby	O
,	O
such	O
findings	O
recommended	O
the	O
usage	O
of	O
GE	O
to	O
prevent	O
and/or	O
decrease	O
the	O
renal	O
damage	O
induced	O
by	O
CP	O
chemotherapeutic	O
treatment	O
.	O

The	O
cyclin	B-GP
D1	E-GP
(	O
CCND1	S-GP
)	O
rs9344	B-GP
G	I-GP
>	I-GP
A	E-GP
polymorphism	O
predicts	O
clinical	O
outcome	O
in	O
colon	O
cancer	O
patients	O
treated	O
with	O
adjuvant	O
5-FU	S-chemical
-based	O
chemotherapy	O
.	O
Recent	O
evidence	O
indicates	O
a	O
potential	O
prognostic	O
and	O
predictive	O
value	O
for	O
germline	O
polymorphisms	O
in	O
genes	O
involved	O
in	O
cell	O
cycle	O
control	O
.	O
We	O
investigated	O
the	O
effect	O
of	O
cyclin	B-GP
D1	E-GP
(	O
CCND1	S-GP
)	O
rs9344	B-GP
G	I-GP
>	I-GP
A	E-GP
in	O
stage	O
II/III	O
colon	O
cancer	O
patients	O
and	O
validated	O
the	O
findings	O
in	O
an	O
independent	O
study	O
cohort	O
.	O
For	O
evaluation	O
and	O
validation	O
set	O
,	O
a	O
total	O
of	O
264	O
and	O
234	O
patients	O
were	O
included	O
.	O
Patients	O
treated	O
with	O
5-fluorouracil	S-chemical
-based	O
chemotherapy	O
,	O
carrying	O
the	O
CCND1	S-GP
rs9344	B-GP
A/A	E-GP
genotype	O
had	O
significantly	O
decreased	O
time-to-tumor	O
recurrence	O
(	O
TTR	O
)	O
in	O
univariate	O
analysis	O
and	O
multivariate	O
analysis	O
(	O
hazard	O
ratio	O
(	O
HR	O
)	O
2.47	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.16-5.29	O
;	O
P=0.019	O
)	O
.	O
There	O
was	O
no	O
significant	O
association	O
between	O
CCND1	S-GP
rs9344	B-GP
G	I-GP
>	I-GP
A	E-GP
and	O
TTR	O
in	O
patients	O
with	O
curative	O
surgery	O
alone	O
.	O
In	O
the	O
validation	O
set	O
,	O
the	O
A	O
allele	O
of	O
CCND1	S-GP
rs9344	B-GP
G	I-GP
>	I-GP
A	E-GP
remained	O
significantly	O
associated	O
with	O
decreased	O
TTR	O
in	O
univariate	O
and	O
multivariate	O
analyses	O
(	O
HR	O
1.94	O
;	O
95	O
%	O
CI	O
1.05-3.58	O
;	O
P=0.035	O
)	O
.	O
CCND1	S-GP
rs9344	B-GP
G	I-GP
>	I-GP
A	E-GP
may	O
be	O
a	O
predictive	O
and/or	O
prognostic	O
biomarker	O
in	O
stage	O
II/III	O
colon	O
cancer	O
patients	O
,	O
however	O
,	O
prospective	O
trials	O
are	O
warranted	O
to	O
confirm	O
our	O
findings.The	O
Pharmacogenomics	O
Journal	O
advance	O
online	O
publication	O
,	O
9	O
April	O
2013	O
;	O
doi:10.1038/tpj.2013.15	O
.	O

Combining	O
quantum	O
mechanical	O
ligand	O
conformation	O
analysis	O
and	O
protein	O
modeling	O
to	O
elucidate	O
GPCR	S-GP
-ligand	O
binding	O
modes	O
.	O
SAR	O
beyond	O
protein-ligand	O
interactions	O
:	O
By	O
combining	O
structure-affinity	O
relationships	O
,	O
protein-ligand	O
modeling	O
studies	O
,	O
and	O
quantum	O
mechanical	O
calculations	O
,	O
we	O
show	O
that	O
ligand	O
conformational	O
energies	O
and	O
basicity	O
play	O
critical	O
roles	O
in	O
ligand	O
binding	O
to	O
the	O
histamine	S-chemical

Cabozantinib	S-chemical
(	O
XL184	S-chemical
)	O
,	O
a	O
novel	O
MET	S-GP
and	O
VEGFR2	S-GP
inhibitor	O
,	O
simultaneously	O
suppresses	O
metastasis	O
,	O
angiogenesis	O
,	O
and	O
tumor	O
growth	O
.	O
The	O
signaling	O
pathway	O
of	O
the	O
receptor	B-GP
tyrosine	I-GP
kinase	I-GP
MET	E-GP
and	O
its	O
ligand	O
hepatocyte	B-GP
growth	I-GP
factor	E-GP
(	O
HGF	S-GP
)	O
is	O
important	O
for	O
cell	O
growth	O
,	O
survival	O
,	O
and	O
motility	O
and	O
is	O
functionally	O
linked	O
to	O
the	O
signaling	O
pathway	O
of	O
VEGF	S-GP
,	O
which	O
is	O
widely	O
recognized	O
as	O
a	O
key	O
effector	O
in	O
angiogenesis	O
and	O
cancer	O
progression	O
.	O
Dysregulation	O
of	O
the	O
MET	S-GP
/	O
VEGF	S-GP
axis	O
is	O
found	O
in	O
a	O
number	O
of	O
human	O
malignancies	O
and	O
has	O
been	O
associated	O
with	O
tumorigenesis	O
.	O
Cabozantinib	S-chemical
(	O
XL184	S-chemical
)	O
is	O
a	O
small-molecule	O
kinase	S-GP
inhibitor	O
with	O
potent	O
activity	O
toward	O
MET	S-GP
and	O
VEGF	B-GP
receptor	I-GP
2	E-GP
(	O
VEGFR2	S-GP
)	O
,	O
as	O
well	O
as	O
a	O
number	O
of	O
other	O
receptor	B-GP
tyrosine	I-GP
kinases	E-GP
that	O
have	O
also	O
been	O
implicated	O
in	O
tumor	O
pathobiology	O
,	O
including	O
RET	S-GP
,	O
KIT	S-GP
,	O
AXL	S-GP
,	O
and	O
FLT3	S-GP
.	O
Treatment	O
with	O
cabozantinib	S-chemical
inhibited	O
MET	S-GP
and	O
VEGFR2	S-GP
phosphorylation	O
in	O
vitro	O
and	O
in	O
tumor	O
models	O
in	O
vivo	O
and	O
led	O
to	O
significant	O
reductions	O
in	O
cell	O
invasion	O
in	O
vitro	O
.	O
In	O
mouse	O
models	O
,	O
cabozantinib	S-chemical
dramatically	O
altered	O
tumor	O
pathology	O
,	O
resulting	O
in	O
decreased	O
tumor	O
and	O
endothelial	O
cell	O
proliferation	O
coupled	O
with	O
increased	O
apoptosis	O
and	O
dose-dependent	O
inhibition	O
of	O
tumor	O
growth	O
in	O
breast	O
,	O
lung	O
,	O
and	O
glioma	O
tumor	O
models	O
.	O
Importantly	O
,	O
treatment	O
with	O
cabozantinib	S-chemical
did	O
not	O
increase	O
lung	O
tumor	O
burden	O
in	O
an	O
experimental	O
model	O
of	O
metastasis	O
,	O
which	O
has	O
been	O
observed	O
with	O
inhibitors	O
of	O
VEGF	S-GP
signaling	O
that	O
do	O
not	O
target	O
MET	S-GP
.	O
Collectively	O
,	O
these	O
data	O
suggest	O
that	O
cabozantinib	S-chemical
is	O
a	O
promising	O
agent	O
for	O
inhibiting	O
tumor	O
angiogenesis	O
and	O
metastasis	O
in	O
cancers	O
with	O
dysregulated	O
MET	S-GP
and	O
VEGFR	S-GP
signaling	O
.	O

Synthesis	O
and	O
structure-activity	O
relationships	O
of	O
indazole	B-chemical
arylsulfonamides	E-chemical
as	O
allosteric	O
CC-chemokine	B-GP
receptor	I-GP
4	E-GP
(	O
CCR4	S-GP
)	O
antagonists	O
.	O
A	O
series	O
of	O
indazole	B-chemical
arylsulfonamides	E-chemical
were	O
synthesized	O
and	O
examined	O
as	O
human	B-GP
CCR4	E-GP
antagonists	O
.	O
Methoxy	S-chemical
-	O
or	O
hydroxyl	S-chemical
-containing	O
groups	O
were	O
the	O
more	O
potent	O
indazole	S-chemical
C4	O
substituents	O
.	O
Only	O
small	O
groups	O
were	O
tolerated	O
at	O
C5	O
,	O
C6	O
,	O
or	O
C7	O
,	O
with	O
the	O
C6	O
analogues	O
being	O
preferred	O
.	O
The	O
most	O
potent	O
N3-substituent	O
was	O
5-chlorothiophene-2-sulfonamide	S-chemical
.	O
N1	O
meta-substituted	O
benzyl	S-chemical
groups	O
possessing	O
an	O
α-amino-	O
3-	B-chemical
[	I-chemical
(	I-chemical
methylamino	I-chemical
)	I-chemical
acyl	I-chemical
]	E-chemical
-group	O
were	O
the	O
most	O
potent	O
N1-substituents	O
.	O
Strongly	O
basic	O
amino	S-chemical
groups	O
had	O
low	O
oral	O
absorption	O
in	O
vivo	O
.	O
Less	O
basic	O
analogues	O
,	O
such	O
as	O
morpholines	S-chemical
,	O
had	O
good	O
oral	O
absorption	O
;	O
however	O
,	O
they	O
also	O
had	O
high	O
clearance	O
.	O
The	O
most	O
potent	O
compound	O
with	O
high	O
absorption	O
in	O
two	O
species	O
was	O
analogue	O
6	O
(	O
GSK2239633A	S-chemical
)	O
,	O
which	O
was	O
selected	O
for	O
further	O
development	O
.	O
Aryl	B-chemical
sulfonamide	E-chemical
antagonists	O
bind	O
to	O
CCR4	S-GP
at	O
an	O
intracellular	O
allosteric	O
site	O
denoted	O
site	O
II	O
.	O
X-ray	O
diffraction	O
studies	O
on	O
two	O
indazole	B-chemical
sulfonamide	E-chemical
fragments	O
suggested	O
the	O
presence	O
of	O
an	O
important	O
intramolecular	O
interaction	O
in	O
the	O
active	O
conformation	O
.	O

The	O
effect	O
of	O
histamine-H1	B-GP
receptor	E-GP
antagonism	O
with	O
terfenadine	S-chemical
on	O
concentration-related	O
AMP	S-chemical
-induced	O
bronchoconstriction	O
in	O
asthma	O
.	O
Selective	O
histamine-H1	B-GP
receptor	E-GP
antagonists	O
inhibit	O
adenosine	B-chemical
5'-monophosphate	E-chemical
(	O
AMP	S-chemical
)	O
-induced	O
bronchoconstriction	O
by	O
greater	O
than	O
80	O
%	O
when	O
expressed	O
as	O
a	O
percentage	O
inhibition	O
of	O
the	O
FEV1	O
time-response	O
curve	O
following	O
inhalation	O
of	O
the	O
provocation	O
concentration	O
of	O
AMP	S-chemical
required	O
to	O
produce	O
a	O
20	O
%	O
decrease	O
in	O
FEV1	O
from	O
baseline	O
(	O
PC20	O
)	O
.	O
To	O
investigate	O
this	O
further	O
we	O
have	O
determined	O
that	O
,	O
in	O
eight	O
mild	O
atopic	O
asthmatic	O
subjects	O
,	O
terfenadine	S-chemical
(	O
180	O
mg	O
)	O
,	O
administered	O
3	O
hr	O
pre-challenge	O
,	O
increases	O
the	O
geometric	O
mean	O
PC20	O
for	O
histamine	S-chemical
from	O
0.4	O
(	O
range	O
0.03-3	O
)	O
mg/ml	O
after	O
placebo	O
,	O
to	O
20.2	O
(	O
range	O
0.6-64	O
)	O
mg/ml	O
following	O
active	O
treatment	O
(	O
P	O
less	O
than	O
0.0001	O
)	O
.	O
For	O
AMP	S-chemical
,	O
the	O
PC20	O
increased	O
from	O
9.3	O
(	O
range	O
1.0-113.3	O
)	O
mg/ml	O
after	O
placebo	O
,	O
to	O
150.2	O
(	O
range	O
32.1-1177.7	O
)	O
mg/ml	O
with	O
terfenadine	S-chemical
(	O
P	O
less	O
than	O
0.0001	O
)	O
.	O
This	O
16.2-fold	O
(	O
range	O
,	O
5.5-47.9	O
)	O
displacement	O
to	O
the	O
right	O
of	O
the	O
AMP	S-chemical
concentration-response	O
curve	O
by	O
a	O
selective	O
histamine-H1	B-GP
receptor	E-GP
antagonist	O
emphasizes	O
the	O
central	O
role	O
of	O
histamine	S-chemical
in	O
the	O
airways	O
response	O
to	O
this	O
nucleotide	O
.	O

Effects-based	O
marine	O
ecological	O
risk	O
assessment	O
at	O
a	O
polychlorinated	B-chemical
biphenyl	E-chemical
-contaminated	O
site	O
in	O
Saglek	O
,	O
Labrador	O
,	O
Canada	O
.	O
Although	O
the	O
presence	O
and	O
distribution	O
of	O
polychlorinated	B-chemical
biphenyls	E-chemical
(	O
PCBs	S-chemical
)	O
in	O
Arctic	O
marine	O
environments	O
has	O
been	O
well	O
documented	O
,	O
the	O
implications	O
for	O
the	O
health	O
of	O
biota	O
are	O
poorly	O
understood	O
.	O
In	O
the	O
present	O
study	O
,	O
multiple	O
lines	O
of	O
evidence	O
,	O
including	O
site-specific	O
effects	O
data	O
,	O
were	O
used	O
to	O
assess	O
PCB	S-chemical
-related	O
risks	O
to	O
marine	O
biota	O
at	O
a	O
contaminated	O
military	O
site	O
in	O
Saglek	O
Bay	O
,	O
Labrador	O
,	O
Canada	O
,	O
from	O
1997	O
to	O
1999	O
.	O
Risks	O
were	O
evaluated	O
for	O
three	O
components	O
of	O
the	O
ecosystem	O
:	O
benthic	O
invertebrates	O
,	O
a	O
bottom-feeding	O
fish	O
(	O
shorthorn	O
sculpin	O
,	O
Myoxocephalus	O
scorpius	O
)	O
,	O
and	O
a	O
diving	O
seabird	O
(	O
black	O
guillemot	O
,	O
Cepphus	O
grylle	O
)	O
.	O
Average	O
sediment	O
PCB	S-chemical
concentrations	O
exceeded	O
the	O
Canadian	O
interim	O
sediment	O
quality	O
guideline	O
level	O
by	O
41-fold	O
.	O
However	O
,	O
sediment	O
toxicity	O
testing	O
and	O
a	O
benthic	O
community	O
survey	O
showed	O
no	O
evidence	O
of	O
adverse	O
effects	O
.	O
In	O
contrast	O
,	O
shorthorn	O
sculpin	O
and	O
black	O
guillemot	O
PCB	S-chemical
exposures	O
(	O
measured	O
as	O
sum	O
of	O
55	O
congeners	O
)	O
were	O
elevated	O
enough	O
to	O
pose	O
risks	O
to	O
survival	O
or	O
reproduction	O
.	O
Based	O
on	O
the	O
collective	O
evidence	O
,	O
the	O
authors	O
estimated	O
that	O
risks	O
were	O
posed	O
by	O
sediment	O
PCB	S-chemical
concentrations	O
greater	O
than	O
77	O
ng/g	O
dry	O
weight	O
for	O
black	O
guillemots	O
and	O
750	O
ng/g	O
dry	O
weight	O
for	O
shorthorn	O
sculpins	O
.	O
The	O
present	O
study	O
,	O
along	O
with	O
two	O
parallel	O
studies	O
,	O
provided	O
information	O
to	O
support	O
the	O
management	O
decisions	O
concerning	O
potential	O
remedial	O
action	O
on	O
the	O
contaminated	O
sediments	O
.	O
This	O
ecological	O
risk	O
assessment	O
describes	O
the	O
steps	O
and	O
rationale	O
taken	O
to	O
evaluate	O
the	O
risk	O
posed	O
by	O
an	O
area	O
of	O
PCB	S-chemical
-contaminated	O
marine	O
sediments	O
in	O
an	O
otherwise	O
relatively	O
pristine	O
northern	O
coastal	O
environment	O
.	O

Hexahydrochromeno	B-chemical
[	I-chemical
4,3-b	I-chemical
]	I-chemical
pyrrole	E-chemical
derivatives	O
as	O
acetylcholinesterase	S-GP
inhibitors	O
.	O
In	O
a	O
search	O
for	O
less	O
flexible	O
analogues	O
of	O
caproctamine	S-chemical
(	O
1	O
)	O
,	O
a	O
diamine	S-chemical
diamide	S-chemical
endowed	O
with	O
an	O
interesting	O
AChE	S-GP
affinity	O
profile	O
,	O
we	O
discovered	O
compound	O
2	O
,	O
in	O
which	O
the	O
terminal	O
2-methoxybenzyl	S-chemical
groups	O
of	O
1	O
have	O
been	O
incorporated	O
into	O
a	O
tricyclic	S-chemical
system	O
.	O
Since	O
this	O
compound	O
retains	O
good	O
AChE	S-GP
inhibitory	O
activity	O
and	O
its	O
hexahydrochromeno	B-chemical
[	I-chemical
4,3-b	I-chemical
]	I-chemical
pyrrole	E-chemical
moiety	O
is	O
reminiscent	O
of	O
the	O
hexahydropyrrolo	B-chemical
[	I-chemical
2,3-b	I-chemical
]	I-chemical
indole	I-chemical
of	I-chemical
physostigmine	E-chemical
(	O
3	O
)	O
,	O
we	O
have	O
designed	O
and	O
synthesized	O
carbamates	S-chemical
4-6	O
,	O
and	O
their	O
biological	O
evaluation	O
has	O
been	O
assessed	O
in	O
vitro	O
against	O
human	B-GP
AChE	E-GP
and	O
BChE	S-GP
.	O
The	O
6-carbamate	S-chemical
4	O
was	O
almost	O
as	O
potent	O
as	O
physostigmine	S-chemical
and	O
was	O
60-	O
and	O
550-fold	O
more	O
potent	O
than	O
the	O
7-carbamate	O
5	O
and	O
the	O
8-carbamate	O
6	O
,	O
respectively	O
.	O
The	O
two	O
enantiomers	O
of	O
4	O
,	O
(	O
-	O
)	O
-4	O
and	O
(	O
+	O
)	O
-4	O
,	O
did	O
not	O
show	O
a	O
marked	O
enantioselectivity	O
.	O
Finally	O
,	O
a	O
similar	O
time-dependent	O
pattern	O
of	O
inhibition	O
of	O
AChE	S-GP
was	O
observed	O
for	O
3	O
and	O
4	O
.	O

How	O
do	O
volatile	O
anesthetics	O
inhibit	O
Ca	B-GP
(	I-GP
2+	I-GP
)	I-GP
-ATPases	E-GP
?	O
Volatile	O
anesthetics	O
at	O
concentrations	O
that	O
are	O
used	O
in	O
clinical	O
practice	O
to	O
induce	O
anesthesia	O
selectively	O
inhibit	O
activity	O
of	O
the	O
plasma	O
membrane	O
Ca	B-GP
(	I-GP
2+	I-GP
)	I-GP
-transport	I-GP
ATPase	E-GP
(	O
Kosk-Kosicka	O
,	O
D.	O
,	O
and	O
Roszczynska	O
,	O
G.	O
(	O
1993	O
)	O
Anesthesiology	O
79	O
,	O
774-780	O
)	O
.	O
We	O
have	O
investigated	O
the	O
mechanism	O
of	O
the	O
inhibitory	O
action	O
of	O
several	O
anesthetics	O
on	O
the	O
purified	O
erythrocyte	O
Ca	B-GP
(	I-GP
2+	I-GP
)	I-GP
-ATPase	E-GP
by	O
employing	O
fluorescence	O
spectroscopy	O
measurements	O
that	O
report	O
changes	O
in	O
the	O
environment	O
of	O
intrinsic	O
tryptophans	S-chemical
and	O
of	O
an	O
extrinsic	O
probe	O
attached	O
in	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
.	O
We	O
have	O
shown	O
that	O
the	O
observed	O
inhibition	O
of	O
the	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
-dependent	O
activation	O
of	O
the	O
enzyme	O
correlates	O
well	O
with	O
the	O
elimination	O
of	O
the	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
-induced	O
conformation	O
change	O
that	O
is	O
important	O
for	O
the	O
proper	O
function	O
of	O
the	O
enzyme	O
.	O
Analysis	O
of	O
the	O
anesthetics	O
effects	O
on	O
the	O
total	O
tryptophan	S-chemical
fluorescence	O
indicates	O
a	O
significant	O
effect	O
on	O
enzyme	O
conformation	O
.	O
Similar	O
changes	O
have	O
been	O
observed	O
in	O
the	O
sarcoplasmic	B-GP
reticulum	I-GP
Ca	I-GP
(	I-GP
2+	I-GP
)	I-GP
-ATPase	E-GP
.	O
We	O
propose	O
that	O
volatile	O
anesthetics	O
inhibit	O
Ca	B-GP
(	I-GP
2+	I-GP
)	I-GP
-ATPase	E-GP
by	O
interacting	O
with	O
nonpolar	O
sites	O
in	O
protein	O
interior	O
,	O
in	O
analogy	O
to	O
the	O
binding	O
demonstrated	O
for	O
myoglobin	S-GP
,	O
hemoglobin	S-GP
,	O
and	O
adenylate	B-GP
kinase	E-GP
(	O
Schoenborn	O
,	O
B.	O
P.	O
,	O
and	O
Featherstone	O
,	O
R.	O
M.	O
(	O
1967	O
)	O
Adv	O
.	O
Pharmacol	O
.	O
5	O
,	O
1-17	O
;	O
Tilton	O
,	O
R.	O
F.	O
,	O
Kuntz	O
,	O
I.	O
D.	O
,	O
and	O
Petsko	O
,	O
G.	O
A	O
.	O
(	O
1984	O
)	O
Biochemistry	O
23	O
,	O
2849-2857	O
)	O
.	O
Such	O
binding	O
is	O
expected	O
to	O
modify	O
conformational	O
substate	O
(	O
s	O
)	O
of	O
the	O
enzyme	O
and	O
perturb	O
its	O
function	O
.	O
We	O
view	O
this	O
process	O
as	O
an	O
example	O
of	O
a	O
general	O
phenomena	O
of	O
interaction	O
of	O
small	O
molecules	O
with	O
internal	O
sites	O
in	O
proteins	O
.	O

Discovery	O
of	O
a	O
Novel	O
Selective	O
PPARγ	S-GP
Ligand	O
with	O
Partial	O
Agonist	O
Binding	O
Properties	O
by	O
Integrated	O
in	O
Silico/in	O
Vitro	O
Work	O
Flow	O
.	O
Full	O
agonists	O
to	O
the	O
peroxisome	B-GP
proliferator-activated	I-GP
receptor	I-GP
(	I-GP
PPAR	I-GP
)	I-GP
γ	E-GP
,	O
such	O
as	O
Rosiglitazone	S-chemical
,	O
have	O
been	O
associated	O
with	O
a	O
series	O
of	O
undesired	O
side	O
effects	O
,	O
such	O
as	O
weight	O
gain	O
,	O
fluid	O
retention	O
,	O
cardiac	O
hypertrophy	O
,	O
and	O
hepatotoxicity	O
.	O
Nevertheless	O
,	O
PPARγ	S-GP
is	O
involved	O
in	O
the	O
expression	O
of	O
genes	O
that	O
control	O
glucose	S-chemical
and	O
lipid	O
metabolism	O
and	O
is	O
an	O
important	O
target	O
for	O
drugs	O
against	O
type	O
2	O
diabetes	O
,	O
dyslipidemia	O
,	O
atherosclerosis	O
,	O
and	O
cardiovascular	O
disease	O
.	O
In	O
an	O
effort	O
to	O
identify	O
novel	O
PPARγ	S-GP
ligands	O
with	O
an	O
improved	O
pharmacological	O
profile	O
,	O
emphasis	O
has	O
shifted	O
to	O
selective	O
ligands	O
with	O
partial	O
agonist	O
binding	O
properties	O
.	O
Toward	O
this	O
end	O
we	O
applied	O
an	O
integrated	O
in	O
silico/in	O
vitro	O
workflow	O
,	O
based	O
on	O
pharmacophore-	O
and	O
structure-based	O
virtual	O
screening	O
of	O
the	O
ZINC	O
library	O
,	O
coupled	O
with	O
competitive	O
binding	O
and	O
transactivation	O
assays	O
,	O
and	O
adipocyte	O
differentiation	O
and	O
gene	O
expression	O
studies	O
.	O
Hit	O
compound	O
9	O
was	O
identified	O
as	O
the	O
most	O
potent	O
ligand	O
(	O
IC50	O
=	O
0.3	O
μM	O
)	O
and	O
a	O
relatively	O
poor	O
inducer	O
of	O
adipocyte	O
differentiation	O
.	O
The	O
binding	O
mode	O
of	O
compound	O
9	O
was	O
confirmed	O
by	O
molecular	O
dynamics	O
simulation	O
,	O
and	O
the	O
calculated	O
free	O
energy	O
of	O
binding	O
was	O
-8.4	O
kcal/mol	O
.	O
A	O
novel	O
functional	O
group	O
,	O
the	O
carbonitrile	S-chemical
group	O
,	O
was	O
identified	O
to	O
be	O
a	O
key	O
substituent	O
in	O
the	O
ligand-protein	O
interactions	O
.	O
Further	O
studies	O
on	O
the	O
transcriptional	O
regulation	O
properties	O
of	O
compound	O
9	O
revealed	O
a	O
gene	O
regulatory	O
profile	O
that	O
was	O
to	O
a	O
large	O
extent	O
unique	O
,	O
however	O
functionally	O
closer	O
to	O
that	O
of	O
a	O
partial	O
agonist	O
.	O

Inhibition	O
of	O
the	O
human	B-GP
ether-a-go-go-related	I-GP
gene	I-GP
(	I-GP
HERG	I-GP
)	I-GP
potassium	I-GP
channel	E-GP
by	O
cisapride	S-chemical
:	O
affinity	O
for	O
open	O
and	O
inactivated	O
states	O
.	O
1	O
Cisapride	S-chemical
is	O
a	O
prokinetic	O
agent	O
which	O
has	O
been	O
associated	O
with	O
QT	O
prolongation	O
,	O
torsades	O
de	O
pointes	O
and	O
cardiac	O
arrest	O
.	O
The	O
cellular	O
mechanism	O
for	O
these	O
observations	O
is	O
high	O
affinity	O
blockade	O
of	O
IKr	S-GP
(	O
encoded	O
by	O
HERG	S-GP
)	O
.	O
2	O
In	O
a	O
chronic	O
transfection	O
model	O
using	O
CHO-K1	O
cells	O
,	O
cisapride	S-chemical
inhibited	O
HERG	S-GP
tail	O
currents	O
after	O
a	O
step	O
to	O
+25	O
mV	O
with	O
similar	O
potency	O
at	O
room	O
and	O
physiological	O
temperatures	O
(	O
IC50	O
16	O
.	O
4	O
nM	O
at	O
20-22	O
degrees	O
C	O
and	O
23.6	O
nM	O
at	O
37	O
degrees	O
C	O
)	O
.	O
3	O
Channel	O
inhibition	O
exhibited	O
time-	O
,	O
voltage-	O
and	O
frequency-dependence	O
.	O
In	O
an	O
envelope	O
of	O
tails	O
test	O
,	O
channel	O
blockade	O
increased	O
from	O
27+/-8	O
%	O
after	O
a	O
120	O
ms	O
depolarizing	O
step	O
to	O
50+/-4	O
%	O
after	O
a	O
1.0	O
s	O
step	O
.	O
These	O
findings	O
suggested	O
affinity	O
for	O
open	O
and/or	O
inactivated	O
channel	O
states	O
.	O
4	O
Inactivation	O
was	O
significantly	O
accelerated	O
by	O
cisapride	S-chemical
in	O
a	O
concentration-dependent	O
manner	O
and	O
there	O
was	O
a	O
small	O
(	O
-7	O
mV	O
)	O
shift	O
in	O
the	O
voltage	O
dependence	O
of	O
steady	O
state	O
inactivation	O
.	O
5	O
Channel	O
blockade	O
by	O
cisapride	S-chemical
was	O
modulated	O
by	O
[	O
K+	S-chemical
]	O
o	O
,	O
with	O
a	O
26	O
%	O
reduction	O
in	O
the	O
potency	O
of	O
channel	O
blockade	O
when	O
[	O
K+	S-chemical
]	O
o	O
was	O
increased	O
from	O
1	O
to	O
10	O
mM	O
.	O
6	O
In	O
conclusion	O
,	O
HERG	S-GP
channel	O
inhibition	O
by	O
cisapride	S-chemical
exhibits	O
features	O
consistent	O
with	O
open	O
and	O
inactivated	O
state	O
binding	O
and	O
is	O
sensitive	O
to	O
external	O
potassium	S-chemical
concentration	O
.	O
These	O
features	O
may	O
have	O
significant	O
clinical	O
implications	O
with	O
regard	O
to	O
the	O
mechanism	O
and	O
treatment	O
of	O
cisapride	S-chemical
-induced	O
proarrhythmia	O
.	O

DNA	B-GP
topoisomerase	I-GP
IIalpha	E-GP
(	O
TOP2A	S-GP
)	O
inhibitors	O
up-regulate	O
fatty	B-GP
acid	I-GP
synthase	E-GP
gene	O
expression	O
in	O
SK-Br3	O
breast	O
cancer	O
cells	O
:	O
in	O
vitro	O
evidence	O
for	O
a	O
'functional	O
amplicon	O
'	O
involving	O
FAS	S-GP
,	O
Her-2	S-GP
/	O
neu	S-GP
and	O
TOP2A	S-GP
genes	O
.	O
Fatty	B-GP
acid	I-GP
synthase	E-GP
(	O
FAS	S-GP
)	O
,	O
the	O
key	O
metabolic	O
multi-enzyme	O
that	O
is	O
responsible	O
for	O
the	O
terminal	O
catalytic	O
step	O
in	O
the	O
de	O
novo	O
fatty	O
acid	O
biosynthesis	O
,	O
plays	O
an	O
active	O
role	O
in	O
the	O
development	O
,	O
maintenance	O
,	O
and	O
enhancement	O
of	O
the	O
malignant	O
phenotype	O
in	O
a	O
subset	O
of	O
breast	O
carcinomas	O
.	O
We	O
recently	O
described	O
that	O
a	O
molecular	O
bi-directional	O
cross-talk	O
between	O
FAS	S-GP
and	O
the	O
Her-2	S-GP
/	O
neu	S-GP
(	O
erbB-2	S-GP
)	O
oncogene	O
is	O
taking	O
place	O
at	O
the	O
level	O
of	O
transcription	O
,	O
translation	O
,	O
and	O
activity	O
in	O
breast	O
cancer	O
cells	O
.	O
Because	O
Her-2	S-GP
/	O
neu	S-GP
has	O
been	O
linked	O
with	O
altered	O
sensitivity	O
to	O
cytotoxic	O
drugs	O
,	O
we	O
envisioned	O
that	O
FAS	S-GP
gene	O
expression	O
may	O
represent	O
a	O
novel	O
predictive	O
molecular	O
factor	O
for	O
breast	O
cancer	O
response	O
to	O
chemotherapy	O
in	O
a	O
Her-2	S-GP
/	O
neu	S-GP
-related	O
manner	O
.	O
We	O
herein	O
evaluated	O
whether	O
chemotherapy-induced	O
cell	O
damage	O
acts	O
in	O
an	O
epigenetic	O
fashion	O
by	O
inducing	O
changes	O
in	O
the	O
transcriptional	O
activation	O
of	O
FAS	S-GP
gene	O
in	O
breast	O
cancer	O
cells	O
.	O
To	O
evaluate	O
this	O
option	O
,	O
FAS	S-GP
-	O
and	O
Her-2	S-GP
/	O
neu	S-GP
-overexpressing	O
SK-Br3	O
breast	O
cancer	O
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
FAS	B-GP
promoter	E-GP
-reporter	O
construct	O
(	O
FAS	S-GP
-Luciferase	O
)	O
harboring	O
all	O
the	O
elements	O
necessary	O
for	O
high	O
level	O
expression	O
in	O
cancer	O
cells	O
.	O
SK-Br3	O
cells	O
cultured	O
in	O
the	O
presence	O
of	O
topoisomerase	B-GP
IIalpha	E-GP
(	O
TOP2A	S-GP
)	O
inhibitors	O
doxorubicin	S-chemical
and	O
etopoxide	S-chemical
(	O
VP-16	S-chemical
)	O
demonstrated	O
a	O
2-	O
to	O
3-fold	O
increase	O
in	O
FAS	B-GP
promoter	E-GP
activity	O
when	O
compared	O
with	O
control	O
cells	O
growing	O
in	O
drug-free	O
culture	O
conditions	O
.	O
We	O
failed	O
to	O
observe	O
any	O
significant	O
activation	O
of	O
FAS	B-GP
promoter	E-GP
following	O
exposure	O
to	O
the	O
anti-metabolite	O
5-fluorouracil	S-chemical
,	O
the	O
alkylating	O
drug	O
cisplatin	S-chemical
,	O
or	O
the	O
microtubule	O
interfering-agents	O
paclitaxel	S-chemical
and	O
vincristine	S-chemical
.	O
Moreover	O
,	O
the	O
up-regulatory	O
effects	O
of	O
TOP2A	S-GP
inhibitors	O
on	O
the	O
transcriptional	O
activation	O
of	O
FAS	S-GP
gene	O
expression	O
were	O
not	O
significantly	O
decreased	O
when	O
the	O
FAS	B-GP
promoter	E-GP
was	O
damaged	O
at	O
the	O
sterol	B-GP
regulatory	I-GP
element	I-GP
binding	I-GP
protein	E-GP
(	O
SREBP	S-GP
)	O
-binding	O
site	O
.	O
Considering	O
that	O
FAS	S-GP
inhibition	O
produces	O
profound	O
inhibition	O
of	O
DNA	O
replication	O
and	O
S-phase	O
progression	O
in	O
cancer	O
cells	O
,	O
we	O
finally	O
asked	O
whether	O
a	O
cross-talk	O
between	O
TOP2A	S-GP
and	O
FAS	S-GP
could	O
exhibit	O
a	O
Her-2	S-GP
/	O
neu	S-GP
-related	O
bi-directional	O
nature	O
.	O
TOP2A	S-GP
protein	O
levels	O
were	O
decreased	O
during	O
treatment	O
with	O
the	O
anti-	O
Her-2	S-GP
/	O
neu	S-GP
antibody	O
trastuzumab	O
while	O
,	O
concomitantly	O
,	O
FAS	B-GP
promoter	E-GP
activity	O
and	O
FAS	S-GP
protein	O
expression	O
were	O
significantly	O
reduced	O
.	O
Of	O
note	O
,	O
when	O
the	O
expression	O
levels	O
of	O
TOP2A	S-GP
protein	O
were	O
analyzed	O
following	O
exposure	O
of	O
SK-Br3	O
cells	O
to	O
increasing	O
concentrations	O
of	O
the	O
novel	O
slow-binding	O
FAS	S-GP
inhibitor	O
C75	O
,	O
a	O
dose-dependent	O
reduction	O
in	O
TOP2A	S-GP
expression	O
was	O
observed	O
.	O
Although	O
FAS	S-GP
gene	O
is	O
not	O
physically	O
located	O
in	O
the	O
Her-2	S-GP
/	O
neu	S-GP
-	O
TOP2A	S-GP
amplicon	O
,	O
our	O
present	O
findings	O
strongly	O
suggest	O
that	O
a	O
tight	O
functional	O
association	O
between	O
FAS	S-GP
,	O
Her-2	S-GP
/	O
neu	S-GP
and	O
TOP2A	S-GP
genes	O
is	O
taking	O
place	O
in	O
a	O
subset	O
of	O
breast	O
carcinoma	O
cells	O
.	O

Trichostatin	B-chemical
A	E-chemical
inhibits	O
transforming	B-GP
growth	I-GP
factor-β	E-GP
-induced	O
reactive	O
oxygen	S-chemical
species	O
accumulation	O
and	O
myofibroblast	O
differentiation	O
via	O
enhanced	O
NF-E2-related	B-GP
factor	I-GP
2	E-GP
-	O
antioxidant	B-GP
response	I-GP
element	E-GP
signaling	O
.	O
Trichostatin	B-chemical
A	E-chemical
(	O
TSA	S-chemical
)	O
has	O
been	O
shown	O
to	O
prevent	O
fibrosis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
The	O
present	O
study	O
aimed	O
at	O
investigating	O
the	O
role	O
of	O
reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
scavenging	O
by	O
TSA	S-chemical
on	O
transforming	B-GP
growth	I-GP
factor-β	E-GP
(	O
TGF-β	B-GP
)	E-GP
-induced	O
myofibroblast	O
differentiation	O
of	O
corneal	O
fibroblasts	O
in	O
vitro	O
.	O
Human	O
immortalized	O
corneal	O
fibroblasts	O
were	O
treated	O
with	O
TGF-β	S-GP
in	O
the	O
presence	O
of	O
TSA	S-chemical
,	O
the	O
NAD	B-GP
(	I-GP
P	I-GP
)	I-GP
H	I-GP
oxidase	E-GP
inhibitor	O
diphenyleneiodonium	S-chemical
(	O
DPI	S-chemical
)	O
,	O
the	O
antioxidant	O
N-acetyl-cysteine	S-chemical
(	O
NAC	S-chemical
)	O
,	O
the	O
NF-E2-related	B-GP
factor	I-GP
2	E-GP
-	O
antioxidant	B-GP
response	I-GP
element	E-GP
(	O
Nrf2	S-GP
-	O
ARE	S-GP
)	O
activator	O
sulforaphane	S-chemical
,	O
or	O
small	O
interfering	O
RNA	O
.	O
Myofibroblast	O
differentiation	O
was	O
assessed	O
by	O
α-smooth	B-GP
muscle	I-GP
actin	E-GP
(	O
α-SMA	S-GP
)	O
expression	O
,	O
F-actin	S-GP
bundle	O
formation	O
,	O
and	O
collagen	S-GP
gel	O
contraction	O
.	O
ROS	O
,	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
O	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
,	O
intracellular	O
glutathione	S-chemical
(	O
GSH	S-chemical
)	O
level	O
,	O
cellular	O
total	O
antioxidant	O
capacity	O
,	O
and	O
the	O
activation	O
of	O
Nrf2	S-GP
-	O
ARE	S-GP
signaling	O
were	O
determined	O
with	O
various	O
assays	O
.	O
Treatment	O
with	O
TSA	S-chemical
and	O
the	O
Nrf2	S-GP
-	O
ARE	S-GP
activator	O
resulted	O
in	O
increased	O
inhibition	O
of	O
the	O
TGF-β	S-GP
-induced	O
myofibroblast	O
differentiation	O
as	O
compared	O
with	O
treatment	O
with	O
DPI	S-chemical
or	O
NAC	S-chemical
.	O
Furthermore	O
,	O
TSA	S-chemical
also	O
decreased	O
cellular	O
ROS	O
and	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
O	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
accumulation	O
induced	O
by	O
TGF-β	S-GP
,	O
whereas	O
it	O
elevated	O
intracellular	O
GSH	S-chemical
level	O
and	O
cellular	O
total	O
antioxidant	O
capacity	O
.	O
In	O
addition	O
,	O
TSA	S-chemical
induced	O
Nrf2	S-GP
nuclear	O
translocation	O
and	O
up-regulated	O
the	O
expression	O
of	O
Nrf2	S-GP
-	O
ARE	S-GP
downstream	O
antioxidant	O
genes	O
,	O
whereas	O
Nrf2	S-GP
knockdown	O
by	O
RNA	O
interference	O
blocked	O
the	O
inhibition	O
of	O
TSA	S-chemical
on	O
myofibroblast	O
differentiation	O
.	O
In	O
conclusion	O
,	O
this	O
study	O
provides	O
the	O
first	O
evidence	O
implicating	O
that	O
TSA	S-chemical
inhibits	O
TGF-β	S-GP
-induced	O
ROS	O
accumulation	O
and	O
myofibroblast	O
differentiation	O
via	O
enhanced	O
Nrf2	S-GP
-	O
ARE	S-GP
signaling	O
.	O

Safety	O
and	O
tolerability	O
of	O
denufosol	B-chemical
tetrasodium	E-chemical
inhalation	O
solution	O
,	O
a	O
novel	O
P2Y2	B-GP
receptor	E-GP
agonist	O
:	O
results	O
of	O
a	O
phase	O
1/phase	O
2	O
multicenter	O
study	O
in	O
mild	O
to	O
moderate	O
cystic	O
fibrosis	O
.	O
Denufosol	B-chemical
tetrasodium	E-chemical
(	O
INS37217	S-chemical
)	O
is	O
a	O
selective	O
P2Y	B-GP
(	I-GP
2	I-GP
)	E-GP
agonist	O
that	O
stimulates	O
ciliary	O
beat	O
frequency	O
and	O
Cl	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
secretion	O
in	O
normal	O
and	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
airway	O
epithelia	O
,	O
and	O
is	O
being	O
investigated	O
as	O
an	O
inhaled	O
treatment	O
for	O
CF	O
.	O
The	O
Cl	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
secretory	O
response	O
is	O
mediated	O
via	O
a	O
non-	O
CFTR	S-GP
pathway	O
,	O
and	O
the	O
driving	O
force	O
for	O
Cl	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
secretion	O
is	O
enhanced	O
by	O
the	O
effect	O
of	O
P2Y	B-GP
(	I-GP
2	I-GP
)	E-GP
activation	O
to	O
also	O
inhibit	O
epithelial	O
Na	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
transport	O
.	O
Denufosol	S-chemical
is	O
metabolically	O
more	O
stable	O
and	O
better	O
tolerated	O
,	O
and	O
may	O
enhance	O
mucociliary	O
clearance	O
for	O
a	O
longer	O
period	O
of	O
time	O
than	O
previously	O
investigated	O
P2Y	B-GP
(	I-GP
2	I-GP
)	E-GP
agonists	O
.	O
The	O
goal	O
of	O
this	O
phase	O
1/phase	O
2	O
study	O
was	O
to	O
assess	O
the	O
safety	O
and	O
tolerability	O
of	O
single	O
and	O
repeated	O
doses	O
of	O
aerosolized	O
denufosol	S-chemical
in	O
subjects	O
with	O
CF	O
.	O
The	O
study	O
was	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
multicenter	O
comparison	O
of	O
ascending	O
single	O
doses	O
of	O
denufosol	S-chemical
(	O
10	O
,	O
20	O
,	O
40	O
,	O
and	O
60	O
mg	O
,	O
administered	O
by	O
inhalation	O
via	O
the	O
Pari	O
LC	O
Star	O
nebulizer	O
)	O
vs.	O
placebo	O
(	O
normal	O
saline	O
)	O
,	O
followed	O
by	O
a	O
comparison	O
of	O
twice-daily	O
administration	O
of	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
denufosol	S-chemical
or	O
placebo	O
for	O
5	O
days	O
.	O
Thirty-seven	O
adult	O
(	O
18	O
years	O
of	O
age	O
or	O
older	O
)	O
and	O
24	O
pediatric	O
(	O
5-17	O
years	O
of	O
age	O
)	O
subjects	O
with	O
CF	O
were	O
evaluated	O
in	O
five	O
cohorts	O
.	O
Subjects	O
were	O
randomized	O
in	O
a	O
3:1	O
ratio	O
to	O
receive	O
either	O
denufosol	S-chemical
or	O
placebo	O
within	O
each	O
cohort	O
.	O
The	O
percent	O
of	O
subjects	O
experiencing	O
adverse	O
events	O
was	O
similar	O
between	O
the	O
denufosol	S-chemical
and	O
placebo	O
groups	O
.	O
The	O
most	O
common	O
adverse	O
event	O
in	O
subjects	O
receiving	O
denufosol	S-chemical
was	O
chest	O
tightness	O
in	O
adult	O
subjects	O
(	O
39	O
%	O
)	O
and	O
cough	O
in	O
pediatric	O
subjects	O
(	O
56	O
%	O
)	O
.	O
Three	O
(	O
7	O
%	O
)	O
subjects	O
receiving	O
denufosol	S-chemical
and	O
one	O
(	O
7	O
%	O
)	O
subject	O
receiving	O
placebo	O
experienced	O
a	O
serious	O
adverse	O
event	O
.	O
Forced	O
expiratory	O
volume	O
in	O
1	O
sec	O
(	O
FEV	O
(	O
1	O
)	O
)	O
profiles	O
following	O
dosing	O
were	O
similar	O
across	O
treatment	O
groups	O
,	O
with	O
some	O
acute	O
,	O
reversible	O
decline	O
seen	O
in	O
both	O
groups	O
,	O
most	O
notably	O
in	O
subjects	O
with	O
lower	O
lung	O
function	O
at	O
baseline	O
.	O
In	O
conclusion	O
,	O
doses	O
up	O
to	O
60	O
mg	O
of	O
denufosol	S-chemical
inhalation	O
solution	O
were	O
well-tolerated	O
in	O
most	O
subjects	O
.	O
Some	O
intolerability	O
was	O
noted	O
among	O
subjects	O
with	O
lower	O
baseline	O
lung	O
function	O
.	O
Based	O
on	O
the	O
results	O
of	O
this	O
phase	O
1/phase	O
2	O
study	O
,	O
the	O
Therapeutics	O
Development	O
Network	O
(	O
TDN	O
)	O
of	O
the	O
Cystic	O
Fibrosis	O
Foundation	O
(	O
CFF	O
)	O
and	O
Inspire	O
Pharmaceuticals	O
,	O
Inc.	O
,	O
recently	O
completed	O
a	O
multicenter	O
,	O
28-day	O
,	O
phase	O
2	O
safety	O
and	O
efficacy	O
clinical	O
trial	O
of	O
denufosol	S-chemical
inhalation	O
solution	O
in	O
CF	O
subjects	O
with	O
mild	O
lung	O
disease	O
.	O

25-Hydroxyvitamin	B-chemical
D	E-chemical
in	O
Obese	O
Youth	O
Across	O
the	O
Spectrum	O
of	O
Glucose	S-chemical
Tolerance	O
From	O
Normal	O
to	O
Prediabetes	O
to	O
Type	O
2	O
Diabetes	O
.	O
OBJECTIVETo	O
1	O
)	O
determine	O
if	O
plasma	O
25-hydroxyvitamin	B-chemical
D	E-chemical
(	O
25	B-chemical
[	I-chemical
OH	I-chemical
]	I-chemical
D	E-chemical
)	O
concentrations	O
differ	O
among	O
obese	O
youth	O
with	O
normal	O
glucose	S-chemical
tolerance	O
(	O
NGT	O
)	O
versus	O
prediabetes	O
versus	O
type	O
2	O
diabetes	O
,	O
and	O
2	O
)	O
assess	O
the	O
relationships	O
between	O
25	B-chemical
(	I-chemical
OH	I-chemical
)	I-chemical
D	E-chemical
and	O
in	O
vivo	O
insulin	S-GP
sensitivity	O
and	O
β-cell	O
function	O
in	O
this	O
cohort.RESEARCH	O
DESIGN	O
AND	O
METHODSPlasma	O
25	B-chemical
(	I-chemical
OH	I-chemical
)	I-chemical
D	E-chemical
concentrations	O
were	O
examined	O
in	O
banked	O
specimens	O
in	O
9-	O
to	O
20-year-old	O
obese	O
youth	O
(	O
n	O
=	O
175	O
;	O
male	O
42.3	O
%	O
,	O
black	O
46.3	O
%	O
)	O
(	O
NGT	O
,	O
n	O
=	O
105	O
;	O
impaired	O
glucose	S-chemical
tolerance	O
[	O
IGT	O
]	O
,	O
n	O
=	O
43	O
;	O
type	O
2	O
diabetes	O
,	O
n	O
=	O
27	O
)	O
who	O
had	O
in	O
vivo	O
insulin	S-GP
sensitivity	O
and	O
secretion	O
measured	O
by	O
hyperinsulinemic-euglycemic	O
and	O
hyperglycemic	O
clamp	O
techniques	O
and	O
had	O
an	O
assessment	O
of	O
total	O
body	O
composition	O
and	O
abdominal	O
adiposity.RESULTSThe	O
mean	O
age	O
and	O
BMI	O
of	O
the	O
subjects	O
were	O
14.3	O
±	O
2.1	O
years	O
and	O
35.7	O
±	O
5.6	O
kg/m	O
(	O
2	O
)	O
,	O
respectively	O
.	O
BMI	O
,	O
plasma	O
25	B-chemical
(	I-chemical
OH	I-chemical
)	I-chemical
D	E-chemical
,	O
and	O
the	O
proportion	O
of	O
vitamin	B-chemical
D	E-chemical
-deficient	O
and	O
-insufficient	O
children	O
did	O
not	O
differ	O
across	O
the	O
three	O
groups	O
.	O
Furthermore	O
,	O
there	O
was	O
no	O
association	O
between	O
25	B-chemical
(	I-chemical
OH	I-chemical
)	I-chemical
D	E-chemical
and	O
in	O
vivo	O
insulin	S-GP
sensitivity	O
or	O
β-cell	O
function	O
relative	O
to	O
insulin	S-GP
sensitivity	O
(	O
disposition	O
index	O
)	O
in	O
all	O
groups	O
combined	O
or	O
in	O
each	O
group	O
separately.CONCLUSIONSOur	O
data	O
in	O
obese	O
youth	O
show	O
1	O
)	O
no	O
differences	O
in	O
plasma	O
25	B-chemical
(	I-chemical
OH	I-chemical
)	I-chemical
D	E-chemical
concentrations	O
across	O
the	O
glucose	S-chemical
tolerance	O
groups	O
,	O
and	O
2	O
)	O
no	O
relationship	O
between	O
25	B-chemical
(	I-chemical
OH	I-chemical
)	I-chemical
D	E-chemical
and	O
in	O
vivo	O
insulin	S-GP
sensitivity	O
and	O
β-cell	O
function	O
relative	O
to	O
insulin	S-GP
sensitivity	O
in	O
any	O
of	O
the	O
groups	O
.	O
It	O
remains	O
uncertain	O
if	O
enhancement	O
of	O
the	O
vitamin	B-chemical
D	E-chemical
status	O
could	O
improve	O
pathophysiological	O
mechanisms	O
of	O
prediabetes	O
and	O
type	O
2	O
diabetes	O
in	O
obese	O
youth	O
.	O

Evaluation	O
of	O
drug	O
interactions	O
of	O
GSK1292263	S-chemical
(	O
a	O
GPR119	S-GP
agonist	O
)	O
with	O
statins	O
:	O
from	O
in	O
vitro	O
data	O
to	O
clinical	O
study	O
design	O
.	O
1	O
.	O
This	O
work	O
investigated	O
the	O
drug	O
interaction	O
potential	O
of	O
GSK1292263	S-chemical
,	O
a	O
novel	O
GPR119	S-GP
agonist	O
,	O
with	O
the	O
HMG-coA	B-GP
reductase	E-GP
inhibitors	O
simvastatin	S-chemical
and	O
rosuvastatin	S-chemical
.	O
2	O
.	O
In	O
vitro	O
experiments	O
assessed	O
the	O
inhibition	O
of	O
transporters	S-GP
and	O
CYP	S-GP
enzymes	O
by	O
GSK1292263	S-chemical
,	O
and	O
a	O
clinical	O
drug	O
interaction	O
study	O
investigated	O
the	O
effect	O
of	O
GSK1292263	S-chemical
(	O
300	O
mg	O
BID	O
)	O
on	O
the	O
pharmacokinetic	O
profile	O
of	O
simvastatin	S-chemical
(	O
40	O
mg	O
single	O
dose	O
)	O
and	O
rosuvastatin	S-chemical
(	O
10	O
mg	O
single	O
dose	O
)	O
.	O
3	O
.	O
In	O
vitro	O
,	O
GSK1292263	S-chemical
demonstrated	O
little/weak	O
inhibition	O
(	O
IC50	O
values	O
>	O
30	O
μM	O
)	O
towards	O
CYPs	S-GP
(	O
CYP1A2	S-GP
,	O
2C9	S-GP
,	O
2C19	S-GP
,	O
2D6	S-GP
,	O
3A4	S-GP
)	O
,	O
Pgp	S-GP
,	O
OATP1B3	S-GP
,	O
or	O
OCT2	S-GP
.	O
However	O
,	O
GSK1292263	S-chemical
inhibited	O
BCRP	S-GP
and	O
OATP1B1	S-GP
,	O
which	O
are	O
transporters	O
involved	O
in	O
statin	O
disposition	O
.	O
4	O
.	O
In	O
the	O
clinical	O
study	O
,	O
small	O
increases	O
in	O
the	O
AUC	O
(	O
0-inf	O
)	O
of	O
simvastatin	S-chemical
[	O
mean	O
ratio	O
(	O
90	O
%	O
CI	O
)	O
of	O
1.34	O
(	O
1.22	O
,	O
1.48	O
)	O
]	O
and	O
rosuvastatin	S-chemical
[	O
mean	O
ratio	O
(	O
90	O
%	O
CI	O
)	O
of	O
1.39	O
(	O
1.30	O
,	O
1.49	O
)	O
]	O
were	O
observed	O
when	O
co-administered	O
with	O
GSK1292263	S-chemical
,	O
which	O
is	O
consistent	O
with	O
an	O
inhibitory	O
effect	O
on	O
intestinal	O
BCRP	S-GP
and	O
CYP3A4	S-GP
.	O
In	O
contrast	O
,	O
GSK1292263	S-chemical
did	O
not	O
inhibit	O
OATP1B1	S-GP
based	O
on	O
the	O
lack	O
of	O
changes	O
in	O
simvastatin	S-chemical
acid	O
exposure	O
[	O
mean	O
AUC	O
(	O
0-inf	O
)	O
ratio	O
(	O
90	O
%	O
CI	O
)	O
of	O
1.05	O
(	O
0.91	O
,	O
1.21	O
)	O
]	O
.	O
5	O
.	O
GSK1292263	S-chemical
has	O
a	O
weak	O
drug	O
interaction	O
with	O
simvastatin	S-chemical
and	O
rosuvastain	S-chemical
.	O
This	O
study	O
provides	O
a	O
mechanistic	O
understanding	O
of	O
the	O
in	O
vivo	O
inhibition	O
of	O
transporters	S-GP
and	O
enzymes	O
by	O
GSK1292263	S-chemical
.	O

Effect	O
of	O
isolated	O
isoflavone	S-chemical
supplementation	O
on	O
ABCA1	S-GP
-dependent	O
cholesterol	S-chemical
efflux	O
potential	O
in	O
postmenopausal	O
women	O
.	O
OBJECTIVE	O
:	O
Isoflavones	S-chemical
may	O
display	O
beneficial	O
health	O
effects	O
in	O
postmenopausal	O
women	O
.	O
We	O
studied	O
in	O
a	O
clinical	O
trial	O
whether	O
isolated	O
isoflavone	S-chemical
treatment	O
in	O
postmenopausal	O
women	O
could	O
affect	O
reverse	O
cholesterol	S-chemical
transport	O
as	O
evaluated	O
by	O
adenosine	B-GP
triphosphate-binding	I-GP
cassette	I-GP
A1	E-GP
-	O
(	O
ABCA1	S-GP
)	O
,	O
dependent	O
cholesterol	S-chemical
efflux	O
from	O
macrophages	O
.	O
In	O
addition	O
,	O
various	O
serum	O
lipid	O
and	O
lipoprotein	S-GP
parameters	O
were	O
investigated	O
.	O
Furthermore	O
,	O
we	O
separately	O
assessed	O
equol-producing	O
and	O
non-equol-producing	O
women	O
.	O
DESIGN	O
:	O
Postmenopausal	O
women	O
(	O
n=56	O
)	O
were	O
treated	O
with	O
either	O
isoflavone	S-chemical
or	O
placebo	O
tablets	O
for	O
3	O
months	O
in	O
a	O
crossover	O
design	O
,	O
separated	O
by	O
a	O
2-month	O
washout	O
period	O
.	O
Fifteen	O
women	O
were	O
classified	O
as	O
equol	O
producers	O
,	O
and	O
15	O
women	O
were	O
classified	O
as	O
non-equol	O
producers	O
.	O
Serum	O
samples	O
were	O
collected	O
before	O
and	O
after	O
each	O
treatment	O
period	O
.	O
[	B-chemical
H	I-chemical
]	I-chemical
-Cholesterol	E-chemical
-labeled	O
J774	O
macrophage	O
cells	O
,	O
with	O
and	O
without	O
ABCA1	S-GP
up-regulation	O
,	O
were	O
incubated	O
with	O
the	O
samples	O
,	O
and	O
ABCA1	S-GP
-dependent	O
cholesterol	S-chemical
efflux	O
and	O
serum	O
lipid	O
and	O
lipoprotein	S-GP
levels	O
were	O
assessed	O
.	O
RESULTS	O
:	O
Serum	O
promoted	O
3.1	O
%	O
+/-1.1	O
%	O
and	O
3.2	O
%	O
+/-1.1	O
%	O
cholesterol	S-chemical
efflux	O
from	O
macrophages	O
after	O
isoflavone	S-chemical
and	O
placebo	O
treatment	O
,	O
respectively	O
.	O
Thus	O
,	O
isoflavone	S-chemical
supplementation	O
did	O
not	O
affect	O
ABCA1	S-GP
-dependent	O
cholesterol	S-chemical
efflux	O
to	O
serum	O
.	O
However	O
,	O
as	O
a	O
novel	O
finding	O
,	O
isoflavone	S-chemical
treatment	O
increased	O
a	O
subclass	O
of	O
high-density	B-GP
lipoprotein	E-GP
,	O
the	O
pre-beta	B-GP
high-density	I-GP
lipoprotein	E-GP
levels	O
by	O
18	O
%	O
without	O
affecting	O
any	O
other	O
serum	O
lipid	O
concentrations	O
.	O
ABCA1	S-GP
-facilitated	O
cholesterol	S-chemical
efflux	O
and	O
lipid	O
parameters	O
did	O
not	O
differ	O
between	O
equol	S-chemical
-producing	O
and	O
non-	O
equol	S-chemical
-producing	O
women	O
.	O
CONCLUSION	O
:	O
In	O
postmenopausal	O
women	O
,	O
isolated	O
isoflavone	S-chemical
treatment	O
does	O
not	O
affect	O
ABCA1	S-GP
-dependent	O
cholesterol	S-chemical
efflux	O
potential	O
from	O
macrophages	O
but	O
increases	O
circulating	O
pre-beta	B-GP
high-density	I-GP
lipoprotein	E-GP
level	O
,	O
which	O
could	O
provide	O
beneficial	O
vascular	O
effects	O
.	O

Design	O
and	O
synthesis	O
of	O
bicyclic	B-chemical
pyrazinone	I-chemical
and	I-chemical
pyrimidinone	I-chemical
amides	E-chemical
as	O
potent	O
TF	S-GP
-	O
FVIIa	S-GP
inhibitors	O
.	O
Bicyclic	B-chemical
pyrazinone	I-chemical
and	I-chemical
pyrimidinone	I-chemical
amides	E-chemical
were	O
designed	O
and	O
synthesized	O
as	O
potent	O
TF	S-GP
-	O
FVIIa	S-GP
inhibitors	O
.	O
SAR	O
demonstrated	O
that	O
the	O
S2	O
and	O
S3	O
pockets	O
of	O
FVIIa	S-GP
prefer	O
to	O
bind	O
small	O
,	O
lipophilic	O
groups	O
.	O
An	O
X-ray	O
crystal	O
structure	O
of	O
optimized	O
compound	O
9b	O
bound	O
in	O
the	O
active	O
site	O
of	O
FVIIa	S-GP
showed	O
that	O
the	O
bicyclic	O
scaffold	O
provides	O
5	O
hydrogen	S-chemical
bonding	O
interactions	O
in	O
addition	O
to	O
projecting	O
groups	O
for	O
interactions	O
within	O
the	O
S1	O
,	O
S2	O
and	O
S3	O
pockets	O
.	O
Compound	O
9b	O
showed	O
excellent	O
FVIIa	S-GP
potency	O
,	O
good	O
selectivity	O
against	O
FIXa	B-GP
,	I-GP
Xa	I-GP
,	I-GP
XIa	E-GP
and	O
chymotrypsin	S-GP
,	O
and	O
good	O
clotting	O
activity	O
.	O

Transcription	O
forms	O
and	O
remodels	O
supercoiling	B-GP
domains	E-GP
unfolding	O
large-scale	O
chromatin	O
structures	O
.	O
DNA	O
supercoiling	O
is	O
an	O
inherent	O
consequence	O
of	O
twisting	O
DNA	O
and	O
is	O
critical	O
for	O
regulating	O
gene	O
expression	O
and	O
DNA	O
replication	O
.	O
However	O
,	O
DNA	O
supercoiling	O
at	O
a	O
genomic	O
scale	O
in	O
human	O
cells	O
is	O
uncharacterized	O
.	O
To	O
map	O
supercoiling	O
,	O
we	O
used	O
biotinylated	B-chemical
trimethylpsoralen	E-chemical
as	O
a	O
DNA	O
structure	O
probe	O
to	O
show	O
that	O
the	O
human	O
genome	O
is	O
organized	O
into	O
supercoiling	B-GP
domains	E-GP
.	O
Domains	O
are	O
formed	O
and	O
remodeled	O
by	O
RNA	B-GP
polymerase	E-GP
and	O
topoisomerase	S-GP
activities	O
and	O
are	O
flanked	O
by	O
GC-AT	O
boundaries	O
and	O
CTCF	S-GP
insulator	O
protein-binding	O
sites	O
.	O
Underwound	B-GP
domains	E-GP
are	O
transcriptionally	O
active	O
and	O
enriched	O
in	O
topoisomerase	B-GP
I	E-GP
,	O
'open	O
'	O
chromatin	O
fibers	O
and	O
DNase	B-GP
I	E-GP
sites	O
,	O
but	O
they	O
are	O
depleted	O
of	O
topoisomerase	B-GP
II	E-GP
.	O
Furthermore	O
,	O
DNA	O
supercoiling	O
affects	O
additional	O
levels	O
of	O
chromatin	O
compaction	O
as	O
underwound	B-GP
domains	E-GP
are	O
cytologically	O
decondensed	O
,	O
topologically	O
constrained	O
and	O
decompacted	O
by	O
transcription	O
of	O
short	O
RNAs	O
.	O
We	O
suggest	O
that	O
supercoiling	O
domains	O
create	O
a	O
topological	O
environment	O
that	O
facilitates	O
gene	O
activation	O
,	O
providing	O
an	O
evolutionary	O
purpose	O
for	O
clustering	O
genes	O
along	O
chromosomes	O
.	O

Puerarin	S-chemical
stimulates	O
proliferation	O
and	O
differentiation	O
and	O
protects	O
against	O
cell	O
death	O
in	O
human	O
osteoblastic	O
MG-63	O
cells	O
via	O
ER	S-GP
-dependent	O
MEK	S-GP
/	O
ERK	S-GP
and	O
PI3K	S-GP
/	O
Akt	S-GP
activation	O
.	O
Puerarin	S-chemical
,	O
the	O
main	O
isoflavone	B-chemical
glycoside	E-chemical
found	O
in	O
the	O
Chinese	O
herb	O
radix	O
of	O
Pueraria	O
lobata	O
(	O
Willd	O
.	O
)	O
Ohwi	O
,	O
has	O
received	O
increasing	O
attention	O
because	O
of	O
its	O
possible	O
role	O
in	O
the	O
prevention	O
of	O
osteoporosis	O
.	O
Previously	O
,	O
we	O
showed	O
that	O
puerarin	S-chemical
could	O
inhibit	O
the	O
bone	O
absorption	O
of	O
osteoclasts	O
and	O
promote	O
long	O
bone	O
growth	O
in	O
fetal	O
mouse	O
in	O
vitro	O
.	O
Further	O
study	O
confirmed	O
that	O
puerarin	S-chemical
stimulated	O
proliferation	O
and	O
differentiation	O
of	O
osteoblasts	O
in	O
rat	O
.	O
However	O
,	O
the	O
mechanisms	O
underlying	O
its	O
actions	O
on	O
human	O
bone	O
cells	O
have	O
not	O
been	O
well	O
defined	O
.	O
Here	O
we	O
show	O
that	O
puerarin	S-chemical
increases	O
proliferation	O
and	O
differentiation	O
and	O
opposes	O
cisplatin	S-chemical
-induced	O
apoptosis	O
in	O
human	O
osteoblastic	O
MG-63	O
cells	O
containing	O
two	O
estrogen	B-GP
receptor	E-GP
(	O
ER	S-GP
)	O
isoforms	O
.	O
Puerarin	S-chemical
promotes	O
proliferation	O
by	O
altering	O
cell	O
cycle	O
distribution	O
whereas	O
puerarin	S-chemical
-mediated	O
survival	O
may	O
be	O
associated	O
with	O
up-regulation	O
of	O
Bcl-xL	S-GP
expression	O
.	O
Treatment	O
with	O
the	O
ER	S-GP
antagonist	O
ICI	B-chemical
182,780	E-chemical
abolishes	O
the	O
above	O
actions	O
of	O
puerarin	S-chemical
on	O
osteoblast-derived	O
cells	O
.	O
Using	O
small	O
interfering	O
double-stranded	O
RNA	O
technology	O
,	O
we	O
further	O
demonstrate	O
that	O
the	O
effects	O
of	O
puerarin	S-chemical
on	O
proliferation	O
,	O
differentiation	O
and	O
survival	O
are	O
mediated	O
by	O
both	O
ERα	S-GP
and	O
ERβ	S-GP
.	O
Moreover	O
,	O
we	O
also	O
demonstrate	O
that	O
puerarin	S-chemical
functions	O
at	O
least	O
partially	O
through	O
activation	O
of	O
MEK	S-GP
/	O
ERK	S-GP
and	O
PI3K	S-GP
/	O
Akt	S-GP
signaling	O
.	O
This	O
agent	O
also	O
shows	O
much	O
weaker	O
effect	O
on	O
breast	O
epithelial	O
cell	O
growth	O
than	O
that	O
of	O
estrogen	S-chemical
.	O
Therefore	O
,	O
puerarin	S-chemical
will	O
be	O
a	O
promising	O
agent	O
that	O
prevents	O
or	O
retards	O
osteoporosis	O
.	O

High-	O
mannose	S-chemical
-type	O
glycan	O
modifications	O
of	O
dihydrofolate	B-GP
reductase	E-GP
using	O
glycan-	O
methotrexate	S-chemical
conjugates	O
.	O
Various	O
high-	O
mannose	S-chemical
-type	O
glycan	O
modifications	O
of	O
dihydrofolate	B-GP
reductase	E-GP
(	O
DHFR	S-GP
)	O
were	O
achieved	O
by	O
ligand-based	O
approach	O
using	O
glycan-	O
methotrexate	S-chemical
(	O
MTX	S-chemical
)	O
conjugates	O
as	O
tight	O
binding	O
glycan	O
bearing	O
ligands	O
for	O
DHFR	S-GP
.	O
The	O
resulting	O
glycan-	O
MTX	S-chemical
conjugates	O
and	O
the	O
corresponding	O
artificial	O
glycoproteins	O
could	O
be	O
useful	O
as	O
oligosaccharide-	O
and	O
glycoprotein-probes	O
to	O
perform	O
quantitative	O
analysis	O
of	O
glycan	B-GP
recognizing	I-GP
protein	E-GP
such	O
as	O
lectins	S-GP
,	O
glycosyltransferases	S-GP
or	O
glycosidases	S-GP
.	O
Moreover	O
,	O
artificial	O
glycoproteins	O
having	O
two	O
different	O
high-	O
mannose	S-chemical
-type	O
glycans	O
were	O
developed	O
for	O
the	O
first	O
time	O
by	O
a	O
combination	O
of	O
two	O
different	O
types	O
of	O
glycan	O
modification	O
strategies	O
.	O

Expression	O
and	O
1,4-dihydropyridine	S-chemical
-binding	O
properties	O
of	O
brain	O
L-type	B-GP
calcium	I-GP
channel	E-GP
isoforms	O
.	O
The	O
L-type	B-GP
calcium	I-GP
channel	E-GP
(	O
LTCC	S-GP
)	O
isoforms	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.2	E-GP
and	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.3	E-GP
display	O
similar	O
1,4-dihydropyridine	S-chemical
(	O
DHP	S-chemical
)	O
binding	O
properties	O
and	O
are	O
both	O
expressed	O
in	O
mammalian	O
brain	O
.	O
Recent	O
work	O
implicates	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.3	E-GP
channels	O
as	O
interesting	O
drug	O
targets	O
,	O
but	O
no	O
isoform-selective	O
modulators	O
exist	O
.	O
It	O
is	O
also	O
unknown	O
to	O
what	O
extent	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.1	E-GP
and	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.4	E-GP
contribute	O
to	O
L-type-specific	O
DHP	S-chemical
binding	O
activity	O
in	O
brain	O
.	O
To	O
address	O
this	O
question	O
and	O
to	O
determine	O
whether	O
DHPs	O
can	O
discriminate	O
between	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.2	E-GP
and	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.3	E-GP
binding	O
pockets	O
,	O
we	O
combined	O
radioreceptor	O
assays	O
and	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
.	O
We	O
bred	O
double	O
mutants	O
(	O
Ca	B-GP
(	I-GP
v	I-GP
)	E-GP
-DM	O
)	O
from	O
mice	O
expressing	O
mutant	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.2	E-GP
channels	O
[	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.2	E-GP
DHP	O
(	O
-/-	O
)	O
]	O
lacking	O
high	O
affinity	O
for	O
DHPs	O
and	O
from	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.3	E-GP
knockouts	O
[	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.3	E-GP
(	O
-/-	O
)	O
]	O
.	O
(	B-chemical
+	I-chemical
)	I-chemical
-	I-chemical
[	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
isradipine	E-chemical
binding	O
to	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.2	E-GP
DHP	O
(	O
-/-	O
)	O
and	O
Ca	B-GP
(	I-GP
v	I-GP
)	E-GP
-DM	O
brains	O
was	O
reduced	O
to	O
15.1	O
and	O
4.4	O
%	O
of	O
wild	O
type	O
,	O
respectively	O
,	O
indicating	O
that	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.3	E-GP
accounts	O
for	O
10.7	O
%	O
of	O
brain	O
LTCCs	S-GP
.	O
qPCR	O
revealed	O
that	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.1	E-GP
and	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.4	I-GP
alpha	I-GP
(	I-GP
1	I-GP
)	E-GP
subunits	O
comprised	O
0.08	O
%	O
of	O
the	O
LTCC	S-GP
transcripts	O
in	O
mouse	O
whole	O
brain	O
,	O
suggesting	O
that	O
they	O
can	O
not	O
account	O
for	O
the	O
residual	O
binding	O
.	O
Instead	O
,	O
this	O
could	O
be	O
explained	O
by	O
low-affinity	O
binding	O
(	O
127-fold	O
K	O
(	O
d	O
)	O
increase	O
)	O
to	O
the	O
mutated	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.2	E-GP
channels	O
.	O
Inhibition	O
of	O
(	B-chemical
+	I-chemical
)	I-chemical
-	I-chemical
[	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
isradipine	E-chemical
binding	O
to	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.2	E-GP
DHP	O
(	O
-/-	O
)	O
(	O
predominantly	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.3	E-GP
)	O
and	O
wild-type	O
(	O
predominantly	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.2	E-GP
)	O
brain	O
membranes	O
by	O
unlabeled	O
DHPs	O
revealed	O
a	O
3-	O
to	O
4-fold	O
selectivity	O
of	O
nitrendipine	S-chemical
and	O
nifedipine	S-chemical
for	O
the	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.2	E-GP
binding	O
pocket	O
,	O
a	O
finding	O
further	O
confirmed	O
with	O
heterologously	O
expressed	O
channels	O
.	O
This	O
suggests	O
that	O
small	O
differences	O
in	O
their	O
binding	O
pockets	O
may	O
allow	O
development	O
of	O
isoform-selective	O
modulators	O
for	O
LTCCs	S-GP
and	O
that	O
,	O
because	O
of	O
their	O
very	O
low	O
expression	O
,	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.1	E-GP
and	O
Ca	B-GP
(	I-GP
v	I-GP
)	I-GP
1.4	E-GP
are	O
unlikely	O
to	O
serve	O
as	O
drug	O
targets	O
to	O
treat	O
CNS	O
diseases	O
.	O

Age-dependent	O
changes	O
of	O
pyridoxal	B-chemical
phosphate	E-chemical
synthesizing	O
enzymes	O
immunoreactivities	O
and	O
activities	O
in	O
the	O
gerbil	O
hippocampal	O
CA1	O
region	O
.	O
In	O
the	O
present	O
study	O
,	O
age-related	O
changes	O
of	O
pyridoxal	B-chemical
5'-phosphate	E-chemical
(	O
PLP	S-chemical
)	O
synthesizing	O
enzymes	O
,	O
pyridoxal	B-GP
kinase	E-GP
(	O
PLK	S-GP
)	O
and	O
pyridoxine	B-GP
5'-phosphate	I-GP
oxidase	E-GP
(	O
PNPO	S-GP
)	O
,	O
their	O
protein	O
contents	O
and	O
activities	O
were	O
examined	O
in	O
the	O
gerbil	O
hippocampus	O
proper	O
.	O
Significant	O
age-dependent	O
changes	O
in	O
PLK	S-GP
and	O
PNPO	S-GP
immunoreactivities	O
were	O
found	O
in	O
the	O
CA1	O
region	O
,	O
but	O
not	O
in	O
the	O
CA2/3	O
region	O
.	O
In	O
the	O
postnatal	O
month	O
1	O
(	O
PM	O
1	O
)	O
group	O
,	O
PLK	S-GP
and	O
PNPO	S-GP
immunoreactivities	O
were	O
detected	O
mainly	O
in	O
the	O
stratum	O
pyramidale	O
of	O
the	O
CA1	O
region	O
.	O
PLK	S-GP
and	O
PNPO	S-GP
immunoreactivities	O
and	O
their	O
protein	O
contents	O
were	O
highest	O
in	O
the	O
PM	O
6	O
group	O
,	O
showing	O
that	O
many	O
CA1	O
pyramidal	O
cells	O
had	O
strong	O
PLK	S-GP
and	O
PNPO	S-GP
immunoreactivities	O
.	O
Thereafter	O
,	O
PLK	S-GP
and	O
PNPO	S-GP
immunoreactivities	O
started	O
to	O
decrease	O
and	O
were	O
very	O
low	O
at	O
PM	O
24	O
.	O
Alterations	O
in	O
the	O
change	O
patterns	O
in	O
protein	O
contents	O
and	O
total	O
activities	O
of	O
PLK	S-GP
and	O
PNPO	S-GP
corresponded	O
to	O
the	O
immunohistochemical	O
data	O
,	O
but	O
their	O
specific	O
activities	O
were	O
not	O
altered	O
in	O
any	O
experimental	O
group	O
.	O
Based	O
on	O
double	O
immunofluorescence	O
study	O
,	O
PLK	S-GP
and	O
PNPO	S-GP
immunoreactive	O
cells	O
in	O
the	O
strata	O
oriens	O
and	O
radiatum	O
were	O
identified	O
as	O
GABAergic	O
cells	O
.	O
Therefore	O
,	O
decreases	O
of	O
PLK	S-GP
and	O
PNPO	S-GP
in	O
the	O
hippocampal	O
CA1	O
region	O
of	O
aged	O
brains	O
may	O
be	O
involved	O
in	O
aging	O
processes	O
related	O
with	O
gamma-aminobutyric	B-chemical
acid	E-chemical
(	O
GABA	S-chemical
)	O
function	O
.	O

Adenosine	B-GP
deaminase	E-GP
is	O
a	O
specific	O
partner	O
for	O
the	O
Grb2	S-GP
isoform	O
Grb3-3	S-GP
.	O
Grb3-3	S-GP
is	O
an	O
isoform	O
of	O
Grb2	S-GP
,	O
thought	O
to	O
arise	O
by	O
alternative	O
splicing	O
,	O
that	O
lacks	O
a	O
functional	O
SH2	B-GP
domain	E-GP
but	O
retains	O
functional	O
SH3	B-GP
domains	E-GP
,	O
which	O
allow	O
interaction	O
with	O
other	O
proteins	O
through	O
binding	O
to	O
prolinerich	O
sequences	O
.	O
Several	O
evidences	O
suggest	O
that	O
besides	O
common	O
partners	O
for	O
Grb2	S-GP
and	O
Grb3-3	S-GP
,	O
specific	O
targets	O
could	O
exist	O
.	O
In	O
order	O
to	O
find	O
specific	O
partners	O
for	O
Grb3-3	S-GP
,	O
we	O
have	O
screened	O
a	O
human	O
cDNA	O
library	O
by	O
the	O
yeast	O
two-hybrid	O
system	O
with	O
Grb3-3	S-GP
as	O
a	O
bait	O
.	O
We	O
have	O
identified	O
adenosine	B-GP
deaminase	E-GP
,	O
an	O
enzyme	O
involved	O
in	O
purine	S-chemical
metabolism	O
whose	O
deficiency	O
is	O
associated	O
with	O
severe	O
combined	O
immunodeficiency	O
,	O
as	O
a	O
Grb3-3	S-GP
binding	O
protein	O
that	O
is	O
not	O
able	O
to	O
bind	O
to	O
Grb2	S-GP
.	O
This	O
interaction	O
has	O
been	O
confirmed	O
in	O
vitro	O
with	O
GST	S-GP
fusion	O
proteins	O
and	O
in	O
vivo	O
by	O
coimmunoprecipitation	O
experiments	O
in	O
NIH3T3	O
cells	O
stably	O
transfected	O
with	O
Grb3-3	S-GP
.	O
The	O
functional	O
significance	O
of	O
this	O
finding	O
is	O
discussed	O
.	O

Cannabinoid	S-chemical
discrimination	O
and	O
antagonism	O
by	O
CB	B-GP
(	I-GP
1	I-GP
)	E-GP
neutral	O
and	O
inverse	O
agonist	O
antagonists	O
.	O
Cannabinoid	B-GP
receptor	I-GP
1	E-GP
(	O
CB	B-GP
(	I-GP
1	I-GP
)	E-GP
)	O
inverse	O
agonists	O
(	O
e.g.	O
,	O
rimonabant	S-chemical
)	O
have	O
been	O
reported	O
to	O
produce	O
adverse	O
effects	O
including	O
nausea	O
,	O
emesis	O
,	O
and	O
anhedonia	O
that	O
limit	O
their	O
clinical	O
applications	O
.	O
Recent	O
laboratory	O
studies	O
suggest	O
that	O
the	O
effects	O
of	O
CB	B-GP
(	I-GP
1	I-GP
)	E-GP
neutral	O
antagonists	O
differ	O
from	O
those	O
of	O
such	O
inverse	O
agonists	O
,	O
raising	O
the	O
possibility	O
of	O
improved	O
clinical	O
utility	O
.	O
However	O
,	O
little	O
is	O
known	O
regarding	O
the	O
antagonist	O
properties	O
of	O
neutral	O
antagonists	O
.	O
In	O
the	O
present	O
studies	O
,	O
the	O
CB	B-GP
(	I-GP
1	I-GP
)	E-GP
inverse	O
agonist	O
SR141716A	S-chemical
(	O
rimonabant	S-chemical
)	O
and	O
the	O
CB	B-GP
(	I-GP
1	I-GP
)	E-GP
neutral	O
antagonist	O
AM4113	S-chemical
were	O
compared	O
for	O
their	O
ability	O
to	O
modify	O
CB	B-GP
(	I-GP
1	I-GP
)	I-GP
receptor	E-GP
-mediated	O
discriminative	O
stimulus	O
effects	O
in	O
nonhuman	O
primates	O
trained	O
to	O
discriminate	O
the	O
novel	O
CB	B-GP
(	I-GP
1	I-GP
)	E-GP
full	O
agonist	O
AM4054	S-chemical
.	O
Results	O
indicate	O
that	O
AM4054	S-chemical
serves	O
as	O
an	O
effective	O
CB	B-GP
(	I-GP
1	I-GP
)	E-GP
discriminative	O
stimulus	O
,	O
with	O
an	O
onset	O
and	O
time	O
course	O
of	O
action	O
comparable	O
with	O
that	O
of	O
the	O
CB	B-GP
(	I-GP
1	I-GP
)	E-GP
agonist	O
Δ	B-chemical
(	I-chemical
9	I-chemical
)	I-chemical
-tetrahydrocannabinol	E-chemical
,	O
and	O
that	O
the	O
inverse	O
agonist	O
rimonabant	S-chemical
and	O
the	O
neutral	O
antagonist	O
AM4113	S-chemical
produce	O
dose-related	O
rightward	O
shifts	O
in	O
the	O
AM4054	S-chemical
dose-effect	O
curve	O
,	O
indicating	O
that	O
both	O
drugs	O
surmountably	O
antagonize	O
the	O
discriminative	O
stimulus	O
effects	O
of	O
AM4054	S-chemical
.	O
Schild	O
analyses	O
further	O
show	O
that	O
rimonabant	S-chemical
and	O
AM4113	S-chemical
produce	O
highly	O
similar	O
antagonist	O
effects	O
,	O
as	O
evident	O
in	O
comparable	O
pA	O
(	O
2	O
)	O
values	O
(	O
6.9	O
)	O
.	O
Taken	O
together	O
with	O
previous	O
studies	O
,	O
the	O
present	O
data	O
suggest	O
that	O
the	O
improved	O
safety	O
profile	O
suggested	O
for	O
CB	B-GP
(	I-GP
1	I-GP
)	E-GP
neutral	O
antagonists	O
over	O
inverse	O
agonists	O
is	O
not	O
accompanied	O
by	O
a	O
loss	O
of	O
antagonist	O
action	O
at	O
CB	B-GP
(	I-GP
1	I-GP
)	I-GP
receptors	E-GP
.	O

In	O
vivo	O
activity	O
of	O
the	O
potent	O
oxytocin	S-chemical
antagonist	O
on	O
uterine	O
activity	O
in	O
the	O
rat	O
.	O
Oxytocin	O
antagonist	O
(	O
OTA	O
)	O
,	O
TT-235	O
,	O
was	O
developed	O
by	O
our	O
group	O
and	O
shown	O
to	O
inhibit	O
either	O
spontaneous	O
or	O
oxytocin	S-GP
-induced	O
uterine	O
contractions	O
in	O
primates	O
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
confirm	O
the	O
duration	O
of	O
TT-235	O
to	O
block	O
oxytocin-induced	O
uterine	O
contractions	O
in	O
estrous	O
rats	O
.	O
In	O
Experiment	O
1	O
,	O
the	O
time-response	O
of	O
the	O
three	O
OTAs	O
on	O
uterine	O
contractility	O
was	O
examined	O
.	O
The	O
rats	O
were	O
anesthetized	O
and	O
cannulas	O
were	O
placed	O
in	O
the	O
jugular	O
vein	O
for	O
infusing	O
vehicle	O
(	O
sterile	O
saline	O
)	O
,	O
Antag	O
I	O
,	O
Antag	O
II	O
and	O
TT-235	O
.	O
The	O
uterine	O
activity	O
was	O
monitored	O
through	O
a	O
water-filled	O
balloon-tipped	O
cannula	O
placed	O
in	O
the	O
uterine	O
horn	O
.	O
The	O
uterine	O
contractile	O
activity	O
was	O
determined	O
as	O
the	O
integrated	O
area	O
for	O
10	O
minutes	O
.	O
Each	O
OTA	O
was	O
administered	O
as	O
a	O
single	O
bolus	O
injection	O
of	O
5	O
microg	O
,	O
followed	O
by	O
100	O
mU	O
of	O
oxytocin	O
5	O
minutes	O
later	O
,	O
also	O
done	O
as	O
a	O
single	O
bolus	O
.	O
Oxytocin	S-chemical

Discovery	O
of	O
7-methoxy-6-	B-chemical
[	I-chemical
4-	I-chemical
(	I-chemical
4-methyl-1,3-thiazol-2-yl	I-chemical
)	I-chemical
-1H-imidazol-5-yl	I-chemical
]	I-chemical
-1,3-benzothiazole	E-chemical
(	O
TASP0382088	S-chemical
)	O
:	O
a	O
potent	O
and	O
selective	O
transforming	B-GP
growth	I-GP
factor-β	I-GP
type	I-GP
I	I-GP
receptor	E-GP
inhibitor	O
as	O
a	O
topical	O
drug	O
for	O
alopecia	O
.	O
7-Methoxy-6-	B-chemical
[	I-chemical
4-	I-chemical
(	I-chemical
4-methyl-1,3-thiazol-2-yl	I-chemical
)	I-chemical
-1H-imidazol-5-yl	I-chemical
]	I-chemical
-1,3-benzothiazole	E-chemical
11	O
(	O
TASP0382088	S-chemical
)	O
was	O
synthesized	O
and	O
evaluated	O
as	O
transforming	B-GP
growth	I-GP
factor-β	I-GP
(	I-GP
TGF-β	I-GP
)	I-GP
type	I-GP
I	I-GP
receptor	E-GP
(	O
also	O
known	O
as	O
activin	B-GP
receptor-like	I-GP
kinase	I-GP
5	E-GP
or	O
ALK5	S-GP
)	O
inhibitor	O
.	O
Compound	O
11	O
,	O
a	O
potent	O
and	O
selective	O
ALK5	S-GP
inhibitor	O
,	O
exhibited	O
good	O
enzyme	O
inhibitory	O
activity	O
(	O
IC50=4.8	O
nM	O
)	O
as	O
well	O
as	O
inhibitory	O
activity	O
against	O
TGF-β	S-GP
-induced	O
Smad2/3	B-GP
phosphorylation	E-GP
at	O
a	O
cellular	O
level	O
(	O
IC50=17	O
nM	O
)	O
.	O
The	O
introduction	O
of	O
a	O
methoxy	S-chemical
group	O
to	O
the	O
benzothiazole	S-chemical
ring	O
in	O
1	O
and	O
the	O
break	O
up	O
of	O
the	O
planarity	O
between	O
the	O
imidazole	S-chemical
ring	O
and	O
the	O
thiazole	S-chemical
ring	O
improved	O
the	O
solubility	O
in	O
the	O
lotion	O
base	O
of	O
11	O
.	O
Furthermore	O
,	O
the	O
topical	O
application	O
of	O
3	O
%	O
11	O
lotion	O
significantly	O
inhibited	O
Smad2	B-GP
phosphorylation	E-GP
in	O
mouse	O
skin	O
at	O
8	O
h	O
after	O
application	O
(	O
71	O
%	O
inhibition	O
,	O
compared	O
with	O
vehicle-treated	O
animals	O
)	O
.	O

Induction	O
of	O
heat	B-GP
shock	I-GP
proteins	E-GP
(	O
HSPs	S-GP
)	O
by	O
sodium	B-chemical
arsenite	E-chemical
in	O
cultured	O
astrocytes	O
and	O
reduction	O
of	O
hydrogen	B-chemical
peroxide	E-chemical
-induced	O
cell	O
death	O
.	O
Induction	O
of	O
heat	B-GP
shock	I-GP
proteins	E-GP
(	O
HSPs	S-GP
)	O
protects	O
cells	O
from	O
oxidative	O
injury	O
.	O
Here	O
Hsp72	S-GP
,	O
Hsp27	S-GP
and	O
heme	B-GP
oxygenase-1	E-GP
(	O
HO-1	S-GP
)	O
were	O
induced	O
in	O
cultured	O
rat	O
astrocytes	O
,	O
and	O
protection	O
against	O
oxidative	O
stress	O
was	O
investigated	O
.	O
Astrocytes	O
were	O
treated	O
with	O
sodium	B-chemical
arsenite	E-chemical
(	O
20-50	O
micro	O
m	O
)	O
for	O
1	O
h	O
,	O
which	O
was	O
non-toxic	O
to	O
cells	O
,	O
24	O
h	O
later	O
they	O
were	O
exposed	O
to	O
400	O
micro	O
m	O
H2O2	S-chemical
for	O
1	O
h	O
,	O
and	O
cell	O
death	O
was	O
evaluated	O
at	O
different	O
time	O
points	O
.	O
Arsenite	S-chemical
triggered	O
strong	O
induction	O
of	O
HSPs	S-GP
,	O
which	O
was	O
prevented	O
by	O
1	O
micro	O
g/mL	O
cycloheximide	S-chemical
(	O
CXH	S-chemical
)	O
.	O
H2O2	S-chemical
caused	O
cell	O
loss	O
and	O
increased	O
cell	O
death	O
with	O
features	O
of	O
apoptosis	O
,	O
i.e	O
.	O
TdT-mediated	O
dUTP	O
nick-end	O
labelling	O
(	O
TUNEL	O
)	O
reaction	O
and	O
caspase-3	S-GP
activation	O
.	O
These	O
features	O
were	O
abrogated	O
by	O
pre-treatment	O
with	O
arsenite	S-chemical
,	O
which	O
prevented	O
cell	O
loss	O
and	O
significantly	O
reduced	O
the	O
number	O
of	O
dead	O
cells	O
.	O
The	O
protective	O
effect	O
of	O
arsenite	S-chemical
was	O
not	O
detected	O
in	O
the	O
presence	O
of	O
CHX	S-chemical
.	O
Pre-treatment	O
with	O
arsenite	O
increased	O
protein	B-GP
kinase	I-GP
B	E-GP
(	O
Akt	S-GP
)	O
and	O
extracellular	B-GP
signal	I-GP
regulated	I-GP
kinase	I-GP
1/2	E-GP
(	O
ERK1/2	S-GP
)	O
phosphorylation	O
after	O
H2O2	S-chemical
.	O
However	O
,	O
while	O
Akt	S-GP
phosphorylation	O
was	O
prevented	O
by	O
CHX	O
,	O
Erk1/2	S-GP
phosphorylation	O
was	O
further	O
enhanced	O
by	O
CHX	S-chemical
.	O
The	O
results	O
show	O
that	O
transient	O
arsenite	S-chemical
pre-treatment	O
induces	O
Hsp72	S-GP
,	O
HO-1	S-GP
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
Hsp27	S-GP
;	O
it	O
reduces	O
H2O2	S-chemical
-induced	O
astrocyte	O
death	O
;	O
and	O
it	O
causes	O
selective	O
activation	O
of	O
Akt	S-GP
following	O
H2O2	S-chemical
.	O
It	O
is	O
suggested	O
that	O
HSP	S-GP
expression	O
at	O
the	O
time	O
of	O
H2O2	S-chemical
exposure	O
protects	O
astrocytes	O
from	O
oxidative	O
injury	O
and	O
apoptotic	O
cell	O
death	O
by	O
means	O
of	O
pro-survival	O
Akt	S-GP
.	O

Effects	O
of	O
smoking	O
on	O
the	O
oxidant/antioxidant	O
balance	O
and	O
the	O
blood	O
lipids	O
in	O
pesticide	O
sprayers	O
.	O
The	O
present	O
study	O
was	O
conducted	O
on	O
80	O
pesticide	O
male	O
sprayers	O
(	O
42	O
nonsmokers	O
and	O
38	O
smokers	O
)	O
.	O
Our	O
aim	O
was	O
to	O
estimate	O
the	O
smoking	O
effects	O
on	O
blood	O
lipids	O
and	O
oxidant/antioxidant	O
status	O
in	O
pesticide	O
sprayers	O
.	O
Results	O
revealed	O
that	O
cholesterol	S-chemical
,	O
low-density	B-GP
lipoprotein	E-GP
(	O
LDL	S-GP
)	O
and	O
glutathion	B-GP
peroxidase	E-GP
(	O
GPx	S-GP
)	O
enzyme	O
were	O
significantly	O
higher	O
in	O
the	O
38	O
smoker	O
sprayers	O
than	O
in	O
the	O
42	O
nonsmoker	O
sprayers	O
.	O
Cholesterol	S-chemical
and	O
LDL	S-GP
were	O
correlated	O
with	O
smoking	O
index	O
and	O
high-density	B-GP
lipoprotein	E-GP
(	O
HDL	S-GP
)	O
,	O
superoxide	B-GP
dismutase	E-GP
(	O
SOD	S-GP
)	O
enzyme	O
and	O
zinc	S-chemical
(	O
Zn	S-chemical
)	O
were	O
inversely	O
correlated	O
with	O
duration	O
of	O
pesticides	O
'	O
exposure	O
.	O
In	O
nonsmokers	O
,	O
LDL	S-GP
and	O
cholesterol	S-chemical
were	O
negatively	O
correlated	O
with	O
SOD	S-GP
and	O
correlated	O
with	O
malondialdehyde	S-chemical
(	O
MDA	S-chemical
)	O
,	O
and	O
cholesterol	S-chemical
was	O
negatively	O
correlated	O
with	O
Zn	S-chemical
.	O
HDL	S-GP
was	O
negatively	O
correlated	O
with	O
MDA	S-chemical
in	O
all	O
the	O
sprayers	O
,	O
but	O
was	O
correlated	O
with	O
GPx	S-GP
in	O
smokers	O
and	O
with	O
Zn	S-chemical
in	O
nonsmokers	O
.	O
In	O
smokers	O
,	O
LDL	S-GP
was	O
negatively	O
correlated	O
with	O
GPx	S-GP
,	O
HDL	S-GP
was	O
negatively	O
correlated	O
with	O
MDA	S-chemical
and	O
triglycerides	S-chemical
and	O
very-low-density	B-GP
lipoprotein	E-GP
were	O
negatively	O
correlated	O
with	O
Zn	S-chemical
.	O
MDA	S-chemical
was	O
negatively	O
correlated	O
with	O
SOD	S-GP
,	O
GPx	S-GP
and	O
Zn	S-chemical
.	O
Smoking	O
and	O
pesticide	O
exposure	O
could	O
be	O
responsible	O
for	O
hyperlipidemia	O
and	O
oxidative	O
stress	O
.	O
Therefore	O
,	O
improvement	O
in	O
the	O
antioxidant	O
status	O
is	O
mandatory	O
for	O
pesticide	O
sprayers	O
especially	O
the	O
ones	O
who	O
smoke	O
.	O

Lignans	S-chemical
extracted	O
from	O
Vitex	O
negundo	O
possess	O
cytotoxic	O
activity	O
by	O
G2/M	O
phase	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
induction	O
.	O
Evn-50	S-chemical
is	O
a	O
lignan	S-chemical
compounds	O
mixture	O
extracted	O
from	O
Vitex	O
negundo	O
,	O
a	O
widely	O
used	O
herb	O
in	O
traditional	O
Chinese	O
medicine	O
.	O
This	O
study	O
is	O
aimed	O
to	O
define	O
the	O
spectrum	O
of	O
cytotoxic	O
activity	O
of	O
EVn-50	S-chemical
,	O
and	O
also	O
to	O
investigate	O
mechanisms	O
underlying	O
the	O
anticancer	O
actions	O
via	O
assessing	O
the	O
influence	O
on	O
cell	O
cycle	O
using	O
EVn-50	S-chemical
,	O
and	O
the	O
lignan	S-chemical
compound	O
VB1	S-chemical
purified	O
from	O
EVn-50	S-chemical
.	O
The	O
cytotoxic	O
effect	O
of	O
EVn-50	S-chemical
and	O
VB1	S-chemical
was	O
determined	O
with	O
SRB	O
assay	O
using	O
a	O
panel	O
of	O
cancer	O
cell	O
lines	O
.	O
Breast	O
cancer	O
cell	O
line	O
MDA-MB-435	O
and	O
liver	O
cancer	O
cell	O
line	O
SMMC-7721	O
were	O
selected	O
for	O
further	O
evaluating	O
the	O
effect	O
of	O
EVn-50	S-chemical
or	O
VB1	S-chemical
on	O
cell	O
cycle	O
by	O
flow	O
cytometric	O
analysis	O
.	O
Apoptosis	O
exerted	O
by	O
EVn-50	S-chemical
or	O
VB1	S-chemical
was	O
measured	O
by	O
TUNEL	O
assay	O
and	O
DAPI	O
staining	O
,	O
and	O
Western	O
blot	O
analysis	O
was	O
utilized	O
to	O
assess	O
the	O
influence	O
on	O
expression	O
and	O
phosphorylation	O
of	O
proteins	O
which	O
are	O
closely	O
related	O
to	O
cell	O
cycle	O
and	O
apoptosis	O
.	O
EVn-50	S-chemical
possessed	O
a	O
broad	O
spectrum	O
of	O
in	O
vitro	O
anticancer	O
activity	O
for	O
those	O
tested	O
cancer	O
cells	O
,	O
especially	O
sensitive	O
to	O
MDA-MB-435	O
,	O
SKOV-3	O
,	O
BXPC-3	O
,	O
SMMC-7721	O
,	O
MCF-7	O
,	O
HO-8910	O
,	O
SGC-7901	O
,	O
BEL-7402	O
,	O
HCT-116	O
,	O
and	O
786-O	O
,	O
with	O
the	O
respective	O
IC50	O
below	O
10μg/ml	O
.	O
Treatment	O
with	O
EVn-50	S-chemical
or	O
VB1	S-chemical
resulted	O
in	O
arresting	O
the	O
MDA-MB-435	O
and	O
SMMC-7721	O
cells	O
at	O
G2/M	O
phase	O
,	O
which	O
was	O
further	O
supported	O
by	O
observations	O
of	O
increased	O
phosphorylation	O
of	O
Histone	B-GP
3	E-GP
at	O
Ser	S-chemical
10	O
,	O
phosphorylation	O
of	O
Cdk1	S-GP
at	O
Tyr	S-chemical
15	O
,	O
expression	O
of	O
cyclin	B-GP
B1	E-GP
,	O
and	O
decreased	O
expression	O
of	O
Cdc25c	S-GP
.	O
Moreover	O
,	O
we	O
found	O
that	O
exposure	O
of	O
MDA-MB-435	O
cells	O
to	O
EVn-50	S-chemical
or	O
VB1	S-chemical
caused	O
obvious	O
apoptosis	O
of	O
MDA-MB-435	O
cells	O
.	O
Our	O
data	O
show	O
that	O
EVn-50	S-chemical
,	O
lignan	S-chemical
compounds	O
extracted	O
from	O
Vitex	O
negundo	O
,	O
possesses	O
a	O
broad	O
spectrum	O
cytotoxic	O
effect	O
via	O
arresting	O
cancer	O
cells	O
at	O
G2/M	O
phase	O
cell	O
cycle	O
and	O
subsequently	O
inducing	O
apoptosis	O
.	O

Ambrisentan	S-chemical
for	O
the	O
treatment	O
of	O
pulmonary	O
arterial	O
hypertension	O
.	O
Ambrisentan	S-chemical
is	O
an	O
endothelin	B-GP
receptor	E-GP
antagonist	O
(	O
ERA	O
)	O
that	O
was	O
recently	O
approved	O
for	O
treatment	O
of	O
pulmonary	O
arterial	O
hypertension	O
(	O
PAH	O
)	O
.	O
Endothelin	S-GP
(	O
ET	S-GP
)	O
is	O
a	O
potent	O
vasoconstrictor	O
with	O
mitogenic	O
,	O
hypertrophic	O
and	O
pro-inflammatory	O
properties	O
that	O
is	O
upregulated	O
in	O
pulmonary	O
hypertensive	O
diseases	O
.	O
The	O
biologic	O
effects	O
of	O
ET	S-GP
are	O
mediated	O
by	O
2	O
cell	O
surface	O
receptors	O
termed	O
ET	B-GP
(	I-GP
A	I-GP
)	E-GP
and	O
ET	B-GP
(	I-GP
B	I-GP
)	E-GP
.	O
ET	B-GP
(	I-GP
A	I-GP
)	E-GP
mediates	O
the	O
vasoconstrictor	O
effect	O
of	O
ET	S-GP
on	O
vascular	O
smooth	O
muscle	O
,	O
whereas	O
ET	B-GP
(	I-GP
B	I-GP
)	E-GP
is	O
expressed	O
primarily	O
on	O
vascular	O
endothelial	O
cells	O
where	O
it	O
induces	O
nitric	B-chemical
oxide	E-chemical
synthesis	O
and	O
acts	O
to	O
clear	O
ET	S-GP
from	O
the	O
circulation	O
.	O
Ambrisentan	S-chemical
is	O
the	O
first	O
ET	B-GP
(	I-GP
A	I-GP
)	E-GP
selective	O
ERA	O
approved	O
for	O
use	O
in	O
the	O
US	O
.	O
Recently	O
published	O
clinical	O
trials	O
in	O
patients	O
with	O
PAH	O
demonstrate	O
improvement	O
in	O
functional	O
capacity	O
and	O
pulmonary	O
hemodynamics	O
similar	O
to	O
other	O
ET	B-GP
(	I-GP
A	I-GP
)	E-GP
selective	O
and	O
non-selective	O
ERAs	O
.	O
Its	O
once	O
daily	O
dosing	O
and	O
lower	O
incidence	O
of	O
serum	O
aminotransferase	S-GP
elevation	O
offer	O
potential	O
advantages	O
over	O
other	O
ERAs	O
,	O
but	O
further	O
experience	O
with	O
this	O
agent	O
is	O
needed	O
to	O
fully	O
understand	O
its	O
long-term	O
efficacy	O
and	O
safety	O
.	O
This	O
review	O
discusses	O
the	O
endothelin	S-GP
family	O
of	O
proteins	O
and	O
receptors	O
and	O
their	O
role	O
in	O
the	O
pathophysiology	O
of	O
pulmonary	O
hypertensive	O
diseases	O
.	O
It	O
also	O
examines	O
the	O
development	O
process	O
,	O
safety	O
profile	O
and	O
clinical	O
trials	O
that	O
have	O
resulted	O
in	O
ambrisentan	S-chemical
being	O
approved	O
for	O
treatment	O
of	O
PAH	O
.	O

Expression	O
of	O
cAMP-responsive	B-GP
element	I-GP
binding	I-GP
proteins	E-GP
(	O
CREBs	S-GP
)	O
in	O
fast-	O
and	O
slow-twitch	O
muscles	O
:	O
A	O
signaling	O
pathway	O
to	O
account	O
for	O
the	O
synaptic	O
expression	O
of	O
collagen-tailed	B-GP
subunit	E-GP
(	O
ColQ	S-GP
)	O
of	O
acetylcholinesterase	S-GP
at	O
the	O
rat	O
neuromuscular	O
junction	O
.	O
The	O
gene	O
encoding	O
the	O
collagen-tailed	B-GP
subunit	E-GP
(	O
ColQ	S-GP
)	O
of	O
acetylcholinesterase	S-GP
(	O
AChE	S-GP
)	O
contains	O
two	O
distinct	O
promoters	O
that	O
drive	O
the	O
production	O
of	O
two	O
ColQ	S-GP
mRNAs	O
,	O
ColQ-1	S-GP
and	O
ColQ-1a	S-GP
,	O
in	O
slow-	O
and	O
fast-twitch	O
muscles	O
,	O
respectively	O
.	O
ColQ-1a	S-GP
is	O
expressed	O
at	O
the	O
neuromuscular	O
junction	O
(	O
NMJ	O
)	O
in	O
fast-twitch	O
muscle	O
,	O
and	O
this	O
expression	O
depends	O
on	O
trophic	O
factors	O
supplied	O
by	O
motor	O
neurons	O
signaling	O
via	O
a	O
cAMP	S-chemical
-dependent	O
pathway	O
in	O
muscle	O
.	O
To	O
further	O
elucidate	O
the	O
molecular	O
basis	O
of	O
ColQ-1a	B-GP
's	E-GP
synaptic	O
expression	O
,	O
here	O
we	O
investigated	O
the	O
expression	O
and	O
localization	O
of	O
cAMP-responsive	B-GP
element	I-GP
binding	I-GP
protein	E-GP
(	O
CREB	S-GP
)	O
at	O
the	O
synaptic	O
and	O
extra-synaptic	O
regions	O
of	O
fast-	O
and	O
slow-twitch	O
muscles	O
from	O
adult	O
rats	O
.	O
The	O
total	O
amount	O
of	O
active	O
,	O
phosphorylated	B-GP
CREB	E-GP
(	O
P-CREB	S-GP
)	O
present	O
in	O
slow-twitch	O
soleus	O
muscle	O
was	O
higher	O
than	O
that	O
in	O
fast-twitch	O
tibialis	O
muscle	O
,	O
but	O
P-CREB	S-GP
was	O
predominantly	O
expressed	O
in	O
the	O
fast-twitch	O
muscle	O
at	O
NMJs	O
.	O
In	O
contrast	O
,	O
P-CREB	S-GP
was	O
detected	O
in	O
both	O
synaptic	O
and	O
extra-synaptic	O
regions	O
of	O
slow-twitch	O
muscle	O
.	O
These	O
results	O
reveal	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
differential	O
distribution	O
of	O
P-CREB	S-GP
in	O
fast-	O
and	O
slow-twitch	O
muscles	O
,	O
which	O
might	O
support	O
the	O
crucial	O
role	O
of	O
cAMP	S-chemical
-dependent	O
signaling	O
in	O
controlling	O
the	O
synapse-specific	O
expression	O
of	O
ColQ-1a	S-GP
in	O
fast-twitch	O
muscles	O
.	O

Intercellular	B-GP
adhesion	I-GP
molecule-2	E-GP
is	O
involved	O
in	O
apical	O
ectoplasmic	O
specialization	O
dynamics	O
during	O
spermatogenesis	O
in	O
the	O
rat	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
intercellular	B-GP
adhesion	I-GP
molecule-2	E-GP
(	O
ICAM2	S-GP
)	O
in	O
the	O
testis	O
.	O
ICAM2	S-GP
is	O
a	O
cell	O
adhesion	O
protein	O
having	O
important	O
roles	O
in	O
cell	O
migration	O
,	O
especially	O
during	O
inflammation	O
when	O
leukocytes	O
cross	O
the	O
endothelium	O
.	O
Herein	O
,	O
we	O
showed	O
ICAM2	S-GP
to	O
be	O
expressed	O
by	O
germ	O
and	O
Sertoli	O
cells	O
in	O
the	O
rat	O
testis	O
.	O
When	O
a	O
monospecific	O
antibody	O
was	O
used	O
for	O
immunolocalization	O
experiments	O
,	O
ICAM2	S-GP
was	O
found	O
to	O
surround	O
the	O
heads	O
of	O
elongating/elongated	O
spermatids	O
in	O
all	O
stages	O
of	O
the	O
seminiferous	O
epithelial	O
cycle	O
.	O
To	O
determine	O
whether	O
ICAM2	S-GP
is	O
a	O
constituent	O
of	O
apical	O
ectoplasmic	O
specialization	O
(	O
ES	O
)	O
,	O
co-immunoprecipitation	O
and	O
dual	O
immunofluorescence	O
staining	O
were	O
performed	O
.	O
Interestingly	O
,	O
ICAM2	S-GP
was	O
found	O
to	O
associate	O
with	O
β1-integrin	S-GP
,	O
nectin-3	S-GP
,	O
afadin	S-GP
,	O
Src	S-GP
,	O
proline-rich	B-GP
tyrosine	I-GP
kinase	I-GP
2	E-GP
,	O
annexin	B-GP
II	E-GP
,	O
and	O
actin	S-GP
.	O
Following	O
CdCl₂	S-chemical
treatment	O
,	O
ICAM2	S-GP
was	O
found	O
to	O
be	O
upregulated	O
during	O
restructuring	O
of	O
the	O
seminiferous	O
epithelium	O
,	O
with	O
round	O
spermatids	O
becoming	O
increasingly	O
immunoreactive	O
for	O
ICAM2	S-GP
by	O
6-16	O
h.	O
Interestingly	O
,	O
there	O
was	O
a	O
loss	O
in	O
the	O
binding	O
of	O
ICAM2	S-GP
to	O
actin	S-GP
during	O
CdCl₂	S-chemical
-induced	O
germ	O
cell	O
loss	O
,	O
suggesting	O
that	O
a	O
loss	O
of	O
ICAM2	S-GP
-	O
actin	S-GP
interactions	O
might	O
have	O
facilitated	O
junction	O
restructuring	O
.	O
Taken	O
collectively	O
,	O
these	O
results	O
illustrate	O
that	O
ICAM2	S-GP
plays	O
an	O
important	O
role	O
in	O
apical	O
ES	O
dynamics	O
during	O
spermatogenesis	O
.	O

Analysis	O
of	O
mammalian	B-GP
alcohol	I-GP
dehydrogenase	I-GP
5	E-GP
(	O
ADH5	S-GP
)	O
:	O
characterisation	O
of	O
rat	B-GP
ADH5	E-GP
with	O
comparisons	O
to	O
the	O
corresponding	O
human	O
variant	O
.	O
Alcohol	B-GP
dehydrogenase	I-GP
5	E-GP
(	O
ADH5	S-GP
)	O
is	O
a	O
member	O
of	O
the	O
mammalian	B-GP
alcohol	I-GP
dehydrogenase	E-GP
family	O
of	O
yet	O
undefined	O
functions	O
.	O
ADH5	S-GP
was	O
first	O
identified	O
at	O
the	O
DNA	O
level	O
in	O
human	O
and	O
deer	O
mouse	O
.	O
A	O
rat	B-GP
alcohol	I-GP
dehydrogenase	E-GP
structure	O
of	O
similar	O
type	O
has	O
been	O
isolated	O
at	O
the	O
cDNA	O
level	O
using	O
human	B-GP
ADH5	E-GP
as	O
a	O
screening	O
probe	O
,	O
where	O
the	O
rat	O
cDNA	O
structure	O
displayed	O
several	O
atypical	O
properties	O
.	O
mRNA	O
for	O
rat	B-GP
ADH5	E-GP
was	O
found	O
in	O
multiple	O
tissues	O
,	O
especially	O
in	O
the	O
kidney	O
.	O
In	O
vitro	O
translation	O
experiments	O
indicated	O
that	O
rat	B-GP
ADH5	E-GP
is	O
expressed	O
as	O
efficiently	O
as	O
ADH1	S-GP
and	O
furthermore	O
,	O
rat	B-GP
ADH5	E-GP
was	O
readily	O
expressed	O
in	O
COS	O
cells	O
fused	O
to	O
Green	O
Fluorescent	O
Protein	O
.	O
However	O
,	O
no	O
soluble	O
ADH5	S-GP
protein	O
could	O
be	O
heterologously	O
expressed	O
in	O
Escherichia	O
coli	O
cells	O
with	O
expression	O
systems	O
successfully	O
used	O
for	O
other	O
mammalian	B-GP
ADHs	E-GP
,	O
including	O
fused	O
to	O
glutathione	S-chemical
-	O
S	S-chemical
-transferase	O
.	O
Molecular	O
modelling	O
of	O
the	O
enzyme	O
indicated	O
that	O
the	O
protein	O
does	O
not	O
fold	O
in	O
a	O
productive	O
way	O
,	O
which	O
can	O
be	O
the	O
explanation	O
why	O
no	O
stable	O
and	O
active	O
ADH5	S-GP
has	O
been	O
isolated	O
.	O
These	O
results	O
indicate	O
that	O
ADH5	S-GP
,	O
while	O
readily	O
expressed	O
at	O
the	O
mRNA	O
level	O
,	O
does	O
not	O
behave	O
similarly	O
to	O
other	O
mammalian	B-GP
ADHs	E-GP
investigated	O
.	O
The	O
results	O
,	O
in	O
vitro	O
and	O
in	O
silico	O
,	O
suggest	O
an	O
unstable	O
ADH5	S-GP
structure	O
,	O
which	O
can	O
explain	O
for	O
why	O
no	O
active	O
and	O
stable	O
protein	O
can	O
be	O
isolated	O
.	O
Further	O
possibilities	O
are	O
conceivable	O
:	O
the	O
ADH5	S-GP
protein	O
may	O
have	O
to	O
interact	O
with	O
a	O
stabiliser	O
,	O
or	O
the	O
gene	O
is	O
actually	O
a	O
pseudogene	O
.	O

Ceftazidime	S-chemical
-	O
avibactam	S-chemical
:	O
a	O
novel	O
cephalosporin	S-chemical
/	O
β-lactamase	S-GP
inhibitor	O
combination	O
.	O
Avibactam	S-chemical
(	O
formerly	O
NXL104	S-chemical
,	O
AVE1330A	S-chemical
)	O
is	O
a	O
synthetic	O
non-	O
β-lactam	S-chemical
,	O
β-lactamase	S-GP
inhibitor	O
that	O
inhibits	O
the	O
activities	O
of	O
Ambler	B-GP
class	I-GP
A	I-GP
and	I-GP
C	I-GP
β-lactamases	E-GP
and	O
some	O
Ambler	B-GP
class	I-GP
D	E-GP
enzymes	O
.	O
This	O
review	O
summarizes	O
the	O
existing	O
data	O
published	O
for	O
ceftazidime	S-chemical
-	O
avibactam	S-chemical
,	O
including	O
relevant	O
chemistry	O
,	O
mechanisms	O
of	O
action	O
and	O
resistance	O
,	O
microbiology	O
,	O
pharmacokinetics	O
,	O
pharmacodynamics	O
,	O
and	O
efficacy	O
and	O
safety	O
data	O
from	O
animal	O
and	O
human	O
trials	O
.	O
Although	O
not	O
a	O
β-lactam	S-chemical
,	O
the	O
chemical	O
structure	O
of	O
avibactam	S-chemical
closely	O
resembles	O
portions	O
of	O
the	O
cephem	S-chemical
bicyclic	O
ring	O
system	O
,	O
and	O
avibactam	S-chemical
has	O
been	O
shown	O
to	O
bond	O
covalently	O
to	O
β-lactamases	S-GP
.	O
Very	O
little	O
is	O
known	O
about	O
the	O
potential	O
for	O
avibactam	S-chemical
to	O
select	O
for	O
resistance	O
.	O
The	O
addition	O
of	O
avibactam	S-chemical
greatly	O
(	O
4-1024-fold	O
minimum	O
inhibitory	O
concentration	O
[	O
MIC	O
]	O
reduction	O
)	O
improves	O
the	O
activity	O
of	O
ceftazidime	S-chemical
versus	O
most	O
species	O
of	O
Enterobacteriaceae	O
depending	O
on	O
the	O
presence	O
or	O
absence	O
of	O
β-lactamase	S-GP
enzyme	O
(	O
s	O
)	O
.	O
Against	O
Pseudomonas	O
aeruginosa	O
,	O
the	O
addition	O
of	O
avibactam	S-chemical
also	O
improves	O
the	O
activity	O
of	O
ceftazidime	S-chemical
(	O
~fourfold	O
MIC	O
reduction	O
)	O
.	O
Limited	O
data	O
suggest	O
that	O
the	O
addition	O
of	O
avibactam	S-chemical
does	O
not	O
improve	O
the	O
activity	O
of	O
ceftazidime	S-chemical
versus	O
Acinetobacter	O
species	O
or	O
most	O
anaerobic	O
bacteria	O
(	O
exceptions	O
:	O
Bacteroides	O
fragilis	O
,	O
Clostridium	O
perfringens	O
,	O
Prevotella	O
spp	O
.	O
and	O
Porphyromonas	O
spp.	O
)	O
.	O
The	O
pharmacokinetics	O
of	O
avibactam	S-chemical
follow	O
a	O
two-compartment	O
model	O
and	O
do	O
not	O
appear	O
to	O
be	O
altered	O
by	O
the	O
co-administration	O
of	O
ceftazidime	S-chemical
.	O
The	O
maximum	O
plasma	O
drug	O
concentration	O
(	O
C	O
(	O
max	O
)	O
)	O
and	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
of	O
avibactam	S-chemical
increase	O
linearly	O
with	O
doses	O
ranging	O
from	O
50	O
mg	O
to	O
2,000	O
mg	O
.	O
The	O
mean	O
volume	O
of	O
distribution	O
and	O
half-life	O
of	O
22	O
L	O
(	O
~0.3	O
L/kg	O
)	O
and	O
~2	O
hours	O
,	O
respectively	O
,	O
are	O
similar	O
to	O
ceftazidime	S-chemical
.	O
Like	O
ceftazidime	S-chemical
,	O
avibactam	S-chemical
is	O
primarily	O
renally	O
excreted	O
,	O
and	O
clearance	O
correlates	O
with	O
creatinine	S-chemical
clearance	O
.	O
Pharmacodynamic	O
data	O
suggest	O
that	O
ceftazidime	S-chemical
-	O
avibactam	S-chemical
is	O
rapidly	O
bactericidal	O
versus	O
β-lactamase	S-GP
-producing	O
Gram-negative	O
bacilli	O
that	O
are	O
not	O
inhibited	O
by	O
ceftazidime	S-chemical
alone.Clinical	O
trials	O
to	O
date	O
have	O
reported	O
that	O
ceftazidime	S-chemical
-	O
avibactam	S-chemical
is	O
as	O
effective	O
as	O
standard	O
carbapenem	S-chemical
therapy	O
in	O
complicated	O
intra-abdominal	O
infection	O
and	O
complicated	O
urinary	O
tract	O
infection	O
,	O
including	O
infection	O
caused	O
by	O
cephalosporin	S-chemical
-resistant	O
Gram-negative	O
isolates	O
.	O
The	O
safety	O
and	O
tolerability	O
of	O
ceftazidime	S-chemical
-	O
avibactam	S-chemical
has	O
been	O
reported	O
in	O
three	O
phase	O
I	O
pharmacokinetic	O
studies	O
and	O
two	O
phase	O
II	O
clinical	O
studies	O
.	O
Ceftazidime	S-chemical
-	O
avibactam	S-chemical
appears	O
to	O
be	O
well	O
tolerated	O
in	O
healthy	O
subjects	O
and	O
hospitalized	O
patients	O
,	O
with	O
few	O
serious	O
drug-related	O
treatment-emergent	O
adverse	O
events	O
reported	O
to	O
date.In	O
conclusion	O
,	O
avibactam	S-chemical
serves	O
to	O
broaden	O
the	O
spectrum	O
of	O
ceftazidime	S-chemical
versus	O
ß-lactamase	S-GP
-producing	O
Gram-negative	O
bacilli	O
.	O
The	O
exact	O
roles	O
for	O
ceftazidime	S-chemical
-	O
avibactam	S-chemical
will	O
be	O
defined	O
by	O
efficacy	O
and	O
safety	O
data	O
from	O
further	O
clinical	O
trials	O
.	O
Potential	O
future	O
roles	O
for	O
ceftazidime	S-chemical
-	O
avibactam	S-chemical
include	O
the	O
treatment	O
of	O
suspected	O
or	O
documented	O
infections	O
caused	O
by	O
resistant	O
Gram-negative-bacilli	O
producing	O
extended-spectrum	B-GP
ß-lactamase	E-GP
(	O
ESBL	S-GP
)	O
,	O
Klebsiella	B-GP
pneumoniae	I-GP
carbapenemases	E-GP
(	O
KPCs	S-GP
)	O
and/or	O
AmpC	B-GP
ß-lactamases	E-GP
.	O
In	O
addition	O
,	O
ceftazidime	S-chemical
-	O
avibactam	S-chemical
may	O
be	O
used	O
in	O
combination	O
(	O
with	O
metronidazole	S-chemical
)	O
for	O
suspected	O
polymicrobial	O
infections	O
.	O
Finally	O
,	O
the	O
increased	O
activity	O
of	O
ceftazidime	S-chemical
-	O
avibactam	S-chemical
versus	O
P.	O
aeruginosa	O
may	O
be	O
of	O
clinical	O
benefit	O
in	O
patients	O
with	O
suspected	O
or	O
documented	O
P.	O
aeruginosa	O
infections	O
.	O

Differential	O
autophagic	O
cell	O
death	O
under	O
stress	O
with	O
ectopic	O
cytoplasmic	O
and	O
mitochondrial-specific	O
PPP2R2B	S-GP
in	O
human	O
neuroblastoma	O
cells	O
.	O
Protein	B-GP
phosphatase	I-GP
2A	E-GP
is	O
one	O
of	O
four	O
major	O
classes	O
of	O
serine/threonine	B-GP
phosphatases	E-GP
.	O
Overexpression	O
of	O
brain-specific	O
regulatory	O
subunit	O
PPP2R2	S-GP
in	O
neuron	O
cells	O
is	O
implicated	O
in	O
pathogenesis	O
.	O
The	O
alternative	O
splicing	O
of	O
PPP2R2B	S-GP
encodes	O
two	O
isoforms	O
.	O
They	O
are	O
subunit	O
of	O
cytoplasmic	O
specific	O
Bβ1	S-GP
and	O
mitochondria-targeted	O
Bβ2	S-GP
.	O
The	O
two	O
constructs	O
were	O
transfected	O
into	O
human	O
neuroblastoma	O
cells	O
,	O
SK-N-SH	O
,	O
respectively	O
,	O
and	O
the	O
stable	O
clones	O
overexpressing	O
either	O
Bβ1	S-GP
or	O
Bβ2	S-GP
established	O
.	O
We	O
have	O
reported	O
that	O
Bβ2	S-GP
clones	O
are	O
sensitive	O
to	O
reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
treatment	O
by	O
inducing	O
autophagic	O
cell	O
death	O
.	O
To	O
study	O
more	O
on	O
the	O
onset	O
of	O
neuropathogenesis	O
under	O
strain	O
,	O
both	O
clones	O
were	O
exposed	O
to	O
different	O
environmental	O
stress	O
,	O
e.g	O
.	O
starvation	O
and	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
.	O
To	O
learn	O
how	O
PPP2R2B	S-GP
overexpression	O
responds	O
to	O
starvation	O
,	O
cells	O
were	O
incubated	O
in	O
Hank	O
's	O
buffered	O
salt	O
solution	O
of	O
deprived	O
nutrient	O
.	O
Cell	O
death	O
was	O
induced	O
in	O
Bβ1	S-GP
clones	O
after	O
6	O
h	O
starvation	O
,	O
but	O
not	O
in	O
Bβ2	S-GP
clones	O
.	O
The	O
pharmacological	O
inhibitor	O
,	O
Bafilomycin	B-chemical
A1	E-chemical
,	O
rescued	O
the	O
cell	O
death	O
while	O
suppressing	O
autophagy	O
.	O
On	O
the	O
other	O
hand	O
,	O
to	O
assess	O
how	O
cells	O
respond	O
to	O
ER	O
stress	O
,	O
the	O
cells	O
were	O
treated	O
with	O
0.1	O
μM	O
of	O
N	S-chemical
-glycosylation	O
inhibitor	O
,	O
tunicamycin	S-chemical
(	O
TM	O
)	O
.	O
In	O
contrast	O
with	O
Bβ1	S-GP
,	O
the	O
apoptotic	O
cell	O
death	O
appeared	O
in	O
Bβ2	S-GP
after	O
48	O
h	O
treatment	O
.	O
The	O
formation	O
of	O
autophagolysosome	O
was	O
detected	O
in	O
Bβ2	S-GP
following	O
12	O
h	O
treatment	O
with	O
TM	O
as	O
evidenced	O
by	O
lysotracker	O
and	O
GFP-LC3	O
staining	O
for	O
fluorescence	O
microscopy	O
analysis	O
.	O
The	O
autophagy	O
inhibitor	O
,	O
3-methyladenine	S-chemical
,	O
salvaged	O
the	O
final	O
apoptosis	O
.	O
The	O
stable	O
cell	O
lines	O
with	O
ectopically	O
transfected	O
PPP2R2B	S-GP
genes	O
encoding	O
isoforms	O
of	O
brain-specific	O
regulatory	O
subunit	O
exhibit	O
distinct	O
apoptosis	O
under	O
different	O
stressors	O
.	O
The	O
induced	O
autophagic	O
apoptotic	O
cell	O
death	O
is	O
related	O
to	O
mitochondrial	O
membrane	O
potential	O
drop	O
and	O
ROS	O
generation	O
.	O
Disturbance	O
of	O
autophagy	O
alleviates	O
the	O
induced	O
cell	O
death	O
.	O
The	O
results	O
promised	O
a	O
good	O
model	O
for	O
understanding	O
the	O
onset	O
in	O
pathogenesis	O
under	O
stress	O
in	O
neuron	O
cells	O
with	O
aberrant	O
PPP2R2B	S-GP
expression	O
.	O

Zolmitriptan	S-chemical
and	O
human	O
aggression	O
:	O
interaction	O
with	O
alcohol	S-chemical
.	O
RATIONALE	O
:	O
The	O
serotonin	B-GP
1	I-GP
(	I-GP
B/D	I-GP
)	E-GP
(	O
5-HT1	B-GP
(	I-GP
B/D	I-GP
)	E-GP
)	O
receptor	O
has	O
shown	O
potential	O
as	O
a	O
target	O
for	O
decreasing	O
aggression	O
.	O
The	O
5-HT1	B-GP
(	I-GP
B/D	I-GP
)	E-GP
agonist	O
zolmitriptan	O
's	O
ability	O
to	O
reduce	O
aggressive	O
behavior	O
in	O
humans	O
and	O
its	O
interaction	O
with	O
the	O
well-known	O
aggression-enhancing	O
drug	O
alcohol	S-chemical
were	O
examined	O
.	O
OBJECTIVES	O
:	O
Our	O
objective	O
was	O
to	O
investigate	O
zolmitriptan	O
's	O
potential	O
to	O
modify	O
human	O
aggression	O
in	O
a	O
laboratory	O
paradigm	O
across	O
a	O
range	O
of	O
alcohol	S-chemical
doses	O
.	O
Alcohol	S-chemical
has	O
been	O
consistently	O
associated	O
with	O
aggression	O
and	O
violence	O
,	O
thus	O
we	O
hoped	O
to	O
expand	O
current	O
understanding	O
of	O
alcohol	O
's	O
role	O
in	O
aggressive	O
behavior	O
via	O
manipulation	O
of	O
the	O
serotonin	S-chemical
(	O
5-HT	S-chemical
)	O
system	O
.	O
METHODS	O
:	O
Eleven	O
social	O
drinkers	O
,	O
seven	O
male	O
,	O
were	O
recruited	O
to	O
participate	O
in	O
a	O
research	O
study	O
lasting	O
3-4	O
weeks	O
.	O
Aggression	O
was	O
measured	O
using	O
the	O
point-subtraction	O
aggression	O
paradigm	O
(	O
PSAP	O
)	O
,	O
a	O
laboratory	O
model	O
widely	O
used	O
in	O
human	O
aggression	O
studies	O
.	O
Subjects	O
were	O
administered	O
5-mg	O
zolmitriptan	S-chemical
and	O
placebo	O
capsules	O
along	O
with	O
alcohol	S-chemical
doses	O
of	O
0.0	O
,	O
0.4	O
and	O
0.8	O
g/kg	O
in	O
a	O
within-subject	O
,	O
counterbalanced	O
dosing	O
design	O
.	O
Data	O
were	O
analyzed	O
as	O
the	O
ratio	O
of	O
aggressive/monetary-earning	O
responses	O
,	O
to	O
account	O
for	O
possible	O
changes	O
in	O
overall	O
motor	O
function	O
due	O
to	O
alcohol	S-chemical
.	O
RESULTS	O
:	O
There	O
was	O
a	O
significant	O
alcohol	S-chemical
by	O
zolmitriptan	S-chemical
interaction	O
on	O
the	O
aggressive/monetary	O
response	O
ratio	O
.	O
Specifically	O
,	O
compared	O
to	O
placebo	O
,	O
zolmitriptan	S-chemical
decreased	O
the	O
aggressive/monetary	O
ratio	O
at	O
the	O
0.4-	O
and	O
0.8-g/kg	O
alcohol	S-chemical
doses	O
.	O
CONCLUSIONS	O
:	O
A	O
5-mg	O
dose	O
of	O
zolmitriptan	S-chemical
effectively	O
reduced	O
alcohol	S-chemical
-related	O
aggression	O
in	O
an	O
acute	O
dosing	O
protocol	O
,	O
demonstrating	O
an	O
interaction	O
of	O
5-HT	S-chemical
and	O
alcohol	S-chemical
in	O
human	O
aggressive	O
behavior	O
.	O

The	O
induction	O
of	O
mitochondria-mediated	O
apoptosis	O
in	O
cancer	O
cells	O
by	O
ruthenium	B-chemical
(	I-chemical
ii	I-chemical
)	E-chemical
asymmetric	O
complexes	O
.	O
Four	O
ruthenium	B-chemical
(	I-chemical
ii	I-chemical
)	E-chemical
asymmetric	O
complexes	O
,	O
[	B-chemical
Ru	I-chemical
(	I-chemical
bpy	I-chemical
)	I-chemical
2	I-chemical
(	I-chemical
PAIDH	I-chemical
)	I-chemical
]	I-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
(	O
bpy	S-chemical
=	O
2,2'-bipyridine	S-chemical
,	O
PAIDH	S-chemical
=	O
2-pyridyl-1H-anthra	B-chemical
[	I-chemical
1,2-d	I-chemical
]	I-chemical
imidazole-6,11-dione	E-chemical
,	O
)	O
,	O
[	B-chemical
Ru	I-chemical
(	I-chemical
phen	I-chemical
)	I-chemical
2	I-chemical
(	I-chemical
PAIDH	I-chemical
)	I-chemical
]	I-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
(	O
phen	S-chemical
=	O
1,10-phenanthroline	S-chemical
,	O
)	O
,	O
[	B-chemical
Ru	I-chemical
(	I-chemical
dmp	I-chemical
)	I-chemical
2	I-chemical
(	I-chemical
PAIDH	I-chemical
)	I-chemical
]	I-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
(	O
dmp	S-chemical
=	O
4,7-dimethyl-1,10-phenanthroline	S-chemical
,	O
)	O
and	O
[	B-chemical
Ru	I-chemical
(	I-chemical
dip	I-chemical
)	I-chemical
2	I-chemical
(	I-chemical
PAIDH	I-chemical
)	I-chemical
]	I-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
(	O
dip	S-chemical
=	O
4,7-diphenyl-1,10-phenanthroline	S-chemical
,	O
)	O
,	O
have	O
been	O
synthesized	O
and	O
characterized	O
.	O
These	O
complexes	O
displayed	O
potent	O
anti-proliferation	O
activity	O
against	O
various	O
cancer	O
cell	O
lines	O
and	O
had	O
high	O
selectivity	O
between	O
tumor	O
cells	O
and	O
normal	O
cells	O
.	O
HeLa	O
cells	O
exhibited	O
the	O
highest	O
sensitivity	O
to	O
complex	O
,	O
accounting	O
for	O
the	O
greatest	O
cellular	O
uptake	O
.	O
Complex	O
was	O
shown	O
to	O
accumulate	O
preferentially	O
in	O
the	O
mitochondria	O
of	O
HeLa	O
cells	O
and	O
induced	O
apoptosis	O
via	O
the	O
mitochondrial	O
pathway	O
,	O
which	O
involved	O
ROS	O
generation	O
,	O
mitochondrial	O
membrane	O
potential	O
depolarisation	O
,	O
and	O
Bcl-2	S-GP
and	O
caspase	S-GP
family	O
members	O
activation	O
.	O
These	O
results	O
demonstrated	O
that	O
complex	O
induced	O
cancer	O
cell	O
apoptosis	O
by	O
acting	O
on	O
mitochondrial	O
pathways	O
.	O

Phosphoinositide-dependent	B-GP
kinase-1	E-GP
and	O
protein	B-GP
kinase	I-GP
Cδ	E-GP
contribute	O
to	O
endothelin-1	S-GP
constriction	O
and	O
elevated	O
blood	O
pressure	O
in	O
intermittent	O
hypoxia	O
.	O
Obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
is	O
associated	O
with	O
cardiovascular	O
complications	O
including	O
hypertension	O
.	O
Previous	O
findings	O
from	O
our	O
laboratory	O
indicate	O
that	O
exposure	O
to	O
intermittent	O
hypoxia	O
(	O
IH	O
)	O
,	O
to	O
mimic	O
sleep	O
apnea	O
,	O
increases	O
blood	O
pressure	O
in	O
rats	O
.	O
IH	O
also	O
increases	O
endothelin-1	S-GP
(	O
ET-1	S-GP
)	O
constrictor	O
sensitivity	O
in	O
a	O
protein	B-GP
kinase	I-GP
C	I-GP
(	I-GP
PKC	I-GP
)	I-GP
δ	E-GP
-dependent	O
manner	O
in	O
mesenteric	O
arteries	O
.	O
Because	O
phosphoinositide-dependent	B-GP
kinase-1	E-GP
(	O
PDK-1	S-GP
)	O
regulates	O
PKCδ	S-GP
activity	O
,	O
we	O
hypothesized	O
that	O
PDK-1	S-GP
contributes	O
to	O
the	O
augmented	O
ET-1	S-GP
constrictor	O
sensitivity	O
and	O
elevated	O
blood	O
pressure	O
following	O
IH	O
.	O
Male	O
Sprague-Dawley	O
rats	O
were	O
exposed	O
to	O
either	O
sham	O
or	O
IH	O
(	O
cycles	O
between	O
21	O
%	O
O	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
/0	O
%	O
CO	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
and	O
5	O
%	O
O	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
/5	O
%	O
CO	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
)	O
conditions	O
for	O
7	O
h/day	O
for	O
14	O
or	O
21	O
days	O
.	O
The	O
contribution	O
of	O
PKCδ	S-GP
and	O
PDK-1	S-GP
to	O
ET-1	S-GP
-mediated	O
vasoconstriction	O
was	O
assessed	O
in	O
mesenteric	O
arteries	O
using	O
pharmacological	O
inhibitors	O
.	O
Constrictor	O
sensitivity	O
to	O
ET-1	S-GP
was	O
enhanced	O
in	O
arteries	O
from	O
IH-exposed	O
rats	O
.	O
Inhibition	O
of	O
PKCδ	S-GP
or	O
PDK-1	S-GP
blunted	O
ET-1	S-GP
constriction	O
in	O
arteries	O
from	O
IH	O
but	O
not	O
sham	O
group	O
rats	O
.	O
Western	O
analysis	O
revealed	O
similar	O
levels	O
of	O
total	O
and	O
phosphorylated	B-GP
PDK-1	E-GP
in	O
arteries	O
from	O
sham	O
and	O
IH	O
group	O
rats	O
but	O
decreased	O
protein-protein	O
interaction	O
between	O
PKCδ	S-GP
and	O
PDK-1	S-GP
in	O
arteries	O
from	O
IH-	O
compared	O
with	O
sham-exposed	O
rats	O
.	O
Blood	O
pressure	O
was	O
increased	O
in	O
rats	O
exposed	O
to	O
IH	O
,	O
and	O
treatment	O
with	O
the	O
PDK-1	S-GP
inhibitor	O
OSU-03012	S-chemical
[	O
2-amino-N-	B-chemical
{	I-chemical
4-	I-chemical
[	I-chemical
5-	I-chemical
(	I-chemical
2-phenanthrenyl	I-chemical
)	I-chemical
-3-	I-chemical
(	I-chemical
trifluoromethyl	I-chemical
)	I-chemical
-1H-pyrazol-1-yl	I-chemical
]	I-chemical
-phenyl	I-chemical
}	I-chemical
-acetamide	E-chemical
]	O
(	O
33	O
mg/day	O
)	O
lowered	O
blood	O
pressure	O
in	O
IH	O
but	O
not	O
sham	O
group	O
rats	O
.	O
Our	O
results	O
suggest	O
that	O
exposure	O
to	O
IH	O
unmasks	O
a	O
role	O
for	O
PDK-1	S-GP
in	O
regulating	O
ET-1	S-GP
constrictor	O
sensitivity	O
and	O
blood	O
pressure	O
that	O
is	O
not	O
present	O
under	O
normal	O
conditions	O
.	O
These	O
novel	O
findings	O
suggest	O
that	O
PDK-1	S-GP
may	O
be	O
a	O
uniquely	O
effective	O
antihypertensive	O
therapy	O
for	O
OSA	O
patients	O
.	O

Orexin-A	S-GP
suppresses	O
postischemic	O
glucose	S-chemical
intolerance	O
and	O
neuronal	O
damage	O
through	O
hypothalamic	O
brain-derived	B-GP
neurotrophic	I-GP
factor	E-GP
.	O
Orexin-A	S-GP
(	O
a	O
glucose	S-chemical
-sensing	O
neuropeptide	O
in	O
the	O
hypothalamus	O
)	O
and	O
brain-derived	B-GP
neurotrophic	I-GP
factor	E-GP
(	O
BDNF	S-GP
;	O
a	O
member	O
of	O
the	O
neurotrophin	S-GP
family	O
)	O
play	O
roles	O
in	O
many	O
physiologic	O
functions	O
,	O
including	O
regulation	O
of	O
glucose	S-chemical
metabolism	O
.	O
We	O
previously	O
showed	O
that	O
the	O
development	O
of	O
postischemic	O
glucose	S-chemical
intolerance	O
is	O
one	O
of	O
the	O
triggers	O
of	O
ischemic	O
neuronal	O
damage	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
there	O
was	O
an	O
interaction	O
between	O
orexin-A	S-GP
and	O
BDNF	S-GP
functions	O
in	O
the	O
hypothalamus	O
after	O
cerebral	O
ischemic	O
stress	O
.	O
Male	O
ddY	O
mice	O
were	O
subjected	O
to	O
2	O
hours	O
of	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
MCAO	O
)	O
.	O
Neuronal	O
damage	O
was	O
estimated	O
by	O
histologic	O
and	O
behavioral	O
analyses	O
.	O
Expression	O
of	O
protein	O
levels	O
was	O
analyzed	O
by	O
Western	O
blot	O
.	O
Small	O
interfering	O
RNA	O
directed	O
BDNF	S-GP
,	O
orexin-A	S-GP
,	O
and	O
SB334867	S-chemical
[	O
N-	B-chemical
(	I-chemical
2-methyl-6-benzoxazolyl	I-chemical
)	I-chemical
-N'-1,5-naphthyridin-4-yl	I-chemical
urea	E-chemical
;	O
a	O
specific	O
orexin-1	B-GP
receptor	E-GP
antagonist	O
]	O
were	O
administered	O
directly	O
into	O
the	O
hypothalamus	O
.	O
The	O
level	O
of	O
hypothalamic	O
orexin-A	S-GP
,	O
detected	O
by	O
immunohistochemistry	O
,	O
was	O
decreased	O
on	O
day	O
1	O
after	O
MCAO	O
.	O
Intrahypothalamic	O
administration	O
of	O
orexin-A	S-GP
(	O
1	O
or	O
5	O
pmol/mouse	O
)	O
significantly	O
and	O
dose-dependently	O
suppressed	O
the	O
development	O
of	O
postischemic	O
glucose	S-chemical
intolerance	O
on	O
day	O
1	O
and	O
development	O
of	O
neuronal	O
damage	O
on	O
day	O
3	O
.	O
The	O
MCAO-induced	O
decrease	O
in	O
insulin	B-GP
receptor	E-GP
levels	O
in	O
the	O
liver	O
and	O
skeletal	O
muscle	O
on	O
day	O
1	O
was	O
recovered	O
to	O
control	O
levels	O
by	O
orexin-A	S-GP
,	O
and	O
this	O
effect	O
of	O
orexin-A	S-GP
was	O
reversed	O
by	O
the	O
administration	O
of	O
SB334867	S-chemical
as	O
well	O
as	O
by	O
hypothalamic	O
BDNF	S-GP
knockdown	O
.	O
These	O
results	O
suggest	O
that	O
suppression	O
of	O
postischemic	O
glucose	S-chemical
intolerance	O
by	O
orexin-A	S-GP
assists	O
in	O
the	O
prevention	O
of	O
cerebral	O
ischemic	O
neuronal	O
damage	O
.	O
In	O
addition	O
,	O
hypothalamic	O
BDNF	S-GP
may	O
play	O
an	O
important	O
role	O
in	O
this	O
effect	O
of	O
orexin-A	S-GP
.	O

Sunitinib	S-chemical
,	O
sorafenib	S-chemical
and	O
mTOR	S-GP
inhibitors	O
in	O
renal	O
cancer	O
.	O
Understanding	O
the	O
alterations	O
in	O
cellular	O
protein	O
interactions	O
and	O
their	O
relations	O
to	O
genetic	O
mutations	O
that	O
cause	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
provides	O
a	O
unique	O
opportunity	O
for	O
the	O
development	O
of	O
disease-specific	O
therapy	O
for	O
patients	O
with	O
advanced	O
forms	O
of	O
this	O
disease	O
.	O
There	O
is	O
substantial	O
evidence	O
of	O
an	O
association	O
between	O
mutation	O
on	O
von	B-GP
Hippel-Lindau	E-GP
(	O
VHL	S-GP
)	O
gene	O
and	O
the	O
earliest	O
stages	O
of	O
tumorigenesis	O
of	O
RCC	O
.	O
The	O
main	O
consequence	O
of	O
VHL	S-GP
loss	O
is	O
the	O
upregulation	O
of	O
downstream	O
proangiogenic	O
factors	O
leading	O
to	O
highly	O
vascular	O
tumors	O
.	O
Overexpression	O
of	O
hypoxia	B-GP
inducible	I-GP
factor	E-GP
(	O
HIF	S-GP
)	O
is	O
also	O
caused	O
by	O
the	O
mammalian	B-GP
target	I-GP
of	I-GP
rapamycin	E-GP
(	O
mTOR	S-GP
)	O
,	O
a	O
key	O
component	O
of	O
signaling	O
pathways	O
inside	O
the	O
cell	O
,	O
involved	O
in	O
cell	O
proliferation	O
.	O
The	O
inhibition	O
of	O
proangiogenic	O
factors	O
and	O
mTOR	S-GP
was	O
the	O
main	O
idea	O
behind	O
the	O
development	O
of	O
new	O
targeted	O
agents	O
in	O
advanced	O
RCC	O
.	O
Since	O
December	O
2005	O
,	O
3	O
targeted	O
agents	O
have	O
been	O
approved	O
by	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
for	O
the	O
treatment	O
of	O
advanced	O
RCC	O
:	O
sorafenib	S-chemical
,	O
sunitinib	S-chemical
and	O
temsirolimus	S-chemical
.	O
Sorafenib	S-chemical
and	O
sunitinib	S-chemical
are	O
synthetic	O
,	O
orally	O
active	O
agents	O
shown	O
to	O
directly	O
inhibit	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	I-GP
receptors	I-GP
-2	I-GP
and	I-GP
-3	E-GP
(	O
VEGFR-2	S-GP
,	O
VEGFR-3	S-GP
)	O
and	O
platelet-derived	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
beta	E-GP
(	O
PDGFR-beta	S-GP
)	O
,	O
while	O
temsirolimus	S-chemical
is	O
an	O
mTOR	S-GP
inhibitor	O
.	O
Recent	O
clinical	O
studies	O
form	O
the	O
basis	O
for	O
new	O
guidelines	O
for	O
the	O
treatment	O
of	O
advanced	O
RCC	O
:	O
sorafenib	S-chemical
should	O
be	O
used	O
as	O
a	O
second-line	O
treatment	O
,	O
sunitinib	S-chemical
as	O
the	O
first-line	O
therapy	O
for	O
good	O
and	O
intermediate-risk	O
patients	O
,	O
and	O
temsirolimus	S-chemical
should	O
be	O
considered	O
as	O
first-line	O
treatment	O
for	O
poor-risk	O
patients	O
.	O
Future	O
approaches	O
to	O
targeted	O
therapy	O
should	O
focus	O
on	O
optimizing	O
the	O
use	O
of	O
current	O
active	O
drugs	O
,	O
exploring	O
their	O
combinations	O
or	O
investigating	O
their	O
sequential	O
use	O
.	O
In	O
addition	O
,	O
it	O
is	O
important	O
to	O
define	O
the	O
mechanisms	O
of	O
resistance	O
on	O
their	O
use	O
and	O
to	O
further	O
investigate	O
biomarkers	O
and	O
enhance	O
treatment	O
efficacy	O
for	O
the	O
individual	O
patients	O
.	O
The	O
development	O
of	O
these	O
targeted	O
therapies	O
represents	O
an	O
exciting	O
step	O
forward	O
in	O
the	O
treatment	O
of	O
advanced	O
RCC	O
.	O

Contribution	O
of	O
the	O
Na+-K+-2Cl-	B-GP
cotransporter	E-GP
NKCC1	S-GP
to	O
Cl-	S-chemical
secretion	O
in	O
rat	O
OMCD	O
.	O
In	O
rat	O
kidney	O
the	O
``	O
secretory	O
''	O
isoform	O
of	O
the	O
Na+-K+-2Cl-	B-GP
cotransporter	E-GP
(	O
NKCC1	S-GP
)	O
localizes	O
to	O
the	O
basolateral	O
membrane	O
of	O
the	O
alpha-intercalated	O
cell	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
rat	O
outer	O
medullary	O
collecting	O
duct	O
(	O
OMCD	O
)	O
secretes	O
Cl-	S-chemical
and	O
whether	O
transepithelial	O
Cl-	S-chemical
transport	O
occurs	O
,	O
in	O
part	O
,	O
through	O
Cl-	S-chemical
uptake	O
across	O
the	O
basolateral	O
membrane	O
mediated	O
by	O
NKCC1	S-GP
in	O
series	O
with	O
Cl-	S-chemical
efflux	O
across	O
the	O
apical	O
membrane	O
.	O
OMCD	O
tubules	O
from	O
rats	O
treated	O
with	O
deoxycorticosterone	B-chemical
pivalate	E-chemical
were	O
perfused	O
in	O
vitro	O
in	O
symmetrical	O
HCO	S-chemical
/	O
CO2	S-chemical
-buffered	O
solutions	O
.	O
Cl-	S-chemical
secretion	O
was	O
observed	O
in	O
this	O
segment	O
,	O
accompanied	O
by	O
a	O
lumen	O
positive	O
transepithelial	O
potential	O
.	O
Bumetanide	S-chemical
(	O
100	O
microM	O
)	O
,	O
when	O
added	O
to	O
the	O
bath	O
,	O
reduced	O
Cl-	S-chemical
secretion	O
by	O
78	O
%	O
,	O
although	O
the	O
lumen	O
positive	O
transepithelial	O
potential	O
and	O
fluid	O
flux	O
were	O
unchanged	O
.	O
Bumetanide	S-chemical
-sensitive	O
Cl-	S-chemical
secretion	O
was	O
dependent	O
on	O
extracellular	O
Na+	S-chemical
and	O
either	O
K+	S-chemical
or	O
NH	S-chemical
,	O
consistent	O
with	O
the	O
ion	O
dependency	O
of	O
NKCC1	S-GP
-mediated	O
Cl-	S-chemical
transport	O
.	O
In	O
conclusion	O
,	O
OMCD	O
tubules	O
from	O
deoxycorticosterone	B-chemical
pivalate	E-chemical
-treated	O
rats	O
secrete	O
Cl-	S-chemical
into	O
the	O
luminal	O
fluid	O
through	O
NKCC1	S-GP
-mediated	O
Cl-	S-chemical
uptake	O
across	O
the	O
basolateral	O
membrane	O
in	O
series	O
with	O
Cl-	S-chemical
efflux	O
across	O
the	O
apical	O
membrane	O
.	O
The	O
physiological	O
role	O
of	O
NKCC1	S-GP
-mediated	O
Cl-	S-chemical
uptake	O
remains	O
to	O
be	O
determined	O
.	O
However	O
,	O
the	O
role	O
of	O
NKCC1	S-GP
in	O
the	O
process	O
of	O
fluid	O
secretion	O
could	O
not	O
be	O
demonstrated	O
.	O

Evaluation	O
of	O
the	O
positive	O
effects	O
on	O
insulin	S-GP
-resistance	O
and	O
β-cell	O
measurements	O
of	O
vildagliptin	S-chemical
in	O
addition	O
to	O
metformin	S-chemical
in	O
type	O
2	O
diabetic	O
patients	O
.	O
We	O
evaluated	O
the	O
positive	O
effects	O
of	O
vildagliptin	S-chemical
in	O
addition	O
to	O
metformin	S-chemical
on	O
glycemic	O
control	O
and	O
β-cell	O
function	O
in	O
type	O
2	O
diabetic	O
patients	O
.	O
One	O
hundred	O
and	O
seventy-one	O
type	O
2	O
diabetic	O
patients	O
were	O
instructed	O
to	O
add	O
vildaglipin	S-chemical
50mg	O
twice	O
a	O
day	O
or	O
placebo	O
to	O
metformin	S-chemical
for	O
12	O
months	O
.	O
Body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
glycemic	O
control	O
,	O
fasting	O
plasma	O
insulin	S-GP
(	O
FPI	O
)	O
,	O
HOMA-IR	O
,	O
HOMA-β	O
,	O
fasting	O
plasma	O
proinsulin	S-GP
(	O
FPPr	O
)	O
,	O
proinsulin	S-GP
/fasting	O
plasma	O
insulin	S-GP
ratio	O
(	O
Pr/FPI	O
ratio	O
)	O
,	O
C-peptide	S-GP
,	O
glucagon	S-GP
,	O
vaspin	S-GP
,	O
visfatin	S-GP
,	O
and	O
omentin-1	S-GP
were	O
evaluated	O
.	O
Before	O
,	O
and	O
after	O
12	O
months	O
since	O
the	O
addition	O
of	O
vildagliptin	S-chemical
,	O
patients	O
underwent	O
a	O
combined	O
euglycemic	O
hyperinsulinemic	O
and	O
hyperglycemic	O
clamp	O
,	O
with	O
subsequent	O
arginine	S-chemical
stimulation	O
.	O
Vildagliptin	S-chemical
+	O
metformin	S-chemical
were	O
more	O
effective	O
than	O
placebo+	O
metformin	S-chemical
in	O
reducing	O
body	O
weight	O
and	O
BMI	O
,	O
glycemic	O
control	O
,	O
HOMA-IR	O
,	O
glucagon	S-GP
and	O
insulin	S-GP
resistance	O
measurements	O
.	O
Vildagliptin	S-chemical
+	O
metformin	S-chemical
gave	O
also	O
a	O
better	O
increase	O
of	O
HOMA-β	O
,	O
and	O
of	O
all	O
β-cell	O
parameters	O
after	O
the	O
clamp	O
.	O
We	O
also	O
recorded	O
a	O
significant	O
correlation	O
between	O
M	O
value	O
increase	O
and	O
the	O
decrease	O
of	O
vaspin	S-GP
,	O
visfatin	S-GP
,	O
and	O
omentin-1	S-GP
obtained	O
with	O
vildagliptin	S-chemical
+	O
metformin	S-chemical
.	O
Vildagliptin	S-chemical
,	O
in	O
addition	O
to	O
metformin	S-chemical
,	O
proved	O
to	O
be	O
effective	O
in	O
improving	O
β-cell	O
function	O
and	O
in	O
reducing	O
insulin	S-GP
resistance	O
measurements	O
.	O

Toxic	O
,	O
halogenated	O
cysteine	B-chemical
S-conjugates	E-chemical
and	O
targeting	O
of	O
mitochondrial	O
enzymes	O
of	O
energy	O
metabolism	O
.	O
Several	O
haloalkenes	S-chemical
are	O
metabolized	O
in	O
part	O
to	O
nephrotoxic	O
cysteine	B-chemical
S-conjugates	E-chemical
;	O
for	O
example	O
,	O
trichloroethylene	S-chemical
and	O
tetrafluoroethylene	S-chemical
are	O
converted	O
to	O
S-	B-chemical
(	I-chemical
1,2-dichlorovinyl	I-chemical
)	I-chemical
-L-cysteine	E-chemical
(	O
DCVC	S-chemical
)	O
and	O
S-	B-chemical
(	I-chemical
1,1,2,2-tetrafluoroethyl	I-chemical
)	I-chemical
-L-cysteine	E-chemical
(	O
TFEC	S-chemical
)	O
,	O
respectively	O
.	O
Although	O
DCVC	S-chemical
-induced	O
toxicity	O
has	O
been	O
investigated	O
since	O
the	O
1950s	O
,	O
the	O
toxicity	O
of	O
TFEC	S-chemical
and	O
other	O
haloalkene-derived	B-chemical
cysteine	I-chemical
S-conjugates	E-chemical
has	O
been	O
studied	O
more	O
recently	O
.	O
Some	O
segments	O
of	O
the	O
US	O
population	O
are	O
exposed	O
to	O
haloalkenes	S-chemical
either	O
through	O
drinking	O
water	O
or	O
in	O
the	O
workplace	O
.	O
Therefore	O
,	O
it	O
is	O
important	O
to	O
define	O
the	O
toxicological	O
consequences	O
of	O
such	O
exposures	O
.	O
Most	O
halogenated	O
cysteine	B-chemical
S-conjugates	E-chemical
are	O
metabolized	O
by	O
cysteine	B-chemical
S-conjugate	E-chemical
beta-lyases	S-GP
to	O
pyruvate	S-chemical
,	O
ammonia	S-chemical
,	O
and	O
an	O
alpha-chloroenethiolate	S-chemical
(	O
with	O
DCVC	S-chemical
)	O
or	O
an	O
alpha-difluoroalkylthiolate	S-chemical
(	O
with	O
TFEC	S-chemical
)	O
that	O
may	O
eliminate	O
halide	S-chemical
to	O
give	O
a	O
thioacyl	B-chemical
halide	E-chemical
,	O
which	O
reacts	O
with	O
epsilon-amino	S-chemical
groups	O
of	O
lysine	S-chemical
residues	O
in	O
proteins	O
.	O
Nine	O
mammalian	O
pyridoxal	B-chemical
5'-phosphate	E-chemical
(	O
PLP	S-chemical
)	O
-containing	O
enzymes	O
catalyze	O
cysteine	B-chemical
S-conjugate	E-chemical
beta-lyase	S-GP
reactions	O
,	O
including	O
mitochondrial	B-GP
aspartate	I-GP
aminotransferase	E-GP
(	O
mitAspAT	S-GP
)	O
,	O
and	O
mitochondrial	B-GP
branched-chain	I-GP
amino	I-GP
acid	I-GP
aminotransferase	E-GP
(	O
BCAT	B-GP
(	I-GP
m	I-GP
)	E-GP
)	O
.	O
Most	O
of	O
the	O
cysteine	B-chemical
S-conjugate	E-chemical
beta-lyases	S-GP
are	O
syncatalytically	O
inactivated	O
.	O
TFEC	S-chemical
-induced	O
toxicity	O
is	O
associated	O
with	O
covalent	O
modification	O
of	O
several	O
mitochondrial	O
enzymes	O
of	O
energy	O
metabolism	O
.	O
Interestingly	O
,	O
the	O
alpha-ketoglutarate-	B-GP
and	I-GP
branched-chain	I-GP
alpha-keto	I-GP
acid	I-GP
dehydrogenase	I-GP
complexes	E-GP
(	O
KGDHC	S-GP
and	O
BCDHC	S-GP
)	O
,	O
but	O
not	O
the	O
pyruvate	B-GP
dehydrogenase	I-GP
complex	E-GP
(	O
PDHC	S-GP
)	O
,	O
are	O
susceptible	O
to	O
inactivation	O
.	O
mitAspAT	S-GP
and	O
BCAT	B-GP
(	I-GP
m	I-GP
)	E-GP
may	O
form	O
metabolons	O
with	O
KGDHC	S-GP
and	O
BCDHC	S-GP
,	O
respectively	O
,	O
but	O
no	O
PLP	B-GP
enzyme	E-GP
is	O
known	O
to	O
associate	O
with	O
PDHC	S-GP
.	O
Consequently	O
,	O
we	O
hypothesize	O
that	O
not	O
only	O
do	O
these	O
metabolons	O
facilitate	O
substrate	O
channeling	O
,	O
but	O
they	O
also	O
facilitate	O
toxicant	O
channeling	O
,	O
thereby	O
promoting	O
the	O
inactivation	O
of	O
proximate	O
mitochondrial	O
enzymes	O
and	O
the	O
induction	O
of	O
mitochondrial	O
dysfunction	O
.	O

Bioinformatics	O
and	O
Molecular	O
Dynamics	O
Simulation	O
Study	O
of	O
L1	B-GP
Stalk	I-GP
Non-Canonical	I-GP
rRNA	I-GP
Elements	E-GP
:	O
Kink-Turns	S-GP
,	O
Loops	O
,	O
and	O
Tetraloops	O
.	O
The	O
L1	B-GP
stalk	E-GP
is	O
a	O
prominent	O
mobile	O
element	O
of	O
the	O
large	O
ribosomal	O
subunit	O
.	O
We	O
explore	O
the	O
structure	O
and	O
dynamics	O
of	O
its	O
non-canonical	O
rRNA	O
elements	O
,	O
which	O
include	O
two	O
kink-turns	S-GP
,	O
an	O
internal	B-GP
loop	E-GP
,	O
and	O
a	O
tetraloop	S-GP
.	O
We	O
use	O
bioinformatics	O
to	O
identify	O
the	O
L1	B-GP
stalk	E-GP
RNA	O
conservation	O
patterns	O
and	O
carry	O
out	O
over	O
11.5	O
μs	O
of	O
MD	O
simulations	O
for	O
a	O
set	O
of	O
systems	O
ranging	O
from	O
isolated	O
RNA	O
building	O
blocks	O
up	O
to	O
complexes	O
of	O
L1	B-GP
stalk	E-GP
rRNA	O
with	O
the	O
L1	B-GP
protein	E-GP
and	O
tRNA	O
fragment	O
.	O
We	O
show	O
that	O
the	O
L1	B-GP
stalk	I-GP
tetraloop	E-GP
has	O
an	O
unusual	O
GNNA	S-GP
or	O
UNNG	S-GP
conservation	O
pattern	O
deviating	O
from	O
major	O
GNRA	S-GP
and	O
YNMG	S-GP
RNA	B-GP
tetraloop	E-GP
families	O
.	O
We	O
suggest	O
that	O
this	O
deviation	O
is	O
related	O
to	O
a	O
highly	O
conserved	O
tertiary	O
contact	O
within	O
the	O
L1	B-GP
stalk	E-GP
.	O
The	O
available	O
X-ray	O
structures	O
contain	O
only	O
UCCG	S-GP
tetraloops	S-GP
which	O
in	O
addition	O
differ	O
in	O
orientation	O
(	O
anti	O
vs	O
syn	O
)	O
of	O
the	O
guanine	S-chemical
.	O
Our	O
analysis	O
suggests	O
that	O
the	O
anti	O
orientation	O
might	O
be	O
a	O
mis-refinement	O
,	O
although	O
even	O
the	O
anti	O
interaction	O
would	O
be	O
compatible	O
with	O
the	O
sequence	O
pattern	O
and	O
observed	O
tertiary	O
interaction	O
.	O
Alternatively	O
,	O
the	O
anti	O
conformation	O
may	O
be	O
a	O
real	O
substate	O
whose	O
population	O
could	O
be	O
pH-dependent	O
,	O
since	O
the	O
guanine	S-chemical
syn	O
orientation	O
requires	O
protonation	O
of	O
cytosine	S-chemical
in	O
the	O
tertiary	O
contact	O
.	O
In	O
absence	O
of	O
structural	O
data	O
,	O
we	O
use	O
molecular	O
modeling	O
to	O
explore	O
the	O
GCCA	S-GP
tetraloop	S-GP
that	O
is	O
dominant	O
in	O
bacteria	O
and	O
suggest	O
that	O
the	O
GCCA	S-GP
tetraloop	S-GP
is	O
structurally	O
similar	O
to	O
the	O
YNMG	S-GP
tetraloop	S-GP
.	O
Kink-turn	B-GP
Kt-77	E-GP
is	O
unusual	O
due	O
to	O
its	O
11-	O
nucleotide	S-chemical
bulge	O
.	O
The	O
simulations	O
indicate	O
that	O
the	O
long	O
bulge	O
is	O
a	O
stalk-specific	O
eight-	O
nucleotide	S-chemical
insertion	O
into	O
consensual	O
kink-turn	S-GP
only	O
subtly	O
modifying	O
its	O
structural	O
dynamics	O
.	O
We	O
discuss	O
a	O
possible	O
evolutionary	O
role	O
of	O
helix	B-GP
H78	E-GP
and	O
a	O
mechanism	O
of	O
L1	B-GP
stalk	E-GP
interaction	O
with	O
tRNA	O
.	O
We	O
also	O
assess	O
the	O
simulation	O
methodology	O
.	O
The	O
simulations	O
provide	O
a	O
good	O
description	O
of	O
the	O
studied	O
systems	O
with	O
the	O
latest	O
bsc0χOL3	O
force	O
field	O
showing	O
improved	O
performance	O
.	O
Still	O
,	O
even	O
bsc0χOL3	O
is	O
unable	O
to	O
fully	O
stabilize	O
an	O
essential	O
sugar	S-chemical
-edge	O
H	S-chemical
-bond	O
between	O
the	O
bulge	O
and	O
non-canonical	O
stem	O
of	O
the	O
kink-turn	S-GP
.	O
Inclusion	O
of	O
Mg	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
ions	O
may	O
deteriorate	O
the	O
simulations	O
.	O
On	O
the	O
other	O
hand	O
,	O
monovalent	O
ions	O
can	O
in	O
simulations	O
readily	O
occupy	O
experimental	O
Mg	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
binding	O
sites	O
.	O

Serum	B-GP
amyloid	I-GP
A	E-GP
upsurge	O
precedes	O
standard	O
biomarkers	O
of	O
hepatotoxicity	O
in	O
ritodrine	S-chemical
-injected	O
mice	O
.	O
The	O
tocolytic	O
agent	O
ritodrine	S-chemical
acts	O
on	O
the	O
β2-adrenoceptor	S-GP
and	O
is	O
an	O
effective	O
treatment	O
option	O
for	O
preterm	O
labor	O
.	O
However	O
,	O
several	O
adverse	O
effects	O
of	O
ritodrine	S-chemical
therapy	O
,	O
including	O
liver	O
damage	O
,	O
have	O
been	O
noted	O
.	O
To	O
elucidate	O
the	O
underlying	O
mechanisms	O
of	O
ritodrine	S-chemical
-induced	O
adverse	O
effects	O
,	O
development	O
of	O
sensitive	O
biomarkers	O
of	O
these	O
adverse	O
events	O
is	O
necessary	O
.	O
Here	O
,	O
we	O
report	O
the	O
development	O
and	O
analysis	O
of	O
an	O
animal	O
model	O
of	O
ritodrine	S-chemical
-induced	O
liver	O
damage	O
.	O
Female	O
mice	O
received	O
daily	O
ritodrine	S-chemical
injections	O
for	O
2	O
weeks	O
;	O
liver	O
samples	O
were	O
then	O
collected	O
and	O
subjected	O
to	O
DNA	O
microarray	O
analysis	O
.	O
Ritodrine	S-chemical
significantly	O
altered	O
the	O
expression	O
of	O
genes	O
related	O
to	O
steroid	S-chemical
and	O
lipid	O
metabolism	O
,	O
as	O
well	O
as	O
the	O
metabolism	O
of	O
ritodrine	S-chemical
itself	O
.	O
Importantly	O
,	O
expression	O
of	O
the	O
acute-phase	O
reactant	O
serum	B-GP
amyloid	I-GP
A	E-GP
(	O
SAA	S-GP
)	O
significantly	O
increased	O
after	O
ritodrine	S-chemical
injection	O
,	O
with	O
values	O
indicating	O
the	O
largest	O
fold-change	O
.	O
This	O
large	O
increase	O
in	O
blood	O
SAA	S-GP
levels	O
serves	O
as	O
a	O
more	O
sensitive	O
biomarker	O
than	O
conventional	O
liver	O
enzymes	O
,	O
such	O
as	O
aspartate	B-GP
aminotransferase	E-GP
and	O
alanine	B-GP
aminotransferase	E-GP
.	O
The	O
increase	O
in	O
SAA	S-GP
expression	O
is	O
specific	O
to	O
ritodrine	S-chemical
-induced	O
liver	O
damage	O
,	O
because	O
SAA	S-GP
expression	O
was	O
not	O
induced	O
by	O
other	O
hepatotoxic	O
drugs	O
such	O
as	O
acetaminophen	S-chemical
,	O
valproic	B-chemical
acid	E-chemical
,	O
or	O
metformin	S-chemical
.	O
Our	O
in	O
vitro	O
studies	O
showed	O
that	O
cyclic	B-chemical
adenosine	I-chemical
3',5'-monophosphate	E-chemical
(	O
cAMP	S-chemical
)	O
accumulation	O
was	O
not	O
a	O
primary	O
cause	O
of	O
the	O
ritodrine	S-chemical
-induced	O
SAA	S-GP
increase	O
.	O
Instead	O
,	O
SAA	S-GP
expression	O
was	O
enhanced	O
by	O
indirect	O
phosphorylation	O
of	O
the	O
signal	B-GP
transducer	I-GP
and	I-GP
activator	I-GP
of	I-GP
transcription-3	E-GP
(	O
STAT3	S-GP
)	O
mediated	O
by	O
interleukin-6	S-GP
.	O
Therefore	O
,	O
our	O
study	O
provides	O
a	O
method	O
for	O
sensitive	O
and	O
early	O
detection	O
of	O
hepatic	O
injury	O
,	O
and	O
may	O
thus	O
help	O
preclude	O
serious	O
liver	O
damage	O
due	O
to	O
ritodrine	S-chemical
use	O
in	O
preterm	O
labor	O
.	O

Methylation-mediated	O
silencing	O
of	O
genes	O
is	O
not	O
altered	O
by	O
selenium	S-chemical
treatment	O
of	O
prostate	O
cancer	O
cells	O
.	O
BACKGROUND	O
:	O
The	O
role	O
of	O
selenium	S-chemical
in	O
reducing	O
the	O
risk	O
of	O
multiple	O
cancers	O
has	O
been	O
described	O
in	O
the	O
literature	O
.	O
Although	O
reports	O
have	O
described	O
the	O
antiproliferative	O
and	O
pro-apoptotic	O
function	O
of	O
selenium	S-chemical
by	O
up-regulation	O
of	O
genes	O
in	O
these	O
pathways	O
,	O
information	O
is	O
lacking	O
on	O
the	O
target	O
mechanisms	O
of	O
selenium	S-chemical
on	O
specific	O
genes	O
.	O
This	O
study	O
examines	O
whether	O
selenium	S-chemical
treatment	O
alters	O
the	O
methylation	O
status	O
of	O
epigenetically	O
silenced	O
genes	O
in	O
prostate	O
cancer	O
cells	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Methylation	O
of	O
glutathione	B-GP
sulfotransferase	I-GP
pi	E-GP
(	O
GSTP1	S-GP
)	O
and	O
Ras	B-GP
associated	I-GP
family	I-GP
1A	E-GP
(	O
RASSF1A	S-GP
)	O
genes	O
was	O
studied	O
using	O
methylation	O
sensitive	O
PCR	O
(	O
MS-PCR	O
)	O
.	O
Gene	O
expression	O
was	O
studied	O
using	O
Reverse	O
Transcriptase	O
PCR	O
and	O
Western	O
Blotting	O
.	O
RESULTS	O
AND	O
CONCLUSION	O
:	O
Treatment	O
of	O
prostate	O
cancer	O
cells	O
with	O
selenium	S-chemical
did	O
not	O
alter	O
the	O
expression	O
of	O
genes	O
that	O
were	O
silenced	O
by	O
DNA	O
methylation	O
.	O
Furthermore	O
,	O
the	O
methylation	O
status	O
of	O
these	O
genes	O
remained	O
unaltered	O
after	O
treatment	O
with	O
seleno-DL-methionine	S-chemical
.	O

Interaction	O
of	O
non	O
steroidal	S-chemical
anti-inflammatory	O
drugs	O
(	O
NSAID	O
)	O
with	O
Helicobacter	O
pylori	O
in	O
the	O
stomach	O
of	O
humans	O
and	O
experimental	O
animals	O
.	O
Helicobacter	O
pylori	O
(	O
H.	O
pylori	O
)	O
and	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAID	O
)	O
are	O
major	O
pathogenic	O
factors	O
in	O
peptic	O
ulcer	O
disease	O
but	O
whether	O
these	O
two	O
factors	O
exert	O
synergistic	O
or	O
antagonistic	O
action	O
on	O
the	O
gastric	O
mucosa	O
has	O
been	O
a	O
subject	O
of	O
controversy	O
.	O
The	O
classic	O
concept	O
states	O
that	O
there	O
is	O
an	O
increased	O
ulcer	O
occurrence	O
and	O
bleeding	O
in	O
patients	O
with	O
both	O
H.	O
pylori	O
infection	O
and	O
NSAID	O
use	O
.	O
However	O
,	O
the	O
question	O
whether	O
the	O
H.	O
pylori	O
eradication	O
therapy	O
in	O
NSAID	O
users	O
reduces	O
the	O
occurrence	O
of	O
peptic	O
ulcer	O
has	O
not	O
been	O
fully	O
addressed	O
.	O
Studies	O
on	O
secondary	O
prevention	O
of	O
NSAID-associated	O
ulcers	O
in	O
H.	O
pylori	O
patients	O
have	O
indicated	O
that	O
H.	O
pylori	O
eradication	O
results	O
in	O
impaired	O
ulcer	O
healing	O
with	O
an	O
effect	O
on	O
the	O
rate	O
of	O
peptic	O
ulcer	O
occurrence	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
treatment	O
of	O
H.	O
pylori	O
in	O
patients	O
with	O
no	O
prior	O
history	O
of	O
chronic	O
NSAID	O
therapy	O
has	O
been	O
shown	O
to	O
decrease	O
the	O
risk	O
of	O
peptic	O
ulcer	O
.	O
Studies	O
in	O
experimental	O
animals	O
revealed	O
for	O
instance	O
,	O
that	O
the	O
H.	O
pylori	O
infection	O
augments	O
the	O
gastric	O
mucosal	O
damage	O
induced	O
by	O
NSAID	O
in	O
Mongolian	O
gerbils	O
.	O
In	O
rats	O
with	O
preexisting	O
chromic	O
gastric	O
ulcers	O
,	O
H.	O
pylori	O
infection	O
attenuated	O
significantly	O
the	O
aspirin	S-chemical
-induced	O
inhibition	O
of	O
ulcer	O
healing	O
and	O
accompanying	O
fall	O
in	O
the	O
gastric	O
blood	O
flow	O
at	O
the	O
margin	O
of	O
these	O
ulcers	O
,	O
suggesting	O
negative	O
interaction	O
between	O
aspirin	S-chemical
and	O
H.	O
pylori	O
on	O
ulcerogenesis	O
.	O
Accumulated	O
evidence	O
in	O
humans	O
and	O
animals	O
shows	O
that	O
both	O
aspirin	S-chemical
and	O
H.	O
pylori	O
upregulate	O
the	O
expression	O
of	O
cyclooxygenase	B-GP
(	I-GP
COX	I-GP
)	I-GP
-2	E-GP
both	O
at	O
mRNA	O
and	O
protein	O
levels	O
at	O
the	O
ulcer	O
margin	O
,	O
but	O
failed	O
to	O
influence	O
significantly	O
that	O
of	O
COX-1	S-GP
.	O
It	O
was	O
,	O
therefore	O
,	O
proposed	O
that	O
H.	O
pylori	O
may	O
in	O
fact	O
,	O
antagonize	O
,	O
aspirin	S-chemical
-induced	O
delay	O
of	O
ulcer	O
healing	O
due	O
to	O
suppression	O
of	O
acid	O
secretion	O
by	O
the	O
enhancement	O
in	O
PGE	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
possibly	O
derived	O
from	O
COX-2	S-GP
expression	O
and	O
activity	O
and	O
to	O
the	O
overexpression	O
of	O
growth	O
factors	O
such	O
as	O
TGF	B-GP
alpha	E-GP
and	O
VEGF	S-GP
.	O
The	O
present	O
review	O
summarizes	O
and	O
further	O
addresses	O
the	O
issue	O
of	O
the	O
interaction	O
between	O
these	O
two	O
major	O
ulcer	O
risk	O
factors	O
determined	O
in	O
the	O
stomach	O
of	O
humans	O
and	O
experimental	O
animals	O
.	O

Discovery	O
of	O
liver-targeted	O
inhibitors	O
of	O
stearoyl-CoA	B-GP
desaturase	E-GP
(	O
SCD1	S-GP
)	O
.	O
Inhibitors	O
based	O
on	O
a	O
benzo-fused	B-chemical
spirocyclic	I-chemical
oxazepine	E-chemical
scaffold	O
were	O
discovered	O
for	O
stearoyl-coenzyme	B-GP
A	I-GP
(	I-GP
CoA	I-GP
)	I-GP
desaturase	I-GP
1	E-GP
(	O
SCD1	S-GP
)	O
and	O
subsequently	O
optimized	O
to	O
potent	O
compounds	O
with	O
favorable	O
pharmacokinetic	O
profiles	O
and	O
in	O
vivo	O
efficacy	O
in	O
reducing	O
the	O
desaturation	O
index	O
in	O
a	O
mouse	O
model	O
.	O
Initial	O
optimization	O
revealed	O
potency	O
preferences	O
for	O
the	O
oxazepine	S-chemical
core	O
and	O
benzylic	S-chemical
positions	O
,	O
while	O
substituents	O
on	O
the	O
piperidine	S-chemical
portions	O
were	O
more	O
tolerant	O
and	O
allowed	O
for	O
tuning	O
of	O
potency	O
and	O
PK	O
properties	O
.	O
After	O
preparation	O
and	O
testing	O
of	O
a	O
range	O
of	O
functional	O
groups	O
on	O
the	O
piperidine	S-chemical
nitrogen	S-chemical
,	O
three	O
classes	O
of	O
analogs	O
were	O
identified	O
with	O
single	O
digit	O
nanomolar	O
potency	O
:	O
glycine	B-chemical
amides	E-chemical
,	O
heterocycle-linked	O
amides	S-chemical
,	O
and	O
thiazoles	S-chemical
.	O
Responding	O
to	O
concerns	O
about	O
target	O
localization	O
and	O
potential	O
mechanism-based	O
side	O
effects	O
,	O
an	O
initial	O
effort	O
was	O
also	O
made	O
to	O
improve	O
liver	O
concentration	O
in	O
an	O
available	O
rat	O
PK	O
model	O
.	O
An	O
advanced	O
compound	O
17m	O
with	O
a	O
5-carboxy-2-thiazole	S-chemical
substructure	O
appended	O
to	O
the	O
spirocyclic	B-chemical
piperidine	E-chemical
scaffold	O
was	O
developed	O
which	O
satisfied	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
requirements	O
for	O
more	O
detailed	O
studies	O
.	O

Inhibition	O
of	O
cPLA2	S-GP
translocation	O
and	O
leukotriene	B-chemical
C4	E-chemical
secretion	O
by	O
fluticasone	B-chemical
propionate	E-chemical
in	O
exogenously	O
activated	O
human	O
eosinophils	O
.	O
We	O
examined	O
the	O
effect	O
of	O
the	O
highly	O
lipophilic	O
corticosteroid	O
,	O
fluticasone	B-chemical
propionate	E-chemical
(	O
FP	S-chemical
)	O
,	O
in	O
causing	O
(	O
1	O
)	O
inhibition	O
of	O
nuclear	O
translocation	O
of	O
cytosolic	B-GP
phospholipase	I-GP
A2	E-GP
(	O
cPLA2	S-GP
)	O
,	O
and	O
(	O
2	O
)	O
blockade	O
of	O
leukotriene	B-chemical
C4	E-chemical
(	O
LTC4	S-chemical
)	O
synthesis	O
in	O
isolated	O
human	O
eosinophils	O
in	O
vitro	O
.	O
Eosinophils	O
were	O
isolated	O
from	O
peripheral	O
blood	O
,	O
treated	O
with	O
either	O
buffer	O
or	O
10	O
(	O
-	O
)	O
10	O
M	O
to	O
10	O
(	O
-	O
)	O
6	O
M	O
FP	S-chemical
in	O
the	O
presence	O
of	O
10	O
pg/ml	O
human	B-GP
recombinant	I-GP
interleukin-5	E-GP
(	O
rhIL-5	S-GP
)	O
and	O
activated	O
with	O
formyl-met-leu-phe	S-chemical
(	O
FMLP	S-chemical
)	O
+	O
cytochalasin	B-chemical
B	E-chemical
(	O
CB	S-chemical
)	O
.	O
At	O
24	O
h	O
,	O
stimulated	O
LTC4	S-chemical
secretion	O
from	O
eosinophils	O
was	O
unchanged	O
;	O
however	O
,	O
when	O
corrected	O
for	O
cell	O
viability	O
,	O
LTC4	S-chemical
secretion	O
decreased	O
from	O
1,429	O
+/-	O
327	O
pg/10	O
(	O
6	O
)	O
cells	O
to	O
762	O
+/-	O
113	O
pg/10	O
(	O
6	O
)	O
cells	O
for	O
eosinophils	O
treated	O
for	O
48	O
h	O
with	O
>	O
/=	O
10	O
(	O
-	O
)	O
8	O
M	O
FP	S-chemical
(	O
p	O
<	O
0.003	O
)	O
.	O
FMLP	S-chemical
/	O
CB	S-chemical
-stimulated	O
translocation	O
of	O
cPLA2	S-GP
to	O
the	O
nuclear	O
envelope	O
assessed	O
by	O
specific	O
immunohistochemical	O
staining	O
also	O
was	O
blocked	O
by	O
FP	S-chemical
.	O
By	O
contrast	O
,	O
membrane	O
expression	O
of	O
annexin-1	S-GP
,	O
which	O
was	O
not	O
minimal	O
at	O
30	O
min	O
,	O
was	O
substantial	O
at	O
48	O
h	O
for	O
eosinophils	O
treated	O
with	O
>	O
10	O
(	O
-	O
)	O
10	O
M	O
FP	S-chemical
,	O
and	O
inhibition	O
of	O
LTC4	S-chemical
synthesis	O
was	O
reversed	O
by	O
exogenous	O
arachidonic	B-chemical
acid	E-chemical
(	O
AA	S-chemical
)	O
.	O
We	O
find	O
that	O
FP	S-chemical
causes	O
a	O
decrease	O
in	O
stimulated	O
eosinophil	O
secretion	O
of	O
LTC4	S-chemical
that	O
is	O
regulated	O
by	O
phospholipase	B-GP
A2	E-GP
(	O
PLA2	S-GP
)	O
.	O
Inhibition	O
of	O
LTC4	S-chemical
synthesis	O
precedes	O
the	O
global	O
cytotoxic	O
effects	O
of	O
FP	S-chemical
as	O
indicated	O
by	O
the	O
simultaneous	O
upregulation	O
of	O
annexin-1	S-GP
expression	O
.	O
Inhibited	O
stimulated	O
secretion	O
corresponds	O
to	O
inhibited	O
translocation	O
of	O
cPLA2	S-GP
to	O
the	O
nuclear	O
envelope	O
during	O
cellular	O
activation	O
.	O

Synthesis	O
and	O
evaluation	O
of	O
8-oxoadenine	S-chemical
derivatives	O
as	O
potent	O
Toll-like	B-GP
receptor	I-GP
7	E-GP
agonists	O
with	O
high	O
water	O
solubility	O
.	O
We	O
report	O
the	O
discovery	O
of	O
novel	O
series	O
of	O
highly	O
potent	O
TLR7	S-GP
agonists	O
based	O
on	O
8-oxoadenines	S-chemical
,	O
1	O
and	O
2	O
by	O
introducing	O
and	O
optimizing	O
various	O
tertiary	B-chemical
amines	E-chemical
onto	O
the	O
N	S-chemical
(	O
9	O
)	O
-position	O
of	O
the	O
adenine	S-chemical
moiety	O
.	O
The	O
introduction	O
of	O
the	O
amino	S-chemical
group	O
resulted	O
in	O
not	O
only	O
improved	O
water	O
solubility	O
but	O
also	O
enhanced	O
TLR7	S-GP
agonistic	O
activity	O
.	O
In	O
particular	O
compound	O
20	O
(	O
DSR-6434	S-chemical
)	O
indicated	O
an	O
optimal	O
balance	O
between	O
the	O
agonistic	O
potency	O
and	O
high	O
water	O
solubility	O
.	O
It	O
also	O
demonstrated	O
a	O
strong	O
antitumor	O
effect	O
in	O
vivo	O
by	O
intravenous	O
administration	O
in	O
a	O
tumor	O
bearing	O
mice	O
model	O
.	O

A	O
novel	O
EPAC	S-GP
-specific	O
inhibitor	O
suppresses	O
pancreatic	O
cancer	O
cell	O
migration	O
and	O
invasion	O
.	O
Exchange	B-GP
protein	I-GP
directly	I-GP
activated	I-GP
by	I-GP
cAMP	E-GP
(	O
EPAC	S-GP
)	O
and	O
cAMP-dependent	B-GP
protein	I-GP
kinase	E-GP
(	O
PKA	S-GP
)	O
are	O
two	O
intracellular	O
receptors	O
that	O
mediate	O
the	O
effects	O
of	O
the	O
prototypic	O
second	O
messenger	O
cAMP	S-chemical
.	O
Identifying	O
pharmacological	O
probes	O
for	O
selectively	O
modulating	O
EPAC	S-GP
activity	O
represents	O
a	O
significant	O
unmet	O
need	O
within	O
the	O
research	O
field	O
.	O
Herein	O
,	O
we	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
3-	B-chemical
(	I-chemical
5-tert-butyl-isoxazol-3-yl	I-chemical
)	I-chemical
-2-	I-chemical
[	I-chemical
(	I-chemical
3-chloro-phenyl	I-chemical
)	I-chemical
-hydrazono	I-chemical
]	I-chemical
-3-oxo-propionitrile	E-chemical
(	O
ESI-09	S-chemical
)	O
,	O
a	O
novel	O
noncyclic	O
nucleotide	S-chemical
EPAC	S-GP
antagonist	O
that	O
is	O
capable	O
of	O
specifically	O
blocking	O
intracellular	O
EPAC	S-GP
-mediated	O
Rap1	S-GP
activation	O
and	O
Akt	S-GP
phosphorylation	O
,	O
as	O
well	O
as	O
EPAC	S-GP
-mediated	O
insulin	S-GP
secretion	O
in	O
pancreatic	O
β	O
cells	O
.	O
Using	O
this	O
novel	O
EPAC	S-GP
-specific	O
inhibitor	O
,	O
we	O
have	O
probed	O
the	O
functional	O
roles	O
of	O
overexpression	O
of	O
EPAC1	S-GP
in	O
pancreatic	O
cancer	O
cells	O
.	O
Our	O
studies	O
show	O
that	O
EPAC1	S-GP
plays	O
an	O
important	O
role	O
in	O
pancreatic	O
cancer	O
cell	O
migration	O
and	O
invasion	O
,	O
and	O
thus	O
represents	O
a	O
potential	O
target	O
for	O
developing	O
novel	O
therapeutic	O
strategies	O
for	O
pancreatic	O
cancer	O
.	O

Neuroprotection	O
by	O
propargylamines	S-chemical
in	O
Parkinson	O
's	O
disease	O
:	O
suppression	O
of	O
apoptosis	O
and	O
induction	O
of	O
prosurvival	O
genes	O
.	O
In	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
,	O
therapies	O
to	O
delay	O
or	O
suppress	O
the	O
progression	O
of	O
cell	O
death	O
in	O
nigrostriatal	O
dopamine	S-chemical
neurons	O
have	O
been	O
proposed	O
by	O
use	O
of	O
various	O
agents	O
.	O
An	O
inhibitor	O
of	O
type	B-GP
B	I-GP
monoamine	I-GP
oxidase	E-GP
(	O
MAO-B	S-GP
)	O
,	O
(	B-chemical
-	I-chemical
)	I-chemical
deprenyl	E-chemical
(	O
selegiline	S-chemical
)	O
,	O
was	O
reported	O
to	O
have	O
neuroprotective	O
activity	O
,	O
but	O
clinical	O
trials	O
failed	O
to	O
confirm	O
it	O
.	O
However	O
,	O
the	O
animal	O
and	O
cellular	O
models	O
of	O
PD	O
proved	O
that	O
selegiline	S-chemical
protects	O
neurons	O
from	O
cell	O
death	O
.	O
Among	O
selegiline	S-chemical
-related	O
propargylamines	S-chemical
,	O
(	B-chemical
R	I-chemical
)	I-chemical
(	I-chemical
+	I-chemical
)	I-chemical
-N-propargyl-1-aminoindan	E-chemical
(	O
rasagiline	S-chemical
)	O
was	O
the	O
most	O
effective	O
to	O
suppress	O
the	O
cell	O
death	O
in	O
in	O
vivo	O
and	O
in	O
vitro	O
experiments	O
.	O
In	O
this	O
paper	O
,	O
the	O
mechanism	O
of	O
the	O
neuroprotection	O
by	O
rasagiline	S-chemical
was	O
examined	O
using	O
human	O
dopaminergic	O
SH-SY5Y	O
cells	O
against	O
cell	O
death	O
induced	O
by	O
an	O
endogenous	O
dopaminergic	O
neurotoxin	O
N-methyl	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
salsolinol	E-chemical
(	O
NM	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
Sal	E-chemical
)	O
.	O
NM	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
Sal	E-chemical
induced	O
apoptosis	O
(	O
but	O
not	O
necrosis	O
)	O
in	O
SH-SY5Y	O
cells	O
,	O
and	O
the	O
apoptotic	O
cascade	O
was	O
initiated	O
by	O
mitochondrial	O
permeability	O
transition	O
(	O
PT	O
)	O
and	O
activated	O
by	O
stepwise	O
reactions	O
.	O
Rasagiline	S-chemical
prevented	O
the	O
PT	O
in	O
mitochondria	O
directly	O
and	O
also	O
indirectly	O
through	O
induction	O
of	O
antiapoptotic	O
Bcl-2	S-GP
and	O
a	O
neurotrophic	B-GP
factor	E-GP
,	O
glial	B-GP
cell	I-GP
line-derived	I-GP
neurotrophic	I-GP
factor	E-GP
(	O
GDNF	S-GP
)	O
.	O
Long-term	O
administration	O
of	O
propargylamines	S-chemical
to	O
rats	O
increased	O
the	O
activities	O
of	O
antioxidative	O
enzymes	O
superoxide	B-GP
dismutase	E-GP
(	O
SOD	S-GP
)	O
and	O
catalase	S-GP
in	O
the	O
brain	O
regions	O
containing	O
dopamine	S-chemical
neurons	O
.	O
Rasagiline	S-chemical
and	O
related	O
propargylamines	S-chemical
may	O
rescue	O
degenerating	O
dopamine	S-chemical
neurons	O
through	O
inhibiting	O
death	O
signal	O
transduction	O
initiated	O
by	O
mitochondria	O
PT	O
.	O

Hypermethylation	O
of	O
P15	S-GP
,	O
P16	S-GP
,	O
and	O
E-cadherin	S-GP
genes	O
in	O
ovarian	O
cancer	O
.	O
Both	O
p16	S-GP
and	O
p15	S-GP
proteins	O
are	O
inhibitors	O
of	O
cyclin-dependent	B-GP
kinases	E-GP
that	O
prevent	O
the	O
cell	O
going	O
through	O
the	O
G1/S	O
phase	O
transaction	O
.	O
E-cadherin	S-GP
is	O
a	O
transmembrane	O
glycoprotein	O
that	O
mediates	O
calcium	S-chemical
-dependent	O
interactions	O
between	O
adjacent	O
epithelial	O
cells	O
.	O
Two	O
groups	O
of	O
patients	O
were	O
selected	O
:	O
the	O
first	O
group	O
suffered	O
from	O
epithelial	O
serous	O
ovarian	O
tumors	O
and	O
the	O
second	O
group	O
suffered	O
from	O
benign	O
ovarian	O
lesions	O
;	O
ovarian	O
tissue	O
samples	O
from	O
all	O
the	O
subjects	O
(	O
benign	O
and	O
malignant	O
)	O
were	O
subjected	O
to	O
methylation-specific	O
polymerase	O
chain	O
reaction	O
for	O
methylated	O
and	O
unmethylated	O
alleles	O
of	O
the	O
genes	O
(	O
E-cadherin	S-GP
,	O
p15	S-GP
,	O
and	O
p16	S-GP
)	O
.	O
Results	O
obtained	O
showed	O
that	O
aberrant	O
methylation	O
of	O
p15	S-GP
and	O
p16	S-GP
genes	O
were	O
detected	O
in	O
64.29	O
and	O
50	O
%	O
of	O
ovarian	O
cancer	O
patients	O
,	O
while	O
E-cadherin	S-GP
hypermethylation	O
was	O
detected	O
in	O
78.57	O
%	O
of	O
ovarian	O
cancer	O
patients	O
.	O
Methylation	O
of	O
E-cadherin	S-GP
was	O
significantly	O
correlated	O
with	O
different	O
stage	O
of	O
disease	O
(	O
p	O
<	O
0.05	O
)	O
.	O
It	O
was	O
found	O
that	O
the	O
risk	O
of	O
E-cadherin	S-GP
hypermethylation	O
was	O
1.347-fold	O
,	O
while	O
risk	O
of	O
p15	S-GP
hypermethylation	O
was	O
1.543-fold	O
and	O
p16	O
was	O
1.2-fold	O
among	O
patients	O
with	O
ovarian	O
cancer	O
than	O
that	O
among	O
patients	O
with	O
benign	O
ovarian	O
lesions	O
.	O
In	O
conclusion	O
,	O
Dysfunction	O
of	O
the	O
cell	O
cycle	O
and/or	O
the	O
cell-cell	O
adhesion	O
molecule	O
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
ovarian	O
cancer	O
and	O
that	O
the	O
analysis	O
of	O
the	O
methylation	O
of	O
p15	S-GP
and	O
E-cadherin	S-GP
genes	O
can	O
provide	O
clinically	O
important	O
evidence	O
on	O
which	O
to	O
base	O
the	O
treatment	O
.	O

The	O
role	O
of	O
extranuclear	O
signaling	O
actions	O
of	O
progesterone	B-GP
receptor	E-GP
in	O
mediating	O
progesterone	S-chemical
regulation	O
of	O
gene	O
expression	O
and	O
the	O
cell	O
cycle	O
.	O
Human	B-GP
progesterone	I-GP
receptor	E-GP
(	O
PR	S-GP
)	O
contains	O
a	O
motif	O
that	O
interacts	O
with	O
the	O
SH3	B-GP
domain	E-GP
of	O
Src	S-GP
and	O
mediates	O
rapid	O
activation	O
of	O
Src	S-GP
and	O
downstream	O
MAPK	S-GP
(	O
Erk-1/-2	S-GP
)	O
without	O
relying	O
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
receptor	O
.	O
Here	O
we	O
investigated	O
the	O
role	O
and	O
intracellular	O
location	O
of	O
this	O
nontranscriptional	O
activity	O
of	O
PR	S-GP
.	O
Progestin	S-chemical
activation	O
of	O
Src	S-GP
/	O
MAPK	S-GP
occurred	O
outside	O
the	O
nucleus	O
with	O
the	O
B	B-GP
isoform	I-GP
of	I-GP
PR	E-GP
that	O
was	O
distributed	O
between	O
the	O
cytoplasm	O
and	O
nucleus	O
,	O
but	O
not	O
with	O
PR-A	S-GP
that	O
was	O
predominantly	O
nuclear	O
.	O
Breast	O
cancer	O
cells	O
stably	O
expressing	O
wild-type	O
PR-B	S-GP
or	O
PR-B	S-GP
with	O
disrupting	O
point	O
mutations	O
in	O
the	O
SH3	B-GP
domain	I-GP
binding	I-GP
motif	E-GP
(	O
PR-BDeltaSH3	S-GP
)	O
that	O
do	O
not	O
affect	O
the	O
transcriptional	O
activity	O
of	O
PR	S-GP
,	O
were	O
compared	O
for	O
effects	O
of	O
progestin	S-chemical
on	O
endogenous	O
target	O
gene	O
expression	O
and	O
cell	O
proliferation	O
.	O
Progestin	S-chemical
induction	O
of	O
the	O
cyclin	B-GP
D1	E-GP
gene	O
,	O
which	O
lacks	O
a	O
progesterone	B-GP
response	I-GP
element	E-GP
,	O
was	O
dependent	O
on	O
PR	S-GP
activation	O
of	O
the	O
Src	S-GP
/	O
MAPK	S-GP
pathway	O
,	O
whereas	O
induction	O
of	O
the	O
Sgk	S-GP
(	O
serum	B-GP
and	I-GP
glucocorticoid	I-GP
regulated	I-GP
kinase	E-GP
)	O
gene	O
that	O
contains	O
a	O
functional	O
progesterone	B-GP
response	I-GP
element	E-GP
was	O
unaffected	O
by	O
mutations	O
that	O
interfere	O
with	O
PR	S-GP
activation	O
of	O
Src	S-GP
.	O
Progestin	S-chemical
induction	O
of	O
cell	O
cycle	O
progression	O
was	O
also	O
abrogated	O
in	O
cells	O
expressing	O
PR-BDeltaSH3	S-GP
,	O
and	O
no	O
effect	O
of	O
progestin	S-chemical
on	O
cyclin	B-GP
D1	E-GP
expression	O
and	O
cell	O
cycle	O
was	O
observed	O
in	O
the	O
presence	O
of	O
PR-A	S-GP
.	O
These	O
results	O
highlight	O
the	O
importance	O
of	O
PR	S-GP
activation	O
of	O
the	O
Src	S-GP
/	O
MAPK	S-GP
signaling	O
pathway	O
for	O
progesterone	S-chemical
-induced	O
transcription	O
of	O
select	O
target	O
genes	O
and	O
cell	O
cycle	O
progression	O
.	O

High	O
salt	O
diets	O
during	O
pregnancy	O
affected	O
fetal	O
and	O
offspring	O
renal	O
renin	S-GP
-	O
angiotensin	S-GP
system	O
.	O
Intrauterine	O
environments	O
are	O
linked	O
to	O
fetal	O
renal	O
development	O
and	O
postnatal	O
health	O
.	O
Influence	O
of	O
salt	O
diets	O
during	O
pregnancy	O
on	O
renal	O
functions	O
and	O
renin	S-GP
-	O
angiotensin	S-GP
system	O
(	O
RAS	O
)	O
were	O
determined	O
in	O
the	O
ovine	O
fetus	O
and	O
offspring	O
.	O
Pregnant	O
ewes	O
were	O
fed	O
high-salt	O
diet	O
(	O
HSD	O
)	O
or	O
normal-salt	O
diet	O
(	O
NSD	O
)	O
for	O
two	O
months	O
during	O
middle-later	O
gestation	O
.	O
Fetal	O
renal	O
functions	O
,	O
plasma	O
hormones	O
,	O
mRNA	O
and	O
protein	O
expressions	O
of	O
the	O
key	O
elements	O
of	O
renal	O
RAS	O
were	O
measured	O
in	O
the	O
fetus	O
and	O
offspring	O
.	O
Fetal	O
renal	O
excretion	O
of	O
sodium	S-chemical
was	O
increased	O
while	O
urine	O
volume	O
decreased	O
in	O
HSD	O
group	O
.	O
Fetal	O
blood	O
urea	S-chemical
nitrogen	S-chemical
was	O
increased	O
,	O
while	O
kidney/body	O
weight	O
ratio	O
decreased	O
in	O
HSD	O
group	O
.	O
The	O
altered	O
ratio	O
also	O
was	O
observed	O
in	O
the	O
offspring	O
at	O
15-day-old	O
and	O
90-day-old	O
.	O
Maternal	O
and	O
fetal	O
plasma	O
antidiuretic	B-GP
hormone	E-GP
was	O
elevated	O
without	O
change	O
in	O
plasma	O
renin	S-GP
activity	O
and	O
Ang	B-GP
I	E-GP
levels	O
,	O
while	O
plasma	O
Ang	B-GP
II	E-GP
was	O
decreased	O
.	O
The	O
key	O
elements	O
of	O
local	O
renal	O
RAS	O
,	O
including	O
angiotensinogen	S-GP
,	O
ACE	S-GP
,	O
ACE2	S-GP
,	O
AT1	S-GP
and	O
AT2	B-GP
receptor	E-GP
expression	O
in	O
both	O
mRNA	O
and	O
protein	O
,	O
except	O
renin	S-GP
,	O
were	O
altered	O
following	O
maternal	O
high	O
salt	O
intake	O
.	O
The	O
results	O
suggest	O
that	O
High	O
intake	O
of	O
salt	O
during	O
pregnancy	O
affected	O
fetal	O
renal	O
development	O
associated	O
with	O
an	O
altered	O
expression	O
of	O
the	O
renal	O
key	O
elements	O
of	O
RAS	O
,	O
some	O
alterations	O
of	O
fetal	O
origins	O
remained	O
after	O
birth	O
as	O
possible	O
risks	O
in	O
developing	O
renal	O
or	O
cardiovascular	O
diseases	O
.	O

RIF1	S-GP
is	O
essential	O
for	O
53BP1	S-GP
-dependent	O
nonhomologous	O
end	O
joining	O
and	O
suppression	O
of	O
DNA	O
double-strand	O
break	O
resection	O
.	O
The	O
appropriate	O
execution	O
of	O
DNA	O
double-strand	O
break	O
(	O
DSB	O
)	O
repair	O
is	O
critical	O
for	O
genome	O
stability	O
and	O
tumor	O
avoidance	O
.	O
53BP1	S-GP
and	O
BRCA1	S-GP
directly	O
influence	O
DSB	O
repair	O
pathway	O
choice	O
by	O
regulating	O
5	O
'	O
end	O
resection	O
,	O
but	O
how	O
this	O
is	O
achieved	O
remains	O
uncertain	O
.	O
Here	O
we	O
report	O
that	O
Rif1	S-GP
(	O
-/-	O
)	O
mice	O
are	O
severely	O
compromised	O
for	O
53BP1	S-GP
-dependent	O
class	O
switch	O
recombination	O
(	O
CSR	O
)	O
and	O
fusion	O
of	O
dysfunctional	O
telomeres	O
.	O
The	O
inappropriate	O
accumulation	O
of	O
RIF1	S-GP
at	O
DSBs	O
in	O
S	O
phase	O
is	O
antagonized	O
by	O
BRCA1	S-GP
,	O
and	O
deletion	O
of	O
Rif1	S-GP
suppresses	O
toxic	O
nonhomologous	O
end	O
joining	O
(	O
NHEJ	O
)	O
induced	O
by	O
PARP	S-GP
inhibition	O
in	O
Brca1	S-GP
-deficient	O
cells	O
.	O
Mechanistically	O
,	O
RIF1	S-GP
is	O
recruited	O
to	O
DSBs	O
via	O
the	O
N-terminal	B-GP
phospho-SQ/TQ	I-GP
domain	E-GP
of	O
53BP1	S-GP
,	O
and	O
DSBs	O
generated	O
by	O
ionizing	O
radiation	O
or	O
during	O
CSR	O
are	O
hyperresected	O
in	O
the	O
absence	O
of	O
RIF1	S-GP
.	O
Thus	O
,	O
RIF1	S-GP
and	O
53BP1	S-GP
cooperate	O
to	O
block	O
DSB	O
resection	O
to	O
promote	O
NHEJ	O
in	O
G1	O
,	O
which	O
is	O
antagonized	O
by	O
BRCA1	S-GP
in	O
S	O
phase	O
to	O
ensure	O
a	O
switch	O
of	O
DSB	O
repair	O
mode	O
to	O
homologous	O
recombination	O
.	O

Design	O
,	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
catecholamine	S-chemical
vehicle	O
for	O
studying	O
dopaminergic	O
system	O
.	O
Catecholamine	S-chemical
mimetic	O
EDTA-bis	B-chemical
(	I-chemical
tyramide	I-chemical
)	E-chemical
was	O
synthesized	O
and	O
characterized	O
by	O
various	O
spectroscopic	O
techniques	O
(	O
NMR	O
,	O
Mass	O
spectroscopy	O
)	O
and	O
λem	O
310	O
nm	O
for	O
the	O
excitation	O
at	O
270	O
nm	O
.	O
Molecular	O
docking	O
studies	O
were	O
performed	O
with	O
Human	B-GP
Serum	I-GP
Albumin	E-GP
(	O
HSA	S-GP
:	O
PDB	O
1E78	O
)	O
,	O
showing	O
binding	O
pattern	O
with	O
amino	B-chemical
acid	E-chemical
residues	O
Arg	S-chemical
218	O
,	O
Arg	S-chemical
222	O
and	O
Lys	S-chemical
444	O
,	O
identifies	O
the	O
ligand-	O
HSA	S-GP
interaction	O
for	O
the	O
transportation	O
affinity	O
of	O
the	O
ligand	O
at	O
the	O
specific	O
site	O
of	O
the	O
target	O
.	O
Subsequently	O
binding	O
study	O
with	O
HSA	O
at	O
λex	O
=350	O
nm	O
found	O
to	O
be	O
5.847x10	O
(	O
4	O
)	O
M	O
(	O
-1	O
)	O
shows	O
effective	O
quenching	O
effect	O
.	O
Additionally	O
to	O
go	O
more	O
insight	O
AChE	O
binding	O
affinity	O
was	O
investigated	O
,	O
which	O
shows	O
90	O
%	O
binding	O
affinity	O
for	O
the	O
10	O
mM	O
concentration	O
.	O
IC50	O
value	O
was	O
was	O
found	O
18.60	O
μM	O
for	O
MAO-B	S-GP
inhibition	O
.	O
Finally	O
,	O
EDTA-bis	B-chemical
(	I-chemical
tyramide	I-chemical
)	E-chemical
labeled	O
with	O
(	B-chemical
99m	I-chemical
)	I-chemical
Tc	E-chemical
to	O
investigate	O
its	O
in-vivo	O
radiopharmaceutical	O
efficiency	O
,	O
having	O
97	O
%	O
binding	O
affinity	O
with	O
98	O
%	O
radiochemical	O
purity	O
.	O
In-vivo	O
studies	O
were	O
carried	O
out	O
for	O
(	B-chemical
99m	I-chemical
)	I-chemical
Tc-	I-chemical
EDTA-bis	I-chemical
(	I-chemical
tyramide	I-chemical
)	E-chemical
included	O
blood	O
kinetics	O
showed	O
a	O
quick	O
wash	O
out	O
from	O
the	O
circulation	O
via	O
renal	O
route	O
and	O
biodistribution	O
revealed	O
that	O
maximum	O
%	O
ID/g	O
was	O
found	O
in	O
kidney	O
at	O
1h	O
and	O
its	O
scintigraphy	O
image	O
shows	O
3.96	O
%	O
brain	O
uptake	O
with	O
respect	O
to	O
whole	O
body	O
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O

Binding	O
of	O
Diverse	O
Environmental	O
Chemicals	O
with	O
Human	B-GP
Cytochromes	I-GP
P450	I-GP
2A13	I-GP
,	I-GP
2A6	I-GP
,	I-GP
and	I-GP
1B1	E-GP
and	O
Enzyme	O
Inhibition	O
.	O
A	O
total	O
of	O
68	O
chemicals	O
including	O
derivatives	O
of	O
naphthalene	S-chemical
,	O
phenanthrene	S-chemical
,	O
fluoranthene	S-chemical
,	O
pyrene	S-chemical
,	O
biphenyl	S-chemical
,	O
and	O
flavone	S-chemical
were	O
examined	O
for	O
their	O
abilities	O
to	O
interact	O
with	O
human	B-GP
P450s	I-GP
2A13	I-GP
and	I-GP
2A6	E-GP
.	O
Fifty-one	O
of	O
these	O
68	O
chemicals	O
induced	O
stronger	O
Type	O
I	O
binding	O
spectra	O
(	O
iron	S-chemical
low-	O
to	O
high-spin	O
state	O
shift	O
)	O
with	O
P450	B-GP
2A13	E-GP
than	O
those	O
seen	O
with	O
P450	B-GP
2A6	E-GP
,	O
i.e.	O
,	O
the	O
spectral	O
binding	O
intensities	O
(	O
ΔAmax/Ks	O
ratio	O
)	O
determined	O
with	O
these	O
chemicals	O
were	O
always	O
higher	O
for	O
P450	B-GP
2A13	E-GP
.	O
In	O
addition	O
,	O
benzo	B-chemical
[	I-chemical
c	I-chemical
]	I-chemical
phenanthrene	E-chemical
,	O
fluoranthene	S-chemical
,	O
2,3-dihydroxy-2,3-dihydrofluoranthene	S-chemical
,	O
pyrene	S-chemical
,	O
1-hydroxypyrene	S-chemical
,	O
1-nitropyrene	S-chemical
,	O
1-acetylpyrene	S-chemical
,	O
2-acetylpyrene	S-chemical
,	O
2,5,2',5'-tetrachlorobiphenyl	S-chemical
,	O
7-hydroxyflavone	S-chemical
,	O
chrysin	S-chemical
,	O
and	O
galangin	S-chemical
were	O
found	O
to	O
induce	O
a	O
Type	O
I	O
spectral	O
change	O
only	O
with	O
P450	B-GP
2A13	E-GP
.	O
Coumarin	S-chemical
7-hydroxylation	O
,	O
catalyzed	O
by	O
P450	B-GP
2A13	E-GP
,	O
was	O
strongly	O
inhibited	O
by	O
2'-methoxy-5,7-dihydroxyflavone	S-chemical
,	O
2-ethynylnaphthalene	S-chemical
,	O
2'-methoxyflavone	S-chemical
,	O
2-naphththalene	B-chemical
propargyl	I-chemical
ether	E-chemical
,	O
acenaphthene	S-chemical
,	O
acenaphthylene	S-chemical
,	O
naphthalene	S-chemical
,	O
1-acetylpyrene	S-chemical
,	O
flavanone	S-chemical
,	O
chrysin	S-chemical
,	O
3-ethynylphenanthrene	S-chemical
,	O
flavone	S-chemical
,	O
and	O
7-hydroxyflavone	S-chemical
;	O
these	O
chemicals	O
induced	O
Type	O
I	O
spectral	O
changes	O
with	O
low	O
Ks	O
values	O
.	O
On	O
the	O
basis	O
of	O
the	O
intensities	O
of	O
the	O
spectral	O
changes	O
and	O
inhibition	O
of	O
P450	B-GP
2A13	E-GP
,	O
we	O
classified	O
the	O
68	O
chemicals	O
into	O
eight	O
groups	O
based	O
on	O
the	O
order	O
of	O
affinities	O
for	O
these	O
chemicals	O
and	O
inhibition	O
of	O
P450	B-GP
2A13	E-GP
.	O
The	O
metabolism	O
of	O
chemicals	O
by	O
P450	B-GP
2A13	E-GP
during	O
the	O
assays	O
explained	O
why	O
some	O
of	O
the	O
chemicals	O
that	O
bound	O
well	O
were	O
poor	O
inhibitors	O
of	O
P450	B-GP
2A13	E-GP
.	O
Finally	O
,	O
we	O
compared	O
the	O
68	O
chemicals	O
for	O
their	O
abilities	O
to	O
induce	O
Type	O
I	O
spectral	O
changes	O
of	O
P450	B-GP
2A13	E-GP
with	O
the	O
Reverse	O
Type	O
I	O
binding	O
spectra	O
observed	O
with	O
P450	B-GP
1B1	E-GP
:	O
45	O
chemicals	O
interacted	O
with	O
both	O
P450s	B-GP
2A13	I-GP
and	I-GP
1B1	E-GP
,	O
indicating	O
that	O
the	O
two	O
enzymes	O
have	O
some	O
similarty	O
of	O
structural	O
features	O
regarding	O
these	O
chemicals	O
.	O
Molecular	O
docking	O
analyses	O
suggest	O
similarities	O
at	O
the	O
active	O
sites	O
of	O
these	O
P450	B-GP
enzymes	E-GP
.	O
These	O
results	O
indicate	O
that	O
P450	B-GP
2A13	E-GP
,	O
as	O
well	O
as	O
Family	O
1	O
P450	B-GP
enzymes	E-GP
,	O
is	O
able	O
to	O
catalyze	O
many	O
detoxication	O
and	O
activation	O
reactions	O
with	O
chemicals	O
of	O
environmental	O
interest	O
.	O

Synthesis	O
of	O
thrombin	S-GP
-inhibiting	O
heparin	O
mimetics	O
without	O
side	O
effects	O
.	O
Unwanted	O
side	O
effects	O
of	O
pharmacologically	O
active	O
compounds	O
can	O
usually	O
be	O
eliminated	O
by	O
structural	O
modifications	O
.	O
But	O
the	O
complex	O
heterogeneous	O
structure	O
of	O
the	O
polysaccharide	O
heparin	O
has	O
limited	O
this	O
approach	O
to	O
fragmentation	O
,	O
leading	O
to	O
slightly	O
better-tolerated	O
heparin	O
preparations	O
of	O
low	O
molecular	O
mass	O
.	O
Despite	O
this	O
improvement	O
,	O
heparin-induced	O
thrombocytopaenia	O
(	O
HIT	O
)	O
,	O
related	O
to	O
an	O
interaction	O
with	O
platelet	B-GP
factor	I-GP
4	E-GP
(	O
PF4	S-GP
)	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
haemorrhages	O
,	O
remain	O
significant	O
side	O
effects	O
of	O
heparinotherapy	O
.	O
Breakthroughs	O
in	O
oligosaccharide	O
chemistry	O
made	O
possible	O
the	O
total	O
synthesis	O
of	O
the	O
pentasaccharide	O
antithrombin	S-GP
-binding	O
site	O
of	O
heparin	O
.	O
This	O
pentasaccharide	O
represents	O
a	O
new	O
family	O
of	O
potential	O
antithrombotic	O
drugs	O
,	O
devoid	O
of	O
thrombin	S-GP
inhibitory	O
properties	O
,	O
and	O
free	O
of	O
undesired	O
interactions	O
with	O
blood	O
and	O
vessel	O
components	O
.	O
To	O
obtain	O
more	O
potent	O
and	O
well-tolerated	O
antithrombotic	O
drugs	O
,	O
we	O
wished	O
to	O
synthesize	O
heparin	O
mimetics	O
able	O
to	O
inhibit	O
thrombin	S-GP
,	O
that	O
is	O
,	O
longer	O
oligosaccharides	O
.	O
Like	O
thrombin	S-GP
inhibition	O
,	O
undesired	O
interactions	O
are	O
directly	O
correlated	O
to	O
the	O
charge	O
and	O
the	O
size	O
of	O
the	O
molecules	O
,	O
so	O
we	O
had	O
to	O
design	O
structures	O
that	O
were	O
able	O
to	O
discriminate	O
between	O
thrombin	S-GP
and	O
other	O
proteins	O
,	O
particularly	O
PF4	S-GP
.	O
Here	O
we	O
describe	O
the	O
use	O
of	O
multistep	O
converging	O
synthesis	O
to	O
obtain	O
sulphated	O
oligosaccharides	O
that	O
meet	O
these	O
requirements	O
.	O

Activity	O
of	O
opioid	O
ligands	O
in	O
cells	O
expressing	O
cloned	O
mu	B-GP
opioid	I-GP
receptors	E-GP
.	O
BACKGROUND	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
describe	O
the	O
activity	O
of	O
a	O
set	O
of	O
opioid	O
drugs	O
,	O
including	O
partial	O
agonists	O
,	O
in	O
a	O
cell	O
system	O
expressing	O
only	O
mu	B-GP
opioid	I-GP
receptors	E-GP
.	O
Receptor	O
activation	O
was	O
assessed	O
by	O
measuring	O
the	O
inhibition	O
of	O
forskolin	S-chemical
-stimulated	O
cyclic	B-chemical
adenosine	I-chemical
mono	I-chemical
phosphate	E-chemical
(	O
cAMP	S-chemical
)	O
production	O
.	O
Efficacies	O
and	O
potencies	O
of	O
these	O
ligands	O
were	O
determined	O
relative	O
to	O
the	O
endogenous	O
ligand	O
beta-endorphin	S-GP
and	O
the	O
common	O
mu	O
agonist	O
,	O
morphine	S-chemical
.	O
RESULTS	O
:	O
Among	O
the	O
ligands	O
studied	O
naltrexone	S-chemical
,	O
WIN	B-chemical
44,441	E-chemical
and	O
SKF	B-chemical
10047	E-chemical
,	O
were	O
classified	O
as	O
antagonists	O
,	O
while	O
the	O
remaining	O
ligands	O
were	O
agonists	O
.	O
Agonist	O
efficacy	O
was	O
assessed	O
by	O
determining	O
the	O
extent	O
of	O
inhibition	O
of	O
forskolin	S-chemical
-stimulated	O
cAMP	S-chemical
production	O
.	O
The	O
rank	O
order	O
of	O
efficacy	O
of	O
the	O
agonists	O
was	O
fentanyl	S-chemical
=	O
hydromorphone	S-chemical
=	O
beta-endorphin	O
>	O
etorphine	S-chemical
=	O
lofentanil	S-chemical
=	O
butorphanol	S-chemical
=	O
morphine	S-chemical
=	O
nalbuphine	S-chemical
=	O
nalorphine	S-chemical
>	O
cyclazocine	S-chemical
=	O
dezocine	S-chemical
=	O
metazocine	S-chemical
>	O
or=	O
xorphanol	S-chemical
.	O
The	O
rank	O
order	O
of	O
potency	O
of	O
these	O
ligands	O
was	O
different	O
from	O
that	O
of	O
their	O
efficacies	O
;	O
etorphine	S-chemical
>	O
hydromorphone	S-chemical
>	O
dezocine	S-chemical
>	O
xorphanol	S-chemical
=	O
nalorphine	S-chemical
=	O
butorphanol	S-chemical
=	O
lofentanil	S-chemical
>	O
metazocine	S-chemical
>	O
nalbuphine	S-chemical
>	O
cyclazocine	S-chemical
>	O
fentanyl	S-chemical
>	O
morphine	S-chemical
>	O
>	O
>	O
>	O
beta-endorphin	O
.	O
CONCLUSION	O
:	O
These	O
results	O
elucidate	O
the	O
relative	O
activities	O
of	O
a	O
set	O
of	O
opioid	O
ligands	O
at	O
mu	B-GP
opioid	I-GP
receptor	E-GP
and	O
can	O
serve	O
as	O
the	O
initial	O
step	O
in	O
a	O
systematic	O
study	O
leading	O
to	O
understanding	O
of	O
the	O
mode	O
of	O
action	O
of	O
opioid	O
ligands	O
at	O
this	O
receptor	O
.	O
Furthermore	O
,	O
these	O
results	O
can	O
assist	O
in	O
understanding	O
the	O
physiological	O
effect	O
of	O
many	O
opioid	O
ligands	O
acting	O
through	O
mu	B-GP
opioid	I-GP
receptors	E-GP
.	O

A	O
fluorescence	O
resonance	O
energy	O
transfer-based	O
M2	B-GP
muscarinic	I-GP
receptor	E-GP
sensor	O
reveals	O
rapid	O
kinetics	O
of	O
allosteric	O
modulation	O
.	O
Allosteric	O
modulators	O
have	O
been	O
identified	O
for	O
several	O
G	B-GP
protein-coupled	I-GP
receptors	E-GP
,	O
most	O
notably	O
muscarinic	B-GP
receptors	E-GP
.	O
To	O
study	O
their	O
mechanism	O
of	O
action	O
,	O
we	O
made	O
use	O
of	O
a	O
recently	O
developed	O
technique	O
to	O
generate	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
-based	O
sensors	O
to	O
monitor	O
G	B-GP
protein-coupled	I-GP
receptor	E-GP
activation	O
.	O
C	S-chemical
yan	O
fluorescent	O
protein	O
was	O
fused	O
to	O
the	O
C	O
terminus	O
of	O
the	O
M	B-GP
(	I-GP
2	I-GP
)	I-GP
muscarinic	I-GP
receptor	E-GP
,	O
and	O
a	O
specific	O
binding	O
sequence	O
for	O
the	O
small	O
fluorescent	O
compound	O
fluorescein	S-chemical
arsenical	O
hairpin	O
binder	O
,	O
FlAsH	O
,	O
was	O
inserted	O
into	O
the	O
third	O
intracellular	O
loop	O
;	O
the	O
latter	O
site	O
was	O
labeled	O
in	O
intact	O
cells	O
by	O
incubation	O
with	O
FlAsH	O
.	O
We	O
then	O
measured	O
FRET	O
between	O
the	O
donor	O
cyan	O
fluorescent	O
protein	O
and	O
the	O
acceptor	O
FlAsH	O
in	O
intact	O
cells	O
and	O
monitored	O
its	O
changes	O
in	O
real	O
time	O
.	O
Agonists	O
such	O
as	O
acetylcholine	S-chemical
and	O
carbachol	S-chemical
induced	O
rapid	O
changes	O
in	O
FRET	O
,	O
indicative	O
of	O
agonist-induced	O
conformational	O
changes	O
.	O
Removal	O
of	O
the	O
agonists	O
or	O
addition	O
of	O
an	O
antagonist	O
caused	O
a	O
reversal	O
of	O
this	O
signal	O
with	O
rate	O
constants	O
between	O
400	O
and	O
1100	O
ms	O
.	O
The	O
allosteric	O
ligands	O
gallamine	S-chemical
and	O
dimethyl-W84	S-chemical
caused	O
no	O
changes	O
in	O
FRET	O
when	O
given	O
alone	O
,	O
but	O
increased	O
FRET	O
when	O
given	O
in	O
the	O
presence	O
of	O
an	O
agonist	O
,	O
compatible	O
with	O
an	O
inactivation	O
of	O
the	O
receptors	O
.	O
The	O
kinetics	O
of	O
these	O
effects	O
were	O
very	O
rapid	O
,	O
with	O
rate	O
constants	O
of	O
80-100	O
ms	O
and	O
approximately	O
200	O
ms	O
for	O
saturating	O
concentrations	O
of	O
gallamine	S-chemical
and	O
dimethyl-W84	S-chemical
,	O
respectively	O
.	O
Because	O
these	O
speeds	O
are	O
significantly	O
faster	O
than	O
the	O
responses	O
to	O
antagonists	O
,	O
these	O
data	O
indicate	O
that	O
gallamine	S-chemical
and	O
dimethyl-W84	S-chemical
are	O
allosteric	O
ligands	O
and	O
actively	O
induce	O
a	O
conformation	O
of	O
the	O
M	B-GP
(	I-GP
2	I-GP
)	I-GP
receptor	E-GP
with	O
a	O
reduced	O
affinity	O
for	O
its	O
agonists	O
.	O

Clinical	O
assessment	O
of	O
norepinephrine	S-chemical

Investigational	O
anti-hyperglycemic	O
agents	O
:	O
the	O
future	O
of	O
type	O
2	O
diabetes	O
therapy	O
?	O
As	O
the	O
pandemic	O
of	O
type	O
2	O
diabetes	O
spreads	O
globally	O
,	O
clinicians	O
face	O
many	O
challenges	O
in	O
treating	O
an	O
increasingly	O
diverse	O
patient	O
population	O
varying	O
in	O
age	O
,	O
comorbidities	O
,	O
and	O
socioeconomic	O
status	O
.	O
Current	O
therapies	O
for	O
type	O
2	O
diabetes	O
are	O
often	O
unable	O
to	O
alter	O
the	O
natural	O
course	O
of	O
the	O
disease	O
and	O
provide	O
durable	O
glycemic	O
control	O
,	O
and	O
side	O
effects	O
in	O
the	O
context	O
of	O
individual	O
patient	O
characteristics	O
often	O
limit	O
treatment	O
choices	O
.	O
This	O
often	O
results	O
in	O
the	O
progression	O
to	O
insulin	S-GP
use	O
and	O
complex	O
regimens	O
that	O
are	O
difficult	O
to	O
maintain	O
.	O
Therefore	O
,	O
a	O
number	O
of	O
agents	O
are	O
being	O
developed	O
to	O
better	O
address	O
the	O
pathogenesis	O
of	O
type	O
2	O
diabetes	O
and	O
to	O
overcome	O
limitations	O
of	O
current	O
therapies	O
.	O
The	O
hope	O
is	O
to	O
provide	O
more	O
options	O
for	O
glucose	S-chemical
lowering	O
and	O
complication	O
reduction	O
with	O
less	O
risk	O
for	O
hypoglycemia	O
and	O
other	O
adverse	O
effects	O
.	O
These	O
agents	O
include	O
newer	O
incretin	S-GP
-based	O
therapies	O
and	O
PPAR	S-GP
agonists	O
,	O
as	O
well	O
as	O
new	O
therapeutic	O
classes	O
such	O
as	O
sodium-coupled	B-GP
glucose	I-GP
cotransporter	I-GP
2	E-GP
inhibitors	O
,	O
free	B-GP
fatty	I-GP
acid	I-GP
receptor	E-GP
agonists	O
,	O
11-β-hydroxysteroid	B-GP
dehydrogenase	I-GP
type	I-GP
1	E-GP
inhibitors	O
,	O
glucokinase	S-GP
activators	O
,	O
and	O
several	O
others	O
that	O
may	O
enter	O
clinical	O
use	O
over	O
the	O
next	O
decade	O
.	O
Herein	O
we	O
review	O
these	O
agents	O
that	O
are	O
advancing	O
through	O
clinical	O
trials	O
and	O
describe	O
the	O
rationale	O
behind	O
their	O
use	O
,	O
mechanisms	O
of	O
action	O
,	O
and	O
potential	O
for	O
glucose	S-chemical
lowering	O
,	O
as	O
well	O
as	O
what	O
is	O
known	O
of	O
their	O
limitations	O
.	O

Retinoid	S-chemical
-induced	O
hemorrhaging	O
and	O
bone	O
toxicity	O
in	O
rats	O
fed	O
diets	O
deficient	O
in	O
vitamin	B-chemical
K	E-chemical
.	O
The	O
recent	O
increase	O
in	O
the	O
clinical	O
use	O
of	O
synthetic	O
vitamin	B-chemical
A	E-chemical
compounds	O
has	O
led	O
to	O
concern	O
of	O
possible	O
side	O
effects	O
.	O
Some	O
of	O
these	O
effects	O
are	O
known	O
to	O
be	O
influenced	O
by	O
dietary	O
levels	O
of	O
vitamin	B-chemical
K	E-chemical
.	O
We	O
therefore	O
compared	O
the	O
toxic	O
effects	O
of	O
13-cis-retinoic	B-chemical
acid	E-chemical
(	O
13cisRA	S-chemical
)	O
,	O
retinyl	B-chemical
acetate	E-chemical
(	O
ROAc	S-chemical
)	O
,	O
and	O
N-	B-chemical
(	I-chemical
4-hydroxyphenyl	I-chemical
)	I-chemical
retinamide	E-chemical
(	O
4HPR	S-chemical
)	O
in	O
male	O
Sprague-Dawley	O
rats	O
maintained	O
on	O
diets	O
containing	O
different	O
levels	O
of	O
vitamin	B-chemical
K	E-chemical
.	O
Animals	O
were	O
fed	O
either	O
an	O
NIH-07	O
diet	O
supplemented	O
with	O
menadione	S-chemical
(	O
3.1	O
ppm	O
vitamin	B-chemical
K3	E-chemical
)	O
,	O
an	O
NIH-07	O
diet	O
not	O
supplemented	O
with	O
menadione	S-chemical
,	O
or	O
an	O
AIN-076	O
purified	O
diet	O
devoid	O
of	O
vitamin	B-chemical
K	E-chemical
.	O
The	O
retinoids	S-chemical
had	O
no	O
effect	O
on	O
prothrombin	S-GP
times	O
of	O
animals	O
fed	O
the	O
supplemented	O
diet	O
.	O
When	O
menadione	S-chemical
was	O
omitted	O
from	O
the	O
diet	O
,	O
however	O
,	O
4HPR	S-chemical
-dosed	O
animals	O
had	O
elevated	O
prothrombin	S-GP
times	O
.	O
This	O
effect	O
was	O
observed	O
as	O
early	O
as	O
Day	O
7	O
and	O
was	O
accompanied	O
by	O
one	O
confirmed	O
hemorrhagic	O
death	O
.	O
13cisRA	S-chemical
-dosed	O
animals	O
showed	O
no	O
change	O
in	O
prothrombin	S-GP
times	O
.	O
In	O
the	O
high-dose	O
ROAc	S-chemical
group	O
,	O
there	O
was	O
a	O
twofold	O
increase	O
in	O
prothrombin	S-GP
times	O
but	O
only	O
after	O
prolonged	O
dosing	O
.	O
In	O
animals	O
fed	O
the	O
NIH-07	O
diets	O
,	O
13cisRA	S-chemical
and	O
ROAc	S-chemical
induced	O
multiple	O
bone	O
fractures	O
at	O
all	O
dose	O
levels	O
.	O
In	O
contrast	O
,	O
4HPR	S-chemical
administered	O
at	O
the	O
highest	O
dose	O
induced	O
only	O
one	O
fracture	O
in	O
one	O
animal	O
.	O
Animals	O
fed	O
the	O
purified	O
diet	O
lost	O
weight	O
faster	O
and	O
diet	O
sooner	O
than	O
those	O
maintained	O
on	O
the	O
other	O
diets	O
.	O
Bone	O
fractures	O
were	O
not	O
observed	O
in	O
these	O
animals	O
because	O
of	O
early	O
deaths	O
resulting	O
from	O
hemorrhaging	O
.	O
For	O
all	O
retinoid	S-chemical
-dosed	O
groups	O
maintained	O
on	O
the	O
purified	O
diet	O
,	O
changes	O
in	O
prothrombin	S-GP
times	O
occured	O
as	O
early	O
as	O
1	O
week	O
.	O
The	O
order	O
of	O
effect	O
was	O
4HPR	S-chemical
greater	O
than	O
ROAc	S-chemical
greater	O
than	O
13cisRA	S-chemical
,	O
with	O
increases	O
in	O
prothrombin	S-GP
times	O
correlating	O
with	O
increases	O
in	O
hemorrhagic	O
deaths	O
.	O
Hence	O
,	O
the	O
degree	O
of	O
retinoid	S-chemical
-induced	O
hemorrhage	O
,	O
but	O
not	O
the	O
incidence	O
of	O
bone	O
fractures	O
,	O
was	O
inversely	O
related	O
to	O
vitamin	B-chemical
K	E-chemical
levels	O
in	O
the	O
diet	O
.	O
13cisRA	S-chemical
and	O
ROAc	S-chemical
,	O
but	O
not	O
4HPR	S-chemical
,	O
caused	O
a	O
dose-dependent	O
reduction	O
in	O
plasma	O
osteocalcin	S-GP
,	O
an	O
effect	O
that	O
correlated	O
with	O
retinoid	S-chemical
-induced	O
bone	O
effects	O
.	O
In	O
contrast	O
,	O
serum	O
alkaline	B-GP
phosphatase	E-GP
was	O
elevated	O
in	O
animals	O
dosed	O
with	O
13cisRA	S-chemical
or	O
4HPR	S-chemical
but	O
not	O
in	O
those	O
dose	O
with	O
ROAc	S-chemical
.	O
For	O
this	O
enzyme	O
,	O
the	O
electrophoretic	O
pattern	O
on	O
agarose	O
gel	O
showed	O
a	O
decrease	O
,	O
compared	O
to	O
controls	O
,	O
in	O
the	O
major	O
isozyme	O
in	O
serum	O
of	O
ROAc	S-chemical
-dosed	O
animals	O
.	O
Hence	O
,	O
plasma	O
osteocalcin	S-GP
is	O
a	O
better	O
predictor	O
of	O
retinoid	S-chemical
-induced	O
bone	O
effects	O
than	O
serum	O
alkaline	B-GP
phosphatase	E-GP
.	O

Effect	O
of	O
miR-21	S-GP
on	O
Renal	O
Fibrosis	O
by	O
Regulating	O
MMP-9	S-GP
and	O
TIMP1	S-GP
in	O
kk-ay	O
Diabetic	O
Nephropathy	O
Mice	O
.	O
MicroRNAs	O
(	O
miRs	O
)	O
play	O
important	O
roles	O
in	O
initiation	O
and	O
progression	O
of	O
many	O
pathologic	O
processes	O
.	O
However	O
,	O
the	O
roles	O
of	O
miRs	O
in	O
diabetic	O
nephropathy	O
remain	O
unclear	O
.	O
This	O
study	O
was	O
to	O
determine	O
whether	O
miR-21	S-GP
was	O
involved	O
in	O
diabetic	O
nephropathy	O
and	O
to	O
explore	O
the	O
relationship	O
between	O
miR-21	S-GP
and	O
MMP9	S-GP
/	O
TIMP1	S-GP
expression	O
in	O
diabetic	O
nephropathy	O
.	O
In	O
situ	O
hybridization	O
studies	O
showed	O
that	O
miR-21	S-GP
was	O
primarily	O
localized	O
and	O
distributed	O
in	O
cortical	O
glomerular	O
and	O
renal	O
tubular	O
cells	O
in	O
diabetic	O
kk-ay	O
kidney	O
.	O
Real-time	O
quantitative	O
RT-PCR	O
demonstrated	O
that	O
the	O
expression	O
of	O
miR-21	S-GP
was	O
significantly	O
increased	O
in	O
kk-ay	O
mice	O
,	O
compared	O
with	O
control	O
C57BL	O
mice	O
.	O
Interestingly	O
,	O
miR-21	S-GP
expression	O
positively	O
correlated	O
with	O
urine	O
albumin	S-GP
creatine	S-chemical
ratio	O
(	O
ACR	O
)	O
,	O
TIMP1	S-GP
,	O
collagen	B-GP
IV	E-GP
(	O
ColIV	S-GP
)	O
,	O
and	O
fibronectin	S-GP
(	O
FN	S-GP
)	O
;	O
while	O
negatively	O
correlated	O
with	O
creatine	S-chemical
clearance	O
ratio	O
(	O
Ccr	O
)	O
and	O
MMP-9	S-GP
protein	O
.	O
Importantly	O
,	O
antagomir-21	O
not	O
only	O
ameliorated	O
Ccr	O
and	O
ACR	O
but	O
also	O
decreased	O
TIMP1	S-GP
,	O
ColIV	S-GP
,	O
and	O
FN	S-GP
proteins	O
.	O
In	O
conclusion	O
,	O
our	O
data	O
demonstrate	O
that	O
miR-21	S-GP
contributes	O
to	O
renal	O
fibrosis	O
by	O
mediating	O
MMP9	S-GP
/	O
TIMP1	S-GP
and	O
that	O
inhibition	O
of	O
miR-21	S-GP
may	O
be	O
a	O
novel	O
target	O
for	O
diabetic	O
nephropathy	O
.	O

Breast	O
cancer	O
and	O
steroid	S-chemical
metabolizing	O
enzymes	O
:	O
the	O
role	O
of	O
progestogens	S-chemical
.	O
It	O
is	O
well	O
documented	O
that	O
breast	O
tissue	O
,	O
both	O
normal	O
and	O
cancerous	O
,	O
contains	O
all	O
the	O
enzymatic	O
systems	O
necessary	O
for	O
the	O
bioformation	O
and	O
metabolic	O
transformation	O
of	O
estrogens	S-chemical
,	O
androgens	S-chemical
and	O
progesterone	S-chemical
.	O
These	O
include	O
sulfatases	S-GP
,	O
aromatase	S-GP
,	O
hydroxysteroid-dehydrogenases	S-GP
,	O
sulfotransferases	S-GP
,	O
hydroxylases	S-GP
and	O
glucuronidases	S-GP
.	O
The	O
control	O
of	O
these	O
enzymes	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
and	O
pathogenesis	O
of	O
hormone-dependent	O
breast	O
cancer	O
.	O
As	O
discussed	O
in	O
this	O
review	O
,	O
various	O
progestogens	S-chemical
including	O
dydrogesterone	S-chemical
and	O
its	O
20alpha-dihydro-derivative	O
,	O
medrogestone	S-chemical
,	O
promegestone	S-chemical
,	O
nomegestrol	B-chemical
acetate	E-chemical
and	O
norelgestromin	S-chemical
can	O
reduce	O
intratissular	O
levels	O
of	O
estradiol	S-chemical
in	O
breast	O
cancer	O
by	O
blocking	O
sulfatase	S-GP
and	O
17beta-hydroxysteroid-dehydrogenase	B-GP
type	I-GP
1	E-GP
activities	O
.	O
A	O
possible	O
correlation	O
has	O
been	O
postulated	O
between	O
breast	O
cell	O
proliferation	O
and	O
estrogen	B-GP
sulfotransferase	E-GP
activity	O
.	O
Progesterone	S-chemical
is	O
largely	O
transformed	O
in	O
the	O
breast	O
;	O
normal	O
breast	O
produces	O
mainly	O
4-ene	O
derivatives	O
,	O
whereas	O
5alpha-derivatives	O
are	O
most	O
common	O
in	O
breast	O
cancer	O
tissue	O
.	O
It	O
has	O
been	O
suggested	O
that	O
this	O
specific	O
conversion	O
of	O
progesterone	S-chemical
may	O
be	O
involved	O
in	O
breast	O
carcinogenesis	O
.	O
In	O
conclusion	O
,	O
treatment	O
with	O
anti-aromatases	O
combined	O
with	O
anti-	O
sulfatase	S-GP
or	O
17beta-hydroxysteroid-dehydrogenase	B-GP
type	I-GP
1	E-GP
could	O
provide	O
new	O
therapeutic	O
possibilities	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
hormone-dependent	O
breast	O
cancer	O
.	O

The	O
effect	O
of	O
various	O
amino	B-chemical
acids	E-chemical
and	O
drugs	O
on	O
the	O
para-	B-chemical
and	I-chemical
meta-hydroxyphenylacetic	I-chemical
acid	E-chemical
concentrations	O
in	O
the	O
mouse	O
caudate	O
nucleus	O
.	O
Injection	O
of	O
L-p-tyrosine	S-chemical
(	O
800	O
mg/kg	O
,	O
2	O
h	O
)	O
increased	O
the	O
mouse	O
striatal	O
para-hydroxyphenylacetic	B-chemical
acid	E-chemical
(	O
p-HPAA	S-chemical
)	O
concentrations	O
.	O
A	O
smaller	O
dose	O
of	O
D	B-chemical
,	I-chemical
L-m-tyrosine	E-chemical
(	O
20	O
mg/kg	O
,	O
2	O
h	O
)	O
produced	O
a	O
larger	O
increase	O
in	O
mouse	O
striatal	O
meta-hydroxyphenylacetic	B-chemical
acid	E-chemical
(	O
m-HPAA	S-chemical
)	O
concentrations	O
.	O
The	O
administration	O
of	O
L-phenylalanine	S-chemical
to	O
mice	O
caused	O
a	O
slight	O
increase	O
in	O
the	O
p-HPAA	S-chemical
concentration	O
in	O
the	O
corpus	O
striatum	O
after	O
2	O
h	O
while	O
a	O
larger	O
dose	O
of	O
L-phenylalanine	S-chemical
(	O
800	O
mg/kg	O
)	O
produced	O
a	O
greater	O
increase	O
.	O
Eight	O
hours	O
following	O
L-phenylalanine	S-chemical
injection	O
,	O
p-HPAA	S-chemical
concentrations	O
were	O
still	O
elevated	O
.	O
With	O
D-phenylalanine	S-chemical
a	O
significant	O
increase	O
was	O
observed	O
at	O
eight	O
hours	O
after	O
drug	O
administration	O
.	O
Two	O
drugs	O
which	O
reduce	O
dopamine	S-chemical
synthesis	O
,	O
alpha-methyl-para-tyrosine	S-chemical
and	O
apomorphine	S-chemical
,	O
decreased	O
m-HPAA	S-chemical
striatal	O
concentrations	O
without	O
affecting	O
p-HPAA	S-chemical
concentrations	O
.	O
From	O
these	O
results	O
,	O
it	O
is	O
proposed	O
that	O
tyrosine	B-GP
hydroxylase	E-GP
activity	O
determines	O
p-HPAA	S-chemical
concentrations	O
by	O
regulating	O
p-tyrosine	S-chemical
availability	O
.	O
This	O
enzyme	O
may	O
also	O
synthesize	O
m-tyrosine	S-chemical
which	O
is	O
subsequently	O
decarboxylated	O
to	O
form	O
m-tyramine	S-chemical
and	O
then	O
oxidatively	O
deaminated	O
to	O
form	O
m-HPAA	S-chemical
.	O

Characterization	O
of	O
the	O
nitrosyl	S-chemical
adduct	O
of	O
substrate-bound	O
mouse	B-GP
cysteine	I-GP
dioxygenase	E-GP
by	O
electron	O
paramagnetic	O
resonance	O
:	O
electronic	O
structure	O
of	O
the	O
active	O
site	O
and	O
mechanistic	O
implications	O
.	O
Mammalian	B-GP
cysteine	I-GP
dioxygenase	E-GP
(	O
CDO	S-GP
)	O
is	O
a	O
non-heme	O
iron	S-chemical
metalloenzyme	O
that	O
catalyzes	O
the	O
first	O
committed	O
step	O
in	O
oxidative	O
cysteine	S-chemical
catabolism	O
.	O
The	O
active	O
site	O
coordination	O
of	O
CDO	S-GP
comprises	O
a	O
mononuclear	O
iron	S-chemical
ligated	O
by	O
the	O
Nepsilon	O
atoms	O
of	O
three	O
protein-derived	O
histidines	S-chemical
,	O
thus	O
representing	O
a	O
new	O
variant	O
on	O
the	O
2-histidine-1-carboxylate	B-GP
(	I-GP
2H1C	I-GP
)	I-GP
facial	I-GP
triad	I-GP
motif	E-GP
.	O
Nitric	B-chemical
oxide	E-chemical
was	O
used	O
as	O
a	O
spectroscopic	O
probe	O
in	O
investigating	O
the	O
order	O
of	O
substrate-	O
O2	S-chemical
binding	O
by	O
EPR	O
spectroscopy	O
.	O
In	O
these	O
experiments	O
,	O
CDO	S-GP
exhibits	O
an	O
ordered	O
binding	O
of	O
l-cysteine	S-chemical
prior	O
to	O
NO	S-chemical
(	O
and	O
presumably	O
O2	S-chemical
)	O
similar	O
to	O
that	O
observed	O
for	O
the	O
2H1C	B-GP
class	I-GP
of	I-GP
non-heme	I-GP
iron	I-GP
enzymes	E-GP
.	O
Moreover	O
,	O
the	O
CDO	S-GP
active	O
site	O
is	O
essentially	O
unreactive	O
toward	O
NO	S-chemical
in	O
the	O
absence	O
of	O
substrate	O
,	O
suggesting	O
an	O
obligate	O
ordered	O
binding	O
of	O
l-cysteine	S-chemical
prior	O
to	O
NO	S-chemical
.	O
Typically	O
,	O
addition	O
of	O
NO	S-chemical
to	O
a	O
mononuclear	O
non-heme	O
iron	S-chemical
center	O
results	O
in	O
the	O
formation	O
of	O
an	O
{	O
FeNO	S-chemical
}	O
7	O
(	O
S	O
=	O
3/2	O
)	O
species	O
characterized	O
by	O
an	O
axial	O
EPR	O
spectrum	O
with	O
gx	O
,	O
gy	O
,	O
and	O
gz	O
values	O
of	O
approximately	O
4	O
,	O
approximately	O
4	O
,	O
and	O
approximately	O
2	O
,	O
respectively	O
.	O
However	O
,	O
upon	O
addition	O
of	O
NO	S-chemical
to	O
CDO	S-GP
in	O
the	O
presence	O
of	O
substrate	O
l-cysteine	S-chemical
,	O
a	O
low-spin	O
{	O
FeNO	S-chemical
}	O
7	O
(	O
S	O
=	O
1/2	O
)	O
signal	O
that	O
accounts	O
for	O
approximately	O
85	O
%	O
of	O
the	O
iron	S-chemical
within	O
the	O
enzyme	O
develops	O
.	O
Similar	O
{	O
FeNO	S-chemical
}	O
7	O
(	O
S	O
=	O
1/2	O
)	O
EPR	O
signals	O
have	O
been	O
observed	O
for	O
a	O
variety	O
of	O
octahedral	O
mononuclear	O
iron-nitrosyl	S-chemical
synthetic	O
complexes	O
;	O
however	O
,	O
this	O
type	O
of	O
iron-nitrosyl	S-chemical
species	O
is	O
not	O
commonly	O
observed	O
for	O
non-heme	O
iron	S-chemical
enzymes	O
.	O
Substitution	O
of	O
l-cysteine	S-chemical
with	O
isosteric	O
substrate	O
analogues	O
cysteamine	S-chemical
,	O
3-mercaptopropionic	B-chemical
acid	E-chemical
,	O
and	O
propane	B-chemical
thiol	E-chemical
did	O
not	O
produce	O
any	O
analogous	O
{	O
FeNO	S-chemical
}	O
7	O
signals	O
(	O
S	O
=	O
1/2	O
or	O
3/2	O
)	O
,	O
thus	O
reflecting	O
the	O
high	O
substrate	O
specificity	O
of	O
the	O
enzyme	O
observed	O
by	O
a	O
number	O
of	O
researchers	O
.	O
The	O
unusual	O
{	O
FeNO	S-chemical
}	O
7	O
(	O
S	O
=	O
1/2	O
)	O
electronic	O
configuration	O
adopted	O
by	O
the	O
substrate-bound	O
iron-nitrosyl	S-chemical
CDO	S-GP
(	O
termed	O
{	O
ES-	O
NO	S-chemical
}	O
7	O
)	O
is	O
a	O
result	O
of	O
the	O
bidentate	B-chemical
thiol/amine	E-chemical
coordination	O
of	O
l-cysteine	S-chemical
in	O
the	O
NO	S-chemical
-bound	O
CDO	S-GP
active	O
site	O
.	O
DFT	O
computations	O
were	O
performed	O
to	O
further	O
characterize	O
this	O
species	O
.	O
The	O
DFT-predicted	O
geometric	O
parameters	O
for	O
{	O
ES-	O
NO	S-chemical
}	O
7	O
are	O
in	O
good	O
agreement	O
with	O
the	O
crystallographically	O
determined	O
substrate-bound	O
active	O
site	O
configuration	O
of	O
CDO	S-GP
and	O
are	O
consistent	O
with	O
known	O
iron-nitrosyl	S-chemical
model	O
complexes	O
.	O
Moreover	O
,	O
the	O
computed	O
EPR	O
parameters	O
(	O
g	O
and	O
A	O
values	O
)	O
are	O
in	O
excellent	O
agreement	O
with	O
experimental	O
results	O
for	O
this	O
CDO	S-GP
species	O
and	O
those	O
obtained	O
from	O
comparable	O
synthetic	O
{	O
FeNO	S-chemical
}	O
7	O
(	O
S	O
=	O
1/2	O
)	O
iron-nitrosyl	S-chemical
complexes	O
.	O

Global	O
target	O
profile	O
of	O
the	O
kinase	S-GP
inhibitor	O
bosutinib	S-chemical
in	O
primary	O
chronic	O
myeloid	O
leukemia	O
cells	O
.	O
The	O
detailed	O
molecular	O
mechanism	O
of	O
action	O
of	O
second-generation	O
BCR	S-GP
-	O
ABL	S-GP
tyrosine	B-GP
kinase	E-GP
inhibitors	O
,	O
including	O
perturbed	O
targets	O
and	O
pathways	O
,	O
should	O
contribute	O
to	O
rationalized	O
therapy	O
in	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
or	O
in	O
other	O
affected	O
diseases	O
.	O
Here	O
,	O
we	O
characterized	O
the	O
target	O
profile	O
of	O
the	O
dual	O
SRC	S-GP
/	O
ABL	S-GP
inhibitor	O
bosutinib	S-chemical
employing	O
a	O
two-tiered	O
approach	O
using	O
chemical	O
proteomics	O
to	O
identify	O
natural	O
binders	O
in	O
whole	O
cell	O
lysates	O
of	O
primary	O
CML	O
and	O
K562	O
cells	O
in	O
parallel	O
to	O
in	O
vitro	O
kinase	S-GP
assays	O
against	O
a	O
large	O
recombinant	O
kinase	S-GP
panel	O
.	O
The	O
combined	O
strategy	O
resulted	O
in	O
a	O
global	O
survey	O
of	O
bosutinib	S-chemical
targets	O
comprised	O
of	O
over	O
45	O
novel	O
tyrosine	B-GP
and	I-GP
serine/threonine	I-GP
kinases	E-GP
.	O
We	O
have	O
found	O
clear	O
differences	O
in	O
the	O
target	O
patterns	O
of	O
bosutinib	S-chemical
in	O
primary	O
CML	O
cells	O
versus	O
the	O
K562	O
cell	O
line	O
.	O
A	O
comparison	O
of	O
bosutinib	S-chemical
with	O
dasatinib	S-chemical
across	O
the	O
whole	O
kinase	S-GP
panel	O
revealed	O
overlapping	O
,	O
but	O
distinct	O
,	O
inhibition	O
profiles	O
.	O
Common	O
among	O
those	O
were	O
the	O
SRC	S-GP
,	O
ABL	S-GP
and	O
TEC	S-GP
family	O
kinases	S-GP
.	O
Bosutinib	S-chemical
did	O
not	O
inhibit	O
KIT	S-GP
or	O
platelet-derived	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
,	O
but	O
prominently	O
targeted	O
the	O
apoptosis-linked	O
STE20	B-GP
kinases	E-GP
.	O
Although	O
in	O
vivo	O
bosutinib	S-chemical
is	O
inactive	O
against	O
ABL	S-GP
T315I	S-GP
,	O
we	O
found	O
this	O
clinically	O
important	O
mutant	O
to	O
be	O
enzymatically	O
inhibited	O
in	O
the	O
mid-nanomolar	O
range	O
.	O
Finally	O
,	O
bosutinib	S-chemical
is	O
the	O
first	O
kinase	S-GP
inhibitor	O
shown	O
to	O
target	O
CAMK2G	S-GP
,	O
recently	O
implicated	O
in	O
myeloid	O
leukemia	O
cell	O
proliferation	O
.	O

Crystallographic	O
analysis	O
of	O
the	O
human	B-GP
phenylalanine	I-GP
hydroxylase	I-GP
catalytic	I-GP
domain	E-GP
with	O
bound	O
catechol	S-chemical
inhibitors	O
at	O
2.0	O
A	O
resolution	O
.	O
The	O
aromatic	B-GP
amino	I-GP
acid	I-GP
hydroxylases	E-GP
represent	O
a	O
superfamily	O
of	O
structurally	O
and	O
functionally	O
closely	O
related	O
enzymes	O
,	O
one	O
of	O
those	O
functions	O
being	O
reversible	O
inhibition	O
by	O
catechol	S-chemical
derivatives	O
.	O
Here	O
we	O
present	O
the	O
crystal	O
structure	O
of	O
the	O
dimeric	O
catalytic	O
domain	O
(	O
residues	O
117-424	O
)	O
of	O
human	B-GP
phenylalanine	I-GP
hydroxylase	E-GP
(	O
hPheOH	S-GP
)	O
,	O
cocrystallized	O
with	O
various	O
potent	O
and	O
well-known	O
catechol	S-chemical
inhibitors	O
and	O
refined	O
at	O
a	O
resolution	O
of	O
2.0	O
A	O
.	O
The	O
catechols	S-chemical
bind	O
by	O
bidentate	O
coordination	O
to	O
each	O
iron	S-chemical
in	O
both	O
subunits	O
of	O
the	O
dimer	O
through	O
the	O
catechol	B-chemical
hydroxyl	E-chemical
groups	O
,	O
forming	O
a	O
blue-green	O
colored	O
ligand-to-metal	O
charge-transfer	O
complex	O
.	O
In	O
addition	O
,	O
Glu330	O
and	O
Tyr325	O
are	O
identified	O
as	O
determinant	O
residues	O
in	O
the	O
recognition	O
of	O
the	O
inhibitors	O
.	O
In	O
particular	O
,	O
the	O
interaction	O
with	O
Glu330	O
conforms	O
to	O
the	O
structural	O
explanation	O
for	O
the	O
pH	O
dependence	O
of	O
catecholamine	S-chemical
binding	O
to	O
PheOH	S-chemical
,	O
with	O
a	O
pKa	O
value	O
of	O
5.1	O
(	O
20	O
degreesC	O
)	O
.	O
The	O
overall	O
structure	O
of	O
the	O
catechol	S-chemical
-bound	O
enzyme	O
is	O
very	O
similar	O
to	O
that	O
of	O
the	O
uncomplexed	O
enzyme	O
(	O
rms	O
difference	O
of	O
0.2	O
A	O
for	O
the	O
Calpha	O
atoms	O
)	O
.	O
Most	O
striking	O
is	O
the	O
replacement	O
of	O
two	O
iron-bound	O
water	O
molecules	O
with	O
catechol	B-chemical
hydroxyl	E-chemical
groups	O
.	O
This	O
change	O
is	O
consistent	O
with	O
a	O
change	O
in	O
the	O
ligand	O
field	O
symmetry	O
of	O
the	O
high-spin	O
(	O
S	O
=	O
5/2	O
)	O
Fe	O
(	O
III	O
)	O
from	O
a	O
rhombic	O
to	O
a	O
nearly	O
axial	O
ligand	O
field	O
symmetry	O
as	O
seen	O
upon	O
noradrenaline	S-chemical
binding	O
using	O
EPR	O
spectroscopy	O
[	O
Martinez	O
,	O
A.	O
,	O
Andersson	O
,	O
K.	O
K.	O
,	O
Haavik	O
,	O
J.	O
,	O
and	O
Flatmark	O
,	O
T.	O
(	O
1991	O
)	O
Eur	O
.	O
J.	O
Biochem	O
.	O
198	O
,	O
675-682	O
]	O
.	O
Crystallographic	O
comparison	O
with	O
the	O
structurally	O
related	O
rat	B-GP
tyrosine	I-GP
hydroxylase	E-GP
binary	O
complex	O
with	O
the	O
oxidized	O
cofactor	O
7,8-dihydrobiopterin	S-chemical
revealed	O
overlapping	O
binding	O
sites	O
for	O
the	O
catechols	S-chemical
and	O
the	O
cofactor	O
,	O
compatible	O
with	O
a	O
competitive	O
type	O
of	O
inhibition	O
of	O
the	O
catechols	S-chemical
versus	O
BH4	O
.	O
The	O
comparison	O
demonstrates	O
some	O
structural	O
differences	O
at	O
the	O
active	O
site	O
as	O
the	O
potential	O
basis	O
for	O
the	O
different	O
substrate	O
specificity	O
of	O
the	O
two	O
enzymes	O
.	O

Strong	O
effects	O
of	O
cluster	O
size	O
and	O
air	O
exposure	O
on	O
oxygen	S-chemical
reduction	O
and	O
carbon	S-chemical
oxidation	O
electrocatalysis	O
by	O
size-selected	O
Pt	B-chemical
(	I-chemical
n	I-chemical
)	E-chemical
(	O
n	O
≤	O
11	O
)	O
on	O
glassy	B-chemical
carbon	E-chemical
electrodes	O
.	O
Model	O
Pt	B-chemical
(	I-chemical
n	I-chemical
)	E-chemical
/	O
glassy	B-chemical
carbon	E-chemical
electrodes	O
(	O
Pt	B-chemical
(	I-chemical
n	I-chemical
)	E-chemical
/GCE	O
)	O
were	O
prepared	O
by	O
deposition	O
of	O
mass-selected	O
Pt	B-chemical
(	I-chemical
n	I-chemical
)	I-chemical
(	I-chemical
+	I-chemical
)	E-chemical
(	O
n	O
≤	O
11	O
)	O
on	O
GCE	O
substrates	O
in	O
ultrahigh	O
vacuum	O
.	O
Electrocatalysis	O
under	O
conditions	O
appropriate	O
for	O
the	O
oxygen	S-chemical
reduction	O
reaction	O
(	O
ORR	O
)	O
was	O
studied	O
,	O
for	O
samples	O
both	O
in	O
situ	O
with	O
no	O
exposure	O
to	O
laboratory	O
air	O
and	O
with	O
air	O
exposure	O
prior	O
to	O
electrochemical	O
measurements	O
.	O
Of	O
the	O
small	O
clusters	O
,	O
only	O
a	O
few	O
cluster	O
sizes	O
show	O
the	O
expected	O
ORR	O
activity	O
,	O
and	O
in	O
those	O
cases	O
,	O
the	O
activity	O
per	O
Pt	S-chemical
atom	O
is	O
similar	O
to	O
that	O
seen	O
under	O
identical	O
conditions	O
with	O
a	O
conventionally	O
prepared	O
electrode	O
with	O
Pt	S-chemical
nanoparticles	O
grown	O
on	O
a	O
GCE	O
.	O
For	O
other	O
small	O
Pt	B-chemical
(	I-chemical
n	I-chemical
)	E-chemical
on	O
GCE	O
,	O
any	O
ORR	O
signal	O
is	O
overwhelmed	O
by	O
large	O
oxidative	O
currents	O
attributed	O
to	O
catalysis	O
of	O
carbon	S-chemical
oxidation	O
by	O
water	O
.	O
If	O
the	O
samples	O
are	O
exposed	O
to	O
air	O
prior	O
to	O
electrochemistry	O
,	O
both	O
ORR	O
and	O
carbon	S-chemical
oxidation	O
signals	O
are	O
absent	O
,	O
and	O
instead	O
only	O
small	O
capacitive	O
currents	O
or	O
currents	O
attributed	O
to	O
redox	O
chemistry	O
of	O
adventitious	O
organic	O
adsorbates	O
are	O
observed	O
,	O
indicating	O
that	O
air	O
exposure	O
results	O
in	O
passivation	O
of	O
the	O
small	O
Pt	S-chemical
clusters	O
.	O

Cardiac	B-GP
natriuretic	I-GP
Peptide	E-GP
gene	O
expression	O
and	O
plasma	O
concentrations	O
during	O
the	O
first	O
72	O
hours	O
of	O
life	O
in	O
piglets	O
.	O
Plasma	O
measurement	O
of	O
cardiac	B-GP
natriuretic	I-GP
peptides	E-GP
constitutes	O
promising	O
markers	O
of	O
congenital	O
heart	O
disease	O
.	O
However	O
,	O
concentrations	O
change	O
rapidly	O
and	O
dramatically	O
during	O
the	O
first	O
days	O
after	O
delivery	O
even	O
in	O
healthy	O
neonates	O
,	O
which	O
complicates	O
clinical	O
interpretation	O
.	O
It	O
is	O
unknown	O
whether	O
these	O
changes	O
in	O
plasma	O
concentrations	O
are	O
explained	O
by	O
corresponding	O
changes	O
in	O
the	O
cardiac	O
gene	O
expression	O
.	O
We	O
quantified	O
the	O
chamber-specific	O
mRNA	O
levels	O
of	O
ANP	S-GP
(	O
A-type	B-GP
natriuretic	I-GP
peptide	E-GP
)	O
and	O
BNP	S-GP
(	O
B-type	B-GP
natriuretic	I-GP
peptide	E-GP
)	O
and	O
plasma	O
pro-	O
ANP	S-GP
and	O
BNP-32	S-GP
concentrations	O
in	O
healthy	O
piglets	O
during	O
the	O
first	O
72	O
hours	O
of	O
life	O
(	O
from	O
2	O
litters	O
,	O
n	O
=	O
44	O
)	O
.	O
Chamber-specific	O
ANP	S-GP
and	O
BNP	S-GP
mRNA	O
levels	O
reflected	O
hemodynamic	O
neonate	O
changes	O
at	O
birth	O
but	O
did	O
not	O
correlate	O
with	O
circulating	O
natriuretic	B-GP
peptide	E-GP
concentrations	O
.	O
However	O
,	O
plasma	O
pro-	O
ANP	S-GP
and	O
creatinine	S-chemical
concentrations	O
were	O
closely	O
correlated	O
(	O
P	O
<	O
.0001	O
;	O
r	O
=	O
0.73	O
)	O
.	O
Plasma	O
pro-	O
ANP	S-GP
levels	O
were	O
highest	O
on	O
the	O
day	O
of	O
delivery	O
(	O
5580	O
pmol/L	O
[	O
4320-6786	O
]	O
decreasing	O
to	O
2484	O
pmol/L	O
[	O
1602-2898	O
]	O
after	O
72	O
hours	O
,	O
P	O
<	O
.0001	O
)	O
.	O
During	O
the	O
72	O
hours	O
,	O
gel	O
chromatography	O
suggested	O
that	O
the	O
translational	O
products	O
in	O
circulation	O
and	O
in	O
atrial	O
tissue	O
were	O
immature	O
,	O
ie	O
,	O
unprocessed	O
pro-	O
ANP	S-GP
.	O
In	O
contrast	O
to	O
pro-	O
ANP	S-GP
,	O
BNP-32	S-GP
plasma	O
concentrations	O
were	O
low	O
at	O
delivery	O
and	O
peaked	O
after	O
48	O
hours	O
(	O
12	O
[	O
10.5-20.6	O
]	O
vs.	O
88.8	O
[	O
71.7-101.4	O
]	O
pmol/L	O
,	O
P	O
<	O
.0001	O
)	O
.	O
To	O
conclude	O
,	O
ANP	S-GP
and	O
BNP	S-GP
gene	O
expression	O
differs	O
considerably	O
between	O
cardiac	O
chambers	O
in	O
the	O
first	O
72	O
hours	O
of	O
life	O
in	O
healthy	O
piglets	O
,	O
resembling	O
the	O
transition	O
from	O
fetal	O
to	O
neonate	O
circulation	O
.	O
However	O
,	O
the	O
cardiac	O
gene	O
expression	O
does	O
not	O
explain	O
plasma	O
concentrations	O
.	O

Purification	O
and	O
characterization	O
of	O
a	O
novel	O
hyaluronan-binding	B-GP
protein	E-GP
(	O
PHBP	S-GP
)	O
from	O
human	O
plasma	O
:	O
it	O
has	O
three	O
EGF	O
,	O
a	O
kringle	O
and	O
a	O
serine	B-GP
protease	I-GP
domain	E-GP
,	O
similar	O
to	O
hepatocyte	O
growth	O
factor	O
activator	O
.	O
A	O
novel	O
hyaluronan-binding	B-GP
protein	E-GP
(	O
PHBP	S-GP
)	O
was	O
purified	O
from	O
human	O
plasma	O
by	O
affinity	O
chromatography	O
on	O
hyaluronan-conjugated	O
Sepharose	O
.	O
The	O
contaminating	O
IgM	S-GP
and	O
albumin	S-GP
in	O
the	O
partially	O
purified	O
preparation	O
were	O
removed	O
with	O
anti-	O
IgG	S-GP
antibody-conjugated	O
Sepharose	O
and	O
anti-	O
albumin	S-GP
antibody-conjugated	O
Sepharose	O
,	O
respectively	O
,	O
and	O
no	O
other	O
contaminant	O
was	O
observed	O
.	O
Finally	O
,	O
800	O
micrograms	O
of	O
PHBP	S-GP
was	O
isolated	O
from	O
500	O
ml	O
of	O
human	O
plasma	O
.	O
PHBP	S-GP
gave	O
a	O
single	O
70-kDa	O
band	O
on	O
SDS-PAGE	O
under	O
non-reducing	O
conditions	O
,	O
and	O
50-kDa	O
and	O
17-kDa	O
bands	O
under	O
reducing	O
conditions	O
.	O
Thus	O
,	O
PHBP	S-GP
was	O
a	O
heterodimer	O
composed	O
of	O
50-kDa	O
and	O
17-kDa	O
subunits	O
,	O
bridged	O
by	O
a	O
disulfide	S-chemical
linkage	O
.	O
Both	O
subunits	O
had	O
novel	O
N-terminal	B-chemical
amino	I-chemical
acid	E-chemical
sequences	O
,	O
indicating	O
that	O
PHBP	S-GP
was	O
a	O
novel	O
hyaluronan-binding	O
protein	O
in	O
human	O
plasma	O
.	O
The	O
amino	B-chemical
acid	E-chemical
sequence	O
deduced	O
from	O
the	O
nucleotide	S-chemical
sequence	O
of	O
the	O
cloned	O
PHBP	S-GP
cDNA	O
exhibited	O
significant	O
homology	O
to	O
that	O
of	O
hepatocyte	B-GP
growth	I-GP
factor	I-GP
activator	E-GP
(	O
HGFA	S-GP
)	O
.	O
The	O
results	O
of	O
Northern	O
blot	O
analysis	O
indicated	O
that	O
liver	O
,	O
kidney	O
,	O
and	O
pancreas	O
expressed	O
PHBP	S-GP
mRNA	O
.	O
The	O
predicted	O
structure	O
of	O
PHBP	S-GP
showed	O
three	O
epidermal	B-GP
growth	I-GP
factor	I-GP
(	I-GP
EGF	I-GP
)	I-GP
domains	E-GP
,	O
a	O
kringle	B-GP
domain	E-GP
and	O
a	O
serine	B-GP
protease	I-GP
domain	E-GP
,	O
from	O
its	O
N	S-chemical
-terminus	O
,	O
although	O
HGFA	S-GP
has	O
a	O
fibronectin	B-GP
type	I-GP
II	I-GP
domain	E-GP
,	O
an	O
EGF	B-GP
domain	E-GP
,	O
a	O
fibronectin	B-GP
type	I-GP
I	I-GP
domain	E-GP
,	O
an	O
EGF	B-GP
domain	E-GP
,	O
a	O
kringle	B-GP
domain	E-GP
,	O
and	O
a	O
serine	B-GP
protease	I-GP
domain	E-GP
,	O
from	O
its	O
N	S-chemical
-terminus	O
.	O

Jostling	O
for	O
position	O
:	O
optimizing	O
linker	O
location	O
in	O
the	O
design	O
of	O
estrogen	B-GP
receptor	E-GP
-targeting	O
PROTACs	O
.	O
Estrogen	B-GP
receptor-alpha	E-GP
(	O
ER	S-GP
)	O
antagonists	O
have	O
been	O
widely	O
used	O
for	O
breast	O
cancer	O
therapy	O
.	O
Despite	O
initial	O
responsiveness	O
,	O
hormone-sensitive	O
ER	S-GP
-positive	O
cancer	O
cells	O
eventually	O
develop	O
resistance	O
to	O
ER	S-GP
antagonists	O
.	O
It	O
has	O
been	O
shown	O
that	O
in	O
most	O
of	O
these	O
resistant	O
tumor	O
cells	O
,	O
the	O
ER	S-GP
is	O
expressed	O
and	O
continues	O
to	O
regulate	O
tumor	O
growth	O
.	O
Recent	O
studies	O
indicate	O
that	O
tamoxifen	S-chemical
initially	O
acts	O
as	O
an	O
antagonist	O
,	O
but	O
later	O
functions	O
as	O
an	O
ER	S-GP
agonist	O
,	O
promoting	O
tumor	O
growth	O
.	O
This	O
suggests	O
that	O
targeted	O
ER	S-GP
degradation	O
may	O
provide	O
an	O
effective	O
therapeutic	O
approach	O
for	O
breast	O
cancers	O
,	O
even	O
those	O
that	O
are	O
resistant	O
to	O
conventional	O
therapies	O
.	O
With	O
this	O
in	O
mind	O
,	O
we	O
previously	O
demonstrated	O
that	O
proteolysis	O
targeting	O
chimeras	O
(	O
PROTACs	O
)	O
effectively	O
induce	O
degradation	O
of	O
the	O
ER	S-GP
as	O
a	O
proof-of-concept	O
experiment	O
.	O
Herein	O
we	O
further	O
refined	O
the	O
PROTAC	O
approach	O
to	O
target	O
the	O
ER	S-GP
for	O
degradation	O
.	O
The	O
ER	S-GP
-targeting	O
PROTACs	O
are	O
composed	O
of	O
an	O
estradiol	S-chemical
on	O
one	O
end	O
and	O
a	O
hypoxia-inducing	B-GP
factor	I-GP
1alpha	E-GP
(	O
HIF-1alpha	S-GP
)	O
-derived	O
synthetic	O
pentapeptide	O
on	O
the	O
other	O
.	O
The	O
pentapeptide	O
is	O
recognized	O
by	O
an	O
E3	B-GP
ubiquitin	I-GP
ligase	E-GP
called	O
the	O
von	B-GP
Hippel	I-GP
Lindau	I-GP
tumor	I-GP
suppressor	I-GP
protein	E-GP
(	O
pVHL	S-GP
)	O
,	O
thereby	O
recruiting	O
the	O
ER	S-GP
to	O
this	O
E3	B-GP
ligase	E-GP
for	O
ubiquitination	O
and	O
degradation	O
.	O
Specifically	O
,	O
the	O
pentapeptide	O
is	O
attached	O
at	O
three	O
different	O
locations	O
on	O
estradiol	S-chemical
to	O
generate	O
three	O
different	O
PROTAC	O
types	O
.	O
With	O
the	O
pentapeptide	O
linked	O
through	O
the	O
C7alpha	O
position	O
of	O
estradiol	S-chemical
,	O
the	O
resulting	O
PROTAC	O
shows	O
the	O
most	O
effective	O
ER	S-GP
degradation	O
and	O
highest	O
affinity	O
for	O
the	O
estrogen	B-GP
receptor	E-GP
.	O
This	O
result	O
provides	O
an	O
opportunity	O
to	O
develop	O
a	O
novel	O
type	O
of	O
ER	S-GP
antagonist	O
that	O
may	O
overcome	O
the	O
resistance	O
of	O
breast	O
tumors	O
to	O
conventional	O
drugs	O
such	O
as	O
tamoxifen	S-chemical
and	O
fulvestrant	S-chemical
(	O
Faslodex	S-chemical
)	O
.	O

The	O
contrasting	O
activity	O
of	O
iodido	S-chemical
versus	O
chlorido	B-chemical
ruthenium	E-chemical
and	O
osmium	B-chemical
arene	I-chemical
azo-	I-chemical
and	I-chemical
imino-pyridine	E-chemical
anticancer	O
complexes	O
:	O
control	O
of	O
cell	O
selectivity	O
,	O
cross-resistance	O
,	O
p53	S-GP
dependence	O
,	O
and	O
apoptosis	O
pathway	O
.	O
Organometallic	O
half-sandwich	O
complexes	O
[	B-chemical
M	I-chemical
(	I-chemical
p-cymene	I-chemical
)	I-chemical
(	I-chemical
azo/imino-pyridine	I-chemical
)	I-chemical
X	I-chemical
]	I-chemical
(	I-chemical
+	I-chemical
)	E-chemical
where	O
M	B-chemical
=	I-chemical
Ru	I-chemical
(	I-chemical
II	I-chemical
)	I-chemical
or	I-chemical
Os	I-chemical
(	I-chemical
II	I-chemical
)	E-chemical
and	O
X	B-chemical
═	I-chemical
Cl	I-chemical
or	I-chemical
I	E-chemical
,	O
exhibit	O
potent	O
antiproliferative	O
activity	O
toward	O
a	O
range	O
of	O
cancer	O
cells	O
.	O
Not	O
only	O
are	O
the	O
iodido	S-chemical
complexes	O
more	O
potent	O
than	O
the	O
chlorido	S-chemical
analogues	O
,	O
but	O
they	O
are	O
not	O
cross-resistant	O
with	O
the	O
clinical	O
platinum	S-chemical
drugs	O
cisplatin	S-chemical
and	O
oxaliplatin	S-chemical
.	O
They	O
are	O
also	O
more	O
selective	O
for	O
cancer	O
cells	O
versus	O
normal	O
cells	O
(	O
fibroblasts	O
)	O
and	O
show	O
high	O
accumulation	O
in	O
cell	O
membranes	O
.	O
They	O
arrest	O
cell	O
growth	O
in	O
G1	O
phase	O
in	O
contrast	O
to	O
cisplatin	S-chemical
(	O
S	O
phase	O
)	O
with	O
a	O
high	O
incidence	O
of	O
late-stage	O
apoptosis	O
.	O
The	O
iodido	S-chemical
complexes	O
retain	O
potency	O
in	O
p53	S-GP
mutant	O
colon	O
cells	O
.	O
All	O
complexes	O
activate	O
caspase	B-GP
3	E-GP
.	O
In	O
general	O
,	O
antiproliferative	O
activity	O
is	O
greatly	O
enhanced	O
by	O
low	O
levels	O
of	O
the	O
glutathione	B-GP
synthase	E-GP
inhibitor	O
l-buthionine	B-chemical
sulfoxime	E-chemical
.	O
The	O
work	O
illustrates	O
how	O
subtle	O
changes	O
to	O
the	O
design	O
of	O
low-spin	O
d	O
(	O
6	O
)	O
metal	O
complexes	O
can	O
lead	O
to	O
major	O
changes	O
in	O
cellular	O
metabolism	O
and	O
to	O
potent	O
complexes	O
with	O
novel	O
mechanisms	O
of	O
anticancer	O
activity	O
.	O

Activation	O
of	O
human	O
platelets	O
by	O
misfolded	O
proteins	O
.	O
OBJECTIVE	O
:	O
Protein	O
misfolding	O
diseases	O
result	O
from	O
the	O
deposition	O
of	O
insoluble	O
protein	O
aggregates	O
that	O
often	O
contain	O
fibrils	O
called	O
amyloid	S-GP
.	O
Amyloids	S-GP
are	O
found	O
in	O
Alzheimer	O
disease	O
,	O
atherosclerosis	O
,	O
diabetes	O
mellitus	O
,	O
and	O
systemic	O
amyloid	S-GP
osis	O
,	O
which	O
are	O
diseases	O
where	O
platelet	O
activation	O
might	O
be	O
implicated	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
We	O
induced	O
amyloid	O
properties	O
in	O
6	O
unrelated	O
proteins	O
and	O
found	O
that	O
all	O
induced	O
platelet	O
aggregation	O
in	O
contrast	O
to	O
fresh	O
controls	O
.	O
Amyloid	S-GP
-induced	O
platelet	O
aggregation	O
was	O
independent	O
of	O
thromboxane	B-chemical
A2	E-chemical
formation	O
and	O
ADP	S-chemical
secretion	O
but	O
enhanced	O
by	O
feedback	O
stimulation	O
through	O
these	O
pathways	O
.	O
Treatments	O
that	O
raised	O
cAMP	S-chemical
(	O
iloprost	S-chemical
)	O
,	O
sequestered	O
Ca2+	S-chemical
(	O
BAPTA-AM	S-chemical
)	O
or	O
prevented	O
amyloid	S-GP
-platelet	O
interaction	O
(	O
sRAGE	O
,	O
tissue-type	B-GP
plasminogen	I-GP
activator	E-GP
[	O
tPA	S-GP
]	O
)	O
induced	O
almost	O
complete	O
inhibition	O
.	O
Modulation	O
of	O
the	O
function	O
of	O
CD36	S-GP
(	O
CD36-/-	O
mice	O
)	O
,	O
p38	S-GP
(	O
MAPK	S-GP
)	O
(	O
SB203580	S-chemical
)	O
,	O
COX-1	S-GP
(	O
indomethacin	S-chemical
)	O
,	O
and	O
glycoprotein	B-GP
Ib	I-GP
alpha	E-GP
(	O
Nk-protease	S-GP
,	O
6D1	O
antibody	O
)	O
induced	O
approximately	O
50	O
%	O
inhibition	O
.	O
Interference	O
with	O
fibrinogen	S-GP
binding	O
(	O
RGDS	O
)	O
revealed	O
a	O
major	O
contribution	O
of	O
alphaIIb	B-GP
beta3	E-GP
-independent	O
aggregation	O
(	O
agglutination	O
)	O
.	O
CONCLUSIONS	O
:	O
Protein	O
misfolding	O
resulting	O
in	O
the	O
appearance	O
of	O
amyloid	S-GP
induces	O
platelet	O
aggregation	O
.	O
Amyloid	S-GP
activates	O
platelets	O
through	O
2	O
pathways	O
:	O
one	O
is	O
through	O
CD36	S-GP
,	O
p38	S-GP
(	O
MAPK	S-GP
)	O
,	O
thromboxane	B-chemical
A2	E-chemical
-mediated	O
induction	O
of	O
aggregation	O
;	O
the	O
other	O
is	O
through	O
glycoprotein	B-GP
Ib	I-GP
alpha	E-GP
-mediated	O
aggregation	O
and	O
agglutination	O
.	O
The	O
platelet	O
stimulating	O
properties	O
of	O
amyloid	O
might	O
explain	O
the	O
enhanced	O
platelet	O
activation	O
observed	O
in	O
many	O
diseases	O
accompanied	O
by	O
the	O
appearance	O
of	O
misfolded	O
proteins	O
with	O
amyloid	O
.	O

Vasopressin	S-chemical

Preclinical	O
pharmacology	O
of	O
lumiracoxib	S-chemical
:	O
a	O
novel	O
selective	O
inhibitor	O
of	O
cyclooxygenase-2	S-GP
.	O
1	O
.	O
This	O
manuscript	O
presents	O
the	O
preclinical	O
profile	O
of	O
lumiracoxib	S-chemical
,	O
a	O
novel	O
cyclooxygenase-2	S-GP
(	O
COX-2	S-GP
)	O
selective	O
inhibitor	O
.	O
2	O
.	O
Lumiracoxib	S-chemical
inhibited	O
purified	O
COX-1	S-GP
and	O
COX-2	S-GP
with	O
K	O
(	O
i	O
)	O
values	O
of	O
3	O
and	O
0.06	O
microM	O
,	O
respectively	O
.	O
In	O
cellular	O
assays	O
,	O
lumiracoxib	S-chemical
had	O
an	O
IC	O
(	O
50	O
)	O
of	O
0.14	O
microM	O
in	O
COX-2	S-GP
-expressing	O
dermal	O
fibroblasts	O
,	O
but	O
caused	O
no	O
inhibition	O
of	O
COX-1	S-GP
at	O
concentrations	O
up	O
to	O
30	O
microM	O
(	O
HEK	O
293	O
cells	O
transfected	O
with	O
human	B-GP
COX-1	E-GP
)	O
.	O
3	O
.	O
In	O
a	O
human	O
whole	O
blood	O
assay	O
,	O
IC	O
(	O
50	O
)	O
values	O
for	O
lumiracoxib	S-chemical
were	O
0.13	O
microM	O
for	O
COX-2	S-GP
and	O
67	O
microM	O
for	O
COX-1	S-GP
(	O
COX-1	S-GP
/	O
COX-2	S-GP
selectivity	O
ratio	O
515	O
)	O
.	O
4	O
.	O
Lumiracoxib	S-chemical
was	O
rapidly	O
absorbed	O
following	O
oral	O
administration	O
in	O
rats	O
with	O
peak	O
plasma	O
levels	O
being	O
reached	O
between	O
0.5	O
and	O
1	O
h.	O
5	O
.	O
Ex	O
vivo	O
,	O
lumiracoxib	S-chemical
inhibited	O
COX-1	S-GP
-derived	O
thromboxane	B-chemical
B	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
(	O
TxB	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
)	O
generation	O
with	O
an	O
ID	O
(	O
50	O
)	O
of	O
33	O
mg	O
kg	O
(	O
-1	O
)	O
,	O
whereas	O
COX-2	S-GP
-derived	O
production	O
of	O
prostaglandin	B-chemical
E	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
(	O
PGE	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
)	O
in	O
the	O
lipopolysaccharide-stimulated	O
rat	O
air	O
pouch	O
was	O
inhibited	O
with	O
an	O
ID	O
(	O
50	O
)	O
value	O
of	O
0.24	O
mg	O
kg	O
(	O
-1	O
)	O
.	O
6	O
.	O
Efficacy	O
of	O
lumiracoxib	S-chemical
in	O
rat	O
models	O
of	O
hyperalgesia	O
,	O
oedema	O
,	O
pyresis	O
and	O
arthritis	O
was	O
dose-dependent	O
and	O
similar	O
to	O
diclofenac	S-chemical
.	O
However	O
,	O
consistent	O
with	O
its	O
low	O
COX-1	S-GP
inhibitory	O
activity	O
,	O
lumiracoxib	S-chemical
at	O
a	O
dose	O
of	O
100	O
mg	O
kg	O
(	O
-1	O
)	O
orally	O
caused	O
no	O
ulcers	O
and	O
was	O
significantly	O
less	O
ulcerogenic	O
than	O
diclofenac	S-chemical
(	O
P	O
<	O
0.05	O
)	O
.	O
7	O
.	O
Lumiracoxib	S-chemical
is	O
a	O
highly	O
selective	O
COX-2	S-GP
inhibitor	O
with	O
anti-inflammatory	O
,	O
analgesic	O
and	O
antipyretic	O
activities	O
comparable	O
with	O
diclofenac	S-chemical
,	O
the	O
reference	O
NSAID	O
,	O
but	O
with	O
much	O
improved	O
gastrointestinal	O
safety	O
.	O

Reduction	O
of	O
cerebral	O
infarct	O
size	O
by	O
the	O
AT1	S-GP
-receptor	O
blocker	O
candesartan	S-chemical
,	O
the	O
HMG-CoA	B-GP
reductase	E-GP
inhibitor	O
rosuvastatin	S-chemical
and	O
their	O
combination	O
.	O
An	O
experimental	O
study	O
in	O
rats	O
.	O
Our	O
purpose	O
was	O
to	O
test	O
the	O
impact	O
of	O
single	O
and/or	O
combined	O
treatment	O
with	O
the	O
AT	B-GP
(	I-GP
1	I-GP
)	E-GP
-receptor	O
blocker	O
candesartan	S-chemical
and	O
the	O
HMG-CoA	B-GP
reductase	E-GP
inhibitor	O
rosuvastatin	S-chemical
on	O
infarct	O
size	O
and	O
neuroscore	O
in	O
transient	O
cerebral	O
ischemia	O
in	O
rats	O
.	O
L-NAME	S-chemical
was	O
used	O
to	O
test	O
whether	O
any	O
potential	O
effect	O
was	O
due	O
to	O
activation	O
of	O
endothelial	B-GP
nitric	I-GP
oxide	I-GP
synthase	E-GP
(	O
eNOS	S-GP
)	O
.	O
Therefore	O
,	O
the	O
middle	O
cerebral	O
artery	O
was	O
occluded	O
for	O
1	O
h	O
(	O
MCAO	O
)	O
followed	O
by	O
7	O
days	O
reperfusion	O
.	O
Rats	O
received	O
candesartan	S-chemical
2h	O
before	O
and	O
daily	O
after	O
MCAO	O
(	O
pretreatment	O
)	O
or	O
daily	O
after	O
MCAO	O
(	O
posttreatment	O
)	O
;	O
rosuvastatin	S-chemical
was	O
given	O
daily	O
for	O
7	O
days	O
before	O
MCAO	O
without	O
or	O
with	O
candesartan	S-chemical
pre-	O
and	O
posttreatment	O
.	O
In	O
addition	O
,	O
candesartan	S-chemical
and	O
rosuvastatin	S-chemical
were	O
combined	O
with	O
L-NAME	S-chemical
.	O
Infarct	O
size	O
and	O
neuroscore	O
at	O
day	O
7	O
were	O
compared	O
to	O
those	O
of	O
controls	O
.	O
As	O
result	O
,	O
compared	O
to	O
controls	O
(	O
109+/-12	O
mm	O
(	O
3	O
)	O
)	O
infarct	O
size	O
with	O
candesartan	S-chemical
(	O
pretreatment	O
:	O
21+/-5	O
mm	O
(	O
3	O
)	O
;	O
posttreatment	O
:	O
68+/-29	O
mm	O
(	O
3	O
)	O
;	O
P	O
<	O
0.05	O
)	O
or	O
rosuvastatin	S-chemical
(	O
69+/-14	O
mm	O
(	O
3	O
)	O
;	O
P	O
<	O
0.05	O
)	O
was	O
smaller	O
.	O
Combined	O
treatment	O
also	O
reduced	O
infarct	O
size	O
(	O
pretreatment	O
:	O
37+/-15	O
mm	O
(	O
3	O
)	O
;	O
posttreatment	O
57+/-20mm	O
(	O
3	O
)	O
;	O
P	O
<	O
0.05	O
)	O
;	O
but	O
there	O
was	O
no	O
benefit	O
of	O
combined	O
treatment	O
over	O
candesartan	S-chemical
pretreatment	O
alone	O
.	O
Compared	O
to	O
controls	O
(	O
2.08+/-0.28	O
)	O
only	O
candesartan	S-chemical
pretreatment	O
and	O
combined	O
treatment	O
improved	O
the	O
neuroscore	O
(	O
0.97+/-0.05	O
,	O
1.10+/-0.33	O
;	O
P	O
<	O
0.05	O
)	O
.	O
L-NAME	S-chemical
abolished	O
the	O
reduction	O
in	O
infarct	O
size	O
and	O
improvement	O
in	O
neuroscore	O
.	O
In	O
conclusion	O
,	O
both	O
,	O
candesartan	S-chemical
or	O
rosuvastatin	S-chemical
treatment	O
alone	O
reduced	O
infarct	O
size	O
in	O
transient	O
cerebral	O
ischemia	O
,	O
and	O
the	O
best	O
result	O
was	O
achieved	O
with	O
candesartan	S-chemical
pretreatment	O
.	O
Combined	O
treatment	O
was	O
superior	O
to	O
rosuvastatin	S-chemical
alone	O
,	O
but	O
not	O
to	O
candesartan	S-chemical
.	O
The	O
therapeutic	O
benefit	O
of	O
both	O
agents	O
was	O
at	O
least	O
in	O
parts	O
mediated	O
by	O
eNOS	S-GP
-activation	O
.	O

Metabolic	O
effects	O
of	O
honey	O
in	O
type	O
1	O
diabetes	O
mellitus	O
:	O
a	O
randomized	O
crossover	O
pilot	O
study	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
metabolic	O
effects	O
of	O
12-week	O
honey	O
consumption	O
on	O
patients	O
suffering	O
from	O
type	O
1	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
.	O
This	O
was	O
a	O
randomized	O
crossover	O
clinical	O
trial	O
done	O
in	O
the	O
National	O
Institute	O
for	O
Diabetes	O
and	O
Endocrinology	O
,	O
Cairo	O
,	O
Egypt	O
.	O
Twenty	O
patients	O
of	O
both	O
sexes	O
aged	O
4-18	O
years	O
with	O
type	O
1	O
DM	O
and	O
HbA1C	S-GP
<	O
10	O
%	O
participated	O
in	O
the	O
study	O
.	O
They	O
were	O
randomized	O
into	O
two	O
equal	O
groups	O
(	O
intervention	O
to	O
control	O
and	O
control	O
to	O
intervention	O
)	O
.	O
The	O
dietary	O
intervention	O
was	O
12-week	O
honey	O
consumption	O
in	O
a	O
dose	O
of	O
0.5	O
mL/kg	O
body	O
weight	O
per	O
day	O
.	O
The	O
main	O
outcome	O
measures	O
were	O
serum	O
glucose	S-chemical
,	O
lipids	O
,	O
and	O
C-peptide	S-GP
,	O
and	O
anthropometric	O
measurements	O
.	O
None	O
of	O
participants	O
were	O
lost	O
in	O
follow-up	O
.	O
The	O
intervention	O
resulted	O
in	O
significant	O
decreases	O
in	O
subscapular	O
skin	O
fold	O
thickness	O
(	O
SSFT	O
;	O
P=.002	O
)	O
,	O
fasting	O
serum	O
glucose	S-chemical
(	O
FSG	O
;	O
P=.001	O
)	O
,	O
total	O
cholesterol	S-chemical
(	O
P=.0001	O
)	O
,	O
serum	O
triglycerides	S-chemical
(	O
TG	O
;	O
P=.0001	O
)	O
,	O
and	O
low-density	B-GP
lipoprotein	E-GP
(	O
P=.0009	O
)	O
,	O
and	O
significant	O
increases	O
in	O
fasting	B-GP
C-peptide	E-GP
(	O
FCP	S-GP
;	O
P=.0004	O
)	O
and	O
2-h	O
postprandial	B-GP
C-peptide	E-GP
(	O
PCP	S-GP
;	O
P=.002	O
)	O
.	O
As	O
possible	O
long-term	O
effects	O
of	O
honey	O
after	O
its	O
withdrawal	O
,	O
statistically	O
significant	O
reductions	O
in	O
midarm	O
circumference	O
(	O
P=.000	O
)	O
,	O
triceps	O
skin	O
fold	O
thickness	O
(	O
P=.006	O
)	O
,	O
SSFT	O
(	O
P=.003	O
)	O
,	O
FSG	O
(	O
P=.005	O
)	O
,	O
2-h	O
postprandial	O
serum	O
glucose	S-chemical
(	O
P=.000	O
)	O
,	O
TG	O
(	O
P=.003	O
)	O
,	O
and	O
HbA1C	S-GP
(	O
P=.043	O
)	O
,	O
and	O
significant	O
increases	O
in	O
FCP	S-GP
(	O
P=.002	O
)	O
and	O
PCP	S-GP
(	O
P=.003	O
)	O
were	O
observed	O
.	O
This	O
small	O
clinical	O
trial	O
suggests	O
that	O
long-term	O
consumption	O
of	O
honey	O
might	O
have	O
positive	O
effects	O
on	O
the	O
metabolic	O
derangements	O
of	O
type	O
1	O
DM	O
.	O

Intestinal	O
permeability	O
and	O
lactose	S-chemical
hydrolysis	O
in	O
human	O
rotaviral	O
gastroenteritis	O
assessed	O
simultaneously	O
by	O
non-invasive	O
differential	O
sugar	O
permeation	O
.	O
Changes	O
in	O
intestinal	O
permeability	O
and	O
lactose	S-chemical
hydrolysis	O
have	O
been	O
investigated	O
in	O
three	O
adults	O
and	O
fifteen	O
infants	O
with	O
acute	O
rotaviral	O
gastroenteritis	O
by	O
differential	O
sugar	O
absorption	O
.	O
The	O
method	O
involves	O
chromatographic	O
measurement	O
of	O
urinary	O
lactose	S-chemical
,	O
lactulose	S-chemical
and	O
L-rhamnose	S-chemical
excretion	O
following	O
combined	O
ingestion	O
in	O
an	O
iso-osmolar	O
test	O
solution	O
.	O
All	O
patients	O
had	O
abnormal	O
intestinal	O
permeability	O
indicated	O
by	O
raised	O
urine	O
lactulose	S-chemical
/	O
L-rhamnose	S-chemical
excretion	O
,	O
ratio	O
of	O
percentages	O
recovered	O
in	O
5	O
h	O
,	O
of	O
0.462	O
(	O
0.100-1.227	O
)	O
mean	O
and	O
range	O
,	O
compared	O
with	O
0.027	O
(	O
0.008-0.052	O
)	O
for	O
healthy	O
controls	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O
Ten	O
patients	O
also	O
had	O
urinary	O
lactose	S-chemical
/	O
lactulose	S-chemical
excretion	O
ratios	O
raised	O
above	O
the	O
normal	O
range	O
(	O
0.014-0.41	O
,	O
mean	O
0.258	O
)	O
during	O
their	O
acute	O
illness	O
,	O
indicating	O
impaired	O
intestinal	O
lactose	S-chemical
hydrolysis	O
.	O
Both	O
indices	O
had	O
become	O
normal	O
4	O
weeks	O
after	O
the	O
acute	O
illness	O
,	O
serial	O
investigation	O
of	O
five	O
patients	O
showing	O
that	O
improvement	O
was	O
complete	O
much	O
earlier	O
.	O
Except	O
for	O
the	O
short	O
duration	O
these	O
changes	O
are	O
similar	O
to	O
those	O
associated	O
with	O
villous	O
atrophy	O
in	O
coeliac	O
disease	O
.	O
The	O
test	O
procedure	O
was	O
verified	O
with	O
respect	O
to	O
intestinal	O
lactose	S-chemical
hydrolysis	O
by	O
demonstrating	O
a	O
linear	O
relationship	O
between	O
lactose	S-chemical
/	O
lactulose	S-chemical
excretion	O
and	O
log	O
jejunal	O
mucosal	O
lactase	S-GP
activity	O
by	O
in	O
vitro	O
assay	O
(	O
R2	O
=	O
0.95	O
)	O
in	O
a	O
further	O
group	O
of	O
subjects	O
.	O
Differential	O
lactose	S-chemical
/	O
lactulose	S-chemical
/	O
L-rhamnose	S-chemical
absorption	O
provides	O
a	O
non-invasive	O
and	O
sensitive	O
index	O
of	O
small	O
intestinal	O
integrity	O
of	O
value	O
for	O
the	O
interpretation	O
of	O
prolonged	O
or	O
otherwise	O
complicated	O
enteritis	O
and	O
the	O
distinction	O
of	O
primary	O
secondary	O
intestinal	O
lactase	S-GP
deficiency	O
.	O

Mercury	S-chemical
induces	O
the	O
expression	O
of	O
cyclooxygenase-2	S-GP
and	O
inducible	B-GP
nitric	I-GP
oxide	I-GP
synthase	E-GP
.	O
Nuclear	B-GP
factor-κB	E-GP
(	O
NF-κB	S-GP
)	O
is	O
a	O
transcription	O
factor	O
that	O
mediates	O
the	O
inducible	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O
NF-κB	S-GP
activation	O
induces	O
numerous	O
proinflammatory	O
gene	O
products	O
including	O
cytokines	S-GP
,	O
cyclooxygenase-2	S-GP
(	O
COX-2	S-GP
)	O
,	O
and	O
inducible	B-GP
nitric	I-GP
oxide	I-GP
synthase	E-GP
(	O
iNOS	S-GP
)	O
.	O
The	O
divalent	O
heavy	O
metal	O
mercury	S-chemical
has	O
been	O
used	O
for	O
thousands	O
of	O
years	O
.	O
Although	O
mercury	S-chemical
is	O
clearly	O
toxic	O
to	O
most	O
mammalian	O
organ	O
systems	O
,	O
especially	O
the	O
immune	O
system	O
,	O
exposure	O
has	O
still	O
increased	O
in	O
some	O
areas	O
of	O
the	O
world	O
.	O
However	O
,	O
the	O
underlying	O
toxic	O
mechanism	O
is	O
not	O
clearly	O
identified	O
.	O
Here	O
,	O
we	O
report	O
biochemical	O
evidence	O
that	O
mercury	S-chemical
alone	O
induces	O
NF-κB	S-GP
activation	O
,	O
resulting	O
in	O
the	O
induced	O
expression	O
of	O
COX-2	S-GP
and	O
iNOS	S-GP
.	O
The	O
results	O
suggest	O
that	O
mercury	S-chemical
can	O
induce	O
inflammatory	O
diseases	O
by	O
lowering	O
host	O
defense	O
.	O

Endothelial	B-GP
nitric	I-GP
oxide	I-GP
synthase	E-GP
genotypes	O
and	O
haplotypes	O
modify	O
the	O
responses	O
to	O
sildenafil	S-chemical
in	O
patients	O
with	O
erectile	O
dysfunction	O
.	O
Erectile	O
dysfunction	O
(	O
ED	O
)	O
is	O
usually	O
treated	O
with	O
sildenafil	S-chemical
.	O
Although	O
genetic	O
polymorphisms	O
in	O
the	O
endothelial	B-GP
nitric	I-GP
oxide	I-GP
synthase	E-GP
(	O
eNOS	S-GP
)	O
gene	O
may	O
impair	O
endogenous	O
NO	S-chemical
formation	O
,	O
there	O
is	O
little	O
information	O
about	O
how	O
eNOS	S-GP
polymorphisms	O
and	O
haplotypes	O
affect	O
the	O
responses	O
to	O
sildenafil	S-chemical
.	O
We	O
studied	O
118	O
patients	O
;	O
63	O
patients	O
had	O
ED	O
secondary	O
to	O
radical	O
prostatectomy	O
(	O
PED	O
)	O
and	O
55	O
had	O
organic	O
,	O
clinical	O
ED	O
.	O
eNOS	S-GP
genotypes	O
for	O
three	O
eNOS	S-GP
polymorphisms	O
(	O
T	O
(	O
-786	O
)	O
C	O
,	O
rs2070744	O
;	O
a	O
variable	O
number	O
of	O
tandem	O
repeats	O
(	O
VNTR	O
)	O
in	O
intron	O
4	O
;	O
and	O
Glu298Asp	O
,	O
rs1799983	O
)	O
were	O
determined	O
,	O
and	O
eNOS	S-GP
haplotypes	O
were	O
estimated	O
using	O
PHASE	O
2.1	O
.	O
The	O
clinical	O
responses	O
to	O
sildenafil	S-chemical
were	O
evaluated	O
and	O
the	O
patients	O
were	O
classified	O
as	O
good	O
responders	O
(	O
GR	O
)	O
or	O
poor	O
responders	O
(	O
PR	O
)	O
when	O
their	O
changes	O
in	O
five-item	O
version	O
of	O
International	O
Index	O
for	O
Erectile	O
Function	O
questionnaire	O
were	O
above	O
or	O
below	O
the	O
median	O
value	O
.	O
The	O
TC/CC	O
genotypes	O
and	O
the	O
C	O
allele	O
for	O
the	O
T	O
(	O
-786	O
)	O
C	O
polymorphism	O
were	O
more	O
common	O
in	O
GR	O
,	O
compared	O
with	O
PR	O
patients	O
with	O
PED	O
.	O
However	O
,	O
the	O
4b4a/4a4a	O
genotypes	O
and	O
the	O
4a	O
allele	O
for	O
the	O
VNTR	O
polymorphism	O
in	O
intron	O
4	O
were	O
more	O
common	O
in	O
GR	O
,	O
compared	O
with	O
PR	O
patients	O
with	O
clinical	O
ED	O
.	O
The	O
C-4a-Glu	O
haplotype	O
was	O
more	O
common	O
in	O
GR	O
than	O
in	O
PR	O
patients	O
with	O
PED	O
.	O
Conversely	O
,	O
the	O
T-4b-Asp	O
haplotype	O
was	O
less	O
common	O
in	O
GR	O
than	O
in	O
PR	O
patients	O
with	O
PED	O
.	O
No	O
other	O
significant	O
differences	O
were	O
found	O
.	O
Our	O
findings	O
show	O
evidence	O
that	O
eNOS	S-GP
polymorphisms	O
affect	O
the	O
responses	O
of	O
PED	O
and	O
clinical	O
ED	O
patients	O
to	O
sildenafil	S-chemical
.	O

Increased	O
human	O
dermal	O
microvascular	O
endothelial	O
cell	O
survival	O
induced	O
by	O
cysteamine	S-chemical
.	O
BACKGROUND	O
:	O
Cystinosis	O
is	O
an	O
autosomal	O
recessive	O
disease	O
caused	O
by	O
intralysosomal	O
cystine	O
accumulation	O
,	O
treated	O
with	O
cysteamine	S-chemical
.	O
Recently	O
,	O
new	O
adverse	O
effects	O
of	O
cysteamine	S-chemical
were	O
reported	O
.	O
Skin	O
biopsies	O
showed	O
microvascular	O
proliferation	O
(	O
angioendotheliomatosis	O
)	O
.	O
To	O
examine	O
the	O
mechanism	O
of	O
angioendotheliomatosis	O
associated	O
with	O
cysteamine	S-chemical
toxicity	O
,	O
we	O
examined	O
the	O
effect	O
of	O
cysteamine	S-chemical
on	O
human	O
dermal	O
microvascular	O
endothelial	O
cells	O
(	O
HDMVEC	O
)	O
.	O
METHODS	O
:	O
After	O
cysteamine	S-chemical
exposure	O
(	O
range	O
0-3.0	O
mM	O
)	O
during	O
24	O
h	O
,	O
cell	O
viability	O
was	O
measured	O
using	O
water	O
soluble	O
tetrazolium	B-chemical
salt-1	E-chemical
(	O
WST-1	O
)	O
in	O
both	O
control	O
HDMVEC	O
and	O
fibroblasts	O
.	O
Cell	O
proliferation	O
and	O
apoptosis	O
rate	O
were	O
measured	O
in	O
HDMVEC	O
by	O
bromodeoxyuridine	S-chemical
(	O
BrdU	S-chemical
)	O
incorporation	O
and	O
caspase	B-GP
3	E-GP
and	O
caspase	B-GP
7	E-GP
activity	O
,	O
respectively	O
.	O
Intracellular	O
glutathione	S-chemical
(	O
GSH	S-chemical
)	O
was	O
measured	O
in	O
HDMVEC	O
after	O
cysteamine	S-chemical
exposure	O
of	O
0	O
,	O
0.1	O
or	O
1.0	O
mM	O
.	O
Medium	O
and	O
cysteamine	S-chemical
were	O
refreshed	O
every	O
6	O
h	O
to	O
mimic	O
the	O
in	O
vivo	O
situation	O
.	O
Next	O
,	O
cell	O
viability	O
in	O
HDMVEC	O
was	O
measured	O
after	O
24	O
h	O
of	O
GSH	S-chemical
exposure	O
(	O
range	O
0-10.0	O
mM	O
)	O
.	O
RESULTS	O
:	O
HDMVEC	O
viability	O
and	O
proliferation	O
increased	O
after	O
cysteamine	S-chemical
exposure	O
0.03-3.0	O
mM	O
(	O
p	O
<	O
0.01	O
)	O
and	O
0.03-1.0	O
mM	O
(	O
p	O
=	O
0.01	O
)	O
respectively	O
;	O
cell	O
viability	O
in	O
fibroblasts	O
was	O
not	O
affected	O
by	O
incubation	O
with	O
cysteamine	S-chemical
.	O
Apoptosis	O
remained	O
unaffected	O
by	O
incubation	O
with	O
0-1.0	O
mM	O
cysteamine	S-chemical
,	O
3.0	O
mM	O
caused	O
increased	O
apoptosis	O
.	O
Intracellular	O
GSH	S-chemical
was	O
significantly	O
increased	O
after	O
incubation	O
with	O
cysteamine	S-chemical
0.1	O
mM	O
(	O
p	O
=	O
0.02	O
)	O
and	O
1.0	O
mM	O
(	O
p	O
<	O
0.01	O
)	O
.	O
HDMVEC	O
viability	O
increased	O
after	O
exposure	O
to	O
GSH	S-chemical
1.0-5.0	O
mM	O
(	O
p	O
<	O
0.01	O
)	O
.	O
CONCLUSION	O
:	O
Cysteamine	S-chemical
concentrations	O
,	O
similar	O
to	O
those	O
described	O
in	O
plasma	O
of	O
cystinosis	O
patients	O
,	O
stimulate	O
HDMVEC	O
viability	O
and	O
proliferation	O
and	O
increase	O
intracellular	O
GSH	S-chemical
content	O
.	O
We	O
postulate	O
that	O
this	O
mechanism	O
might	O
underlie	O
angioendotheliomatosis	O
induced	O
by	O
cysteamine	S-chemical
.	O

Relative	O
expression	O
of	O
c	O
holesterol	B-GP
transport-related	I-GP
proteins	E-GP
and	O
inflammation	O
markers	O
through	O
the	O
induction	O
of	O
7-ketosterol	S-chemical
-mediated	O
stress	O
in	O
Caco-2	O
cells	O
.	O
Human	O
diets	O
contain	O
sterol	S-chemical
oxidation	O
products	O
that	O
can	O
induce	O
cytotoxic	O
effects	O
,	O
mainly	O
caused	O
by	O
cholesterol	B-chemical
oxides	E-chemical
.	O
However	O
,	O
phytosterol	B-chemical
oxides	E-chemical
effects	O
have	O
been	O
less	O
extensively	O
investigated	O
.	O
This	O
study	O
evaluates	O
the	O
production	O
of	O
inflammatory	O
biomarkers	O
(	O
IL-1β	S-GP
,	O
IL-8	S-GP
,	O
IL-10	S-GP
,	O
TNFα	S-GP
)	O
and	O
the	O
influence	O
of	O
gene	O
expression	O
transporters	O
and	O
enzymes	O
related	O
to	O
cholesterol	S-chemical
absorption	O
and	O
metabolism	O
(	O
NPC1L1	S-GP
,	O
ABCG5/8	S-GP
,	O
HMGCoA	S-chemical
,	O
ACAT	S-GP
)	O
produced	O
by	O
7-ketosterols	S-chemical
(	O
stigmasterol	S-chemical
/	O
cholesterol	S-chemical
)	O
in	O
Caco-2	O
cells	O
.	O
These	O
effects	O
were	O
linked	O
to	O
intracellular	O
signaling	O
pathways	O
by	O
using	O
several	O
inhibitors	O
.	O
Results	O
showed	O
7-ketostigmasterol	S-chemical
to	O
have	O
a	O
greater	O
proinflammatory	O
potential	O
than	O
7-ketocholesterol	S-chemical
.	O
In	O
non-pre-treated	O
cells	O
,	O
only	O
efflux	B-GP
transporters	E-GP
were	O
down-regulated	O
by	O
7-ketosterols	S-chemical
,	O
showing	O
a	O
greater	O
influence	O
upon	O
ABCG5	S-GP
expression	O
.	O
Cell-pre-incubation	O
with	O
bradykinin	S-chemical
induced	O
changes	O
in	O
ABCG	S-GP
expression	O
levels	O
after	O
7-ketostigmasterol	S-chemical
-incubation	O
;	O
however	O
,	O
the	O
energetic	O
metabolism	O
inhibition	O
reduced	O
NPC1L1	S-GP
expression	O
only	O
in	O
7-ketocholesterol	S-chemical
-incubated	O
cells	O
.	O
In	O
non-pre-treated	O
cells	O
,	O
HMG-CoA	S-GP
was	O
up-regulated	O
by	O
both	O
7-ketosterols	S-chemical
.	O
However	O
,	O
exposure	O
to	O
inhibitors	O
down-regulated	O
the	O
expression	O
levels	O
,	O
mainly	O
in	O
7-ketocholesterol	S-chemical
-incubated	O
cells	O
.	O
While	O
ACAT	S-GP
expression	O
values	O
in	O
non-pre-treated	O
cells	O
were	O
unchanged	O
,	O
exposure	O
to	O
inhibitors	O
caused	O
down-regulation	O
of	O
mRNA	O
levels	O
.	O
These	O
results	O
suggest	O
that	O
internalization	O
and	O
excretion	O
of	O
7-ketostigmasterol	S-chemical
is	O
probably	O
influenced	O
by	O
[	O
Ca	S-chemical
]	O
i	O
,	O
which	O
also	O
could	O
mediate	O
HMGCoA	S-GP
activity	O
in	O
POPs	O
metabolism	O
.	O
However	O
,	O
energetic	O
metabolism	O
and	O
reducing	O
equivalents	O
exert	O
different	O
influences	O
upon	O
the	O
7-ketosterol	S-chemical
internalization	O
.	O

Role	O
of	O
oxidative	O
stress	O
in	O
chemical	O
allergens	O
induced	O
skin	O
cells	O
activation	O
.	O
Allergic	O
contact	O
dermatitis	O
(	O
ACD	O
)	O
is	O
an	O
important	O
occupational	O
and	O
environmental	O
disease	O
caused	O
by	O
topical	O
exposure	O
to	O
chemical	O
allergens	O
.	O
It	O
describes	O
the	O
adverse	O
effects	O
that	O
may	O
results	O
when	O
exposure	O
to	O
a	O
chemical	O
elicits	O
a	O
T	O
cell-mediated	O
inflammatory	O
skin	O
disease	O
.	O
The	O
ability	O
of	O
contact	O
sensitizers	O
to	O
induce	O
the	O
oxidative	O
stress	O
pathway	O
in	O
keratinocytes	O
and	O
dendritic	O
cells	O
has	O
been	O
confirmed	O
by	O
several	O
authors	O
.	O
Reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
can	O
serve	O
as	O
essential	O
second	O
messengers	O
mediating	O
cellular	O
responses	O
resulting	O
in	O
immune	O
cells	O
activation	O
.	O
Oxidative	O
stress	O
may	O
be	O
the	O
starter	O
point	O
,	O
as	O
it	O
leads	O
to	O
the	O
activation	O
of	O
transcription	O
factors	O
and	O
signaling	O
pathways	O
,	O
including	O
NF-kB	S-GP
and	O
p38	S-GP
MAPK	S-GP
,	O
which	O
leads	O
to	O
the	O
release	O
of	O
cytokines	S-GP
and	O
chemokines	S-GP
.	O
ROS	O
are	O
also	O
involved	O
in	O
the	O
activation	O
of	O
the	O
NLRP3	S-GP
/	O
NALP3	S-GP
inflammasome	O
,	O
which	O
is	O
required	O
to	O
direct	O
the	O
proteolytic	O
maturation	O
of	O
inflammatory	O
cytokines	S-GP
such	O
as	O
IL-1β	S-GP
and	O
IL-18	S-GP
,	O
which	O
are	O
all	O
integral	O
to	O
the	O
process	O
of	O
dendritic	O
cells	O
mobilization	O
,	O
migration	O
and	O
functional	O
maturation	O
.	O
Moreover	O
,	O
emerging	O
evidence	O
correlates	O
ROS	O
to	O
changes	O
in	O
the	O
constitution	O
of	O
the	O
extracellular	O
microenvironment	O
found	O
to	O
facilitate	O
ACD	O
.	O
The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
provide	O
both	O
conceptual	O
and	O
technical	O
frameworks	O
on	O
the	O
role	O
of	O
oxidative	O
stress	O
in	O
chemical	O
allergy	O
.	O

A	O
study	O
of	O
parabens	S-chemical
and	O
bisphenol	B-chemical
A	E-chemical
in	O
surface	O
water	O
and	O
fish	O
brain	O
tissue	O
from	O
the	O
Greater	O
Pittsburgh	O
Area	O
.	O
Pollution	O
from	O
xenoestrogens	S-chemical
has	O
been	O
discovered	O
in	O
the	O
aquatic	O
environment	O
of	O
the	O
Greater	O
Pittsburgh	O
Area	O
and	O
is	O
suspected	O
to	O
be	O
caused	O
by	O
the	O
failing	O
sewer	O
system	O
.	O
Personal	O
care	O
products	O
and	O
plasticizers	O
have	O
the	O
potential	O
to	O
enter	O
the	O
water	O
supply	O
though	O
treated	O
and	O
untreated	O
sewage	O
.	O
Many	O
of	O
these	O
compounds	O
are	O
suspected	O
xenoestrogens	S-chemical
.	O
Paraben	S-chemical
detection	O
in	O
surface	O
waters	O
was	O
as	O
follows	O
:	O
methyl	B-chemical
paraben	E-chemical
ranged	O
between	O
2.2	O
to	O
17.3	O
ppt	O
;	O
ethyl	B-chemical
paraben	E-chemical
was	O
not	O
detectable	O
;	O
propyl	B-chemical
paraben	E-chemical
was	O
detected	O
at	O
9.2	O
and	O
12.0	O
ppt	O
;	O
butyl	B-chemical
paraben	E-chemical
was	O
detected	O
at	O
0.2	O
ppt	O
.	O
BPA	S-chemical
was	O
detected	O
between	O
0.6	O
and	O
15.4	O
ppt	O
.	O
Estrogenic	O
potential	O
of	O
extracts	O
from	O
fish	O
brain	O
tissue	O
was	O
tested	O
via	O
Bromodeoxyuridine	S-chemical
MCF-7	O
analysis	O
and	O
paired	O
with	O
HPLC-MS	O
to	O
investigate	O
the	O
presence	O
of	O
xenoestrogens	S-chemical
.	O
All	O
samples	O
were	O
non-detectable	O
for	O
parabens	O
.	O
BPA	S-chemical
was	O
detected	O
in	O
44	O
of	O
the	O
58	O
samples	O
,	O
with	O
a	O
range	O
from	O
non-detectable	O
to	O
120	O
pg/g	O
.	O
BCFs	O
were	O
calculated	O
.	O
Results	O
were	O
statistically	O
significant	O
for	O
location	O
of	O
capture	O
(	O
p	O
<	O
0.05	O
)	O
and	O
correlation	O
existed	O
between	O
estrogenicity	O
and	O
BPA	S-chemical
.	O

[	O
Lipoprotein	B-GP
(	I-GP
a	I-GP
)	E-GP
:	O
a	O
link	O
between	O
thrombogenesis	O
and	O
atherogenesis	O
]	O
.	O
INTRODUCTION	O
:	O
It	O
is	O
well	O
known	O
that	O
numerous	O
mechanisms	O
of	O
thrombogenesis	O
can	O
participate	O
in	O
every	O
stage	O
of	O
atherosclerotic	O
disease	O
.	O
The	O
discovery	O
of	O
Lp	B-GP
(	I-GP
a	I-GP
)	E-GP
lipoprotein	S-GP
and	O
its	O
structural	O
similarity	O
with	O
plasminogen	S-GP
suggests	O
another	O
pathogenic	O
link	O
between	O
atherogenesis	O
and	O
thrombogenesis	O
.	O
SOME	O
CHARACTERISTICS	O
OF	O
LP	B-GP
(	I-GP
A	I-GP
)	E-GP
LIPOPROTEIN	S-GP
:	O
This	O
lipoprotein	O
is	O
present	O
in	O
the	O
whole	O
human	O
population	O
in	O
a	O
wide	O
range	O
of	O
plasma	O
concentrations	O
.	O
It	O
has	O
numerous	O
different	O
isoforms	O
.	O
Its	O
synthesis	O
occurs	O
in	O
the	O
liver	O
,	O
but	O
it	O
is	O
practically	O
metabolically	O
independent	O
from	O
other	O
lipoproteins	S-GP
.	O
Today	O
,	O
Lp	B-GP
(	I-GP
a	I-GP
)	E-GP
lipoprotein	S-GP
is	O
considered	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
heart	O
and	O
brain	O
ischemic	O
disease	O
.	O
FIBRINOLYTIC	O
MECHANISMS	O
:	O
The	O
primary	O
role	O
of	O
the	O
fibrinolytic	O
mechanism	O
is	O
to	O
prevent	O
thrombus	O
Jormation	O
during	O
circulation	O
and	O
to	O
remove	O
already	O
formed	O
ones	O
.	O
Plasmin	S-GP
has	O
a	O
central	O
role	O
in	O
this	O
process	O
,	O
due	O
to	O
the	O
inactive	O
proenzyme	O
plasminogen	S-GP
.	O
Its	O
basic	O
activators	O
are	O
tissue-type	B-GP
plasminogen	I-GP
activator	E-GP
(	O
t-PA	S-GP
)	O
and	O
urokinase	B-GP
plasminogen	I-GP
activator	E-GP
(	O
u-PA	S-GP
)	O
.	O
The	O
most	O
important	O
inhibitors	O
of	O
plasminogen	S-GP
are	O
alpha2-antiplasmin	S-GP
and	O
plasminogen	B-GP
activator	I-GP
inhibitors	I-GP
1	I-GP
and	I-GP
2	E-GP
(	O
PA-1	S-GP
and	O
PAI-2	S-GP
)	O
.	O
Structural	O
similarity	O
of	O
Lp	B-GP
(	I-GP
a	I-GP
)	E-GP
and	O
plasminogen	S-GP
The	O
apo	B-GP
(	I-GP
a	I-GP
)	E-GP
and	O
plasminogen	S-GP
genes	O
are	O
very	O
closely	O
linked	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
6	O
.	O
Because	O
of	O
that	O
they	O
are	O
structuraly	O
very	O
similar	O
and	O
they	O
have	O
a	O
cross	O
immunological	O
reactivity	O
.	O
Their	O
common	O
elements	O
are	O
so-called	O
``	O
kringle	O
''	O
structures	O
.	O
The	O
key	O
difference	O
in	O
structure	O
of	O
Lp	B-GP
(	I-GP
a	I-GP
)	E-GP
and	O
plasminogen	S-GP
is	O
replacement	O
of	O
Arg	S-chemical
with	O
Ser	S-chemical
at	O
position	O
560	O
.	O
This	O
prevents	O
splitting	O
of	O
apo	B-GP
(	I-GP
a	I-GP
)	E-GP
by	O
plasminogen	B-GP
activators	E-GP
.	O
LP	B-GP
(	I-GP
A	I-GP
)	E-GP
AND	O
FIBRINOLYSIS	O
:	O
Lp	B-GP
(	I-GP
a	I-GP
)	E-GP
lipoprotein	S-GP
inhibits	O
activation	O
of	O
plasminogen	S-GP
by	O
streptokinase	S-GP
.	O
It	O
is	O
also	O
a	O
competitive	O
inhibitor	O
of	O
plasminogen	S-GP
for	O
its	O
binding	O
to	O
plasminogen	B-GP
receptors	E-GP
.	O
Furthermore	O
,	O
it	O
successfully	O
achieves	O
competitive	O
inhibition	O
of	O
plasminogen	S-GP
for	O
binding	O
to	O
tetranectin	S-GP
and	O
thrombospondin	S-GP
.	O
Also	O
,	O
Lp	B-GP
(	I-GP
a	I-GP
)	E-GP
inhibits	O
activation	O
of	O
transforming	B-GP
growth	I-GP
factor	I-GP
alpha	E-GP
(	O
TGF-alpha	S-GP
)	O
.	O
It	O
positively	O
correlates	O
with	O
PAI-1	S-GP
and	O
it	O
is	O
assumed	O
that	O
it	O
promotes	O
release	O
of	O
tissue	B-GP
factor	E-GP
pathway	O
inhibitor	O
(	O
17FPI	O
)	O
from	O
endothelial	O
cell	O
surfaces	O
.	O
CONCLUSION	O
:	O
In	O
regulation	O
of	O
the	O
hemostatic	O
system	O
via	O
apolipoprotein	B-GP
(	I-GP
a	I-GP
)	E-GP
antifibrinolytic	O
effects	O
,	O
Lp	B-GP
(	I-GP
a	I-GP
)	E-GP
lipoprotein	S-GP
ojfers	O
a	O
molecular	O
solution	O
to	O
the	O
link	O
between	O
thrombogenesis	O
and	O
atherogenesis	O
.	O

Role	O
of	O
extracellular	O
calcium	S-chemical
and	O
calmodulin	S-GP
in	O
prolactin	S-GP
secretion	O
induced	O
by	O
hyposmolarity	O
,	O
thyrotropin-releasing	B-GP
hormone	E-GP
,	O
and	O
high	O
K+	S-chemical
in	O
GH4C1	O
cells	O
.	O
The	O
mechanism	O
by	O
which	O
30	O
%	O
medium	O
hyposmolarity	O
induces	O
PRL	S-GP
secretion	O
by	O
GH4C1	O
cells	O
was	O
compared	O
with	O
that	O
induced	O
by	O
100	O
nmol/l	O
TRH	S-GP
or	O
30	O
mmol/l	O
K+	S-chemical
.	O
Removing	O
medium	O
Ca2+	S-chemical
,	O
blocking	O
Ca2+	B-GP
channels	E-GP
with	O
50	O
mumol/l	O
verapamil	S-chemical
,	O
or	O
inhibiting	O
calmodulin	S-GP
activation	O
with	O
20	O
mumol/l	O
trifluoperazine	S-chemical
,	O
10	O
mumol/l	O
chlorpromazine	S-chemical
or	O
10	O
mumol/l	O
pimozide	S-chemical
almost	O
completely	O
blocked	O
hyposmolarity-induced	O
secretion	O
.	O
The	O
smooth	O
muscle	O
relaxant	O
,	O
W-7	S-chemical
,	O
which	O
is	O
believed	O
relatively	O
specific	O
in	O
inhibiting	O
the	O
Ca2	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-	O
calmodulin	S-GP
interaction	O
,	O
depressed	O
hyposmolarity-induced	O
PRL	S-GP
secretion	O
in	O
a	O
dose-dependent	O
manner	O
(	O
r	O
=	O
-0.991	O
,	O
p	O
less	O
than	O
0.01	O
)	O
.	O
The	O
above	O
drugs	O
also	O
blocked	O
or	O
decreased	O
high	O
K	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-induced	O
secretion	O
,	O
but	O
had	O
much	O
less	O
effect	O
on	O
TRH	S-GP
-induced	O
secretion	O
.	O
Secretion	O
induced	O
by	O
TRH	S-GP
,	O
hyposmolarity	O
,	O
or	O
high	O
K+	S-chemical
was	O
optimal	O
at	O
pH	O
7.3-7.65	O
and	O
was	O
significantly	O
depressed	O
at	O
pH	O
6.0	O
or	O
8.0	O
,	O
indicating	O
that	O
release	O
of	O
hormone	O
induced	O
by	O
all	O
3	O
stimuli	O
is	O
due	O
to	O
an	O
active	O
cell	O
process	O
requiring	O
a	O
physiologic	O
extracellular	O
pH	O
and	O
is	O
not	O
produced	O
by	O
nonspecific	O
cell	O
toxicity	O
.	O
The	O
data	O
suggest	O
hyposmolarity	O
and	O
high	O
K+	S-chemical
may	O
share	O
some	O
similarities	O
in	O
their	O
mechanism	O
of	O
stimulating	O
secretion	O
,	O
which	O
is	O
different	O
from	O
that	O
of	O
TRH	S-GP
.	O

Activity-dependent	O
cleavage	O
of	O
brain	O
glutamic	B-GP
acid	I-GP
decarboxylase	I-GP
65	E-GP
by	O
calpain	S-GP
.	O
Previously	O
,	O
we	O
reported	O
that	O
l-glutamic	B-GP
acid	I-GP
decarboxylase	I-GP
isoform	I-GP
65	E-GP
(	O
GAD65	S-GP
)	O
could	O
be	O
cleaved	O
in	O
vitro	O
to	O
release	O
a	O
stable	O
truncated	O
form	O
which	O
lacks	O
amino	B-chemical
acid	E-chemical
1-69	O
from	O
the	O
N	S-chemical
-terminus	O
,	O
GAD65	B-GP
(	I-GP
Delta1-69	I-GP
)	E-GP
.	O
However	O
,	O
whether	O
such	O
a	O
truncated	O
form	O
is	O
also	O
present	O
under	O
certain	O
physiological	O
conditions	O
remains	O
elusive	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
,	O
upon	O
sustained	O
neuronal	O
stimulation	O
,	O
GAD65	S-GP
could	O
be	O
cleaved	O
into	O
a	O
truncated	O
form	O
in	O
a	O
rat	O
synaptosomal	O
preparation	O
.	O
This	O
truncated	O
form	O
had	O
similar	O
electrophoretic	O
mobility	O
to	O
purified	O
recombinant	O
human	B-GP
GAD65	I-GP
(	I-GP
Delta1-69	E-GP
)	O
.	O
Furthermore	O
,	O
we	O
demonstrated	O
that	O
this	O
conversion	O
was	O
calcium	S-chemical
dependent	O
.	O
Calcium	S-chemical
-chelating	O
reagents	O
such	O
as	O
EDTA	S-chemical
and	O
1,2-bis-	B-chemical
(	I-chemical
o-aminphenoxy	I-chemical
)	I-chemical
-ethane-N	I-chemical
,	I-chemical
N	I-chemical
,	I-chemical
N	I-chemical
'	I-chemical
,	I-chemical
N'-tetra-acetic	I-chemical
acid	I-chemical
tetra-acetoxy-methyl	I-chemical
ester	E-chemical
prevented	O
the	O
cleavage	O
of	O
GAD65	S-GP
.	O
In	O
addition	O
,	O
our	O
data	O
suggested	O
that	O
calpain	S-GP
,	O
a	O
calcium-dependent	B-GP
cysteine	I-GP
protease	E-GP
,	O
is	O
activated	O
upon	O
neuronal	O
stimulation	O
and	O
could	O
be	O
responsible	O
for	O
the	O
conversion	O
of	O
full-length	O
GAD65	S-GP
to	O
truncated	O
GAD65	S-GP
in	O
the	O
brain	O
.	O
Moreover	O
,	O
calpain	S-GP
inhibitors	O
such	O
as	O
calpain	O
inhibitor	O
I	O
or	O
calpastatin	S-GP
could	O
block	O
the	O
cleavage	O
.	O
Results	O
of	O
our	O
in	O
vitro	O
cleavage	O
assay	O
using	O
purified	O
calpain	S-GP
and	O
immunopurified	O
rat	B-GP
GAD65	E-GP
also	O
supported	O
the	O
idea	O
that	O
GAD65	S-GP
could	O
be	O
directly	O
cleaved	O
by	O
calpain	S-GP
.	O

Cannabinoid	B-GP
CB1	I-GP
receptors	E-GP
in	O
the	O
paraventricular	O
nucleus	O
and	O
central	O
control	O
of	O
penile	O
erection	O
:	O
immunocytochemistry	O
,	O
autoradiography	O
and	O
behavioral	O
studies	O
.	O
[	O
N-	B-chemical
(	I-chemical
piperidin-1-yl	I-chemical
)	I-chemical
-5-	I-chemical
(	I-chemical
4-chlorophenyl	I-chemical
)	I-chemical
-4-methyl-1H-pyrazole-3-carboxyamide	E-chemical
]	O
(	O
SR	B-chemical
141716A	E-chemical
)	O
,	O
a	O
selective	O
cannabinoid	B-GP
CB1	I-GP
receptor	E-GP
antagonist	O
,	O
injected	O
into	O
the	O
paraventricular	O
nucleus	O
of	O
the	O
hypothalamus	O
(	O
PVN	O
)	O
of	O
male	O
rats	O
,	O
induces	O
penile	O
erection	O
.	O
This	O
effect	O
is	O
mediated	O
by	O
the	O
release	O
of	O
glutamic	B-chemical
acid	E-chemical
,	O
which	O
in	O
turn	O
activates	O
central	O
oxytocinergic	O
neurons	O
mediating	O
penile	O
erection	O
.	O
Double	O
immunofluorescence	O
studies	O
with	O
selective	O
antibodies	O
against	O
CB1	B-GP
receptors	E-GP
,	O
glutamic	B-GP
acid	I-GP
transporters	E-GP
(	O
vesicular	B-GP
glutamate	I-GP
transporters	I-GP
1	I-GP
and	I-GP
2	E-GP
(	O
VGlut1	S-GP
and	O
VGlut2	S-GP
)	O
,	O
glutamic	B-GP
acid	I-GP
decarboxylase-67	E-GP
(	O
GAD67	S-GP
)	O
and	O
oxytocin	S-chemical
itself	O
,	O
have	O
shown	O
that	O
CB1	B-GP
receptors	E-GP
in	O
the	O
PVN	O
are	O
located	O
mainly	O
in	O
GABAergic	O
terminals	O
and	O
fibers	O
surrounding	O
oxytocinergic	O
cell	O
bodies	O
.	O
As	O
GABAergic	O
synapses	O
in	O
the	O
PVN	O
impinge	O
directly	O
on	O
oxytocinergic	O
neurons	O
or	O
on	O
excitatory	O
glutamatergic	O
synapses	O
,	O
which	O
also	O
impinge	O
on	O
oxytocinergic	O
neurons	O
,	O
these	O
results	O
suggest	O
that	O
the	O
blockade	O
of	O
CB1	B-GP
receptors	E-GP
decreases	O
GABA	S-chemical
release	O
in	O
the	O
PVN	O
,	O
increasing	O
in	O
turn	O
glutamatergic	O
neurotransmission	O
to	O
activate	O
oxytocinergic	O
neurons	O
mediating	O
penile	O
erection	O
.	O
Autoradiography	O
studies	O
with	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
(	I-chemical
-	I-chemical
)	I-chemical
-CP	I-chemical
55,940	E-chemical
show	O
that	O
chronic	O
treatment	O
with	O
SR	B-chemical
141716A	E-chemical
for	O
15	O
days	O
twice	O
daily	O
(	O
1	O
mg/kg	O
i.p	O
.	O
)	O
significantly	O
increases	O
the	O
density	O
of	O
CB1	B-GP
receptors	E-GP
in	O
the	O
PVN	O
.	O
This	O
increase	O
occurs	O
concomitantly	O
with	O
an	O
almost	O
twofold	O
increase	O
in	O
the	O
pro-erectile	O
effect	O
of	O
SR	B-chemical
141716A	E-chemical
injected	O
into	O
the	O
PVN	O
as	O
compared	O
with	O
control	O
rats	O
.	O
The	O
present	O
findings	O
confirm	O
that	O
PVN	O
CB1	B-GP
receptors	E-GP
,	O
localized	O
mainly	O
in	O
GABAergic	O
synapses	O
that	O
control	O
in	O
an	O
inhibitory	O
fashion	O
excitatory	O
synapses	O
,	O
exert	O
an	O
inhibitory	O
control	O
on	O
penile	O
erection	O
,	O
demonstrating	O
for	O
the	O
first	O
time	O
that	O
chronic	O
blockade	O
of	O
CB1	B-GP
receptors	E-GP
by	O
SR	B-chemical
141716A	E-chemical
increases	O
the	O
density	O
of	O
these	O
receptors	O
in	O
the	O
PVN	O
.	O
This	O
increase	O
is	O
related	O
to	O
an	O
enhanced	O
pro-erectile	O
effect	O
of	O
SR	B-chemical
141716A	E-chemical
,	O
which	O
is	O
still	O
present	O
3	O
days	O
after	O
the	O
end	O
of	O
the	O
chronic	O
treatment	O
.	O

PPARgamma	S-GP
controls	O
CD1d	S-GP
expression	O
by	O
turning	O
on	O
retinoic	B-chemical
acid	E-chemical
synthesis	O
in	O
developing	O
human	O
dendritic	O
cells	O
.	O
Dendritic	O
cells	O
(	O
DCs	O
)	O
expressing	O
CD1d	S-GP
,	O
a	O
molecule	O
responsible	O
for	O
lipid	O
antigen	O
presentation	O
,	O
are	O
capable	O
of	O
enhancing	O
natural	O
killer	O
T	O
(	O
iNKT	O
)	O
cell	O
proliferation	O
.	O
The	O
signals	O
controlling	O
CD1	S-GP
expression	O
and	O
lipid	O
antigen	O
presentation	O
are	O
poorly	O
defined	O
.	O
We	O
have	O
shown	O
previously	O
that	O
stimulation	O
of	O
the	O
lipid-activated	B-GP
transcription	I-GP
factor	E-GP
,	O
peroxisome	B-GP
proliferator-activated	I-GP
receptor	I-GP
(	I-GP
PPAR	I-GP
)	I-GP
gamma	E-GP
,	O
indirectly	O
regulates	O
CD1d	S-GP
expression	O
.	O
Here	O
we	O
demonstrate	O
that	O
PPARgamma	S-GP
,	O
turns	O
on	O
retinoic	B-chemical
acid	E-chemical
synthesis	O
by	O
inducing	O
the	O
expression	O
of	O
retinol	S-chemical
and	O
retinal	S-chemical
metabolizing	O
enzymes	O
such	O
as	O
retinol	B-GP
dehydrogenase	I-GP
10	E-GP
and	O
retinaldehyde	B-GP
dehydrogenase	I-GP
type	I-GP
2	E-GP
(	O
RALDH2	S-GP
)	O
.	O
PPARgamma	S-GP
-regulated	O
expression	O
of	O
these	O
enzymes	O
leads	O
to	O
an	O
increase	O
in	O
the	O
intracellular	O
generation	O
of	O
all-trans	B-chemical
retinoic	I-chemical
acid	E-chemical
(	O
ATRA	S-chemical
)	O
from	O
retinol	S-chemical
.	O
ATRA	S-chemical
regulates	O
gene	O
expression	O
via	O
the	O
activation	O
of	O
the	O
retinoic	B-GP
acid	I-GP
receptor	I-GP
(	I-GP
RAR	I-GP
)	I-GP
alpha	E-GP
in	O
human	O
DCs	O
,	O
and	O
RARalpha	S-GP
acutely	O
regulates	O
CD1d	S-GP
expression	O
.	O
The	O
retinoic	B-chemical
acid	E-chemical
-induced	O
elevated	O
expression	O
of	O
CD1d	S-GP
is	O
coupled	O
to	O
enhanced	O
iNKT	O
cell	O
activation	O
.	O
Furthermore	O
,	O
in	O
vivo	O
relevant	O
lipids	O
such	O
as	O
oxidized	O
low-density	O
lipoprotein	O
can	O
also	O
elicit	O
retinoid	S-chemical
signaling	O
leading	O
to	O
CD1d	S-GP
up-regulation	O
.	O
These	O
data	O
show	O
that	O
regulation	O
of	O
retinoid	S-chemical
metabolism	O
and	O
signaling	O
is	O
part	O
of	O
the	O
PPARgamma	S-GP
-controlled	O
transcriptional	O
events	O
in	O
DCs	O
.	O
The	O
uncovered	O
mechanisms	O
allow	O
the	O
DCs	O
to	O
respond	O
to	O
altered	O
lipid	O
homeostasis	O
by	O
changing	O
CD1	S-GP
gene	O
expression	O
.	O

Central	O
effects	O
of	O
fexofenadine	S-chemical
and	O
cetirizine	S-chemical
:	O
measurement	O
of	O
psychomotor	O
performance	O
,	O
subjective	O
sleepiness	O
,	O
and	O
brain	O
histamine	B-GP
H1-receptor	E-GP
occupancy	O
using	O
11C-doxepin	S-chemical
positron	O
emission	O
tomography	O
.	O
Histamine	B-GP
H1-receptor	E-GP
(	O
H1R	S-GP
)	O
antagonists	O
,	O
or	O
antihistamines	S-chemical
,	O
often	O
induce	O
sedative	O
side	O
effects	O
when	O
used	O
for	O
the	O
treatment	O
of	O
allergic	O
disorders	O
.	O
This	O
study	O
compared	O
the	O
sedative	O
profiles	O
of	O
the	O
second-generation	O
antihistamines	S-chemical
,	O
fexofenadine	S-chemical
and	O
cetirizine	S-chemical
,	O
using	O
3	O
different	O
criteria	O
:	O
subjective	O
sleepiness	O
evaluated	O
by	O
the	O
Stanford	O
Sleepiness	O
Scale	O
,	O
objective	O
psychomotor	O
tests	O
(	O
simple	O
and	O
choice	O
reaction	O
time	O
tests	O
and	O
visual	O
discrimination	O
tests	O
at	O
4	O
different	O
exposure	O
durations	O
)	O
,	O
and	O
measurement	O
of	O
histamine	B-GP
H1-receptor	E-GP
occupancy	O
(	O
H1RO	O
)	O
in	O
the	O
brain	O
.	O
Subjective	O
sleepiness	O
and	O
psychomotor	O
performance	O
were	O
measured	O
in	O
20	O
healthy	O
Japanese	O
volunteers	O
at	O
baseline	O
and	O
90	O
min	O
after	O
administration	O
of	O
fexofenadine	S-chemical
120	O
mg	O
or	O
cetirizine	S-chemical
20	O
mg	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
.	O
Hydroxyzine	S-chemical
30	O
mg	O
was	O
included	O
as	O
a	O
positive	O
control	O
.	O
H1RO	O
was	O
measured	O
using	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
with	O
(	B-chemical
11	I-chemical
)	I-chemical
C-doxepin	E-chemical
in	O
12	O
of	O
the	O
20	O
subjects	O
,	O
and	O
a	O
further	O
11	O
volunteers	O
were	O
recruited	O
to	O
act	O
as	O
controls	O
.	O
In	O
psychomotor	O
tests	O
,	O
fexofenadine	S-chemical
was	O
not	O
significantly	O
different	O
from	O
placebo	O
and	O
significantly	O
less	O
impairing	O
than	O
cetirizine	S-chemical
on	O
some	O
tasks	O
,	O
as	O
well	O
as	O
significantly	O
less	O
impairing	O
than	O
hydroxyzine	S-chemical
on	O
all	O
tasks	O
.	O
For	O
subjective	O
sleepiness	O
,	O
fexofenadine	S-chemical
was	O
not	O
significantly	O
different	O
from	O
placebo	O
,	O
whereas	O
cetirizine	S-chemical
showed	O
a	O
trend	O
toward	O
increased	O
sleepiness	O
compared	O
with	O
fexofenadine	S-chemical
and	O
placebo	O
.	O
H1RO	O
was	O
negligible	O
with	O
fexofenadine	S-chemical
(	O
-0.1	O
%	O
)	O
but	O
moderately	O
high	O
with	O
cetirizine	S-chemical
(	O
26.0	O
%	O
)	O
.	O
In	O
conclusion	O
,	O
fexofenadine	S-chemical
120	O
mg	O
is	O
distinguishable	O
from	O
cetirizine	S-chemical
20	O
mg	O
,	O
as	O
assessed	O
by	O
H1RO	O
and	O
psychomotor	O
testing	O
.	O

Histamine	B-GP
H1	I-GP
receptor	E-GP
involvement	O
in	O
prepulse	O
inhibition	O
and	O
memory	O
function	O
:	O
relevance	O
for	O
the	O
antipsychotic	O
actions	O
of	O
clozapine	S-chemical
.	O
Histamine	B-GP
H	I-GP
(	I-GP
1	I-GP
)	E-GP
blockade	O
is	O
one	O
of	O
the	O
more	O
prominent	O
actions	O
of	O
the	O
multi-receptor	O
acting	O
antipsychotic	O
clozapine	S-chemical
.	O
It	O
is	O
currently	O
not	O
known	O
how	O
much	O
this	O
H	B-GP
(	I-GP
1	I-GP
)	E-GP
antagonism	O
of	O
clozapine	S-chemical
contributes	O
to	O
the	O
therapeutic	O
or	O
adverse	O
side	O
effects	O
of	O
clozapine	S-chemical
.	O
The	O
current	O
studies	O
with	O
Sprague-Dawley	O
rats	O
were	O
conducted	O
to	O
determine	O
the	O
participation	O
of	O
histaminergic	B-GP
H	I-GP
(	I-GP
1	I-GP
)	I-GP
receptor	E-GP
subtype	O
in	O
sensorimotor	O
plasticity	O
and	O
memory	O
function	O
affected	O
by	O
clozapine	S-chemical
using	O
tests	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
and	O
radial-arm	O
maze	O
choice	O
accuracy	O
.	O
The	O
PPI	O
impairment	O
caused	O
by	O
the	O
glutamate	S-chemical
antagonist	O
dizocilpine	S-chemical
(	O
MK-801	S-chemical
)	O
was	O
significantly	O
attenuated	O
by	O
clozapine	S-chemical
.	O
In	O
the	O
current	O
project	O
,	O
we	O
found	O
that	O
the	O
selective	O
H	B-GP
(	I-GP
1	I-GP
)	E-GP
antagonist	O
pyrilamine	S-chemical
also	O
reversed	O
the	O
dizocilpine	S-chemical
-induced	O
impairment	O
in	O
PPI	O
of	O
tactile	O
startle	O
with	O
an	O
auditory	O
prepulse	O
.	O
In	O
the	O
radial-arm	O
maze	O
(	O
RAM	O
)	O
,	O
pyrilamine	S-chemical
,	O
like	O
clozapine	S-chemical
,	O
impaired	O
working	O
memory	O
and	O
caused	O
a	O
significant	O
dose-related	O
slowing	O
of	O
response	O
.	O
Pyrilamine	S-chemical
,	O
however	O
,	O
decreased	O
the	O
number	O
of	O
reference	O
memory	O
errors	O
.	O
We	O
have	O
previously	O
shown	O
that	O
nicotine	S-chemical
effectively	O
attenuates	O
the	O
clozapine	S-chemical
-induced	O
working	O
memory	O
impairment	O
,	O
but	O
in	O
the	O
current	O
study	O
,	O
nicotine	S-chemical
did	O
not	O
significantly	O
alter	O
the	O
effects	O
of	O
pyrilamine	S-chemical
on	O
the	O
RAM	O
.	O
In	O
summary	O
,	O
the	O
therapeutic	O
effect	O
of	O
clozapine	S-chemical
in	O
reversing	O
PPI	O
impairment	O
was	O
mimicked	O
by	O
the	O
H	B-GP
(	I-GP
1	I-GP
)	E-GP
antagonist	O
pyrilamine	S-chemical
,	O
while	O
pyrilamine	S-chemical
had	O
a	O
mixed	O
effect	O
on	O
cognition	O
.	O
Pyrilamine	S-chemical
impaired	O
working	O
memory	O
but	O
improved	O
reference	O
memory	O
in	O
rats	O
.	O
Thus	O
,	O
H	B-GP
(	I-GP
1	I-GP
)	E-GP
antagonism	O
seems	O
to	O
play	O
a	O
role	O
in	O
part	O
of	O
the	O
beneficial	O
actions	O
of	O
antipsychotics	O
,	O
such	O
as	O
clozapine	S-chemical
.	O

Evaluation	O
of	O
7-O-galloyl-d-sedoheptulose	S-chemical
,	O
isolated	O
from	O
Corni	O
Fructus	O
,	O
in	O
the	O
adipose	O
tissue	O
of	O
type	O
2	O
diabetic	O
db/db	O
mice	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
beneficial	O
effects	O
of	O
7-O-galloyl-d-sedoheptulose	S-chemical
(	O
GS	O
)	O
,	O
isolated	O
from	O
Corni	O
Fructus	O
,	O
using	O
type	O
2	O
diabetic	O
mice	O
.	O
GS	O
was	O
orally	O
administered	O
to	O
db/db	O
mice	O
at	O
doses	O
of	O
20	O
and	O
100mg/kg	O
body	O
weight	O
per	O
day	O
for	O
6weeks	O
,	O
and	O
the	O
effects	O
of	O
GS	O
on	O
biochemical	O
factors	O
in	O
serum	O
and	O
adipose	O
tissue	O
were	O
investigated	O
.	O
To	O
define	O
the	O
underlying	O
mechanism	O
of	O
these	O
effects	O
,	O
protein	O
expressions	O
related	O
to	O
lipid	O
metabolism	O
,	O
inflammation	O
,	O
fibrosis	O
,	O
and	O
apoptosis	O
,	O
were	O
measured	O
.	O
The	O
results	O
showed	O
that	O
levels	O
of	O
glucose	S-chemical
,	O
leptin	S-GP
,	O
insulin	S-GP
,	O
C-peptide	S-GP
,	O
resistin	S-GP
,	O
tumor	B-GP
necrosis	I-GP
factor-α	E-GP
,	O
interleukin-6	S-GP
,	O
triglycerides	S-chemical
,	O
total	O
cholesterol	S-chemical
,	O
non-esterified	O
fatty	B-chemical
acids	E-chemical
,	O
high-density	B-GP
lipoprotein	E-GP
cholesterol	S-chemical
,	O
very	O
low-density	B-GP
lipoprotein	E-GP
cholesterol	S-chemical
/	O
low-density	B-GP
lipoprotein	E-GP
cholesterol	S-chemical
,	O
reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
,	O
and	O
thiobarbituric	B-chemical
acid	E-chemical
-reactive	O
substance	O
(	O
TBARS	O
)	O
in	O
serum	O
were	O
down-regulated	O
,	O
while	O
adiponectin	S-GP
was	O
augmented	O
by	O
GS	O
treatment	O
.	O
In	O
addition	O
,	O
the	O
elevated	O
lipid	O
,	O
ROS	O
,	O
and	O
TBARS	O
contents	O
in	O
adipose	O
tissue	O
as	O
well	O
as	O
serum	O
levels	O
in	O
db/db	O
mice	O
were	O
significantly	O
decreased	O
by	O
the	O
oral	O
administration	O
of	O
GS	O
.	O
From	O
protein	O
analysis	O
,	O
the	O
decreased	O
expressions	O
of	O
peroxisome	B-GP
proliferator	I-GP
activated	I-GP
receptor	I-GP
(	I-GP
PPAR	I-GP
)	I-GP
α	E-GP
,	O
PPARγ	S-GP
,	O
and	O
B-cell	B-GP
lymphoma	I-GP
2	E-GP
were	O
up-regulated	O
in	O
the	O
adipose	O
tissue	O
of	O
db/db	O
mice	O
.	O
The	O
administration	O
of	O
GS	O
significantly	O
decreased	O
sterol	B-GP
regulatory	I-GP
element	I-GP
binding	I-GP
protein-1	E-GP
,	O
nuclear	B-GP
factor-kappa	E-GP
?	O
>	O
Bp65	O
,	O
cyclooxygenase-2	S-GP
,	O
inducible	B-GP
nitric	I-GP
oxide	I-GP
synthase	E-GP
,	O
monocyte	B-GP
chemotactic	I-GP
protein-1	E-GP
,	O
intracellular	B-GP
adhesion	I-GP
molecule-1	E-GP
,	O
phosphor	B-GP
c-Jun	E-GP
N	S-chemical
-terminal	O
kinase	S-GP
,	O
activator	B-GP
protein-1	E-GP
,	O
transforming	B-GP
growth	I-GP
factor-β1	E-GP
,	O
Bax	S-GP
,	O
cytochrome	B-GP
c	E-GP
,	O
and	O
caspase-3	S-GP
expressions	O
.	O
These	O
results	O
suggest	O
that	O
GS	O
acts	O
as	O
a	O
regulator	O
of	O
oxidative	O
stress	O
,	O
inflammation	O
,	O
fibrosis	O
,	O
and	O
apoptosis	O
in	O
the	O
adipose	O
tissue	O
of	O
db/db	O
mice	O
.	O

Metformin	S-chemical
directly	O
inhibits	O
ghrelin	S-GP
secretion	O
through	O
AMP-activated	B-GP
protein	I-GP
kinase	E-GP
in	O
rat	O
primary	O
gastric	O
cells	O
.	O
The	O
antidiabetic	O
drug	O
Metformin	S-chemical
causes	O
weight	O
loss	O
in	O
both	O
diabetic	O
and	O
non-diabetic	O
individuals	O
.	O
Metformin	S-chemical
treatment	O
is	O
also	O
associated	O
with	O
lower	O
circulating	O
levels	O
of	O
the	O
orexigenic	B-GP
hormone	E-GP
ghrelin	S-GP
.	O
To	O
test	O
whether	O
Metformin	S-chemical
directly	O
affects	O
ghrelin	S-GP
cells	O
,	O
rat	O
primary	O
stomach	O
cells	O
were	O
treated	O
with	O
Metformin	S-chemical
and	O
the	O
levels	O
of	O
ghrelin	S-GP
secretion	O
,	O
proghrelin	S-GP
gene	O
expression	O
and	O
activation	O
of	O
adenosine	B-GP
monophosphate-activated	I-GP
protein	I-GP
kinase	E-GP
(	O
AMPK	S-GP
)	O
were	O
examined	O
.	O
Metformin	S-chemical
significantly	O
reduced	O
ghrelin	S-GP
secretion	O
and	O
proghrelin	S-GP
mRNA	O
production	O
and	O
both	O
these	O
effects	O
were	O
blocked	O
by	O
co-incubation	O
with	O
the	O
AMPK	S-GP
inhibitor	O
compound	B-chemical
C	E-chemical
.	O
Furthermore	O
,	O
the	O
AMPK	S-GP
activator	O
5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide	S-chemical
(	O
AICAR	S-chemical
)	O
significantly	O
inhibited	O
ghrelin	S-GP
secretion	O
.	O
Additionally	O
,	O
ghrelin	S-GP
cells	O
were	O
shown	O
to	O
express	O
AMPK	S-GP
.	O
Finally	O
,	O
Metformin	S-chemical
treatment	O
caused	O
a	O
significant	O
increase	O
in	O
the	O
level	O
of	O
phosphorylated	B-GP
(	I-GP
active	I-GP
)	I-GP
AMPK	E-GP
.	O
Our	O
results	O
show	O
that	O
Metformin	S-chemical
directly	O
inhibits	O
stomach	O
ghrelin	S-GP
production	O
and	O
secretion	O
through	O
AMPK	S-GP
.	O
This	O
reduction	O
in	O
ghrelin	O
secretion	O
may	O
be	O
one	O
of	O
the	O
key	O
components	O
in	O
Metformin	S-chemical
's	O
mechanism	O
of	O
weight	O
loss	O
.	O

Effect	O
of	O
cromolyn	O
on	O
S100P	S-GP
interactions	O
with	O
RAGE	O
and	O
pancreatic	O
cancer	O
growth	O
and	O
invasion	O
in	O
mouse	O
models	O
.	O
BACKGROUND	O
:	O
We	O
previously	O
found	O
that	O
S100P	S-GP
,	O
a	O
member	O
of	O
the	O
S100	S-GP
protein	O
family	O
,	O
is	O
expressed	O
in	O
more	O
than	O
90	O
%	O
of	O
pancreatic	O
tumors	O
and	O
is	O
associated	O
with	O
tumor	O
growth	O
and	O
invasion	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
the	O
antiallergy	O
drug	O
,	O
cromolyn	O
,	O
to	O
block	O
S100P	S-GP
function	O
.	O
METHODS	O
:	O
Interactions	O
between	O
cromolyn	O
and	O
S100P	S-GP
were	O
investigated	O
using	O
a	O
drug	O
affinity	O
column	O
and	O
by	O
examining	O
cromolyn	O
's	O
effects	O
on	O
coimmunoprecipitation	O
of	O
S100P	S-GP
and	O
receptor	O
for	O
advanced	O
glycation	O
end-products	O
(	O
RAGE	O
)	O
.	O
The	O
effects	O
of	O
cromolyn	O
on	O
cell	O
growth	O
,	O
invasion	O
,	O
and	O
nuclear	B-GP
factor-kappaB	E-GP
(	O
NFkappaB	S-GP
)	O
activity	O
of	O
pancreatic	O
cancer	O
cells	O
with	O
(	O
BxPC-3	O
and	O
MPanc-96	O
)	O
and	O
without	O
(	O
Panc-1	O
)	O
endogenous	O
S100P	S-GP
were	O
investigated	O
by	O
cell	O
proliferation	O
assay	O
,	O
by	O
cell	O
invasion	O
assay	O
,	O
and	O
by	O
luciferase	O
reporter	O
gene	O
assay	O
,	O
respectively	O
.	O
The	O
effects	O
of	O
cromolyn	O
on	O
tumor	O
growth	O
in	O
vivo	O
were	O
investigated	O
in	O
three	O
orthotopic	O
models	O
(	O
n	O
=	O
20	O
mice	O
per	O
model	O
)	O
by	O
administration	O
of	O
cromolyn	O
(	O
5	O
mg/kg	O
body	O
weight	O
,	O
daily	O
)	O
with	O
and	O
without	O
gemcitabine	S-chemical
(	O
125	O
mg/kg	O
body	O
weight	O
,	O
biweekly	O
)	O
,	O
the	O
drug	O
currently	O
used	O
to	O
treat	O
pancreatic	O
cancer	O
.	O
Tumor	O
growth	O
was	O
assayed	O
by	O
reporter	O
gene	O
expression	O
.	O
All	O
statistical	O
tests	O
were	O
two-sided	O
.	O
RESULTS	O
:	O
S100P	S-GP
was	O
retained	O
on	O
a	O
cromolyn	O
affinity	O
column	O
.	O
Cromolyn	O
blocked	O
the	O
coimmunoprecipitation	O
of	O
S100P	S-GP
and	O
RAGE	O
.	O
In	O
vitro	O
,	O
cromolyn	O
(	O
100	O
microM	O
)	O
inhibited	O
S100P	S-GP
-stimulated	O
Panc-1	O
cell	O
proliferation	O
(	O
S100P	S-GP
,	O
mean	O
=	O
0.93	O
U	O
,	O
versus	O
S100P	S-GP
+	O
cromolyn	O
,	O
mean	O
=	O
0.56	O
U	O
,	O
difference	O
=	O
0.37	O
U	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
0.24	O
to	O
0.49	O
U	O
;	O
P	O
=	O
.001	O
,	O
n	O
=	O
3	O
)	O
,	O
invasion	O
(	O
S100P	S-GP
,	O
mean	O
=	O
58.0	O
%	O
,	O
versus	O
S100P	S-GP
+	O
cromolyn	O
,	O
mean	O
=	O
9.4	O
%	O
,	O
difference	O
=	O
48.6	O
%	O
;	O
95	O
%	O
CI	O
=	O
38.8	O
%	O
to	O
58.8	O
%	O
;	O
P	O
<	O
.001	O
,	O
n	O
=	O
3	O
)	O
,	O
and	O
NFkappaB	S-GP
activity	O
(	O
S100P	S-GP
,	O
mean	O
=	O
14,460	O
,	O
versus	O
S100P	S-GP
+	O
cromolyn	O
,	O
mean	O
=	O
7360	O
photons/s	O
,	O
difference	O
=	O
7100	O
photons/s	O
;	O
95	O
%	O
CI	O
=	O
3689	O
to	O
10	O
510	O
photons/s	O
;	O
P	O
=	O
.005	O
,	O
n	O
=	O
3	O
)	O
.	O
In	O
vivo	O
,	O
cromolyn	O
inhibited	O
tumor	O
growth	O
in	O
mice	O
bearing	O
tumor	O
with	O
endogenous	O
S100P	S-GP
(	O
BxPC-3	O
:	O
control	O
,	O
mean	O
=	O
1.6	O
x	O
10	O
(	O
9	O
)	O
photons/s	O
,	O
versus	O
cromolyn	O
,	O
mean	O
=	O
4.4	O
x	O
10	O
(	O
8	O
)	O
photons/s	O
,	O
difference	O
=	O
1.2	O
x	O
10	O
(	O
9	O
)	O
photons/s	O
;	O
95	O
%	O
CI	O
=	O
6.2	O
x	O
10	O
(	O
8	O
)	O
to	O
1.6	O
x	O
10	O
(	O
9	O
)	O
photons/s	O
;	O
P	O
<	O
.001	O
,	O
n	O
=	O
5	O
;	O
MPanc-96	O
:	O
control	O
,	O
mean	O
=	O
1.1	O
x	O
10	O
(	O
10	O
)	O
photons/s	O
,	O
versus	O
cromolyn	O
,	O
mean	O
=	O
4.8	O
x	O
10	O
(	O
9	O
)	O
photons/s	O
,	O
difference	O
=	O
6.2	O
x	O
10	O
(	O
9	O
)	O
photons/s	O
;	O
95	O
%	O
CI	O
=	O
1.9	O
x	O
10	O
(	O
9	O
)	O
to	O
1.0	O
x	O
10	O
(	O
10	O
)	O
photons/s	O
;	O
P	O
=	O
.009	O
,	O
n	O
=	O
5	O
)	O
and	O
increased	O
the	O
effectiveness	O
of	O
gemcitabine	S-chemical
(	O
BxPC-3	O
:	O
gemcitabine	S-chemical
,	O
mean	O
=	O
9.2	O
x	O
10	O
(	O
8	O
)	O
photons/s	O
,	O
versus	O
combination	O
,	O
mean	O
=	O
1.8	O
x	O
10	O
(	O
8	O
)	O
photons/s	O
,	O
difference	O
=	O
7.4	O
x	O
10	O
(	O
8	O
)	O
photons/s	O
;	O
95	O
%	O
CI	O
=	O
4.5	O
x	O
10	O
(	O
8	O
)	O
to	O
1.0	O
x	O
10	O
(	O
9	O
)	O
photons/s	O
;	O
P	O
<	O
.001	O
;	O
MPanc-96	O
:	O
gemcitabine	S-chemical
,	O
mean	O
=	O
4.1	O
x	O
10	O
(	O
9	O
)	O
photons/s	O
,	O
versus	O
combination	O
,	O
mean	O
=	O
2.0	O
x	O
10	O
(	O
9	O
)	O
photons/s	O
,	O
difference	O
=	O
2.1	O
x	O
10	O
(	O
9	O
)	O
photons/s	O
;	O
95	O
%	O
CI	O
=	O
4.4	O
x	O
10	O
(	O
8	O
)	O
to	O
3.8	O
x	O
10	O
(	O
9	O
)	O
photons/s	O
;	O
P	O
<	O
.001	O
)	O
.	O
However	O
,	O
cromolyn	O
had	O
no	O
effect	O
on	O
growth	O
of	O
tumors	O
lacking	O
S100P	S-GP
(	O
Panc-1	O
)	O
.	O
CONCLUSION	O
:	O
Cromolyn	O
binds	O
S100P	S-GP
,	O
prevents	O
activation	O
of	O
RAGE	O
,	O
inhibits	O
tumor	O
growth	O
,	O
and	O
increases	O
the	O
effectiveness	O
of	O
gemcitabine	S-chemical
in	O
experimental	O
models	O
.	O

Novel	O
inhibitors	O
complexed	O
with	O
glutamate	B-GP
dehydrogenase	E-GP
:	O
allosteric	O
regulation	O
by	O
control	O
of	O
protein	O
dynamics	O
.	O
Mammalian	B-GP
glutamate	I-GP
dehydrogenase	E-GP
(	O
GDH	S-GP
)	O
is	O
a	O
homohexameric	O
enzyme	O
that	O
catalyzes	O
the	O
reversible	O
oxidative	O
deamination	O
of	O
l-glutamate	S-chemical
to	O
2-oxoglutarate	S-chemical
using	O
NAD	B-chemical
(	I-chemical
P	I-chemical
)	I-chemical
(	I-chemical
+	I-chemical
)	E-chemical
as	O
coenzyme	O
.	O
Unlike	O
its	O
counterparts	O
from	O
other	O
animal	O
kingdoms	O
,	O
mammalian	B-GP
GDH	E-GP
is	O
regulated	O
by	O
a	O
host	O
of	O
ligands	O
.	O
The	O
recently	O
discovered	O
hyperinsulinism/hyperammonemia	O
disorder	O
showed	O
that	O
the	O
loss	O
of	O
allosteric	O
inhibition	O
of	O
GDH	S-GP
by	O
GTP	S-chemical
causes	O
excessive	O
secretion	O
of	O
insulin	S-GP
.	O
Subsequent	O
studies	O
demonstrated	O
that	O
wild-type	O
and	O
hyperinsulinemia/hyperammonemia	O
forms	O
of	O
GDH	S-GP
are	O
inhibited	O
by	O
the	O
green	O
tea	O
polyphenols	O
,	O
epigallocatechin	B-chemical
gallate	E-chemical
and	O
epicatechin	B-chemical
gallate	E-chemical
.	O
This	O
was	O
followed	O
by	O
high	O
throughput	O
studies	O
that	O
identified	O
more	O
stable	O
inhibitors	O
,	O
including	O
hexachlorophene	S-chemical
,	O
GW5074	S-chemical
,	O
and	O
bithionol	S-chemical
.	O
Shown	O
here	O
are	O
the	O
structures	O
of	O
GDH	S-GP
complexed	O
with	O
these	O
three	O
compounds	O
.	O
Hexachlorophene	S-chemical
forms	O
a	O
ring	O
around	O
the	O
internal	O
cavity	O
in	O
GDH	S-GP
through	O
aromatic	O
stacking	O
interactions	O
between	O
the	O
drug	O
and	O
GDH	S-GP
as	O
well	O
as	O
between	O
the	O
drug	O
molecules	O
themselves	O
.	O
In	O
contrast	O
,	O
GW5074	S-chemical
and	O
bithionol	S-chemical
both	O
bind	O
as	O
pairs	O
of	O
stacked	O
compounds	O
at	O
hexameric	O
2-fold	O
axes	O
between	O
the	O
dimers	O
of	O
subunits	O
.	O
The	O
internal	O
core	O
of	O
GDH	S-GP
contracts	O
when	O
the	O
catalytic	O
cleft	O
closes	O
during	O
enzymatic	O
turnover	O
.	O
None	O
of	O
the	O
drugs	O
cause	O
conformational	O
changes	O
in	O
the	O
contact	O
residues	O
,	O
but	O
all	O
bind	O
to	O
key	O
interfaces	O
involved	O
in	O
this	O
contraction	O
process	O
.	O
Therefore	O
,	O
it	O
seems	O
likely	O
that	O
the	O
drugs	O
inhibit	O
enzymatic	O
turnover	O
by	O
inhibiting	O
this	O
transition	O
.	O
Indeed	O
,	O
this	O
expansion/contraction	O
process	O
may	O
play	O
a	O
major	O
role	O
in	O
the	O
inter-subunit	O
communication	O
and	O
allosteric	O
regulation	O
observed	O
in	O
GDH	S-GP
.	O

Cloning	O
,	O
characterization	O
,	O
and	O
expression	O
of	O
a	O
calcitonin	B-GP
receptor	E-GP
from	O
guinea	O
pig	O
brain	O
.	O
A	O
calcitonin	B-GP
receptor	E-GP
was	O
cloned	O
from	O
guinea	O
pig	O
brain	O
by	O
using	O
a	O
degenerate	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
strategy	O
.	O
When	O
the	O
cloned	O
guinea	B-GP
pig	I-GP
calcitonin	I-GP
receptor	E-GP
was	O
transfected	O
into	O
COS	O
1	O
cells	O
,	O
salmon	B-GP
calcitonin	E-GP
stimulated	O
intracellular	O
cyclic	B-chemical
AMP	E-chemical
accumulation	O
with	O
an	O
EC50	O
of	O
0.1	O
nM	O
,	O
whereas	O
human	B-GP
calcitonin	E-GP
was	O
>	O
250-fold	O
less	O
potent	O
(	O
EC50	O
27.6	O
nM	O
)	O
.	O
Related	O
neuropeptides	O
rat	B-GP
alphaCGRP	E-GP
and	O
rat	B-GP
amylin	E-GP
did	O
not	O
activate	O
the	O
guinea	B-GP
pig	I-GP
calcitonin	I-GP
receptor	E-GP
at	O
physiologic	O
concentrations	O
.	O
Stimulation	O
of	O
the	O
transfected	O
guinea	B-GP
pig	I-GP
calcitonin	I-GP
receptor	E-GP
by	O
salmon	O
calcitonin	O
also	O
resulted	O
in	O
phosphatidylinositol	S-chemical
hydrolysis	O
with	O
an	O
EC50	O
of	O
2.5	O
nM	O
.	O
Expression	O
of	O
the	O
calcitonin	B-GP
receptor	E-GP
was	O
mapped	O
by	O
a	O
combination	O
of	O
RT-PCR	O
,	O
northern	O
analysis	O
,	O
and	O
expression	O
in	O
Xenopus	O
oocytes	O
.	O
The	O
guinea	B-GP
pig	I-GP
calcitonin	I-GP
receptor	E-GP
was	O
most	O
highly	O
expressed	O
in	O
diencephalon	O
and	O
a	O
single	O
subtype	O
was	O
detected	O
.	O

Effect	O
of	O
5-azacytidine	S-chemical
and	O
procainamide	S-chemical
on	O
CD3-zeta	B-GP
chain	E-GP
expression	O
in	O
Jurkat	O
T	O
cells	O
.	O
It	O
has	O
been	O
observed	O
that	O
decrease	O
of	O
DNA	B-GP
methyltransferase	I-GP
1	E-GP
(	O
DNMT1	S-GP
)	O
activity	O
is	O
associated	O
with	O
low	O
content	O
of	O
the	O
CD3-zeta	B-GP
(	I-GP
zeta	I-GP
)	I-GP
chain	E-GP
in	O
T	B-GP
cell	I-GP
receptor	E-GP
(	O
TCR	S-GP
)	O
/	O
CD3	S-GP
complex	O
of	O
T	O
cells	O
in	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
patients	O
.	O
The	O
CD3-zeta	B-GP
chain	E-GP
plays	O
a	O
pivotal	O
role	O
in	O
intracellular	O
signal	O
transmission	O
between	O
TCR	S-GP
/	O
CD3	S-GP
complex	O
and	O
nuclei	O
.	O
The	O
compounds	O
5'-azacytidine	S-chemical
(	O
AZC	S-chemical
)	O
and	O
procainamide	S-chemical
(	O
PCA	S-chemical
)	O
belong	O
to	O
inhibitors	O
of	O
DNMT1	S-GP
,	O
whose	O
low	O
activity	O
correlates	O
with	O
increase	O
in	O
transcription	O
of	O
various	O
genes	O
.	O
Using	O
the	O
reverse-transcription	O
and	O
real-time	O
quantitative	O
PCR	O
(	O
RQ-PCR	O
)	O
analysis	O
,	O
we	O
indicated	O
that	O
AZC	S-chemical
and	O
PCA	S-chemical
did	O
not	O
profoundly	O
affect	O
on	O
CD3-zeta	B-GP
chain	E-GP
transcription	O
in	O
Jurkat	O
T	O
leukemia	O
cells	O
clone	O
E6-1	O
.	O
However	O
,	O
the	O
flowcytometric	O
analysis	O
revealed	O
that	O
AZC	S-chemical
and	O
PCA	S-chemical
decreased	O
intracellular	O
contents	O
of	O
CD3-zeta	B-GP
chain	E-GP
in	O
these	O
cells	O
in	O
dose	O
dependent	O
manner	O
.	O
Our	O
results	O
suggest	O
that	O
decrease	O
of	O
DNMT1	S-GP
activity	O
may	O
alter	O
intracellular	O
signal	O
transmission	O
without	O
effect	O
on	O
transcription	O
level	O
of	O
CD3-zeta	B-GP
chain	E-GP
.	O

Induction	O
of	O
HO-1	S-GP
through	O
p38	S-GP
MAPK	S-GP
/	O
Nrf2	S-GP
signaling	O
pathway	O
by	O
ethanol	S-chemical
extract	O
of	O
Inula	O
helenium	O
L.	O
reduces	O
inflammation	O
in	O
LPS-activated	O
RAW	O
264.7	O
cells	O
and	O
CLP-induced	O
septic	O
mice	O
.	O
High	B-GP
mobility	I-GP
group	I-GP
box	I-GP
1	E-GP
(	O
HMGB1	S-GP
)	O
plays	O
a	O
crucial	O
mediator	O
in	O
the	O
pathogenesis	O
of	O
many	O
inflammatory	O
diseases	O
.	O
We	O
recently	O
proposed	O
that	O
heme	B-GP
oxygenase-1	E-GP
(	O
HO-1	S-GP
)	O
negatively	O
regulates	O
HMGB1	S-GP
in	O
inflammatory	O
conditions	O
.	O
We	O
investigated	O
whether	O
ethanol	S-chemical
extract	O
of	O
Inula	O
helenium	O
L.	O
(	O
EIH	O
)	O
activates	O
p38	S-GP
MAPK	S-GP
/	O
Nrf2	S-GP
/	O
HO-1	S-GP
pathways	O
in	O
RAW264.7	O
cells	O
and	O
reduces	O
inflammation	O
in	O
CLP-induced	O
septic	O
mice	O
.	O
EIH	O
induced	O
expression	O
of	O
HO-1	S-GP
protein	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
.	O
EIH	O
significantly	O
diminished	O
HO-1	S-GP
expression	O
in	O
siNrf2	S-GP
RNA-transfected	O
cells	O
.	O
As	O
expected	O
,	O
the	O
inhibited	O
expression	O
of	O
iNOS	S-GP
/NO	O
,	O
COX-2	S-GP
/PGE2	O
,	O
HMGB1	S-GP
release	O
by	O
EIH	O
in	O
LPS-activated	O
RAW264.7	O
cells	O
was	O
significantly	O
reversed	O
by	O
siHO-1	S-GP
RNA	O
transfection	O
.	O
Furthermore	O
,	O
EIH	O
not	O
only	O
inhibited	O
NF-κB	S-GP
luciferase	O
activity	O
,	O
phosphorylation	O
of	O
IκBα	S-GP
in	O
LPS-activated	O
cells	O
but	O
also	O
significantly	O
suppressed	O
expression	O
of	O
adhesion	O
molecules	O
(	O
ICAM-1	S-GP
and	O
VCAM-1	S-GP
)	O
in	O
TNF-α	S-GP
activated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O
The	O
induction	O
of	O
HO-1	S-GP
by	O
EIH	O
was	O
inhibited	O
by	O
SB203580	S-chemical
but	O
not	O
by	O
SP600125	S-chemical
,	O
PD98059	S-chemical
,	O
nor	O
LY294002	S-chemical
.	O
Most	O
importantly	O
,	O
administration	O
of	O
EIH	O
significantly	O
reduced	O
not	O
only	O
increase	O
in	O
blood	O
HMGB1	S-GP
,	O
ALT	B-GP
,	E-GP
AST	S-GP
,	O
BUN	O
,	O
creatinine	S-chemical
levels	O
but	O
also	O
decrease	O
macrophage	O
infiltrate	O
in	O
the	O
liver	O
of	O
septic	O
mice	O
,	O
which	O
were	O
reversed	O
by	O
ZnPPIX	O
,	O
a	O
HO-1	S-GP
inhibitor	O
.	O
We	O
concluded	O
that	O
EIH	O
has	O
anti-inflammatory	O
effect	O
via	O
the	O
induction	O
of	O
p38	S-GP
MAPK	S-GP
-dependent	O
HO-1	S-GP
signaling	O
pathway	O
.	O

The	O
effect	O
of	O
a	O
peripheral	O
block	O
on	O
inflammation-induced	O
prostaglandin	B-chemical
E2	E-chemical
and	O
cyclooxygenase	S-GP
expression	O
in	O
rats	O
.	O
BACKGROUND	O
:	O
Peripheral	O
inflammatory	O
pain	O
is	O
associated	O
with	O
an	O
upregulation	O
of	O
spinal	O
cord	O
COX-2	S-GP
(	O
cyclooxygenase-2	S-GP
)	O
,	O
with	O
a	O
subsequent	O
increase	O
in	O
central	O
prostaglandin	B-chemical
E2	E-chemical
(	O
PGE2	S-chemical
)	O
levels	O
associated	O
with	O
the	O
development	O
of	O
hyperalgesia	O
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
bupivacaine	S-chemical
administered	O
via	O
a	O
nerve	O
block	O
or	O
via	O
a	O
systemic	O
route	O
on	O
the	O
spinal	O
expression	O
of	O
PGE2	S-chemical
and	O
COX	S-GP
in	O
a	O
model	O
of	O
peripheral	O
inflammation	O
in	O
rats	O
.	O
METHODS	O
:	O
All	O
rats	O
randomly	O
received	O
three	O
injections	O
:	O
1	O
)	O
a	O
left	O
subcutaneous	O
hindpaw	O
injection	O
(	O
0.2	O
mL	O
with	O
either	O
carrageenan	O
2	O
%	O
w/v	O
or	O
saline	O
)	O
,	O
2	O
)	O
a	O
left	O
sciatic	O
block	O
(	O
0.2	O
mL	O
with	O
either	O
bupivacaine	S-chemical
0.5	O
%	O
or	O
saline	O
)	O
,	O
and	O
3	O
)	O
a	O
systemic	O
injection	O
(	O
subcutaneous	O
interscapular	O
with	O
0.2	O
mL	O
with	O
either	O
bupivacaine	S-chemical
0.5	O
%	O
or	O
saline	O
)	O
.	O
Local	O
edema	O
,	O
thermal	O
,	O
and	O
mechanical	O
hyperalgesia	O
as	O
well	O
as	O
cerebrospinal	O
fluid	O
PGE2	S-chemical
concentration	O
and	O
COX-1	S-GP
and	O
COX-2	S-GP
expression	O
in	O
the	O
spinal	O
cord	O
in	O
dorsal	O
root	O
ganglions	O
were	O
measured	O
.	O
RESULTS	O
:	O
We	O
confirmed	O
that	O
a	O
bupivacaine	S-chemical
block	O
attenuates	O
hyperalgesia	O
and	O
local	O
inflammation	O
in	O
a	O
model	O
of	O
inflammatory	O
pain	O
.	O
This	O
effect	O
was	O
associated	O
with	O
an	O
inhibition	O
of	O
the	O
increase	O
in	O
COX-2	S-GP
expression	O
induced	O
by	O
peripheral	O
inflammation	O
in	O
dorsal	O
root	O
ganglions	O
and	O
cord	O
.	O
The	O
subsequent	O
production	O
of	O
PGE2	S-chemical
in	O
cerebrospinal	O
fluid	O
was	O
also	O
impaired	O
.	O
Systemic	O
bupivacaine	S-chemical
did	O
not	O
modify	O
either	O
the	O
hyperalgesia	O
and	O
local	O
inflammation	O
or	O
COX	S-GP
expression	O
.	O
CONCLUSION	O
:	O
These	O
results	O
constitute	O
a	O
key	O
element	O
strongly	O
suggesting	O
that	O
local	O
anesthetics	O
act	O
at	O
a	O
different	O
level	O
when	O
administered	O
systematically	O
or	O
via	O
a	O
nerve	O
block	O
.	O

Induction	O
of	O
heparin-binding	B-GP
EGF-like	I-GP
growth	I-GP
factor	E-GP
and	O
activation	O
of	O
EGF	B-GP
receptor	E-GP
in	O
imatinib	B-chemical
mesylate	E-chemical
-treated	O
squamous	O
carcinoma	O
cells	O
.	O
Imatinib	B-chemical
mesylate	E-chemical
is	O
a	O
tyrosine	B-GP
kinase	E-GP
inhibitor	O
of	O
the	O
ABL	S-GP
,	O
platelet-derived	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
(	O
PDGFR	S-GP
)	O
,	O
and	O
c-kit	S-GP
kinases	S-GP
.	O
Inhibition	O
of	O
BCR	S-GP
-	O
ABL	S-GP
and	O
c-kit	S-GP
accounts	O
for	O
its	O
clinical	O
activity	O
in	O
leukemia	O
and	O
sarcoma	O
,	O
respectively	O
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
other	O
cellular	O
targets	O
for	O
imatinib	S-chemical
.	O
Treatment	O
of	O
head	O
and	O
neck	O
squamous	O
carcinoma	O
cells	O
with	O
clinically	O
relevant	O
concentrations	O
of	O
imatinib	S-chemical
-induced	O
changes	O
in	O
cell	O
morphology	O
and	O
growth	O
similar	O
to	O
changes	O
associated	O
with	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
(	O
EGFR	S-GP
)	O
activation	O
.	O
Imatinib	S-chemical
-induced	O
changes	O
were	O
blocked	O
with	O
the	O
EGFR	S-GP
antagonist	O
cetuximab	O
,	O
which	O
suggested	O
direct	O
involvement	O
of	O
EGFR	S-GP
in	O
this	O
process	O
.	O
Western	O
blot	O
analysis	O
of	O
cells	O
incubated	O
with	O
imatinib	S-chemical
demonstrated	O
activation	O
of	O
EGFR	S-GP
and	O
downstream	O
signaling	O
that	O
was	O
reduced	O
by	O
inhibition	O
of	O
mitogen-activated	B-GP
protein/extracellular	I-GP
signal-regulated	I-GP
kinase	I-GP
kinase	I-GP
1	E-GP
(	O
MEK1	S-GP
)	O
and	O
EGFR	S-GP
,	O
but	O
not	O
Her2	S-GP
/	O
ErbB2	S-GP
.	O
An	O
in	O
vitro	O
kinase	S-GP
assay	O
showed	O
that	O
imatinib	S-chemical
did	O
not	O
directly	O
affect	O
EGFR	S-GP
kinase	S-GP
activity	O
,	O
suggesting	O
involvement	O
of	O
EGFR	S-GP
-activating	O
molecules	O
.	O
Inhibitors	O
and	O
neutralizing	O
antibodies	O
against	O
heparin-binding	B-GP
epidermal	I-GP
growth	I-GP
factor-like	I-GP
growth	I-GP
factor	E-GP
(	O
HB-EGF	S-GP
)	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
transforming	B-GP
growth	I-GP
factor-alpha	E-GP
,	O
reduced	O
imatinib	S-chemical
-mediated	O
mitogen	B-GP
activated	I-GP
protein	I-GP
kinase	E-GP
(	O
MAPK	S-GP
)	O
activation	O
.	O
Imatinib	S-chemical
stimulated	O
the	O
rapid	O
release	O
of	O
soluble	O
HB-EGF	S-GP
and	O
the	O
subsequent	O
induction	O
of	O
membrane-bound	O
HB-EGF	S-GP
,	O
which	O
correlated	O
with	O
biphasic	O
MAPK	S-GP
activation	O
.	O
Together	O
,	O
these	O
results	O
suggested	O
that	O
imatinib	S-chemical
affects	O
EGFR	S-GP
activation	O
and	O
signaling	O
pathways	O
through	O
rapid	O
release	O
and	O
increased	O
expression	O
of	O
endogenous	O
EGFR	S-GP
-activating	O
ligands	O
.	O
Although	O
,	O
imatinib	S-chemical
primarily	O
inhibits	O
tyrosine	B-GP
kinases	E-GP
,	O
it	O
also	O
stimulates	O
the	O
activity	O
of	O
EGFR	S-GP
tyrosine	B-GP
kinase	E-GP
in	O
head	O
and	O
neck	O
squamous	O
tumors	O
.	O
This	O
finding	O
demonstrates	O
the	O
need	O
for	O
careful	O
use	O
of	O
this	O
drug	O
in	O
cancer	O
patients	O
.	O

Evaluation	O
of	O
a	O
predictive	O
in	O
vitro	O
Leydig	O
cell	O
assay	O
for	O
anti-androgenicity	O
of	O
phthalate	B-chemical
esters	E-chemical
in	O
the	O
rat	O
.	O
An	O
in	O
vitro	O
assay	O
using	O
the	O
rat	O
Leydig	O
cell	O
line	O
R2C	O
was	O
evaluated	O
for	O
its	O
ability	O
to	O
quantitatively	O
predict	O
inhibition	O
of	O
testosterone	S-chemical
synthesis	O
.	O
Results	O
obtained	O
for	O
endocrine	O
active	O
phthalates	S-chemical
(	O
MEHP	S-chemical
,	O
MBP	S-chemical
)	O
,	O
and	O
inactive	O
phthalates	S-chemical
(	O
MMP	S-chemical
and	O
MEP	S-chemical
)	O
were	O
highly	O
consistent	O
with	O
in	O
vivo	O
results	O
based	O
on	O
tissue	O
and	O
media	O
concentrations	O
.	O
Statistically	O
significant	O
inhibition	O
of	O
testosterone	S-chemical
synthesis	O
(	O
p	O
<	O
0.05	O
,	O
1-way	O
ANOVA	O
)	O
was	O
observed	O
at	O
1μM	O
MBP	S-chemical
and	O
3μM	O
MEHP	S-chemical
,	O
while	O
MEP	S-chemical
and	O
MMP	S-chemical
did	O
not	O
affect	O
inhibition	O
of	O
testosterone	S-chemical
synthesis	O
until	O
much	O
higher	O
concentrations	O
(	O
≫100μM	O
)	O
.	O
Concentrations	O
causing	O
50	O
%	O
inhibition	O
of	O
testosterone	S-chemical
synthesis	O
for	O
MBP	S-chemical
and	O
MEHP	S-chemical
(	O
3	O
and	O
6μM	O
respectively	O
)	O
,	O
were	O
similar	O
to	O
in	O
vivo	O
values	O
(	O
3	O
and	O
7μM	O
)	O
.	O
The	O
R2C	O
assay	O
was	O
used	O
to	O
determine	O
the	O
relative	O
potency	O
of	O
14	O
structurally	O
diverse	O
monoesters	S-chemical
and	O
oxidative	O
metabolites	O
of	O
MEHP	S-chemical
.	O
Monoesters	S-chemical
with	O
alkyl	O
chains	O
4-5	O
carbons	S-chemical
in	O
length	O
had	O
the	O
highest	O
potency	O
for	O
testosterone	S-chemical
inhibition	O
,	O
while	O
0-2	O
carbon	S-chemical
alkyl	O
chains	O
were	O
least	O
potent	O
.	O
Phase	O
I	O
metabolism	O
did	O
not	O
completely	O
inactivate	O
MEHP	S-chemical
,	O
underscoring	O
the	O
need	O
for	O
metabolism	O
data	O
when	O
interpreting	O
in	O
vitro	O
pharmacodynamic	O
data	O
.	O
This	O
steroid	S-chemical
inhibition	O
assay	O
provides	O
a	O
predictive	O
in	O
vitro	O
alternative	O
to	O
expensive	O
and	O
timeconsuming	O
developmental	O
rat	O
studies	O
for	O
phthalate	S-chemical
-induced	O
antiandrogenicity	O
.	O

Hypoxemia	O
associated	O
with	O
cimetidine	S-chemical
therapy	O
in	O
a	O
newborn	O
infant	O
.	O
Cimetidine	S-chemical
therapy	O
used	O
for	O
the	O
treatment	O
of	O
gastric	O
bleeding	O
due	O
to	O
tolazoline	S-chemical
therapy	O
in	O
a	O
newborn	O
infant	O
was	O
temporally	O
associated	O
with	O
episodes	O
of	O
severe	O
hypoxemia	O
.	O
It	O
appears	O
likely	O
that	O
the	O
histamine	B-GP
H2	I-GP
receptor	E-GP
blocked	O
by	O
cimetidine	S-chemical
obviated	O
the	O
pulmonary	O
vasodilator	O
effect	O
of	O
tolazoline	S-chemical
therapy	O
.	O

Cystathionase	S-GP
mediates	O
senescence	O
evasion	O
in	O
melanocytes	O
and	O
melanoma	O
cells	O
.	O
The	O
development	O
of	O
malignant	O
melanoma	O
is	O
a	O
highly	O
complex	O
process	O
,	O
which	O
is	O
still	O
poorly	O
understood	O
.	O
A	O
majority	O
of	O
human	O
melanomas	O
are	O
found	O
to	O
express	O
a	O
few	O
oncogenic	O
proteins	O
,	O
such	O
as	O
mutant	O
RAS	S-GP
and	O
BRAF	S-GP
variants	O
.	O
However	O
,	O
these	O
oncogenes	O
are	O
also	O
found	O
in	O
nevi	O
,	O
and	O
it	O
is	O
now	O
a	O
well-accepted	O
fact	O
that	O
their	O
expression	O
alone	O
leads	O
to	O
senescence	O
.	O
This	O
renders	O
the	O
understanding	O
of	O
senescence	O
escape	O
mechanisms	O
an	O
important	O
point	O
to	O
understand	O
tumor	O
development	O
.	O
Here	O
,	O
we	O
approached	O
the	O
question	O
of	O
senescence	O
evasion	O
by	O
expressing	O
the	O
transcription	O
factor	O
v-myc	B-GP
myelocytomatosis	I-GP
viral	I-GP
oncogene	I-GP
homolog	E-GP
(	O
c-MYC	S-GP
)	O
,	O
which	O
is	O
known	O
to	O
act	O
synergistically	O
with	O
many	O
oncogenes	O
,	O
in	O
melanocytes	O
.	O
We	O
observed	O
that	O
MYC	S-GP
drives	O
the	O
evasion	O
of	O
reactive-	O
oxygen	S-chemical
stress-induced	O
melanocyte	O
senescence	O
,	O
caused	O
by	O
activated	O
receptor	B-GP
tyrosine	I-GP
kinase	E-GP
signaling	O
.	O
Conversely	O
,	O
MIZ1	S-GP
,	O
the	O
growth	O
suppressing	O
interaction	O
partner	O
of	O
MYC	S-GP
,	O
is	O
involved	O
in	O
mediating	O
melanocyte	O
senescence	O
.	O
Both	O
,	O
MYC	S-GP
overexpression	O
and	O
Miz1	S-GP
knockdown	O
led	O
to	O
a	O
strong	O
reduction	O
of	O
endogenous	O
reactive-	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
,	O
DNA	O
damage	O
and	O
senescence	O
.	O
We	O
identified	O
the	O
cystathionase	S-GP
(	O
CTH	S-GP
)	O
gene	O
product	O
as	O
mediator	O
of	O
the	O
ROS-related	O
MYC	S-GP
and	O
MIZ1	S-GP
effects	O
.	O
Blocking	O
CTH	S-GP
enzymatic	O
activity	O
in	O
MYC	S-GP
-overexpressing	O
and	O
Miz1	S-GP
knockdown	O
cells	O
increased	O
intracellular	O
stress	O
and	O
senescence	O
.	O
Importantly	O
,	O
pharmacological	O
inhibition	O
of	O
CTH	S-GP
in	O
human	O
melanoma	O
cells	O
also	O
reconstituted	O
senescence	O
in	O
the	O
majority	O
of	O
cell	O
lines	O
,	O
and	O
CTH	S-GP
knockdown	O
reduced	O
tumorigenic	O
effects	O
such	O
as	O
proliferation	O
,	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
O	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
resistance	O
and	O
soft	O
agar	O
growth	O
.	O
Thus	O
,	O
we	O
identified	O
CTH	S-GP
as	O
new	O
MYC	S-GP
target	O
gene	O
with	O
an	O
important	O
function	O
in	O
senescence	O
evasion.Oncogene	O
advance	O
online	O
publication	O
,	O
28	O
January	O
2013	O
;	O
doi:10.1038/onc.2012.641	O
.	O

Bioimaging	O
real-time	O
PXR	S-GP
-dependent	O
mdr1a	S-GP
gene	O
regulation	O
in	O
mdr1a	S-GP
.fLUC	O
reporter	O
mice	O
.	O
The	O
MDR1	S-GP
gene	O
encodes	O
P-glycoprotein	B-GP
,	E-GP
a	O
transmembrane	B-GP
drug	I-GP
efflux	I-GP
transporter	E-GP
that	O
confers	O
multidrug	O
resistance	O
in	O
cancer	O
cells	O
and	O
affects	O
drug	O
pharmacokinetics	O
by	O
virtue	O
of	O
its	O
expression	O
in	O
the	O
liver	O
,	O
kidney	O
,	O
and	O
colon	O
.	O
Nuclear	B-GP
receptors	E-GP
SXR	S-GP
and	O
CAR	S-GP
are	O
possible	O
master	O
regulators	O
of	O
xenobiotic-inducible	O
MDR1	S-GP
expression	O
in	O
drug	O
processing	O
organs	O
,	O
but	O
the	O
mechanism	O
of	O
MDR1	S-GP
regulation	O
has	O
yet	O
to	O
be	O
directly	O
demonstrated	O
in	O
vivo	O
.	O
Moreover	O
,	O
it	O
has	O
previously	O
been	O
impossible	O
to	O
determine	O
the	O
sustained	O
or	O
cumulative	O
effect	O
of	O
repeated	O
doses	O
of	O
xenobiotics	O
on	O
in	O
vivo	O
MDR1	S-GP
expression	O
.	O
We	O
previously	O
reported	O
a	O
mouse	O
model	O
containing	O
firefly	O
luciferase	O
(	O
fLUC	O
)	O
knocked	O
into	O
the	O
mdr1a	S-GP
genomic	O
locus	O
,	O
allowing	O
non-invasive	O
bioimaging	O
of	O
intestinal	O
mdr1a	S-GP
gene	O
expression	O
in	O
live	O
animals	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
crossed	O
mdr1a	S-GP
.fLUC	O
mice	O
into	O
the	O
pxr	S-GP
knockout	O
(	O
pxr	S-GP
(	O
-/-	O
)	O
)	O
genetic	O
background	O
and	O
injected	O
mice	O
with	O
pregnenolone-16α-carbonitrile	S-chemical
(	O
PCN	S-chemical
)	O
,	O
a	O
strong	O
PXR	S-GP
ligand	O
,	O
and	O
two	O
therapeutically	O
relevant	O
taxanes	S-chemical
,	O
paclitaxel	S-chemical
and	O
docetaxel	S-chemical
.	O
All	O
three	O
agents	O
induced	O
mdr1a	S-GP
.fLUC	O
expression	O
(	O
bioluminescence	O
)	O
,	O
but	O
only	O
PCN	S-chemical
and	O
docetaxel	S-chemical
appeared	O
to	O
act	O
primarily	O
via	O
PXR	S-GP
.	O
Luminescence	O
returned	O
to	O
baseline	O
by	O
24-48	O
hrs	O
after	O
drug	O
injection	O
and	O
was	O
re-inducible	O
over	O
two	O
additional	O
rounds	O
of	O
drug	O
dosing	O
in	O
pxr	S-GP
(	O
+/+	O
)	O
mice	O
.	O
TCPOBOP	S-chemical
,	O
a	O
CAR	S-GP
ligand	O
,	O
modestly	O
induced	O
mdr1a	S-GP
.fLUC	O
in	O
pxr	S-GP
(	O
+/+	O
)	O
and	O
pxr	S-GP
(	O
-/-	O
)	O
strains	O
,	O
consistent	O
with	O
CAR	S-GP
's	O
minor	O
role	O
in	O
mdr1a	S-GP
regulation	O
.	O
Collectively	O
,	O
these	O
results	O
demonstrate	O
that	O
the	O
mdr1a	S-GP
.fLUC	O
bioimaging	O
model	O
can	O
capture	O
changes	O
in	O
mdr1	S-GP
gene	O
expression	O
under	O
conditions	O
of	O
repeated	O
xenobiotic	O
treatment	O
in	O
vivo	O
and	O
that	O
it	O
can	O
be	O
used	O
to	O
probe	O
the	O
mechanism	O
of	O
gene	O
regulation	O
in	O
response	O
to	O
different	O
xenobiotic	O
agents	O
.	O

Correlation	O
of	O
high	O
urinary	O
Smad1	S-GP
level	O
with	O
glomerular	O
hyperfiltration	O
in	O
type	O
2	O
diabetes	O
mellitus	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
relationship	O
between	O
urinary	O
Smad1	S-GP
and	O
glomerular	O
hyperfiltration	O
(	O
GHF	O
)	O
in	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
,	O
and	O
to	O
explore	O
the	O
factors	O
related	O
to	O
the	O
urinary	O
Smad1	S-GP
in	O
T2DM	O
.	O
The	O
reference	O
value	O
of	O
the	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
was	O
determined	O
in	O
248	O
healthy	O
individuals	O
.	O
30	O
patients	O
with	O
GHF	O
,	O
58	O
patients	O
with	O
norm-GFR	O
T2DM	O
,	O
and	O
24	O
healthy	O
patients	O
who	O
served	O
as	O
controls	O
were	O
recruited	O
.	O
Urinary	O
Smad1	S-GP
,	O
fasting	O
plasma	O
glucose	S-chemical
(	O
FPG	O
)	O
,	O
fasting	O
serum	O
C-Peptide	S-GP
(	O
C-P	S-GP
)	O
,	O
hemoglobin	B-GP
A1C	E-GP
(	O
HbA1c	S-GP
)	O
,	O
cystatin	B-GP
C	E-GP
,	O
and	O
other	O
chemistry	O
laboratory	O
parameters	O
of	O
T2DM	O
participants	O
and	O
controls	O
were	O
measured	O
.	O
Patients	O
with	O
GHF	O
had	O
higher	O
levels	O
of	O
urinary	O
Smad1	S-GP
than	O
the	O
control	O
group	O
,	O
and	O
those	O
with	O
norm-GFR	O
.	O
For	O
T2DM	O
patients	O
with	O
body	O
mass	O
index	O
,	O
age	O
,	O
and	O
gender	O
adjustments	O
,	O
urinary	O
Smad1	S-GP
was	O
positively	O
correlated	O
with	O
FPG	O
,	O
HbA1C	S-GP
,	O
and	O
eGFR	O
,	O
but	O
negatively	O
correlated	O
with	O
fasting	O
serum	O
C-P	S-GP
.	O
Multivariate	O
linear	O
regression	O
analysis	O
demonstrated	O
that	O
eGFR	O
,	O
HbA1C	S-GP
,	O
and	O
fasting	O
serum	O
C-P	S-GP
were	O
independently	O
associated	O
with	O
urinary	O
Smad1	S-GP
.	O
High	O
levels	O
of	O
urinary	O
Smad1	S-GP
were	O
found	O
in	O
GHF	O
patients	O
with	O
T2DM	O
,	O
which	O
may	O
be	O
another	O
potential	O
mechanism	O
of	O
GHF	O
in	O
relation	O
to	O
diabetic	O
nephropathy	O
.	O

Organic	B-GP
cation	I-GP
transporter	E-GP
mRNA	O
and	O
function	O
in	O
the	O
rat	O
superior	O
cervical	O
ganglion	O
.	O
Reuptake	O
of	O
extracellular	O
noradrenaline	S-chemical
(	O
NA	S-chemical
)	O
into	O
superior	O
cervical	O
ganglion	O
(	O
SCG	O
)	O
neurones	O
is	O
mediated	O
by	O
means	O
of	O
the	O
noradrenaline	B-GP
transporter	E-GP
(	O
NAT	S-GP
,	O
uptake	O
1	O
)	O
.	O
We	O
now	O
demonstrate	O
by	O
single-cell	O
RT-PCR	O
that	O
mRNA	O
of	O
the	O
organic	B-GP
cation	I-GP
transporter	I-GP
3	E-GP
(	O
OCT3	S-GP
,	O
uptake	O
2	O
)	O
occurs	O
in	O
rat	O
SCG	O
neurones	O
as	O
well	O
.	O
Furthermore	O
,	O
our	O
RT-PCR	O
analyses	O
reveal	O
the	O
presence	O
of	O
mRNA	O
for	O
novel	B-GP
organic	I-GP
cation	I-GP
transporters	I-GP
1	I-GP
and	I-GP
2	E-GP
(	O
OCTN1	S-GP
and	O
OCTN2	S-GP
)	O
,	O
but	O
not	O
for	O
OCT1	S-GP
or	O
OCT2	S-GP
in	O
the	O
ganglion	O
.	O
Making	O
use	O
of	O
the	O
NAT	S-GP
as	O
a	O
powerful	O
,	O
neurone-specific	O
transporter	O
system	O
,	O
we	O
loaded	O
[	B-chemical
3H	I-chemical
]	I-chemical
-N-methyl-4-phenylpyridinium	E-chemical
(	O
[	B-chemical
3H	I-chemical
]	I-chemical
-MPP+	E-chemical
)	O
into	O
cultured	O
rat	O
SCG	O
neurones	O
.	O
The	O
ensuing	O
radioactive	O
outflow	O
from	O
these	O
cultures	O
was	O
enhanced	O
by	O
desipramine	S-chemical
and	O
reserpine	S-chemical
,	O
but	O
reduced	O
(	O
in	O
the	O
presence	O
of	O
desipramine	S-chemical
)	O
by	O
the	O
OCT3	S-GP
inhibitors	O
cyanine	O
863	O
,	O
oestradiol	S-chemical
and	O
corticosterone	S-chemical
.	O
In	O
contrast	O
,	O
cyanine	O
863	O
enhanced	O
the	O
radioactive	O
outflow	O
from	O
cultures	O
preloaded	O
with	O
[	B-chemical
3H	I-chemical
]	I-chemical
-NA	E-chemical
.	O
Two	O
observations	O
suggest	O
that	O
a	O
depletion	O
of	O
storage	O
vesicles	O
by	O
cyanine	O
863	O
accounts	O
for	O
the	O
latter	O
phenomenon	O
:	O
first	O
,	O
the	O
primary	O
radioactive	O
product	O
isolated	O
from	O
supernatants	O
of	O
cultures	O
loaded	O
with	O
[	B-chemical
3H	I-chemical
]	I-chemical
-NA	E-chemical
was	O
the	O
metabolite	O
[	B-chemical
3H	I-chemical
]	I-chemical
-DHPG	E-chemical
;	O
and	O
second	O
,	O
inhibition	O
of	O
MAO	S-GP
significantly	O
reduced	O
the	O
radioactive	O
outflow	O
in	O
response	O
to	O
cyanine	O
863	O
.	O
The	O
outflow	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-MPP+	E-chemical
was	O
significantly	O
enhanced	O
by	O
MPP+	S-chemical
,	O
guanidine	S-chemical
,	O
choline	S-chemical
and	O
amantadine	S-chemical
as	O
potential	O
substrates	O
for	O
OCT	S-GP
-related	O
transmembrane	B-GP
transporters	E-GP
.	O
However	O
,	O
desipramine	S-chemical
at	O
a	O
low	O
concentration	O
essentially	O
blocked	O
the	O
radioactive	O
outflow	O
induced	O
by	O
all	O
of	O
these	O
substances	O
with	O
the	O
exception	O
of	O
MPP+	S-chemical
,	O
indicating	O
the	O
NAT	S-GP
and	O
not	O
an	O
OCT	S-GP
as	O
their	O
primary	O
site	O
of	O
action	O
.	O
The	O
MPP+	S-chemical
-induced	O
release	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-MPP+	E-chemical
was	O
fully	O
prevented	O
by	O
a	O
combined	O
application	O
of	O
desipramine	S-chemical
and	O
cyanine	O
863	O
.	O
No	O
trans-stimulation	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-MPP+	E-chemical
outflow	O
was	O
observed	O
by	O
the	O
OCTN1	S-GP
and	O
OCTN2	S-GP
substrate	O
carnitine	O
at	O
100	O
microM	O
.	O
Our	O
observations	O
indicate	O
an	O
OCT	S-GP
-mediated	O
transmembrane	O
transport	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-MPP+	E-chemical
.	O
Amongst	O
the	O
three	O
OCTs	S-GP
expressed	O
in	O
the	O
SCG	O
,	O
OCT3	S-GP
best	O
fits	O
the	O
profile	O
of	O
substrates	O
and	O
antagonists	O
that	O
cause	O
trans-stimulation	O
and	O
trans-inhibition	O
,	O
respectively	O
,	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-MPP+	E-chemical
release	O
.	O

Transplacental	O
exposure	O
to	O
inorganic	B-chemical
arsenic	E-chemical
at	O
a	O
hepatocarcinogenic	O
dose	O
induces	O
fetal	O
gene	O
expression	O
changes	O
in	O
mice	O
indicative	O
of	O
aberrant	O
estrogen	S-chemical
signaling	O
and	O
disrupted	O
steroid	S-chemical
metabolism	O
.	O
Exposure	O
to	O
inorganic	B-chemical
arsenic	E-chemical
in	O
utero	O
in	O
C3H	O
mice	O
produces	O
hepatocellular	O
carcinoma	O
in	O
male	O
offspring	O
when	O
they	O
reach	O
adulthood	O
.	O
To	O
help	O
define	O
the	O
molecular	O
events	O
associated	O
with	O
the	O
fetal	O
onset	O
of	O
arsenic	S-chemical
hepatocarcinogenesis	O
,	O
pregnant	O
C3H	O
mice	O
were	O
given	O
drinking	O
water	O
containing	O
0	O
(	O
control	O
)	O
or	O
85	O
ppm	O
arsenic	S-chemical
from	O
day	O
8	O
to	O
18	O
of	O
gestation	O
.	O
At	O
the	O
end	O
of	O
the	O
arsenic	S-chemical
exposure	O
period	O
,	O
male	O
fetal	O
livers	O
were	O
removed	O
and	O
RNA	O
isolated	O
for	O
microarray	O
analysis	O
using	O
22K	O
oligo	O
chips	O
.	O
Arsenic	S-chemical
exposure	O
in	O
utero	O
produced	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
alterations	O
in	O
expression	O
of	O
187	O
genes	O
,	O
with	O
approximately	O
25	O
%	O
of	O
aberrantly	O
expressed	O
genes	O
related	O
to	O
either	O
estrogen	S-chemical
signaling	O
or	O
steroid	S-chemical
metabolism	O
.	O
Real-time	O
RT-PCR	O
on	O
selected	O
genes	O
confirmed	O
these	O
changes	O
.	O
Various	O
genes	O
controlled	O
by	O
estrogen	S-chemical
,	O
including	O
X-inactive-specific	B-GP
transcript	E-GP
,	O
anterior	B-GP
gradient-2	E-GP
,	O
trefoil	B-GP
factor-1	E-GP
,	O
CRP-ductin	S-GP
,	O
ghrelin	S-GP
,	O
and	O
small	B-GP
proline-rich	I-GP
protein-2A	E-GP
,	O
were	O
dramatically	O
over-expressed	O
.	O
Estrogen	S-chemical
-regulated	O
genes	O
including	O
cytokeratin	B-GP
1-19	E-GP
and	O
Cyp2a4	S-GP
were	O
over-expressed	O
,	O
although	O
Cyp3a25	S-GP
was	O
suppressed	O
.	O
Several	O
genes	O
involved	O
with	O
steroid	S-chemical
metabolism	O
also	O
showed	O
remarkable	O
expression	O
changes	O
,	O
including	O
increased	O
expression	O
of	O
17beta-hydroxysteroid	B-GP
dehydrogenase-7	E-GP
(	O
HSD17beta7	S-GP
;	O
involved	O
in	O
estradiol	S-chemical
production	O
)	O
and	O
decreased	O
expression	O
of	O
HSD17beta5	S-GP
(	O
involved	O
in	O
testosterone	S-chemical
production	O
)	O
.	O
The	O
expression	O
of	O
key	O
genes	O
important	O
in	O
methionine	S-chemical
metabolism	O
,	O
such	O
as	O
methionine	B-GP
adenosyltransferase-1a	E-GP
,	O
betaine-homocysteine	B-GP
methyltransferase	E-GP
and	O
thioether	B-GP
S-methyltransferase	E-GP
,	O
were	O
suppressed	O
.	O
Thus	O
,	O
exposure	O
of	O
mouse	O
fetus	O
to	O
inorganic	B-chemical
arsenic	E-chemical
during	O
a	O
critical	O
period	O
in	O
development	O
significantly	O
alters	O
the	O
expression	O
of	O
various	O
genes	O
encoding	O
estrogen	S-chemical
signaling	O
and	O
steroid	S-chemical
or	O
methionine	S-chemical
metabolism	O
.	O
These	O
alterations	O
could	O
disrupt	O
genetic	O
programming	O
at	O
the	O
very	O
early	O
life	O
stage	O
,	O
which	O
could	O
impact	O
tumor	O
formation	O
much	O
later	O
in	O
adulthood	O
.	O

Targeted	O
disruption	O
of	O
inducible	B-GP
nitric	I-GP
oxide	I-GP
synthase	E-GP
protects	O
against	O
aging	O
,	O
S	S-chemical
-nitrosation	O
,	O
and	O
insulin	S-GP
resistance	O
in	O
muscle	O
of	O
male	O
mice	O
.	O
Accumulating	O
evidence	O
has	O
demonstrated	O
that	O
S	S-chemical
-nitrosation	O
of	O
proteins	O
plays	O
a	O
critical	O
role	O
in	O
several	O
human	O
diseases	O
.	O
Here	O
,	O
we	O
explored	O
the	O
role	O
of	O
inducible	B-GP
nitric	I-GP
oxide	I-GP
synthase	E-GP
(	O
iNOS	S-GP
)	O
in	O
the	O
S	S-chemical
-nitrosation	O
of	O
proteins	O
involved	O
in	O
the	O
early	O
steps	O
of	O
the	O
insulin	S-GP
-signaling	O
pathway	O
and	O
insulin	S-GP
resistance	O
in	O
the	O
skeletal	O
muscle	O
of	O
aged	O
mice	O
.	O
Aging	O
increased	O
iNOS	S-GP
expression	O
and	O
S	S-chemical
-nitrosation	O
of	O
major	O
proteins	O
involved	O
in	O
insulin	S-GP
signaling	O
,	O
thereby	O
reducing	O
insulin	S-GP
sensitivity	O
in	O
skeletal	O
muscle	O
.	O
Conversely	O
,	O
aged	O
iNOS	S-GP
-null	O
mice	O
were	O
protected	O
from	O
S	S-chemical
-nitrosation-induced	O
insulin	S-GP
resistance	O
.	O
Moreover	O
,	O
pharmacological	O
treatment	O
with	O
an	O
iNOS	S-GP
inhibitor	O
and	O
acute	O
exercise	O
reduced	O
iNOS	S-GP
-induced	O
S	S-chemical
-nitrosation	O
and	O
increased	O
insulin	S-GP
sensitivity	O
in	O
the	O
muscle	O
of	O
aged	O
animals	O
.	O
These	O
findings	O
indicate	O
that	O
the	O
insulin	S-GP
resistance	O
observed	O
in	O
aged	O
mice	O
is	O
mainly	O
mediated	O
through	O
the	O
S	S-chemical
-nitrosation	O
of	O
the	O
insulin	S-GP
-signaling	O
pathway	O
.	O

Inhibition	O
of	O
cardiac	O
voltage-gated	B-GP
sodium	I-GP
channels	E-GP
by	O
grape	O
polyphenols	O
.	O
BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
cardiovascular	O
benefits	O
of	O
red	O
wine	O
consumption	O
are	O
often	O
attributed	O
to	O
the	O
antioxidant	O
effects	O
of	O
its	O
polyphenolic	O
constituents	O
,	O
including	O
quercetin	S-chemical
,	O
catechin	S-chemical
and	O
resveratrol	S-chemical
.	O
Inhibition	O
of	O
cardiac	O
voltage-gated	B-GP
sodium	I-GP
channels	E-GP
(	O
VGSCs	S-GP
)	O
is	O
antiarrhythmic	O
and	O
cardioprotective	O
.	O
As	O
polyphenols	O
may	O
also	O
modulate	O
ion	O
channels	O
,	O
and	O
possess	O
structural	O
similarities	O
to	O
several	O
antiarrhythmic	O
VGSC	S-GP
inhibitors	O
,	O
we	O
hypothesised	O
that	O
VGSC	S-GP
inhibition	O
may	O
contribute	O
to	O
cardioprotection	O
by	O
these	O
polyphenols	O
.	O
EXPERIMENTAL	O
APPROACH	O
:	O
The	O
whole-cell	O
voltage-clamp	O
technique	O
was	O
used	O
to	O
record	O
peak	O
and	O
late	O
VGSC	S-GP
currents	O
(	O
INa	O
)	O
from	O
recombinant	O
human	B-GP
heart	I-GP
NaV1.5	E-GP
channels	O
expressed	O
in	O
tsA201	O
cells	O
.	O
Right	O
ventricular	O
myocytes	O
from	O
rat	O
heart	O
were	O
isolated	O
and	O
single	O
myocytes	O
were	O
field-stimulated	O
.	O
Either	O
calcium	S-chemical
transients	O
or	O
contractility	O
were	O
measured	O
using	O
the	O
calcium	S-chemical
-sensitive	O
dye	O
Calcium	S-chemical
-Green	O
1AM	O
or	O
video	O
edge	O
detection	O
,	O
respectively	O
.	O
KEY	O
RESULTS	O
:	O
The	O
red	O
grape	O
polyphenols	O
quercetin	S-chemical
,	O
catechin	S-chemical
and	O
resveratrol	S-chemical
blocked	O
peak	O
INa	O
with	O
IC50s	O
of	O
19.4	O
microM	O
,	O
76.8	O
microM	O
and	O
77.3	O
microM	O
,	O
respectively	O
.	O
In	O
contrast	O
to	O
lidocaine	S-chemical
,	O
resveratrol	S-chemical
did	O
not	O
exhibit	O
any	O
frequency-dependence	O
of	O
peak	O
INa	O
block	O
.	O
Late	O
INa	O
induced	O
by	O
the	O
VGSC	S-GP
long	O
QT	O
mutant	O
R1623Q	S-GP
was	O
reduced	O
by	O
resveratrol	S-chemical
and	O
quercetin	S-chemical
.	O
Resveratrol	S-chemical
and	O
quercetin	S-chemical
also	O
blocked	O
late	O
INa	O
induced	O
by	O
the	O
toxin	O
,	O
ATX	O
II	O
,	O
with	O
IC50s	O
of	O
26.1	O
microM	O
and	O
24.9	O
microM	O
,	O
respectively	O
.	O
In	O
field-stimulated	O
myocytes	O
,	O
ATXII-induced	O
increases	O
in	O
diastolic	O
calcium	S-chemical
were	O
prevented	O
and	O
reversed	O
by	O
resveratrol	S-chemical
.	O
ATXII-induced	O
contractile	O
dysfunction	O
was	O
delayed	O
and	O
reduced	O
by	O
resveratrol	S-chemical
.	O
CONCLUSIONS	O
AND	O
IMPLICATIONS	O
:	O
Our	O
results	O
indicate	O
that	O
several	O
red	O
grape	O
polyphenols	O
inhibit	O
cardiac	O
VGSCs	S-GP
and	O
that	O
this	O
effect	O
may	O
contribute	O
to	O
the	O
documented	O
cardioprotective	O
efficacy	O
of	O
red	O
grape	O
products	O
.	O

Circulating	O
glucagon	S-GP
to	O
ghrelin	S-GP
ratio	O
as	O
a	O
determinant	O
of	O
insulin	S-GP
resistance	O
in	O
hyperthyroidism	O
.	O
Due	O
to	O
stimulated	O
overall	O
metabolism	O
,	O
a	O
state	O
of	O
nutritional	O
inadequacy	O
often	O
ensues	O
,	O
during	O
thyrotoxicosis	O
.	O
We	O
aimed	O
to	O
investigate	O
circulating	O
levels	O
of	O
some	O
major	O
components	O
of	O
the	O
system	O
that	O
regulates	O
energy	O
stores	O
,	O
glucose	S-chemical
,	O
and	O
fat	O
metabolism	O
,	O
during	O
thyrotoxicosis	O
compared	O
to	O
euthyroidism	O
.	O
Fasting	O
serum	O
ghrelin	S-GP
,	O
leptin	S-GP
,	O
adiponectin	S-GP
,	O
insulin	S-GP
,	O
glucagon	S-GP
,	O
glucose	S-chemical
,	O
as	O
well	O
as	O
body	O
fat	O
composition	O
were	O
analyzed	O
during	O
thyrotoxicosis	O
in	O
40	O
hyperthyroid	O
patients	O
(	O
50.5	O
±	O
15.2	O
years	O
old	O
,	O
22	O
females	O
,	O
31	O
with	O
Graves	O
disease	O
,	O
and	O
9	O
with	O
toxic	O
nodular	O
goiter	O
)	O
.	O
The	O
same	O
measurements	O
were	O
repeated	O
an	O
average	O
3	O
months	O
later	O
,	O
when	O
all	O
patients	O
achieved	O
euthyroidism	O
.	O
Compared	O
to	O
euthyroidism	O
,	O
in	O
thyrotoxicosis	O
,	O
patients	O
had	O
lower	O
ghrelin	S-GP
and	O
fat	O
mass	O
;	O
had	O
comparable	O
insulin	S-GP
,	O
HOMA-IR	O
,	O
glucagon	S-GP
,	O
and	O
leptin	S-GP
levels	O
;	O
higher	O
levels	O
of	O
circulating	O
adiponectin	S-GP
.	O
Fasting	O
serum	O
glucose	S-chemical
tended	O
to	O
be	O
higher	O
during	O
thyrotoxicosis	O
.	O
The	O
unique	O
correlation	O
of	O
HOMA-IR	O
was	O
with	O
the-	O
glucagon	S-GP
to	O
ghrelin	S-GP
ratio-	O
(	O
r	O
=	O
0.801	O
,	O
p	O
<	O
0.001	O
)	O
in	O
hyperthyrodism	O
,	O
and	O
with	O
glucagon	S-GP
itself	O
in	O
euthyroidism	O
(	O
r	O
=	O
-0.844	O
,	O
p	O
<	O
0.001	O
)	O
.	O
Circulating	O
levels	O
of	O
ghrelin	S-GP
are	O
decreased	O
;	O
leptin	S-GP
,	O
insulin	S-GP
,	O
glucagon	S-GP
are	O
unchanged	O
;	O
adiponectin	S-GP
are	O
increased	O
during	O
hyperthyroidism	O
.	O
The	O
fasting	O
HOMA-IR	O
tends	O
to	O
be	O
higher	O
,	O
despite	O
the	O
decreased	O
adiposity	O
in	O
hyperthyroidism	O
.	O
The-	O
glucagon	S-GP
to	O
ghrelin	S-GP
ratio-strongly	O
correlates	O
with	O
fasting	O
HOMA-IR	O
in	O
hyperthyroidism	O
.	O

Inactivation	O
of	O
prostaglandin	B-GP
H	I-GP
synthase	E-GP
and	O
prostacyclin	B-GP
synthase	E-GP
by	O
phenylbutazone	S-chemical
.	O
Requirement	O
for	O
peroxidative	O
metabolism	O
.	O
Phenylbutazone	S-chemical
(	O
PB	S-chemical
)	O
,	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
,	O
is	O
an	O
efficient	O
reducing	O
cofactor	O
for	O
the	O
peroxidase	O
activity	O
of	O
prostaglandin	B-GP
H	I-GP
synthase	E-GP
(	O
PHS	S-GP
)	O
.	O
Most	O
reducing	O
cofactors	O
for	O
the	O
peroxidase	O
protect	O
PHS	S-GP
and	O
prostacyclin	B-GP
synthase	E-GP
from	O
inactivation	O
by	O
hydroperoxides	S-chemical
.	O
PB	S-chemical
,	O
however	O
,	O
does	O
not	O
protect	O
these	O
enzymes	O
,	O
but	O
rather	O
augments	O
their	O
hydroperoxide	S-chemical
-dependent	O
inactivation	O
.	O
Using	O
ram	O
seminal	O
vesicle	O
microsomes	O
as	O
a	O
source	O
of	O
PHS	S-GP
and	O
prostacyclin	B-GP
synthase	E-GP
,	O
we	O
have	O
examined	O
the	O
interaction	O
of	O
PB	S-chemical
and	O
exogenous	O
hydroperoxides	S-chemical
.	O
Chromatographic	O
analysis	O
of	O
the	O
metabolism	O
of	O
14C-labeled	B-chemical
arachidonic	I-chemical
acid	E-chemical
in	O
this	O
system	O
revealed	O
that	O
PB	S-chemical
-dependent	O
inactivation	O
of	O
PHS	S-GP
is	O
markedly	O
increased	O
in	O
the	O
presence	O
of	O
100	O
microM	O
H2O2	S-chemical
.	O
This	O
inactivation	O
is	O
a	O
linear	O
function	O
of	O
PB	S-chemical
concentration	O
between	O
10	O
and	O
250	O
microM	O
,	O
with	O
a	O
half-maximal	O
effect	O
in	O
this	O
range	O
at	O
about	O
100	O
microM	O
PB	O
.	O
Prostacyclin	B-GP
synthase	E-GP
is	O
even	O
more	O
sensitive	O
to	O
inactivation	O
by	O
the	O
combined	O
PB	S-chemical
and	O
H2O2	S-chemical
treatment	O
,	O
with	O
a	O
corresponding	O
half-maximal	O
effect	O
at	O
PB	S-chemical
concentrations	O
near	O
25	O
microM	O
.	O
This	O
PB	S-chemical
-	O
and	O
H2O2	S-chemical
-dependent	O
inactivation	O
is	O
demonstrable	O
whether	O
PGH2	S-chemical
is	O
generated	O
in	O
situ	O
from	O
arachidonic	B-chemical
acid	E-chemical
or	O
is	O
added	O
exogenously	O
,	O
supporting	O
a	O
direct	O
effect	O
of	O
the	O
treatment	O
on	O
prostacyclin	B-GP
synthase	E-GP
.	O
As	O
PB	S-chemical
undergoes	O
peroxide	S-chemical
-dependent	O
co-oxygenation	O
catalyzed	O
by	O
PHS	S-GP
,	O
we	O
propose	O
that	O
it	O
is	O
an	O
oxygenated	O
derivative	O
of	O
PB	S-chemical
,	O
rather	O
than	O
the	O
parent	O
compound	O
,	O
which	O
is	O
responsible	O
for	O
the	O
inactivation	O
of	O
PHS	S-GP
and	O
prostacyclin	B-GP
synthase	E-GP
.	O
Nafazatrom	S-chemical
,	O
a	O
competitive	O
inhibitor	O
of	O
PB	S-chemical
co-oxygenation	O
,	O
blocks	O
the	O
effects	O
of	O
the	O
PB	S-chemical
and	O
H2O2	S-chemical
treatment	O
,	O
supporting	O
our	O
proposal	O
.	O

Androgens	S-chemical
directly	O
stimulate	O
proliferation	O
of	O
bone	O
cells	O
in	O
vitro	O
.	O
This	O
report	O
describes	O
the	O
first	O
observation	O
of	O
a	O
direct	O
mitogenic	O
effect	O
of	O
androgens	S-chemical
on	O
isolated	O
osteoblastic	O
cells	O
in	O
serum-free	O
culture	O
.	O
[	B-chemical
3H	I-chemical
]	I-chemical
thymidine	E-chemical
incorporation	O
into	O
DNA	O
and	O
cell	O
counts	O
were	O
used	O
as	O
measures	O
of	O
cell	O
proliferation	O
.	O
The	O
percentage	O
of	O
cells	O
that	O
stained	O
for	O
alkaline	B-GP
phosphatase	E-GP
was	O
used	O
as	O
a	O
measure	O
of	O
differentiation	O
.	O
Dihydrotestosterone	S-chemical
(	O
DHT	S-chemical
)	O
enhanced	O
mouse	O
osteoblastic	O
cell	O
proliferation	O
in	O
a	O
dose	O
dependent	O
manner	O
over	O
a	O
wide	O
range	O
of	O
doses	O
(	O
10	O
(	O
-8	O
)	O
to	O
10	O
(	O
-11	O
)	O
molar	O
)	O
,	O
and	O
was	O
maximally	O
active	O
at	O
10	O
(	O
-9	O
)	O
M	O
.	O
DHT	S-chemical
also	O
stimulated	O
proliferation	O
in	O
human	O
osteoblast	O
cell	O
cultures	O
and	O
in	O
cultures	O
of	O
the	O
human	O
osteosarcoma	O
cell	O
line	O
,	O
TE89	O
.	O
Testosterone	S-chemical
,	O
fluoxymesterone	S-chemical
(	O
a	O
synthetic	O
androgenic	O
steroid	S-chemical
)	O
and	O
methenolone	S-chemical
(	O
an	O
anabolic	O
steroid	S-chemical
)	O
were	O
also	O
mitogenic	O
in	O
the	O
mouse	O
bone	O
cell	O
system	O
.	O
The	O
mitogenic	O
effect	O
of	O
DHT	S-chemical
on	O
bone	O
cells	O
was	O
inhibited	O
by	O
antiandrogens	O
(	O
hydroxyflutamide	S-chemical
and	O
cyproterone	B-chemical
acetate	E-chemical
)	O
which	O
compete	O
for	O
binding	O
to	O
the	O
androgen	B-GP
receptor	E-GP
.	O
In	O
addition	O
to	O
effects	O
on	O
cell	O
proliferation	O
,	O
DHT	S-chemical
increased	O
the	O
percentage	O
of	O
alkaline	B-GP
phosphatase	E-GP
(	O
ALP	S-GP
)	O
positive	O
cells	O
in	O
all	O
three	O
bone	O
cell	O
systems	O
tested	O
,	O
and	O
this	O
effect	O
was	O
inhibited	O
by	O
anti	O
androgens	S-chemical
.	O
We	O
conclude	O
that	O
androgens	O
can	O
stimulate	O
human	O
and	O
murine	O
osteoblastic	O
cell	O
proliferation	O
in	O
vitro	O
,	O
and	O
induce	O
expression	O
of	O
the	O
osteoblast-line	B-GP
differentiation	I-GP
marker	E-GP
ALP	S-GP
,	O
presumably	O
by	O
an	O
androgen	B-GP
receptor	E-GP
mediated	O
mechanism	O
.	O

The	O
effect	O
of	O
a	O
novel	O
transition	O
state	O
inhibitor	O
of	O
methylthioadenosine	B-GP
phosphorylase	E-GP
on	O
pemetrexed	S-chemical
activity	O
.	O
Pemetrexed	O
is	O
a	O
new-generation	O
antifolate	O
inhibitor	O
of	O
thymidylate	B-GP
synthase	E-GP
(	O
TS	S-GP
)	O
and	O
a	O
weaker	O
inhibitor	O
of	O
glycinamide	B-GP
ribonucleotide	I-GP
transformylase	E-GP
(	O
GARFT	S-GP
)	O
required	O
for	O
de	O
novo	O
purine	S-chemical
synthesis	O
.	O
Methylthioadenosine	B-GP
phosphorylase	E-GP
(	O
MTAP	S-GP
)	O
salvages	O
purines	S-chemical
by	O
releasing	O
adenine	S-chemical
from	O
methylthioadenosine	S-chemical
and	O
is	O
often	O
deleted	O
in	O
mesothelioma	O
.	O
The	O
current	O
study	O
addresses	O
the	O
effect	O
of	O
MTAP	S-GP
on	O
pemetrexed	S-chemical
activity	O
using	O
a	O
highly	O
potent	O
transition	O
state	O
inhibitor	O
of	O
MTAP	S-GP
,	O
MT-DADMe-Immucillin	O
A	O
(	O
ImmA	O
;	O
K	O
(	O
i	O
)	O
=	O
86	O
pmol/L	O
)	O
in	O
the	O
MTAP	S-GP
(	O
+	O
)	O
NCI-H28	O
and	O
MTAP	S-GP
(	O
-	O
)	O
NCI-H2052	O
mesothelioma	O
cell	O
lines	O
.	O
Based	O
on	O
selective	O
nucleoside	O
protection	O
,	O
TS	S-GP
was	O
found	O
to	O
be	O
the	O
primary	O
pemetrexed	S-chemical
target	O
in	O
both	O
cell	O
lines	O
with	O
GARFT	S-GP
inhibition	O
requiring	O
20-	O
to	O
30-fold	O
higher	O
pemetrexed	S-chemical
concentrations	O
.	O
ImmA	O
had	O
no	O
effect	O
on	O
pemetrexed	S-chemical
activity	O
but	O
,	O
when	O
thymidine	S-chemical
was	O
added	O
,	O
the	O
pemetrexed	S-chemical
IC	O
(	O
50	O
)	O
decreased	O
by	O
a	O
factor	O
of	O
approximately	O
3	O
in	O
MTAP	S-GP
(	O
+	O
)	O
H28	O
cells	O
with	O
no	O
effect	O
in	O
MTAP	S-GP
(	O
-	O
)	O
H2052	O
cells	O
.	O
Conversely	O
,	O
the	O
transfection	O
of	O
MTAP	S-GP
into	O
H2052	O
cells	O
increased	O
the	O
pemetrexed	S-chemical
IC	O
(	O
50	O
)	O
by	O
nearly	O
3-fold	O
but	O
only	O
in	O
the	O
presence	O
of	O
thymidine	S-chemical
;	O
this	O
was	O
reversed	O
by	O
ImmA	O
.	O
An	O
MTAP	S-GP
-specific	O
short	O
interfering	O
RNA	O
produced	O
a	O
2-fold	O
decrease	O
in	O
pemetrexed	S-chemical
IC	O
(	O
50	O
)	O
in	O
MTAP	S-GP
(	O
+	O
)	O
HeLa	O
cells	O
in	O
the	O
presence	O
of	O
thymidine	S-chemical
.	O
These	O
data	O
indicate	O
that	O
suppression	O
of	O
constitutive	O
MTAP	S-GP
has	O
no	O
effect	O
on	O
pemetrexed	S-chemical
activity	O
when	O
the	O
primary	O
target	O
is	O
TS	S-GP
.	O
There	O
is	O
a	O
modest	O
salutary	O
effect	O
when	O
the	O
pemetrexed	S-chemical
target	O
is	O
GARFT	S-GP
alone	O
.	O

Amine	B-GP
oxidase	E-GP
activities	O
in	O
brown	O
adipose	O
tissue	O
of	O
the	O
rat	O
:	O
identification	O
of	O
semicarbazide	S-chemical
-sensitive	O
(	O
clorgyline	S-chemical
-resistant	O
)	O
activity	O
at	O
the	O
fat	O
cell	O
membrane	O
.	O
Amine	B-GP
oxidase	E-GP
activity	O
,	O
previously	O
described	O
in	O
homogenates	O
of	O
brown	O
adipose	O
tissue	O
of	O
the	O
rat	O
,	O
has	O
now	O
been	O
investigated	O
in	O
preparations	O
of	O
isolated	O
fat	O
cells	O
.	O
It	O
was	O
found	O
that	O
the	O
specific	O
activities	O
of	O
both	O
monoamine	B-GP
oxidase	I-GP
A	E-GP
(	O
MAO	S-GP
)	O
and	O
of	O
the	O
semicarbazide-sensitive	B-GP
clorgyline-resistant	I-GP
amine	I-GP
oxidase	E-GP
(	O
SSAO	S-GP
)	O
were	O
higher	O
in	O
isolated	O
fat	O
cells	O
than	O
in	O
the	O
original	O
whole	O
tissue	O
.	O
Brown	O
adipocytes	O
therefore	O
represent	O
a	O
major	O
source	O
of	O
both	O
these	O
enzymes	O
.	O
In	O
plasma	O
membranes	O
prepared	O
from	O
these	O
isolated	O
brown	O
fat	O
cells	O
by	O
borate	S-chemical
extraction	O
there	O
was	O
a	O
similar	O
enrichment	O
of	O
activity	O
of	O
SSAO	S-GP
and	O
of	O
the	O
plasma	O
membrane	O
marker	O
enzyme	O
,	O
phosphodiesterase	B-GP
I	E-GP
.	O
However	O
in	O
preparations	O
of	O
cell	O
membranes	O
made	O
by	O
binding	O
the	O
cells	O
to	O
polycation-coated	O
beads	O
,	O
enrichment	O
of	O
phosphodiesterase	B-GP
I	E-GP
activity	O
was	O
much	O
greater	O
than	O
that	O
of	O
SSAO	S-GP
.	O
It	O
is	O
suggested	O
that	O
the	O
disposition	O
of	O
the	O
enzyme	O
within	O
the	O
cell	O
membrane	O
may	O
account	O
for	O
the	O
discrepancy	O
in	O
these	O
results	O
,	O
i.e	O
.	O
the	O
sidedness	O
of	O
the	O
membrane	O
may	O
be	O
important	O
.	O
Histochemical	O
visualization	O
of	O
enzyme	O
activity	O
in	O
whole	O
tissue	O
at	O
the	O
ultrastructural	O
level	O
was	O
undertaken	O
.	O
Positive	O
staining	O
of	O
mitochondria	O
was	O
achieved	O
in	O
the	O
presence	O
of	O
the	O
MAO	S-GP
substrate	O
,	O
tryptamine	S-chemical
.	O
Staining	O
around	O
the	O
edges	O
of	O
the	O
brown	O
fat	O
cells	O
was	O
observed	O
with	O
the	O
SSAO	S-GP
substrates	O
,	O
tyramine	S-chemical
and	O
benzylamine	S-chemical
.	O
Staining	O
was	O
largely	O
absent	O
when	O
substrate	O
was	O
omitted	O
or	O
after	O
pretreatment	O
with	O
the	O
irreversible	O
SSAO	S-GP
inhibitor	O
,	O
hydralazine	S-chemical
and	O
the	O
slowly	O
reversible	O
inhibitor	O
,	O
semicarbazide	S-chemical
.	O
It	O
is	O
not	O
definitely	O
proven	O
that	O
this	O
staining	O
represents	O
sites	O
of	O
enzyme	O
activity	O
but	O
the	O
results	O
are	O
consistent	O
with	O
evidence	O
from	O
other	O
studies	O
indicating	O
that	O
SSAO	S-GP
in	O
brown	O
adipose	O
tissue	O
of	O
the	O
rat	O
may	O
be	O
found	O
predominantly	O
at	O
the	O
fat	O
cell	O
surface	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Molecular	O
mechanism	O
regulating	O
24-hour	O
rhythm	O
of	O
dopamine	B-GP
d3	I-GP
receptor	E-GP
expression	O
in	O
mouse	O
ventral	O
striatum	O
.	O
The	O
dopamine	B-GP
D3	I-GP
receptor	E-GP
(	O
DRD3	S-GP
)	O
in	O
the	O
ventral	O
striatum	O
is	O
thought	O
to	O
influence	O
motivation	O
and	O
motor	O
functions	O
.	O
Although	O
the	O
expression	O
of	O
DRD3	S-GP
in	O
the	O
ventral	O
striatum	O
has	O
been	O
shown	O
to	O
exhibit	O
24-hour	O
variations	O
,	O
the	O
mechanisms	O
underlying	O
the	O
variation	O
remain	O
obscure	O
.	O
Here	O
,	O
we	O
demonstrated	O
that	O
molecular	O
components	O
of	O
the	O
circadian	O
clock	O
act	O
as	O
regulators	O
that	O
control	O
the	O
24-hour	O
variation	O
in	O
the	O
expression	O
of	O
DRD3	S-GP
.	O
The	O
transcription	O
of	O
DRD3	S-GP
was	O
enhanced	O
by	O
the	O
retinoic	B-GP
acid-related	I-GP
orphan	I-GP
receptor	I-GP
α	E-GP
(	O
RORα	S-GP
)	O
,	O
and	O
its	O
activation	O
was	O
inhibited	O
by	O
the	O
orphan	B-GP
receptor	E-GP
REV-ERBα	S-GP
,	O
an	O
endogenous	O
antagonist	O
of	O
RORα	S-GP
.	O
The	O
serum	O
or	O
dexamethasone	S-chemical
-induced	O
oscillation	O
in	O
the	O
expression	O
of	O
DRD3	S-GP
in	O
cells	O
was	O
abrogated	O
by	O
the	O
downregulation	O
or	O
overexpression	O
of	O
REV-ERBα	S-GP
,	O
suggesting	O
that	O
REV-ERBα	S-GP
functions	O
as	O
a	O
regulator	O
of	O
DRD3	S-GP
oscillations	O
in	O
the	O
cellular	O
autonomous	O
clock	O
.	O
Chromatin	O
immunoprecipitation	O
assays	O
of	O
the	O
DRD3	B-GP
promoter	E-GP
indicated	O
that	O
the	O
binding	O
of	O
the	O
REV-ERBα	S-GP
protein	O
to	O
the	O
DRD3	B-GP
promoter	E-GP
increased	O
in	O
the	O
early	O
dark	O
phase	O
.	O
DRD3	S-GP
protein	O
expression	O
varied	O
with	O
higher	O
levels	O
during	O
the	O
dark	O
phase	O
.	O
Moreover	O
,	O
the	O
effects	O
of	O
the	O
DRD3	S-GP
agonist	O
7-hydroxy-N	B-chemical
,	I-chemical
N-dipropyl-2-aminotetralin	E-chemical
(	O
7-OH-DPAT	S-chemical
)	O
-induced	O
locomotor	O
hypoactivity	O
were	O
significantly	O
increased	O
when	O
DRD3	S-GP
proteins	O
were	O
abundant	O
.	O
These	O
results	O
suggest	O
that	O
RORα	S-GP
and	O
REV-ERBα	S-GP
consist	O
of	O
a	O
reciprocating	O
mechanism	O
wherein	O
RORα	S-GP
upregulates	O
the	O
expression	O
of	O
DRD3	S-GP
,	O
whereas	O
REV-ERBα	S-GP
periodically	O
suppresses	O
the	O
expression	O
at	O
the	O
time	O
of	O
day	O
when	O
REV-ERBα	S-GP
is	O
abundant	O
.	O
Our	O
present	O
findings	O
revealed	O
that	O
a	O
molecular	O
link	O
between	O
the	O
circadian	O
clock	O
and	O
the	O
function	O
of	O
DRD3	S-GP
in	O
the	O
ventral	O
striatum	O
acts	O
as	O
a	O
modulator	O
of	O
the	O
pharmacological	O
actions	O
of	O
DRD3	S-GP
agonists/antagonists	O
.	O

TGF-β	S-GP
and	O
NF-κB	S-GP
signal	O
pathway	O
cross-talk	O
is	O
mediated	O
through	O
TAK1	S-GP
and	O
SMAD7	S-GP
in	O
a	O
subset	O
of	O
head	O
and	O
neck	O
cancers	O
.	O
Transforming	B-GP
growth	I-GP
factor-beta	E-GP
(	O
TGF-β	S-GP
)	O
has	O
a	O
dual	O
role	O
in	O
epithelial	O
malignancies	O
,	O
including	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(	O
HNSCC	O
)	O
.	O
Attenuation	O
of	O
canonical	O
TGF-β	S-GP
signaling	O
enhances	O
de	O
novo	O
tumor	O
development	O
,	O
whereas	O
TGF-β	S-GP
overexpression	O
and	O
signaling	O
paradoxically	O
promotes	O
malignant	O
progression	O
.	O
We	O
recently	O
observed	O
that	O
TGF-β	S-GP
-induced	O
growth	O
arrest	O
response	O
is	O
attenuated	O
,	O
in	O
association	O
with	O
aberrant	O
activation	O
of	O
nuclear	B-GP
factor-κB	E-GP
(	O
NF-κB	S-GP
)	O
,	O
a	O
transcription	O
factor	O
,	O
which	O
promotes	O
malignant	O
progression	O
in	O
HNSCC	O
.	O
However	O
,	O
what	O
role	O
cross-talk	O
between	O
components	O
of	O
the	O
TGF-β	S-GP
and	O
NF-κB	S-GP
pathways	O
plays	O
in	O
altered	O
activation	O
of	O
these	O
pathways	O
has	O
not	O
been	O
established	O
.	O
Here	O
,	O
we	O
show	O
TGF-β	B-GP
receptor	I-GP
II	E-GP
and	O
TGF-β-activated	B-GP
kinase	I-GP
1	E-GP
(	O
TAK1	S-GP
)	O
are	O
predominantly	O
expressed	O
in	O
a	O
subset	O
of	O
HNSCC	O
tumors	O
with	O
nuclear	O
activation	O
of	O
NF-κB	S-GP
family	O
member	O
RELA	S-GP
(	O
p65	S-GP
)	O
.	O
Further	O
,	O
TGF-β1	S-GP
treatment	O
induced	O
sequential	O
phosphorylation	O
of	O
TAK1	S-GP
,	O
IKK	S-GP
,	O
IκBα	S-GP
and	O
RELA	S-GP
in	O
human	O
HNSCC	O
lines	O
.	O
TAK1	S-GP
enhances	O
TGF-β	S-GP
-induced	O
NF-κB	S-GP
activation	O
,	O
as	O
TAK1	S-GP
siRNA	O
knockdown	O
decreased	O
TGF-β1	S-GP
-induced	O
phosphorylation	O
of	O
IKK	S-GP
,	O
IκB	S-GP
and	O
RELA	S-GP
,	O
degradation	O
of	O
IκBα	S-GP
,	O
RELA	S-GP
nuclear	O
translocation	O
and	O
DNA	O
binding	O
,	O
and	O
NF-κB	S-GP
-induced	O
reporter	O
and	O
target	O
gene	O
transcription	O
.	O
Functionally	O
,	O
TAK1	S-GP
siRNA	O
inhibited	O
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
.	O
Celastrol	S-chemical
,	O
a	O
TAK1	S-GP
inhibitor	O
and	O
anti-inflammatory	O
compound	O
used	O
in	O
traditional	O
Chinese	O
medicine	O
,	O
also	O
decreased	O
TGF-β1	S-GP
-induced	O
phosphorylation	O
of	O
TAK1	S-GP
and	O
RELA	S-GP
,	O
and	O
suppressed	O
basal	O
,	O
TGF-β1	S-GP
-	O
and	O
tumor	B-GP
necrosis	I-GP
factor-alpha	E-GP
(	O
TNF-α	S-GP
)	O
-induced	O
NF-κB	S-GP
reporter	O
gene	O
activity	O
.	O
Celastrol	S-chemical
also	O
inhibited	O
cell	O
proliferation	O
,	O
while	O
increasing	O
sub-G0	O
DNA	O
fragmentation	O
and	O
Annexin	B-GP
V	E-GP
markers	O
of	O
apoptosis	O
.	O
Furthermore	O
,	O
TGF-β	S-GP
and	O
RELA	S-GP
activation	O
promoted	O
SMAD7	S-GP
expression	O
.	O
In	O
turn	O
,	O
SMAD7	S-GP
preferentially	O
suppressed	O
TGF-β	S-GP
-induced	O
SMAD	S-GP
and	O
NF-κB	S-GP
reporters	O
when	O
compared	O
with	O
constitutive	O
or	O
TNF-α	S-GP
-induced	O
NF-κB	S-GP
reporter	O
gene	O
activation	O
.	O
Thus	O
,	O
cross-talk	O
by	O
TGF-β	S-GP
via	O
TAK1	S-GP
and	O
NF-κB	S-GP
promotes	O
the	O
malignant	O
phenotype	O
of	O
HNSCC	O
.	O
Moreover	O
,	O
NF-κB	S-GP
may	O
contribute	O
to	O
the	O
downstream	O
attenuation	O
of	O
canonical	O
TGF-β	S-GP
signaling	O
through	O
increased	O
SMAD7	S-GP
expression	O
.	O
Celastrol	S-chemical
highlights	O
the	O
therapeutic	O
potential	O
of	O
agents	O
targeting	O
TAK1	S-GP
as	O
a	O
key	O
node	O
in	O
this	O
pro-oncogenic	O
TGF-β	S-GP
-	O
NF-κB	S-GP
signal	O
pathway	O
.	O

Thymidylate	B-GP
synthase	E-GP
expression	O
in	O
resectable	O
and	O
unresectable	O
pancreatic	O
cancer	O
:	O
role	O
as	O
predictive	O
or	O
prognostic	O
marker	O
?	O
BACKGROUND	O
AND	O
AIMS	O
:	O
Thymidylate	B-GP
synthase	E-GP
(	O
TS	S-GP
)	O
is	O
an	O
important	O
enzyme	O
for	O
DNA	O
synthesis	O
and	O
the	O
target	O
for	O
5-fluorouracil	S-chemical
(	O
5-FU	S-chemical
)	O
.	O
Its	O
expression	O
may	O
determine	O
the	O
outcome	O
of	O
patients	O
with	O
gastrointestinal	O
cancers	O
.	O
We	O
examined	O
the	O
prognostic	O
and	O
predictive	O
value	O
of	O
TS	S-GP
-protein	O
expression	O
in	O
patients	O
with	O
ductal	O
adenocarcinoma	O
of	O
the	O
pancreas	O
.	O
METHODS	O
:	O
TS	S-GP
expression	O
from	O
131	O
patients	O
with	O
ductal	O
adenocarcinoma	O
of	O
the	O
pancreas	O
was	O
analyzed	O
by	O
immunohistochemistry	O
in	O
paraffin-embedded	O
primary	O
tumour	O
specimens	O
or	O
biopsies	O
.	O
RESUL	O
TS	S-GP
:	O
The	O
median	O
disease-specific	O
survival	O
among	O
all	O
patients	O
(	O
n=131	O
)	O
was	O
13	O
months	O
.	O
The	O
invasion	O
depth	O
,	O
the	O
presence	O
of	O
metastases	O
,	O
grading	O
and	O
Union	O
Internationale	O
Contre	O
le	O
Cancer	O
[	O
International	O
Union	O
Against	O
Cancer	O
]	O
(	O
UICC	O
)	O
stage	O
were	O
associated	O
with	O
survival	O
.	O
Among	O
resected	O
patients	O
(	O
n=98	O
)	O
,	O
a	O
difference	O
in	O
median	O
survival	O
was	O
seen	O
in	O
the	O
group	O
receiving	O
postoperative	O
adjuvant	O
treatment	O
(	O
21.1	O
months	O
)	O
compared	O
with	O
the	O
group	O
treated	O
by	O
surgery	O
alone	O
(	O
12.4	O
months	O
)	O
(	O
p=0.025	O
)	O
.	O
Low-	O
and	O
high-	O
TS	S-GP
immunoreactivity	O
was	O
present	O
in	O
74	O
(	O
56	O
%	O
)	O
and	O
56	O
(	O
43	O
%	O
)	O
of	O
the	O
cancers	O
,	O
respectively	O
.	O
One	O
sample	O
was	O
not	O
evaluable	O
.	O
No	O
difference	O
in	O
median	O
survival	O
was	O
observed	O
among	O
low-	O
and	O
high-	O
TS	S-GP
-expressing	O
tumours	O
.	O
Among	O
patients	O
undergoing	O
resection	O
and	O
receiving	O
postoperative	O
intra-arterial	O
chemotherapy	O
(	O
n=23	O
)	O
,	O
a	O
marked	O
trend	O
to	O
a	O
longer	O
median	O
survival	O
was	O
seen	O
for	O
the	O
group	O
with	O
low-	O
TS	S-GP
-expressing	O
tumours	O
compared	O
with	O
the	O
corresponding	O
high-	O
TS	S-GP
group	O
(	O
25.0	O
vs	O
16.0	O
months	O
)	O
(	O
p=0.3834	O
)	O
.	O
There	O
was	O
no	O
difference	O
in	O
survival	O
among	O
all	O
palliative	O
treated	O
patients	O
with	O
low-	O
and	O
high-	O
TS	S-GP
-expressing	O
tumours	O
.	O
CONCLUSION	O
:	O
Especially	O
patients	O
undergoing	O
tumour	O
resection	O
with	O
low-TS	O
values	O
seemed	O
to	O
have	O
taken	O
advantage	O
from	O
an	O
intensified	O
postoperative	O
chemotherapeutic	O
protocol	O
.	O
However	O
due	O
to	O
the	O
heterogeneous	O
group	O
of	O
patients	O
in	O
the	O
present	O
report	O
,	O
larger	O
trials	O
of	O
more	O
homogenous	O
patient	O
populations	O
will	O
be	O
necessary	O
to	O
confirm	O
this	O
hypothesis	O
.	O

Differential	O
binding	O
mode	O
of	O
diverse	O
cyclooxygenase	S-GP
inhibitors	O
.	O
Non-	O
steroidal	S-chemical
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
competitive	O
inhibitors	O
of	O
cyclooxygenase	S-GP
(	O
COX	S-GP
)	O
,	O
the	O
enzyme	O
that	O
mediates	O
biosynthesis	O
of	O
prostaglandins	S-chemical
and	O
thromboxanes	S-chemical
from	O
arachidonic	B-chemical
acid	E-chemical
.	O
There	O
are	O
at	O
least	O
two	O
different	O
isoforms	O
of	O
the	O
enzyme	O
known	O
as	O
COX-1	B-GP
and	I-GP
-2	E-GP
.	O
Site	O
directed	O
mutagenesis	O
studies	O
suggest	O
that	O
non-selective	O
COX	S-GP
inhibitors	O
of	O
diverse	O
chemical	O
families	O
exhibit	O
differential	O
binding	O
modes	O
to	O
the	O
two	O
isozymes	O
.	O
These	O
results	O
can	O
not	O
clearly	O
be	O
explained	O
from	O
the	O
sole	O
analysis	O
of	O
the	O
crystal	O
structures	O
of	O
COX	S-GP
available	O
from	O
X-ray	O
diffraction	O
studies	O
.	O
With	O
the	O
aim	O
to	O
elucidate	O
the	O
structural	O
features	O
governing	O
the	O
differential	O
inhibitory	O
binding	O
behavior	O
of	O
these	O
inhibitors	O
,	O
molecular	O
modeling	O
studies	O
were	O
undertaken	O
to	O
generate	O
atomic	O
models	O
compatible	O
with	O
the	O
experimental	O
data	O
available	O
.	O
Accordingly	O
,	O
docking	O
of	O
different	O
COX	S-GP
inhibitors	O
,	O
including	O
selective	O
and	O
non-selective	O
ligands	O
:	O
rofecoxib	S-chemical
,	O
ketoprofen	S-chemical
,	O
suprofen	S-chemical
,	O
carprofen	S-chemical
,	O
zomepirac	S-chemical
,	O
indomethacin	S-chemical
,	O
diclofenac	S-chemical
and	O
meclofenamic	B-chemical
acid	E-chemical
were	O
undertaken	O
using	O
the	O
AMBER	O
program	O
.	O
The	O
results	O
of	O
the	O
present	O
study	O
provide	O
new	O
insights	O
into	O
a	O
better	O
understanding	O
of	O
the	O
differential	O
binding	O
mode	O
of	O
diverse	O
families	O
of	O
COX	S-GP
inhibitors	O
,	O
and	O
are	O
expected	O
to	O
contribute	O
to	O
the	O
design	O
of	O
new	O
selective	O
compounds	O
.	O

Effects	O
of	O
silver	S-chemical
nanoparticles	O
on	O
the	O
liver	O
and	O
hepatocytes	O
in	O
vitro	O
.	O
With	O
the	O
increasing	O
use	O
and	O
incorporation	O
of	O
nanoparticles	O
(	O
NPs	O
)	O
into	O
consumer	O
products	O
,	O
screening	O
for	O
potential	O
toxicity	O
is	O
necessary	O
to	O
ensure	O
customer	O
safety	O
.	O
NPs	O
have	O
been	O
shown	O
to	O
translocate	O
to	O
the	O
bloodstream	O
following	O
inhalation	O
and	O
ingestion	O
,	O
and	O
such	O
studies	O
demonstrate	O
that	O
the	O
liver	O
is	O
an	O
important	O
organ	O
for	O
accumulation	O
.	O
Silver	S-chemical
(	O
Ag	S-chemical
)	O
NPs	O
are	O
highly	O
relevant	O
for	O
human	O
exposure	O
due	O
to	O
their	O
use	O
in	O
food	O
contact	O
materials	O
,	O
dietary	O
supplements	O
,	O
and	O
antibacterial	O
wound	O
treatments	O
.	O
Due	O
to	O
the	O
large	O
number	O
of	O
different	O
NPs	O
already	O
used	O
in	O
various	O
products	O
and	O
being	O
developed	O
for	O
new	O
applications	O
,	O
it	O
is	O
essential	O
that	O
relevant	O
,	O
quick	O
,	O
and	O
cheap	O
methods	O
of	O
in	O
vitro	O
risk	O
assessment	O
suitable	O
for	O
these	O
new	O
materials	O
are	O
established	O
.	O
Therefore	O
,	O
this	O
study	O
used	O
a	O
simple	O
hepatocytes	O
model	O
combined	O
with	O
an	O
in	O
vivo	O
injection	O
model	O
to	O
simulate	O
the	O
passage	O
of	O
a	O
small	O
amount	O
of	O
NPs	O
into	O
the	O
bloodstream	O
following	O
exposure	O
,	O
e.g.	O
,	O
via	O
ingestion	O
or	O
inhalation	O
,	O
and	O
examined	O
the	O
potential	O
of	O
Ag	S-chemical
NPs	O
of	O
20	O
nm	O
diameter	O
to	O
cause	O
toxicity	O
,	O
inflammation	O
,	O
and	O
oxidative	O
stress	O
in	O
the	O
liver	O
following	O
in	O
vivo	O
exposures	O
of	O
female	O
Wistar	O
rats	O
via	O
iv	O
injection	O
to	O
50	O
μg	O
of	O
NPs	O
and	O
in	O
vitro	O
exposures	O
using	O
the	O
human	O
hepatocyte	O
cell	O
line	O
C3A	O
.	O
We	O
found	O
that	O
Ag	S-chemical
NPs	O
were	O
highly	O
cytotoxic	O
to	O
hepatocytes	O
(	O
LC	O
(	O
50	O
)	O
lactate	B-GP
dehydrogenase	E-GP
:	O
2.5	O
μg/cm	O
(	O
2	O
)	O
)	O
and	O
affected	O
hepatocyte	O
homeostasis	O
by	O
reducing	O
albumin	S-GP
release	O
.	O
At	O
sublethal	O
concentrations	O
with	O
normal	O
cell	O
or	O
tissue	O
morphology	O
,	O
Ag	S-chemical
NPs	O
were	O
detected	O
in	O
cytoplasm	O
and	O
nuclei	O
of	O
hepatocytes	O
.	O
We	O
observed	O
similar	O
effects	O
of	O
Ag	S-chemical
NPs	O
on	O
inflammatory	O
mediator	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
increase	O
of	O
interleukin-8	S-GP
(	O
IL-8	S-GP
)	O
/	O
macrophage	B-GP
inflammatory	I-GP
protein	I-GP
2	E-GP
,	O
IL-1RI	S-GP
,	O
and	O
tumor	B-GP
necrosis	I-GP
factor-α	E-GP
expression	O
in	O
both	O
models	O
and	O
increased	O
IL-8	S-GP
protein	O
release	O
in	O
vitro	O
.	O
This	O
article	O
presents	O
evidence	O
of	O
the	O
potential	O
toxicity	O
and	O
inflammogenic	O
potential	O
of	O
Ag	S-chemical
NPs	O
in	O
the	O
liver	O
following	O
ingestion	O
.	O
In	O
addition	O
,	O
the	O
similarities	O
between	O
in	O
vitro	O
and	O
in	O
vivo	O
responses	O
are	O
striking	O
and	O
encouraging	O
for	O
future	O
reduction	O
,	O
refinement	O
,	O
and	O
replacement	O
of	O
animal	O
studies	O
by	O
the	O
use	O
of	O
hepatocyte	O
cell	O
lines	O
in	O
particle	O
risk	O
assessment	O
.	O

Alendronate	S-chemical
inhibition	O
of	O
protein-tyrosine-phosphatase-meg1	S-GP
.	O
Alendronate	S-chemical
(	O
4-amino-1-hydroxybutylidene-1,1-bisphosphonate	S-chemical
)	O
is	O
a	O
potent	O
bisphosphonate	S-chemical
that	O
inhibits	O
osteoclastic	O
bone	O
resorption	O
and	O
has	O
proven	O
effective	O
for	O
the	O
treatment	O
of	O
osteoporosis	O
.	O
Its	O
molecular	O
mechanism	O
of	O
action	O
,	O
however	O
,	O
has	O
not	O
been	O
defined	O
precisely	O
.	O
Here	O
we	O
report	O
that	O
alendronate	S-chemical
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
protein-tyrosine-phosphatase-meg1	S-GP
(	O
PTPmeg1	S-GP
)	O
.	O
Two	O
substrates	O
were	O
employed	O
in	O
this	O
study	O
:	O
fluorescein	O
diphosphate	S-chemical
and	O
the	O
phosphotyrosyl	O
peptide	O
src	S-GP
-pY527	O
.	O
With	O
either	O
substrate	O
,	O
alendronate	S-chemical
was	O
a	O
slow	O
binding	O
inhibitor	O
of	O
PTPmeg1	S-GP
.	O
Among	O
the	O
other	O
bisphosphonates	S-chemical
studied	O
,	O
alendronate	S-chemical
was	O
more	O
potent	O
and	O
selective	O
for	O
PTPmeg1	S-GP
.	O
The	O
hydrolysis	O
of	O
fluorescein	O
diphosphate	S-chemical
by	O
PTP	B-GP
epsilon	E-GP
and	O
PTPmeg1	S-GP
was	O
sensitive	O
to	O
alendronate	S-chemical
,	O
with	O
IC50	O
values	O
of	O
less	O
than	O
1	O
microM	O
;	O
PTPsigma	S-GP
,	O
however	O
,	O
under	O
the	O
same	O
conditions	O
,	O
was	O
inhibited	O
by	O
only	O
50	O
%	O
with	O
141	O
microM	O
alendronate	S-chemical
.	O
Similarly	O
,	O
with	O
the	O
src	S-GP
-pY527	O
substrate	O
,	O
alendronate	S-chemical
inhibition	O
was	O
also	O
PTP	S-GP
dependent	O
.	O
Alendronate	S-chemical
inhibited	O
PTPmeg1	S-GP
with	O
an	O
IC50	O
value	O
of	O
23	O
microM	O
,	O
PTPsigma	S-GP
with	O
an	O
IC50	O
value	O
of	O
2	O
microM	O
,	O
and	O
did	O
not	O
inhibit	O
PTP	B-GP
epsilon	E-GP
at	O
concentrations	O
up	O
to	O
1	O
mM	O
.	O
The	O
alendronate	S-chemical
inhibition	O
of	O
these	O
three	O
PTPs	S-GP
and	O
two	O
substrates	O
is	O
consistent	O
with	O
the	O
formation	O
of	O
a	O
ternary	O
complex	O
comprised	O
of	O
enzyme	O
,	O
substrate	O
,	O
and	O
inhibitor	O
.	O
PTP	S-GP
inhibition	O
by	O
hisphosphonates	S-chemical
or	O
vanadate	S-chemical
was	O
diminished	O
by	O
the	O
metal	O
chelating	O
agent	O
EDTA	S-chemical
,	O
or	O
by	O
the	O
reducing	O
agent	O
dithiothreitol	S-chemical
,	O
suggesting	O
that	O
a	O
metal	O
ion	O
and	O
the	O
oxidation	O
of	O
a	O
cysteine	S-chemical
residue	O
are	O
required	O
for	O
full	O
inhibition	O
.	O
These	O
observations	O
show	O
substrate-	O
and	O
enzyme-specific	O
PTP	S-GP
inhibition	O
by	O
alendronate	S-chemical
and	O
support	O
the	O
possibility	O
that	O
a	O
certain	O
PTP	S-GP
(	O
s	O
)	O
may	O
be	O
the	O
molecular	O
target	O
for	O
alendronate	S-chemical
action	O
.	O

Tricycloalternarenes	B-chemical
F-H	E-chemical
:	O
three	O
new	O
mixed	O
terpenoids	S-chemical
produced	O
by	O
an	O
endolichenic	O
fungus	O
Ulocladium	O
sp	O
.	O
using	O
OSMAC	O
method	O
.	O
Three	O
new	O
mixed	O
terpenoids	S-chemical
,	O
tricycloalternarenes	S-chemical
(	O
TCAs	S-chemical
)	O
F-H	O
(	O
1-3	O
)	O
,	O
together	O
with	O
ten	O
known	O
tricycloalternarenes	S-chemical
(	O
4-13	O
)	O
,	O
were	O
isolated	O
from	O
the	O
Czapek	O
's	O
culture	O
of	O
an	O
endophytic	O
fungus	O
Ulocladium	O
sp	O
.	O
Their	O
structures	O
were	O
identified	O
by	O
extensive	O
spectroscopic	O
experiments	O
(	O
NMR	O
and	O
MS	O
)	O
and	O
comparison	O
with	O
literature	O
data	O
.	O
TCA	S-chemical
1b	O
(	O
5	O
)	O
showed	O
weak	O
activity	O
against	O
the	O
Bacille	O
Calmette-Guerin	O
strain	O
with	O
the	O
MIC	O
of	O
125μg/mL	O
.	O
TCA	S-chemical
9b	O
(	O
10	O
)	O
exhibited	O
strong	O
cytotoxic	O
activity	O
against	O
Hela	O
cell	O
line	O
with	O
IC50	O
of	O
8.58μM	O
.	O

Serotonergic	O
effects	O
and	O
extracellular	O
brain	O
levels	O
of	O
eletriptan	S-chemical
,	O
zolmitriptan	S-chemical
and	O
sumatriptan	S-chemical
in	O
rat	O
brain	O
.	O
In	O
vivo	O
microdialysis	O
was	O
used	O
to	O
assess	O
the	O
central	O
serotonergic	O
effects	O
and	O
extracellular	O
brain	O
levels	O
of	O
the	O
5-HT	B-GP
(	I-GP
1B/1D	I-GP
)	E-GP
receptor	O
agonists	O
eletriptan	S-chemical
,	O
zolmitriptan	S-chemical
and	O
sumatriptan	S-chemical
in	O
rats	O
after	O
intravenous	O
and	O
intracerebral	O
administration	O
,	O
while	O
their	O
binding	O
affinities	O
and	O
functional	O
potencies	O
were	O
determined	O
at	O
5-HT	B-GP
(	I-GP
1B	I-GP
)	E-GP
,	O
5-HT	B-GP
(	I-GP
1D	I-GP
)	E-GP
and	O
5-HT	B-GP
(	I-GP
1A	I-GP
)	E-GP
receptors	O
.	O
In	O
vitro	O
studies	O
showed	O
that	O
all	O
three	O
triptans	S-chemical
are	O
high	O
affinity	O
,	O
full	O
agonists	O
at	O
5-HT	B-GP
(	I-GP
1B/1D	I-GP
)	E-GP
receptors	O
,	O
but	O
that	O
sumatriptan	S-chemical
is	O
functionally	O
less	O
potent	O
as	O
a	O
5-HT	B-GP
(	I-GP
1B/1D	I-GP
)	E-GP
agonist	O
than	O
zolmitriptan	S-chemical
and	O
eletriptan	S-chemical
.	O
Local	O
intracortical	O
perfusion	O
with	O
the	O
compounds	O
via	O
the	O
dialysis	O
probe	O
decreased	O
cortical	O
5-HT	S-chemical
(	O
5-hydroxytryptamine	S-chemical
,	O
serotonin	S-chemical
)	O
release	O
with	O
ED	O
(	O
50	O
)	O
values	O
of	O
approximately	O
0.1	O
microM	O
for	O
eletriptan	S-chemical
and	O
zolmitriptan	S-chemical
and	O
0.5	O
microM	O
for	O
sumatriptan	S-chemical
.	O
At	O
3.2	O
mg/kg	O
i.v.	O
,	O
both	O
eletriptan	S-chemical
and	O
zolmitriptan	S-chemical
decreased	O
5-HT	S-chemical
levels	O
by	O
about	O
35	O
%	O
,	O
while	O
sumatriptan	S-chemical
had	O
no	O
effect	O
,	O
despite	O
the	O
fact	O
that	O
maximal	O
sumatriptan	S-chemical
concentrations	O
in	O
cortical	O
dialysates	O
were	O
higher	O
(	O
8.8	O
nM	O
at	O
20	O
min	O
)	O
than	O
those	O
of	O
zolmitriptan	S-chemical
(	O
5.9	O
nM	O
at	O
20	O
min	O
)	O
and	O
eletriptan	S-chemical
(	O
2.6	O
nM	O
at	O
40	O
min	O
)	O
.	O
The	O
observation	O
that	O
eletriptan	S-chemical
and	O
zolmitriptan	S-chemical
produce	O
almost	O
identical	O
central	O
serotonergic	O
effects	O
,	O
after	O
intracerebral	O
as	O
well	O
as	O
after	O
systemic	O
administration	O
,	O
is	O
in	O
agreement	O
with	O
their	O
comparable	O
functional	O
5-HT	B-GP
(	I-GP
1B/1D	I-GP
)	E-GP
receptor	O
agonist	O
potencies	O
and	O
their	O
free	O
levels	O
in	O
cortical	O
dialysates	O
after	O
3.2	O
mg/kg	O
i.v	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
lack	O
of	O
central	O
serotonergic	O
effects	O
of	O
3.2	O
mg/kg	O
i.v	O
.	O
sumatriptan	S-chemical
is	O
likely	O
due	O
to	O
its	O
weaker	O
functional	O
5-HT	B-GP
(	I-GP
1B/1D	I-GP
)	E-GP
receptor	O
agonist	O
potency	O
than	O
eletriptan	S-chemical
and	O
zolmitriptan	S-chemical
,	O
rather	O
than	O
lower	O
brain	O
levels	O
,	O
consistent	O
with	O
sumatriptan	O
's	O
fivefold	O
lower	O
potency	O
after	O
intracerebral	O
administration	O
.	O

Viability	O
assessment	O
in	O
sandwich-cultured	O
rat	O
hepatocytes	O
after	O
xenobiotic	O
exposure	O
.	O
Troglitazone	S-chemical
,	O
bosentan	S-chemical
and	O
glibenclamide	S-chemical
inhibit	O
the	O
bile	B-GP
salt	I-GP
export	I-GP
pump	E-GP
(	O
Bsep	S-GP
)	O
which	O
transports	O
taurocholate	S-chemical
into	O
bile	O
.	O
Sandwich-cultured	O
rat	O
hepatocytes	O
maintain	O
functional	O
sodium	B-GP
taurocholate	I-GP
co-transporting	I-GP
polypeptide	E-GP
and	O
Bsep	S-GP
transport	O
proteins	O
,	O
and	O
may	O
be	O
useful	O
to	O
study	O
inhibition	O
of	O
transport	O
by	O
xenobiotics	O
at	O
concentrations	O
below	O
the	O
lowest	O
observable	O
adverse	O
effect	O
level	O
(	O
LOAEL	O
)	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
viability	O
assessments	O
determined	O
with	O
the	O
neutral	O
red	O
,	O
lactate	B-GP
dehydrogenase	E-GP
(	O
LDH	S-GP
)	O
,	O
alamar	B-chemical
blue	E-chemical
,	O
3-	B-chemical
[	I-chemical
4,5-dimethylthiazol-2-yl	I-chemical
]	I-chemical
-2,5-diphenyltetrazolium	I-chemical
bromide	E-chemical
(	O
MTT	S-chemical
)	O
and	O
propidium	B-chemical
iodide	E-chemical
assays	O
in	O
sandwich-cultured	O
rat	O
hepatocytes	O
following	O
exposure	O
to	O
xenobiotics	O
known	O
to	O
inhibit	O
Bsep	S-GP
,	O
and	O
to	O
define	O
the	O
LOAEL	O
for	O
these	O
xenobiotics	O
in	O
this	O
system	O
.	O
The	O
neutral	O
red	O
assay	O
was	O
not	O
amenable	O
to	O
use	O
in	O
this	O
model	O
due	O
to	O
crystal	O
formation	O
on	O
the	O
collagen	S-GP
.	O
Troglitazone	S-chemical
decreased	O
viability	O
in	O
every	O
assay	O
examined	O
,	O
with	O
a	O
LOAEL	O
approximately	O
100	O
microM	O
.	O
Bosentan	S-chemical
also	O
decreased	O
viability	O
as	O
measured	O
by	O
the	O
LDH	S-GP
,	O
MTT	S-chemical
and	O
propidium	B-chemical
iodide	E-chemical
assays	O
,	O
with	O
a	O
LOAEL	O
approximately	O
200	O
microM	O
;	O
however	O
,	O
a	O
significant	O
decrease	O
in	O
viability	O
was	O
not	O
observed	O
with	O
the	O
alamar	B-chemical
blue	E-chemical
assay	O
.	O
Glibenclamide	S-chemical
did	O
not	O
decrease	O
viability	O
with	O
any	O
assay	O
at	O
the	O
xenobiotic	O
concentrations	O
examined	O
in	O
this	O
study	O
.	O
Based	O
on	O
the	O
results	O
of	O
this	O
study	O
,	O
the	O
LDH	S-GP
or	O
propidium	B-chemical
iodide	E-chemical
assays	O
would	O
be	O
the	O
methods	O
of	O
choice	O
to	O
assess	O
viability	O
in	O
sandwich-cultured	O
rat	O
hepatocytes	O
after	O
xenobiotic	O
exposure	O
.	O

Identification	O
of	O
Dlk1	S-GP
-	O
Dio3	S-GP
imprinted	O
gene	O
cluster	O
noncoding	O
RNAs	O
as	O
novel	O
candidate	O
biomarkers	O
for	O
liver	O
tumor	O
promotion	O
.	O
The	O
molecular	O
events	O
during	O
nongenotoxic	O
carcinogenesis	O
and	O
their	O
temporal	O
order	O
are	O
poorly	O
understood	O
but	O
thought	O
to	O
include	O
long-lasting	O
perturbations	O
of	O
gene	O
expression	O
.	O
Here	O
,	O
we	O
have	O
investigated	O
the	O
temporal	O
sequence	O
of	O
molecular	O
and	O
pathological	O
perturbations	O
at	O
early	O
stages	O
of	O
phenobarbital	S-chemical
(	O
PB	O
)	O
mediated	O
liver	O
tumor	O
promotion	O
in	O
vivo	O
.	O
Molecular	O
profiling	O
(	O
mRNA	O
,	O
microRNA	O
[	O
miRNA	O
]	O
,	O
DNA	O
methylation	O
,	O
and	O
proteins	O
)	O
of	O
mouse	O
liver	O
during	O
13	O
weeks	O
of	O
PB	O
treatment	O
revealed	O
progressive	O
increases	O
in	O
hepatic	O
expression	O
of	O
long	O
noncoding	O
RNAs	O
and	O
miRNAs	O
originating	O
from	O
the	O
Dlk1	S-GP
-	O
Dio3	S-GP
imprinted	O
gene	O
cluster	O
,	O
a	O
locus	O
that	O
has	O
recently	O
been	O
associated	O
with	O
stem	O
cell	O
pluripotency	O
in	O
mice	O
and	O
various	O
neoplasms	O
in	O
humans	O
.	O
PB	O
induction	O
of	O
the	O
Dlk1	S-GP
-	O
Dio3	S-GP
cluster	O
noncoding	O
RNA	O
(	O
ncRNA	O
)	O
Meg3	O
was	O
localized	O
to	O
glutamine	B-GP
synthetase	E-GP
-positive	O
hypertrophic	O
perivenous	O
hepatocytes	O
,	O
suggesting	O
a	O
role	O
for	O
β-catenin	S-GP
signaling	O
in	O
the	O
dysregulation	O
of	O
Dlk1	S-GP
-	O
Dio3	S-GP
ncRNAs	O
.	O
The	O
carcinogenic	O
relevance	O
of	O
Dlk1	S-GP
-	O
Dio3	S-GP
locus	O
ncRNA	O
induction	O
was	O
further	O
supported	O
by	O
in	O
vivo	O
genetic	O
dependence	O
on	O
constitutive	B-GP
androstane	I-GP
receptor	E-GP
and	O
β-catenin	S-GP
pathways	O
.	O
Our	O
data	O
identify	O
Dlk1	S-GP
-	O
Dio3	S-GP
ncRNAs	O
as	O
novel	O
candidate	O
early	O
biomarkers	O
for	O
mouse	O
liver	O
tumor	O
promotion	O
and	O
provide	O
new	O
opportunities	O
for	O
assessing	O
the	O
carcinogenic	O
potential	O
of	O
novel	O
compounds	O
.	O

The	O
S349T	S-GP
mutation	O
of	O
SQSTM1	S-GP
links	O
Keap1	S-GP
/	O
Nrf2	S-GP
signalling	O
to	O
Paget	O
's	O
disease	O
of	O
bone	O
.	O
Mutations	O
affecting	O
the	O
Sequestosome	B-GP
1	E-GP
(	O
SQSTM1	S-GP
)	O
gene	O
commonly	O
occur	O
in	O
patients	O
with	O
the	O
skeletal	O
disorder	O
Paget	O
's	O
disease	O
of	O
bone	O
(	O
PDB	O
)	O
,	O
a	O
condition	O
characterised	O
by	O
defective	O
osteoclast	O
differentiation	O
and	O
function	O
.	O
Whilst	O
most	O
mutations	O
cluster	O
within	O
the	O
ubiquitin-associated	B-GP
(	I-GP
UBA	I-GP
)	I-GP
domain	E-GP
of	O
the	O
SQSTM1	S-GP
protein	O
,	O
and	O
are	O
associated	O
with	O
dysregulated	O
NFκB	S-GP
signalling	O
,	O
several	O
non-	O
UBA	B-GP
domain	E-GP
mutations	O
have	O
also	O
been	O
identified	O
.	O
Keap1	S-GP
is	O
a	O
SQSTM1	S-GP
-interacting	O
protein	O
that	O
regulates	O
the	O
levels	O
and	O
activity	O
of	O
the	O
Nrf2	S-GP
transcription	O
factor	O
.	O
This	O
in	O
turn	O
controls	O
the	O
expression	O
of	O
numerous	O
cytoprotective	O
genes	O
that	O
contribute	O
to	O
the	O
cell	O
's	O
capacity	O
to	O
defend	O
itself	O
against	O
chemical	O
and	O
oxidative	O
stress	O
,	O
through	O
binding	O
to	O
the	O
antioxidant	B-GP
response	I-GP
element	E-GP
(	O
ARE	S-GP
)	O
.	O
The	O
PDB-associated	O
S349T	S-GP
mutation	O
maps	O
to	O
the	O
Keap1-interacting	B-GP
region	E-GP
(	O
KIR	S-GP
)	O
of	O
SQSTM1	S-GP
,	O
however	O
the	O
effects	O
of	O
PDB	O
mutant	O
SQSTM1	S-GP
on	O
Keap1	S-GP
function	O
have	O
not	O
been	O
investigated	O
.	O
Here	O
we	O
show	O
that	O
unlike	O
other	O
SQSTM1	S-GP
mutations	O
,	O
the	O
S349T	S-GP
mutation	O
results	O
in	O
neither	O
impaired	O
ubiquitin	S-GP
-binding	O
function	O
in	O
pull-down	O
assays	O
,	O
nor	O
dysregulated	O
NFκB	S-GP
signalling	O
in	O
luciferase	O
reporter	O
assays	O
.	O
Keap1	S-GP
is	O
expressed	O
in	O
differentiating	O
osteoclast-like	O
cells	O
and	O
the	O
S349T	S-GP
mutation	O
selectively	O
impairs	O
the	O
SQSTM1	S-GP
-	O
Keap1	S-GP
interaction	O
in	O
co-immunoprecipitations	O
,	O
which	O
molecular	O
modelling	O
indicates	O
results	O
from	O
effects	O
on	O
critical	O
hydrogen	S-chemical
bonds	O
required	O
to	O
stabilise	O
the	O
KIR	S-GP
-	O
Keap1	S-GP
complex	O
.	O
Further	O
,	O
S349T	S-GP
mutant	O
SQSTM1	S-GP
,	O
but	O
not	O
other	O
PDB-associated	O
mutants	O
,	O
showed	O
reduced	O
ability	O
to	O
activate	O
Nrf2	S-GP
signalling	O
as	O
assessed	O
by	O
ARE	S-GP
-luciferase	O
reporter	O
assays	O
.	O
Thus	O
,	O
SQSTM1	S-GP
-mediated	O
dysregulation	O
of	O
the	O
Keap1	S-GP
-	O
Nrf2	S-GP
axis	O
,	O
which	O
could	O
potentially	O
lead	O
to	O
aberrant	O
production	O
of	O
oxidative	O
response	O
genes	O
,	O
may	O
contribute	O
to	O
disease	O
aetiology	O
in	O
a	O
subset	O
of	O
PDB	O
patients	O
.	O

Current	O
and	O
future	O
prospects	O
for	O
anticoagulant	O
therapy	O
:	O
inhibitors	O
of	O
factor	B-GP
Xa	E-GP
and	O
factor	B-GP
IIa	E-GP
.	O
Indirect	O
systemic	O
and	O
direct	O
oral	O
factor	O
Xa	O
and	O
direct	O
oral	O
factor	B-GP
IIa	E-GP
inhibitors	O
with	O
improved	O
pharmacologic	O
profiles	O
compared	O
with	O
heparins	O
and	O
vitamin	B-chemical
K	E-chemical
antagonists	O
are	O
currently	O
in	O
clinical	O
development	O
.	O
This	O
overview	O
focuses	O
on	O
the	O
indirect	O
antithrombin	O
dependent	O
pentasaccharide	S-chemical
derivatives	O
of	O
idraparinux	S-chemical
and	O
on	O
the	O
most	O
advanced	O
oral	O
direct	O
inhibitors	O
to	O
factor	B-GP
Xa	E-GP
(	O
rivaroxaban	S-chemical
and	O
apixaban	S-chemical
)	O
and	O
IIa	O
(	O
dabigatran	S-chemical
)	O
.	O
Specifically	O
,	O
the	O
results	O
of	O
dose-finding	O
studies	O
for	O
the	O
prevention	O
of	O
venous	O
thromboembolism	O
after	O
elective	O
orthopedic	O
surgery	O
,	O
the	O
results	O
of	O
dose-finding	O
studies	O
for	O
treatment	O
of	O
acute	O
venous	O
thromboembolism	O
including	O
prolonged	O
prophylaxis	O
of	O
recurrent	O
events	O
,	O
and	O
the	O
designs	O
of	O
ongoing	O
clinical	O
trials	O
are	O
reviewed	O
.	O

Ramelteon	S-chemical
:	O
a	O
novel	O
hypnotic	O
lacking	O
abuse	O
liability	O
and	O
sedative	O
adverse	O
effects	O
.	O
CONTEXT	O
:	O
Ramelteon	S-chemical
is	O
a	O
novel	O
MT1	S-GP
and	O
MT2	B-GP
melatonin	I-GP
receptor	E-GP
selective	O
agonist	O
recently	O
approved	O
for	O
insomnia	O
treatment	O
.	O
Most	O
approved	O
insomnia	O
medications	O
have	O
potential	O
for	O
abuse	O
and	O
cause	O
motor	O
and	O
cognitive	O
impairment	O
.	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
potential	O
for	O
abuse	O
,	O
subjective	O
effects	O
,	O
and	O
motor	O
and	O
cognitive-impairing	O
effects	O
of	O
ramelteon	S-chemical
compared	O
with	O
triazolam	S-chemical
,	O
a	O
classic	O
benzodiazepine	S-chemical
sedative-hypnotic	O
drug	O
.	O
DESIGN	O
:	O
In	O
this	O
double-blind	O
crossover	O
study	O
,	O
each	O
participant	O
received	O
oral	O
doses	O
of	O
ramelteon	S-chemical
(	O
16	O
,	O
80	O
,	O
or	O
160	O
mg	O
)	O
,	O
triazolam	S-chemical
(	O
0.25	O
,	O
0.5	O
,	O
or	O
0.75	O
mg	O
)	O
,	O
and	O
placebo	O
during	O
approximately	O
18	O
days	O
.	O
All	O
participants	O
received	O
each	O
treatment	O
on	O
different	O
days	O
.	O
Most	O
outcome	O
measures	O
were	O
assessed	O
at	O
0.5	O
hours	O
before	O
drug	O
administration	O
and	O
repeatedly	O
up	O
to	O
24	O
hours	O
after	O
drug	O
administration	O
.	O
SETTING	O
:	O
Residential	O
research	O
facility	O
.	O
PARTICIPANTS	O
:	O
Fourteen	O
adults	O
with	O
histories	O
of	O
sedative	O
abuse	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Subject-rated	O
measures	O
included	O
items	O
relevant	O
to	O
potential	O
for	O
abuse	O
(	O
eg	O
,	O
drug	O
liking	O
,	O
street	O
value	O
,	O
and	O
pharmacological	O
classification	O
)	O
,	O
as	O
well	O
as	O
assessments	O
of	O
a	O
broad	O
range	O
of	O
stimulant	O
and	O
sedative	O
subjective	O
effects	O
.	O
Observer-rated	O
measures	O
included	O
assessments	O
of	O
sedation	O
and	O
impairment	O
.	O
Motor	O
and	O
cognitive	O
performance	O
measures	O
included	O
psychomotor	O
and	O
memory	O
tasks	O
and	O
a	O
standing	O
balance	O
task	O
.	O
RESULTS	O
:	O
Compared	O
with	O
placebo	O
,	O
ramelteon	S-chemical
(	O
16	O
,	O
80	O
,	O
and	O
160	O
mg	O
)	O
showed	O
no	O
significant	O
effect	O
on	O
any	O
of	O
the	O
subjective	O
effect	O
measures	O
,	O
including	O
those	O
related	O
to	O
potential	O
for	O
abuse	O
.	O
In	O
the	O
pharmacological	O
classification	O
,	O
79	O
%	O
(	O
11/14	O
)	O
of	O
subjects	O
identified	O
the	O
highest	O
dose	O
of	O
ramelteon	S-chemical
as	O
placebo	O
.	O
Similarly	O
,	O
compared	O
with	O
placebo	O
,	O
ramelteon	S-chemical
had	O
no	O
effect	O
at	O
any	O
dose	O
on	O
any	O
observer-rated	O
or	O
motor	O
and	O
cognitive	O
performance	O
measure	O
.	O
In	O
contrast	O
,	O
triazolam	S-chemical
showed	O
dose-related	O
effects	O
on	O
a	O
wide	O
range	O
of	O
subject-rated	O
,	O
observer-rated	O
,	O
and	O
motor	O
and	O
cognitive	O
performance	O
measures	O
,	O
consistent	O
with	O
its	O
profile	O
as	O
a	O
sedative	O
drug	O
with	O
abuse	O
liability	O
.	O
CONCLUSION	O
:	O
Ramelteon	S-chemical
demonstrated	O
no	O
significant	O
effects	O
indicative	O
of	O
potential	O
for	O
abuse	O
or	O
motor	O
and	O
cognitive	O
impairment	O
at	O
up	O
to	O
20	O
times	O
the	O
recommended	O
therapeutic	O
dose	O
and	O
may	O
represent	O
a	O
useful	O
alternative	O
to	O
existing	O
insomnia	O
medications	O
.	O

Four	O
new	O
eudesmane	S-chemical
-type	O
sesquiterpenoid	B-chemical
lactones	E-chemical
from	O
atractylenolide	B-chemical
II	E-chemical
by	O
biotransformation	O
of	O
rat	O
hepatic	O
microsomes	O
.	O
The	O
biotransformation	O
of	O
atractylenolide	B-chemical
II	E-chemical
,	O
a	O
major	O
bioactive	O
principle	O
of	O
the	O
rhizomes	O
of	O
Atractylodes	O
macrocephala	O
Koidz.	O
,	O
was	O
investigated	O
in	O
vitro	O
by	O
incubation	O
with	O
rat	O
hepatic	O
microsomes	O
pretreated	O
with	O
sodium	B-chemical
phenobarbital	E-chemical
.	O
The	O
biotransformation	O
products	O
were	O
extracted	O
and	O
purified	O
by	O
chromatographic	O
methods	O
.	O
Seven	O
biotransformation	O
products	O
(	O
BP1-BP7	O
)	O
were	O
obtained	O
and	O
their	O
structures	O
were	O
elucidated	O
by	O
NMR	O
and	O
MS	O
data	O
analyses	O
and	O
by	O
comparison	O
with	O
the	O
previously	O
reported	O
values	O
,	O
including	O
four	O
new	O
compounds	O
,	O
namely	O
4	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
,15-epoxy-atractylenolide	I-chemical
II	E-chemical
(	O
BP1	O
)	O
,	O
4	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
,15-epoxy-13-hydroxyatractylenolide	I-chemical
II	E-chemical
(	O
BP5	O
)	O
,	O
4	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
,15-epoxy-1β-hydroxyatractylenolide	I-chemical
II	E-chemical
(	O
BP6	O
)	O
,	O
and	O
4	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
,15-dihydroxyatractylenolide	I-chemical
II	E-chemical
(	O
BP7	O
)	O
.	O
The	O
biotransformation	O
pathway	O
of	O
atractylenolide	B-chemical
II	E-chemical
by	O
hepatic	O
microsomes	O
was	O
deducted	O
based	O
on	O
the	O
structure	O
resolution	O
of	O
the	O
products	O
.	O

Synthesis	O
of	O
derivatives	O
of	O
methyl	B-chemical
rosmarinate	E-chemical
and	O
their	O
inhibitory	O
activities	O
against	O
matrix	B-GP
metalloproteinase-1	E-GP
(	O
MMP-1	S-GP
)	O
.	O
A	O
series	O
of	O
MMP-1	S-GP
inhibitors	O
have	O
been	O
identified	O
based	O
upon	O
a	O
methyl	B-chemical
rosmarinate	E-chemical
scaffold	O
using	O
structure-based	O
drug	O
design	O
methods	O
.	O
The	O
best	O
compound	O
in	O
the	O
series	O
showed	O
an	O
IC50	O
value	O
of	O
0.4	O
μM	O
.	O
A	O
docking	O
study	O
was	O
conducted	O
for	O
compound	O
(	O
S	O
)	O
-10n	O
in	O
order	O
to	O
investigate	O
its	O
binding	O
interactions	O
with	O
MMP-1	S-GP
.	O
The	O
structure-activity	O
relationships	O
(	O
SAR	O
)	O
were	O
also	O
briefly	O
discussed	O
.	O
Useful	O
SAR	O
was	O
established	O
which	O
provides	O
important	O
guidelines	O
for	O
the	O
design	O
of	O
future	O
generations	O
of	O
potent	O
inhibitors	O
against	O
MMP-1	S-GP
.	O

Regulation	O
of	O
gluconeogenesis	O
by	O
Kruppel-like	B-GP
factor	I-GP
15	E-GP
.	O
In	O
the	O
postabsorptive	O
state	O
,	O
certain	O
tissues	O
,	O
including	O
the	O
brain	O
,	O
require	O
glucose	S-chemical
as	O
the	O
sole	O
source	O
of	O
energy	O
.	O
After	O
an	O
overnight	O
fast	O
,	O
hepatic	O
glycogen	O
stores	O
are	O
depleted	O
,	O
and	O
gluconeogenesis	O
becomes	O
essential	O
for	O
preventing	O
life-threatening	O
hypoglycemia	O
.	O
Mice	O
with	O
a	O
targeted	O
deletion	O
of	O
KLF15	S-GP
,	O
a	O
member	O
of	O
the	O
Kruppel-like	S-GP
family	O
of	O
transcription	O
factors	O
,	O
display	O
severe	O
hypoglycemia	O
after	O
an	O
overnight	O
(	O
18	O
hr	O
)	O
fast	O
.	O
We	O
provide	O
evidence	O
that	O
defective	O
amino	B-chemical
acid	E-chemical
catabolism	O
promotes	O
the	O
development	O
of	O
fasting	O
hypoglycemia	O
in	O
KLF15	S-GP
-/-	O
mice	O
by	O
limiting	O
gluconeogenic	O
substrate	O
availability	O
.	O
KLF15	S-GP
-/-	O
liver	O
and	O
skeletal	O
muscle	O
show	O
markedly	O
reduced	O
mRNA	O
expression	O
of	O
amino	B-chemical
acid	E-chemical
-degrading	O
enzymes	O
.	O
Furthermore	O
,	O
the	O
enzymatic	O
activity	O
of	O
alanine	B-GP
aminotransferase	E-GP
(	O
ALT	S-GP
)	O
,	O
which	O
converts	O
the	O
critical	O
gluconeogenic	O
amino	B-chemical
acid	E-chemical
alanine	S-chemical
into	O
pyruvate	S-chemical
,	O
is	O
decreased	O
(	O
approximately	O
50	O
%	O
)	O
in	O
KLF15	S-GP
-/-	O
hepatocytes	O
.	O
Consistent	O
with	O
this	O
observation	O
,	O
intraperitoneal	O
injection	O
of	O
pyruvate	S-chemical
,	O
but	O
not	O
alanine	S-chemical
,	O
rescues	O
fasting	O
hypoglycemia	O
in	O
KLF15	S-GP
-/-	O
mice	O
.	O
We	O
conclude	O
that	O
KLF15	S-GP
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gluconeogenesis	O
.	O

A	O
low	O
toxicity	O
maintenance	O
regime	O
,	O
using	O
eicosapentaenoic	B-chemical
acid	E-chemical
and	O
readily	O
available	O
drugs	O
,	O
for	O
mantle	O
cell	O
lymphoma	O
and	O
other	O
malignancies	O
with	O
excess	O
cyclin	B-GP
D1	E-GP
levels	O
.	O
Mantle	O
cell	O
lymphoma	O
is	O
a	O
difficult	O
to	O
treat	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
whose	O
biochemistry	O
is	O
unusually	O
well	O
characterised	O
.	O
Almost	O
all	O
and	O
perhaps	O
all	O
patients	O
overexpress	O
the	O
cyclin	B-GP
D1	E-GP
protein	O
which	O
is	O
crucial	O
in	O
driving	O
cells	O
from	O
the	O
G1	O
to	O
the	O
S	O
phase	O
.	O
This	O
overexpression	O
may	O
be	O
responsible	O
for	O
the	O
refractoriness	O
.	O
Despite	O
this	O
understanding	O
,	O
treatments	O
for	O
mantle	O
cell	O
lymphoma	O
are	O
based	O
on	O
standard	O
NHL	O
regimes	O
of	O
cyclophosphamide	S-chemical
,	O
doxorubicin	S-chemical
,	O
vincristine	S-chemical
and	O
prednisone	S-chemical
,	O
perhaps	O
supplemented	O
with	O
the	O
monoclonal	O
antibody	O
rituximab	O
.	O
There	O
has	O
never	O
been	O
any	O
attempt	O
to	O
direct	O
treatment	O
to	O
the	O
cyclin	B-GP
D1	E-GP
mechanism	O
or	O
to	O
angiogenesis	O
which	O
is	O
now	O
known	O
to	O
be	O
important	O
in	O
all	O
lymphomas	O
.	O
Both	O
these	O
targets	O
lend	O
themselves	O
to	O
long-term	O
maintenance	O
regimes	O
of	O
relatively	O
low	O
toxicity	O
which	O
can	O
be	O
used	O
as	O
adjuvants	O
to	O
standard	O
therapy	O
.	O
Agents	O
which	O
have	O
recently	O
been	O
shown	O
to	O
block	O
cyclin	B-GP
D1	E-GP
translation	O
by	O
regulating	O
calcium	O
levels	O
are	O
the	O
unsaturated	B-chemical
essential	I-chemical
fatty	I-chemical
acid	E-chemical
,	O
eicosapentaenoic	B-chemical
acid	E-chemical
(	O
EPA	S-chemical
)	O
,	O
the	O
antidiabetic	O
thiazolidinediones	S-chemical
,	O
and	O
the	O
antifungal	O
agent	O
,	O
clotrimazole	S-chemical
.	O
Two	O
types	O
of	O
agent	O
which	O
have	O
been	O
shown	O
to	O
inhibit	O
angiogenesis	O
are	O
the	O
teratogen	O
,	O
thalidomide	S-chemical
,	O
and	O
the	O
selective	O
inhibitors	O
of	O
cyclo-oxygenase	B-GP
2	E-GP
(	O
COX-2	S-GP
)	O
.	O
Retinoids	S-chemical
exert	O
synergistic	O
effects	O
with	O
EPA	S-chemical
and	O
have	O
been	O
shown	O
to	O
inhibit	O
both	O
tumour	O
growth	O
and	O
angiogenesis	O
.	O
The	O
mechanisms	O
of	O
action	O
of	O
these	O
various	O
agents	O
are	O
discussed	O
,	O
and	O
specific	O
suggestions	O
are	O
made	O
for	O
low	O
toxicity	O
maintenance	O
therapy	O
of	O
mantle	O
cell	O
lymphoma	O
and	O
of	O
other	O
tumours	O
which	O
overexpress	O
cyclin	B-GP
D1	E-GP
.	O

A	O
unique	O
cytosolic	O
activity	O
related	O
but	O
distinct	O
from	O
NQO1	S-GP
catalyses	O
metabolic	O
activation	O
of	O
mitomycin	B-chemical
C	E-chemical
.	O
Mitomycin	B-chemical
C	E-chemical
(	O
MMC	S-chemical
)	O
is	O
a	O
prototype	O
bioreductive	O
drug	O
employed	O
to	O
treat	O
a	O
variety	O
of	O
cancers	O
including	O
head	O
and	O
neck	O
cancer	O
.	O
Among	O
the	O
various	O
enzymes	O
,	O
dicoumarol	S-chemical
inhibitable	O
cytosolic	O
NAD	B-GP
(	I-GP
P	I-GP
)	I-GP
H	I-GP
:	I-GP
quinone	I-GP
oxidoreductase1	E-GP
(	O
NQO1	S-GP
)	O
was	O
shown	O
to	O
catalyse	O
bioreductive	O
activation	O
of	O
MMC	S-chemical
leading	O
to	O
cross-linking	O
of	O
the	O
DNA	O
and	O
cytotoxicity	O
.	O
However	O
,	O
the	O
role	O
of	O
NQO1	S-GP
in	O
metabolic	O
activation	O
of	O
MMC	S-chemical
has	O
been	O
disputed	O
.	O
In	O
this	O
report	O
,	O
we	O
present	O
cellular	O
and	O
animal	O
models	O
to	O
demonstrate	O
that	O
NQO1	S-GP
may	O
play	O
only	O
a	O
minor	O
role	O
in	O
metabolic	O
activation	O
of	O
MMC	S-chemical
.	O
We	O
further	O
demonstrate	O
that	O
bioreductive	O
activation	O
of	O
MMC	S-chemical
is	O
catalysed	O
by	O
a	O
unique	O
cytosolic	O
activity	O
which	O
is	O
related	O
but	O
distinct	O
from	O
NQO1	S-GP
.	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
were	O
developed	O
that	O
permanently	O
express	O
higher	O
levels	O
of	O
cDNA-derived	O
NQO1	S-GP
.	O
These	O
cells	O
showed	O
significantly	O
increased	O
protection	O
against	O
menadione	S-chemical
toxicity	O
.	O
However	O
,	O
they	O
failed	O
to	O
demonstrate	O
higher	O
cytotoxicity	O
due	O
to	O
exposure	O
to	O
MMC	S-chemical
under	O
oxygen	S-chemical
(	O
normal	O
air	O
)	O
or	O
hypoxia	O
,	O
as	O
compared	O
to	O
the	O
wild-type	O
control	O
CHO	O
cells	O
.	O
Disruption	O
of	O
the	O
NQO1	S-GP
gene	O
by	O
homologous	O
recombination	O
generated	O
NQO1	S-GP
-/-	O
mice	O
that	O
do	O
not	O
express	O
the	O
NQO1	S-GP
gene	O
resulting	O
in	O
the	O
loss	O
of	O
NQO1	S-GP
protein	O
and	O
activity	O
.	O
The	O
cytosolic	O
fractions	O
from	O
liver	O
and	O
colon	O
tissues	O
of	O
NQO1	S-GP
-/-	O
mice	O
showed	O
similar	O
amounts	O
of	O
DNA	O
cross-linking	O
upon	O
exposure	O
to	O
MMC	S-chemical
,	O
as	O
observed	O
in	O
NQO1	S-GP
+/+	O
mice	O
.	O
The	O
unique	O
cytosolic	O
activity	O
that	O
activated	O
MMC	S-chemical
in	O
cytosolic	O
fractions	O
of	O
liver	O
and	O
colon	O
tissues	O
of	O
NQO1	S-GP
-/-	O
mice	O
was	O
designated	O
as	O
cytosolic	O
MMC	B-GP
reductase	E-GP
.	O
This	O
activity	O
,	O
like	O
NQO1	S-GP
,	O
was	O
inhibited	O
by	O
dicoumarol	S-chemical
and	O
immunologically	O
related	O
to	O
NQO1	S-GP
.	O

Characterization	O
of	O
beta	B-GP
3-adrenoceptor	E-GP
-mediated	O
relaxation	O
in	O
rat	O
abdominal	O
aorta	O
smooth	O
muscle	O
.	O
The	O
present	O
study	O
was	O
carried	O
out	O
to	O
characterize	O
beta-adrenoceptor	S-GP
subtypes	O
mediating	O
relaxation	O
of	O
rat	O
abdominal	O
aorta	O
smooth	O
muscle	O
.	O
(	B-chemical
-	I-chemical
)	I-chemical
-Isoprenaline	E-chemical
and	O
a	O
nonconventional	O
beta	B-GP
(	I-GP
3	I-GP
)	I-GP
-adrenoceptor	E-GP
agonist	O
,	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-	I-chemical
[	I-chemical
4-	I-chemical
[	I-chemical
3-	I-chemical
[	I-chemical
(	I-chemical
1,1-dimethylethyl	I-chemical
)	I-chemical
amino	I-chemical
]	I-chemical
-2-hydroxypropoxy	I-chemical
]	I-chemical
-1,3-dihydro-2H-benzimida	I-chemical
zol-2-one	I-chemical
]	I-chemical
hydrochloride	E-chemical
(	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-CGP12177A	E-chemical
)	O
,	O
induced	O
concentration-dependent	O
relaxation	O
of	O
(	B-chemical
-	I-chemical
)	I-chemical
-phenylephrine	E-chemical
(	O
0.3	O
microM	O
)	O
preconstricted	O
spiral	O
preparations	O
.	O
Pretreatment	O
with	O
a	O
combination	O
of	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-2-hydroxy-5-	I-chemical
[	I-chemical
2-	I-chemical
[	I-chemical
[	I-chemical
2-hydroxy-3-	I-chemical
[	I-chemical
4-	I-chemical
[	I-chemical
1-methyl-4-	I-chemical
(	I-chemical
trifluoromethyl	I-chemical
)	I-chemical
-1H-imidazol-2	I-chemical
-yl	I-chemical
]	I-chemical
phenoxy	I-chemical
]	I-chemical
propyl	I-chemical
]	I-chemical
amino	I-chemical
]	I-chemical
ethoxy	I-chemical
]	I-chemical
-benzamide	I-chemical
methanesulfonate	E-chemical
(	O
CGP20712A	S-chemical
,	O
a	O
selective	O
beta	B-GP
(	I-GP
1	I-GP
)	I-GP
-adrenoceptor	E-GP
antagonist	O
)	O
and	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-1-	I-chemical
[	I-chemical
2,3-	I-chemical
(	I-chemical
dihydro-7-methyl-1H-inden-4-yl	I-chemical
)	I-chemical
oxy	I-chemical
]	I-chemical
-3-	I-chemical
[	I-chemical
(	I-chemical
1-methylethyl	I-chemical
)	I-chemical
amino	I-chemical
]	I-chemical
-2-buta	I-chemical
nol	I-chemical
hydrochloride	E-chemical
(	O
ICI-118,5511	S-chemical
,	O
a	O
selective	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenoceptor	E-GP
antagonist	O
)	O
(	O
0.1	O
microM	O
for	O
each	O
)	O
produced	O
a	O
14-fold	O
rightward	O
shift	O
of	O
the	O
concentration-response	O
curve	O
for	O
(	B-chemical
-	I-chemical
)	I-chemical
-isoprenaline	E-chemical
;	O
however	O
,	O
the	O
relaxation	O
in	O
response	O
to	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-CGP12177A	E-chemical
was	O
unaffected	O
by	O
the	O
blockade	O
of	O
beta	B-GP
(	I-GP
1	I-GP
)	I-GP
-	I-GP
and	I-GP
beta	I-GP
(	I-GP
2	I-GP
)	I-GP
-adrenoceptors	E-GP
.	O
In	O
the	O
presence	O
of	O
CGP20712A	S-chemical
and	O
ICI-118,551	S-chemical
(	O
0.1	O
microM	O
for	O
each	O
)	O
,	O
the	O
concentration-response	O
curves	O
for	O
(	B-chemical
-	I-chemical
)	I-chemical
-isoprenaline	E-chemical
and	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-CGP12177A	E-chemical
were	O
shifted	O
to	O
the	O
right	O
by	O
a	O
nonselective	O
beta	B-GP
(	I-GP
1	I-GP
)	I-GP
-	I-GP
,	I-GP
beta	I-GP
(	I-GP
2	I-GP
)	I-GP
-	I-GP
and	I-GP
beta	I-GP
(	I-GP
3	I-GP
)	I-GP
-adrenoceptor	E-GP
antagonist	O
,	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-bupranolol	E-chemical
(	O
3	O
and	O
10	O
microM	O
)	O
.	O
These	O
results	O
clearly	O
suggest	O
that	O
beta	B-GP
(	I-GP
3	I-GP
)	I-GP
-adrenoceptors	E-GP
are	O
involved	O
in	O
beta-adrenoceptor	S-GP
-mediated	O
relaxation	O
of	O
rat	O
abdominal	O
aorta	O
smooth	O
muscle	O
.	O

Determination	O
of	O
dimethylarginine	B-GP
dimethylaminohydrolase	E-GP
activity	O
in	O
the	O
kidney	O
.	O
Dimethylarginine	B-GP
dimethylaminohydrolase	E-GP
(	O
DDAH	S-GP
)	O
metabolizes	O
asymmetric	O
dimethylarginine	S-chemical
to	O
generate	O
L-citrulline	S-chemical
and	O
is	O
present	O
in	O
large	O
quantities	O
in	O
the	O
kidney	O
.	O
We	O
present	O
a	O
new	O
study	O
that	O
optimizes	O
the	O
Prescott-Jones	O
colorimetric	O
assay	O
to	O
measure	O
DDAH	S-GP
-dependent	O
L-citrulline	S-chemical
generation	O
in	O
kidney	O
homogenates	O
.	O
We	O
found	O
that	O
the	O
removal	O
of	O
urea	S-chemical
with	O
urease	S-GP
is	O
necessary	O
since	O
urea	S-chemical
also	O
produces	O
a	O
positive	O
reaction	O
.	O
Deproteinization	O
with	O
sulfosalicylic	B-chemical
acid	E-chemical
was	O
found	O
to	O
be	O
optimal	O
and	O
that	O
protease	S-GP
inhibitors	O
were	O
not	O
necessary	O
.	O
All	O
assays	O
were	O
conducted	O
in	O
phosphate	S-chemical
buffer	O
,	O
since	O
other	O
common	O
additives	O
can	O
create	O
false	O
positive	O
and	O
false	O
negative	O
reactions	O
.	O
Arginase	S-GP
or	O
nitric	B-GP
oxide	I-GP
synthase	E-GP
isoenzymes	O
were	O
not	O
found	O
to	O
influence	O
L-citrulline	S-chemical
production	O
.	O
Our	O
optimized	O
L-citrulline	S-chemical
production	O
assay	O
to	O
measure	O
DDAH	S-GP
activity	O
correlated	O
closely	O
with	O
the	O
direct	O
measure	O
of	O
the	O
rate	O
of	O
asymmetric	O
dimethylarginine	S-chemical
consumption	O
.	O
Using	O
this	O
assay	O
,	O
we	O
found	O
that	O
both	O
superoxide	S-chemical
and	O
nitric	B-chemical
oxide	E-chemical
inhibit	O
renal	O
cortical	O
DDAH	S-GP
activity	O
in	O
vitro	O
.	O

The	O
role	O
of	O
glutathione	B-GP
transferases	I-GP
M1	I-GP
and	I-GP
T1	E-GP
in	O
individual	O
susceptibility	O
to	O
bladder	O
cancer	O
in	O
a	O
Tunisian	O
population	O
.	O
BACKGROUND	O
:	O
Susceptibility	O
to	O
bladder	O
cancer	O
is	O
thought	O
to	O
depend	O
on	O
interplay	O
between	O
genetic	O
factors	O
and	O
environmental	O
chemical	O
carcinogens	O
.	O
AIM	O
:	O
This	O
study	O
seeks	O
to	O
determine	O
the	O
role	O
of	O
the	O
glutathione	B-GP
transferases	I-GP
M1	I-GP
and	I-GP
T1	E-GP
null	O
genotypes	O
(	O
GSTM1	S-GP
*0	O
and	O
GSTT1	S-GP
*0	O
)	O
in	O
individual	O
susceptibility	O
to	O
bladder	O
cancer	O
in	O
a	O
Tunisian	O
population	O
.	O
METHOD	O
:	O
Sixty-two	O
patients	O
with	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
bladder	O
cancer	O
and	O
79	O
controls	O
were	O
examined	O
with	O
respect	O
to	O
the	O
frequency	O
of	O
GSTM1	S-GP
and	O
GSTT1	S-GP
null	O
genotypes	O
.	O
RESULTS	O
:	O
The	O
frequencies	O
of	O
the	O
GSTT1	S-GP
null	O
in	O
the	O
total	O
group	O
of	O
bladder	O
cancer	O
cases	O
vs.	O
controls	O
did	O
not	O
differ	O
statistically	O
.	O
The	O
proportion	O
of	O
GSTM1	S-GP
null	O
genotype	O
in	O
patients	O
was	O
63	O
%	O
compared	O
to	O
45	O
%	O
in	O
controls	O
group	O
(	O
OR	O
=	O
2.03	O
;	O
95	O
%	O
CI	O
0.97-4.24	O
;	O
p	O
=	O
0.04	O
)	O
.	O
A	O
significantly	O
higher	O
incidence	O
of	O
GSTM1	S-GP
deletion	O
genotype	O
was	O
found	O
in	O
smokers	O
with	O
bladder	O
cancer	O
compared	O
to	O
the	O
controls	O
(	O
65.38	O
%	O
vs.	O
45.5	O
%	O
)	O
.	O
Smokers	O
lacking	O
the	O
GSTM1	S-GP
gene	O
are	O
at	O
an	O
approximately	O
2.2-fold	O
higher	O
risk	O
of	O
bladder	O
cancer	O
(	O
OR=	O
2.23	O
,	O
95	O
%	O
CI	O
1-5.15	O
;	O
p	O
=	O
0.03	O
)	O
.	O
CONCLUSION	O
:	O
This	O
study	O
suggests	O
that	O
in	O
Tunisian	O
subjects	O
the	O
GSTM1	S-GP
null	O
genotype	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
bladder	O
cancer	O
.	O
This	O
association	O
appears	O
to	O
depend	O
upon	O
smoking	O
status	O
.	O

Caffeic	B-chemical
acid	E-chemical
treatment	O
alters	O
the	O
extracellular	O
adenine	B-chemical
nucleotide	E-chemical
hydrolysis	O
in	O
platelets	O
and	O
lymphocytes	O
of	O
adult	O
rats	O
.	O
This	O
study	O
evaluated	O
the	O
effects	O
of	O
caffeic	B-chemical
acid	E-chemical
on	O
ectonucleotidase	O
activities	O
such	O
as	O
NTPDase	S-GP
(	O
nucleoside	B-GP
triphosphate	I-GP
diphosphohydrolase	E-GP
)	O
,	O
Ecto-NPP	B-GP
(	I-GP
nucleotide	I-GP
pyrophosphatase/phosphodiesterase	I-GP
)	E-GP
,	O
5'-nucleotidase	S-GP
and	O
adenosine	B-GP
deaminase	E-GP
(	O
ADA	S-GP
)	O
in	O
platelets	O
and	O
lymphocytes	O
of	O
rats	O
,	O
as	O
well	O
as	O
in	O
the	O
profile	O
of	O
platelet	O
aggregation	O
.	O
Animals	O
were	O
divided	O
into	O
five	O
groups	O
:	O
I	O
(	O
control	O
)	O
;	O
II	O
(	O
oil	O
)	O
;	O
III	O
(	O
caffeic	B-chemical
acid	E-chemical
10mg/kg	O
)	O
;	O
IV	O
(	O
caffeic	B-chemical
acid	E-chemical
50mg/kg	O
)	O
;	O
and	O
V	O
(	O
caffeic	B-chemical
acid	E-chemical
100mg/kg	O
)	O
.	O
Animals	O
were	O
treated	O
with	O
caffeic	B-chemical
acid	E-chemical
diluted	O
in	O
oil	O
for	O
30days	O
.	O
In	O
platelets	O
,	O
caffeic	B-chemical
acid	E-chemical
decreased	O
the	O
ATP	S-chemical
hydrolysis	O
and	O
increased	O
ADP	S-chemical
hydrolysis	O
in	O
groups	O
III	O
,	O
IV	O
and	O
V	O
when	O
compared	O
to	O
control	O
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
5'-nucleotidase	O
activity	O
was	O
decreased	O
,	O
while	O
E-NPP	S-GP
and	O
ADA	S-GP
activities	O
were	O
increased	O
in	O
platelets	O
of	O
rats	O
of	O
groups	O
III	O
,	O
IV	O
and	O
V	O
(	O
P	O
<	O
0.05	O
)	O
.	O
Caffeic	B-chemical
acid	E-chemical
reduced	O
significantly	O
the	O
platelet	O
aggregation	O
in	O
the	O
animals	O
of	O
groups	O
III	O
,	O
IV	O
and	O
V	O
in	O
relation	O
to	O
group	O
I	O
(	O
P	O
<	O
0.05	O
)	O
.	O
In	O
lymphocytes	O
,	O
the	O
NTPDase	S-GP
and	O
ADA	S-GP
activities	O
were	O
increased	O
in	O
all	O
groups	O
treated	O
with	O
caffeic	B-chemical
acid	E-chemical
when	O
compared	O
to	O
control	O
(	O
P	O
<	O
0.05	O
)	O
.	O
These	O
findings	O
demonstrated	O
that	O
the	O
enzymes	O
were	O
altered	O
in	O
tissues	O
by	O
caffeic	B-chemical
acid	E-chemical
and	O
this	O
compound	O
decreased	O
the	O
platelet	O
aggregation	O
suggesting	O
that	O
caffeic	B-chemical
acid	E-chemical
should	O
be	O
considered	O
a	O
potentially	O
therapeutic	O
agent	O
in	O
disorders	O
related	O
to	O
the	O
purinergic	O
system	O
.	O

Atorvastatin	S-chemical
withdrawal	O
elicits	O
oxidative/nitrosative	O
damage	O
in	O
the	O
rat	O
cerebral	O
cortex	O
.	O
Statins	O
are	O
inhibitors	O
of	O
the	O
enzyme	O
3-hydroxy-3-methylglutaryl	B-GP
coenzyme	I-GP
A	I-GP
reductase	E-GP
,	O
the	O
rate-limiting	O
step	O
in	O
cholesterol	S-chemical
biosynthesis	O
.	O
Statins	O
effectively	O
prevent	O
and	O
reduce	O
the	O
risk	O
of	O
coronary	O
artery	O
disease	O
through	O
lowering	O
serum	O
cholesterol	S-chemical
,	O
and	O
also	O
exert	O
anti-thrombotic	O
,	O
anti-inflammatory	O
and	O
antioxidant	O
effects	O
independently	O
of	O
changes	O
in	O
cholesterol	S-chemical
levels	O
.	O
On	O
the	O
other	O
hand	O
,	O
clinical	O
and	O
experimental	O
evidence	O
suggests	O
that	O
abrupt	O
cessation	O
of	O
statin	O
treatment	O
(	O
i.e	O
.	O
statin	O
withdrawal	O
)	O
is	O
associated	O
with	O
a	O
deleterious	O
rebound	O
phenomenon	O
.	O
In	O
fact	O
,	O
statin	O
withdrawal	O
increases	O
the	O
risk	O
of	O
thrombotic	O
vascular	O
events	O
,	O
causes	O
impairment	O
of	O
endothelium-dependent	O
relaxation	O
and	O
facilitates	O
experimental	O
seizures	O
.	O
However	O
,	O
evidence	O
for	O
statin	O
withdrawal-induced	O
detrimental	O
effects	O
to	O
the	O
brain	O
parenchyma	O
is	O
still	O
lacking	O
.	O
In	O
the	O
present	O
study	O
adult	O
male	O
Wistar	O
rats	O
were	O
treated	O
with	O
atorvastatin	S-chemical
for	O
seven	O
days	O
(	O
10mg/kg/day	O
)	O
and	O
neurochemical	O
assays	O
were	O
performed	O
in	O
the	O
cerebral	O
cortex	O
30min	O
(	O
atorvastatin	S-chemical
treatment	O
)	O
or	O
24h	O
(	O
atorvastatin	S-chemical
withdrawal	O
)	O
after	O
the	O
last	O
atorvastatin	S-chemical
administration	O
.	O
We	O
found	O
that	O
atorvastatin	S-chemical
withdrawal	O
decreased	O
levels	O
of	O
nitric	B-chemical
oxide	E-chemical
and	O
mitochondrial	B-GP
superoxide	I-GP
dismutase	E-GP
activity	O
,	O
whereas	O
increased	O
NADPH	B-GP
oxidase	E-GP
activity	O
and	O
immunoreactivity	O
for	O
the	O
protein	O
nitration	O
marker	O
3-nitrotyrosine	S-chemical
in	O
the	O
cerebral	O
cortex	O
.	O
Catalase	S-GP
,	O
glutathione-S-transferase	S-GP
and	O
xanthine	B-GP
oxidase	E-GP
activities	O
were	O
not	O
altered	O
by	O
atorvastatin	S-chemical
treatment	O
or	O
withdrawal	O
,	O
as	O
well	O
as	O
protein	O
carbonyl	S-chemical
and	O
4-hydroxy-2-nonenal	S-chemical
immunoreactivity	O
.	O
Immunoprecipitation	O
of	O
mitochondrial	B-GP
SOD	E-GP
followed	O
by	O
analysis	O
of	O
3-nitrotyrosine	S-chemical
revealed	O
increased	O
levels	O
of	O
nitrated	O
mitochondrial	B-GP
SOD	E-GP
,	O
suggesting	O
the	O
mechanism	O
underlying	O
the	O
atorvastatin	S-chemical
withdrawal-induced	O
decrease	O
in	O
enzyme	O
activity	O
.	O
Altogether	O
,	O
our	O
results	O
indicate	O
the	O
atorvastatin	S-chemical
withdrawal	O
elicits	O
oxidative/nitrosative	O
damage	O
in	O
the	O
rat	O
cerebral	O
cortex	O
,	O
and	O
that	O
changes	O
in	O
NADPH	B-GP
oxidase	E-GP
activity	O
and	O
mitochondrial	B-GP
superoxide	I-GP
dismutase	E-GP
activities	O
may	O
underlie	O
such	O
harmful	O
effects	O
.	O

2-Hydroxychalcone	S-chemical
and	O
xanthohumol	S-chemical
inhibit	O
invasion	O
of	O
triple	O
negative	O
breast	O
cancer	O
cells	O
.	O
Breast	O
cancer	O
is	O
estimated	O
as	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
cancer	O
death	O
among	O
women	O
.	O
In	O
particular	O
,	O
triple	O
negative	O
breast	O
cancers	O
(	O
TNBCs	O
)	O
,	O
which	O
do	O
not	O
express	O
the	O
genes	O
for	O
estrogen	S-chemical
/	O
progesterone	B-GP
receptors	E-GP
(	O
ER	S-GP
/	O
PR	S-GP
)	O
and	O
human	B-GP
epidermal	I-GP
growth	I-GP
factor	I-GP
receptor	I-GP
2	E-GP
(	O
HER2	S-GP
)	O
,	O
have	O
been	O
associated	O
with	O
poor	O
prognosis	O
and	O
metastasis	O
.	O
Chalcones	S-chemical
,	O
the	O
biosynthetic	O
precursors	O
of	O
flavonoids	S-chemical
present	O
in	O
edible	O
plants	O
,	O
exert	O
cytotoxic	O
and	O
chemopreventive	O
activities	O
.	O
Although	O
mounting	O
evidence	O
suggests	O
the	O
anticancer	O
properties	O
of	O
chalcones	S-chemical
,	O
limited	O
information	O
is	O
available	O
regarding	O
the	O
inhibitory	O
effects	O
of	O
chalcones	S-chemical
on	O
the	O
aggressiveness	O
of	O
breast	O
cancer	O
cells	O
.	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
chalcone	S-chemical
and	O
its	O
derivatives	O
on	O
the	O
growth	O
and	O
the	O
invasiveness	O
of	O
TNBC	O
cells	O
.	O
Here	O
,	O
we	O
showed	O
that	O
treatment	O
with	O
chalcone	S-chemical
,	O
2-hydroxychalcone	S-chemical
,	O
and	O
xanthohumol	S-chemical
for	O
24h	O
inhibited	O
the	O
growth	O
of	O
MDA-MB-231cells	O
with	O
IC50	O
values	O
of	O
18.1	O
,	O
4.6	O
,	O
and	O
6.7μM	O
,	O
respectively	O
.	O
Similarly	O
,	O
Chalcone	S-chemical
,	O
2-hydroxychalcone	S-chemical
,	O
and	O
xanthohumol	S-chemical
also	O
exerted	O
cytotoxicity	O
in	O
another	O
TNBC	O
cell	O
line	O
,	O
Hs578T	O
.	O
Neohesperidin	B-chemical
dihydrochalcone	E-chemical
,	O
4-methoxychalcone	S-chemical
,	O
and	O
hesperidin	B-chemical
methylchalcone	E-chemical
did	O
not	O
show	O
the	O
cytotoxicity	O
on	O
the	O
MDA-MB-231cells	O
.	O
Xanthohumol	S-chemical
and	O
2-hydroxychalcone	S-chemical
induced	O
apoptosis	O
by	O
Bcl-2	S-GP
downregulation	O
.	O
Importantly	O
,	O
2-hydroxychalcone	S-chemical
and	O
xanthohumol	S-chemical
exerted	O
more	O
potent	O
inhibitory	O
effects	O
on	O
the	O
proliferation	O
,	O
MMP-9	S-GP
expression	O
and	O
invasive	O
phenotype	O
of	O
MDA-MB-231	O
than	O
chalcone	S-chemical
.	O
These	O
results	O
suggest	O
a	O
potential	O
application	O
of	O
these	O
chalcones	S-chemical
as	O
anticancer	O
agents	O
that	O
can	O
alleviate	O
malignant	O
progression	O
of	O
TNBC	O
.	O

Trim24	S-GP
-repressed	O
VL30	B-GP
retrotransposons	E-GP
regulate	O
gene	O
expression	O
by	O
producing	O
noncoding	O
RNA	O
.	O
Trim24	S-GP
(	O
Tif1α	S-GP
)	O
and	O
Trim33	S-GP
(	O
Tif1γ	S-GP
)	O
interact	O
to	O
form	O
a	O
co-repressor	O
complex	O
that	O
suppresses	O
murine	O
hepatocellular	O
carcinoma	O
.	O
Here	O
we	O
show	O
that	O
Trim24	S-GP
and	O
Trim33	S-GP
cooperatively	O
repress	O
retinoic	B-GP
acid	I-GP
receptor	E-GP
-dependent	O
activity	O
of	O
VL30	S-GP
-class	O
endogenous	O
retroviruses	O
(	O
ERVs	O
)	O
in	O
liver	O
.	O
In	O
Trim24	S-GP
-knockout	O
hepatocytes	O
,	O
VL30	S-GP
derepression	O
leads	O
to	O
accumulation	O
of	O
reverse-transcribed	O
VL30	S-GP
cDNA	O
in	O
the	O
cytoplasm	O
that	O
correlates	O
with	O
activation	O
of	O
the	O
viral-defense	O
interferon	S-GP
responses	O
mimicking	O
the	O
preneoplastic	O
inflammatory	O
state	O
seen	O
in	O
human	O
liver	O
following	O
exogenous	O
viral	O
infection	O
.	O
Furthermore	O
,	O
upon	O
derepression	O
,	O
VL30	B-GP
long	I-GP
terminal	I-GP
repeats	E-GP
(	O
LTRs	S-GP
)	O
act	O
as	O
promoter	B-GP
and	I-GP
enhancer	I-GP
elements	E-GP
deregulating	O
expression	O
of	O
neighboring	O
genes	O
and	O
generating	O
enhancer	O
RNAs	O
that	O
are	O
required	O
for	O
LTR	B-GP
enhancer	E-GP
activity	O
in	O
hepatocytes	O
in	O
vivo	O
.	O
These	O
data	O
reinforce	O
the	O
role	O
of	O
the	O
TRIM	S-GP
family	O
of	O
proteins	O
in	O
retroviral	O
restriction	O
and	O
antiviral	O
defense	O
and	O
provide	O
an	O
example	O
of	O
an	O
ERV-derived	O
oncogenic	O
regulatory	O
network	O
.	O

The	O
structures	O
of	O
thymidine	B-GP
kinase	E-GP
from	O
herpes	O
simplex	O
virus	O
type	O
1	O
in	O
complex	O
with	O
substrates	O
and	O
a	O
substrate	O
analogue	O
.	O
Thymidine	B-GP
kinase	E-GP
from	O
Herpes	O
simplex	O
virus	O
type	O
1	O
(	O
TK	S-GP
)	O
was	O
crystallized	O
in	O
an	O
N	S-chemical
-terminally	O
truncated	O
but	O
fully	O
active	O
form	O
.	O
The	O
structures	O
of	O
TK	S-GP
complexed	O
with	O
ADP	S-chemical
at	O
the	O
ATP	S-chemical
-site	O
and	O
deoxythymidine-5'-monophosphate	S-chemical
(	O
dTMP	S-chemical
)	O
,	O
deoxythymidine	S-chemical
(	O
dT	S-chemical
)	O
,	O
or	O
idoxuridine-5'-phosphate	S-chemical
(	O
5-iodo-dUMP	S-chemical
)	O
at	O
the	O
substrate-site	O
were	O
refined	O
to	O
2.75	O
A	O
,	O
2.8	O
A	O
,	O
and	O
3.0	O
A	O
resolution	O
,	O
respectively	O
.	O
TK	S-chemical
catalyzes	O
the	O
phosphorylation	O
of	O
dT	S-chemical
resulting	O
in	O
an	O
ester	S-chemical
,	O
and	O
the	O
phosphorylation	O
of	O
dTMP	S-chemical
giving	O
rise	O
to	O
an	O
anhydride	S-chemical
.	O
The	O
presented	O
TK	S-chemical
structures	O
indicate	O
that	O
there	O
are	O
only	O
small	O
differences	O
between	O
these	O
two	O
modes	O
of	O
action	O
.	O
Glu83	O
serves	O
as	O
a	O
general	O
base	O
in	O
the	O
ester	S-chemical
reaction	O
.	O
Arg163	O
parks	O
at	O
an	O
internal	O
aspartate	S-chemical
during	O
ester	S-chemical
formation	O
and	O
binds	O
the	O
alpha-phosphate	S-chemical
of	O
dTMP	S-chemical
during	O
anhydride	S-chemical
formation	O
.	O
The	O
bound	O
deoxythymidine	S-chemical
leaves	O
a	O
35	O
A3	O
cavity	O
at	O
position	O
5	O
of	O
the	O
base	O
and	O
two	O
sequestered	O
water	O
molecules	O
at	O
position	O
2	O
.	O
Cavity	O
and	O
water	O
molecules	O
reduce	O
the	O
substrate	O
specificity	O
to	O
such	O
an	O
extent	O
that	O
TK	S-chemical
can	O
phosphorylate	S-chemical
various	O
substrate	O
analogues	O
useful	O
in	O
pharmaceutical	O
applications	O
.	O
TK	S-GP
is	O
structurally	O
homologous	O
to	O
the	O
well-known	O
nucleoside	B-GP
monophosphate	I-GP
kinases	E-GP
but	O
contains	O
large	O
additional	O
peptide	O
segments	O
.	O

Practical	O
asymmetric	O
synthesis	O
of	O
aprepitant	S-chemical
,	O
a	O
potent	O
human	O
NK-1	B-GP
receptor	E-GP
antagonist	O
,	O
via	O
a	O
stereoselective	O
Lewis	O
acid-catalyzed	O
trans	O
acetalization	O
reaction	O
.	O
A	O
streamlined	O
and	O
high-yielding	O
synthesis	O
of	O
aprepitant	S-chemical
(	O
1	O
)	O
,	O
a	O
potent	O
substance	B-GP
P	I-GP
(	I-GP
SP	I-GP
)	I-GP
receptor	E-GP
antagonist	O
,	O
is	O
described	O
.	O
The	O
enantiopure	O
oxazinone	S-chemical
16	O
starting	O
material	O
was	O
synthesized	O
via	O
a	O
novel	O
crystallization-induced	O
dynamic	O
resolution	O
process	O
.	O
Conversion	O
of	O
16	O
to	O
the	O
penultimate	O
intermediate	O
cis-sec-amine	S-chemical
9	O
features	O
a	O
highly	O
stereoselective	O
Lewis	O
acid-catalyzed	O
trans	O
acetalization	O
of	O
chiral	B-chemical
alcohol	E-chemical
3	O
with	O
trichloroacetimidate	S-chemical
18	O
followed	O
by	O
inversion	O
of	O
the	O
adjacent	O
chiral	O
center	O
on	O
the	O
morpholine	S-chemical
ring	O
.	O
The	O
six-step	O
process	O
for	O
the	O
synthesis	O
of	O
9	O
was	O
accomplished	O
in	O
extremely	O
high	O
overall	O
yield	O
(	O
81	O
%	O
)	O
and	O
with	O
only	O
two	O
isolations	O
.	O

Comparison	O
of	O
orientation	O
and	O
rotational	O
motion	O
of	O
skeletal	O
muscle	O
cross-bridges	O
containing	O
phosphorylated	B-GP
and	I-GP
dephosphorylated	I-GP
myosin	I-GP
regulatory	I-GP
light	I-GP
chain	E-GP
.	O
Calcium	S-chemical
binding	O
to	O
thin	O
filaments	O
is	O
a	O
major	O
element	O
controlling	O
active	O
force	O
generation	O
in	O
striated	O
muscles	O
.	O
Recent	O
evidence	O
suggests	O
that	O
processes	O
other	O
than	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
binding	O
,	O
such	O
as	O
phosphorylation	O
of	O
myosin	B-GP
regulatory	I-GP
light	I-GP
chain	E-GP
(	O
RLC	S-GP
)	O
also	O
controls	O
contraction	O
of	O
vertebrate	O
striated	O
muscle	O
(	O
Cooke	O
,	O
R.	O
(	O
2011	O
)	O
Biophys	O
.	O
Rev	O
.	O
3	O
,	O
33-45	O
)	O
.	O
Electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
studies	O
using	O
nucleotide	S-chemical
analog	O
spin	O
label	O
probes	O
showed	O
that	O
dephosphorylated	B-GP
myosin	E-GP
heads	O
are	O
highly	O
ordered	O
in	O
the	O
relaxed	O
fibers	O
and	O
have	O
very	O
low	O
ATPase	S-GP
activity	O
.	O
This	O
ordered	O
structure	O
of	O
myosin	S-GP
cross-bridges	O
disappears	O
with	O
the	O
phosphorylation	O
of	O
RLC	O
(	O
Stewart	O
,	O
M.	O
(	O
2010	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U.S.A.	O
107	O
,	O
430-435	O
)	O
.	O
The	O
slower	O
ATPase	S-GP
activity	O
in	O
the	O
dephosporylated	O
moiety	O
has	O
been	O
defined	O
as	O
a	O
new	O
super-relaxed	O
state	O
(	O
SRX	O
)	O
.	O
It	O
can	O
be	O
observed	O
in	O
both	O
skeletal	O
and	O
cardiac	O
muscle	O
fibers	O
(	O
Hooijman	O
,	O
P.	O
,	O
Stewart	O
,	O
M.	O
A.	O
,	O
and	O
Cooke	O
,	O
R.	O
(	O
2011	O
)	O
Biophys	O
.	O
J	O
.	O
100	O
,	O
1969-1976	O
)	O
.	O
Given	O
the	O
importance	O
of	O
the	O
finding	O
that	O
suggests	O
a	O
novel	O
pathway	O
of	O
regulation	O
of	O
skeletal	O
muscle	O
,	O
we	O
aim	O
to	O
examine	O
the	O
effects	O
of	O
phosphorylation	O
on	O
cross-bridge	O
orientation	O
and	O
rotational	O
motion	O
.	O
We	O
find	O
that	O
:	O
(	O
i	O
)	O
relaxed	O
cross-bridges	O
,	O
but	O
not	O
active	O
ones	O
,	O
are	O
statistically	O
better	O
ordered	O
in	O
muscle	O
where	O
the	O
RLC	S-GP
is	O
dephosporylated	O
compared	O
with	O
phosphorylated	B-GP
RLC	E-GP
;	O
(	O
ii	O
)	O
relaxed	O
phosphorylated	O
and	O
dephosphorylated	O
cross-bridges	O
rotate	O
equally	O
slowly	O
;	O
and	O
(	O
iii	O
)	O
active	O
phosphorylated	O
cross-bridges	O
rotate	O
considerably	O
faster	O
than	O
dephosphorylated	O
ones	O
during	O
isometric	O
contraction	O
but	O
the	O
duty	O
cycle	O
remained	O
the	O
same	O
,	O
suggesting	O
that	O
both	O
phosphorylated	O
and	O
dephosphorylated	O
muscles	O
develop	O
the	O
same	O
isometric	O
tension	O
at	O
full	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
saturation	O
.	O
A	O
simple	O
theory	O
was	O
developed	O
to	O
account	O
for	O
this	O
fact	O
.	O

Effects	O
of	O
granulocyte	B-GP
colony-stimulating	I-GP
factor	E-GP
(	O
G-CSF	S-GP
)	O
and	O
neutrophil	B-GP
elastase	E-GP
inhibitor	O
(	O
ONO-5046	S-chemical
)	O
on	O
acid-induced	O
lung	O
injury	O
in	O
rats	O
.	O
It	O
has	O
been	O
suggested	O
that	O
neutrophils	O
play	O
an	O
important	O
role	O
in	O
acid-aspirated	O
lung	O
injury	O
.	O
We	O
examined	O
the	O
effects	O
of	O
the	O
high	O
dose	O
of	O
granulocyte-colony	B-GP
stimulating	I-GP
factor	E-GP
(	O
G-CSF	S-GP
)	O
,	O
which	O
is	O
capable	O
of	O
increasing	O
peripheral	O
neutrophils	O
,	O
and	O
a	O
specific	O
neutrophil	B-GP
elastase	E-GP
inhibitor	O
(	O
ONO-5046	S-chemical
)	O
on	O
acid	O
lung	O
injury	O
in	O
rats	O
.	O
Animals	O
were	O
anesthetized	O
and	O
normal	O
saline	O
(	O
NS	O
,	O
2	O
mL	O
kg	O
(	O
-1	O
)	O
)	O
or	O
hydrochloric	B-chemical
acid	E-chemical
(	O
HCl	S-chemical
,	O
0.1	O
N	O
2	O
mL	O
kg	O
(	O
-1	O
)	O
)	O
was	O
then	O
instilled	O
into	O
trachea	O
.	O
Thirty	O
minutes	O
before	O
HCl	S-chemical
instillation	O
,	O
G-CSF	S-GP
(	O
150	O
microg	O
kg	O
(	O
-1	O
)	O
)	O
was	O
injected	O
subcutaneously	O
or	O
ONO-5046	S-chemical
(	O
10	O
mg	O
kg	O
(	O
-1	O
)	O
h	O
(	O
-1	O
)	O
)	O
was	O
infused	O
continuously	O
into	O
the	O
right	O
jugular	O
vein	O
.	O
Animals	O
were	O
ventilated	O
during	O
the	O
experiments	O
.	O
Five	O
hours	O
after	O
HCl	S-chemical
or	O
NS	O
instillation	O
,	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
and	O
lung	O
tissue	O
samples	O
were	O
obtained	O
.	O
Total	O
nuclear	O
cell	O
count	O
,	O
absorbance	O
,	O
albumin	S-GP
,	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
(	I-GP
TNF	I-GP
)	I-GP
-alpha	E-GP
,	O
interleukin	B-GP
(	I-GP
IL	I-GP
)	I-GP
-6	E-GP
,	O
cytokine-induced	B-GP
neutrophil	I-GP
chemoattractant	E-GP
(	O
CINC	S-GP
)	O
,	O
neutrophil	B-GP
elastase	E-GP
in	O
BALF	O
,	O
wet-to-dry	O
(	O
W/D	O
)	O
ratio	O
were	O
measured	O
.	O
HCl	S-chemical
aspiration	O
markedly	O
increased	O
these	O
values	O
in	O
BALF	O
and	O
W/D	O
ratio	O
.	O
Both	O
ONO-5046	S-chemical
and	O
G-CSF	S-GP
attenuated	O
the	O
parameters	O
increased	O
by	O
acid-induced	O
lung	O
injury	O
in	O
rats	O
.	O
The	O
data	O
suggests	O
that	O
neutrophils	O
play	O
an	O
important	O
role	O
in	O
acid-induced	O
lung	O
injury	O
.	O
However	O
,	O
high-dose	O
G-CSF	S-GP
does	O
not	O
exacerbate	O
acid-aspirated	O
lung	O
injury	O
in	O
rats	O
,	O
although	O
this	O
agent	O
causes	O
an	O
increase	O
in	O
peripheral	O
neutrophils	O
.	O

Mutant	O
B-RAF	S-GP
-	O
Mcl-1	S-GP
survival	O
signaling	O
depends	O
on	O
the	O
STAT3	S-GP
transcription	O
factor	O
.	O
Approximately	O
50	O
%	O
of	O
melanomas	O
depend	O
on	O
mutant	O
B-RAF	S-GP
for	O
proliferation	O
,	O
metastasis	O
and	O
survival	O
.	O
The	O
inhibition	O
of	O
oncogenic	O
B-RAF	S-GP
with	O
highly	O
targeted	O
compounds	O
has	O
produced	O
remarkable	O
albeit	O
short-lived	O
clinical	O
responses	O
in	O
B-RAF	S-GP
mutant	O
melanoma	O
patients	O
.	O
Reactivation	O
of	O
signaling	O
downstream	O
of	O
B-RAF	S-GP
is	O
frequently	O
associated	O
with	O
acquired	O
resistance	O
to	O
B-RAF	S-GP
inhibitors	O
,	O
and	O
the	O
identification	O
of	O
B-RAF	S-GP
targets	O
may	O
provide	O
new	O
strategies	O
for	O
managing	O
melanoma	O
.	O
Oncogenic	O
B-RAF	S-GP
(	O
V600E	S-GP
)	O
is	O
known	O
to	O
promote	O
the	O
stabilizing	O
phosphorylation	O
of	O
the	O
anti-apoptotic	O
protein	O
Mcl-1	S-GP
,	O
implicated	O
in	O
melanoma	O
survival	O
and	O
chemoresistance	O
.	O
We	O
now	O
show	O
that	O
B-RAF	S-GP
(	O
V600E	S-GP
)	O
signaling	O
also	O
induces	O
the	O
transcription	O
of	O
Mcl-1	S-GP
in	O
melanocytes	O
and	O
melanoma	O
.	O
We	O
demonstrate	O
that	O
activation	O
of	O
STAT3	S-GP
serine	S-chemical
-727	O
and	O
tyrosine	S-chemical
-705	O
phosphorylations	O
is	O
promoted	O
by	O
B-RAF	S-GP
(	O
V600E	S-GP
)	O
activity	O
and	O
that	O
the	O
Mcl-1	B-GP
promoter	E-GP
is	O
dependent	O
on	O
a	O
STAT	S-GP
consensus-site	O
for	O
B-RAF	S-GP
-mediated	O
activation	O
.	O
Consequently	O
,	O
suppression	O
of	O
STAT3	S-GP
activity	O
disrupted	O
B-RAF	S-GP
(	O
V600E	S-GP
)	O
-mediated	O
induction	O
of	O
Mcl-1	S-GP
and	O
reduced	O
melanoma	O
cell	O
survival	O
.	O
We	O
propose	O
that	O
STAT3	S-GP
has	O
a	O
central	O
role	O
in	O
the	O
survival	O
and	O
contributes	O
to	O
chemoresistance	O
of	O
B-RAF	S-GP
(	O
V600E	S-GP
)	O
melanoma.Oncogene	O
advance	O
online	O
publication	O
,	O
4	O
March	O
2013	O
;	O
doi:10.1038/onc.2013.45	O
.	O

Exploring	O
the	O
Interplay	O
Between	O
Ligand	O
Derivatisation	O
and	O
Cation	O
Type	O
in	O
the	O
Assembly	O
of	O
Hybrid	O
Polyoxometalate	S-chemical
Mn	S-chemical
-Andersons	O
.	O
Herein	O
a	O
library	O
of	O
hybrid	O
Mn	S-chemical
-Anderson	O
polyoxometalates	S-chemical
anions	O
are	O
presented	O
:	O
1	O
,	O
[	B-chemical
(	I-chemical
MnMo	I-chemical
(	I-chemical
6	I-chemical
)	I-chemical
O	I-chemical
(	I-chemical
18	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
(	I-chemical
OCH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
-C-	I-chemical
(	I-chemical
CH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
7	I-chemical
)	I-chemical
CHCH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
]	I-chemical
(	I-chemical
3-	I-chemical
)	E-chemical
;	O
compound	O
2	O
,	O
[	B-chemical
(	I-chemical
MnMo	I-chemical
(	I-chemical
6	I-chemical
)	I-chemical
O	I-chemical
(	I-chemical
18	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
(	I-chemical
OCH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
C-NHCH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
C	I-chemical
(	I-chemical
16	I-chemical
)	I-chemical
H	I-chemical
(	I-chemical
9	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
]	I-chemical
(	I-chemical
3-	I-chemical
)	E-chemical
;	O
compound	O
3	O
,	O
[	B-chemical
(	I-chemical
MnMo	I-chemical
(	I-chemical
6	I-chemical
)	I-chemical
O	I-chemical
(	I-chemical
18	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
(	I-chemical
OCH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
C-	I-chemical
(	I-chemical
CH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
7	I-chemical
)	I-chemical
CHCH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
1	I-chemical
)	I-chemical
(	I-chemical
(	I-chemical
OCH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
C-NHCH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
C	I-chemical
(	I-chemical
16	I-chemical
)	I-chemical
H	I-chemical
(	I-chemical
9	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
1	I-chemical
)	I-chemical
]	I-chemical
(	I-chemical
3-	I-chemical
)	E-chemical
;	O
compound	O
4	O
,	O
[	B-chemical
(	I-chemical
MnMo	I-chemical
(	I-chemical
6	I-chemical
)	I-chemical
O	I-chemical
(	I-chemical
18	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
(	I-chemical
OCH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
C-NHC	I-chemical
(	I-chemical
O	I-chemical
)	I-chemical
CH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
CHCH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
]	I-chemical
(	I-chemical
3-	I-chemical
)	E-chemical
and	O
compounds	O
5-9	O
,	O
[	B-chemical
(	I-chemical
MnMo	I-chemical
(	I-chemical
6	I-chemical
)	I-chemical
O	I-chemical
(	I-chemical
18	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
(	I-chemical
OCH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
C-NHC	I-chemical
(	I-chemical
O	I-chemical
)	I-chemical
(	I-chemical
CH	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
x	I-chemical
)	I-chemical
CH	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
)	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
]	E-chemical
)	O
,	O
where	O
x	O
=	O
4	O
,	O
10	O
,	O
12	O
,	O
14	O
,	O
and	O
18	O
respectively	O
.	O
The	O
compounds	O
resulting	O
from	O
the	O
cation	O
exchange	O
of	O
the	O
anions	O
1-9	O
to	O
give	O
TBA	S-chemical
(	O
a	O
)	O
and	O
DMDOA	S-chemical
(	O
b	O
)	O
salts	O
,	O
and	O
additionally	O
for	O
compounds	O
1	O
,	O
2	O
and	O
3	O
,	O
tetraphenylphosphonium	S-chemical
(	O
PPh	B-chemical
(	I-chemical
4	I-chemical
)	E-chemical
)	O
(	O
c	O
)	O
salts	O
,	O
are	O
explored	O
at	O
the	O
air/water	O
interface	O
using	O
scanning	O
force	O
microscopy	O
,	O
showing	O
a	O
range	O
of	O
architectures	O
including	O
hexagonal	O
structures	O
,	O
nanofibers	O
and	O
other	O
supramolecular	O
forms	O
.	O
Additionally	O
the	O
solid-state	O
structures	O
for	O
compounds	O
1c	O
,	O
2c	O
,	O
4a	O
,	O
6a	O
,	O
9a	O
,	O
are	O
presented	O
for	O
the	O
first	O
time	O
and	O
these	O
investigations	O
demonstrate	O
the	O
delicate	O
interplay	O
between	O
the	O
structure	O
of	O
the	O
covalently	O
derivatised	O
hybrid	O
organo-clusters	O
as	O
well	O
as	O
the	O
ion-exchange	O
cation	O
types	O
.	O

AT1	S-GP
-receptor	O
antagonism	O
in	O
hypertension	O
:	O
what	O
has	O
been	O
learned	O
with	O
irbesartan	S-chemical
?	O
Irbesartan	S-chemical
is	O
a	O
long-acting	O
angiotensin	B-GP
II	E-GP
antagonist	O
acting	O
specifically	O
at	O
the	O
level	O
of	O
the	O
Type	O
1-receptor	O
subtype	O
(	O
AT1	S-GP
-receptor	O
)	O
.	O
This	O
compound	O
lowers	O
blood	O
pressure	O
dose-dependently	O
in	O
hypertensive	O
patients	O
and	O
has	O
a	O
placebo-like	O
tolerability	O
.	O
The	O
antihypertensive	O
efficacy	O
of	O
irbesartan	S-chemical
is	O
greatly	O
enhanced	O
by	O
the	O
coadministration	O
of	O
a	O
diuretic	O
,	O
and	O
fixed-dose	O
combinations	O
of	O
irbesartan	S-chemical
and	O
hydrochlorothiazide	S-chemical
are	O
now	O
available	O
.	O
Irbesartan	S-chemical
-based	O
treatment	O
appears	O
especially	O
effective	O
for	O
high-risk	O
patients	O
,	O
such	O
as	O
those	O
with	O
diabetes	O
,	O
renal	O
disease	O
and	O
cardiac	O
hypertrophy	O
.	O
In	O
patients	O
with	O
Type	O
2	O
diabetes	O
,	O
irbesartan	S-chemical
delays	O
the	O
development	O
of	O
nephropathy	O
as	O
well	O
as	O
the	O
progression	O
of	O
renal	O
failure	O
.	O
Irbesartan	S-chemical
may	O
have	O
antiatherosclerotic	O
properties	O
beyond	O
those	O
expected	O
from	O
blood	O
pressure	O
lowering	O
per	O
se	O
:	O
this	O
AT1	S-GP
-blocker	O
decreases	O
the	O
vascular	O
oxidative	O
stress	O
and	O
prevents	O
the	O
procoagulant	O
as	O
well	O
as	O
the	O
pro-inflammatory	O
effects	O
of	O
angiotensin	B-GP
II	E-GP
.	O
Irbesartan	O
given	O
alone	O
or	O
in	O
combination	O
with	O
a	O
diuretic	O
therefore	O
represents	O
a	O
rational	O
approach	O
to	O
treat	O
hypertensive	O
patients	O
.	O

Osteoblasts	O
survive	O
the	O
arsenic	B-chemical
trioxide	E-chemical
treatment	O
by	O
activation	O
of	O
ATM	S-GP
-mediated	O
pathway	O
.	O
Arsenic	B-chemical
trioxide	E-chemical
(	O
ATO	S-chemical
)	O
is	O
widely	O
used	O
in	O
tumor	O
treatment	O
,	O
but	O
excessive	O
arsenic	S-chemical
exposure	O
can	O
have	O
adverse	O
effects	O
.	O
We	O
recently	O
found	O
that	O
,	O
in	O
primary	O
osteoblasts	O
,	O
ATO	S-chemical
produces	O
oxidative	O
stress	O
and	O
causes	O
DNA	O
tailing	O
,	O
but	O
does	O
not	O
induce	O
apoptosis	O
.	O
We	O
further	O
examined	O
the	O
signaling	O
pathway	O
by	O
which	O
osteoblasts	O
survive	O
ATO	S-chemical
treatment	O
,	O
and	O
found	O
that	O
they	O
were	O
arrested	O
at	O
G2/M	O
phase	O
of	O
the	O
cell	O
cycle	O
at	O
30h	O
and	O
overrode	O
the	O
G2/M	O
boundary	O
at	O
48h	O
.	O
After	O
treatment	O
for	O
30h	O
,	O
there	O
was	O
increased	O
Cdc2	S-GP
phosphorylation	O
and	O
expression	O
of	O
Wee1	S-GP
,	O
a	O
Cdc2	S-GP
kinase	S-GP
,	O
and	O
expression	O
of	O
the	O
cell	O
cycle	O
inhibitor	O
,	O
p21	S-GP
(	O
waf1	S-GP
/	O
cip1	S-GP
)	O
,	O
which	O
interacts	O
with	O
Cdc2	S-GP
.	O
Furthermore	O
,	O
levels	O
of	O
the	O
phosphatase	B-GP
Cdc25C	E-GP
,	O
which	O
activates	O
Cdc2	S-GP
,	O
were	O
decreased	O
,	O
while	O
the	O
ratio	O
of	O
its	O
phosphorylated/inactivated	O
form	O
to	O
the	O
total	O
amount	O
was	O
increased	O
.	O
Moreover	O
,	O
phosphorylation/activation	O
of	O
the	O
checkpoint	O
kinases	O
Chk1	S-GP
,	O
Chk2	S-GP
and	O
p53	S-GP
levels	O
were	O
increased	O
,	O
as	O
were	O
levels	O
of	O
activated	O
ATM	S-GP
and	O
γ-	O
H2AX	S-GP
.	O
The	O
cell	O
viability	O
was	O
decreased	O
as	O
an	O
ATM	S-GP
inhibitor	O
was	O
added	O
.	O
Additionally	O
,	O
these	O
effects	O
of	O
ATO	S-chemical
on	O
γ-	O
H2AX	S-GP
,	O
Chk1	S-GP
,	O
Chk2	S-GP
,	O
p53	S-GP
,	O
and	O
p21	S-GP
(	O
waf1	S-GP
/	O
cip1	S-GP
)	O
were	O
reduced	O
by	O
an	O
ATM	S-GP
inhibitor	O
.	O
These	O
findings	O
suggest	O
that	O
G2/M	O
phase	O
arrest	O
of	O
osteoblasts	O
is	O
mediated	O
by	O
Chk1	S-GP
/	O
Chk2	S-GP
activation	O
via	O
an	O
ATM	S-GP
-dependent	O
pathway	O
by	O
which	O
osteoblasts	O
survive	O
.	O

Novel	O
pentablock	O
copolymer	O
(	O
PLA	S-chemical
-	O
PCL	S-chemical
-	O
PEG	S-chemical
-	O
PCL	S-chemical
-	O
PLA	S-chemical
)	O
based	O
nanoparticles	O
for	O
controlled	O
drug	O
delivery	O
:	O
Effect	O
of	O
copolymer	O
compositions	O
on	O
the	O
crystallinity	O
of	O
copolymers	O
and	O
in	O
vitro	O
drug	O
release	O
profile	O
from	O
nanoparticles	O
.	O
The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
design	O
novel	O
pentablock	O
copolymers	O
(	O
polylatide	S-chemical
-	O
polycaprolactone	S-chemical
-	O
polyethylene	B-chemical
glycol	E-chemical
-	O
polycaprolactone	S-chemical
-	O
polylatide	S-chemical
)	O
(	O
PLA	S-chemical
-	O
PCL	S-chemical
-	O
PEG	S-chemical
-	O
PCL	S-chemical
-	O
PLA	S-chemical
)	O
to	O
prepare	O
nanoparticle	O
formulations	O
which	O
provide	O
continuous	O
delivery	O
of	O
steroids	S-chemical
over	O
a	O
longer	O
duration	O
with	O
minimal	O
burst	O
effect	O
.	O
Another	O
purpose	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
poly	B-chemical
(	I-chemical
L-lactide	I-chemical
)	E-chemical
(	O
PLLA	S-chemical
)	O
or	O
poly	B-chemical
(	I-chemical
D	I-chemical
,	I-chemical
L-lactide	I-chemical
)	E-chemical
(	O
PDLLA	S-chemical
)	O
incorporation	O
on	O
crystallinity	O
of	O
pentablock	O
copolymers	O
and	O
in	O
vitro	O
release	O
profile	O
of	O
triamcinolone	B-chemical
acetonide	E-chemical
(	O
selected	O
as	O
model	O
drug	O
)	O
from	O
nanoparticles	O
.	O
PLA	S-chemical
-	O
PCL	S-chemical
-	O
PEG	S-chemical
-	O
PCL	S-chemical
-	O
PLA	S-chemical
copolymers	O
with	O
different	O
block	O
ratio	O
of	O
PCL	S-chemical
/	O
PLA	S-chemical
segment	O
were	O
synthesized	O
.	O
Release	O
of	O
triamcinolone	B-chemical
acetonide	E-chemical
from	O
nanoparticles	O
was	O
significantly	O
affected	O
by	O
crystallinity	O
of	O
the	O
copolymers	O
.	O
Burst	O
release	O
of	O
triamcinolone	B-chemical
acetonide	E-chemical
from	O
nanoparticles	O
was	O
significantly	O
minimized	O
with	O
incorporation	O
of	O
proper	O
ratio	O
of	O
PDLLA	S-chemical
in	O
the	O
existing	O
triblock	O
(	O
PCL	S-chemical
-	O
PEG	S-chemical
-	O
PCL	S-chemical
)	O
copolymer	O
.	O
Moreover	O
,	O
pentablock	O
copolymer	O
based	O
nanoparticles	O
exhibited	O
continuous	O
release	O
of	O
triamcinolone	B-chemical
acetonide	E-chemical
.	O
Pentablock	O
copolymer	O
based	O
nanoparticles	O
can	O
be	O
utilized	O
to	O
achieve	O
continuous	O
near	O
zero-order	O
delivery	O
of	O
corticosteroids	O
from	O
nanoparticles	O
without	O
any	O
burst	O
effect	O
.	O

Fragment-based	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
N-substituted-5-	B-chemical
(	I-chemical
4-isopropylthiophenol	I-chemical
)	I-chemical
-2-hydroxynicotinamide	E-chemical
derivatives	O
as	O
novel	O
Mcl-1	S-GP
inhibitors	O
.	O
We	O
have	O
previously	O
reported	O
a	O
nanomolar	O
inhibitor	O
of	O
antiapoptotic	O
Mcl-1	S-GP
protein	O
,	O
3-thiomorpholin-8-oxo-8H-acenaphtho	B-chemical
[	I-chemical
1,2-b	I-chemical
]	I-chemical
pyrrole-9-carbonitrile	E-chemical
(	O
S1	O
)	O
.	O
S1	O
plays	O
its	O
function	O
by	O
binding	O
to	O
the	O
BH3	O
groove	O
of	O
Mcl-1	S-GP
.	O
Basing	O
on	O
this	O
spacial	O
structural	O
characteristic	O
,	O
we	O
developed	O
a	O
novel	O
class	O
of	O
Mcl-1	S-GP
inhibitor	O
using	O
fragment-based	O
drug	O
discovery	O
approach	O
.	O
By	O
dissecting	O
S1	O
,	O
we	O
identified	O
the	O
compound	O
4	O
with	O
a	O
2-hydroxypyridine	S-chemical
core	O
as	O
the	O
starting	O
fragment	O
.	O
In	O
the	O
following	O
molecular	O
growth	O
,	O
we	O
used	O
the	O
ligand	O
efficiency	O
evaluation	O
and	O
fit	O
quality	O
score	O
to	O
assess	O
the	O
fragments	O
.	O
A	O
novel	O
potent	O
compound	O
,	O
N-benzyl-5-	B-chemical
(	I-chemical
4-isopropylthiophenol	I-chemical
)	I-chemical
-2-hydroxyl	I-chemical
nicotinamide	E-chemical
(	O
12c	O
)	O
,	O
which	O
binds	O
Mcl-1	S-GP
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
54	O
nM	O
was	O
obtained	O
.	O
Compound	O
12c	O
demonstrated	O
a	O
better	O
aqueous	O
solubility	O
than	O
S1	O
.	O

Interactions	O
of	O
rifamycin	B-chemical
SV	E-chemical
and	O
rifampicin	S-chemical
with	O
organic	O
anion	O
uptake	O
systems	O
of	O
human	O
liver	O
.	O
The	O
antibiotics	O
rifamycin	B-chemical
SV	E-chemical
and	O
rifampicin	S-chemical
substantially	O
reduce	O
sulfobromophthalein	S-chemical
(	O
BSP	S-chemical
)	O
elimination	O
in	O
humans	O
.	O
In	O
rats	O
,	O
rifamycin	B-chemical
SV	E-chemical
and	O
rifampicin	S-chemical
were	O
shown	O
to	O
interfere	O
with	O
hepatic	O
organic	O
anion	O
uptake	O
by	O
inhibition	O
of	O
the	O
organic	B-GP
anion	I-GP
transporting	I-GP
polypeptides	E-GP
Oatp1	S-GP
and	O
Oatp2	S-GP
.	O
Therefore	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
rifamycin	B-chemical
SV	E-chemical
and	O
rifampicin	S-chemical
on	O
the	O
OATPs	S-GP
of	O
human	O
liver	O
and	O
determined	O
whether	O
rifampicin	S-chemical
is	O
a	O
substrate	O
of	O
1	O
or	O
several	O
of	O
these	O
carriers	O
.	O
In	O
complementary	O
RNA	O
(	O
cRNA	O
)	O
-injected	O
Xenopus	O
laevis	O
oocytes	O
,	O
rifamycin	B-chemical
SV	E-chemical
(	O
10	O
micromol/L	O
)	O
cis-inhibited	O
human	B-GP
organic	I-GP
anion	I-GP
transporting	I-GP
polypeptide	I-GP
C	E-GP
(	O
SLC21A6	S-GP
)	O
(	O
OATP-C	S-GP
)	O
,	O
human	B-GP
organic	I-GP
anion	I-GP
transporting	I-GP
polypeptide	I-GP
8	E-GP
(	O
SLC21A8	S-GP
)	O
(	O
OATP8	S-GP
)	O
,	O
human	B-GP
organic	I-GP
anion	I-GP
transporting	I-GP
polypeptide	I-GP
B	E-GP
(	O
SLC21A9	S-GP
)	O
(	O
OATP-B	S-GP
)	O
,	O
and	O
human	B-GP
organic	I-GP
anion	I-GP
transporting	I-GP
polypeptide	I-GP
A	E-GP
(	O
SLC21A3	S-GP
)	O
(	O
OATP-A	S-GP
)	O
mediated	O
BSP	O
uptake	O
by	O
69	O
%	O
,	O
79	O
%	O
,	O
89	O
%	O
,	O
and	O
57	O
%	O
,	O
respectively	O
,	O
as	O
compared	O
with	O
uptake	O
into	O
control	O
oocytes	O
.	O
In	O
the	O
presence	O
of	O
100	O
micromol/L	O
rifamycin	B-chemical
SV	E-chemical
,	O
BSP	S-chemical
uptake	O
was	O
almost	O
completely	O
abolished	O
.	O
Approximate	O
K	O
(	O
i	O
)	O
values	O
were	O
2	O
micromol/L	O
for	O
OATP-C	S-GP
,	O
3	O
micromol/L	O
for	O
OATP8	S-GP
,	O
3	O
micromol/L	O
for	O
OATP-B	S-GP
and	O
11	O
micromol/L	O
for	O
OATP-A	S-GP
.	O
Rifampicin	S-chemical
(	O
10	O
micromol/L	O
)	O
inhibited	O
OATP8	S-GP
-mediated	O
BSP	S-chemical
uptake	O
by	O
50	O
%	O
,	O
whereas	O
inhibition	O
of	O
OATP-C	S-GP
-	O
,	O
OATP-B	S-GP
-	O
,	O
and	O
OATP-A	S-GP
-mediated	O
BSP	S-chemical
transport	O
was	O
below	O
15	O
%	O
.	O
100	O
micromol/L	O
rifampicin	S-chemical
inhibited	O
OATP-C	S-GP
-	O
and	O
OATP8	S-GP
-	O
,	O
OATP-B	S-GP
-	O
and	O
OATP-A	S-GP
-mediated	O
BSP	S-chemical
uptake	O
by	O
66	O
%	O
,	O
96	O
%	O
,	O
25	O
%	O
,	O
and	O
49	O
%	O
,	O
respectively	O
.	O
The	O
corresponding	O
K	O
(	O
i	O
)	O
values	O
were	O
17	O
micromol/L	O
for	O
OATP-C	S-GP
,	O
5	O
micromol/L	O
for	O
OATP8	S-GP
,	O
and	O
51	O
micromol/L	O
for	O
OATP-A	S-GP
.	O
Direct	O
transport	O
of	O
rifampicin	S-chemical
could	O
be	O
shown	O
for	O
OATP-C	S-GP
(	O
apparent	O
K	O
(	O
m	O
)	O
value	O
13	O
micromol/L	O
)	O
and	O
OATP8	S-GP
(	O
2.3	O
micromol/L	O
)	O
.	O
In	O
conclusion	O
,	O
these	O
results	O
show	O
that	O
rifamycin	B-chemical
SV	E-chemical
and	O
rifampicin	S-chemical
interact	O
with	O
OATP	S-GP
-mediated	O
substrate	O
transport	O
to	O
different	O
extents	O
.	O
Inhibition	O
of	O
human	B-GP
liver	I-GP
OATPs	E-GP
can	O
explain	O
the	O
previously	O
observed	O
effects	O
of	O
rifamycin	B-chemical
SV	E-chemical
and	O
rifampicin	S-chemical
on	O
hepatic	O
organic	O
anion	O
elimination	O
.	O

Signaling	O
through	O
Gi	S-GP
family	O
members	O
in	O
platelets	O
.	O
Redundancy	O
and	O
specificity	O
in	O
the	O
regulation	O
of	O
adenylyl	B-GP
cyclase	E-GP
and	O
other	O
effectors	O
.	O
Platelet	O
responses	O
at	O
sites	O
of	O
vascular	O
injury	O
are	O
regulated	O
by	O
intracellular	O
cAMP	S-chemical
levels	O
,	O
which	O
rise	O
rapidly	O
when	O
prostacyclin	S-chemical
(	O
PGI	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
)	O
is	O
released	O
from	O
endothelial	O
cells	O
.	O
Platelet	O
agonists	O
such	O
as	O
ADP	S-chemical
and	O
epinephrine	O
suppress	O
PGI	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
-stimulated	O
cAMP	S-chemical
formation	O
by	O
activating	O
receptors	O
coupled	O
to	O
G	B-GP
(	I-GP
i	I-GP
)	E-GP
family	O
members	O
,	O
four	O
of	O
which	O
are	O
present	O
in	O
platelets	O
.	O
To	O
address	O
questions	O
about	O
the	O
specificity	O
of	O
receptor	O
:	O
G	B-GP
protein	E-GP
coupling	O
,	O
the	O
regulation	O
of	O
cAMP	S-chemical
formation	O
in	O
vivo	O
and	O
the	O
contribution	O
of	O
G	B-GP
(	I-GP
i	I-GP
)	E-GP
-mediated	O
pathways	O
that	O
do	O
not	O
involve	O
adenylyl	B-GP
cyclase	E-GP
,	O
we	O
studied	O
platelets	O
from	O
mice	O
that	O
lacked	O
the	O
alpha	O
subunits	O
of	O
one	O
or	O
more	O
of	O
the	O
three	O
most	O
abundantly	O
expressed	O
G	B-GP
(	I-GP
i	I-GP
)	E-GP
family	O
members	O
and	O
compared	O
the	O
results	O
with	O
platelets	O
from	O
mice	O
that	O
lacked	O
the	O
PGI	B-GP
(	I-GP
2	I-GP
)	I-GP
receptor	E-GP
,	O
IP	S-GP
.	O
As	O
reported	O
previously	O
,	O
loss	O
of	O
G	B-GP
(	I-GP
i2	I-GP
)	I-GP
alpha	E-GP
or	O
G	B-GP
(	I-GP
z	I-GP
)	I-GP
alpha	E-GP
inhibited	O
aggregation	O
in	O
response	O
to	O
ADP	S-chemical
and	O
epinephrine	S-chemical
,	O
respectively	O
,	O
producing	O
defects	O
that	O
could	O
not	O
be	O
reversed	O
by	O
adding	O
an	O
adenylyl	B-GP
cyclase	E-GP
inhibitor	O
.	O
Platelets	O
that	O
lacked	O
both	O
G	B-GP
(	I-GP
i2	I-GP
)	I-GP
alpha	E-GP
and	O
G	B-GP
(	I-GP
z	I-GP
)	I-GP
alpha	E-GP
showed	O
impaired	O
responses	O
to	O
both	O
agonists	O
,	O
but	O
the	O
impairment	O
was	O
no	O
greater	O
than	O
in	O
the	O
individual	O
knockouts	O
.	O
Loss	O
of	O
G	B-GP
(	I-GP
i3	I-GP
)	I-GP
alpha	E-GP
had	O
no	O
effect	O
either	O
alone	O
or	O
in	O
combination	O
with	O
G	B-GP
(	I-GP
z	I-GP
)	I-GP
alpha	E-GP
.	O
Loss	O
of	O
either	O
G	B-GP
(	I-GP
z	I-GP
)	I-GP
alpha	E-GP
or	O
G	B-GP
(	I-GP
i2	I-GP
)	I-GP
alpha	E-GP
impaired	O
the	O
ability	O
of	O
ADP	S-chemical
and	O
epinephrine	S-chemical
to	O
inhibit	O
PGI	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
-stimulated	O
adenylyl	B-GP
cyclase	E-GP
activity	O
and	O
caused	O
a	O
40	O
%	O
-50	O
%	O
rise	O
in	O
basal	O
cAMP	S-chemical
levels	O
,	O
whereas	O
loss	O
of	O
G	B-GP
(	I-GP
i3	I-GP
)	I-GP
alpha	E-GP
did	O
not	O
.	O
Conversely	O
,	O
deletion	O
of	O
IP	S-GP
abolished	O
responses	O
to	O
PGI	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
and	O
caused	O
cAMP	S-chemical
levels	O
to	O
fall	O
by	O
30	O
%	O
,	O
effects	O
that	O
did	O
not	O
translate	O
into	O
enhanced	O
responsiveness	O
to	O
agonists	O
ex	O
vivo	O
.	O
From	O
these	O
results	O
we	O
conclude	O
that	O
1	O
)	O
cAMP	S-chemical
levels	O
in	O
circulating	O
platelets	O
reflect	O
ongoing	O
signaling	O
through	O
G	B-GP
(	I-GP
i2	I-GP
)	E-GP
,	O
G	B-GP
(	I-GP
z	I-GP
)	E-GP
,	O
and	O
IP	S-GP
,	O
but	O
not	O
G	B-GP
(	I-GP
i3	I-GP
)	E-GP
;	O
2	O
)	O
platelet	O
epinephrine	S-chemical
(	B-GP
alpha	I-GP
(	I-GP
2A	I-GP
)	I-GP
-adrenergic	E-GP
)	O
and	O
ADP	S-chemical
(	O
P2Y12	S-GP
)	O
receptors	O
display	O
strong	O
preferences	O
among	O
G	B-GP
(	I-GP
i	I-GP
)	E-GP
family	O
members	O
with	O
little	O
evidence	O
of	O
redundancy	O
;	O
and	O
3	O
)	O
these	O
receptor	O
preferences	O
do	O
not	O
extend	O
to	O
G	B-GP
(	I-GP
i3	I-GP
)	E-GP
.	O
Finally	O
,	O
the	O
failure	O
of	O
ADP	S-chemical
and	O
epinephrine	S-chemical
to	O
inhibit	O
basal	O
,	O
as	O
opposed	O
to	O
PGI	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
-stimulated	O
,	O
cAMP	S-chemical
formation	O
highlights	O
the	O
need	O
during	O
platelet	O
activation	O
for	O
G	B-GP
(	I-GP
i	I-GP
)	E-GP
signaling	O
pathways	O
that	O
involve	O
effectors	O
other	O
than	O
adenylyl	B-GP
cyclase	E-GP
.	O

Phospholipase	B-GP
Cgamma1	E-GP
negatively	O
regulates	O
growth	B-GP
hormone	E-GP
signalling	O
by	O
forming	O
a	O
ternary	O
complex	O
with	O
Jak2	S-GP
and	O
protein	B-GP
tyrosine	I-GP
phosphatase-1B	E-GP
.	O
Growth	B-GP
hormone	E-GP
binds	O
to	O
its	O
membrane	O
receptor	O
(	O
GHR	S-GP
)	O
,	O
whereby	O
it	O
regulates	O
many	O
cellular	O
functions	O
,	O
including	O
proliferation	O
,	O
differentiation	O
and	O
chemotaxis	O
.	O
However	O
,	O
although	O
the	O
activation	O
of	O
growth	B-GP
hormone	E-GP
-mediated	O
signalling	O
is	O
well	O
understood	O
,	O
the	O
precise	O
mechanism	O
responsible	O
for	O
its	O
regulation	O
has	O
not	O
been	O
elucidated	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
phospholipase	B-GP
Cgamma1	E-GP
(	O
PLCgamma1	S-GP
)	O
modulates	O
the	O
action	O
of	O
growth	B-GP
hormone	E-GP
-mediated	O
signalling	O
by	O
interacting	O
with	O
tyrosine	B-GP
kinase	I-GP
Jak2	E-GP
(	O
janus	B-GP
kinase	I-GP
2	E-GP
)	O
in	O
a	O
growth	B-GP
hormone	E-GP
-dependent	O
manner	O
.	O
In	O
the	O
absence	O
of	O
PLCgamma1	S-GP
(	O
PLCgamma1	S-GP
(	O
-/-	O
)	O
)	O
,	O
growth	B-GP
hormone	E-GP
-induced	O
JAK2	S-GP
and	O
STAT5	S-GP
phosphorylation	O
significantly	O
increased	O
in	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
.	O
Furthermore	O
,	O
the	O
re-expression	O
of	O
PLCgamma1	S-GP
reduced	O
growth	B-GP
hormone	E-GP
-induced	O
Jak2	S-GP
activation	O
.	O
Growth	B-GP
hormone	E-GP
-induced	O
Jak2	S-GP
phosphorylation	O
was	O
enhanced	O
by	O
siRNA-specific	O
knockdown	O
of	O
PLCgamma1	S-GP
.	O
Interestingly	O
,	O
PLCgamma1	S-GP
physically	O
linked	O
Jak2	S-GP
and	O
protein	B-GP
tyrosine	I-GP
phosphatase-1B	E-GP
(	O
PTP-1B	S-GP
)	O
by	O
binding	O
to	O
both	O
using	O
different	O
domains	O
,	O
and	O
this	O
process	O
was	O
implicated	O
in	O
the	O
modulation	O
of	O
cytokine	S-GP
signalling	O
through	O
Jak2	S-GP
.	O
In	O
addition	O
,	O
in	O
PLCgamma1	S-GP
(	O
-/-	O
)	O
MEFs	O
,	O
growth	B-GP
hormone	E-GP
-dependent	O
c-Fos	S-GP
activation	O
was	O
upregulated	O
and	O
growth	B-GP
hormone	E-GP
-induced	O
proliferation	O
was	O
potentiated	O
.	O
These	O
results	O
suggest	O
that	O
PLCgamma1	S-GP
has	O
a	O
key	O
function	O
in	O
the	O
regulation	O
of	O
growth	B-GP
hormone	E-GP
-mediated	O
signalling	O
by	O
negatively	O
regulating	O
Jak2	S-GP
activation	O
.	O

Maqui	O
berry	O
(	O
Aristotelia	O
chilensis	O
)	O
and	O
the	O
constituent	O
delphinidin	B-chemical
glycoside	E-chemical
inhibit	O
photoreceptor	S-GP
cell	O
death	O
induced	O
by	O
visible	O
light	O
.	O
The	O
protective	O
effects	O
of	O
maqui	O
berry	O
(	O
Aristotelia	O
chilensis	O
)	O
extract	O
(	O
MBE	O
)	O
and	O
its	O
major	O
anthocyanins	S-chemical
[	O
delphinidin	B-chemical
3,5-O-diglucoside	E-chemical
(	O
D3G5G	S-chemical
)	O
and	O
delphinidin	B-chemical
3-O-sambubioside-5-O-glucoside	E-chemical
(	O
D3S5G	S-chemical
)	O
]	O
against	O
light-induced	O
murine	O
photoreceptor	O
cells	O
(	O
661W	O
)	O
death	O
were	O
evaluated	O
.	O
Viability	O
of	O
661W	O
after	O
light	O
treatment	O
for	O
24h	O
,	O
assessed	O
by	O
the	O
tetrazolium	S-chemical
salt	O
(	O
WST-8	O
)	O
assay	O
and	O
Hoechst	B-chemical
33342	E-chemical
nuclear	O
staining	O
,	O
was	O
improved	O
by	O
addition	O
of	O
MBE	O
,	O
D3G5G	S-chemical
,	O
and	O
D3S5G	S-chemical
.	O
Intracellular	O
radical	O
activation	O
in	O
661W	O
,	O
evaluated	O
using	O
the	O
reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
-sensitive	O
probe	O
5-	B-chemical
(	I-chemical
and-6	I-chemical
)	I-chemical
-chloromethyl-2,7-dichlorodihydro	I-chemical
fluorescein	I-chemical
diacetate	I-chemical
acetyl	I-chemical
ester	E-chemical
(	O
CM-H2DCFDA	S-chemical
)	O
,	O
was	O
reduced	O
by	O
MBE	O
and	O
its	O
anthocyanins	S-chemical
.	O
The	O
anti-apoptosis	O
mechanism	O
of	O
MBE	O
was	O
evaluated	O
by	O
light-induced	O
phosphorylation	O
of	O
p38	S-GP
.	O
MBE	O
significantly	O
suppressed	O
the	O
light-induced	O
phosphorylation	O
of	O
p38	S-GP
.	O
These	O
findings	O
indicate	O
that	O
MBE	O
and	O
its	O
anthocyanidins	S-chemical
suppress	O
the	O
light-induced	O
photoreceptor	O
cell	O
death	O
by	O
inhibiting	O
ROS	O
production	O
,	O
suggesting	O
that	O
the	O
inhibition	O
of	O
phosphorylated-p38	S-GP
may	O
be	O
involved	O
in	O
the	O
underlying	O
mechanism	O
.	O

Comparative	O
efficacy	O
and	O
safety	O
of	O
the	O
novel	O
oral	O
anticoagulants	O
dabigatran	S-chemical
,	O
rivaroxaban	S-chemical
and	O
apixaban	S-chemical
in	O
preclinical	O
and	O
clinical	O
development	O
.	O
Therapeutic	O
oral	O
anticoagulation	O
is	O
still	O
commonly	O
achieved	O
by	O
administration	O
of	O
warfarin	S-chemical
or	O
other	O
vitamin	B-chemical
K	E-chemical
antagonists	O
that	O
are	O
associated	O
with	O
an	O
untoward	O
pharmacokinetic	O
/	O
pharmacodynamic	O
(	O
PK/PD	O
)	O
profile	O
leading	O
to	O
a	O
high	O
incidence	O
of	O
bleeding	O
complications	O
or	O
therapeutic	O
failure	O
.	O
Hence	O
,	O
there	O
is	O
an	O
unmet	O
medical	O
need	O
of	O
novel	O
easy-to-use	O
oral	O
anticoagulants	O
with	O
improved	O
efficacy	O
and	O
safety	O
.	O
Recent	O
developments	O
include	O
the	O
identification	O
of	O
non-peptidic	O
small-molecules	O
that	O
selectively	O
inhibit	O
certain	O
serine	B-GP
proteases	E-GP
within	O
the	O
coagulation	O
cascade	O
.	O
Of	O
these	O
,	O
the	O
thrombin	S-GP
inhibitor	O
dabigatran	S-chemical
and	O
factor	B-GP
Xa	E-GP
inhibitor	O
rivaroxaban	S-chemical
have	O
recently	O
been	O
licensed	O
for	O
thromboprophylaxis	O
after	O
orthopaedic	O
surgery	O
mainly	O
in	O
Europe	O
.	O
In	O
addition	O
,	O
the	O
factor	B-GP
Xa	E-GP
inhibitor	O
apixaban	S-chemical
is	O
in	O
late-stage	O
clinical	O
development	O
.	O
Each	O
drug	O
is	O
prescribed	O
at	O
fixed	O
doses	O
without	O
the	O
need	O
of	O
anticoagulant	O
monitoring	O
.	O
Phase	O
III	O
trials	O
in	O
orthopaedic	O
patients	O
essentially	O
resulted	O
in	O
non-inferior	O
efficacy	O
of	O
dabigatran	S-chemical
and	O
superior	O
efficacy	O
of	O
rivaroxaban	S-chemical
over	O
enoxaparin	O
without	O
any	O
marked	O
differences	O
of	O
drug	O
safety	O
,	O
while	O
apixaban	S-chemical
data	O
is	O
still	O
controversial	O
.	O
However	O
,	O
alterations	O
of	O
rivaroxaban	S-chemical
and	O
apixaban	S-chemical
pharmacokinetics	O
upon	O
interactions	O
with	O
inhibitors	O
and	O
inducers	O
of	O
CYP3A4	S-GP
or	O
P-glycoprotein	S-GP
may	O
complicate	O
the	O
use	O
of	O
these	O
compounds	O
in	O
daily	O
practice	O
,	O
whereas	O
dabigatran	S-chemical
elimination	O
largely	O
depends	O
on	O
renal	O
function	O
.	O
Hence	O
,	O
this	O
review	O
reports	O
PK/PD	O
,	O
efficacy	O
and	O
safety	O
data	O
of	O
dabigatran	S-chemical
,	O
rivaroxaban	S-chemical
and	O
apixaban	S-chemical
throughout	O
preclinical	O
and	O
clinical	O
development	O
.	O

Analysis	O
of	O
coenzyme	O
binding	O
by	O
human	B-GP
placental	I-GP
3	I-GP
beta-hydroxy-5-ene-steroid	I-GP
dehydrogenase	E-GP
and	O
steroid	B-GP
5	I-GP
--	I-GP
--	I-GP
4-ene-isomerase	E-GP
using	O
5'-	B-chemical
[	I-chemical
p-	I-chemical
(	I-chemical
fluorosulfonyl	I-chemical
)	I-chemical
benzoyl	I-chemical
]	I-chemical
adenosine	E-chemical
,	O
an	O
affinity	O
labeling	O
cofactor	O
analog	O
.	O
3	B-GP
beta-Hydroxy-5-ene-steroid	I-GP
dehydrogenase	E-GP
and	O
steroid	B-GP
5	I-GP
--	I-GP
--	I-GP
4-ene-isomerase	E-GP
copurify	O
as	O
a	O
single	O
,	O
homogeneous	O
protein	O
from	O
human	O
placental	O
microsomes	O
.	O
Affinity	O
alkylation	O
with	O
2	O
alpha-bromoacetoxyprogesterone	S-chemical
suggests	O
that	O
the	O
dehydrogenase	S-GP
and	O
isomerase	O
substrate	O
steroids	S-chemical
bind	O
at	O
different	O
sites	O
on	O
the	O
same	O
protein	O
.	O
However	O
,	O
the	O
coenzyme	O
,	O
NADH	S-chemical
,	O
completely	O
abolishes	O
the	O
alkylation	O
of	O
both	O
enzyme	O
activities	O
by	O
the	O
progestin	S-chemical
analog	O
[	O
Thomas	O
J	O
.L.	O
,	O
Myers	O
R.	O
P.	O
,	O
Rosik	O
L.	O
O.	O
and	O
Strickler	O
R.	O
C.	O
,	O
J.	O
Steroid	O
Biochem	O
.	O
36	O
(	O
1990	O
)	O
117-123	O
]	O
.	O
Unlike	O
bacterial	O
3-keto-5-ene-steroid	B-GP
isomerase	E-GP
,	O
the	O
human	O
isomerase	O
reaction	O
is	O
stimulated	O
by	O
diphosphopyridine	B-chemical
nucleotides	E-chemical
(	O
NADH	S-chemical
,	O
NAD+	S-chemical
)	O
.	O
The	O
affinity	O
labeling	O
nucleotide	S-chemical
analog	O
,	O
5'-	B-chemical
[	I-chemical
p-	I-chemical
(	I-chemical
fluorosulfonyl	I-chemical
)	I-chemical
benzoyl	I-chemical
]	I-chemical
adenosine	E-chemical
(	O
FSA	S-chemical
)	O
,	O
inactivates	O
the	O
dehydrogenase	S-GP
and	O
isomerase	O
activities	O
at	O
similar	O
rates	O
in	O
an	O
irreversible	O
manner	O
which	O
follows	O
first	O
order	O
kinetics	O
with	O
respect	O
to	O
both	O
time	O
and	O
alkylator	O
concentration	O
(	O
0.2-0.6	O
mM	O
)	O
.	O
FSA	O
is	O
a	O
cofactor	O
site-directed	O
reagent	O
that	O
binds	O
with	O
similar	O
affinity	O
as	O
a	O
competitive	O
inhibitor	O
of	O
NAD+	S-chemical
reduction	O
by	O
dehydrogenase	S-GP
(	O
Ki	O
=	O
162	O
microM	O
)	O
or	O
as	O
a	O
stimulator	O
of	O
isomerase	O
(	O
Km	O
=	O
153	O
microM	O
)	O
.	O
Parallel	O
plots	O
derived	O
from	O
Kitz	O
and	O
Wilson	O
analysis	O
indicate	O
that	O
FSA	S-chemical
inactivates	O
the	O
two	O
enzyme	O
activities	O
with	O
equal	O
alkylation	O
efficiency	O
(	O
k3/Ki	O
=	O
1/slope	O
=	O
0.51/mol-s	O
for	O
both	O
)	O
.	O
The	O
3	B-chemical
beta-hydroxysteroid	E-chemical
substrate	O
,	O
pregnenolone	S-chemical
,	O
protects	O
isomerase	O
as	O
well	O
as	O
dehydrogenase	S-GP
from	O
inactivation	O
by	O
FSA	S-chemical
.	O
These	O
observations	O
are	O
evidence	O
for	O
a	O
single	O
cofactor	O
binding	O
region	O
which	O
services	O
both	O
enzyme	O
activities	O
.	O

Crystal	O
structure	O
of	O
serine	B-GP
dehydratase	E-GP
from	O
rat	O
liver	O
.	O
SDH	S-GP
(	B-GP
L-serine	I-GP
dehydratase	E-GP
,	O
EC	B-GP
4.3.1.17	E-GP
)	O
catalyzes	O
the	O
pyridoxal	B-chemical
5'-phosphate	E-chemical
(	O
PLP	S-chemical
)	O
-dependent	O
dehydration	O
of	O
L-serine	S-chemical
to	O
yield	O
pyruvate	S-chemical
and	O
ammonia	S-chemical
.	O
Liver	O
SDH	S-GP
plays	O
an	O
important	O
role	O
in	O
gluconeogenesis	O
.	O
Formation	O
of	O
pyruvate	S-chemical
by	O
SDH	S-GP
is	O
a	O
two-step	O
reaction	O
in	O
which	O
the	O
hydroxyl	S-chemical
group	O
of	O
serine	S-chemical
is	O
cleaved	O
to	O
produce	O
aminoacrylate	S-chemical
,	O
and	O
then	O
the	O
aminoacrylate	S-chemical
is	O
deaminated	O
by	O
nonenzymatic	O
hydrolysis	O
to	O
produce	O
pyruvate	S-chemical
.	O
The	O
crystal	O
structure	O
of	O
rat	B-GP
liver	I-GP
apo-SDH	E-GP
was	O
determined	O
by	O
single	O
isomorphous	O
replacement	O
at	O
2.8	O
A	O
resolution	O
.	O
The	O
holo-SDH	S-GP
crystallized	O
with	O
O-methylserine	S-chemical
(	O
OMS	S-chemical
)	O
was	O
also	O
determined	O
at	O
2.6	O
A	O
resolution	O
by	O
molecular	O
replacement	O
.	O
SDH	S-GP
is	O
composed	O
of	O
two	O
domains	O
,	O
and	O
each	O
domain	O
has	O
a	O
typical	O
alphabeta-open	O
structure	O
.	O
The	O
active	O
site	O
is	O
located	O
in	O
the	O
cleft	O
between	O
the	O
two	O
domains	O
.	O
The	O
holo-SDH	S-GP
contained	O
PLP-OMS	O
aldimine	S-chemical
in	O
the	O
active	O
site	O
,	O
indicating	O
that	O
OMS	S-chemical
can	O
form	O
the	O
Schiff	B-chemical
base	E-chemical
linkage	O
with	O
PLP	S-chemical
,	O
but	O
the	O
subsequent	O
dehydration	O
did	O
not	O
occur	O
.	O
Apo-SDH	S-GP
forms	O
a	O
dimer	O
by	O
inserting	O
the	O
small	O
domain	O
into	O
the	O
catalytic	O
cleft	O
of	O
the	O
partner	O
subunit	O
so	O
that	O
the	O
active	O
site	O
is	O
closed	O
.	O
Holo-SDH	S-GP
also	O
forms	O
a	O
dimer	O
by	O
making	O
contacts	O
at	O
the	O
back	O
of	O
the	O
clefts	O
so	O
that	O
the	O
dimerization	O
does	O
not	O
close	O
the	O
catalytic	O
cleft	O
.	O
The	O
phosphate	O
group	O
of	O
PLP	S-chemical
is	O
surrounded	O
by	O
a	O
characteristic	O
G-rich	B-GP
sequence	E-GP
(	O
(	O
168	O
)	O
GGGGL	S-GP
(	O
172	O
)	O
)	O
and	O
forms	O
hydrogen	S-chemical
bonds	O
with	O
the	O
amide	S-chemical
groups	O
of	O
those	O
amino	B-chemical
acid	E-chemical
residues	O
,	O
suggesting	O
that	O
the	O
phosphate	S-chemical
group	O
can	O
be	O
protonated	O
.	O
N	O
(	O
1	O
)	O
of	O
PLP	S-chemical
participates	O
in	O
a	O
hydrogen	S-chemical
bond	O
with	O
Cys303	O
,	O
and	O
similar	O
hydrogen	S-chemical
bonds	O
with	O
N	O
(	O
1	O
)	O
participating	O
are	O
seen	O
in	O
other	O
beta-elimination	O
enzymes	O
.	O
These	O
hydrogen	S-chemical
bonding	O
schemes	O
indicate	O
that	O
N	O
(	O
1	O
)	O
is	O
not	O
protonated	O
,	O
and	O
thus	O
,	O
the	O
pyridine	S-chemical
ring	O
can	O
not	O
take	O
a	O
quinone	S-chemical
-like	O
structure	O
.	O
These	O
characteristics	O
of	O
the	O
bound	O
PLP	S-chemical
suggest	O
that	O
SDH	S-GP
catalysis	O
is	O
not	O
facilitated	O
by	O
forming	O
the	O
resonance-stabilized	O
structure	O
of	O
the	O
PLP-Ser	B-chemical
aldimine	E-chemical
as	O
seen	O
in	O
aminotransferases	S-GP
.	O
A	O
possible	O
catalytic	O
mechanism	O
involves	O
the	O
phosphate	S-chemical
group	O
,	O
surrounded	O
by	O
the	O
characteristic	O
sequence	O
,	O
acting	O
as	O
a	O
general	O
acid	O
to	O
donate	O
a	O
proton	O
to	O
the	O
leaving	O
hydroxyl	S-chemical
group	O
of	O
serine	S-chemical
.	O

Biosynthesis	O
of	O
selenocysteine	S-chemical
on	O
its	O
tRNA	O
in	O
eukaryotes	O
.	O
Selenocysteine	S-chemical
(	O
Sec	S-chemical
)	O
is	O
cotranslationally	O
inserted	O
into	O
protein	O
in	O
response	O
to	O
UGA	S-GP
codons	O
and	O
is	O
the	O
21st	O
amino	B-chemical
acid	E-chemical
in	O
the	O
genetic	O
code	O
.	O
However	O
,	O
the	O
means	O
by	O
which	O
Sec	S-chemical
is	O
synthesized	O
in	O
eukaryotes	O
is	O
not	O
known	O
.	O
Herein	O
,	O
comparative	O
genomics	O
and	O
experimental	O
analyses	O
revealed	O
that	O
the	O
mammalian	B-GP
Sec	I-GP
synthase	E-GP
(	O
SecS	S-GP
)	O
is	O
the	O
previously	O
identified	O
pyridoxal	B-chemical
phosphate	E-chemical
-containing	O
protein	O
known	O
as	O
the	O
soluble	B-GP
liver	I-GP
antigen	E-GP
.	O
SecS	S-GP
required	O
selenophosphate	S-chemical
and	O
O-phosphoseryl	S-chemical
-tRNA	O
(	O
[	O
Ser	O
]	O
Sec	O
)	O
as	O
substrates	O
to	O
generate	O
selenocysteyl	S-chemical
-tRNA	O
(	O
[	O
Ser	O
]	O
Sec	S-chemical
)	O
.	O
Moreover	O
,	O
it	O
was	O
found	O
that	O
Sec	O
was	O
synthesized	O
on	O
the	O
tRNA	O
scaffold	O
from	O
selenide	S-chemical
,	O
ATP	S-chemical
,	O
and	O
serine	S-chemical
using	O
tRNA	O
(	O
[	O
Ser	O
]	O
Sec	O
)	O
,	O
seryl-tRNA	B-GP
synthetase	E-GP
,	O
O-phosphoseryl-tRNA	B-GP
(	I-GP
[	I-GP
Ser	I-GP
]	I-GP
Sec	I-GP
)	I-GP
kinase	E-GP
,	O
selenophosphate	B-GP
synthetase	E-GP
,	O
and	O
SecS	S-GP
.	O
By	O
identifying	O
the	O
pathway	O
of	O
Sec	S-chemical
biosynthesis	O
in	O
mammals	O
,	O
this	O
study	O
not	O
only	O
functionally	O
characterized	O
SecS	S-GP
but	O
also	O
assigned	O
the	O
function	O
of	O
the	O
O-phosphoseryl-tRNA	B-GP
(	I-GP
[	I-GP
Ser	I-GP
]	I-GP
Sec	I-GP
)	I-GP
kinase	E-GP
.	O
In	O
addition	O
,	O
we	O
found	O
that	O
selenophosphate	B-GP
synthetase	I-GP
2	E-GP
could	O
synthesize	O
monoselenophosphate	S-chemical
in	O
vitro	O
but	O
selenophosphate	B-GP
synthetase	I-GP
1	E-GP
could	O
not	O
.	O
Conservation	O
of	O
the	O
overall	O
pathway	O
of	O
Sec	O
biosynthesis	O
suggests	O
that	O
this	O
pathway	O
is	O
also	O
active	O
in	O
other	O
eukaryotes	O
and	O
archaea	O
that	O
synthesize	O
selenoproteins	S-GP
.	O

Three-Dimensional	O
CdS	S-chemical
-	O
Titanate	S-chemical
Composite	O
Nanomaterials	O
for	O
Enhanced	O
Visible-Light-Driven	O
Hydrogen	S-chemical
Evolution	O
.	O
3D	O
Hierarchical	O
echinus-like	O
titanate	S-chemical
spheres	O
(	O
HETSs	O
)	O
,	O
serving	O
as	O
the	O
supporting	O
material	O
for	O
CdS	S-chemical
nanoparticles	O
,	O
are	O
synthesized	O
via	O
a	O
fast	O
one-step	O
hydrothermal	O
method	O
.	O
The	O
obtained	O
3D	O
CdS	S-chemical
-HETS	O
composite	O
materials	O
show	O
enhanced	O
H2	S-chemical
generation	O
under	O
visible	O
light	O
irradiation	O
.	O

An	O
Intracellular	O
Domain	O
Fragment	O
of	O
the	O
p75	B-GP
Neurotrophin	I-GP
Receptor	E-GP
(	O
p75NTR	S-GP
)	O
Enhances	O
Tropomyosin	B-GP
Receptor	I-GP
Kinase	I-GP
A	E-GP
(	O
TrkA	S-GP
)	O
Receptor	O
Function	O
.	O
Facilitation	O
of	O
nerve	B-GP
growth	I-GP
factor	E-GP
(	O
NGF	S-GP
)	O
signaling	O
by	O
the	O
p75	B-GP
neurotrophin	I-GP
receptor	E-GP
(	O
p75	B-GP
(	I-GP
NTR	I-GP
)	E-GP
)	O
is	O
critical	O
for	O
neuronal	O
survival	O
and	O
differentiation	O
.	O
However	O
,	O
the	O
interaction	O
between	O
p75	B-GP
(	I-GP
NTR	I-GP
)	E-GP
and	O
TrkA	S-GP
receptors	O
required	O
for	O
this	O
activity	O
is	O
not	O
understood	O
.	O
Here	O
,	O
we	O
report	O
that	O
a	O
specific	O
29-	O
amino	B-chemical
acid	E-chemical
peptide	O
derived	O
from	O
the	O
intracellular	O
domain	O
fragment	O
of	O
p75	B-GP
(	I-GP
NTR	I-GP
)	E-GP
interacts	O
with	O
and	O
potentiates	O
binding	O
of	O
NGF	S-GP
to	O
TrkA	S-GP
-expressing	O
cells	O
,	O
leading	O
to	O
increased	O
neurite	O
outgrowth	O
in	O
sympathetic	O
neurons	O
as	O
a	O
result	O
of	O
enhanced	O
Erk1/2	S-GP
and	O
Akt	S-GP
signaling	O
.	O
An	O
endogenous	O
intracellular	O
domain	O
fragment	O
of	O
p75	B-GP
(	I-GP
NTR	I-GP
)	E-GP
(	O
p75	B-GP
(	I-GP
ICD	I-GP
)	E-GP
)	O
containing	O
these	O
29	O
amino	B-chemical
acids	E-chemical
is	O
produced	O
by	O
regulated	O
proteolysis	O
of	O
the	O
full-length	O
receptor	O
.	O
We	O
demonstrate	O
that	O
generation	O
of	O
this	O
fragment	O
is	O
a	O
requirement	O
for	O
p75	B-GP
(	I-GP
NTR	I-GP
)	E-GP
to	O
facilitate	O
TrkA	S-GP
signaling	O
in	O
neurons	O
and	O
propose	O
that	O
the	O
juxtamembrane	O
region	O
of	O
p75	B-GP
(	I-GP
ICD	I-GP
)	E-GP
acts	O
to	O
cause	O
a	O
conformational	O
change	O
within	O
the	O
extracellular	O
domain	O
of	O
TrkA	S-GP
.	O
This	O
finding	O
provides	O
new	O
insight	O
into	O
the	O
mechanism	O
by	O
which	O
p75	B-GP
(	I-GP
NTR	I-GP
)	E-GP
and	O
TrkA	S-GP
interact	O
to	O
enhance	O
neurotrophic	O
signaling	O
.	O

Mechanism	O
of	O
right	O
precordial	O
ST-segment	O
elevation	O
in	O
structural	O
heart	O
disease	O
:	O
excitation	O
failure	O
by	O
current-to-load	O
mismatch	O
.	O
BACKGROUND	O
:	O
The	O
Brugada	O
sign	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
SCN5A	S-GP
and	O
with	O
right	O
ventricular	O
structural	O
abnormalities	O
.	O
Their	O
role	O
in	O
the	O
Brugada	O
sign	O
and	O
the	O
associated	O
ventricular	O
arrhythmias	O
is	O
unknown	O
.	O
OBJECTIVE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
delineate	O
the	O
role	O
of	O
structural	O
abnormalities	O
and	O
sodium	B-GP
channel	E-GP
dysfunction	O
in	O
the	O
Brugada	O
sign	O
.	O
METHODS	O
:	O
Activation	O
and	O
repolarization	O
characteristics	O
of	O
the	O
explanted	O
heart	O
of	O
a	O
patient	O
with	O
a	O
loss-of-function	O
mutation	O
in	O
SCN5A	S-GP
(	O
G752R	S-GP
)	O
and	O
dilated	O
cardiomyopathy	O
were	O
determined	O
after	O
induction	O
of	O
right-sided	O
ST-segment	O
elevation	O
by	O
ajmaline	S-chemical
.	O
In	O
addition	O
,	O
right	O
ventricular	O
structural	O
discontinuities	O
and	O
sodium	B-GP
channel	E-GP
dysfunction	O
were	O
simulated	O
in	O
a	O
computer	O
model	O
encompassing	O
the	O
heart	O
and	O
thorax	O
.	O
RESULTS	O
:	O
In	O
the	O
explanted	O
heart	O
,	O
disappearance	O
of	O
local	O
activation	O
in	O
unipolar	O
electrograms	O
at	O
the	O
basal	O
right	O
ventricular	O
epicardium	O
was	O
followed	O
by	O
monophasic	O
ST-segment	O
elevation	O
.	O
The	O
local	O
origin	O
of	O
this	O
phenomenon	O
was	O
confirmed	O
by	O
coaxial	O
electrograms	O
.	O
Neither	O
early	O
repolarization	O
nor	O
late	O
activation	O
correlated	O
with	O
ST-segment	O
elevation	O
.	O
At	O
sites	O
of	O
local	O
ST-segment	O
elevation	O
,	O
the	O
subepicardium	O
was	O
interspersed	O
with	O
adipose	O
tissue	O
and	O
contained	O
more	O
fibrous	O
tissue	O
than	O
either	O
the	O
left	O
ventricle	O
or	O
control	O
hearts	O
.	O
In	O
computer	O
simulations	O
entailing	O
right	O
ventricular	O
structural	O
discontinuities	O
,	O
reduction	O
of	O
sodium	B-GP
channel	E-GP
conductance	O
or	O
size	O
of	O
the	O
gaps	O
between	O
introduced	O
barriers	O
resulted	O
in	O
subepicardial	O
excitation	O
failure	O
or	O
delayed	O
activation	O
by	O
current-to-load	O
mismatch	O
and	O
in	O
the	O
Brugada	O
sign	O
on	O
the	O
ECG	O
.	O
CONCLUSION	O
:	O
Right	O
ventricular	O
excitation	O
failure	O
and	O
activation	O
delay	O
by	O
current-to-load	O
mismatch	O
in	O
the	O
subepicardium	O
can	O
cause	O
the	O
Brugada	O
sign	O
.	O
Therefore	O
,	O
current-to-load	O
mismatch	O
may	O
underlie	O
the	O
ventricular	O
arrhythmias	O
in	O
patients	O
with	O
the	O
Brugada	O
sign	O
.	O

Histamine	S-chemical
enhances	O
the	O
depolarizing	O
afterpotential	O
of	O
immunohistochemically	O
identified	O
vasopressin	S-chemical
neurons	O
in	O
the	O
rat	O
supraoptic	O
nucleus	O
via	O
H1-receptor	S-GP
activation	O
.	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
histamine	S-chemical
primarily	O
excites	O
unidentified	O
neurons	O
in	O
the	O
rat	O
supraoptic	O
nucleus	O
.	O
We	O
investigated	O
the	O
neuromodulatory	O
effects	O
of	O
histamine	S-chemical
on	O
immunohistochemically	O
identified	O
vasopressin	S-chemical
neurons	O
in	O
the	O
rat	O
supraoptic	O
nucleus	O
using	O
intracellular	O
recording	O
techniques	O
from	O
the	O
hypothalamo-neurohypophysial	O
explant	O
.	O
Exogenous	O
application	O
of	O
histamine	S-chemical
(	O
0.1-100	O
microM	O
)	O
to	O
vasopressinergic	O
neurons	O
produced	O
a	O
small	O
membrane	O
depolarization	O
accompanied	O
by	O
an	O
increase	O
of	O
up	O
to	O
100	O
%	O
in	O
the	O
amplitude	O
of	O
the	O
depolarizing	O
afterpotential	O
that	O
follows	O
current-evoked	O
trains	O
of	O
action	O
potentials	O
.	O
The	O
enhancement	O
of	O
the	O
depolarizing	O
afterpotential	O
by	O
histamine	S-chemical
did	O
not	O
depend	O
upon	O
the	O
depolarization	O
.	O
Further	O
,	O
histamine	S-chemical
enhanced	O
the	O
amplitude	O
of	O
the	O
depolarizing	O
afterpotential	O
when	O
blocking	O
the	O
afterhyperpolarizing	O
potential	O
with	O
d-tubocurarine	S-chemical
or	O
apamin	O
,	O
and	O
in	O
the	O
presence	O
of	O
tetrodotoxin	S-chemical
and	O
d-tubocurarine	S-chemical
or	O
apamin	O
,	O
indicating	O
a	O
postsynaptic	O
action	O
of	O
histamine	S-chemical
on	O
the	O
depolarizing	O
afterpotential	O
that	O
is	O
not	O
simply	O
a	O
reflection	O
of	O
a	O
decrease	O
in	O
the	O
afterhyperpolarizing	O
potential	O
.	O
These	O
toxins	O
also	O
had	O
no	O
effect	O
on	O
the	O
histamine	S-chemical
-induced	O
depolarization	O
.	O
The	O
enhancement	O
of	O
the	O
depolarizing	O
afterpotential	O
by	O
histamine	S-chemical
was	O
mimicked	O
by	O
the	O
histamine	B-GP
H1-receptor	E-GP
agonist	O
2-thiazolylethylamine	S-chemical
and	O
was	O
reduced	O
or	O
blocked	O
by	O
the	O
H1-receptor	S-GP
antagonist	O
promethazine	S-chemical
,	O
but	O
was	O
not	O
blocked	O
or	O
reduced	O
in	O
the	O
presence	O
of	O
the	O
histamine	B-GP
H2-receptor	E-GP
antagonist	O
,	O
cimetidine	S-chemical
.	O
In	O
summary	O
,	O
these	O
results	O
show	O
that	O
the	O
excitatory	O
effect	O
of	O
histamine	S-chemical
on	O
immunohistochemically	O
identified	O
vasopressin	S-chemical
neurons	O
in	O
the	O
supraoptic	O
nucleus	O
is	O
due	O
in	O
part	O
to	O
the	O
H1-receptor	S-GP
-mediated	O
enhancement	O
of	O
the	O
depolarizing	O
afterpotential	O
independent	O
of	O
any	O
change	O
in	O
the	O
afterhyperpolarizing	O
potential	O
or	O
membrane	O
potential	O
.	O

An	O
angiotensin	B-GP
II	I-GP
AT1	I-GP
receptor	E-GP
antagonist	O
,	O
telmisartan	S-chemical
augments	O
glucose	S-chemical
uptake	O
and	O
GLUT4	S-GP
protein	O
expression	O
in	O
3T3-L1	O
adipocytes	O
.	O
Evidence	O
has	O
accumulated	O
that	O
some	O
of	O
the	O
angiotensin	B-GP
II	I-GP
AT1	I-GP
receptor	E-GP
antagonists	O
have	O
insulin	S-GP
-sensitizing	O
property	O
.	O
We	O
thus	O
examined	O
the	O
effect	O
of	O
telmisartan	S-chemical
on	O
insulin	S-GP
action	O
using	O
3T3-L1	O
adipocytes	O
.	O
With	O
standard	O
differentiation	O
inducers	O
,	O
a	O
higher	O
dose	O
of	O
telmisartan	S-chemical
effectively	O
facilitated	O
differentiation	O
of	O
3T3-L1	O
preadipocytes	O
.	O
Treatment	O
of	O
both	O
differentiating	O
adipocytes	O
and	O
fully	O
differentiated	O
adipocytes	O
with	O
telmisartan	S-chemical
caused	O
a	O
dose-dependent	O
increase	O
in	O
mRNA	O
levels	O
for	O
PPARgamma	S-GP
target	O
genes	O
such	O
as	O
aP2	S-GP
and	O
adiponectin	S-GP
.	O
By	O
contrast	O
,	O
telmisartan	S-chemical
attenuated	O
11beta-hydroxysteroid	B-GP
dehydrogenase	I-GP
type	I-GP
1	E-GP
mRNA	O
level	O
in	O
differentiated	O
adipocytes	O
.	O
Of	O
note	O
,	O
we	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
telmisartan	S-chemical
augmented	O
GLUT4	S-GP
protein	O
expression	O
and	O
2-deoxy	B-chemical
glucose	E-chemical
uptake	O
both	O
in	O
basal	O
and	O
insulin	S-GP
-stimulated	O
state	O
of	O
adipocytes	O
,	O
which	O
may	O
contribute	O
,	O
at	O
least	O
partly	O
,	O
to	O
its	O
insulin	S-GP
-sensitizing	O
ability	O
.	O

The	O
atypical	O
antidepressant	O
mianserin	S-chemical
exhibits	O
agonist	O
activity	O
at	O
kappa-opioid	B-GP
receptors	E-GP
.	O
BACKGROUND	O
AND	O
PURPOSE	O
:	O
Antidepressants	O
are	O
known	O
to	O
interact	O
with	O
the	O
opioid	O
system	O
through	O
mechanisms	O
not	O
completely	O
understood	O
.	O
We	O
previously	O
reported	O
that	O
tricyclic	S-chemical
antidepressants	O
act	O
as	O
agonists	O
at	O
distinct	O
opioid	B-GP
receptors	E-GP
.	O
Here	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
the	O
atypical	O
antidepressant	O
mianserin	S-chemical
at	O
cloned	O
and	O
native	O
opioid	B-GP
receptors	E-GP
.	O
EXPERIMENTAL	O
APPROACH	O
:	O
Effects	O
of	O
mianserin	S-chemical
were	O
examined	O
in	O
CHO	O
cells	O
transfected	O
with	O
human	B-GP
opioid	I-GP
receptors	E-GP
,	O
C6	O
glioma	O
cells	O
and	O
rat	O
brain	O
membranes	O
by	O
the	O
use	O
of	O
radioligand	O
binding	O
and	O
functional	O
assays	O
including	O
the	O
stimulation	O
of	O
[	B-chemical
(	I-chemical
35	I-chemical
)	I-chemical
S	I-chemical
]	I-chemical
GTPgammaS	E-chemical
binding	O
and	O
MAPK	S-GP
phosphorylation	O
.	O
KEY	O
RESULTS	O
:	O
Mianserin	S-chemical
displayed	O
12-	O
and	O
18-fold	O
higher	O
affinity	O
for	O
kappa-	B-GP
than	I-GP
micro-	I-GP
and	I-GP
delta-opioid	I-GP
receptors	E-GP
respectively	O
.	O
In	O
[	B-chemical
(	I-chemical
35	I-chemical
)	I-chemical
S	I-chemical
]	I-chemical
GTPgammaS	E-chemical
assays	O
,	O
mianserin	S-chemical
selectively	O
activated	O
kappa-opioid	B-GP
receptors	E-GP
.	O
The	O
agonist	O
activity	O
was	O
antagonized	O
by	O
the	O
selective	O
kappa-opioid	S-GP
blocker	O
nor-binaltorphimine	S-chemical
(	O
nor-BNI	S-chemical
)	O
.	O
The	O
mianserin	S-chemical
analogue	O
mirtazapine	S-chemical
also	O
displayed	O
kappa-opioid	S-GP
agonist	O
activity	O
.	O
Mianserin	S-chemical
and	O
mirtazapine	S-chemical
increased	O
ERK1/2	S-GP
phosphorylation	O
in	O
CHO	O
cells	O
expressing	O
kappa-opioid	B-GP
receptors	E-GP
and	O
C6	O
cells	O
,	O
and	O
these	O
effects	O
were	O
antagonized	O
by	O
nor-BNI	S-chemical
.	O
In	O
rat	O
striatum	O
and	O
nucleus	O
accumbens	O
,	O
mianserin	S-chemical
stimulated	O
[	B-chemical
35S	I-chemical
]	I-chemical
GTPgammaS	E-chemical
binding	O
in	O
a	O
nor-BNI	S-chemical
-sensitive	O
manner	O
with	O
maximal	O
effects	O
lower	O
than	O
those	O
of	O
the	O
full	O
kappa-opioid	S-GP
agonists	O
(	B-chemical
-	I-chemical
)	I-chemical
-U50,488	E-chemical
and	O
dynorphin	B-GP
A	E-GP
.	O
When	O
combined	O
,	O
mianserin	S-chemical
antagonized	O
the	O
effects	O
of	O
the	O
full	O
kappa-opioid	B-GP
receptor	E-GP
agonists	O
in	O
[	B-chemical
(	I-chemical
35	I-chemical
)	I-chemical
S	I-chemical
]	I-chemical
GTPgammaS	E-chemical
assays	O
and	O
reduced	O
the	O
stimulation	O
of	O
p38	S-GP
MAPK	S-GP
and	O
ERK1/2	S-GP
phosphorylation	O
by	O
dynorphin	B-chemical
A	E-chemical
.	O
CONCLUSIONS	O
AND	O
IMPLICATIONS	O
:	O
In	O
different	O
cell	O
systems	O
,	O
mianserin	S-chemical
directly	O
activates	O
kappa-opioid	B-GP
receptors	E-GP
,	O
displaying	O
partial	O
agonist	O
activity	O
at	O
brain	O
receptors	O
.	O
Thus	O
,	O
this	O
property	O
appears	O
to	O
be	O
a	O
common	O
feature	O
of	O
different	O
classes	O
of	O
antidepressants	O
.	O

Design	O
,	O
Synthesis	O
and	O
Biological	O
Evaluation	O
of	O
Aminoalkylindole	S-chemical
Derivatives	O
as	O
Cannabinoid	B-GP
Receptor	E-GP
Ligands	O
with	O
Potential	O
for	O
Treatment	O
of	O
Alcohol	S-chemical
Abuse	O
.	O
Attenuation	O
of	O
increased	O
endocannabinoid	O
signaling	O
with	O
a	O
CB1R	S-GP
neutral	O
antagonist	O
might	O
offer	O
a	O
new	O
therapeutic	O
direction	O
for	O
treatment	O
of	O
alcohol	S-chemical
abuse	O
.	O
We	O
have	O
recently	O
reported	O
that	O
a	O
mono-hydroxylated	O
metabolite	O
of	O
the	O
synthetic	O
aminoalkylindole	S-chemical
cannabinoid	O
JHW-073	S-chemical
(	O
3	O
)	O
exhibits	O
neutral	O
antagonist	O
activity	O
at	O
CB1Rs	S-GP
and	O
thus	O
may	O
serve	O
as	O
a	O
promising	O
lead	O
for	O
the	O
development	O
of	O
novel	O
alcohol	S-chemical
abuse	O
therapies	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
show	O
that	O
systematic	O
modification	O
of	O
an	O
aminoalkylindole	S-chemical
scaffold	O
identifies	O
two	O
new	O
compounds	O
with	O
dual	O
CB1R	S-GP
antagonist/	O
CB2R	S-GP
agonist	O
activity	O
.	O
Similar	O
to	O
the	O
CB1R	S-GP
antagonist/inverse	O
agonist	O
rimonabant	O
,	O
analogues	O
27	O
and	O
30	O
decrease	O
oral	O
alcohol	S-chemical
self-administration	O
,	O
without	O
affecting	O
total	O
fluid	O
intake	O
and	O
block	O
the	O
development	O
of	O
alcohol	S-chemical
-conditioned	O
place	O
preference	O
.	O
Collectively	O
,	O
these	O
initial	O
findings	O
suggest	O
that	O
design	O
and	O
systematic	O
modification	O
of	O
aminoalkylindoles	S-chemical
such	O
as	O
3	O
may	O
lead	O
to	O
development	O
of	O
novel	O
cannabinoid	O
ligands	O
with	O
dual	O
CB1R	S-GP
antagonist/	O
CB2R	S-GP
agonist	O
activity	O
with	O
potential	O
for	O
use	O
as	O
treatments	O
of	O
alcohol	S-chemical
abuse	O
.	O

Structure	O
and	O
energetics	O
of	O
gas	O
phase	O
halogen	S-chemical
-bonding	O
in	O
mono-	B-GP
,	I-GP
bi-	I-GP
,	I-GP
and	I-GP
tri-dentate	I-GP
anion	I-GP
receptors	E-GP
as	O
studied	O
by	O
BIRD	O
.	O
Complexes	O
of	O
mono-	B-GP
,	I-GP
bi-	I-GP
(	I-GP
RB	I-GP
)	I-GP
,	I-GP
and	I-GP
tridentate	I-GP
(	I-GP
RT	I-GP
)	I-GP
receptors	E-GP
with	O
a	O
range	O
of	O
anions	O
(	O
Cl	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
Br	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
I	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
NO3	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
H2PO4	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
HSO4	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
and	O
tosylate	S-chemical
(	O
TsO	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
)	O
)	O
have	O
been	O
studied	O
in	O
the	O
gas	O
phase	O
by	O
both	O
experimental	O
and	O
theoretical	O
methods	O
.	O
Temperature	O
dependent	O
blackbody	O
infrared	O
radiative	O
dissociation	O
(	O
BIRD	O
)	O
experiments	O
were	O
performed	O
on	O
complexes	O
of	O
C8F17I	S-chemical
with	O
Br	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
and	O
I	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
RB	O
with	O
I	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
NO3	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
HSO4	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
H2PO4	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
and	O
TsO	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
and	O
RT	O
with	O
I	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
HSO4	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
and	O
TsO	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
and	O
the	O
observed	O
Arrhenius	O
parameters	O
are	O
reported	O
here	O
.	O
Master	O
equation	O
modeling	O
of	O
the	O
BIRD	O
kinetics	O
data	O
was	O
carried	O
out	O
to	O
determine	O
threshold	O
dissociation	O
energies	O
.	O
Geometry	O
optimizations	O
and	O
thermochemistry	O
calculations	O
were	O
performed	O
using	O
the	O
B3LYP/6-31+G	O
(	O
d	O
,	O
p	O
)	O
level	O
of	O
theory	O
.	O
Additional	O
single	O
point	O
energies	O
were	O
calculated	O
using	O
MP2/6-311++G	O
(	O
2d	O
,	O
p	O
)	O
.	O
Results	O
were	O
examined	O
in	O
terms	O
of	O
the	O
binding	O
order	O
of	O
various	O
anions	O
as	O
well	O
as	O
the	O
added	O
binding	O
strength	O
from	O
additional	O
halogen	S-chemical
bonding	O
(	O
XB	O
)	O
interactions	O
.	O
The	O
relative	O
binding	O
energies	O
of	O
ions	O
were	O
generally	O
consistent	O
with	O
the	O
ordering	O
previously	O
reported	O
from	O
solution	O
phase	O
experiments	O
;	O
however	O
,	O
the	O
relatively	O
strong	O
binding	O
of	O
H2PO4	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
to	O
the	O
bidentate	O
receptor	O
contrasted	O
the	O
solution	O
phase	O
observation	O
of	O
oxo	S-chemical
anions	O
having	O
weaker	O
interactions	O
when	O
compared	O
to	O
halides	S-chemical
.	O
An	O
increase	O
in	O
the	O
energy	O
required	O
to	O
remove	O
the	O
same	O
anion	O
from	O
the	O
tridentate	B-GP
receptor	E-GP
when	O
compared	O
to	O
the	O
bidentate	B-GP
and	I-GP
monodentate	I-GP
receptors	E-GP
is	O
explained	O
as	O
being	O
due	O
to	O
the	O
increase	O
in	O
halogen	S-chemical
bonding	O
interactions	O
.	O
The	O
possibility	O
of	O
mixed	O
halogen	S-chemical
and	O
hydrogen	S-chemical
bonded	O
complexes	O
were	O
considered	O
.	O

Human	B-GP
ether-a-go-go-related	I-GP
gene	E-GP
channel	O
blockers	O
and	O
its	O
structural	O
analysis	O
for	O
drug	O
design	O
.	O
The	O
human	B-GP
ether-a-go-go-related	I-GP
gene	E-GP
(	O
hERG	S-GP
)	O
is	O
a	O
K+	B-GP
channel	E-GP
protein	O
mainly	O
expressed	O
in	O
the	O
heart	O
and	O
the	O
nervous	O
systems	O
and	O
its	O
blockade	O
by	O
non-cardiovascular	O
acting	O
drugs	O
resulted	O
in	O
tachycardia	O
and	O
sudden	O
death	O
.	O
In	O
this	O
present	O
review	O
,	O
we	O
have	O
focused	O
the	O
physicochemical	O
properties	O
responsible	O
for	O
the	O
hERG	S-GP
blocking	O
activity	O
of	O
structurally	O
different	O
compounds	O
.	O
The	O
reported	O
research	O
works	O
showed	O
that	O
the	O
hydrophobicity	O
on	O
the	O
van	O
der	O
Waals	O
(	O
vdW	O
)	O
surface	O
of	O
the	O
molecules	O
(	O
aroused	O
from	O
the	O
aromatic	O
ring	O
)	O
necessary	O
for	O
the	O
hERG	S-GP
blocking	O
activity	O
along	O
with	O
topological	O
and	O
electronic	O
properties	O
.	O
The	O
quinolizidine	B-chemical
alkaloids	E-chemical
(	O
natural	O
products	O
)	O
such	O
as	O
oxymatrine	S-chemical
,	O
sophoridine	S-chemical
,	O
sophocarpine	S-chemical
and	O
matrine	S-chemical
carry	O
the	O
common	O
molecular	O
structure	O
of	O
O=C=N-C-C-C-N	S-chemical
that	O
possessed	O
positive	O
ionotropic	O
effect	O
and	O
hERG	S-GP
blocking	O
activity	O
.	O
Acehytisine	B-chemical
hydrochloride	E-chemical
(	O
previously	O
named	O
Guangfu	B-chemical
base	I-chemical
A	E-chemical
)	O
was	O
isolated	O
from	O
the	O
root	O
of	O
Aconitum	O
coreanum	O
(	O
Levl	O
.	O
)	O
,	O
is	O
an	O
anti-arrhythmic	O
drug	O
in	O
phase	O
IV	O
clinical	O
trial	O
.	O
The	O
isoquinoline	B-chemical
alkaloid	E-chemical
,	O
neferine	S-chemical
(	O
Nef	S-chemical
)	O
induces	O
a	O
concentration-dependent	O
decrease	O
in	O
current	O
amplitude	O
(	O
IC50	O
of	O
7.419	O
MM	O
)	O
.	O
Most	O
of	O
these	O
natural	O
product	O
compounds	O
contain	O
non-flexible	O
aromatic	O
structures	O
but	O
have	O
significant	O
activity	O
due	O
to	O
the	O
presence	O
of	O
optimum	O
hydrophobicity	O
.	O
Recent	O
research	O
works	O
revealed	O
that	O
Eag	S-GP
and	O
hERG	S-GP
channels	O
are	O
expressed	O
by	O
a	O
variety	O
of	O
cancer	O
cell	O
lines	O
and	O
tissues	O
.	O
The	O
Eag	S-GP
channel	O
showed	O
an	O
oncogenic	O
potential	O
while	O
hERG	S-GP
channels	O
are	O
associated	O
with	O
more	O
aggressive	O
tumors	O
and	O
have	O
a	O
role	O
in	O
mediating	O
invasion	O
.	O
This	O
review	O
concluded	O
that	O
the	O
consideration	O
of	O
physicochemical	O
properties	O
necessary	O
for	O
the	O
hERG	S-GP
blocking	O
activity	O
will	O
guide	O
to	O
develop	O
novel	O
drugs	O
with	O
less	O
cardiotoxicity	O
.	O

EphA5	S-GP
-	O
EphrinA5	S-GP
interactions	O
within	O
the	O
ventromedial	O
hypothalamus	O
influence	O
counterregulatory	O
hormone	O
release	O
and	O
local	O
glutamine	S-chemical
/	O
glutamate	S-chemical
balance	O
during	O
hypoglycemia	O
.	O
Activation	O
of	O
β-cell	O
EphA5	B-GP
receptors	E-GP
by	O
its	O
ligand	O
ephrinA5	S-GP
from	O
adjacent	O
β-cells	O
has	O
been	O
reported	O
to	O
decrease	O
insulin	O
secretion	O
during	O
hypoglycemia	O
.	O
Given	O
the	O
similarities	O
between	O
islet	O
and	O
ventromedial	O
hypothalamus	O
(	O
VMH	O
)	O
glucose	S-chemical
sensing	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
the	O
EphA5	S-GP
/	O
ephrinA5	S-GP
system	O
might	O
function	O
within	O
the	O
VMH	O
during	O
hypoglycemia	O
to	O
stimulate	O
counterregulatory	O
hormone	O
release	O
as	O
well	O
.	O
Counterregulatory	O
responses	O
and	O
glutamine	S-chemical
/	O
glutamate	S-chemical
concentrations	O
in	O
the	O
VMH	O
were	O
assessed	O
during	O
a	O
hyperinsulinemic-hypoglycemic	O
glucose	S-chemical
clamp	O
study	O
in	O
chronically	O
catheterized	O
awake	O
male	O
Sprague-Dawley	O
rats	O
that	O
received	O
an	O
acute	O
VMH	O
microinjection	O
of	O
ephrinA5	S-GP
-Fc	O
,	O
chronic	O
VMH	O
knockdown	O
,	O
or	O
overexpression	O
of	O
ephrinA5	S-GP
using	O
an	O
adenoassociated	O
viral	O
construct	O
.	O
Local	O
stimulation	O
of	O
VMH	O
EphA5	B-GP
receptors	E-GP
by	O
ephrinA5-Fc	S-GP
or	O
ephrinA5	S-GP
overexpression	O
increased	O
,	O
whereas	O
knockdown	O
of	O
VMH	O
ephrinA5	S-GP
reduced	O
counterregulatory	O
responses	O
during	O
hypoglycemia	O
.	O
Overexpression	O
of	O
VMH	O
ephrinA5	S-GP
transiently	O
increased	O
local	O
glutamate	S-chemical
concentrations	O
,	O
whereas	O
ephrinA5	S-GP
knockdown	O
produced	O
profound	O
suppression	O
of	O
VMH	O
interstitial	O
fluid	O
glutamine	S-chemical
concentrations	O
in	O
the	O
basal	O
state	O
and	O
during	O
hypoglycemia	O
.	O
Changes	O
in	O
ephrinA5	S-GP
/	O
EphA5	S-GP
interactions	O
within	O
the	O
VMH	O
,	O
a	O
key	O
brain	O
glucose	S-chemical
-sensing	O
region	O
,	O
act	O
in	O
concert	O
with	O
islets	O
to	O
restore	O
glucose	S-chemical
homeostasis	O
during	O
acute	O
hypoglycemia	O
,	O
and	O
its	O
effect	O
on	O
counterregulation	O
may	O
be	O
mediated	O
by	O
changes	O
in	O
glutamate	S-chemical
/	O
glutamine	S-chemical
cycling	O
.	O

Developing	O
Predictive	O
Approaches	O
to	O
Characterize	O
Adaptive	O
Responses	O
of	O
the	O
Reproductive	O
Endocrine	O
Axis	O
to	O
Aromatase	S-GP
Inhibition	O
:	O
II	O
.	O
Computational	O
Modeling	O
.	O
Endocrine-disrupting	O
chemicals	O
can	O
affect	O
reproduction	O
and	O
development	O
in	O
humans	O
and	O
wildlife	O
.	O
We	O
developed	O
a	O
computational	O
model	O
of	O
the	O
hypothalamic-pituitary-gonadal	O
(	O
HPG	O
)	O
axis	O
in	O
female	O
fathead	O
minnows	O
to	O
predict	O
dose-response	O
and	O
time-course	O
(	O
DRTC	O
)	O
behaviors	O
for	O
endocrine	O
effects	O
of	O
the	O
aromatase	S-GP
inhibitor	O
,	O
fadrozole	S-chemical
(	O
FAD	S-chemical
)	O
.	O
The	O
model	O
describes	O
adaptive	O
responses	O
to	O
endocrine	O
stress	O
involving	O
regulated	O
secretion	O
of	O
a	O
generic	O
gonadotropin	S-GP
(	O
LH	S-GP
/	O
FSH	S-GP
)	O
from	O
the	O
hypothalamic-pituitary	O
complex	O
.	O
For	O
model	O
development	O
,	O
we	O
used	O
plasma	O
17β-estradiol	S-chemical
(	O
E2	O
)	O
concentrations	O
and	O
ovarian	O
cytochrome	B-GP
P450	I-GP
(	I-GP
CYP	I-GP
)	I-GP
19A	I-GP
aromatase	E-GP
mRNA	O
data	O
from	O
two	O
time-course	O
experiments	O
,	O
each	O
of	O
which	O
included	O
both	O
an	O
exposure	O
and	O
a	O
depuration	O
phase	O
,	O
and	O
plasma	O
E2	O
data	O
from	O
a	O
third	O
4-day	O
study	O
.	O
Model	O
parameters	O
were	O
estimated	O
using	O
E2	O
concentrations	O
for	O
0	O
,	O
0.5	O
,	O
and	O
3	O
µg/l	O
FAD	S-chemical
exposure	O
concentrations	O
,	O
and	O
good	O
fits	O
to	O
these	O
data	O
were	O
obtained	O
.	O
The	O
model	O
accurately	O
predicted	O
CYP19A	S-GP
mRNA	O
fold	O
changes	O
for	O
controls	O
and	O
three	O
FAD	S-chemical
doses	O
(	O
0	O
,	O
0.5	O
,	O
and	O
3	O
µg/l	O
)	O
and	O
plasma	O
E2	O
dose	O
response	O
from	O
the	O
4-day	O
study	O
.	O
Comparing	O
the	O
model-predicted	O
DRTC	O
with	O
experimental	O
data	O
provided	O
insight	O
into	O
how	O
the	O
feedback	O
control	O
mechanisms	O
in	O
the	O
HPG	O
axis	O
mediate	O
these	O
changes	O
:	O
specifically	O
,	O
adaptive	O
changes	O
in	O
plasma	O
E2	O
levels	O
occurring	O
during	O
exposure	O
and	O
``	O
overshoot	O
''	O
occurring	O
postexposure	O
.	O
This	O
study	O
demonstrates	O
the	O
value	O
of	O
mechanistic	O
modeling	O
to	O
examine	O
and	O
predict	O
dynamic	O
behaviors	O
in	O
perturbed	O
systems	O
.	O
As	O
this	O
work	O
progresses	O
,	O
we	O
will	O
obtain	O
a	O
refined	O
understanding	O
of	O
how	O
adaptive	O
responses	O
within	O
the	O
vertebrate	O
HPG	O
axis	O
affect	O
DRTC	O
behaviors	O
for	O
aromatase	S-GP
inhibitors	O
and	O
other	O
types	O
of	O
endocrine-active	O
chemicals	O
and	O
apply	O
that	O
knowledge	O
in	O
support	O
of	O
risk	O
assessments	O
.	O

Hepatotoxicity	O
of	O
commonly	O
used	O
drugs	O
:	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
antihypertensives	O
,	O
antidiabetic	O
agents	O
,	O
anticonvulsants	O
,	O
lipid-lowering	O
agents	O
,	O
psychotropic	O
drugs	O
.	O
Hepatotoxic	O
adverse	O
drug	O
reactions	O
have	O
contributed	O
to	O
the	O
decline	O
of	O
many	O
promising	O
therapies	O
,	O
even	O
among	O
mainstream	O
medication	O
classes	O
(	O
bromfenac	S-chemical
and	O
troglitazone	S-chemical
are	O
recent	O
examples	O
)	O
.	O
The	O
spectrum	O
of	O
nonsteroidal	O
anti-inflammatory	O
drug-related	O
liver	O
toxicity	O
continues	O
to	O
expand	O
,	O
with	O
reports	O
in	O
children	O
,	O
interactive	O
toxicity	O
in	O
persons	O
with	O
hepatitis	O
C	O
,	O
and	O
recognition	O
of	O
the	O
toxicity	O
of	O
both	O
the	O
preferential	O
and	O
selective	O
cyclooxygenase-2	S-GP
inhibitors	O
.	O
Of	O
the	O
antihypertensive	O
agents	O
,	O
methyldopa	O
is	O
now	O
rarely	O
prescribed	O
and	O
adverse	O
effects	O
are	O
reported	O
infrequently	O
,	O
whereas	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
the	O
angiotensin	B-GP
receptor	E-GP
and	O
converting	B-GP
enzyme	E-GP
inhibitors	O
are	O
increasingly	O
reported	O
.	O
Of	O
the	O
antidiabetic	O
agents	O
,	O
acarbose	S-chemical
,	O
gliclazide	S-chemical
,	O
metformin	S-chemical
,	O
and	O
human	B-GP
insulin	E-GP
have	O
been	O
implicated	O
in	O
causing	O
liver	O
injury	O
.	O
To	O
date	O
,	O
the	O
newer	O
thiazolidinediones	S-chemical
do	O
not	O
appear	O
to	O
share	O
the	O
hepatotoxic	O
potential	O
of	O
troglitazone	S-chemical
,	O
although	O
a	O
few	O
reports	O
of	O
acute	O
hepatitis	O
have	O
accrued	O
.	O
Although	O
liver	O
injury	O
has	O
been	O
associated	O
with	O
the	O
``	O
statins	O
,	O
''	O
the	O
frequency	O
of	O
such	O
toxicity	O
is	O
lower	O
than	O
that	O
of	O
the	O
background	O
population	O
and	O
the	O
value	O
of	O
biochemical	O
monitoring	O
remains	O
unproved	O
.	O
Newer	O
concepts	O
in	O
anticonvulsant	O
hepatotoxicity	O
have	O
been	O
the	O
recognition	O
of	O
the	O
reactive	O
metabolite	O
syndrome	O
,	O
delineation	O
of	O
the	O
risk	O
factors	O
for	O
valproic	B-chemical
acid	E-chemical
toxicity	O
,	O
the	O
potential	O
role	O
of	O
carnitine	S-chemical
in	O
preventing	O
valproic	B-chemical
acid	E-chemical
hepatotoxicity	O
,	O
and	O
the	O
toxicity	O
of	O
second-line	O
antiepileptic	O
drugs	O
.	O
Liver	O
injury	O
associated	O
with	O
newer	O
psychotropic	O
agents	O
,	O
particularly	O
the	O
selective	O
serotonin	S-chemical
reuptake	O
inhibitors	O
,	O
is	O
also	O
discussed	O
.	O
The	O
focus	O
of	O
the	O
review	O
is	O
the	O
hepatotoxicity	O
of	O
commonly	O
used	O
drugs	O
with	O
particular	O
reference	O
to	O
recent	O
and	O
novel	O
reports	O
of	O
toxicity	O
.	O
Well-known	O
causes	O
of	O
liver	O
injury	O
such	O
as	O
chlorpromazine	S-chemical
,	O
phenytoin	S-chemical
,	O
and	O
methyldopa	S-chemical
are	O
not	O
discussed	O
.	O

Electrical	O
Stimuli	O
Release	O
ATP	S-chemical
to	O
Increase	O
GLUT4	S-GP
Translocation	O
and	O
Glucose	S-chemical
Uptake	O
via	O
PI3Kγ	S-GP
-	O
Akt	S-GP
-	O
AS160	S-GP
in	O
Skeletal	O
Muscle	O
Cells	O
.	O
Skeletal	O
muscle	O
glucose	S-chemical
uptake	O
in	O
response	O
to	O
exercise	O
is	O
preserved	O
in	O
insulin	S-GP
-resistant	O
conditions	O
,	O
but	O
the	O
signals	O
involved	O
are	O
debated	O
.	O
ATP	S-chemical
is	O
released	O
from	O
skeletal	O
muscle	O
by	O
contractile	O
activity	O
and	O
can	O
autocrinely	O
signal	O
through	O
purinergic	B-GP
receptors	E-GP
,	O
and	O
we	O
hypothesized	O
it	O
may	O
influence	O
glucose	S-chemical
uptake	O
.	O
Electrical	O
stimulation	O
,	O
ATP	S-chemical
,	O
and	O
insulin	S-GP
each	O
increased	O
fluorescent	O
2-NBD-Glucose	S-chemical
(	O
2-NBDG	S-chemical
)	O
uptake	O
in	O
primary	O
myotubes	O
,	O
but	O
only	O
electrical	O
stimulation	O
and	O
ATP	S-chemical
-dependent	O
2-NBDG	S-chemical
uptake	O
were	O
inhibited	O
by	O
adenosine-phosphate	B-GP
phosphatase	E-GP
and	O
by	O
purinergic	B-GP
receptor	E-GP
blockade	O
(	O
suramin	S-chemical
)	O
.	O
Electrical	O
stimulation	O
transiently	O
elevated	O
extracellular	O
ATP	S-chemical
and	O
caused	O
Akt	S-GP
phosphorylation	O
that	O
was	O
additive	O
to	O
insulin	S-GP
and	O
inhibited	O
by	O
suramin	S-chemical
.	O
Exogenous	O
ATP	S-chemical
transiently	O
activated	O
Akt	S-GP
and	O
,	O
inhibiting	O
phosphatidylinositol	B-GP
3-kinase	E-GP
(	O
PI3K	S-GP
)	O
or	O
Akt	S-GP
as	O
well	O
as	O
dominant-negative	O
Akt	S-GP
mutant	O
,	O
reduced	O
ATP	S-chemical
-dependent	O
2-NBDG	S-chemical
uptake	O
and	O
Akt	S-GP
phosphorylation	O
.	O
ATP	S-chemical
-dependent	O
2-NBDG	S-chemical
uptake	O
was	O
also	O
inhibited	O
by	O
the	O
G	B-GP
protein	I-GP
βγ	E-GP
subunit-interacting	O
peptide	O
βark-ct	O
and	O
by	O
the	O
phosphatidylinositol	B-GP
3-kinase-γ	E-GP
(	O
PI3Kγ	S-GP
)	O
inhibitor	O
AS605240	S-chemical
.	O
ATP	S-chemical
caused	O
translocation	O
of	O
GLUT4	S-GP
myc-eGFP	O
to	O
the	O
cell	O
surface	O
,	O
mechanistically	O
mediated	O
by	O
increased	O
exocytosis	O
involving	O
AS160	S-GP
/	O
Rab8A	S-GP
reduced	O
by	O
dominant-negative	O
Akt	S-GP
or	O
PI3Kγ	S-GP
kinase	S-GP
-dead	O
mutants	O
,	O
and	O
potentiated	O
by	O
myristoylated	B-GP
PI3Kγ	E-GP
.	O
ATP	S-chemical
stimulated	O
2-NBDG	S-chemical
uptake	O
in	O
normal	O
and	O
insulin	S-GP
-resistant	O
adult	O
muscle	O
fibers	O
,	O
resembling	O
the	O
reported	O
effect	O
of	O
exercise	O
.	O
Hence	O
,	O
the	O
ATP	S-chemical
-induced	O
pathway	O
may	O
be	O
tapped	O
to	O
bypass	O
insulin	S-GP
resistance	O
.	O

Comparison	O
of	O
captopril	S-chemical
and	O
enalapril	S-chemical
to	O
study	O
the	O
role	O
of	O
the	O
sulfhydryl	S-chemical
-group	O
in	O
improvement	O
of	O
endothelial	O
dysfunction	O
with	O
ACE	S-GP
inhibitors	O
in	O
high	O
dieted	O
methionine	S-chemical
mice	O
.	O
To	O
examine	O
the	O
role	O
of	O
sulfhydryl	S-chemical
(	O
-	O
SH	S-chemical
)	O
group	O
in	O
improvement	O
of	O
endothelial	O
dysfunction	O
with	O
angiotensin-converting	B-GP
enzyme	E-GP
(	O
ACE	S-GP
)	O
inhibitors	O
in	O
experimental	O
high	O
dose	O
of	O
methionine	S-chemical
dieted	O
rats	O
.	O
We	O
compared	O
the	O
effects	O
of	O
Captopril	S-chemical
(	O
an	O
ACE	S-GP
inhibitor	O
with	O
-	O
SH	S-chemical
group	O
)	O
,	O
enalapril	S-chemical
(	O
an	O
ACE	S-GP
-inhibitor	O
without	O
-	O
SH	S-chemical
group	O
)	O
,	O
N-acetylcysteine	S-chemical
(	O
only	O
-	O
SH	S-chemical
group	O
not	O
ACE	S-GP
inhibitor	O
)	O
on	O
endothelial	O
dysfunction	O
injured	O
by	O
methionine	S-chemical
-induced	O
hyperhomocysteinemia	O
(	O
HHcy	O
)	O
in	O
rats	O
.	O
Male	O
Sprague-Dawley	O
rats	O
were	O
divided	O
randomly	O
into	O
seven	O
groups	O
:	O
control	O
group	O
,	O
L-methionine	S-chemical
group	O
,	O
low	O
dose	O
Captopril	S-chemical
(	O
15	O
mg/kg	O
)	O
,	O
middle	O
dose	O
Captopril	S-chemical
(	O
30	O
mg/kg	O
)	O
,	O
high	O
dose	O
Captopril	S-chemical
(	O
45	O
mg/kg	O
)	O
,	O
enalapril	S-chemical
(	O
20	O
mg/kg	O
)	O
,	O
N-acetylcysteine	S-chemical
(	O
200	O
mg/kg	O
)	O
;	O
control	O
group	O
were	O
intragastric	O
gavaged	O
by	O
water	O
and	O
others	O
groups	O
were	O
intragastric	O
gavaged	O
by	O
L-methionine	S-chemical
and	O
drugs	O
in	O
water	O
one	O
time	O
every	O
day	O
.	O
Acetylcholine	S-chemical
(	O
ACh	S-chemical
)	O
-induced	O
endothelium-dependent	O
relaxation	O
(	O
EDR	O
)	O
,	O
sodium	B-chemical
nitroprusside	E-chemical
(	O
SNP	S-chemical
)	O
-induced	O
endothelium-independent	O
relaxation	O
of	O
aortic	O
rings	O
were	O
examined	O
.	O
Paraoxonase1	S-GP
(	O
PON1	S-GP
)	O
and	O
ACE	S-GP
activity	O
,	O
malondialdehyde	S-chemical
(	O
MDA	S-chemical
)	O
,	O
nitric	B-chemical
oxide	E-chemical
(	O
NO	S-chemical
)	O
,	O
superoxide	B-GP
dismutase	E-GP
(	O
SOD	S-GP
)	O
in	O
serum	O
were	O
analyzed	O
.	O
It	O
was	O
found	O
that	O
a	O
single	O
intragastric	O
gavage	O
by	O
L-methionine	S-chemical
resulted	O
in	O
inhibition	O
of	O
endothelium-dependent	O
relaxation	O
,	O
markedly	O
increased	O
the	O
serum	O
level	O
of	O
malondialdehyde	S-chemical
and	O
decreased	O
the	O
activity	O
of	O
PON1	S-GP
and	O
SOD	S-GP
,	O
similarly	O
decreased	O
the	O
level	O
of	O
NO	S-chemical
in	O
the	O
serum	O
;	O
but	O
had	O
no	O
effects	O
on	O
endothelium-independent	O
relaxation	O
and	O
angiotensin-converting	B-GP
enzyme	E-GP
activity	O
compared	O
with	O
the	O
control	O
group	O
.	O
Given	O
the	O
treatment	O
with	O
three	O
doses	O
of	O
Captopril	S-chemical
(	O
15	O
approximately	O
45	O
mg/kg	O
)	O
markedly	O
attenuated	O
inhibition	O
of	O
vasodilator	O
responses	O
to	O
ACh	S-chemical
,	O
and	O
eliminated	O
the	O
increased	O
level	O
of	O
malondialdehyde	S-chemical
,	O
the	O
decreased	O
level	O
of	O
NO	S-chemical
,	O
activity	O
of	O
PON1	S-GP
and	O
SOD	S-GP
in	O
serum	O
by	O
single	O
intragastric	O
gavaged	O
L-methionine	S-chemical
.	O
However	O
,	O
there	O
were	O
some	O
significant	O
differences	O
among	O
Captopril	S-chemical
(	O
30	O
mg/kg	O
or	O
45	O
mg/kg	O
)	O
,	O
enalapril	S-chemical
(	O
20	O
mg/kg	O
)	O
,	O
and	O
N-acetylcysteine	S-chemical
particular	O
in	O
the	O
activity	O
of	O
PON1	S-GP
and	O
ACE	S-GP
.	O
These	O
results	O
suggested	O
that	O
Captopril	S-chemical
can	O
protect	O
the	O
vascular	O
endothelium	O
against	O
the	O
damages	O
induced	O
by	O
L-methionine	S-chemical
in	O
rats	O
,	O
and	O
the	O
beneficial	O
effects	O
of	O
Captopril	S-chemical
may	O
be	O
related	O
to	O
attenuating	O
the	O
decrease	O
in	O
PON1	S-GP
activity	O
and	O
NO	S-chemical
levels	O
.	O
Furthermore	O
,	O
this	O
protective	O
effect	O
may	O
be	O
concerned	O
with	O
the	O
sulfhydryl	S-chemical
group	O
.	O

Investigation	O
of	O
bradykinin	S-chemical
metabolism	O
in	O
human	O
and	O
rat	O
plasma	O
in	O
the	O
presence	O
of	O
the	O
dual	O
ACE	S-GP
/	O
NEP	S-GP
inhibitors	O
GW660511X	S-chemical
and	O
omapatrilat	S-chemical
.	O
Several	O
studies	O
have	O
suggested	O
that	O
the	O
accumulation	O
of	O
bradykinin	S-chemical
,	O
or	O
that	O
of	O
one	O
its	O
metabolites	O
BK1-8	O
,	O
is	O
involved	O
in	O
the	O
occurrence	O
of	O
side	O
effects	O
such	O
as	O
AE	O
associated	O
with	O
the	O
use	O
of	O
various	O
ACE	S-GP
i	O
.	O
In	O
this	O
work	O
a	O
novel	O
approach	O
combining	O
HPLC-UV	O
on-line	O
with	O
oaTOF-MS	O
and	O
ICPMS	O
was	O
applied	O
to	O
investigate	O
in	O
human	O
and	O
rat	O
plasma	O
the	O
metabolism	O
of	O
labelled	O
BK	S-chemical
(	O
79/81	B-GP
Br-Phe5	E-GP
)	O
BrBK	S-chemical
in	O
the	O
presence	O
of	O
two	O
new	O
dual	O
ACE	S-GP
/	O
NEP	S-GP
inhibitors	O
(	O
GW660511X	S-chemical
and	O
omapatrilat	S-chemical
)	O
currently	O
under	O
clinical	O
trial	O
.	O
In	O
human	O
plasma	O
the	O
BrBK	S-chemical
half-life	O
values	O
in	O
the	O
absence	O
or	O
in	O
the	O
presence	O
of	O
GW660511X	S-chemical
(	O
3.8	O
microM	O
)	O
or	O
omapatrilat	S-chemical
(	O
32	O
nM	O
)	O
were	O
38.7	O
+/-	O
2.4	O
,	O
51.2	O
+/-	O
4.7	O
and	O
114.7	O
+/-	O
9.3	O
min	O
,	O
respectively	O
and	O
BrBK	S-chemical
was	O
degraded	O
into	O
BrBK1-8	S-chemical
,	O
BrBK1-7	S-chemical
,	O
BrBK1-5	S-chemical
and	O
Br-Phe	S-chemical
.	O
In	O
the	O
presence	O
of	O
inhibitors	O
,	O
however	O
,	O
the	O
levels	O
of	O
these	O
resultant	O
metabolites	O
were	O
different	O
.	O
Unlike	O
GW660511X	S-chemical
,	O
omapatrilat	S-chemical
abolished	O
the	O
production	O
of	O
BrBK1-5	S-chemical
and	O
BrBK1-7	S-chemical
,	O
suggesting	O
a	O
better	O
ACE	S-GP
inhibition	O
effect	O
over	O
GW660511X	S-chemical
as	O
no	O
NEP	S-GP
activity	O
was	O
found	O
.	O
In	O
addition	O
the	O
production	O
of	O
BrBK1-8	S-chemical
was	O
enhanced	O
in	O
the	O
presence	O
of	O
these	O
inhibitors	O
with	O
a	O
greater	O
accumulation	O
being	O
observed	O
with	O
omapatrilat	S-chemical
.	O
The	O
production	O
of	O
Br-Phe5	S-chemical
was	O
reduced	O
with	O
GW660511X	S-chemical
while	O
no	O
significant	O
change	O
was	O
observed	O
with	O
omapatrilat	S-chemical
after	O
4	O
h	O
of	O
incubation	O
.	O
In	O
rat	O
plasma	O
the	O
BrBK	S-GP
half-life	O
values	O
in	O
the	O
absence	O
or	O
in	O
the	O
presence	O
of	O
GW660511X	S-chemical
(	O
530	O
nM	O
)	O
or	O
omapatrilat	S-chemical
(	O
50	O
nM	O
)	O
were	O
9.31	O
+/-	O
1.7	O
,	O
22.06	O
+/-	O
3.1	O
and	O
25.3	O
+/-	O
1.7	O
min	O
,	O
respectively	O
and	O
BrBK	S-GP
was	O
degraded	O
into	O
BrBK1-8	S-chemical
,	O
BrBK1-7	S-chemical
,	O
BrBK1-5	S-chemical
and	O
Br-Phe5	S-chemical
plus	O
BrBK2-9	S-chemical
,	O
BrBK4-8	S-chemical
and	O
BrBK2-8	S-chemical
metabolites	O
not	O
found	O
in	O
human	O
plasma	O
.	O
GW660511X	S-chemical
and	O
omapatrilat	S-chemical
reduced	O
the	O
production	O
of	O
BrBK1-5	S-chemical
and	O
BrBK1-7	S-chemical
with	O
more	O
effect	O
being	O
observed	O
with	O
omapatrilat	S-chemical
.	O
GW660511X	S-chemical
and	O
omapatrilat	S-chemical
increased	O
the	O
production	O
of	O
both	O
BrBK1-8	S-chemical
and	O
Br-Phe5	S-chemical
but	O
not	O
that	O
of	O
BrBK4-8	S-chemical
and	O
BrBK2-8	S-chemical
.	O
This	O
study	O
shows	O
that	O
the	O
potency	O
of	O
GW660511X	S-chemical
in	O
comparison	O
with	O
omapatrilat	S-chemical
is	O
more	O
than	O
100-fold	O
lower	O
in	O
human	O
,	O
but	O
less	O
than	O
10-fold	O
lower	O
in	O
rat	O
plasma	O
,	O
suggesting	O
that	O
rat	O
may	O
not	O
be	O
a	O
suitable	O
in	O
vivo	O
model	O
for	O
the	O
evaluation	O
of	O
ACE	S-GP
/	O
NEP	S-GP
inhibition	O
in	O
relation	O
to	O
effects	O
in	O
humans	O
.	O

Effective	O
phagocytosis	O
of	O
low	O
Her2	S-GP
tumor	O
cell	O
lines	O
with	O
engineered	O
,	O
aglycosylated	B-GP
IgG	E-GP
displaying	O
high	O
FcγRIIa	S-GP
affinity	O
and	O
selectivity	O
.	O
Glycans	O
anchored	O
to	O
residue	O
N297	O
of	O
the	O
antibody	O
IgG	B-GP
Fc	I-GP
domain	E-GP
are	O
critical	O
in	O
mediating	O
binding	O
toward	O
FcγRs	S-GP
to	O
direct	O
both	O
adaptive	O
and	O
innate	O
immune	O
responses	O
.	O
However	O
,	O
using	O
a	O
full	O
length	O
bacterial	B-GP
IgG	E-GP
display	O
system	O
,	O
we	O
have	O
isolated	O
aglycosylated	B-GP
Fc	I-GP
domains	E-GP
with	O
mutations	O
that	O
confer	O
up	O
to	O
a	O
160-fold	O
increase	O
in	O
the	O
affinity	O
toward	O
the	O
low	O
affinity	O
FcγRIIa	S-GP
-R131	O
allele	O
as	O
well	O
as	O
high	O
selectivity	O
against	O
binding	O
to	O
the	O
remarkably	O
homologous	O
human	O
inhibitory	O
receptor	O
,	O
FcγRIIb	S-GP
.	O
The	O
mutant	O
Fc	B-GP
domain	E-GP
(	O
AglycoT-Fc1004	S-GP
)	O
contained	O
a	O
total	O
of	O
5	O
amino	B-chemical
acid	E-chemical
substitutions	O
that	O
conferred	O
an	O
activating	O
to	O
inhibitory	O
ratio	O
of	O
25	O
(	O
A/I	O
ratio	O
;	O
FcyRIIa	S-GP
-R131	O
:	O
FcγRIIb	S-GP
)	O
.	O
Incorporation	O
of	O
this	O
engineered	O
Fc	S-GP
into	O
trastuzumab	O
,	O
an	O
anti-	O
Her2	S-GP
antibody	O
,	O
resulted	O
in	O
a	O
75	O
%	O
increase	O
in	O
tumor	O
cell	O
phagocytosis	O
by	O
macrophages	O
compared	O
to	O
that	O
of	O
the	O
parental	O
glycosylated	O
trastuzumab	O
with	O
both	O
medium	O
and	O
low	O
Her2	S-GP
-expressing	O
cancer	O
cells	O
.	O
A	O
mathematical	O
model	O
has	O
been	O
developed	O
to	O
help	O
explain	O
how	O
receptor	O
affinity	O
and	O
the	O
A/I	O
ratio	O
relate	O
to	O
improved	O
antibody	O
dependent	O
cell-mediated	O
phagocytosis	O
.	O
Our	O
model	O
provides	O
guidelines	O
for	O
the	O
future	O
engineering	O
of	O
Fc	B-GP
domains	E-GP
with	O
enhanced	O
effector	O
function	O
.	O

New	O
standards	O
in	O
hypertension	O
and	O
cardiovascular	O
risk	O
management	O
:	O
focus	O
on	O
telmisartan	S-chemical
.	O
Blockade	O
of	O
the	O
renin	S-GP
-	O
angiotensin	S-GP
system	O
is	O
an	O
important	O
approach	O
in	O
managing	O
high	O
blood	O
pressure	O
,	O
and	O
has	O
increasingly	O
been	O
shown	O
to	O
affect	O
cardiovascular	O
disease	O
processes	O
mediated	O
by	O
angiotensin	B-GP
II	E-GP
throughout	O
the	O
cardiovascular	O
and	O
renal	O
continua	O
.	O
Telmisartan	S-chemical
is	O
an	O
angiotensin	B-GP
II	I-GP
receptor	E-GP
blocker	O
(	O
ARB	O
)	O
displaying	O
unique	O
pharmacologic	O
properties	O
,	O
including	O
a	O
longer	O
half	O
life	O
than	O
any	O
other	O
ARB	O
,	O
that	O
result	O
in	O
large	O
and	O
sustained	O
reductions	O
of	O
blood	O
pressure	O
.	O
In	O
patients	O
with	O
mild-to-moderate	O
hypertension	O
,	O
telmisartan	S-chemical
has	O
proved	O
superior	O
to	O
other	O
antihypertensive	O
agents	O
(	O
valsartan	S-chemical
,	O
losartan	S-chemical
,	O
ramipril	S-chemical
,	O
perindopril	S-chemical
,	O
and	O
atenolol	S-chemical
)	O
in	O
controlling	O
blood	O
pressure	O
particularly	O
towards	O
the	O
end	O
of	O
the	O
dosing	O
interval	O
.	O
There	O
is	O
also	O
clinical	O
evidence	O
that	O
telmisartan	S-chemical
reduces	O
left	O
ventricular	O
hypertrophy	O
,	O
reduces	O
arterial	O
stiffness	O
and	O
the	O
recurrence	O
of	O
atrial	O
fibrillation	O
,	O
and	O
confers	O
renoprotection	O
.	O
The	O
ONgoing	O
Telmisartan	S-chemical
Alone	O
and	O
in	O
combination	O
with	O
Ramipril	S-chemical
Global	O
Endpoint	O
Trial	O
(	O
ONTARGET	O
)	O
study	O
has	O
demonstrated	O
that	O
telmisartan	S-chemical
has	O
similar	O
cardiovascular	O
protective	O
effects	O
to	O
ramipril	S-chemical
in	O
a	O
large	O
,	O
high-risk	O
patient	O
population	O
but	O
was	O
better	O
tolerated	O
.	O
The	O
powerful	O
and	O
sustained	O
blood	O
pressure	O
control	O
apparent	O
in	O
clinical	O
trials	O
,	O
together	O
with	O
cardiovascular	O
protection	O
and	O
tolerability	O
demonstrated	O
in	O
ONTARGET	O
means	O
that	O
telmisartan	S-chemical
may	O
be	O
a	O
preferred	O
option	O
for	O
patients	O
with	O
hypertension	O
.	O

Discovery	O
of	O
aryl	B-chemical
ureas	E-chemical
and	O
aryl	B-chemical
amides	E-chemical
as	O
potent	O
and	O
selective	O
histamine	B-GP
H3	I-GP
receptor	E-GP
antagonists	O
for	O
the	O
treatment	O
of	O
obesity	O
(	O
Part	O
I	O
)	O
.	O
A	O
series	O
of	O
structurally	O
novel	O
aryl	B-chemical
ureas	E-chemical
was	O
derived	O
from	O
optimization	O
of	O
the	O
HTS	O
lead	O
as	O
selective	O
histamine	B-GP
H3	I-GP
receptor	E-GP
(	O
H3R	S-GP
)	O
antagonists	O
.	O
The	O
SAR	O
was	O
explored	O
and	O
the	O
data	O
obtained	O
set	O
up	O
the	O
starting	O
point	O
and	O
foundation	O
for	O
further	O
optimization	O
.	O
The	O
most	O
potent	O
tool	O
compounds	O
,	O
as	O
exemplified	O
by	O
compounds	O
2l	O
,	O
5b	O
,	O
5d	O
,	O
and	O
5e	O
,	O
displayed	O
antagonism	O
potencies	O
in	O
the	O
subnanomolar	O
range	O
in	O
in	O
vitro	O
human-H3R	S-GP
FLIPR	O
assays	O
and	O
rhesus	B-GP
monkey	I-GP
H3R	E-GP
binding	O
assays	O
.	O

Pure	O
antiestrogens	O
and	O
breast	O
cancer	O
.	O
Tamoxifen	S-chemical
,	O
which	O
is	O
the	O
most	O
commonly	O
used	O
drug	O
for	O
treatment	O
of	O
breast	O
cancer	O
,	O
has	O
both	O
estrogen	S-chemical
agonist	O
and	O
antagonist	O
actions	O
.	O
Pure	O
anti	O
estrogen	S-chemical
s	O
are	O
devoid	O
of	O
any	O
estrogen	O
agonist	O
effects	O
.	O
ICI	B-chemical
182,780	E-chemical
(	O
fulvestrant	S-chemical
)	O
(	O
Faslodex	S-chemical
)	O
and	O
ICI	B-chemical
164,384	E-chemical
are	O
competitive	O
inhibitors	O
of	O
estrogen	S-chemical
by	O
binding	O
to	O
the	O
estrogen	B-GP
receptor	E-GP
(	O
ER	S-GP
)	O
.	O
Preclinical	O
and	O
clinical	O
studies	O
show	O
that	O
fulvestrant	S-chemical
and	O
ICI	B-chemical
164,384	E-chemical
are	O
more	O
potent	O
than	O
tamoxifen	S-chemical
in	O
inhibiting	O
the	O
growth	O
of	O
breast	O
cancer	O
cells	O
.	O
They	O
are	O
devoid	O
of	O
any	O
estrogen	S-chemical
-agonist	O
action	O
on	O
the	O
uterus	O
and	O
vagina	O
but	O
lack	O
the	O
beneficial	O
effects	O
of	O
tamoxifen	S-chemical
on	O
the	O
bone	O
and	O
serum	O
lipid	O
profile	O
.	O
Fulvestrant	S-chemical
is	O
the	O
first	O
pure	O
antiestrogen	S-chemical
to	O
complete	O
phase	O
III	O
clinical	O
trials	O
.	O
Such	O
studies	O
have	O
shown	O
that	O
fulvestrant	S-chemical
is	O
at	O
least	O
as	O
good	O
as	O
anastrozole	S-chemical
in	O
the	O
treatment	O
of	O
post-menopausal	O
women	O
with	O
advanced	O
breast	O
cancer	O
who	O
had	O
relapsed	O
or	O
progressed	O
on	O
prior	O
endocrine	O
therapy	O
.	O
The	O
drug	O
was	O
well	O
tolerated	O
and	O
only	O
minor	O
side-effects	O
were	O
reported	O
.	O
Its	O
potential	O
role	O
in	O
the	O
adjuvant	O
setting	O
will	O
be	O
determined	O
by	O
its	O
adverse	O
effects	O
on	O
bone	O
mass	O
and	O
serum	O
lipids	O
.	O
EM-800	S-chemical
and	O
EM-652	S-chemical
are	O
the	O
most	O
potent	O
pure	O
antiestrogens	O
and	O
EM-652	S-chemical
has	O
the	O
highest	O
affinity	O
of	O
all	O
antiestrogens	O
to	O
ER	S-GP
.	O
They	O
have	O
no	O
stimulatory	O
effects	O
on	O
the	O
uterus	O
or	O
vagina	O
.	O
It	O
seems	O
reasonable	O
to	O
expect	O
that	O
pure	O
antiestrogens	O
will	O
be	O
good	O
alternatives	O
to	O
tamoxifen	S-chemical
and	O
aromatase	O
inhibitors	O
in	O
the	O
treatment	O
of	O
breast	O
cancer	O
.	O

A	O
molecular	O
mechanism	O
of	O
action	O
of	O
theophylline	S-chemical
:	O
Induction	O
of	O
histone	B-GP
deacetylase	E-GP
activity	O
to	O
decrease	O
inflammatory	O
gene	O
expression	O
.	O
The	O
molecular	O
mechanism	O
for	O
the	O
anti-inflammatory	O
action	O
of	O
theophylline	S-chemical
is	O
currently	O
unknown	O
,	O
but	O
low-dose	O
theophylline	S-chemical
is	O
an	O
effective	O
add-on	O
therapy	O
to	O
corticosteroids	O
in	O
controlling	O
asthma	O
.	O
Corticosteroids	S-chemical
act	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
recruitment	O
of	O
histone	B-GP
deacetylases	E-GP
(	O
HDACs	S-GP
)	O
to	O
the	O
site	O
of	O
active	O
inflammatory	O
gene	O
transcription	O
.	O
They	O
thereby	O
inhibit	O
the	O
acetylation	O
of	O
core	O
histones	O
that	O
is	O
necessary	O
for	O
inflammatory	O
gene	O
transcription	O
.	O
We	O
show	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
that	O
low-dose	O
theophylline	S-chemical
enhances	O
HDAC	S-GP
activity	O
in	O
epithelial	O
cells	O
and	O
macrophages	O
.	O
This	O
increased	O
HDAC	S-GP
activity	O
is	O
then	O
available	O
for	O
corticosteroid	S-chemical
recruitment	O
and	O
predicts	O
a	O
cooperative	O
interaction	O
between	O
corticosteroids	S-chemical
and	O
theophylline	S-chemical
.	O
This	O
mechanism	O
occurs	O
at	O
therapeutic	O
concentrations	O
of	O
theophylline	S-chemical
and	O
is	O
dissociated	O
from	O
phosphodiesterase	S-GP
inhibition	O
(	O
the	O
mechanism	O
of	O
bronchodilation	O
)	O
or	O
the	O
blockade	O
of	O
adenosine	B-GP
receptors	E-GP
,	O
which	O
are	O
partially	O
responsible	O
for	O
its	O
side	O
effects	O
.	O
Thus	O
we	O
have	O
shown	O
that	O
low-dose	O
theophylline	S-chemical
exerts	O
an	O
anti-asthma	O
effect	O
through	O
increasing	O
activation	O
of	O
HDAC	S-GP
which	O
is	O
subsequently	O
recruited	O
by	O
corticosteroids	S-chemical
to	O
suppress	O
inflammatory	O
genes	O
.	O

The	O
ability	O
of	O
sorafenib	S-chemical
to	O
inhibit	O
oncogenic	O
PDGFRbeta	S-GP
and	O
FLT3	S-GP
mutants	O
and	O
overcome	O
resistance	O
to	O
other	O
small	O
molecule	O
inhibitors	O
.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Activated	O
tyrosine	B-GP
kinases	E-GP
are	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
and	O
acute	O
leukemia	O
,	O
and	O
represent	O
attractive	O
targets	O
for	O
therapy	O
.	O
Sorafenib	S-chemical
(	O
BAY43-9006	S-chemical
,	O
Nexavar	S-chemical
)	O
is	O
a	O
small	O
molecule	O
B-RAF	S-GP
inhibitor	O
that	O
is	O
used	O
for	O
the	O
treatment	O
of	O
renal	O
cell	O
carcinoma	O
,	O
and	O
has	O
been	O
shown	O
to	O
have	O
activity	O
against	O
receptor	B-GP
tyrosine	I-GP
kinases	E-GP
from	O
the	O
platelet-derived	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
(	O
PDGFR	S-GP
)	O
and	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	I-GP
receptor	E-GP
(	O
VEGFR	S-GP
)	O
families	O
.	O
We	O
investigated	O
the	O
efficacy	O
of	O
sorafenib	S-chemical
at	O
inhibiting	O
mutants	O
of	O
the	O
receptor	B-GP
tyrosine	I-GP
kinases	E-GP
PDGFRbeta	S-GP
,	O
KIT	S-GP
,	O
and	O
FLT3	S-GP
,	O
which	O
are	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
myeloid	O
malignancies	O
.	O
DESIGN	O
AND	O
METHODS	O
:	O
We	O
tested	O
the	O
effect	O
of	O
sorafenib	S-chemical
on	O
the	O
proliferation	O
of	O
hematopoietic	O
cells	O
transformed	O
by	O
ETV6	S-GP
-	O
PDGFRbeta	S-GP
,	O
FLT3	S-GP
with	O
an	O
internal	O
tandem	O
duplication	O
or	O
D835Y	S-GP
point	O
mutation	O
,	O
and	O
the	O
KIT	S-GP
(	O
D816V	S-GP
)	O
mutant	O
.	O
The	O
direct	O
effect	O
of	O
sorafenib	S-chemical
on	O
the	O
activity	O
of	O
these	O
kinases	S-GP
and	O
their	O
downstream	O
signaling	O
was	O
tested	O
using	O
phospho	S-chemical
-specific	O
antibodies	O
.	O
RESULTS	O
:	O
We	O
show	O
that	O
sorafenib	S-chemical
is	O
a	O
potent	O
inhibitor	O
of	O
ETV6	S-GP
-	O
PDGFRbeta	S-GP
and	O
FLT3	S-GP
mutants	O
,	O
including	O
some	O
of	O
the	O
mutants	O
that	O
confer	O
resistance	O
to	O
PKC412	O
and	O
other	O
FLT3	S-GP
inhibitors	O
.	O
Sorafenib	S-chemical
induced	O
a	O
cell	O
cycle	O
block	O
and	O
apoptosis	O
in	O
the	O
acute	O
myeloid	O
leukemia	O
cell	O
lines	O
MV4-11	O
and	O
MOLM-13	O
,	O
both	O
expressing	O
FLT3	S-GP
with	O
an	O
internal	O
tandem	O
duplication	O
,	O
whereas	O
no	O
effect	O
was	O
observed	O
on	O
four	O
other	O
acute	O
myeloid	O
leukemia	O
cell	O
lines	O
.	O
The	O
imatinib	S-chemical
-resistant	O
KIT	S-GP
(	O
D816V	S-GP
)	O
mutant	O
,	O
associated	O
with	O
systemic	O
mastocytosis	O
,	O
was	O
found	O
to	O
be	O
resistant	O
to	O
sorafenib	S-chemical
.	O
INTERPRETATION	O
AND	O
CONCLUSIONS	O
:	O
These	O
results	O
warrant	O
further	O
clinical	O
studies	O
of	O
sorafenib	S-chemical
for	O
the	O
treatment	O
of	O
myeloid	O
malignancies	O
expressing	O
activated	O
forms	O
of	O
PDGFRbeta	S-GP
and	O
FLT3	S-GP
.	O

Crizotinib	S-chemical
in	O
the	O
treatment	O
of	O
non-small-cell	O
lung	O
cancer	O
.	O
INTRODUCTION	O
:	O
Recent	O
progress	O
in	O
identifying	O
distinct	O
subsets	O
of	O
lung	O
cancer	O
,	O
based	O
on	O
critical	O
driver	O
mutations	O
,	O
has	O
led	O
to	O
increasingly	O
focused	O
efforts	O
in	O
the	O
development	O
of	O
selectively	O
targeted	O
therapies	O
.	O
The	O
fusion	O
oncogene	O
,	O
echinoderm	B-GP
microtubule-associated	I-GP
protein-like	I-GP
4	E-GP
-	O
anaplastic	B-GP
lymphoma	I-GP
kinase	E-GP
(	O
EML4	S-GP
-	O
ALK	S-GP
)	O
,	O
is	O
present	O
in	O
approximately	O
5	O
%	O
of	O
non-small-cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
tumors	O
.	O
Crizotinib	S-chemical
is	O
an	O
oral	O
tyrosine	B-GP
kinase	E-GP
inhibitor	O
(	O
TKI	O
)	O
,	O
which	O
silences	O
the	O
protein	O
product	O
of	O
the	O
ALK	S-GP
fusion	O
gene	O
and	O
has	O
recently	O
been	O
approved	O
for	O
the	O
treatment	O
of	O
NSCLC	O
aberrantly	O
expressing	O
ALK	S-GP
.	O
Emerging	O
data	O
suggest	O
that	O
crizotinib	S-chemical
may	O
also	O
have	O
activity	O
in	O
other	O
subsets	O
of	O
lung	O
cancer	O
,	O
including	O
tumors	O
demonstrating	O
amplification	O
or	O
mutation	O
of	O
the	O
MET	S-GP
oncogene	O
,	O
or	O
translocation	O
of	O
the	O
ROS1	S-GP
oncogene	O
.	O
AREAS	O
COVERED	O
:	O
This	O
paper	O
gives	O
an	O
overview	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
ALK	S-GP
-associated	O
NSCLC	O
.	O
It	O
also	O
reviews	O
the	O
pharmacokinetic	O
and	O
pharmacodynamic	O
data	O
on	O
crizotinib	S-chemical
and	O
outlines	O
the	O
preclinical	O
and	O
clinical	O
studies	O
leading	O
to	O
the	O
approval	O
of	O
crizotinib	S-chemical
.	O
In	O
addition	O
,	O
it	O
discusses	O
its	O
role	O
in	O
the	O
treatment	O
of	O
NSCLC	O
expressing	O
ALK	S-GP
.	O
EXPERT	O
OPINION	O
:	O
Crizotinib	S-chemical
represents	O
the	O
newest	O
example	O
of	O
a	O
focused	O
strategy	O
for	O
drug	O
development	O
in	O
lung	O
cancer	O
,	O
based	O
on	O
identification	O
and	O
targeted	O
inhibition	O
of	O
critical	O
tumor-specific	O
driver	O
mutations	O
.	O
Crizotinib	S-chemical
has	O
demonstrated	O
efficacy	O
against	O
ALK	S-GP
-rearranged	O
NSCLC	O
,	O
and	O
has	O
potential	O
for	O
broader	O
application	O
in	O
select	O
subsets	O
of	O
lung	O
cancer	O
.	O

Oncolytic	O
activity	O
and	O
mechanism	O
of	O
action	O
of	O
a	O
novel	O
L-cysteine	S-chemical
derivative	O
,	O
L-cysteine	B-chemical
,	I-chemical
ethyl	I-chemical
ester	I-chemical
,	I-chemical
S-	I-chemical
(	I-chemical
N-methylcarbamate	I-chemical
)	I-chemical
monohydrochloride	E-chemical
.	O
A	O
study	O
on	O
the	O
oncolytic	O
activity	O
of	O
the	O
L-cysteine	S-chemical
derivative	O
L-cysteine	B-chemical
,	I-chemical
ethyl	I-chemical
ester	I-chemical
,	I-chemical
S-	I-chemical
(	I-chemical
N-methylcarbamate	I-chemical
)	I-chemical
monohydrochloride	E-chemical
(	O
NSC	B-chemical
303861	E-chemical
)	O
,	O
revealed	O
that	O
the	O
drug	O
caused	O
complete	O
regression	O
of	O
the	O
MX-1	O
human	O
mammary	O
tumor	O
xenograft	O
.	O
The	O
compound	O
also	O
exhibited	O
moderate	O
antitumor	O
activity	O
against	O
murine	O
leukemia	O
P388	O
(	O
T/C	O
value	O
of	O
169	O
%	O
at	O
a	O
daily	O
dose	O
of	O
400	O
mg/kg	O
)	O
and	O
against	O
M5076	O
sarcoma	O
(	O
T/C	O
value	O
of	O
135	O
%	O
at	O
a	O
daily	O
dose	O
of	O
600	O
mg/kg	O
)	O
.	O
The	O
drug	O
was	O
inactive	O
against	O
B16	O
melanoma	O
,	O
Lewis	O
lung	O
,	O
colon	O
38	O
and	O
CD8F1	O
mammary	O
carcinomas	O
.	O
The	O
compound	O
exhibited	O
significant	O
cytotoxicity	O
against	O
hepatoma	O
3924A	O
cells	O
in	O
culture	O
(	O
LC50	O
=	O
6	O
microM	O
)	O
.	O
Studies	O
on	O
the	O
mechanism	O
of	O
action	O
revealed	O
that	O
the	O
cytotoxicity	O
of	O
the	O
drug	O
could	O
be	O
partially	O
abrogated	O
by	O
protecting	O
hepatoma	O
3924A	O
cells	O
in	O
culture	O
with	O
L-glutamine	S-chemical
.	O
At	O
6	O
h	O
after	O
injection	O
of	O
the	O
compound	O
(	O
400	O
mg/kg	O
)	O
into	O
rats	O
bearing	O
hepatoma	O
3924A	O
,	O
the	O
pools	O
of	O
L-glutamine	S-chemical
and	O
L-glutamate	S-chemical
in	O
the	O
tumor	O
decreased	O
to	O
33	O
%	O
and	O
71	O
%	O
,	O
respectively	O
,	O
of	O
control	O
levels	O
;	O
the	O
drug	O
selectively	O
inhibited	O
the	O
activities	O
of	O
L-glutamine	S-chemical
-requiring	O
enzymes	O
of	O
purine	B-chemical
nucleotide	E-chemical
biosynthesis	O
,	O
amidophosphoribosyltransferase	S-GP
,	O
FGAM	B-GP
synthase	E-GP
,	O
and	O
GMP	B-GP
synthase	E-GP
,	O
to	O
21	O
%	O
,	O
1	O
%	O
,	O
and	O
69	O
%	O
,	O
respectively	O
,	O
without	O
significantly	O
altering	O
the	O
activities	O
of	O
pyrimidine	S-chemical
biosynthetic	O
enzymes	O
,	O
carbamoylphosphate	B-GP
synthase	I-GP
II	E-GP
and	O
CTP	B-GP
synthase	E-GP
.	O
Measurement	O
of	O
the	O
nucleotide	S-chemical
concentrations	O
further	O
corroborated	O
the	O
actions	O
of	O
the	O
drug	O
on	O
the	O
purine	B-chemical
nucleotide	E-chemical
biosynthetic	O
enzyme	O
activities	O
.	O
Drug	O
injection	O
(	O
400	O
mg/kg	O
)	O
in	O
the	O
hepatoma	O
3924A-bearing	O
rats	O
reduced	O
the	O
concentrations	O
of	O
IMP	S-chemical
in	O
the	O
tumor	O
to	O
52	O
%	O
,	O
those	O
of	O
total	O
adenylates	S-chemical
to	O
52	O
%	O
,	O
those	O
of	O
total	O
guanylates	S-chemical
to	O
57	O
%	O
,	O
and	O
those	O
of	O
NAD	S-chemical
to	O
73	O
%	O
,	O
without	O
significantly	O
perturbing	O
the	O
pyrimidine	B-chemical
nucleotide	E-chemical
pools	O
.	O
Studies	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
L-cysteine	S-chemical
derivative	O
suggested	O
that	O
the	O
compound	O
behaved	O
as	O
an	O
L-glutamine	S-chemical
antagonist	O
,	O
selectively	O
acting	O
on	O
the	O
enzymes	O
of	O
purine	B-chemical
nucleotide	E-chemical
biosynthesis	O
.	O

New	O
oral	O
anticoagulants	O
:	O
comparative	O
pharmacology	O
with	O
vitamin	B-chemical
K	E-chemical
antagonists	O
.	O
New	O
oral	O
anticoagulants	O
(	O
OACs	O
)	O
that	O
directly	O
inhibit	O
Factor	B-GP
Xa	E-GP
(	O
FXa	S-GP
)	O
or	O
thrombin	S-GP
have	O
been	O
developed	O
for	O
the	O
long-term	O
prevention	O
of	O
thromboembolic	O
disorders	O
.	O
These	O
novel	O
agents	O
provide	O
numerous	O
benefits	O
over	O
older	O
vitamin	B-chemical
K	E-chemical
antagonists	O
(	O
VKAs	O
)	O
due	O
to	O
major	O
pharmacological	O
differences	O
.	O
VKAs	O
are	O
economical	O
and	O
very	O
well	O
characterized	O
,	O
but	O
have	O
important	O
limitations	O
that	O
can	O
outweigh	O
these	O
advantages	O
,	O
such	O
as	O
slow	O
onset	O
of	O
action	O
,	O
narrow	O
therapeutic	O
window	O
and	O
unpredictable	O
anticoagulant	O
effect	O
.	O
VKA-associated	O
dietary	O
precautions	O
,	O
monitoring	O
and	O
dosing	O
adjustments	O
to	O
maintain	O
international	O
normalized	O
ratio	O
(	O
INR	O
)	O
within	O
therapeutic	O
range	O
,	O
and	O
bridging	O
therapy	O
,	O
are	O
inconvenient	O
for	O
patients	O
,	O
expensive	O
,	O
and	O
may	O
result	O
in	O
inappropriate	O
use	O
of	O
VKA	O
therapy	O
.	O
This	O
may	O
lead	O
to	O
increased	O
bleeding	O
risk	O
or	O
reduced	O
anticoagulation	O
and	O
increased	O
risk	O
of	O
thrombotic	O
events	O
.	O
The	O
new	O
OACs	O
have	O
rapid	O
onset	O
of	O
action	O
,	O
low	O
potential	O
for	O
food	O
and	O
drug	O
interactions	O
,	O
and	O
predictable	O
anticoagulant	O
effect	O
that	O
removes	O
the	O
need	O
for	O
routine	O
monitoring	O
.	O
FXa	S-GP
inhibitors	O
,	O
e.g	O
.	O
rivaroxaban	S-chemical
and	O
apixaban	S-chemical
,	O
are	O
potent	O
,	O
oral	O
direct	O
inhibitors	O
of	O
prothrombinase	S-GP
-bound	O
,	O
clot-associated	O
or	O
free	O
FXa	S-GP
.	O
Both	O
agents	O
have	O
a	O
rapid	O
onset	O
of	O
action	O
,	O
a	O
wide	O
therapeutic	O
window	O
,	O
little	O
or	O
no	O
interaction	O
with	O
food	O
and	O
other	O
drugs	O
,	O
minimal	O
inter-patient	O
variability	O
,	O
and	O
display	O
similar	O
pharmacokinetics	O
in	O
different	O
patient	O
populations	O
.	O
Since	O
both	O
are	O
substrates	O
,	O
co-administration	O
of	O
rivaroxaban	S-chemical
and	O
apixaban	S-chemical
with	O
strong	O
cytochrome	B-GP
P450	I-GP
(	I-GP
CYP	I-GP
)	I-GP
3A4	E-GP
and	O
permeability	B-GP
glycoprotein	E-GP
(	O
P-gp	S-GP
)	O
inhibitors	O
and	O
inducers	O
can	O
result	O
in	O
substantial	O
changes	O
in	O
plasma	O
concentrations	O
due	O
to	O
altered	O
clearance	O
rates	O
;	O
consequently	O
,	O
their	O
concomitant	O
use	O
is	O
contraindicated	O
and	O
caution	O
is	O
required	O
when	O
used	O
concomitantly	O
with	O
strong	O
CYP3A4	S-GP
and	O
P-gp	S-GP
inducers	O
.	O
Although	O
parenteral	O
oral	O
direct	O
thrombin	S-GP
inhibitors	O
(	O
DTIs	O
)	O
,	O
such	O
as	O
argatroban	S-chemical
and	O
bivalirudin	O
,	O
have	O
been	O
on	O
the	O
market	O
for	O
years	O
,	O
DTIs	O
such	O
as	O
dabigatran	S-chemical
are	O
novel	O
synthetic	O
thrombin	S-GP
antagonists	O
.	O
Dabigatran	B-chemical
etexilate	E-chemical
is	O
a	O
low-molecular-weight	O
non-active	O
pro-drug	O
that	O
is	O
administered	O
orally	O
and	O
converted	O
rapidly	O
to	O
its	O
active	O
form	O
,	O
dabigatran	S-chemical
--	O
a	O
potent	O
,	O
competitive	O
and	O
reversible	O
DTI	O
.	O
Dabigatran	S-chemical
has	O
an	O
advantage	O
over	O
the	O
indirect	O
thrombin	S-GP
inhibitors	O
,	O
unfractionated	O
heparin	O
and	O
low-molecular-weight	O
heparin	O
,	O
in	O
that	O
it	O
inhibits	O
free	O
and	O
fibrin	S-GP
-bound	O
thrombin	S-GP
.	O
The	O
reversible	O
binding	O
of	O
dabigatran	S-chemical
may	O
provide	O
safer	O
and	O
more	O
predictable	O
anticoagulant	O
treatment	O
than	O
seen	O
with	O
irreversible	O
,	O
non-covalent	O
thrombin	S-GP
inhibitors	O
,	O
e.g	O
.	O
hirudin	O
.	O
Dabigatran	S-chemical
shows	O
a	O
very	O
low	O
potential	O
for	O
drug-drug	O
interactions	O
.	O
However	O
,	O
co-administration	O
of	O
dabigatran	B-chemical
etexilate	E-chemical
with	O
other	O
anticoagulants	O
and	O
antiplatelet	O
agents	O
can	O
increase	O
the	O
bleeding	O
risk	O
.	O
Although	O
the	O
new	O
agents	O
are	O
pharmacologically	O
better	O
than	O
VKAs	O
--	O
particularly	O
in	O
terms	O
of	O
fixed	O
dosing	O
,	O
rapid	O
onset	O
of	O
action	O
,	O
no	O
INR	O
monitoring	O
and	O
lower	O
risk	O
of	O
drug	O
interactions	O
--	O
there	O
are	O
some	O
differences	O
between	O
them	O
:	O
the	O
bioavailability	O
of	O
dabigatran	S-chemical
is	O
lower	O
than	O
rivaroxaban	S-chemical
and	O
apixaban	S-chemical
,	O
and	O
so	O
the	O
dabigatran	S-chemical
dosage	O
required	O
is	O
higher	O
;	O
lower	O
protein	O
binding	O
of	O
dabigatran	S-chemical
reduces	O
the	O
variability	O
related	O
to	O
albuminaemia	O
.	O
The	O
risk	O
of	O
metabolic	O
drug-drug	O
interactions	O
also	O
appears	O
to	O
differ	O
between	O
OACs	O
:	O
VKAs	O
>	O
rivaroxaban	S-chemical
>	O
apixaban	S-chemical
>	O
dabigatran	S-chemical
.	O
The	O
convenience	O
of	O
the	O
new	O
OACs	O
has	O
translated	O
into	O
improvements	O
in	O
efficacy	O
and	O
safety	O
as	O
shown	O
in	O
phase	O
III	O
randomized	O
trials	O
.	O
The	O
new	O
anticoagulants	O
so	O
far	O
offer	O
the	O
greatest	O
promise	O
and	O
opportunity	O
for	O
the	O
replacement	O
of	O
VKAs	O
.	O

Inhibition	O
of	O
EGF	S-GP
/	O
EGFR	S-GP
activation	O
with	O
naphtho	B-chemical
[	I-chemical
1,2-b	I-chemical
]	I-chemical
furan-4,5-dione	E-chemical
blocks	O
migration	O
and	O
invasion	O
of	O
MDA-MB-231	O
cells	O
.	O
Naphtho	B-chemical
[	I-chemical
1,2-b	I-chemical
]	I-chemical
furan-4,5-dione	E-chemical
(	O
NFD	S-chemical
)	O
,	O
a	O
bioactive	O
component	O
of	O
Avicennia	O
marina	O
,	O
has	O
been	O
demonstrated	O
to	O
display	O
anti-cancer	O
activity	O
.	O
Activation	O
of	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
(	O
EGFR	S-GP
)	O
-induced	O
signaling	O
pathway	O
has	O
been	O
correlated	O
with	O
cancer	O
metastasis	O
in	O
various	O
tumors	O
,	O
including	O
breast	O
carcinoma	O
.	O
We	O
use	O
EGF	S-GP
as	O
a	O
metastatic	O
inducer	O
of	O
MDA-MB-231	O
cells	O
to	O
investigate	O
the	O
effect	O
of	O
NFD	S-chemical
on	O
cell	O
migration	O
and	O
invasion	O
.	O
NFD	S-chemical
suppressed	O
EGF	S-GP
-mediated	O
protein	O
levels	O
of	O
c-Jun	S-GP
and	O
c-Fos	S-GP
,	O
and	O
reduced	O
MMP-9	S-GP
expression	O
and	O
activity	O
,	O
concomitantly	O
with	O
a	O
marked	O
inhibition	O
on	O
cell	O
migration	O
and	O
invasion	O
without	O
obvious	O
cellular	O
cytotoxicity	O
.	O
NFD	S-chemical
abrogated	O
EGF	S-GP
-induced	O
phosphorylation	O
of	O
EGF	B-GP
receptor	E-GP
(	O
EGFR	S-GP
)	O
and	O
phosphatidylinositol	B-GP
3-kinase	E-GP
(	O
PI3K	S-GP
)	O
/	O
Akt	S-GP
.	O
The	O
specific	O
PI3K	S-GP
inhibitor	O
,	O
wortmannin	S-chemical
,	O
blocked	O
significantly	O
EGF	S-GP
-induced	O
cell	O
migration	O
and	O
invasion	O
.	O
Furthermore	O
,	O
the	O
EGFR	S-GP
inhibitor	O
AG1478	S-chemical
inhibited	O
EGF	S-GP
-induced	O
MMP-9	S-GP
expression	O
,	O
cell	O
migration	O
and	O
invasion	O
,	O
as	O
well	O
as	O
the	O
activation	O
of	O
PI3K	S-GP
/	O
Akt	S-GP
,	O
suggesting	O
that	O
PI3K	S-GP
/	O
Akt	S-GP
activation	O
occur	O
downstream	O
of	O
EGFR	S-GP
activation	O
.	O
These	O
findings	O
suggest	O
that	O
NFD	S-chemical
inhibited	O
the	O
EGF	S-GP
-induced	O
invasion	O
and	O
migration	O
of	O
MDA-MB-231	O
cells	O
via	O
EGFR	S-GP
-dependent	O
PI3K	S-GP
/	O
Akt	S-GP
signaling	O
,	O
leading	O
to	O
the	O
down-regulation	O
of	O
MMP-9	S-GP
expression	O
.	O
These	O
results	O
provide	O
a	O
novel	O
mechanism	O
to	O
explain	O
the	O
role	O
of	O
NFD	S-chemical
as	O
a	O
potent	O
anti-metastatic	O
agent	O
in	O
MDA-MB-231	O
cells	O
.	O

24	B-chemical
(	I-chemical
S	I-chemical
)	I-chemical
-hydroxycholesterol	E-chemical
is	O
actively	O
eliminated	O
from	O
neuronal	O
cells	O
by	O
ABCA1	S-GP
.	O
High	O
cholesterol	S-chemical
turnover	O
catalyzed	O
by	O
cholesterol	B-GP
24-hydroxylase	E-GP
is	O
essential	O
for	O
neural	O
functions	O
,	O
especially	O
learning	O
.	O
Because	O
24	B-chemical
(	I-chemical
S	I-chemical
)	I-chemical
-hydroxycholesterol	E-chemical
(	O
24-OHC	S-chemical
)	O
,	O
produced	O
by	O
24-hydroxylase	S-GP
,	O
induces	O
apoptosis	O
of	O
neuronal	O
cells	O
,	O
it	O
is	O
vital	O
to	O
eliminate	O
it	O
rapidly	O
from	O
cells	O
.	O
Here	O
,	O
using	O
differentiated	O
SH-SY5Y	O
neuron-like	O
cells	O
as	O
a	O
model	O
,	O
we	O
examined	O
whether	O
24-OHC	S-chemical
is	O
actively	O
eliminated	O
via	O
transporters	S-GP
induced	O
by	O
its	O
accumulation	O
.	O
The	O
expression	O
of	O
ABCA1	S-GP
and	O
ABCG1	S-GP
was	O
induced	O
by	O
24-OHC	S-chemical
,	O
as	O
well	O
as	O
TO901317	S-chemical
and	O
retinoic	B-chemical
acid	E-chemical
,	O
which	O
are	O
ligands	O
of	O
the	O
nuclear	B-GP
receptors	E-GP
LXR	S-GP
/	O
RXR	S-GP
.	O
When	O
the	O
expression	O
of	O
ABCA1	S-GP
and	O
ABCG1	S-GP
was	O
induced	O
,	O
24-OHC	S-chemical
efflux	O
was	O
stimulated	O
in	O
the	O
presence	O
of	O
high	B-GP
density	I-GP
lipoprotein	E-GP
(	O
HDL	S-GP
)	O
,	O
whereas	O
apolipoprotein	B-GP
A-I	E-GP
was	O
not	O
an	O
efficient	O
acceptor	O
.	O
The	O
efflux	O
was	O
suppressed	O
by	O
the	O
addition	O
of	O
siRNA	O
against	O
ABCA1	S-GP
,	O
but	O
not	O
by	O
ABCG1	S-GP
siRNA	O
.	O
To	O
confirm	O
the	O
role	O
of	O
each	O
transporter	O
,	O
we	O
analyzed	O
HEK293	O
cells	O
stably	O
expressing	O
human	B-GP
ABCA1	E-GP
or	O
ABCG1	S-GP
;	O
we	O
clearly	O
observed	O
24-OHC	S-chemical
efflux	O
in	O
the	O
presence	O
of	O
HDL	S-GP
,	O
whereas	O
efflux	O
in	O
the	O
presence	O
of	O
apolipoprotein	B-GP
A-I	E-GP
was	O
marginal	O
.	O
Furthermore	O
,	O
the	O
treatment	O
of	O
primary	O
cerebral	O
neurons	O
with	O
LXR	S-GP
/	O
RXR	S-GP
ligands	O
suppressed	O
the	O
toxicity	O
of	O
24-OHC	S-chemical
.	O
These	O
results	O
suggest	O
that	O
ABCA1	S-GP
actively	O
eliminates	O
24-OHC	S-chemical
in	O
the	O
presence	O
of	O
HDL	S-GP
as	O
a	O
lipid	O
acceptor	O
and	O
protects	O
neuronal	O
cells	O
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O

Ocular	O
hypotensive	O
FP	O
prostaglandin	S-chemical
(	O
PG	S-chemical
)	O
analogs	O
:	O
PG	B-GP
receptor	E-GP
subtype	O
binding	O
affinities	O
and	O
selectivities	O
,	O
and	O
agonist	O
potencies	O
at	O
FP	S-GP
and	O
other	O
PG	B-GP
receptors	E-GP
in	O
cultured	O
cells	O
.	O
Natural	O
prostaglandins	S-chemical
(	O
PGs	S-chemical
)	O
such	O
as	O
PGD2	S-chemical
,	O
PGE2	S-chemical
,	O
PGF2	B-chemical
(	I-chemical
2alpha	I-chemical
)	E-chemical
,	O
and	O
PGI2	S-chemical
exhibited	O
the	O
highest	O
affinity	O
for	O
their	O
respective	O
cognate	O
receptors	O
,	O
but	O
were	O
the	O
least	O
selective	O
agents	O
when	O
tested	O
in	O
receptor	O
binding	O
assays	O
.	O
Travoprost	B-chemical
acid	E-chemical
(	O
[	B-chemical
+	I-chemical
]	I-chemical
-fluprostenol	E-chemical
)	O
was	O
the	O
most	O
FP-receptor	S-GP
-selective	O
compound	O
,	O
exhibiting	O
a	O
high	O
affinity	O
(	O
Ki	O
=	O
35	O
+/-	O
5	O
nM	O
)	O
for	O
the	O
FP	B-GP
receptor	E-GP
,	O
and	O
minimal	O
affinity	O
for	O
DP	S-GP
(	O
Ki	O
=	O
52,000	O
nM	O
)	O
,	O
EP1	S-GP
(	O
Ki	O
=	O
9540	O
nM	O
)	O
,	O
EP3	S-GP
(	O
Ki	O
=	O
3501	O
nM	O
)	O
,	O
EP4	S-GP
(	O
Ki	O
=	O
41,000	O
nM	O
)	O
,	O
IP	S-GP
(	O
Ki	O
>	O
90,000	O
nM	O
)	O
,	O
and	O
TP	S-GP
(	O
Ki	O
=	O
121,000	O
nM	O
)	O
receptors	O
.	O
Travoprost	B-chemical
acid	E-chemical
was	O
the	O
most	O
potent	O
PG	S-chemical
analog	O
tested	O
in	O
FP	B-GP
receptor	E-GP
functional	O
phosphoinositide	S-chemical
turnover	O
assays	O
in	O
the	O
following	O
cell	O
types	O
:	O
human	O
ciliary	O
muscle	O
(	O
EC50	O
=	O
1.4	O
nM	O
)	O
,	O
human	O
trabecular	O
meshwork	O
(	O
EC50	O
=	O
3.6	O
nM	O
)	O
,	O
and	O
mouse	O
fibroblasts	O
and	O
rat	O
aortic	O
smooth	O
muscle	O
cells	O
(	O
EC50	O
=	O
2.6	O
nM	O
)	O
.	O
Although	O
latanoprost	B-chemical
acid	E-chemical
exhibited	O
a	O
relatively	O
high	O
affinity	O
for	O
the	O
FP	B-GP
receptor	E-GP
(	O
Ki	O
=	O
98	O
nM	O
)	O
,	O
it	O
had	O
significant	O
functional	O
activity	O
at	O
FP	S-GP
(	O
EC50	O
=	O
32-124	O
nM	O
)	O
and	O
EP1	S-GP
(	O
EC50	O
=	O
119	O
nM	O
)	O
receptors	O
.	O
Bimatoprost	B-chemical
acid	E-chemical
was	O
less	O
selective	O
,	O
exhibiting	O
a	O
relatively	O
high	O
affinity	O
for	O
the	O
FP	S-GP
(	O
Ki	O
=	O
83	O
nM	O
)	O
,	O
EP1	S-GP
(	O
Ki	O
=	O
95	O
nM	O
)	O
,	O
and	O
EP3	S-GP
(	O
Ki	O
=	O
387	O
nM	O
)	O
receptors	O
.	O
Bimatoprost	B-chemical
acid	E-chemical
exhibited	O
functional	O
activity	O
at	O
the	O
EP1	S-GP
(	O
EC50	O
=	O
2.7	O
nM	O
)	O
and	O
FP	S-GP
(	O
EC50	O
=	O
2.8-3.8	O
nM	O
in	O
most	O
cells	O
)	O
receptors	O
.	O
Bimatoprost	S-chemical
(	O
nonhydrolyzed	O
amide	O
)	O
also	O
behaved	O
as	O
an	O
FP	S-GP
agonist	O
at	O
the	O
cloned	O
human	B-GP
FP	I-GP
receptor	E-GP
(	O
EC50	O
=	O
681	O
nM	O
)	O
,	O
in	O
h-TM	O
(	O
EC50	O
=	O
3245	O
nM	O
)	O
and	O
other	O
cell	O
types	O
.	O
Unoprostone	S-chemical
and	O
S-1033	S-chemical
bound	O
with	O
low	O
affinity	O
(	O
Ki	O
=	O
5.9	O
microM	O
to	O
>	O
22	O
microM	O
)	O
to	O
the	O
FP	B-GP
receptor	E-GP
,	O
were	O
not	O
selective	O
,	O
but	O
activated	O
the	O
FP	B-GP
receptor	E-GP
.	O
In	O
conclusion	O
,	O
travoprost	B-chemical
acid	E-chemical
has	O
the	O
highest	O
affinity	O
,	O
the	O
highest	O
FP-receptor	S-GP
-selectivity	O
,	O
and	O
the	O
highest	O
potency	O
at	O
the	O
FP	B-GP
receptor	E-GP
as	O
compared	O
to	O
the	O
other	O
ocular	O
hypotensive	O
PG	O
analogs	O
known	O
so	O
far	O
,	O
including	O
free	B-chemical
acids	I-chemical
of	I-chemical
latanoprost	I-chemical
,	I-chemical
bimatoprost	I-chemical
,	I-chemical
and	I-chemical
unoprostone	I-chemical
isopropyl	I-chemical
ester	E-chemical
.	O

Metabolism	O
of	O
triethylenetetramine	S-chemical
and	O
1,12-diamino-3,6,9-triazadodecane	S-chemical
by	O
the	O
spermidine	S-chemical
/spermine-N	O
(	O
1	O
)	O
-acetyltransferase	O
and	O
thialysine	O
acetyltransferase	O
.	O
Triethylenetetramine	O
(	O
TETA	O
;	O
Syprine	O
;	O
Merck	O
Rahway	O
,	O
NJ	O
)	O
,	O
a	O
drug	O
for	O
Wilson	O
's	O
disease	O
,	O
is	O
a	O
copper	O
chelator	O
and	O
a	O
charge-deficient	O
analog	O
of	O
polyamine	O
spermidine	O
.	O
We	O
recently	O
showed	O
that	O
TETA	O
is	O
metabolized	O
in	O
vitro	O
by	O
polyamine	O
catabolic	O
enzyme	O
spermidine/spermine-N	B-GP
(	I-GP
1	I-GP
)	I-GP
-acetyltransferase	E-GP
(	O
SSAT1	O
)	O
and	O
by	O
thialysine	O
acetyltransferase	O
(	O
SSAT2	O
)	O
to	O
its	O
monoacetylated	O
derivative	O
(	O
MAT	O
)	O
.	O
The	O
acetylation	O
of	O
TETA	O
is	O
increased	O
in	O
SSAT1-overexpressing	O
mice	O
compared	O
with	O
wild-type	O
mice	O
.	O
However	O
,	O
SSAT1-deficient	O
mice	O
metabolize	O
TETA	O
at	O
the	O
same	O
rate	O
as	O
the	O
wild-type	O
mice	O
,	O
indicating	O
the	O
existence	O
of	O
another	O
N-acetylase	O
respons	O
2ible	O
for	O
its	O
metabolism	O
in	O
mice	O
.	O
Here	O
,	O
we	O
show	O
that	O
siRNA-mediated	O
knockdown	O
of	O
SSAT2	O
in	O
HEPG2	O
cells	O
and	O
in	O
primary	O
hepatocytes	O
from	O
the	O
SSAT1-deficient	O
or	O
wild-type	O
mice	O
reduced	O
the	O
metabolism	O
of	O
TETA	O
to	O
MAT	O
.	O
By	O
contrast	O
,	O
1,12-diamino-3,6,9-triazadodecane	O
(	O
SpmTrien	O
)	O
,	O
a	O
charge-deficient	O
spermine	S-chemical

Effect	O
of	O
nuclear	O
vibrations	O
,	O
temperature	O
,	O
co-adsorbed	O
water	O
,	O
and	O
dye	O
orientation	O
on	O
light	O
absorption	O
,	O
charge	O
injection	O
and	O
recombination	O
conditions	O
in	O
organic	O
dyes	O
on	O
TiO2	S-chemical
.	O
We	O
study	O
the	O
effect	O
of	O
nuclear	O
motions	O
at	O
different	O
temperatures	O
,	O
including	O
the	O
effect	O
of	O
a	O
dye	O
molecule	O
's	O
orientation	O
with	O
respect	O
to	O
the	O
oxide	S-chemical
surface	O
,	O
on	O
factors	O
determining	O
the	O
performance	O
of	O
dye	O
sensitized	O
solar	O
cells	O
:	O
light	O
absorption	O
,	O
electron	O
injection	O
,	O
and	O
back-donation	O
.	O
We	O
perform	O
ab	O
initio	O
molecular	O
dynamics	O
simulations	O
of	O
aminophenyl	B-chemical
acid	E-chemical
dyes	O
NK1	S-chemical
and	O
NK7	S-chemical
,	O
differing	O
by	O
the	O
electron	O
donating	O
group	O
,	O
in	O
a	O
vacuum	O
and	O
adsorbed	O
in	O
mono-	O
and	O
bi-dentate	O
modes	O
on	O
a	O
dry	O
and	O
a	O
water-covered	O
anatase	B-chemical
(	I-chemical
101	I-chemical
)	E-chemical
surface	O
of	O
TiO	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
,	O
at	O
300	O
and	O
350	O
K.	O
Nuclear	O
vibrations	O
and	O
an	O
increase	O
of	O
temperature	O
cause	O
a	O
red	O
shift	O
in	O
the	O
absorption	O
spectra	O
of	O
free	O
dyes	O
.	O
This	O
effect	O
is	O
preserved	O
in	O
dyes	O
on	O
dry	O
TiO	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
but	O
largely	O
disappears	O
in	O
the	O
presence	O
of	O
water	O
.	O
Averaged	O
over	O
nuclear	O
vibrations	O
,	O
the	O
driving	O
force	O
to	O
injection	O
,	O
ΔG	O
,	O
differs	O
from	O
the	O
static	O
estimate	O
.	O
It	O
depends	O
on	O
the	O
adsorption	O
mode	O
and	O
the	O
presence	O
of	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
O	E-chemical
but	O
is	O
almost	O
the	O
same	O
for	O
300	O
and	O
350	O
K.	O
Recombination	O
to	O
the	O
dye	O
cation	O
is	O
expected	O
to	O
be	O
much	O
enhanced	O
by	O
the	O
approach	O
of	O
the	O
dye	O
oxidation	O
equivalent	O
hole	O
to	O
the	O
surface	O
during	O
dye	O
wagging	O
around	O
TiO	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
.	O
This	O
effect	O
is	O
somewhat	O
mitigated	O
by	O
the	O
co-adsorbed	O
water	O
.	O
The	O
dynamics	O
of	O
ΔG	O
(	O
t	O
)	O
are	O
explained	O
by	O
uncorrelated	O
evolution	O
of	O
the	O
energies	O
of	O
the	O
dye	O
excited	O
state	O
and	O
the	O
conduction	O
band	O
minimum	O
of	O
the	O
oxide	S-chemical
due	O
to	O
their	O
respective	O
vibrations	O
,	O
and	O
are	O
almost	O
independent	O
of	O
dye	O
orientation	O
.	O
It	O
may	O
therefore	O
be	O
possible	O
to	O
independently	O
control	O
the	O
conditions	O
of	O
recombination	O
and	O
of	O
injection	O
.	O

Free	O
volume	O
in	O
ionic	O
liquids	O
:	O
a	O
connection	O
of	O
experimentally	O
accessible	O
observables	O
from	O
PALS	O
and	O
PVT	O
experiments	O
with	O
the	O
molecular	O
structure	O
from	O
XRD	O
data	O
.	O
In	O
the	O
current	O
work	O
,	O
free	O
volume	O
concepts	O
,	O
primarily	O
applied	O
to	O
glass	O
formers	O
in	O
the	O
literature	O
,	O
were	O
transferred	O
to	O
ionic	O
liquids	O
(	O
ILs	O
)	O
.	O
A	O
series	O
of	O
1-butyl-3-methylimidazolium	S-chemical
(	O
[	B-chemical
C4MIM	I-chemical
]	I-chemical
(	I-chemical
+	I-chemical
)	E-chemical
)	O
based	O
ILs	O
was	O
investigated	O
by	O
Positron	O
Annihilation	O
Lifetime	O
Spectroscopy	O
(	O
PALS	O
)	O
.	O
The	O
phase	O
transition	O
and	O
dynamic	O
properties	O
of	O
the	O
ILs	O
[	O
C4MIM	S-chemical
]	O
[	O
X	O
]	O
with	O
[	O
X	O
]	O
(	O
-	O
)	O
=	O
[	B-chemical
Cl	I-chemical
]	I-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
[	B-chemical
BF4	I-chemical
]	I-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
[	B-chemical
PF6	I-chemical
]	I-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
[	B-chemical
OTf	I-chemical
]	I-chemical
(	I-chemical
-	I-chemical
)	E-chemical
,	O
[	B-chemical
NTf2	I-chemical
]	I-chemical
(	I-chemical
-	I-chemical
)	E-chemical
and	O
[	B-chemical
B	I-chemical
(	I-chemical
hfip	I-chemical
)	I-chemical
4	I-chemical
]	I-chemical
(	I-chemical
-	I-chemical
)	E-chemical
were	O
reported	O
recently	O
(	O
Yu	O
et	O
al.	O
,	O
Phys	O
.	O
Chem	O
.	O
Chem	O
.	O
Phys.	O
,	O
2012	O
,	O
14	O
,	O
6856-6868	O
)	O
.	O
In	O
this	O
subsequent	O
work	O
,	O
attention	O
was	O
paid	O
to	O
the	O
connection	O
of	O
the	O
free	O
volume	O
from	O
PALS	O
(	O
here	O
the	O
mean	O
hole	O
volume	O
,	O
〈vh〉	O
)	O
with	O
the	O
molecular	O
structure	O
,	O
represented	O
by	O
volumes	O
derived	O
from	O
X-ray	O
diffraction	O
(	O
XRD	O
)	O
data	O
.	O
These	O
were	O
the	O
scaled	O
molecular	O
volume	O
Vm	O
,	O
scaled	O
and	O
the	O
van	O
der	O
Waals	O
volume	O
Vvdw	O
.	O
Linear	O
correlations	O
of	O
〈vh〉	O
at	O
the	O
``	O
knee	O
''	O
temperature	O
(	O
〈vh〉	O
(	O
Tk	O
)	O
)	O
with	O
Vm	O
,	O
scaled	O
and	O
Vvdw	O
gave	O
good	O
results	O
for	O
the	O
[	B-chemical
C4MIM	I-chemical
]	I-chemical
(	I-chemical
+	I-chemical
)	E-chemical
series	O
.	O
Further	O
relationships	O
between	O
volumes	O
from	O
XRD	O
data	O
with	O
the	O
occupied	O
volume	O
Vocc	O
determined	O
from	O
PALS/PVT	O
(	O
Pressure	O
Volume	O
Temperature	O
)	O
measurements	O
and	O
from	O
Sanchez-Lacombe	O
Equation	O
of	O
State	O
(	O
SL-EOS	O
)	O
fits	O
were	O
elaborated	O
(	O
Vocc	O
(	O
SL-EOS	O
)	O
≈	O
1.63	O
Vvdw	O
,	O
R	O
(	O
2	O
)	O
=	O
0.981	O
and	O
Vocc	O
(	O
SL-EOS	O
)	O
≈	O
1.12	O
Vm	O
,	O
scaled	O
,	O
R	O
(	O
2	O
)	O
=	O
0.980	O
)	O
.	O
Finally	O
,	O
the	O
usability	O
of	O
Vm	O
,	O
scaled	O
was	O
justified	O
in	O
terms	O
of	O
the	O
Cohen-Turnbull	O
(	O
CT	O
)	O
free	O
volume	O
theory	O
.	O
Empirical	O
CT	O
type	O
plots	O
of	O
viscosity	O
and	O
electrical	O
conductivity	O
showed	O
a	O
systematic	O
increase	O
in	O
the	O
critical	O
free	O
volume	O
with	O
molecular	O
size	O
.	O
Such	O
correlations	O
allow	O
descriptions	O
of	O
IL	O
properties	O
with	O
the	O
easily	O
accessible	O
quantity	O
Vm	O
,	O
scaled	O
within	O
the	O
context	O
of	O
the	O
free	O
volume	O
.	O

Pharmacological	O
and	O
genetic	O
evidence	O
for	O
pre-	O
and	O
postsynaptic	O
D2	B-GP
receptor	E-GP
involvement	O
in	O
motor	O
responses	O
to	O
nociceptin/orphanin	B-GP
FQ	I-GP
receptor	E-GP
ligands	O
.	O
A	O
combined	O
pharmacological	O
and	O
genetic	O
approach	O
was	O
undertaken	O
to	O
investigate	O
the	O
contribution	O
of	O
endogenous	O
dopamine	S-chemical
to	O
the	O
motor	O
actions	O
of	O
nociceptin/orphanin	B-GP
FQ	I-GP
(	I-GP
N/OFQ	I-GP
)	I-GP
receptor	E-GP
(	O
NOP	B-GP
receptor	E-GP
)	O
ligands	O
.	O
Motor	O
activity	O
was	O
evaluated	O
by	O
a	O
battery	O
of	O
behavioural	O
tests	O
in	O
mice	O
.	O
The	O
involvement	O
of	O
the	O
various	O
DA	B-GP
receptor	E-GP
subtypes	O
in	O
the	O
motor	O
effects	O
of	O
N/OFQ	S-GP
and	O
NOP	B-GP
receptor	E-GP
antagonists	O
was	O
evaluated	O
pharmacologically	O
,	O
using	O
D1	S-GP
/	O
D5	S-GP
(	O
SCH23390	S-chemical
)	O
,	O
D2	S-GP
/	O
D3	S-GP
(	O
raclopride	S-chemical
,	O
amisulpride	S-chemical
)	O
and	O
D3	S-GP
(	O
S33084	S-chemical
)	O
receptor	O
antagonists	O
,	O
and	O
by	O
using	O
D2	B-GP
receptor	E-GP
knockout	O
mice	O
.	O
Low	O
doses	O
of	O
N/OFQ	S-GP
and	O
NOP	B-GP
receptor	E-GP
antagonists	O
promoted	O
movement	O
whereas	O
higher	O
doses	O
inhibited	O
it	O
.	O
Motor	O
facilitation	O
was	O
selectively	O
prevented	O
by	O
raclopride	S-chemical
while	O
motor	O
inhibition	O
was	O
prevented	O
by	O
amisulpride	S-chemical
.	O
Amisulpride	S-chemical
also	O
attenuated	O
the	O
hypolocomotion	O
induced	O
by	O
the	O
D2/D3	B-GP
receptor	E-GP
agonist	O
pramipexole	S-chemical
and	O
dopamine	S-chemical
precursor	O
L-3,4-dihydroxyphenylalanine	S-chemical
,	O
whereas	O
raclopride	S-chemical
(	O
and	O
S33084	S-chemical
)	O
worsened	O
it	O
.	O
To	O
dissect	O
out	O
the	O
contribution	O
of	O
pre-	O
and	O
postsynaptic	O
D2	B-GP
receptors	E-GP
,	O
mice	O
lacking	O
the	O
D2	B-GP
receptor	E-GP
(	O
D2R	S-GP
(	O
-/-	O
)	O
)	O
or	O
its	O
long	O
isoform	O
(	O
D2L	S-GP
(	O
-/-	O
)	O
)	O
were	O
used	O
.	O
Motor	O
facilitation	O
induced	O
by	O
N/OFQ	S-GP
and	O
NOP	B-GP
receptor	E-GP
antagonists	O
was	O
lost	O
in	O
D2R	S-GP
(	O
-/-	O
)	O
and	O
D2L	S-GP
(	O
-/-	O
)	O
mice	O
whereas	O
motor	O
inhibition	O
induced	O
by	O
NOP	B-GP
receptor	E-GP
antagonists	O
(	O
and	O
pramipexole	S-chemical
)	O
was	O
lost	O
in	O
D2R	S-GP
(	O
-/-	O
)	O
but	O
preserved	O
in	O
D2L	S-GP
(	O
-/-	O
)	O
mice	O
.	O
N/OFQ	S-GP
-induced	O
hypolocomotion	O
was	O
observed	O
in	O
both	O
genotypes	O
.	O
We	O
demonstrate	O
that	O
motor	O
actions	O
of	O
NOP	B-GP
receptor	E-GP
ligands	O
rely	O
on	O
the	O
modulation	O
of	O
endogenous	O
dopamine	S-chemical
.	O
Motor	O
facilitation	O
induced	O
by	O
NOP	B-GP
receptor	E-GP
antagonists	O
as	O
well	O
as	O
low	O
dose	O
N/OFQ	S-GP
is	O
mediated	O
through	O
D2L	S-GP
postsynaptic	O
receptors	O
whereas	O
motor	O
inhibition	O
observed	O
with	O
higher	O
doses	O
of	O
N/OFQ	S-GP
occurs	O
by	O
direct	O
inhibition	O
of	O
mesencephalic	O
DA	O
neurons	O
.	O
Motor	O
inhibition	O
seen	O
with	O
high	O
doses	O
of	O
NOP	B-GP
receptor	E-GP
antagonists	O
appears	O
to	O
be	O
mediated	O
through	O
the	O
D2	B-GP
presynaptic	I-GP
autoreceptors	E-GP
.	O
These	O
data	O
confirm	O
that	O
endogenous	O
N/OFQ	S-GP
is	O
a	O
powerful	O
modulator	O
of	O
dopamine	O
transmission	O
in	O
vivo	O
and	O
that	O
the	O
effects	O
of	O
NOP	B-GP
receptor	E-GP
antagonists	O
on	O
motor	O
function	O
reflect	O
the	O
blockade	O
of	O
this	O
endogenous	O
N/OFQ	S-GP
tone	O
.	O

Proposed	O
diagnostic	O
criteria	O
for	O
subclinical	O
Cushing	O
's	O
syndrome	O
associated	O
with	O
adrenal	O
incidentaloma	O
.	O
Subclinical	O
Cushing	O
's	O
syndrome	O
(	O
SCS	O
)	O
associated	O
with	O
adrenal	O
incidentaloma	O
is	O
usually	O
characterized	O
by	O
autonomous	O
cortisol	S-chemical
secretion	O
without	O
overt	O
symptoms	O
of	O
Cushing	O
's	O
syndrome	O
(	O
CS	O
)	O
.	O
Although	O
the	O
diagnostic	O
criteria	O
for	O
SCS	O
differ	O
among	O
countries	O
,	O
the	O
1	O
mg	O
dexamethasone	S-chemical
suppression	O
test	O
(	O
DST	O
)	O
is	O
essential	O
to	O
confirm	O
the	O
presence	O
and	O
the	O
extent	O
of	O
cortisol	S-chemical
overproduction	O
.	O
Since	O
1995	O
,	O
SCS	O
has	O
been	O
diagnosed	O
in	O
Japan	O
based	O
on	O
serum	O
cortisol	S-chemical
levels	O
≥3	O
μg/dl	O
(	O
measured	O
by	O
radioimmunoassay	O
[	O
RIA	O
]	O
)	O
after	O
a	O
1	O
mg	O
DST	O
.	O
However	O
,	O
the	O
increasing	O
use	O
of	O
enzyme	O
immunoassays	O
(	O
EIA	O
)	O
instead	O
of	O
RIA	O
has	O
hindered	O
the	O
diagnosis	O
of	O
SCS	O
because	O
of	O
the	O
differing	O
sensitivities	O
of	O
commercially	O
available	O
assays	O
,	O
particularly	O
for	O
serum	O
cortisol	S-chemical
levels	O
of	O
around	O
3	O
μg/dl	O
.	O
One	O
way	O
to	O
overcome	O
this	O
problem	O
is	O
to	O
lower	O
the	O
cortisol	S-chemical
threshold	O
level	O
after	O
a	O
1	O
mg	O
DST	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
clinical	O
applicability	O
of	O
lowering	O
the	O
cortisol	S-chemical
threshold	O
to	O
1.8	O
μg/dl	O
,	O
similar	O
to	O
the	O
American	O
Endocrine	O
Society	O
's	O
guidelines	O
for	O
CS	O
,	O
by	O
reanalyzing	O
119	O
patients	O
with	O
adrenal	O
incidentaloma	O
.	O
Our	O
findings	O
indicate	O
that	O
serum	O
cortisol	S-chemical
levels	O
≥1.8	O
μg/dl	O
after	O
1	O
mg	O
DST	O
are	O
useful	O
to	O
confirm	O
the	O
diagnosis	O
of	O
SCS	O
if	O
both	O
of	O
the	O
following	O
criteria	O
are	O
met	O
:	O
(	O
1	O
)	O
basal	O
ACTH	S-GP
level	O
<	O
10	O
pg/ml	O
(	O
or	O
poor	O
plasma	O
ACTH	S-GP
response	O
to	O
corticotrophin-releasing	B-GP
hormone	E-GP
)	O
and	O
(	O
2	O
)	O
serum	O
cortisol	S-chemical
≥5	O
μg/dl	O
at	O
21:00	O
to	O
23:00	O
h.	O
If	O
only	O
one	O
of	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
are	O
met	O
,	O
we	O
recommend	O
that	O
other	O
clinical	O
features	O
are	O
considered	O
in	O
the	O
diagnosis	O
of	O
SCS	O
,	O
including	O
serum	O
dehydroepiandrosterone	B-chemical
sulfate	E-chemical
levels	O
,	O
urine	O
free	O
cortisol	S-chemical
levels	O
,	O
adrenal	O
scintigraphy	O
,	O
and	O
clinical	O
manifestation	O
.	O

Haloperidol	S-chemical
promotes	O
mTORC1	S-GP
-dependent	O
phosphorylation	O
of	O
ribosomal	B-GP
protein	I-GP
S6	E-GP
via	O
dopamine-	B-GP
and	I-GP
cAMP-regulated	I-GP
phosphoprotein	I-GP
of	I-GP
32	I-GP
kDa	E-GP
and	O
inhibition	O
of	O
protein	B-GP
phosphatase-1	E-GP
.	O
The	O
ribosomal	B-GP
protein	I-GP
S6	E-GP
(	O
rpS6	S-GP
)	O
is	O
a	O
component	O
of	O
the	O
small	O
40S	B-GP
ribosomal	I-GP
subunit	E-GP
,	O
involved	O
in	O
multiple	O
physiological	O
functions	O
.	O
Here	O
,	O
we	O
examined	O
the	O
effects	O
produced	O
by	O
haloperidol	S-chemical
,	O
a	O
typical	O
antipsychotic	O
drug	O
,	O
on	O
the	O
phosphorylation	O
of	O
rpS6	S-GP
at	O
Ser	S-chemical
240/244	O
in	O
the	O
striatum	O
,	O
a	O
brain	O
region	O
involved	O
in	O
neurodegenerative	O
and	O
neuropsychiatric	O
disorders	O
.	O
Administration	O
of	O
haloperidol	S-chemical
increased	O
Ser	S-chemical
240/244	O
phosphorylation	O
in	O
a	O
subpopulation	O
of	O
GABA	S-chemical
-ergic	O
medium	O
spiny	O
neurons	O
(	O
MSNs	O
)	O
,	O
which	O
express	O
dopamine	B-GP
D2	I-GP
receptors	E-GP
(	O
D2Rs	S-GP
)	O
.	O
This	O
effect	O
was	O
prevented	O
by	O
rapamycin	S-chemical
,	O
an	O
inhibitor	O
of	O
the	O
mammalian	B-GP
target	I-GP
of	I-GP
rapamycin	I-GP
complex	I-GP
1	E-GP
(	O
mTORC1	S-GP
)	O
,	O
or	O
by	O
PF470867	S-chemical
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
p70	B-GP
ribosomal	I-GP
S6	I-GP
kinase	I-GP
1	E-GP
(	O
S6K1	S-GP
)	O
.	O
We	O
also	O
found	O
that	O
the	O
effect	O
of	O
haloperidol	S-chemical
on	O
Ser	S-chemical
240/244	O
phosphorylation	O
was	O
prevented	O
by	O
functional	O
inactivation	O
of	O
dopamine-	B-GP
and	I-GP
cAMP-regulated	I-GP
phosphoprotein	I-GP
of	I-GP
32	I-GP
kDa	E-GP
(	O
DARPP-32	S-GP
)	O
,	O
an	O
endogenous	O
inhibitor	O
of	O
protein	B-GP
phosphatase-1	E-GP
(	O
PP-1	S-GP
)	O
.	O
In	O
line	O
with	O
this	O
observation	O
,	O
incubation	O
of	O
striatal	O
slices	O
with	O
okadaic	B-chemical
acid	E-chemical
and	O
calyculin	B-chemical
A	E-chemical
,	O
two	O
inhibitors	O
of	O
PP-1	S-GP
,	O
increased	O
Ser	S-chemical
240/244	O
phosphorylation	O
.	O
These	O
results	O
show	O
that	O
haloperidol	S-chemical
promotes	O
mTORC1	S-GP
-	O
and	O
S6K1	S-GP
-dependent	O
phosphorylation	O
of	O
rpS6	S-GP
at	O
Ser	S-chemical
240/244	O
,	O
in	O
a	O
subpopulation	O
of	O
striatal	O
MSNs	O
expressing	O
D2Rs	S-GP
.	O
They	O
also	O
indicate	O
that	O
this	O
effect	O
is	O
exerted	O
by	O
suppressing	O
dephosphorylation	O
at	O
Ser	S-chemical
240/244	O
,	O
through	O
PKA	S-GP
-dependent	O
activation	O
of	O
DARPP-32	S-GP
and	O
inhibition	O
of	O
PP-1	S-GP
.	O

Two	O
pharmacologically	O
distinct	O
alpha	B-GP
1-adrenoceptor	E-GP
subtypes	O
in	O
the	O
contraction	O
of	O
rabbit	O
aorta	O
:	O
each	O
subtype	O
couples	O
with	O
a	O
different	O
Ca2+	S-chemical
signalling	O
mechanism	O
and	O
plays	O
a	O
different	O
physiological	O
role	O
.	O
Using	O
the	O
alpha	B-GP
1-adrenoceptor	E-GP
subtype-selective	O
antagonists	O
chlorethylclonidine	S-chemical
(	O
CEC	S-chemical
)	O
,	O
WB4101	S-chemical
,	O
and	O
5-methyl-urapidil	S-chemical
,	O
we	O
have	O
examined	O
the	O
possible	O
heterogeneity	O
in	O
the	O
alpha	B-GP
1-adrenoceptor	E-GP
populations	O
in	O
rabbit	O
aorta	O
.	O
The	O
alpha	B-GP
1-adrenoceptor	E-GP
alkylating	O
agent	O
CEC	O
selectively	O
inhibited	O
the	O
phasic	O
component	O
of	O
the	O
norepinephrine	S-chemical
-induced	O
contractile	O
response	O
,	O
with	O
little	O
effect	O
on	O
the	O
tonic	O
component	O
.	O
The	O
alpha	B-GP
1-adrenoceptor	E-GP
occupancy-response	O
relationship	O
defined	O
by	O
the	O
phenoxybenzamine	S-chemical
inactivation	O
method	O
was	O
rectangular	O
hyperbolic	O
for	O
the	O
tonic	O
response	O
,	O
whereas	O
that	O
for	O
the	O
phasic	O
response	O
was	O
linear	O
,	O
indicating	O
the	O
different	O
degree	O
of	O
receptor	O
reserve	O
for	O
the	O
two	O
responses	O
.	O
Radioligand	O
binding	O
studies	O
with	O
the	O
nonselective	O
alpha	B-GP
1-adrenoceptor	E-GP
antagonist	O
radioligand	O
125I-BE2254	S-chemical
showed	O
that	O
73-87	O
%	O
of	O
the	O
binding	O
sites	O
in	O
rabbit	O
aorta	O
are	O
CEC	S-chemical
sensitive	O
and	O
they	O
are	O
predominantly	O
low	O
affinity	O
sites	O
both	O
for	O
WB4101	S-chemical
(	O
pKd	O
=	O
8.1	O
)	O
and	O
for	O
5-methylurapidil	S-chemical
(	O
pKd	O
=	O
7.1	O
)	O
.	O
Moreover	O
,	O
alpha	B-GP
1-adrenoceptor	E-GP
-mediated	O
phosphatidylinositol	S-chemical
(	O
PI	S-chemical
)	O
hydrolysis	O
was	O
CEC	S-chemical
sensitive	O
,	O
and	O
fractional	O
inactivation	O
of	O
alpha	B-GP
1	I-GP
receptors	E-GP
with	O
CEC	S-chemical
showed	O
equivalent	O
increments	O
in	O
the	O
reduction	O
of	O
PI	S-chemical
hydrolysis	O
and	O
phasic	O
contractile	O
response	O
,	O
suggesting	O
that	O
both	O
responses	O
are	O
linearly	O
related	O
to	O
the	O
CEC	S-chemical
-sensitive	O
receptor	O
sites	O
.	O
The	O
Schild	O
plots	O
for	O
the	O
competitive	O
antagonists	O
WB4101	S-chemical
and	O
5-methyl-urapidil	S-chemical
against	O
alpha	B-GP
1a-adrenoceptor	E-GP
-selective	O
agonist	O
methoxamine	S-chemical
-induced	O
contraction	O
were	O
linear	O
and	O
had	O
slopes	O
not	O
significantly	O
different	O
from	O
unity	O
,	O
with	O
a	O
pA2	O
of	O
9.07	O
+/-	O
0.07	O
(	O
n	O
=	O
5	O
)	O
for	O
WB4101	S-chemical
and	O
9.09	O
+/-	O
0.05	O
(	O
n	O
=	O
3	O
)	O
for	O
5-methyl-urapidil	S-chemical
.	O
However	O
,	O
the	O
Schilod	O
plots	O
for	O
these	O
antagonists	O
against	O
norepinephrine	S-chemical
were	O
curvilinear	O
.	O
Computer-assisted	O
analysis	O
of	O
these	O
curvilinear	O
Schild	O
plots	O
in	O
a	O
two-receptor	O
system	O
indicated	O
that	O
alpha	B-GP
1-adrenoceptor	E-GP
populations	O
responsible	O
for	O
the	O
constrictive	O
response	O
are	O
predominantly	O
(	O
approximately	O
80-90	O
%	O
)	O
low	O
affinity	O
sites	O
for	O
the	O
two	O
antagonists	O
(	O
pKd	O
approximately	O
8.1	O
for	O
WB4101	S-chemical
and	O
pKd	O
approximately	O
7.1	O
for	O
5-methyl-urapidil	S-chemical
)	O
and	O
a	O
small	O
population	O
(	O
approximately	O
10-20	O
%	O
)	O
are	O
high	O
affinity	O
sites	O
(	O
pKd	O
approximately	O
9.1	O
for	O
both	O
WB4101	S-chemical
and	O
5-methyl-urapidil	S-chemical
)	O
,	O
which	O
was	O
in	O
good	O
agreement	O
with	O
radioligand	O
binding	O
studies	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Lixisenatide	O
:	O
first	O
global	O
approval	O
.	O
The	O
selective	O
once-daily	O
prandial	O
glucagon-like	B-GP
peptide-1	I-GP
(	I-GP
GLP-1	I-GP
)	I-GP
receptor	E-GP
agonist	O
lixisenatide	O
(	O
Lyxumia	O
(	O
®	O
)	O
)	O
is	O
under	O
development	O
with	O
Sanofi	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
mellitus	O
.	O
Lixisenatide	O
belongs	O
to	O
a	O
class	O
of	O
GLP-1	S-GP
compounds	O
designed	O
to	O
mimic	O
the	O
endogenous	O
hormone	O
GLP-1	S-GP
.	O
Native	O
GLP-1	S-GP
stimulates	O
insulin	S-GP
secretion	O
in	O
a	O
glucose	S-chemical
-dependent	O
manner	O
,	O
as	O
well	O
as	O
suppressing	O
glucagon	S-GP
production	O
and	O
slowing	O
gastric	O
emptying	O
.	O
A	O
once-daily	O
subcutaneous	O
formulation	O
of	O
lixisenatide	O
has	O
been	O
approved	O
in	O
the	O
EU	O
,	O
Iceland	O
,	O
Liechtenstein	O
,	O
Norway	O
and	O
Mexico	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
,	O
and	O
is	O
under	O
regulatory	O
review	O
in	O
the	O
USA	O
,	O
Switzerland	O
,	O
Brazil	O
,	O
Canada	O
,	O
Ukraine	O
,	O
South	O
Africa	O
,	O
Japan	O
and	O
Australia	O
.	O
This	O
article	O
summarizes	O
the	O
milestones	O
in	O
the	O
development	O
of	O
lixisenatide	O
,	O
leading	O
to	O
this	O
first	O
approval	O
for	O
use	O
in	O
adults	O
with	O
type	O
2	O
diabetes	O
.	O

Thymidylate	B-GP
synthase	E-GP
:	O
a	O
critical	O
target	O
in	O
cancer	O
therapy	O
?	O
For	O
the	O
last	O
four	O
decades	O
,	O
synthesis	O
and	O
testing	O
of	O
potentially	O
active	O
drugs	O
(	O
e.g.	O
,	O
antimetabolites	O
)	O
have	O
focused	O
on	O
structural	O
modification	O
of	O
existing	O
metabolites	O
as	O
precursors	O
of	O
DNA	O
and	O
RNA	O
synthesis	O
.	O
In	O
recent	O
years	O
,	O
the	O
focus	O
has	O
shifted	O
to	O
synthesis	O
of	O
target-specific	O
agents	O
.	O
Thus	O
,	O
the	O
current	O
emphasis	O
of	O
drug	O
development	O
is	O
directed	O
at	O
inhibiting	O
specific	O
target	O
(	O
s	O
)	O
expressed	O
preferentially	O
,	O
if	O
not	O
exclusively	O
,	O
in	O
tumor	O
tissues	O
,	O
with	O
the	O
ultimate	O
goal	O
of	O
improving	O
the	O
therapeutic	O
efficacy	O
and	O
selectivity	O
of	O
these	O
new	O
agents	O
.	O
Preclinically	O
,	O
proof-of-principle	O
studies	O
were	O
carried	O
out	O
in	O
tumors	O
with	O
specific	O
expression	O
of	O
the	O
intended	O
target	O
.	O
With	O
the	O
hope	O
of	O
translating	O
preclinical	O
findings	O
to	O
the	O
design	O
of	O
implementation	O
of	O
clinical	O
trials	O
.	O
Thymidylate	B-GP
synthase	E-GP
(	O
TS	S-GP
)	O
continues	O
to	O
be	O
a	O
critical	O
target	O
for	O
5-fluorouracil	S-chemical
(	O
5-FU	S-chemical
)	O
and	O
its	O
prodrugs	O
,	O
UFT	S-chemical
/	O
LV	S-chemical
(	O
Orzel	S-chemical
)	O
,	O
capecitabine	S-chemical
(	O
Xeloda	S-chemical
)	O
,	O
and	O
S-1	S-chemical
,	O
primarily	O
because	O
this	O
enzyme	O
is	O
essential	O
for	O
the	O
synthesis	O
of	O
2-deoxythymidine-5-monophosphate	S-chemical
,	O
a	O
precursor	O
for	O
DNA	O
synthesis	O
.	O
While	O
fluoropyrimidine	S-chemical
antimetabolites	O
have	O
other	O
sites	O
of	O
action	O
,	O
antifolates	O
ZD1694	S-chemical
(	O
raltitrexed	S-chemical
,	O
Tomudex	S-chemical
)	O
and	O
AG337	S-chemical
(	O
Thymitag	S-chemical
)	O
are	O
more	O
specific	O
and	O
potent	O
TS	S-GP
inhibitors	O
.	O
Thus	O
,	O
it	O
is	O
hoped	O
that	O
pronounced	O
and	O
sustained	O
inhibition	O
of	O
this	O
enzyme	O
could	O
result	O
in	O
downstream	O
regulation	O
of	O
molecular	O
markers	O
associated	O
with	O
sensitivity	O
and	O
resistance	O
to	O
these	O
agents	O
.	O
It	O
is	O
also	O
critical	O
to	O
recognize	O
that	O
the	O
degree	O
and	O
duration	O
of	O
inhibition	O
of	O
the	O
target	O
enzyme	O
may	O
depend	O
on	O
the	O
expression	O
level	O
of	O
the	O
target	O
enzyme	O
,	O
thymidylate	B-GP
synthase	E-GP
.	O
Correlative	O
studies	O
in	O
preclinical	O
and	O
clinical	O
systems	O
demonstrated	O
a	O
close	O
relationship	O
between	O
the	O
enzyme	O
level	O
(	O
mRNA	O
and	O
protein	O
)	O
and	O
response	O
to	O
therapy	O
of	O
colorectal	O
cancer	O
patients	O
treated	O
with	O
fluoropyrimidine	S-chemical
or	O
Tomudex	S-chemical
.	O
However	O
,	O
significant	O
overlap	O
was	O
demonstrated	O
between	O
responders	O
and	O
non-responders	O
.	O
These	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
prediction	O
of	O
response	O
to	O
anticancer	O
drugs	O
is	O
multifactorial	O
,	O
and	O
TS	S-GP
is	O
one	O
target	O
.	O
Clinically	O
,	O
although	O
overall	O
response	O
of	O
colorectal	O
cancer	O
patients	O
to	O
a	O
variety	O
of	O
TS	S-GP
inhibitors	O
is	O
similar	O
,	O
toxicity	O
profiles	O
are	O
different	O
.	O
The	O
availability	O
of	O
the	O
5-FU	S-chemical
prodrugs	O
offers	O
the	O
possibility	O
of	O
greater	O
therapeutic	O
selectivity	O
based	O
on	O
the	O
demonstration	O
that	O
thymidine	B-GP
phosphorylase	E-GP
,	O
the	O
activating	O
enzyme	O
for	O
5-FU	S-chemical
,	O
is	O
expressed	O
at	O
a	O
higher	O
level	O
in	O
tumor	O
tissue	O
compared	O
with	O
normal	O
tissue	O
counterparts	O
.	O
It	O
is	O
likely	O
that	O
successful	O
application	O
of	O
TS	S-GP
inhibitors	O
will	O
not	O
only	O
be	O
based	O
on	O
measurement	O
of	O
the	O
TS	S-GP
level	O
in	O
tumors	O
vs.	O
normal	O
tissues	O
,	O
but	O
on	O
the	O
delineation	O
of	O
the	O
consequences	O
of	O
this	O
inhibition	O
on	O
molecular	O
markers	O
associated	O
with	O
cellular	O
proliferation	O
,	O
apoptosis	O
and	O
cell	O
cycle	O
regulation	O
.	O

In	O
vitro	O
metabolism	O
of	O
the	O
5-hydroxytryptamine1B	S-GP
receptor	O
antagonist	O
elzasonan	S-chemical
.	O
The	O
metabolism	O
of	O
elzasonan	S-chemical
has	O
been	O
examined	O
in	O
vitro	O
using	O
hepatic	O
microsomes	O
from	O
human	O
and	O
recombinant	O
heterologously	O
expressed	O
P450	B-GP
enzymes	E-GP
(	O
rCYP	S-GP
)	O
.	O
Metabolism	O
occurs	O
primarily	O
via	O
oxidative	O
N	S-chemical
-demethylation	O
to	O
form	O
M4	O
and	O
oxidation	O
reactions	O
to	O
form	O
elzasonan	B-chemical
N-oxide	E-chemical
(	O
M5	O
)	O
and	O
5-hydroxyelzasonan	S-chemical
metabolite	O
(	O
M3	O
)	O
.	O
Additionally	O
,	O
elzasonan	S-chemical
was	O
shown	O
to	O
be	O
metabolized	O
to	O
the	O
novel	O
cyclized	O
indole	S-chemical
metabolite	O
(	O
M6	O
)	O
which	O
undergoes	O
subsequent	O
oxidation	O
to	O
form	O
the	O
iminium	S-chemical
ion	O
metabolite	O
(	O
M3a	O
)	O
.	O
The	O
rCYP	S-GP
data	O
was	O
normalized	O
relative	O
to	O
the	O
levels	O
of	O
each	O
CYP	S-GP
form	O
in	O
native	O
human	O
liver	O
microsomes	O
to	O
better	O
assess	O
the	O
contribution	O
of	O
each	O
rCYP	S-GP
in	O
the	O
metabolism	O
of	O
elzasonan	S-chemical
.	O
Results	O
demonstrated	O
the	O
involvement	O
of	O
CYP3A4	S-GP
in	O
the	O
pathways	O
leading	O
to	O
M3a	O
,	O
M3	O
,	O
M5	O
and	O
M6	O
and	O
CYP2C8	S-GP
in	O
the	O
formation	O
of	O
M4	O
.	O
Kinetic	O
constants	O
for	O
the	O
formation	O
of	O
M3	O
were	O
determined	O
and	O
correlation	O
and	O
inhibition	O
studies	O
suggested	O
that	O
CYP3A4	S-GP
is	O
primarily	O
responsible	O
for	O
the	O
formation	O
of	O
M3	O
and	O
CYP2C19	S-GP
plays	O
a	O
very	O
minor	O
role	O
in	O
its	O
formation	O
.	O
Cytochrome	B-GP
b5	E-GP
has	O
shown	O
to	O
be	O
an	O
essential	O
component	O
in	O
P450	B-GP
3A4	E-GP
catalyzed	O
5-hydroxyelzasonan	S-chemical
formation	O
and	O
provides	O
insights	O
on	O
the	O
disconnect	O
between	O
human	O
liver	O
microsomes	O
data	O
and	O
that	O
of	O
rCYP	S-GP
.	O
Furthermore	O
,	O
rCYP3A4	S-GP
containing	O
b5	O
are	O
useful	O
models	O
for	O
predicting	O
the	O
rates	O
for	O
liver	O
microsomes	O
P450	S-GP
-dependent	O
drug	O
oxidations	O
and	O
should	O
be	O
utilized	O
routinely	O
.	O

Aldehyde	B-GP
oxidase	E-GP
importance	O
in	O
vivo	O
in	O
xenobiotic	O
metabolism	O
:	O
imidacloprid	S-chemical
nitroreduction	O
in	O
mice	O
.	O
Aldehyde	B-GP
oxidase	E-GP
(	O
AOX	S-GP
)	O
metabolizes	O
many	O
xenobiotics	O
in	O
vitro	O
,	O
but	O
its	O
importance	O
in	O
vivo	O
is	O
usually	O
unknown	O
relative	O
to	O
cytochrome	B-GP
P450s	E-GP
(	O
CYPs	S-GP
)	O
and	O
other	O
detoxification	O
systems	O
.	O
Currently	O
,	O
the	O
most	O
important	O
insecticides	O
are	O
neonicotinoids	S-chemical
,	O
which	O
are	O
metabolized	O
in	O
vitro	O
by	O
AOX	S-GP
on	O
reduction	O
of	O
the	O
nitroimino	S-chemical
group	O
and	O
by	O
CYPs	S-GP
via	O
oxidation	O
reactions	O
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
establish	O
the	O
relative	O
importance	O
of	O
AOX	S-GP
and	O
CYPs	S-GP
in	O
vivo	O
using	O
the	O
mouse	O
model	O
.	O
The	O
procedure	O
was	O
to	O
reduce	O
liver	O
AOX	S-GP
activity	O
by	O
providing	O
tungsten	S-chemical
or	O
hydralazine	S-chemical
in	O
the	O
drinking	O
water	O
or	O
to	O
use	O
the	O
AOX	S-GP
-deficient	O
DBA/2	O
mouse	O
strain	O
.	O
None	O
of	O
these	O
approaches	O
reduced	O
CYP	S-GP
activity	O
measured	O
in	O
vitro	O
with	O
an	O
isozyme	O
nonspecific	O
substrate	O
.	O
Liver	O
AOX	S-GP
activity	O
was	O
reduced	O
by	O
45	O
%	O
with	O
tungsten	S-chemical
and	O
61	O
%	O
with	O
hydralazine	S-chemical
and	O
81	O
%	O
in	O
AOX	S-GP
-deficient	O
mice	O
relative	O
to	O
controls	O
.	O
When	O
mice	O
were	O
treated	O
ip	O
with	O
the	O
major	O
neonicotinoid	O
imidacloprid	S-chemical
(	O
IMI	S-chemical
)	O
,	O
metabolism	O
by	O
CYP	S-GP
oxidation	O
reactions	O
was	O
not	O
appreciably	O
affected	O
,	O
whereas	O
the	O
AOX	S-GP
-generated	O
nitrosoguanidine	S-chemical
metabolite	O
was	O
decreased	O
by	O
30	O
%	O
with	O
tungsten	S-chemical
and	O
56	O
%	O
with	O
hydralazine	S-chemical
and	O
86	O
%	O
in	O
the	O
AOX	S-GP
-deficient	O
mice	O
.	O
The	O
other	O
IMI	S-chemical
nitroreduction	O
metabolite	O
,	O
desnitro-	O
IMI	S-chemical
,	O
was	O
decreased	O
by	O
55	O
%	O
,	O
65	O
%	O
,	O
and	O
81	O
%	O
with	O
tungsten	S-chemical
,	O
hydralazine	S-chemical
,	O
and	O
in	O
the	O
AOX	S-GP
-deficient	O
mice	O
,	O
respectively	O
.	O
Thus	O
,	O
decreasing	O
liver	O
AOX	S-GP
activity	O
by	O
three	O
quite	O
different	O
procedures	O
gave	O
a	O
corresponding	O
decrease	O
for	O
in	O
vivo	O
reductive	O
metabolites	O
in	O
the	O
liver	O
of	O
IMI	S-chemical
-treated	O
mice	O
.	O
Possible	O
AOX	S-GP
involvement	O
in	O
IMI	S-chemical
metabolism	O
in	O
insects	O
was	O
evaluated	O
using	O
AOX	S-GP
-expressing	O
and	O
AOX	S-GP
-deficient	O
Drosophila	O
,	O
but	O
no	O
differences	O
were	O
found	O
in	O
IMI	S-chemical
nitroreduction	O
or	O
sensitivity	O
between	O
the	O
two	O
strains	O
.	O
This	O
is	O
the	O
first	O
study	O
to	O
establish	O
the	O
in	O
vivo	O
relevance	O
of	O
AOX	S-GP
in	O
neonicotinoid	S-chemical
metabolism	O
in	O
mammals	O
and	O
one	O
of	O
the	O
first	O
for	O
xenobiotics	O
in	O
general	O
.	O

Determinants	O
of	O
voltage-dependent	O
inactivation	O
affect	O
Mibefradil	S-chemical
block	O
of	O
calcium	B-GP
channels	E-GP
.	O
The	O
voltage	B-GP
gated	I-GP
calcium	I-GP
channel	E-GP
family	O
is	O
a	O
major	O
target	O
for	O
a	O
range	O
of	O
therapeutic	O
drugs	O
.	O
Mibefradil	S-chemical
(	O
Ro	B-chemical
40-5967	E-chemical
)	O
belongs	O
to	O
a	O
new	O
chemical	O
class	O
of	O
these	O
molecules	O
which	O
differs	O
from	O
other	O
Ca2+	S-chemical
antagonists	O
by	O
its	O
ability	O
to	O
potently	O
block	O
T-type	B-GP
Ca2+	I-GP
channels	E-GP
.	O
However	O
,	O
this	O
molecule	O
has	O
also	O
been	O
shown	O
to	O
inhibit	O
other	O
Ca2+	B-GP
channel	E-GP
subtypes	O
.	O
To	O
further	O
analyze	O
the	O
mechanism	O
governing	O
the	O
Ca2+	B-GP
channel	E-GP
-	O
Mibefradil	S-chemical
interaction	O
,	O
we	O
examined	O
the	O
effect	O
of	O
Mibefradil	S-chemical
on	O
various	O
recombinant	O
Ca2+	B-GP
channels	E-GP
expressed	O
in	O
mammalian	O
cells	O
from	O
their	O
cloned	O
cDNAs	O
,	O
using	O
Ca2+	S-chemical
as	O
the	O
permeant	O
ion	O
at	O
physiological	O
concentration	O
.	O
Expression	O
of	O
alpha1A	O
,	O
alpha1C	O
,	O
and	O
alpha1E	O
in	O
tsA	O
201	O
cells	O
resulted	O
in	O
Ca2+	S-chemical
currents	O
with	O
functional	O
characteristics	O
closely	O
related	O
to	O
those	O
of	O
their	O
native	O
counterparts	O
.	O
Mibefradil	S-chemical
blocked	O
alpha1A	O
and	O
alpha1E	O
with	O
a	O
Kd	O
comparable	O
to	O
that	O
reported	O
for	O
T-type	B-GP
channels	E-GP
,	O
but	O
had	O
a	O
lower	O
affinity	O
(	O
approximately	O
30-fold	O
)	O
for	O
alpha1C	O
.	O
For	O
each	O
channel	O
,	O
inhibition	O
by	O
Mibefradil	S-chemical
was	O
consistent	O
with	O
high-affinity	O
binding	O
to	O
the	O
inactivated	O
state	O
.	O
Modulation	O
of	O
the	O
voltage-dependent	O
inactivation	O
properties	O
by	O
the	O
nature	O
of	O
the	O
coexpressed	O
beta	O
subunit	O
or	O
the	O
alpha1	O
splice	O
variant	O
altered	O
block	O
at	O
the	O
Mibefradil	S-chemical
receptor	O
site	O
.	O
Therefore	O
,	O
we	O
conclude	O
that	O
the	O
tissue	O
and	O
sub-cellular	O
localization	O
of	O
calcium	B-GP
channel	E-GP
subunits	O
as	O
well	O
as	O
their	O
specific	O
associations	O
are	O
essential	O
parameters	O
to	O
understand	O
the	O
in	O
vivo	O
effects	O
of	O
Mibefradil	S-chemical
.	O

Central	O
adenosinergic	O
system	O
involvement	O
in	O
ethanol	S-chemical
-induced	O
motor	O
incoordination	O
in	O
mice	O
.	O
To	O
clarify	O
if	O
the	O
behavioral	O
interaction	O
between	O
ethanol	S-chemical
and	O
adenosine	S-chemical
reported	O
previously	O
occur	O
centrally	O
or	O
due	O
to	O
a	O
peripheral	O
hemodynamic	O
change	O
,	O
the	O
effect	O
of	O
i.c.v	O
.	O
adenosine	S-chemical
agonists	O
,	O
N6-	B-chemical
(	I-chemical
R-phenylisopropyl	I-chemical
)	I-chemical
adenosine	E-chemical
(	O
R-PIA	S-chemical
)	O
,	O
N6-	B-chemical
(	I-chemical
S-phenylisopropyl	I-chemical
)	I-chemical
adenosine	E-chemical
,	O
5'-	B-chemical
(	I-chemical
N-cyclopropyl	I-chemical
)	I-chemical
-carboxamidoadenosine	E-chemical
,	O
antagonists	O
,	O
theophylline	S-chemical
and	O
8-p-	B-chemical
(	I-chemical
sulfophenyl	I-chemical
)	I-chemical
theophylline	E-chemical
as	O
well	O
as	O
enprofylline	S-chemical
on	O
ethanol	S-chemical
-	O
(	O
i.p	O
.	O
)	O
-induced	O
motor	O
incoordination	O
was	O
evaluated	O
by	O
rotorod	O
.	O
Adenosine	S-chemical
agonists	O
and	O
antagonists	O
dose	O
dependently	O
accentuated	O
and	O
attenuated	O
,	O
respectively	O
,	O
ethanol	S-chemical
-induced	O
motor	O
incoordination	O
,	O
thereby	O
suggesting	O
a	O
central	O
mechanism	O
of	O
adenosine	S-chemical
modulation	O
of	O
this	O
effect	O
of	O
ethanol	S-chemical
and	O
confirmed	O
our	O
previous	O
reports	O
in	O
which	O
adenosine	S-chemical
agonists	O
and	O
antagonists	O
were	O
given	O
i.p	O
.	O
Enprofylline	S-chemical
,	O
a	O
weak	O
adenosine	S-chemical
antagonist	O
but	O
potent	O
inhibitor	O
of	O
cyclic	B-GP
AMP	I-GP
phosphodiesterase	E-GP
,	O
did	O
not	O
alter	O
ethanol	O
's	O
motor	O
incoordination	O
,	O
further	O
supporting	O
involvement	O
of	O
brain	O
adenosine	B-GP
receptor	E-GP
mechanism	O
(	O
s	O
)	O
in	O
ethanol	S-chemical
-	O
adenosine	S-chemical
interactions	O
.	O
Results	O
from	O
R-PIA	O
and	O
N6-	B-chemical
(	I-chemical
S-phenylisopropyl	I-chemical
)	I-chemical
adenosine	E-chemical
experiments	O
showed	O
nearly	O
a	O
40-fold	O
greater	O
potency	O
of	O
R-vs.	O
S-diastereoisomer	O
,	O
suggesting	O
predominance	O
of	O
adenosine	B-GP
A1	E-GP
subtype	O
.	O
However	O
,	O
5'-	B-chemical
(	I-chemical
N-cyclopropyl	I-chemical
)	I-chemical
-carboxamidoadenosine	E-chemical
data	O
indicate	O
complexity	O
of	O
the	O
mechanism	O
(	O
s	O
)	O
and	O
point	O
toward	O
an	O
additional	O
involvement	O
of	O
a	O
yet	O
unknown	O
subtype	O
of	O
adenosine	B-GP
A2	E-GP
.	O
No	O
effect	O
of	O
ethanol	O
on	O
blood	O
or	O
brain	O
levels	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
R-PIA	E-chemical
was	O
noted	O
and	O
sufficient	O
amount	O
of	O
the	O
latter	O
entered	O
the	O
brain	O
to	O
suggest	O
adenosine	B-GP
receptor	E-GP
activation	O
adequate	O
to	O
produce	O
behavioral	O
interaction	O
with	O
ethanol	S-chemical
.	O
There	O
was	O
no	O
escape	O
of	O
i.c.v.-administered	O
[	B-chemical
3H	I-chemical
]	I-chemical
R-PIA	E-chemical
from	O
brain	O
to	O
the	O
peripheral	O
circulation	O
ruling	O
out	O
a	O
peripheral	O
and	O
supporting	O
a	O
central	O
mechanism	O
of	O
ethanol	S-chemical
-	O
adenosine	S-chemical
interaction	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Bcl-2	S-GP
phosphorylation	O
has	O
pathological	O
significance	O
in	O
human	O
breast	O
cancer	O
.	O
The	O
anti-apoptotic	O
molecule	O
,	O
Bcl-2	S-GP
,	O
is	O
well	O
known	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
chemoresistance	O
of	O
breast	O
cancer	O
.	O
We	O
have	O
previously	O
demonstrated	O
that	O
phosphorylation	O
of	O
Fas-associated	B-GP
death	I-GP
domain-containing	I-GP
protein	E-GP
(	O
FADD	S-GP
)	O
at	O
194	O
serine	S-chemical
through	O
c-jun	B-GP
NH2-terminal	I-GP
kinase	E-GP
(	O
JNK	S-GP
)	O
activation	O
sensitizes	O
breast	O
cancer	O
cells	O
to	O
chemotherapy	O
through	O
accelerating	O
cell	O
cycle	O
arrest	O
at	O
G2/M	O
,	O
and	O
that	O
Bcl-2	S-GP
phosphorylation	O
downstream	O
of	O
JNK	S-GP
/	O
FADD	S-GP
plays	O
an	O
important	O
role	O
in	O
cell	O
growth	O
suppression	O
by	O
paclitaxel	S-chemical
.	O
In	O
this	O
study	O
,	O
the	O
clinicopathological	O
association	O
of	O
phosphorylated	B-GP
Bcl-2	E-GP
(	O
P-Bcl-2	S-GP
)	O
with	O
estrogen	B-GP
,	I-GP
progesterone	I-GP
,	I-GP
c-erbB-2	I-GP
receptors	E-GP
,	O
p53	S-GP
expressions	O
and	O
phosphorylated	B-GP
FADD	E-GP
/	O
JNK	S-GP
(	O
P-FADD	S-GP
/	O
JNK	S-GP
)	O
was	O
analyzed	O
immunohistochemically	O
using	O
107	O
human	O
breast	O
cancer	O
specimens	O
.	O
Expression	O
of	O
P-Bcl-2	S-GP
was	O
found	O
to	O
significantly	O
correlate	O
with	O
lymphatic	O
invasion	O
,	O
lymph	O
node	O
metastasis	O
,	O
but	O
not	O
histological	O
differentiation	O
,	O
tumor	O
grade	O
or	O
vascular	O
and	O
fatty	O
invasion	O
.	O
The	O
positivity	O
of	O
P-Bcl-2	S-GP
was	O
also	O
significantly	O
correlated	O
to	O
that	O
of	O
P-FADD	S-GP
/	O
JNK	S-GP
.	O
Thus	O
,	O
P-Bcl-2	S-GP
as	O
well	O
as	O
the	O
P-FADD	S-GP
/	O
JNK	S-GP
parameter	O
might	O
be	O
useful	O
markers	O
for	O
cancer	O
progression	O
,	O
independent	O
of	O
the	O
hormone	O
receptor	O
status	O
,	O
in	O
human	O
breast	O
cancers	O
.	O

Characteristics	O
of	O
the	O
binding	O
of	O
phenoxybenzamine	S-chemical
to	O
calmodulin	S-GP
.	O
To	O
determine	O
the	O
factors	O
that	O
influence	O
the	O
interaction	O
between	O
phenoxybenzamine	S-chemical
and	O
calmodulin	S-GP
,	O
the	O
binding	O
of	O
phenoxybenzamine	S-chemical
to	O
calmodulin	S-GP
was	O
determined	O
by	O
equilibrium	O
dialysis	O
under	O
a	O
variety	O
of	O
experimental	O
conditions	O
.	O
This	O
interaction	O
was	O
found	O
to	O
be	O
similar	O
in	O
some	O
respects	O
to	O
the	O
interaction	O
between	O
phenothiazines	S-chemical
and	O
calmodulin	S-GP
.	O
It	O
was	O
saturable	O
,	O
with	O
between	O
1	O
and	O
2	O
mol	O
of	O
phenoxybenzamine	S-chemical
bound	O
to	O
1	O
mol	O
of	O
calmodulin	S-GP
.	O
It	O
was	O
also	O
dependent	O
upon	O
temperature	O
,	O
the	O
presence	O
of	O
a	O
divalent	O
cation	O
such	O
as	O
calcium	S-chemical
,	O
and	O
on	O
pH	O
,	O
showing	O
maximum	O
binding	O
at	O
pH	O
6.5	O
with	O
little	O
binding	O
at	O
pH	O
values	O
below	O
4.2	O
or	O
above	O
8.0	O
.	O
The	O
site	O
at	O
which	O
phenoxybenzamine	S-chemical
bound	O
to	O
calmodulin	S-GP
appears	O
to	O
be	O
similar	O
to	O
that	O
at	O
which	O
certain	O
antipsychotic	O
agents	O
bind	O
,	O
since	O
several	O
of	O
them	O
,	O
including	O
penfluridol	S-chemical
,	O
pimozide	S-chemical
and	O
spiroperidol	S-chemical
,	O
prevented	O
the	O
binding	O
of	O
phenoxybenzamine	S-chemical
to	O
calmodulin	S-GP
.	O
However	O
,	O
in	O
contrast	O
to	O
the	O
reversible	O
binding	O
of	O
most	O
phenothiazines	S-chemical
to	O
calmodulin	S-GP
,	O
phenoxybenzamine	S-chemical
bound	O
to	O
calmodulin	S-GP
irreversibly	O
.	O
The	O
binding	O
of	O
phenoxybenzamine	S-chemical
to	O
calmodulin	S-GP
was	O
fairly	O
selective	O
in	O
that	O
other	O
alpha-adrenergic	S-GP
agents	O
such	O
as	O
prazosin	S-chemical
,	O
yohimbine	S-chemical
and	O
clonidine	S-chemical
failed	O
to	O
bind	O
to	O
calmodulin	S-GP
when	O
examined	O
under	O
the	O
same	O
experimental	O
conditions	O
.	O
In	O
addition	O
,	O
phenoxybenzamine	S-chemical
showed	O
little	O
or	O
no	O
calcium	S-chemical
-dependent	O
binding	O
to	O
the	O
S-100	B-GP
protein	E-GP
,	O
bovine	B-GP
serum	I-GP
albumin	E-GP
or	O
cytochrome	B-GP
c	E-GP
.	O
The	O
irreversible	O
complex	O
between	O
phenoxybenzamine	S-chemical
and	O
calmodulin	S-GP
may	O
be	O
useful	O
for	O
inhibiting	O
certain	O
calmodulin	S-GP
-dependent	O
reactions	O
and	O
for	O
studying	O
the	O
various	O
biological	O
functions	O
of	O
calmodulin	S-GP
.	O

Multiple	O
affinity	O
states	O
of	O
opiate	B-GP
receptor	E-GP
in	O
neuroblastoma	O
x	O
glioma	O
NG108-15	O
hybrid	O
cells	O
.	O
Opiate	O
agonist	O
association	O
rate	O
is	O
a	O
function	O
of	O
receptor	O
occupancy	O
.	O
The	O
existence	O
of	O
multiple	O
affinity	O
states	O
for	O
the	O
opiate	O
receptor	O
in	O
neuroblastoma	O
x	O
glioma	O
NG108-15	O
hybrid	O
cells	O
has	O
been	O
demonstrated	O
by	O
competition	O
binding	O
studies	O
with	O
tritiated	B-chemical
diprenorphine	E-chemical
and	O
[	B-chemical
D-Ala2	I-chemical
,	I-chemical
D-Leu5	I-chemical
]	I-chemical
enkephalin	E-chemical
(	O
DADLE	S-chemical
)	O
.	O
In	O
the	O
presence	O
of	O
10	O
mM	O
Mg2+	S-chemical
,	O
all	O
receptors	O
exist	O
in	O
a	O
high	O
affinity	O
state	O
with	O
Kd	O
=	O
1.88	O
+/-	O
0.16	O
nM	O
.	O
Addition	O
of	O
10	O
microM	O
guanyl-5'-yl	B-chemical
imidodiphosphate	E-chemical
(	O
Gpp	B-chemical
(	I-chemical
NH	I-chemical
)	I-chemical
p	E-chemical
)	O
decreased	O
the	O
affinity	O
of	O
DADLE	S-chemical
to	O
Kd	O
=	O
8.08	O
+/-	O
0.93	O
nM	O
.	O
However	O
,	O
in	O
the	O
presence	O
of	O
100	O
mM	O
Na+	S-chemical
,	O
which	O
is	O
required	O
for	O
opiate	O
inhibition	O
of	O
adenylate	B-GP
cyclase	E-GP
activity	O
,	O
analysis	O
of	O
competition	O
binding	O
data	O
revealed	O
three	O
sites	O
:	O
the	O
first	O
,	O
consisting	O
of	O
17.5	O
%	O
of	O
total	O
receptor	O
population	O
has	O
a	O
Kd	O
=	O
0.38	O
+/-	O
0.18	O
nM	O
;	O
the	O
second	O
,	O
50.6	O
%	O
of	O
the	O
population	O
,	O
has	O
a	O
Kd	O
=	O
6.8	O
+/-	O
2.2	O
nM	O
;	O
and	O
the	O
third	O
,	O
31.9	O
%	O
of	O
the	O
population	O
,	O
has	O
a	O
Kd	O
of	O
410	O
+/-	O
110	O
nM	O
.	O
Thus	O
,	O
in	O
the	O
presence	O
of	O
sodium	S-chemical
,	O
a	O
high	O
affinity	O
complex	O
between	O
receptor	O
(	O
R	O
)	O
,	O
GTP	S-chemical
binding	O
component	O
(	O
Ni	O
)	O
,	O
and	O
ligand	O
(	O
L	O
)	O
was	O
formed	O
which	O
was	O
different	O
from	O
that	O
formed	O
in	O
the	O
absence	O
of	O
sodium	S-chemical
.	O
These	O
multiple	O
affinity	O
states	O
of	O
receptor	O
in	O
the	O
hybrid	O
cells	O
are	O
agonist-specific	O
,	O
and	O
the	O
percentage	O
of	O
total	O
opiate	B-GP
receptor	E-GP
in	O
high	O
affinity	O
state	O
is	O
relatively	O
constant	O
in	O
various	O
concentrations	O
of	O
Na+	S-chemical
.	O
Multiple	O
affinity	O
states	O
of	O
opiate	B-GP
receptor	E-GP
can	O
be	O
demonstrated	O
further	O
by	O
Scatchard	O
analysis	O
of	O
saturation	O
binding	O
studies	O
with	O
[	B-chemical
3H	I-chemical
]	I-chemical
DADLE	E-chemical
.	O
In	O
the	O
presence	O
of	O
Mg2+	S-chemical
,	O
or	O
Gpp	B-chemical
(	I-chemical
NH	I-chemical
)	I-chemical
p	E-chemical
,	O
analysis	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
DADLE	E-chemical
binding	O
demonstrates	O
that	O
opiate	O
receptor	O
can	O
exist	O
in	O
a	O
single	O
affinity	O
state	O
,	O
with	O
apparent	O
Kd	O
values	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
DADLE	E-chemical
in	O
10	O
mM	O
Mg2+	O
=	O
1.75	O
+/-	O
0.28	O
nM	O
and	O
in	O
10	O
microM	O
Gpp	B-chemical
(	I-chemical
NH	I-chemical
)	I-chemical
p	E-chemical
=	O
0.85	O
+/-	O
0.12	O
nM	O
.	O
There	O
is	O
a	O
reduction	O
of	O
Bmax	O
value	O
from	O
0.19	O
+/-	O
0.02	O
nM	O
in	O
the	O
presence	O
of	O
Mg2+	S-chemical
to	O
0.14	O
+/-	O
0.03	O
nM	O
in	O
the	O
presence	O
of	O
Gpp	B-chemical
(	I-chemical
NH	I-chemical
)	I-chemical
p	E-chemical
.	O
In	O
the	O
presence	O
of	O
100	O
mM	O
Na+	S-chemical
,	O
Scatchard	O
analysis	O
of	O
saturation	O
binding	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
DADLE	E-chemical
reveals	O
nonlinear	O
plots	O
;	O
two-site	O
analysis	O
of	O
the	O
curves	O
yields	O
Kd	O
=	O
0.43	O
+/-	O
0.09	O
and	O
7.9	O
+/-	O
3.2	O
nM	O
.	O
These	O
Kd	O
values	O
are	O
analogous	O
to	O
that	O
obtained	O
with	O
competition	O
binding	O
studies	O
.	O
Again	O
,	O
this	O
conversion	O
of	O
single	O
site	O
binding	O
Scatchard	O
plots	O
to	O
multiple	O
sites	O
binding	O
plots	O
in	O
the	O
presence	O
of	O
Na+	S-chemical
is	O
restricted	O
to	O
3H	S-chemical
-agonist	O
binding	O
only	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Increased	O
responsiveness	O
of	O
rat	O
colonic	O
splanchnic	O
afferents	O
to	O
5-HT	S-chemical
after	O
inflammation	O
and	O
recovery	O
.	O
5-Hydroxytryptamine	S-chemical
(	O
5-HT	S-chemical
)	O
activates	O
colonic	O
splanchnic	O
afferents	O
,	O
a	O
mechanism	O
by	O
which	O
it	O
has	O
been	O
implicated	O
in	O
generating	O
symptoms	O
in	O
postinfectious	O
and	O
postinflammatory	O
states	O
in	O
humans	O
.	O
Here	O
we	O
compared	O
mechanisms	O
of	O
colonic	O
afferent	O
activation	O
by	O
5-HT	S-chemical
and	O
mechanical	O
stimuli	O
in	O
normal	O
and	O
inflamed	O
rat	O
colon	O
,	O
and	O
after	O
recovery	O
from	O
inflammation	O
.	O
Colonic	O
inflammation	O
was	O
induced	O
in	O
rats	O
by	O
dextran	B-chemical
sulphate	I-chemical
sodium	E-chemical
.	O
Single-fibre	O
recordings	O
of	O
colonic	O
lumbar	O
splanchnic	O
afferents	O
revealed	O
that	O
58	O
%	O
of	O
endings	O
responded	O
to	O
5-HT	S-chemical
(	O
10	O
(	O
-4	O
)	O
m	O
)	O
in	O
controls	O
,	O
88	O
%	O
in	O
acute	O
inflammation	O
(	O
P	O
<	O
0.05	O
)	O
and	O
75	O
%	O
after	O
21	O
days	O
recovery	O
(	O
P	O
<	O
0.05	O
versus	O
control	O
)	O
.	O
Maximal	O
responses	O
to	O
5-HT	S-chemical
were	O
also	O
larger	O
,	O
and	O
the	O
estimated	O
EC50	O
was	O
reduced	O
from	O
3.2	O
x	O
10	O
(	O
-6	O
)	O
to	O
8	O
x	O
10	O
(	O
-7	O
)	O
m	O
in	O
acute	O
inflammation	O
and	O
recovered	O
to	O
2	O
x	O
10	O
(	O
-6	O
)	O
m	O
after	O
recovery	O
.	O
Responsiveness	O
to	O
mechanical	O
stimulation	O
was	O
unaffected	O
.	O
5-HT3	B-GP
receptor	E-GP
antagonism	O
with	O
alosetron	S-chemical
reduced	O
responses	O
to	O
5-HT	S-chemical
in	O
controls	O
but	O
not	O
during	O
inflammation	O
.	O
Responses	O
to	O
the	O
mast	O
cell	O
degranulator	O
48/80	O
mimicked	O
those	O
to	O
5-HT	S-chemical
in	O
inflamed	O
tissue	O
but	O
not	O
in	O
controls	O
,	O
and	O
more	O
5-HT	S-chemical
-containing	O
mast	O
cells	O
were	O
seen	O
close	O
to	O
calcitonin	B-GP
gene-related	I-GP
peptide	E-GP
-containing	O
fibres	O
in	O
inflamed	O
serosa	O
.	O
We	O
conclude	O
that	O
colonic	O
serosal	O
and	O
mesenteric	O
endings	O
exhibit	O
increased	O
sensitivity	O
to	O
5-HT	S-chemical
in	O
inflammation	O
,	O
with	O
both	O
an	O
increase	O
in	O
proportion	O
of	O
responders	O
and	O
an	O
increase	O
in	O
sensitivity	O
,	O
which	O
is	O
maintained	O
after	O
healing	O
of	O
inflammation	O
.	O
This	O
is	O
associated	O
with	O
alterations	O
in	O
the	O
roles	O
of	O
5-HT3	B-GP
receptors	E-GP
and	O
mast	O
cells	O
.	O

Adenosine	B-GP
receptors	E-GP
:	O
development	O
of	O
selective	O
agonists	O
and	O
antagonists	O
.	O
Adenosine	S-chemical
modulates	O
a	O
variety	O
of	O
physiological	O
functions	O
through	O
interaction	O
with	O
A1	B-GP
and	I-GP
A2	I-GP
adenosine	I-GP
receptors	E-GP
,	O
where	O
agonists	O
mediate	O
inhibition	O
and	O
stimulation	O
,	O
respectively	O
,	O
of	O
adenylate	B-GP
cyclase	E-GP
.	O
In	O
the	O
cardiovascular	O
system	O
,	O
A2	B-GP
receptors	E-GP
mediate	O
vasodilation	O
and	O
reduction	O
in	O
blood	O
pressure	O
,	O
while	O
A1	B-GP
receptors	E-GP
mediate	O
cardiac	O
depression	O
.	O
The	O
involvement	O
of	O
adenylate	B-GP
cyclase	E-GP
in	O
these	O
responses	O
remains	O
unresolved	O
.	O
Adenosine	S-chemical
analogs	O
in	O
particular	O
the	O
N6	S-chemical
-substituted	O
compounds	O
are	O
more	O
potent	O
at	O
A1	B-GP
receptors	E-GP
than	O
at	O
A2	B-GP
receptors	E-GP
.	O
The	O
subregion	O
of	O
the	O
adenosine	B-GP
receptor	E-GP
that	O
interacts	O
with	O
the	O
N6	S-chemical
-substituent	O
is	O
different	O
for	O
A1	B-GP
and	I-GP
A2	I-GP
receptors	E-GP
,	O
particularly	O
with	O
respect	O
to	O
phenyl	S-chemical
interactions	O
,	O
bulk	O
tolerance	O
and	O
stereoselectivity	O
.	O
A	O
series	O
of	O
para-substituted	O
N6-phenyladenosines	S-chemical
have	O
been	O
synthesized	O
based	O
on	O
a	O
``	O
functionalized	O
congener	O
''	O
approach	O
in	O
which	O
a	O
chemically	O
reactive	O
group	O
,	O
such	O
as	O
an	O
amine	S-chemical
or	O
carboxylic	B-chemical
acid	E-chemical
,	O
is	O
introduced	O
at	O
the	O
terminus	O
of	O
a	O
chain	O
.	O
From	O
the	O
``	O
functionalized	O
congener	O
''	O
are	O
synthesized	O
a	O
variety	O
of	O
conjugates	O
each	O
containing	O
a	O
common	O
pharmacophore	O
.	O
Certain	O
of	O
the	O
adenosine	S-chemical
conjugates	O
are	O
highly	O
selective	O
for	O
A1	B-GP
receptors	E-GP
.	O
Xanthines	S-chemical
are	O
classical	O
antagonists	O
for	O
adenosine	B-GP
receptors	E-GP
for	O
many	O
of	O
their	O
pharmacological	O
actions	O
may	O
be	O
due	O
to	O
blockade	O
of	O
adenosine	B-GP
receptors	E-GP
.	O
Caffeine	S-chemical
and	O
theophylline	S-chemical
are	O
virtually	O
non-selective	O
for	O
A2	B-GP
and	I-GP
A2	I-GP
receptors	E-GP
.	O
Replacement	O
of	O
the	O
methyl	S-chemical
groups	O
of	O
theophylline	S-chemical
with	O
n-propyl	S-chemical
or	O
larger	O
alkyl	S-chemical
groups	O
yields	O
xanthines	S-chemical
with	O
selectivity	O
for	O
A1	B-GP
receptors	E-GP
,	O
particularly	O
when	O
combined	O
with	O
an	O
8-phenyl	S-chemical
moiety	O
.	O
Most	O
1,3-dialkyl-8-phenyl	B-chemical
xanthines	E-chemical
are	O
very	O
insoluble	O
,	O
but	O
incorporation	O
of	O
polar	O
aryl	S-chemical
substituents	O
,	O
such	O
as	O
sulfo	S-chemical
or	O
carboxy	S-chemical
to	O
increase	O
solubility	O
,	O
results	O
in	O
marked	O
reduction	O
in	O
potency	O
and	O
selectivity	O
.	O
A	O
new	O
series	O
of	O
more	O
hydrophilic	O
1,3-dipropyl-8-phenylxanthines	S-chemical
has	O
been	O
synthesized	O
using	O
the	O
``	O
functionalized	O
congener	O
''	O
approach	O
.	O
Certain	O
conjugates	O
of	O
8-	B-chemical
[	I-chemical
4-	I-chemical
(	I-chemical
carboxymethyloxy	I-chemical
)	I-chemical
phenyl	I-chemical
1	I-chemical
]	I-chemical
1,3-dipropylxanthine	E-chemical
display	O
A1	O
selectivity	O
in	O
biochemical	O
and	O
cardiovascular	O
models	O
.	O
Certain	O
analogs	O
of	O
caffeine	S-chemical
in	O
which	O
the	O
methyl	S-chemical
group	O
at	O
the	O
1-	O
or	O
7-position	O
is	O
replaced	O
with	O
a	O
propargyl	O
or	O
propyl	S-chemical
group	O
display	O
selectivity	O
for	O
A2	B-GP
receptors	E-GP
.	O
The	O
profile	O
of	O
a	O
series	O
of	O
adenosine	S-chemical
analogs	O
or	O
of	O
xanthine	S-chemical
antagonists	O
can	O
be	O
used	O
to	O
define	O
the	O
nature	O
of	O
adenosine	B-GP
receptors	E-GP
.	O

A	O
nonsense	O
mutation	O
in	O
the	O
NDUFS4	S-GP
gene	O
encoding	O
the	O
18	B-GP
kDa	I-GP
(	I-GP
AQDQ	I-GP
)	I-GP
subunit	I-GP
of	I-GP
complex	I-GP
I	E-GP
abolishes	O
assembly	O
and	O
activity	O
of	O
the	O
complex	O
in	O
a	O
patient	O
with	O
Leigh-like	O
syndrome	O
.	O
Sequence	O
analysis	O
of	O
mitochondrial	O
and	O
nuclear	O
candidate	O
genes	O
of	O
complex	B-GP
I	E-GP
in	O
children	O
with	O
deficiency	O
of	O
this	O
complex	O
and	O
exhibiting	O
Leigh-like	O
syndrome	O
has	O
revealed	O
,	O
in	O
one	O
of	O
them	O
,	O
a	O
novel	O
mutation	O
in	O
the	O
NDUFS4	S-GP
gene	O
encoding	O
the	O
18	O
kDa	O
subunit	O
.	O
Phosphorylation	O
of	O
this	O
subunit	O
by	O
cAMP-dependent	B-GP
protein	I-GP
kinase	E-GP
has	O
previously	O
been	O
found	O
to	O
activate	O
the	O
complex	O
.	O
The	O
present	O
mutation	O
consists	O
of	O
a	O
homozygous	O
G	O
--	O
>	O
A	O
transition	O
at	O
nucleotide	O
position	O
+44	O
of	O
the	O
coding	O
sequence	O
of	O
the	O
gene	O
,	O
resulting	O
in	O
the	O
change	O
of	O
a	O
tryptophan	S-chemical
codon	O
to	O
a	O
stop	O
codon	O
.	O
Such	O
mutation	O
causes	O
premature	O
termination	O
of	O
the	O
protein	O
after	O
only	O
14	O
amino	B-chemical
acids	E-chemical
of	O
the	O
putative	O
mitochondrial	O
targeting	O
peptide	O
.	O
Fibroblast	O
cultures	O
from	O
the	O
patient	O
exhibited	O
severe	O
reduction	O
of	O
the	O
rotenone-sensitive	O
NADH	B-GP
--	I-GP
>	I-GP
UQ	I-GP
oxidoreductase	E-GP
activity	O
of	O
complex	B-GP
I	E-GP
,	O
which	O
was	O
insensitive	O
to	O
cAMP	S-chemical
stimulation	O
.	O
Two-dimensional	O
electrophoresis	O
showed	O
the	O
absence	O
of	O
detectable	O
normally	O
assembled	O
complex	B-GP
I	E-GP
in	O
the	O
inner	O
mitochondrial	O
membrane	O
.	O
These	O
findings	O
show	O
that	O
the	O
expression	O
of	O
the	O
NDUFS4	S-GP
gene	O
is	O
essential	O
for	O
the	O
assembly	O
of	O
a	O
functional	O
complex	B-GP
I	E-GP
.	O

Binding	O
and	O
GTPgammaS	S-chemical
autoradiographic	O
analysis	O
of	O
preproorphanin	B-GP
precursor	I-GP
peptide	E-GP
products	O
at	O
the	O
ORL1	S-GP
and	O
opioid	B-GP
receptors	E-GP
.	O
Utilizing	O
agonist-stimulated	O
GTPgammaS	S-chemical
autoradiography	O
,	O
we	O
analyzed	O
the	O
ability	O
of	O
preproorphanin	B-GP
FQ	I-GP
(	I-GP
ppOFQ	I-GP
)	I-GP
peptides	E-GP
to	O
stimulate	O
[	B-chemical
35S	I-chemical
]	I-chemical
-GTPgammaS	E-chemical
binding	O
in	O
adult	O
rat	O
brain	O
.	O
Orphanin	B-GP
FQ	E-GP
(	O
OFQ	S-GP
)	O
stimulated	O
[	B-chemical
35S	I-chemical
]	I-chemical
-GTPgammaS	E-chemical
binding	O
in	O
a	O
pattern	O
similar	O
to	O
that	O
described	O
for	O
[	O
125I	S-chemical
]	O
-	O
OFQ	S-GP
at	O
the	O
endogenous	O
opioid	B-GP
receptor-like	I-GP
(	I-GP
ORL1	I-GP
)	I-GP
receptor	E-GP
.	O
The	O
ppOFQ	S-GP
peptides	O
nocistatin	O
and	O
orphanin	B-GP
FQ2	E-GP
(	O
OFQ	B-GP
II	I-GP
(	I-GP
1-17	I-GP
)	E-GP
)	O
had	O
no	O
effect	O
,	O
suggesting	O
that	O
they	O
do	O
not	O
mediate	O
their	O
reported	O
analgesic	O
effects	O
via	O
a	O
G	B-GP
(	I-GP
i/o	I-GP
)	I-GP
-coupled	I-GP
receptor	E-GP
(	O
i.e	O
.	O
opioid	O
or	O
ORL1	S-GP
)	O
.	O
Unlike	O
OFQ	B-GP
II	I-GP
(	I-GP
1-17	I-GP
)	E-GP
,	O
high	O
concentrations	O
of	O
its	O
C	S-chemical
-terminal	O
extension	O
,	O
OFQ	B-GP
II	I-GP
(	I-GP
1-28	I-GP
)	E-GP
,	O
stimulated	O
[	B-chemical
35S	I-chemical
]	I-chemical
-GTPgammaS	E-chemical
binding	O
in	O
a	O
mu	B-GP
(	I-GP
mu	I-GP
)	I-GP
opioid	I-GP
receptor	E-GP
-like	O
distribution	O
and	O
the	O
effect	O
was	O
blocked	O
by	O
naloxone	S-chemical
.	O
To	O
explore	O
these	O
observations	O
,	O
we	O
evaluated	O
the	O
receptor	O
binding	O
profile	O
of	O
OFQ	B-GP
II	I-GP
(	I-GP
1-28	I-GP
)	E-GP
at	O
the	O
cloned	O
ORL1	S-GP
and	O
mu	B-GP
opioid	I-GP
receptors	E-GP
.	O
OFQ	B-GP
II	I-GP
(	I-GP
1-28	I-GP
)	E-GP
had	O
no	O
specific	O
binding	O
at	O
either	O
ORL1	S-GP
or	O
mu	B-GP
opioid	I-GP
receptors	E-GP
at	O
concentrations	O
up	O
to	O
50	O
microM	O
.	O
This	O
lack	O
of	O
affinity	O
was	O
not	O
consistent	O
with	O
a	O
mu-mediated	O
effect	O
,	O
as	O
suggested	O
by	O
preliminary	O
observation	O
using	O
functional	O
autoradiography	O
in	O
rat	O
brain	O
sections	O
.	O
Although	O
behavioral	O
studies	O
suggest	O
that	O
OFQ	B-GP
II	I-GP
(	I-GP
1-28	I-GP
)	E-GP
possesses	O
analgesic	O
activity	O
,	O
this	O
effect	O
does	O
not	O
appear	O
to	O
be	O
mediated	O
via	O
direct	O
binding	O
at	O
the	O
mu	B-GP
opioid	I-GP
receptor	E-GP
.	O
Taken	O
together	O
,	O
these	O
findings	O
support	O
the	O
view	O
that	O
(	O
1	O
)	O
OFQ	S-GP
is	O
the	O
only	O
ppOFQ	S-GP
peptide	O
that	O
binds	O
to	O
and	O
activates	O
the	O
ORL1	S-GP
receptor	O
and	O
(	O
2	O
)	O
OFQ	B-GP
II	I-GP
(	I-GP
1-28	I-GP
)	E-GP
does	O
not	O
bind	O
or	O
stimulate	O
[	B-chemical
35S	I-chemical
]	I-chemical
-GTPgammaS	E-chemical
binding	O
in	O
cells	O
expressing	O
the	O
mu	B-GP
opioid	I-GP
receptor	E-GP
.	O

Yohimbine	S-chemical
dimers	O
exhibiting	O
selectivity	O
for	O
the	O
human	B-GP
alpha	I-GP
2C-adrenoceptor	E-GP
subtype	O
.	O
Yohimbine	S-chemical
is	O
a	O
potent	O
and	O
selective	O
alpha2-	B-GP
versus	I-GP
alpha1-adrenoceptor	E-GP
antagonist	O
.	O
To	O
date	O
,	O
drugs	O
with	O
high	O
specificity	O
for	O
the	O
alpha2-adrenoceptor	S-GP
show	O
marginal	O
selectivity	O
among	O
the	O
three	O
alpha2-adrenoceptor	S-GP
subtypes	O
.	O
Initial	O
studies	O
showed	O
that	O
yohimbine	S-chemical
was	O
about	O
4-	O
and	O
15-fold	O
more	O
selective	O
for	O
the	O
human	B-GP
alpha2C-adrenoceptor	E-GP
in	O
comparison	O
with	O
the	O
alpha2A-	B-GP
and	I-GP
alpha2B-adrenoceptors	E-GP
,	O
respectively	O
.	O
To	O
improve	O
on	O
this	O
alpha2-adrenoceptor	S-GP
subtype	O
selectivity	O
,	O
a	O
series	O
of	O
yohimbine	S-chemical
dimers	O
(	O
varying	O
from	O
n	O
=	O
2	O
to	O
24	O
spacer	O
atoms	O
)	O
were	O
prepared	O
and	O
evaluated	O
for	O
receptor	O
binding	O
on	O
human	B-GP
alpha2-adrenoceptor	E-GP
subtypes	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O
Each	O
dimeric	O
analog	O
showed	O
higher	O
affinities	O
for	O
alpha2A-	B-GP
and	I-GP
alpha2C-adrenoceptor	E-GP
versus	O
the	O
alpha2B-adrenoceptor	S-GP
;	O
and	O
yohimbine	S-chemical
dimers	O
with	O
spacers	O
of	O
n	O
=	O
2	O
,	O
3	O
,	O
4	O
,	O
18	O
,	O
and	O
24	O
exhibited	O
selectivity	O
for	O
the	O
alpha2C-adrenoceptor	S-GP
.	O
The	O
yohimbine	S-chemical
dimers	O
n	O
=	O
3	O
and	O
n	O
=	O
24	O
showed	O
the	O
highest	O
potency	O
and	O
selectivity	O
(	O
32-	O
and	O
82-fold	O
.	O
respectively	O
)	O
for	O
the	O
alpha2C-adrenoceptor	S-GP
in	O
receptor	O
binding	O
and	O
in	O
functional	O
studies	O
(	O
42-	O
and	O
29-fold	O
,	O
respectively	O
)	O
measuring	O
cAMP	S-chemical
changes	O
using	O
a	O
cell-based	O
luciferase	O
reporter	O
gene	O
assay	O
.	O
The	O
dimers	O
(	O
n	O
=	O
3	O
and	O
n	O
=	O
24	O
)	O
had	O
high	O
selectivity	O
(	O
>	O
1000-fold	O
)	O
for	O
the	O
alpha2C-adrenoceptor	S-GP
compared	O
with	O
the	O
three	O
alpha1-adrenoceptor	S-GP
subtypes	O
.	O
These	O
findings	O
demonstrate	O
that	O
the	O
addition	O
of	O
spacer	O
linkages	O
to	O
bivalent	O
yohimbine	S-chemical
molecules	O
provides	O
a	O
successful	O
approach	O
to	O
the	O
development	O
of	O
ligands	O
that	O
are	O
potent	O
and	O
highly	O
selective	O
for	O
the	O
alpha2C-adrenoceptor	S-GP
.	O

Synthesis	O
of	O
quinoline	S-chemical
derivatives	O
:	O
discovery	O
of	O
a	O
potent	O
and	O
selective	O
phosphodiesterase	B-GP
5	E-GP
inhibitor	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
.	O
Phosphodiesterase	B-GP
type	I-GP
5	E-GP
(	O
PDE5	S-GP
)	O
mediates	O
the	O
degradation	O
of	O
cGMP	S-chemical
in	O
a	O
variety	O
of	O
tissues	O
including	O
brain	O
.	O
Recent	O
studies	O
have	O
demonstrated	O
the	O
importance	O
of	O
the	O
nitric	B-chemical
oxide	E-chemical
/	O
cGMP	S-chemical
/	O
cAMP-responsive	B-GP
element-binding	I-GP
protein	E-GP
(	O
CREB	S-GP
)	O
pathway	O
to	O
the	O
process	O
of	O
learning	O
and	O
memory	O
.	O
Thus	O
,	O
PDE5	S-GP
inhibitors	O
(	O
PDE5Is	O
)	O
are	O
thought	O
to	O
be	O
promising	O
new	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
a	O
neurodegenerative	O
disorder	O
characterized	O
by	O
memory	O
loss	O
.	O
To	O
explore	O
this	O
possibility	O
,	O
a	O
series	O
of	O
quinoline	S-chemical
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
.	O
We	O
found	O
that	O
compound	O
7a	O
selectively	O
inhibits	O
PDE5	S-GP
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
0.27	O
nM	O
and	O
readily	O
crosses	O
the	O
blood	O
brain	O
barrier	O
.	O
In	O
an	O
in	O
vivo	O
mouse	O
model	O
of	O
AD	O
,	O
compound	O
7a	O
rescues	O
synaptic	O
and	O
memory	O
defects	O
.	O
Quinoline	S-chemical
-based	O
,	O
CNS-permeant	O
PDE5Is	O
have	O
potential	O
for	O
AD	O
therapeutic	O
development	O
.	O

Inhibition	O
of	O
Th1/Th17	O
responses	O
via	O
suppression	O
of	O
STAT1	S-GP
and	O
STAT3	S-GP
activation	O
contributes	O
to	O
the	O
amelioration	O
of	O
murine	O
experimental	O
colitis	O
by	O
a	O
natural	O
flavonoid	S-chemical
glucoside	O
icariin	S-chemical
.	O
Inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
is	O
a	O
chronic	O
inflammatory	O
disorder	O
in	O
the	O
intestine	O
which	O
involves	O
overproduction	O
of	O
pro-inflammatory	O
cytokines	S-GP
and	O
excessive	O
functions	O
of	O
inflammatory	O
cells	O
.	O
However	O
,	O
current	O
treatments	O
for	O
IBD	O
may	O
have	O
potential	O
adverse	O
effects	O
including	O
steroid	S-chemical
dependence	O
,	O
infections	O
and	O
lymphoma	O
.	O
Therefore	O
new	O
therapies	O
or	O
drug	O
candidates	O
for	O
the	O
treatment	O
of	O
IBD	O
are	O
desperately	O
needed	O
.	O
In	O
the	O
present	O
study	O
we	O
found	O
that	O
icariin	S-chemical
,	O
a	O
major	O
bioactive	O
compound	O
from	O
plants	O
in	O
Epimedium	O
family	O
,	O
exerted	O
protective	O
effect	O
on	O
intestinal	O
inflammation	O
in	O
mice	O
induced	O
by	O
dextran	O
sulfate	S-chemical
sodium	S-chemical
.	O
Oral	O
administration	O
of	O
icariin	S-chemical
significantly	O
attenuated	O
the	O
disease	O
progression	O
and	O
alleviated	O
the	O
pathological	O
changes	O
of	O
colitis	O
.	O
It	O
also	O
inhibited	O
the	O
production	O
of	O
pro-inflammatory	O
cytokines	S-GP
and	O
expression	O
of	O
p-p65	S-GP
,	O
p-STAT1	S-GP
and	O
p-STAT3	S-GP
in	O
colon	O
tissues	O
.	O
Further	O
study	O
showed	O
that	O
icariin	S-chemical
dose-dependently	O
inhibited	O
the	O
proliferation	O
and	O
activation	O
of	O
T	O
lymphocytes	O
,	O
and	O
suppressed	O
pro-inflammatory	O
cytokine	S-GP
levels	O
of	O
activated	O
T	O
cells	O
.	O
Moreover	O
,	O
icariin	S-chemical
treatment	O
inhibited	O
the	O
phosphorylations	O
of	O
STAT1	S-GP
and	O
STAT3	S-GP
in	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
,	O
which	O
were	O
the	O
crucial	O
transcription	O
factors	O
for	O
Th1	O
and	O
Th17	O
respectively	O
.	O
Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
icariin	S-chemical
is	O
a	O
potential	O
therapeutic	O
agent	O
for	O
IBD	O
.	O

Apelin	S-GP
inhibits	O
diet-induced	O
obesity	O
by	O
enhancing	O
lymphatic	O
and	O
blood	O
vessel	O
integrity	O
.	O
Angiogenesis	O
is	O
tightly	O
associated	O
with	O
the	O
outgrowth	O
of	O
adipose	O
tissue	O
,	O
leading	O
to	O
obesity	O
,	O
which	O
is	O
a	O
risk	O
factor	O
for	O
type	O
2	O
diabetes	O
and	O
hypertension	O
,	O
mainly	O
because	O
expanding	O
adipose	O
tissue	O
requires	O
an	O
increased	O
nutrient	O
supply	O
from	O
blood	O
vessels	O
.	O
Therefore	O
,	O
induction	O
of	O
vessel	O
abnormality	O
by	O
adipokines	S-GP
has	O
been	O
well	O
studied	O
,	O
whereas	O
how	O
altered	O
vascular	O
function	O
promotes	O
obesity	O
is	O
relatively	O
unexplored	O
.	O
Also	O
,	O
surviving	O
Prox1	S-GP
heterozygous	O
mice	O
showed	O
abnormal	O
lymphatic	O
patterning	O
and	O
adult-onset	O
obesity	O
,	O
indicating	O
that	O
accumulation	O
of	O
adipocytes	O
could	O
be	O
closely	O
linked	O
with	O
lymphatic	O
function	O
.	O
Here	O
we	O
propose	O
a	O
new	O
anti-obesity	O
strategy	O
based	O
on	O
enhancement	O
of	O
lymphatic	O
and	O
blood	O
vessel	O
integrity	O
with	O
apelin	S-GP
.	O
Apelin	S-GP
-knockout	O
mice	O
given	O
a	O
high-fat	O
diet	O
showed	O
an	O
obese	O
phenotype	O
associated	O
with	O
abnormal	O
lymphatic	O
and	O
blood	O
vessel	O
enlargement	O
.	O
Fatty	B-chemical
acids	E-chemical
present	O
in	O
the	O
high-fat	O
diet	O
induced	O
hyperpermeability	O
of	O
endothelial	O
cells	O
,	O
causing	O
adipocyte	O
differentiation	O
,	O
whereas	O
apelin	S-GP
promoted	O
vascular	O
stabilization	O
.	O
Moreover	O
,	O
treatment	O
of	O
high-fat-diet-fed	O
apelin-knockout	O
mice	O
with	O
a	O
selective	O
cyclooxygenase-2	S-GP
inhibitor	O
,	O
celecoxib	S-chemical
,	O
improved	O
vascular	O
function	O
,	O
and	O
also	O
attenuated	O
obesity	O
.	O
Finally	O
,	O
apelin	S-GP
transgenic	O
mice	O
showed	O
decreased	O
subcutaneous	O
adipose	O
tissue	O
owing	O
to	O
inhibition	O
of	O
high-fat-diet-induced	O
hyperpermeability	O
of	O
vessels	O
.	O
These	O
results	O
indicate	O
that	O
apelin	O
inhibits	O
high-fat-diet-induced	O
obesity	O
by	O
enhancing	O
vessel	O
integrity	O
.	O
Apelin	S-GP
could	O
serve	O
as	O
a	O
therapeutic	O
target	O
for	O
treating	O
obesity	O
and	O
related	O
diseases	O
.	O

Antifungal	O
agents	O
:	O
mode	O
of	O
action	O
in	O
yeast	O
cells	O
.	O
Different	O
kinds	O
of	O
mycoses	O
,	O
especially	O
invasive	O
,	O
have	O
become	O
an	O
important	O
public	O
health	O
problem	O
as	O
their	O
incidence	O
has	O
increased	O
dramatically	O
in	O
the	O
last	O
decades	O
in	O
relation	O
to	O
AIDS	O
,	O
hematological	O
malignancies	O
,	O
transplant	O
recipients	O
and	O
other	O
immunosuppressed	O
individuals	O
.	O
Management	O
of	O
fungal	O
infections	O
is	O
markedly	O
limited	O
by	O
problems	O
of	O
drug	O
safety	O
,	O
resistance	O
and	O
effectiveness	O
profile	O
.	O
Current	O
therapy	O
for	O
invasive	O
mycoses	O
uses	O
a	O
relatively	O
reduced	O
number	O
of	O
antifungal	O
drugs	O
,	O
such	O
as	O
amphotericin	B-chemical
B	E-chemical
,	O
fluconazole	S-chemical
and	O
itraconazole	S-chemical
.	O
Other	O
new	O
antifungal	O
agents	O
from	O
old	O
and	O
new	O
chemical	O
families	O
,	O
like	O
voriconazole	S-chemical
,	O
posaconazole	S-chemical
,	O
ravuconazole	S-chemical
,	O
caspofungin	S-chemical
and	O
micafungin	S-chemical
,	O
have	O
been	O
introduced	O
into	O
the	O
armamentarium	O
for	O
fungal	O
infections	O
management	O
.	O
This	O
review	O
is	O
focused	O
on	O
the	O
mode	O
of	O
action	O
of	O
those	O
antifungal	O
drugs	O
used	O
against	O
pathogenic	O
yeasts	O
.	O
The	O
interaction	O
of	O
amphotericin	B-chemical
B	E-chemical
with	O
ergosterol	S-chemical
and	O
other	O
membrane	O
sterols	S-chemical
results	O
in	O
the	O
production	O
of	O
aqueous	O
pores	O
of	O
drug	O
and	O
the	O
ergosterol	S-chemical
biosynthetic	O
pathway	O
is	O
the	O
target	O
of	O
the	O
allylamines	S-chemical
,	O
phenylmorpholines	S-chemical
and	O
azole	S-chemical
antifungal	O
agents	O
.	O
The	O
main	O
molecular	O
target	O
of	O
azole	S-chemical
antifungals	O
is	O
the	O
cytochrome	B-GP
P-450	E-GP
protein	O
Erg11p	S-GP
/	O
Cyp51p	S-GP
.	O
Echinocandins	O
,	O
a	O
new	O
class	O
of	O
antifungal	O
drugs	O
,	O
are	O
fungal	O
secondary	O
metabolites	O
that	O
act	O
against	O
beta-1-3-D-glucan	O
synthesis	O
.	O
The	O
phenylmorpholines	S-chemical
,	O
of	O
which	O
amorolfine	S-chemical
is	O
the	O
sole	O
representative	O
in	O
human	O
therapy	O
,	O
affect	O
two	O
targets	O
in	O
the	O
ergosterol	O
pathway	O
:	O
Erg24p	S-GP
(	O
delta	B-GP
14	I-GP
reductase	E-GP
)	O
and	O
Erg2p	S-GP
(	O
delta	B-GP
8-delta	I-GP
7	I-GP
isomerase	E-GP
)	O
.	O
The	O
sordarins	S-chemical
group	O
are	O
protein	O
synthesis	O
inhibitors	O
that	O
work	O
by	O
blocking	O
the	O
function	O
of	O
fungal	B-GP
translation	I-GP
elongation	I-GP
factor	I-GP
2	E-GP
.	O
Other	O
protein	O
inhibitors	O
are	O
zofimarin	S-chemical
,	O
BE31045	S-chemical
,	O
SCH57504	S-chemical
,	O
xylarin	S-chemical
,	O
hypoxysordarin	S-chemical
and	O
GR135402	S-chemical
.	O
In	O
order	O
to	O
overcome	O
the	O
problems	O
derived	O
from	O
the	O
exploitation	O
of	O
azole	S-chemical
drugs	O
,	O
macrolides	O
and	O
echinocandins	S-chemical
,	O
novel	O
targets	O
were	O
explored	O
.	O
Proposed	O
antifungal	O
drugs	O
have	O
been	O
developed	O
against	O
potential	O
targets	O
like	O
the	O
N	S-chemical
-myristylation	O
of	O
fungal	O
proteins	O
,	O
with	O
inhibitors	O
like	O
myristate	S-chemical
and	O
histidine	S-chemical
analogues	O
or	O
myristoylpeptide	O
derivatives	O
,	O
aminobenzothiazoles	S-chemical
,	O
quinolines	S-chemical
and	O
benzofurans	S-chemical
.	O
Polymerization	O
of	O
cell	O
wall	O
carbohydrates	O
from	O
uridine	B-chemical
di-phospho	I-chemical
sugars	E-chemical
is	O
another	O
potential	O
target	O
.	O

Inhibition	O
of	O
Ebola	O
Virus	O
Infection	O
:	O
Identification	O
of	O
Niemann-Pick	B-GP
C1	E-GP
as	O
the	O
Target	O
by	O
Optimization	O
of	O
a	O
Chemical	O
Probe	O
.	O
A	O
high	O
throughput	O
screen	O
identified	O
adamantane	S-chemical
dipeptide	O
1	O
as	O
an	O
inhibitor	O
of	O
Ebola	O
virus	O
(	O
EboV	O
)	O
infection	O
.	O
Hit-to-lead	O
optimization	O
to	O
determine	O
the	O
structure-activity	O
relationship	O
(	O
SAR	O
)	O
identified	O
the	O
more	O
potent	O
EboV	O
inhibitor	O
2	O
and	O
a	O
photoaffinity	O
labeling	O
agent	O
3	O
.	O
These	O
anti-viral	O
compounds	O
were	O
employed	O
to	O
identify	O
the	O
target	O
as	O
Niemann-Pick	B-GP
C1	E-GP
(	O
NPC1	S-GP
)	O
,	O
a	O
host	O
protein	O
that	O
binds	O
the	O
EboV	B-GP
glycoprotein	E-GP
and	O
is	O
essential	O
for	O
infection	O
.	O
These	O
studies	O
establish	O
NPC1	S-GP
as	O
a	O
promising	O
target	O
for	O
anti-viral	O
therapy	O
.	O

Mesenteric	O
artery	O
remodeling	O
and	O
effects	O
of	O
imidapril	S-chemical
and	O
irbesartan	S-chemical
on	O
it	O
in	O
spontaneously	O
hypertensive	O
rats	O
.	O
AIM	O
:	O
To	O
investigate	O
the	O
remodeling	O
of	O
mesenteric	O
artery	O
and	O
the	O
expression	O
of	O
TGF-beta1	S-GP
,	O
c-Jun	S-GP
in	O
mesenteric	O
artery	O
and	O
effects	O
of	O
imidapril	S-chemical
and	O
irbesartan	S-chemical
on	O
the	O
remodeling	O
in	O
spontaneously	O
hypertensive	O
rats	O
(	O
SHR	O
)	O
.	O
METHODS	O
:	O
Thirty	O
SHR	O
(	O
male/female	O
,	O
21/9	O
)	O
,	O
aged	O
13	O
wk	O
,	O
were	O
randomly	O
divided	O
into	O
3	O
groups	O
(	O
7	O
male	O
rats	O
and	O
3	O
female	O
rats	O
each	O
group	O
)	O
:	O
SHR	O
group	O
,	O
imidapril	S-chemical
group	O
(	O
imidapril	S-chemical
3	O
mg/kg.d	O
was	O
given	O
in	O
drinking	O
water	O
for	O
14	O
wk	O
)	O
,	O
and	O
irbesartan	S-chemical
group	O
(	O
irbesartan	S-chemical
50	O
mg/kg.d	O
was	O
given	O
in	O
drinking	O
water	O
foe	O
14	O
wk	O
)	O
.	O
Ten	O
homogeneous	O
Wistar	O
Kyoto	O
rats	O
,	O
5	O
males	O
and	O
5	O
females	O
,	O
weighing	O
206+/-49	O
g	O
,	O
were	O
selected	O
as	O
normal	O
control	O
group	O
(	O
WKY	O
group	O
)	O
.	O
Systolic	O
pressure	O
was	O
measured	O
on	O
d	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
8	O
,	O
10	O
,	O
12	O
and	O
14	O
during	O
the	O
experiment	O
and	O
the	O
rats	O
were	O
killed	O
at	O
the	O
end	O
of	O
the	O
experiment	O
.	O
Angiotensin	B-chemical
II	E-chemical
(	O
Ang	B-chemical
II	E-chemical
)	O
level	O
in	O
plasma	O
and	O
mesenteric	O
arteries	O
was	O
measured	O
by	O
radioimmunoassay	O
.	O
The	O
morphology	O
of	O
the	O
secondary	O
branches	O
of	O
mesenteric	O
artery	O
were	O
examined	O
by	O
light	O
microscopy	O
and	O
electron	O
microscopy	O
.	O
Reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
was	O
used	O
to	O
detect	O
the	O
expression	O
of	O
transforming	B-GP
growth	I-GP
factor	E-GP
TGF-beta1	S-GP
and	O
c-Jun	S-GP
mRNA	O
.	O
RESULTS	O
:	O
Compared	O
with	O
imidapril	S-chemical
group	O
and	O
irbesartan	S-chemical
group	O
,	O
the	O
blood	O
pressure	O
was	O
remarkably	O
increased	O
in	O
SHR	O
group	O
.	O
Ang	B-GP
II	E-GP
level	O
in	O
plasma	O
and	O
mesenteric	O
arteries	O
in	O
SHR	O
group	O
was	O
the	O
same	O
or	O
lower	O
than	O
that	O
in	O
WKY	O
group	O
,	O
and	O
was	O
higher	O
in	O
irbesartan	S-chemical
group	O
and	O
lower	O
in	O
imidapril	S-chemical
group	O
.	O
The	O
remodeling	O
of	O
mesenteric	O
arteries	O
in	O
SHR	O
group	O
was	O
mostly	O
obvious	O
among	O
the	O
4	O
groups	O
.	O
The	O
ratio	O
of	O
TGF-beta1	S-GP
absorbed	O
light	O
value	O
to	O
GAPDH	S-GP
absorbed	O
light	O
value	O
in	O
the	O
SHR	O
group	O
was	O
0.887+/-0.019	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
WKY	O
group	O
,	O
imidapril	S-chemical
group	O
,	O
and	O
irbesartan	S-chemical
group	O
with	O
the	O
ratios	O
of	O
0.780+/-0.018	O
,	O
0.803+/-0.005	O
,	O
and	O
0.847+/-0.017	O
,	O
respectively	O
(	O
P	O
<	O
0.01	O
)	O
.	O
Ang	B-chemical
II	E-chemical
level	O
in	O
plasma	O
and	O
mesenteric	O
arteries	O
in	O
imidapril	S-chemical
group	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
irbesartan	S-chemical
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
c-Jun	S-GP
absorbed	O
light	O
value/	O
GAPDH	S-GP
absorbed	O
light	O
value	O
of	O
mesenteric	O
arteries	O
in	O
the	O
SHR	O
group	O
was	O
0.850+/-0.015	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
WKY	O
,	O
imidapril	S-chemical
,	O
and	O
irbesartan	S-chemical
groups	O
(	O
0.582+/-0.013	O
,	O
0.743+/-0.012	O
,	O
and	O
0.789+/-0.013	O
,	O
respectively	O
,	O
P	O
<	O
0.01	O
)	O
,	O
and	O
was	O
significantly	O
lower	O
in	O
imidapril	S-chemical
group	O
than	O
in	O
irbesartan	S-chemical
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O
CONCLUSION	O
:	O
Imidapril	S-chemical
and	O
irbesartan	S-chemical
can	O
not	O
only	O
control	O
blood	O
pressure	O
but	O
also	O
inhibit	O
mesenteric	O
arteries	O
remodeling	O
and	O
mRNA	O
expression	O
of	O
TGF-beta1	S-GP
,	O
c-Jun	S-GP
in	O
SHR	O
.	O
Imidapril	S-chemical
is	O
more	O
effective	O
than	O
irbesartan	S-chemical
.	O

[	O
Pharmacological	O
treatment	O
of	O
obesity	O
]	O
.	O
The	O
pharmacological	O
treatment	O
of	O
obesity	O
should	O
be	O
considered	O
when	O
can	O
not	O
be	O
achieved	O
a	O
10	O
%	O
weight	O
loss	O
with	O
diet	O
therapy	O
and	O
physical	O
activity	O
.	O
The	O
drugs	O
effective	O
in	O
obesity	O
treatment	O
may	O
act	O
by	O
different	O
mechanisms	O
such	O
as	O
reduction	O
in	O
food	O
intake	O
,	O
inhibition	O
of	O
fat	O
absorption	O
,	O
increase	O
of	O
thermogenesis	O
and	O
stimulation	O
of	O
adipocyte	O
apoptosis	O
.	O
At	O
present	O
,	O
we	O
only	O
have	O
two	O
marketed	O
drugs	O
for	O
obesity	O
treatment	O
.	O
Sibutramine	S-chemical
is	O
an	O
inhibitor	O
of	O
norepinephrine	S-chemical
,	O
dopamine	S-chemical
and	O
serotonina	O
reuptake	O
which	O
inhibits	O
food	O
intake	O
and	O
increases	O
thermogenesis	O
.	O
Sibutramine	S-chemical
administration	O
for	O
a	O
year	O
can	O
induce	O
a	O
weight	O
loss	O
of	O
4-7	O
%	O
.	O
Its	O
main	O
side	O
effects	O
are	O
hypertension	O
,	O
headache	O
,	O
insomnia	O
and	O
constipation	O
.	O
Orlistat	S-chemical
is	O
an	O
inhibitor	O
of	O
pancreatic	B-GP
lipase	E-GP
which	O
is	O
able	O
to	O
block	O
the	O
absorption	O
of	O
30	O
%	O
of	O
ingested	O
fat	O
.	O
Its	O
administration	O
induces	O
weight	O
loss	O
and	O
reduction	O
of	O
ulterior	O
weight	O
regain	O
.	O
Also	O
,	O
this	O
drug	O
improves	O
hypertension	O
dyslipdaemia	O
and	O
helps	O
to	O
prevent	O
diabetes	O
in	O
52	O
%	O
of	O
cases	O
when	O
administered	O
over	O
four	O
years	O
.	O
The	O
increase	O
in	O
frequency	O
of	O
stools	O
and	O
interference	O
with	O
vitamin	O
absorption	O
are	O
its	O
main	O
side	O
effects	O
.	O
Glucagon-like	B-GP
peptide	I-GP
1	E-GP
,	O
which	O
increases	O
insulin	S-GP
sensitivity	O
and	O
satiety	O
,	O
adiponectin	S-GP
and	O
PPAR-gamma	S-GP
agonists	O
which	O
reduce	O
insulin	S-GP
resistance	O
and	O
modulates	O
adipocyte	O
generation	O
are	O
the	O
basis	O
for	O
future	O
therapeutic	O
approaches	O
of	O
obesity	O
.	O
Phosphatase	S-GP
inhibitors	O
induce	O
PPAR-gamma	S-GP
phosphorylation	O
and	O
UCP-1	S-GP
expression	O
leading	O
to	O
an	O
increase	O
in	O
thermogenesis	O
and	O
reduction	O
in	O
appetite	O
.	O

n-3	B-chemical
and	I-chemical
n-6	I-chemical
polyunsaturated	I-chemical
fatty	I-chemical
acids	E-chemical
induce	O
the	O
expression	O
of	O
COX-2	S-GP
via	O
PPARgamma	S-GP
activation	O
in	O
human	O
keratinocyte	O
HaCaT	O
cells	O
.	O
Polyunsaturated	B-chemical
fatty	I-chemical
acids	I-chemical
(	I-chemical
PUFA	I-chemical
)	I-chemical
n-3	E-chemical
inhibit	O
inflammation	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
in	O
keratinocytes	O
.	O
We	O
examined	O
in	O
HaCaT	O
keratinocyte	O
cell	O
line	O
whether	O
eicosapentaenoic	B-chemical
acid	E-chemical
(	O
EPA	S-chemical
)	O
a	O
n-3	B-chemical
PUFA	E-chemical
,	O
gamma-linoleic	B-chemical
acid	E-chemical
(	O
GLA	S-chemical
)	O
a	O
n-6	B-chemical
PUFA	E-chemical
,	O
and	O
arachidic	B-chemical
acid	E-chemical
a	O
saturated	B-chemical
fatty	I-chemical
acid	E-chemical
,	O
modulate	O
expression	O
of	O
cyclooxygenase-2	S-GP
(	O
COX-2	S-GP
)	O
,	O
an	O
enzyme	O
pivotal	O
to	O
skin	O
inflammation	O
and	O
reparation	O
.	O
We	O
demonstrate	O
that	O
only	O
treatment	O
of	O
HaCaT	O
with	O
GLA	S-chemical
and	O
EPA	S-chemical
or	O
a	O
PPARgamma	S-GP
ligand	O
(	O
roziglitazone	S-chemical
)	O
,	O
induced	O
COX-2	S-GP
expression	O
(	O
protein	O
and	O
mRNA	O
)	O
.	O
Moreover	O
stimulation	O
of	O
COX-2	B-GP
promoter	E-GP
activity	O
was	O
increased	O
by	O
those	O
PUFAs	S-chemical
or	O
rosiglitazone	S-chemical
.	O
The	O
inhibitory	O
effects	O
of	O
GW9662	S-chemical
and	O
T0070907	S-chemical
(	O
PPARgamma	S-GP
antagonists	O
)	O
,	O
on	O
COX-2	S-GP
expression	O
and	O
on	O
stimulation	O
of	O
COX-2	B-GP
promoter	E-GP
activity	O
by	O
EPA	S-chemical
and	O
GLA	S-chemical
suggest	O
that	O
PPARgamma	S-GP
is	O
implicated	O
in	O
COX-2	S-GP
induction	O
.	O
Finally	O
,	O
PLA2	S-GP
inhibitor	O
methyl	O
arachidonyl	B-chemical
fluorophosphonate	E-chemical
blocked	O
the	O
PUFA	S-chemical
effects	O
on	O
COX-2	S-GP
induction	O
,	O
promoter	O
activity	O
and	O
arachidonic	B-chemical
acid	E-chemical
mobilization	O
suggesting	O
involvement	O
of	O
AA	S-chemical
metabolites	O
in	O
PPAR	S-GP
activation	O
.	O
These	O
findings	O
demonstrate	O
that	O
n-3	B-chemical
and	I-chemical
n-6	I-chemical
PUFA	E-chemical
increased	O
PPARgamma	S-GP
activity	O
is	O
necessary	O
for	O
the	O
COX-2	S-GP
induction	O
in	O
HaCaT	O
human	O
keratinocyte	O
cells	O
.	O
Given	O
the	O
anti-inflammatory	O
properties	O
of	O
EPA	S-chemical
,	O
we	O
suggest	O
that	O
induction	O
of	O
COX-2	S-GP
in	O
keratinocytes	O
may	O
be	O
important	O
in	O
the	O
anti-inflammatory	O
and	O
protective	O
mechanism	O
of	O
action	O
of	O
PUFAs	B-chemical
n-3	E-chemical
or	O
n-6	O
.	O

Platycodi	O
Radix	O
attenuates	O
dimethylnitrosamine	S-chemical
-induced	O
liver	O
fibrosis	O
in	O
rats	O
by	O
inducing	O
Nrf2	S-GP
-mediated	O
antioxidant	O
enzymes	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
anti-fibrotic	O
effects	O
of	O
the	O
aqueous	O
extract	O
of	O
the	O
Platycodi	O
Radix	O
root	O
(	O
Changkil	O
:	O
CK	O
)	O
on	O
dimethylnitrosamine	S-chemical
(	O
DMN	S-chemical
)	O
-induced	O
liver	O
fibrosis	O
in	O
rats	O
.	O
DMN	S-chemical
treatment	O
for	O
4weeks	O
led	O
to	O
marked	O
liver	O
fibrosis	O
as	O
assessed	O
by	O
serum	O
biochemistry	O
,	O
histopathological	O
examination	O
,	O
and	O
hepatic	O
lipid	O
peroxidation	O
and	O
collagen	S-GP
content	O
.	O
CK	O
significantly	O
inhibited	O
DMN	S-chemical
-induced	O
increases	O
in	O
serum	O
alanine	B-GP
aminotransferase	E-GP
(	O
ALT	S-GP
)	O
and	O
aspartate	B-GP
aminotransferase	E-GP
(	O
AST	S-GP
)	O
activities	O
,	O
fibrosis	O
score	O
,	O
and	O
hepatic	O
malondialdehyde	S-chemical
and	O
collagen	S-GP
content	O
.	O
CK	O
also	O
inhibited	O
DMN	S-chemical
-induced	O
reductions	O
in	O
rat	O
body	O
and	O
liver	O
weights	O
.	O
Reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
and	O
western	O
blot	O
analyses	O
revealed	O
that	O
CK	O
inhibited	O
DMN	S-chemical
-induced	O
increases	O
in	O
matrix	B-GP
metalloproteinase-13	E-GP
(	O
MMP-13	S-GP
)	O
,	O
tissue	B-GP
inhibitor	I-GP
of	I-GP
metalloproteinase-1	E-GP
(	O
TIMP-1	S-GP
)	O
,	O
and	O
tumor	B-GP
necrosis	I-GP
factor-α	E-GP
(	O
TNF-α	S-GP
)	O
mRNA	O
,	O
and	O
collagen	B-GP
type	I-GP
I	E-GP
and	O
α-smooth	B-GP
muscle	I-GP
actin	E-GP
protein	O
.	O
DMN	S-chemical
-induced	O
cyclooxygenase-2	S-GP
(	O
COX-2	S-GP
)	O
expression	O
and	O
nuclear	B-GP
factor-kappa	I-GP
B	E-GP
(	O
NF-κB	S-GP
)	O
activation	O
was	O
reduced	O
by	O
CK	O
treatment	O
.	O
Furthermore	O
,	O
CK	O
induced	O
activation	O
of	O
nuclear	B-GP
erythroid	I-GP
2-related	I-GP
factor	I-GP
2	E-GP
(	O
Nrf2	S-GP
)	O
-mediated	O
antioxidant	O
enzymes	O
such	O
as	O
γ-glutamylcysteine	B-GP
synthetase	E-GP
(	O
γ-GCS	S-GP
)	O
,	O
heme	B-GP
oxygenase-1	E-GP
(	O
HO-1	S-GP
)	O
,	O
NAD	B-GP
(	I-GP
P	I-GP
)	I-GP
H	I-GP
quinone	I-GP
oxidoreductase	I-GP
1	E-GP
(	O
NQO1	S-GP
)	O
,	O
and	O
glutathione-S-transferase	S-GP
(	O
GST	S-GP
)	O
in	O
HepG2	O
cells	O
.	O
These	O
results	O
demonstrated	O
that	O
CK	O
attenuates	O
DMN	S-chemical
-induced	O
liver	O
fibrosis	O
through	O
the	O
activation	O
of	O
Nrf2	S-GP
-mediated	O
antioxidant	O
enzymes	O
.	O

Catalpol	S-chemical
inhibits	O
LPS	O
plus	O
IFN-γ	S-GP
-induced	O
inflammatory	O
response	O
in	O
astrocytes	O
primary	O
cultures	O
.	O
A	O
large	O
body	O
of	O
evidence	O
suggests	O
that	O
the	O
inflammatory	O
reaction	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
neurodegenerative	O
diseases	O
.	O
Our	O
previous	O
studies	O
described	O
the	O
neuroprotective	O
effects	O
of	O
catalpol	S-chemical
in	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
inflammatory	O
models	O
,	O
in	O
which	O
catalpol	S-chemical
was	O
shown	O
to	O
prevent	O
mesencephalic	O
neuron	O
death	O
and	O
ameliorate	O
cognitive	O
ability	O
animals	O
.	O
To	O
further	O
investigate	O
the	O
protective	O
effect	O
and	O
underlying	O
mechanism	O
of	O
catalpol	S-chemical
,	O
astrocytes	O
were	O
pretreated	O
with	O
low	O
(	O
0.1mM	O
)	O
and	O
high	O
dose	O
(	O
0.5mM	O
)	O
catalpol	S-chemical
for	O
1h	O
prior	O
to	O
LPS	O
plus	O
interferon-γ	S-GP
stimulation	O
.	O
Biochemical	O
analyses	O
showed	O
that	O
NO	S-chemical
and	O
ROS	O
production	O
and	O
iNOS	S-GP
activity	O
were	O
significantly	O
reduced	O
by	O
catalpol	S-chemical
.	O
Data	O
at	O
transcriptional	O
level	O
also	O
demonstrated	O
that	O
catalpol	S-chemical
potently	O
attenuated	O
gene	O
expressions	O
involved	O
in	O
inflammation	O
,	O
such	O
as	O
iNOS	S-GP
,	O
COX-2	S-GP
and	O
TLR4	S-GP
.	O
In	O
addition	O
,	O
our	O
exploration	O
further	O
revealed	O
that	O
the	O
suppressive	O
action	O
of	O
catalpol	S-chemical
on	O
inflammation	O
was	O
mediated	O
via	O
inhibiting	O
nuclear	B-GP
factor-κB	E-GP
(	O
NF-κB	S-GP
)	O
activation	O
.	O
Collectively	O
,	O
these	O
results	O
suggest	O
that	O
catalpol	S-chemical
can	O
exert	O
inhibitory	O
effects	O
on	O
the	O
inflammatory	O
reaction	O
in	O
astrocytes	O
and	O
that	O
inactivation	O
of	O
NF-κB	S-GP
could	O
be	O
the	O
major	O
determinant	O
for	O
its	O
anti-inflammatory	O
mechanism	O
.	O
Therefore	O
,	O
catalpol	S-chemical
may	O
potentially	O
be	O
a	O
highly	O
effective	O
therapeutic	O
agent	O
in	O
treating	O
neurodegenerative	O
diseases	O
associated	O
with	O
inflammation	O
.	O

Auranofin	S-chemical
increases	O
apoptosis	O
and	O
ischaemia-reperfusion	O
injury	O
in	O
the	O
rat	O
isolated	O
heart	O
.	O
Auranofin	S-chemical
,	O
an	O
antirheumatic	O
gold	O
compound	O
,	O
is	O
an	O
inhibitor	O
of	O
selenocysteine	B-GP
enzymes	E-GP
,	O
such	O
as	O
thioredoxin	B-GP
reductase	E-GP
and	O
glutathione	B-GP
peroxidase	E-GP
.	O
These	O
enzymes	O
play	O
an	O
important	O
role	O
in	O
protecting	O
cardiac	O
tissue	O
from	O
oxidative	O
stress	O
generated	O
during	O
ischaemia-reperfusion	O
.	O
Auranofin	S-chemical
(	O
100	O
mg/kg	O
)	O
was	O
administered	O
to	O
rats	O
and	O
their	O
hearts	O
were	O
subjected	O
to	O
an	O
in	O
vitro	O
model	O
of	O
ischaemia-reperfusion	O
.	O
The	O
activity	O
of	O
thioredoxin	B-GP
reductase	E-GP
and	O
glutathione	B-GP
peroxidase	E-GP
was	O
determined	O
in	O
liver	O
and	O
heart	O
tissues	O
in	O
an	O
attempt	O
to	O
correlate	O
enzymatic	O
activity	O
with	O
heart	O
recovery	O
after	O
ischaemia-reperfusion	O
.	O
There	O
was	O
significantly	O
less	O
thioredoxin	B-GP
reductase	E-GP
activity	O
in	O
rat	O
liver	O
extracts	O
,	O
whereas	O
the	O
level	O
of	O
glutathione	S-chemical
activity	O
remained	O
unchanged	O
,	O
demonstrating	O
that	O
the	O
dose	O
of	O
auranofin	S-chemical
used	O
was	O
able	O
to	O
selectively	O
inhibit	O
one	O
of	O
these	O
enzyme	O
systems	O
.	O
Rats	O
administered	O
auranofin	S-chemical
displayed	O
significantly	O
impaired	O
recovery	O
from	O
ischaemic	O
insult	O
.	O
The	O
end	O
diastolic	O
pressure	O
was	O
increased	O
,	O
whereas	O
the	O
rate	O
pressure	O
product	O
was	O
significantly	O
decreased	O
.	O
The	O
level	O
of	O
postischaemic	O
apoptosis	O
was	O
also	O
assessed	O
by	O
examining	O
caspase-3	S-GP
activity	O
in	O
tissue	O
homogenates	O
.	O
Auranofin	S-chemical
significantly	O
increased	O
the	O
degree	O
of	O
postischaemic	O
apoptosis	O
,	O
leading	O
to	O
poor	O
postischaemic	O
recovery	O
.	O

Aberrant	O
activation	O
of	O
M	B-GP
phase	I-GP
proteins	E-GP
by	O
cell	O
proliferation-evoking	O
carcinogens	O
after	O
28-day	O
administration	O
in	O
rats	O
.	O
We	O
have	O
previously	O
reported	O
that	O
hepatocarcinogens	O
increase	O
liver	O
cells	O
expressing	O
p21	S-GP
(	O
Cip1	S-GP
)	O
,	O
a	O
G1	O
checkpoint	O
protein	O
and	O
M	B-GP
phase	I-GP
proteins	E-GP
after	O
28-day	O
treatment	O
in	O
rats	O
.	O
This	O
study	O
aimed	O
to	O
identify	O
early	O
prediction	O
markers	O
of	O
carcinogens	O
available	O
in	O
many	O
target	O
organs	O
after	O
28-day	O
treatment	O
in	O
rats	O
.	O
Immunohistochemical	O
analysis	O
was	O
performed	O
on	O
Ki-67	S-GP
,	O
p21	S-GP
(	O
Cip1	S-GP
)	O
and	O
M	B-GP
phase	I-GP
proteins	E-GP
[	O
nuclear	O
Cdc2	S-GP
,	O
phospho-Histone	B-GP
H3	E-GP
(	O
p-Histone	B-GP
H3	E-GP
)	O
,	O
Aurora	B-GP
B	E-GP
and	O
heterochromatin	B-GP
protein	I-GP
1α	E-GP
(	O
HP1α	S-GP
)	O
]	O
with	O
carcinogens	O
targeting	O
different	O
organs	O
.	O
Carcinogens	O
targeting	O
thyroid	O
(	O
sulfadimethoxine	S-chemical
;	O
SDM	S-chemical
)	O
,	O
urinary	O
bladder	O
(	O
phenylethyl	B-chemical
isothiocyanate	E-chemical
)	O
,	O
forestomach	O
(	O
butylated	B-chemical
hydroxyanisole	E-chemical
;	O
BHA	S-chemical
)	O
,	O
glandular	O
stomach	O
(	O
catechol	S-chemical
;	O
CC	O
)	O
,	O
and	O
colon	O
(	O
2-amino-1-methyl-6-phenylimidazo	B-chemical
[	I-chemical
4,5-b	I-chemical
]	I-chemical
pyridine	E-chemical
and	O
chenodeoxycholic	B-chemical
acid	E-chemical
)	O
were	O
examined	O
using	O
a	O
non-carcinogenic	O
toxicant	O
(	O
caprolactam	S-chemical
)	O
and	O
carcinogens	O
targeting	O
other	O
organs	O
as	O
negative	O
controls	O
.	O
All	O
carcinogens	O
increased	O
Ki-67	S-GP
(	O
+	O
)	O
,	O
nuclear	O
Cdc2	S-GP
(	O
+	O
)	O
,	O
p-Histone	B-GP
H3	E-GP
(	O
+	O
)	O
or	O
Aurora	B-GP
B	E-GP
(	O
+	O
)	O
carcinogenic	O
target	O
cells	O
,	O
except	O
for	O
both	O
colon	O
carcinogens	O
,	O
which	O
did	O
not	O
increase	O
cell	O
proliferation	O
.	O
On	O
the	O
other	O
hand	O
,	O
p21	S-GP
(	O
Cip1	S-GP
+	O
)	O
cells	O
increased	O
with	O
SDM	O
and	O
CC	O
.	O
HP1α	S-GP
responded	O
only	O
to	O
BHA	S-chemical
.	O
Results	O
revealed	O
carcinogens	O
evoking	O
cell	O
proliferation	O
concurrently	O
induced	O
cell	O
cycle	O
arrest	O
at	O
M	O
phase	O
or	O
showing	O
chromosomal	O
instability	O
reflecting	O
aberration	O
in	O
cell	O
cycle	O
regulation	O
,	O
irrespective	O
of	O
target	O
organs	O
,	O
after	O
28-day	O
treatment	O
.	O
Therefore	O
,	O
M	B-GP
phase	I-GP
proteins	E-GP
may	O
be	O
early	O
prediction	O
markers	O
of	O
carcinogens	O
evoking	O
cell	O
proliferation	O
in	O
many	O
target	O
organs	O
.	O

Ergovaline	S-chemical
binding	O
and	O
activation	O
of	O
D2	B-GP
dopamine	I-GP
receptors	E-GP
in	O
GH4ZR7	O
cells	O
.	O
Ergovaline	S-chemical
inhibition	O
of	O
radioligand	O
binding	O
to	O
the	O
D2	B-GP
dopamine	I-GP
receptor	E-GP
and	O
ergot	B-chemical
alkaloid	E-chemical
inhibition	O
of	O
vasoactive	B-GP
intestinal	I-GP
peptide	E-GP
(	O
VIP	S-GP
)	O
-stimulated	O
cyclic	B-chemical
AMP	E-chemical
production	O
in	O
GH4ZR7	O
cells	O
,	O
stably	O
transfected	O
with	O
a	O
rat	B-GP
D2	I-GP
dopamine	I-GP
receptor	E-GP
,	O
were	O
evaluated	O
.	O
Ergovaline	S-chemical
inhibition	O
of	O
the	O
binding	O
of	O
the	O
D2	S-GP
-specific	O
radioligand	O
,	O
[	B-chemical
3H	I-chemical
]	I-chemical
YM-09151-2	E-chemical
,	O
exhibited	O
a	O
KI	O
(	O
inhibition	O
constant	O
)	O
of	O
6.9	O
+/-	O
2.6	O
nM	O
,	O
whereas	O
dopamine	S-chemical
was	O
much	O
less	O
potent	O
(	O
370	O
+/-	O
160	O
nM	O
)	O
.	O
Ergot	B-chemical
alkaloids	E-chemical
were	O
also	O
effective	O
in	O
inhibiting	O
VIP	S-GP
-stimulated	O
cyclic	B-chemical
AMP	E-chemical
production	O
,	O
with	O
EC50	O
values	O
for	O
ergovaline	S-chemical
,	O
ergonovine	S-chemical
,	O
alpha-ergocryptine	S-chemical
,	O
ergotamine	S-chemical
,	O
and	O
dopamine	S-chemical
of	O
8	O
+/-	O
2	O
,	O
47	O
+/-	O
2	O
,	O
28	O
+/-	O
2	O
,	O
2	O
+/-	O
1	O
,	O
and	O
8	O
+/-	O
1	O
nM	O
,	O
respectively	O
.	O
Inhibition	O
of	O
cyclic	B-chemical
AMP	E-chemical
production	O
by	O
ergovaline	S-chemical
was	O
blocked	O
by	O
the	O
dopamine	B-GP
receptor	E-GP
antagonist	O
,	O
(	B-chemical
-	I-chemical
)	I-chemical
-sulpiride	E-chemical
(	O
IC50	O
,	O
300	O
+/-	O
150	O
nM	O
)	O
.	O
Our	O
results	O
indicate	O
that	O
ergot	O
compounds	O
,	O
especially	O
ergovaline	S-chemical
,	O
bind	O
to	O
D2	B-GP
dopamine	I-GP
receptors	E-GP
and	O
elicit	O
second	O
messenger	O
responses	O
similar	O
to	O
that	O
of	O
dopamine	S-chemical
.	O
These	O
findings	O
suggest	O
that	O
some	O
of	O
the	O
deleterious	O
effects	O
of	O
consumption	O
of	O
endophyte-infected	O
tall	O
fescue	O
,	O
which	O
contains	O
several	O
ergot	B-chemical
alkaloids	E-chemical
including	O
ergovaline	S-chemical
,	O
may	O
be	O
due	O
to	O
D2	B-GP
dopamine	I-GP
receptor	E-GP
activation	O
.	O

Sedation	O
and	O
histamine	S-chemical
H1-receptor	O
antagonism	O
:	O
studies	O
in	O
man	O
with	O
the	O
enantiomers	O
of	O
chlorpheniramine	O
and	O
dimethindene	O
.	O
1	O
.	O
The	O
effects	O
of	O
10	O
mg	O
(	O
+	O
)	O
-	O
and	O
(	O
-	O
)	O
-chlorpheniramine	O
and	O
5	O
mg	O
(	O
+	O
)	O
-	O
and	O
(	O
-	O
)	O
-dimethindene	O
on	O
daytime	O
sleep	O
latencies	O
,	O
digit	O
symbol	O
substitution	O
and	O
subjective	O
assessments	O
of	O
mood	O
and	O
well-being	O
were	O
studied	O
in	O
6	O
healthy	O
young	O
adult	O
humans	O
.	O
Each	O
subject	O
also	O
took	O
5	O
mg	O
triprolidine	O
hydrochloride	O
as	O
an	O
active	O
control	O
and	O
two	O
placebos	O
.	O
2	O
.	O
Daytime	O
sleep	O
latencies	O
were	O
reduced	O
with	O
triprolidine	O
,	O
(	O
+	O
)	O
-chlorpheniramine	O
and	O
(	O
-	O
)	O
-dimethindene	O
,	O
and	O
subjects	O
also	O
reported	O
that	O
they	O
felt	O
more	O
sleepy	O
after	O
(	O
+	O
)	O
-chlorpheniramine	O
and	O
(	O
-	O
)	O
-dimethindene	O
.	O
Performance	O
on	O
digit	O
symbol	O
substitution	O
was	O
impaired	O
with	O
(	O
+	O
)	O
-chlorpheniramine	O
.	O
3	O
.	O
Changes	O
in	O
measures	O
with	O
(	O
-	O
)	O
-chlorpheniramine	O
and	O
(	O
+	O
)	O
-dimethindene	O
were	O
not	O
different	O
from	O
changes	O
with	O
placebo	O
.	O
4	O
.	O
In	O
the	O
present	O
study	O
,	O
changes	O
in	O
measures	O
of	O
drowsiness	O
and	O
performance	O
were	O
limited	O
to	O
the	O
enantiomers	O
with	O
high	O
affinity	O
for	O
the	O
histamine	B-GP
H1-receptor	E-GP

The	O
selectivity	O
of	O
beta-adrenoceptor	S-GP
agonists	O
at	O
human	B-GP
beta1-	I-GP
,	I-GP
beta2-	I-GP
and	I-GP
beta3-adrenoceptors	E-GP
.	O
BACKGROUND	O
AND	O
PURPOSE	O
:	O
There	O
are	O
two	O
important	O
properties	O
of	O
receptor-ligand	O
interactions	O
:	O
affinity	O
(	O
the	O
ability	O
of	O
the	O
ligand	O
to	O
bind	O
to	O
the	O
receptor	O
)	O
and	O
efficacy	O
(	O
the	O
ability	O
of	O
the	O
receptor-ligand	O
complex	O
to	O
induce	O
a	O
response	O
)	O
.	O
Ligands	O
are	O
classified	O
as	O
agonists	O
or	O
antagonists	O
depending	O
on	O
whether	O
or	O
not	O
they	O
have	O
efficacy	O
.	O
In	O
theory	O
,	O
it	O
is	O
possible	O
to	O
develop	O
selective	O
agonists	O
based	O
on	O
selective	O
affinity	O
,	O
selective	O
intrinsic	O
efficacy	O
or	O
both	O
.	O
This	O
study	O
examined	O
the	O
affinity	O
and	O
intrinsic	O
efficacy	O
of	O
31	O
beta-adrenoceptor	S-GP
agonists	O
at	O
the	O
three	O
human	B-GP
beta-adrenoceptors	E-GP
to	O
determine	O
whether	O
the	O
current	O
agonists	O
are	O
subtype	O
selective	O
because	O
of	O
affinity	O
or	O
intrinsic	O
efficacy	O
.	O
EXPERIMENTAL	O
APPROACH	O
:	O
Stable	O
clonal	O
CHO-K1	O
cell	O
lines	O
,	O
transfected	O
with	O
either	O
the	O
human	B-GP
beta	I-GP
(	I-GP
1	I-GP
)	I-GP
,	I-GP
beta	I-GP
(	I-GP
2	I-GP
)	I-GP
or	I-GP
beta	I-GP
(	I-GP
3	I-GP
)	I-GP
-adrenoceptor	E-GP
,	O
were	O
used	O
,	O
and	O
whole-cell	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
-CGP	I-chemical
12177	E-chemical
radioligand	O
binding	O
and	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
-cAMP	E-chemical
accumulation	O
were	O
measured	O
.	O
KEY	O
RESULTS	O
:	O
Several	O
agonists	O
were	O
found	O
to	O
be	O
highly	O
subtype	O
selective	O
because	O
of	O
selective	O
affinity	O
(	O
e.g	O
.	O
salmeterol	S-chemical
and	O
formoterol	S-chemical
,	O
for	O
the	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenoceptor	E-GP
over	O
the	O
beta	B-GP
(	I-GP
1	I-GP
)	E-GP
or	O
beta	B-GP
(	I-GP
3	I-GP
)	E-GP
)	O
,	O
while	O
others	O
(	O
e.g	O
.	O
isoprenaline	S-chemical
)	O
had	O
little	O
affinity-selectivity	O
.	O
However	O
,	O
the	O
intrinsic	O
efficacy	O
of	O
salmeterol	S-chemical
,	O
formoterol	S-chemical
and	O
isoprenaline	S-chemical
was	O
similar	O
across	O
all	O
three	O
receptor	O
subtypes	O
.	O
Other	O
ligands	O
(	O
e.g	O
.	O
denopamine	S-chemical
for	O
beta	B-GP
(	I-GP
1	I-GP
)	E-GP
;	O
clenbuterol	S-chemical
,	O
AZ	B-chemical
40140d	E-chemical
,	O
salbutamol	S-chemical
for	O
beta	B-GP
(	I-GP
2	I-GP
)	E-GP
)	O
were	O
found	O
to	O
have	O
subtype-selective	O
intrinsic	O
efficacy	O
.	O
Several	O
ligands	O
appeared	O
to	O
activate	O
two	O
agonist	O
conformations	O
of	O
the	O
beta	B-GP
(	I-GP
1	I-GP
)	I-GP
-	I-GP
and	I-GP
beta	I-GP
(	I-GP
3	I-GP
)	I-GP
-adrenoceptors	E-GP
.	O
CONCLUSIONS	O
AND	O
IMPLICATIONS	O
:	O
There	O
are	O
agonists	O
with	O
subtype	O
selectivity	O
based	O
upon	O
both	O
selective	O
affinity	O
and	O
selective	O
intrinsic	O
efficacy	O
.	O
Therefore	O
,	O
there	O
is	O
scope	O
to	O
develop	O
better	O
selective	O
agonists	O
based	O
upon	O
both	O
selective	O
affinity	O
and	O
selective	O
intrinsic	O
efficacy	O
.	O

Pharmacological	O
therapy	O
of	O
Cushing	O
's	O
syndrome	O
:	O
drugs	O
and	O
indications	O
.	O
OBJECTIVE	O
:	O
To	O
review	O
the	O
main	O
pharmacological	O
properties	O
and	O
clinical	O
applications	O
of	O
the	O
drugs	O
used	O
in	O
the	O
medical	O
therapy	O
of	O
Cushing	O
's	O
syndrome	O
.	O
DATA	O
SOURCES	O
:	O
Search	O
for	O
articles	O
were	O
performed	O
in	O
the	O
following	O
dababases	O
:	O
MEDLINE	O
,	O
EMBASE	O
,	O
Cochrane	O
Database	O
of	O
systematic	O
Reviews	O
and	O
The	O
Cochrane	O
Central	O
Register	O
of	O
Controlled	O
Trials	O
(	O
CENTRAL	O
)	O
.	O
Search	O
terms	O
included	O
Cushing	O
's	O
syndrome	O
and	O
drug	O
therapy	O
.	O
DATA	O
SYNTHESIS	O
:	O
Available	O
data	O
suggest	O
that	O
neuromodulatory	O
compounds	O
affect	O
corticotropin	S-GP
(	O
ACTH	S-GP
)	O
or	O
ACTH-releasing	B-GP
hormone	E-GP
(	O
CRH	S-GP
)	O
synthesis	O
and	O
release	O
.	O
They	O
include	O
serotonin	S-chemical
antagonists	O
,	O
dopaminergic	O
agonists	O
,	O
valproic	B-chemical
acid	E-chemical
,	O
reserpine	S-chemical
,	O
somatostatin	S-GP
analogs	O
and	O
thiazolidinediones	S-chemical
.	O
These	O
agents	O
have	O
been	O
effective	O
in	O
a	O
limited	O
number	O
of	O
patients	O
with	O
ACTH	S-GP
-dependent	O
Cushing	O
's	O
syndrome	O
.	O
Inhibitors	O
of	O
steroidogenesis	O
reduce	O
cortisol	O
production	O
by	O
blocking	O
one	O
(	O
metyrapone	S-chemical
,	O
trilostane	S-chemical
)	O
or	O
several	O
(	O
aminoglutethimide	S-chemical
,	O
ketoconazole	S-chemical
,	O
fluconazole	S-chemical
,	O
etomidate	S-chemical
)	O
enzymes	O
involved	O
in	O
steroid	O
biosynthesis	O
.	O
Mitotane	S-chemical
is	O
a	O
steroidogenesis	O
inhibitor	O
with	O
adrenolitic	O
properties	O
.	O
Mifepriston'e	S-chemical
blocks	O
glucocorticoid	B-GP
receptor	E-GP
activation	O
without	O
modifying	O
cortisol	S-chemical
synthesis	O
.	O
CONCLUSION	O
:	O
Agents	O
that	O
inhibit	O
steroidogenesis	O
are	O
useful	O
in	O
all	O
forms	O
of	O
Cushing	O
's	O
syndrome	O
and	O
are	O
effective	O
in	O
about	O
70	O
%	O
of	O
patients	O
.	O
Main	O
indications	O
for	O
drug	O
therapy	O
include	O
preparation	O
for	O
surgery	O
,	O
persistence	O
or	O
recurrence	O
after	O
surgery	O
,	O
while	O
awaiting	O
for	O
the	O
effect	O
of	O
radiation	O
therapy	O
,	O
occult	O
ectopic	O
ACTH	S-GP
syndrome	O
,	O
severe	O
hypercortisolism	O
and	O
malignancy	O
related	O
hypercortisolism	O
.	O

Further	O
exploration	O
of	O
M₁	O
allosteric	O
agonists	O
:	O
subtle	O
structural	O
changes	O
abolish	O
M₁	O
allosteric	O
agonism	O
and	O
result	O
in	O
pan-	O
mAChR	S-GP
orthosteric	O
antagonism	O
.	O
This	O
letter	O
describes	O
the	O
further	O
exploration	O
of	O
two	O
series	O
of	O
M	O
(	O
1	O
)	O
allosteric	O
agonists	O
,	O
TBPB	S-chemical
and	O
VU0357017	S-chemical
,	O
previously	O
reported	O
from	O
our	O
lab	O
.	O
Within	O
the	O
TPBP	S-chemical
scaffold	O
,	O
either	O
electronic	O
or	O
steric	O
perturbations	O
to	O
the	O
central	O
piperidine	S-chemical
ring	O
led	O
to	O
a	O
loss	O
of	O
selective	O
M	O
(	O
1	O
)	O
allosteric	O
agonism	O
and	O
afforded	O
pan-	O
mAChR	S-GP
antagonism	O
,	O
which	O
was	O
demonstrated	O
to	O
be	O
mediated	O
via	O
the	O
orthosteric	O
site	O
.	O
Additional	O
SAR	O
around	O
a	O
related	O
M	O
(	O
1	O
)	O
allosteric	O
agonist	O
family	O
(	O
VU0357017	S-chemical
)	O
identified	O
similar	O
,	O
subtle	O
'molecular	O
switches	O
'	O
that	O
modulated	O
modes	O
of	O
pharmacology	O
from	O
allosteric	O
agonism	O
to	O
pan-	O
mAChR	S-GP
orthosteric	O
antagonism	O
.	O
Therefore	O
,	O
all	O
of	O
these	O
ligands	O
are	O
best	O
classified	O
as	O
bi-topic	O
ligands	O
that	O
possess	O
high	O
affinity	O
binding	O
at	O
an	O
allosteric	O
site	O
to	O
engender	O
selective	O
M	O
(	O
1	O
)	O
activation	O
,	O
but	O
all	O
bind	O
,	O
at	O
higher	O
concentrations	O
,	O
to	O
the	O
orthosteric	O
ACh	O
site	O
,	O
leading	O
to	O
non-selective	O
orthosteric	O
site	O
binding	O
and	O
mAChR	S-GP
antagonism	O
.	O

Rapid	O
quantitation	O
of	O
plasma	O
2'-deoxyuridine	S-chemical
by	O
high-performance	O
liquid	O
chromatography/atmospheric	O
pressure	O
chemical	O
ionization	O
mass	O
spectrometry	O
and	O
its	O
application	O
to	O
pharmacodynamic	O
studies	O
in	O
cancer	O
patients	O
.	O
A	O
novel	O
method	O
employing	O
high-performance	O
liquid	O
chromatograph-mass	O
spectrometry	O
(	O
LC-MS	O
)	O
has	O
been	O
developed	O
and	O
validated	O
for	O
the	O
quantitation	O
of	O
plasma	O
2'-deoxyuridine	S-chemical
(	O
UdR	S-chemical
)	O
.	O
It	O
involves	O
a	O
plasma	O
clean-up	O
step	O
with	O
strong	O
anion-exchange	O
solid-phase	O
extraction	O
(	O
SAX-SPE	O
)	O
followed	O
by	O
HPLC	O
separation	O
and	O
atmospheric	O
pressure	O
chemical	O
ionization	O
mass	O
spectrometry	O
detection	O
(	O
APCI-MS	O
)	O
in	O
a	O
selected-ion	O
monitoring	O
(	O
SIM	O
)	O
mode	O
.	O
The	O
ionization	O
conditions	O
were	O
optimised	O
in	O
negative	O
ion	O
mode	O
to	O
give	O
the	O
best	O
intensity	O
of	O
the	O
dominant	O
formate	S-chemical
adduct	O
[	O
M+	O
HCOO	S-chemical
]	O
-	O
at	O
m/z	O
273	O
.	O
Retention	O
times	O
were	O
7.5	O
and	O
12.5	O
min	O
for	O
2'-deoxyuridine	S-chemical
and	O
5-iodo-2'-deoxyuridine	S-chemical
,	O
an	O
iodinated	O
analogue	O
internal	O
standard	O
(	O
IS	O
)	O
,	O
respectively	O
.	O
Peak	O
area	O
ratios	O
of	O
2'-deoxyuridine	S-chemical
to	O
IS	O
were	O
used	O
for	O
regression	O
analysis	O
of	O
the	O
calibration	O
curve	O
.	O
The	O
latter	O
was	O
linear	O
from	O
5	O
to	O
400	O
nmol/l	O
using	O
1	O
ml	O
sample	O
volume	O
of	O
plasma	O
.	O
The	O
average	O
recovery	O
was	O
81.5	O
%	O
and	O
78.6	O
%	O
for	O
2'-deoxyuridine	S-chemical
and	O
5-iodo-deoxyuridine	S-chemical
,	O
respectively	O
.	O
The	O
method	O
provides	O
sufficient	O
sensitivity	O
,	O
precision	O
,	O
accuracy	O
and	O
selectivity	O
for	O
routine	O
analysis	O
of	O
human	O
plasma	O
2'-deoxyuridine	S-chemical
concentration	O
with	O
the	O
lowest	O
limit	O
of	O
quantitation	O
(	O
LLOQ	O
)	O
of	O
5	O
nmol/l	O
.	O
Clinical	O
studies	O
in	O
cancer	O
patients	O
treated	O
with	O
the	O
new	O
fluoropyrimidine	S-chemical
analogue	O
capecitabine	S-chemical
(	O
N4-pentoxycarbonyl-5'-5-fluorocytidine	S-chemical
)	O
have	O
shown	O
that	O
plasma	O
2'-deoxyuridine	S-chemical
was	O
significantly	O
elevated	O
after	O
1	O
week	O
of	O
treatment	O
,	O
consistent	O
with	O
inhibition	O
of	O
thymidylate	B-GP
synthase	E-GP
(	O
TS	S-GP
)	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
mechanism	O
of	O
antiproliferative	O
toxicity	O
of	O
capecitabine	S-chemical
is	O
at	O
least	O
partly	O
due	O
to	O
TS	S-GP
inhibitory	O
activity	O
of	O
its	O
active	O
metabolite	O
5-fluoro-2'-deoxyuridine	B-chemical
monophosphate	E-chemical
(	O
FdUMP	S-chemical
)	O
.	O
Monitoring	O
of	O
plasma	O
UdR	S-chemical
concentrations	O
have	O
the	O
potential	O
to	O
help	O
clinicians	O
to	O
guide	O
scheduling	O
of	O
capecitabine	S-chemical
or	O
other	O
TS	S-GP
inhibitors	O
in	O
clinical	O
trials	O
.	O
Marked	O
differences	O
of	O
plasma	O
2'-deoxyuridine	S-chemical
between	O
human	O
and	O
rodents	O
have	O
also	O
been	O
confirmed	O
.	O
In	O
conclusion	O
,	O
the	O
LC-MS	O
method	O
developed	O
is	O
simple	O
,	O
highly	O
selective	O
and	O
sensitive	O
and	O
permits	O
pharmacodynamic	O
studies	O
of	O
TS	S-GP
inhibitors	O
in	O
several	O
species	O
.	O

Identification	O
of	O
neuronal	O
target	O
areas	O
for	O
nerve	O
agents	O
and	O
specification	O
of	O
receptors	O
for	O
pharmacological	O
treatment	O
.	O
In	O
order	O
to	O
shorten	O
the	O
list	O
of	O
candidate	O
drugs	O
with	O
anticonvulsant	O
potential	O
against	O
nerve	O
agents	O
,	O
critical	O
subreceptors	O
in	O
seizure	O
controlling	O
brain	O
regions	O
should	O
be	O
specified	O
.	O
Epileptiform	O
activity	O
does	O
not	O
spread	O
randomly	O
throughout	O
the	O
brain	O
,	O
but	O
appears	O
to	O
be	O
generated	O
and	O
propagated	O
by	O
specific	O
anatomical	O
routes	O
.	O
Nerve	O
agents	O
evoke	O
seizure	O
activity	O
in	O
the	O
forebrain	O
that	O
progresses	O
to	O
the	O
hind	O
brain	O
resulting	O
in	O
tonic-clonic	O
convulsions	O
.	O
In	O
some	O
recent	O
studies	O
,	O
it	O
was	O
shown	O
that	O
lesion	O
of	O
the	O
area	O
tempestas	O
(	O
AT	O
)	O
,	O
medial	O
septum	O
(	O
MS	O
)	O
,	O
perirhinal	O
cortex	O
(	O
PRC	O
)	O
,	O
or	O
posterior	O
piriform	O
cortex	O
(	O
PPC	O
)	O
produces	O
anticonvulsant	O
effects	O
(	O
prevention	O
of	O
convulsions	O
or	O
delayed	O
onset	O
of	O
convulsions	O
)	O
in	O
rats	O
exposed	O
to	O
soman	S-chemical
,	O
whereas	O
damage	O
to	O
nucleus	O
accumbens	O
,	O
nucleus	O
basalis	O
magnocellularis	O
,	O
amygdala	O
,	O
hippocampus	O
,	O
or	O
entorhinal	O
cortex	O
does	O
not	O
cause	O
anticonvulsant	O
impact	O
.	O
These	O
results	O
are	O
in	O
compliance	O
with	O
findings	O
that	O
seizures	O
can	O
be	O
generated	O
in	O
AT	O
,	O
MS	O
,	O
PRC	O
,	O
and	O
PPC	O
by	O
means	O
of	O
nerve	O
agents	O
,	O
chemoconvulsants	O
,	O
or	O
kindling	O
.	O
Results	O
from	O
microinfusion	O
studies	O
show	O
that	O
anticonvulsant	O
efficacy	O
is	O
obtained	O
by	O
GABA	B-GP
(	I-GP
A	I-GP
)	E-GP
modulators	O
or	O
cholinergic	O
antagonists	O
(	O
M1	S-GP
-	O
M5	S-GP
)	O
in	O
AT	O
,	O
cholinergic	O
antagonists	O
(	O
M1	S-GP
-	O
M5	S-GP
)	O
in	O
MS	O
,	O
combined	O
glutamatergic	O
(	O
NMDA	S-chemical
)	O
and	O
cholinergic	O
antagonist	O
(	O
M1	S-GP
-	O
M4	S-GP
)	O
,	O
AMPA	S-chemical
antagonist	O
,	O
or	O
modulators	O
of	O
metabotropic	B-GP
glutamate	I-GP
receptors	E-GP
(	O
mGluR5	S-GP
,	O
mGluR2/3	S-GP
)	O
in	O
PRC	O
,	O
and	O
cholinergic	O
antagonist	O
(	O
M1	S-GP
-	O
M5	S-GP
)	O
or	O
GABA	B-GP
(	I-GP
A	I-GP
)	E-GP
agonist	O
in	O
PPC	O
.	O
Calculation	O
of	O
impact	O
factors	O
for	O
the	O
most	O
potent	O
drugs	O
(	O
percentage	O
of	O
positive	O
effects	O
in	O
the	O
seizure	O
controlling	O
sites	O
)	O
showed	O
that	O
scopolamine	S-chemical
and	O
procyclidine	S-chemical
were	O
ranking	O
highest	O
(	O
75	O
)	O
followed	O
by	O
muscimol	S-chemical
(	O
50	O
)	O
,	O
NBQX	S-chemical
(	O
33	O
)	O
,	O
and	O
caramiphen	S-chemical
(	O
33	O
)	O
.	O
Potential	O
strategies	O
for	O
prophylactic	O
and	O
post-exposure	O
treatments	O
are	O
discussed	O
.	O

Cellular	O
signaling	O
crosstalk	O
between	O
multiple	O
receptors	O
for	O
investigation	O
of	O
pathophysiology	O
in	O
multifactorial	O
diseases	O
--	O
what	O
is	O
clinically-relevant	O
crosstalk	O
?	O
Recently	O
,	O
genomics	O
and	O
proteomics	O
have	O
been	O
utilized	O
as	O
advanced	O
tools	O
for	O
investigation	O
of	O
cellular	O
signaling	O
pathways	O
and	O
molecular	O
interactions	O
,	O
and	O
elucidated	O
promiscuous	O
networks	O
composed	O
of	O
numerous	O
interactions	O
among	O
pathways	O
.	O
However	O
,	O
some	O
of	O
these	O
interactions	O
are	O
considered	O
to	O
be	O
simply	O
contributing	O
to	O
background	O
'noise	O
'	O
and	O
others	O
are	O
as	O
'crosstalk	O
'	O
biologically-relevant	O
to	O
cellular	O
physiology	O
,	O
leading	O
to	O
synergy	O
effects	O
more	O
than	O
additive	O
responses	O
in	O
an	O
entire	O
organism	O
.	O
Effort	O
is	O
now	O
required	O
to	O
determine	O
which	O
interactions	O
truly	O
contribute	O
to	O
final	O
physiological	O
output	O
.	O
A	O
receptor	O
is	O
the	O
prime	O
example	O
of	O
connectors	O
among	O
the	O
networks	O
.	O
It	O
functions	O
,	O
not	O
simply	O
as	O
a	O
signaling	O
gateway	O
,	O
but	O
also	O
as	O
an	O
active	O
trader	O
by	O
forming	O
inter-receptor	O
dimers	O
.	O
Furthermore	O
,	O
various	O
receptors	O
can	O
modulate	O
the	O
function	O
of	O
the	O
other	O
receptors	O
by	O
input	O
to	O
common	O
intracellular	O
signaling	O
pathways	O
,	O
establishing	O
functional	O
crosstalk	O
among	O
networks	O
.	O
Our	O
findings	O
by	O
combined	O
analyses	O
of	O
gene	O
polymorphisms	O
of	O
two	O
separate	O
genes	O
present	O
evidences	O
that	O
such	O
is	O
the	O
case	O
with	O
human	O
body	O
in	O
a	O
clinical	O
setting	O
:	O
1	O
)	O
an	O
integrated	O
effect	O
of	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
(	O
EGFR	S-GP
)	O
and	O
protease	B-GP
activated	I-GP
receptor-1	E-GP
(	O
PAR-1	S-GP
)	O
on	O
susceptibility	O
to	O
airway	O
hyperresponsiveness	O
(	O
AHR	O
)	O
,	O
and	O
2	O
)	O
a	O
crosstalk	O
effect	O
between	O
muscarinic	B-GP
acetylcholine	I-GP
receptor	E-GP
(	O
mAChRs	S-GP
)	O
and	O
β	B-GP
(	I-GP
2	I-GP
)	I-GP
adrenoceptor	E-GP
(	O
β	B-GP
(	I-GP
2	I-GP
)	I-GP
AR	E-GP
)	O
on	O
bronchodilatory	O
response	O
to	O
anticholinergic	O
agents	O
in	O
patients	O
with	O
COPD	O
.	O
These	O
results	O
indicate	O
that	O
these	O
interactions	O
are	O
unlikely	O
to	O
be	O
'noise	O
'	O
but	O
functionally-relevant	O
'crosstalk	O
'	O
in	O
a	O
human	O
body	O
.	O
This	O
review	O
attempts	O
to	O
highlight	O
the	O
clinically-relevant	O
'crosstalk	O
'	O
paradigm	O
in	O
a	O
human	O
body	O
which	O
provides	O
us	O
a	O
novel	O
insight	O
necessary	O
to	O
investigate	O
pathophysiology	O
in	O
common	O
multifactorial	O
diseases	O
and	O
to	O
develop	O
new	O
drugs	O
.	O

Regulation	O
of	O
hepatic	O
phase	O
II	O
metabolism	O
in	O
pregnant	O
mice	O
.	O
Phase	O
II	O
enzymes	O
,	O
including	O
Ugts	S-GP
,	O
Sults	S-GP
,	O
and	O
Gsts	S-GP
,	O
are	O
critical	O
for	O
the	O
disposition	O
and	O
detoxification	O
of	O
endo-	O
and	O
xenobiotics	O
.	O
In	O
this	O
study	O
,	O
the	O
mRNA	O
and	O
protein	O
expression	O
of	O
major	O
phase	O
II	O
enzymes	O
,	O
as	O
well	O
as	O
key	O
regulatory	O
transcription	O
factors	O
,	O
were	O
quantified	O
in	O
livers	O
of	O
time-matched	O
pregnant	O
and	O
virgin	O
control	O
C57BL/6	O
mice	O
on	O
gestation	O
days	O
(	O
GD	O
)	O
7	O
,	O
11	O
,	O
14	O
,	O
17	O
,	O
and	O
postnatal	O
days	O
(	O
PND	O
)	O
1	O
,	O
15	O
,	O
and	O
30	O
.	O
Compared	O
with	O
virgin	O
controls	O
,	O
the	O
mRNA	O
expression	O
of	O
Ugt1a1	B-GP
,	I-GP
1a6	I-GP
,	I-GP
1a9	I-GP
,	I-GP
2a3	I-GP
,	I-GP
2b1	I-GP
,	I-GP
2b34	I-GP
,	I-GP
and	I-GP
2b35	E-GP
decreased	O
40	O
to	O
80	O
%	O
in	O
pregnant	O
dams	O
.	O
Protein	O
expression	O
of	O
Ugt1a6	S-GP
also	O
decreased	O
and	O
corresponded	O
with	O
reduced	O
in	O
vitro	O
glucuronidation	O
of	O
bisphenol	B-chemical
A	E-chemical
in	O
S9	O
fractions	O
from	O
livers	O
of	O
pregnant	O
mice	O
.	O
Similar	O
to	O
Ugts	S-GP
levels	O
,	O
Gsta1	B-GP
and	I-GP
a4	E-GP
mRNAs	O
were	O
reduced	O
in	O
pregnant	O
dams	O
in	O
mid	O
to	O
late	O
gestation	O
;	O
however	O
no	O
change	O
in	O
protein	O
expression	O
was	O
observed	O
.	O
Conversely	O
,	O
Sult1a1	B-GP
,	I-GP
2a1/2	I-GP
,	I-GP
and	I-GP
3a1	E-GP
mRNAs	O
increased	O
100	O
to	O
500	O
%	O
at	O
various	O
time	O
points	O
in	O
pregnant	O
and	O
lactating	O
mice	O
and	O
corresponded	O
with	O
enhanced	O
in	O
vitro	O
sulfation	O
of	O
acetaminophen	S-chemical
in	O
liver	O
S9	O
fractions	O
.	O
Coinciding	O
with	O
maximal	O
decreases	O
in	O
Ugts	S-GP
as	O
well	O
as	O
increases	O
in	O
Sults	S-GP
,	O
the	O
expression	O
of	O
transcription	O
factors	O
CAR	S-GP
,	O
PPARα	S-GP
,	O
and	O
PXR	S-GP
and	O
their	O
target	O
genes	O
were	O
downregulated	O
,	O
whereas	O
ERα	S-GP
mRNA	O
was	O
upregulated	O
.	O
Collectively	O
,	O
these	O
data	O
demonstrate	O
altered	O
regulation	O
of	O
hepatic	O
phase	O
II	O
metabolism	O
in	O
mice	O
during	O
pregnancy	O
and	O
suggest	O
that	O
CAR	S-GP
,	O
PPARα	S-GP
,	O
PXR	S-GP
,	O
and	O
ERα	S-GP
signaling	O
pathways	O
may	O
be	O
candidate	O
signaling	O
pathways	O
responsible	O
for	O
these	O
changes	O
.	O

Tamsulosin	S-chemical
,	O
the	O
first	O
prostate-selective	O
alpha	B-GP
1A-adrenoceptor	E-GP
antagonist	O
.	O
A	O
meta-analysis	O
of	O
two	O
randomized	O
,	O
placebo-controlled	O
,	O
multicentre	O
studies	O
in	O
patients	O
with	O
benign	O
prostatic	O
obstruction	O
(	O
symptomatic	O
BPH	O
)	O
.	O
European	O
Tamsulosin	S-chemical
Study	O
Group	O
.	O
OBJECTIVE	O
:	O
This	O
meta-analysis	O
of	O
two	O
European	O
studies	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
modified-release	O
tamsulosin	S-chemical
0.4	O
mg	O
once	O
daily	O
compared	O
with	O
placebo	O
in	O
patients	O
with	O
benign	O
prostatic	O
enlargement	O
,	O
lower	O
urinary	O
tract	O
symptoms	O
and	O
prostatic	O
obstruction	O
(	O
symptomatic	O
BPH	O
)	O
.	O
METHODS	O
:	O
Patients	O
entered	O
a	O
2-week	O
placebo	O
run-in	O
period	O
,	O
followed	O
by	O
randomization	O
to	O
treatment	O
with	O
tamsulosin	S-chemical
(	O
382	O
patients	O
)	O
or	O
placebo	O
(	O
193	O
patients	O
)	O
once	O
daily	O
for	O
12	O
weeks	O
.	O
RESULTS	O
:	O
Maximum	O
urinary	O
flow	O
rate	O
improved	O
to	O
a	O
greater	O
extent	O
in	O
the	O
tamsulosin	S-chemical
group	O
(	O
1.6	O
ml/s	O
,	O
16	O
%	O
)	O
than	O
the	O
placebo	O
group	O
(	O
0.6	O
ml/s	O
,	O
6	O
%	O
)	O
(	O
p	O
=	O
0.002	O
)	O
.	O
Total	O
Boyarsky	O
symptom	O
score	O
also	O
improved	O
to	O
a	O
greater	O
extent	O
in	O
the	O
tamsulosin	S-chemical
group	O
(	O
3.3	O
points	O
,	O
35.1	O
%	O
reduction	O
)	O
than	O
the	O
placebo	O
group	O
(	O
2.4	O
points	O
,	O
25.5	O
%	O
reduction	O
)	O
(	O
p	O
=	O
0.002	O
)	O
.	O
Significantly	O
more	O
tamsulosin	S-chemical
patients	O
(	O
66	O
%	O
)	O
than	O
placebo	O
patients	O
(	O
49	O
%	O
)	O
had	O
a	O
>	O
or	O
=	O
25	O
%	O
decrease	O
in	O
total	O
symptom	O
score	O
at	O
endpoint	O
(	O
p	O
<	O
0.001	O
)	O
.	O
Twelve	O
weeks	O
of	O
treatment	O
with	O
tamsulosin	S-chemical
also	O
produced	O
significant	O
improvements	O
in	O
average	O
urinary	O
flow	O
rate	O
(	O
p	O
=	O
0.005	O
)	O
and	O
voiding	O
or	O
``	O
obstructive	O
''	O
(	O
p	O
=	O
0.008	O
)	O
and	O
storage	O
or	O
``	O
irritative	O
'	O
(	O
p	O
=	O
0.017	O
)	O
symptom	O
scores	O
.	O
The	O
incidence	O
of	O
drug-related	O
adverse	O
events	O
was	O
comparable	O
for	O
the	O
tamsulosin	S-chemical
and	O
placebo	O
groups	O
(	O
13	O
and	O
12	O
%	O
respectively	O
,	O
p	O
=	O
0.802	O
)	O
.	O
The	O
same	O
applies	O
to	O
the	O
incidence	O
of	O
adverse	O
events	O
commonly	O
attributed	O
to	O
alpha	B-GP
1-adrenoceptor	E-GP
antagonists	O
,	O
such	O
as	O
dizziness	O
,	O
headache	O
,	O
postural	O
hypotension	O
,	O
syncope	O
,	O
asthenia	O
,	O
somnolence	O
and	O
rhinitis	O
.	O
There	O
were	O
no	O
clinically	O
significant	O
changes	O
in	O
blood	O
pressure	O
or	O
pulse	O
rate	O
in	O
tamsulosin	S-chemical
patients	O
compared	O
with	O
placebo	O
patients	O
both	O
in	O
hypertensive	O
and	O
normotensive	O
BPH	O
patients	O
.	O
CONCLUSION	O
:	O
Tamsulosin	S-chemical
0.4	O
mg	O
once	O
daily	O
is	O
safe	O
,	O
well-tolerated	O
and	O
improves	O
both	O
the	O
symptoms	O
and	O
urinary	O
flow	O
rate	O
in	O
patients	O
with	O
benign	O
prostatic	O
obstruction	O
(	O
symptomatic	O
BPH	O
)	O
.	O

Dual	O
Growth	O
Factor	O
Delivery	O
Using	O
Biocompatible	O
Core-Shell	O
Microcapsules	O
for	O
Angiogenesis	O
.	O
An	O
optimized	O
electrodropping	O
system	O
produces	O
homogeneous	O
core-shell	O
microcapsules	O
(	O
C-S	O
MCs	O
)	O
by	O
using	O
poly	B-chemical
(	I-chemical
L-lactic-co-glycolic	I-chemical
acid	I-chemical
)	E-chemical
(	O
PLGA	S-chemical
)	O
and	O
alginate	O
.	O
Fluorescence	O
imaging	O
clearly	O
shows	O
the	O
C-S	O
domain	O
in	O
the	O
MC	O
.	O
For	O
release	O
control	O
,	O
the	O
use	O
of	O
high-molecular-weight	O
PLGA	S-chemical
(	O
HMW	O
270	O
000	O
)	O
restrains	O
the	O
initial	O
burst	O
release	O
of	O
protein	O
compared	O
to	O
that	O
of	O
low-MW	O
PLGA	S-chemical
(	O
LMW	O
40	O
000	O
)	O
.	O
Layer-by-layer	O
(	O
LBL	O
)	O
assembly	O
of	O
chitosan	O
and	O
alginate	O
on	O
MCs	O
is	O
also	O
useful	O
in	O
controlling	O
the	O
release	O
profile	O
of	O
biomolecules	O
.	O
LBL	O
(	O
7-layer	O
)	O
treatment	O
is	O
effective	O
in	O
suppressing	O
the	O
initial	O
burst	O
release	O
of	O
protein	O
compared	O
to	O
no	O
LBL	O
(	O
0-layer	O
)	O
.	O
The	O
difference	O
of	O
cumulative	O
albumin	O
release	O
between	O
HMW	O
(	O
7-layer	O
LBL	O
)	O
and	O
LMW	O
(	O
0-layer	O
LBL	O
)	O
PLGA	S-chemical
is	O
determined	O
to	O
be	O
more	O
than	O
40	O
%	O
on	O
day	O
5	O
.	O
When	O
dual	O
angiogenic	O
growth	O
factors	O
(	O
GFs	O
)	O
,	O
such	O
as	O
platelet-derived	B-GP
GF	E-GP
(	O
PDGF	S-GP
)	O
and	O
vascular	B-GP
endothelial	I-GP
GF	E-GP
(	O
VEGF	S-GP
)	O
,	O
are	O
encapsulated	O
separately	O
in	O
the	O
core	O
and	O
shell	O
domains	O
,	O
respectively	O
,	O
the	O
VEGF	S-GP
release	O
rate	O
is	O
much	O
greater	O
than	O
that	O
of	O
PDGF	S-GP
,	O
and	O
the	O
difference	O
of	O
the	O
cumulative	O
release	O
percentage	O
between	O
the	O
two	O
GFs	O
is	O
about	O
30	O
%	O
on	O
day	O
7	O
with	O
LMW	O
core	O
PLGA	S-chemical
and	O
more	O
than	O
45	O
%	O
with	O
HMW	O
core	O
PLGA	S-chemical
.	O
As	O
for	O
the	O
angiogenic	O
potential	O
of	O
MC	O
GFs	O
with	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
the	O
fluorescence	O
signal	O
of	O
CD31	S-GP
+	O
suggests	O
that	O
the	O
angiogenic	O
sprout	O
of	O
ECs	O
is	O
more	O
active	O
in	O
MC-mediated	O
GF	O
delivery	O
than	O
conventional	O
GF	O
delivery	O
,	O
and	O
this	O
difference	O
is	O
significant	O
,	O
based	O
on	O
the	O
number	O
of	O
capillary	O
branches	O
in	O
the	O
unit	O
area	O
.	O
This	O
study	O
demonstrates	O
that	O
the	O
fabrication	O
of	O
biocompatible	O
C-S	O
MCs	O
is	O
possible	O
,	O
and	O
that	O
the	O
release	O
control	O
of	O
biomolecules	O
is	O
adjustable	O
.	O
Furthermore	O
,	O
MC-mediated	O
GFs	O
remain	O
in	O
an	O
active	O
form	O
and	O
can	O
upregulate	O
the	O
angiogenic	O
activity	O
of	O
ECs	O
.	O

Loss	O
of	O
Calcium/Calmodulin-Dependent	B-GP
Protein	I-GP
Kinase	I-GP
II	E-GP
Activity	O
in	O
Cortical	O
Astrocytes	O
Decreases	O
Glutamate	S-chemical
Uptake	O
and	O
Induces	O
Neurotoxic	O
Release	O
of	O
ATP	S-chemical
.	O
The	O
extent	O
of	O
calcium/calmodulin-dependent	B-GP
protein	I-GP
kinase	I-GP
II	E-GP
(	O
CaMKII	S-GP
)	O
inactivation	O
in	O
the	O
brain	O
following	O
ischemia	O
correlates	O
with	O
the	O
extent	O
of	O
damage	O
.	O
We	O
have	O
previously	O
shown	O
that	O
a	O
loss	O
of	O
CaMKII	S-GP
activity	O
in	O
neurons	O
is	O
detrimental	O
to	O
neuronal	O
viability	O
by	O
inducing	O
excitotoxic	O
glutamate	S-chemical
release	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
extend	O
these	O
findings	O
to	O
show	O
that	O
the	O
ability	O
of	O
astrocytes	O
to	O
buffer	O
extracellular	O
glutamate	S-chemical
is	O
reduced	O
when	O
CaMKII	S-GP
is	O
inhibited	O
.	O
Furthermore	O
,	O
CaMKII	S-GP
inhibition	O
in	O
astrocytes	O
is	O
associated	O
with	O
the	O
rapid	O
onset	O
of	O
intracellular	O
calcium	S-chemical
oscillations	O
.	O
Surprisingly	O
,	O
this	O
rapid	O
calcium	S-chemical
influx	O
is	O
blocked	O
by	O
the	O
N-type	B-GP
calcium	I-GP
channel	E-GP
antagonist	O
,	O
omega-conotoxin	S-GP
.	O
While	O
the	O
function	O
of	O
N-type	B-GP
calcium	I-GP
channels	E-GP
within	O
astrocytes	O
is	O
controversial	O
,	O
these	O
voltage-gated	B-GP
calcium	I-GP
channels	E-GP
have	O
been	O
linked	O
to	O
calcium	S-chemical
-dependent	O
vesicular	O
gliotransmitter	O
release	O
.	O
When	O
extracellular	O
glutamate	S-chemical
and	O
ATP	S-chemical
levels	O
are	O
measured	O
following	O
CaMKII	S-GP
inhibition	O
within	O
our	O
enriched	O
astrocyte	O
cultures	O
,	O
no	O
alterations	O
in	O
glutamate	S-chemical
levels	O
are	O
observed	O
,	O
whereas	O
ATP	S-chemical
levels	O
in	O
the	O
extracellular	O
environment	O
significantly	O
increase	O
.	O
Extracellular	O
ATP	S-chemical
accumulation	O
associated	O
with	O
CaMKII	S-GP
inhibition	O
contributes	O
both	O
to	O
calcium	S-chemical
oscillations	O
within	O
astrocytes	O
and	O
ultimately	O
cortical	O
neuron	O
toxicity	O
.	O
Thus	O
,	O
a	O
loss	O
of	O
CaMKII	S-GP
signaling	O
within	O
astrocytes	O
dysregulates	O
glutamate	S-chemical
uptake	O
and	O
supports	O
ATP	S-chemical
release	O
,	O
two	O
processes	O
that	O
would	O
compromise	O
neuronal	O
survival	O
following	O
ischemic/excitotoxic	O
insults	O
.	O

Stable	O
and	O
high-rate	O
overcharge	O
protection	O
for	O
rechargeable	O
lithium	S-chemical
batteries	O
.	O
Rechargeable	O
lithium	S-chemical
or	O
lithium	S-chemical
-ion	O
cells	O
can	O
be	O
overcharge-protected	O
by	O
an	O
electroactive	O
polymer	O
composite	O
separator	O
.	O
The	O
use	O
of	O
non-woven	O
fibrous	O
membranes	O
instead	O
of	O
conventional	O
microporous	O
membranes	O
as	O
the	O
composite	O
substrates	O
allowed	O
better	O
distribution	O
of	O
the	O
electroactive	O
polymer	O
,	O
which	O
led	O
to	O
improved	O
utilization	O
and	O
a	O
40-fold	O
increase	O
in	O
sustainable	O
current	O
density	O
.	O
For	O
the	O
first	O
time	O
,	O
stable	O
overcharge	O
protection	O
for	O
hundreds	O
of	O
cycles	O
was	O
demonstrated	O
in	O
several	O
cell	O
chemistries	O
,	O
including	O
LiNi1	S-chemical
/	O
3Co1	S-chemical
/	O
3Mn1	S-chemical
/	O
3O2	S-chemical
,	O
LiFePO4	S-chemical
,	O
and	O
spinel	O
Li1.05Mn1.95O4	S-chemical
half-cells	O
.	O
Protection	O
at	O
a	O
charging	O
rate	O
as	O
high	O
as	O
5	O
C	O
was	O
achieved	O
at	O
a	O
steady	O
state	O
cell	O
potential	O
below	O
4.85	O
V	O
.	O

The	O
effect	O
of	O
vitamin	B-chemical
B6	E-chemical
deficiency	O
on	O
alanine	B-GP
:	I-GP
glyoxylate	I-GP
aminotransferase	E-GP
isoenzymes	O
in	O
rat	O
liver	O
.	O
Endogenous	O
synthesis	O
of	O
oxalate	S-chemical
has	O
been	O
reported	O
to	O
increase	O
in	O
vitamin	B-chemical
B6	E-chemical
deficiency	O
probably	O
due	O
to	O
defective	O
transamination	O
of	O
glyoxylate	S-chemical
,	O
the	O
direct	O
source	O
of	O
oxalate	S-chemical
,	O
to	O
glycine	S-chemical
.	O
Alanine	B-GP
:	I-GP
glyoxylate	I-GP
aminotransferase	E-GP
(	O
AGT	S-GP
)	O
in	O
the	O
liver	O
catalyzes	O
most	O
of	O
the	O
glyoxylate	S-chemical
transamination	O
in	O
mammalian	O
tissues	O
(	O
E.	O
V.	O
Rowsell	O
,	O
K.	O
Snell	O
,	O
J	O
.	O
A.	O
Carnie	O
,	O
and	O
K.	O
V.	O
Rowsell	O
(	O
1972	O
)	O
Biochem	O
.	O
J	O
.	O
127	O
,	O
155-165	O
)	O
.	O
The	O
effects	O
of	O
vitamin	B-chemical
B6	E-chemical
deficiency	O
on	O
hepatic	O
AGT	S-GP
isoenzymes	O
,	O
designated	O
AGT	B-GP
1	E-GP
and	O
AGT	B-GP
2	E-GP
,	O
respectively	O
,	O
were	O
examined	O
with	O
male	O
rats	O
;	O
AGT	B-GP
1	E-GP
is	O
located	O
both	O
in	O
the	O
peroxisomes	O
and	O
in	O
the	O
mitochondria	O
,	O
and	O
AGT	B-GP
2	E-GP
only	O
in	O
the	O
mitochondria	O
.	O
The	O
holo	O
activity	O
of	O
combined	O
peroxisomal	O
and	O
mitochondrial	O
AGT	B-GP
1	E-GP
with	O
a	O
low	O
Km	O
for	O
L-alanine	S-chemical
rapidly	O
decreased	O
after	O
a	O
lag	O
time	O
of	O
about	O
2	O
days	O
during	O
feeding	O
of	O
the	O
vitamin	B-chemical
B6	E-chemical
-deficient	O
diet	O
(	O
by	O
50	O
%	O
in	O
5	O
days	O
,	O
by	O
86	O
%	O
in	O
14	O
days	O
)	O
.	O
Peroxisomal	O
AGT	B-GP
1	E-GP
activity	O
was	O
more	O
affected	O
than	O
the	O
mitochondrial	O
.	O
The	O
holo	O
activity	O
of	O
AGT	B-GP
2	E-GP
with	O
a	O
high	O
Km	O
for	O
L-alanine	S-chemical
decreased	O
more	O
slowly	O
than	O
AGT	B-GP
1	E-GP
(	O
by	O
33	O
%	O
in	O
14	O
days	O
,	O
by	O
60	O
%	O
in	O
28	O
days	O
)	O
.	O
Urinary	O
excretion	O
of	O
oxalate	S-chemical
began	O
to	O
increase	O
in	O
8-9	O
days	O
,	O
when	O
AGT	B-GP
2	E-GP
remained	O
intact	O
but	O
most	O
of	O
AGT	B-GP
1	E-GP
is	O
depleted	O
.	O
When	O
the	O
defect	O
in	O
the	O
glyoxylate	S-chemical
transamination	O
in	O
vivo	O
in	O
vitamin	B-chemical
B6	E-chemical
deficiency	O
is	O
considered	O
,	O
these	O
findings	O
suggest	O
that	O
it	O
is	O
due	O
to	O
the	O
deficiency	O
of	O
AGT	B-GP
1	E-GP
.	O
The	O
importance	O
of	O
peroxisomal	O
AGT	B-GP
1	E-GP
is	O
discussed	O
,	O
since	O
peroxisomes	O
have	O
been	O
described	O
to	O
be	O
probably	O
the	O
major	O
site	O
of	O
glyoxylate	S-chemical
formation	O
.	O

Effects	O
of	O
induced	O
hyperinsulinaemia	O
with	O
and	O
without	O
hyperglycaemia	O
on	O
measures	O
of	O
cardiac	O
vagal	O
control	O
.	O
AIMS/HYPOTHESIS	O
:	O
We	O
examined	O
the	O
effects	O
of	O
serum	B-GP
insulin	E-GP
levels	O
on	O
vagal	O
control	O
over	O
the	O
heart	O
and	O
tested	O
the	O
hypothesis	O
that	O
higher	O
fasting	O
insulin	S-GP
levels	O
are	O
associated	O
with	O
lower	O
vagal	O
control	O
.	O
We	O
also	O
examined	O
whether	O
experimentally	O
induced	O
increases	O
in	O
insulin	S-GP
by	O
beta	O
cell	O
secretagogues	O
,	O
including	O
glucagon-like	B-GP
peptide-1	E-GP
(	O
GLP-1	S-GP
)	O
,	O
will	O
decrease	O
vagal	O
control	O
.	O
METHODS	O
:	O
Respiration	O
and	O
ECGs	O
were	O
recorded	O
for	O
130	O
healthy	O
participants	O
undergoing	O
clamps	O
.	O
Three	O
variables	O
of	O
cardiac	O
vagal	O
effects	O
(	O
the	O
root	O
mean	O
square	O
of	O
successive	O
differences	O
[	O
rMSSD	O
]	O
in	O
the	O
interbeat	O
interval	O
of	O
the	O
heart	O
rate	O
[	O
IBI	O
]	O
,	O
heart-rate	O
variability	O
[	O
HRV	O
]	O
caused	O
by	O
peak-valley	O
respiratory	O
sinus	O
arrhythmia	O
[	O
pvRSA	O
]	O
,	O
and	O
high-frequency	O
power	O
[	O
HF	O
]	O
)	O
and	O
heart	O
rate	O
(	O
HR	O
)	O
were	O
obtained	O
at	O
seven	O
time	O
points	O
during	O
the	O
clamps	O
,	O
characterised	O
by	O
increasing	O
levels	O
of	O
insulin	S-GP
(	O
achieved	O
by	O
administering	O
insulin	S-GP
plus	O
glucose	S-chemical
,	O
glucose	S-chemical
only	O
,	O
glucose	S-chemical
and	O
GLP-1	S-GP
,	O
and	O
glucose	S-chemical
and	O
GLP-1	S-GP
combined	O
with	O
arginine	S-chemical
)	O
.	O
RESULTS	O
:	O
Serum	B-GP
insulin	E-GP
level	O
was	O
positively	O
associated	O
with	O
HR	O
at	O
all	O
time	O
points	O
during	O
the	O
clamps	O
except	O
the	O
first-phase	O
hyperglycaemic	O
clamp	O
.	O
Insulin	S-GP
levels	O
were	O
negatively	O
correlated	O
with	O
variables	O
of	O
vagal	O
control	O
,	O
reaching	O
significance	O
for	O
rMSSD	O
and	O
log	O
(	O
10	O
)	O
HF	O
,	O
but	O
not	O
for	O
pvRSA	O
,	O
during	O
the	O
last	O
four	O
phases	O
of	O
the	O
hyperglycaemic	O
clamp	O
(	O
hyperglycaemic	O
second	O
phase	O
,	O
GLP-1	S-GP
first	O
and	O
second	O
phases	O
,	O
and	O
arginine	S-chemical
)	O
.	O
These	O
associations	O
disappeared	O
when	O
adjusted	O
for	O
age	O
,	O
BMI	O
and	O
insulin	S-GP
sensitivity	O
.	O
Administration	O
of	O
the	O
beta	O
cell	O
secretagogues	O
GLP-1	S-GP
and	O
arginine	S-chemical
led	O
to	O
a	O
significant	O
increase	O
in	O
HR	O
,	O
but	O
this	O
was	O
not	O
paired	O
with	O
a	O
significant	O
reduction	O
in	O
HRV	O
measures	O
.	O
CONCLUSION/INTERPRETATION	O
:	O
Experimentally	O
induced	O
hyper	O
insulin	S-GP
aemia	O
is	O
not	O
correlated	O
with	O
cardiac	O
vagal	O
control	O
or	O
HR	O
when	O
adjusting	O
for	O
age	O
,	O
BMI	O
and	O
insulin	O
sensitivity	O
index	O
.	O
Our	O
findings	O
suggest	O
that	O
exposure	O
to	O
a	O
GLP-1	S-GP
during	O
hyperglycaemia	O
leads	O
to	O
a	O
small	O
acute	O
increase	O
in	O
HR	O
but	O
not	O
to	O
an	O
acute	O
decrease	O
in	O
cardiac	O
vagal	O
control	O
.	O

Propranolol	S-chemical
restores	O
cognitive	O
deficits	O
and	O
improves	O
amyloid	S-GP
and	O
Tau	S-GP
pathologies	O
in	O
a	O
senescence-accelerated	O
mouse	O
model	O
.	O
Ageing	O
is	O
associated	O
with	O
a	O
deterioration	O
of	O
cognitive	O
performance	O
and	O
with	O
increased	O
risk	O
of	O
neurodegenerative	O
disorders	O
.	O
Hypertension	O
is	O
the	O
most-prevalent	O
modifiable	O
risk	O
factor	O
for	O
cardiovascular	O
morbidity	O
and	O
mortality	O
worldwide	O
,	O
and	O
clinical	O
data	O
suggest	O
that	O
hypertension	O
is	O
a	O
risk	O
factor	O
for	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O
In	O
the	O
present	O
study	O
we	O
tested	O
whether	O
propranolol	S-chemical
,	O
a	O
β-receptor	S-GP
antagonist	O
commonly	O
used	O
as	O
antihypertensive	O
drug	O
,	O
could	O
ameliorate	O
the	O
cognitive	O
impairments	O
and	O
increases	O
in	O
AD-related	O
markers	O
shown	O
by	O
the	O
senescence-accelerated	O
mouse	O
prone-8	O
(	O
SAMP8	O
)	O
.	O
Propranolol	S-chemical
administration	O
(	O
5	O
mg/kg	O
for	O
3	O
weeks	O
)	O
to	O
6-month-old	O
SAMP8	O
mice	O
attenuated	O
cognitive	O
memory	O
impairments	O
shown	O
by	O
these	O
mice	O
in	O
the	O
novel	O
object	O
recognition	O
test	O
.	O
In	O
the	O
hippocampus	O
of	O
SAMP8	O
mice	O
it	O
has	O
been	O
found	O
increases	O
in	O
Aβ	B-GP
(	I-GP
42	I-GP
)	E-GP
levels	O
,	O
the	O
principal	O
constituent	O
of	O
amyloid	S-GP
plaques	O
observed	O
in	O
AD	O
,	O
accompanied	O
by	O
both	O
an	O
increased	O
expression	O
of	O
the	O
cleaving	O
enzyme	O
BACE1	S-GP
and	O
a	O
decreased	O
expression	O
of	O
the	O
degrading	O
enzyme	O
IDE	S-GP
.	O
All	O
these	O
effects	O
were	O
reversed	O
by	O
propranolol	S-chemical
treatment	O
.	O
Tau	S-GP
hyperphosphorylation	O
(	O
PHF-1	O
epitope	O
)	O
shown	O
by	O
SAMP8	O
mice	O
at	O
this	O
age	O
was	O
also	O
decreased	O
in	O
the	O
hippocampus	O
of	O
propranolol	S-chemical
-treated	O
mice	O
,	O
an	O
effect	O
probably	O
related	O
to	O
a	O
decrease	O
in	O
JNK1	S-GP
expression	O
.	O
Interestingly	O
,	O
propranolol	S-chemical
also	O
phosphorylated	O
Akt	S-GP
in	O
SAMP8	O
mice	O
,	O
which	O
was	O
associated	O
with	O
an	O
increase	O
of	O
glycogen	B-GP
synthase	I-GP
kinase-3β	E-GP
phosphorylation	O
,	O
contributing	O
therefore	O
to	O
the	O
reductions	O
in	O
Tau	S-GP
hyperphosphorylation	O
.	O
Synaptic	O
pathology	O
in	O
SAMP8	O
mice	O
,	O
as	O
shown	O
by	O
decreases	O
in	O
synaptophysin	S-GP
and	O
BDNF	S-GP
,	O
was	O
also	O
counteracted	O
by	O
propranolol	S-chemical
treatment	O
.	O
Overall	O
,	O
propranolol	S-chemical
might	O
be	O
beneficial	O
in	O
age-related	O
brain	O
dysfunction	O
and	O
could	O
be	O
an	O
emerging	O
candidate	O
for	O
the	O
treatment	O
of	O
other	O
neurodegenerative	O
diseases	O
.	O
This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'Cognitive	O
Enhancers	O
'	O
.	O

Anti-clastogenic	O
effect	O
of	O
beta-glucan	O
extracted	O
from	O
barley	O
towards	O
chemically	O
induced	O
DNA	O
damage	O
in	O
rodent	O
cells	O
.	O
beta-Glucan	O
(	O
BG	O
)	O
was	O
tested	O
in	O
vitro	O
to	O
determine	O
its	O
potential	O
clastogenic	O
and/or	O
anti-clastogenic	O
activity	O
,	O
and	O
attempts	O
were	O
made	O
to	O
elucidate	O
its	O
possible	O
mechanism	O
of	O
action	O
by	O
using	O
combinations	O
with	O
an	O
inhibitor	O
of	O
DNA	B-GP
polymerase	E-GP
.	O
The	O
study	O
was	O
carried	O
out	O
on	O
cells	O
deficient	O
(	O
CHO-k1	O
)	O
and	O
cells	O
proficient	O
(	O
HTC	O
)	O
in	O
phases	O
I	O
and	O
II	O
enzymes	O
,	O
and	O
the	O
DNA	O
damage	O
was	O
assessed	O
by	O
the	O
chromosomal	O
aberration	O
assay	O
.	O
BG	O
did	O
not	O
show	O
a	O
clastogenic	O
effect	O
,	O
but	O
was	O
anti-clastogenic	O
in	O
both	O
cell	O
lines	O
used	O
,	O
and	O
at	O
all	O
concentrations	O
tested	O
(	O
2.5	O
,	O
5	O
and	O
10	O
microg/mL	O
)	O
in	O
combination	O
with	O
damage	O
inducing	O
agents	O
(	O
methylmethane	B-chemical
sulfonate	E-chemical
in	O
cell	O
line	O
CHO-k1	O
,	O
and	O
methylmethane	B-chemical
sulfonate	E-chemical
or	O
2-aminoanthracene	S-chemical
in	O
cell	O
line	O
HTC	O
)	O
.	O
BG	O
also	O
showed	O
a	O
protective	O
effect	O
in	O
the	O
presence	O
of	O
a	O
DNA	B-GP
polymerase	I-GP
beta	E-GP
inhibitor	O
(	O
cytosine	B-chemical
arabinoside-3-phosphate	E-chemical
,	O
Ara-C	S-chemical
)	O
,	O
demonstrating	O
that	O
BG	O
does	O
not	O
act	O
through	O
an	O
anti-mutagenic	O
mechanism	O
of	O
action	O
involving	O
DNA	B-GP
polymerase	I-GP
beta	E-GP
.	O

Protein	B-GP
tyrosine	I-GP
phosphatase	I-GP
1B	E-GP
inhibitory	O
effect	O
by	O
dammarane-type	O
triterpenes	O
from	O
hydrolyzate	O
of	O
total	O
Gynostemma	O
pentaphyllum	O
saponins	O
.	O
Protein	O
tyrosine	S-chemical

AMPA	B-GP
receptor	E-GP
heterogeneity	O
in	O
rat	O
hippocampal	O
neurons	O
revealed	O
by	O
differential	O
sensitivity	O
to	O
cyclothiazide	S-chemical
.	O
1	O
.	O
The	O
kinetics	O
of	O
onset	O
of	O
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic	B-chemical
acid	E-chemical
(	B-GP
AMPA	I-GP
)	I-GP
receptor	E-GP
desensitization	O
by	O
glutamate	S-chemical
,	O
and	O
the	O
extent	O
of	O
attenuation	O
of	O
AMPA	B-GP
receptor	E-GP
desensitization	O
by	O
cyclothiazide	S-chemical
,	O
showed	O
pronounced	O
cell-to-cell	O
variation	O
in	O
cultures	O
of	O
rat	O
hippocampal	O
neurons	O
.	O
Cultures	O
prepared	O
from	O
area	O
CA1	O
stratum	O
radiatum	O
tended	O
to	O
show	O
weaker	O
modulation	O
by	O
cyclothiazide	S-chemical
than	O
cultures	O
prepared	O
from	O
the	O
whole	O
hippocampus	O
.	O
2	O
.	O
Kinetic	O
analysis	O
of	O
concentration	O
jump	O
responses	O
to	O
glutamate	S-chemical
revealed	O
multiple	O
populations	O
of	O
receptors	O
with	O
fast	O
(	O
approximately	O
400	O
ms	O
)	O
,	O
intermediate	O
(	O
approximately	O
2-4	O
s	O
)	O
,	O
and	O
slow	O
(	O
>	O
20	O
s	O
)	O
time	O
constants	O
for	O
recovery	O
from	O
modulation	O
by	O
cyclothiazide	S-chemical
.	O
The	O
amplitudes	O
of	O
these	O
components	O
varied	O
widely	O
between	O
cells	O
,	O
suggesting	O
the	O
existence	O
of	O
at	O
least	O
three	O
populations	O
of	O
AMPA	B-GP
receptor	E-GP
subtypes	O
,	O
the	O
relative	O
density	O
of	O
which	O
varied	O
from	O
cell	O
to	O
cell	O
.	O
3	O
.	O
The	O
complex	O
patterns	O
of	O
sensitivity	O
to	O
cyclothiazide	S-chemical
seen	O
in	O
hippocampal	O
neurons	O
could	O
be	O
reconstituted	O
by	O
assembly	O
of	O
recombinant	O
AMPA	B-GP
receptor	E-GP
subunits	O
generated	O
from	O
cDNAs	O
encoding	O
the	O
flip	O
(	O
i	O
)	O
and	O
flop	O
(	O
o	O
)	O
splice	O
variants	O
of	O
the	O
GluR-A	S-GP
and	O
GluR-B	S-GP
subunits	O
.	O
Recovery	O
from	O
modulation	O
by	O
cyclothiazide	S-chemical
was	O
slower	O
for	O
GluR-AiBi	S-GP
and	O
GluR-AoBi	S-GP
than	O
for	O
GluR-AiBo	S-GP
and	O
GluR-AoBo	S-GP
.	O
4	O
.	O
Coexpression	O
of	O
the	O
flip	O
and	O
flop	O
splice	O
variants	O
of	O
GluR-A	S-GP
,	O
in	O
the	O
absence	O
of	O
GluR-B	S-GP
,	O
revealed	O
that	O
heteromeric	O
AMPA	B-GP
receptors	E-GP
with	O
intermediate	O
sensitivity	O
to	O
cyclothiazide	S-chemical
,	O
similar	O
to	O
responses	O
observed	O
for	O
the	O
combinations	O
GluR-AoBi	S-GP
or	O
GluR-AiBo	S-GP
,	O
could	O
be	O
generated	O
independently	O
of	O
the	O
presence	O
of	O
the	O
GluR-B	S-GP
subunit	O
.	O
However	O
,	O
recovery	O
from	O
modulation	O
by	O
cyclothiazide	S-chemical
was	O
twofold	O
slower	O
for	O
GluR-AiBi	S-GP
than	O
for	O
homomeric	O
GluR-Ai	S-GP
,	O
indicating	O
that	O
the	O
GluR-A	S-GP
and	O
GluR-B	S-GP
subunits	O
are	O
not	O
functionally	O
equivalent	O
in	O
controlling	O
sensitivity	O
to	O
cyclothiazide	S-chemical
.	O
5	O
.	O
These	O
results	O
demonstrate	O
that	O
AMPA	B-GP
receptors	E-GP
expressed	O
in	O
hippocampal	O
neurons	O
are	O
assembled	O
in	O
a	O
variety	O
of	O
subunit	O
and	O
splice	O
variant	O
combinations	O
that	O
might	O
serve	O
as	O
a	O
mechanism	O
to	O
fine-tune	O
the	O
kinetics	O
of	O
synaptic	O
transmission	O
.	O

Ligand	O
binding	O
specificities	O
of	O
the	O
eight	O
types	O
and	O
subtypes	O
of	O
the	O
mouse	B-GP
prostanoid	I-GP
receptors	E-GP
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O
1	O
.	O
Eight	O
types	O
and	O
subtypes	O
of	O
the	O
mouse	B-GP
prostanoid	I-GP
receptor	E-GP
,	O
the	O
prostaglandin	B-GP
D	I-GP
(	I-GP
DP	I-GP
)	I-GP
receptor	E-GP
,	O
the	O
prostaglandin	B-GP
F	I-GP
(	I-GP
FP	I-GP
)	I-GP
receptor	E-GP
,	O
the	O
prostaglandin	B-GP
I	I-GP
(	I-GP
IP	I-GP
)	I-GP
receptor	E-GP
,	O
the	O
thromboxane	B-GP
A	I-GP
(	I-GP
TP	I-GP
)	I-GP
receptor	E-GP
and	O
the	O
EP1	S-GP
,	O
EP2	S-GP
,	O
EP3	S-GP
and	O
EP4	S-GP
subtypes	O
of	O
the	O
prostaglandin	B-GP
E	I-GP
receptor	E-GP
,	O
were	O
stably	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O
Their	O
ligand	O
binding	O
characteristics	O
were	O
examined	O
with	O
thirty	O
two	O
prostanoids	S-chemical
and	O
their	O
analogues	O
by	O
determining	O
the	O
Ki	O
values	O
from	O
the	O
displacement	O
curves	O
of	O
radioligand	O
binding	O
to	O
the	O
respective	O
receptors	O
.	O
2	O
.	O
The	O
DP	S-GP
,	O
IP	S-GP
and	O
TP	B-GP
receptors	E-GP
showed	O
high	O
ligand	O
binding	O
specificity	O
and	O
only	O
bound	O
their	O
own	O
putative	O
ligands	O
with	O
high	O
affinity	O
such	O
as	O
PGD2	S-chemical
,	O
BW245C	S-chemical
and	O
BW868C	S-chemical
for	O
DP	S-GP
,	O
cicaprost	S-chemical
,	O
iloprost	S-chemical
and	O
isocabacyclin	S-chemical
for	O
IP	S-GP
,	O
and	O
S-145	S-chemical
,	O
I-BOP	S-chemical
and	O
GR	B-chemical
32191	E-chemical
for	O
TP	S-GP
.	O
3	O
.	O
The	O
FP	B-GP
receptor	E-GP
bound	O
PGF2	S-chemical
alpha	O
and	O
fluprostenol	S-chemical
with	O
Ki	O
values	O
of	O
3-4	O
nM	O
.	O
In	O
addition	O
,	O
PGD2	S-chemical
,	O
17-phenyl-PGE2	S-chemical
,	O
STA2	S-chemical
,	O
I-BOP	S-chemical
,	O
PGE2	S-chemical
and	O
M	B-chemical
&	I-chemical
B-28767	E-chemical
bound	O
to	O
this	O
receptor	O
with	O
Ki	O
values	O
less	O
than	O
100	O
nM	O
.	O
4	O
.	O
The	O
EP1	S-GP
receptor	O
bound	O
17-phenyl-PGE2	S-chemical
,	O
sulprostone	S-chemical
and	O
iloprost	S-chemical
in	O
addition	O
to	O
PGE2	S-chemical
and	O
PGE1	S-chemical
,	O
with	O
Ki	O
values	O
of	O
14-36	O
nM	O
.	O
16,16-dimethyl-PGE2	S-chemical
and	O
two	O
putative	O
EP1	S-GP
antagonists	O
,	O
AH6809	S-chemical
and	O
SC-19220	S-chemical
,	O
did	O
not	O
show	O
any	O
significant	O
binding	O
to	O
this	O
receptor	O
.	O
M	B-chemical
&	I-chemical
B-28767	E-chemical
,	O
a	O
putative	O
EP3	S-GP
agonist	O
,	O
and	O
misoprostol	S-chemical
,	O
a	O
putative	O
EP2	S-GP
/	O
EP3	S-GP
agonist	O
,	O
also	O
bound	O
to	O
this	O
receptor	O
with	O
Ki	O
values	O
of	O
120	O
nM	O
.	O
5	O
.	O
The	O
EP2	S-GP
and	O
EP4	S-GP
receptors	O
showed	O
similar	O
binding	O
profiles	O
.	O
They	O
bound	O
16,16-dimethyl	B-chemical
PGE2	E-chemical
and	O
11-deoxy-PGE1	S-chemical
in	O
addition	O
to	O
PGE2	S-chemical
and	O
PGE1	S-chemical
.	O
The	O
two	O
receptors	O
were	O
discriminated	O
by	O
butaprost	S-chemical
,	O
AH-13205	S-chemical
and	O
AH-6809	S-chemical
that	O
bound	O
to	O
the	O
EP2	S-GP
receptor	O
but	O
not	O
to	O
the	O
EP4	S-GP
receptor	O
,	O
and	O
by	O
1-OH-PGE1	S-chemical
that	O
bound	O
to	O
the	O
EP4	S-GP
but	O
not	O
to	O
the	O
EP2	S-GP
receptor	O
.	O
6	O
.	O
The	O
EP3	S-GP
receptor	O
showed	O
the	O
broadest	O
binding	O
profile	O
,	O
and	O
bound	O
sulprostone	S-chemical
,	O
M	B-chemical
&	I-chemical
B-28767	E-chemical
,	O
GR63799X	S-chemical
,	O
11-deoxy-PGE1	S-chemical
,	O
16,16-dimethyl-PGE2	S-chemical
and	O
17-phenyl-PGE2	S-chemical
,	O
in	O
addition	O
to	O
PGE2	S-chemical
and	O
PGE1	S-chemical
,	O
with	O
Ki	O
values	O
of	O
0.6-3.7	O
nM	O
.	O
In	O
addition	O
,	O
three	O
IP	S-chemical
ligands	O
,	O
iloprost	S-chemical
,	O
carbacyclin	S-chemical
and	O
isocarbacyclin	S-chemical
,	O
and	O
one	O
TP	S-chemical
ligand	O
,	O
STA2	S-chemical
,	O
bound	O
to	O
this	O
receptor	O
with	O
Ki	O
values	O
comparable	O
to	O
the	O
Ki	O
values	O
of	O
these	O
compounds	O
for	O
the	O
IP	S-chemical
and	O
TP	B-GP
receptors	E-GP
,	O
respectively	O
.	O
7	B-chemical
.	I-chemical
8-Epi-PGF2	E-chemical
alpha	O
showed	O
only	O
weak	O
binding	O
to	O
the	O
IP	S-chemical
,	O
TP	S-chemical
,	O
FP	S-chemical
,	O
EP2	S-GP
and	O
EP3	S-GP
receptor	O
at	O
10	O
microM	O
concentration	O
.	O

Metabolism	O
Studies	O
of	O
Unformulated	O
Internally	O
[	O
3H	S-chemical
]	O
-labeled	O
siRNAs	O
in	O
Mice	O
.	O
Absorption	O
,	O
distribution	O
,	O
metabolism	O
,	O
and	O
excretion	O
properties	O
of	O
two	O
unformulated	O
model	O
siRNAs	O
were	O
determined	O
using	O
a	O
single	O
internal	O
[	O
(	B-chemical
3	I-chemical
)	I-chemical
H	E-chemical
]	O
-radiolabeling	O
procedure	O
,	O
where	O
the	O
full-length	O
oligonucleotides	O
were	O
radiolabeled	O
by	O
Br	S-chemical
/	O
(	B-chemical
3	I-chemical
)	I-chemical
H	E-chemical
-exchange	O
.	O
Tissue	O
distribution	O
,	O
excretion	O
,	O
and	O
mass	O
balance	O
of	O
radioactivity	O
were	O
investigated	O
in	O
male	O
CD-1	O
mice	O
,	O
following	O
a	O
single	O
intravenous	O
administration	O
of	O
the	O
[	O
(	B-chemical
3	I-chemical
)	I-chemical
H	E-chemical
]	O
-siRNAs	O
,	O
at	O
a	O
target	O
dose	O
level	O
of	O
5	O
mg/kg	O
.	O
Quantitative	O
whole-body	O
autoradiography	O
(	O
QWBA	O
)	O
and	O
liquid	O
scintillation	O
counting	O
techniques	O
were	O
used	O
to	O
determine	O
tissue	O
distribution	O
.	O
Radiochromatogram	O
profiles	O
were	O
determined	O
in	O
plasma	O
,	O
tissue	O
extracts	O
and	O
urine	O
.	O
Metabolites	O
were	O
separated	O
by	O
liquid	O
chromatography	O
and	O
identified	O
by	O
radiodetection	O
and	O
high-resolution	O
accurate	O
mass	O
spectrometry	O
.	O
In	O
general	O
,	O
there	O
was	O
little	O
difference	O
in	O
the	O
distribution	O
of	O
total	O
radiolabeled	O
components	O
after	O
administration	O
of	O
the	O
two	O
unformulated	O
[	O
(	B-chemical
3	I-chemical
)	I-chemical
H	E-chemical
]	O
-siRNAs	O
.	O
The	O
radioactivity	O
was	O
rapidly	O
and	O
widely	O
distributed	O
throughout	O
the	O
body	O
,	O
and	O
remained	O
detectable	O
in	O
all	O
tissues	O
investigated	O
at	O
later	O
time	O
points	O
(	O
24	O
and	O
48	O
hours	O
for	O
[	O
(	B-chemical
3	I-chemical
)	I-chemical
H	E-chemical
]	O
-	O
MRP4	S-GP
and	O
[	O
(	B-chemical
3	I-chemical
)	I-chemical
H	E-chemical
]	O
-SSB	O
siRNA	O
,	O
respectively	O
)	O
.	O
After	O
an	O
initial	O
rapid	O
decline	O
,	O
concentrations	O
of	O
total	O
radiolabeled	O
components	O
in	O
dried	O
blood	O
declined	O
at	O
a	O
much	O
slower	O
rate	O
.	O
A	O
nearly	O
complete	O
mass	O
balance	O
was	O
obtained	O
for	O
the	O
[	O
(	B-chemical
3	I-chemical
)	I-chemical
H	E-chemical
]	O
-SSB	O
siRNA	O
and	O
renal	O
excretion	O
was	O
the	O
main	O
route	O
of	O
elimination	O
(	O
38	O
%	O
)	O
.	O
The	O
metabolism	O
of	O
the	O
two	O
model	O
siRNAs	O
was	O
rapid	O
and	O
extensive	O
.	O
Five	O
minutes	O
after	O
administration	O
,	O
no	O
parent	O
compound	O
could	O
be	O
detected	O
in	O
plasma	O
.	O
Instead	O
,	O
radiolabeled	O
nucleosides	S-chemical
resulting	O
from	O
nuclease	S-GP
hydrolysis	O
were	O
observed	O
.	O
In	O
the	O
metabolism	O
profiles	O
obtained	O
from	O
various	O
tissues	O
only	O
radiolabeled	O
nucleosides	S-chemical
were	O
found	O
,	O
suggesting	O
that	O
siRNAs	O
are	O
rapidly	O
metabolized	O
and	O
that	O
the	O
distribution	O
pattern	O
of	O
total	O
radiolabeled	O
components	O
can	O
be	O
ascribed	O
to	O
small	O
molecular	O
weight	O
metabolites	O
.	O

Flexibly	O
timed	O
once-daily	O
dosing	O
with	O
degludec	O
:	O
a	O
new	O
ultra-long-acting	O
basal	O
insulin	S-GP
.	O
Insulin	S-GP
treatment	O
in	O
type	O
1	O
and	O
type	O
2	O
diabetes	O
(	O
T1D	O
and	O
T2D	O
)	O
is	O
highly	O
efficacious	O
,	O
but	O
in	O
practice	O
,	O
non-adherence	O
and	O
ineffective	O
dose	O
titration	O
limit	O
its	O
effectiveness	O
.	O
Barriers	O
to	O
more	O
effective	O
insulin	S-GP
treatment	O
are	O
numerous	O
,	O
including	O
hypoglycaemia	O
,	O
fear	O
of	O
hypoglycaemia	O
and	O
concern	O
about	O
weight	O
gain	O
.	O
The	O
regular	O
treatment	O
timing	O
needed	O
with	O
conventional	O
basal	O
insulins	S-GP
[	O
neutral	O
protamine	O
Hagedorn	O
(	O
NPH	O
)	O
insulin	S-GP
and	O
the	O
first-generation	O
analogues	O
glargine	O
and	O
detemir	O
]	O
may	O
also	O
make	O
adherence	O
to	O
these	O
treatments	O
problematic	O
for	O
many	O
patients	O
.	O
Indeed	O
,	O
surveys	O
indicate	O
that	O
the	O
rigidity	O
of	O
this	O
schedule	O
induces	O
some	O
patients	O
with	O
T1D	O
and	O
T2D	O
to	O
omit	O
insulin	S-GP
doses	O
.	O
Degludec	O
is	O
a	O
novel	O
,	O
ultra-long-acting	O
basal	O
insulin	S-GP
analogue	O
that	O
is	O
as	O
effective	O
as	O
insulin	S-GP
glargine	O
,	O
but	O
significantly	O
reduces	O
patients	O
'	O
risk	O
of	O
nocturnal	O
hypoglycaemia	O
.	O
Because	O
of	O
its	O
peakless	O
,	O
extended	O
and	O
highly	O
predictable	O
glucose	S-chemical
-lowering	O
effect	O
,	O
once-daily	O
dosing	O
on	O
a	O
flexible	O
schedule	O
may	O
be	O
feasible	O
with	O
degludec	O
.	O
Studies	O
testing	O
this	O
possibility	O
suggest	O
that	O
degludec	O
tolerates	O
day-to-day	O
variation	O
in	O
dose	O
timing	O
while	O
maintaining	O
full	O
efficacy	O
and	O
low	O
risk	O
of	O
nocturnal	O
hypoglycaemia	O
.	O
Degludec	O
would	O
appear	O
to	O
be	O
an	O
appropriate	O
choice	O
for	O
patients	O
being	O
considered	O
for	O
a	O
basal	O
analogue	O
,	O
and	O
it	O
may	O
be	O
particularly	O
well	O
suited	O
to	O
patients	O
with	O
unpredictable	O
social	O
or	O
work	O
schedules	O
,	O
those	O
who	O
travel	O
frequently	O
and	O
those	O
who	O
find	O
rigid	O
scheduling	O
of	O
their	O
insulin	S-GP
injections	O
a	O
burden	O
or	O
barrier	O
to	O
regular	O
treatment	O
.	O

Combination	O
therapy	O
with	O
mitiglinide	S-chemical
and	O
voglibose	S-chemical
improves	O
glycemic	O
control	O
in	O
type	O
2	O
diabetic	O
patients	O
on	O
hemodialysis	O
.	O
OBJECTIVE	O
:	O
Mitiglinide	S-chemical
,	O
a	O
rapid-	O
and	O
short-acting	O
insulinotropic	O
sulfonylurea	B-GP
receptor	E-GP
ligand	O
,	O
exhibits	O
hypoglycemic	O
action	O
unlike	O
other	O
sulfonylureas	S-chemical
.	O
The	O
efficacy	O
of	O
the	O
combination	O
of	O
mitiglinide	S-chemical
and	O
alpha-glucosidase	S-GP
inhibitors	O
for	O
diabetic	O
patients	O
on	O
hemodialysis	O
(	O
HD	O
)	O
has	O
not	O
been	O
prospectively	O
evaluated	O
;	O
therefore	O
,	O
we	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
mitiglinide	S-chemical
in	O
these	O
patients	O
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
We	O
performed	O
an	O
open-label	O
randomized	O
study	O
with	O
36	O
type	O
2	O
diabetics	O
with	O
poor	O
glycemic	O
control	O
on	O
HD	O
and	O
receiving	O
daily	O
doses	O
of	O
voglibose	S-chemical
(	O
0.9	O
mg	O
)	O
.	O
The	O
patients	O
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
:	O
a	O
combination-therapy	O
group	O
(	O
mitiglinide	S-chemical
group	O
)	O
,	O
mitiglinide	S-chemical
initial	O
dose	O
7.5	O
-	O
15	O
mg	O
titrated	O
to	O
30	O
mg	O
daily	O
and	O
constant	O
daily	O
dose	O
0.9	O
mg	O
of	O
voglibose	S-chemical
,	O
and	O
a	O
monotherapy	O
group	O
(	O
control	O
group	O
)	O
,	O
constant	O
daily	O
dose	O
0.9	O
mg	O
of	O
voglibose	S-chemical
alone	O
.	O
The	O
efficacy	O
of	O
the	O
treatment	O
was	O
determined	O
by	O
monitoring	O
plasma	O
glucose	S-chemical
,	O
hemoglobin	B-GP
A1c	E-GP
(	O
Hb	B-GP
(	I-GP
A1c	I-GP
)	E-GP
)	O
,	O
and	O
glycated	B-GP
albumin	E-GP
(	O
GA	S-GP
)	O
levels	O
and	O
using	O
homeostasis	O
model	O
assessment	O
of	O
insulin	S-GP
resistance	O
(	O
HOMA-IR	O
)	O
.	O
Safety	O
and	O
tolerance	O
were	O
determined	O
by	O
monitoring	O
clinical	O
and	O
laboratory	O
parameters	O
.	O
RESULTS	O
:	O
The	O
final	O
dose	O
of	O
mitiglinide	S-chemical
was	O
22.9	O
+/-	O
8.9	O
(	O
mean	O
+/-	O
s.d	O
.	O
)	O
mg	O
(	O
0.41	O
mg/kg	O
)	O
daily	O
.	O
Mitiglinide	S-chemical
reduced	O
fasting	O
plasma	O
glucose	S-chemical
and	O
GA	S-GP
levels	O
after	O
4	O
weeks	O
and	O
Hb	B-GP
(	I-GP
A1c	I-GP
)	E-GP
levels	O
after	O
8	O
weeks	O
.	O
Triglyceride	S-chemical
levels	O
and	O
HOMA-IR	O
values	O
also	O
decreased	O
significantly	O
after	O
mitiglinide	S-chemical
treatment	O
.	O
No	O
significant	O
changes	O
in	O
blood	O
pressure	O
levels	O
or	O
serious	O
adverse	O
effects	O
such	O
as	O
hypoglycemia	O
or	O
liver	O
impairment	O
were	O
observed	O
.	O
CONCLUSIONS	O
:	O
This	O
study	O
suggests	O
a	O
combination	O
therapy	O
of	O
mitiglinide	S-chemical
and	O
voglibose	S-chemical
may	O
have	O
potential	O
for	O
the	O
treatment	O
of	O
diabetics	O
on	O
HD	O
.	O
Due	O
to	O
the	O
small	O
sample	O
size	O
used	O
,	O
further	O
studies	O
should	O
be	O
performed	O
,	O
particularly	O
to	O
assess	O
the	O
safety	O
of	O
mitiglinide	S-chemical
treatment	O
.	O

Effects	O
of	O
Yerba	O
Mate	O
tea	O
(	O
Ilex	O
paraguariensis	O
)	O
on	O
vascular	O
endothelial	O
function	O
and	O
liver	O
lipoprotein	B-GP
receptor	E-GP
gene	O
expression	O
in	O
hyperlipidemic	O
rats	O
.	O
Yerba	O
Mate	O
tea	O
(	O
Mate	O
)	O
,	O
an	O
infusion	O
made	O
from	O
the	O
leaves	O
of	O
the	O
tree	O
Ilex	O
paraguariensis	O
,	O
is	O
a	O
widely	O
consumed	O
beverage	O
in	O
South	O
America	O
.	O
This	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
effect	O
of	O
Mate	O
tea	O
on	O
vascular	O
endothelial	O
dysfunction	O
and	O
liver	O
lipoprotein	B-GP
receptor	E-GP
gene	O
expression	O
in	O
hyperlipidemic	O
rats	O
,	O
with	O
the	O
aim	O
of	O
gaining	O
insight	O
into	O
its	O
known	O
lipid-lowering	O
protective	O
mechanisms	O
.	O
Sixty	O
male	O
Sprague-Dawley	O
rats	O
were	O
randomly	O
divided	O
into	O
five	O
groups	O
:	O
a	O
normal	O
control	O
group	O
(	O
NC	O
)	O
,	O
a	O
high-fat	O
diet	O
group	O
(	O
HC	O
)	O
,	O
and	O
three	O
Mate	O
tea-treated	O
groups	O
.	O
In	O
the	O
NC	O
group	O
,	O
rats	O
were	O
fed	O
with	O
standard	O
diet	O
while	O
in	O
the	O
other	O
groups	O
the	O
rats	O
were	O
fed	O
a	O
high-fat	O
diet	O
for	O
8weeks	O
.	O
In	O
the	O
Mate	O
tea-treated	O
groups	O
,	O
the	O
rats	O
were	O
fed	O
a	O
high-fat	O
diet	O
supplemented	O
with	O
low	O
,	O
moderate	O
or	O
high	O
concentrations	O
of	O
aqueous	O
Mate	O
tea	O
extract	O
for	O
the	O
final	O
4weeks	O
.	O
Compared	O
to	O
the	O
HC	O
group	O
,	O
aqueous	O
Mate	O
tea	O
extract	O
significantly	O
reduced	O
endothelin	S-GP
(	O
ET	S-GP
)	O
and	O
thromboxane	B-chemical
B	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
(	O
TXB	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
)	O
levels	O
and	O
increased	O
nitric	B-chemical
oxide	E-chemical
(	O
NO	S-chemical
)	O
and	O
6-keto	B-chemical
prostaglandin	I-chemical
F	I-chemical
(	I-chemical
1α	I-chemical
)	E-chemical
(	O
6-keto-PGF	B-chemical
(	I-chemical
1α	I-chemical
)	E-chemical
)	O
levels	O
in	O
the	O
blood	O
,	O
reduced	O
the	O
pathological	O
damage	O
of	O
vascular	O
endothelial	O
cells	O
,	O
decreased	O
intercellular	B-GP
adhesion	I-GP
molecule-1	E-GP
(	O
ICAM-1	S-GP
)	O
protein	O
expression	O
in	O
the	O
thoracic	O
aorta	O
,	O
and	O
upregulated	O
mRNA	O
expression	O
of	O
hepatic	O
low	B-GP
density	I-GP
lipoprotein	I-GP
receptor	E-GP
(	O
LDLR	S-GP
)	O
and	O
scavenger	B-GP
receptor	I-GP
B1	E-GP
(	O
SR-B1	S-GP
)	O
.	O
These	O
findings	O
indicate	O
that	O
Mate	O
tea	O
administration	O
might	O
have	O
a	O
regulatory	O
effect	O
on	O
blood	O
fat	O
and	O
endothelial	O
function	O
in	O
hyperlipidemia	O
rats	O
.	O
The	O
mechanism	O
may	O
involve	O
protecting	O
vascular	O
endothelial	O
cell	O
function	O
and	O
upregulating	O
the	O
expression	O
of	O
LDLR	S-GP
and	O
SR-B1	S-GP
genes	O
,	O
thereby	O
inhibiting	O
the	O
occurrence	O
of	O
atherosclerosis	O
.	O

The	O
selective	O
SYK	S-GP
inhibitor	O
P505-15	S-chemical
(	O
PRT062607	S-chemical
)	O
inhibits	O
B	O
cell	O
signaling	O
and	O
function	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
augments	O
the	O
activity	O
of	O
fludarabine	S-chemical
in	O
chronic	O
lymphocytic	O
leukemia	O
.	O
B-cell	B-GP
receptor	E-GP
(	O
BCR	S-GP
)	O
associated	O
kinases	S-GP
including	O
spleen	B-GP
tyrosine	I-GP
kinase	E-GP
(	O
SYK	S-GP
)	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
B-cell	O
malignancies	O
.	O
SYK	S-GP
is	O
persistently	O
phosphorylated	O
in	O
a	O
subset	O
of	O
non-Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
and	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
,	O
and	O
SYK	S-GP
inhibition	O
results	O
in	O
abrogation	O
of	O
downstream	O
kinase	S-GP
activity	O
and	O
apoptosis	O
.	O
P505-15	S-chemical
(	O
also	O
known	O
as	O
PRT062607	S-chemical
)	O
is	O
a	O
novel	O
,	O
highly	O
selective	O
,	O
and	O
orally	O
bioavailable	O
small	O
molecule	O
SYK	S-GP
inhibitor	O
(	O
SYK	S-GP
IC	O
(	O
50	O
)	O
=	O
1	O
nM	O
)	O
with	O
anti-	O
SYK	S-GP
activity	O
that	O
is	O
at	O
least	O
80-fold	O
greater	O
than	O
its	O
affinity	O
for	O
other	O
kinases	S-GP
.	O
We	O
evaluated	O
the	O
preclinical	O
characteristics	O
of	O
P505-15	S-chemical
in	O
models	O
of	O
NHL	O
and	O
CLL	O
.	O
P505-15	S-chemical
successfully	O
inhibited	O
SYK	S-GP
-mediated	O
B-cell	B-GP
receptor	E-GP
signaling	O
and	O
decreased	O
cell	O
viability	O
in	O
NHL	O
and	O
CLL	O
.	O
Oral	O
dosing	O
in	O
mice	O
prevented	O
BCR	S-GP
-mediated	O
splenomegaly	O
and	O
significantly	O
inhibited	O
NHL	O
tumor	O
growth	O
in	O
a	O
xenograft	O
model	O
.	O
In	O
addition	O
,	O
combination	O
treatment	O
of	O
primary	O
CLL	O
cells	O
with	O
P505-15	S-chemical
plus	O
fludarabine	S-chemical
produced	O
synergistic	O
enhancement	O
of	O
activity	O
at	O
nanomolar	O
concentrations	O
.	O
Our	O
findings	O
support	O
the	O
ongoing	O
development	O
of	O
P505-15	S-chemical
as	O
a	O
therapeutic	O
agent	O
for	O
B-cell	O
malignancies	O
.	O
A	O
dose	O
finding	O
study	O
in	O
healthy	O
volunteers	O
has	O
been	O
completed	O
.	O

Claudin-3	S-GP
and	O
claudin-4	S-GP
regulate	O
sensitivity	O
to	O
cisplatin	S-chemical
by	O
controlling	O
expression	O
of	O
the	O
copper	B-GP
and	I-GP
cisplatin	I-GP
influx	I-GP
transporter	E-GP
CTR1	S-GP
.	O
Claudin-3	S-GP
(	O
CLDN3	S-GP
)	O
and	O
claudin-4	S-GP
(	O
CLDN4	S-GP
)	O
are	O
the	O
major	O
structural	O
molecules	O
that	O
form	O
tight	O
junctions	O
(	O
TJs	O
)	O
between	O
epithelial	O
cells	O
.	O
We	O
found	O
that	O
knockdown	O
of	O
the	O
expression	O
of	O
either	O
CLDN3	S-GP
or	O
CLDN4	S-GP
produced	O
marked	O
changes	O
in	O
the	O
phenotype	O
of	O
ovarian	O
cancer	O
cells	O
,	O
including	O
an	O
increase	O
in	O
resistance	O
to	O
cisplatin	S-chemical
(	O
cDDP	O
)	O
.	O
The	O
effect	O
of	O
CLND3	S-GP
and	O
CLDN4	S-GP
on	O
cDDP	O
cytotoxicity	O
,	O
cDDP	O
cellular	O
accumulation	O
,	O
and	O
DNA	O
adduct	O
formation	O
was	O
compared	O
in	O
the	O
CLDN3	S-GP
-	O
and	O
CLDN4	S-GP
-expressing	O
parental	O
human	O
ovarian	O
carcinoma	O
2008	O
cells	O
and	O
CLDN3	S-GP
and	O
CLDN4	S-GP
knockdown	O
sublines	O
(	O
CLDN3	S-GP
KD	O
and	O
CLDN4	S-GP
KD	O
,	O
respectively	O
)	O
.	O
Knockdown	O
of	O
CLDN3	S-GP
or	O
CLDN4	S-GP
rendered	O
human	O
ovarian	O
carcinoma	O
2008	O
cells	O
resistant	O
to	O
cDDP	O
in	O
both	O
in	O
vitro	O
culture	O
and	O
in	O
vivo	O
xenograft	O
model	O
.	O
The	O
net	O
accumulation	O
of	O
platinum	S-chemical
(	O
Pt	S-chemical
)	O
and	O
the	O
Pt	S-chemical
-DNA	O
adduct	O
levels	O
were	O
reduced	O
in	O
CLDN3	S-GP
KD	O
and	O
CLDN4	S-GP
KD	O
cells	O
.	O
The	O
endogenous	O
mRNA	O
levels	O
of	O
copper	B-GP
influx	I-GP
transporter	E-GP
CTR1	S-GP
were	O
found	O
to	O
be	O
significantly	O
reduced	O
in	O
the	O
knockdown	O
cells	O
,	O
and	O
exogenous	O
expression	O
of	O
CTR1	S-GP
restored	O
their	O
sensitivity	O
to	O
cDDP	O
.	O
Reexpression	O
of	O
an	O
shRNAi-resistant	O
CLDN3	S-GP
or	O
CLDN4	S-GP
up-regulated	O
CTR1	S-GP
levels	O
,	O
reversed	O
the	O
cDDP	O
resistance	O
,	O
and	O
enhanced	O
TJ	O
formation	O
in	O
the	O
knockdown	O
cells	O
.	O
Baseline	O
copper	S-chemical
(	O
Cu	S-chemical
)	O
level	O
,	O
Cu	S-chemical
uptake	O
,	O
and	O
Cu	S-chemical
cytotoxicity	O
were	O
also	O
reduced	O
in	O
CLDN3	S-GP
KD	O
and	O
CLDN4	S-GP
KD	O
cells	O
.	O
Cu	S-chemical
-dependent	O
tyrosinase	S-GP
activity	O
was	O
also	O
markedly	O
reduced	O
in	O
both	O
types	O
of	O
CLDN	S-GP
knockdown	O
cells	O
when	O
incubated	O
with	O
the	O
substrate	O
l-DOPA	S-chemical
.	O
These	O
results	O
indicate	O
that	O
CLDN3	S-GP
and	O
CLDN4	S-GP
affect	O
sensitivity	O
of	O
the	O
ovarian	O
cancer	O
cells	O
to	O
the	O
cytotoxic	O
effect	O
of	O
cDDP	O
by	O
regulating	O
expression	O
of	O
the	O
Cu	B-GP
transporter	E-GP
CTR1	S-GP
.	O

Enhanced	O
beta	O
cell	O
function	O
and	O
anti-inflammatory	O
effect	O
after	O
chronic	O
treatment	O
with	O
the	O
dipeptidyl	B-GP
peptidase-4	E-GP
inhibitor	O
vildagliptin	S-chemical
in	O
an	O
advanced-aged	O
diet-induced	O
obesity	O
mouse	O
model	O
.	O
AIMS/HYPOTHESIS	O
:	O
Studies	O
have	O
shown	O
that	O
dipeptidyl	B-GP
peptidase-4	E-GP
(	O
DPP4	S-GP
)	O
inhibitors	O
stimulate	O
insulin	S-GP
secretion	O
and	O
increase	O
beta	O
cell	O
mass	O
in	O
rodents	O
.	O
However	O
,	O
in	O
these	O
models	O
hyperglycaemia	O
has	O
been	O
induced	O
early	O
on	O
in	O
life	O
and	O
the	O
treatment	O
periods	O
have	O
been	O
short	O
.	O
To	O
explore	O
the	O
long-term	O
effects	O
of	O
DPP4	S-GP
inhibition	O
on	O
insulin	S-GP
secretion	O
and	O
beta	O
cell	O
mass	O
,	O
we	O
have	O
generated	O
a	O
high-fat	O
diet	O
(	O
HFD	O
)	O
-induced-obesity	O
model	O
in	O
mice	O
of	O
advanced	O
age	O
(	O
10	O
months	O
old	O
)	O
.	O
METHODS	O
:	O
After	O
1	O
month	O
of	O
HFD	O
alone	O
,	O
the	O
mice	O
were	O
given	O
the	O
DPP4	S-GP
inhibitor	O
vildagliptin	S-chemical
for	O
a	O
further	O
11	O
months	O
.	O
At	O
multiple	O
time	O
points	O
throughout	O
the	O
study	O
,	O
OGTTs	O
were	O
performed	O
and	O
beta	O
cell	O
area	O
and	O
long-term	O
survival	O
were	O
evaluated	O
.	O
RESULTS	O
:	O
Beta	O
cell	O
function	O
and	O
glucose	S-chemical
tolerance	O
were	O
significantly	O
improved	O
by	O
vildagliptin	S-chemical
with	O
both	O
diets	O
.	O
In	O
contrast	O
,	O
in	O
spite	O
of	O
the	O
long	O
treatment	O
period	O
,	O
beta	O
cell	O
area	O
was	O
not	O
significantly	O
different	O
between	O
vildagliptin	S-chemical
-treated	O
mice	O
and	O
controls	O
.	O
Mice	O
of	O
advanced	O
age	O
chronically	O
fed	O
an	O
HFD	O
displayed	O
clear	O
and	O
extensive	O
pancreatic	O
inflammation	O
and	O
peri-insulitis	O
,	O
mainly	O
formed	O
by	O
CD3-positive	O
T	O
cells	O
,	O
which	O
were	O
completely	O
prevented	O
by	O
vildagliptin	S-chemical
treatment	O
.	O
Chronic	O
vildagliptin	S-chemical
treatment	O
also	O
improved	O
survival	O
rates	O
for	O
HFD-fed	O
mice	O
.	O
CONCLUSIONS/INTERPRETATION	O
:	O
In	O
a	O
unique	O
advanced-aged	O
HFD-induced-obesity	O
mouse	O
model	O
,	O
insulin	S-GP
secretion	O
was	O
improved	O
and	O
the	O
extensive	O
peri-insulitis	O
prevented	O
by	O
chronic	O
DPP4	S-GP
inhibition	O
.	O
The	O
improved	O
survival	O
rates	O
for	O
obese	O
mice	O
chronically	O
treated	O
with	O
vildagliptin	S-chemical
suggest	O
that	O
chronic	O
DPP4	S-GP
inhibition	O
potentially	O
results	O
in	O
additional	O
quality-adjusted	O
life-years	O
for	O
individuals	O
with	O
type	O
2	O
diabetes	O
,	O
which	O
is	O
the	O
primary	O
goal	O
of	O
any	O
diabetes	O
therapy	O
.	O

Activation	O
of	O
Rac1	S-GP
GTPase	S-GP
by	O
nanoparticulate	O
structures	O
in	O
human	O
macrophages	O
.	O
Inflammatory	O
activation	O
of	O
alveolar	O
macrophages	O
by	O
ambient	O
particles	O
can	O
be	O
facilitated	O
via	O
Toll-like	B-GP
receptors	E-GP
(	O
TLR	S-GP
)	O
.	O
The	O
action	O
of	O
TLR	S-GP
agonists	O
and	O
antagonists	O
has	O
been	O
reported	O
to	O
depend	O
on	O
the	O
formation	O
of	O
nanoparticulate	O
structures	O
.	O
Aim	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
the	O
signaling	O
pathways	O
induced	O
by	O
nanoparticulate	O
structures	O
in	O
human	O
macrophages	O
,	O
which	O
might	O
be	O
critical	O
for	O
inflammatory	O
cell	O
activation	O
.	O
METHODS	O
:	O
Studies	O
were	O
performed	O
in	O
primary	O
human	O
alveolar	O
macrophages	O
or	O
in	O
differentiated	O
THP-1	O
macrophages	O
.	O
Silica	S-chemical
nanoparticles	O
were	O
prepared	O
by	O
Stöber	O
synthesis	O
and	O
characterized	O
by	O
dynamic	O
light	O
scattering	O
and	O
scanning	O
electron	O
microscopy	O
.	O
Mycobacterial	O
DNA	O
was	O
isolated	O
from	O
Mycobacterium	O
bovis	O
BCG	O
,	O
and	O
nanoparticle	O
formation	O
was	O
assessed	O
by	O
atomic	O
force	O
microscopy	O
and	O
dynamic	O
light	O
scattering	O
.	O
Actin	S-GP
polymerization	O
was	O
measured	O
by	O
phalloidin	S-chemical
-	O
TRITC	S-chemical
staining	O
,	O
and	O
cell	O
activation	O
was	O
determined	O
by	O
reverse	O
transcription	O
quantitative	O
PCR	O
analysis	O
,	O
L929	O
cytotoxicity	O
assay	O
(	O
cytokine	S-GP
induction	O
)	O
,	O
and	O
pull-down	O
assays	O
(	O
Rho	S-GP
GTPases	S-GP
)	O
.	O
RESULTS	O
:	O
In	O
contrast	O
to	O
immune	O
stimulatory	O
sequence	O
ISS	O
1018	O
,	O
BCG	O
DNA	O
spontaneously	O
formed	O
nanoparticulate	O
structures	O
and	O
induced	O
actin	S-GP
polymerization	O
as	O
did	O
synthetic	O
silica	S-chemical
nanoparticles	O
.	O
Co-incubation	O
with	O
silica	S-chemical
nanoparticles	O
amplified	O
the	O
responsiveness	O
of	O
macrophages	O
toward	O
the	O
TLR9	S-GP
ligand	O
ISS	O
1018	O
.	O
The	O
activation	O
of	O
Rac1	S-GP
was	O
induced	O
by	O
silica	S-chemical
nanoparticles	O
as	O
well	O
as	O
BCG	O
DNA	O
and	O
is	O
suggested	O
as	O
the	O
critical	O
signaling	O
event	O
inducing	O
both	O
cytoskeleton	O
changes	O
as	O
well	O
as	O
inflammatory	O
cell	O
activation	O
.	O
CONCLUSION	O
:	O
Nanoparticles	O
can	O
induce	O
signaling	O
pathways	O
,	O
which	O
amplify	O
an	O
inflammatory	O
response	O
in	O
macrophages	O
.	O

Reinforcement	O
enhancing	O
effects	O
of	O
nicotine	S-chemical
via	O
smoking	O
.	O
RATIONALE	O
:	O
In	O
animals	O
,	O
nicotine	S-chemical
enhances	O
reinforcement	O
from	O
stimuli	O
unrelated	O
to	O
nicotine	S-chemical
intake	O
.	O
Human	O
research	O
is	O
suggestive	O
but	O
has	O
not	O
clearly	O
shown	O
a	O
similar	O
influence	O
of	O
nicotine	S-chemical
.	O
OBJECTIVES	O
:	O
We	O
assessed	O
acute	O
effects	O
of	O
nicotine	S-chemical
via	O
smoking	O
on	O
enhancement	O
of	O
positive	O
(	O
money	O
,	O
music	O
)	O
or	O
negative	O
(	O
termination	O
of	O
noise	O
)	O
reinforcers	O
,	O
or	O
no	O
``	O
reward	O
''	O
(	O
control	O
)	O
.	O
These	O
different	O
rewards	O
determined	O
the	O
generalizability	O
of	O
nicotine	S-chemical
effects	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Dependent	O
(	O
n	O
=	O
25	O
)	O
and	O
nondependent	O
(	O
n	O
=	O
27	O
)	O
smokers	O
participated	O
in	O
three	O
sessions	O
,	O
each	O
after	O
overnight	O
abstinence	O
.	O
Using	O
a	O
within-subjects	O
design	O
,	O
sessions	O
involved	O
no	O
smoking	O
or	O
smoking	O
denicotinized	O
(	O
0.05	O
mg	O
)	O
or	O
nicotine	S-chemical
(	O
0.6	O
mg	O
)	O
Quest	O
(	O
R	O
)	O
brand	O
cigarettes	O
.	O
For	O
comparison	O
,	O
a	O
fourth	O
session	O
involved	O
no	O
abstinence	O
prior	O
to	O
smoking	O
one	O
's	O
own	O
brand	O
to	O
gauge	O
responses	O
under	O
typical	O
nicotine	S-chemical
satiation	O
.	O
Reinforcement	O
was	O
assessed	O
by	O
responses	O
on	O
a	O
simple	O
operant	O
computer	O
task	O
for	O
the	O
rewards	O
,	O
each	O
available	O
singly	O
on	O
a	O
progressive	O
ratio	O
schedule	O
during	O
separate	O
trials	O
.	O
RESULTS	O
:	O
The	O
reinforcing	O
effect	O
of	O
music	O
,	O
but	O
not	O
other	O
rewards	O
,	O
was	O
greater	O
due	O
to	O
the	O
nicotine	S-chemical
cigarette	O
,	O
compared	O
to	O
the	O
denicotinized	O
cigarette	O
or	O
no	O
smoking	O
.	O
Reinforcement	O
enhancing	O
effects	O
of	O
nicotine	S-chemical
did	O
not	O
differ	O
between	O
dependent	O
and	O
nondependent	O
groups	O
,	O
indicating	O
no	O
influence	O
of	O
withdrawal	O
relief	O
.	O
Responding	O
due	O
to	O
acute	O
nicotine	S-chemical
after	O
abstinence	O
was	O
very	O
similar	O
to	O
responding	O
to	O
one	O
's	O
own	O
brand	O
after	O
no	O
abstinence	O
.	O
CONCLUSIONS	O
:	O
Acute	O
nicotine	S-chemical
intake	O
per	O
se	O
from	O
smoking	O
after	O
abstinence	O
enhances	O
the	O
reinforcing	O
value	O
of	O
rewards	O
unassociated	O
with	O
smoking	O
,	O
perhaps	O
in	O
a	O
manner	O
comparable	O
to	O
ad	O
lib	O
smoking	O
after	O
no	O
abstinence	O
.	O
Nicotine	S-chemical
's	O
reinforcement	O
enhancing	O
effects	O
may	O
be	O
specific	O
to	O
certain	O
rewards	O
,	O
perhaps	O
those	O
sensory	O
in	O
nature	O
.	O

Rasagiline	S-chemical
:	O
a	O
novel	O
anti-Parkinsonian	O
monoamine	B-GP
oxidase-B	E-GP
inhibitor	O
with	O
neuroprotective	O
activity	O
.	O
Rasagiline	S-chemical
(	O
N-propargyl-1-	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
-aminoindan	E-chemical
)	O
is	O
a	O
novel	O
,	O
highly	O
potent	O
irreversible	O
monoamine	B-GP
oxidase	I-GP
(	I-GP
MAO	I-GP
)	I-GP
-B	E-GP
inhibitor	O
,	O
anti-Parkinsonian	O
drug	O
.	O
Rasagiline	S-chemical
is	O
effective	O
as	O
monotherapy	O
or	O
adjunct	O
to	O
L-Dopa	S-chemical
for	O
patients	O
with	O
early	O
and	O
late	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O
Its	O
S-isomer	O
,	O
TVP1022	S-chemical
is	O
thousand	O
times	O
less	O
potent	O
as	O
an	O
MAO-B	S-GP
inhibitor	O
.	O
However	O
,	O
both	O
compounds	O
have	O
similar	O
molecular	O
mechanisms	O
of	O
neuroprotection	O
in	O
neuronal	O
cell	O
cultures	O
and	O
animal	O
neurodegenerative	O
models	O
,	O
indicating	O
that	O
the	O
neuroprotective	O
effect	O
of	O
rasagiline	S-chemical
does	O
not	O
depend	O
on	O
inhibition	O
of	O
MAO-B	S-GP
,	O
but	O
rather	O
is	O
associated	O
with	O
the	O
N-propargyl	S-chemical
moiety	O
,	O
which	O
promotes	O
mitochondrial	O
viability	O
and	O
stabilizes	O
permeability	O
transition	O
by	O
regulating	O
Bcl-2	S-GP
family	O
proteins	O
.	O
Novel	O
findings	O
demonstrated	O
that	O
the	O
major	O
metabolite	O
of	O
rasagiline	S-chemical
,	O
1-	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
-aminoindan	E-chemical
has	O
antioxidant	O
and	O
neuroprotective	O
capabilities	O
and	O
thus	O
,	O
may	O
contribute	O
to	O
the	O
overt	O
activity	O
of	O
its	O
parent	O
compound	O
,	O
rasagiline	S-chemical
.	O
This	O
paper	O
will	O
review	O
the	O
earlier	O
and	O
present	O
studies	O
in	O
the	O
development	O
of	O
rasagiline	S-chemical
for	O
treatment	O
of	O
PD	O
and	O
discuss	O
its	O
pharmacology	O
and	O
applicable	O
mechanism	O
of	O
action	O
.	O

Structure-based	O
design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
novel	O
anthra	B-chemical
[	I-chemical
1,2-d	I-chemical
]	I-chemical
imidazole-6,11-dione	E-chemical
derivatives	O
as	O
telomerase	S-GP
inhibitors	O
and	O
potential	O
for	O
cancer	O
polypharmacology	O
.	O
A	O
series	O
of	O
anthra	B-chemical
[	I-chemical
1,2-d	I-chemical
]	I-chemical
imidazole-6,11-dione	E-chemical
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
for	O
telomerase	S-GP
inhibition	O
,	O
hTERT	S-GP
expression	O
and	O
suppression	O
of	O
cancer	O
cell	O
growth	O
in	O
vitro	O
.	O
All	O
of	O
the	O
compounds	O
tested	O
,	O
except	O
for	O
compounds	O
4	O
,	O
7	O
,	O
16	O
,	O
24	O
,	O
27	O
and	O
28	O
were	O
selected	O
by	O
the	O
NCI	O
screening	O
system	O
.	O
Among	O
them	O
,	O
compounds	O
16	O
,	O
39	O
,	O
and	O
40	O
repressed	O
hTERT	S-GP
expression	O
without	O
greatly	O
affecting	O
cell	O
growth	O
,	O
suggesting	O
for	O
the	O
selectivity	O
toward	O
hTERT	S-GP
expression	O
.	O
Taken	O
together	O
,	O
our	O
findings	O
indicated	O
that	O
the	O
analysis	O
of	O
cytotoxicity	O
and	O
telomerase	S-GP
inhibition	O
might	O
provide	O
information	O
applicable	O
for	O
further	O
developing	O
potential	O
telomerase	S-GP
and	O
polypharmacological	O
targeting	O
strategy	O
.	O

Isolation	O
and	O
function	O
of	O
the	O
amino	B-GP
acid	I-GP
transporter	I-GP
PAT1	E-GP
(	O
slc36a1	S-GP
)	O
from	O
rabbit	O
and	O
discrimination	O
between	O
transport	O
via	O
PAT1	S-GP
and	O
system	B-GP
IMINO	E-GP
in	O
renal	O
brush-border	O
membrane	O
vesicles	O
.	O
Reabsorption	O
of	O
amino	B-chemical
acids	E-chemical
is	O
an	O
important	O
function	O
of	O
the	O
renal	O
proximal	O
tubule	O
.	O
pH-dependent	O
amino	B-chemical
acid	E-chemical
transport	O
has	O
been	O
measured	O
previously	O
using	O
rabbit	O
renal	O
brush-border	O
membrane	O
vesicles	O
(	O
BBMV	O
)	O
.	O
The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
whether	O
this	O
pH-dependent	O
uptake	O
represents	O
H	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
/	O
amino	B-chemical
acid	E-chemical
cotransport	O
via	O
a	O
PAT1	S-GP
-like	O
transport	O
system	O
.	O
The	O
rabbit	B-GP
PAT1	E-GP
cDNA	O
was	O
isolated	O
(	O
2296bp	O
including	O
both	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
and	O
poly	B-GP
(	I-GP
A	I-GP
)	I-GP
tail	I-GP
)	E-GP
and	O
the	O
open	B-GP
reading	I-GP
frame	E-GP
codes	O
for	O
a	O
protein	O
of	O
475	O
amino	B-chemical
acids	E-chemical
(	O
92	O
%	O
identity	O
to	O
human	B-GP
PAT1	E-GP
)	O
.	O
Rabbit	B-GP
PAT1	E-GP
mRNA	O
was	O
found	O
in	O
all	O
tissues	O
investigated	O
including	O
kidney	O
.	O
When	O
expressed	O
heterologously	O
in	O
a	O
mammalian	O
cell	O
line	O
,	O
rabbit	B-GP
PAT1	E-GP
mediates	O
pH-dependent	O
,	O
Na	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-independent	O
uptake	O
of	O
proline	S-chemical
,	O
glycine	S-chemical
,	O
l-alanine	S-chemical
and	O
alpha-	B-chemical
(	I-chemical
methylamino	I-chemical
)	I-chemical
isobutyric	I-chemical
acid	E-chemical
.	O
Proline	S-chemical
uptake	O
was	O
maximal	O
at	O
pH	O
5.0	O
(	O
K	O
(	O
m	O
)	O
2.2+/-0.7	O
mM	O
)	O
.	O
A	O
transport	O
system	O
with	O
identical	O
characteristics	O
(	O
ion	O
dependency	O
,	O
substrate	O
specificity	O
)	O
was	O
detected	O
in	O
rabbit	O
renal	O
BBMV	O
where	O
an	O
overshoot	O
was	O
observed	O
in	O
the	O
absence	O
of	O
Na+	S-chemical
but	O
in	O
the	O
presence	O
of	O
an	O
inwardly	O
directed	O
H+	S-chemical
gradient	O
.	O
In	O
the	O
presence	O
of	O
Na+	S-chemical
and	O
under	O
conditions	O
in	O
which	O
PAT1	S-GP
transport	O
function	O
was	O
suppressed	O
,	O
a	O
second	O
proline	S-chemical
uptake	O
system	O
was	O
detected	O
that	O
exhibited	O
functional	O
characteristics	O
similar	O
to	O
those	O
of	O
the	O
IMINO	B-GP
system	E-GP
.	O
The	O
functional	O
characteristics	O
of	O
rabbit	B-GP
PAT1	E-GP
in	O
either	O
mammalian	O
cells	O
or	O
renal	O
BBMV	O
suggest	O
that	O
PAT1	S-GP
is	O
the	O
low-affinity	O
transporter	O
of	O
proline	S-chemical
,	O
glycine	S-chemical
and	O
hydroxyproline	S-chemical
believed	O
to	O
be	O
defective	O
in	O
patients	O
with	O
iminoglycinuria	O
.	O

Apocynin	S-chemical
and	O
raisanberine	S-chemical
alleviate	O
intermittent	O
hypoxia	O
induced	O
abnormal	O
StAR	S-GP
and	O
3β-HSD	S-GP
and	O
low	O
testosterone	S-chemical
by	O
suppressing	O
endoplasmic	O
reticulum	O
stress	O
and	O
activated	O
p66Shc	S-GP
in	O
rat	O
testes	O
.	O
We	O
hypothesized	O
that	O
hypoxia	O
induced	O
testicular	O
damage	O
is	O
mediated	O
by	O
an	O
activated	O
NADPH	B-GP
oxidase	E-GP
(	O
NOX	S-GP
)	O
,	O
therefore	O
,	O
APO	S-chemical
(	O
apocynin	S-chemical
)	O
an	O
inhibitor	O
of	O
NOX	S-GP
and	O
raisanberine	S-chemical
(	O
RS	O
)	O
,	O
a	O
calcium	S-chemical
influx	O
inhibitor	O
were	O
tested	O
if	O
they	O
could	O
attenuate	O
hypoxic	O
toxicity	O
to	O
the	O
testis	O
.	O
Male	O
Sprague-Dawley	O
rats	O
were	O
exposed	O
to	O
hypoxia	O
(	O
10±0.5	O
%	O
O2	O
)	O
for	O
17d	O
and	O
intervened	O
with	O
APO	S-chemical
and	O
RS	O
in	O
the	O
last	O
6d	O
.	O
Histological	O
changes	O
and	O
expression	O
of	O
pro-inflammation	O
factors	O
were	O
evaluated	O
in	O
vivo	O
.	O
Biomarkers	O
in	O
isolated	O
Leydig	O
cells	O
incubated	O
with	O
H2O2	S-chemical
were	O
also	O
assayed	O
in	O
vitro	O
.	O
Hypoxic	O
rats	O
displayed	O
lower	O
serum	O
testosterone	S-chemical
and	O
higher	O
LH	S-GP
and	O
FSH	S-GP
.	O
Upregulation	O
of	O
p22/p47	B-GP
(	I-GP
phox	I-GP
)	E-GP
,	O
NOX2	S-GP
,	O
MMP9	S-GP
,	O
PERK	S-GP
and	O
p66Shc	S-GP
was	O
associated	O
with	O
downregulation	O
of	O
StAR	S-GP
,	O
3β-HSD	S-GP
and	O
Cx43	S-GP
in	O
the	O
hypoxia	O
testis	O
,	O
revealed	O
by	O
Western	O
blot	O
and	O
immunohistochemical	O
assay	O
,	O
respectively	O
.	O
APO	S-chemical
and	O
RS	O
at	O
least	O
partially	O
normalize	O
hypoxia	O
caused	O
male	O
hypogonadism	O
by	O
suppressing	O
ER	O
stress	O
,	O
and	O
p66Shc	S-GP
in	O
testes	O
.	O

Type	O
2	O
diabetes	O
and	O
oral	O
antihyperglycemic	O
drugs	O
.	O
Type	O
II	O
diabetes	O
is	O
a	O
heterogeneous	O
disease	O
where	O
environment	O
and	O
genetics	O
are	O
important	O
factors	O
for	O
the	O
expression	O
of	O
the	O
disease	O
.	O
The	O
high	O
cost	O
for	O
treating	O
complications	O
of	O
diabetes	O
is	O
a	O
burden	O
for	O
public	O
health	O
systems	O
and	O
governments	O
worldwide	O
.	O
Type	O
II	O
diabetes	O
has	O
been	O
causing	O
debilitation	O
worldwide	O
for	O
many	O
decades	O
,	O
and	O
a	O
single	O
drug	O
that	O
safely	O
treats	O
the	O
disease	O
has	O
yet	O
to	O
be	O
discovered	O
.	O
Sulfonylureas	S-chemical
,	O
biguanides	S-chemical
,	O
alpha-glucosidase	S-GP
,	O
meglitinides	S-chemical
,	O
DPP-4	S-chemical
inhibitors	O
and	O
thiazolidinediones	S-chemical
are	O
among	O
the	O
classes	O
of	O
oral	O
hypoglycemic	O
drugs	O
available	O
to	O
treat	O
Type	O
II	O
diabetes	O
,	O
but	O
concerns	O
exist	O
regarding	O
safety	O
and	O
efficacy	O
of	O
these	O
drugs	O
.	O
In	O
this	O
article	O
we	O
present	O
the	O
pros	O
and	O
cons	O
of	O
the	O
six	O
classes	O
and	O
discuss	O
some	O
of	O
the	O
latest	O
advances	O
towards	O
the	O
development	O
of	O
new	O
drugs	O
for	O
the	O
treatment	O
of	O
Type	O
II	O
diabetes	O
.	O

Effects	O
of	O
single	O
or	O
repeated	O
silymarin	O
administration	O
on	O
pharmacokinetics	O
of	O
risperidone	S-chemical
and	O
its	O
major	O
metabolite	O
,	O
9-hydroxyrisperidone	S-chemical
in	O
rats	O
.	O
1	O
.	O
The	O
interactions	O
between	O
herbal	O
dietary	O
supplements	O
and	O
therapeutic	O
drugs	O
have	O
emerged	O
as	O
an	O
important	O
issue	O
and	O
P-glycoprotein	S-GP
(	O
P-gp	S-GP
)	O
has	O
been	O
reported	O
as	O
one	O
of	O
the	O
significant	O
factors	O
of	O
these	O
interactions	O
.	O
2	O
.	O
The	O
objective	O
of	O
this	O
article	O
is	O
to	O
examine	O
the	O
effects	O
of	O
single	O
and	O
repeated	O
administrations	O
of	O
silymarin	O
on	O
pharmacokinetics	O
of	O
a	O
P-gp	S-GP
substrate	O
,	O
risperidone	S-chemical
,	O
and	O
its	O
major	O
metabolite	O
,	O
9-hydroxyrisperidone	S-chemical
,	O
in	O
rats	O
.	O
3	O
.	O
To	O
determine	O
the	O
plasma	O
levels	O
of	O
risperidone	S-chemical
and	O
9-hydroxyrisperidone	S-chemical
in	O
rats	O
,	O
a	O
HPLC	O
method	O
was	O
developed	O
using	O
a	O
liquid-liquid	O
acid	O
back	O
extraction	O
.	O
When	O
risperidone	S-chemical
(	O
6	O
mg/kg	O
)	O
was	O
co-administered	O
with	O
silymarin	O
(	O
40	O
mg/kg	O
)	O
to	O
rats	O
orally	O
,	O
the	O
C	O
(	O
max	O
)	O
of	O
9-hydroxyrisperidone	S-chemical
was	O
significantly	O
increased	O
to1.3-fold	O
(	O
p	O
<	O
0.05	O
)	O
,	O
while	O
the	O
other	O
pharmacokinetic	O
parameters	O
did	O
not	O
show	O
any	O
significant	O
differences	O
.	O
Expanding	O
the	O
experiment	O
where	O
rats	O
were	O
repeatedly	O
administered	O
with	O
silymarin	O
for	O
5	O
days	O
prior	O
to	O
giving	O
risperidone	S-chemical
,	O
the	O
C	O
(	O
max	O
)	O
of	O
risperidone	S-chemical
and	O
9-hydroxyrisperidone	S-chemical
were	O
significantly	O
increased	O
to	O
2.4-fold	O
(	O
p	O
<	O
0.001	O
)	O
and	O
1.7-fold	O
(	O
p	O
<	O
0.001	O
)	O
,	O
respectively	O
,	O
and	O
the	O
AUC	O
(	O
0-t	O
)	O
,	O
as	O
well	O
to	O
1.7-fold	O
(	O
p	O
<	O
0.05	O
)	O
and	O
2.1-fold	O
(	O
p	O
<	O
0.01	O
)	O
,	O
respectively	O
.	O
4	O
.	O
The	O
repeated	O
exposures	O
of	O
silymarin	O
,	O
compared	O
to	O
single	O
administration	O
of	O
silymarin	O
,	O
increased	O
oral	O
bioavailability	O
and	O
affected	O
the	O
pharmacokinetics	O
of	O
risperidone	S-chemical
and	O
9-hydroxyrisperidone	S-chemical
,	O
by	O
inhibiting	O
P-gp	S-GP
.	O

Novel	O
locus	O
including	O
FGF21	S-GP
is	O
associated	O
with	O
dietary	O
macronutrient	O
intake	O
.	O
Dietary	O
intake	O
of	O
macronutrients	O
(	O
carbohydrate	S-chemical
,	O
protein	O
,	O
and	O
fat	O
)	O
has	O
been	O
associated	O
with	O
risk	O
of	O
chronic	O
conditions	O
such	O
as	O
obesity	O
and	O
diabetes	O
.	O
Family	O
studies	O
have	O
reported	O
a	O
moderate	O
contribution	O
of	O
genetics	O
to	O
variation	O
in	O
macronutrient	O
intake	O
.	O
In	O
a	O
genome-wide	O
meta-analysis	O
of	O
a	O
population-based	O
discovery	O
cohort	O
(	O
n	O
=	O
33	O
533	O
)	O
,	O
rs838133	O
in	O
FGF21	S-GP
(	O
19q13.33	O
)	O
,	O
rs197273	O
near	O
TRAF	B-GP
family	I-GP
member-associated	I-GP
NF-kappa-B	I-GP
activator	E-GP
(	O
TANK	S-GP
)	O
(	O
2p24.2	O
)	O
,	O
and	O
rs10163409	O
in	O
FTO	S-GP
(	O
16q12.2	O
)	O
were	O
among	O
the	O
top	O
associations	O
(	O
P	O
<	O
10	O
(	O
-5	O
)	O
)	O
for	O
percentage	O
of	O
total	O
caloric	O
intake	O
from	O
protein	O
and	O
carbohydrate	S-chemical
.	O
rs838133	O
was	O
replicated	O
in	O
silico	O
in	O
an	O
independent	O
sample	O
from	O
the	O
Cohorts	O
for	O
Heart	O
and	O
Aging	O
Research	O
in	O
Genomic	O
Epidemiology	O
Consortium	O
(	O
CHARGE	O
)	O
Nutrition	O
Working	O
Group	O
(	O
n	O
=	O
38	O
360	O
)	O
and	O
attained	O
genome-wide	O
significance	O
in	O
combined	O
analysis	O
(	O
Pjoint	O
=	O
7.9	O
×	O
10	O
(	O
-9	O
)	O
)	O
.	O
A	O
cytokine	S-GP
involved	O
in	O
cellular	O
metabolism	O
,	O
FGF21	S-GP
is	O
a	O
potential	O
susceptibility	O
gene	O
for	O
obesity	O
and	O
type	O
2	O
diabetes	O
.	O
Our	O
results	O
highlight	O
the	O
potential	O
of	O
genetic	O
variation	O
for	O
determining	O
dietary	O
macronutrient	O
intake	O
.	O

Adenovirus-delivered	O
angiopoietin-1	S-GP
treatment	O
for	O
phosgene	S-chemical
-induced	O
acute	O
lung	O
injury	O
.	O
Abstract	O
Context	O
:	O
Exposure	O
to	O
phosgene	S-chemical
can	O
result	O
in	O
an	O
acute	O
lung	O
injury	O
,	O
leading	O
to	O
pulmonary	O
edema	O
and	O
even	O
death	O
.	O
Angiopoietin-1	S-GP
(	O
Ang1	S-GP
)	O
is	O
a	O
critical	O
factor	O
for	O
vascular	O
stabilization	O
due	O
to	O
its	O
ability	O
to	O
reduce	O
endothelial	O
permeability	O
and	O
inflammation	O
.	O
Objective	O
:	O
In	O
this	O
study	O
,	O
the	O
histopathological	O
changes	O
of	O
the	O
lungs	O
after	O
exposure	O
to	O
phosgene	S-chemical
and	O
the	O
effect	O
of	O
Ang1	S-GP
treatment	O
were	O
examined	O
.	O
Materials	O
and	O
methods	O
:	O
Rats	O
were	O
exposed	O
to	O
phosgene	S-chemical
gas	O
at	O
8.33	O
g/m	O
(	O
3	O
)	O
for	O
5	O
min	O
.	O
Ang1	S-GP
overexpressing	O
rats	O
were	O
established	O
by	O
an	O
intravenous	O
injection	O
of	O
adenovirus-	O
Ang1	S-GP
(	O
Ad/Ang1	O
)	O
.	O
The	O
histological	O
changes	O
of	O
the	O
lung	O
were	O
examined	O
by	O
Haematoxylin	S-chemical
-	O
Eosin	S-chemical
(	O
H	O
&	O
E	O
)	O
staining	O
and	O
fluorescence	O
microscopy	O
.	O
The	O
inferior	O
lobe	O
was	O
used	O
for	O
the	O
determination	O
of	O
the	O
ratio	O
of	O
wet	O
weight	O
to	O
dry	O
weight	O
of	O
the	O
lung	O
.	O
The	O
concentration	O
of	O
cytokines	S-GP
in	O
the	O
serum	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
was	O
determined	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O
Results	O
:	O
The	O
pathological	O
analysis	O
showed	O
signs	O
of	O
inflammation	O
and	O
edema	O
,	O
evident	O
from	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
leukocytes	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
and	O
the	O
ratio	O
of	O
wet	O
to	O
dry	O
weight	O
of	O
the	O
lungs	O
.	O
The	O
lung	O
injury	O
induced	O
by	O
phosgene	S-chemical
was	O
markedly	O
reduced	O
after	O
the	O
injection	O
of	O
Ad/	O
Ang1	S-GP
.	O
The	O
increase	O
of	O
IL-1β	S-GP
and	O
IL-17	S-GP
and	O
decrease	O
of	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	E-GP
in	O
the	O
serum	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
of	O
phosgene	S-chemical
-exposed	O
animals	O
were	O
abolished	O
by	O
the	O
administration	O
of	O
Ad/	O
Ang1	S-GP
.	O
Discussion	O
and	O
conclusions	O
:	O
Ang1	S-GP
has	O
the	O
beneficial	O
effects	O
on	O
phosgene	S-chemical
-induced	O
lung	O
injury	O
.	O
The	O
adenovirus-delivered	O
Ang1	S-GP
may	O
have	O
the	O
potential	O
as	O
a	O
novel	O
approach	O
for	O
the	O
treatment	O
of	O
the	O
acute	O
lung	O
injury	O
caused	O
by	O
phosgene	S-chemical
gas	O
inhalation	O
in	O
humans	O
.	O

Anandamide	S-chemical
deficiency	O
and	O
heightened	O
neuropathic	O
pain	O
in	O
aged	O
mice	O
.	O
Damaging	O
of	O
peripheral	O
nerves	O
may	O
result	O
in	O
chronic	O
neuropathic	O
pain	O
for	O
which	O
the	O
likelihood	O
is	O
increased	O
in	O
the	O
elderly	O
.	O
We	O
assessed	O
in	O
mice	O
if	O
age-dependent	O
alterations	O
of	O
endocannabinoids	O
contributed	O
to	O
the	O
heightened	O
vulnerability	O
to	O
neuropathic	O
pain	O
at	O
old	O
age	O
.	O
We	O
assessed	O
nociception	O
,	O
endocannabinoids	O
and	O
the	O
therapeutic	O
efficacy	O
of	O
R-flurbiprofen	S-chemical
in	O
young	O
and	O
aged	O
mice	O
in	O
the	O
spared	O
nerve	O
injury	O
model	O
of	O
neuropathic	O
pain	O
.	O
R-flurbiprofen	S-chemical
was	O
used	O
because	O
it	O
is	O
able	O
to	O
reduce	O
neuropathic	O
pain	O
in	O
young	O
mice	O
in	O
part	O
by	O
increasing	O
anandamide	S-chemical
.	O
Aged	O
mice	O
developed	O
stronger	O
nociceptive	O
hypersensitivity	O
after	O
sciatic	O
nerve	O
injury	O
than	O
young	O
mice	O
.	O
This	O
was	O
associated	O
with	O
low	O
anandamide	S-chemical
levels	O
in	O
the	O
dorsal	O
root	O
ganglia	O
,	O
spinal	O
cord	O
,	O
thalamus	O
and	O
cortex	O
,	O
which	O
further	O
decreased	O
after	O
nerve	O
injury	O
.	O
In	O
aged	O
mice	O
,	O
R-flurbiprofen	S-chemical
had	O
only	O
weak	O
antinociceptive	O
efficacy	O
and	O
it	O
failed	O
to	O
restore	O
normal	O
anandamide	S-chemical
levels	O
after	O
nerve	O
injury	O
.	O
In	O
terms	O
of	O
the	O
mechanisms	O
,	O
we	O
found	O
that	O
fatty	B-GP
acid	I-GP
amide	I-GP
hydrolase	E-GP
(	O
FAAH	S-GP
)	O
which	O
degrades	O
anandamide	S-chemical
,	O
was	O
upregulated	O
after	O
nerve	O
injury	O
at	O
both	O
ages	O
,	O
so	O
that	O
this	O
upregulation	O
likely	O
did	O
not	O
account	O
for	O
the	O
age-dependent	O
differences	O
.	O
However	O
,	O
enzymes	O
contributing	O
to	O
oxidative	O
metabolism	O
of	O
anandamide	S-chemical
,	O
namely	O
cyclooxygenase-1	S-GP
and	O
Cyp2D6	S-GP
,	O
were	O
increased	O
in	O
the	O
brain	O
of	O
aged	O
mice	O
,	O
possibly	O
enhancing	O
the	O
oxidative	O
breakdown	O
of	O
anandamide	S-chemical
.	O
This	O
may	O
overwhelm	O
the	O
capacity	O
of	O
R-flurbiprofen	S-chemical
to	O
restore	O
anandamide	S-chemical
homeostasis	O
and	O
may	O
contribute	O
to	O
the	O
heightened	O
risk	O
for	O
neuropathic	O
pain	O
at	O
old	O
age	O
.	O

Glucagon-like	B-GP
peptide	I-GP
(	I-GP
GLP	I-GP
)	I-GP
-2	E-GP
reduces	O
chemotherapy-associated	O
mortality	O
and	O
enhances	O
cell	O
survival	O
in	O
cells	O
expressing	O
a	O
transfected	O
GLP-2	B-GP
receptor	E-GP
.	O
Chemotherapeutic	O
agents	O
produce	O
cytotoxicity	O
via	O
induction	O
of	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
.	O
Rapidly	O
proliferating	O
cells	O
in	O
the	O
bone	O
marrow	O
and	O
intestinal	O
crypts	O
are	O
highly	O
susceptible	O
to	O
chemotherapy	O
,	O
and	O
damage	O
to	O
these	O
cellular	O
compartments	O
may	O
preclude	O
maximally	O
effective	O
chemotherapy	O
administration	O
.	O
Glucagon-like	B-GP
peptide	I-GP
(	I-GP
GLP	I-GP
)	I-GP
-2	E-GP
is	O
an	O
enteroendocrine-derived	O
regulatory	O
peptide	O
that	O
inhibits	O
crypt	O
cell	O
apoptosis	O
after	O
administration	O
of	O
agents	O
that	O
damage	O
the	O
intestinal	O
epithelium	O
.	O
We	O
report	O
here	O
that	O
a	O
human	O
degradation-resistant	O
GLP-2	S-GP
analogue	O
,	O
h	O
[	O
Gly2	S-chemical
]	O
-	O
GLP-2	S-GP
significantly	O
improves	O
survival	O
,	O
reduces	O
bacteremia	O
,	O
attenuates	O
epithelial	O
injury	O
,	O
and	O
inhibits	O
crypt	O
apoptosis	O
in	O
the	O
murine	O
gastrointestinal	O
tract	O
after	O
administration	O
of	O
topoisomerase	B-GP
I	E-GP
inhibitor	O
irinotecan	B-chemical
hydrochloride	E-chemical
or	O
the	O
antimetabolite	O
5-fluorouracil	S-chemical
.	O
h	O
[	O
Gly2	S-chemical
]	O
-	O
GLP-2	S-GP
significantly	O
improved	O
survival	O
and	O
reduced	O
weight	O
loss	O
but	O
did	O
not	O
impair	O
chemotherapy	O
effectiveness	O
in	O
tumor-bearing	O
mice	O
treated	O
with	O
cyclical	O
irinotecan	O
.	O
Furthermore	O
,	O
h	O
[	O
Gly2	S-chemical
]	O
-	O
GLP-2	S-GP
reduced	O
chemotherapy-induced	O
apoptosis	O
,	O
decreased	O
activation	O
of	O
caspase-8	B-GP
and	I-GP
-3	E-GP
,	O
and	O
inhibited	O
poly	B-GP
(	I-GP
ADP-ribose	I-GP
)	I-GP
polymerase	E-GP
cleavage	O
in	O
heterologous	O
cells	O
transfected	O
with	O
the	O
GLP-2	B-GP
receptor	E-GP
.	O
These	O
observations	O
demonstrate	O
that	O
the	O
antiapoptotic	O
effects	O
of	O
GLP-2	S-GP
on	O
intestinal	O
crypt	O
cells	O
may	O
be	O
useful	O
for	O
the	O
attenuation	O
of	O
chemotherapy-induced	O
intestinal	O
mucositis	O
.	O

Retinoic	B-chemical
acid	E-chemical
is	O
required	O
for	O
specification	O
of	O
the	O
ventral	O
eye	O
field	O
and	O
for	O
Rathke	O
's	O
pouch	O
in	O
the	O
avian	O
embryo	O
.	O
We	O
have	O
investigated	O
the	O
role	O
of	O
retinoic	B-chemical
acid	E-chemical
(	O
RA	S-chemical
)	O
in	O
eye	O
development	O
using	O
the	O
vitamin	B-chemical
A	E-chemical
deficient	O
quail	O
model	O
system	O
,	O
which	O
overcomes	O
problems	O
of	O
retinoic	B-chemical
acid	E-chemical
synthesising	O
enzyme	O
redundancy	O
in	O
the	O
embryo	O
.	O
In	O
the	O
absence	O
of	O
retinoic	B-chemical
acid	E-chemical
,	O
the	O
ventral	O
optic	O
stalk	O
and	O
ventral	O
retina	O
are	O
missing	O
,	O
whereas	O
the	O
dorsal	O
optic	O
stalk	O
and	O
dorsal	O
retina	O
develop	O
appropriately	O
.	O
Other	O
ocular	O
abnormalities	O
observed	O
were	O
a	O
thinner	O
retina	O
and	O
the	O
lack	O
of	O
differentiation	O
of	O
the	O
lens	O
.	O
In	O
an	O
attempt	O
to	O
explain	O
this	O
,	O
we	O
studied	O
the	O
expression	O
of	O
various	O
dorsally	O
and	O
ventrally	O
expressed	O
genes	O
such	O
as	O
Pax2	S-GP
,	O
Pax6	S-GP
,	O
Tbx6	S-GP
,	O
Vax2	S-GP
,	O
Raldh1	S-GP
and	O
Raldh3	S-GP
and	O
noted	O
that	O
they	O
were	O
unchanged	O
in	O
their	O
expression	O
patterns	O
.	O
In	O
contrast	O
,	O
the	O
RA	S-chemical
catabolising	O
enzymes	O
Cyp26A1	S-GP
and	O
Cyp26B1	S-GP
which	O
are	O
known	O
to	O
be	O
RA	S-chemical
-responsive	O
were	O
not	O
expressed	O
at	O
all	O
in	O
the	O
developing	O
eye	O
.	O
At	O
much	O
earlier	O
stages	O
,	O
the	O
expression	O
domain	O
of	O
Shh	S-GP
in	O
the	O
prechordal	O
plate	O
was	O
reduced	O
,	O
as	O
was	O
Nkx2.1	S-GP
and	O
we	O
suggest	O
a	O
model	O
whereby	O
the	O
eye	O
field	O
is	O
specified	O
according	O
to	O
the	O
concentration	O
of	O
SHH	S-GP
protein	O
that	O
is	O
present	O
.	O
We	O
also	O
describe	O
another	O
organ	O
,	O
Rathke	O
's	O
pouch	O
which	O
fails	O
to	O
develop	O
in	O
the	O
absence	O
of	O
retinoic	B-chemical
acid	E-chemical
.	O
We	O
attribute	O
this	O
to	O
the	O
down-regulation	O
of	O
Bmp2	S-GP
,	O
Shh	S-GP
and	O
Fgf8	S-GP
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
induction	O
of	O
this	O
structure	O
.	O

An	O
investigation	O
of	O
the	O
absolute	O
configuration	O
of	O
the	O
potent	O
histamine	B-GP
H3	I-GP
receptor	E-GP
antagonist	O
GT-2331	S-chemical
using	O
vibrational	O
circular	O
dichroism	O
.	O
GT-2331	S-chemical
[	O
(	O
+	O
)	O
-1	O
]	O
is	O
one	O
of	O
the	O
most	O
potent	O
members	O
of	O
a	O
class	O
of	O
chiral	O
drug	O
substances	O
used	O
to	O
regulate	O
the	O
synthesis	O
and	O
release	O
of	O
histamine	S-chemical
by	O
the	O
histamine	B-GP
H3	I-GP
receptor	E-GP
,	O
and	O
as	O
such	O
,	O
is	O
an	O
important	O
biomarker	O
for	O
pharmaceutical	O
companies	O
conducting	O
research	O
in	O
this	O
field	O
.	O
In	O
addition	O
to	O
overall	O
structural	O
features	O
,	O
the	O
bioactivity	O
of	O
this	O
molecule	O
has	O
also	O
been	O
found	O
to	O
be	O
highly	O
dependent	O
on	O
absolute	O
stereochemistry	O
,	O
making	O
the	O
reliable	O
assignment	O
of	O
this	O
property	O
a	O
necessity	O
.	O
X-ray	O
diffraction	O
studies	O
have	O
provided	O
conflicting	O
data	O
,	O
leaving	O
its	O
three-dimensional	O
structure	O
uncertain	O
.	O
In	O
view	O
of	O
this	O
,	O
its	O
absolute	O
configuration	O
was	O
investigated	O
by	O
vibrational	O
circular	O
dichroism	O
.	O
Results	O
from	O
this	O
study	O
provided	O
independent	O
assignment	O
of	O
this	O
important	O
molecule	O
as	O
the	O
(	O
1S,2S	O
)	O
-enantiomer	O
.	O

Measurement	O
of	O
Transport	O
Activities	O
of	O
3β-Hydroxy-Δ	B-chemical
(	I-chemical
5	I-chemical
)	I-chemical
-bile	I-chemical
Acids	E-chemical
in	O
Bile	B-GP
Salt	I-GP
Export	I-GP
Pump	E-GP
and	O
Multidrug	B-GP
Resistance-Associated	I-GP
Proteins	E-GP
Using	O
LC-MS/MS	O
.	O
A	O
method	O
has	O
been	O
developed	O
for	O
the	O
measurement	O
of	O
transport	O
activities	O
in	O
membrane	O
vesicles	O
obtained	O
from	O
Sf9	O
cells	O
for	O
3β-hydroxy-Δ	B-chemical
(	I-chemical
5	I-chemical
)	I-chemical
-bile	I-chemical
acids	E-chemical
by	O
high-performance	O
liquid	O
chromatography-electrospray	O
ionization-tandem	O
mass	O
spectrometry	O
.	O
Calibration	O
curves	O
for	O
the	O
bile	B-chemical
acids	E-chemical
were	O
linear	O
over	O
the	O
range	O
of	O
10	O
to	O
2000	O
pmol/mL	O
,	O
and	O
the	O
detection	O
limit	O
was	O
less	O
than	O
1	O
pmol/mL	O
for	O
3β-hydroxy-Δ	B-chemical
(	I-chemical
5	I-chemical
)	I-chemical
-bile	I-chemical
acids	E-chemical
using	O
selected	O
reaction	O
monitoring	O
analysis	O
.	O
The	O
analytical	O
method	O
was	O
applied	O
to	O
measurements	O
of	O
transport	O
activities	O
in	O
membrane	O
vesicles	O
obtained	O
from	O
human	B-GP
multidrug	I-GP
resistance-associated	I-GP
protein	I-GP
2-	I-GP
,	I-GP
3	E-GP
-	O
,	O
and	O
human	B-GP
bile	I-GP
salt	I-GP
export	I-GP
pump	E-GP
-expressing	O
Sf9	O
cells	O
for	O
conjugated	O
3β-hydroxy-Δ	B-chemical
(	I-chemical
5	I-chemical
)	I-chemical
-bile	I-chemical
acids	E-chemical
.	O
The	O
present	O
study	O
demonstrated	O
that	O
human	B-GP
multidrug	I-GP
resistance-associated	I-GP
protein	I-GP
3	E-GP
vesicles	O
accepted	O
conjugated	O
3β-hydroxy-Δ	B-chemical
(	I-chemical
5	I-chemical
)	I-chemical
-bile	I-chemical
acids	E-chemical
along	O
with	O
common	O
bile	B-chemical
acids	E-chemical
such	O
as	O
glycocholic	B-chemical
acid	E-chemical
and	O
taurolithocholic	B-chemical
acid	I-chemical
3-sulfate	E-chemical
.	O

Nobiletin	S-chemical
attenuates	O
metastasis	O
via	O
both	O
ERK	S-GP
and	O
PI3K	S-GP
/	O
Akt	S-GP
pathways	O
in	O
HGF	S-GP
-treated	O
liver	O
cancer	O
HepG2	O
cells	O
.	O
Hepatocyte	B-GP
growth	I-GP
factor	E-GP
(	O
HGF	S-GP
)	O
,	O
and	O
its	O
receptor	O
,	O
c-Met	S-GP
activation	O
has	O
recently	O
been	O
shown	O
to	O
play	O
important	O
roles	O
in	O
cancer	O
invasion	O
and	O
metastasis	O
in	O
a	O
wide	O
variety	O
of	O
tumor	O
cells	O
.	O
We	O
use	O
HGF	S-GP
as	O
an	O
invasive	O
inducer	O
of	O
human	O
HepG2	O
cells	O
to	O
investigate	O
the	O
effect	O
of	O
four	O
flavones	O
including	O
apigenin	S-chemical
,	O
tricetin	S-chemical
,	O
tangeretin	S-chemical
,	O
and	O
nobiletin	S-chemical
on	O
HGF	S-GP
/	O
c-Met	S-GP
-mediated	O
tumor	O
invasion	O
and	O
metastasis	O
.	O
Among	O
them	O
,	O
nobiletin	S-chemical
markedly	O
inhibited	O
HGF	S-GP
-induced	O
the	O
abilities	O
of	O
the	O
adhesion	O
,	O
invasion	O
,	O
and	O
migration	O
by	O
cell-matrix	O
adhesion	O
assay	O
and	O
transwell-chamber	O
invasion/migration	O
assay	O
under	O
non-cytotoxic	O
concentrations	O
.	O
Data	O
also	O
showed	O
nobiletin	S-chemical
inhibited	O
HGF	S-GP
-induced	O
cell	O
scattering	O
and	O
cytoskeleton	O
changed	O
such	O
as	O
filopodia	O
and	O
lamellipodia	O
.	O
Furthermore	O
,	O
nobiletin	S-chemical
could	O
inhibit	O
HGF	S-GP
-induced	O
the	O
membrane	O
localization	O
of	O
phosphorylated	O
c-Met	S-GP
,	O
ERK2	S-GP
,	O
and	O
Akt	S-GP
,	O
but	O
not	O
phosphorylated	B-GP
JNK1/2	E-GP
and	O
p38	S-GP
.	O
Next	O
,	O
nobiletin	S-chemical
significantly	O
decreased	O
the	O
levels	O
of	O
phospho-ERK2	S-GP
and	O
phospho-Akt	S-GP
in	O
ERK2	S-GP
or	O
Akt	S-GP
siRNA-transfected	O
cells	O
concomitantly	O
with	O
a	O
marked	O
reduction	O
on	O
cell	O
invasion	O
and	O
migration	O
.	O
In	O
conclusion	O
,	O
nobiletin	S-chemical
attenuates	O
HGF	S-GP
-induced	O
HepG2	O
cells	O
metastasis	O
involving	O
both	O
ERK	S-GP
and	O
PI3K	S-GP
/	O
Akt	S-GP
pathways	O
and	O
are	O
potentially	O
useful	O
as	O
anti-metastatic	O
agents	O
for	O
the	O
treatment	O
of	O
hepatoma	O
.	O

Phenformin	S-chemical
has	O
a	O
direct	O
inhibitory	O
effect	O
on	O
the	O
ATP-sensitive	B-GP
potassium	I-GP
channel	E-GP
.	O
The	O
biguanides	S-chemical
,	O
phenformin	S-chemical
and	O
metformin	S-chemical
,	O
are	O
used	O
in	O
the	O
treatment	O
of	O
type	O
II	O
diabetes	O
mellitus	O
,	O
as	O
well	O
as	O
being	O
routinely	O
used	O
in	O
studies	O
investigating	O
AMPK	S-GP
activity	O
.	O
We	O
used	O
the	O
patch-clamp	O
technique	O
and	O
rubidium	S-chemical
flux	O
assays	O
to	O
determine	O
the	O
role	O
of	O
these	O
drugs	O
in	O
ATP-sensitive	B-GP
K+	I-GP
channel	E-GP
(	O
K	B-GP
(	I-GP
ATP	I-GP
)	E-GP
)	O
regulation	O
in	O
cell	O
lines	O
expressing	O
the	O
cloned	O
components	O
of	O
K	B-GP
(	I-GP
ATP	I-GP
)	E-GP
and	O
the	O
current	O
natively	O
expressed	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
.	O
Phenformin	S-chemical
but	O
not	O
metformin	S-chemical
inhibits	O
a	O
number	O
of	O
variants	O
of	O
K	B-GP
(	I-GP
ATP	I-GP
)	E-GP
including	O
the	O
cloned	O
equivalents	O
of	O
currents	O
present	O
in	O
vascular	O
and	O
non-vascular	O
smooth	O
muscle	O
(	O
Kir6.1	S-GP
/	O
SUR2B	S-GP
and	O
Kir6.2	S-GP
/	O
SUR2B	S-GP
)	O
and	O
pancreatic	O
beta-cells	O
(	O
Kir6.2	S-GP
/	O
SUR1	S-GP
)	O
.	O
However	O
it	O
does	O
not	O
inhibit	O
the	O
current	O
potentially	O
present	O
in	O
cardiac	O
myocytes	O
(	O
Kir6.2	S-GP
/	O
SUR2A	S-GP
)	O
.	O
The	O
highest	O
affinity	O
interaction	O
is	O
seen	O
with	O
Kir6.1	S-GP
/	O
SUR2B	S-GP
(	O
IC50=0.55	O
mM	O
)	O
and	O
it	O
also	O
inhibits	O
the	O
current	O
in	O
native	O
vascular	O
smooth	O
muscle	O
cells	O
.	O
The	O
extent	O
and	O
rate	O
of	O
inhibition	O
are	O
similar	O
to	O
that	O
seen	O
with	O
the	O
known	O
K	B-GP
(	I-GP
ATP	I-GP
)	E-GP
blocker	O
PNU	B-chemical
37883A	E-chemical
.	O
Additionally	O
,	O
phenformin	S-chemical
inhibited	O
the	O
current	O
elicited	O
through	O
the	O
Kir6.2DeltaC26	S-GP
(	O
functional	O
without	O
SUR	S-GP
)	O
channel	O
with	O
an	O
IC50	O
of	O
1.78	O
mM	O
.	O
Phenformin	S-chemical
reduced	O
the	O
open	O
probability	O
of	O
Kir6.1	S-GP
/	O
SUR2B	S-GP
channels	O
by	O
approximately	O
90	O
%	O
in	O
inside-out	O
patches	O
.	O
These	O
findings	O
suggest	O
that	O
phenformin	S-chemical
interacts	O
directly	O
with	O
the	O
pore-forming	O
Kir6.0	S-GP
subunit	O
however	O
the	O
sulphonylurea	B-GP
receptor	E-GP
is	O
able	O
to	O
significantly	O
modulate	O
the	O
affinity	O
.	O
It	O
is	O
likely	O
to	O
block	O
from	O
the	O
intracellular	O
side	O
of	O
the	O
channel	O
in	O
a	O
manner	O
analogous	O
to	O
that	O
of	O
PNU	B-chemical
37883A	E-chemical
.	O

ABCA12	S-GP
is	O
the	O
major	O
harlequin	O
ichthyosis	O
gene	O
.	O
Harlequin	O
ichthyosis	O
(	O
HI	O
)	O
is	O
the	O
most	O
severe	O
form	O
of	O
autosomal-recessive	O
,	O
congenital	O
ichthyosis	O
.	O
Affected	O
infants	O
have	O
markedly	O
impaired	O
barrier	O
function	O
and	O
are	O
more	O
susceptible	O
to	O
infection	O
.	O
Abnormalities	O
in	O
the	O
localization	O
of	O
epidermal	O
lipids	O
as	O
well	O
as	O
abnormal	O
lamellar	O
granule	O
formation	O
are	O
features	O
of	O
HI	O
skin	O
.	O
Previously	O
,	O
we	O
and	O
others	O
have	O
shown	O
that	O
mutations	O
in	O
the	O
ABCA12	S-GP
gene	O
encoding	O
an	O
adenosine	B-GP
triphosphate-binding	I-GP
cassette	I-GP
(	I-GP
ABC	I-GP
)	I-GP
transporter	E-GP
underlie	O
the	O
skin	O
disease	O
HI	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
sequenced	O
the	O
ABCA12	S-GP
gene	O
in	O
an	O
additional	O
14	O
patients	O
and	O
show	O
that	O
all	O
contain	O
mutations	O
,	O
with	O
the	O
majority	O
being	O
either	O
nonsense	O
substitution	O
or	O
frameshift	O
mutations	O
.	O
Eleven	O
HI	O
patients	O
had	O
bi-allelic	O
ABCA12	S-GP
mutations	O
,	O
whereas	O
in	O
the	O
remaining	O
three	O
HI	O
patients	O
in	O
this	O
study	O
,	O
ABCA12	S-GP
mutations	O
were	O
detected	O
on	O
only	O
one	O
allele	O
by	O
sequencing	O
.	O
In	O
addition	O
,	O
the	O
one	O
patient	O
from	O
the	O
previous	O
study	O
where	O
no	O
sequence	O
mutations	O
were	O
detected	O
was	O
screened	O
for	O
heterozygous	O
deletions	O
.	O
A	O
combination	O
of	O
oligo	O
nucleotide	S-chemical
arrays	O
,	O
multiplex	O
PCR	O
analysis	O
and	O
single-nucleotide	O
polymorphism	O
genotyping	O
revealed	O
a	O
heterozygous	O
intragenic	O
deletion	O
in	O
exon	O
8	O
.	O
These	O
mutation	O
data	O
establish	O
ABCA12	S-GP
as	O
the	O
major	O
HI	O
gene	O
.	O

Assessment	O
of	O
developmental	O
delay	O
in	O
the	O
zebrafish	O
embryo	O
teratogenicity	O
assay	O
.	O
In	O
this	O
study	O
we	O
analyzed	O
some	O
aspects	O
of	O
the	O
assessment	O
of	O
developmental	O
delay	O
in	O
the	O
zebrafish	O
embryotoxicity/teratogenicity	O
test	O
and	O
explored	O
the	O
suitability	O
of	O
acetylcholinesterase	S-GP
(	O
AChE	S-GP
)	O
activity	O
as	O
a	O
biochemical	O
marker	O
and	O
as	O
a	O
higher	O
throughput	O
alternative	O
to	O
morphological	O
endpoints	O
such	O
as	O
head-trunk	O
angle	O
,	O
tail	O
length	O
and	O
morphological	O
score	O
.	O
Embryos	O
were	O
exposed	O
from	O
4	O
to	O
52	O
h	O
post-fertilization	O
(	O
hpf	O
)	O
to	O
a	O
selection	O
of	O
known	O
embryotoxic/teratogen	O
compounds	O
(	O
valproic	B-chemical
acid	E-chemical
,	O
retinoic	B-chemical
acid	E-chemical
,	O
caffeine	S-chemical
,	O
sodium	B-chemical
salicylate	E-chemical
,	O
glucose	S-chemical
,	O
hydroxyurea	S-chemical
,	O
methoxyacetic	B-chemical
acid	E-chemical
,	O
boric	B-chemical
acid	E-chemical
and	O
paraoxon-methyl	S-chemical
)	O
over	O
a	O
concentration	O
range	O
.	O
They	O
were	O
evaluated	O
for	O
AChE	S-GP
activity	O
,	O
head-trunk	O
angle	O
,	O
tail	O
length	O
and	O
several	O
qualitative	O
parameters	O
integrated	O
in	O
a	O
morphological	O
score	O
.	O
In	O
general	O
,	O
the	O
different	O
patterns	O
of	O
the	O
concentration-response	O
curves	O
allowed	O
distinguishing	O
between	O
chemicals	O
that	O
produced	O
growth	O
retardation	O
(	O
valproic	B-chemical
and	I-chemical
methoxyacetic	I-chemical
acid	E-chemical
)	O
and	O
chemicals	O
that	O
produced	O
non-growth-delay	O
related	O
malformations	O
.	O
An	O
acceptable	O
correlation	O
between	O
the	O
morphological	O
score	O
,	O
AChE	S-GP
activity	O
and	O
head-trunk	O
angle	O
as	O
markers	O
of	O
developmental	O
delay	O
was	O
observed	O
,	O
being	O
AChE	S-GP
activity	O
particularly	O
sensitive	O
to	O
detect	O
delay	O
in	O
the	O
absence	O
of	O
malformations	O
.	O

Binding	O
of	O
thalidomide	S-chemical
to	O
alpha1-acid	B-GP
glycoprotein	E-GP
may	O
be	O
involved	O
in	O
its	O
inhibition	O
of	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
alpha	E-GP
production	O
.	O
In	O
addition	O
to	O
its	O
well	O
known	O
sedative	O
and	O
teratogenic	O
effects	O
,	O
thalidomide	S-chemical
also	O
possesses	O
potent	O
immunomodulatory	O
and	O
antiinflammatory	O
activities	O
,	O
being	O
most	O
effective	O
against	O
leprosy	O
and	O
chronic	O
graft-versus-host	O
disease	O
.	O
The	O
immunomodulatory	O
activity	O
of	O
thalidomide	O
has	O
been	O
ascribed	O
to	O
the	O
selective	O
inhibition	O
of	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
alpha	E-GP
from	O
monocytes	O
.	O
The	O
molecular	O
mechanism	O
for	O
the	O
immunomodulatory	O
effect	O
of	O
thalidomide	S-chemical
remains	O
unknown	O
.	O
To	O
elucidate	O
this	O
mechanism	O
,	O
we	O
synthesized	O
an	O
active	O
photoaffinity	O
label	O
of	O
thalidomide	S-chemical
as	O
a	O
probe	O
to	O
identify	O
the	O
molecular	O
target	O
of	O
the	O
drug	O
.	O
Using	O
the	O
probe	O
,	O
we	O
specifically	O
labeled	O
a	O
pair	O
of	O
proteins	O
of	O
43-45	O
kDa	O
with	O
high	O
acidity	O
from	O
bovine	O
thymus	O
extract	O
.	O
Purification	O
of	O
these	O
proteins	O
and	O
partial	O
peptide	O
sequence	O
determination	O
revealed	O
them	O
to	O
be	O
alpha1-acid	B-GP
glycoprotein	E-GP
(	O
AGP	S-GP
)	O
.	O
We	O
show	O
that	O
the	O
binding	O
of	O
thalidomide	S-chemical
photoaffinity	O
label	O
to	O
authentic	O
human	B-GP
AGP	E-GP
is	O
competed	O
with	O
both	O
thalidomide	S-chemical
and	O
the	O
nonradioactive	O
photoaffinity	O
label	O
at	O
concentrations	O
comparable	O
to	O
those	O
required	O
for	O
inhibition	O
of	O
production	O
of	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
alpha	E-GP
from	O
human	O
monocytes	O
,	O
suggesting	O
that	O
AGP	S-GP
may	O
be	O
involved	O
in	O
the	O
immunomodulatory	O
activity	O
of	O
thalidomide	S-chemical
.	O

Silica	S-chemical
precipitation	O
by	O
synthetic	O
minicollagens	O
.	O
Oligomeric	O
Pro-Hyp-Gly	S-chemical
-	O
(	O
POG-	O
)	O
peptides	O
,	O
wherein	O
the	O
collagenous	B-GP
triple	I-GP
helix	E-GP
is	O
supported	O
by	O
C	S-chemical
-terminal	O
capping	O
,	O
exhibit	O
silica	S-chemical
precipitation	O
properties	O
(	O
O	O
,	O
Hyp	S-chemical
=	O
(	B-chemical
2S,4R	I-chemical
)	I-chemical
hydroxyproline	E-chemical
)	O
.	O
As	O
quantified	O
by	O
a	O
molybdate	O
assay	O
,	O
the	O
length	O
of	O
the	O
covalently	O
tethered	O
triple	B-GP
helix	E-GP
(	O
number	O
of	O
POG	O
units	O
)	O
determines	O
the	O
amount	O
of	O
amorphous	O
silica	S-chemical
obtained	O
from	O
silicic	B-chemical
acid	E-chemical
solution	O
.	O
Although	O
lacking	O
charged	O
side	O
chains	O
,	O
the	O
synthetic	O
collagens	S-GP
precipitate	O
large	O
quantities	O
of	O
silicic	B-chemical
acid	E-chemical
resulting	O
in	O
micrometer-sized	O
spheres	O
of	O
varying	O
surface	O
morphologies	O
as	O
analyzed	O
by	O
scanning	O
electron	O
microscopy	O
.	O
Similar	O
precipitation	O
efficiencies	O
on	O
a	O
fast	O
time	O
scale	O
of	O
less	O
than	O
10	O
min	O
were	O
previously	O
described	O
only	O
for	O
biogenic	O
diatom	O
proteins	O
and	O
sponge	B-GP
collagen	E-GP
,	O
respectively	O
,	O
which	O
have	O
a	O
considerably	O
higher	O
structural	O
complexity	O
and	O
limited	O
accessibility	O
.	O
The	O
minicollagens	O
described	O
here	O
provide	O
an	O
unexpected	O
alternative	O
to	O
the	O
widely	O
used	O
precipitation	O
conditions	O
,	O
which	O
generally	O
depend	O
on	O
(	B-chemical
poly-	I-chemical
)	I-chemical
amines	E-chemical
in	O
phosphate	S-chemical
buffer	O
.	O
Collagen	S-GP
can	O
form	O
intimate	O
connections	O
with	O
inorganic	O
matter	O
.	O
Hence	O
,	O
silica	S-chemical
-enclosed	O
collagens	S-GP
have	O
promising	O
perspectives	O
as	O
composite	O
materials	O
.	O

Molecular	O
analyses	O
of	O
dinosaur	O
osteocytes	O
support	O
the	O
presence	O
of	O
endogenous	O
molecules	O
.	O
The	O
discovery	O
of	O
soft	O
,	O
transparent	O
microstructures	O
in	O
dinosaur	O
bone	O
consistent	O
in	O
morphology	O
with	O
osteocytes	O
was	O
controversial	O
.	O
We	O
hypothesize	O
that	O
,	O
if	O
original	O
,	O
these	O
microstructures	O
will	O
have	O
molecular	O
features	O
in	O
common	O
with	O
extant	O
osteocytes	O
.	O
We	O
present	O
immunological	O
and	O
mass	O
spectrometry	O
evidence	O
for	O
preservation	O
of	O
proteins	O
comprising	O
extant	O
osteocytes	O
(	O
Actin	S-GP
,	O
Tubulin	S-GP
,	O
PHEX	S-GP
,	O
Histone	B-GP
H4	E-GP
)	O
in	O
osteocytes	O
recovered	O
from	O
two	O
non-avian	O
dinosaurs	O
.	O
Furthermore	O
,	O
antibodies	O
to	O
DNA	O
show	O
localized	O
binding	O
to	O
these	O
microstructures	O
,	O
which	O
also	O
react	O
positively	O
with	O
DNA	O
intercalating	O
stains	O
propidium	B-chemical
iodide	E-chemical
(	O
PI	O
)	O
and	O
4',6'-diamidino-2-phenylindole	B-chemical
dihydrochloride	E-chemical
(	O
DAPI	S-chemical
)	O
.	O
Each	O
antibody	O
binds	O
dinosaur	O
cells	O
in	O
patterns	O
similar	O
to	O
extant	O
cells	O
.	O
These	O
data	O
are	O
the	O
first	O
to	O
support	O
preservation	O
of	O
multiple	O
proteins	O
and	O
to	O
present	O
multiple	O
lines	O
of	O
evidence	O
for	O
material	O
consistent	O
with	O
DNA	O
in	O
dinosaurs	O
,	O
supporting	O
the	O
hypothesis	O
that	O
these	O
structures	O
were	O
part	O
of	O
the	O
once	O
living	O
animals	O
.	O
We	O
propose	O
mechanisms	O
for	O
preservation	O
of	O
cells	O
and	O
component	O
molecules	O
,	O
and	O
discuss	O
implications	O
for	O
dinosaurian	O
cellular	O
biology	O
.	O

Glucagon	S-GP
-induced	O
acetylation	O
of	O
Foxa2	S-GP
regulates	O
hepatic	O
lipid	O
metabolism	O
.	O
Circulating	O
levels	O
of	O
insulin	S-GP
and	O
glucagon	S-GP
reflect	O
the	O
nutritional	O
state	O
of	O
animals	O
and	O
elicit	O
regulatory	O
responses	O
in	O
the	O
liver	O
that	O
maintain	O
glucose	S-chemical
and	O
lipid	O
homeostasis	O
.	O
The	O
transcription	O
factor	O
Foxa2	S-GP
activates	O
lipid	O
metabolism	O
and	O
ketogenesis	O
during	O
fasting	O
and	O
is	O
inhibited	O
via	O
insulin	S-GP
-	O
PI3K	S-GP
-	O
Akt	S-GP
signaling-mediated	O
phosphorylation	O
at	O
Thr156	O
and	O
nuclear	O
exclusion	O
.	O
Here	O
we	O
show	O
that	O
,	O
in	O
addition	O
,	O
Foxa2	S-GP
is	O
acetylated	O
at	O
the	O
conserved	O
residue	O
Lys259	O
following	O
inhibition	O
of	O
histone	B-GP
deacetylases	I-GP
(	I-GP
HDACs	I-GP
)	I-GP
class	I-GP
I-III	E-GP
and	O
the	O
cofactors	O
p300	S-GP
and	O
SirT1	S-GP
are	O
involved	O
in	O
Foxa2	S-GP
acetylation	O
and	O
deacetylation	O
,	O
respectively	O
.	O
Physiologically	O
,	O
fasting	O
states	O
and	O
glucagon	S-GP
stimulation	O
are	O
sufficient	O
to	O
induce	O
Foxa2	S-GP
acetylation	O
.	O
Introduction	O
of	O
the	O
acetylation-mimicking	O
(	O
K259Q	S-GP
)	O
or	O
-deficient	O
(	O
K259R	S-GP
)	O
mutations	O
promotes	O
or	O
inhibits	O
Foxa2	S-GP
activity	O
,	O
respectively	O
,	O
and	O
adenoviral	O
expression	O
of	O
Foxa2	S-GP
-	O
K259Q	S-GP
augments	O
expression	O
of	O
genes	O
involved	O
in	O
fatty	B-chemical
acid	E-chemical
oxidation	O
and	O
ketogenesis	O
.	O
Our	O
study	O
reveals	O
a	O
molecular	O
mechanism	O
by	O
which	O
glucagon	S-GP
signaling	O
activates	O
a	O
fasting	O
response	O
through	O
acetylation	O
of	O
Foxa2	S-GP
.	O

Blockade	O
of	O
LTC4	S-chemical
synthesis	O
caused	O
by	O
additive	O
inhibition	O
of	O
gIV-PLA2	S-GP
phosphorylation	O
:	O
Effect	O
of	O
salmeterol	S-chemical
and	O
PDE4	S-chemical
inhibition	O
in	O
human	O
eosinophils	O
.	O
BACKGROUND	O
:	O
Prior	O
investigations	O
have	O
demonstrated	O
that	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenoceptor	E-GP
stimulation	O
is	O
ineffective	O
in	O
inhibiting	O
synthesis	O
of	O
eicosanoids	O
in	O
human	O
eosinophils	O
.	O
This	O
effect	O
has	O
been	O
postulated	O
to	O
relate	O
to	O
density	O
or	O
structural	O
differences	O
in	O
the	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenoceptor	E-GP
or	O
its	O
coupled	O
G-protein	S-GP
.	O
However	O
,	O
recent	O
reports	O
indicate	O
that	O
cAMP-specific	B-GP
PDE4	E-GP
activity	O
in	O
eosinophils	O
is	O
10-fold	O
that	O
of	O
other	O
inflammatory	O
cells	O
.	O
We	O
postulated	O
that	O
selective	O
blockade	O
of	O
PDE4	S-chemical
in	O
eosinophils	O
would	O
unmask	O
the	O
inhibitory	O
effect	O
of	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenoceptor	E-GP
stimulation	O
and	O
that	O
this	O
inhibition	O
would	O
result	O
from	O
decreased	O
phosphor-ylation	O
of	O
cytosolic	B-GP
group	I-GP
IV-PLA	I-GP
(	I-GP
2	I-GP
)	E-GP
(	O
gIV-PLA	B-GP
(	I-GP
2	I-GP
)	E-GP
)	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
(	O
a	O
)	O
whether	O
PDE4	S-chemical
inhibition	O
alone	O
with	O
rolipram	S-chemical
blocked	O
secretions	O
of	O
arachidonic	B-chemical
acid	E-chemical
(	O
AA	S-chemical
)	O
and	O
leukotriene	B-chemical
C	I-chemical
(	I-chemical
4	I-chemical
)	E-chemical
(	O
LTC	B-chemical
(	I-chemical
4	I-chemical
)	E-chemical
)	O
caused	O
by	O
activation	O
of	O
eosinophils	O
with	O
formyl-met-leu-phe	S-chemical
plus	O
cytochalasin	B-chemical
B	E-chemical
(	O
FMLP/B	O
)	O
,	O
(	O
b	O
)	O
to	O
determine	O
if	O
PDE4	S-chemical
inhibition	O
plus	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenoceptor	E-GP
agonist	O
act	O
additively	O
to	O
augment	O
endogenous	O
cAMP	S-chemical
concentration	O
,	O
and	O
(	O
c	O
)	O
to	O
determine	O
the	O
mechanism	O
by	O
which	O
additive	O
inhibition	O
of	O
AA	S-chemical
and	O
LTC	B-chemical
(	I-chemical
4	I-chemical
)	E-chemical
synthesis	O
is	O
regulated	O
by	O
cAMP	S-chemical
.	O
METHODS	O
:	O
Human	O
eosinophils	O
were	O
pretreated	O
with	O
buffer	O
,	O
salmeterol	S-chemical
or	O
rolipram	S-chemical
(	O
singly	O
or	O
combination	O
)	O
before	O
FMLP/B	O
activation	O
.	O
Release	O
of	O
AA	S-chemical
and	O
LTC	B-chemical
(	I-chemical
4	I-chemical
)	E-chemical
,	O
intracellular	O
cAMP	S-chemical
concentration	O
,	O
and	O
phosphorylation	O
and	O
activation	O
of	O
gIV-PLA	B-GP
(	I-GP
2	I-GP
)	E-GP
were	O
determined	O
.	O
RESULTS	O
:	O
Rolipram	S-chemical
unmasked	O
the	O
inhibitory	O
effect	O
of	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenoceptor	E-GP
stimulation	O
with	O
salmeterol	S-chemical
and	O
significantly	O
attenuated	O
the	O
stimulated	O
release	O
of	O
AA	S-chemical
and	O
subsequent	O
LTC	B-chemical
(	I-chemical
4	I-chemical
)	E-chemical
.	O
Inhibition	O
corresponded	O
to	O
increased	O
cAMP	S-chemical
production	O
caused	O
by	O
rolipram	S-chemical
alone	O
or	O
rolipram	S-chemical
plus	O
salmeterol	S-chemical
and	O
blocked	O
proportionately	O
the	O
phosphorylation	O
and	O
activation	O
of	O
gIV-PLA	B-GP
(	I-GP
2	I-GP
)	E-GP
in	O
FMLP/B-activated	O
eosinophils	O
.	O
CONCLUSIONS	O
:	O
Inhibition	O
of	O
PDE4	S-chemical
by	O
rolipram	S-chemical
unmasks	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenergic	E-GP
blockade	O
of	O
LTC	B-chemical
(	I-chemical
4	I-chemical
)	E-chemical
synthesis	O
caused	O
by	O
FMLP/B	O
.	O

GnRH	S-chemical
pulse	O
frequency-dependent	O
stimulation	O
of	O
FSHβ	O
transcription	O
is	O
mediated	O
via	O
activation	O
of	O
PKA	O
and	O
CREB	O
.	O
Expression	O
of	O
pituitary	O
FSH	O
and	O
LH	O
,	O
under	O
the	O
control	O
of	O
pulsatile	O
GnRH	S-GP
,	O
is	O
essential	O
for	O
fertility	O
.	O
cAMP	O
response	O
element-binding	O
protein	O
(	O
CREB	O
)	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
FSHβ	S-GP
gene	O
expression	O
,	O
but	O
the	O
molecular	O
mechanisms	O
by	O
which	O
pulsatile	O
GnRH	O
regulates	O
CREB	O
activation	O
remain	O
poorly	O
understood	O
.	O
We	O
hypothesized	O
that	O
CREB	O
is	O
activated	O
by	O
a	O
distinct	O
signaling	O
pathway	O
in	O
response	O
to	O
pulsatile	O
GnRH	O
in	O
a	O
frequency-dependent	O
manner	O
to	O
dictate	O
the	O
FSHβ	O
transcriptional	O
response	O
.	O
GnRH	O
stimulation	O
of	O
CREB	O
phosphorylation	O
(	O
pCREB	O
)	O
in	O
the	O
gonadotrope-derived	O
LβT2	O
cell	O
line	O
was	O
attenuated	O
by	O
a	O
protein	O
kinase	O
A	O
(	O
PKA	S-GP
)	O
inhibitor	O
,	O
H89	O
.	O
A	O
dominant	O
negative	O
PKA	O
(	O
DNPKA	O
)	O
reduced	O
GnRH-stimulated	O
p	O
CREB	S-GP
and	O
markedly	O
decreased	O
GnRH	O
stimulation	O
of	O
FSH	S-GP
β	O
mRNA	O
and	O
FSHβLUC	O
activity	O
,	O
but	O
had	O
little	O
effect	O
on	O
LH	S-GP
βLUC	O
activity	O
,	O
indicating	O
relative	O
specificity	O
of	O
this	O
pathway	O
.	O
In	O
perifusion	O
studies	O
,	O
FSHβ	O
mRNA	O
levels	O
and	O
FSHβLUC	O
activities	O
were	O
increased	O
by	O
pulsatile	O
GnRH	S-chemical

The	O
CRF	B-GP
(	I-GP
1	I-GP
)	I-GP
receptor	E-GP
antagonist	O
SSR125543	S-chemical
prevents	O
stress-induced	O
cognitive	O
deficit	O
associated	O
with	O
hippocampal	O
dysfunction	O
:	O
Comparison	O
with	O
paroxetine	S-chemical
and	O
D-cycloserine	S-chemical
.	O
RATIONALE	O
:	O
The	O
selective	O
CRF	B-GP
(	I-GP
1	I-GP
)	I-GP
(	I-GP
corticotropin	I-GP
releasing	I-GP
factor	I-GP
type	I-GP
1	I-GP
)	I-GP
receptor	E-GP
antagonist	O
SSR125543	S-chemical
has	O
been	O
previously	O
shown	O
to	O
attenuate	O
the	O
long-term	O
cognitive	O
deficit	O
produced	O
by	O
traumatic	O
stress	O
exposure	O
.	O
Memory	O
disturbances	O
described	O
in	O
post-traumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
patients	O
are	O
believed	O
to	O
be	O
associated	O
with	O
changes	O
in	O
neuronal	O
activity	O
,	O
in	O
particular	O
at	O
the	O
level	O
of	O
the	O
hippocampus	O
.	O
OBJECTIVES	O
:	O
The	O
present	O
study	O
aims	O
at	O
investigating	O
whether	O
the	O
effects	O
of	O
SSR125543	S-chemical
(	O
10	O
mg/kg/day	O
for	O
2	O
weeks	O
)	O
on	O
cognitive	O
impairment	O
induced	O
by	O
traumatic	O
stress	O
exposure	O
are	O
associated	O
with	O
changes	O
in	O
hippocampal	O
excitability	O
.	O
Effects	O
of	O
SSR125543	S-chemical
were	O
compared	O
to	O
those	O
of	O
the	O
5-HT	S-chemical
reuptake	O
inhibitor	O
,	O
paroxetine	S-chemical
(	O
10	O
mg/kg/day	O
)	O
,	O
and	O
the	O
partial	O
N-methyl-D-aspartate	B-GP
(	I-GP
NMDA	I-GP
)	I-GP
receptor	E-GP
agonist	O
,	O
D-cycloserine	S-chemical
(	O
10	O
mg/kg/day	O
)	O
,	O
two	O
compounds	O
which	O
have	O
demonstrated	O
clinical	O
efficacy	O
against	O
PTSD	O
.	O
METHODS	O
:	O
Mice	O
received	O
two	O
unavoidable	O
electric	O
foot-shocks	O
.	O
Then	O
,	O
1	O
or	O
16	O
days	O
after	O
stress	O
,	O
they	O
were	O
tested	O
for	O
their	O
memory	O
performance	O
using	O
the	O
object	O
recognition	O
test	O
.	O
Neuronal	O
excitability	O
was	O
recorded	O
during	O
the	O
third	O
week	O
post-stress	O
in	O
the	O
CA1	O
area	O
of	O
the	O
hippocampus	O
.	O
Drugs	O
were	O
administered	O
from	O
day	O
1	O
post-stress	O
to	O
the	O
day	O
preceding	O
the	O
electrophysiological	O
study	O
.	O
RESULTS	O
:	O
Application	O
of	O
electric	O
shocks	O
produced	O
cognitive	O
impairment	O
16	O
,	O
but	O
not	O
1	O
day	O
after	O
stress	O
,	O
an	O
effect	O
which	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
hippocampal	O
neuronal	O
excitability	O
.	O
Both	O
stress-induced	O
effects	O
were	O
prevented	O
by	O
repeated	O
administration	O
of	O
SSR125543	S-chemical
,	O
paroxetine	S-chemical
and	O
D-cycloserine	S-chemical
.	O
CONCLUSIONS	O
:	O
These	O
findings	O
confirm	O
that	O
the	O
CRF	B-GP
(	I-GP
1	I-GP
)	I-GP
receptor	E-GP
antagonist	O
SSR125543	S-chemical
is	O
able	O
to	O
attenuate	O
the	O
behavioral	O
effects	O
of	O
traumatic	O
stress	O
exposure	O
and	O
indicate	O
that	O
these	O
effects	O
are	O
associated	O
with	O
a	O
normalization	O
of	O
hippocampal	O
neuronal	O
excitability	O
impaired	O
by	O
stress	O
.	O

Green	O
tea	O
catechin	S-chemical
leads	O
to	O
global	O
improvement	O
among	O
Alzheimer	O
's	O
disease-related	O
phenotypes	O
in	O
NSE	S-GP
/	O
hAPP	S-GP
-	O
C105	S-GP
Tg	O
mice	O
.	O
Amyloid	B-GP
β	E-GP
(	O
Αβ	S-GP
)	O
has	O
been	O
reported	O
to	O
be	O
responsible	O
for	O
the	O
functional	O
and	O
structural	O
abnormalities	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
through	O
the	O
induction	O
of	O
oxidative	O
stress	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
or	O
not	O
treatment	O
of	O
transgenic	O
(	O
Tg	O
)	O
mice	O
with	O
green	O
tea	O
catechin	S-chemical
(	O
GTC	O
)	O
,	O
a	O
radical	O
scavenger	O
,	O
improves	O
AD	O
phenotypes	O
.	O
To	O
test	O
this	O
,	O
7-month-old	O
Tg	O
mice	O
were	O
treated	O
with	O
a	O
low	O
(	O
1	O
mg	O
)	O
or	O
high	O
(	O
10	O
mg	O
)	O
dose	O
of	O
GTC	O
for	O
6	O
months	O
.	O
Surprisingly	O
,	O
GTC-treated	O
Tg	O
mice	O
exhibited	O
significant	O
decreases	O
in	O
behavioral	O
impairment	O
,	O
Aβ-42	S-GP
production	O
,	O
APP	S-GP
-	O
C99/89	S-GP
expression	O
,	O
γ-secretase	S-GP
component	O
and	O
Wnt	S-GP
protein	O
levels	O
,	O
γ-secretase	S-GP
activity	O
and	O
MAPK	S-GP
activation	O
.	O
In	O
contrast	O
,	O
the	O
levels	O
of	O
APP	S-GP
-	O
C83	S-GP
protein	O
and	O
enzyme	O
activities	O
(	O
α-secretase	S-GP
,	O
neprilysin	S-GP
and	O
Pin1	S-GP
)	O
were	O
elevated	O
in	O
the	O
GTC-treated	O
groups	O
.	O
Moreover	O
,	O
GTC-treated	O
groups	O
showed	O
lower	O
levels	O
of	O
total	O
cholesterol	S-chemical
and	O
low-density	B-GP
lipoprotein	E-GP
cholesterol	S-chemical
,	O
whereas	O
the	O
level	O
of	O
high-density	B-GP
lipoprotein	E-GP
cholesterol	S-chemical
increased	O
.	O
These	O
results	O
provide	O
the	O
first	O
experimental	O
evidence	O
that	O
GTC	O
improves	O
AD	O
phenotypes	O
,	O
thereby	O
suggesting	O
that	O
GTC	O
can	O
be	O
used	O
in	O
the	O
prevention	O
of	O
AD	O
or	O
treatment	O
of	O
AD	O
patients	O
.	O

A	O
heterozygote	O
phenotype	O
is	O
present	O
in	O
the	O
jvs	O
+/-	O
mutant	O
mouse	O
livers	O
.	O
The	O
juvenile	O
visceral	O
steatosis	O
(	O
jvs	O
)	O
mouse	O
,	O
having	O
a	O
mutation	O
in	O
the	O
carnitine	S-chemical
transporter	O
gene	O
Octn2	S-GP
,	O
is	O
a	O
model	O
of	O
primary	O
systemic	O
carnitine	S-chemical
deficiency	O
in	O
humans	O
(	O
SCD	O
,	O
OMIM	O
212140	O
)	O
.	O
Like	O
humans	O
with	O
SCD	O
,	O
homozygous	O
jvs	O
-/-	O
mice	O
have	O
hepatic	O
and	O
cardiac	O
steatoses	O
,	O
reduced	O
plasma	O
and	O
tissue	O
carnitines	S-chemical
,	O
and	O
increased	O
urinary	O
carnitine	S-chemical
clearance	O
.	O
Because	O
symptomatic	O
heterozygotes	O
have	O
been	O
reported	O
for	O
some	O
fatty	B-chemical
acid	E-chemical
oxidation	O
disorders	O
,	O
including	O
SCD	O
,	O
we	O
compared	O
the	O
jvs	O
heterozygotes	O
to	O
normal	O
control	O
mice	O
.	O
We	O
measured	O
the	O
free	O
and	O
esterified	O
carnitine	S-chemical
,	O
total	O
cholesterol	S-chemical
,	O
and	O
triglycerides	S-chemical
in	O
adult	O
liver	O
samples	O
,	O
myocardium	O
,	O
and	O
skeletal	O
muscle	O
.	O
Our	O
results	O
indicate	O
significant	O
differences	O
between	O
the	O
livers	O
of	O
nonfasting	O
adult	O
normal	O
(	O
n	O
=	O
8	O
)	O
vs	O
jvs	O
heterozygotes	O
(	O
n	O
=	O
8	O
)	O
(	O
means	O
+/-	O
SEM	O
,	O
p	O
<	O
0.01	O
)	O
for	O
the	O
following	O
parameters	O
:	O
free	O
carnitine	S-chemical
,	O
2.28	O
+/-	O
0.36	O
nmol/mg	O
protein	O
vs	O
0.41	O
+/-	O
0.13	O
;	O
total	O
carnitine	S-chemical
,	O
3.48	O
+/-	O
0.36	O
vs	O
1.27	O
+/-	O
0.25	O
;	O
triglycerides	S-chemical
,	O
0.14	O
+/-	O
0.04	O
vs	O
0.39	O
+/-	O
0.02	O
;	O
and	O
total	O
cholesterol	S-chemical
,	O
0.21	O
+/-	O
0.02	O
vs	O
0.39	O
+/-	O
0.04	O
,	O
but	O
not	O
for	O
esterified	O
carnitine	S-chemical
,	O
1.18	O
+/-	O
0.17	O
vs	O
0.90	O
+/-	O
0.17	O
(	O
p	O
>	O
0.05	O
)	O
.	O
There	O
is	O
also	O
a	O
negative	O
correlation	O
between	O
hepatic	O
free	O
carnitine	S-chemical
and	O
triglycerides	S-chemical
from	O
jvs	O
heterozygotes	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Similar	O
results	O
were	O
obtained	O
with	O
myocardium	O
and	O
skeletal	O
muscle	O
.	O
We	O
conclude	O
that	O
free	O
and	O
total	O
carnitine	S-chemical
levels	O
are	O
significantly	O
lower	O
in	O
the	O
heterozygote	O
mouse	O
liver	O
and	O
heart	O
while	O
triglyceride	S-chemical
and	O
total	O
cholesterol	S-chemical
levels	O
are	O
significantly	O
higher	O
.	O
We	O
speculate	O
that	O
in	O
situations	O
of	O
lipolytic	O
stress	O
,	O
some	O
SCD	O
heterozygotes	O
might	O
develop	O
clinical	O
symptoms	O
of	O
carnitine	S-chemical
deficiency	O
.	O

Clonal	O
CD8+	O
and	O
CD52	S-GP
-	O
T	O
cells	O
are	O
induced	O
in	O
responding	O
B	O
cell	O
lymphoma	O
patients	O
treated	O
with	O
Campath-1H	O
(	O
anti-	O
CD52	S-GP
)	O
.	O
Five	O
patients	O
with	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
and	O
4	O
patients	O
with	O
chronic	O
lymphocytic	O
leukaemia	O
(	O
CLL	O
)	O
were	O
treated	O
with	O
the	O
CDR-grafted	O
(	O
rat	O
x	O
human	O
)	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
Campath-1H	O
(	O
anti-	O
CD52	S-GP
)	O
.	O
Tumour	O
regression	O
was	O
noted	O
preferentially	O
in	O
peripheral	O
blood	O
and	O
in	O
the	O
bone	O
marrow	O
but	O
lymph	O
nodes	O
were	O
less	O
affected	O
.	O
Normal	O
blood	O
B	O
and	O
T	O
cells	O
were	O
profoundly	O
reduced	O
in	O
all	O
patients	O
whereas	O
CD16+	O
NK	O
cells	O
and	O
CD14+	O
monocytes	O
decreased	O
marginally	O
.	O
In	O
all	O
responding	O
CLL	O
patients	O
CD52-negative	O
T	O
but	O
not	O
B	O
cells	O
appeared	O
during	O
treatment	O
and	O
persisted	O
for	O
several	O
months	O
(	O
4-19+	O
)	O
during	O
unmaintained	O
follow-up	O
.	O
Clonal	O
T	O
cells	O
defined	O
as	O
a	O
predominance	O
of	O
a	O
single	O
T	B-GP
cell	I-GP
receptor	I-GP
(	I-GP
TCR	I-GP
)	I-GP
V	E-GP
gene	O
usage	O
,	O
in	O
one	O
case	O
verified	O
by	O
TCR	S-GP
CDR3	O
fragment	O
analysis	O
and	O
nucleotide	S-chemical
sequencing	O
,	O
emerged	O
within	O
the	O
CD52-/CD8+	O
cell	O
population	O
during	O
Campath-1H	O
therapy	O
in	O
2	O
CLL	O
patients	O
,	O
both	O
achieving	O
a	O
long-lasting	O
remission	O
.	O
The	O
increase	O
in	O
CD8+	O
T	O
cell	O
expansions	O
(	O
up	O
to	O
23-fold	O
)	O
during	O
unmaintained	O
remission	O
and	O
follow-up	O
suggest	O
that	O
the	O
clonal	O
CD8+	O
cells	O
may	O
represent	O
regulatory	O
T	O
cells	O
controlling	O
the	O
growth	O
of	O
the	O
tumour	O
B	O
cell	O
clone	O
.	O
Clonal	O
T	O
cells	O
might	O
thus	O
be	O
a	O
target	O
for	O
an	O
immune	O
therapeutic	O
intervention	O
in	O
B	O
cell	O
tumours	O
.	O

Addition	O
of	O
artificial	O
salt	O
bridge	O
by	O
Ile646Lys	S-GP
mutation	O
in	O
gp41	B-GP
coiled-coil	I-GP
domain	E-GP
regulates	O
6-helical	O
bundle	O
formation	O
.	O
HIV	O
entry	O
is	O
mediated	O
by	O
the	O
envelope	B-GP
glycoproteins	I-GP
gp120	E-GP
and	O
gp41	S-GP
.	O
The	O
gp41	S-GP
subunit	O
contains	O
several	O
functional	O
domains	O
:	O
the	O
N-terminal	B-GP
heptad	I-GP
repeat	I-GP
(	I-GP
NHR	I-GP
)	I-GP
domains	E-GP
fold	O
a	O
triple	O
stranded	O
coiled-coil	O
forming	O
a	O
meta-stable	O
prefusion	O
intermediate	O
.	O
C	S-chemical
-terminal	O
heptad	O
repeat	O
(	O
CHR	O
)	O
subsequently	O
folds	O
onto	O
the	O
hydrophobic	O
grooves	O
of	O
the	O
NHR	O
coiled-coil	O
to	O
form	O
a	O
stable	O
6-helix	O
bundle	O
,	O
which	O
juxtaposes	O
the	O
viral	O
and	O
cellular	O
membranes	O
for	O
fusion	O
.	O
The	O
C34	O
which	O
has	O
34	O
amino	B-chemical
acid	E-chemical
residues	O
is	O
known	O
as	O
the	O
core	O
structure	O
in	O
CHR	O
.	O
A	O
highly	O
anti-HIV	O
peptide	O
inhibitor	O
derived	O
from	O
C34	O
was	O
designed	O
.	O
An	O
artificial	O
salt	O
bridge	O
was	O
added	O
in	O
the	O
6-helical	O
bundle	O
by	O
substitution	O
of	O
lysine	S-chemical
for	O
Ile	S-chemical
646	O
.	O
With	O
a	O
cholesterol	S-chemical
modification	O
at	O
C	S-chemical
-terminal	O
,	O
the	O
inhibitor	O
containing	O
I646K	S-GP
mutation	O
represented	O
higher	O
anti-viral	O
activity	O
than	O
C34-	O
cholesterol	S-chemical
combination	O
without	O
mutation	O
.	O

Extracellular	B-GP
Signal-Regulated	I-GP
Kinases	E-GP
(	O
ERK	S-GP
)	O
Inhibitors	O
from	O
Aristolochia	O
yunnanensis	O
.	O
Six	O
new	O
sesquiterpenoids	S-chemical
,	O
aristoyunnolins	B-chemical
A-F	E-chemical
(	O
1-6	O
)	O
,	O
an	O
artifact	O
of	O
isolation	O
[	O
7-O-ethyl	B-chemical
madolin	I-chemical
W	E-chemical
(	O
7	O
)	O
]	O
,	O
and	O
12	O
known	O
analogues	O
were	O
isolated	O
from	O
stems	O
of	O
Aristolochia	O
yunnanensis	O
.	O
The	O
structures	O
were	O
determined	O
by	O
combined	O
chemical	O
and	O
spectral	O
methods	O
,	O
and	O
the	O
absolute	O
configurations	O
of	O
compounds	O
2	O
,	O
3	O
,	O
5-7	O
,	O
9	O
,	O
14	O
,	O
and	O
17	O
were	O
determined	O
by	O
the	O
modified	O
Mosher	O
's	O
method	O
and	O
CD	O
analysis	O
.	O
Compounds	O
1-19	O
were	O
screened	O
using	O
a	O
bioassay	O
system	O
designed	O
to	O
evaluate	O
the	O
effect	O
on	O
mitogen-activated	B-GP
protein	I-GP
kinases	E-GP
(	O
MAPKs	S-GP
)	O
signaling	O
pathways	O
.	O
Among	O
three	O
MAPKs	S-GP
(	O
ERK1/2	S-GP
,	O
JNK	S-GP
,	O
and	O
p38	S-GP
)	O
,	O
compounds	O
1	O
,	O
4	O
,	O
10-13	O
,	O
16	O
,	O
18	O
,	O
and	O
19	O
exhibited	O
selective	O
inhibition	O
of	O
the	O
phosphorylation	O
of	O
ERK1/2	S-GP
.	O
Compounds	O
16	O
and	O
19	O
were	O
more	O
active	O
than	O
the	O
positive	O
control	O
PD98059	S-chemical
,	O
a	O
known	O
inhibitor	O
of	O
the	O
ERK1/2	S-GP
signaling	O
pathway	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
anti-inflammatory	O
potential	O
of	O
pentahydroxy-pregn-14-ol	B-chemical
,	I-chemical
20-one-β-d-thevetopyranoside	E-chemical
in	O
rats	O
.	O
Polyhydroxy	B-chemical
pregnane	I-chemical
glycoside	E-chemical
(	O
PPG	S-chemical
)	O
,	O
a	O
steroidal	B-chemical
glycoside	E-chemical
was	O
isolated	O
from	O
Wattakaka	O
volubilis	O
Linn	O
.	O
(	O
Stap.f	O
.	O
)	O
.	O
PPG	S-chemical
was	O
evaluated	O
for	O
in	O
vivo	O
and	O
in	O
vitro	O
anti-inflammatory	O
activity	O
using	O
acute	O
inflammation	O
and	O
chronic	O
model	O
of	O
inflammation	O
in	O
rats	O
and	O
LPS-induced	O
RAW	O
264.7	O
macrophage	O
cells	O
.	O
PPG	S-chemical
seemed	O
to	O
be	O
responsible	O
for	O
the	O
anti-inflammatory	O
activity	O
in	O
the	O
studied	O
models	O
.	O
PPG	S-chemical
at	O
dose	O
level	O
of	O
both	O
5	O
and	O
10mg/kg	O
significantly	O
reduced	O
the	O
edema	O
induced	O
by	O
the	O
carrageenan	O
in	O
acute	O
model	O
of	O
inflammation	O
.	O
It	O
also	O
showed	O
significant	O
anti-proliferative	O
effect	O
(	O
dry	O
pellet	O
weight	O
basis	O
)	O
in	O
chronic	O
model	O
of	O
inflammation	O
.	O
Cellular	O
content	O
of	O
granuloma	O
was	O
measured	O
by	O
assaying	O
activity	O
of	O
N-acetyl	S-chemical
glucosaminidase	O
(	O
NAG	O
)	O
and	O
total	O
nucleic	O
acid	O
content	O
.	O
PPG	S-chemical
at	O
5	O
and	O
10mg/kg	O
significantly	O
suppressed	O
the	O
cellular	O
infiltration	O
measured	O
by	O
total	O
nucleic	O
acid	O
content	O
.	O
In	O
contrast	O
,	O
NAG	O
activity	O
decreased	O
over	O
a	O
period	O
of	O
10	O
days	O
resulting	O
in	O
inhibition	O
of	O
granuloma	O
weight	O
gain	O
.	O
PPG	S-chemical
had	O
a	O
more	O
effective	O
response	O
than	O
the	O
reference	O
drug	O
diclofenac	B-chemical
sodium	E-chemical
in	O
both	O
the	O
models	O
of	O
inflammation	O
.	O
Wattakaka	O
volubilis	O
steroidal	B-chemical
glycoside	E-chemical
mixture	O
(	O
WVSM	O
)	O
and	O
PPG	S-chemical
(	O
1-50μM	O
)	O
significantly	O
inhibited	O
the	O
COX-2	S-GP
and	O
iNOS	S-GP
enzymes	O
resulting	O
in	O
low	O
levels	O
of	O
PGE2	O
and	O
NO	O
in	O
LPS-induced	O
RAW	O
264.7	O
macrophage	O
cells	O
.	O
Hence	O
the	O
study	O
supports	O
the	O
traditional	O
use	O
of	O
Wattakaka	O
volubilis	O
and	O
its	O
constituent	O
PPG	S-chemical
in	O
treatment	O
of	O
inflammatory	O
disorders	O
.	O

Protease-activated	B-GP
receptor	I-GP
(	I-GP
PAR	I-GP
)	I-GP
1	E-GP
and	O
PAR4	S-GP
differentially	O
regulate	O
factor	B-GP
V	E-GP
expression	O
from	O
human	O
platelets	O
.	O
With	O
the	O
recent	O
interest	O
of	O
protease-activated	B-GP
receptors	I-GP
(	I-GP
PAR	I-GP
)	I-GP
1	E-GP
and	O
PAR4	S-GP
as	O
possible	O
targets	O
for	O
the	O
treatment	O
of	O
thrombotic	O
disorders	O
,	O
we	O
compared	O
the	O
efficacy	O
of	O
protease-activated	B-GP
receptor	I-GP
(	I-GP
PAR	I-GP
)	I-GP
1	E-GP
and	O
PAR4	S-GP
in	O
the	O
generation	O
of	O
procoagulant	O
phenotypes	O
on	O
platelet	O
membranes	O
.	O
PAR4	S-GP
-activating	O
peptide	O
(	O
AP	O
)	O
-stimulated	O
platelets	O
promoted	O
thrombin	S-GP
generation	O
in	O
plasma	O
up	O
to	O
5	O
minutes	O
earlier	O
than	O
PAR1	S-GP
-AP-stimulated	O
platelets	O
.	O
PAR4	S-GP
-AP-mediated	O
factor	B-GP
V	E-GP
(	O
FV	S-GP
)	O
association	O
with	O
the	O
platelet	O
surface	O
was	O
1.6-fold	O
greater	O
than	O
for	O
PAR1	S-GP
-AP	O
.	O
Moreover	O
,	O
PAR4	S-GP
stimulation	O
resulted	O
in	O
a	O
3-fold	O
greater	O
release	O
of	O
microparticles	O
,	O
compared	O
with	O
PAR1	S-GP
stimulation	O
.	O
More	O
robust	O
FV	S-GP
secretion	O
and	O
microparticle	O
generation	O
with	O
PAR4	S-GP
-AP	O
was	O
attributable	O
to	O
stronger	O
and	O
more	O
sustained	O
phosphorylation	O
of	O
myosin	O
light	O
chain	O
at	O
serine	S-chemical
19	O
and	O
threonine	S-chemical
18	O
.	O
Inhibition	O
of	O
Rho-kinase	S-GP
reduced	O
PAR4	S-GP
-AP-mediated	O
FV	S-GP
secretion	O
and	O
microparticle	O
generation	O
to	O
PAR1	S-GP
-AP-mediated	O
levels	O
.	O
Thrombin	S-GP
generation	O
assays	O
measuring	O
prothrombinase	S-GP
complex	O
activity	O
demonstrated	O
1.5-fold	O
higher	O
peak	O
thrombin	S-GP
levels	O
on	O
PAR4	S-GP
-AP-stimulated	O
platelets	O
,	O
compared	O
with	O
PAR1	S-GP
-AP-stimulated	O
platelets	O
.	O
Rho-kinase	S-GP
inhibition	O
reduced	O
PAR4	S-GP
-AP-mediated	O
peak	O
thrombin	O
generation	O
by	O
25	O
%	O
but	O
had	O
no	O
significant	O
effect	O
on	O
PAR1	S-GP
-AP-mediated	O
thrombin	S-GP
generation	O
.	O
In	O
conclusion	O
,	O
stimulation	O
of	O
PAR4	S-GP
on	O
platelets	O
leads	O
to	O
faster	O
and	O
more	O
robust	O
thrombin	O
generation	O
,	O
compared	O
with	O
PAR1	S-GP
stimulation	O
.	O
The	O
greater	O
procoagulant	O
potential	O
is	O
related	O
to	O
more	O
efficient	O
FV	S-GP
release	O
from	O
intracellular	O
stores	O
and	O
microparticle	O
production	O
driven	O
by	O
stronger	O
and	O
more	O
sustained	O
myosin	O
light	O
chain	O
phosphorylation	O
.	O
These	O
data	O
have	O
implications	O
about	O
the	O
role	O
of	O
PAR4	S-GP
during	O
hemostasis	O
and	O
are	O
clinically	O
relevant	O
in	O
light	O
of	O
recent	O
efforts	O
to	O
develop	O
PAR	S-GP
antagonists	O
to	O
treat	O
thrombotic	O
disorders	O
.	O

Pharmacogenetic	O
differences	O
in	O
response	O
to	O
albuterol	S-chemical
between	O
Puerto	O
Ricans	O
and	O
Mexicans	O
with	O
asthma	O
.	O
BACKGROUND	O
:	O
In	O
the	O
United	O
States	O
,	O
Puerto	O
Ricans	O
and	O
Mexicans	O
have	O
the	O
highest	O
and	O
lowest	O
asthma	O
prevalence	O
,	O
morbidity	O
,	O
and	O
mortality	O
,	O
respectively	O
.	O
Ethnic-specific	O
differences	O
in	O
the	O
response	O
to	O
drug	O
treatment	O
may	O
contribute	O
to	O
differences	O
in	O
disease	O
outcomes	O
.	O
Genetic	O
variants	O
at	O
the	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenergic	I-GP
receptor	E-GP
(	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
AR	E-GP
)	O
may	O
modify	O
asthma	O
severity	O
and	O
albuterol	S-chemical
responsiveness	O
.	O
We	O
tested	O
the	O
association	O
of	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
AR	E-GP
genotypes	O
with	O
asthma	O
severity	O
and	O
bronchodilator	O
response	O
to	O
albuterol	S-chemical
in	O
Puerto	O
Ricans	O
and	O
Mexicans	O
with	O
asthma	O
.	O
METHODS	O
:	O
We	O
used	O
both	O
family-based	O
and	O
cross-sectional	O
tests	O
of	O
association	O
with	O
8	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
AR	E-GP
single	O
nucleotide	S-chemical
polymorphisms	O
in	O
684	O
Puerto	O
Rican	O
and	O
Mexican	O
families	O
.	O
Regression	O
analyses	O
were	O
used	O
to	O
determine	O
the	O
interaction	O
between	O
genotype	O
,	O
asthma	O
severity	O
,	O
and	O
bronchodilator	O
drug	O
responsiveness	O
.	O
RESULTS	O
:	O
Among	O
Puerto	O
Ricans	O
with	O
asthma	O
,	O
the	O
arginine	S-chemical
(	O
Arg	S-chemical
)	O
16	O
allele	O
was	O
associated	O
with	O
greater	O
bronchodilator	O
response	O
using	O
both	O
family-based	O
and	O
cross-sectional	O
tests	O
(	O
p	O
=	O
0.00001-0.01	O
)	O
.	O
We	O
found	O
a	O
strong	O
interaction	O
of	O
baseline	O
FEV	O
(	O
1	O
)	O
with	O
the	O
Arg16Glycine	S-GP
(	O
Gly	S-chemical
)	O
polymorphism	O
in	O
predicting	O
bronchodilator	O
response	O
.	O
Among	O
Puerto	O
Ricans	O
with	O
asthma	O
with	O
baseline	O
FEV	O
(	O
1	O
)	O
<	O
80	O
%	O
of	O
predicted	O
,	O
but	O
not	O
in	O
those	O
with	O
FEV	O
(	O
1	O
)	O
>	O
80	O
%	O
,	O
there	O
was	O
a	O
very	O
strong	O
association	O
between	O
the	O
Arg16	O
genotype	O
and	O
greater	O
bronchodilator	O
responsiveness	O
.	O
No	O
association	O
was	O
observed	O
between	O
Arg16Gly	S-GP
genotypes	O
and	O
drug	O
responsiveness	O
among	O
Mexicans	O
with	O
asthma	O
.	O
CONCLUSIONS	O
:	O
Ethnic-specific	O
pharmacogenetic	O
differences	O
exist	O
between	O
Arg16Gly	S-GP
genotypes	O
,	O
asthma	O
severity	O
,	O
and	O
bronchodilator	O
response	O
in	O
Puerto	O
Ricans	O
and	O
Mexicans	O
with	O
asthma	O
.	O
These	O
findings	O
underscore	O
the	O
need	O
for	O
additional	O
research	O
on	O
racial/ethnic	O
differences	O
in	O
asthma	O
morbidity	O
and	O
drug	O
responsiveness	O
.	O

Anti-inflammatory	O
trends	O
of	O
1	B-chemical
,	I-chemical
3-diphenyl-2-propen-1-one	E-chemical
derivatives	O
.	O
Chalcones	S-chemical
(	O
1	B-chemical
,	I-chemical
3-Diphenyl-2-propen-1-one	E-chemical
)	O
are	O
constituted	O
by	O
a	O
three	O
carbon	S-chemical
α	B-chemical
,	I-chemical
β-unsaturated	I-chemical
carbonyl	E-chemical
system	O
.	O
The	O
biosynthesis	O
of	O
flavonoids	S-chemical
and	O
isoflavonoids	S-chemical
is	O
initiated	O
by	O
chalcones	S-chemical
.	O
Notable	O
pharmacological	O
activities	O
of	O
chalcones	S-chemical
and	O
its	O
derivatives	O
include	O
anti-inflammatory	O
,	O
antifungal	O
,	O
antibacterial	O
,	O
antimalarial	O
,	O
antituberculosis	O
,	O
antitumor	O
,	O
antimicrobial	O
and	O
antiviral	O
effects	O
respectively	O
.	O
Owing	O
to	O
simplicity	O
of	O
the	O
chemical	O
structures	O
and	O
a	O
huge	O
variety	O
of	O
pharmacological	O
actions	O
exhibited	O
,	O
the	O
entities	O
derived	O
from	O
chalcones	S-chemical
are	O
subjected	O
to	O
extensive	O
consideration	O
.	O
This	O
review	O
article	O
is	O
an	O
effort	O
to	O
sum	O
up	O
the	O
anti-inflammatory	O
activities	O
of	O
chalcone	S-chemical
derived	O
chemical	O
entities	O
.	O
Effect	O
of	O
chalcones	S-chemical
on	O
lipid	O
peroxidation	O
,	O
heme	B-GP
oxygenase	I-GP
1	E-GP
(	O
HO-1	S-GP
)	O
,	O
cyclooxygenase	S-GP
(	O
COX	S-GP
)	O
,	O
interleukin	B-GP
5	E-GP
(	O
IL-5	S-GP
)	O
,	O
nitric	B-chemical
oxide	E-chemical
(	O
NO	S-chemical
)	O
and	O
expression	O
of	O
cell	O
adhesion	O
molecules	O
(	O
CAM	O
)	O
is	O
summarized	O
stepwise	O
.	O

Metformin	S-chemical
increases	O
AMP-activated	B-GP
protein	I-GP
kinase	E-GP
activity	O
in	O
skeletal	O
muscle	O
of	O
subjects	O
with	O
type	O
2	O
diabetes	O
.	O
Metformin	S-chemical
is	O
an	O
effective	O
hypoglycemic	O
drug	O
that	O
lowers	O
blood	O
glucose	S-chemical
concentrations	O
by	O
decreasing	O
hepatic	O
glucose	S-chemical
production	O
and	O
increasing	O
glucose	S-chemical
disposal	O
in	O
skeletal	O
muscle	O
;	O
however	O
,	O
the	O
molecular	O
site	O
of	O
metformin	S-chemical
action	O
is	O
not	O
well	O
understood	O
.	O
AMP-activated	B-GP
protein	I-GP
kinase	E-GP
(	O
AMPK	S-GP
)	O
activity	O
increases	O
in	O
response	O
to	O
depletion	O
of	O
cellular	O
energy	O
stores	O
,	O
and	O
this	O
enzyme	O
has	O
been	O
implicated	O
in	O
the	O
stimulation	O
of	O
glucose	S-chemical
uptake	O
into	O
skeletal	O
muscle	O
and	O
the	O
inhibition	O
of	O
liver	O
gluconeogenesis	O
.	O
We	O
recently	O
reported	O
that	O
AMPK	S-GP
is	O
activated	O
by	O
metformin	S-chemical
in	O
cultured	O
rat	O
hepatocytes	O
,	O
mediating	O
the	O
inhibitory	O
effects	O
of	O
the	O
drug	O
on	O
hepatic	O
glucose	S-chemical
production	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
whether	O
therapeutic	O
doses	O
of	O
metformin	S-chemical
increase	O
AMPK	S-GP
activity	O
in	O
vivo	O
in	O
subjects	O
with	O
type	O
2	O
diabetes	O
.	O
Metformin	S-chemical
treatment	O
for	O
10	O
weeks	O
significantly	O
increased	O
AMPK	B-GP
alpha2	E-GP
activity	O
in	O
the	O
skeletal	O
muscle	O
,	O
and	O
this	O
was	O
associated	O
with	O
increased	O
phosphorylation	O
of	O
AMPK	S-GP
on	O
Thr172	O
and	O
decreased	O
acetyl-CoA	B-GP
carboxylase-2	E-GP
activity	O
.	O
The	O
increase	O
in	O
AMPK	B-GP
alpha2	E-GP
activity	O
was	O
likely	O
due	O
to	O
a	O
change	O
in	O
muscle	O
energy	O
status	O
because	O
ATP	S-chemical
and	O
phosphocreatine	S-chemical
concentrations	O
were	O
lower	O
after	O
metformin	S-chemical
treatment	O
.	O
Metformin	S-chemical
-induced	O
increases	O
in	O
AMPK	S-GP
activity	O
were	O
associated	O
with	O
higher	O
rates	O
of	O
glucose	S-chemical
disposal	O
and	O
muscle	O
glycogen	O
concentrations	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
metabolic	O
effects	O
of	O
metformin	O
in	O
subjects	O
with	O
type	O
2	O
diabetes	O
may	O
be	O
mediated	O
by	O
the	O
activation	O
of	O
AMPK	B-GP
alpha2	E-GP
.	O

Effects	O
of	O
the	O
EGFR	S-GP
/	O
HER2	S-GP
kinase	S-GP
inhibitor	O
GW572016	S-chemical
on	O
EGFR	S-GP
-	O
and	O
HER2	S-GP
-overexpressing	O
breast	O
cancer	O
cell	O
line	O
proliferation	O
,	O
radiosensitization	O
,	O
and	O
resistance	O
.	O
PURPOSE	O
:	O
Two	O
members	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
family	O
,	O
EGFR	S-GP
and	O
HER2	S-GP
,	O
have	O
been	O
implicated	O
in	O
radioresistance	O
in	O
breast	O
cancer	O
and	O
other	O
malignancies	O
.	O
To	O
gauge	O
the	O
potential	O
clinical	O
utility	O
of	O
targeting	O
both	O
EGFR	S-GP
and	O
HER2	S-GP
to	O
control	O
growth	O
and	O
radiosensitize	O
human	O
breast	O
cancers	O
,	O
we	O
examined	O
the	O
effect	O
of	O
a	O
dual	O
EGFR	S-GP
/	O
HER2	S-GP
inhibitor	O
,	O
GW572016	S-chemical
,	O
on	O
the	O
proliferation	O
and	O
radiation	O
response	O
of	O
either	O
EGFR	S-GP
-	O
or	O
HER2	S-GP
-overexpressing	O
human	O
breast	O
cancer	O
cell	O
lines	O
.	O
METHODS	O
AND	O
MATERIALS	O
:	O
Primary	O
human	O
breast	O
cancer	O
cell	O
lines	O
that	O
endogenously	O
overexpress	O
EGFR	S-GP
or	O
HER2	S-GP
and	O
luminal	O
mammary	O
epithelial	O
H16N2	O
cells	O
stably	O
transfected	O
with	O
HER2	S-GP
were	O
evaluated	O
for	O
the	O
effect	O
of	O
GW572016	S-chemical
on	O
inhibition	O
of	O
ligand-induced	O
or	O
constitutive	B-GP
receptor	E-GP
phosphorylation	O
,	O
proliferation	O
,	O
radiosensitization	O
,	O
and	O
inhibition	O
of	O
downstream	O
signaling	O
.	O
RESULTS	O
:	O
GW572016	S-chemical
inhibited	O
constitutive	O
and/or	O
ligand-induced	O
EGFR	S-GP
or	O
HER2	S-GP
tyrosine	S-chemical
phosphorylation	O
of	O
all	O
five	O
cell	O
lines	O
,	O
which	O
correlated	O
with	O
the	O
antiproliferative	O
response	O
in	O
all	O
but	O
one	O
cell	O
line	O
.	O
GW572016	S-chemical
radiosensitized	O
EGFR	S-GP
-overexpressing	O
cell	O
lines	O
,	O
but	O
HER2	S-GP
-overexpressing	O
cells	O
were	O
unable	O
to	O
form	O
colonies	O
after	O
brief	O
exposure	O
to	O
GW572016	S-chemical
even	O
in	O
the	O
absence	O
of	O
radiation	O
,	O
and	O
thus	O
could	O
not	O
be	O
evaluated	O
for	O
radiosensitization	O
.	O
One	O
cell	O
line	O
was	O
resistant	O
to	O
the	O
antiproliferative	O
and	O
radiosensitizing	O
effects	O
of	O
GW572016	S-chemical
,	O
despite	O
receptor	O
inhibition	O
.	O
Exploration	O
of	O
potential	O
mechanisms	O
of	O
resistance	O
in	O
SUM185	O
cells	O
revealed	O
failure	O
of	O
GW572016	S-chemical
to	O
inhibit	O
downstream	O
ERK	S-GP
and	O
Akt	S-GP
activation	O
,	O
despite	O
inhibition	O
of	O
HER2	S-GP
phosphorylation	O
.	O
In	O
contrast	O
,	O
sensitive	O
HER2	S-GP
-overexpressing	O
cell	O
lines	O
demonstrated	O
inhibition	O
of	O
both	O
ERK	S-GP
and	O
Akt	S-GP
phosphorylation	O
.	O
CONCLUSION	O
:	O
GW572016	S-chemical
potently	O
inhibits	O
receptor	O
phosphorylation	O
in	O
either	O
EGFR	S-GP
-	O
or	O
HER2	S-GP
-overexpressing	O
cell	O
lines	O
and	O
has	O
both	O
antiproliferative	O
and	O
radiosensitizing	O
effects	O
.	O
Resistance	O
to	O
GW572016	S-chemical
was	O
not	O
due	O
to	O
a	O
lack	O
of	O
receptor	O
inhibition	O
,	O
but	O
rather	O
with	O
a	O
lack	O
of	O
inhibition	O
of	O
ERK	S-GP
and	O
Akt	S-GP
,	O
suggesting	O
that	O
measurement	O
of	O
inhibition	O
of	O
crucial	O
signaling	O
pathways	O
may	O
better	O
predict	O
response	O
than	O
inhibition	O
of	O
receptor	O
phosphorylation	O
.	O
The	O
SUM185	O
cell	O
line	O
provides	O
a	O
valuable	O
model	O
for	O
studying	O
mechanisms	O
of	O
resistance	O
of	O
EGFR	S-GP
/	O
HER2	S-GP
inhibitor	O
therapy	O
.	O

Use	O
of	O
the	O
norepinephrine	B-GP
transporter	E-GP
as	O
a	O
reporter	O
gene	O
for	O
non-invasive	O
imaging	O
of	O
genetically	O
modified	O
cells	O
.	O
BACKGROUND	O
:	O
The	O
norepinephrine	B-GP
transporter	E-GP
(	O
NET	S-GP
)	O
is	O
a	O
high-affinity	O
transporter	O
for	O
catecholamines	S-chemical
.	O
Its	O
expression	O
is	O
almost	O
exclusively	O
restricted	O
to	O
the	O
sympathetic	O
nervous	O
system	O
.	O
In	O
this	O
study	O
we	O
evaluated	O
whether	O
the	O
NET	S-GP
can	O
be	O
used	O
as	O
a	O
reporter	O
gene	O
for	O
non-invasive	O
imaging	O
of	O
genetically	O
modified	O
cells	O
with	O
radiolabeled	O
probes	O
.	O
METHODS	O
:	O
Human	O
A431	O
,	O
HT1080	O
and	O
murine	O
CMS-5	O
cells	O
were	O
retrovirally	O
transduced	O
with	O
bovine	B-GP
NET	E-GP
cDNA	O
.	O
Transduced	O
and	O
parental	O
cells	O
were	O
incubated	O
in	O
vitro	O
with	O
[	B-chemical
(	I-chemical
131	I-chemical
)	I-chemical
I	I-chemical
]	I-chemical
meta-iodobenzylguanidine	E-chemical
(	O
[	B-chemical
(	I-chemical
131	I-chemical
)	I-chemical
I	I-chemical
]	I-chemical
MIBG	E-chemical
)	O
.	O
The	O
specificity	O
of	O
tracer	O
uptake	O
was	O
determined	O
by	O
adding	O
the	O
NET	S-GP
inhibitor	O
imipramine	S-chemical
.	O
Rat	O
PC12	O
cells	O
served	O
as	O
positive	O
controls	O
.	O
Parental	O
and	O
A431	O
NET	S-GP
cells	O
were	O
xenotransplanted	O
into	O
nude	O
mice	O
and	O
tumor	O
uptake	O
of	O
[	B-chemical
(	I-chemical
123	I-chemical
)	I-chemical
I	I-chemical
]	I-chemical
MIBG	E-chemical
in	O
vivo	O
was	O
determined	O
after	O
tracer	O
administration	O
.	O
RESULTS	O
:	O
In	O
vitro	O
stably	O
transduced	O
cells	O
showed	O
a	O
66-	O
to	O
120-fold	O
higher	O
[	B-chemical
(	I-chemical
131	I-chemical
)	I-chemical
I	I-chemical
]	I-chemical
MIBG	E-chemical
uptake	O
than	O
parental	O
cells	O
.	O
Incubation	O
with	O
imipramine	S-chemical
reduced	O
[	B-chemical
(	I-chemical
131	I-chemical
)	I-chemical
I	I-chemical
]	I-chemical
MIBG	E-chemical
uptake	O
of	O
transduced	O
cells	O
to	O
the	O
level	O
found	O
in	O
parental	O
cells	O
.	O
More	O
than	O
70	O
%	O
of	O
the	O
initial	O
radioactivity	O
was	O
retained	O
in	O
all	O
transduced	O
cell	O
lines	O
after	O
2	O
h	O
incubation	O
with	O
tracer-free	O
medium	O
.	O
[	B-chemical
(	I-chemical
131	I-chemical
)	I-chemical
I	I-chemical
]	I-chemical
MIBG	E-chemical
uptake	O
in	O
PC12	O
cells	O
,	O
which	O
express	O
the	O
NET	S-GP
endogenously	O
,	O
was	O
20-	O
to	O
28-fold	O
lower	O
than	O
in	O
transduced	O
cells	O
.	O
In	O
vivo	O
,	O
A431	O
NET	S-GP
tumors	O
demonstrated	O
a	O
33-fold	O
higher	O
[	B-chemical
(	I-chemical
123	I-chemical
)	I-chemical
I	I-chemical
]	I-chemical
MIBG	E-chemical
uptake	O
than	O
parental	O
tumors	O
.	O
Gamma	O
camera	O
images	O
24	O
h	O
after	O
tracer	O
injection	O
showed	O
no	O
tracer	O
uptake	O
in	O
parental	O
A431	O
tumors	O
,	O
but	O
clear	O
images	O
of	O
A431	O
NET	S-GP
tumors	O
.	O
CONCLUSIONS	O
:	O
Transduction	O
of	O
tumor	O
cells	O
with	O
NET	S-GP
cDNA	O
causes	O
highly	O
specific	O
uptake	O
and	O
significant	O
retention	O
of	O
catecholamine	S-chemical
analogs	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
These	O
characteristics	O
make	O
the	O
NET	S-GP
suitable	O
as	O
a	O
reporter	O
gene	O
for	O
non-invasive	O
monitoring	O
of	O
gene	O
transfer	O
.	O

Aquaporin-1	S-GP
deletion	O
reduces	O
osmotic	O
water	O
permeability	O
and	O
cerebrospinal	O
fluid	O
production	O
.	O
Aquaporin-1	S-GP
(	O
AQP1	S-GP
)	O
is	O
a	O
water	B-GP
channel	E-GP
that	O
is	O
strongly	O
expressed	O
at	O
the	O
ventricular-facing	O
surface	O
of	O
choroid	O
plexus	O
epithelium	O
.	O
Using	O
wildtype	O
and	O
AQP1	S-GP
null	O
mice	O
,	O
we	O
developed	O
novel	O
methods	O
to	O
compare	O
the	O
water	O
permeability	O
in	O
isolated	O
choroid	O
plexus	O
,	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
production	O
in	O
living	O
mice	O
.	O
Osmotically-induced	O
water	O
transport	O
was	O
rapid	O
in	O
freshly	O
isolated	O
choroid	O
plexus	O
from	O
wildtype	O
mice	O
as	O
measured	O
by	O
a	O
spatial-filtering	O
optical	O
method	O
,	O
and	O
reduced	O
by	O
5-fold	O
by	O
AQP1	S-GP
deletion	O
.	O
CSF	O
production	O
,	O
an	O
isosmolar	O
fluid	O
secretion	O
process	O
,	O
was	O
measured	O
by	O
a	O
dye	O
dilution	O
method	O
involving	O
fluid	O
collections	O
using	O
a	O
second	O
microneedle	O
introduced	O
into	O
the	O
cisterna	O
magna	O
.	O
CSF	O
production	O
in	O
wildtype	O
mice	O
was	O
(	O
in	O
microl/min	O
)	O
0.37	O
+/-	O
0.04	O
microl/min	O
(	O
control	O
)	O
,	O
0.16	O
+/-	O
0.03	O
microl/min	O
(	O
acetazolamide	S-chemical
-treated	O
)	O
and	O
1.14	O
+/-	O
0.15	O
microl/min	O
(	O
forskolin	S-chemical
-treated	O
)	O
,	O
and	O
reduced	O
by	O
up	O
to	O
25	O
%	O
in	O
AQP1	S-GP
null	O
mice	O
.	O
The	O
impaired	O
CSF	O
production	O
in	O
AQP1	S-GP
null	O
mice	O
provides	O
direct	O
functional	O
evidence	O
for	O
the	O
involvement	O
of	O
AQP1	S-GP
in	O
CSF	O
formation	O
.	O

Antidepressants	O
suppress	O
production	O
of	O
the	O
Th1	O
cytokine	S-GP
interferon-gamma	S-GP
,	O
independent	O
of	O
monoamine	B-GP
transporter	E-GP
blockade	O
.	O
In	O
this	O
study	O
,	O
antidepressants	O
with	O
selectivity	O
for	O
the	O
noradrenaline	B-GP
transporter	E-GP
(	O
reboxetine	S-chemical
and	O
desipramine	S-chemical
)	O
,	O
or	O
the	O
serotonin	B-GP
transporter	E-GP
(	O
fluoxetine	S-chemical
and	O
clomipramine	S-chemical
)	O
were	O
examined	O
in	O
terms	O
of	O
their	O
ability	O
to	O
promote	O
an	O
anti-inflammatory	O
cytokine	S-GP
phenotype	O
in	O
human	O
blood	O
.	O
In	O
addition	O
,	O
we	O
examined	O
the	O
ability	O
of	O
trimipramine	S-chemical
;	O
a	O
tricyclic	S-chemical
antidepressant	O
that	O
is	O
devoid	O
of	O
monoamine	S-chemical
reuptake	O
inhibitory	O
properties	O
on	O
cytokine	S-GP
production	O
.	O
Lipopolysaccharide	O
(	O
LPS	O
)	O
was	O
used	O
to	O
stimulate	O
monocyte-derived	O
pro-inflammatory	O
(	O
IL-1beta	S-GP
,	O
TNF-alpha	S-GP
,	O
IL-12	S-GP
)	O
and	O
anti-inflammatory	O
(	O
IL-10	S-GP
)	O
cytokines	S-GP
,	O
whilst	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
was	O
used	O
to	O
stimulate	O
T-cell	O
(	O
Th	O
(	O
1	O
)	O
:	O
IFN-gamma	S-GP
and	O
Th	O
(	O
2/3	O
)	O
:	O
IL-10	S-GP
)	O
cytokines	S-GP
.	O
All	O
of	O
the	O
antidepressants	O
suppressed	O
IFN-gamma	S-GP
production	O
in	O
the	O
10-50	O
microM	O
concentration	O
range	O
,	O
irrespective	O
of	O
their	O
preference	O
for	O
serotonin	B-GP
or	I-GP
noradrenaline	I-GP
transporters	E-GP
.	O
This	O
suppression	O
of	O
IFN-gamma	S-GP
production	O
was	O
paralleled	O
by	O
reduced	O
T-cell	O
proliferation	O
,	O
therefore	O
we	O
suggest	O
that	O
the	O
ability	O
of	O
antidepressants	O
to	O
suppress	O
IFN-gamma	S-GP
production	O
may	O
be	O
related	O
to	O
their	O
anti-proliferative	O
properties	O
.	O
The	O
fact	O
that	O
trimipramine	S-chemical
also	O
suppressed	O
IFN-gamma	S-GP
production	O
and	O
T-cell	O
proliferation	O
indicates	O
that	O
these	O
immunomodulatory	O
actions	O
of	O
antidepressants	O
are	O
most	O
likely	O
unrelated	O
to	O
inhibition	O
of	O
monoamine	S-chemical
reuptake	O
.	O
Interestingly	O
,	O
exposure	O
to	O
a	O
lower	O
concentration	O
(	O
1	O
microM	O
)	O
of	O
the	O
antidepressants	O
tended	O
to	O
increase	O
T-cell-derived	O
IL-10	S-GP
production	O
,	O
with	O
significant	O
effects	O
elicited	O
by	O
the	O
noradrenaline	S-chemical
reuptake	O
inhibitors	O
reboxetine	S-chemical
and	O
desipramine	S-chemical
.	O
In	O
contrast	O
to	O
the	O
robust	O
actions	O
of	O
antidepressants	O
on	O
T-cell	O
derived	O
cytokine	S-GP
production	O
,	O
they	O
failed	O
to	O
induce	O
any	O
consistent	O
change	O
in	O
LPS-induced	O
monocyte	O
cytokine	S-GP
production	O
.	O
Overall	O
,	O
our	O
results	O
indicate	O
that	O
IFN-gamma	S-GP
producing	O
T-cells	O
(	O
Th	O
(	O
1	O
)	O
cells	O
)	O
are	O
the	O
major	O
target	O
for	O
the	O
immunomodulatory	O
actions	O
of	O
antidepressants	O
,	O
and	O
provide	O
evidence	O
questioning	O
the	O
relationship	O
between	O
the	O
monoaminergic	O
reuptake	O
properties	O
of	O
antidepressants	O
and	O
their	O
immunomodulatory	O
effects	O
.	O
The	O
potential	O
clinical	O
significance	O
of	O
the	O
anti-inflammatory	O
actions	O
of	O
antidepressants	O
is	O
discussed	O
.	O

Comparative	O
effects	O
of	O
three	O
different	O
potent	O
renin	S-GP
inhibitors	O
in	O
primates	O
.	O
The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
three	O
potent	O
reference	O
renin	S-GP
inhibitors	O
(	O
remikiren	S-chemical
,	O
CGP	B-chemical
38560A	E-chemical
,	O
and	O
enalkiren	S-chemical
)	O
in	O
sodium	S-chemical
-depleted	O
normotensive	O
squirrel	O
monkeys	O
.	O
In	O
these	O
monkeys	O
,	O
arterial	O
pressure	O
was	O
measured	O
in	O
the	O
conscious	O
state	O
with	O
a	O
telemetry	O
system	O
.	O
Oral	O
and	O
intravenous	O
maximal	O
effective	O
doses	O
of	O
the	O
three	O
renin	S-GP
inhibitors	O
were	O
compared	O
in	O
parallel	O
groups	O
of	O
monkeys	O
.	O
In	O
additional	O
experiments	O
,	O
remikiren	O
was	O
given	O
on	O
top	O
of	O
either	O
CGP	B-chemical
38560A	E-chemical
or	O
enalkiren	S-chemical
in	O
the	O
same	O
animals	O
.	O
Finally	O
,	O
the	O
three	O
drugs	O
were	O
compared	O
with	O
the	O
angiotensin	B-GP
converting	I-GP
enzyme	E-GP
inhibitor	O
cilazapril	S-chemical
.	O
The	O
effects	O
of	O
the	O
three	O
drugs	O
on	O
the	O
plasma	O
components	O
of	O
the	O
renin	S-GP
-	O
angiotensin	S-GP
system	O
(	O
plasma	O
renin	S-GP
activity	O
,	O
immunoreactive	O
renin	S-GP
,	O
and	O
immunoreactive	O
angiotensin	B-GP
II	E-GP
concentrations	O
)	O
were	O
also	O
measured	O
.	O
Our	O
results	O
show	O
that	O
remikiren	S-chemical
was	O
as	O
effective	O
as	O
cilazapril	S-chemical
and	O
markedly	O
more	O
effective	O
than	O
CGP	B-chemical
38560A	E-chemical
or	O
enalkiren	S-chemical
in	O
reducing	O
arterial	O
pressure	O
in	O
our	O
monkey	O
model	O
.	O
Interestingly	O
,	O
these	O
differences	O
in	O
arterial	O
pressure	O
could	O
not	O
be	O
explained	O
by	O
differences	O
of	O
in	O
vitro	O
potency	O
or	O
different	O
biochemical	O
changes	O
of	O
the	O
plasma	O
components	O
of	O
the	O
renin	S-GP
-	O
angiotensin	S-GP
system	O
,	O
because	O
the	O
inhibitors	O
all	O
reduced	O
immunoreactive	O
angiotensin	B-GP
II	E-GP
to	O
similarly	O
low	O
levels	O
.	O
One	O
possible	O
explanation	O
is	O
that	O
,	O
in	O
our	O
model	O
,	O
remikiren	S-chemical
in	O
contrast	O
to	O
CGP	B-chemical
38560A	E-chemical
and	O
enalkiren	S-chemical
is	O
able	O
to	O
inhibit	O
renin	S-GP
in	O
a	O
functionally	O
important	O
extraplasmatic	O
compartment	O
.	O

Simvastatin	S-chemical
induces	O
interleukin-18	S-GP
production	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
The	O
effects	O
of	O
statins	O
on	O
immune	O
response	O
depend	O
on	O
the	O
inhibition	O
of	O
3-hydroxy-3-methylglutaryl	B-GP
coenzyme-A	I-GP
(	I-GP
HMG-CoA	I-GP
)	I-GP
reductase	E-GP
and	O
leukocyte	B-GP
function-associated	I-GP
antigen	I-GP
(	I-GP
LFA	I-GP
)	I-GP
-1	E-GP
,	O
which	O
is	O
a	O
ligand	O
of	O
intercellular	B-GP
adhesion	I-GP
molecule	I-GP
(	I-GP
ICAM	I-GP
)	I-GP
-1	E-GP
.	O
Simvastatin	S-chemical
,	O
an	O
HMG-CoA	B-GP
reductase	E-GP
inhibitor	O
with	O
mild	O
inhibition	O
of	O
LFA-1	S-GP
,	O
induced	O
the	O
production	O
of	O
interleukin	B-GP
(	I-GP
IL	I-GP
)	I-GP
-18	E-GP
,	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
(	I-GP
TNF	I-GP
)	I-GP
-alpha	E-GP
and	O
interferon	B-GP
(	I-GP
IFN	I-GP
)	I-GP
-gamma	E-GP
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O
The	O
IL-18	S-GP
production	O
is	O
located	O
upstream	O
of	O
the	O
cytokine	S-GP
cascade	O
activated	O
by	O
simvastatin	S-chemical
.	O
Moreover	O
,	O
simvastatin	S-chemical
concentration-dependently	O
inhibited	O
the	O
expression	O
of	O
ICAM-1	S-GP
and	O
induced	O
the	O
expression	O
of	O
CD40	S-GP
on	O
monocytes	O
.	O
In	O
the	O
presence	O
of	O
IL-18	S-GP
,	O
simvastatin	S-chemical
suppressed	O
the	O
expression	O
of	O
ICAM-1	S-GP
and	O
CD40	S-GP
as	O
well	O
as	O
the	O
production	O
of	O
IL-12	S-GP
,	O
TNF-alpha	S-GP
and	O
IFN-gamma	S-GP
in	O
PBMC	O
,	O
contributing	O
to	O
the	O
anti-inflammatory	O
effect	O
of	O
simvastatin	S-chemical
.	O
The	O
effects	O
of	O
simvastatin	S-chemical
were	O
abolished	O
by	O
the	O
addition	O
of	O
the	O
product	O
of	O
the	O
HMG-CoA	B-GP
reductase	E-GP
,	O
mevalonate	S-chemical
,	O
indicating	O
the	O
involvement	O
of	O
HMG-CoA	B-GP
reductase	E-GP
in	O
the	O
action	O
of	O
simvastatin	S-chemical
.	O

Intercalation	O
pathway	O
in	O
many-particle	O
LiFePO4	S-chemical
electrode	O
revealed	O
by	O
nanoscale	O
state-of-charge	O
mapping	O
.	O
The	O
intercalation	O
pathway	O
of	O
lithium	B-chemical
iron	I-chemical
phosphate	E-chemical
(	O
LFP	S-chemical
)	O
in	O
the	O
positive	O
electrode	O
of	O
a	O
lithium	S-chemical
-ion	O
battery	O
was	O
probed	O
at	O
the	O
∼40	O
nm	O
length	O
scale	O
using	O
oxidation-state-sensitive	O
X-ray	O
microscopy	O
.	O
Combined	O
with	O
morphological	O
observations	O
of	O
the	O
same	O
exact	O
locations	O
using	O
transmission	O
electron	O
microscopy	O
,	O
we	O
quantified	O
the	O
local	O
state-of-charge	O
of	O
approximately	O
450	O
individual	O
LFP	S-chemical
particles	O
over	O
nearly	O
the	O
entire	O
thickness	O
of	O
the	O
porous	O
electrode	O
.	O
With	O
the	O
electrode	O
charged	O
to	O
50	O
%	O
state-of-charge	O
in	O
0.5	O
h	O
,	O
we	O
observed	O
that	O
the	O
overwhelming	O
majority	O
of	O
particles	O
were	O
either	O
almost	O
completely	O
delithiated	O
or	O
lithiated	O
.	O
Specifically	O
,	O
only	O
∼2	O
%	O
of	O
individual	O
particles	O
were	O
at	O
an	O
intermediate	O
state-of-charge	O
.	O
From	O
this	O
small	O
fraction	O
of	O
particles	O
that	O
were	O
actively	O
undergoing	O
delithiation	O
,	O
we	O
conclude	O
that	O
the	O
time	O
needed	O
to	O
charge	O
a	O
particle	O
is	O
∼1/50	O
the	O
time	O
needed	O
to	O
charge	O
the	O
entire	O
particle	O
ensemble	O
.	O
Surprisingly	O
,	O
we	O
observed	O
a	O
very	O
weak	O
correlation	O
between	O
the	O
sequence	O
of	O
delithiation	O
and	O
the	O
particle	O
size	O
,	O
contrary	O
to	O
the	O
common	O
expectation	O
that	O
smaller	O
particles	O
delithiate	O
before	O
larger	O
ones	O
.	O
Our	O
quantitative	O
results	O
unambiguously	O
confirm	O
the	O
mosaic	O
(	O
particle-by-particle	O
)	O
pathway	O
of	O
intercalation	O
and	O
suggest	O
that	O
the	O
rate-limiting	O
process	O
of	O
charging	O
is	O
initiating	O
the	O
phase	O
transformation	O
by	O
,	O
for	O
example	O
,	O
a	O
nucleation-like	O
event	O
.	O
Therefore	O
,	O
strategies	O
for	O
further	O
enhancing	O
the	O
performance	O
of	O
LFP	S-chemical
electrodes	O
should	O
not	O
focus	O
on	O
increasing	O
the	O
phase-boundary	O
velocity	O
but	O
on	O
the	O
rate	O
of	O
phase-transformation	O
initiation	O
.	O

Role	O
of	O
quercetin	S-chemical
in	O
cadmium	S-chemical
-induced	O
oxidative	O
stress	O
,	O
neuronal	O
damage	O
,	O
and	O
apoptosis	O
in	O
rats	O
.	O
The	O
present	O
study	O
was	O
carried	O
out	O
to	O
evaluate	O
the	O
neuroprotective	O
effect	O
of	O
quercetin	S-chemical
(	O
QE	O
)	O
in	O
protecting	O
the	O
cadmium	S-chemical
(	O
Cd	S-chemical
)	O
-induced	O
neuronal	O
injury	O
in	O
frontal	O
cortex	O
of	O
rats	O
.	O
A	O
total	O
of	O
30	O
adult	O
male	O
Sprague-Dawley	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
of	O
10	O
animals	O
each	O
:	O
control	O
,	O
Cd	S-chemical
treated	O
and	O
Cd	S-chemical
treated	O
with	O
QE	O
.	O
The	O
Cd	S-chemical
-treated	O
group	O
was	O
injected	O
subcutaneously	O
with	O
cadmium	B-chemical
chloride	E-chemical
(	O
CdCl2	S-chemical
)	O
dissolved	O
in	O
saline	O
at	O
a	O
dose	O
of	O
2	O
ml/kg/day	O
for	O
30	O
days	O
,	O
resulting	O
in	O
a	O
dosage	O
of	O
1	O
mg/kg	O
Cd	S-chemical
.	O
The	O
rats	O
in	O
QE-treated	O
groups	O
were	O
given	O
QE	O
(	O
15	O
mg/kg	O
body	O
weight	O
)	O
once	O
a	O
day	O
intraperitoneally	O
starting	O
2	O
days	O
prior	O
to	O
Cd	S-chemical
injection	O
,	O
during	O
the	O
study	O
period	O
.	O
Rats	O
were	O
sacrificed	O
at	O
the	O
end	O
of	O
the	O
study	O
and	O
the	O
frontal	O
cortex	O
tissues	O
were	O
removed	O
for	O
biochemical	O
and	O
histopathological	O
investigation	O
.	O
To	O
date	O
,	O
there	O
is	O
no	O
available	O
information	O
on	O
the	O
effect	O
of	O
QE	O
on	O
neuronal	O
injury	O
after	O
Cd	S-chemical
exposure	O
.	O
Rats	O
intoxicated	O
with	O
Cd	S-chemical
for	O
30	O
days	O
,	O
significantly	O
increased	O
tissue	O
malondialdehyde	S-chemical
(	O
MDA	S-chemical
)	O
levels	O
and	O
significantly	O
decreased	O
enzymatic	O
antioxidants	O
superoxide	B-GP
dismutase	E-GP
,	O
glutathione	B-GP
peroxidase	E-GP
and	O
catalase	S-GP
in	O
the	O
frontal	O
cortex	O
tissue	O
.	O
Administration	O
of	O
QE	O
with	O
Cd	S-chemical
significantly	O
diminished	O
the	O
levels	O
of	O
MDA	S-chemical
and	O
significantly	O
elevated	O
the	O
levels	O
of	O
enzymatic	O
antioxidants	O
in	O
the	O
frontal	O
cortex	O
tissue	O
.	O
The	O
histopathological	O
studies	O
in	O
the	O
brain	O
of	O
rats	O
also	O
supported	O
that	O
QE	O
markedly	O
reduced	O
the	O
Cd	S-chemical
-induced	O
histopathological	O
changes	O
and	O
well	O
preserved	O
the	O
normal	O
histological	O
architecture	O
of	O
the	O
frontal	O
cortex	O
tissue	O
.	O
The	O
caspase-3	S-GP
immunopositivity	O
was	O
increased	O
in	O
degenerating	O
neurons	O
of	O
the	O
Cd	S-chemical
group	O
.	O
Treatment	O
with	O
QE	O
markedly	O
reduced	O
the	O
immunoreactivity	O
of	O
degenerating	O
neurons	O
.	O
In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
current	O
study	O
suggest	O
that	O
QE	O
may	O
be	O
beneficial	O
in	O
combating	O
the	O
Cd	S-chemical
-induced	O
neurotoxicity	O
in	O
the	O
brain	O
of	O
rats	O
.	O
We	O
believe	O
that	O
further	O
preclinical	O
research	O
into	O
the	O
utility	O
of	O
QE	O
may	O
indicate	O
its	O
usefulness	O
as	O
a	O
potential	O
treatment	O
for	O
neurodegeneration	O
after	O
Cd	S-chemical
exposure	O
in	O
rats	O
.	O

Hydrogen	B-chemical
peroxide	E-chemical
-mediated	O
oxidative	O
stress	O
disrupts	O
calcium	S-chemical
binding	O
on	O
calmodulin	S-GP
:	O
more	O
evidence	O
for	O
oxidative	O
stress	O
in	O
vitiligo	O
.	O
Patients	O
with	O
acute	O
vitiligo	O
have	O
low	O
epidermal	O
catalase	S-GP
expression/activities	O
and	O
accumulate	O
10	O
(	O
-3	O
)	O
M	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
O	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
.	O
One	O
consequence	O
of	O
this	O
severe	O
oxidative	O
stress	O
is	O
an	O
altered	O
calcium	S-chemical
homeostasis	O
in	O
epidermal	O
keratinocytes	O
and	O
melanocytes	O
.	O
Here	O
,	O
we	O
show	O
decreased	O
epidermal	O
calmodulin	S-GP
expression	O
in	O
acute	O
vitiligo	O
.	O
Since	O
10	O
(	O
-3	O
)	O
M	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
O	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
oxidises	O
methionine	S-chemical
and	O
tryptophan	S-chemical
residues	O
in	O
proteins	O
,	O
we	O
examined	O
calcium	S-chemical
binding	O
to	O
calmodulin	S-GP
in	O
the	O
presence	O
and	O
absence	O
of	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
O	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
utilising	O
(	O
45	O
)	O
calcium	S-chemical
.	O
The	O
results	O
showed	O
that	O
all	O
four	O
calcium	S-chemical
atoms	O
exchanged	O
per	O
molecule	O
of	O
calmodulin	S-GP
.	O
Since	O
oxidised	O
calmodulin	S-GP
looses	O
its	O
ability	O
to	O
activate	O
calcium	B-GP
ATPase	E-GP
,	O
enzyme	O
activities	O
were	O
followed	O
in	O
full	O
skin	O
biopsies	O
from	O
lesional	O
skin	O
of	O
patients	O
with	O
acute	O
vitiligo	O
(	O
n=6	O
)	O
and	O
healthy	O
controls	O
(	O
n=6	O
)	O
.	O
The	O
results	O
yielded	O
a	O
4-fold	O
decrease	O
of	O
ATPase	O
activities	O
in	O
the	O
patients	O
.	O
Computer	O
simulation	O
of	O
native	O
and	O
oxidised	O
calmodulin	S-GP
confirmed	O
the	O
loss	O
of	O
all	O
four	O
calcium	S-chemical
ions	O
from	O
their	O
specific	O
EF-hand	B-GP
domains	E-GP
.	O
Taken	O
together	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
O	I-chemical
(	I-chemical
2	I-chemical
)	E-chemical
-mediated	O
oxidation	O
affects	O
calcium	S-chemical
binding	O
in	O
calmodulin	S-GP
leading	O
to	O
perturbed	O
calcium	S-chemical
homeostasis	O
and	O
perturbed	O
l-phenylalanine	S-chemical
-uptake	O
in	O
the	O
epidermis	O
of	O
acute	O
vitiligo	O
.	O

The	O
increased	O
number	O
of	O
Leydig	O
cells	O
by	O
di	B-chemical
(	I-chemical
2-ethylhexyl	I-chemical
)	I-chemical
phthalate	E-chemical
comes	O
from	O
the	O
differentiation	O
of	O
stem	O
cells	O
into	O
Leydig	O
cell	O
lineage	O
in	O
the	O
adult	O
rat	O
testis	O
.	O
The	O
objective	O
of	O
the	O
present	O
study	O
is	O
to	O
determine	O
whether	O
di	B-chemical
(	I-chemical
2-ethylhexyl	I-chemical
)	I-chemical
phthalate	E-chemical
(	O
DEHP	S-chemical
)	O
exposure	O
at	O
adulthood	O
increases	O
rat	O
Leydig	O
cell	O
number	O
and	O
to	O
investigate	O
the	O
possible	O
mechanism	O
.	O
90-day-old	O
Long-Evans	O
rats	O
were	O
randomly	O
divided	O
into	O
3	O
groups	O
,	O
and	O
were	O
gavaged	O
with	O
the	O
corn	O
oil	O
(	O
control	O
)	O
or	O
10	O
or	O
750mg/kg	O
DEHP	S-chemical
daily	O
for	O
7	O
days	O
,	O
and	O
then	O
received	O
an	O
intraperitoneal	O
injection	O
of	O
75mg/kg	O
ethane	B-chemical
dimethanesulfonate	E-chemical
(	O
EDS	S-chemical
)	O
to	O
eliminate	O
Leydig	O
cells	O
.	O
Serum	O
testosterone	S-chemical
concentrations	O
were	O
assessed	O
by	O
RIA	O
,	O
and	O
the	O
mRNA	O
levels	O
of	O
Leydig	O
cell	O
genes	O
were	O
measured	O
by	O
qPCR	O
.	O
EDS	S-chemical
eliminated	O
all	O
Leydig	O
cells	O
in	O
the	O
control	O
testis	O
on	O
day	O
4	O
post-	O
EDS	S-chemical
,	O
as	O
judged	O
by	O
undetectable	O
serum	O
testosterone	S-chemical
level	O
and	O
no	O
3β-hydroxysteroid	B-GP
dehydrogenase	E-GP
positive	O
(	O
3β-HSD	S-GP
(	O
pos	O
)	O
)	O
cells	O
in	O
the	O
interstitium	O
.	O
However	O
,	O
in	O
DEHP	S-chemical
-treated	O
groups	O
,	O
there	O
were	O
detectable	O
serum	O
testosterone	S-chemical
concentrations	O
and	O
some	O
oval-shaped	O
3β-HSD	S-GP
(	O
pos	O
)	O
cells	O
in	O
the	O
interstitium	O
.	O
These	O
3β-HSD	S-GP
(	O
pos	O
)	O
cells	O
were	O
not	O
stained	O
by	O
the	O
antibody	O
against	O
11β-hydroxysteroid	B-GP
dehydrogenase	I-GP
1	E-GP
(	O
11β-HSD	S-GP
1	O
)	O
,	O
a	O
marker	O
for	O
Leydig	O
cells	O
at	O
a	O
more	O
advanced	O
stage	O
.	O
The	O
disappearance	O
of	O
mRNAs	O
of	O
Leydig	O
cell	O
biomarkers	O
including	O
Lhcgr	O
,	O
Cyp11a1	O
,	O
Cyp17a1	O
,	O
Insl3	O
and	O
Hsd11b1	O
in	O
the	O
control	O
testis	O
was	O
observed	O
on	O
day	O
4	O
post-	O
EDS	S-chemical
.	O
However	O
,	O
there	O
were	O
detectable	O
concentrations	O
of	O
Lhcgr	S-GP
,	O
Cyp11a1	S-GP
and	O
Cyp17a1	S-GP
mRNAs	O
but	O
undetectable	O
concentrations	O
of	O
Insl3	S-GP
,	O
Hsd17b3	S-GP
and	O
Hsd11b1	S-GP
in	O
the	O
DEHP	S-chemical
-treated	O
testes	O
,	O
indicating	O
that	O
these	O
3β-HSD	S-GP
(	O
pos	O
)	O
cells	O
were	O
newly	O
formed	O
progenitor	O
Leydig	O
cells	O
.	O
The	O
mRNA	O
level	O
for	O
nestin	S-GP
(	O
Nes	S-GP
,	O
biomarker	O
for	O
stem	O
Leydig	O
cells	O
)	O
was	O
significantly	O
increased	O
in	O
the	O
control	O
testis	O
on	O
day	O
4	O
post-	O
EDS	S-chemical
,	O
but	O
not	O
in	O
the	O
DEHP	S-chemical
treated	O
testes	O
,	O
suggesting	O
that	O
these	O
nestin	S-GP
positive	O
stem	O
cells	O
were	O
differentiated	O
into	O
progenitor	O
Leydig	O
cells	O
in	O
the	O
DEHP	S-chemical
-treated	O
testes	O
.	O
The	O
present	O
study	O
suggests	O
that	O
DEHP	S-chemical
increases	O
the	O
differentiation	O
of	O
stem	O
cells	O
into	O
progenitor	O
Leydig	O
cells	O
.	O

Tyrosinase	S-GP
inhibitors	O
from	O
Rhododendron	O
collettianum	O
and	O
their	O
structure-activity	O
relationship	O
(	O
SAR	O
)	O
studies	O
.	O
A	O
new	O
coumarinolignoid	S-chemical
8'-epi-cleomiscosin	B-chemical
A	E-chemical
(	O
1	O
)	O
together	O
with	O
the	O
new	O
glycoside	O
8-O-beta-D-glucopyranosyl-6-hydroxy-2-methyl-4H-1-benzopyrane-4-one	S-chemical
(	O
2	O
)	O
have	O
been	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Rhododendron	O
collettianum	O
and	O
their	O
structures	O
determined	O
on	O
the	O
basis	O
of	O
spectroscopic	O
evidences	O
.	O
Tyrosinase	S-GP
inhibition	O
study	O
of	O
these	O
compounds	O
and	O
their	O
structure-activity	O
relationship	O
(	O
SAR	O
)	O
were	O
also	O
investigated	O
.	O
The	O
compounds	O
exhibited	O
potent	O
to	O
mild	O
inhibition	O
activity	O
against	O
the	O
enzyme	O
.	O
Especially	O
,	O
the	O
compound	O
1	O
showed	O
strong	O
inhibition	O
(	O
IC50=1.33	O
microM	O
)	O
against	O
the	O
enzyme	O
tyrosinase	S-GP
,	O
as	O
compared	O
to	O
the	O
standard	O
tyrosinase	O
inhibitors	O
kojic	B-chemical
acid	E-chemical
(	O
IC50=16.67	O
microM	O
)	O
and	O
L-mimosine	S-chemical
(	O
IC50=3.68	O
microM	O
)	O
,	O
indicating	O
its	O
potential	O
used	O
for	O
the	O
treatment	O
of	O
hyperpigmentation	O
associated	O
with	O
the	O
high	O
production	O
of	O
melanocytes	O
.	O

Development	O
of	O
hypoxia-inducible	B-GP
factor	I-GP
(	I-GP
HIF	I-GP
)	I-GP
-1α	E-GP
inhibitors	O
:	O
effect	O
of	O
ortho-carborane	S-chemical
substituents	O
on	O
HIF	S-GP
transcriptional	O
activity	O
under	O
hypoxia	O
.	O
A	O
series	O
of	O
substituted	O
ortho-carboranylphenoxyacetanilides	S-chemical
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
ability	O
to	O
inhibit	O
hypoxia-induced	O
HIF-1	S-GP
transcriptional	O
activity	O
using	O
a	O
cell-based	O
reporter	O
assay	O
in	O
HeLa	O
cells	O
expressing	O
the	O
HRE	S-GP
-dependent	O
firefly	O
luciferase	O
reporter	O
construct	O
(	O
HRE	S-GP
-Luc	O
)	O
and	O
constitutively	O
expressing	O
CMV-driven	O
Renilla	O
luciferase	O
reporter	O
,	O
and	O
their	O
ability	O
to	O
inhibit	O
cell	O
growth	O
(	O
GI	O
(	O
50	O
)	O
)	O
using	O
the	O
MTT	S-chemical
assay	O
.	O
Among	O
the	O
compounds	O
synthesized	O
,	O
1g	O
and	O
1l	O
showed	O
significant	O
inhibition	O
of	O
hypoxia-induced	O
HIF-1	S-GP
transcriptional	O
activity	O
(	O
IC	O
(	O
50	O
)	O
:	O
1.9	O
±	O
0.4	O
and	O
1.4	O
±	O
0.2	O
μM	O
,	O
respectively	O
)	O
.	O
Both	O
compounds	O
suppressed	O
HIF-1α	S-GP
accumulation	O
in	O
a	O
concentration-dependent	O
manner	O
.	O
The	O
porcine	B-GP
heart	I-GP
malate	I-GP
dehydrogenase	E-GP
(	O
MDH	S-GP
)	O
refolding	O
assay	O
revealed	O
that	O
compound	O
1l	O
inhibited	O
human	B-GP
Hsp60	E-GP
chaperone	O
activity	O
(	O
IC	O
(	O
50	O
)	O
:	O
6.80	O
±	O
0.25	O
μM	O
)	O
and	O
this	O
inhibition	O
activity	O
was	O
higher	O
than	O
that	O
of	O
ETB	S-chemical
(	O
IC	O
(	O
50	O
)	O
:	O
10.9	O
±	O
0.63	O
μM	O
)	O
.	O

Muscarinic	O
cholinergic	O
and	O
histamine	B-GP
H1	I-GP
receptor	E-GP
binding	O
of	O
phenothiazine	S-chemical
drug	O
metabolites	O
.	O
In	O
vitro	O
binding	O
affinities	O
of	O
chlorpromazine	S-chemical
,	O
fluphenazine	S-chemical
,	O
levomepromazine	S-chemical
,	O
perphenazine	S-chemical
and	O
some	O
of	O
their	O
metabolites	O
for	O
dopamine	B-GP
D2	I-GP
receptors	E-GP
,	O
alpha	B-GP
1-	I-GP
and	I-GP
alpha	I-GP
2	I-GP
adrenoceptors	E-GP
in	O
rat	O
brain	O
were	O
previously	O
reported	O
from	O
our	O
laboratories	O
.	O
The	O
present	O
study	O
reports	O
the	O
in	O
vitro	O
binding	O
affinities	O
of	O
the	O
same	O
compounds	O
for	O
muscarinic	B-GP
cholinergic	I-GP
receptors	E-GP
and	O
for	O
histamine	B-GP
H1	I-GP
receptors	E-GP
in	O
rat	O
brain	O
,	O
using	O
3H-quinuclidinyl	B-chemical
benzilate	E-chemical
and	O
3H-mepyramine	S-chemical
as	O
radioligands	O
.	O
Chlorpromazine	S-chemical
,	O
levomepromazine	S-chemical
,	O
and	O
their	O
metabolites	O
had	O
5-30	O
times	O
higher	O
binding	O
affinities	O
for	O
muscarinic	B-GP
cholinergic	I-GP
receptors	E-GP
than	O
fluphenazine	S-chemical
,	O
perphenazine	S-chemical
and	O
their	O
metabolites	O
.	O
Levomepromazine	S-chemical
was	O
the	O
most	O
potent	O
and	O
fluphenazine	S-chemical
the	O
least	O
potent	O
of	O
the	O
four	O
drugs	O
in	O
histamine	B-GP
H1	I-GP
receptor	E-GP
binding	O
.	O
7-Hydroxy	B-chemical
levomepromazine	E-chemical
,	O
3-hydroxy	B-chemical
levomepromazine	E-chemical
and	O
7-hydroxy	B-chemical
fluphenazine	E-chemical
had	O
only	O
10	O
%	O
of	O
the	O
potency	O
of	O
the	O
parent	O
drug	O
in	O
histamine	B-GP
H1	I-GP
receptor	E-GP
binding	O
,	O
while	O
the	O
7-hydroxy	S-chemical
-metabolites	O
of	O
chlorpromazine	S-chemical
and	O
perphenazine	S-chemical
had	O
about	O
75	O
%	O
of	O
the	O
potency	O
of	O
the	O
parent	O
drug	O
in	O
this	O
binding	O
system	O
.	O
Their	O
histamine	B-GP
H1	I-GP
receptor	E-GP
binding	O
affinities	O
indicate	O
that	O
metabolites	O
may	O
contribute	O
to	O
the	O
sedative	O
effects	O
of	O
chlorpromazine	S-chemical
and	O
levomepromazine	S-chemical
.	O

Localization	O
of	O
an	O
11	B-GP
beta	I-GP
hydroxysteroid	I-GP
dehydrogenase	E-GP
activity	O
to	O
the	O
distal	O
nephron	O
.	O
Evidence	O
for	O
the	O
existence	O
of	O
two	O
species	O
of	O
dehydrogenase	S-GP
in	O
the	O
rat	O
kidney	O
.	O
An	O
11	B-GP
beta	I-GP
hydroxysteroid	I-GP
dehydrogenase	E-GP
(	O
11	B-GP
beta	I-GP
HSD	E-GP
)	O
activity	O
has	O
been	O
localized	O
in	O
the	O
rat	O
kidney	O
by	O
a	O
histochemical	O
technique	O
which	O
links	O
steroid	S-chemical
metabolism	O
with	O
the	O
production	O
of	O
a	O
color	O
reaction	O
.	O
Oxidation	O
of	O
11	B-chemical
beta-hydroxyandrostenedione	E-chemical
was	O
observed	O
in	O
cortical	O
distal	O
convoluted	O
tubules	O
and	O
in	O
medullary	O
collecting	O
ducts	O
.	O
Carbenoxolone	S-chemical
abolished	O
staining	O
,	O
no	O
reaction	O
was	O
obtained	O
with	O
androstenedione	S-chemical
hydroxylated	O
at	O
the	O
17	O
or	O
19	O
position	O
,	O
and	O
oxidation	O
of	O
11	B-chemical
beta-hydroxyandrostenedione	E-chemical
was	O
nicotinamide-adenine	B-chemical
dinucleotide	E-chemical
(	O
NAD	S-chemical
)	O
dependent	O
.	O
These	O
results	O
demonstrate	O
the	O
presence	O
of	O
a	O
dehydrogenase	S-GP
activity	O
separate	O
from	O
the	O
nicotinamide-adenine	B-chemical
dinucleotide	I-chemical
phosphate	E-chemical
(	O
NADP	S-chemical
)	O
-dependent	O
11	B-GP
beta	I-GP
hydroxysteroid	I-GP
dehydrogenase	E-GP
recently	O
purified	O
and	O
cloned	O
from	O
rat	O
liver	O
.	O
We	O
have	O
named	O
this	O
activity	O
11	B-GP
beta	I-GP
HSD2	E-GP
to	O
distinguish	O
it	O
from	O
the	O
NADP	S-chemical
-dependent	O
11	B-GP
beta	I-GP
HSD	E-GP
.	O
Histological	O
studies	O
showed	O
that	O
11	B-GP
beta	I-GP
HSD2	E-GP
activity	O
does	O
not	O
correlate	O
with	O
the	O
immunocytochemical	O
localization	O
of	O
the	O
previously	O
defined	O
11	B-GP
beta	I-GP
HSD	E-GP
enzyme	O
,	O
but	O
rather	O
the	O
11	B-GP
beta	I-GP
HSD2	E-GP
activity	O
is	O
localized	O
in	O
the	O
distal	O
tubules	O
of	O
the	O
rat	O
kidney	O
.	O
In	O
this	O
respect	O
11	B-GP
beta	I-GP
HSD2	E-GP
colocalizes	O
with	O
the	O
mineralocorticoid	B-GP
receptor	E-GP
.	O
No	O
reaction	O
product	O
was	O
obtained	O
using	O
cortisol	S-chemical
or	O
corticosterone	S-chemical
as	O
substrate	O
with	O
either	O
NAD	S-chemical
or	O
NADP	S-chemical
as	O
cofactor	O
.	O
Furthermore	O
incubation	O
of	O
tissue	O
sections	O
with	O
11	B-chemical
beta	I-chemical
androstenedione	E-chemical
in	O
the	O
presence	O
of	O
deoxycorticosterone	S-chemical
completely	O
inhibited	O
cytochemical	O
staining	O
.	O
We	O
interpret	O
these	O
results	O
as	O
evidence	O
of	O
20	B-GP
reductase	E-GP
activity	O
which	O
uses	O
the	O
reduced	O
cofactor	O
at	O
the	O
expense	O
of	O
the	O
color	O
reaction	O
.	O
These	O
results	O
support	O
the	O
crucial	O
role	O
played	O
by	O
an	O
11	B-GP
beta	I-GP
hydroxysteroid	I-GP
dehydrogenase	E-GP
in	O
the	O
local	O
protection	O
of	O
type	O
I	O
receptors	O
in	O
mineralocorticoid	O
selective	O
tissues	O
.	O

Reactive	O
Metabolite	O
Trapping	O
Studies	O
on	O
Imidazo-	B-chemical
and	I-chemical
2-Methylimidazo	I-chemical
[	I-chemical
2,1-b	I-chemical
]	I-chemical
thiazole	E-chemical
-based	O
Inverse	O
Agonists	O
of	O
the	O
Ghrelin	B-GP
Receptor	E-GP
.	O
The	O
current	O
study	O
examined	O
the	O
bioactivation	O
potential	O
of	O
ghrelin	B-GP
receptor	E-GP
inverse	O
agonists	O
,	O
1-	B-chemical
(	I-chemical
2-	I-chemical
(	I-chemical
2-chloro-4-	I-chemical
(	I-chemical
2H-1,2,3-triazol-2-yl	I-chemical
)	I-chemical
benzyl	I-chemical
)	I-chemical
-2,7-diazaspiro	I-chemical
[	I-chemical
3.5	I-chemical
]	I-chemical
nonan-7-yl	I-chemical
)	I-chemical
-2-	I-chemical
(	I-chemical
imidazo	I-chemical
[	I-chemical
2,1-b	I-chemical
]	I-chemical
thiazol-6-yl	I-chemical
)	I-chemical
ethanone	E-chemical
(	O
1	O
)	O
and	O
1-	B-chemical
(	I-chemical
2-	I-chemical
(	I-chemical
2-chloro-4-	I-chemical
(	I-chemical
2H-1,2,3-triazol-2-yl	I-chemical
)	I-chemical
benzyl	I-chemical
)	I-chemical
-2,7-diazaspiro	I-chemical
[	I-chemical
3.5	I-chemical
]	I-chemical
nonan-7-yl	I-chemical
)	I-chemical
-2-	I-chemical
(	I-chemical
2-methylimidazo	I-chemical
[	I-chemical
2,1-b	I-chemical
]	I-chemical
thiazol-6-yl	I-chemical
)	I-chemical
ethanone	E-chemical
(	O
2	O
)	O
,	O
containing	O
a	O
fused	O
imidazo	B-chemical
[	I-chemical
2,1-b	I-chemical
]	I-chemical
thiazole	E-chemical
motif	O
in	O
the	O
core	O
structure	O
.	O
Both	O
compounds	O
underwent	O
oxidative	O
metabolism	O
in	O
NADPH	S-chemical
-	O
and	O
glutathione	S-chemical
-supplemented	O
human	O
liver	O
microsomes	O
to	O
yield	O
glutathione	S-chemical
conjugates	O
,	O
which	O
was	O
consistent	O
with	O
their	O
bioactivation	O
to	O
reactive	O
species	O
.	O
Mass	O
spectral	O
fragmentation	O
and	O
NMR	O
analysis	O
indicated	O
that	O
the	O
site	O
of	O
attachment	O
of	O
the	O
glutathionyl	S-chemical
moiety	O
in	O
the	O
thiol	S-chemical
conjugates	O
was	O
on	O
the	O
thiazole	S-chemical
ring	O
within	O
the	O
bicycle	O
.	O
Two	O
glutathione	S-chemical
conjugates	O
were	O
discerned	O
with	O
the	O
imidazo	B-chemical
[	I-chemical
2,1-b	I-chemical
]	I-chemical
thiazole	E-chemical
derivative	O
1	O
.	O
One	O
adduct	O
was	O
derived	O
from	O
the	O
Michael	O
addition	O
of	O
glutathione	S-chemical
to	O
a	O
putative	O
S-oxide	S-chemical
metabolite	O
of	O
1	O
,	O
whereas	O
,	O
the	O
second	O
adduct	O
was	O
formed	O
via	O
the	O
reaction	O
of	O
a	O
second	O
glutathione	S-chemical
molecule	O
with	O
the	O
initial	O
glutathione-S-oxide	S-chemical
adduct	O
.	O
In	O
the	O
case	O
of	O
the	O
2-methylimidazo	B-chemical
[	I-chemical
2,1-b	I-chemical
]	I-chemical
thiazole	E-chemical
analog	O
2	O
,	O
glutathione	S-chemical
conjugation	O
occurred	O
via	O
an	O
oxidative	O
desulfation	O
mechanism	O
,	O
possibly	O
involving	O
thiazole	S-chemical
ring	O
epoxidation	O
as	O
the	O
rate-limiting	O
step	O
.	O
Additional	O
insights	O
into	O
the	O
mechanism	O
were	O
obtained	O
via	O
18O	S-chemical
exchange	O
and	O
trapping	O
studies	O
with	O
potassium	B-chemical
cyanide	E-chemical
.	O
The	O
mechanistic	O
insights	O
into	O
the	O
bioactivation	O
pathways	O
of	O
1	O
and	O
2	O
allowed	O
the	O
deployment	O
of	O
a	O
rational	O
chemical	O
intervention	O
strategy	O
that	O
involved	O
replacement	O
of	O
the	O
thiazole	S-chemical
ring	O
with	O
a	O
1,2,4-thiadiazole	S-chemical
group	O
to	O
yield	O
-	B-chemical
(	I-chemical
2-	I-chemical
(	I-chemical
2-chloro-4-	I-chemical
(	I-chemical
2H-1,2,3-triazol-2-yl	I-chemical
)	I-chemical
benzyl	I-chemical
)	I-chemical
-2,7-diazaspiro	I-chemical
[	I-chemical
3.5	I-chemical
]	I-chemical
nonan-7-yl	I-chemical
)	I-chemical
-2-	I-chemical
(	I-chemical
2-methylimidazo	I-chemical
[	I-chemical
2,1-b	I-chemical
]	I-chemical
[	I-chemical
1,3,4	I-chemical
]	I-chemical
thiadiazol-6-yl	I-chemical
)	I-chemical
ethanone	E-chemical
(	O
3	O
)	O
.	O
These	O
structural	O
changes	O
not	O
only	O
abrogated	O
the	O
bioactivation	O
liability	O
but	O
also	O
retained	O
the	O
attractive	O
pharmacological	O
attributes	O
of	O
the	O
prototype	O
agents	O
.	O

Interaction	O
of	O
silymarin	O
flavonolignans	S-chemical
with	O
organic	B-GP
anion-transporting	I-GP
polypeptides	E-GP
.	O
Organic	B-GP
anion-transporting	I-GP
polypeptides	E-GP
(	O
OATPs	S-GP
)	O
are	O
multispecific	B-GP
transporters	E-GP
mediating	O
the	O
uptake	O
of	O
endogenous	O
compounds	O
and	O
xenobiotics	O
in	O
tissues	O
that	O
are	O
important	O
for	O
drug	O
absorption	O
and	O
elimination	O
,	O
including	O
the	O
intestine	O
and	O
liver	O
.	O
Silymarin	O
is	O
a	O
popular	O
herbal	O
supplement	O
often	O
used	O
by	O
patients	O
with	O
chronic	O
liver	O
disease	O
;	O
higher	O
oral	O
doses	O
than	O
those	O
customarily	O
used	O
(	O
140	O
mg	O
three	O
times/day	O
)	O
are	O
being	O
evaluated	O
clinically	O
.	O
The	O
present	O
study	O
examined	O
the	O
effect	O
of	O
silymarin	O
flavonolignans	S-chemical
on	O
OATP1B1	S-GP
-	O
,	O
OATP1B3	S-GP
-	O
,	O
and	O
OATP2B1	S-GP
-mediated	O
transport	O
in	O
cell	O
lines	O
stably	O
expressing	O
these	O
transporters	O
and	O
in	O
human	O
hepatocytes	O
.	O
In	O
overexpressing	O
cell	O
lines	O
,	O
OATP1B1	S-GP
-	O
and	O
OATP1B3	S-GP
-mediated	O
estradiol-17β-glucuronide	S-chemical
uptake	O
and	O
OATP2B1	S-GP
-mediated	O
estrone-3-sulfate	S-chemical
uptake	O
were	O
inhibited	O
by	O
most	O
of	O
the	O
silymarin	O
flavonolignans	S-chemical
investigated	O
.	O
OATP1B1	S-GP
-	O
,	O
OATP1B3	S-GP
-	O
,	O
and	O
OATP2B1	S-GP
-mediated	O
substrate	O
transport	O
was	O
inhibited	O
efficiently	O
by	O
silymarin	O
(	O
IC50	O
values	O
of	O
1.3	O
,	O
2.2	O
and	O
0.3	O
µM	O
,	O
respectively	O
)	O
,	O
silybin	B-chemical
A	E-chemical
(	O
IC50	O
values	O
of	O
9.7	O
,	O
2.7	O
and	O
4.5	O
µM	O
,	O
respectively	O
)	O
,	O
silybin	B-chemical
B	E-chemical
(	O
IC50	O
values	O
of	O
8.5	O
,	O
5.0	O
and	O
0.8	O
µM	O
,	O
respectively	O
)	O
,	O
and	O
silychristin	S-chemical
(	O
IC50	O
values	O
of	O
9.0	O
,	O
36.4	O
,	O
and	O
3.6	O
µM	O
,	O
respectively	O
)	O
.	O
Furthermore	O
,	O
silymarin	O
,	O
silybin	B-chemical
A	E-chemical
,	O
and	O
silybin	B-chemical
B	E-chemical
(	O
100	O
µM	O
)	O
significantly	O
inhibited	O
OATP	S-GP
-mediated	O
estradiol-17β-glucuronide	S-chemical
and	O
rosuvastatin	S-chemical
uptake	O
into	O
human	O
hepatocytes	O
.	O
Calculation	O
of	O
the	O
maximal	O
unbound	O
portal	O
vein	O
concentrations/IC50	O
values	O
indicated	O
a	O
low	O
risk	O
for	O
silymarin-drug	O
interactions	O
in	O
hepatic	O
uptake	O
with	O
a	O
customary	O
silymarin	O
dose	O
.	O
The	O
extent	O
of	O
silymarin-drug	O
interactions	O
depends	O
on	O
OATP	S-GP
isoform	O
specificity	O
and	O
concentrations	O
of	O
flavonolignans	S-chemical
at	O
the	O
site	O
of	O
drug	O
transport	O
.	O
Higher	O
than	O
customary	O
doses	O
of	O
silymarin	O
,	O
or	O
formulations	O
with	O
improved	O
bioavailability	O
,	O
may	O
increase	O
the	O
risk	O
of	O
flavonolignan	S-chemical
interactions	O
with	O
OATP	S-GP
substrates	O
in	O
patients	O
.	O

RDH12	S-GP
,	O
a	O
retinol	B-GP
dehydrogenase	E-GP
causing	O
Leber	O
's	O
congenital	O
amaurosis	O
,	O
is	O
also	O
involved	O
in	O
steroid	O
metabolism	O
.	O
Three	O
retinol	B-GP
dehydrogenases	E-GP
(	O
RDHs	S-GP
)	O
were	O
tested	O
for	O
steroid	O
converting	O
abilities	O
:	O
human	B-GP
and	I-GP
murine	I-GP
RDH	I-GP
12	E-GP
and	O
human	B-GP
RDH13	E-GP
.	O
RDH12	S-GP
is	O
involved	O
in	O
retinal	O
degeneration	O
in	O
Leber	O
's	O
congenital	O
amaurosis	O
(	O
LCA	O
)	O
.	O
We	O
show	O
that	O
murine	B-GP
Rdh12	E-GP
and	O
human	B-GP
RDH13	E-GP
do	O
not	O
reveal	O
activity	O
towards	O
the	O
checked	O
steroids	O
,	O
but	O
that	O
human	B-GP
type	I-GP
12	I-GP
RDH	E-GP
reduces	O
dihydrotestosterone	O
to	O
androstanediol	S-chemical
,	O
and	O
is	O
thus	O
also	O
involved	O
in	O
steroid	O
metabolism	O
.	O
Furthermore	O
,	O
we	O
analyzed	O
both	O
expression	O
and	O
subcellular	O
localization	O
of	O
these	O
enzymes	O
.	O

Adipose	O
tissue	O
as	O
a	O
source	O
of	O
nicotinamide	B-GP
N-methyltransferase	E-GP
and	O
homocysteine	S-chemical
.	O
Nicotinamide	B-GP
N-methyltransferase	E-GP
(	O
NNMT	S-GP
)	O
catalyses	O
the	O
conversion	O
of	O
nicotinamide	S-chemical
to	O
1-methylnicotinamide	S-chemical
and	O
plays	O
an	O
important	O
role	O
in	O
hepatic	O
detoxification	O
reactions	O
.	O
Here	O
we	O
show	O
that	O
,	O
in	O
addition	O
to	O
the	O
liver	O
,	O
3T3-L1	O
adipocytes	O
as	O
well	O
as	O
human	O
and	O
murine	O
adipose	O
tissue	O
explants	O
express	O
high	O
amounts	O
of	O
enzymatically	O
active	O
NNMT	S-GP
.	O
NNMT	S-GP
mRNA	O
levels	O
and	O
enzyme	O
activity	O
increased	O
in	O
3T3-L1	O
cells	O
in	O
a	O
differentiation-dependent	O
manner	O
.	O
Homocysteine	S-chemical
,	O
the	O
atherogenic	O
product	O
of	O
the	O
NNMT	S-GP
-catalyzed	O
reaction	O
,	O
was	O
secreted	O
from	O
3T3-L1	O
cells	O
or	O
adipose	O
tissue	O
cultures	O
.	O
Homocysteine	S-chemical
release	O
increased	O
during	O
3T3-L1	O
differentiation	O
and	O
was	O
reduced	O
when	O
adipose	O
tissue	O
was	O
treated	O
with	O
the	O
NNMT	S-GP
inhibitor	O
1-methylnicotinamide	S-chemical
.	O
Nicotinic	B-chemical
acid	E-chemical
(	O
NA	S-chemical
)	O
,	O
a	O
widely	O
used	O
drug	O
to	O
lower	O
elevated	O
plasma	O
lipid	O
levels	O
,	O
induced	O
NNMT	S-GP
enzyme	O
activity	O
in	O
white	O
adipose	O
tissue	O
of	O
mice	O
.	O
In	O
tissue	O
culture	O
nicotinamide	S-chemical
treatment	O
led	O
to	O
an	O
increase	O
in	O
adipose	O
tissue	O
homocysteine	S-chemical
secretion	O
.	O
These	O
data	O
support	O
the	O
concept	O
that	O
adipose	O
tissue	O
NNMT	S-GP
contributes	O
to	O
the	O
increased	O
plasma	O
homocysteine	S-chemical
levels	O
in	O
patients	O
treated	O
with	O
NA	S-chemical
.	O

Chemotherapy	O
and	O
targeted	O
therapy	O
combinations	O
in	O
advanced	O
melanoma	O
.	O
For	O
three	O
decades	O
,	O
clinical	O
trials	O
with	O
chemotherapy	O
in	O
melanoma	O
have	O
failed	O
to	O
show	O
superiority	O
of	O
any	O
one	O
regimen	O
over	O
another	O
.	O
Dacarbazine	S-chemical
remains	O
the	O
only	O
``	O
standard	O
''	O
agent	O
.	O
With	O
response	O
rates	O
of	O
<	O
10	O
%	O
and	O
median	O
progression-free	O
survival	O
of	O
2	O
months	O
or	O
less	O
in	O
contemporary	O
trials	O
,	O
there	O
is	O
a	O
need	O
to	O
improve	O
systemic	O
therapy	O
.	O
Combination	O
chemotherapy	O
is	O
associated	O
with	O
higher	O
response	O
rates	O
than	O
single-agent	O
therapy	O
but	O
this	O
has	O
not	O
translated	O
into	O
improved	O
survival	O
.	O
An	O
increasing	O
number	O
of	O
potential	O
therapeutic	O
targets	O
have	O
been	O
identified	O
.	O
For	O
some	O
,	O
pharmacologic	O
inhibitors	O
are	O
available	O
,	O
including	O
sorafenib	S-chemical
for	O
BRAF	S-GP
,	O
farnesyltransferase	S-GP
inhibitors	O
for	O
NRAS	S-GP
,	O
PD-0325901	S-chemical
for	O
mitogen-activated	B-GP
protein	I-GP
kinase	E-GP
/	O
extracellular	B-GP
signal-regulated	I-GP
kinase	I-GP
kinase	E-GP
,	O
rapamycin	S-chemical
analogues	O
for	O
mammalian	B-GP
target	I-GP
of	I-GP
rapamycin	E-GP
,	O
and	O
agents	O
that	O
inhibit	O
either	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	E-GP
or	O
its	O
receptors	O
.	O
Several	O
multitargeted	O
kinase	S-GP
inhibitors	O
have	O
potency	O
against	O
the	O
fibroblast	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
,	O
c-kit	S-GP
,	O
and	O
platelet-derived	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
.	O
Small-molecule	O
inhibitors	O
of	O
c-met	S-GP
and	O
Akt	S-GP
are	O
in	O
preclinical	O
development	O
.	O
Another	O
class	O
of	O
agents	O
indirectly	O
affect	O
aberrant	O
signaling	O
,	O
including	O
inhibitors	O
of	O
chaperones	S-GP
and	O
proteasomes	S-GP
.	O
Several	O
targeted	O
agents	O
seem	O
to	O
enhance	O
the	O
cytotoxicity	O
of	O
chemotherapy	O
in	O
preclinical	O
models	O
.	O
The	O
mechanism	O
by	O
which	O
signaling	O
inhibition	O
might	O
synergize	O
with	O
chemotherapy	O
requires	O
more	O
study	O
so	O
that	O
rational	O
combinations	O
move	O
forward	O
.	O
Very	O
few	O
targeted	O
agents	O
have	O
been	O
studied	O
rigorously	O
in	O
this	O
fashion	O
.	O

Zinc	B-chemical
sulphate	E-chemical
and	O
vitamin	B-chemical
E	E-chemical
alleviate	O
reproductive	O
toxicity	O
caused	O
by	O
aluminium	B-chemical
sulphate	E-chemical
in	O
male	O
albino	O
rats	O
.	O
This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
reproductive	O
toxicity	O
of	O
aluminium	B-chemical
sulphate	E-chemical
and	O
the	O
therapeutic	O
effects	O
of	O
administration	O
of	O
zinc	B-chemical
sulphate	E-chemical
and	O
vitamin	B-chemical
E	E-chemical
individually	O
or	O
in	O
combination	O
against	O
the	O
toxic	O
effect	O
caused	O
by	O
aluminium	S-chemical
(	O
Al	S-chemical
)	O
in	O
male	O
albino	O
rats	O
.	O
The	O
animals	O
were	O
divided	O
into	O
five	O
groups	O
:	O
group	O
1	O
received	O
distilled	O
water	O
and	O
served	O
as	O
control	O
;	O
group	O
2	O
received	O
only	O
aluminium	B-chemical
sulphate	E-chemical
(	O
50	O
mg/kg	O
body	O
weight	O
(	O
b.w	O
.	O
)	O
)	O
;	O
group	O
3	O
received	O
aluminium	B-chemical
sulphate	E-chemical
(	O
50	O
mg/kg	O
b.w	O
.	O
)	O
plus	O
zinc	B-chemical
sulphate	E-chemical
(	O
50	O
mg/kg	O
b.w	O
.	O
)	O
;	O
group	O
4	O
received	O
aluminium	B-chemical
sulphate	E-chemical
(	O
50	O
mg/kg	O
b.w	O
.	O
)	O
and	O
vitamin	B-chemical
E	E-chemical
(	O
15	O
mg/kg	O
b.w	O
.	O
)	O
;	O
group	O
5	O
received	O
aluminium	B-chemical
sulphate	E-chemical
plus	O
a	O
combination	O
of	O
zinc	B-chemical
sulphate	E-chemical
and	O
vitamin	B-chemical
E	E-chemical
in	O
similar	O
doses	O
as	O
above	O
.	O
Doses	O
were	O
administered	O
orally	O
once	O
daily	O
for	O
45	O
consecutive	O
days	O
.	O
The	O
results	O
revealed	O
that	O
aluminium	B-chemical
sulphate	E-chemical
induced	O
significant	O
decrease	O
in	O
body	O
weight	O
gain	O
and	O
testis	O
weight	O
and	O
significant	O
increase	O
in	O
Al	S-chemical
level	O
in	O
both	O
serum	O
and	O
testes	O
of	O
male	O
rats	O
.	O
Biochemical	O
analysis	O
showed	O
significant	O
decrease	O
in	O
serum	O
total	O
protein	O
and	O
phospholipids	O
levels	O
,	O
while	O
serum	O
total	O
lipid	O
was	O
significantly	O
elevated	O
post	O
Al	S-chemical
treatment	O
.	O
In	O
addition	O
,	O
significant	O
decrease	O
in	O
total	O
protein	O
,	O
phospholipids	O
and	O
cholesterol	S-chemical
levels	O
in	O
the	O
testes	O
of	O
Al	S-chemical
-treated	O
rats	O
was	O
recorded	O
.	O
The	O
data	O
also	O
showed	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
serum	O
testosterone	S-chemical
,	O
leutinizing	B-GP
hormone	E-GP
and	O
follicle	B-GP
stimulating	I-GP
hormone	E-GP
and	O
significant	O
increase	O
in	O
the	O
level	O
of	O
serum	O
prolactin	S-GP
in	O
Al	S-chemical
-intoxicated	O
rats	O
.	O
Moreover	O
,	O
histological	O
examination	O
showed	O
that	O
aluminium	B-chemical
sulphate	E-chemical
caused	O
apparent	O
alterations	O
in	O
the	O
testicular	O
structure	O
of	O
the	O
treated	O
animals	O
.	O
Treatment	O
with	O
zinc	B-chemical
sulphate	E-chemical
and	O
vitamin	B-chemical
E	E-chemical
individually	O
or	O
in	O
combination	O
ameliorated	O
the	O
harmful	O
effects	O
of	O
Al	S-chemical
,	O
which	O
was	O
proved	O
histopathologically	O
by	O
the	O
noticeable	O
improvement	O
in	O
the	O
testicular	O
tissues	O
.	O
We	O
can	O
conclude	O
that	O
the	O
tested	O
dose	O
of	O
aluminium	B-chemical
sulphate	E-chemical
induced	O
toxic	O
effect	O
on	O
the	O
reproductive	O
system	O
of	O
male	O
albino	O
rats	O
and	O
the	O
treatment	O
with	O
zinc	B-chemical
sulphate	E-chemical
and/or	O
vitamin	B-chemical
E	E-chemical
alleviated	O
these	O
toxic	O
effects	O
.	O
In	O
some	O
cases	O
,	O
vitamin	B-chemical
E	E-chemical
exerted	O
a	O
more	O
potent	O
effect	O
,	O
while	O
in	O
other	O
cases	O
,	O
the	O
more	O
potent	O
effect	O
is	O
related	O
to	O
zinc	B-chemical
sulphate	E-chemical
and	O
the	O
combination	O
of	O
both	O
at	O
most	O
of	O
the	O
recorded	O
data	O
.	O

The	O
inhibitory	O
effect	O
of	O
the	O
leukotriene	B-GP
receptor	E-GP
antagonist	O
on	O
leukotriene	B-chemical
D4	E-chemical
-induced	O
MUC2/5AC	S-GP
gene	O
expression	O
and	O
mucin	S-GP
secretion	O
in	O
human	O
airway	O
epithelial	O
cells	O
.	O
OBJECTIVES	O
:	O
Mucin	S-GP
gene	O
expression	O
and	O
mucin	S-GP
production	O
are	O
markedly	O
increased	O
in	O
inflammatory	O
airway	O
disorders	O
such	O
as	O
asthma	O
,	O
chronic	O
bronchitis	O
and	O
rhinosinusitis	O
.	O
Cytokines	S-GP
,	O
lipopolysaccharides	O
and	O
other	O
inflammatory	O
mediators	O
such	O
as	O
prostaglandin	S-chemical
and	O
leukotriene	S-chemical
are	O
related	O
to	O
the	O
secretion	O
and	O
production	O
of	O
mucin	S-GP
.	O
However	O
,	O
the	O
relationship	O
of	O
leukotrienes	S-chemical
with	O
mucin	S-GP
genes	O
expression	O
is	O
not	O
clear	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
MUC2/5AC	S-GP
gene	O
expression	O
and	O
mucin	S-GP
secretion	O
by	O
the	O
leukotriene	B-GP
receptor	E-GP
in	O
human	O
airway	O
epithelial	O
cells	O
.	O
METHODS	O
:	O
The	O
effect	O
of	O
leukotriene	B-chemical
D	I-chemical
(	I-chemical
4	I-chemical
)	E-chemical
and	O
the	O
leukotriene	B-GP
receptor	E-GP
antagonist	O
,	O
pranlukast	B-chemical
hydrate	E-chemical
(	O
ONO-1078	S-chemical
)	O
on	O
the	O
regulation	O
of	O
MUC2/5AC	S-GP
gene	O
expression	O
and	O
mucin	S-GP
secretion	O
were	O
observed	O
in	O
human	O
airway	O
NCI-H292	O
epithelial	O
cells	O
.	O
The	O
mRNA	O
levels	O
of	O
MUC2/5AC	S-GP
and	O
the	O
amount	O
of	O
mucin	S-GP
were	O
determined	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
and	O
immunoassay	O
.	O
RESULTS	O
:	O
Leukotriene	B-chemical
D	I-chemical
(	I-chemical
4	I-chemical
)	E-chemical
upregulated	O
MUC2/5AC	S-GP
gene	O
expression	O
and	O
mucin	S-GP
secretion	O
in	O
a	O
dose	O
dependent	O
pattern	O
.	O
Pranlukast	B-chemical
hydrate	E-chemical
(	O
ONO-1078	S-chemical
,	O
100	O
microM	O
)	O
downregulated	O
the	O
leukotriene	B-chemical
D	I-chemical
(	I-chemical
4	I-chemical
)	E-chemical
-induced	O
MUC2/5AC	S-GP
gene	O
expression	O
and	O
mucin	S-GP
secretion	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
the	O
leukotriene	B-GP
receptor	E-GP
system	O
is	O
one	O
of	O
the	O
mechanisms	O
related	O
to	O
MUC2/5AC	S-GP
gene	O
expression	O
and	O
mucin	S-GP
secretion	O
in	O
the	O
human	O
airway	O
epithelium	O
.	O

Evolution	O
of	O
the	O
aminoacyl-tRNA	B-GP
synthetase	E-GP
family	O
and	O
the	O
organization	O
of	O
the	O
Drosophila	O
glutamyl-prolyl-tRNA	B-GP
synthetase	E-GP
gene	O
.	O
Intron/exon	O
structure	O
of	O
the	O
gene	O
,	O
control	O
of	O
expression	O
of	O
the	O
two	O
mRNAs	O
,	O
selective	O
advantage	O
of	O
the	O
multienzyme	O
complex	O
.	O
In	O
Drosophila	O
,	O
glutamyl-prolyl-tRNA	B-GP
synthetase	E-GP
is	O
a	O
multifunctional	O
synthetase	O
encoded	O
by	O
a	O
unique	O
gene	O
and	O
composed	O
of	O
three	O
domains	O
:	O
the	O
amino	S-chemical
-	O
and	O
carboxy	S-chemical
-terminal	O
domains	O
catalyze	O
the	O
aminoacylation	O
of	O
glutamic	B-chemical
acid	E-chemical
and	O
proline	O
tRNA	O
species	O
,	O
respectively	O
,	O
and	O
the	O
central	O
domain	O
is	O
made	O
of	O
75	O
amino	B-chemical
acids	E-chemical
repeated	O
six	O
times	O
amongst	O
which	O
46	O
are	O
highly	O
conserved	O
and	O
constitute	O
the	O
repeated	O
motifs	O
[	O
Cerini	O
,	O
C.	O
,	O
Kerjan	O
,	O
P.	O
,	O
Astier	O
,	O
M.	O
,	O
Gratecos	O
,	O
D.	O
,	O
Mirande	O
,	O
M.	O
&	O
Semeriva	O
,	O
M.	O
(	O
1991	O
)	O
EMBO	O
J	O
.	O
10	O
,	O
4267-4277	O
]	O
.	O
The	O
intron/exon	O
organization	O
of	O
the	O
Drosophila	O
gene	O
reveals	O
the	O
presence	O
of	O
six	O
exons	O
among	O
which	O
four	O
are	O
in	O
the	O
5'-end	O
encoding	O
glutamic	B-chemical
acid	E-chemical
activity	O
.	O
Only	O
one	O
exon	O
encodes	O
the	O
repeated	O
motifs	O
.	O
A	O
comparison	O
of	O
introns	O
positions	O
,	O
intron	O
classes	O
and	O
intron/exon	O
boundaries	O
in	O
the	O
Drosophila	O
gene	O
and	O
in	O
its	O
human	O
counterpart	O
is	O
compatible	O
with	O
the	O
intron-early	O
hypothesis	O
presiding	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
evolution	O
of	O
the	O
synthetases	S-GP
.	O
The	O
full-length	O
fly	O
protein	O
is	O
encoded	O
by	O
a	O
6.1-kb	O
mRNA	O
which	O
is	O
expressed	O
throughout	O
development	O
.	O
In	O
addition	O
,	O
a	O
shorter	O
transcript	O
encompasses	O
the	O
3'-end	O
of	O
the	O
cDNA	O
and	O
it	O
is	O
especially	O
abundant	O
in	O
5-10-h	O
embryos	O
until	O
the	O
first	O
larval	O
stage	O
.	O
Expression	O
of	O
these	O
two	O
mRNAs	O
seems	O
to	O
be	O
controlled	O
by	O
two	O
independent	O
promoters	O
.	O
The	O
6.1-kb	O
mRNA	O
promoter	O
is	O
probably	O
localized	O
in	O
the	O
5'-end	O
of	O
the	O
gene	O
.	O
The	O
small	O
mRNA	O
promoter	O
resides	O
in	O
the	O
4th	O
intron	O
and	O
evidence	O
is	O
provided	O
that	O
the	O
mRNA	O
encodes	O
only	O
the	O
domain	O
corresponding	O
to	O
prolyl-tRNA	B-GP
synthetase	E-GP
and	O
is	O
functional	O
in	O
vivo	O
.	O
Finally	O
,	O
transgenic	O
flies	O
have	O
been	O
established	O
by	O
using	O
constructs	O
corresponding	O
to	O
the	O
three	O
domains	O
of	O
the	O
protein	O
.	O
Overexpression	O
of	O
the	O
repeated	O
motifs	O
leads	O
to	O
a	O
sterility	O
of	O
the	O
flies	O
that	O
suggests	O
a	O
role	O
of	O
these	O
motifs	O
in	O
linking	O
the	O
multienzyme	O
complex	O
to	O
an	O
,	O
as	O
yet	O
,	O
unknown	O
structure	O
of	O
the	O
protein	O
synthesis	O
apparatus	O
.	O

D-glucose	S-chemical
stimulation	O
of	O
L-arginine	S-chemical
transport	O
and	O
nitric	B-chemical
oxide	E-chemical
synthesis	O
results	O
from	O
activation	O
of	O
mitogen-activated	B-GP
protein	I-GP
kinases	I-GP
p42/44	E-GP
and	O
Smad2	S-GP
requiring	O
functional	O
type	B-GP
II	I-GP
TGF-beta	I-GP
receptors	E-GP
in	O
human	O
umbilical	O
vein	O
endothelium	O
.	O
Elevated	O
extracellular	O
D-glucose	S-chemical
increases	O
transforming	B-GP
growth	I-GP
factor	I-GP
beta1	E-GP
(	O
TGF-beta1	S-GP
)	O
release	O
from	O
human	O
umbilical	O
vein	O
endothelium	O
(	O
HUVEC	O
)	O
.	O
TGF-beta1	S-GP
,	O
via	O
TGF-beta	B-GP
receptors	I-GP
I	E-GP
(	O
TbetaRI	S-GP
)	O
and	O
TbetaRII	S-GP
,	O
activates	O
Smad2	S-GP
and	O
mitogen-activated	B-GP
protein	I-GP
kinases	E-GP
p44	S-GP
and	O
p42	S-GP
(	O
p42/44	S-GP
(	O
mapk	S-GP
)	O
)	O
.	O
We	O
studied	O
whether	O
D-glucose	S-chemical
-stimulation	O
of	O
L-arginine	S-chemical
transport	O
and	O
nitric	B-chemical
oxide	E-chemical
synthesis	O
involves	O
TGF-beta1	S-GP
in	O
primary	O
cultures	O
of	O
HUVEC	O
.	O
TGF-beta1	S-GP
release	O
was	O
higher	O
(	O
approximately	O
1.6-fold	O
)	O
in	O
25	O
mM	O
(	O
high	O
)	O
compared	O
with	O
5	O
mM	O
(	O
normal	O
)	O
D-glucose	S-chemical
.	O
TGF-beta1	S-GP
increases	O
L-arginine	S-chemical
transport	O
(	O
half	O
maximal	O
effect	O
approximately	O
1.6	O
ng/ml	O
)	O
in	O
normal	O
D-glucose	S-chemical
,	O
but	O
did	O
not	O
alter	O
high	O
D-glucose	S-chemical
-increased	O
L-arginine	S-chemical
transport	O
.	O
TGF-beta1	S-GP
and	O
high	O
D-glucose	S-chemical
increased	O
hCAT-1	S-GP
mRNA	O
expression	O
(	O
approximately	O
8-fold	O
)	O
and	O
maximal	O
transport	O
velocity	O
(	O
V	O
(	O
max	O
)	O
)	O
,	O
L-	B-chemical
[	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
citrulline	E-chemical
formation	O
from	O
L-	B-chemical
[	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
arginine	E-chemical
(	O
index	O
of	O
NO	S-chemical
synthesis	O
)	O
and	O
endothelial	B-GP
NO	I-GP
synthase	E-GP
(	O
eNOS	S-GP
)	O
protein	O
abundance	O
,	O
but	O
did	O
not	O
alter	O
eNOS	S-GP
phosphorylation	O
.	O
TGF-beta1	S-GP
and	O
high	O
D-glucose	S-chemical
increased	O
p42/44	S-GP
(	O
mapk	S-GP
)	O
and	O
Smad2	S-GP
phosphorylation	O
,	O
an	O
effect	O
blocked	O
by	O
PD-98059	S-chemical
(	O
MEK1/2	S-GP
inhibitor	O
)	O
.	O
However	O
,	O
TGF-beta1	S-GP
and	O
high	O
D-glucose	S-chemical
were	O
ineffective	O
in	O
cells	O
expressing	O
a	O
truncated	O
,	O
negative	O
dominant	O
TbetaRII	S-GP
.	O
High	O
D-glucose	S-chemical
increases	O
L-arginine	S-chemical
transport	O
and	O
eNOS	S-GP
expression	O
following	O
TbetaRII	S-GP
activation	O
by	O
TGF-beta1	S-GP
involving	O
p42/44	S-GP
(	O
mapk	S-GP
)	O
and	O
Smad2	S-GP
in	O
HUVEC	O
.	O
Thus	O
,	O
TGF-beta1	S-GP
could	O
play	O
a	O
crucial	O
role	O
under	O
conditions	O
of	O
hyperglycemia	O
,	O
such	O
as	O
gestational	O
diabetes	O
mellitus	O
,	O
which	O
is	O
associated	O
with	O
fetal	O
endothelial	O
dysfunction	O
.	O

Boron	S-chemical
-based	O
inhibitors	O
of	O
acyl	B-GP
protein	I-GP
thioesterases	I-GP
1	I-GP
and	I-GP
2	E-GP
.	O
Ras	S-GP
proteins	O
are	O
of	O
importance	O
in	O
cell	O
proliferation	O
,	O
and	O
hence	O
their	O
mutated	O
forms	O
play	O
causative	O
roles	O
in	O
many	O
kinds	O
of	O
cancer	O
in	O
different	O
tissues	O
.	O
Inhibition	O
of	O
the	O
Ras	S-GP
-depalmitoylating	O
enzyme	O
acyl	B-GP
protein	I-GP
thioesterases	I-GP
APT1	I-GP
and	I-GP
-2	E-GP
is	O
a	O
new	O
approach	O
to	O
modulating	O
the	O
Ras	S-GP
cycle	O
.	O
Here	O
we	O
present	O
boronic	S-chemical
and	O
borinic	B-chemical
acid	E-chemical
derivatives	O
as	O
a	O
new	O
class	O
of	O
potent	O
and	O
nontoxic	O
APT	S-GP
inhibitors	O
.	O
These	O
compounds	O
were	O
detected	O
by	O
extensive	O
library	O
screening	O
using	O
chemical	O
arrays	O
and	O
turned	O
out	O
to	O
inhibit	O
human	B-GP
APT1	I-GP
and	I-GP
-2	E-GP
in	O
a	O
competitive	O
mode	O
.	O
Furthermore	O
,	O
one	O
of	O
the	O
molecules	O
was	O
demonstrated	O
to	O
inhibit	O
Erk1/2	S-GP
phosphorylation	O
significantly	O
.	O

Mediation	O
of	O
noradrenaline	S-chemical
-induced	O
contractions	O
of	O
rat	O
aorta	O
by	O
the	O
alpha	B-GP
1B-adrenoceptor	E-GP
subtype	O
.	O
1	O
.	O
The	O
subtypes	O
of	O
alpha	B-GP
1-adrenoceptor	E-GP
mediating	O
contractions	O
to	O
exogenous	O
noradrenaline	S-chemical
(	O
NA	S-chemical
)	O
in	O
rat	O
aorta	O
have	O
been	O
examined	O
in	O
both	O
biochemical	O
and	O
functional	O
studies	O
.	O
2	O
.	O
Incubation	O
of	O
rat	O
aortic	O
membranes	O
with	O
the	O
irreversible	O
alpha	B-GP
1B-adrenoceptor	E-GP
antagonist	O
,	O
chloroethylclonidine	S-chemical
(	O
CEC	S-chemical
:	O
10	O
microM	O
)	O
did	O
not	O
change	O
the	O
KD	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-prazosin	E-chemical
binding	O
in	O
comparison	O
to	O
untreated	O
membranes	O
,	O
but	O
reduced	O
by	O
88	O
%	O
the	O
total	O
number	O
of	O
binding	O
sites	O
(	O
Bmax	O
)	O
.	O
3	O
.	O
Contractions	O
of	O
rat	O
aortic	O
strips	O
to	O
NA	S-chemical
after	O
CEC	S-chemical
(	O
50	O
microM	O
for	O
30	O
min	O
)	O
incubation	O
followed	O
by	O
repetitive	O
washing	O
,	O
showed	O
a	O
marked	O
shift	O
in	O
the	O
potency	O
of	O
NA	S-chemical
and	O
a	O
partial	O
reduction	O
in	O
the	O
maximum	O
response	O
.	O
The	O
residual	O
contractions	O
to	O
NA	S-chemical
after	O
CEC	S-chemical
incubation	O
were	O
not	O
affected	O
by	O
prazosin	S-chemical
(	O
10	O
nM	O
)	O
.	O
4	O
.	O
The	O
competitive	O
antagonists	O
prazosin	S-chemical
,	O
terazosin	S-chemical
,	O
(	B-chemical
R	I-chemical
)	I-chemical
-YM-12617	E-chemical
,	O
phentolamine	S-chemical
,	O
5-methylurapidil	S-chemical
and	O
spiperone	S-chemical
inhibited	O
contractions	O
to	O
NA	S-chemical
with	O
estimated	O
pA2	O
values	O
of	O
9.85	O
,	O
8.54	O
,	O
9.34	O
,	O
7.71	O
,	O
7.64	O
and	O
8.41	O
,	O
respectively	O
.	O
5	O
.	O
The	O
affinity	O
of	O
the	O
same	O
antagonists	O
for	O
the	O
alpha	B-GP
1A-	I-GP
and	I-GP
alpha	I-GP
1B-	I-GP
adrenoceptors	E-GP
was	O
evaluated	O
by	O
utilizing	O
membranes	O
from	O
rat	O
hippocampus	O
pretreated	O
with	O
CEC	S-chemical
,	O
and	O
rat	O
liver	O
,	O
respectively	O
.	O
5-Methylurapidil	S-chemical
and	O
phentolamine	S-chemical
were	O
confirmed	O
as	O
selective	O
for	O
the	O
alpha	B-GP
1A-adrenoceptors	E-GP
,	O
whereas	O
spiperone	S-chemical
was	O
alpha	O
1B-selective	O
.	O
6	O
.	O
A	O
significant	O
correlation	O
was	O
found	O
between	O
the	O
pA2	O
values	O
of	O
the	O
alpha	B-GP
1-adrenoceptor	E-GP
antagonists	O
tested	O
and	O
their	O
affinity	O
for	O
the	O
alpha	B-GP
1B-adrenoceptor	E-GP
subtype	O
,	O
but	O
not	O
for	O
the	O
alpha	O
1A-subtype	O
.	O
7	O
.	O
In	O
conclusion	O
,	O
these	O
findings	O
indicate	O
that	O
in	O
rat	O
aorta	O
most	O
of	O
the	O
contraction	O
is	O
mediated	O
by	O
alpha	B-GP
1B-adrenoceptors	E-GP
,	O
and	O
that	O
the	O
potency	O
(	O
pA2	O
)	O
of	O
an	O
antagonist	O
in	O
this	O
tissue	O
should	O
be	O
related	O
to	O
its	O
antagonistic	O
effect	O
on	O
this	O
subtype	O
of	O
the	O
alpha	B-GP
1-adrenoceptor	E-GP
population	O
.	O

Soluble	O
polysialylated	B-GP
NCAM	E-GP
:	O
a	O
novel	O
player	O
of	O
the	O
innate	O
immune	O
system	O
in	O
the	O
lung	O
.	O
Posttranslational	O
modification	O
of	O
the	O
neural	B-GP
cell	I-GP
adhesion	I-GP
molecule	E-GP
(	O
NCAM	S-GP
)	O
by	O
polysialic	B-chemical
acid	E-chemical
(	O
polySia	S-chemical
)	O
is	O
well	O
studied	O
in	O
the	O
nervous	O
system	O
and	O
described	O
as	O
a	O
dynamic	O
modulator	O
of	O
plastic	O
processes	O
like	O
precursor	O
cell	O
migration	O
,	O
axon	O
fasciculation	O
,	O
and	O
synaptic	O
plasticity	O
.	O
Here	O
,	O
we	O
describe	O
a	O
novel	O
function	O
of	O
polysialylated	B-GP
NCAM	E-GP
(	O
polySia-NCAM	S-GP
)	O
in	O
innate	O
immunity	O
of	O
the	O
lung	O
.	O
In	O
mature	O
lung	O
tissue	O
of	O
healthy	O
donors	O
,	O
polySia	S-chemical
was	O
exclusively	O
attached	O
to	O
the	O
transmembrane	O
isoform	O
NCAM-140	S-GP
and	O
located	O
to	O
intracellular	O
compartments	O
of	O
epithelial	O
cells	O
.	O
In	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
however	O
,	O
increased	O
polySia	S-chemical
levels	O
and	O
processing	O
of	O
the	O
NCAM	S-GP
carrier	O
were	O
observed	O
.	O
Processing	O
of	O
polysialylated	B-GP
NCAM	E-GP
was	O
reproduced	O
in	O
a	O
mouse	O
model	O
by	O
bleomycin	S-chemical
administration	O
leading	O
to	O
an	O
activation	O
of	O
the	O
inflammasome	O
and	O
secretion	O
of	O
interleukin	B-GP
(	I-GP
IL	I-GP
)	I-GP
-1β	E-GP
.	O
As	O
shown	O
in	O
a	O
cell	O
culture	O
model	O
,	O
polySia	S-chemical
-	O
NCAM-140	S-GP
was	O
kept	O
in	O
the	O
late	O
trans-Golgi	O
apparatus	O
of	O
lung	O
epithelial	O
cells	O
and	O
stimulation	O
by	O
IL-1β	S-GP
or	O
lipopolysaccharide	O
induced	O
metalloprotease	S-GP
-mediated	O
ectodomain	S-GP
shedding	O
,	O
resulting	O
in	O
the	O
secretion	O
of	O
soluble	O
polySia-NCAM	S-GP
.	O
Interestingly	O
,	O
polySia	S-chemical
chains	O
of	O
secreted	O
NCAM	S-GP
neutralized	O
the	O
cytotoxic	O
activity	O
of	O
extracellular	O
histones	S-GP
as	O
well	O
as	O
DNA/	O
histone	S-GP
-network-containing	O
``	O
neutrophil	O
extracellular	O
traps	O
''	O
,	O
which	O
are	O
formed	O
during	O
invasion	O
of	O
microorganisms	O
.	O
Thus	O
,	O
shedding	O
of	O
polySia-NCAM	S-GP
by	O
lung	O
epithelial	O
cells	O
may	O
provide	O
a	O
host-protective	O
mechanism	O
to	O
reduce	O
tissue	O
damage	O
during	O
inflammatory	O
processes	O
.	O

Aryl	B-GP
hydrocarbon	I-GP
receptor	E-GP
is	O
a	O
target	O
of	O
17-Allylamino-17-demethoxygeldanamycin	S-chemical
and	O
enhances	O
its	O
anticancer	O
activity	O
in	O
lung	O
adenocarcinoma	O
cells	O
.	O
We	O
have	O
demonstrated	O
that	O
aryl	B-GP
hydrocarbon	I-GP
receptor	E-GP
(	O
AhR	S-GP
)	O
is	O
overexpressed	O
in	O
lung	O
adenocarcinoma	O
(	O
AD	O
)	O
.	O
AhR	S-GP
is	O
usually	O
associated	O
with	O
heat	B-GP
shock	I-GP
protein	I-GP
90	E-GP
(	O
Hsp90	S-GP
)	O
in	O
the	O
cytoplasm	O
.	O
17-Allylamino-17-demethoxygeldanamycin	S-chemical
(	O
17-AAG	S-chemical
)	O
,	O
an	O
Hsp90	S-GP
inhibitor	O
,	O
is	O
currently	O
under	O
evaluation	O
for	O
its	O
anticancer	O
activity	O
in	O
clinical	O
trials	O
.	O
Here	O
we	O
investigated	O
whether	O
AhR	S-GP
plays	O
a	O
role	O
in	O
17-AAG	S-chemical
-mediated	O
anticancer	O
activity	O
by	O
functioning	O
as	O
a	O
downstream	O
target	O
or	O
by	O
modulating	O
its	O
anticancer	O
efficacy	O
.	O
AhR	S-GP
expression	O
in	O
lung	O
AD	O
cells	O
was	O
modulated	O
by	O
siRNA	O
interference	O
or	O
overexpression	O
.	O
Tumor	O
growth	O
was	O
determined	O
with	O
colony	O
formation	O
in	O
vitro	O
or	O
in	O
vivo	O
.	O
Anticancer	O
activity	O
of	O
17-AAG	S-chemical
was	O
determined	O
by	O
measuring	O
cell	O
viability	O
,	O
cell	O
cycle	O
distribution	O
,	O
and	O
expression	O
of	O
cell	O
cycle	O
regulators	O
.	O
Proteins	O
and	O
mRNA	O
levels	O
were	O
examined	O
by	O
immunoblotting	O
and	O
the	O
real-time	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
,	O
respectively	O
.	O
In	O
this	O
study	O
,	O
AhR	S-GP
overexpression	O
positively	O
modulated	O
growth	O
of	O
lung	O
AD	O
cells	O
,	O
at	O
least	O
partially	O
,	O
via	O
RelA	S-GP
-dependent	O
mechanisms	O
.	O
Although	O
treatment	O
with	O
17-AAG	S-chemical
reduced	O
AhR	S-GP
levels	O
and	O
AhR	S-GP
-regulated	O
gene	O
expression	O
in	O
lung	O
AD	O
cells	O
,	O
AhR	S-GP
expression	O
increased	O
anticancer	O
activity	O
of	O
17-AAG	S-chemical
.	O
In	O
addition	O
,	O
17-AAG	S-chemical
treatment	O
reduced	O
cell	O
viability	O
,	O
CDK2	S-GP
,	O
CDK4	S-GP
,	O
cyclin	B-GP
E	E-GP
,	O
cyclin	B-GP
D1	E-GP
,	O
and	O
phosphorylated	B-GP
Rb	E-GP
levels	O
in	O
AhR	S-GP
-expressing	O
lung	O
AD	O
cells	O
.	O
NAD	B-GP
(	I-GP
P	I-GP
)	I-GP
H	I-GP
:	I-GP
quinone	I-GP
oxidoreductase	E-GP
(	O
NQO1	S-GP
)	O
,	O
which	O
is	O
regulated	O
by	O
AhR	S-GP
,	O
was	O
shown	O
to	O
increase	O
anticancer	O
activity	O
of	O
17-AAG	S-chemical
in	O
cells	O
.	O
Knockdown	O
of	O
NQO1	S-GP
expression	O
attenuated	O
the	O
reduction	O
of	O
cell	O
cycle	O
regulators	O
by	O
17-AAG	S-chemical
treatment	O
in	O
AhR	S-GP
overexpressed	O
cells	O
.	O
We	O
demonstrated	O
that	O
AhR	S-GP
protein	O
not	O
only	O
functions	O
as	O
a	O
downstream	O
target	O
of	O
17-AAG	S-chemical
,	O
but	O
also	O
enhances	O
anticancer	O
activity	O
of	O
17-AAG	S-chemical
in	O
lung	O
AD	O
cells	O
.	O

Human	B-GP
plasma-derived	I-GP
BuChE	E-GP
as	O
a	O
stoichiometric	O
bioscavenger	O
for	O
treatment	O
of	O
nerve	O
agent	O
poisoning	O
.	O
Potent	O
organophosphorous	S-chemical
(	O
OP	O
)	O
agents	O
,	O
such	O
as	O
VX	O
,	O
are	O
hazardous	O
by	O
absorption	O
through	O
the	O
skin	O
and	O
are	O
resistant	O
to	O
conventional	O
pharmacological	O
antidotal	O
treatments	O
.	O
The	O
residence	O
time	O
of	O
a	O
stoichiometric	O
bioscavenger	O
,	O
human	B-GP
butyrylcholinesterase	E-GP
(	O
huBuChE	S-GP
)	O
,	O
in	O
the	O
plasma	O
more	O
closely	O
matches	O
that	O
of	O
VX	O
than	O
do	O
the	O
residence	O
times	O
of	O
conventional	O
therapy	O
drugs	O
(	O
oxime	S-chemical
,	O
anti-muscarinic	O
,	O
anticonvulsant	O
)	O
.	O
Intramuscular	O
(	O
i.m	O
.	O
)	O
huBuChE	S-GP
afforded	O
almost	O
complete	O
protection	O
when	O
administered	O
prior	O
to	O
the	O
onset	O
of	O
observable	O
cholinergic	O
signs	O
of	O
VX	O
poisoning	O
,	O
but	O
once	O
signs	O
of	O
poisoning	O
became	O
evident	O
the	O
efficacy	O
of	O
i.m	O
.	O
huBuChE	S-GP
decreased	O
.	O
A	O
combination	O
of	O
nerve	O
agent	O
therapy	O
drugs	O
(	O
oxime	S-chemical
,	O
anti-muscarinic	O
,	O
anticonvulsant	O
)	O
with	O
huBuChE	S-GP
(	O
i.m	O
.	O
)	O
protected	O
100	O
%	O
(	O
8/8	O
)	O
of	O
guinea-pigs	O
from	O
a	O
lethal	O
dose	O
of	O
VX	O
(	O
0.74mg/kg	O
)	O
to	O
48h	O
,	O
even	O
when	O
administered	O
on	O
signs	O
of	O
poisoning	O
.	O
Survival	O
was	O
presumed	O
to	O
be	O
due	O
to	O
immediate	O
alleviation	O
of	O
the	O
cholinergic	O
crisis	O
by	O
the	O
conventional	O
pharmacological	O
treatment	O
drugs	O
,	O
in	O
conjunction	O
with	O
bioscavenger	O
that	O
prevented	O
further	O
absorbed	O
agent	O
reaching	O
the	O
AChE	S-GP
targets	O
.	O
Evidence	O
to	O
support	O
this	O
proposed	O
mechanism	O
of	O
action	O
was	O
obtained	O
from	O
PKPD	O
experiments	O
in	O
which	O
multiple	O
blood	O
samples	O
and	O
microdialysate	O
samples	O
were	O
collected	O
from	O
individual	O
conscious	O
ambulatory	O
animals	O
.	O
Plasma	O
concentrations	O
of	O
intramuscularly-administered	O
atropine	S-chemical
,	O
diazepam	S-chemical
and	O
HI-6	S-chemical
reached	O
a	O
peak	O
within	O
15min	O
and	O
were	O
eliminated	O
rapidly	O
within	O
4h	O
.	O
Plasma	O
concentrations	O
of	O
huBuChE	S-GP
administered	O
by	O
the	O
i.m	O
.	O
route	O
took	O
approximately	O
24h	O
to	O
reach	O
a	O
peak	O
,	O
but	O
were	O
well-maintained	O
over	O
the	O
subsequent	O
7days	O
.	O
Thus	O
,	O
the	O
pharmacological	O
therapy	O
rapidly	O
treated	O
the	O
initial	O
signs	O
of	O
poisoning	O
,	O
whilst	O
the	O
bioscavenger	O
provided	O
prolonged	O
protection	O
by	O
neutralising	O
further	O
nerve	O
agent	O
entering	O
the	O
bloodstream	O
and	O
preventing	O
it	O
from	O
reaching	O
the	O
target	O
organs	O
.	O

The	O
catalytic	O
competence	O
of	O
cytochrome	B-GP
P450	E-GP
in	O
the	O
synthesis	O
of	O
serotonin	S-chemical
from	O
5-methoxytryptamine	S-chemical
in	O
the	O
brain	O
:	O
an	O
in	O
vitro	O
study	O
.	O
Brain	O
serotonin	S-chemical
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
a	O
wide	O
spectrum	O
of	O
psychiatric	O
disorders	O
,	O
as	O
well	O
as	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
psychotropic	O
drugs	O
.	O
The	O
aim	O
of	O
present	O
study	O
was	O
to	O
identify	O
rat	B-GP
cytochrome	I-GP
P450	E-GP
(	O
CYP	S-GP
)	O
isoforms	O
which	O
can	O
catalyze	O
the	O
O	S-chemical
-demethylation	O
of	O
5-methoxytryptamine	S-chemical
to	O
serotonin	S-chemical
,	O
and	O
to	O
find	O
out	O
whether	O
that	O
alternative	O
pathway	O
of	O
serotonin	S-chemical
synthesis	O
may	O
take	O
place	O
in	O
the	O
brain	O
.	O
The	O
study	O
was	O
conducted	O
on	O
cDNA-expressed	O
CYPs	S-GP
(	O
rat	B-GP
CYP1A1/2	I-GP
,	I-GP
2A1/2	I-GP
,	I-GP
2B1	I-GP
,	I-GP
2C6/11/13	I-GP
,	I-GP
2D1/2/4/18	I-GP
,	I-GP
2E1	I-GP
,	I-GP
3A2	E-GP
and	O
human	B-GP
CYP2D6	E-GP
)	O
,	O
on	O
rat	O
brain	O
and	O
liver	O
microsomes	O
and	O
on	O
human	O
liver	O
microsomes	O
(	O
the	O
wild-type	O
CYP2D6	S-GP
or	O
the	O
allelic	O
variant	O
2D6	S-GP
*4*4	O
)	O
.	O
Of	O
the	O
rat	B-GP
CYP	E-GP
isoforms	O
studied	O
,	O
CYP2D	S-GP
isoforms	O
were	O
the	O
most	O
efficient	O
in	O
catalyzing	O
the	O
O	S-chemical
-demethylation	O
of	O
5-methoxytryptamine	S-chemical
to	O
serotonin	S-chemical
,	O
but	O
they	O
were	O
less	O
effective	O
than	O
the	O
human	B-GP
isoform	I-GP
CYP2D6	E-GP
.	O
Microsomes	O
from	O
different	O
brain	O
regions	O
were	O
capable	O
of	O
metabolizing	O
5-methoxytryptamine	S-chemical
to	O
serotonin	S-chemical
.	O
The	O
reaction	O
was	O
inhibited	O
by	O
the	O
specific	O
CYP2D	S-GP
inhibitors	O
quinine	S-chemical
and	O
fluoxetine	S-chemical
.	O
Human	O
liver	O
microsomes	O
of	O
the	O
wild-type	O
CYP2D6	S-GP
metabolized	O
5-methoxytryptamine	S-chemical
to	O
serotonin	S-chemical
more	O
effectively	O
than	O
did	O
the	O
defective	O
CYP2D6	S-GP
*4*4	O
ones	O
.	O
The	O
obtained	O
results	O
indicate	O
that	O
rat	B-GP
brain	I-GP
CYP2D	E-GP
isoforms	O
catalyze	O
the	O
formation	O
of	O
serotonin	S-chemical
from	O
5-methoxytryptamine	S-chemical
,	O
and	O
that	O
the	O
deficit	O
or	O
genetic	O
defect	O
of	O
CYP2D	S-GP
may	O
affect	O
serotonin	S-chemical
metabolism	O
in	O
the	O
brain	O
.	O
The	O
results	O
are	O
discussed	O
in	O
the	O
context	O
of	O
their	O
possible	O
physiological	O
and	O
pharmacological	O
significance	O
in	O
vivo	O
.	O

Thalidomide	S-chemical
prevents	O
alcoholic	S-chemical
liver	O
injury	O
in	O
rats	O
through	O
suppression	O
of	O
Kupffer	O
cell	O
sensitization	O
and	O
TNF-alpha	S-GP
production	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
Sensitization	O
of	O
Kupffer	O
cells	O
(	O
KCs	O
)	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
overproduction	O
of	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
(	I-GP
TNF	I-GP
)	I-GP
alpha	E-GP
are	O
critical	O
for	O
progression	O
of	O
alcoholic	S-chemical
liver	O
injury	O
.	O
Thalidomide	S-chemical
has	O
been	O
shown	O
to	O
suppress	O
TNF-alpha	S-GP
production	O
from	O
macrophages	O
.	O
Accordingly	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
thalidomide	S-chemical
could	O
prevent	O
alcohol	S-chemical
-induced	O
liver	O
injury	O
.	O
METHODS	O
:	O
Rats	O
were	O
given	O
ethanol	S-chemical
(	O
5	O
g/kg	O
body	O
wt	O
)	O
and	O
thalidomide	S-chemical
(	O
5	O
mg/kg	O
)	O
once	O
every	O
24	O
hours	O
intragastrically	O
.	O
To	O
assess	O
the	O
sensitization	O
of	O
Kupffer	O
cells	O
,	O
LPS	O
(	O
5	O
mg/kg	O
intravenously	O
)	O
was	O
administered	O
and	O
liver	O
histology	O
was	O
evaluated	O
24	O
hours	O
later	O
.	O
KCs	O
were	O
isolated	O
after	O
4	O
weeks	O
of	O
ethanol	S-chemical
treatment	O
and	O
intracellular	O
Ca2+	S-chemical
(	O
[	O
Ca2+	S-chemical
]	O
i	O
)	O
was	O
measured	O
using	O
fura-2	O
,	O
whereas	O
TNF-alpha	S-GP
was	O
evaluated	O
by	O
reverse-transcription	O
polymerase	O
chain	O
reaction	O
and	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O
CD14	S-GP
was	O
determined	O
by	O
Western	O
and	O
fluorescence	O
staining	O
.	O
RESULTS	O
:	O
Treatment	O
with	O
ethanol	S-chemical
for	O
8	O
weeks	O
caused	O
marked	O
steatosis	O
,	O
necrosis	O
,	O
and	O
inflammation	O
in	O
the	O
liver	O
.	O
These	O
pathologic	O
parameters	O
were	O
diminished	O
markedly	O
by	O
treatment	O
with	O
thalidomide	S-chemical
.	O
In	O
the	O
4-week	O
ethanol	S-chemical
group	O
,	O
the	O
LPS-induced	O
liver	O
damage	O
was	O
aggravated	O
and	O
KCs	O
were	O
sensitized	O
to	O
LPS	O
.	O
Coadministration	O
of	O
thalidomide	S-chemical
with	O
ethanol	S-chemical
prevented	O
the	O
KC	O
sensitization	O
completely	O
.	O
Furthermore	O
,	O
thalidomide	S-chemical
abolished	O
the	O
LPS-induced	O
increase	O
in	O
CD14	S-GP
expression	O
and	O
[	O
Ca2+	S-chemical
]	O
i	O
elevation	O
in	O
KCs	O
.	O
Gut	O
permeability	O
was	O
increased	O
about	O
10-fold	O
after	O
4	O
weeks	O
of	O
ethanol	S-chemical
exposure	O
,	O
which	O
was	O
not	O
affected	O
by	O
thalidomide	S-chemical
.	O
Moreover	O
,	O
thalidomide	S-chemical
reduced	O
the	O
LPS-induced	O
TNF-alpha	S-GP
production	O
by	O
KCs	O
by	O
decreasing	O
TNF-alpha	S-GP
messenger	O
RNA	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
collectively	O
indicate	O
that	O
thalidomide	S-chemical
prevents	O
alcoholic	O
liver	O
injury	O
through	O
suppression	O
of	O
TNF-alpha	S-GP
production	O
and	O
abolishment	O
of	O
KC	O
sensitization	O
.	O

Effect	O
of	O
nicotine	S-chemical
pretreatment	O
on	O
arsenic	S-chemical
-induced	O
oxidative	O
stress	O
in	O
male	O
Wistar	O
rats	O
.	O
Humans	O
are	O
commonly	O
exposed	O
to	O
nicotine	S-chemical
,	O
one	O
of	O
the	O
most	O
important	O
lifestyle	O
chemicals	O
.	O
The	O
occurrence	O
of	O
high	O
levels	O
of	O
arsenic	S-chemical
in	O
the	O
groundwater	O
of	O
the	O
southeast	O
region	O
of	O
Asia	O
has	O
received	O
much	O
attention	O
in	O
the	O
past	O
decade	O
and	O
has	O
become	O
a	O
global	O
health	O
concern	O
.	O
Predominant	O
occurrence	O
of	O
both	O
these	O
chemicals	O
and	O
ease	O
of	O
their	O
human	O
exposure	O
led	O
us	O
to	O
investigate	O
the	O
effect	O
of	O
nicotine	S-chemical
,	O
a	O
major	O
tobacco	O
alkaloid	O
,	O
on	O
arsenic	S-chemical
toxicity	O
.	O
Adult	O
male	O
rats	O
were	O
pre-exposed	O
to	O
two	O
different	O
doses	O
of	O
nicotine	S-chemical
(	O
0.75	O
and	O
3	O
mg/kg	O
,	O
intraperitoneally	O
)	O
for	O
7	O
days	O
followed	O
by	O
30	O
days	O
of	O
arsenic	S-chemical
exposure	O
(	O
50	O
ppm	O
sodium	B-chemical
arsenite	E-chemical
in	O
drinking	O
water	O
)	O
.	O
Nicotine	S-chemical
pre-exposure	O
resulted	O
in	O
an	O
increased	O
brain	O
arsenic	S-chemical
accumulation	O
and	O
a	O
decreased	O
liver	O
arsenic	S-chemical
concentration	O
.	O
Arsenic	S-chemical
also	O
caused	O
a	O
significant	O
oxidative	O
stress	O
in	O
the	O
blood	O
,	O
brain	O
and	O
liver	O
of	O
the	O
exposed	O
rats	O
.	O
Glutathione-S-transferase	S-GP
,	O
a	O
phase	O
II	O
enzyme	O
,	O
was	O
inhibited	O
by	O
both	O
arsenic	S-chemical
and	O
nicotine	S-chemical
but	O
no	O
such	O
inhibition	O
was	O
noted	O
in	O
arsenic	S-chemical
-treated	O
animals	O
pre-exposed	O
to	O
nicotine	S-chemical
.	O
Upon	O
nicotine	S-chemical
pre-exposure	O
,	O
brain	O
acetylcholinesterase	S-GP
increased	O
,	O
while	O
monoamine	B-GP
oxidase	E-GP
(	O
MAO	S-GP
)	O
decreased	O
.	O
The	O
toxic	O
effects	O
of	O
MAO	S-GP
significantly	O
attenuated	O
with	O
nicotine	S-chemical
pre-exposure	O
.	O
The	O
present	O
study	O
suggests	O
that	O
nicotine	S-chemical
may	O
not	O
be	O
the	O
major	O
contributing	O
factor	O
for	O
the	O
previously	O
reported	O
synergistic	O
toxic	O
interaction	O
between	O
tobacco	O
and	O
arsenic	S-chemical
.	O
Nicotine	S-chemical
pre-exposure	O
in	O
arsenic	S-chemical
-exposed	O
animals	O
revealed	O
interesting	O
toxicokinetics	O
and	O
oxidative	O
stress	O
modulating	O
interactions	O
in	O
the	O
brain	O
and	O
liver	O
of	O
rats	O
,	O
which	O
requires	O
further	O
exploration	O
.	O

Abnormal	O
uterine	O
bleeding	O
and	O
dysfunctional	O
uterine	O
bleeding	O
in	O
pediatric	O
and	O
adolescent	O
gynecology	O
.	O
Abnormal	O
uterine	O
bleeding	O
(	O
AUB	O
)	O
,	O
which	O
is	O
defined	O
as	O
excessively	O
heavy	O
,	O
prolonged	O
and/or	O
frequent	O
bleeding	O
of	O
uterine	O
origin	O
,	O
is	O
a	O
frequent	O
cause	O
of	O
visits	O
to	O
the	O
Emergency	O
Department	O
and/or	O
health	O
care	O
provider	O
.	O
While	O
there	O
are	O
many	O
etiologies	O
of	O
AUB	O
,	O
the	O
one	O
most	O
likely	O
among	O
otherwise	O
healthy	O
adolescents	O
is	O
dysfunctional	O
uterine	O
bleeding	O
(	O
DUB	O
)	O
,	O
which	O
is	O
characterizing	O
any	O
AUB	O
when	O
all	O
possible	O
underlying	O
pathologic	O
causes	O
have	O
been	O
previously	O
excluded	O
.	O
The	O
most	O
common	O
cause	O
of	O
DUB	O
in	O
adolescence	O
is	O
anovulation	O
,	O
which	O
is	O
very	O
frequent	O
in	O
the	O
first	O
2-3	O
post-menarchal	O
years	O
and	O
is	O
associated	O
with	O
immaturity	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
ovarian	O
axis	O
.	O
Management	O
of	O
AUB	O
is	O
based	O
on	O
the	O
underlying	O
etiology	O
and	O
the	O
severity	O
of	O
the	O
bleeding	O
and	O
primary	O
goals	O
are	O
prevention	O
of	O
complications	O
,	O
such	O
as	O
anemia	O
and	O
reestablishment	O
of	O
regular	O
cyclical	O
bleeding	O
,	O
while	O
the	O
management	O
of	O
DUB	O
can	O
in	O
part	O
be	O
directed	O
by	O
the	O
amount	O
of	O
flow	O
,	O
the	O
degree	O
of	O
associated	O
anemia	O
,	O
as	O
well	O
as	O
patient	O
and	O
family	O
comfort	O
with	O
different	O
treatment	O
modalities	O
.	O
Treatment	O
options	O
for	O
DUB	O
are	O
:	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
,	O
progestogens	S-chemical
,	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
tranexamic	B-chemical
acid	E-chemical
(	O
anti-fibrinolytic	O
)	O
,	O
GnRH	S-chemical
analogues	O
,	O
Danazol	S-chemical
and	O
Levonorgestrel	S-chemical
releasing	O
intra	O
uterine	O
system	O
(	O
LNG	O
IUS	O
)	O
.	O

Nicotinic-receptor	S-GP
potentiator	O
drugs	O
,	O
huprine	O
X	O
and	O
galantamine	S-chemical
,	O
increase	O
ACh	S-chemical
release	O
by	O
blocking	O
AChE	S-GP
activity	O
but	O
not	O
acting	O
on	O
nicotinic	B-GP
receptors	E-GP
.	O
The	O
main	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
analyse	O
the	O
effects	O
of	O
(	O
+/-	O
)	O
-huprine	O
X	O
(	O
(	O
+/-	O
)	O
-HX	O
)	O
and	O
galantamine	O
(	O
GAL	O
)	O
,	O
with	O
potentiating	O
action	O
on	O
nicotinic	B-GP
receptors	E-GP
,	O
and	O
huperzine	O
A	O
(	O
HPA	O
)	O
,	O
devoid	O
of	O
nicotinic	O
activity	O
,	O
on	O
[	B-chemical
3H	I-chemical
]	I-chemical
-acetylcholine	E-chemical
(	O
[	B-chemical
3H	I-chemical
]	I-chemical
-ACh	E-chemical
)	O
release	O
in	O
striatal	O
slices	O
of	O
rat	O
brain	O
.	O
All	O
compounds	O
are	O
non-covalent	O
and	O
reversible	O
inhibitors	O
of	O
AChE	S-GP
.	O
Addition	O
of	O
(	O
+/-	O
)	O
-HX	O
(	O
0.01	O
microM	O
)	O
,	O
GAL	O
(	O
10	O
microM	O
)	O
and	O
HPA	O
(	O
0.1	O
microM	O
)	O
to	O
the	O
superfusion	O
medium	O
decreased	O
the	O
release	O
of	O
the	O
ACh	S-chemical
neurotransmitter	O
to	O
a	O
similar	O
extent	O
:	O
36	O
%	O
,	O
30	O
%	O
and	O
34	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0.01	O
)	O
.	O
This	O
effect	O
was	O
reverted	O
in	O
the	O
presence	O
of	O
atropine	S-chemical
(	O
ATR	S-chemical
;	O
0.1	O
microM	O
)	O
,	O
which	O
blocks	O
the	O
pre-synaptic	O
muscarinic	B-GP
M2	I-GP
receptor	E-GP
.	O
After	O
that	O
,	O
a	O
wide	O
range	O
of	O
concentrations	O
of	O
drugs	O
,	O
concomitantly	O
with	O
ATR	S-chemical
(	O
0.1	O
microM	O
)	O
,	O
was	O
studied	O
in	O
the	O
presence	O
of	O
haloperidol	S-chemical
(	O
HAL	S-chemical
;	O
0.01	O
microM	O
)	O
,	O
a	O
dopamine	B-GP
D2	E-GP
antagonist	O
.	O
In	O
these	O
conditions	O
,	O
a	O
dose-dependent	O
increase	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-ACh	E-chemical
release	O
was	O
observed	O
in	O
the	O
presence	O
of	O
(	O
+/-	O
)	O
-HX	O
,	O
GAL	O
and	O
HPA	O
.	O
To	O
test	O
the	O
role	O
of	O
nicotinic	B-GP
receptors	E-GP
in	O
the	O
drugs	O
'	O
effects	O
on	O
[	B-chemical
3H	I-chemical
]	I-chemical
-ACh	E-chemical
release	O
,	O
mecamylamine	S-chemical
(	O
MEC	S-chemical
)	O
100	O
microM	O
was	O
used	O
to	O
block	O
such	O
receptors	O
.	O
MEC	S-chemical
alone	O
significantly	O
decreased	O
neurotransmitter	O
release	O
by	O
18	O
%	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
no	O
change	O
was	O
obtained	O
in	O
the	O
presence	O
of	O
both	O
ATR	S-chemical
and	O
MEC	S-chemical
.	O
Under	O
these	O
conditions	O
,	O
(	O
+/-	O
)	O
-HX	O
,	O
GAL	O
and	O
HPA	O
increased	O
the	O
release	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
-ACh	E-chemical
by	O
37	O
%	O
,	O
25	O
%	O
and	O
38	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0.01	O
)	O
.	O
Taking	O
into	O
account	O
all	O
of	O
these	O
data	O
,	O
the	O
present	O
results	O
suggest	O
that	O
the	O
effects	O
induced	O
by	O
(	O
+/-	O
)	O
-HX	O
and	O
GAL	O
nicotinic-receptor	S-GP
potentiators	O
seem	O
to	O
be	O
mainly	O
due	O
to	O
their	O
ability	O
in	O
inhibiting	O
acetylcholinesterase	S-GP
activity	O
,	O
but	O
not	O
by	O
interaction	O
on	O
the	O
nicotinic	B-GP
receptors	E-GP
.	O

Irbesartan	S-chemical
:	O
a	O
review	O
of	O
its	O
use	O
in	O
hypertension	O
and	O
diabetic	O
nephropathy	O
.	O
Irbesartan	S-chemical
(	O
Aprovel	S-chemical
,	O
Avapro	S-chemical
,	O
Irbetan	S-chemical
,	O
Karvea	S-chemical
)	O
,	O
an	O
angiotensin	B-GP
II	I-GP
receptor	I-GP
type	I-GP
1	E-GP
antagonist	O
,	O
is	O
approved	O
in	O
many	O
countries	O
worldwide	O
for	O
the	O
treatment	O
of	O
hypertension	O
.	O
It	O
is	O
also	O
approved	O
in	O
some	O
regions	O
for	O
the	O
treatment	O
of	O
nephropathy	O
in	O
patients	O
with	O
hypertension	O
and	O
type	O
2	O
diabetes	O
mellitus	O
.	O
In	O
adults	O
with	O
essential	O
hypertension	O
,	O
irbesartan	S-chemical
is	O
effective	O
at	O
reducing	O
blood	O
pressure	O
(	O
BP	O
)	O
over	O
a	O
24-hour	O
period	O
with	O
once-daily	O
administration	O
.	O
Irbesartan	S-chemical
also	O
slows	O
the	O
progression	O
of	O
renal	O
disease	O
in	O
hypertensive	O
patients	O
with	O
type	O
2	O
diabetes	O
,	O
with	O
this	O
effect	O
partly	O
independent	O
of	O
its	O
BP-lowering	O
effect	O
.	O
In	O
addition	O
,	O
irbesartan	S-chemical
was	O
generally	O
well	O
tolerated	O
in	O
clinical	O
trials	O
.	O
Thus	O
,	O
irbesartan	S-chemical
is	O
a	O
useful	O
treatment	O
option	O
for	O
patients	O
with	O
hypertension	O
,	O
including	O
those	O
with	O
type	O
2	O
diabetes	O
and	O
nephropathy	O
.	O

Static	O
Laue	O
diffraction	O
studies	O
on	O
acetylcholinesterase	S-GP
.	O
Acetylcholinesterase	S-GP
(	O
AChE	S-GP
)	O
is	O
one	O
of	O
nature	O
's	O
fastest	O
enzymes	O
,	O
despite	O
the	O
fact	O
that	O
its	O
three-dimensional	O
structure	O
reveals	O
its	O
active	O
site	O
to	O
be	O
deeply	O
sequestered	O
within	O
the	O
molecule	O
.	O
This	O
raises	O
questions	O
with	O
respect	O
to	O
traffic	O
of	O
substrate	O
to	O
,	O
and	O
products	O
from	O
,	O
the	O
active	O
site	O
,	O
which	O
may	O
be	O
investigated	O
by	O
time-resolved	O
crystallography	O
.	O
In	O
order	O
to	O
address	O
one	O
aspect	O
of	O
the	O
feasibility	O
of	O
performing	O
time-resolved	O
studies	O
on	O
AChE	S-GP
,	O
a	O
data	O
set	O
has	O
been	O
collected	O
using	O
the	O
Laue	O
technique	O
on	O
a	O
trigonal	O
crystal	O
of	O
Torpedo	B-GP
californica	I-GP
AChE	E-GP
soaked	O
with	O
the	O
reversible	O
inhibitor	O
edrophonium	S-chemical
,	O
using	O
a	O
total	O
X-ray	O
exposure	O
time	O
of	O
24	O
ms.	O
Electron-density	O
maps	O
obtained	O
from	O
the	O
Laue	O
data	O
,	O
which	O
are	O
of	O
surprisingly	O
good	O
quality	O
compared	O
with	O
similar	O
maps	O
from	O
monochromatic	O
data	O
,	O
show	O
essentially	O
the	O
same	O
features	O
.	O
They	O
clearly	O
reveal	O
the	O
bound	O
ligand	O
,	O
as	O
well	O
as	O
a	O
structural	O
change	O
in	O
the	O
conformation	O
of	O
the	O
active-site	O
Ser200	O
induced	O
upon	O
binding	O
.	O

Novel	O
insights	O
on	O
the	O
effect	O
of	O
nicotine	S-chemical
in	O
a	O
murine	O
colitis	O
model	O
.	O
Studies	O
showed	O
that	O
nicotine	S-chemical
has	O
a	O
positive	O
influence	O
on	O
symptoms	O
of	O
ulcerative	O
colitis	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
explored	O
the	O
effect	O
of	O
nicotine	S-chemical
treatment	O
using	O
different	O
routes	O
of	O
administration	O
in	O
the	O
dextran	O
sodium	B-chemical
sulfate	E-chemical
(	O
DSS	O
)	O
colitis	O
mouse	O
model	O
.	O
We	O
also	O
investigated	O
the	O
effects	O
of	O
cotinine	S-chemical
,	O
a	O
major	O
metabolite	O
of	O
nicotine	S-chemical
,	O
in	O
the	O
model	O
.	O
C57BL6	O
adult	O
male	O
mice	O
were	O
given	O
DSS	O
solution	O
freely	O
in	O
the	O
drinking	O
water	O
for	O
seven	O
consecutive	O
days	O
,	O
and	O
tap	O
water	O
was	O
given	O
thereafter	O
.	O
Disease	O
severity	O
,	O
length	O
of	O
the	O
colon	O
,	O
colon	O
tissue	O
histology	O
,	O
and	O
inflammatory	O
markers	O
,	O
including	O
colonic	B-GP
myeloperoxidase	E-GP
activity	O
and	O
colonic	B-GP
tumor	I-GP
necrosis	I-GP
factor-α	E-GP
levels	O
,	O
were	O
evaluated	O
.	O
The	O
effect	O
of	O
nicotine	S-chemical
and	O
cotinine	S-chemical
treatments	O
via	O
various	O
different	O
routes	O
of	O
administration	O
were	O
examined	O
the	O
DSS	O
model	O
.	O
In	O
addition	O
,	O
we	O
measured	O
the	O
plasma	O
levels	O
of	O
nicotine	S-chemical
and	O
cotinine	S-chemical
in	O
our	O
treatment	O
protocols	O
.	O
Administration	O
of	O
low	O
,	O
but	O
not	O
high	O
,	O
doses	O
of	O
oral	O
nicotine	S-chemical
in	O
DSS-treated	O
mice	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
disease	O
severity	O
,	O
histologic	O
damage	O
scores	O
,	O
as	O
well	O
as	O
colonic	O
level	O
of	O
tumor	B-GP
necrosis	I-GP
factor-α	E-GP
.	O
However	O
,	O
the	O
anti-inflammatory	O
effect	O
of	O
nicotine	S-chemical
was	O
not	O
seen	O
after	O
chronic	O
s.c.	O
or	O
minipump	O
infusion	O
of	O
the	O
drug	O
.	O
Differences	O
in	O
plasma	O
levels	O
of	O
nicotine	S-chemical
and	O
cotinine	S-chemical
do	O
not	O
seem	O
to	O
account	O
for	O
this	O
lack	O
of	O
effect	O
.	O
Finally	O
,	O
oral	O
cotinine	S-chemical
alone	O
failed	O
to	O
show	O
a	O
significant	O
effect	O
in	O
the	O
DSS	O
model	O
of	O
colitis	O
.	O
These	O
results	O
highlight	O
that	O
dose	O
and	O
route	O
of	O
administration	O
play	O
a	O
critical	O
role	O
in	O
the	O
protective	O
effect	O
of	O
nicotine	S-chemical
in	O
the	O
DSS	O
mouse	O
colitis	O
model	O
.	O

Ibrutinib	S-chemical
:	O
a	O
review	O
of	O
its	O
use	O
in	O
patients	O
with	O
mantle	O
cell	O
lymphoma	O
or	O
chronic	O
lymphocytic	O
leukaemia	O
.	O
Ibrutinib	S-chemical
(	O
Imbruvica	B-chemical
(	I-chemical
R	I-chemical
)	E-chemical
)	O
is	O
a	O
first-in-class	O
,	O
potent	O
,	O
orally	O
administered	O
,	O
covalent	O
inhibitor	O
of	O
Bruton	B-GP
's	I-GP
tyrosine	I-GP
kinase	E-GP
(	O
BTK	S-GP
)	O
that	O
inhibits	O
B-cell	B-GP
antigen	I-GP
receptor	E-GP
signalling	O
downstream	O
of	O
BTK	S-GP
.	O
Oral	O
ibrutinib	S-chemical
is	O
indicated	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
relapsed/refractory	O
mantle	O
cell	O
lymphoma	O
(	O
MCL	O
)	O
or	O
chronic	O
lymphocytic	O
leukaemia	O
(	O
CLL	O
)	O
and	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
CLL	O
and	O
a	O
chromosome	O
17	O
deletion	O
(	O
del	O
17p	O
)	O
or	O
TP53	S-GP
mutation	O
.	O
This	O
article	O
summarizes	O
pharmacological	O
,	O
efficacy	O
and	O
tolerability	O
data	O
relevant	O
to	O
the	O
use	O
of	O
ibrutinib	S-chemical
in	O
these	O
indications	O
.	O
In	O
clinical	O
studies	O
,	O
ibrutinib	S-chemical
induced	O
a	O
high	O
overall	O
response	O
rate	O
in	O
patients	O
with	O
relapsed/refractory	O
MCL	O
(	O
phase	O
II	O
study	O
)	O
.	O
In	O
addition	O
,	O
ibrutinib	S-chemical
significantly	O
prolonged	O
progression-free	O
survival	O
and	O
significantly	O
improved	O
the	O
partial	O
response	O
rate	O
and	O
overall	O
survival	O
in	O
patients	O
with	O
relapsed/refractory	O
CLL	O
(	O
RESONATE	O
study	O
)	O
,	O
including	O
in	O
those	O
with	O
del	O
17p	O
,	O
a	O
subgroup	O
with	O
a	O
poor	O
prognosis	O
.	O
Ibrutinib	S-chemical
had	O
an	O
acceptable	O
tolerability	O
profile	O
in	O
these	O
studies	O
with	O
<	O
10	O
%	O
of	O
patients	O
discontinuing	O
treatment	O
because	O
of	O
adverse	O
events	O
.	O
Given	O
its	O
efficacy	O
and	O
tolerability	O
,	O
once-daily	O
,	O
oral	O
ibrutinib	S-chemical
is	O
an	O
emerging	O
treatment	O
option	O
for	O
patients	O
with	O
relapsed/refractory	O
MCL	O
or	O
CLL	O
and	O
CLL	O
patients	O
with	O
del	O
17p	O
or	O
TP53	S-GP
mutation	O
.	O

High-affinity	O
blockade	O
of	O
voltage-operated	B-GP
skeletal	I-GP
muscle	I-GP
and	I-GP
neuronal	I-GP
sodium	I-GP
channels	E-GP
by	O
halogenated	B-chemical
propofol	E-chemical
analogues	O
.	O
BACKGROUND	O
AND	O
PURPOSE	O
:	O
Voltage-operated	B-GP
sodium	I-GP
channels	E-GP
constitute	O
major	O
target	O
sites	O
for	O
local	O
anaesthetic-like	O
action	O
.	O
The	O
clinical	O
use	O
of	O
local	O
anaesthetics	O
is	O
still	O
limited	O
by	O
severe	O
side	O
effects	O
,	O
in	O
particular	O
,	O
arrhythmias	O
and	O
convulsions	O
.	O
These	O
side	O
effects	O
render	O
the	O
search	O
for	O
new	O
local	O
anaesthetics	O
a	O
matter	O
of	O
high	O
interest	O
.	O
EXPERIMENTAL	O
APPROACH	O
:	O
We	O
have	O
investigated	O
the	O
effects	O
of	O
three	O
halogenated	O
structural	O
analogues	O
of	O
propofol	S-chemical
on	O
voltage-operated	B-GP
human	I-GP
skeletal	I-GP
muscle	I-GP
sodium	I-GP
channels	E-GP
(	O
Na	B-GP
(	I-GP
V	I-GP
)	I-GP
1.4	E-GP
)	O
and	O
the	O
effect	O
of	O
one	O
compound	O
(	O
4-chloropropofol	S-chemical
)	O
on	O
neuronal	B-GP
sodium	I-GP
channels	E-GP
(	O
Na	B-GP
(	I-GP
V	I-GP
)	I-GP
1.2	E-GP
)	O
heterologously	O
expressed	O
in	O
human	O
embryonic	O
kidney	O
cell	O
line	O
293	O
.	O
KEY	O
RESULTS	O
:	O
4-Iodo	S-chemical
-	O
,	O
4-bromo	S-chemical
-	O
and	O
4-chloropropofol	S-chemical
reversibly	O
suppressed	O
depolarization-induced	O
whole-cell	O
sodium	S-chemical
inward	O
currents	O
with	O
high	O
potency	O
.	O
The	O
IC	O
(	O
50	O
)	O
for	O
block	O
of	O
resting	O
channels	O
at	O
-150	O
mV	O
was	O
2.3	O
,	O
3.9	O
and	O
11.3	O
microM	O
in	O
Na	B-GP
(	I-GP
V	I-GP
)	I-GP
1.4	E-GP
,	O
respectively	O
,	O
and	O
29.2	O
microM	O
for	O
4-chloropropofol	S-chemical
in	O
Na	B-GP
(	I-GP
V	I-GP
)	I-GP
1.2	E-GP
.	O
Membrane	O
depolarization	O
inducing	O
inactivation	O
strongly	O
increased	O
the	O
blocking	O
potency	O
of	O
all	O
compounds	O
.	O
Estimated	O
affinities	O
for	O
the	O
fast-inactivated	O
channel	O
state	O
were	O
81	O
nM	O
,	O
312	O
nM	O
and	O
227	O
nM	O
for	O
4-iodopropofol	S-chemical
,	O
4-bromopropofol	S-chemical
and	O
4-chloropropofol	S-chemical
in	O
Na	B-GP
(	I-GP
V	I-GP
)	I-GP
1.4	E-GP
,	O
and	O
450	O
nM	O
for	O
4-chloropropofol	S-chemical
in	O
Na	B-GP
(	I-GP
V	I-GP
)	I-GP
1.2	E-GP
.	O
Recovery	O
from	O
fast	O
inactivation	O
was	O
prolonged	O
in	O
the	O
presence	O
of	O
drug	O
leading	O
to	O
an	O
accumulation	O
of	O
block	O
during	O
repetitive	O
stimulation	O
at	O
high	O
frequencies	O
(	O
100	O
Hz	O
)	O
.	O
CONCLUSIONS	O
AND	O
IMPLICATIONS	O
:	O
Halogenated	B-chemical
propofol	E-chemical
analogues	O
constitute	O
a	O
novel	O
class	O
of	O
sodium	B-GP
channel	E-GP
-blocking	O
drugs	O
possessing	O
almost	O
100-fold	O
higher	O
potency	O
compared	O
with	O
the	O
local	O
anaesthetic	O
and	O
anti-arrhythmic	O
drug	O
lidocaine	S-chemical
.	O
Preferential	O
drug	O
binding	O
to	O
inactivated	O
channel	O
states	O
suggests	O
that	O
halogenated	B-chemical
propofol	E-chemical
analogues	O
might	O
be	O
especially	O
effective	O
in	O
suppressing	O
ectopic	O
discharges	O
in	O
a	O
variety	O
of	O
pathological	O
conditions	O
.	O

The	O
apoptosome	O
:	O
heart	O
and	O
soul	O
of	O
the	O
cell	O
death	O
machine	O
.	O
Apoptosis	O
is	O
a	O
fundamental	O
biologic	O
process	O
by	O
which	O
metazoan	O
cells	O
orchestrate	O
their	O
own	O
self-demise	O
.	O
Genetic	O
analyses	O
of	O
the	O
nematode	O
C	O
elegans	O
identified	O
three	O
core	O
components	O
of	O
the	O
suicide	O
apparatus	O
which	O
include	O
CED-3	S-GP
,	O
CED-4	S-GP
,	O
and	O
CED-9	S-GP
.	O
An	O
analogous	O
set	O
of	O
core	O
constituents	O
exists	O
in	O
mammalian	O
cells	O
and	O
includes	O
caspase-9	S-GP
,	O
Apaf-1	S-GP
,	O
and	O
bcl-2/xL	S-GP
,	O
respectively	O
.	O
CED-3	S-GP
and	O
CED-4	S-GP
,	O
along	O
with	O
their	O
mammalian	O
counterparts	O
,	O
function	O
to	O
kill	O
cells	O
,	O
whereas	O
CED-9	S-GP
and	O
its	O
mammalian	O
equivalents	O
protect	O
cells	O
from	O
death	O
.	O
These	O
central	O
components	O
biochemically	O
intermingle	O
in	O
a	O
ternary	O
complex	O
recently	O
dubbed	O
the	O
``	O
apoptosome	O
.	O
''	O
The	O
C	O
elegans	O
protein	O
EGL-1	S-GP
and	O
its	O
mammalian	O
counterparts	O
,	O
pro-apoptotic	O
members	O
of	O
the	O
bcl-2	S-GP
family	O
,	O
induce	O
cell	O
death	O
by	O
disrupting	O
apoptosome	O
interactions	O
.	O
Thus	O
,	O
EGL-1	S-GP
may	O
represent	O
a	O
primordial	O
signal	O
integrator	O
for	O
the	O
apoptosome	O
.	O
Various	O
biochemical	O
processes	O
including	O
oligomerization	O
,	O
adenosine	B-chemical
triphosphate	E-chemical
ATP	S-chemical
/dATP	O
binding	O
,	O
and	O
cytochrome	B-GP
c	E-GP
interaction	O
play	O
a	O
role	O
in	O
regulating	O
the	O
ternary	O
death	O
complex	O
.	O
Recent	O
studies	O
suggest	O
that	O
cell	O
death	B-GP
receptors	E-GP
,	O
such	O
as	O
CD95	S-GP
,	O
may	O
amplify	O
their	O
suicide	O
signal	O
by	O
activating	O
the	O
apoptosome	O
.	O
These	O
mutual	O
associations	O
by	O
core	O
components	O
of	O
the	O
suicide	O
apparatus	O
provide	O
a	O
molecular	O
framework	O
in	O
which	O
diverse	O
death	O
signals	O
likely	O
interface	O
.	O
Understanding	O
the	O
apoptosome	O
and	O
its	O
cellular	O
connections	O
will	O
facilitate	O
the	O
design	O
of	O
novel	O
therapeutic	O
strategies	O
for	O
cancer	O
and	O
other	O
disease	O
states	O
in	O
which	O
apoptosis	O
plays	O
a	O
pivotal	O
role	O
.	O

Losartan	S-chemical
:	O
a	O
selective	O
angiotensin	B-GP
II	I-GP
type	I-GP
1	I-GP
(	I-GP
AT1	I-GP
)	I-GP
receptor	E-GP
antagonist	O
for	O
the	O
treatment	O
of	O
heart	O
failure	O
.	O
Losartan	S-chemical
(	O
COZAAR	S-chemical
)	O
is	O
the	O
prototype	O
of	O
a	O
new	O
class	O
of	O
potent	O
and	O
selective	O
angiotensin	B-GP
II	I-GP
(	I-GP
AII	I-GP
)	I-GP
type	I-GP
1	I-GP
(	I-GP
AT	I-GP
(	I-GP
1	I-GP
)	I-GP
)	I-GP
receptor	E-GP
antagonists	O
with	O
the	O
largest	O
published	O
preclinical	O
and	O
clinical	O
data	O
base	O
.	O
Since	O
all	O
of	O
the	O
AII	S-chemical
antagonists	O
are	O
selective	O
for	O
the	O
AT	B-GP
(	I-GP
1	I-GP
)	I-GP
receptor	E-GP
,	O
these	O
drugs	O
should	O
exhibit	O
similar	O
cardiovascular	O
effects	O
.	O
However	O
,	O
since	O
the	O
pharmacokinetic/pharmacodynamic	O
profiles	O
of	O
these	O
agents	O
and	O
their	O
degree	O
of	O
affinity	O
for	O
the	O
AT	B-GP
(	I-GP
1	I-GP
)	I-GP
receptor	E-GP
differ	O
,	O
it	O
is	O
likely	O
that	O
differences	O
in	O
clinical	O
profiles	O
between	O
these	O
drugs	O
exist	O
and	O
will	O
require	O
investigation	O
.	O
Losartan	S-chemical
(	O
parent	O
compound	O
)	O
,	O
has	O
moderate	O
affinity	O
for	O
the	O
AT	B-GP
(	I-GP
1	I-GP
)	I-GP
receptor	E-GP
(	O
competitive	O
inhibition	O
)	O
.	O
Losartan	S-chemical
is	O
well-absorbed	O
orally	O
as	O
an	O
active	O
drug	O
and	O
is	O
rapidly	O
converted	O
via	O
oxidation	O
in	O
the	O
human	O
liver	O
to	O
a	O
more	O
potent	O
metabolite	O
(	O
designated	O
E3174	O
)	O
with	O
an	O
affinity	O
20-	O
to	O
30-times	O
greater	O
for	O
the	O
AT	B-GP
(	I-GP
1	I-GP
)	I-GP
receptor	E-GP
(	O
non-competitive	O
inhibition	O
)	O
.	O
E3174	O
has	O
a	O
half-life	O
of	O
6	O
-	O
9	O
h	O
;	O
elimination	O
is	O
via	O
renal	O
and	O
hepatic	O
routes	O
.	O
Antihypertensive	O
and	O
,	O
in	O
heart	O
failure	O
patients	O
,	O
haemodynamic	O
activity	O
is	O
observed	O
over	O
a	O
24	O
h	O
period	O
with	O
once	O
daily	O
dosing	O
.	O
Over	O
6	O
million	O
patients	O
have	O
been	O
treated	O
for	O
hypertension	O
with	O
continued	O
excellent	O
tolerability	O
.	O
Clinical	O
experience	O
in	O
heart	O
failure	O
is	O
growing	O
,	O
and	O
recent	O
data	O
suggest	O
an	O
improved	O
survival	O
with	O
losartan	S-chemical
versus	O
captopril	S-chemical
,	O
a	O
drug	O
from	O
the	O
angiotensin-converting-enzyme	S-GP
inhibitor	O
class	O
with	O
proven	O
benefit	O
in	O
this	O
population	O
.	O
The	O
current	O
comprehensive	O
losartan	S-chemical
clinical	O
end-point	O
programme	O
(	O
4	O
large	O
scale	O
morbidity/mortality	O
trials	O
)	O
should	O
provide	O
evidence	O
regarding	O
the	O
efficacy	O
of	O
direct	O
blockade	O
of	O
the	O
AT	B-GP
(	I-GP
1	I-GP
)	I-GP
receptor	E-GP
with	O
losartan	S-chemical
compared	O
to	O
standard	O
therapy	O
:	O
1	O
)	O
The	O
Losartan	S-chemical
Heart	O
Failure	O
Survival	O
Study	O
-	O
ELITE	O
II	O
,	O
2	O
)	O
The	O
Losartan	S-chemical
Post-Myocardial	O
Infarction	O
Survival	O
Study	O
-	O
OPTIMAAL	O
,	O
3	O
)	O
The	O
Losartan	S-chemical
Hypertension	O
Survival	O
Study	O
-	O
LIFE	O
and	O
4	O
)	O
The	O
Losartan	S-chemical
Renal	O
Protection	O
Study	O
-	O
RENAAL	O
.	O

CCAAT/Enhancer-binding	B-GP
protein-homologous	I-GP
protein	E-GP
sensitizes	O
to	O
SU5416	S-chemical
by	O
modulating	O
p21	S-GP
and	O
PI3K	S-GP
/	O
Akt	S-GP
signal	O
pathway	O
in	O
FRO	O
anaplastic	O
thyroid	O
carcinoma	O
cells	O
.	O
SU5416	S-chemical
,	O
vascular	O
endothelial	O
cell	O
growth	O
factor	O
receptor	O
inhibitor	O
,	O
suppresses	O
hypoxia-induced	O
angiogenesis	O
,	O
growth	O
,	O
proliferation	O
,	O
and	O
metastasis	O
in	O
cancer	O
cells	O
.	O
CCAAT/enhancer-binding	B-GP
protein-homologous	I-GP
protein	E-GP
(	O
CHOP	S-GP
)	O
has	O
pivotal	O
roles	O
in	O
regulation	O
of	O
growth	O
and	O
survival	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
SU5416	S-chemical
on	O
cell	O
survival	O
,	O
p21	S-GP
,	O
and	O
PI3K	S-GP
/	O
Akt	S-GP
signal	O
pathway	O
in	O
FRO	O
anaplastic	O
thyroid	O
carcinoma	O
(	O
ATC	O
)	O
cells	O
.	O
Moreover	O
,	O
we	O
investigated	O
the	O
roles	O
of	O
CHOP	S-GP
in	O
cell	O
survival	O
under	O
condition	O
of	O
SU5416	S-chemical
treatment	O
in	O
FRO	O
ATC	O
cells	O
.	O
After	O
SU5416	S-chemical
treatment	O
,	O
cell	O
viability	O
,	O
PARP-1	S-GP
,	O
and	O
caspase-3	S-GP
protein	O
levels	O
were	O
not	O
changed	O
.	O
p53	S-GP
and	O
p27	S-GP
protein	O
levels	O
decreased	O
while	O
p21	S-GP
protein	O
levels	O
increased	O
.	O
Phospho-Akt	S-GP
protein	O
levels	O
were	O
not	O
altered	O
.	O
In	O
SU5416	S-chemical
-treated	O
situation	O
,	O
cell	O
viability	O
was	O
not	O
different	O
before	O
and	O
after	O
administration	O
of	O
either	O
p21	S-GP
siRNA	O
or	O
LY294002	S-chemical
whereas	O
it	O
was	O
lessened	O
after	O
co-administration	O
of	O
p21	S-GP
siRNA	O
and	O
LY294002	S-chemical
.	O
Compared	O
to	O
SU5416	S-chemical
treatment	O
alone	O
,	O
cell	O
viability	O
was	O
reduced	O
with	O
CHOP	S-GP
plasmid	O
but	O
it	O
was	O
unchanged	O
with	O
CHOP	S-GP
siRNA	O
.	O
PARP-1	S-GP
and	O
caspase-3	S-GP
protein	O
levels	O
with	O
CHOP	S-GP
plasmid	O
were	O
elevated	O
whereas	O
the	O
protein	O
levels	O
with	O
CHOP	S-GP
siRNA	O
were	O
similar	O
.	O
While	O
CHOP	S-GP
plasmid	O
transfection	O
diminished	O
p21	S-GP
and	O
phospho-Akt	S-GP
protein	O
levels	O
,	O
CHOP	S-GP
siRNA	O
transfection	O
did	O
not	O
alter	O
the	O
protein	O
levels	O
.	O
In	O
conclusion	O
,	O
these	O
results	O
suggest	O
that	O
CHOP	S-GP
may	O
sensitize	O
FRO	O
ATC	O
cells	O
to	O
SU5416	S-chemical
thereby	O
inhibiting	O
cell	O
survival	O
by	O
modulating	O
p21	S-GP
and	O
PI3K	S-GP
/	O
Akt	S-GP
signal	O
pathway	O
.	O
Furthermore	O
,	O
these	O
findings	O
imply	O
that	O
CHOP	S-GP
may	O
be	O
a	O
possible	O
candidate	O
as	O
the	O
chemosensitizing	O
factor	O
for	O
induction	O
of	O
cytotoxicity	O
in	O
ATC	O
cells	O
exposed	O
to	O
SU5416	S-chemical
.	O

Sirtuins	S-GP
as	O
emerging	O
anti-parasitic	O
targets	O
.	O
Silent	B-GP
information	I-GP
regulator	I-GP
2	E-GP
(	O
Sir2	S-GP
)	O
enzymes	O
or	O
sirtuins	S-GP
are	O
a	O
family	O
of	O
NAD	B-GP
(	I-GP
+	I-GP
)	I-GP
-dependent	I-GP
protein	I-GP
N	I-GP
(	I-GP
ε	I-GP
)	I-GP
-acetyl-lysine	I-GP
(	I-GP
AcK	I-GP
)	I-GP
deacetylases	E-GP
.	O
Sirtuins	S-GP
are	O
also	O
evolutionarily	O
conserved	O
proteins	O
that	O
are	O
present	O
in	O
all	O
kingdoms	O
of	O
life	O
ranging	O
from	O
bacteria	O
to	O
humans	O
.	O
Interestingly	O
,	O
it	O
was	O
recently	O
found	O
that	O
the	O
sirtuins	S-GP
found	O
in	O
various	O
human	O
parasites	O
(	O
especially	O
the	O
Plasmodium	O
,	O
Trypanosoma	O
,	O
and	O
Leishmania	O
species	O
)	O
were	O
pro-survival	O
for	O
the	O
parasites	O
under	O
various	O
conditions	O
.	O
Therefore	O
,	O
these	O
parasitic	B-GP
sirtuins	E-GP
have	O
emerged	O
as	O
novel	O
anti-parasitic	O
therapeutic	O
targets	O
.	O
This	O
article	O
reviews	O
the	O
currently	O
available	O
structural	O
,	O
biochemical	O
,	O
pharmacological	O
,	O
and	O
medicinal	O
chemistry	O
studies	O
on	O
these	O
enzymes	O
,	O
and	O
discusses	O
the	O
perspectives	O
of	O
selectively	O
targeting	O
the	O
parasitic	B-GP
sirtuins	E-GP
as	O
a	O
novel	O
therapeutic	O
strategy	O
for	O
the	O
human	O
parasitic	O
diseases	O
.	O

Atomoxetine	S-chemical
:	O
a	O
review	O
of	O
its	O
use	O
in	O
attention-deficit	O
hyperactivity	O
disorder	O
in	O
children	O
and	O
adolescents	O
.	O
Atomoxetine	S-chemical
(	O
Strattera	S-chemical
(	O
R	O
)	O
)	O
is	O
a	O
selective	O
norepinephrine	S-chemical
(	O
noradrenaline	S-chemical
)	O
reuptake	O
inhibitor	O
that	O
is	O
not	O
classified	O
as	O
a	O
stimulant	O
,	O
and	O
is	O
indicated	O
for	O
use	O
in	O
patients	O
with	O
attention-deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
.	O
Atomoxetine	S-chemical
is	O
effective	O
and	O
generally	O
well	O
tolerated	O
.	O
It	O
is	O
significantly	O
more	O
effective	O
than	O
placebo	O
and	O
standard	O
current	O
therapy	O
and	O
does	O
not	O
differ	O
significantly	O
from	O
or	O
is	O
noninferior	O
to	O
immediate-release	O
methylphenidate	S-chemical
;	O
however	O
,	O
it	O
is	O
significantly	O
less	O
effective	O
than	O
the	O
extended-release	O
methylphenidate	S-chemical
formulation	O
OROS	O
(	O
R	O
)	O
methylphenidate	S-chemical
(	O
hereafter	O
referred	O
to	O
as	O
osmotically	O
released	O
methylphenidate	S-chemical
)	O
and	O
extended-release	O
mixed	O
amfetamine	S-chemical
salts	O
.	O
Atomoxetine	S-chemical
can	O
be	O
administered	O
either	O
as	O
a	O
single	O
daily	O
dose	O
or	O
split	O
into	O
two	O
evenly	O
divided	O
doses	O
,	O
has	O
a	O
negligible	O
risk	O
of	O
abuse	O
or	O
misuse	O
,	O
and	O
is	O
not	O
a	O
controlled	O
substance	O
in	O
the	O
US	O
.	O
Atomoxetine	S-chemical
is	O
particularly	O
useful	O
for	O
patients	O
at	O
risk	O
of	O
substance	O
abuse	O
,	O
as	O
well	O
as	O
those	O
who	O
have	O
co-morbid	O
anxiety	O
or	O
tics	O
,	O
or	O
who	O
do	O
not	O
wish	O
to	O
take	O
a	O
controlled	O
substance	O
.	O
Thus	O
,	O
atomoxetine	S-chemical
is	O
a	O
useful	O
option	O
in	O
the	O
treatment	O
of	O
ADHD	O
in	O
children	O
and	O
adolescents	O
.	O
The	O
mechanism	O
of	O
action	O
of	O
atomoxetine	S-chemical
is	O
unclear	O
,	O
but	O
is	O
thought	O
to	O
be	O
related	O
to	O
its	O
selective	O
inhibition	O
of	O
presynaptic	O
norepinephrine	S-chemical
reuptake	O
in	O
the	O
prefrontal	O
cortex	O
.	O
Atomoxetine	S-chemical
has	O
a	O
high	O
affinity	O
and	O
selectivity	O
for	O
norepinephrine	B-GP
transporters	E-GP
,	O
but	O
little	O
or	O
no	O
affinity	O
for	O
various	O
neurotransmitter	B-GP
receptors	E-GP
.	O
Atomoxetine	S-chemical
has	O
a	O
demonstrated	O
ability	O
to	O
selectively	O
inhibit	O
norepinephrine	S-chemical
uptake	O
in	O
humans	O
and	O
animals	O
,	O
and	O
studies	O
have	O
shown	O
that	O
it	O
preferentially	O
binds	O
to	O
areas	O
of	O
known	O
high	O
distribution	O
of	O
noradrenergic	O
neurons	O
,	O
such	O
as	O
the	O
fronto-cortical	O
subsystem	O
.	O
Atomoxetine	S-chemical
was	O
generally	O
associated	O
with	O
statistically	O
,	O
but	O
not	O
clinically	O
,	O
significant	O
increases	O
in	O
both	O
heart	O
rate	O
and	O
blood	O
pressure	O
in	O
pediatric	O
patients	O
with	O
ADHD	O
.	O
While	O
there	O
was	O
an	O
initial	O
loss	O
in	O
expected	O
height	O
and	O
weight	O
among	O
atomoxetine	S-chemical
recipients	O
,	O
this	O
eventually	O
returned	O
to	O
normal	O
in	O
the	O
longer	O
term	O
.	O
Data	O
suggest	O
that	O
atomoxetine	S-chemical
is	O
unlikely	O
to	O
have	O
any	O
abuse	O
potential	O
.	O
Atomoxetine	S-chemical
appeared	O
less	O
likely	O
than	O
methylphenidate	S-chemical
to	O
exacerbate	O
disordered	O
sleep	O
in	O
pediatric	O
patients	O
with	O
ADHD	O
.	O
Atomoxetine	S-chemical
is	O
rapidly	O
absorbed	O
,	O
and	O
demonstrates	O
dose-proportional	O
increases	O
in	O
plasma	O
exposure	O
.	O
It	O
undergoes	O
extensive	O
biotransformation	O
,	O
which	O
is	O
affected	O
by	O
poor	O
metabolism	O
by	O
cytochrome	B-GP
P450	I-GP
(	I-GP
CYP	I-GP
)	I-GP
2D6	E-GP
in	O
a	O
small	O
percentage	O
of	O
the	O
population	O
;	O
these	O
patients	O
have	O
greater	O
exposure	O
to	O
and	O
slower	O
elimination	O
of	O
atomoxetine	S-chemical
than	O
extensive	O
metabolizers	O
.	O
Patients	O
with	O
hepatic	O
insufficiency	O
show	O
an	O
increase	O
in	O
atomoxetine	S-chemical
exposure	O
.	O
CYP2D6	S-GP
inhibitors	O
,	O
such	O
as	O
paroxetine	S-chemical
,	O
are	O
associated	O
with	O
changes	O
in	O
atomoxetine	S-chemical
pharmacokinetics	O
similar	O
to	O
those	O
observed	O
among	O
poor	O
CYP2D6	S-GP
metabolizers	O
.	O
Once-	O
or	O
twice-daily	O
atomoxetine	S-chemical
was	O
effective	O
in	O
the	O
short-term	O
treatment	O
of	O
ADHD	O
in	O
children	O
and	O
adolescents	O
,	O
as	O
observed	O
in	O
several	O
well	O
designed	O
placebo-controlled	O
trials	O
.	O
Atomoxetine	S-chemical
also	O
demonstrated	O
efficacy	O
in	O
the	O
longer	O
term	O
treatment	O
of	O
these	O
patients	O
.	O
A	O
single	O
morning	O
dose	O
was	O
shown	O
to	O
be	O
effective	O
into	O
the	O
evening	O
,	O
and	O
discontinuation	O
of	O
atomoxetine	S-chemical
was	O
not	O
associated	O
with	O
symptom	O
rebound	O
.	O
Atomoxetine	S-chemical
efficacy	O
did	O
not	O
appear	O
to	O
differ	O
between	O
children	O
and	O
adolescents	O
.	O
Stimulant-naive	O
patients	O
also	O
responded	O
well	O
to	O
atomoxetine	S-chemical
treatment	O
.	O
Atomoxetine	S-chemical
did	O
not	O
differ	O
significantly	O
from	O
or	O
was	O
noninferior	O
to	O
immediate-release	O
methylphenidate	S-chemical
in	O
children	O
and	O
adolescents	O
with	O
ADHD	O
with	O
regard	O
to	O
efficacy	O
,	O
and	O
was	O
significantly	O
more	O
effective	O
than	O
standard	O
current	O
therapy	O
(	O
any	O
combination	O
of	O
medicines	O
[	O
excluding	O
atomoxetine	S-chemical
]	O
and/or	O
behavioral	O
counseling	O
,	O
or	O
no	O
treatment	O
)	O
.	O
However	O
,	O
atomoxetine	S-chemical
was	O
significantly	O
less	O
effective	O
than	O
osmotically	O
released	O
methylphenidate	S-chemical
and	O
extended-release	O
mixed	O
amfetamine	S-chemical
salts	O
.	O
The	O
efficacy	O
of	O
atomoxetine	S-chemical
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
presence	O
of	O
co-morbid	O
disorders	O
,	O
and	O
symptoms	O
of	O
the	O
co-morbid	O
disorders	O
were	O
not	O
affected	O
or	O
were	O
improved	O
by	O
atomoxetine	S-chemical
administration	O
.	O
Health-related	O
quality	O
of	O
life	O
(	O
HR-QOL	O
)	O
appeared	O
to	O
be	O
positively	O
affected	O
by	O
atomoxetine	S-chemical
in	O
both	O
short-	O
and	O
long-term	O
studies	O
;	O
atomoxetine	S-chemical
also	O
improved	O
HR-QOL	O
to	O
a	O
greater	O
extent	O
than	O
standard	O
current	O
therapy	O
.	O
Atomoxetine	S-chemical
was	O
generally	O
well	O
tolerated	O
in	O
children	O
and	O
adolescents	O
with	O
ADHD	O
.	O
Common	O
adverse	O
events	O
included	O
headache	O
,	O
abdominal	O
pain	O
,	O
decreased	O
appetite	O
,	O
vomiting	O
,	O
somnolence	O
,	O
and	O
nausea	O
.	O
The	O
majority	O
of	O
adverse	O
events	O
were	O
mild	O
or	O
moderate	O
;	O
there	O
was	O
a	O
very	O
low	O
incidence	O
of	O
serious	O
adverse	O
events	O
.	O
Few	O
patients	O
discontinued	O
atomoxetine	S-chemical
treatment	O
because	O
of	O
adverse	O
events	O
.	O
Atomoxetine	S-chemical
discontinuation	O
appeared	O
to	O
be	O
well	O
tolerated	O
,	O
with	O
a	O
low	O
incidence	O
of	O
discontinuation-emergent	O
adverse	O
events	O
.	O
Atomoxetine	S-chemical
appeared	O
better	O
tolerated	O
among	O
extensive	O
CYP2D6	S-GP
metabolizers	O
than	O
among	O
poor	O
metabolizers	O
.	O
Slight	O
differences	O
were	O
evident	O
in	O
the	O
adverse	O
event	O
profiles	O
of	O
atomoxetine	S-chemical
and	O
stimulants	O
,	O
both	O
immediate-	O
and	O
extended-release	O
.	O
Somnolence	O
appeared	O
more	O
common	O
among	O
atomoxetine	S-chemical
recipients	O
and	O
insomnia	O
appeared	O
more	O
common	O
among	O
stimulant	O
recipients	O
.	O
A	O
black-box	O
warning	O
for	O
suicidal	O
ideation	O
has	O
been	O
published	O
in	O
the	O
US	O
prescribing	O
information	O
,	O
based	O
on	O
findings	O
from	O
a	O
meta-analysis	O
showing	O
that	O
atomoxetine	S-chemical
is	O
associated	O
with	O
a	O
significantly	O
higher	O
incidence	O
of	O
suicidal	O
ideation	O
than	O
placebo	O
.	O
Rarely	O
,	O
atomoxetine	S-chemical
may	O
also	O
be	O
associated	O
with	O
serious	O
liver	O
injury	O
;	O
postmarketing	O
data	O
show	O
that	O
three	O
patients	O
have	O
had	O
liver-related	O
adverse	O
events	O
deemed	O
probably	O
related	O
to	O
atomoxetine	S-chemical
treatment	O
.	O
Treatment	O
algorithms	O
involving	O
the	O
initial	O
use	O
of	O
atomoxetine	S-chemical
appear	O
cost	O
effective	O
versus	O
algorithms	O
involving	O
initial	O
methylphenidate	S-chemical
(	O
immediate-	O
or	O
extended-release	O
)	O
,	O
dexamfetamine	S-chemical
,	O
tricyclic	S-chemical
antidepressants	O
,	O
or	O
no	O
treatment	O
in	O
stimulant-naive	O
,	O
-failed	O
,	O
and	O
-contraindicated	O
children	O
and	O
adolescents	O
with	O
ADHD	O
.	O
The	O
incremental	O
cost	O
per	O
quality-adjusted	O
life-year	O
is	O
below	O
commonly	O
accepted	O
cost-effectiveness	O
thresholds	O
,	O
as	O
shown	O
in	O
several	O
Markov	O
model	O
analyses	O
conducted	O
from	O
the	O
perspective	O
of	O
various	O
European	O
countries	O
,	O
with	O
a	O
time	O
horizon	O
of	O
1	O
year	O
.	O

Cloning	O
,	O
sequencing	O
,	O
structural	O
and	O
molecular	O
biological	O
characterization	O
of	O
placental	B-GP
protein	I-GP
20	E-GP
(	O
PP20	S-GP
)	O
/	O
human	B-GP
thiamin	I-GP
pyrophosphokinase	E-GP
(	O
hTPK	S-GP
)	O
.	O
Full-length	O
cDNAs	O
of	O
placental	B-GP
protein	I-GP
20	E-GP
(	O
PP20	S-GP
)	O
were	O
cloned	O
by	O
screening	O
a	O
human	O
placental	O
cDNA	O
library	O
,	O
which	O
encode	O
a	O
243	O
amino	O
acid	O
protein	O
,	O
identical	O
to	O
human	B-GP
thiamin	I-GP
pyrophosphokinase	E-GP
(	O
hTPK	S-GP
)	O
as	O
confirmed	O
by	O
protein	O
sequence	O
analysis	O
.	O
Genomic	O
alignment	O
showed	O
that	O
the	O
PP20	S-GP
/	O
hTPK	S-GP
gene	O
contains	O
9	O
exons	O
.	O
It	O
is	O
abundantly	O
expressed	O
in	O
placenta	O
,	O
as	O
numerous	O
EST	O
clones	O
were	O
identified	O
.	O
As	O
thiamine	S-chemical
metabolism	O
deficiencies	O
have	O
been	O
seen	O
in	O
placental	O
infarcts	O
previously	O
,	O
these	O
indicate	O
that	O
PP20	S-GP
/	O
hTPK	S-GP
may	O
have	O
a	O
role	O
in	O
placental	O
diseases	O
.	O
Analysis	O
of	O
the	O
1kb	O
promoter	O
region	O
showed	O
numerous	O
putative	O
transcription	O
factor	O
binding	O
sites	O
,	O
which	O
might	O
be	O
responsible	O
for	O
the	O
ubiquitous	O
PP20	S-GP
/	O
hTPK	S-GP
expression	O
.	O
This	O
may	O
also	O
be	O
in	O
accordance	O
with	O
the	O
presence	O
of	O
the	O
protein	O
in	O
tissues	O
responsible	O
for	O
the	O
regulation	O
of	O
the	O
exquisite	O
balance	O
between	O
cell	O
division	O
,	O
differentiation	O
and	O
survival	O
.	O
TPK	S-GP
activity	O
of	O
the	O
purified	O
and	O
recombinant	O
protein	O
was	O
proved	O
by	O
mass	O
spectrometry	O
with	O
electrospray	O
ionization	O
.	O
By	O
Western	O
blot	O
,	O
PP20	S-GP
/	O
hTPK	S-GP
was	O
found	O
in	O
all	O
human	O
normal	O
and	O
tumorous	O
adult	O
and	O
fetal	O
tissues	O
in	O
nearly	O
equal	O
amounts	O
,	O
but	O
not	O
in	O
sera	O
.	O
By	O
immunohistochemical	O
and	O
immunofluorescent	O
confocal	O
imaging	O
methods	O
,	O
diffuse	O
labelling	O
in	O
the	O
cytoplasm	O
of	O
the	O
syncytiotrophoblasts	O
and	O
weak	O
staining	O
of	O
the	O
trophoblasts	O
were	O
observed	O
,	O
and	O
the	O
amount	O
of	O
PP20	S-GP
/	O
hTPK	S-GP
decreased	O
from	O
the	O
first	O
trimester	O
to	O
the	O
end	O
of	O
gestation	O
.	O
A	O
3D	O
model	O
of	O
PP20	S-GP
/	O
hTPK	S-GP
was	O
computed	O
(	O
PDB	O
No	O
.	O
:	O
1OLY	O
)	O
by	O
homology	O
modelling	O
.	O
A	O
high	O
degree	O
of	O
structural	O
homology	O
showed	O
that	O
the	O
thiamin	S-chemical
binding	O
site	O
was	O
highly	O
similar	O
to	O
that	O
of	O
the	O
mouse	O
enzyme	O
,	O
but	O
highly	O
different	O
from	O
the	O
bacterial	O
ones	O
.	O
Comparison	O
of	O
the	O
catalytic	O
centre	O
sequences	O
revealed	O
differences	O
,	O
raising	O
the	O
possibility	O
of	O
designing	O
new	O
drugs	O
which	O
specifically	O
inhibit	O
bacterial	O
and	O
fungal	O
enzymes	O
without	O
affecting	O
PP20	S-GP
/	O
hTPK	S-GP
and	O
offering	O
the	O
possibility	O
for	O
safe	O
antimicrobial	O
therapy	O
during	O
pregnancy	O
.	O

Defective	O
processing	O
of	O
the	O
transforming	B-GP
growth	I-GP
factor-beta1	E-GP
in	O
azoxymethane	S-chemical
-induced	O
mouse	O
colon	O
tumors	O
.	O
High	O
levels	O
of	O
the	O
cell	O
growth	O
inhibitor	O
transforming	B-GP
growth	I-GP
factor-beta1	E-GP
(	O
TGF-beta1	S-GP
)	O
are	O
often	O
found	O
in	O
a	O
variety	O
of	O
human	O
cancers	O
.	O
However	O
,	O
the	O
physiological	O
significance	O
of	O
this	O
overexpression	O
depends	O
on	O
the	O
availability	O
of	O
the	O
biologically	O
active	O
form	O
of	O
TGF-beta1	S-GP
within	O
the	O
extracellular	O
matrix	O
of	O
the	O
tumor	O
microenvironment	O
.	O
To	O
determine	O
the	O
expression	O
and	O
activation	O
status	O
of	O
TGF-beta1	S-GP
in	O
chemically	O
induced	O
tumors	O
,	O
6-wk-old	O
A/J	O
mice	O
were	O
injected	O
intraperitoneally	O
with	O
either	O
azoxymethane	S-chemical
(	O
AOM	S-chemical
)	O
(	O
10	O
mg/kg	O
body	O
weight	O
,	O
once	O
a	O
week	O
for	O
6	O
wk	O
)	O
or	O
normal	O
saline	O
solution	O
,	O
and	O
colon	O
tumors	O
were	O
isolated	O
24	O
wk	O
following	O
the	O
last	O
injection	O
.	O
An	O
enzyme-linked	O
immunosorbent	O
assay	O
for	O
TGF-beta1	S-GP
revealed	O
a	O
significant	O
increase	O
(	O
1.7-fold	O
,	O
P	O
<	O
0.05	O
)	O
in	O
total	O
TGF-beta1	S-GP
protein	O
in	O
tumors	O
.	O
Interestingly	O
,	O
while	O
80	O
%	O
of	O
the	O
total	O
TGF-beta1	S-GP
in	O
the	O
control	O
colon	O
tissues	O
was	O
in	O
the	O
active	O
form	O
,	O
only	O
50	O
%	O
was	O
found	O
to	O
be	O
active	O
in	O
tumors	O
.	O
Together	O
with	O
our	O
earlier	O
observations	O
that	O
TGF-beta1	S-GP
mRNA	O
levels	O
are	O
unchanged	O
in	O
A/J	O
tumors	O
,	O
these	O
data	O
further	O
support	O
a	O
mechanism	O
whereby	O
elevated	O
TGF-beta1	S-GP
levels	O
result	O
from	O
a	O
defective	O
activation	O
and	O
turnover	O
of	O
this	O
protein	O
.	O
Because	O
plasmin	S-GP
is	O
known	O
to	O
be	O
a	O
major	O
activator	O
of	O
TGF-beta1	S-GP
in	O
vivo	O
,	O
we	O
hypothesized	O
that	O
reduced	O
plasmin	S-GP
activity	O
may	O
be	O
responsible	O
for	O
the	O
observed	O
dysregulation	O
of	O
TGF-beta1	S-GP
processing	O
in	O
these	O
behaviorally	O
benign	O
tumors	O
.	O
With	O
a	O
fluorogenic	O
peptide	O
substrate	O
for	O
serine	B-GP
proteases	E-GP
,	O
a	O
deficiency	O
in	O
plasmin	S-GP
activity	O
was	O
found	O
in	O
the	O
tumors	O
.	O
Furthermore	O
,	O
semiquantitative	O
reverse	O
transcription	O
(	O
RT	O
)	O
-polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
analysis	O
of	O
a	O
panel	O
of	O
genes	O
involved	O
in	O
the	O
plasminogen	S-GP
activation	O
system	O
,	O
including	O
plasminogen	B-GP
activator	I-GP
inhibitor-1	E-GP
(	O
PAI-1	S-GP
)	O
,	O
urokinase-plasminogen	B-GP
activator	E-GP
(	O
u-PA	S-GP
)	O
,	O
and	O
urokinase-receptor	S-GP
(	O
u-PAR-1	S-GP
)	O
,	O
demonstrated	O
a	O
significant	O
upregulation	O
(	O
approximately	O
fourfold	O
to	O
sixfold	O
,	O
P	O
<	O
0.05	O
)	O
in	O
the	O
expression	O
of	O
each	O
of	O
these	O
genes	O
in	O
the	O
tumor	O
tissue	O
.	O
In	O
addition	O
,	O
no	O
significant	O
changes	O
were	O
observed	O
in	O
the	O
expression	O
levels	O
of	O
thrombospondin-1	S-GP
(	O
TSP-1	S-GP
)	O
and	O
insulin-like	B-GP
growth	I-GP
factor	I-GP
type	I-GP
II	I-GP
receptor	E-GP
(	O
IGF-IIR	S-GP
)	O
,	O
which	O
also	O
mediate	O
the	O
activation	O
of	O
latent	O
TGF-beta1	S-GP
.	O
To	O
gain	O
further	O
insight	O
into	O
the	O
functionality	O
of	O
the	O
TGF-beta1	S-GP
pathway	O
,	O
cDNA	O
microarrays	O
were	O
performed	O
and	O
the	O
expression	O
levels	O
of	O
a	O
panel	O
of	O
21	O
TGF-beta1	S-GP
-specific	O
target	O
genes	O
were	O
determined	O
in	O
AOM	S-chemical
-induced	O
tumors	O
that	O
overexpress	O
the	O
ligand	O
.	O
A	O
significant	O
dysregulation	O
in	O
the	O
expression	O
of	O
each	O
of	O
these	O
targets	O
was	O
observed	O
,	O
providing	O
evidence	O
of	O
aberrant	O
TGF-beta1	S-GP
signaling	O
in	O
tumors	O
.	O
Overall	O
,	O
the	O
present	O
study	O
demonstrates	O
a	O
very	O
low	O
plasmin	S-GP
activity	O
in	O
A/J	O
colon	O
tumors	O
,	O
possibly	O
as	O
a	O
result	O
of	O
the	O
potent	O
inhibitory	O
effect	O
of	O
PAI-1	S-GP
on	O
the	O
plasminogen	S-GP
activation	O
cascade	O
.	O
The	O
observed	O
deficiency	O
in	O
plasmin	S-GP
activity	O
may	O
not	O
be	O
sufficiently	O
compensated	O
for	O
by	O
other	O
mechanisms	O
of	O
latent	O
TGF-beta1	S-GP
activation	O
,	O
including	O
TSP-1	S-GP
and	O
IGF-IIR	S-GP
,	O
thereby	O
resulting	O
in	O
a	O
decreased	O
fraction	O
of	O
the	O
biologically	O
active	O
form	O
of	O
TGF-beta1	S-GP
and	O
subsequent	O
aberration	O
in	O
TGF-beta1	S-GP
-specific	O
gene	O
regulation	O
in	O
A/J	O
tumors	O
.	O

Fungicide	O
prochloraz	S-chemical
and	O
environmental	O
pollutant	O
dioxin	S-chemical
induce	O
the	O
ABCG2	S-GP
transporter	O
in	O
bovine	O
mammary	O
epithelial	O
cells	O
by	O
the	O
arylhydrocarbon	B-GP
receptor	E-GP
signaling	O
pathway	O
.	O
The	O
molecular	O
mechanisms	O
by	O
which	O
environmental	O
pollutants	O
including	O
2,3,7,8-tetrachlorodibenzo-p-dioxin	S-chemical
(	O
TCDD	S-chemical
)	O
or	O
widely	O
used	O
imidazole	S-chemical
fungicide	O
prochloraz	S-chemical
display	O
their	O
toxic	O
effects	O
in	O
vertebrates	O
are	O
still	O
not	O
well	O
understood	O
.	O
Using	O
computer	O
analysis	O
,	O
we	O
recently	O
identified	O
nuclear	O
aryl	B-GP
hydrocarbon	I-GP
receptor	E-GP
(	O
AhR	S-GP
)	O
binding	O
sites	O
termed	O
``	O
dioxin	B-GP
response	I-GP
elements	E-GP
``	O
(	O
DREs	S-GP
)	O
in	O
the	O
5'-untranslated	O
region	O
(	O
5'-UTR	O
)	O
of	O
efflux	B-GP
transporter	E-GP
ABCG2	S-GP
(	O
Accession	O
No	O
.	O
EU570105	S-GP
)	O
from	O
the	O
bovine	O
mammary	O
gland	O
.	O
As	O
these	O
regulatory	O
motifs	O
mediate	O
regulation	O
of	O
target	O
genes	O
by	O
AhR	S-GP
agonists	O
including	O
TCDD	S-chemical
and	O
prochloraz	S-chemical
,	O
we	O
have	O
systematically	O
investigated	O
the	O
effect	O
of	O
both	O
contaminants	O
on	O
functional	O
ABCG2	S-GP
transport	O
activity	O
in	O
primary	O
bovine	O
mammary	O
epithelial	O
cells	O
.	O
TCDD	S-chemical
or	O
prochloraz	S-chemical
doubled	O
ABCG2	S-GP
-mediated	O
Hoechst	B-chemical
H33342	E-chemical
secretion	O
.	O
This	O
effect	O
was	O
almost	O
completely	O
reversed	O
by	O
specific	O
ABCG2	S-GP
inhibitor	O
Ko143	S-chemical
.	O
In	O
further	O
mechanistic	O
studies	O
,	O
we	O
showed	O
that	O
this	O
induction	O
was	O
due	O
to	O
binding	O
of	O
activated	O
AhR	S-GP
to	O
DRE	S-GP
sequences	O
in	O
the	O
ABCG2	S-GP
5'-UTR	O
.	O
Receptor	O
binding	O
was	O
significantly	O
reduced	O
by	O
specific	O
AhR	S-GP
antagonist	O
salicyl	B-chemical
amide	E-chemical
.	O
Induction	O
of	O
AhR	S-GP
by	O
TCDD	S-chemical
and	O
prochloraz	S-chemical
resulted	O
in	O
a	O
time-	O
and	O
dose-dependent	O
increase	O
of	O
ABCG2	S-GP
gene	O
expression	O
and	O
transporter	O
protein	O
levels	O
.	O
As	O
ABCG2	S-GP
represents	O
the	O
main	O
mammary	O
transporter	O
for	O
xenobiotics	O
including	O
drugs	O
and	O
toxins	O
,	O
exposure	O
to	O
prevalent	O
AhR	S-GP
agonists	O
may	O
enhance	O
transporter-mediated	O
secretion	O
of	O
potential	O
harmful	O
compounds	O
into	O
milk	O
.	O
Through	O
identification	O
of	O
mammary	O
ABCG2	S-GP
as	O
a	O
novel	O
target	O
gene	O
of	O
pesticide	O
prochloraz	S-chemical
and	O
dioxin	S-chemical
,	O
our	O
results	O
may	O
therefore	O
help	O
to	O
improve	O
the	O
protection	O
of	O
breast-feeding	O
infants	O
and	O
the	O
consumer	O
of	O
dairy	O
products	O
.	O

3-Methylglutaconic	S-chemical
aciduria-lessons	O
from	O
50	O
genes	O
and	O
977	O
patients	O
.	O
Elevated	O
urinary	O
excretion	O
of	O
3-methylglutaconic	B-chemical
acid	E-chemical
is	O
considered	O
rare	O
in	O
patients	O
suspected	O
of	O
a	O
metabolic	O
disorder	O
.	O
In	O
3-methylglutaconyl-CoA	B-GP
hydratase	E-GP
deficiency	O
(	O
mutations	O
in	O
AUH	S-GP
)	O
,	O
it	O
derives	O
from	O
leucine	S-chemical
degradation	O
.	O
In	O
all	O
other	O
disorders	O
with	O
3-methylglutaconic	S-chemical
aciduria	O
the	O
origin	O
is	O
unknown	O
,	O
yet	O
mitochondrial	O
dysfunction	O
is	O
thought	O
to	O
be	O
the	O
common	O
denominator	O
.	O
We	O
investigate	O
the	O
biochemical	O
,	O
clinical	O
and	O
genetic	O
data	O
of	O
388	O
patients	O
referred	O
to	O
our	O
centre	O
under	O
suspicion	O
of	O
a	O
metabolic	O
disorder	O
showing	O
3-methylglutaconic	S-chemical
aciduria	O
in	O
routine	O
metabolic	O
screening	O
.	O
Furthermore	O
,	O
we	O
investigate	O
591	O
patients	O
with	O
50	O
different	O
,	O
genetically	O
proven	O
,	O
mitochondrial	O
disorders	O
for	O
the	O
presence	O
of	O
3-methylglutaconic	S-chemical
aciduria	O
.	O
Three	O
percent	O
of	O
all	O
urine	O
samples	O
of	O
the	O
patients	O
referred	O
showed	O
3-methylglutaconic	S-chemical
aciduria	O
,	O
often	O
in	O
correlation	O
with	O
disorders	O
not	O
reported	O
earlier	O
in	O
association	O
with	O
3-methylglutaconic	S-chemical
aciduria	O
(	O
e.g	O
.	O
organic	O
acidurias	O
,	O
urea	S-chemical
cycle	O
disorders	O
,	O
haematological	O
and	O
neuromuscular	O
disorders	O
)	O
.	O
In	O
the	O
patient	O
cohort	O
with	O
genetically	O
proven	O
mitochondrial	O
disorders	O
11	O
%	O
presented	O
3-methylglutaconic	S-chemical
aciduria	O
.	O
It	O
was	O
more	O
frequently	O
seen	O
in	O
ATPase	S-GP
related	O
disorders	O
,	O
with	O
mitochondrial	O
DNA	O
depletion	O
or	O
deletion	O
,	O
but	O
not	O
in	O
patients	O
with	O
single	O
respiratory	B-GP
chain	I-GP
complex	E-GP
deficiencies	O
.	O
Besides	O
,	O
it	O
was	O
a	O
consistent	O
feature	O
of	O
patients	O
with	O
mutations	O
in	O
TAZ	S-GP
,	O
SERAC1	S-GP
,	O
OPA3	S-GP
,	O
DNAJC19	S-GP
and	O
TMEM70	S-GP
accounting	O
for	O
mitochondrial	O
membrane	O
related	O
pathology	O
.	O
3-methylglutaconic	S-chemical
aciduria	O
is	O
found	O
quite	O
frequently	O
in	O
patients	O
suspected	O
of	O
a	O
metabolic	O
disorder	O
,	O
and	O
mitochondrial	O
dysfunction	O
is	O
indeed	O
a	O
common	O
denominator	O
.	O
It	O
is	O
only	O
a	O
discriminative	O
feature	O
of	O
patients	O
with	O
mutations	O
in	O
AUH	S-GP
,	O
TAZ	S-GP
,	O
SERAC1	S-GP
,	O
OPA3	S-GP
,	O
DNAJC19	S-GP
TMEM70	S-GP
.	O
These	O
conditions	O
should	O
therefore	O
be	O
referred	O
to	O
as	O
inborn	O
errors	O
of	O
metabolism	O
with	O
3-methylglutaconic	S-chemical
aciduria	O
as	O
discriminative	O
feature	O
.	O

Binding	O
domains	O
of	O
the	O
oxytocin	B-GP
receptor	E-GP
for	O
the	O
selective	O
oxytocin	B-GP
receptor	E-GP
antagonist	O
barusiban	S-chemical
in	O
comparison	O
to	O
the	O
agonists	O
oxytocin	S-chemical
and	O
carbetocin	S-chemical
.	O
We	O
have	O
analyzed	O
binding	O
domains	O
of	O
the	O
oxytocin	B-GP
receptor	E-GP
for	O
barusiban	S-chemical
,	O
a	O
highly	O
selective	O
oxytocin	B-GP
receptor	E-GP
antagonist	O
,	O
in	O
comparison	O
to	O
the	O
combined	O
vasopressin	B-GP
V1A/oxytocin	I-GP
receptor	E-GP
antagonist	O
atosiban	S-chemical
and	O
the	O
agonists	O
oxytocin	S-chemical
and	O
carbetocin	S-chemical
.	O
For	O
this	O
purpose	O
,	O
chimeric	O
'gain-in	O
function	O
'	O
oxytocin/vasopressin	B-GP
V2	I-GP
receptors	E-GP
were	O
expressed	O
in	O
COS-7	O
cells	O
.	O
These	O
recombinant	O
receptors	O
have	O
been	O
produced	O
by	O
transfer	O
of	O
domains	O
from	O
the	O
oxytocin	B-GP
receptor	E-GP
into	O
the	O
related	O
vasopressin	B-GP
V2	I-GP
receptor	E-GP
and	O
have	O
already	O
been	O
successfully	O
employed	O
for	O
the	O
identification	O
of	O
ligand	O
binding	O
domains	O
at	O
the	O
oxytocin	B-GP
receptor	E-GP
(	O
Postina	O
,	O
R.	O
,	O
Kojro	O
,	O
E.	O
,	O
Fahrenholz	O
,	O
F.	O
,	O
1996	O
.	O
Separate	O
agonist	O
and	O
peptide	O
antagonist	O
binding	O
sites	O
of	O
the	O
oxytocin	B-GP
receptor	E-GP
defined	O
by	O
their	O
transfer	O
into	O
the	O
V2	B-GP
vasopressin	I-GP
receptor	E-GP
.	O
J.	O
Biol	O
.	O
Chem	O
.	O
271	O
,	O
31593-31601	O
)	O
.	O
In	O
displacement	O
studies	O
with	O
10	O
chimeric	O
receptor	O
constructs	O
,	O
the	O
binding	O
profile	O
of	O
barusiban	S-chemical
was	O
compared	O
with	O
the	O
binding	O
profiles	O
of	O
the	O
ligands	O
oxytocin	S-chemical
,	O
[	B-chemical
Arg8	I-chemical
]	I-chemical
vasopressin	E-chemical
,	O
carbetocin	S-chemical
,	O
and	O
atosiban	S-chemical
.	O
The	O
binding	O
profiles	O
for	O
the	O
agonists	O
oxytocin	S-chemical
and	O
carbetocin	S-chemical
were	O
found	O
to	O
be	O
similar	O
.	O
For	O
both	O
agonists	O
,	O
important	O
binding	O
domains	O
were	O
the	O
extracellular	O
N	S-chemical
-terminus	O
(	O
=E1	O
)	O
and	O
the	O
extracellular	O
loops	O
E2	O
and	O
E3	O
from	O
the	O
oxytocin	B-GP
receptor	E-GP
.	O
For	O
the	O
vasopressin	B-GP
V1A/oxytocin	I-GP
receptor	E-GP
antagonist	O
atosiban	S-chemical
,	O
none	O
of	O
the	O
receptor	O
constructs	O
were	O
able	O
to	O
provide	O
a	O
binding	O
with	O
higher	O
affinity	O
than	O
the	O
starting	O
vasopressin	B-GP
V2	I-GP
receptor	E-GP
.	O
In	O
contrast	O
,	O
the	O
binding	O
of	O
barusiban	S-chemical
was	O
significantly	O
improved	O
when	O
the	O
transmembrane	O
domains	O
1	O
and	O
2	O
were	O
transferred	O
from	O
the	O
oxytocin	S-chemical
receptor	O
to	O
the	O
vasopressin	B-GP
V2	I-GP
receptor	E-GP
.	O
The	O
binding	O
domain	O
of	O
barusiban	S-chemical
differs	O
from	O
the	O
binding	O
domain	O
of	O
the	O
agonists	O
and	O
the	O
nonselective	O
oxytocin	B-GP
receptor	E-GP
antagonist	O
d	B-chemical
(	I-chemical
CH2	I-chemical
)	I-chemical
5	I-chemical
[	I-chemical
Tyr-	I-chemical
(	I-chemical
Me	I-chemical
)	I-chemical
2	I-chemical
,	I-chemical
Thr4	I-chemical
,	I-chemical
Orn8	I-chemical
,	I-chemical
Tyr9	I-chemical
]	I-chemical
vasotocin	E-chemical
that	O
has	O
been	O
used	O
in	O
previous	O
studies	O
.	O
Overall	O
,	O
the	O
data	O
supported	O
the	O
concept	O
of	O
a	O
central	O
pocket	O
site	O
within	O
the	O
oxytocin	B-GP
receptor	E-GP
.	O

The	O
aromatic-L-amino	B-GP
acid	I-GP
decarboxylase	E-GP
inhibitor	O
carbidopa	O
is	O
selectively	O
cytotoxic	O
to	O
human	O
pulmonary	O
carcinoid	O
and	O
small	O
cell	O
lung	O
carcinoma	O
cells	O
.	O
The	O
carcinoid	O
tumor	O
is	O
an	O
uncommon	O
neuroendocrine	O
neoplasm	O
the	O
hallmark	O
of	O
which	O
is	O
excessive	O
serotonin	S-chemical
production	O
.	O
In	O
studying	O
kinetics	O
of	O
tryptophan	B-GP
hydroxylase	E-GP
and	O
aromatic-L-amino	B-GP
acid	I-GP
decarboxylase	E-GP
(	O
AAAD	S-GP
)	O
in	O
human	O
carcinoid	O
hepatic	O
metastases	O
and	O
adjacent	O
normal	O
liver	O
(	O
J	O
.	O
A.	O
Gilbert	O
et	O
al	O
,	O
Biochem	O
.	O
Pharmacol.	O
,	O
50	O
:	O
845-850	O
,	O
1995	O
)	O
,	O
we	O
identified	O
one	O
significant	O
difference	O
:	O
the	O
Vmax	O
of	O
carcinoid	O
AAAD	S-GP
was	O
50-fold	O
higher	O
than	O
that	O
in	O
normal	O
liver	O
.	O
Here	O
,	O
we	O
report	O
Western	O
and	O
Northern	O
analyses	O
detecting	O
large	O
quantities	O
of	O
AAAD	S-GP
polypeptide	O
and	O
mRNA	O
in	O
human	O
carcinoid	O
primary	O
as	O
well	O
as	O
metastatic	O
tumors	O
compared	O
with	O
normal	O
surrounding	O
tissues	O
.	O
To	O
assess	O
the	O
feasibility	O
of	O
targeting	O
these	O
high	O
AAAD	S-GP
levels	O
for	O
chemotherapy	O
,	O
AAAD	S-GP
inhibitors	O
carbidopa	S-chemical
(	O
alpha-methyl-dopahydrazine	S-chemical
)	O
,	O
alpha-monofluoromethyldopa	S-chemical
(	O
MFMD	S-chemical
)	O
,	O
and	O
3-hydroxybenzylhydrazine	S-chemical
(	O
NSD-1015	S-chemical
)	O
were	O
incubated	O
(	O
72	O
h	O
)	O
with	O
NCI-H727	O
human	O
lung	O
carcinoid	O
cells	O
.	O
Carbidopa	S-chemical
and	O
MFMD	S-chemical
were	O
lethal	O
(	O
IC50	O
=	O
29	O
+/-	O
2	O
microM	O
and	O
56	O
+/-	O
6	O
microM	O
,	O
respectively	O
)	O
;	O
NSD-1015	S-chemical
had	O
no	O
effect	O
on	O
proliferation	O
.	O
On	O
exposure	O
to	O
other	O
human	O
tumor	O
lines	O
,	O
carbidopa	S-chemical
was	O
lethal	O
only	O
to	O
NCI-H146	O
and	O
NCI-H209	O
small	O
cell	O
lung	O
carcinoma	O
(	O
SCLC	O
)	O
lines	O
(	O
IC50	O
=	O
12	O
+/-	O
1	O
microM	O
and	O
22	O
+/-	O
5	O
microM	O
,	O
respectively	O
)	O
.	O
Carbidopa	S-chemical
(	O
100	O
microM	O
)	O
decreased	O
growth	O
of	O
(	O
but	O
did	O
not	O
kill	O
)	O
SK-N-SH	O
neuroblastoma	O
and	O
A204	O
rhabdomyosarcoma	O
cells	O
and	O
did	O
not	O
affect	O
proliferation	O
of	O
DU	O
145	O
prostate	O
,	O
MCF7	O
breast	O
,	O
or	O
NCI-H460	O
large	O
cell	O
lung	O
carcinoma	O
lines	O
.	O
The	O
rank	O
order	O
of	O
lines	O
by	O
AAAD	S-GP
activity	O
was	O
NCI-H146	O
>	O
NCI-H209	O
>	O
SK-N-SH	O
>	O
NCI-H727	O
,	O
whereas	O
A204	O
,	O
DU	O
145	O
,	O
MCF7	O
,	O
and	O
NCI-H460	O
had	O
no	O
measurable	O
activity	O
.	O
For	O
lung	O
tumor	O
lines	O
(	O
carcinoid	O
,	O
two	O
SCLC	O
,	O
and	O
one	O
large	O
cell	O
lung	O
carcinoma	O
)	O
,	O
AAAD	S-GP
activity	O
was	O
correlated	O
with	O
the	O
potency	O
of	O
carbidopa	S-chemical
-induced	O
cytotoxicity	O
.	O
However	O
,	O
carcinoid	O
cell	O
death	O
was	O
not	O
solely	O
attributable	O
to	O
complete	O
inhibition	O
of	O
either	O
AAAD	S-GP
activity	O
or	O
the	O
serotonin	S-chemical
synthetic	O
pathway	O
.	O
In	O
further	O
evaluating	O
potential	O
applications	O
of	O
these	O
findings	O
with	O
carbidopa	S-chemical
,	O
we	O
determined	O
that	O
sublethal	O
doses	O
of	O
carbidopa	S-chemical
produced	O
additive	O
cytotoxic	O
effects	O
in	O
carcinoid	O
cells	O
in	O
combination	O
with	O
etoposide	O
and	O
cytotoxic	O
synergy	O
in	O
SCLC	O
cells	O
when	O
coincubated	O
with	O
topotecan	S-chemical
.	O

Cooperative	O
binding	O
of	O
ATP	S-chemical
and	O
MgADP	S-chemical
in	O
the	O
sulfonylurea	B-GP
receptor	E-GP
is	O
modulated	O
by	O
glibenclamide	S-chemical
.	O
The	O
ATP-sensitive	B-GP
potassium	I-GP
(	I-GP
KATP	I-GP
)	I-GP
channels	E-GP
in	O
pancreatic	O
beta	O
cells	O
are	O
critical	O
in	O
the	O
regulation	O
of	O
glucose	S-chemical
-induced	O
insulin	S-GP
secretion	O
.	O
Although	O
electrophysiological	O
studies	O
provide	O
clues	O
to	O
the	O
complex	O
control	O
of	O
KATP	B-GP
channels	E-GP
by	O
ATP	S-chemical
,	O
MgADP	S-chemical
,	O
and	O
pharmacological	O
agents	O
,	O
the	O
molecular	O
mechanism	O
of	O
KATP-channel	S-GP
regulation	O
remains	O
unclear	O
.	O
The	O
KATP	B-GP
channel	E-GP
is	O
a	O
heterooligomeric	O
complex	O
of	O
SUR1	S-GP
subunits	O
of	O
the	O
ATP	S-chemical
-binding-cassette	O
superfamily	O
with	O
two	O
nucleotide-binding	B-GP
folds	E-GP
(	O
NBF1	S-GP
and	O
NBF2	S-GP
)	O
and	O
the	O
pore-forming	O
Kir6.2	S-GP
subunits	O
.	O
Here	O
,	O
we	O
report	O
that	O
MgATP	S-chemical
and	O
MgADP	S-chemical
,	O
but	O
not	O
the	O
Mg	S-chemical
salt	O
of	O
gamma-thio-ATP	S-chemical
,	O
stabilize	O
the	O
binding	O
of	O
prebound	O
8-azido-	B-chemical
[	I-chemical
alpha-32P	I-chemical
]	I-chemical
ATP	E-chemical
to	O
SUR1	S-GP
.	O
Mutation	O
in	O
the	O
Walker	B-GP
A	I-GP
and	I-GP
B	I-GP
motifs	E-GP
of	O
NBF2	S-GP
of	O
SUR1	S-GP
abolished	O
this	O
stabilizing	O
effect	O
of	O
MgADP	S-chemical
.	O
These	O
results	O
suggest	O
that	O
SUR1	S-GP
binds	O
8-azido-ATP	S-chemical
strongly	O
at	O
NBF1	S-GP
and	O
that	O
MgADP	S-chemical
,	O
either	O
by	O
direct	O
binding	O
to	O
NBF2	S-GP
or	O
by	O
hydrolysis	O
of	O
bound	O
MgATP	S-chemical
at	O
NBF2	S-GP
,	O
stabilizes	O
prebound	O
8-azido-ATP	S-chemical
binding	O
at	O
NBF1	S-GP
.	O
The	O
sulfonylurea	B-chemical
glibenclamide	E-chemical
caused	O
release	O
of	O
prebound	O
8-azido-	B-chemical
[	I-chemical
alpha-32P	I-chemical
]	I-chemical
ATP	E-chemical
from	O
SUR1	S-GP
in	O
the	O
presence	O
of	O
MgADP	S-chemical
or	O
MgATP	S-chemical
in	O
a	O
concentration-dependent	O
manner	O
.	O
This	O
direct	O
biochemical	O
evidence	O
of	O
cooperative	O
interaction	O
in	O
nucleotide	S-chemical
binding	O
of	O
the	O
two	O
NBFs	S-GP
of	O
SUR1	S-GP
suggests	O
that	O
glibenclamide	S-chemical
both	O
blocks	O
this	O
cooperative	O
binding	O
of	O
ATP	S-chemical
and	O
MgADP	S-chemical
and	O
,	O
in	O
cooperation	O
with	O
the	O
MgADP	S-chemical
bound	O
at	O
NBF2	S-GP
,	O
causes	O
ATP	S-chemical
to	O
be	O
released	O
from	O
NBF1	S-GP
.	O

Effects	O
of	O
pentosan	O
polysulfate	O
sodium	S-chemical
on	O
the	O
estrogen	S-chemical
-induced	O
pituitary	O
prolactinoma	O
in	O
Fischer	O
344	O
rats	O
.	O
The	O
development	O
of	O
estrogen	S-chemical
-induced	O
pituitary	O
prolactinoma	O
in	O
Fischer	O
344	O
(	O
F344	O
)	O
rats	O
is	O
associated	O
with	O
enhanced	O
neovascularization	O
.	O
This	O
type	O
of	O
tumor	O
is	O
a	O
rich	O
source	O
of	O
basic	B-GP
fibroblast	I-GP
growth	I-GP
factor	E-GP
(	O
bFGF	S-GP
)	O
,	O
which	O
possesses	O
strong	O
mitogenic	O
and	O
angiogenic	O
properties	O
.	O
Pentosan	O
polysulfate	O
sodium	S-chemical
(	O
PPS	O
)	O
has	O
been	O
shown	O
to	O
exert	O
antitumor	O
activity	O
by	O
antagonizing	O
the	O
binding	O
of	O
bFGF	S-GP
to	O
cell	O
surface	O
receptors	O
.	O
We	O
have	O
examined	O
the	O
effects	O
of	O
pentosan	O
on	O
tumor	O
growth	O
,	O
hyperprolactinemia	O
and	O
angiogenesis	O
in	O
diethylstilbestrol	S-chemical
-induced	O
anterior	O
pituitary	O
adenoma	O
in	O
F344	O
rats	O
.	O
Chronic	O
treatment	O
with	O
PPS	O
did	O
not	O
cause	O
any	O
changes	O
in	O
the	O
pituitary	O
weight	O
and	O
serum	O
prolactin	O
concentration	O
in	O
comparison	O
with	O
untreated	O
animals	O
.	O
The	O
density	O
of	O
microvessels	O
identified	O
by	O
CD-31	O
was	O
also	O
not	O
affected	O
by	O
the	O
tested	O
drug	O
.	O
On	O
the	O
other	O
hand	O
,	O
pentosan	O
has	O
been	O
found	O
to	O
decrease	O
cell	O
proliferation	O
evaluated	O
by	O
a	O
number	O
of	O
PCNA-positive	O
stained	O
cell	O
nuclei	O
.	O
Moreover	O
,	O
the	O
TUNEL	O
method	O
has	O
revealed	O
an	O
increased	O
number	O
of	O
apoptotic	O
bodies	O
within	O
the	O
anterior	O
pituitary	O
after	O
treatment	O
with	O
PPS	O
.	O
Despite	O
the	O
antiproliferative	O
and	O
proapoptotic	O
activity	O
of	O
pentosan	O
,	O
the	O
drug	O
failed	O
to	O
inhibit	O
tumor	O
growth	O
.	O
This	O
fact	O
might	O
be	O
due	O
to	O
the	O
lack	O
of	O
antiangiogenic	O
activity	O
of	O
PPS	O
in	O
this	O
experimental	O
design	O
.	O

Cembranoid	S-chemical
and	O
long-chain	B-chemical
alkanol	E-chemical
sites	O
on	O
the	O
nicotinic	B-GP
acetylcholine	I-GP
receptor	E-GP
and	O
their	O
allosteric	O
interaction	O
.	O
Long-chain	B-chemical
alkanols	E-chemical
are	O
general	O
anesthetics	O
which	O
can	O
also	O
act	O
as	O
uncharged	O
noncompetitive	O
inhibitors	O
of	O
the	O
peripheral	O
nicotinic	B-GP
acetylcholine	I-GP
receptor	E-GP
(	O
AChR	S-GP
)	O
by	O
binding	O
to	O
one	O
or	O
more	O
specific	O
sites	O
on	O
the	O
AChR	S-GP
.	O
Cembranoids	S-chemical
are	O
naturally	O
occurring	O
,	O
uncharged	O
noncompetitive	O
inhibitors	O
of	O
peripheral	O
and	O
neuronal	O
AChRs	S-GP
,	O
which	O
have	O
no	O
demonstrable	O
general	O
anesthetic	O
activity	O
in	O
vivo	O
.	O
In	O
this	O
study	O
,	O
[	B-chemical
3H	I-chemical
]	I-chemical
tenocyclidine	E-chemical
(	O
[	B-chemical
3H	I-chemical
]	I-chemical
TCP	E-chemical
)	O
,	O
an	O
analogue	O
of	O
the	O
cationic	O
noncompetitive	O
inhibitor	O
phencyclidine	S-chemical
(	O
PCP	S-chemical
)	O
,	O
was	O
used	O
to	O
characterize	O
the	O
cembranoid	S-chemical
and	O
long-chain	B-chemical
alkanol	E-chemical
sites	O
on	O
the	O
desensitized	O
Torpedo	O
californica	O
AChR	S-GP
and	O
to	O
investigate	O
if	O
these	O
sites	O
interact	O
.	O
These	O
studies	O
confirm	O
that	O
there	O
is	O
a	O
single	O
cembranoid	O
site	O
which	O
sterically	O
overlaps	O
the	O
[	B-chemical
3H	I-chemical
]	I-chemical
TCP	E-chemical
channel	O
site	O
.	O
This	O
cembranoid	S-chemical
site	O
probably	O
also	O
overlaps	O
the	O
sites	O
for	O
the	O
cationic	O
noncompetitive	O
inhibitors	O
,	O
procaine	S-chemical
and	O
quinacrine	S-chemical
.	O
Evidence	O
is	O
also	O
presented	O
for	O
one	O
or	O
more	O
allosteric	O
cembranoid	S-chemical
sites	O
which	O
negatively	O
modulate	O
cembranoid	O
affinity	O
for	O
the	O
inhibitory	O
site	O
.	O
In	O
contrast	O
,	O
long-chain	B-chemical
alkanols	E-chemical
inhibit	O
[	B-chemical
3H	I-chemical
]	I-chemical
TCP	E-chemical
binding	O
through	O
an	O
allosteric	O
mechanism	O
involving	O
two	O
or	O
more	O
alkanol	S-chemical
sites	O
which	O
display	O
positive	O
cooperativity	O
toward	O
each	O
other	O
.	O
Double	O
inhibitor	O
studies	O
show	O
that	O
the	O
cembranoid	S-chemical
inhibitory	O
site	O
and	O
the	O
alkanol	S-chemical
sites	O
are	O
not	O
independent	O
of	O
each	O
other	O
but	O
interfere	O
allosterically	O
with	O
each	O
other	O
's	O
inhibition	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
TCP	E-chemical
binding	O
.	O
The	O
simplest	O
models	O
consistent	O
with	O
the	O
observed	O
data	O
are	O
presented	O
and	O
discussed	O
.	O

Estrogen	S-chemical

Captopril	S-chemical
directly	O
inhibits	O
matrix	B-GP
metalloproteinase-2	E-GP
activity	O
in	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
therapy	O
.	O
BACKGROUND	O
:	O
Matrix	B-GP
metalloproteinase	I-GP
(	I-GP
MMP	I-GP
)	I-GP
-2	E-GP
plays	O
an	O
important	O
role	O
in	O
tissue	O
remodeling	O
related	O
to	O
inflammation	O
during	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
therapy	O
.	O
But	O
its	O
inhibitors	O
were	O
not	O
applied	O
clinically	O
.	O
We	O
determined	O
whether	O
an	O
angiotensin-converting	B-GP
enzyme	E-GP
(	O
ACE	S-GP
)	O
inhibitor	O
,	O
captopril	S-chemical
,	O
inhibits	O
MMP-2	S-GP
activity	O
in	O
peritoneal	O
effluents	O
from	O
patients	O
on	O
CAPD	O
,	O
and	O
simulated	O
molecular	O
models	O
of	O
the	O
MMP-2	S-GP
-	O
captopril	S-chemical
complex	O
.	O
METHODS	O
:	O
The	O
inhibitory	O
effect	O
of	O
captopril	S-chemical
on	O
MMP-2	S-GP
activity	O
was	O
measured	O
in	O
peritoneal	O
effluents	O
from	O
17	O
patients	O
on	O
CAPD	O
.	O
Molecular	O
models	O
of	O
the	O
MMP-2	S-GP
-	O
captopril	S-chemical
complex	O
were	O
simulated	O
by	O
1000	O
iterations	O
of	O
random	O
docking	O
and	O
energy	O
minimization	O
.	O
RESULTS	O
:	O
Captopril	S-chemical
directly	O
inhibited	O
MMP-2	S-GP
activity	O
in	O
peritoneal	O
effluents	O
from	O
patients	O
on	O
CAPD	O
(	O
IC50	O
;	O
48	O
micromol/l	O
)	O
,	O
and	O
that	O
captopril	S-chemical
binding	O
to	O
the	O
MMP-2	S-GP
active	O
site	O
could	O
be	O
formed	O
in	O
each	O
complex	O
model	O
without	O
molecular	O
distortion	O
.	O
CONCLUSION	O
:	O
ACE	S-GP
inhibitors	O
,	O
such	O
as	O
captopril	S-chemical
,	O
may	O
be	O
applied	O
as	O
important	O
compounds	O
for	O
MMP-2	S-GP
inhibition	O
in	O
inflammation	O
caused	O
by	O
CAPD	O
.	O

Enzymatic	O
and	O
biochemical	O
properties	O
of	O
a	O
novel	O
human	B-GP
serine	I-GP
dehydratase	E-GP
isoform	O
.	O
A	O
cDNA	O
clone	O
similar	O
to	O
human	B-GP
serine	I-GP
dehydratase	E-GP
(	O
SDH	S-GP
)	O
is	O
deposited	O
in	O
the	O
GenBank/EMBL	O
databases	O
,	O
but	O
its	O
structural	O
and	O
functional	O
bases	O
remain	O
unknown	O
.	O
Despite	O
the	O
occurrence	O
of	O
mRNA	O
,	O
the	O
expected	O
protein	O
level	O
was	O
found	O
to	O
be	O
low	O
in	O
cultured	O
cells	O
.	O
To	O
learn	O
about	O
physicochemical	O
properties	O
of	O
the	O
protein	O
,	O
we	O
expressed	O
the	O
cDNA	O
in	O
Escherichia	O
coli	O
,	O
and	O
compared	O
the	O
expressed	O
protein	O
with	O
that	O
of	O
a	O
hepatic	O
SDH	S-GP
.	O
The	O
purified	O
protein	O
showed	O
l-serine	B-GP
and	I-GP
l-threonine	I-GP
dehydratase	E-GP
activity	O
,	O
demonstrating	O
to	O
be	O
an	O
isoform	O
of	O
SDH	S-GP
.	O
However	O
,	O
their	O
Km	O
and	O
Vmax	O
constants	O
were	O
different	O
in	O
a	O
range	O
of	O
two-order	O
.	O
Removal	O
of	O
Pro128	O
from	O
the	O
hepatic	O
SDH	S-GP
consisting	O
of	O
328	O
residues	O
,	O
which	O
is	O
missing	O
in	O
the	O
corresponding	O
position	O
of	O
the	O
isoform	O
consisting	O
of	O
329	O
residues	O
,	O
significantly	O
changed	O
the	O
Michaelis	O
constants	O
and	O
Kd	O
value	O
for	O
pyridoxal	B-chemical
5'-phosphate	E-chemical
,	O
whereas	O
addition	O
of	O
a	O
proline	S-chemical
residue	O
to	O
the	O
isoform	O
was	O
without	O
effect	O
.	O
These	O
findings	O
suggest	O
the	O
difference	O
in	O
the	O
structures	O
of	O
the	O
active	O
sites	O
of	O
the	O
two	O
enzymes	O
.	O
Another	O
striking	O
feature	O
was	O
that	O
the	O
expressed	O
level	O
of	O
the	O
isoform	O
in	O
E.	O
coli	O
was	O
7-fold	O
lower	O
than	O
that	O
of	O
the	O
hepatic	O
SDH	S-GP
.	O
Substitution	O
of	O
Val	B-GP
for	I-GP
Leu287	E-GP
in	O
the	O
isoform	O
dramatically	O
increased	O
the	O
protein	O
level	O
.	O
The	O
high	O
yield	O
of	O
the	O
mutated	O
isoform	O
was	O
also	O
confirmed	O
by	O
the	O
in	O
vitro	O
transcription	O
and	O
translation	O
experiment	O
.	O
The	O
poor	O
expression	O
of	O
the	O
isoform	O
could	O
be	O
explained	O
by	O
the	O
more	O
stable	O
secondary	O
structure	O
of	O
the	O
mRNA	O
than	O
that	O
of	O
the	O
hepatic	O
SDH	S-GP
mRNA	O
.	O
The	O
present	O
findings	O
may	O
provide	O
a	O
clue	O
as	O
to	O
why	O
the	O
protein	O
level	O
in	O
cultured	O
cells	O
is	O
low	O
.	O

Amelioration	O
of	O
palmitate	S-chemical
-induced	O
insulin	S-GP
resistance	O
in	O
C2C12	O
muscle	O
cells	O
by	O
rooibos	O
(	O
Aspalathus	O
linearis	O
)	O
.	O
Increased	O
levels	O
of	O
free	B-chemical
fatty	I-chemical
acids	E-chemical
(	O
FFAs	S-chemical
)	O
,	O
specifically	O
saturated	B-chemical
free	I-chemical
fatty	I-chemical
acids	E-chemical
such	O
as	O
palmitate	S-chemical
are	O
associated	O
with	O
insulin	S-GP
resistance	O
of	O
muscle	O
,	O
fat	O
and	O
liver	O
.	O
Skeletal	O
muscle	O
,	O
responsible	O
for	O
up	O
to	O
80	O
%	O
of	O
the	O
glucose	S-chemical
disposal	O
from	O
the	O
peripheral	O
circulation	O
,	O
is	O
particularly	O
vulnerable	O
to	O
increased	O
levels	O
of	O
saturated	O
FFAs	S-chemical
.	O
Rooibos	O
(	O
Aspalathus	O
linearis	O
)	O
and	O
its	O
unique	O
dihydrochalcone	B-chemical
C-glucoside	E-chemical
,	O
aspalathin	S-chemical
,	O
shown	O
to	O
reduce	O
hyperglycemia	O
in	O
diabetic	O
rats	O
,	O
could	O
play	O
a	O
role	O
in	O
preventing	O
or	O
ameliorating	O
the	O
development	O
of	O
insulin	S-GP
resistance	O
.	O
This	O
study	O
aims	O
to	O
establish	O
whether	O
rooibos	O
can	O
ameliorate	O
experimentally-induced	O
insulin	S-GP
-resistance	O
in	O
C2C12	O
skeletal	O
muscle	O
cells	O
.	O
Palmitate	S-chemical
-induced	O
insulin	O
resistant	O
C2C12	O
cells	O
were	O
treated	O
with	O
an	O
aspalathin	S-chemical
-enriched	O
green	O
(	O
unfermented	O
)	O
rooibos	O
extract	O
(	O
GRE	O
)	O
,	O
previously	O
shown	O
for	O
its	O
blood	O
glucose	S-chemical
lowering	O
effect	O
in	O
vitro	O
and	O
in	O
vivo	O
or	O
an	O
aqueous	O
extract	O
of	O
fermented	O
rooibos	O
(	O
FRE	O
)	O
.	O
Glucose	S-chemical
uptake	O
and	O
mitochondrial	O
activity	O
were	O
measured	O
using	O
2-deoxy-	B-chemical
[	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
-d-glucose	E-chemical
,	O
MTT	S-chemical
and	O
ATP	S-chemical
assays	O
,	O
respectively	O
.	O
Expression	O
of	O
proteins	O
relevant	O
to	O
glucose	S-chemical
metabolism	O
was	O
analysed	O
by	O
Western	O
blot	O
.	O
GRE	O
contained	O
higher	O
levels	O
of	O
all	O
compounds	O
,	O
except	O
the	O
enolic	O
phenylpyruvic	B-chemical
acid-2-O-glucoside	E-chemical
and	O
luteolin-7-O-glucoside	S-chemical
.	O
Both	O
rooibos	O
extracts	O
increased	O
glucose	S-chemical
uptake	O
,	O
mitochondrial	O
activity	O
and	O
ATP	S-chemical
production	O
.	O
Compared	O
to	O
FRE	O
,	O
GRE	O
was	O
more	O
effective	O
at	O
increasing	O
glucose	S-chemical
uptake	O
and	O
ATP	S-chemical
production	O
.	O
At	O
a	O
mechanistic	O
level	O
both	O
extracts	O
down-regulated	O
PKC	B-GP
θ	E-GP
activation	O
,	O
which	O
is	O
associated	O
with	O
palmitate	S-chemical
-induced	O
insulin	S-GP
resistance	O
.	O
Furthermore	O
,	O
the	O
extracts	O
increased	O
activation	O
of	O
key	O
regulatory	O
proteins	O
(	O
AKT	S-GP
and	O
AMPK	S-GP
)	O
involved	O
in	O
insulin	S-GP
-dependent	O
and	O
non-	O
insulin	S-GP
regulated	O
signalling	O
pathways	O
.	O
Protein	O
levels	O
of	O
the	O
glucose	B-GP
transporter	E-GP
(	O
GLUT4	S-GP
)	O
involved	O
in	O
glucose	S-chemical
transport	O
via	O
these	O
two	O
pathways	O
were	O
also	O
increased	O
.	O
This	O
in	O
vitro	O
study	O
therefore	O
confirms	O
that	O
rooibos	O
can	O
ameliorate	O
palmitate	S-chemical
-induced	O
insulin	S-GP
resistance	O
in	O
C2C12	O
skeletal	O
muscle	O
cells	O
.	O
Inhibition	O
of	O
PKC	B-GP
θ	E-GP
activation	O
and	O
increased	O
activation	O
of	O
AMPK	S-GP
and	O
AKT	S-GP
offer	O
a	O
plausible	O
mechanistic	O
explanation	O
for	O
this	O
ameliorative	O
effect	O
.	O

cDNA	O
cloning	O
and	O
functional	O
properties	O
of	O
human	B-GP
glutamate	I-GP
receptor	E-GP
EAA3	S-GP
(	O
GluR5	S-GP
)	O
in	O
homomeric	O
and	O
heteromeric	O
configuration	O
.	O
We	O
have	O
isolated	O
a	O
new	O
member	O
of	O
the	O
human	B-GP
glutamate	I-GP
receptor	E-GP
family	O
from	O
a	O
fetal	O
brain	O
cDNA	O
library	O
.	O
This	O
cDNA	O
clone	O
,	O
designated	O
EAA3a	S-GP
,	O
shares	O
a	O
90	O
%	O
nucleotide	S-chemical
identity	O
with	O
the	O
previously	O
reported	O
rat	B-GP
GluR5-2b	E-GP
cDNA	O
splice	O
variant	O
and	O
differed	O
from	O
human	B-GP
GluR5-1d	E-GP
in	O
the	O
amino	S-chemical
and	O
carboxy	S-chemical
terminal	O
regions	O
.	O
Cell	O
lines	O
stably	O
expressing	O
EAA3a	S-GP
protein	O
formed	O
homomeric	O
ligand-gated	B-GP
ion	I-GP
channels	E-GP
responsive	O
,	O
in	O
order	O
of	O
decreasing	O
affinity	O
to	O
domoate	O
,	O
kainate	S-chemical
,	O
L-glutamate	S-chemical
and	O
(	B-chemical
RS	I-chemical
)	I-chemical
-alpha-amino-3-hydroxy-5-	I-chemical
methylisoxazole-propionate	E-chemical
(	O
AMPA	S-chemical
)	O
.	O
Kainate	S-chemical
-evoked	O
currents	O
showed	O
partial	O
desensitization	O
that	O
was	O
reduced	O
on	O
incubation	O
with	O
concanavalin	B-GP
A	E-GP
(	O
conA	S-GP
)	O
but	O
not	O
cyclothiazide	S-chemical
and	O
were	O
attenuated	O
by	O
the	O
non-	O
N-methyl-D-aspartate	B-GP
(	I-GP
NMDA	I-GP
)	I-GP
receptor	E-GP
antagonist	O
CNQX	S-chemical
(	O
6-cyano-7-nitro-quinoxalinedione	S-chemical
)	O
.	O
Coexpression	O
of	O
EAA3a	S-GP
and	O
human	B-GP
EAA1	E-GP
cDNAs	O
in	O
HEK	O
293	O
cells	O
formed	O
a	O
heteromeric	O
channel	O
with	O
unique	O
properties	O
.	O
Kainate	S-chemical
and	O
AMPA	S-chemical
activated	O
the	O
heteromeric	O
channel	O
with	O
significantly	O
higher	O
affinities	O
than	O
observed	O
for	O
EAA3a	S-GP
alone	O
.	O
Ligand	O
binding	O
studies	O
with	O
the	O
recombinant	O
EAA3a	S-GP
receptor	O
expressed	O
in	O
mammalian	O
cells	O
indicated	O
a	O
high	O
affinity	O
kainate	S-chemical
binding	O
site	O
(	O
Kd	O
=	O
120	O
+/-	O
15.0	O
nM	O
)	O
.	O
The	O
relative	O
potency	O
of	O
compounds	O
in	O
displacing	O
[	B-chemical
3H	I-chemical
]	I-chemical
-kainate	E-chemical
binding	O
to	O
EAA3a	S-GP
receptor	O
was	O
:	O
domoate	O
>	O
kainate	S-chemical
>	O
L-glutamate	S-chemical
=	O
quisqualate	S-chemical
>	O
6,7-dinitroquinoxaline-2,3-dione	S-chemical
(	O
DNQX	S-chemical
)	O
=	O
CNQX	S-chemical
>	O
AMPA	S-chemical
>	O
dihydrokainate	S-chemical
>	O
NMDA	S-chemical
.	O

Advances	O
in	O
antihypertensive	O
combination	O
therapy	O
:	O
benefits	O
of	O
low-dose	O
thiazide	S-chemical
diuretics	O
in	O
conjunction	O
with	O
omapatrilat	S-chemical
,	O
a	O
vasopeptidase	S-GP
inhibitor	O
.	O
The	O
preferred	O
initial	O
agents	O
for	O
the	O
treatment	O
of	O
high	O
blood	O
pressure	O
are	O
low-dose	O
thiazide	S-chemical
diuretics	O
,	O
beta	O
blockers	O
,	O
calcium	S-chemical
antagonists	O
,	O
and	O
angiotensin-converting	B-GP
enzyme	E-GP
(	O
ACE	S-GP
)	O
inhibitors	O
.	O
In	O
high-risk	O
patients	O
,	O
including	O
those	O
with	O
diabetes	O
,	O
renal	O
insufficiency	O
,	O
left	O
ventricular	O
dysfunction	O
,	O
and	O
atherosclerosis	O
,	O
ACE	S-GP
inhibitors	O
may	O
have	O
specific	O
benefit	O
in	O
reducing	O
cardiovascular	O
morbidity	O
and	O
mortality	O
.	O
Omapatrilat	S-chemical
,	O
the	O
prototypical	O
vasopeptidase	S-GP
inhibitor	O
,	O
inhibits	O
not	O
only	O
ACE	S-GP
but	O
also	O
neutral	B-GP
endopeptidase	E-GP
.	O
Like	O
conventional	O
ACE	S-GP
inhibitors	O
,	O
omapatrilat	S-chemical
causes	O
extracellular	O
volume	O
reduction	O
and	O
vasodilatation	O
;	O
moreover	O
,	O
it	O
increases	O
levels	O
of	O
atrial	B-GP
and	I-GP
brain	I-GP
natriuretic	I-GP
peptides	E-GP
and	O
bradykinin	S-chemical
.	O
Effective	O
blood	O
pressure	O
control	O
,	O
especially	O
in	O
the	O
high-risk	O
patient	O
,	O
usually	O
necessitates	O
combination	O
therapy	O
.	O
A	O
recent	O
study	O
randomized	O
274	O
subjects	O
with	O
mild	O
to	O
severe	O
hypertension	O
(	O
stages	O
1-3	O
diastolic	O
blood	O
pressure	O
elevation	O
)	O
and	O
confirmed	O
the	O
benefits	O
of	O
omapatrilat	S-chemical
combined	O
with	O
hydrochlorothiazide	S-chemical
in	O
patients	O
not	O
controlled	O
on	O
hydrochlorothiazide	S-chemical
alone	O
.	O
The	O
frequencies	O
of	O
adverse	O
events	O
,	O
serious	O
adverse	O
events	O
,	O
and	O
discontinuation	O
attributed	O
to	O
adverse	O
events	O
were	O
similar	O
for	O
omapatrilat	S-chemical
and	O
placebo	O
.	O
Furthermore	O
,	O
there	O
were	O
no	O
clinically	O
significant	O
changes	O
in	O
serum	O
creatinine	S-chemical
,	O
potassium	S-chemical
,	O
or	O
other	O
laboratory	O
parameters	O
.	O
Adding	O
omapatrilat	S-chemical
to	O
the	O
background	O
of	O
hydrochlorothiazide	S-chemical
treatment	O
produced	O
statistically	O
significant	O
additional	O
reductions	O
in	O
trough	O
diastolic	O
and	O
systolic	O
blood	O
pressures	O
at	O
weeks	O
4	O
and	O
8	O
.	O

Multifunctional	O
targets	O
of	O
dietary	O
polyphenols	S-chemical
in	O
disease	O
:	O
a	O
case	O
for	O
the	O
chemokine	S-GP
network	O
and	O
energy	O
metabolism	O
.	O
Chronic	O
,	O
non-acute	O
inflammation	O
is	O
behind	O
conditions	O
that	O
represent	O
most	O
of	O
the	O
disease	O
burden	O
in	O
humans	O
and	O
is	O
clearly	O
linked	O
to	O
immune	O
and	O
metabolic	O
mechanisms	O
.	O
The	O
convergence	O
of	O
pathways	O
involving	O
the	O
immune	O
response	O
,	O
oxidative	O
stress	O
,	O
increased	O
circulating	O
lipids	O
and	O
aberrant	O
insulin	S-GP
signaling	O
results	O
in	O
CCL2	S-GP
-associated	O
macrophage	O
recruitment	O
and	O
altered	O
energy	O
metabolism	O
.	O
The	O
CCL2	S-GP
/	O
CCR2	S-GP
pathway	O
and	O
the	O
energy	O
sensor	O
AMP-activated	B-GP
protein	I-GP
kinase	E-GP
(	O
AMPK	S-GP
)	O
are	O
attractive	O
therapeutic	O
targets	O
as	O
a	O
part	O
of	O
preventive	O
management	O
of	O
disease	O
.	O
Several	O
effects	O
of	O
polyphenols	S-chemical
are	O
useful	O
in	O
this	O
scenario	O
,	O
including	O
a	O
reduction	O
in	O
the	O
activities	O
of	O
cytokines	S-GP
and	O
modulation	O
of	O
cellular	O
metabolism	O
through	O
histone	B-GP
deacetylase	E-GP
inhibitors	O
,	O
AMPK	S-GP
activators	O
,	O
calorie-restriction	O
mimetics	O
or	O
epigenetic	O
regulators	O
.	O
Research	O
is	O
currently	O
underway	O
to	O
develop	O
orally	O
active	O
drugs	O
with	O
these	O
effects	O
,	O
but	O
it	O
is	O
convenient	O
to	O
examine	O
more	O
closely	O
what	O
we	O
are	O
eating	O
.	O
If	O
a	O
lack	O
of	O
relevance	O
in	O
terms	O
of	O
toxicity	O
and	O
substantial	O
effectiveness	O
are	O
confirmed	O
,	O
plant-derived	O
components	O
may	O
provide	O
useful	O
druggable	O
components	O
and	O
dietary	O
supplements	O
.	O
We	O
consider	O
therapeutic	O
actions	O
as	O
a	O
combination	O
of	O
synergistic	O
and/or	O
antagonistic	O
interactions	O
in	O
a	O
multi-target	O
strategy	O
.	O
Hence	O
,	O
improvement	O
in	O
food	O
through	O
enrichment	O
with	O
polyphenols	S-chemical
with	O
demonstrated	O
activity	O
may	O
represent	O
a	O
major	O
advance	O
in	O
the	O
design	O
of	O
diets	O
with	O
both	O
industrial	O
and	O
sanitary	O
value	O
.	O

Neonatal	O
red	O
blood	O
cells	O
:	O
amiloride	S-chemical
-insensitive	O
Na+	S-chemical
-	O
H+	S-chemical
transport	O
isoform	O
would	O
express	O
Na+	S-chemical
-	O
Li+	S-chemical
exchange	O
.	O
Neonatal	O
red	O
cells	O
(	O
umbilical	O
cord	O
blood	O
)	O
were	O
in	O
vitro	O
incubated	O
in	O
isotonic	O
media	O
(	O
thiocyanate	S-chemical
as	O
predominant	O
anion	O
)	O
.	O
This	O
experimental	O
condition	O
was	O
selected	O
as	O
it	O
was	O
known	O
that	O
this	O
chaotropic	O
anion	O
induced	O
activation	O
of	O
Na+	S-chemical
-	O
H+	S-chemical
exchange	O
.	O
The	O
transport	O
amiloride	S-chemical
-sensitive	O
mechanism	O
,	O
that	O
decreased	O
the	O
acidic	O
intracellular	O
pH	O
change	O
occurring	O
in	O
this	O
medium	O
,	O
would	O
correspond	O
to	O
Na+	S-chemical
-	O
H+	S-chemical
exchange	O
(	O
NHE1	S-GP
isoform	O
)	O
.	O
However	O
,	O
the	O
Na+	S-chemical
-	O
Li+	S-chemical
exchange	O
,	O
also	O
determined	O
in	O
the	O
cells	O
in	O
the	O
above-mentioned	O
medium	O
was	O
not	O
affected	O
by	O
amiloride	S-chemical
.	O
The	O
present	O
data	O
suggest	O
that	O
an	O
amiloride	S-chemical
insensitive	O
Na+	S-chemical
-	O
H+	S-chemical
exchange	O
isoform	O
would	O
express	O
Na+	S-chemical
-	O
Li+	S-chemical
countertransport	O
in	O
these	O
cells	O
.	O

Characterization	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
increased	O
insulin	S-GP
secretion	O
in	O
rats	O
with	O
acute	O
liver	O
failure	O
.	O
To	O
investigate	O
the	O
mechanism	O
of	O
hyperinsulinaemia	O
in	O
rats	O
with	O
acute	O
liver	O
failure	O
induced	O
by	O
the	O
administration	O
of	O
d-galactosamine	S-chemical
(	O
GalN	S-chemical
)	O
,	O
we	O
focused	O
on	O
the	O
role	O
of	O
polyprimidine	B-GP
tract-binding	I-GP
protein	E-GP
(	O
PTB	S-GP
)	O
in	O
islet	O
insulin	S-GP
synthesis	O
.	O
Recent	O
reports	O
indicate	O
that	O
PTB	S-GP
binds	O
and	O
stabilizes	O
mRNA	O
encoding	O
insulin	S-GP
and	O
insulin	B-GP
secretory	I-GP
granule	I-GP
proteins	E-GP
,	O
including	O
islet	B-GP
cell	I-GP
autoantigen	I-GP
512	E-GP
(	O
ICA512	S-GP
)	O
,	O
prohormone	B-GP
convertase	I-GP
1/3	E-GP
(	O
PC1/3	S-GP
)	O
,	O
and	O
PC2	S-GP
.	O
In	O
the	O
present	O
study	O
,	O
glucose	S-chemical
-stimulated	O
insulin	S-GP
secretion	O
was	O
significantly	O
increased	O
in	O
GalN	S-chemical
-treated	O
rats	O
compared	O
to	O
controls	O
.	O
Levels	O
of	O
mRNA	O
encoding	O
insulin	B-GP
1	E-GP
,	O
ICA512	S-GP
,	O
and	O
PC1/3	S-GP
were	O
increased	O
in	O
the	O
pancreatic	O
islets	O
of	O
GalN	S-chemical
-treated	O
rats	O
.	O
This	O
mRNA	O
level	O
elevation	O
was	O
not	O
prevented	O
by	O
pretreatment	O
with	O
actinomycin	B-chemical
D	E-chemical
.	O
When	O
the	O
PTB-binding	B-GP
site	E-GP
in	O
insulin	B-GP
1	E-GP
mRNA	O
was	O
incubated	O
with	O
the	O
islet	O
cytosolic	O
fraction	O
,	O
the	O
RNA-protein	O
complex	O
level	O
was	O
increased	O
in	O
the	O
cytosolic	O
fraction	O
obtained	O
from	O
GalN	S-chemical
-treated	O
rats	O
compared	O
to	O
the	O
level	O
in	O
control	O
rats	O
.	O
The	O
cytosolic	O
fraction	O
obtained	O
from	O
pancreatic	O
islets	O
obtained	O
from	O
GalN	S-chemical
-treated	O
rats	O
had	O
an	O
increased	O
PTB	S-GP
level	O
compared	O
to	O
the	O
levels	O
obtained	O
from	O
the	O
pancreatic	O
islets	O
of	O
control	O
rats	O
.	O
These	O
findings	O
suggest	O
that	O
,	O
in	O
rats	O
with	O
acute	O
liver	O
failure	O
,	O
cytosolic	O
PTB	S-GP
binds	O
and	O
stabilizes	O
mRNA	O
encoding	O
insulin	S-GP
and	O
its	O
secretory	B-GP
granule	I-GP
proteins	E-GP
.	O

Binding	O
of	O
antipsychotic	O
drugs	O
at	O
alpha	B-GP
1A-	I-GP
and	I-GP
alpha	I-GP
1B-adrenoceptors	E-GP
:	O
risperidone	S-chemical
is	O
selective	O
for	O
the	O
alpha	B-GP
1B-adrenoceptors	E-GP
.	O
The	O
binding	O
of	O
the	O
antipsychotic	O
drugs	O
risperidone	S-chemical
,	O
(	B-chemical
+	I-chemical
)	I-chemical
-butaclamol	E-chemical
,	O
clozapine	S-chemical
,	O
haloperidol	S-chemical
,	O
spiperone	S-chemical
,	O
thioridazine	S-chemical
and	O
YM-09151-2	S-chemical
was	O
studied	O
at	O
the	O
subtypes	O
of	O
the	O
alpha	B-GP
1-adrenoceptor	E-GP
.	O
Saturation	O
experiments	O
showed	O
that	O
[	B-chemical
3H	I-chemical
]	I-chemical
prazosin	E-chemical
labelled	O
a	O
single	O
population	O
of	O
binding	O
sites	O
in	O
the	O
spleen	O
(	O
alpha	B-GP
1B	E-GP
)	O
and	O
hippocampus	O
(	O
alpha	B-GP
1A	E-GP
and	O
alpha	B-GP
1B	E-GP
)	O
(	O
dissociation	O
constants	O
(	O
KD	O
)	O
:	O
0.26	O
nM	O
and	O
0.14	O
nM	O
respectively	O
)	O
.	O
Prazosin	S-chemical
displaced	O
the	O
radioligand	O
in	O
a	O
monophasic	O
manner	O
in	O
both	O
the	O
spleen	O
and	O
hippocampus	O
whereas	O
5-methyl-urapidil	S-chemical
,	O
phentolamine	S-chemical
and	O
WB	B-chemical
4101	E-chemical
displaced	O
the	O
radioligand	O
in	O
a	O
monophasic	O
manner	O
in	O
the	O
spleen	O
but	O
in	O
a	O
biphasic	O
manner	O
in	O
the	O
hippocampus	O
.	O
The	O
affinity	O
of	O
these	O
three	O
compounds	O
for	O
the	O
low	O
affinity	O
site	O
in	O
the	O
hippocampus	O
was	O
similar	O
to	O
that	O
observed	O
in	O
the	O
spleen	O
,	O
suggesting	O
that	O
all	O
three	O
were	O
selective	O
for	O
the	O
alpha	B-GP
1A-adrenoceptor	E-GP
.	O
Furthermore	O
,	O
the	O
affinities	O
for	O
the	O
alpha	B-GP
1A-	I-GP
and	I-GP
alpha	I-GP
1B-adrenoceptors	E-GP
calculated	O
in	O
this	O
manner	O
were	O
in	O
agreement	O
with	O
literature	O
values	O
.	O
With	O
the	O
exception	O
of	O
risperidone	S-chemical
,	O
all	O
the	O
antipsychotic	O
drugs	O
tested	O
failed	O
to	O
show	O
selectivity	O
for	O
either	O
of	O
the	O
alpha	B-GP
1-adrenoceptor	E-GP
subtypes	O
.	O
Risperidone	S-chemical
was	O
120-fold	O
more	O
selective	O
for	O
the	O
alpha	B-GP
1B-adrenoceptor	E-GP
with	O
respect	O
to	O
the	O
alpha	B-GP
1A-adrenoceptor	E-GP
(	O
Ki	O
values	O
:	O
2.3	O
+/-	O
1.2	O
nM	O
and	O
283.6	O
+/-	O
174.1	O
nM	O
respectively	O
)	O
.	O

Drug-protein	O
interactions	O
:	O
isolation	O
and	O
characterization	O
of	O
covalent	O
adducts	O
of	O
phenoxybenzamine	S-chemical
and	O
calmodulin	S-GP
.	O
Phenoxybenzamine	S-chemical
,	O
an	O
alpha-adrenergic	O
antagonist	O
containing	O
a	O
(	B-chemical
chloroethyl	I-chemical
)	I-chemical
amine	E-chemical
group	O
,	O
labels	O
calmodulin	S-GP
in	O
the	O
presence	O
of	O
calcium	S-chemical
.	O
The	O
covalent	O
interaction	O
is	O
inhibited	O
by	O
chlorpromazine	S-chemical
in	O
a	O
concentration-dependent	O
manner	O
.	O
Adducts	O
of	O
calmodulin	S-GP
and	O
phenoxybenzamine	S-chemical
were	O
separated	O
by	O
high-performance	O
liquid	O
chromatography	O
into	O
four	O
major	O
fractions	O
:	O
two	O
containing	O
0.6	O
and	O
1.2	O
mol	O
of	O
drug	O
per	O
mol	O
of	O
protein	O
and	O
two	O
different	O
fractions	O
each	O
containing	O
2.0	O
mol/mol	O
.	O
Each	O
adduct	O
had	O
a	O
reduced	O
ability	O
to	O
activate	O
cyclic	B-GP
nucleotide	I-GP
phosphodiesterase	E-GP
and	O
myosin	B-GP
light	I-GP
chain	I-GP
kinase	E-GP
,	O
and	O
the	O
chlorpromazine	S-chemical
binding	O
capacities	O
of	O
the	O
phenoxybenzamine	S-chemical
-	O
calmodulin	S-GP
adducts	O
were	O
diminished	O
to	O
the	O
extent	O
of	O
phenoxybenzamine	S-chemical
incorporation	O
into	O
each	O
adduct	O
.	O
Isolation	O
and	O
characterization	O
of	O
labeled	O
peptides	O
from	O
phenoxybenzamine	S-chemical
-modified	O
calmodulins	S-GP
indicated	O
that	O
peptides	O
encompassing	O
residues	O
38-75	O
,	O
107-126	O
,	O
and	O
127-148	O
contained	O
phenoxybenzamine	S-chemical
label	O
.	O
These	O
studies	O
directly	O
demonstrate	O
the	O
relatedness	O
between	O
the	O
binding	O
activities	O
of	O
two	O
structurally	O
dissimilar	O
calmodulin	S-GP
antagonists	O
,	O
demonstrate	O
that	O
covalent	O
adducts	O
of	O
calmodulin	S-GP
and	O
drugs	O
with	O
equal	O
stoichiometries	O
of	O
labeling	O
can	O
have	O
quantitative	O
differences	O
in	O
activity	O
and	O
sites	O
of	O
modification	O
,	O
and	O
provide	O
direct	O
evidence	O
of	O
distinct	O
drug	O
binding	O
regions	O
in	O
calmodulin	S-GP
located	O
in	O
the	O
amphipathic	O
alpha-helical	O
regions	O
of	O
the	O
second	O
and	O
fourth	O
domains	O
.	O

Penicillin-binding	B-GP
proteins	E-GP
and	O
role	O
of	O
amdinocillin	S-chemical
in	O
causing	O
bacterial	O
cell	O
death	O
.	O
The	O
activity	O
of	O
penicillins	S-chemical
against	O
bacteria	O
is	O
in	O
large	O
part	O
related	O
to	O
binding	O
to	O
specific	O
receptor	O
proteins	O
involved	O
in	O
cell	O
wall	O
biosynthesis	O
.	O
These	O
proteins	O
have	O
been	O
designated	O
penicillin-binding	B-GP
proteins	E-GP
.	O
They	O
can	O
be	O
separated	O
into	O
distinct	O
entities	O
through	O
the	O
use	O
of	O
acrylamide	S-chemical
gel	O
electrophoresis	O
and	O
binding	O
of	O
radioactive	O
14C-labeled	B-chemical
penicillin	I-chemical
G	E-chemical
.	O
Six	O
major	O
proteins	O
have	O
been	O
defined	O
in	O
the	O
Enterobacteriaceae	O
,	O
penicillin-binding	B-GP
proteins	I-GP
1	I-GP
to	I-GP
6	E-GP
.	O
Selection	O
of	O
mutants	O
has	O
shown	O
that	O
there	O
are	O
three	O
essential	O
proteins	O
:	O
penicillin-binding	B-GP
protein	I-GP
1	E-GP
,	O
which	O
is	O
divided	O
into	O
penicillin-binding	B-GP
protein	I-GP
1Bs	E-GP
,	O
a	O
peptidoglycan	B-GP
transpeptidase	E-GP
,	O
and	O
penicillin-binding	B-GP
protein	I-GP
1A	E-GP
,	O
which	O
acts	O
as	O
a	O
replacement	O
for	O
penicillin-binding	B-GP
protein	I-GP
1Bs	E-GP
.	O
Penicillin-binding	B-GP
protein	I-GP
2	E-GP
is	O
a	O
murein	S-GP
-elongation	O
initiating	O
enzyme	O
and	O
penicillin-binding	B-GP
protein	I-GP
3	E-GP
is	O
a	O
septal	O
murein	S-GP
-synthesizing	O
enzyme	O
.	O
Penicillin-binding	B-GP
proteins	I-GP
4	I-GP
,	I-GP
5	I-GP
,	I-GP
and	I-GP
6	E-GP
are	O
not	O
essential	O
for	O
bacterial	O
survival	O
.	O
Binding	O
of	O
penicillins	S-chemical
to	O
penicillin-binding	B-GP
protein	I-GP
1Bs	E-GP
produces	O
lysis	O
,	O
binding	O
to	O
penicillin-binding	B-GP
protein	I-GP
2	E-GP
produces	O
round	O
cells	O
,	O
and	O
binding	O
to	O
penicillin-binding	B-GP
protein	I-GP
3	E-GP
produces	O
long	O
filaments	O
.	O
Amdinocillin	S-chemical
is	O
a	O
beta-amidino	B-chemical
penicillanic	I-chemical
acid	E-chemical
derivative	O
that	O
binds	O
specifically	O
to	O
penicillin-binding	B-GP
protein	I-GP
2	E-GP
.	O
The	O
compound	O
is	O
more	O
beta-lactamase	S-GP
stable	O
than	O
ampicillin	S-chemical
and	O
has	O
no	O
major	O
delay	O
in	O
entry	O
into	O
the	O
periplasmic	O
space	O
as	O
do	O
some	O
penicillins	S-chemical
.	O
Amdinocillin	S-chemical
inhibits	O
most	O
of	O
the	O
Enterobacteriaceae	O
,	O
with	O
the	O
exception	O
of	O
some	O
indole	S-chemical
-positive	O
Proteus	O
species	O
,	O
but	O
it	O
does	O
not	O
inhibit	O
gram-positive	O
cocci	O
or	O
Pseudomonas	O
aeruginosa	O
.	O
Amdinocillin	S-chemical
produces	O
spherical	O
bacterial	O
cells	O
that	O
eventually	O
lyse	O
.	O
Its	O
activity	O
in	O
vitro	O
is	O
markedly	O
affected	O
by	O
ionic	O
content	O
of	O
media	O
.	O
This	O
agent	O
acts	O
synergistically	O
with	O
many	O
penicillins	S-chemical
,	O
such	O
as	O
ampicillin	S-chemical
,	O
carbenicillin	S-chemical
,	O
and	O
the	O
like	O
,	O
and	O
with	O
cephalosporins	S-chemical
,	O
cefazolin	S-chemical
,	O
cefamandole	S-chemical
,	O
or	O
cefoxitin	S-chemical
to	O
inhibit	O
gram-negative	O
bacilli	O
,	O
probably	O
on	O
the	O
basis	O
of	O
binding	O
to	O
different	O
proteins	O
needed	O
for	O
the	O
production	O
of	O
the	O
peptidoglycan	S-GP
of	O
the	O
bacterial	O
cell	O
wall	O
.	O
Amdinocillin	S-chemical
possesses	O
a	O
number	O
of	O
the	O
essentials	O
for	O
effective	O
antimicrobial	O
activity	O
and	O
,	O
by	O
virtue	O
of	O
its	O
enhancement	O
of	O
the	O
activity	O
of	O
other	O
beta-lactams	S-chemical
,	O
may	O
prove	O
to	O
be	O
a	O
useful	O
agent	O
in	O
the	O
chemotherapy	O
of	O
certain	O
infections	O
.	O

Influence	O
of	O
triterpenoids	S-chemical
present	O
in	O
apple	O
peel	O
on	O
inflammatory	O
gene	O
expression	O
associated	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O
Various	O
ursanic	B-chemical
,	I-chemical
oleanic	I-chemical
and	I-chemical
lupanic	I-chemical
pentacyclic	I-chemical
triterpenoids	E-chemical
found	O
in	O
apple	O
peel	O
were	O
studied	O
for	O
anti-inflammatory	O
effects	O
in	O
vitro	O
using	O
T84	O
colon	O
carcinoma	O
cells	O
.	O
After	O
pretreatment	O
with	O
single	O
triterpenoids	S-chemical
,	O
cells	O
were	O
stimulated	O
with	O
pro-inflammatory	O
cytokines	S-GP
(	O
TNF-α	S-GP
,	O
INF-γ	S-GP
,	O
IL-1β	S-GP
)	O
.	O
Regulation	O
of	O
mRNA	O
expression	O
was	O
analysed	O
for	O
three	O
specific	O
inflammation-associated	O
marker	O
genes	O
(	O
TNF-α	S-GP
,	O
IL-8	S-GP
,	O
IP-10	S-GP
)	O
using	O
qRT-PCR	O
.	O
Furthermore	O
,	O
the	O
effects	O
of	O
ursolic	B-chemical
acid	E-chemical
(	O
UA	O
)	O
and	O
oleanolic	B-chemical
acid	E-chemical
(	O
OA	O
)	O
on	O
the	O
synthesis	O
of	O
certain	O
pro-inflammatory	O
proteins	O
were	O
examined	O
.	O
IP-10	S-GP
expression	O
was	O
inhibited	O
in	O
a	O
dose-dependent	O
manner	O
by	O
all	O
the	O
tested	O
compounds	O
at	O
concentrations	O
⩾25μM	O
.	O
The	O
mRNA	O
expression	O
of	O
TNF-α	S-GP
was	O
slightly	O
affected	O
and	O
the	O
IL-8	S-GP
level	O
was	O
increased	O
.	O
At	O
the	O
protein	O
level	O
,	O
UA	O
and	O
OA	O
(	O
25μM	O
)	O
reduced	O
the	O
synthesis	O
of	O
IP-10	S-GP
;	O
sICAM-1	S-GP
,	O
IL-23	S-GP
and	O
GROα	S-GP
were	O
slightly	O
repressed	O
.	O
The	O
TNF-α	S-GP
level	O
was	O
not	O
modulated	O
,	O
whereas	O
induction	O
of	O
IL-8	S-GP
was	O
increased	O
.	O
UA	O
also	O
enhanced	O
the	O
synthesis	O
of	O
IL-1ra	S-GP
,	O
while	O
OA	O
suppressed	O
the	O
level	O
of	O
I-TAC	S-GP
.	O
The	O
present	O
study	O
confirms	O
that	O
triterpenoids	S-chemical
present	O
in	O
apple	O
peel	O
and	O
β-damascone	S-chemical
may	O
be	O
implicated	O
in	O
the	O
anti-inflammatory	O
properties	O
of	O
apple	O
constituents	O
,	O
suggesting	O
that	O
these	O
substances	O
might	O
be	O
helpful	O
in	O
the	O
treatment	O
of	O
IBD	O
as	O
nutrient	O
supplements	O
.	O

Zinc	S-chemical
-dependent	O
lysosomal	O
enlargement	O
in	O
TRPML1	S-GP
-deficient	O
cells	O
involves	O
MTF-1	S-GP
transcription	O
factor	O
and	O
ZnT4	S-GP
(	O
Slc30a4	S-GP
)	O
transporter	O
.	O
Zinc	S-chemical
is	O
critical	O
for	O
a	O
multitude	O
of	O
cellular	O
processes	O
,	O
including	O
gene	O
expression	O
,	O
secretion	O
and	O
enzymatic	O
activities	O
.	O
Cellular	O
zinc	S-chemical
is	O
controlled	O
by	O
zinc-chelating	B-GP
proteins	E-GP
and	O
by	O
zinc	B-GP
transporters	E-GP
.	O
The	O
recent	O
identification	O
of	O
zinc	S-chemical
permeability	O
of	O
the	O
lysosomal	O
ion	B-GP
channel	E-GP
TRPML1	S-GP
(	O
transient	B-GP
receptor	I-GP
potential	I-GP
mucolipin	I-GP
1	E-GP
)	O
,	O
and	O
the	O
evidence	O
of	O
abnormal	O
zinc	S-chemical
levels	O
in	O
cells	O
deficient	O
in	O
TRPML1	S-GP
,	O
suggested	O
a	O
role	O
for	O
TRPML1	S-GP
in	O
zinc	S-chemical
transport	O
.	O
In	O
the	O
present	O
study	O
we	O
provide	O
new	O
evidence	O
for	O
such	O
a	O
role	O
and	O
identify	O
additional	O
cellular	O
components	O
responsible	O
for	O
it	O
.	O
In	O
agreement	O
with	O
the	O
previously	O
published	O
data	O
,	O
an	O
acute	O
siRNA	O
(	O
small	O
interfering	O
RNA	O
)	O
-driven	O
TRPML1	S-GP
KD	O
(	O
knockdown	O
)	O
leads	O
to	O
the	O
build-up	O
of	O
large	O
cytoplasmic	O
vesicles	O
positive	O
for	O
LysoTracker™	O
and	O
zinc	S-chemical
staining	O
,	O
when	O
cells	O
are	O
exposed	O
to	O
high	O
concentrations	O
of	O
zinc	S-chemical
.	O
We	O
now	O
show	O
that	O
lysosomal	O
enlargement	O
and	O
zinc	S-chemical
build-up	O
in	O
TRPML1	S-GP
-KD	O
cells	O
exposed	O
to	O
zinc	S-chemical
are	O
ameliorated	O
by	O
KD	O
of	O
the	O
zinc-sensitive	B-GP
transcription	I-GP
factor	E-GP
MTF-1	S-GP
(	O
metal-regulatory-element-binding	B-GP
transcription	I-GP
factor-1	E-GP
)	O
or	O
the	O
zinc	B-GP
transporter	I-GP
ZnT4	E-GP
.	O
TRPML1	S-GP
KD	O
is	O
associated	O
with	O
a	O
build-up	O
of	O
cytoplasmic	O
zinc	S-chemical
and	O
with	O
enhanced	O
transcriptional	O
response	O
of	O
mRNA	O
for	O
MT2a	S-GP
(	O
metallothionein	B-GP
2a	E-GP
)	O
.	O
TRPML1	S-GP
KD	O
did	O
not	O
suppress	O
lysosomal	O
secretion	O
,	O
but	O
it	O
did	O
delay	O
zinc	S-chemical
leak	O
from	O
the	O
lysosomes	O
into	O
the	O
cytoplasm	O
.	O
These	O
results	O
underscore	O
a	O
role	O
for	O
TRPML1	S-GP
in	O
zinc	S-chemical
metabolism	O
.	O
Furthermore	O
,	O
they	O
suggest	O
that	O
TRPML1	S-GP
works	O
in	O
concert	O
with	O
ZnT4	S-GP
to	O
regulate	O
zinc	S-chemical
translocation	O
between	O
the	O
cytoplasm	O
and	O
lysosomes	O
.	O

Synthesis	O
,	O
biological	O
evaluation	O
,	O
and	O
molecular	O
modeling	O
of	O
glycyrrhizin	S-chemical
derivatives	O
as	O
potent	O
high-mobility	B-GP
group	I-GP
box-1	E-GP
inhibitors	O
with	O
anti-heart-failure	O
activity	O
in	O
vivo	O
.	O
Novel	O
glycyrrhizin	S-chemical
(	O
GL	O
)	O
derivatives	O
were	O
designed	O
and	O
synthesized	O
by	O
introducing	O
various	O
amine	S-chemical
or	O
amino	B-chemical
acid	E-chemical
residues	O
into	O
the	O
carbohydrate	S-chemical
chain	O
and	O
at	O
C-30	O
.	O
Their	O
inhibitory	O
effects	O
on	O
high-mobility	B-GP
group	I-GP
box	I-GP
1	E-GP
(	O
HMGB1	S-GP
)	O
were	O
evaluated	O
using	O
a	O
cell-based	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induced	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
α	E-GP
(	O
TNF-α	S-GP
)	O
release	O
study	O
.	O
Compounds	O
10	O
,	O
12	O
,	O
18-20	O
,	O
23	O
,	O
and	O
24	O
,	O
which	O
had	O
substituents	O
introduced	O
at	O
C-30	O
,	O
demonstrated	O
moderate	O
HMGB1	S-GP
inhibition	O
with	O
ED₅₀	O
values	O
ranging	O
from	O
337	O
to	O
141	O
μM	O
,	O
which	O
are	O
values	O
comparable	O
to	O
that	O
of	O
the	O
leading	O
GL	O
compound	O
(	O
1	O
)	O
(	O
ED₅₀	O
=	O
70	O
μM	O
)	O
.	O
Compounds	O
23	O
and	O
24	O
emerged	O
as	O
novel	O
and	O
interesting	O
HMGB1	S-GP
inhibitors	O
.	O
These	O
compounds	O
were	O
able	O
to	O
extend	O
the	O
survival	O
of	O
mice	O
with	O
chronic	O
heart	O
failure	O
(	O
CHF	O
)	O
and	O
acute	O
heart	O
failure	O
(	O
AHF	O
)	O
,	O
respectively	O
.	O
In	O
addition	O
,	O
molecular	O
modeling	O
studies	O
were	O
performed	O
to	O
support	O
the	O
biological	O
data	O
.	O

Cresyl	B-chemical
saligenin	I-chemical
phosphate	E-chemical
makes	O
multiple	O
adducts	O
on	O
free	O
histidine	S-chemical
,	O
but	O
does	O
not	O
form	O
an	O
adduct	O
on	O
histidine	S-chemical
438	O
of	O
human	B-GP
butyrylcholinesterase	E-GP
.	O
Cresyl	B-chemical
saligenin	I-chemical
phosphate	E-chemical
(	O
CBDP	S-chemical
)	O
is	O
a	O
suspected	O
causative	O
agent	O
of	O
``	O
aerotoxic	O
syndrome	O
''	O
,	O
affecting	O
pilots	O
,	O
crew	O
members	O
and	O
passengers	O
.	O
CBDP	S-chemical
is	O
produced	O
in	O
vivo	O
from	O
ortho-containing	O
isomers	O
of	O
tricresyl	B-chemical
phosphate	E-chemical
(	O
TCP	S-chemical
)	O
,	O
a	O
component	O
of	O
jet	O
engine	O
lubricants	O
and	O
hydraulic	O
fluids	O
.	O
CBDP	S-chemical
irreversibly	O
inhibits	O
butyrylcholinesterase	S-GP
(	O
BChE	S-GP
)	O
in	O
human	O
plasma	O
by	O
forming	O
adducts	O
on	O
the	O
active	O
site	O
serine	S-chemical
(	O
Ser	S-chemical
-198	O
)	O
.	O
Inhibited	O
BChE	S-GP
undergoes	O
aging	O
to	O
release	O
saligenin	S-chemical
and	O
o-cresol	S-chemical
.	O
The	O
active	O
site	O
histidine	S-chemical
(	O
His	S-chemical
-438	O
)	O
was	O
hypothesized	O
to	O
abstract	O
o-hydroxybenzyl	S-chemical
moiety	O
from	O
the	O
initial	O
adduct	O
on	O
Ser	S-chemical
-198	O
.	O
Our	O
goal	O
was	O
to	O
test	O
this	O
hypothesis	O
.	O
Mass	O
spectral	O
analysis	O
of	O
CBDP	S-chemical
-inhibited	O
BChE	S-GP
digested	O
with	O
Glu	S-chemical
-C	O
showed	O
an	O
o-hydroxybenzyl	S-chemical
adduct	O
(	O
+106amu	O
)	O
on	O
lysine	S-chemical
499	O
,	O
a	O
residue	O
far	O
from	O
the	O
active	O
site	O
,	O
but	O
not	O
on	O
His	S-chemical
-438	O
.	O
Nevertheless	O
,	O
the	O
nitrogen	S-chemical
of	O
the	O
imidazole	S-chemical
ring	O
of	O
free	O
l-histidine	S-chemical
formed	O
a	O
variety	O
of	O
adducts	O
upon	O
reaction	O
with	O
CBDP	S-chemical
,	O
including	O
the	O
o-hydroxybenzyl	S-chemical
adduct	O
,	O
suggesting	O
that	O
histidine	S-chemical
-	O
CBDP	S-chemical
adducts	O
may	O
form	O
on	O
other	O
proteins	O
.	O

Imatinib	S-chemical
resistance	O
in	O
gastrointestinal	O
stromal	O
tumors	O
.	O
Conventional	O
chemotherapeutic	O
drugs	O
are	O
ineffective	O
in	O
treatment	O
of	O
gastrointestinal	O
stromal	O
tumors	O
(	O
GISTs	O
)	O
.	O
Imatinib	S-chemical
(	O
STI571	S-chemical
,	O
Gleevec	S-chemical
,	O
Glivec	S-chemical
;	O
Novartis	O
Pharmaceuticals	O
,	O
East	O
Hanover	O
,	O
NJ	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
KIT	S-GP
,	O
ABL	S-GP
,	O
BCR	S-GP
-	O
ABL	S-GP
,	O
PDGFRA	S-GP
,	O
and	O
PDGFRB	B-GP
,	E-GP
represents	O
a	O
new	O
paradigm	O
of	O
targeted	O
cancer	O
therapy	O
and	O
has	O
revolutionized	O
the	O
treatment	O
of	O
patients	O
with	O
chronic	O
myelogenous	O
leukemia	O
and	O
GISTs	O
.	O
Unfortunately	O
,	O
imatinib	S-chemical
resistance	O
has	O
emerged	O
.	O
The	O
reported	O
mechanism	O
of	O
imatinib	S-chemical
resistance	O
in	O
GISTs	O
involves	O
missense	O
mutation	O
in	O
the	O
kinase	B-GP
domain	E-GP
of	O
KIT	B-GP
,	E-GP
including	O
Thr670Ile	S-GP
,	O
Tyr823Asp	S-GP
,	O
and	O
Val654Ala	S-GP
.	O
The	O
established	O
mechanisms	O
and	O
potential	O
mechanisms	O
of	O
imatinib	S-chemical
resistance	O
in	O
GISTs	O
,	O
the	O
imaging	O
studies	O
indicative	O
of	O
early	O
development	O
of	O
imatinib	S-chemical
resistance	O
,	O
and	O
the	O
management	O
of	O
imatinib	S-chemical
-resistant	O
GISTs	O
are	O
discussed	O
.	O

Transdermal	O
selegiline	S-chemical
for	O
the	O
treatment	O
of	O
major	O
depressive	O
disorder	O
.	O
Non-selective	O
inhibition	O
of	O
monoamine	B-GP
oxidase	E-GP
(	O
MAO	S-GP
)	O
enzymes	O
(	O
ie	O
,	O
isoforms	O
A	O
and	O
B	O
)	O
in	O
the	O
brain	O
are	O
associated	O
with	O
clinically	O
significant	O
antidepressant	O
effects	O
.	O
In	O
the	O
US	O
,	O
the	O
selegiline	S-chemical
transdermal	O
system	O
(	O
STS	O
;	O
EMSAM	O
)	O
is	O
the	O
first	O
antidepressant	O
transdermal	O
delivery	O
system	O
to	O
receive	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
approved	O
labeling	O
for	O
the	O
treatment	O
of	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O
Currently	O
,	O
the	O
use	O
of	O
orally	O
administered	O
MAO	S-GP
inhibitor	O
antidepressants	O
(	O
eg	O
,	O
phenelzine	S-chemical
,	O
tranylcypromine	S-chemical
)	O
is	O
limited	O
by	O
the	O
risk	O
of	O
tyramine	S-chemical
-provoked	O
events	O
(	O
eg	O
,	O
acute	O
hypertension	O
and	O
headache	O
,	O
also	O
known	O
as	O
the	O
``	O
cheese	O
reaction	O
''	O
)	O
when	O
combined	O
with	O
dietary	O
tyramine	S-chemical
.	O
The	O
selegiline	S-chemical
transdermal	O
system	O
is	O
the	O
only	O
MAOI	O
available	O
in	O
the	O
US	O
for	O
the	O
treatment	O
of	O
MDD	O
that	O
does	O
not	O
require	O
dietary	O
restriction	O
at	O
the	O
clinically	O
effective	O
dose	O
of	O
6	O
mg/24	O
hours	O
.	O
Delivery	O
of	O
selegiline	O
transdermally	O
(	O
EMSAM	O
(	O
(	O
R	O
)	O
)	O
)	O
bypasses	O
hepatic	O
first	O
pass	O
metabolism	O
,	O
thereby	O
avoiding	O
significant	O
inhibition	O
of	O
gastrointestinal	O
and	O
hepatic	O
MAO-A	S-GP
activity	O
(	O
ie	O
,	O
reduced	O
risk	O
of	O
tyramine	S-chemical
-provoked	O
events	O
)	O
while	O
still	O
providing	O
sufficient	O
levels	O
of	O
selegiline	S-chemical
in	O
the	O
brain	O
to	O
produce	O
an	O
antidepressant	O
effect	O
.	O
At	O
dosages	O
of	O
6-12	O
mg/24	O
hours	O
,	O
EMSAM	O
has	O
been	O
shown	O
to	O
improve	O
symptoms	O
of	O
depression	O
,	O
have	O
good	O
tolerability	O
,	O
and	O
have	O
high	O
rates	O
of	O
medication	O
adherence	O
.	O
However	O
,	O
at	O
higher	O
doses	O
of	O
EMSAM	O
(	O
ie	O
,	O
9	O
mg/24	O
hours	O
or	O
more	O
)	O
,	O
dietary	O
restriction	O
of	O
tyramine	S-chemical
intake	O
is	O
recommended	O
.	O
The	O
introduction	O
of	O
EMSAM	O
overcomes	O
many	O
of	O
the	O
safety	O
concerns	O
affiliated	O
with	O
the	O
conventional	O
oral	O
MAO	S-GP
inhibitors	O
and	O
EMSAM	O
may	O
be	O
considered	O
another	O
strategy	O
for	O
the	O
treatment	O
of	O
MDD	O
,	O
especially	O
in	O
patients	O
who	O
can	O
not	O
tolerate	O
oral	O
antidepressants	O
,	O
are	O
poorly	O
adherent	O
,	O
who	O
present	O
with	O
atypical	O
depressive	O
symptoms	O
,	O
or	O
have	O
failed	O
other	O
antidepressants	O
.	O

Glutamate	S-chemical
stimulates	O
glutamate	B-GP
receptor	I-GP
interacting	I-GP
protein	I-GP
1	E-GP
degradation	O
by	O
ubiquitin	S-GP
-	O
proteasome	S-GP
system	O
to	O
regulate	O
surface	O
expression	O
of	O
GluR2	S-GP
.	O
The	O
glutamate	B-GP
receptor	I-GP
interacting	I-GP
protein	I-GP
1	E-GP
(	O
GRIP1	S-GP
)	O
is	O
a	O
scaffolding	O
protein	O
in	O
postsynaptic	O
density	O
(	O
PSD	O
)	O
,	O
tethering	O
AMPA	B-GP
receptors	E-GP
to	O
other	O
signaling	O
proteins	O
.	O
Here	O
we	O
report	O
that	O
glutamate	S-chemical
stimulation	O
caused	O
a	O
rapid	O
reduction	O
in	O
protein	O
levels	O
of	O
GRIP1	S-GP
,	O
but	O
not	O
that	O
of	O
glutamate	S-chemical
receptor	O
(	B-GP
GluR	I-GP
)	I-GP
1	E-GP
,	O
GluR2	S-GP
and	O
protein	B-GP
interacting	I-GP
with	I-GP
C	I-GP
kinase	I-GP
1	E-GP
(	O
PICK1	S-GP
)	O
in	O
rat	O
primary	O
cortical	O
neuron	O
cultures	O
.	O
Down-regulation	O
of	O
GRIP1	S-GP
by	O
glutamate	S-chemical
was	O
blocked	O
by	O
carbobenzoxyl-leucinyl-leucinyl-leucinal	S-chemical
(	O
MG132	S-chemical
)	O
,	O
a	O
proteasome	S-GP
inhibitor	O
and	O
by	O
expression	O
of	O
K48R	S-GP
-	O
ubiquitin	S-GP
,	O
a	O
dominant	O
negative	O
form	O
of	O
ubiquitin	S-GP
.	O
The	O
GRIP1	S-GP
reduction	O
was	O
inhibited	O
by	O
MK-801	S-chemical
,	O
an	O
N-methyl-d-aspartate	B-GP
(	I-GP
NMDA	I-GP
)	I-GP
receptor	E-GP
antagonist	O
,	O
but	O
not	O
by	O
6-cyano-7-nitroquinoxaline-2,3-dione	S-chemical
(	O
CNQX	S-chemical
)	O
,	O
an	O
AMPA	B-GP
receptor	E-GP
antagonist	O
.	O
EGTA	S-chemical
and	O
1,2-bis	B-chemical
(	I-chemical
2-aminophenoxy	I-chemical
)	I-chemical
ethane-N	I-chemical
,	I-chemical
N	I-chemical
,	I-chemical
N	I-chemical
'	I-chemical
,	I-chemical
N'-tetra	I-chemical
acetic	I-chemical
acid	I-chemical
tetrakis	E-chemical
(	O
BAPTA	S-chemical
)	O
,	O
two	O
Ca2+	S-chemical
chelators	O
,	O
but	O
not	O
nifedipine	S-chemical
,	O
an	O
L-type	B-GP
Ca2+	I-GP
channel	E-GP
blocker	O
,	O
prevented	O
GRIP1	S-GP
degradation	O
.	O
Furthermore	O
,	O
MG132	S-chemical
prevented	O
glutamate	S-chemical
-stimulated	O
reduction	O
in	O
surface	O
amount	O
of	O
GluR2	S-GP
,	O
and	O
knockdown	O
of	O
GRIP1	S-GP
by	O
RNAi	O
against	O
GRIP1	S-GP
reduced	O
surface	O
GluR2	S-GP
in	O
neurons	O
.	O
Our	O
results	O
suggest	O
that	O
glutamate	S-chemical
induces	O
GRIP1	S-GP
degradation	O
by	O
proteasome	S-GP
through	O
an	O
NMDA	B-GP
receptor	E-GP
-	O
Ca2+	S-chemical
pathway	O
and	O
that	O
GRIP1	S-GP
degradation	O
may	O
play	O
an	O
important	O
role	O
in	O
regulating	O
GluR2	S-GP
surface	O
expression	O
.	O

Valdecoxib	S-chemical
:	O
assessment	O
of	O
cyclooxygenase-2	S-GP
potency	O
and	O
selectivity	O
.	O
The	O
discovery	O
of	O
a	O
second	B-GP
isoform	I-GP
of	I-GP
cyclooxygenase	E-GP
(	O
COX	S-GP
)	O
led	O
to	O
the	O
search	O
for	O
compounds	O
that	O
could	O
selectively	O
inhibit	O
COX-2	S-GP
in	O
humans	O
while	O
sparing	O
prostaglandin	S-chemical
formation	O
from	O
COX-1	S-GP
.	O
Celecoxib	S-chemical
and	O
rofecoxib	S-chemical
were	O
among	O
the	O
molecules	O
developed	O
from	O
these	O
efforts	O
.	O
We	O
report	O
here	O
the	O
pharmacological	O
properties	O
of	O
a	O
third	O
selective	O
COX-2	S-GP
inhibitor	O
,	O
valdecoxib	S-chemical
,	O
which	O
is	O
the	O
most	O
potent	O
and	O
in	O
vitro	O
selective	O
of	O
the	O
marketed	O
COX-2	S-GP
inhibitors	O
that	O
we	O
have	O
studied	O
.	O
Recombinant	O
human	B-GP
COX-1	E-GP
and	O
COX-2	S-GP
were	O
used	O
to	O
screen	O
for	O
new	O
highly	O
potent	O
and	O
in	O
vitro	O
selective	O
COX-2	S-GP
inhibitors	O
and	O
compare	O
kinetic	O
mechanisms	O
of	O
binding	O
and	O
enzyme	O
inhibition	O
with	O
other	O
COX	S-GP
inhibitors	O
.	O
Valdecoxib	S-chemical
potently	O
inhibits	O
recombinant	O
COX-2	S-GP
,	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
0.005	O
microM	O
;	O
this	O
compares	O
with	O
IC	O
values	O
of	O
0.05	O
microM	O
for	O
celecoxib	S-chemical
,	O
0.5	O
microM	O
for	O
rofecoxib	S-chemical
,	O
and	O
5	O
microM	O
for	O
etoricoxib	S-chemical
.	O
Unique	O
binding	O
interactions	O
of	O
valdecoxib	S-chemical
with	O
COX-2	S-GP
translate	O
into	O
a	O
fast	O
rate	O
of	O
inactivation	O
of	O
COX-2	S-GP
(	O
110,000	O
M/s	O
compared	O
with	O
7000	O
M/s	O
for	O
rofecoxib	S-chemical
and	O
80	O
M/s	O
for	O
etoricoxib	S-chemical
)	O
.	O
The	O
overall	O
saturation	O
binding	O
affinity	O
for	O
COX-2	S-GP
of	O
valdecoxib	S-chemical
is	O
2.6	O
nM	O
(	O
compared	O
with	O
1.6	O
nM	O
for	O
celecoxib	S-chemical
,	O
51	O
nM	O
for	O
rofecoxib	S-chemical
,	O
and	O
260	O
nM	O
for	O
etoricoxib	S-chemical
)	O
,	O
with	O
a	O
slow	O
off-rate	O
(	O
t	O
(	O
1/2	O
)	O
approximately	O
98	O
min	O
)	O
.	O
Valdecoxib	S-chemical
inhibits	O
COX-1	S-GP
in	O
a	O
competitive	O
fashion	O
only	O
at	O
very	O
high	O
concentrations	O
(	O
IC	O
(	O
50	O
)	O
=	O
150	O
microM	O
)	O
.	O
Collectively	O
,	O
these	O
data	O
provide	O
a	O
mechanistic	O
basis	O
for	O
the	O
potency	O
and	O
in	O
vitro	O
selectivity	O
of	O
valdecoxib	S-chemical
for	O
COX-2	S-GP
.	O
Valdecoxib	S-chemical
showed	O
similar	O
activity	O
in	O
the	O
human	B-GP
whole-blood	I-GP
COX	E-GP
assay	O
(	O
COX-2	S-GP
IC	O
(	O
50	O
)	O
=	O
0.24	O
microM	O
;	O
COX-1	S-GP
IC	O
(	O
50	O
)	O
=	O
21.9	O
microM	O
)	O
.	O
We	O
also	O
determined	O
whether	O
this	O
in	O
vitro	O
potency	O
and	O
selectivity	O
translated	O
to	O
significant	O
potency	O
in	O
vivo	O
.	O
In	O
rats	O
,	O
valdecoxib	S-chemical
demonstrated	O
marked	O
potency	O
in	O
acute	O
and	O
chronic	O
models	O
of	O
inflammation	O
(	O
air	O
pouch	O
ED	O
(	O
50	O
)	O
=	O
0.06	O
mg/kg	O
;	O
paw	O
edema	O
ED	O
(	O
50	O
)	O
=	O
5.9	O
mg/kg	O
;	O
adjuvant	O
arthritis	O
ED	O
(	O
50	O
)	O
=	O
0.03	O
mg/kg	O
)	O
.	O
In	O
these	O
same	O
animals	O
,	O
COX-1	S-GP
was	O
spared	O
at	O
doses	O
greater	O
than	O
200	O
mg/kg	O
.	O
These	O
data	O
provide	O
a	O
basis	O
for	O
the	O
observed	O
potent	O
anti-inflammatory	O
activity	O
of	O
valdecoxib	S-chemical
in	O
humans	O
.	O

Effect	O
of	O
lintitript	S-chemical
,	O
a	O
new	O
CCK-A	B-GP
receptor	E-GP
antagonist	O
,	O
on	O
gastric	O
emptying	O
of	O
a	O
solid-liquid	O
meal	O
in	O
humans	O
.	O
The	O
role	O
of	O
cholecystokinin	S-GP
(	O
CCK	S-GP
)	O
in	O
the	O
regulation	O
of	O
gastric	O
emptying	O
of	O
physiological	O
meals	O
containing	O
solids	O
and	O
liquids	O
in	O
humans	O
remains	O
controversial	O
.	O
We	O
studied	O
the	O
role	O
of	O
endogenous	O
CCK	S-GP
in	O
the	O
emptying	O
of	O
a	O
solid/liquid	O
meal	O
administering	O
the	O
new	O
,	O
highly	O
specific	O
and	O
potent	O
CCK-A	B-GP
receptor	E-GP
antagonist	O
lintitript	S-chemical
.	O
Gastric	O
emptying	O
was	O
assessed	O
in	O
nine	O
healthy	O
male	O
volunteers	O
using	O
a	O
randomized	O
,	O
double	O
blind	O
,	O
two-period	O
crossover	O
design	O
with	O
oral	O
lintitript	S-chemical
(	O
15	O
mg	O
1	O
h	O
prior	O
to	O
meal	O
intake	O
)	O
or	O
placebo	O
on	O
two	O
different	O
days	O
.	O
After	O
ingestion	O
of	O
a	O
pancake	O
(	O
570	O
kcal	O
)	O
labelled	O
with	O
500	O
microCi	O
of	O
99mTc-sulfur	S-chemical
colloid	O
and	O
500	O
ml	O
10	O
%	O
dextrose	O
containing	O
80	O
microCi	O
.	O
111In-DTPA	S-chemical
,	O
subjects	O
were	O
studied	O
in	O
a	O
sitting	O
position	O
,	O
using	O
a	O
dual-headed	O
gamma	O
camera	O
.	O
Plasma	O
CCK	S-GP
and	O
pancreatic	B-GP
polypeptide	E-GP
(	O
PP	S-GP
)	O
were	O
measured	O
by	O
a	O
specific	O
RIA	O
.	O
Lintitript	S-chemical
distinctly	O
accelerated	O
gastric	O
emptying	O
of	O
solids	O
,	O
while	O
gastric	O
emptying	O
of	O
liquids	O
was	O
not	O
significantly	O
altered	O
.	O
The	O
lag	O
period	O
was	O
shortened	O
by	O
20	O
%	O
(	O
P	O
<	O
0.05	O
)	O
,	O
AUC	O
and	O
half	O
emptying	O
time	O
of	O
solid	O
emptying	O
were	O
lowered	O
by	O
12	O
%	O
and	O
13	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0.03	O
)	O
.	O
Lintitript	S-chemical
markedly	O
increased	O
postprandial	O
plasma	O
CCK	S-GP
release	O
(	O
P	O
<	O
0.001	O
)	O
while	O
distinctly	O
reducing	O
postprandial	O
PP	S-GP
levels	O
(	O
P	O
<	O
0.01	O
)	O
as	O
compared	O
to	O
placebo	O
.	O
These	O
data	O
provide	O
further	O
evidence	O
for	O
a	O
significant	O
role	O
of	O
CCK	S-GP
in	O
the	O
regulation	O
of	O
gastric	O
emptying	O
of	O
solids	O
.	O
The	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
the	O
marked	O
gastrokinetic	O
properties	O
of	O
the	O
new	O
CCK-A	B-GP
receptor	E-GP
antagonist	O
lintitript	S-chemical
in	O
humans	O
.	O

Incretin	S-GP
and	O
pancreatic	O
hormone	O
secretion	O
in	O
Caucasian	O
non-diabetic	O
carriers	O
of	O
the	O
TCF7L2	S-GP
rs7903146	O
risk	O
T	O
allele	O
.	O
We	O
characterised	O
62	O
non-diabetic	O
,	O
middle-aged	O
,	O
Caucasians	O
with	O
and	O
without	O
the	O
T	O
risk	O
allele	O
of	O
rs7903146	O
in	O
transcription	B-GP
factor	I-GP
7-like	I-GP
2	E-GP
(	O
TCF7L2	S-GP
)	O
with	O
regard	O
to	O
secretion	O
of	O
insulin	S-GP
,	O
glucagon	S-GP
,	O
glucose-dependent	B-GP
insulinotropic	I-GP
polypeptide	E-GP
(	O
GIP	S-GP
)	O
,	O
glucagon-like	B-GP
peptide-1	E-GP
(	O
GLP-1	S-GP
)	O
as	O
well	O
as	O
insulin	S-GP
sensitivity	O
and	O
endogenous	O
glucose	S-chemical
production	O
.	O
All	O
participants	O
had	O
a	O
3-h	O
oral	O
glucose	S-chemical
tolerance	O
test	O
(	O
OGTT	O
)	O
,	O
an	O
intravenous	O
glucose	S-chemical
tolerance	O
test	O
and	O
a	O
euglycaemic	O
,	O
hyperinsulinaemic	O
clamp	O
.	O
After	O
adjustment	O
for	O
age	O
and	O
sex	O
,	O
risk	O
T	O
allele	O
carriers	O
had	O
higher	O
haemoglobin	B-GP
A1c	E-GP
levels	O
(	O
p	O
=	O
0.030	O
)	O
,	O
reduced	O
first-phase	O
insulin	S-GP
response	O
(	O
p	O
=	O
0.048	O
)	O
,	O
higher	O
peripheral	O
insulin	S-GP
sensitivity	O
(	O
p	O
=	O
0.050	O
)	O
and	O
lower	O
fasting	O
GIP	S-GP
concentrations	O
(	O
p	O
=	O
0.003	O
)	O
than	O
CC	O
allele	O
carriers	O
.	O
The	O
latter	O
was	O
also	O
reflected	O
by	O
lower	O
total	O
GIP	S-GP
secretion	O
during	O
the	O
OGTT	O
(	O
p	O
=	O
0.018	O
)	O
.	O
We	O
found	O
no	O
significant	O
differences	O
in	O
endogenous	O
glucose	S-chemical
production	O
,	O
hepatic	O
insulin	S-GP
sensitivity	O
or	O
fasting	O
concentrations	O
of	O
glucose	S-chemical
,	O
insulin	S-GP
,	O
glucagon	S-GP
and	O
GLP-1	S-GP
between	O
the	O
groups	O
.	O
The	O
findings	O
suggest	O
that	O
the	O
effect	O
of	O
TCF7L2	S-GP
on	O
diabetes	O
risk	O
may	O
include	O
reduced	O
secretion	O
of	O
GIP	S-GP
.	O

Decreased	O
intracellular	O
proteolysis	O
correlates	O
with	O
the	O
maintenance	O
of	O
a	O
specific	O
isoenzyme	O
of	O
cytochrome	B-GP
P-450	E-GP
.	O
The	O
rates	O
of	O
intracellular	O
protein	O
degradation	O
,	O
of	O
identically	O
labelled	O
populations	O
of	O
proteins	O
,	O
were	O
compared	O
in	O
hepatocytes	O
cultured	O
at	O
37	O
degrees	O
(	O
on	O
an	O
adsorbed	O
collagen	O
layer	O
)	O
and	O
in	O
cells	O
preserved	O
on	O
gelatin	O
gels	O
at	O
10	O
degrees	O
C.	O
The	O
half-lives	O
of	O
the	O
long-lived	O
proteins	O
were	O
35.4+/-8.6	O
h	O
(	O
N=4	O
)	O
and	O
692.9+/-216.9	O
h	O
(	O
N=4	O
)	O
respectively	O
.	O
Proteolysis	O
was	O
substantially	O
decreased	O
at	O
10	O
degrees	O
C	O
but	O
the	O
rate	O
of	O
decrease	O
remained	O
constant	O
.	O
Hepatocytes	O
rapidly	O
removed	O
resorufin	S-chemical
from	O
the	O
culture	O
medium	O
.	O
The	O
resorufin	S-chemical
was	O
not	O
being	O
conjugated	O
or	O
accumulated	O
within	O
the	O
cells	O
.	O
Dicumarol	S-chemical
,	O
a	O
potent	O
inhibitor	O
of	O
quinone	B-GP
oxidoreductase	E-GP
,	O
at	O
high	O
concentration	O
(	O
500	O
microm	O
)	O
caused	O
only	O
a	O
72	O
%	O
decrease	O
in	O
the	O
utilization	O
of	O
resorufin	S-chemical
.	O
The	O
microsomal	O
detoxifying	O
enzyme	O
,	O
cytochrome	B-GP
P-450	I-GP
1A1	E-GP
remained	O
at	O
a	O
constant	O
level	O
in	O
the	O
preserved	O
hepatocyte	O
monolayers	O
.	O
The	O
results	O
of	O
this	O
study	O
strongly	O
favour	O
storing	O
hepatocytes	O
at	O
10	O
degrees	O
C	O
rather	O
than	O
at	O
4	O
degrees	O
or	O
37	O
degrees	O
C	O
.	O

Hybrid	O
carbon	S-chemical
nanotube	O
networks	O
as	O
efficient	O
hole	O
extraction	O
layers	O
for	O
organic	O
photovoltaics	O
.	O
Transparent	O
,	O
highly	O
percolated	O
networks	O
of	O
regioregular	O
poly	B-chemical
(	I-chemical
3-hexylthiophene	I-chemical
)	E-chemical
(	O
rr-	O
P3HT	S-chemical
)	O
-wrapped	O
semiconducting	O
single-walled	O
carbon	S-chemical
nanotubes	O
(	O
s-SWNTs	O
)	O
are	O
deposited	O
,	O
and	O
the	O
charge	O
transfer	O
processes	O
of	O
these	O
nanohybrids	O
are	O
studied	O
using	O
spectroscopic	O
and	O
electrical	O
measurements	O
.	O
The	O
data	O
disclose	O
hole	O
doping	O
of	O
s-SWNTs	O
by	O
the	O
polymer	O
,	O
challenging	O
the	O
prevalent	O
electron-doping	O
hypothesis	O
.	O
Through	O
controlled	O
fabrication	O
,	O
high-	O
to	O
low-density	O
nanohybrid	O
networks	O
are	O
achieved	O
,	O
with	O
low-density	O
hybrid	O
carbon	S-chemical
nanotube	O
networks	O
tested	O
as	O
hole	O
transport	O
layers	O
(	O
HTLs	O
)	O
for	O
bulk	O
heterojunction	O
(	O
BHJ	O
)	O
organic	O
photovoltaics	O
(	O
OPV	O
)	O
.	O
OPVs	O
incorporating	O
these	O
rr-	O
P3HT	S-chemical
/s-SWNT	O
networks	O
as	O
the	O
HTL	O
demonstrate	O
the	O
best	O
large	O
area	O
(	O
70	O
mm	O
(	O
2	O
)	O
)	O
carbon	S-chemical
nanotube	O
incorporated	O
organic	O
solar	O
cells	O
to	O
date	O
with	O
a	O
power	O
conversion	O
efficiency	O
of	O
7.6	O
%	O
.	O
This	O
signifies	O
the	O
strong	O
capability	O
of	O
nanohybrids	O
as	O
an	O
efficient	O
hole	O
extraction	O
layer	O
,	O
and	O
we	O
believe	O
that	O
dense	O
nanohybrid	O
networks	O
have	O
the	O
potential	O
to	O
replace	O
expensive	O
and	O
material	O
scarce	O
inorganic	O
transparent	O
electrodes	O
in	O
large	O
area	O
electronics	O
toward	O
the	O
realization	O
of	O
low-cost	O
flexible	O
electronics	O
.	O

Inhibition	O
of	O
5-lipoxygenase	S-GP
pathway	O
of	O
arachidonic	B-chemical
acid	E-chemical
metabolism	O
in	O
human	O
neutrophils	O
by	O
sulfasalazine	S-chemical
and	O
5-aminosalicylic	B-chemical
acid	E-chemical
.	O
The	O
possible	O
effect	O
of	O
sulfasalazine	S-chemical
,	O
5-aminosalicylic	B-chemical
acid	E-chemical
,	O
and	O
acetyl-5-aminosalicylic	B-chemical
acid	E-chemical
on	O
endogenous	O
arachidonic	B-chemical
acid	E-chemical
release	O
and	O
metabolism	O
was	O
studied	O
in	O
human	O
polymorphonuclear	O
leukocytes	O
(	O
PMNs	O
)	O
.	O
A	O
new	O
in	O
vitro	O
assay	O
was	O
used	O
by	O
which	O
[	B-chemical
1-14C	I-chemical
]	I-chemical
arachidonic	I-chemical
acid	E-chemical
is	O
incorporated	O
by	O
purified	O
peripheral	O
PMNs	O
until	O
steady	O
state	O
was	O
obtained	O
(	O
5	O
hr	O
)	O
.	O
After	O
preincubation	O
with	O
the	O
test	O
drugs	O
prior	O
to	O
activation	O
with	O
calcium	B-chemical
ionophore	I-chemical
A23187	E-chemical
,	O
the	O
released	O
eicosanoids	S-chemical
were	O
isolated	O
by	O
extraction	O
and	O
thin-layer	O
chromatography	O
(	O
TLC	O
)	O
and	O
quantitated	O
by	O
autoradiography	O
and	O
laser	O
densitometry	O
.	O
Median	O
drug	O
concentrations	O
needed	O
for	O
50	O
%	O
inhibition	O
of	O
leukotriene	B-chemical
B4	E-chemical
and	O
5-hydroxyeicosatetraenoic	B-chemical
acid	E-chemical
(	O
5-HETE	S-chemical
)	O
release	O
was	O
4-5	O
mM	O
(	O
range	O
1-9	O
mM	O
)	O
for	O
both	O
sulfasalazine	S-chemical
and	O
5-aminosalicylic	B-chemical
acid	E-chemical
.	O
The	O
acetylated	B-chemical
derivative	I-chemical
of	I-chemical
5-aminosalicylic	I-chemical
acid	E-chemical
was	O
ineffective	O
.	O
The	O
present	O
data	O
suggest	O
that	O
inhibition	O
of	O
arachidonic	B-chemical
acid	E-chemical
lipoxygenation	O
may	O
be	O
an	O
essential	O
action	O
of	O
sulfasalazine	S-chemical
and	O
its	O
active	O
metabolite	O
,	O
5-aminosalicylic	B-chemical
acid	E-chemical
.	O
Interference	O
with	O
lipoxygenase	S-GP
enzymes	O
,	O
rather	O
than	O
a	O
steroid	S-chemical
-like	O
inhibition	O
of	O
arachidonic	B-chemical
acid	E-chemical
release	O
from	O
intracellular	O
phospholipids	O
,	O
seems	O
to	O
be	O
the	O
mode	O
of	O
action	O
.	O

Inhibition	O
of	O
phosphatidylserine	O
biosynthesis	O
in	O
developing	O
rat	O
brain	O
by	O
maternal	O
exposure	O
to	O
ethanol	S-chemical
.	O
Phosphatidylserine	O
(	O
PtdSer	O
)	O
,	O
major	O
acidic	O
phospholipids	O
in	O
neuronal	O
membranes	O
,	O
participate	O
in	O
important	O
cell	O
signaling	O
processes	O
.	O
The	O
PtdSer	O
in	O
brain	O
is	O
highly	O
enriched	O
with	O
docosahexaenoic	B-chemical
acid	E-chemical
(	O
DHA	S-chemical
;	O
22:6n-3	O
)	O
,	O
and	O
the	O
DHA	S-chemical
status	O
or	O
ethanol	S-chemical
exposure	O
has	O
been	O
shown	O
to	O
influence	O
the	O
PtdSer	O
level	O
.	O
This	O
study	O
shows	O
that	O
ethanol	S-chemical
exposure	O
during	O
prenatal	O
and	O
developmental	O
period	O
significantly	O
attenuates	O
microsomal	O
PtdSer	O
biosynthetic	O
activities	O
and	O
reduces	O
PtdSer	O
,	O
particularly	O
18:0	O
,	O
22:6-PtdSer	O
,	O
in	O
developing	O
rat	O
brain	O
cortices	O
.	O
Brain	O
microsomes	O
were	O
incubated	O
with	O
deuterium	S-chemical
labeled	O
exogenous	O
substrates	O
in	O
vitro	O
and	O
the	O
products	O
formed	O
were	O
detected	O
by	O
reversed	O
phase	O
HPLC-electrospray	O
ionization	O
mass	O
spectrometry	O
(	O
ESI-MS	O
)	O
.	O
These	O
in	O
vitro	O
bioassays	O
showed	O
that	O
1-stearoyl-2-docosahexaenoyl	S-chemical
(	O
18:0	O
,	O
22:6	O
)	O
species	O
is	O
the	O
best	O
substrate	O
for	O
PtdSer	O
synthesis	O
from	O
both	O
phosphatidylcholine	S-chemical
(	O
PtdCho	S-chemical
)	O
and	O
phosphatidylethanolamine	S-chemical
(	O
PtdEtn	S-chemical
)	O
.	O
The	O
PtdSer	O
biosynthetic	O
activity	O
of	O
brain	O
,	O
especially	O
for	O
18:0	O
,	O
22:6-PtdSer	O
production	O
,	O
was	O
hampered	O
significantly	O
by	O
maternal	O
exposure	O
to	O
ethanol	S-chemical
.	O
PtdSer	O
levels	O
were	O
consistently	O
reduced	O
significantly	O
in	O
brain	O
cortices	O
of	O
the	O
pups	O
from	O
ethanol	S-chemical
-exposed	O
dams	O
,	O
due	O
mainly	O
to	O
the	O
depletion	O
of	O
18:0	O
,	O
22:6-PtdSer	O
.	O
The	O
mRNA	O
expression	O
of	O
PtdSer	B-GP
synthase	I-GP
1	E-GP
(	O
PSS1	S-GP
)	O
and	O
PtdSer	B-GP
synthase	I-GP
2	E-GP
(	O
PSS2	S-GP
)	O
was	O
not	O
reduced	O
by	O
ethanol	S-chemical
.	O
Similarly	O
,	O
the	O
PSS1	S-GP
enzyme	O
level	O
did	O
not	O
change	O
after	O
ethanol	S-chemical
exposure	O
but	O
PSS2	S-GP
could	O
not	O
be	O
probed	O
with	O
the	O
antibody	O
available	O
currently	O
.	O
Degradation	O
of	O
PtdSer	O
by	O
mitochondrial	O
PtdSer	O
decarboxylation	O
was	O
not	O
enhanced	O
but	O
also	O
inhibited	O
.	O
Taken	O
together	O
,	O
attenuated	O
PtdSer	O
biosynthetic	O
activities	O
are	O
largely	O
responsible	O
for	O
the	O
PtdSer	O
reduction	O
observed	O
in	O
developing	O
rat	O
brains	O
after	O
maternal	O
exposure	O
to	O
ethanol	S-chemical
.	O

Compensatory	O
changes	O
in	O
enzymes	O
of	O
arginine	S-chemical
metabolism	O
during	O
renal	O
hypertrophy	O
in	O
mice	O
.	O
The	O
present	O
study	O
investigates	O
enzyme	O
activities	O
of	O
the	O
urea	O
cycle	O
,	O
transamidinase	S-GP
and	O
ornithine	S-chemical
-	O
proline	S-chemical
inter-conversion	O
in	O
the	O
hypertrophied	O
kidney	O
after	O
unilateral	O
nephrectomy	O
in	O
mice	O
.	O
Surgical	O
removal	O
of	O
the	O
left	O
kidney	O
in	O
mice	O
led	O
to	O
compensatory	O
enlargement	O
of	O
the	O
right	O
kidney	O
after	O
1	O
and	O
14	O
days	O
.	O
This	O
renal	O
growth	O
was	O
associated	O
with	O
an	O
increase	O
in	O
glomerular	O
volume	O
(	O
but	O
not	O
number	O
)	O
and	O
enlargement	O
of	O
the	O
proximal	O
convoluted	O
tubules	O
.	O
The	O
total	O
renal	O
protein	O
content	O
increased	O
in	O
proportion	O
to	O
the	O
increase	O
in	O
kidney	O
weight	O
,	O
but	O
the	O
protein	O
per	O
gram	O
weight	O
of	O
kidney	O
did	O
not	O
change	O
.	O
The	O
specific	O
activity	O
of	O
only	O
ornithine	B-GP
aminotransferase	E-GP
(	O
OAT	S-GP
)	O
,	O
the	O
rate-limiting	O
enzyme	O
in	O
the	O
conversion	O
of	O
ornithine	S-chemical
to	O
proline	S-chemical
,	O
increased	O
in	O
2	O
weeks	O
of	O
hypertrophy	O
.	O
The	O
specific	O
activity	O
of	O
all	O
other	O
enzymes	O
was	O
unchanged	O
.	O
However	O
,	O
the	O
total	O
enzyme	O
activity	O
per	O
kidney	O
of	O
all	O
the	O
enzymes	O
,	O
without	O
exception	O
,	O
was	O
elevated	O
in	O
the	O
hypertrophied	O
kidney	O
.	O
While	O
the	O
increase	O
in	O
total	O
OAT	S-GP
activity	O
was	O
much	O
more	O
than	O
the	O
increase	O
in	O
kidney	O
weight	O
,	O
all	O
other	O
enzymes	O
increased	O
more	O
or	O
less	O
in	O
proportion	O
to	O
the	O
increase	O
in	O
renal	O
mass	O
.	O
The	O
results	O
suggest	O
that	O
compensation	O
in	O
OAT	S-GP
activity	O
to	O
chronic	O
reduction	O
in	O
renal	O
mass	O
was	O
complete	O
,	O
but	O
only	O
partial	O
in	O
the	O
case	O
of	O
other	O
enzymes	O
.	O

On	O
the	O
relationship	O
between	O
the	O
dopamine	B-GP
transporter	E-GP
and	O
the	O
reinforcing	O
effects	O
of	O
local	O
anesthetics	O
in	O
rhesus	O
monkeys	O
:	O
practical	O
and	O
theoretical	O
concerns	O
.	O
RATIONALE	O
:	O
Drugs	O
that	O
are	O
self-administered	O
appear	O
to	O
vary	O
in	O
their	O
potency	O
and	O
effectiveness	O
as	O
positive	O
reinforcers	O
.	O
Understanding	O
mechanisms	O
that	O
determine	O
relative	O
effectiveness	O
of	O
drugs	O
as	O
reinforcers	O
will	O
enhance	O
our	O
understanding	O
of	O
drug	O
abuse	O
.	O
OBJECTIVES	O
:	O
The	O
hypothesis	O
of	O
the	O
present	O
study	O
was	O
that	O
differences	O
among	O
dopamine	B-GP
transporter	E-GP
(	O
DAT	S-GP
)	O
ligands	O
in	O
potency	O
and	O
effectiveness	O
as	O
a	O
positive	O
reinforcers	O
were	O
related	O
to	O
potency	O
and	O
effectiveness	O
as	O
DA	S-chemical
uptake	O
inhibitors	O
.	O
Accordingly	O
,	O
self-administration	O
of	O
a	O
group	O
of	O
local	O
anesthetics	O
that	O
are	O
DAT	S-GP
ligands	O
was	O
compared	O
to	O
their	O
effects	O
as	O
DA	S-chemical
uptake	O
blockers	O
in	O
vitro	O
in	O
brain	O
tissue	O
.	O
METHODS	O
:	O
Rhesus	O
monkeys	O
were	O
allowed	O
to	O
self-administer	O
cocaine	S-chemical
and	O
other	O
local	O
anesthetics	O
i.v	O
.	O
under	O
a	O
progressive-ratio	O
schedule	O
.	O
The	O
same	O
compounds	O
were	O
compared	O
in	O
standard	O
in	O
vitro	O
DA	S-chemical
uptake	O
assays	O
using	O
monkey	O
caudate	O
tissue	O
.	O
RESULTS	O
:	O
The	O
rank	O
order	O
of	O
both	O
potency	O
and	O
effectiveness	O
as	O
reinforcers	O
was	O
cocaine	S-chemical
>	O
dimethocaine	S-chemical
>	O
procaine	S-chemical
>	O
chloroprocaine	S-chemical
.	O
Tetracaine	S-chemical
did	O
not	O
maintain	O
self-administration	O
.	O
For	O
inhibiting	O
DA	S-chemical
uptake	O
,	O
the	O
potency	O
order	O
was	O
cocaine	S-chemical
>	O
dimethocaine	S-chemical
>	O
tetracaine	S-chemical
>	O
procaine	S-chemical
>	O
chloro-procaine	S-chemical
.	O
At	O
maximum	O
,	O
these	O
compounds	O
were	O
equally	O
effective	O
in	O
blocking	O
DA	S-chemical
uptake	O
.	O
Lidocaine	S-chemical
did	O
not	O
inhibit	O
DA	S-chemical
uptake	O
.	O
CONCLUSIONS	O
:	O
The	O
potency	O
of	O
local	O
anesthetics	O
as	O
positive	O
reinforcers	O
is	O
likely	O
related	O
to	O
their	O
potency	O
as	O
DA	S-chemical
uptake	O
inhibitors	O
.	O
Variation	O
in	O
their	O
effectiveness	O
as	O
positive	O
reinforcers	O
was	O
not	O
a	O
function	O
of	O
differences	O
in	O
effectiveness	O
as	O
DA	S-chemical
uptake	O
blockers	O
,	O
but	O
may	O
be	O
related	O
to	O
relative	O
potency	O
over	O
the	O
concentrations	O
that	O
are	O
achieved	O
in	O
vivo	O
.	O
Effects	O
at	O
sodium	B-GP
channels	E-GP
may	O
limit	O
the	O
reinforcing	O
effects	O
of	O
local	O
anesthetics	O
.	O

The	O
effect	O
of	O
triclosan	S-chemical
on	O
mediators	O
of	O
gingival	O
inflammation	O
.	O
Triclosan	S-chemical
(	O
2,4,4	B-chemical
'	I-chemical
,	I-chemical
-trichloro-2'-hydroxydiphenylether	E-chemical
)	O
is	O
a	O
well-known	O
and	O
widely	O
used	O
nonionic	O
antibacterial	O
agent	O
which	O
has	O
recently	O
been	O
introduced	O
in	O
toothpastes	O
and	O
mouthrinses	O
.	O
The	O
efficacy	O
of	O
triclosan	S-chemical
-containing	O
toothpaste	O
and	O
mouthrinse	O
to	O
reduce	O
both	O
plaque	O
and	O
gingivitis	O
in	O
long-term	O
clinical	O
trials	O
has	O
been	O
well	O
documented	O
.	O
Until	O
recently	O
,	O
it	O
was	O
generally	O
assumed	O
that	O
triclosan	S-chemical
's	O
effect	O
on	O
gingival	O
inflammation	O
was	O
due	O
to	O
its	O
antimicrobial	O
and	O
anti-plaque	O
effect	O
.	O
It	O
has	O
now	O
become	O
apparent	O
that	O
triclosan	S-chemical
may	O
have	O
a	O
direct	O
anti-inflammatory	O
effect	O
on	O
the	O
gingival	O
tissues	O
.	O
Several	O
in	O
vitro	O
studies	O
were	O
conducted	O
to	O
evaluate	O
the	O
effect	O
of	O
triclosan	O
on	O
4	O
primary	O
enzymes	O
of	O
the	O
pathways	O
of	O
arachidonic	B-chemical
acid	E-chemical
metabolism	O
,	O
cyclo-oxygenase	B-GP
1	E-GP
,	O
cyclo-oxygenase	B-GP
2	E-GP
,	O
5-lipoxygenase	S-GP
and	O
15-lipoxygenase	S-GP
.	O
These	O
pathways	O
lead	O
to	O
the	O
production	O
of	O
known	O
mediators	O
of	O
inflammation	O
such	O
as	O
the	O
prostaglandins	S-chemical
,	O
leukotrienes	S-chemical
and	O
lipoxins	S-chemical
.	O
Triclosan	S-chemical
inhibited	O
both	O
cyclooxygenase	B-GP
1	E-GP
and	O
cyclo-oxygenase	B-GP
2	E-GP
with	O
IC-50	O
values	O
of	O
43	O
microM	O
and	O
227	O
microM	O
,	O
respectively	O
.	O
Triclosan	S-chemical
also	O
inhibited	O
5-lipoxygenase	S-GP
with	O
an	O
IC-50	O
of	O
43	O
microM	O
.	O
The	O
15-lipoxygenase	S-GP
was	O
similarly	O
inhibited	O
by	O
triclosan	S-chemical
with	O
an	O
IC-50	O
of	O
61	O
microM	O
.	O
Hence	O
,	O
triclosan	S-chemical
has	O
the	O
ability	O
to	O
inhibit	O
both	O
the	O
cyclo-oxygenase	S-GP
and	O
lipoxygenase	S-GP
pathways	O
of	O
arachidonic	B-chemical
acid	E-chemical
metabolism	O
with	O
similar	O
efficacy	O
.	O
In	O
cell	O
culture	O
experiments	O
,	O
it	O
was	O
found	O
that	O
triclosan	S-chemical
inhibited	O
IL-1	B-GP
beta	E-GP
induced	O
prostaglandin	B-chemical
E2	E-chemical
production	O
by	O
human	O
gingival	O
fibroblasts	O
in	O
a	O
concentration	O
dependent	O
manner	O
,	O
and	O
at	O
relatively	O
low	O
concentrations	O
.	O
These	O
data	O
,	O
taken	O
together	O
,	O
indicate	O
that	O
triclosan	S-chemical
can	O
inhibit	O
formation	O
of	O
several	O
important	O
mediators	O
of	O
gingival	O
inflammation	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Low	O
incidence	O
of	O
paradoxical	O
platelet	O
activation	O
by	O
glycoprotein	B-GP
IIb/IIIa	E-GP
inhibitors	O
.	O
The	O
human	B-GP
platelet	I-GP
antigen-1	E-GP
(	O
HPA-1	S-GP
,	O
Pl	B-GP
(	I-GP
A	I-GP
)	E-GP
)	O
polymorphism	O
has	O
been	O
proposed	O
to	O
influence	O
the	O
inhibitory	O
actions	O
of	O
abciximab	O
.	O
Thus	O
,	O
we	O
hypothesized	O
that	O
this	O
polymorphism	O
might	O
also	O
be	O
the	O
cause	O
for	O
paradoxical	O
activation	O
of	O
platelets	O
by	O
GPIIb/IIIa	S-GP
inhibitors	O
.	O
The	O
effects	O
of	O
abciximab	O
(	O
1-10	O
microg/ml	O
)	O
,	O
tirofiban	S-chemical
(	O
3-30	O
nM	O
)	O
,	O
or	O
eptifibatide	S-chemical
(	O
0.3-3	O
microg/ml	O
)	O
on	O
basal	O
and	O
ADP	S-chemical
(	O
3	O
microM	O
)	O
-induced	O
CD62P	S-GP
externalization	O
were	O
measured	O
in	O
n=62	O
healthy	O
blood	O
donors	O
and	O
n=177	O
patients	O
with	O
stable	O
coronary	O
artery	O
disease	O
.	O
All	O
subjects	O
were	O
genotyped	O
for	O
the	O
human	B-GP
platelet	I-GP
antigen-1	E-GP
(	O
HPA-1	S-GP
,	O
Pl	B-GP
(	I-GP
A	I-GP
)	E-GP
)	O
polymorphism	O
by	O
GALIOS	O
(	O
R	O
)	O
and	O
fluorescence	O
correlation	O
spectroscopy	O
.	O
Although	O
a	O
significant	O
platelet	O
hyperreactivity	O
was	O
observed	O
in	O
the	O
patients	O
,	O
the	O
HPA-1	S-GP
genotype	O
did	O
not	O
influence	O
basal	O
or	O
ADP	S-chemical
-induced	O
CD62P	S-GP
expression	O
.	O
A	O
moderate	O
(	O
twofold	O
)	O
stimulation	O
of	O
CD62P	S-GP
expression	O
by	O
abciximab	O
but	O
not	O
by	O
tirofiban	S-chemical
or	O
eptifibatide	S-chemical
was	O
observed	O
in	O
one	O
patient	O
.	O
Interestingly	O
,	O
this	O
patient	O
carried	O
the	O
HPA-1	S-GP
b/b	O
genotype	O
.	O
In	O
no	O
other	O
subject	O
any	O
activation	O
of	O
platelets	O
by	O
GP	B-GP
IIb/IIIa	E-GP
inhibitors	O
was	O
observed	O
and	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
HPA-1	S-GP
genotypes	O
with	O
respect	O
to	O
the	O
effects	O
of	O
GP	B-GP
IIb/IIIa	E-GP
inhibitors	O
on	O
basal	O
or	O
ADP	S-chemical
-stimulated	O
CD62P	S-GP
expression	O
.	O
It	O
is	O
concluded	O
that	O
paradoxical	O
platelet	O
activation	O
by	O
abciximab	O
is	O
a	O
rare	O
(	O
<	O
2	O
%	O
)	O
phenomenon	O
.	O
HPA-1	S-GP
b/b	O
genotype	O
might	O
be	O
a	O
contributing	O
factor	O
but	O
clearly	O
does	O
not	O
predict	O
platelet	O
activation	O
by	O
GP	B-GP
IIb/IIIa	E-GP
inhibitors	O
.	O

Effect	O
of	O
long-term	O
fluoxetine	S-chemical
treatment	O
on	O
the	O
human	B-GP
serotonin	I-GP
transporter	E-GP
in	O
Caco-2	O
cells	O
.	O
Fluoxetine	S-chemical
is	O
a	O
selective	O
serotonin	S-chemical
reuptake	O
inhibitor	O
(	O
SSRI	O
)	O
broadly	O
used	O
in	O
the	O
treatment	O
of	O
human	O
mood	O
disorders	O
and	O
gastrointestinal	O
diseases	O
involving	O
the	O
serotoninergic	O
system	O
.	O
The	O
effectiveness	O
of	O
this	O
therapy	O
depends	O
on	O
repeated	O
long-term	O
treatment	O
.	O
Most	O
of	O
the	O
long-term	O
studies	O
in	O
vivo	O
of	O
SSRI	O
effects	O
on	O
serotoninergic	O
activity	O
have	O
focused	O
on	O
their	O
effects	O
on	O
autoreceptors	O
or	O
postsynaptic	O
receptors	O
.	O
The	O
chronic	O
effect	O
of	O
SSRIs	O
on	O
the	O
activity	O
of	O
the	O
serotonin	B-GP
transporter	E-GP
(	O
SERT	S-GP
)	O
has	O
been	O
less	O
studied	O
and	O
the	O
results	O
have	O
been	O
contradictory	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
specific	O
effect	O
of	O
long-term	O
fluoxetine	S-chemical
treatment	O
on	O
human	B-GP
serotonin	I-GP
transporter	E-GP
(	O
hSERT	S-GP
)	O
in	O
vitro	O
,	O
by	O
using	O
the	O
human	O
enterocyte-like	O
cell	O
line	O
Caco-2	O
.	O
Results	O
show	O
that	O
fluoxetine	S-chemical
diminished	O
the	O
5-HT	S-chemical
uptake	O
in	O
a	O
concentration-dependent	O
way	O
and	O
that	O
this	O
effect	O
was	O
reversible	O
.	O
Fluoxetine	S-chemical
affected	O
mainly	O
the	O
hSERT	S-GP
transport	O
rate	O
by	O
reducing	O
the	O
availability	O
of	O
the	O
transporter	O
in	O
the	O
membrane	O
with	O
no	O
significant	O
alteration	O
of	O
either	O
the	O
total	O
hSERT	S-GP
protein	O
content	O
or	O
the	O
hSERT	S-GP
mRNA	O
level	O
.	O
These	O
results	O
suggest	O
that	O
the	O
effect	O
of	O
fluoxetine	S-chemical
on	O
the	O
expression	O
of	O
hSERT	S-GP
is	O
post-translational	O
and	O
has	O
shown	O
itself	O
to	O
be	O
independent	O
of	O
PKC	S-GP
and	O
PKA	S-GP
activity	O
.	O
This	O
study	O
may	O
be	O
useful	O
to	O
clarify	O
the	O
effect	O
of	O
the	O
long-term	O
fluoxetine	S-chemical
therapy	O
in	O
both	O
gastrointestinal	O
and	O
central	O
nervous	O
system	O
disorders	O
.	O

Effects	O
of	O
the	O
antidepressant/antipanic	O
drug	O
phenelzine	S-chemical
on	O
alanine	S-chemical
and	O
alanine	B-GP
transaminase	E-GP
in	O
rat	O
brain	O
.	O
1	O
.	O
Phenelzine	S-chemical
(	O
PLZ	S-chemical
)	O
is	O
an	O
antidepressant	O
with	O
anxiolytic	O
properties	O
.	O
Acute	O
and	O
chronic	O
PLZ	S-chemical
administration	O
increase	O
brain	O
GABA	S-chemical
levels	O
,	O
an	O
effect	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
an	O
inhibition	O
of	O
the	O
activity	O
of	O
the	O
GABA	S-chemical
metabolizing	O
enzyme	O
,	O
GABA	B-GP
transaminase	E-GP
(	O
GABA-T	S-GP
)	O
.	O
2	O
.	O
Previous	O
preliminary	O
reports	O
have	O
indicated	O
that	O
acute	O
PLZ	S-chemical
treatment	O
also	O
elevates	O
brain	O
alanine	S-chemical
levels	O
.	O
As	O
with	O
GABA	S-chemical
,	O
the	O
metabolism	O
of	O
alanine	S-chemical
involves	O
a	O
pyridoxal	B-GP
phosphate-dependent	I-GP
transaminase	E-GP
.	O
3	O
.	O
In	O
the	O
study	O
reported	O
here	O
,	O
the	O
effects	O
of	O
acute	O
PLZ	S-chemical
treatment	O
on	O
the	O
levels	O
of	O
various	O
amino	B-chemical
acids	E-chemical
,	O
some	O
of	O
which	O
are	O
also	O
metabolized	O
by	O
pyridoxal	B-GP
phosphate-dependent	I-GP
transaminases	E-GP
were	O
compared	O
in	O
rat	O
whole	O
brain	O
.	O
Of	O
the	O
6	O
amino	B-chemical
acids	E-chemical
investigated	O
,	O
only	O
GABA	S-chemical
and	O
alanine	S-chemical
levels	O
were	O
elevated	O
(	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
)	O
.	O
4	O
.	O
The	O
elevation	O
in	O
brain	O
alanine	S-chemical
levels	O
could	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
time-	O
and	O
dose-dependent	O
inhibitory	O
effect	O
of	O
PLZ	S-chemical
on	O
alanine	B-GP
transaminase	E-GP
(	O
ALA-T	S-GP
)	O
,	O
although	O
as	O
with	O
GABA	S-chemical
the	O
increases	O
are	O
higher	O
than	O
expected	O
from	O
the	O
degree	O
of	O
enzyme	O
inhibition	O
produced	O
.	O
In	O
addition	O
,	O
we	O
also	O
showed	O
that	O
the	O
elevation	O
in	O
alanine	S-chemical
levels	O
and	O
the	O
inhibition	O
of	O
alanine	B-GP
transaminase	E-GP
in	O
the	O
brain	O
are	O
retained	O
after	O
14	O
days	O
of	O
PLZ	S-chemical
treatment	O
,	O
and	O
that	O
PLZ	S-chemical
produces	O
a	O
marked	O
increase	O
in	O
extracellular	O
levels	O
of	O
alanine	S-chemical
.	O
5	O
.	O
These	O
results	O
are	O
discussed	O
in	O
terms	O
of	O
their	O
relevance	O
to	O
synaptic	O
function	O
and	O
to	O
the	O
pharmacological	O
profile	O
of	O
PLZ	S-chemical
.	O

Protective	O
effect	O
of	O
Codium	O
fragile	O
against	O
UVB-induced	O
pro-inflammatory	O
and	O
oxidative	O
damages	O
in	O
HaCaT	O
cells	O
and	O
BALB/c	O
mice	O
.	O
Acute	O
exposure	O
to	O
ultraviolet	O
(	O
UV	O
)	O
radiation	O
causes	O
pro-inflammatory	O
responses	O
via	O
diverse	O
mechanisms	O
including	O
oxidative	O
stress	O
.	O
Codium	O
fragile	O
is	O
a	O
green	O
alga	O
of	O
Codiales	O
family	O
and	O
has	O
been	O
reported	O
to	O
exhibit	O
anti-edema	O
,	O
anti-allergic	O
,	O
anti-protozoal	O
and	O
anti-mycobacterial	O
activities	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
a	O
novel	O
anti-inflammatory	O
potential	O
of	O
C.	O
fragile	O
using	O
in	O
vitro	O
cell	O
culture	O
as	O
well	O
as	O
in	O
vivo	O
animal	O
models	O
.	O
In	O
HaCaT	O
cells	O
,	O
buthanol	S-chemical
and	O
ethylacetate	S-chemical
fractions	O
of	O
80	O
%	O
methanol	S-chemical
C.	O
fragile	O
extract	O
(	O
CFB	O
or	O
CFE	O
)	O
and	O
a	O
single	O
compound	O
,	O
clerosterol	S-chemical
(	O
CLS	S-chemical
)	O
isolated	O
from	O
CFE	O
attenuated	O
UVB	O
(	O
60mJ/cm	O
(	O
2	O
)	O
)	O
-induced	O
cytotoxicity	O
and	O
reduced	O
expression	O
of	O
pro-inflammatory	O
proteins	O
including	O
cyclooxygenase-2	S-GP
(	O
COX-2	S-GP
)	O
,	O
inducible	B-GP
nitric	I-GP
oxide	I-GP
synthase	E-GP
(	O
iNOS	S-GP
)	O
,	O
and	O
tumor	B-GP
necrosis	I-GP
factor-α	E-GP
(	O
TNF-	B-GP
α	E-GP
)	O
.	O
Moreover	O
,	O
CFB	O
,	O
CFE	O
and	O
CLS	S-chemical
effectively	O
suppressed	O
UVB-induced	O
production	O
of	O
pro-inflammatory	O
mediators	O
such	O
as	O
prostaglandin	B-chemical
E2	E-chemical
(	O
PGE2	S-chemical
)	O
and	O
nitric	B-chemical
oxide	E-chemical
(	O
NO	S-chemical
)	O
.	O
In	O
another	O
experiment	O
,	O
topical	O
application	O
of	O
CFB	O
,	O
CFE	O
or	O
CLS	S-chemical
prior	O
to	O
UVB	O
irradiation	O
(	O
200mJ/cm	O
(	O
2	O
)	O
)	O
on	O
BALB/c	O
mice	O
,	O
inhibited	O
the	O
UVB-elevated	O
protein	O
levels	O
of	O
COX-2	S-GP
,	O
iNOS	S-GP
,	O
and	O
TNF-α	S-GP
.	O
Furthermore	O
,	O
CFB	O
,	O
CFE	O
and	O
CLS	S-chemical
suppressed	O
oxidative	O
damages	O
caused	O
by	O
UVB	O
irradiation	O
for	O
example	O
lipid	O
peroxidation	O
and/or	O
protein	O
carbonylation	O
,	O
which	O
seemed	O
to	O
be	O
mediated	O
by	O
up-regulation	O
of	O
antioxidant	O
defense	O
enzymes	O
.	O
These	O
results	O
suggest	O
that	O
C.	O
fragile	O
could	O
be	O
an	O
effective	O
therapeutic	O
agent	O
providing	O
protection	O
against	O
UVB-induced	O
inflammatory	O
and	O
oxidative	O
skin	O
damages	O
.	O

Loss	O
of	O
beta-adrenoceptor	S-GP
response	O
in	O
myocytes	O
overexpressing	O
the	O
Na+/Ca	B-GP
(	I-GP
2+	I-GP
)	I-GP
-exchanger	E-GP
.	O
Increased	O
Na+/Ca	B-GP
(	I-GP
2+	I-GP
)	I-GP
-exchanger	E-GP
(	O
NCX	S-GP
)	O
and	O
altered	O
beta-adrenoceptor	S-GP
(	O
betaAR	S-GP
)	O
responses	O
are	O
observed	O
in	O
failing	O
human	O
heart	O
.	O
To	O
determine	O
the	O
possible	O
interaction	O
between	O
these	O
changes	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
NCX	S-GP
overexpression	O
on	O
responses	O
to	O
isoproterenol	S-chemical
in	O
adult	O
rat	O
ventricular	O
myocytes	O
.	O
Responses	O
to	O
isoproterenol	O
were	O
largely	O
mediated	O
through	O
the	O
beta1AR	S-GP
in	O
control	O
myocytes	O
.	O
Adenovirally-mediated	O
overexpression	O
of	O
NCX	S-GP
,	O
at	O
levels	O
,	O
which	O
did	O
not	O
alter	O
basal	O
contraction	O
of	O
myocytes	O
,	O
markedly	O
depressed	O
the	O
isoproterenol	S-chemical
concentration-response	O
curve	O
.	O
Responses	O
to	O
isoproterenol	S-chemical
could	O
be	O
restored	O
to	O
normal	O
by	O
beta2AR	S-GP
blockade	O
,	O
suggesting	O
a	O
beta2AR	S-GP
-mediated	O
inhibition	O
of	O
beta1AR	S-GP
signalling	O
.	O
Pertussis	B-GP
toxin	E-GP
normalised	O
isoproterenol	S-chemical
responses	O
in	O
NCX	S-GP
cells	O
,	O
indicating	O
that	O
beta2AR	S-GP
effects	O
were	O
mediated	O
by	O
Gi	S-GP
.	O
Negative-inotropic	O
effects	O
of	O
high	O
concentrations	O
of	O
ICI	O
118,551	O
,	O
previously	O
shown	O
to	O
be	O
due	O
to	O
beta2AR	S-GP
-	O
Gi	S-GP
coupling	O
,	O
were	O
increased	O
in	O
NCX	S-GP
cells	O
.	O
We	O
conclude	O
that	O
NCX	S-GP
upregulation	O
can	O
markedly	O
alter	O
the	O
consequences	O
of	O
betaAR	S-GP
stimulation	O
and	O
that	O
this	O
may	O
contribute	O
to	O
the	O
alterations	O
in	O
betaAR	S-GP
response	O
seen	O
in	O
failing	O
human	O
heart	O
.	O

Cell-cycle	O
and	O
DNA	O
damage	O
regulation	O
of	O
the	O
DNA	B-GP
mismatch	I-GP
repair	I-GP
protein	I-GP
Msh2	E-GP
occurs	O
at	O
the	O
transcriptional	O
and	O
post-transcriptional	O
level	O
.	O
DNA	O
mismatch	O
repair	O
during	O
replication	O
is	O
a	O
conserved	O
process	O
essential	O
for	O
maintaining	O
genomic	O
stability	O
.	O
Mismatch	O
repair	O
is	O
also	O
implicated	O
in	O
cell-cycle	O
arrest	O
and	O
apoptosis	O
after	O
DNA	O
damage	O
.	O
Because	O
yeast	O
and	O
human	O
mismatch	O
repair	O
systems	O
are	O
well	O
conserved	O
,	O
we	O
have	O
employed	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
to	O
understand	O
the	O
regulation	O
and	O
function	O
of	O
the	O
mismatch	O
repair	O
gene	O
MSH2	S-GP
.	O
Using	O
a	O
luciferase-based	O
transcriptional	O
reporter	O
,	O
we	O
defined	O
a	O
218-bp	O
region	O
upstream	O
of	O
MSH2	S-GP
that	O
contains	O
cell-cycle	B-GP
and	I-GP
DNA	I-GP
damage	I-GP
responsive	I-GP
elements	E-GP
.	O
The	O
5	O
'	O
end	O
of	O
the	O
MSH2	S-GP
transcript	O
was	O
mapped	O
by	O
primer	O
extension	O
and	O
was	O
found	O
to	O
encode	O
a	O
small	O
upstream	B-GP
open	I-GP
reading	I-GP
frame	E-GP
(	O
uORF	S-GP
)	O
.	O
Mutagenesis	O
of	O
the	O
uORF	B-GP
start	I-GP
codon	E-GP
or	O
of	O
the	O
uORF	B-GP
stop	I-GP
codon	E-GP
,	O
which	O
creates	O
a	O
continuous	O
reading	O
frame	O
with	O
MSH2	S-GP
,	O
increased	O
Msh2	S-GP
steady-state	O
protein	O
levels	O
∼2-fold	O
.	O
Furthermore	O
,	O
we	O
found	O
that	O
the	O
cell-cycle	O
transcription	O
factors	O
Swi6	S-GP
,	O
Swi4	S-GP
,	O
and	O
Mbp1	S-GP
-along	O
with	O
SCB/MCB	B-GP
cell-cycle	I-GP
binding	I-GP
site	E-GP
s	O
upstream	O
of	O
MSH2	S-GP
-are	O
all	O
required	O
for	O
full	O
basal	O
expression	O
of	O
MSH2	S-GP
.	O
Mutagenesis	O
of	O
the	O
cell-cycle	B-GP
boxes	E-GP
resulted	O
in	O
a	O
minor	O
reduction	O
in	O
basal	O
Msh2	S-GP
levels	O
and	O
a	O
3-fold	O
defect	O
in	O
mismatch	O
repair	O
.	O
Disruption	O
of	O
the	O
cell-cycle	B-GP
boxes	E-GP
also	O
affected	O
growth	O
in	O
a	O
DNA	B-GP
polymerase	E-GP
-defective	O
strain	O
background	O
where	O
mismatch	O
repair	O
is	O
essential	O
,	O
particularly	O
in	O
the	O
presence	O
of	O
the	O
DNA	O
damaging	O
agent	O
methyl	B-chemical
methane	I-chemical
sulfonate	E-chemical
(	O
MMS	S-chemical
)	O
.	O
Promoter	O
replacements	O
conferring	O
constitutive	O
expression	O
of	O
MSH2	S-GP
revealed	O
that	O
the	O
transcriptional	O
induction	O
in	O
response	O
to	O
MMS	S-chemical
is	O
required	O
to	O
maintain	O
induced	O
levels	O
of	O
Msh2	S-GP
.	O
Turnover	O
experiments	O
confirmed	O
an	O
elevated	O
rate	O
of	O
degradation	O
in	O
the	O
presence	O
of	O
MMS	S-chemical
.	O
Taken	O
together	O
,	O
the	O
data	O
show	O
that	O
the	O
DNA	O
damage	O
regulation	O
of	O
Msh2	S-GP
occurs	O
at	O
the	O
transcriptional	O
and	O
post-transcriptional	O
levels	O
.	O
The	O
transcriptional	O
and	O
translational	O
control	O
elements	O
identified	O
are	O
conserved	O
in	O
mammalian	O
cells	O
,	O
underscoring	O
the	O
use	O
of	O
yeast	O
as	O
a	O
model	O
system	O
to	O
examine	O
the	O
regulation	O
of	O
MSH2	S-GP
.	O

Roles	O
played	O
by	O
lymphocyte	B-GP
function-associated	I-GP
antigen-1	E-GP
in	O
the	O
regulation	O
of	O
lymphocytic	O
cholinergic	O
activity	O
.	O
Lymphocytes	O
possess	O
the	O
essential	O
components	O
of	O
a	O
cholinergic	O
system	O
,	O
including	O
acetylcholine	S-chemical
(	O
ACh	S-chemical
)	O
;	O
choline	B-GP
acetyltransferase	E-GP
(	O
ChAT	S-GP
)	O
,	O
its	O
synthesizing	O
enzyme	O
;	O
and	O
both	O
muscarinic	B-GP
and	I-GP
nicotinic	I-GP
ACh	I-GP
receptors	E-GP
(	O
mAChRs	S-GP
and	O
nAChRs	S-GP
,	O
respectively	O
)	O
.	O
Stimulation	O
of	O
lymphocytes	O
with	O
phytohemagglutinin	S-GP
,	O
which	O
activates	O
T	O
cells	O
via	O
the	O
T	B-GP
cell	I-GP
receptor	E-GP
/	O
CD3	S-GP
complex	O
,	O
enhances	O
the	O
synthesis	O
and	O
release	O
of	O
ACh	S-chemical
and	O
up-regulates	O
expression	O
of	O
ChAT	S-GP
and	O
M	B-GP
(	I-GP
5	I-GP
)	I-GP
mAChR	E-GP
mRNAs	O
.	O
In	O
addition	O
,	O
activation	O
of	O
protein	B-GP
kinase	I-GP
C	E-GP
and	O
increases	O
in	O
intracellular	O
cAMP	S-chemical
also	O
enhance	O
cholinergic	O
activity	O
in	O
T	O
cells	O
,	O
and	O
lymphocyte	B-GP
function	I-GP
associated	I-GP
antigen-1	E-GP
(	O
LFA-1	S-GP
;	O
CD11a	S-GP
/	O
CD18	S-GP
)	O
is	O
an	O
important	O
mediator	O
of	O
leukocyte	O
migration	O
and	O
T	O
cell	O
activation	O
.	O
Anti-	O
CD11a	S-GP
monoclonal	O
antibody	O
(	O
mAb	O
)	O
as	O
well	O
as	O
antithymocyte	O
globulin	S-GP
containing	O
antibodies	O
against	O
CD2	S-GP
,	O
CD7	S-GP
and	O
CD11a	S-GP
all	O
increase	O
ChAT	S-GP
activity	O
,	O
ACh	S-chemical
synthesis	O
and	O
release	O
,	O
and	O
expression	O
of	O
ChAT	S-GP
and	O
M	B-GP
(	I-GP
5	I-GP
)	I-GP
mAChR	E-GP
mRNAs	O
in	O
T	O
cells	O
.	O
The	O
cholesterol	S-chemical
-lowering	O
drug	O
simvastatin	O
inhibits	O
LFA-1	S-GP
signaling	O
by	O
binding	O
to	O
an	O
allosteric	O
site	O
on	O
CD11a	S-GP
(	O
LFA-1	B-GP
alpha	E-GP
chain	O
)	O
,	O
which	O
leads	O
to	O
immunomodulation	O
.	O
We	O
found	O
that	O
simvastatin	S-chemical
abolishes	O
anti-	O
CD11a	S-GP
mAb-induced	O
increases	O
in	O
lymphocytic	O
cholinergic	O
activity	O
in	O
a	O
manner	O
independent	O
of	O
its	O
cholesterol	S-chemical
-lowering	O
activity	O
.	O
Collectively	O
then	O
,	O
these	O
results	O
indicate	O
that	O
LFA-1	S-GP
contributes	O
to	O
the	O
regulation	O
of	O
lymphocytic	O
cholinergic	O
activity	O
via	O
CD11a	S-GP
-mediated	O
pathways	O
and	O
suggest	O
that	O
simvastatin	S-chemical
exerts	O
its	O
immunosuppressive	O
effects	O
in	O
part	O
via	O
modification	O
of	O
lymphocytic	O
cholinergic	O
activity	O
.	O

Differences	O
in	O
conformational	O
stability	O
between	O
native	O
and	O
phosphorylated	B-GP
acetylcholinesterase	E-GP
as	O
evidenced	O
by	O
a	O
monoclonal	O
antibody	O
.	O
Monoclonal	O
antibody	O
25B1	O
generated	O
against	O
diisopropyl	B-chemical
phosphorofluoridate	E-chemical
inhibited	O
fetal	O
bovine	B-GP
serum	I-GP
acetylcholinesterase	E-GP
has	O
been	O
extensively	O
characterized	O
with	O
respect	O
to	O
its	O
anticholinesterase	S-GP
properties	O
.	O
This	O
antibody	O
demonstrated	O
considerably	O
different	O
properties	O
from	O
previously	O
reported	O
inhibitory	O
antibodies	O
raised	O
against	O
acetylcholinesterase	S-GP
in	O
terms	O
of	O
the	O
degree	O
of	O
inhibition	O
(	O
greater	O
than	O
98	O
%	O
)	O
,	O
the	O
high	O
degree	O
of	O
specificity	O
,	O
and	O
the	O
stability	O
of	O
the	O
antigen-antibody	O
complex	O
.	O
Monoclonal	O
antibody	O
25B1	O
appears	O
to	O
be	O
directed	O
against	O
a	O
conformational	O
epitope	O
located	O
in	O
close	O
proximity	O
to	O
the	O
catalytic	O
center	O
of	O
the	O
enzyme	O
and	O
was	O
found	O
to	O
be	O
most	O
suitable	O
for	O
studying	O
the	O
stabilization	O
of	O
the	O
active	O
site	O
of	O
acetylcholinesterase	S-GP
against	O
denaturation	O
by	O
heat	O
or	O
guanidine	S-chemical
following	O
phosphorylation	O
by	O
organophosphorus	O
anticholinesterase	S-GP
compounds	O
.	O
This	O
approach	O
allowed	O
the	O
determination	O
of	O
stability	O
rank	O
order	O
of	O
various	O
phosphorylated	B-GP
acetylcholinesterases	E-GP
.	O
Among	O
all	O
the	O
organophosphates	S-chemical
tested	O
,	O
the	O
combination	O
of	O
a	O
methyl	O
group	O
and	O
a	O
negatively	O
charged	O
oxygen	S-chemical
attached	O
to	O
the	O
P	S-chemical
atom	O
,	O
CH3P	B-chemical
(	I-chemical
O	I-chemical
)	I-chemical
(	I-chemical
O-	I-chemical
)	E-chemical
-	O
AChE	S-GP
,	O
conferred	O
the	O
greatest	O
protection	O
to	O
the	O
active	O
site	O
of	O
aged	O
or	O
nonaged	O
organophosphoryl	S-chemical
conjugates	O
of	O
acetylcholinesterase	S-GP
.	O

Gallium	S-chemical
and	O
other	O
main	O
group	O
metal	O
compounds	O
as	O
antitumor	O
agents	O
.	O
Gallium	S-chemical
has	O
been	O
the	O
second	O
metal	O
to	O
show	O
activity	O
against	O
malignant	O
tumors	O
in	O
humans	O
soon	O
after	O
the	O
establishment	O
of	O
platinum	S-chemical
drugs	O
in	O
routine	O
clinical	O
practice	O
.	O
It	O
has	O
the	O
unique	O
property	O
of	O
inhibiting	O
tumor	O
growth	O
as	O
a	O
simple	O
cation	O
,	O
mainly	O
because	O
of	O
its	O
close	O
resemblance	O
to	O
ferric	B-chemical
iron	E-chemical
.	O
Even	O
though	O
its	O
inability	O
to	O
shift	O
between	O
the	O
trivalent	O
and	O
a	O
divalent	O
oxidation	O
state	O
precludes	O
that	O
gallium	S-chemical
behaves	O
as	O
an	O
iron	S-chemical
analogue	O
in	O
every	O
respect	O
,	O
it	O
strongly	O
interferes	O
with	O
cellular	O
acquisition	O
of	O
iron	O
from	O
blood	O
by	O
competitive	O
interaction	O
with	O
transferrin	S-GP
and	O
transferrin	B-GP
receptor	E-GP
-mediated	O
endocytosis	O
.	O
Furthermore	O
,	O
gallium	S-chemical
also	O
seems	O
to	O
affect	O
intracellular	O
availability	O
of	O
iron	S-chemical
already	O
taken	O
up	O
via	O
this	O
pathway	O
,	O
probably	O
due	O
to	O
its	O
inhibitory	O
activity	O
on	O
vacuolar-type	B-GP
H	I-GP
(	I-GP
+	I-GP
)	I-GP
-ATPases	E-GP
.	O
Apart	O
from	O
the	O
consequences	O
of	O
iron	S-chemical
deprivation	O
,	O
gallium	S-chemical
exerts	O
cytotoxic	O
effects	O
by	O
direct	O
interaction	O
with	O
the	O
iron	S-chemical
-dependent	O
enzyme	O
ribonucleotide	B-GP
reductase	E-GP
,	O
resulting	O
in	O
reduced	O
dNTP	O
pools	O
and	O
inhibition	O
of	O
DNA	O
synthesis	O
.	O
Both	O
the	O
abundance	O
of	O
transferrin	B-GP
receptors	E-GP
and	O
upregulation	O
of	O
ribonucleotide	B-GP
reductase	E-GP
render	O
tumors	O
susceptible	O
to	O
gallium	S-chemical
-induced	O
cytotoxicity	O
.	O
However	O
,	O
some	O
experimental	O
findings	O
raise	O
the	O
question	O
whether	O
these	O
effects	O
resulting	O
from	O
the	O
iron	S-chemical
-mimicking	O
properties	O
of	O
gallium	S-chemical
are	O
solely	O
responsible	O
for	O
its	O
antineoplastic	O
activity	O
or	O
whether	O
additional	O
mechanisms	O
are	O
involved	O
,	O
such	O
as	O
antimitotic	O
effects	O
which	O
result	O
from	O
its	O
capability	O
of	O
inhibiting	O
tubulin	S-GP
polymerization	O
.	O
The	O
limitations	O
experienced	O
with	O
gallium	B-chemical
nitrate	E-chemical
and	O
gallium	B-chemical
chloride	E-chemical
,	O
which	O
call	O
for	O
a	O
prolonged	O
exposure	O
to	O
low	O
steady-state	O
gallium	S-chemical
levels	O
in	O
blood	O
in	O
order	O
to	O
adequately	O
exploit	O
the	O
affinity	O
of	O
gallium	S-chemical
to	O
tumor	O
tissues	O
and	O
to	O
avoid	O
severe	O
toxic	O
effects	O
,	O
may	O
be	O
overcome	O
by	O
oral	O
gallium	S-chemical
complexes	O
such	O
as	O
tris	B-chemical
(	I-chemical
3-hydroxy-2-methyl-4H-pyran-4-onato	I-chemical
)	I-chemical
gallium	I-chemical
(	I-chemical
III	I-chemical
)	E-chemical
(	O
gallium	B-chemical
maltolate	E-chemical
)	O
or	O
tris	B-chemical
(	I-chemical
8-quinolinolato	I-chemical
)	I-chemical
gallium	I-chemical
(	I-chemical
III	I-chemical
)	E-chemical
(	O
KP46	S-chemical
)	O
,	O
which	O
are	O
currently	O
being	O
evaluated	O
in	O
clinical	O
trials	O
and	O
show	O
promise	O
to	O
initiate	O
a	O
revival	O
of	O
gallium	S-chemical
in	O
the	O
clinical	O
setting	O
.	O
These	O
two	O
investigational	O
drugs	O
,	O
albeit	O
differing	O
in	O
their	O
complex	O
stability	O
,	O
have	O
both	O
been	O
developed	O
with	O
the	O
intention	O
of	O
providing	O
gallium	S-chemical
in	O
a	O
form	O
which	O
allows	O
sufficient	O
intestinal	O
absorption	O
,	O
but	O
without	O
altering	O
its	O
pharmacodynamic	O
effects	O
.	O
Gallium	S-chemical
complexes	O
based	O
on	O
other	O
rationales	O
are	O
scarce	O
and	O
,	O
with	O
regard	O
to	O
the	O
well-known	O
antineoplastic	O
potential	O
of	O
this	O
metal	O
,	O
noticeably	O
under-explored	O
.	O
With	O
the	O
recent	O
approval	O
of	O
arsenic	O
trioxide	S-chemical
for	O
the	O
second-line	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
,	O
the	O
clinical	O
revival	O
of	O
arsenic	S-chemical
compounds	O
,	O
which	O
have	O
been	O
the	O
mainstay	O
of	O
antileukemic	O
therapy	O
before	O
the	O
age	O
of	O
modern	O
cancer	O
chemotherapy	O
,	O
has	O
already	O
begun	O
.	O
Currently	O
,	O
strong	O
efforts	O
are	O
being	O
made	O
to	O
explore	O
the	O
activity	O
spectrum	O
in	O
other	O
(	O
less	O
rare	O
)	O
malignancies	O
and	O
to	O
gain	O
a	O
deeper	O
insight	O
into	O
the	O
mode	O
of	O
action	O
.	O
Although	O
this	O
development	O
is	O
currently	O
focusing	O
on	O
arsenic	B-chemical
trioxide	E-chemical
,	O
it	O
should	O
be	O
suited	O
to	O
stimulate	O
investigations	O
into	O
the	O
therapeutic	O
potential	O
of	O
other	O
arsenic	S-chemical
compounds	O
as	O
well	O
.	O

Arsenic	S-chemical
suppresses	O
cell	O
survival	O
via	O
Pirh2	S-GP
-mediated	O
proteasomal	O
degradation	O
of	O
ΔNp63	S-GP
protein	O
.	O
Transcription	B-GP
factor	I-GP
p63	E-GP
,	O
a	O
member	O
of	O
the	O
p53	S-GP
family	O
,	O
shares	O
a	O
high	O
degree	O
of	O
sequence	O
similarity	O
with	O
p53	S-GP
.	O
Because	O
of	O
transcription	O
from	O
two	O
distinct	O
promoters	O
,	O
the	O
p63	S-GP
gene	O
encodes	O
two	O
isoforms	O
,	O
TAp63	S-GP
and	O
ΔNp63	S-GP
.	O
Although	O
TAp63	S-GP
acts	O
as	O
a	O
tumor	O
suppressor	O
,	O
ΔNp63	S-GP
functions	O
as	O
an	O
oncogene	O
and	O
is	O
often	O
overexpressed	O
in	O
squamous	O
cell	O
carcinomas	O
.	O
Thus	O
,	O
therapeutic	O
agents	O
targeting	O
ΔNp63	S-GP
might	O
be	O
used	O
to	O
manage	O
tumors	O
that	O
overexpress	O
ΔNp63	S-GP
.	O
Here	O
we	O
found	O
that	O
arsenic	B-chemical
trioxide	E-chemical
,	O
a	O
frontline	O
agent	O
for	O
acute	O
promyelocytic	O
leukemia	O
,	O
inhibits	O
ΔNp63	S-GP
but	O
not	O
TAp63	S-GP
expression	O
in	O
time-	O
and	O
dose-dependent	O
manners	O
.	O
In	O
addition	O
,	O
we	O
found	O
that	O
arsenic	B-chemical
trioxide	E-chemical
decreases	O
the	O
stability	O
of	O
ΔNp63	S-GP
protein	O
via	O
a	O
proteasome	S-GP
-dependent	O
pathway	O
but	O
has	O
little	O
effect	O
on	O
the	O
level	O
of	O
ΔNp63	S-GP
transcript	O
.	O
Furthermore	O
,	O
we	O
found	O
that	O
arsenic	B-chemical
trioxide	E-chemical
activates	O
the	O
Pirh2	B-GP
promoter	E-GP
and	O
consequently	O
induces	O
Pirh2	S-GP
expression	O
.	O
Consistent	O
with	O
this	O
,	O
we	O
found	O
that	O
knockdown	O
of	O
Pirh2	S-GP
inhibits	O
,	O
whereas	O
ectopic	O
expression	O
of	O
Pirh2	S-GP
enhances	O
,	O
arsenic	S-chemical
-induced	O
degradation	O
of	O
ΔNp63	S-GP
protein	O
.	O
Importantly	O
,	O
we	O
found	O
that	O
knockdown	O
of	O
ΔNp63	S-GP
sensitizes	O
,	O
whereas	O
ectopic	O
expression	O
of	O
ΔNp63	S-GP
inhibits	O
,	O
growth	O
suppression	O
induced	O
by	O
arsenic	S-chemical
.	O
Together	O
,	O
these	O
data	O
suggest	O
that	O
arsenic	S-chemical
degrades	O
ΔNp63	S-GP
protein	O
at	O
least	O
in	O
part	O
via	O
Pirh2	S-GP
-dependent	O
proteolysis	O
and	O
that	O
inhibition	O
of	O
ΔNp63	S-GP
expression	O
facilitates	O
tumor	O
cells	O
to	O
arsenic	S-chemical
-induced	O
death	O
.	O

COX-1	S-GP
and	O
COX-2	S-GP
inhibition	O
in	O
horse	O
blood	O
by	O
phenylbutazone	S-chemical
,	O
flunixin	S-chemical
,	O
carprofen	S-chemical
and	O
meloxicam	S-chemical
:	O
an	O
in	O
vitro	O
analysis	O
.	O
We	O
report	O
on	O
the	O
inhibitory	O
activity	O
of	O
the	O
NSAIDs	O
meloxicam	S-chemical
,	O
carprofen	S-chemical
,	O
phenylbutazone	S-chemical
and	O
flunixin	S-chemical
,	O
on	O
blood	O
cyclooxygenases	S-GP
in	O
the	O
horse	O
using	O
in	O
vitro	O
enzyme-linked	O
assays	O
.	O
As	O
expected	O
,	O
comparison	O
of	O
IC50	O
indicated	O
that	O
meloxicam	S-chemical
and	O
carprofen	S-chemical
are	O
more	O
selective	O
inhibitors	O
of	O
COX-2	S-GP
than	O
phenylbutazone	S-chemical
and	O
flunixin	S-chemical
;	O
meloxicam	S-chemical
was	O
the	O
most	O
advantageous	O
for	O
horses	O
of	O
four	O
NSAIDs	O
examined	O
.	O
However	O
at	O
IC80	O
,	O
phenylbutazone	S-chemical
(	O
+134.4	O
%	O
)	O
and	O
flunixin	S-chemical
(	O
+29.7	O
%	O
)	O
had	O
greater	O
COX-2	S-GP
selectivity	O
than	O
at	O
IC50	O
,	O
and	O
meloxicam	S-chemical
(	O
-41.2	O
%	O
)	O
and	O
carprofen	S-chemical
(	O
-12.9	O
%	O
)	O
had	O
lower	O
COX-2	S-GP
selectivity	O
than	O
at	O
IC50	O
.	O
We	O
therefore	O
propose	O
that	O
the	O
selectivity	O
of	O
NSAIDs	O
should	O
be	O
assessed	O
at	O
the	O
80	O
%	O
as	O
well	O
as	O
50	O
%	O
inhibition	O
level	O
.	O

Cardiolipin	S-chemical
-dependent	O
reconstitution	O
of	O
respiratory	O
supercomplexes	O
from	O
purified	O
Saccharomyces	O
cerevisiae	O
complexes	O
III	O
and	O
IV	O
.	O
Here	O
,	O
we	O
report	O
for	O
the	O
first	O
time	O
in	O
vitro	O
reconstitution	O
of	O
the	O
respiratory	O
supercomplexes	O
from	O
individual	O
complexes	O
III	O
and	O
IV	O
.	O
Complexes	O
III	O
and	O
IV	O
were	O
purified	O
from	O
Saccharomyces	O
cerevisiae	O
mitochondria	O
.	O
Complex	O
III	O
contained	O
eight	O
molecules	O
of	O
cardiolipin	S-chemical
,	O
and	O
complex	O
IV	O
contained	O
two	O
molecules	O
of	O
cardiolipin	S-chemical
,	O
as	O
determined	O
by	O
electrospray	O
ionization-mass	O
spectrometry	O
.	O
Complex	O
IV	O
also	O
contained	O
Rcf1p	S-GP
.	O
No	O
supercomplexes	O
were	O
formed	O
upon	O
mixing	O
of	O
the	O
purified	O
complexes	O
,	O
and	O
low	O
amounts	O
of	O
the	O
supercomplex	O
trimer	O
III	O
(	O
2	O
)	O
IV	O
(	O
1	O
)	O
were	O
formed	O
after	O
reconstitution	O
into	O
proteoliposomes	O
containing	O
only	O
phosphatidylcholine	S-chemical
and	O
phosphatidylethanolamine	S-chemical
.	O
Further	O
addition	O
of	O
cardiolipin	S-chemical
to	O
the	O
proteoliposome	O
reconstitution	O
mixture	O
resulted	O
in	O
distinct	O
formation	O
of	O
both	O
the	O
III	O
(	O
2	O
)	O
IV	O
(	O
1	O
)	O
supercomplex	O
trimer	O
and	O
III	O
(	O
2	O
)	O
IV	O
(	O
2	O
)	O
supercomplex	O
tetramer	O
.	O
No	O
other	O
anionic	O
phospholipid	O
was	O
as	O
effective	O
as	O
cardiolipin	O
in	O
supporting	O
tetramer	O
formation	O
.	O
Phospholipase	S-GP
treatment	O
of	O
complex	O
IV	O
prevented	O
trimer	O
formation	O
in	O
the	O
absence	O
of	O
cardiolipin	S-chemical
.	O
Both	O
trimer	O
and	O
tetramer	O
formations	O
were	O
restored	O
by	O
cardiolipin	S-chemical
.	O
Analysis	O
of	O
the	O
reconstituted	O
tetramer	O
by	O
single	O
particle	O
electron	O
microscopy	O
confirmed	O
native	O
organization	O
of	O
individual	O
complexes	O
within	O
the	O
supercomplex	O
.	O
In	O
conclusion	O
,	O
although	O
some	O
trimer	O
formation	O
occurred	O
dependent	O
only	O
on	O
tightly	O
bound	O
cardiolipin	S-chemical
,	O
tetramer	O
formation	O
required	O
additional	O
cardiolipin	S-chemical
.	O
This	O
is	O
consistent	O
with	O
the	O
high	O
cardiolipin	S-chemical
content	O
in	O
the	O
native	O
tetramer	O
.	O
The	O
dependence	O
on	O
cardiolipin	S-chemical
for	O
supercomplex	O
formation	O
suggests	O
that	O
changes	O
in	O
cardiolipin	S-chemical
levels	O
resulting	O
from	O
changes	O
in	O
physiological	O
conditions	O
may	O
control	O
the	O
equilibrium	O
between	O
individual	O
respiratory	O
complexes	O
and	O
supercomplexes	O
in	O
vivo	O
.	O

Cortisol	S-chemical
metabolism	O
in	O
hypertension	O
.	O
Corticosteroids	S-chemical
are	O
critically	O
involved	O
in	O
blood	O
pressure	O
regulation	O
.	O
Lack	O
of	O
adrenal	O
steroids	S-chemical
in	O
Addison	O
's	O
disease	O
causes	O
life-threatening	O
hypotension	O
,	O
whereas	O
glucocorticoid	O
excess	O
in	O
Cushing	O
's	O
syndrome	O
invariably	O
results	O
in	O
high	O
blood	O
pressure	O
.	O
At	O
a	O
pre-receptor	O
level	O
,	O
glucocorticoid	O
action	O
is	O
modulated	O
by	O
11beta-hydroxysteroid	B-GP
dehydrogenases	E-GP
(	O
11beta-HSDs	S-GP
)	O
.	O
11Beta-HSD1	S-GP
activates	O
cortisone	S-chemical
to	O
cortisol	S-chemical
to	O
facilitate	O
glucocorticoid	B-GP
receptor	E-GP
(	O
GR	S-GP
)	O
-mediated	O
action	O
.	O
By	O
contrast	O
,	O
11beta-HSD2	S-GP
plays	O
a	O
pivotal	O
role	O
in	O
aldosterone	S-chemical
target	O
tissues	O
where	O
it	O
catalyses	O
the	O
opposite	O
reaction	O
(	O
i.e	O
.	O
inactivation	O
of	O
cortisol	S-chemical
to	O
cortisone	S-chemical
)	O
to	O
prevent	O
activation	O
of	O
the	O
mineralocorticoid	B-GP
receptor	E-GP
(	O
MR	S-GP
)	O
by	O
cortisol	S-chemical
.	O
Mutations	O
in	O
the	O
11beta-HSD2	S-GP
gene	O
cause	O
a	O
rare	O
form	O
of	O
inherited	O
hypertension	O
,	O
the	O
syndrome	O
of	O
apparent	O
mineralocorticoid	O
excess	O
(	O
AME	O
)	O
,	O
in	O
which	O
cortisol	S-chemical
activates	O
the	O
MR	S-GP
resulting	O
in	O
severe	O
hypertension	O
and	O
hypokalemia	O
.	O
Ingestion	O
of	O
competitive	O
inhibitors	O
of	O
11beta-HSD2	S-GP
such	O
as	O
liquorice	O
and	O
carbenoxolone	S-chemical
result	O
in	O
a	O
similar	O
but	O
milder	O
clinical	O
phenotype	O
.	O
Epidemiological	O
data	O
suggests	O
that	O
polymorphic	O
variability	O
in	O
the	O
HSD11B2	S-GP
gene	O
determines	O
salt	O
sensitivity	O
in	O
the	O
general	O
population	O
,	O
which	O
is	O
a	O
key	O
predisposing	O
factor	O
to	O
adult	O
onset	O
hypertension	O
in	O
some	O
patients	O
.	O
Extrarenal	O
sites	O
of	O
glucocorticoid	O
action	O
and	O
metabolism	O
that	O
might	O
impact	O
on	O
blood	O
pressure	O
include	O
the	O
vasculature	O
and	O
the	O
central	O
nervous	O
system	O
.	O
Intriguingly	O
,	O
increased	O
exposure	O
to	O
glucocorticoids	O
during	O
fetal	O
life	O
promotes	O
high	O
blood	O
pressure	O
in	O
adulthood	O
suggesting	O
an	O
early	O
programming	O
effect	O
.	O
Thus	O
,	O
metabolism	O
and	O
action	O
in	O
many	O
peripheral	O
tissues	O
might	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
human	O
hypertension	O
.	O

Comparison	O
of	O
the	O
novel	O
antipsychotic	O
ziprasidone	S-chemical
with	O
clozapine	S-chemical
and	O
olanzapine	S-chemical
:	O
inhibition	O
of	O
dorsal	O
raphe	O
cell	O
firing	O
and	O
the	O
role	O
of	O
5-HT1A	B-GP
receptor	E-GP
activation	O
.	O
Ziprasidone	S-chemical
is	O
a	O
novel	O
antipsychotic	O
agent	O
which	O
binds	O
with	O
high	O
affinity	O
to	O
5-HT1A	B-GP
receptors	E-GP
(	O
Ki	O
=	O
3.4	O
nM	O
)	O
,	O
in	O
addition	O
to	O
5-HT1D	S-GP
,	O
5-HT2	S-GP
,	O
and	O
D2	S-GP
sites	O
.	O
While	O
it	O
is	O
an	O
antagonist	O
at	O
these	O
latter	O
receptors	O
,	O
ziprasidone	S-chemical
behaves	O
as	O
a	O
5-HT1A	S-GP
agonist	O
in	O
vitro	O
in	O
adenylate	B-GP
cyclase	E-GP
measurements	O
.	O
The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
5-HT1A	S-GP
properties	O
of	O
ziprasidone	S-chemical
in	O
vivo	O
using	O
as	O
a	O
marker	O
of	O
central	O
5-HT1A	S-GP
activity	O
the	O
inhibition	O
of	O
firing	O
of	O
serotonin	S-chemical
-containing	O
neurons	O
in	O
the	O
dorsal	O
raphe	O
nucleus	O
.	O
In	O
anesthetized	O
rats	O
,	O
ziprasidone	S-chemical
dose-dependently	O
slowed	O
raphe	O
unit	O
activity	O
(	O
ED50	O
=	O
300	O
micrograms/kg	O
i.v	O
.	O
)	O
as	O
did	O
the	O
atypical	O
antipsychotics	O
clozapine	S-chemical
(	O
ED50	O
=	O
250	O
micrograms/kg	O
i.v	O
.	O
)	O
and	O
olanzapine	S-chemical
(	O
ED50	O
=	O
1000	O
micrograms/kg	O
i.v.	O
)	O
.	O
Pretreatment	O
with	O
the	O
5-HT1A	S-GP
antagonist	O
WAY-100,635	S-chemical
(	O
10	O
micrograms/kg	O
i.v	O
.	O
)	O
prevented	O
the	O
ziprasidone	S-chemical
-induced	O
inhibition	O
;	O
the	O
same	O
dose	O
of	O
WAY-100,635	S-chemical
had	O
little	O
effect	O
on	O
the	O
inhibition	O
produced	O
by	O
clozapine	S-chemical
and	O
olanzapine	S-chemical
.	O
Because	O
all	O
three	O
agents	O
also	O
bind	O
to	O
alpha	B-GP
1	I-GP
receptors	E-GP
,	O
antagonists	O
of	O
which	O
inhibit	O
serotonin	S-chemical
neuronal	O
firing	O
,	O
this	O
aspect	O
of	O
their	O
pharmacology	O
was	O
assessed	O
with	O
desipramine	S-chemical
(	O
DMI	S-chemical
)	O
,	O
a	O
NE	S-chemical
re-uptake	O
blocker	O
previously	O
shown	O
to	O
reverse	O
the	O
effects	O
of	O
alpha	O
1	O
antagonists	O
on	O
raphe	O
unit	O
activity	O
.	O
DMI	S-chemical
(	O
5	O
mg/kg	O
i.v	O
.	O
)	O
failed	O
to	O
reverse	O
the	O
inhibitory	O
effect	O
of	O
ziprasidone	S-chemical
but	O
produced	O
nearly	O
complete	O
reversal	O
of	O
that	O
of	O
clozapine	S-chemical
and	O
olanzapine	S-chemical
.	O
These	O
profiles	O
suggest	O
a	O
mechanism	O
of	O
action	O
for	O
each	O
agent	O
,	O
5-HT1A	S-GP
agonism	O
for	O
ziprasidone	S-chemical
and	O
alpha	O
1	O
antagonism	O
for	O
clozapine	S-chemical
and	O
olanzapine	S-chemical
.	O
The	O
5-HT1A	S-GP
agonist	O
activity	O
reported	O
here	O
clearly	O
distinguishes	O
ziprasidone	S-chemical
from	O
currently	O
available	O
antipsychotic	O
agents	O
and	O
suggests	O
that	O
this	O
property	O
may	O
play	O
a	O
significant	O
role	O
in	O
its	O
pharmacologic	O
actions	O
.	O

Quercetin	S-chemical
suppressed	O
CYP2E1	S-GP
-dependent	O
ethanol	S-chemical
hepatotoxicity	O
via	O
depleting	O
heme	O
pool	O
and	O
releasing	O
CO	S-chemical
.	O
Naturally	O
occuring	O
quercetin	S-chemical
protects	O
hepatocytes	O
from	O
ethanol	S-chemical
-induced	O
oxidative	O
stress	O
,	O
and	O
heme	B-GP
oxygenase-1	E-GP
(	O
HO-1	S-GP
)	O
induction	O
and	O
carbon	B-chemical
monoxide	E-chemical
(	O
CO	S-chemical
)	O
metabolite	O
may	O
be	O
implicated	O
in	O
the	O
beneficial	O
effect	O
.	O
However	O
,	O
the	O
precise	O
mechanism	O
by	O
which	O
quercetin	S-chemical
counteracts	O
CYP2E1	S-GP
-mediated	O
ethanol	S-chemical
hepatotoxicity	O
through	O
HO-1	S-GP
system	O
is	O
still	O
remained	O
unclear	O
.	O
To	O
explore	O
the	O
potential	O
mechanism	O
,	O
herein	O
,	O
ethanol	S-chemical
(	O
4.0g/kg.bw	O
.	O
)	O
was	O
administrated	O
to	O
rats	O
for	O
90	O
days	O
.	O
Our	O
data	O
showed	O
that	O
chronic	O
ethanol	S-chemical
over-activated	O
CYP2E1	S-GP
but	O
suppressed	O
HO-1	S-GP
with	O
concurrent	O
hepatic	O
oxidative	O
damage	O
,	O
which	O
was	O
partially	O
normalized	O
by	O
quercetin	S-chemical
(	O
100mg/kg.bw	O
.	O
)	O
.	O
Quercetin	S-chemical
(	O
100μM	O
)	O
induced	O
HO-1	S-GP
and	O
depleted	O
heme	O
pool	O
when	O
incubated	O
to	O
human	O
hepatocytes	O
.	O
Ethanol	S-chemical
-stimulated	O
(	O
100mM	O
)	O
CYP2E1	S-GP
upregulation	O
was	O
suppressed	O
by	O
quercetin	S-chemical
but	O
further	O
enhanced	O
by	O
HO-1	S-GP
inhibition	O
with	O
resultant	O
heme	S-chemical
accumulation	O
.	O
CO	S-chemical
scavenging	O
blocked	O
the	O
suppression	O
of	O
quercetin	S-chemical
only	O
on	O
CYP2E1	S-GP
activity	O
.	O
CO	S-chemical
donor	O
dose-dependently	O
inactivated	O
CYP2E1	S-GP
of	O
ethanol	S-chemical
-incubated	O
microsome	O
,	O
which	O
was	O
mimicked	O
by	O
HO-1	S-GP
substrate	O
but	O
abolished	O
by	O
CO	S-chemical
scavenger	O
.	O
Thus	O
,	O
CYP2E1	S-GP
-mediated	O
ethanol	S-chemical
hepatotoxicity	O
was	O
alleviated	O
by	O
quercetin	S-chemical
through	O
HO-1	S-GP
induction	O
.	O
Depleted	O
heme	O
pool	O
and	O
CO	S-chemical
releasing	O
limited	O
protein	O
synthesis	O
and	O
inhibited	O
enzymatic	O
activity	O
of	O
CYP2E1	S-GP
,	O
respectively	O
.	O

Peginesatide	S-chemical
clearance	O
,	O
distribution	O
,	O
metabolism	O
,	O
and	O
excretion	O
in	O
monkeys	O
following	O
intravenous	O
administration	O
.	O
Peginesatide	S-chemical
,	O
a	O
polyethylene	B-chemical
glycol	E-chemical
(	O
PEG	S-chemical
)	O
ylated	O
peptide-based	O
erythropoiesis-stimulating	O
agent	O
,	O
stimulates	O
the	O
erythropoietin	B-GP
receptor	E-GP
dimer	O
that	O
governs	O
erythropoiesis	O
.	O
Studies	O
were	O
designed	O
to	O
determine	O
the	O
erythropoietic	O
response	O
,	O
pharmacokinetics	O
(	O
PK	O
)	O
,	O
tissue	O
distribution	O
,	O
metabolism	O
,	O
and	O
excretion	O
of	O
peginesatide	S-chemical
in	O
nonhuman	O
primates	O
following	O
a	O
single	O
i.v	O
.	O
dose	O
.	O
The	O
PK	O
profile	O
of	O
peginesatide	S-chemical
(	O
0.1-5	O
mg/kg	O
)	O
is	O
characterized	O
by	O
low	O
,	O
dose-dependent	O
plasma	O
clearance	O
;	O
small	O
volume	O
of	O
distribution	O
;	O
and	O
long	O
half-life	O
.	O
The	O
peginesatide	S-chemical
PK	O
profile	O
following	O
a	O
single	O
i.v	O
.	O
dose	O
is	O
consistent	O
with	O
the	O
sustained	O
erythropoiesis	O
.	O
Biodistribution	O
quantitative	O
whole-body	O
autoradiography	O
demonstrated	O
high	O
peginesatide	S-chemical
levels	O
in	O
bone	O
marrow	O
(	O
i.e.	O
,	O
primary	O
hematopoietic	O
site	O
)	O
as	O
well	O
as	O
other	O
known	O
hematopoietic	O
sites	O
persisting	O
through	O
at	O
least	O
3	O
weeks	O
at	O
2.1	O
mg/kg	O
.	O
Microautoradiography	O
analysis	O
at	O
48	O
hours	O
postdose	O
revealed	O
uniform	O
and	O
high	O
distribution	O
of	O
radioactivity	O
in	O
the	O
bone	O
marrow	O
and	O
splenic	O
red	O
pulp	O
with	O
less	O
extensive	O
distribution	O
in	O
the	O
renal	O
cortex	O
(	O
glomeruli	O
,	O
associated	O
ducts	O
,	O
interstitial	O
cells	O
)	O
.	O
Radioactivity	O
in	O
the	O
kidney	O
was	O
most	O
prominent	O
in	O
the	O
outer	O
medullary	O
and	O
papillary	O
interstitium	O
.	O
At	O
2	O
weeks	O
after	O
dosing	O
,	O
cumulative	O
radioactivity	O
recovery	O
in	O
the	O
urine	O
and	O
feces	O
was	O
60	O
and	O
7	O
%	O
of	O
the	O
administered	O
dose	O
,	O
respectively	O
,	O
with	O
most	O
of	O
the	O
radioactivity	O
associated	O
with	O
the	O
parent	O
molecule	O
.	O
In	O
conclusion	O
,	O
the	O
PK	O
characteristics	O
are	O
consistent	O
with	O
a	O
PEGylated	O
peptide	O
of	O
a	O
45-kDa	O
molecular	O
mass	O
,	O
specifically	O
low	O
volume	O
of	O
distribution	O
and	O
long	O
half-life	O
.	O
Drug	O
was	O
localized	O
principally	O
to	O
hematopoietic	O
sites	O
,	O
and	O
nonspecific	O
tissue	O
retention	O
was	O
not	O
observed	O
.	O
The	O
nonhuman	O
primate	O
data	O
indicate	O
that	O
peginesatide	S-chemical
is	O
metabolically	O
stable	O
and	O
primarily	O
excreted	O
in	O
the	O
urine	O
.	O

Hydrogen	B-chemical
sulfide	E-chemical
inhibits	O
nitric	B-chemical
oxide	E-chemical
production	O
and	O
nuclear	B-GP
factor-kappaB	E-GP
via	O
heme	B-GP
oxygenase-1	E-GP
expression	O
in	O
RAW264.7	O
macrophages	O
stimulated	O
with	O
lipopolysaccharide	O
.	O
Hydrogen	B-chemical
sulfide	E-chemical
(	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
)	O
,	O
a	O
regulatory	O
gaseous	O
molecule	O
that	O
is	O
endogenously	O
synthesized	O
by	O
cystathionine	B-GP
gamma-lyase	E-GP
(	O
CSE	S-GP
)	O
and/or	O
cystathionine	B-GP
beta-synthase	E-GP
(	O
CBS	S-GP
)	O
from	O
L-cysteine	S-chemical
(	O
L-Cys	S-chemical
)	O
metabolism	O
,	O
is	O
a	O
putative	O
vasodilator	O
,	O
and	O
its	O
role	O
in	O
nitric	B-chemical
oxide	E-chemical
(	O
NO	S-chemical
)	O
production	O
is	O
unexplored	O
.	O
Here	O
,	O
we	O
show	O
that	O
at	O
noncytotoxic	O
concentrations	O
,	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
was	O
able	O
to	O
inhibit	O
NO	S-chemical
production	O
and	O
inducible	B-GP
NO	I-GP
synthase	E-GP
(	O
iNOS	S-GP
)	O
expression	O
via	O
heme	B-GP
oxygenase	E-GP
(	O
HO-1	S-GP
)	O
expression	O
in	O
RAW264.7	O
macrophages	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
Both	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
solution	O
prepared	O
by	O
bubbling	O
pure	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
gas	O
and	O
NaSH	S-chemical
,	O
a	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
donor	O
,	O
dose	O
dependently	O
induced	O
HO-1	S-GP
expression	O
through	O
the	O
activation	O
of	O
the	O
extracellular	B-GP
signal-regulated	I-GP
kinase	E-GP
(	O
ERK	S-GP
)	O
.	O
Pretreatment	O
with	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
or	O
NaHS	S-chemical
significantly	O
inhibited	O
LPS-induced	O
iNOS	S-GP
expression	O
and	O
NO	S-chemical
production	O
.	O
Moreover	O
,	O
NO	S-chemical
production	O
in	O
LPS-stimulated	O
macrophages	O
that	O
are	O
expressing	O
CSE	S-GP
mRNA	O
was	O
significantly	O
reduced	O
by	O
the	O
addition	O
of	O
L-Cys	S-chemical
,	O
a	O
substrate	O
for	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
,	O
but	O
enhanced	O
by	O
the	O
selective	O
CSE	S-GP
inhibitor	O
beta-cyano-L-alanine	S-chemical
but	O
not	O
by	O
the	O
CBS	S-GP
inhibitor	O
aminooxyacetic	B-chemical
acid	E-chemical
.	O
While	O
either	O
blockage	O
of	O
HO	S-GP
activity	O
by	O
the	O
HO	S-GP
inhibitor	O
,	O
tin	O
protoporphyrin	O
IX	O
,	O
or	O
down-regulation	O
of	O
HO-1	S-GP
expression	O
by	O
HO-1	S-GP
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
reversed	O
the	O
inhibitory	O
effects	O
of	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
on	O
iNOS	S-GP
expression	O
and	O
NO	S-chemical
production	O
,	O
HO-1	S-GP
overexpression	O
produced	O
the	O
same	O
inhibitory	O
effects	O
of	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
.	O
In	O
addition	O
,	O
LPS-induced	O
nuclear	O
factor	O
(	B-GP
NF	I-GP
)	I-GP
-kappaB	E-GP
activation	O
was	O
diminished	O
in	O
RAW264.7	O
macrophages	O
preincubated	O
with	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
.	O
Interestingly	O
,	O
the	O
inhibitory	O
effect	O
of	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
on	O
NF-kappaB	S-GP
activation	O
was	O
reversed	O
by	O
the	O
transient	O
transfection	O
with	O
HO-1	S-GP
siRNA	O
,	O
but	O
was	O
mimicked	O
by	O
either	O
HO-1	S-GP
gene	O
transfection	O
or	O
treatment	O
with	O
carbon	B-chemical
monoxide	E-chemical
(	O
CO	S-chemical
)	O
,	O
an	O
end	O
product	O
of	O
HO-1	S-GP
.	O
CO	S-chemical
treatment	O
also	O
inhibited	O
LPS-induced	O
NO	S-chemical
production	O
and	O
iNOS	S-GP
expression	O
via	O
its	O
inactivation	O
of	O
NF-kappaB	S-GP
.	O
Collectively	O
,	O
our	O
results	O
suggest	O
that	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
can	O
inhibit	O
NO	S-chemical
production	O
and	O
NF-kappaB	S-GP
activation	O
in	O
LPS-stimulated	O
macrophages	O
through	O
a	O
mechanism	O
that	O
involves	O
the	O
action	O
of	O
HO-1	S-GP
/	O
CO	S-chemical
.	O

Therapeutic	O
targets	O
in	O
melanoma	O
:	O
map	B-GP
kinase	E-GP
pathway	O
.	O
Recent	O
progress	O
in	O
our	O
understanding	O
of	O
the	O
genetic	O
alterations	O
that	O
occur	O
in	O
the	O
pathogenesis	O
of	O
melanoma	O
provides	O
exciting	O
opportunities	O
for	O
therapy	O
.	O
The	O
most	O
important	O
signaling	O
pathways	O
in	O
melanoma	O
lie	O
downstream	O
of	O
NRAS	S-GP
:	O
the	O
RAS	S-GP
-	O
BRAF	S-GP
-	O
MAPK	S-GP
pathway	O
.	O
A	O
great	O
deal	O
of	O
attention	O
has	O
been	O
focused	O
on	O
the	O
high	O
mutation	O
rate	O
in	O
the	O
BRAF	S-GP
oncogene	O
,	O
which	O
approaches	O
60	O
%	O
,	O
because	O
BRAF	S-GP
itself	O
is	O
an	O
appealing	O
drug	O
substrate	O
and	O
because	O
of	O
the	O
central	O
contribution	O
of	O
BRAF	S-GP
function	O
to	O
melanoma	O
development	O
that	O
the	O
mutation	O
rate	O
signifies	O
.	O
Agents	O
that	O
specifically	O
target	O
BRAF	S-GP
,	O
such	O
as	O
sorafenib	S-chemical
,	O
as	O
well	O
as	O
new	O
molecules	O
that	O
function	O
both	O
upstream	O
and	O
downstream	O
of	O
BRAF	S-GP
,	O
are	O
being	O
actively	O
investigated	O
.	O

Caffeine	S-chemical
as	O
a	O
psychomotor	O
stimulant	O
:	O
mechanism	O
of	O
action	O
.	O
The	O
popularity	O
of	O
caffeine	S-chemical
as	O
a	O
psychoactive	O
drug	O
is	O
due	O
to	O
its	O
stimulant	O
properties	O
,	O
which	O
depend	O
on	O
its	O
ability	O
to	O
reduce	O
adenosine	S-chemical
transmission	O
in	O
the	O
brain	O
.	O
Adenosine	B-GP
A	I-GP
(	I-GP
1	I-GP
)	I-GP
and	I-GP
A	I-GP
(	I-GP
2A	I-GP
)	I-GP
receptors	E-GP
are	O
expressed	O
in	O
the	O
basal	O
ganglia	O
,	O
a	O
group	O
of	O
structures	O
involved	O
in	O
various	O
aspects	O
of	O
motor	O
control	O
.	O
Caffeine	S-chemical
acts	O
as	O
an	O
antagonist	O
to	O
both	O
types	O
of	O
receptors	O
.	O
Increasing	O
evidence	O
indicates	O
that	O
the	O
psychomotor	O
stimulant	O
effect	O
of	O
caffeine	S-chemical
is	O
generated	O
by	O
affecting	O
a	O
particular	O
group	O
of	O
projection	O
neurons	O
located	O
in	O
the	O
striatum	O
,	O
the	O
main	O
receiving	O
area	O
of	O
the	O
basal	O
ganglia	O
.	O
These	O
cells	O
express	O
high	O
levels	O
of	O
adenosine	B-GP
A	I-GP
(	I-GP
2A	I-GP
)	I-GP
receptors	E-GP
,	O
which	O
are	O
involved	O
in	O
various	O
intracellular	O
processes	O
,	O
including	O
the	O
expression	O
of	O
immediate	O
early	O
genes	O
and	O
regulation	O
of	O
the	O
dopamine-	B-GP
and	I-GP
cyclic	I-GP
AMP-regulated	I-GP
32-kDa	I-GP
phosphoprotein	E-GP
DARPP-32	S-GP
.	O
The	O
present	O
review	O
focuses	O
on	O
the	O
effects	O
of	O
caffeine	S-chemical
on	O
striatal	O
signal	O
transduction	O
and	O
on	O
their	O
involvement	O
in	O
caffeine	S-chemical
-mediated	O
motor	O
stimulation	O
.	O

Dynamics	O
and	O
structural	O
changes	O
of	O
small	O
water	O
clusters	O
on	O
ionization	O
.	O
Despite	O
utmost	O
importance	O
in	O
understanding	O
water	O
ionization	O
process	O
,	O
reliable	O
theoretical	O
results	O
of	O
structural	O
changes	O
and	O
molecular	O
dynamics	O
(	O
MD	O
)	O
of	O
water	O
clusters	O
on	O
ionization	O
have	O
hardly	O
been	O
reported	O
yet	O
.	O
Here	O
,	O
we	O
investigate	O
the	O
water	O
cations	O
[	O
(	B-chemical
H2	I-chemical
O	I-chemical
)	I-chemical
n	E-chemical
=	O
2-6	O
(	O
+	O
)	O
]	O
with	O
density	O
functional	O
theory	O
(	O
DFT	O
)	O
,	O
Möller-Plesset	O
second-order	O
perturbation	O
theory	O
(	O
MP2	O
)	O
,	O
and	O
coupled	O
cluster	O
theory	O
with	O
single	O
,	O
double	O
,	O
and	O
perturbative	O
triple	O
excitations	O
[	O
CCSD	O
(	O
T	O
)	O
]	O
.	O
The	O
complete	O
basis	O
set	O
limits	O
of	O
interaction	O
energies	O
at	O
the	O
CCSD	O
(	O
T	O
)	O
level	O
are	O
reported	O
,	O
and	O
the	O
geometrical	O
structures	O
,	O
electronic	O
properties	O
,	O
and	O
infrared	O
spectra	O
are	O
investigated	O
.	O
The	O
characteristics	O
of	O
structures	O
and	O
spectra	O
of	O
the	O
water	O
cluster	O
cations	O
reflect	O
the	O
formation	O
of	O
the	O
hydronium	S-chemical
cation	O
moiety	O
(	O
H3	B-chemical
O	I-chemical
(	I-chemical
+	I-chemical
)	E-chemical
)	O
and	O
the	O
hydroxyl	S-chemical
radical	O
.	O
Although	O
most	O
density	O
functionals	O
fail	O
to	O
predict	O
reasonable	O
energetics	O
of	O
the	O
water	O
cations	O
,	O
some	O
functionals	O
are	O
found	O
to	O
be	O
reliable	O
,	O
in	O
reasonable	O
agreement	O
with	O
high-level	O
ab	O
initio	O
results	O
.	O
To	O
understand	O
the	O
ionization	O
process	O
of	O
water	O
clusters	O
,	O
DFT-	O
and	O
MP2-based	O
Born-Oppenheimer	O
MD	O
(	O
BOMD	O
)	O
simulations	O
are	O
performed	O
on	O
ionization	O
.	O
On	O
ionization	O
,	O
the	O
water	O
clusters	O
tend	O
to	O
have	O
an	O
Eigen-like	O
form	O
with	O
the	O
hydronium	S-chemical
cation	O
instead	O
of	O
a	O
Zundel-like	O
form	O
,	O
based	O
on	O
reliable	O
BOMD	O
simulations	O
.	O
For	O
the	O
vertically	O
ionized	O
water	O
hexamer	O
,	O
the	O
relatively	O
stable	O
(	B-chemical
H2	I-chemical
O	I-chemical
)	I-chemical
5	I-chemical
(	I-chemical
+	I-chemical
)	E-chemical
(	O
5sL4A	O
)	O
cluster	O
tends	O
to	O
form	O
with	O
a	O
detached	O
water	O
molecule	O
(	O
H2	B-chemical
O	E-chemical
)	O
.	O
©	O
2013	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Curcumin	S-chemical
inhibits	O
invasion	O
and	O
metastasis	O
in	O
K1	O
papillary	O
thyroid	O
cancer	O
cells	O
.	O
Curcumin	S-chemical
,	O
the	O
active	O
constituent	O
of	O
dietary	O
spice	O
turmeric	O
,	O
possesses	O
a	O
strong	O
potential	O
for	O
cancer	O
prevention	O
and	O
treatment	O
.	O
However	O
,	O
there	O
is	O
no	O
study	O
to	O
address	O
the	O
effects	O
of	O
curcumin	S-chemical
on	O
invasion	O
and	O
metastasis	O
of	O
thyroid	O
cancers	O
.	O
Thyroid	O
cancer	O
is	O
the	O
most	O
common	O
malignancy	O
of	O
endocrine	O
organs	O
,	O
and	O
its	O
incidence	O
rates	O
have	O
steadily	O
increased	O
over	O
recent	O
decades	O
.	O
Although	O
most	O
indolent	O
tumours	O
can	O
be	O
effectively	O
managed	O
,	O
metastatic	O
tumours	O
at	O
distant	O
secondary	O
sites	O
behave	O
aggressively	O
and	O
currently	O
there	O
is	O
no	O
effective	O
form	O
of	O
treatment	O
.	O
Here	O
,	O
for	O
the	O
first	O
time	O
it	O
has	O
been	O
reported	O
that	O
curcumin	S-chemical
inhibit	O
multiple	O
metastasis	O
steps	O
of	O
K1	O
papillary	O
thyroid	O
cancer	O
cells	O
.	O
Curcumin	S-chemical
dose-dependently	O
suppressed	O
viability	O
of	O
K1	O
cells	O
as	O
well	O
as	O
its	O
cell	O
attachment	O
,	O
spreading	O
,	O
migration	O
and	O
invasion	O
abilities	O
.	O
Moreover	O
,	O
curcumin	S-chemical
could	O
also	O
down-regulate	O
the	O
expression	O
and	O
activity	O
of	O
matrix	B-GP
metalloproteinase-9	E-GP
(	O
MMP-9	S-GP
)	O
.	O
The	O
findings	O
showed	O
that	O
curcumin	S-chemical
might	O
be	O
an	O
effective	O
tumouristatic	O
agent	O
for	O
the	O
treatment	O
of	O
aggressive	O
papillary	O
thyroid	O
carcinomas	O
.	O

Probing	O
the	O
Role	O
of	O
the	O
Vancomycin	S-chemical
E-Ring	O
Aryl	B-chemical
Chloride	E-chemical
:	O
Selective	O
Divergent	O
Synthesis	O
and	O
Evaluation	O
of	O
Alternatively	O
Substituted	O
E-Ring	O
Analogues	O
.	O
The	O
selective	O
functionalization	O
of	O
a	O
vancomycin	S-chemical
aglycon	O
derivative	O
through	O
direct	O
conversion	O
of	O
the	O
E-ring	O
aryl	B-chemical
chloride	E-chemical
to	O
a	O
reactive	O
boronic	B-chemical
acid	E-chemical
,	O
and	O
its	O
use	O
in	O
the	O
synthesis	O
of	O
a	O
systematic	O
series	O
of	O
vancomycin	S-chemical
E-ring	O
analogues	O
are	O
described	O
.	O
The	O
series	O
of	O
analogues	O
was	O
used	O
to	O
examine	O
the	O
impact	O
of	O
the	O
E-ring	O
chloride	O
in	O
binding	O
D-Ala-D-Ala	S-chemical
and	O
on	O
antimicrobial	O
activity	O
.	O
In	O
contrast	O
to	O
the	O
reduced	O
activity	O
of	O
the	O
unsubstituted	O
E-ring	O
derivatives	O
,	O
hydrophobic	O
and	O
relatively	O
non-polar	O
substituents	O
approach	O
or	O
match	O
the	O
chloro	B-chemical
substituted	I-chemical
vancomycin	E-chemical
and	O
was	O
insensitive	O
to	O
the	O
electronic	O
character	O
of	O
the	O
substituent	O
(	O
e.g	O
.	O
Cl	S-chemical
vs	O
CN	S-chemical
or	O
OMe	S-chemical
)	O
,	O
whereas	O
highly	O
polar	O
substituents	O
fail	O
to	O
provide	O
the	O
enhancements	O
.	O
Moreover	O
,	O
the	O
active	O
permethylated	O
vancomycin	S-chemical
aglycon	O
derivatives	O
examined	O
exhibit	O
VanB	S-chemical
VRE	O
antimicrobial	O
activity	O
at	O
levels	O
that	O
approach	O
(	O
typically	O
within	O
2-fold	O
)	O
their	O
activity	O
against	O
sensitive	O
bacteria	O
.	O
The	O
robust	O
borylation	O
reaction	O
also	O
enabled	O
the	O
selective	O
functionalization	O
of	O
a	O
minimally	O
protected	O
vancomycin	S-chemical
aglycon	O
(	O
N-Boc	S-chemical
vancomycin	S-chemical
aglycon	O
)	O
,	O
and	O
provides	O
a	O
direct	O
method	O
for	O
the	O
preparation	O
of	O
previously	O
inaccessible	O
analogues	O
.	O

Stimulation	O
of	O
N-methyl-D-aspartate	B-GP
receptors	E-GP
modulates	O
Jurkat	O
T	O
cell	O
growth	O
and	O
adhesion	O
to	O
fibronectin	S-GP
.	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
investigate	O
the	O
expression	O
and	O
the	O
functional	O
roles	O
of	O
N-methyl-d-aspartate	B-GP
(	I-GP
NMDA	I-GP
)	I-GP
receptors	E-GP
in	O
leukemic	O
Jurkat	O
T	O
cells	O
.	O
RT-PCR	O
and	O
immunofluorescence/confocal	O
microscopy	O
analysis	O
showed	O
that	O
Jurkat	O
T	O
cells	O
express	O
the	O
NR1	S-GP
and	O
NR2B	S-GP
subunits	O
of	O
the	O
NMDA	B-GP
receptors	E-GP
.	O
Exposure	O
of	O
Jurkat	O
cells	O
to	O
either	O
(	B-chemical
5S,10R	I-chemical
)	I-chemical
-	I-chemical
(	I-chemical
+	I-chemical
)	I-chemical
-5-methyl-10,11-dihydro-5H-dibenzo	I-chemical
[	I-chemical
a	I-chemical
,	I-chemical
b	I-chemical
]	I-chemical
cyclohepten-5,10-imine	E-chemical
[	O
(	B-chemical
+	I-chemical
)	I-chemical
-MK	I-chemical
801	E-chemical
]	O
or	O
D-	B-chemical
(	I-chemical
-	I-chemical
)	I-chemical
-2-amino-5-phosphonopentanoic	I-chemical
acid	E-chemical
(	O
D-AP5	S-chemical
)	O
,	O
two	O
selective	O
NMDA	B-GP
receptor	E-GP
antagonists	O
,	O
limited	O
cell	O
growth	O
by	O
inhibiting	O
cell	O
cycle	O
progression	O
and	O
inducing	O
apoptosis	O
,	O
whereas	O
l-glutamate	S-chemical
(	O
1	O
microM	O
)	O
and	O
NMDA	S-chemical
(	O
10	O
microM	O
)	O
significantly	O
increased	O
(	O
137.2+/-22.0	O
%	O
;	O
P	O
<	O
0.01	O
)	O
Jurkat	O
T	O
cell	O
adhesion	O
to	O
fibronectin	S-GP
.	O
In	O
conclusion	O
,	O
our	O
results	O
demonstrate	O
that	O
Jurkat	O
T	O
cells	O
express	O
NMDA	B-GP
receptors	E-GP
functionally	O
active	O
in	O
controlling	O
cell	O
growth	O
and	O
adhesion	O
to	O
fibronectin	S-GP
.	O

Liver	B-GP
X	I-GP
Receptors	E-GP
and	O
female	O
reproduction	O
:	O
when	O
cholesterol	S-chemical
meets	O
fertility	O
!	O
The	O
role	O
of	O
cholesterol	S-chemical
in	O
female	O
reproductive	O
physiology	O
has	O
been	O
suspected	O
for	O
a	O
long	O
time	O
,	O
while	O
the	O
molecular	O
bases	O
were	O
unknown	O
.	O
Cholesterol	S-chemical
is	O
the	O
precursor	O
of	O
ovarian	O
steroid	S-chemical
biosynthesis	O
and	O
is	O
also	O
essential	O
for	O
fertility	O
.	O
In	O
the	O
uterus	O
,	O
cholesterol	S-chemical
is	O
essential	O
to	O
achieve	O
correct	O
contractions	O
at	O
term	O
,	O
but	O
an	O
excessive	O
uterine	O
cholesterol	S-chemical
concentration	O
has	O
been	O
associated	O
with	O
contractility	O
defects	O
.	O
Liver	B-GP
X	I-GP
Receptor	I-GP
(	I-GP
LXR	I-GP
)	I-GP
α	E-GP
and	O
LXR	B-GP
β	E-GP
are	O
nuclear	O
receptors	O
activated	O
by	O
oxysterols	S-chemical
,	O
oxidized	O
derivatives	O
of	O
cholesterol	S-chemical
.	O
Since	O
their	O
discovery	O
,	O
the	O
role	O
of	O
LXR	S-GP
in	O
the	O
control	O
of	O
cholesterol	S-chemical
homeostasis	O
has	O
been	O
widely	O
described	O
.	O
Beyond	O
their	O
cholesterol	S-chemical
-lowering	O
role	O
,	O
more	O
recent	O
data	O
have	O
linked	O
these	O
nuclear	O
receptors	O
to	O
various	O
physiological	O
processes	O
.	O
In	O
particular	O
,	O
they	O
control	O
ovarian	O
endocrine	O
and	O
exocrine	O
functions	O
,	O
as	O
well	O
as	O
uterine	O
contractility	O
.	O
Their	O
contribution	O
to	O
female	O
reproductive	O
cancers	O
will	O
also	O
be	O
discussed	O
.	O
This	O
review	O
will	O
try	O
to	O
enlighten	O
on	O
the	O
LXR	S-GP
as	O
a	O
molecular	O
link	O
between	O
dietary	O
cholesterol	S-chemical
and	O
reproductive	O
diseases	O
in	O
women	O
.	O
In	O
the	O
future	O
,	O
a	O
better	O
comprehension	O
of	O
the	O
various	O
physiological	O
processes	O
regulated	O
by	O
the	O
LXR	S-GP
will	O
help	O
to	O
develop	O
new	O
ligands	O
to	O
prevent	O
or	O
to	O
cure	O
these	O
pathologies	O
in	O
women	O
.	O

Identification	O
of	O
cDNAs	O
encoding	O
two	O
human	B-GP
alpha	I-GP
class	I-GP
glutathione	I-GP
transferases	E-GP
(	O
GSTA3	S-GP
and	O
GSTA4	S-GP
)	O
and	O
the	O
heterologous	O
expression	O
of	O
GSTA4-4	S-GP
.	O
The	O
Expressed	O
Sequence	O
Tag	O
database	O
has	O
been	O
searched	O
for	O
examples	O
of	O
previously	O
undescribed	O
human	B-GP
Alpha	I-GP
class	I-GP
glutathione	I-GP
transferases	E-GP
.	O
An	O
incomplete	O
transcript	O
of	O
the	O
previously	O
described	O
GSTA3	S-GP
gene	O
was	O
identified	O
in	O
a	O
cDNA	O
library	O
derived	O
from	O
8-9	O
week	O
placenta	O
.	O
This	O
indicates	O
that	O
the	O
GSTA3	S-GP
gene	O
is	O
functional	O
and	O
is	O
possibly	O
under	O
specific	O
developmental	O
regulation	O
.	O
A	O
second	O
cDNA	O
,	O
termed	O
GSTA4	S-GP
,	O
was	O
identified	O
in	O
a	O
brain	O
cDNA	O
library	O
.	O
The	O
encoded	O
GSTA4-4	S-GP
enzyme	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
was	O
found	O
to	O
be	O
immunologically	O
distinct	O
from	O
GSTA1-1	S-GP
and	O
to	O
have	O
high	O
activity	O
with	O
alk-2-enals	O
.	O
Although	O
GSTA4-4	S-GP
appears	O
to	O
be	O
functionally	O
similar	O
to	O
the	O
mouse	B-GP
GST5.7	E-GP
and	O
rat	B-GP
GST8-8	E-GP
Alpha	O
class	O
enzymes	O
,	O
sequence	O
comparisons	O
and	O
phylogenetic	O
analysis	O
suggest	O
that	O
GSTA4-4	S-GP
may	O
be	O
a	O
member	O
of	O
a	O
distinct	O
Alpha	O
class	O
subgroup	O
.	O

Dietary	O
relevant	O
mixtures	O
of	O
phytoestrogens	O
inhibit	O
adipocyte	O
differentiation	O
in	O
vitro	O
.	O
Phytoestrogens	O
(	O
PEs	O
)	O
are	O
naturally	O
occurring	O
plant	O
components	O
,	O
with	O
the	O
ability	O
to	O
induce	O
biological	O
responses	O
in	O
vertebrates	O
by	O
mimicking	O
or	O
modulating	O
the	O
action	O
of	O
endogenous	O
hormones	O
.	O
Single	O
isoflavones	S-chemical
have	O
been	O
shown	O
to	O
affect	O
adipocyte	O
differentiation	O
,	O
but	O
knowledge	O
on	O
the	O
effect	O
of	O
dietary	O
relevant	O
mixtures	O
of	O
PEs	O
,	O
including	O
for	O
instance	O
lignans	O
,	O
is	O
lacking	O
.	O
In	O
the	O
current	O
study	O
dietary	O
relevant	O
mixtures	O
of	O
isoflavones	S-chemical
and	O
their	O
metabolites	O
,	O
lignans	S-chemical
and	O
their	O
metabolites	O
,	O
coumestrol	S-chemical
,	O
and	O
a	O
mixture	O
containing	O
all	O
of	O
them	O
,	O
were	O
examined	O
for	O
effects	O
on	O
adipogenesis	O
in	O
3T3-L1	O
adipocytes	O
,	O
as	O
well	O
as	O
tested	O
for	O
their	O
PPARγ	S-GP
activating	O
abilities	O
.	O
The	O
results	O
showed	O
that	O
mixtures	O
of	O
isoflavonoid	S-chemical
parent	O
compounds	O
and	O
metabolites	O
,	O
respectively	O
,	O
a	O
mixture	O
of	O
lignan	S-chemical
metabolites	O
,	O
as	O
well	O
as	O
coumestrol	S-chemical
concentration-dependently	O
inhibited	O
adipocyte	O
differentiation	O
.	O
Furthermore	O
,	O
a	O
mixture	O
of	O
isoflavonoid	S-chemical
parent	O
compounds	O
,	O
and	O
a	O
mixture	O
of	O
isoflavonoid	S-chemical
metabolites	O
were	O
found	O
to	O
have	O
PPARγ	S-GP
activating	O
abilities	O
.	O
These	O
results	O
suggest	O
that	O
PEs	O
can	O
affect	O
pathways	O
known	O
to	O
play	O
a	O
role	O
in	O
obesity	O
development	O
,	O
and	O
indicate	O
that	O
the	O
inhibitory	O
effect	O
on	O
adipocyte	O
differentiation	O
does	O
not	O
appear	O
to	O
be	O
strictly	O
associated	O
with	O
PPARγ	S-GP
activation/inhibition	O
.	O
The	O
current	O
study	O
support	O
the	O
hypothesis	O
that	O
compounds	O
with	O
endocrine	O
activity	O
can	O
affect	O
pathways	O
playing	O
a	O
role	O
in	O
the	O
development	O
obesity	O
and	O
obesity	O
related	O
diseases	O
.	O

Two	O
new	O
C-15	O
enolic	B-chemical
acyl	I-chemical
phragmalin	E-chemical
-type	O
limonoids	S-chemical
from	O
Chukrasia	O
tabularis	O
var	O
.	O
velutina	O
.	O
Two	O
new	O
C-15	O
enolic	B-chemical
acyl	I-chemical
phragmalin	E-chemical
-type	O
limonoid	B-chemical
orthoesters	E-chemical
,	O
chukvelutilide	B-chemical
G	E-chemical
(	O
1	O
)	O
and	O
chukrasine	B-chemical
F	E-chemical
(	O
2	O
)	O
,	O
were	O
isolated	O
from	O
the	O
stem	O
barks	O
of	O
Chukrasia	O
tabularis	O
var	O
.	O
velutina	O
.	O
Their	O
structures	O
were	O
elucidated	O
by	O
their	O
extensive	O
high	O
resolution-electrospray	O
ionization	O
mass	O
spectrometry	O
(	O
HR-ESI-MS	O
)	O
,	O
one-	O
and	O
two-dimensional	O
spectroscopic	O
analysis	O
,	O
including	O
heteronuclear	O
single	O
quantum	O
coherence	O
(	O
HSQC	O
)	O
,	O
HMBC	O
and	O
NOESY	O
experiments	O
.	O

Neuroprotective	O
and	O
anti-inflammatory	O
properties	O
of	O
a	O
coffee	O
component	O
in	O
the	O
MPTP	S-chemical
model	O
of	O
Parkinson	O
's	O
disease	O
.	O
Consumption	O
of	O
coffee	O
is	O
associated	O
with	O
reduced	O
risk	O
of	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
,	O
an	O
effect	O
that	O
has	O
largely	O
been	O
attributed	O
to	O
caffeine	O
.	O
However	O
,	O
coffee	O
contains	O
numerous	O
components	O
that	O
may	O
also	O
be	O
neuroprotective	O
.	O
One	O
of	O
these	O
compounds	O
is	O
eicosanoyl-5-hydroxytryptamide	S-chemical
(	O
EHT	S-chemical
)	O
,	O
which	O
ameliorates	O
the	O
phenotype	O
of	O
α-synuclein	S-GP
transgenic	O
mice	O
associated	O
with	O
decreased	O
protein	O
aggregation	O
and	O
phosphorylation	O
,	O
improved	O
neuronal	O
integrity	O
and	O
reduced	O
neuroinflammation	O
.	O
Here	O
,	O
we	O
sought	O
to	O
investigate	O
if	O
EHT	S-chemical
has	O
an	O
effect	O
in	O
the	O
MPTP	S-chemical
model	O
of	O
PD	O
.	O
Mice	O
fed	O
a	O
diet	O
containing	O
EHT	S-chemical
for	O
four	O
weeks	O
exhibited	O
dose-dependent	O
preservation	O
of	O
nigral	O
dopaminergic	O
neurons	O
following	O
MPTP	S-chemical
challenge	O
compared	O
to	O
animals	O
given	O
control	O
feed	O
.	O
Reductions	O
in	O
striatal	O
dopamine	S-chemical
and	O
tyrosine	B-GP
hydroxylase	E-GP
content	O
were	O
also	O
less	O
pronounced	O
with	O
EHT	S-chemical
treatment	O
.	O
The	O
neuroinflammatory	O
response	O
to	O
MPTP	S-chemical
was	O
markedly	O
attenuated	O
,	O
and	O
indices	O
of	O
oxidative	O
stress	O
and	O
JNK	S-GP
activation	O
were	O
significantly	O
prevented	O
with	O
EHT	S-chemical
.	O
In	O
cultured	O
primary	O
microglia	O
and	O
astrocytes	O
,	O
EHT	S-chemical
had	O
a	O
direct	O
anti-inflammatory	O
effect	O
demonstrated	O
by	O
repression	O
of	O
lipopolysaccharide-induced	O
NFκB	S-GP
activation	O
,	O
iNOS	S-GP
induction	O
,	O
and	O
nitric	B-chemical
oxide	E-chemical
production	O
.	O
EHT	S-chemical
also	O
exhibited	O
a	O
robust	O
anti-oxidant	O
activity	O
in	O
vitro	O
.	O
Additionally	O
,	O
in	O
SH-SY5Y	O
cells	O
,	O
MPP	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-induced	O
demethylation	O
of	O
phosphoprotein	B-GP
phosphatase	I-GP
2A	E-GP
(	O
PP2A	S-GP
)	O
,	O
the	O
master	O
regulator	O
of	O
the	O
cellular	O
phosphoregulatory	O
network	O
,	O
and	O
cytotoxicity	O
were	O
ameliorated	O
by	O
EHT	S-chemical
.	O
These	O
findings	O
indicate	O
that	O
the	O
neuroprotective	O
effect	O
of	O
EHT	S-chemical
against	O
MPTP	S-chemical
is	O
through	O
several	O
mechanisms	O
including	O
its	O
anti-inflammatory	O
and	O
antioxidant	O
activities	O
as	O
well	O
as	O
its	O
ability	O
to	O
modulate	O
the	O
methylation	O
and	O
hence	O
activity	O
of	O
PP2A	S-GP
.	O
Our	O
data	O
,	O
therefore	O
,	O
reveal	O
a	O
strong	O
beneficial	O
effect	O
of	O
a	O
novel	O
component	O
of	O
coffee	O
in	O
multiple	O
endpoints	O
relevant	O
to	O
PD	O
.	O

Benzenesulfonamides	S-chemical
:	O
a	O
unique	O
class	O
of	O
chemokine	B-GP
receptor	I-GP
type	I-GP
4	E-GP
inhibitors	O
.	O
The	O
interaction	O
of	O
CXCR4	S-GP
with	O
CXCL12	S-GP
(	O
SDF-1	S-GP
)	O
plays	O
a	O
critical	O
role	O
in	O
cancer	O
metastasis	O
by	O
facilitating	O
the	O
homing	O
of	O
tumor	O
cells	O
to	O
metastatic	O
sites	O
.	O
Based	O
on	O
our	O
previously	O
published	O
work	O
on	O
CXCR4	S-GP
antagonists	O
,	O
we	O
have	O
synthesized	O
a	O
series	O
of	O
aryl	B-chemical
sulfonamides	E-chemical
that	O
inhibit	O
the	O
CXCR4	S-GP
/	O
CXCL12	S-GP
interaction	O
.	O
Analogue	O
bioactivities	O
were	O
assessed	O
with	O
binding	O
affinity	O
and	O
Matrigel	O
invasion	O
assays	O
.	O
Computer	O
modeling	O
was	O
employed	O
to	O
evaluate	O
a	O
selection	O
of	O
the	O
new	O
analogues	O
docked	O
into	O
the	O
CXCR4	S-GP
X-ray	O
structure	O
and	O
to	O
rationalize	O
discrepancies	O
between	O
the	O
affinity	O
and	O
Matrigel	O
in	O
vitro	O
assays	O
.	O
A	O
lead	O
compound	O
displays	O
nanomolar	O
potency	O
in	O
the	O
binding	O
affinity	O
assay	O
(	O
IC	O
(	O
50	O
)	O
=8.0	O
nM	O
)	O
and	O
the	O
Matrigel	O
invasion	O
assay	O
(	O
100	O
%	O
blockade	O
of	O
invasion	O
at	O
10	O
nM	O
)	O
.	O
These	O
data	O
demonstrate	O
that	O
benzenesulfonamides	S-chemical
are	O
a	O
unique	O
class	O
of	O
CXCR4	S-GP
inhibitors	O
with	O
high	O
potency	O
.	O

Butyrylcholinesterase	S-GP
:	O
an	O
important	O
new	O
target	O
in	O
Alzheimer	O
's	O
disease	O
therapy	O
.	O
Acetylcholinesterase	S-GP
(	O
AChE	S-GP
)	O
predominates	O
in	O
the	O
healthy	O
brain	O
,	O
with	O
butyrylcholinesterase	S-GP
(	O
BuChE	S-GP
)	O
considered	O
to	O
play	O
a	O
minor	O
role	O
in	O
regulating	O
brain	O
acetylcholine	S-chemical
(	O
ACh	S-chemical
)	O
levels	O
.	O
However	O
,	O
BuChE	S-GP
activity	O
progressively	O
increases	O
in	O
patients	O
with	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
while	O
AChE	S-GP
activity	O
remains	O
unchanged	O
or	O
declines	O
.	O
Both	O
enzymes	O
therefore	O
represent	O
legitimate	O
therapeutic	O
targets	O
for	O
ameliorating	O
the	O
cholinergic	O
deficit	O
considered	O
to	O
be	O
responsible	O
for	O
the	O
declines	O
in	O
cognitive	O
,	O
behavioral	O
and	O
global	O
functioning	O
characteristic	O
of	O
AD	O
.	O
The	O
two	O
enzymes	O
differ	O
in	O
substrate	O
specificity	O
,	O
kinetics	O
and	O
activity	O
in	O
different	O
brain	O
regions	O
.	O
Experimental	O
evidence	O
from	O
the	O
use	O
of	O
agents	O
with	O
enhanced	O
selectivity	O
for	O
BuChE	S-GP
(	O
cymserine	S-chemical
analogues	O
,	O
MF-8622	S-chemical
)	O
and	O
the	O
dual	O
inhibitor	O
of	O
both	O
AChE	S-GP
and	O
BuChE	S-GP
,	O
rivastigmine	S-chemical
,	O
indicates	O
potential	O
therapeutic	O
benefits	O
of	O
inhibiting	O
both	O
AChE	S-GP
and	O
BuChE	S-GP
in	O
AD	O
and	O
related	O
dementias	O
.	O
Recent	O
evidence	O
suggests	O
that	O
both	O
AChE	S-GP
and	O
BuChE	S-GP
may	O
have	O
roles	O
in	O
the	O
aetiology	O
and	O
progression	O
of	O
AD	O
beyond	O
regulation	O
of	O
synaptic	O
ACh	O
levels	O
.	O
The	O
development	O
of	O
specific	O
BuChE	S-GP
inhibitors	O
and	O
further	O
experience	O
with	O
the	O
dual	O
enzyme	O
inhibitor	O
rivastigmine	S-chemical
will	O
improve	O
understanding	O
of	O
the	O
aetiology	O
of	O
AD	O
and	O
should	O
lead	O
to	O
a	O
wider	O
variety	O
of	O
potent	O
treatment	O
options	O
.	O

Protein	B-GP
kinase	I-GP
C	E-GP
potentiates	O
homologous	O
desensitization	O
of	O
the	O
beta2-adrenoceptor	S-GP
in	O
bovine	O
tracheal	O
smooth	O
muscle	O
.	O
Preincubation	O
(	O
30	O
min	O
)	O
of	O
bovine	O
tracheal	O
smooth	O
muscle	O
with	O
various	O
concentrations	O
(	O
0.1	O
,	O
1	O
and	O
10	O
microM	O
)	O
of	O
fenoterol	S-chemical
decreased	O
isoprenaline	S-chemical
-induced	O
maximal	O
relaxation	O
(	O
E	O
(	O
max	O
)	O
)	O
of	O
methacholine	S-chemical
-contracted	O
preparations	O
in	O
a	O
concentration	O
dependent	O
fashion	O
,	O
indicating	O
desensitization	O
of	O
the	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenoceptor	E-GP
.	O
Preincubation	O
with	O
1	O
microM	O
of	O
the	O
protein	B-GP
kinase	I-GP
C	E-GP
(	O
PKC	S-GP
)	O
activator	O
phorbol	B-chemical
12-myristate	I-chemical
13-acetate	E-chemical
(	O
PMA	S-chemical
)	O
caused	O
a	O
small	O
but	O
significant	O
decrease	O
in	O
isoprenaline	S-chemical
-induced	O
E	O
(	O
max	O
)	O
,	O
indicating	O
activated	O
PKC	S-GP
-mediated	O
heterologous	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenoceptor	E-GP
desensitization	O
.	O
To	O
investigate	O
the	O
capacity	O
of	O
activated	O
PKC	S-GP
to	O
regulate	O
homologous	O
desensitization	O
,	O
we	O
incubated	O
the	O
smooth	O
muscle	O
strips	O
with	O
the	O
combination	O
of	O
both	O
1	O
microM	O
PMA	O
and	O
1	O
microM	O
fenoterol	S-chemical
.	O
This	O
combined	O
treatment	O
synergistically	O
decreased	O
the	O
isoprenaline	S-chemical
-induced	O
maximal	O
relaxation	O
,	O
as	O
compared	O
to	O
the	O
individual	O
effects	O
of	O
PMA	S-chemical
and	O
fenoterol	S-chemical
alone	O
,	O
indicating	O
a	O
common	O
pathway	O
for	O
heterologous	O
and	O
homologous	O
desensitization	O
.	O
Moreover	O
,	O
the	O
specific	O
PKC	S-GP
-inhibitor	O
2-	B-chemical
[	I-chemical
1-	I-chemical
(	I-chemical
3-dimethylaminopropyl	I-chemical
)	I-chemical
-1H-indol-3-yl	I-chemical
]	I-chemical
-3-	I-chemical
(	I-chemical
1H-indol-3-yl	I-chemical
)	I-chemical
maleimide	E-chemical
(	O
GF	B-chemical
109203X	E-chemical
)	O
markedly	O
increased	O
the	O
potency	O
and	O
E	O
(	O
max	O
)	O
of	O
isoprenaline	S-chemical
for	O
all	O
conditions	O
used	O
,	O
including	O
control	O
conditions	O
,	O
and	O
the	O
synergistic	O
effects	O
of	O
PMA	S-chemical
and	O
fenoterol	S-chemical
were	O
completely	O
prevented	O
.	O
In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
homologous	O
desensitization	O
of	O
the	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenergic	I-GP
receptor	E-GP
can	O
be	O
enhanced	O
by	O
PKC	S-GP
activation	O
.	O
For	O
the	O
first	O
time	O
we	O
have	O
provided	O
evidence	O
that	O
this	O
concept	O
is	O
functionally	O
operative	O
in	O
airway	O
smooth	O
muscle	O
,	O
and	O
it	O
may	O
explain	O
the	O
reduced	O
bronchodilator	O
response	O
to	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenoceptor	E-GP
agonists	O
in	O
patients	O
with	O
asthma	O
during	O
a	O
severe	O
exacerbation	O
.	O

A	O
novel	O
membrane	O
sensor	O
for	O
histamine	S-chemical

Comparison	O
of	O
ligand	O
binding	O
affinities	O
at	O
human	B-GP
I1-imidazoline	I-GP
binding	I-GP
sites	E-GP
and	O
the	O
high	O
affinity	O
state	O
of	O
alpha-2	B-GP
adrenoceptor	E-GP
subtypes	O
.	O
To	O
identify	O
selective	O
compounds	O
for	O
nonadrenergic	O
I1-imidazoline	B-GP
receptors	E-GP
(	O
I1	S-GP
)	O
,	O
the	O
affinities	O
of	O
22	O
ligands	O
for	O
[	B-chemical
125I	I-chemical
]	I-chemical
p-iodoclonidine	E-chemical
binding	O
have	O
been	O
compared	O
at	O
human	B-GP
platelet	I-GP
I1-imidazoline	I-GP
binding	I-GP
sites	E-GP
(	O
analyzed	O
under	O
norepinephrine	S-chemical
mask	O
of	O
alpha-2	B-GP
AR	E-GP
)	O
and	O
at	O
human	B-GP
alpha-2A	E-GP
,	O
alpha-2B	S-GP
and	O
alpha-2C	B-GP
adrenoceptors	E-GP
stably	O
expressed	O
on	O
transfected	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O
Competition	O
curves	O
at	O
the	O
platelet	O
I1-imidazoline	B-GP
binding	I-GP
site	E-GP
were	O
biphasic	O
for	O
most	O
compounds	O
.	O
Only	O
tizanidine	S-chemical
and	O
BDF,6143	S-chemical
displayed	O
monophasic	O
I1	O
competition	O
curves	O
.	O
Agmatine	S-chemical
,	O
an	O
endogenous	O
neurotransmitter	O
candidate	O
for	O
the	O
I1-imidazoline	B-GP
receptor	E-GP
,	O
was	O
identified	O
as	O
the	O
most	O
selective	O
agent	O
for	O
a	O
subcomponent	O
of	O
platelet	O
I1	B-GP
sites	E-GP
.	O
The	O
affinity	O
of	O
agmatine	S-chemical
at	O
the	O
high	O
affinity	O
component	O
of	O
platelet	O
I1	B-GP
sites	E-GP
was	O
1400-fold	O
selective	O
over	O
alpha-2A	B-GP
adrenoceptors	E-GP
,	O
5000-fold	O
selective	O
over	O
alpha-2B	B-GP
adrenoceptors	E-GP
and	O
800-fold	O
selective	O
over	O
alpha-2C	B-GP
adrenoceptors	E-GP
.	O
Moxonidine	S-chemical
and	O
tizanidine	S-chemical
also	O
displayed	O
selectivities	O
for	O
a	O
high	O
affinity	O
component	O
of	O
the	O
platelet	O
I1	B-GP
binding	I-GP
sites	E-GP
over	O
alpha-2	B-GP
adrenoceptors	E-GP
.	O
Naphazoline	S-chemical
was	O
the	O
most	O
selective	O
compound	O
for	O
the	O
high	O
affinity	O
state	O
of	O
the	O
alpha-2A	B-GP
adrenoceptor	E-GP
,	O
displaying	O
7-	O
,	O
23-	O
and	O
9-fold	O
higher	O
affinity	O
than	O
alpha-2B	S-GP
,	O
alpha-2C	S-GP
and	O
platelet	O
I1-midazoline	B-GP
binding	I-GP
sites	E-GP
,	O
respectively	O
.	O
No	O
single	O
selective	O
compound	O
was	O
identified	O
for	O
the	O
alpha-2B	B-GP
adrenoceptor	E-GP
.	O
Norepinephrine	S-chemical
displayed	O
,	O
respectively	O
,	O
18-	O
and	O
31-fold	O
selectivity	O
for	O
the	O
high	O
affinity	O
state	O
of	O
the	O
alpha-2C	B-GP
adrenoceptor	E-GP
as	O
compared	O
to	O
alpha-2A	S-GP
-	O
or	O
alpha-2B	B-GP
adrenoceptors	E-GP
,	O
and	O
was	O
>	O
100,000-	O
fold	O
selective	O
over	O
platelet	O
I1-imidazoline	B-GP
sites	E-GP
.	O
Thus	O
,	O
human	B-GP
alpha-2	I-GP
adrenoceptors	E-GP
and	O
the	O
platelet	O
I1-imidazoline	B-GP
binding	I-GP
site	E-GP
can	O
be	O
clearly	O
discriminated	O
based	O
on	O
their	O
affinities	O
for	O
certain	O
compounds	O
.	O

Pharmacological	O
,	O
pharmacokinetic	O
and	O
clinical	O
properties	O
of	O
olopatadine	B-chemical
hydrochloride	E-chemical
,	O
a	O
new	O
antiallergic	O
drug	O
.	O
Olopatadine	B-chemical
hydrochloride	E-chemical
(	O
olopatadine	S-chemical
,	O
11-	B-chemical
[	I-chemical
(	I-chemical
Z	I-chemical
)	I-chemical
-3-	I-chemical
(	I-chemical
dimethylamino	I-chemical
)	I-chemical
propylidene	I-chemical
]	I-chemical
-6,11-dihydrodibenz	I-chemical
[	I-chemical
b	I-chemical
,	I-chemical
e	I-chemical
]	I-chemical
oxepin-2-acetic	I-chemical
acid	I-chemical
monohydrochloride	E-chemical
)	O
is	O
a	O
novel	O
antiallergic/	O
histamine	B-GP
H1-receptor	E-GP
antagonistic	O
drug	O
that	O
was	O
synthesized	O
and	O
evaluated	O
in	O
our	O
laboratories	O
.	O
Oral	O
administration	O
of	O
olopatadine	S-chemical
at	O
doses	O
of	O
0.03	O
mg/kg	O
or	O
higher	O
inhibited	O
the	O
symptoms	O
of	O
experimental	O
allergic	O
skin	O
responses	O
,	O
rhinoconjunctivitis	O
and	O
bronchial	O
asthma	O
in	O
sensitized	O
guinea	O
pigs	O
and	O
rats	O
.	O
Olopatadine	S-chemical
is	O
a	O
selective	O
histamine	B-GP
H1-receptor	E-GP
antagonist	O
possessing	O
inhibitory	O
effects	O
on	O
the	O
release	O
of	O
inflammatory	O
lipid	O
mediators	O
such	O
as	O
leukotriene	S-chemical
and	O
thromboxane	S-chemical
from	O
human	O
polymorphonuclear	O
leukocytes	O
and	O
eosinophils	O
.	O
Olopatadine	S-chemical
also	O
inhibited	O
the	O
tachykininergic	O
contraction	O
in	O
the	O
guinea	O
pig	O
bronchi	O
by	O
prejunctional	O
inhibition	O
of	O
peripheral	O
sensory	O
nerves	O
.	O
Olopatadine	S-chemical
exerted	O
no	O
significant	O
effects	O
on	O
action	O
potential	O
duration	O
in	O
isolated	O
guinea	O
pig	O
ventricular	O
myocytes	O
,	O
myocardium	O
and	O
human	B-GP
ether-a-go-go-related	I-GP
gene	I-GP
channel	E-GP
.	O
Olopatadine	S-chemical
was	O
highly	O
and	O
rapidly	O
absorbed	O
in	O
healthy	O
human	O
volunteers	O
.	O
The	O
urinary	O
excretion	O
of	O
olopatadine	S-chemical
accounted	O
for	O
not	O
less	O
than	O
58	O
%	O
and	O
the	O
contribution	O
of	O
metabolism	O
was	O
considerably	O
low	O
in	O
the	O
clearance	O
of	O
olopatadine	S-chemical
in	O
humans	O
.	O
Olopatadine	S-chemical
is	O
one	O
of	O
the	O
few	O
renal	O
clearance	O
drugs	O
in	O
antiallergic	O
drugs	O
.	O
Olopatadine	S-chemical
was	O
shown	O
to	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
allergic	O
rhinitis	O
and	O
chronic	O
urticaria	O
in	O
double-blind	O
clinical	O
trials	O
.	O
Olopatadine	S-chemical
was	O
approved	O
in	O
Japan	O
for	O
the	O
treatment	O
of	O
allergic	O
rhinitis	O
,	O
chronic	O
urticaria	O
,	O
eczema	O
dermatitis	O
,	O
prurigo	O
,	O
pruritus	O
cutaneous	O
,	O
psoriasis	O
vulgaris	O
and	O
erythema	O
exsudativum	O
multiforme	O
in	O
December	O
,	O
2000	O
.	O
Ophthalmic	O
solution	O
of	O
olopatadine	S-chemical
was	O
also	O
approved	O
in	O
the	O
United	O
States	O
for	O
the	O
treatment	O
of	O
seasonal	O
allergic	O
conjunctivitis	O
in	O
December	O
,	O
1996	O
(	O
Appendix	O
:	O
also	O
in	O
the	O
European	O
Union	O
,	O
it	O
was	O
approved	O
in	O
February	O
2002	O
)	O
.	O

Various	O
glucocorticoids	O
differ	O
in	O
their	O
ability	O
to	O
induce	O
gene	O
expression	O
,	O
apoptosis	O
and	O
to	O
repress	O
NF-kappaB	S-GP
-dependent	O
transcription	O
.	O
Glucocorticoids	O
(	O
GCs	O
)	O
influence	O
a	O
great	O
variety	O
of	O
cellular	O
functions	O
by	O
at	O
least	O
three	O
important	O
modes	O
of	O
action	O
:	O
the	O
activation	O
(	O
or	O
repression	O
)	O
of	O
genes	O
controlled	O
by	O
binding	O
sites	O
for	O
the	O
glucocorticoid	B-GP
receptor	E-GP
(	O
GR	S-GP
)	O
,	O
the	O
induction	O
of	O
apoptosis	O
in	O
lymphocytes	O
and	O
the	O
recently	O
discovered	O
cross-talk	O
to	O
other	O
transcription	O
factors	O
such	O
as	O
NF-kappaB	S-GP
.	O
In	O
this	O
study	O
we	O
systematically	O
compared	O
various	O
natural	O
and	O
synthetic	O
steroid	S-chemical
hormones	O
frequently	O
used	O
as	O
therapeutic	O
agents	O
on	O
their	O
ability	O
to	O
mediate	O
these	O
three	O
modes	O
of	O
action	O
.	O
Betamethasone	S-chemical
,	O
triamcinolone	S-chemical
,	O
dexamethasone	S-chemical
and	O
clobetasol	S-chemical
turned	O
out	O
to	O
be	O
the	O
best	O
inducers	O
of	O
gene	O
expression	O
and	O
apoptosis	O
.	O
All	O
GCs	O
including	O
the	O
antagonistic	O
compound	O
RU486	S-chemical
efficiently	O
reduced	O
NF-kappaB	S-GP
-mediated	O
transactivation	O
to	O
comparable	O
extents	O
,	O
suggesting	O
that	O
ligand-induced	O
nuclear	O
localization	O
of	O
the	O
GR	S-GP
is	O
sufficient	O
for	O
transrepression	O
.	O
Glucocorticoid	O
treatment	O
of	O
cells	O
did	O
not	O
result	O
in	O
elevated	O
IkappaB-alpha	S-GP
expression	O
,	O
but	O
impaired	O
the	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
(	I-GP
TNF	I-GP
)	I-GP
-alpha	E-GP
-induced	O
degradation	O
of	O
IkappaB-alpha	S-GP
without	O
affecting	O
DNA	O
binding	O
of	O
NF-kappaB	S-GP
.	O
The	O
structural	O
requirements	O
for	O
the	O
various	O
functions	O
of	O
glucocorticoids	O
are	O
discussed	O
.	O

The	O
Fer	S-GP
tyrosine	B-GP
kinase	E-GP
is	O
important	O
for	O
platelet-derived	B-GP
growth	I-GP
factor-BB	E-GP
-induced	O
Stat3	S-GP
phosphorylation	O
,	O
colony	O
formation	O
in	O
soft	O
agar	O
and	O
tumor	O
growth	O
in	O
vivo	O
.	O
Fer	S-GP
is	O
a	O
cytoplasmic	O
tyrosine	B-GP
kinase	E-GP
that	O
is	O
activated	O
in	O
response	O
to	O
platelet-derived	B-GP
growth	I-GP
factor	E-GP
(	O
PDGF	S-GP
)	O
stimulation	O
.	O
In	O
the	O
present	O
report	O
,	O
we	O
show	O
that	O
Fer	S-GP
associates	O
with	O
the	O
activated	O
PDGFbeta	B-GP
receptor	E-GP
(	O
PDGFRbeta	S-GP
)	O
through	O
multiple	O
autophosphorylation	O
sites	O
,	O
i.e	O
.	O
Tyr	S-chemical
579	O
,	O
Tyr	S-chemical
581	O
,	O
Tyr	S-chemical
740	O
and	O
Tyr	S-chemical
1021	O
.	O
Using	O
low	O
molecular	O
weight	O
inhibitors	O
,	O
we	O
found	O
that	O
PDGF-BB	S-GP
-induced	O
Fer	S-GP
activation	O
is	O
dependent	O
on	O
PDGFRbeta	S-GP
kinase	S-GP
activity	O
,	O
but	O
not	O
on	O
the	O
enzymatic	O
activity	O
of	O
Src	S-GP
or	O
Jak	S-GP
kinases	S-GP
.	O
In	O
cells	O
in	O
which	O
Fer	S-GP
was	O
downregulated	O
using	O
siRNA	O
,	O
PDGF-BB	S-GP
was	O
unable	O
to	O
induce	O
phosphorylation	O
of	O
Stat3	S-GP
,	O
whereas	O
phosphorylations	O
of	O
Stat5	S-GP
,	O
Erk1/2	S-GP
and	O
Akt	S-GP
were	O
unaffected	O
.	O
PDGF-BB	S-GP
-induced	O
activation	O
of	O
Stat3	S-GP
occurred	O
also	O
in	O
cells	O
expressing	O
kinase	S-GP
-dead	O
Fer	S-GP
,	O
suggesting	O
a	O
kinase	S-GP
-independent	O
adaptor	O
role	O
of	O
Fer	S-GP
.	O
Expression	O
of	O
Fer	S-GP
was	O
dispensable	O
for	O
PDGF-BB	S-GP
-induced	O
proliferation	O
and	O
migration	O
,	O
but	O
essential	O
for	O
colony	O
formation	O
in	O
soft	O
agar	O
.	O
Tumor	O
growth	O
in	O
vivo	O
was	O
delayed	O
in	O
cells	O
depleted	O
of	O
Fer	S-GP
expression	O
.	O
Our	O
data	O
suggests	O
a	O
critical	O
role	O
of	O
Fer	S-GP
in	O
PDGF-BB	S-GP
-induced	O
Stat3	S-GP
activation	O
and	O
cell	O
transformation	O
.	O

Exposure	O
to	O
valproic	B-chemical
acid	E-chemical
inhibits	O
chondrogenesis	O
and	O
osteogenesis	O
in	O
mid-organogenesis	O
mouse	O
limbs	O
.	O
In	O
utero	O
exposure	O
to	O
valproic	B-chemical
acid	E-chemical
(	O
VPA	S-chemical
)	O
,	O
a	O
histone	B-GP
deacetylase	E-GP
(	O
HDAC	S-GP
)	O
inhibitor	O
,	O
causes	O
neural	O
tube	O
,	O
heart	O
,	O
and	O
limb	O
defects	O
.	O
Valpromide	S-chemical
(	O
VPD	S-chemical
)	O
,	O
the	O
amide	S-chemical
derivative	O
of	O
VPA	S-chemical
,	O
does	O
not	O
inhibit	O
HDAC	S-GP
activity	O
and	O
is	O
a	O
weak	O
teratogen	O
in	O
vivo	O
.	O
The	O
detailed	O
mechanism	O
of	O
action	O
of	O
VPA	S-chemical
as	O
a	O
teratogen	O
is	O
not	O
known	O
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
VPA	S-chemical
disrupts	O
regulation	O
of	O
the	O
expression	O
of	O
genes	O
that	O
are	O
critical	O
in	O
chondrogenesis	O
and	O
osteogenesis	O
during	O
limb	O
development	O
.	O
Murine	O
gestation	O
day-12	O
embryonic	O
forelimbs	O
were	O
excised	O
and	O
exposed	O
to	O
VPA	S-chemical
or	O
VPD	S-chemical
in	O
a	O
limb	O
bud	O
culture	O
system	O
.	O
VPA	S-chemical
caused	O
a	O
significant	O
concentration-	O
dependent	O
increase	O
in	O
limb	O
abnormalities	O
,	O
which	O
was	O
correlated	O
with	O
its	O
HDAC	S-GP
inhibitory	O
effect	O
.	O
The	O
signaling	O
of	O
both	O
Sox9	S-GP
and	O
Runx2	S-GP
,	O
key	O
regulators	O
of	O
chondrogenesis	O
,	O
was	O
downregulated	O
by	O
VPA	S-chemical
.	O
In	O
contrast	O
,	O
VPD	S-chemical
had	O
little	O
effect	O
on	O
limb	O
morphology	O
and	O
no	O
significant	O
effect	O
on	O
HDAC	S-GP
activity	O
or	O
the	O
expression	O
of	O
marker	O
genes	O
.	O
Thus	O
,	O
VPA	S-chemical
exposure	O
dysregulated	O
the	O
expression	O
of	O
target	O
genes	O
directly	O
involved	O
in	O
chondrogenesis	O
and	O
osteogenesis	O
in	O
the	O
developing	O
limb	O
.	O
Disturbances	O
in	O
these	O
signaling	O
pathways	O
are	O
likely	O
to	O
be	O
a	O
consequence	O
of	O
HDAC	S-GP
inhibition	O
because	O
VPD	S-chemical
did	O
not	O
affect	O
their	O
expressions	O
.	O

An	O
overview	O
of	O
transcriptional	O
regulation	O
in	O
response	O
to	O
toxicological	O
insult	O
.	O
The	O
completion	O
of	O
the	O
human	O
genome	O
project	O
and	O
the	O
subsequent	O
advent	O
of	O
DNA	O
microarray	O
and	O
high-throughput	O
sequencing	O
technologies	O
have	O
led	O
to	O
a	O
renaissance	O
in	O
molecular	O
toxicology	O
.	O
Toxicogenomic	O
data	O
sets	O
,	O
from	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
,	O
are	O
growing	O
exponentially	O
,	O
providing	O
a	O
wealth	O
of	O
information	O
on	O
regulation	O
of	O
stress	O
pathways	O
at	O
the	O
transcriptome	O
level	O
.	O
Through	O
such	O
studies	O
,	O
we	O
are	O
now	O
beginning	O
to	O
appreciate	O
the	O
diversity	O
and	O
complexity	O
of	O
biological	O
responses	O
to	O
xenobiotics	O
.	O
In	O
this	O
review	O
,	O
we	O
aim	O
to	O
consolidate	O
and	O
summarise	O
the	O
major	O
toxicologically	O
relevant	O
transcription	O
factor-governed	O
molecular	O
pathways	O
.	O
It	O
is	O
becoming	O
clear	O
that	O
different	O
chemical	O
entities	O
can	O
cause	O
oxidative	O
,	O
genotoxic	O
and	O
proteotoxic	O
stress	O
,	O
which	O
induce	O
cellular	O
responses	O
in	O
an	O
effort	O
to	O
restore	O
homoeostasis	O
.	O
Primary	O
among	O
the	O
response	O
pathways	O
involved	O
are	O
NFE2L2	S-GP
(	O
Nrf2	S-GP
)	O
,	O
NFE2L1	S-GP
(	O
Nrf1	S-GP
)	O
,	O
p53	S-GP
,	O
heat	B-GP
shock	I-GP
factor	E-GP
and	O
the	O
unfolded	O
protein	O
response	O
.	O
Additionally	O
,	O
more	O
specific	O
mechanisms	O
exist	O
where	O
xenobiotics	O
act	O
as	O
ligands	O
,	O
including	O
the	O
aryl	B-GP
hydrocarbon	I-GP
receptor	E-GP
,	O
metal-responsive	B-GP
transcription	I-GP
factor-1	E-GP
and	O
the	O
nuclear	B-GP
receptor	E-GP
family	O
of	O
transcription	O
factors	O
.	O
Other	O
pathways	O
including	O
the	O
immunomodulatory	O
transcription	O
factors	O
NF-κB	S-GP
and	O
STAT	S-GP
together	O
with	O
the	O
hypoxia-inducible	B-GP
transcription	I-GP
factor	E-GP
HIF	S-GP
are	O
also	O
implicated	O
in	O
cellular	O
responses	O
to	O
xenobiotic	O
exposure	O
.	O
A	O
less	O
specific	O
but	O
equally	O
important	O
aspect	O
to	O
cellular	O
injury	O
controlled	O
by	O
transcriptional	O
activity	O
is	O
loss	O
of	O
tissue-specific	O
gene	O
expression	O
,	O
resulting	O
in	O
dedifferentiation	O
of	O
target	O
cells	O
and	O
compromise	O
of	O
tissue	O
function	O
.	O
Here	O
,	O
we	O
review	O
these	O
pathways	O
and	O
the	O
genes	O
they	O
regulate	O
in	O
order	O
to	O
provide	O
an	O
overview	O
of	O
this	O
growing	O
field	O
of	O
molecular	O
toxicology	O
.	O

STZ	O
transport	O
and	O
cytotoxicity	O
.	O
Specific	O
enhancement	O
in	O
GLUT2	S-GP
-expressing	O
cells	O
.	O
The	O
glucose	S-chemical
analog	O
streptozotocin	S-chemical
(	O
STZ	S-chemical
)	O
has	O
long	O
been	O
used	O
as	O
a	O
tool	O
for	O
creating	O
experimental	O
diabetes	O
because	O
of	O
its	O
relatively	O
specific	O
beta-cell	O
cytotoxic	O
effect	O
,	O
but	O
the	O
mechanism	O
by	O
which	O
systemic	O
injection	O
of	O
STZ	S-chemical
causes	O
beta-cell	O
destruction	O
is	O
not	O
well	O
understood	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
have	O
used	O
insulinoma	O
(	O
RIN	O
)	O
and	O
AtT-20ins	O
cell	O
lines	O
engineered	O
for	O
overexpression	O
of	O
GLUT2	S-GP
or	O
GLUT1	S-GP
to	O
investigate	O
the	O
role	O
of	O
glucose	B-GP
transporter	E-GP
isoforms	O
in	O
mediating	O
STZ	S-chemical
cytotoxicity	O
.	O
The	O
in	O
vivo	O
effects	O
of	O
STZ	S-chemical
were	O
evaluated	O
by	O
implantation	O
of	O
RIN	O
cells	O
expressing	O
or	O
lacking	O
GLUT2	S-GP
into	O
athymic	O
nude	O
rats	O
.	O
The	O
drug	O
had	O
a	O
potent	O
cytotoxic	O
effect	O
on	O
RIN	O
cells	O
expressing	O
GLUT2	S-GP
,	O
but	O
had	O
no	O
effect	O
on	O
cells	O
lacking	O
GLUT2	S-GP
expression	O
,	O
as	O
indicated	O
by	O
histological	O
analysis	O
and	O
measurement	O
of	O
the	O
blood	O
glucose	S-chemical
levels	O
of	O
treated	O
animals	O
.	O
The	O
preferential	O
cytotoxic	O
effect	O
of	O
STZ	S-chemical
on	O
GLUT2	S-GP
-expressing	O
cell	O
lines	O
was	O
confirmed	O
by	O
in	O
vitro	O
analysis	O
of	O
GLUT2	S-GP
-expressing	O
and	O
untransfected	O
RIN	O
cells	O
,	O
as	O
well	O
as	O
GLUT2	S-GP
-	O
and	O
GLUT1	S-GP
-overexpressing	O
AtT-20ins	O
cells	O
.	O
Consistent	O
with	O
these	O
data	O
,	O
only	O
GLUT2	S-GP
-expressing	O
RIN	O
or	O
AtT-20ins	O
cells	O
transported	O
STZ	S-chemical
efficiently	O
.	O
We	O
conclude	O
that	O
expression	O
of	O
GLUT2	S-GP
is	O
required	O
for	O
efficient	O
killing	O
of	O
neuroendocrine	O
cells	O
by	O
STZ	S-chemical
,	O
and	O
this	O
effect	O
is	O
related	O
to	O
specific	O
recognition	O
of	O
the	O
drug	O
as	O
a	O
transported	O
substrate	O
by	O
GLUT2	S-GP
but	O
not	O
GLUT1	S-GP
.	O

Cadmium	B-chemical
telluride	E-chemical
quantum	O
dots	O
cause	O
oxidative	O
stress	O
leading	O
to	O
extrinsic	O
and	O
intrinsic	O
apoptosis	O
in	O
hepatocellular	O
carcinoma	O
HepG2	O
cells	O
.	O
The	O
mechanisms	O
of	O
toxicity	O
related	O
to	O
human	O
hepatocellular	O
carcinoma	O
HepG2	O
cell	O
exposures	O
to	O
cadmium	B-chemical
telluride	E-chemical
quantum	O
dots	O
(	O
CdTe	S-chemical
-QDs	O
)	O
were	O
investigated	O
.	O
CdTe	S-chemical
-QDs	O
caused	O
cytotoxicity	O
in	O
HepG2	O
cells	O
in	O
a	O
dose-	O
and	O
time-dependent	O
manner	O
.	O
Treated	O
cells	O
showed	O
an	O
increase	O
in	O
reactive	O
oxygen	S-chemical
species	O
(	O
ROS	O
)	O
.	O
Altered	O
antioxidant	O
levels	O
were	O
demonstrated	O
by	O
depletion	O
of	O
reduced	B-chemical
glutathione	E-chemical
(	O
GSH	S-chemical
)	O
,	O
a	O
decreased	O
ratio	O
of	O
reduced	O
glutathione	S-chemical
to	O
oxidized	B-chemical
glutathione	E-chemical
(	O
GSH	S-chemical
/	O
GSSG	S-chemical
)	O
and	O
an	O
increased	O
NF-E2-related	B-GP
Factor	I-GP
2	E-GP
(	O
Nrf2	S-GP
)	O
activation	O
.	O
Enzyme	O
assays	O
showed	O
that	O
superoxide	B-GP
dismutase	E-GP
(	O
SOD	S-GP
)	O
activity	O
was	O
elevated	O
whereas	O
catalase	S-GP
(	O
CAT	S-GP
)	O
and	O
glutathione-S-transferase	S-GP
(	O
GST	S-GP
)	O
activities	O
were	O
depressed	O
.	O
Further	O
analyses	O
revealed	O
that	O
CdTe	S-chemical
-QD	O
exposure	O
resulted	O
in	O
apoptosis	O
,	O
indicated	O
by	O
changes	O
in	O
levels	O
of	O
caspase-3	S-GP
activity	O
,	O
poly	B-GP
ADP-ribose	I-GP
polymerase	E-GP
(	O
PARP	S-GP
)	O
cleavage	O
and	O
phosphatidylserine	S-chemical
externalization	O
.	O
Extrinsic	O
apoptotic	O
pathway	O
markers	O
such	O
as	O
Fas	S-GP
levels	O
and	O
caspase-8	S-GP
activity	O
increased	O
as	O
a	O
result	O
of	O
CdTe	S-chemical
-QD	O
exposure	O
.	O
Involvement	O
of	O
the	O
intrinsic/mitochondrial	O
apoptotic	O
pathway	O
was	O
indicated	O
by	O
decreased	O
levels	O
of	O
B-cell	B-GP
lymphoma	I-GP
2	E-GP
(	O
Bcl2	S-GP
)	O
protein	O
and	O
mitochondrial	O
cytochrome	B-GP
c	E-GP
,	O
and	O
by	O
increased	O
levels	O
of	O
mitochondrial	O
Bcl-2-associated	B-GP
X	I-GP
protein	E-GP
(	O
Bax	S-GP
)	O
and	O
cytosolic	O
cytochrome	B-GP
c	E-GP
.	O
Further	O
,	O
mitogen-activated	B-GP
protein	I-GP
kinases	E-GP
(	O
MAPKs	S-GP
)	O
such	O
as	O
c-Jun	B-GP
N-terminal	I-GP
kinases	E-GP
(	O
JNK	S-GP
)	O
,	O
extracellular	B-GP
signal-regulated	I-GP
kinases	E-GP
(	O
Erk1/2	S-GP
)	O
,	O
and	O
p38	S-GP
were	O
all	O
activated	O
.	O
Our	O
findings	O
reveal	O
that	O
CdTe	S-chemical
-QDs	O
cause	O
oxidative	O
stress	O
,	O
interfere	O
with	O
antioxidant	O
defenses	O
and	O
activate	O
protein	O
kinases	S-GP
,	O
leading	O
to	O
apoptosis	O
via	O
both	O
extrinsic	O
and	O
intrinsic	O
pathways	O
.	O
Since	O
the	O
effects	O
of	O
CdTe	S-chemical
-QDs	O
on	O
selected	O
biomarkers	O
were	O
similar	O
or	O
greater	O
compared	O
to	O
those	O
of	O
CdCl2	S-chemical
at	O
equivalent	O
concentrations	O
of	O
cadmium	S-chemical
,	O
the	O
study	O
suggests	O
that	O
the	O
toxicity	O
of	O
CdTe	S-chemical
-QDs	O
arises	O
from	O
a	O
combination	O
of	O
the	O
effects	O
of	O
cadmium	O
and	O
ROS	O
generated	O
from	O
the	O
NPs	O
.	O

The	O
persistent	O
membrane	O
retention	O
of	O
desipramine	S-chemical
causes	O
lasting	O
inhibition	O
of	O
norepinephrine	B-GP
transporter	E-GP
function	O
.	O
The	O
present	O
study	O
examined	O
the	O
potential	O
membrane	O
retention	O
of	O
desipramine	S-chemical
(	O
DMI	S-chemical
)	O
following	O
exposures	O
of	O
293-	O
hNET	S-GP
cells	O
to	O
DMI	S-chemical
,	O
and	O
its	O
effect	O
on	O
[	B-chemical
3H	I-chemical
]	I-chemical
NE	E-chemical
uptake	O
.	O
Incubation	O
of	O
cells	O
with	O
500	O
nM	O
DMI	S-chemical
for	O
1	O
h	O
or	O
1	O
day	O
persistently	O
inhibited	O
the	O
uptake	O
of	O
[	B-chemical
3H	I-chemical
]	I-chemical
NE	E-chemical
up	O
to	O
7	O
days	O
,	O
despite	O
daily	O
repeated	O
washing	O
of	O
cells	O
with	O
drug-free	O
medium	O
.	O
Uptake	O
inhibition	O
was	O
paralleled	O
by	O
persistent	O
retention	O
of	O
DMI	S-chemical
associated	O
with	O
cells	O
,	O
as	O
determined	O
by	O
HPLC	O
and	O
by	O
radiotracer	O
experiments	O
using	O
[	B-chemical
3H	I-chemical
]	I-chemical
DMI	E-chemical
.	O
[	B-chemical
3H	I-chemical
]	I-chemical
DMI	E-chemical
trapped	O
in	O
membranes	O
was	O
displaceable	O
by	O
the	O
structurally	O
unrelated	O
NET	S-GP
inhibitor	O
,	O
nisoxetine	S-chemical
,	O
in	O
a	O
concentration-dependent	O
manner	O
,	O
implying	O
interaction	O
of	O
retained	O
[	B-chemical
3H	I-chemical
]	I-chemical
DMI	E-chemical
with	O
the	O
NET	S-GP
.	O
A	O
similar	O
cellular	O
retention	O
was	O
observed	O
following	O
incubation	O
of	O
cells	O
with	O
nisoxetine	S-chemical
.	O
The	O
results	O
demonstrate	O
that	O
DMI	S-chemical
and	O
nisoxetine	S-chemical
are	O
persistently	O
retained	O
in	O
cell	O
membranes	O
,	O
at	O
least	O
partly	O
in	O
association	O
with	O
the	O
NET	S-GP
.	O
The	O
retention	O
and	O
slow	O
diffusion	O
of	O
DMI	S-chemical
and	O
nisoxetine	S-chemical
from	O
membranes	O
may	O
contribute	O
to	O
their	O
pharmacological	O
and	O
modulatory	O
action	O
on	O
NET	S-GP
.	O

The	O
propeptides	O
of	O
VEGF-D	S-GP
determine	O
heparin	O
binding	O
,	O
receptor	O
heterodimerization	O
,	O
and	O
effects	O
on	O
tumor	O
biology	O
.	O
VEGF-D	S-GP
is	O
an	O
angiogenic	O
and	O
lymphangiogenic	O
glycoprotein	O
that	O
can	O
be	O
proteolytically	O
processed	O
generating	O
various	O
forms	O
differing	O
in	O
subunit	O
composition	O
due	O
to	O
the	O
presence	O
or	O
absence	O
of	O
N	S-chemical
-	O
and	O
C	S-chemical
-terminal	O
propeptides	O
.	O
These	O
propeptides	O
flank	O
the	O
central	O
VEGF	B-GP
homology	I-GP
domain	E-GP
,	O
that	O
contains	O
the	O
binding	O
sites	O
for	O
VEGF	B-GP
receptors	E-GP
(	O
VEGFRs	S-GP
)	O
,	O
but	O
their	O
biological	O
functions	O
were	O
unclear	O
.	O
Characterization	O
of	O
propeptide	O
function	O
will	O
be	O
important	O
to	O
clarify	O
which	O
forms	O
of	O
VEGF-D	S-GP
are	O
biologically	O
active	O
and	O
therefore	O
clinically	O
relevant	O
.	O
Here	O
we	O
use	O
VEGF-D	S-GP
mutants	O
deficient	O
in	O
either	O
propeptide	O
,	O
and	O
in	O
the	O
capacity	O
to	O
process	O
the	O
remaining	O
propeptide	O
,	O
to	O
monitor	O
the	O
functions	O
of	O
these	O
domains	O
.	O
We	O
report	O
for	O
the	O
first	O
time	O
that	O
VEGF-D	S-GP
binds	O
heparin	O
,	O
and	O
that	O
the	O
C	S-chemical
-terminal	O
propeptide	O
significantly	O
enhances	O
this	O
interaction	O
(	O
removal	O
of	O
this	O
propeptide	O
from	O
full-length	O
VEGF-D	S-GP
completely	O
prevents	O
heparin	O
binding	O
)	O
.	O
We	O
also	O
show	O
that	O
removal	O
of	O
either	O
the	O
N	S-chemical
-	O
or	O
C	S-chemical
-terminal	O
propeptide	O
is	O
required	O
for	O
VEGF-D	S-GP
to	O
drive	O
formation	O
of	O
VEGFR-2	S-GP
/	O
VEGFR-3	S-GP
heterodimers	O
which	O
have	O
recently	O
been	O
shown	O
to	O
positively	O
regulate	O
angiogenic	O
sprouting	O
.	O
The	O
mature	O
form	O
of	O
VEGF-D	S-GP
,	O
lacking	O
both	O
propeptides	O
,	O
can	O
also	O
promote	O
formation	O
of	O
these	O
receptor	O
heterodimers	O
.	O
In	O
a	O
mouse	O
tumor	O
model	O
,	O
removal	O
of	O
only	O
the	O
C	S-chemical
-terminal	O
propeptide	O
from	O
full-length	O
VEGF-D	S-GP
was	O
sufficient	O
to	O
enhance	O
angiogenesis	O
and	O
tumor	O
growth	O
.	O
In	O
contrast	O
,	O
removal	O
of	O
both	O
propeptides	O
is	O
required	O
for	O
high	O
rates	O
of	O
lymph	O
node	O
metastasis	O
.	O
The	O
findings	O
reported	O
here	O
show	O
that	O
the	O
propeptides	O
profoundly	O
influence	O
molecular	O
interactions	O
of	O
VEGF-D	S-GP
with	O
VEGF	B-GP
receptors	E-GP
,	O
co-receptors	O
,	O
and	O
heparin	O
,	O
and	O
its	O
effects	O
on	O
tumor	O
biology	O
.	O

Desvenlafaxine	B-chemical
succinate	E-chemical
identifies	O
novel	O
antagonist	O
binding	O
determinants	O
in	O
the	O
human	B-GP
norepinephrine	I-GP
transporter	E-GP
.	O
Desvenlafaxine	B-chemical
succinate	E-chemical
(	O
DVS	S-chemical
)	O
is	O
a	O
recently	O
introduced	O
antagonist	O
of	O
the	O
human	B-GP
norepinephrine	I-GP
and	I-GP
serotonin	I-GP
transporters	E-GP
(	O
hNET	S-GP
and	O
hSERT	S-GP
,	O
respectively	O
)	O
,	O
currently	O
in	O
clinical	O
development	O
for	O
use	O
in	O
the	O
treatment	O
of	O
major	O
depressive	O
disorder	O
and	O
vasomotor	O
symptoms	O
associated	O
with	O
menopause	O
.	O
Initial	O
evaluation	O
of	O
the	O
pharmacological	O
properties	O
of	O
DVS	S-chemical
(	O
J	O
Pharmacol	O
Exp	O
Ther	O
318:657-665	O
,	O
2006	O
)	O
revealed	O
significantly	O
reduced	O
potency	O
for	O
the	O
hNET	S-GP
expressed	O
in	O
membranes	O
compared	O
with	O
whole	O
cells	O
when	O
competing	O
for	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
nisoxetine	E-chemical
(	O
NIS	S-chemical
)	O
binding	O
.	O
Using	O
hNET	S-GP
in	O
transfected	O
human	O
embryonic	O
kidney-293	O
cells	O
,	O
this	O
difference	O
in	O
potency	O
for	O
DVS	S-chemical
at	O
sites	O
labeled	O
by	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
NIS	E-chemical
was	O
found	O
to	O
distinguish	O
DVS	S-chemical
,	O
the	O
DVS	S-chemical
analog	O
rac-	B-chemical
(	I-chemical
1-	I-chemical
[	I-chemical
1-	I-chemical
(	I-chemical
3-chloro-phenyl	I-chemical
)	I-chemical
-2-	I-chemical
(	I-chemical
4-methylpiperazin-1-yl	I-chemical
)	I-chemical
-ethyl	I-chemical
]	I-chemical
cyclohexanol	E-chemical
(	O
WY-46824	S-chemical
)	O
,	O
methylphenidate	S-chemical
,	O
and	O
the	O
cocaine	S-chemical
analog	O
3beta-	B-chemical
(	I-chemical
4-iodophenyl	I-chemical
)	I-chemical
tropane-2beta-carboxylic	I-chemical
acid	I-chemical
methyl	I-chemical
ester	E-chemical
(	O
RTI-55	S-chemical
)	O
from	O
other	O
hNET	S-GP
antagonists	O
,	O
such	O
as	O
NIS	S-chemical
,	O
mazindol	S-chemical
,	O
tricyclic	S-chemical
antidepressants	O
,	O
and	O
cocaine	S-chemical
.	O
These	O
differences	O
seem	O
not	O
to	O
arise	O
from	O
preparation-specific	O
perturbations	O
of	O
ligand	O
intrinsic	O
affinity	O
or	O
antagonist-specific	O
surface	O
trafficking	O
but	O
rather	O
from	O
protein	O
conformational	O
alterations	O
that	O
perturb	O
the	O
relationships	O
between	O
distinct	O
hNET	S-GP
binding	O
sites	O
.	O
In	O
an	O
initial	O
search	O
for	O
molecular	O
features	O
that	O
differentially	O
define	O
antagonist	O
binding	O
determinants	O
,	O
we	O
document	O
that	O
Val148	O
in	O
hNET	B-GP
transmembrane	I-GP
domain	I-GP
3	E-GP
selectively	O
disrupts	O
NIS	S-chemical
binding	O
but	O
not	O
that	O
of	O
DVS	O
.	O

Ligand-dependent	O
transcriptional	O
activities	O
of	O
four	O
torafugu	O
pufferfish	O
Takifugu	O
rubripes	O
peroxisome	B-GP
proliferator-activated	I-GP
receptors	E-GP
.	O
Structural	O
and	O
functional	O
properties	O
were	O
investigated	O
for	O
four	O
peroxisome	B-GP
proliferator-activated	I-GP
receptors	E-GP
(	O
PPARs	S-GP
)	O
,	O
PPARalpha1	S-GP
,	O
PPARalpha2	S-GP
,	O
PPARbeta	S-GP
,	O
and	O
PPARgamma	S-GP
,	O
from	O
torafugu	O
pufferfish	O
Takifugu	O
rubripes	O
and	O
determined	O
for	O
their	O
transcriptional	O
activity	O
by	O
the	O
reporter	O
assay	O
using	O
reporter	O
plasmids	O
containing	O
three	O
copies	O
of	O
the	O
acyl-CoA	B-GP
oxidase	I-GP
PPAR	I-GP
response	I-GP
element	E-GP
.	O
Although	B-GP
torafugu	I-GP
PPARs	E-GP
showed	O
a	O
high	O
similarity	O
in	O
the	O
primary	O
structure	O
to	O
other	O
vertebrate	O
counterparts	O
,	O
torafugu	B-GP
PPARalpha2	I-GP
and	I-GP
gamma	E-GP
contained	O
additional	O
sequences	O
of	O
21	O
and	O
28	O
amino	B-chemical
acids	E-chemical
,	O
respectively	O
,	O
as	O
in	O
the	O
case	O
of	O
other	O
teleost	O
fish	O
species	O
when	O
compared	O
with	O
African	O
clawed	O
frog	O
counterparts	O
.	O
The	O
transcriptional	O
activity	O
of	O
torafugu	O
PPARalpha1	S-GP
was	O
enhanced	O
4.5-	O
and	O
11.5-fold	O
by	O
Wy-14643	S-chemical
and	O
5,8,11,14-eicosatetraynoic	B-chemical
acid	E-chemical
(	O
ETYA	S-chemical
)	O
each	O
at	O
10	O
microM	O
,	O
respectively	O
,	O
whereas	O
that	O
of	O
PPARalpha2	S-GP
,	O
4.5-	O
and	O
7.3-fold	O
at	O
the	O
same	O
concentration	O
of	O
the	O
respective	O
ligands	O
,	O
respectively	O
.	O
The	O
activities	O
of	O
torafugu	O
PPARalpha1	B-GP
and	I-GP
alpha2	E-GP
were	O
also	O
enhanced	O
5.6-	O
and	O
6.3-fold	O
by	O
ETYA	S-chemical
at	O
1	O
microM	O
,	O
respectively	O
,	O
but	O
not	O
by	O
Wy-14643	S-chemical
at	O
this	O
concentration	O
.	O
Furthermore	O
,	O
the	O
activities	O
of	O
the	O
two	O
torafugu	B-GP
PPARalphas	E-GP
were	O
enhanced	O
4.3-	O
and	O
7.6-fold	O
by	O
arachidonic	B-chemical
acid	E-chemical
,	O
4.4-	O
and	O
5.2-fold	O
by	O
docosahexaenoic	B-chemical
acid	E-chemical
,	O
and	O
6.7-	O
and	O
8.0-fold	O
by	O
eicosapentaenoic	B-chemical
acid	E-chemical
each	O
at	O
50	O
microM	O
,	O
respectively	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
activities	O
of	O
torafugu	B-GP
PPARbeta	I-GP
and	I-GP
gamma	E-GP
were	O
not	O
changed	O
by	O
Wy-14643	S-chemical
,	O
ETYA	S-chemical
,	O
rosiglitazone	S-chemical
,	O
nor	O
PUFAs	O
.	O
These	O
results	O
suggest	O
that	O
the	O
activities	O
of	O
torafugu	B-GP
PPARbeta	I-GP
and	I-GP
gamma	E-GP
require	O
undefined	O
ligands	O
.	O
Alternatively	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
their	O
activation	O
are	O
different	O
from	O
those	O
of	O
other	O
vertebrates	O
.	O

Mechanistic	O
Aspects	O
of	O
hSOD1	S-GP
Maturation	O
from	O
the	O
Solution	O
Structure	O
of	O
Cu	B-chemical
(	I-chemical
I	I-chemical
)	E-chemical
-Loaded	O
hCCS	B-GP
Domain	I-GP
1	E-GP
and	O
Analysis	O
of	O
Disulfide	S-chemical
-Free	O
hSOD1	S-GP
Mutants	O
.	O
Superoxide	B-GP
dismutase	I-GP
1	E-GP
(	O
SOD1	S-GP
)	O
maturation	O
within	O
the	O
cell	O
is	O
mainly	O
accomplished	O
with	O
the	O
SOD1-specific	B-GP
chaperone	E-GP
,	O
CCS	S-GP
,	O
a	O
dimeric	O
protein	O
with	O
three	O
distinct	O
domains	O
in	O
each	O
monomer	O
.	O
We	O
recently	O
showed	O
that	O
the	O
first	O
domain	O
of	O
human	B-GP
CCS	E-GP
(	O
hCCSD1	S-GP
)	O
is	O
responsible	O
for	O
copper	S-chemical
transfer	O
to	O
its	O
protein	O
partner	O
,	O
human	B-GP
SOD1	E-GP
(	O
hSOD1	S-GP
)	O
.	O
The	O
NMR	O
solution	O
structure	O
of	O
the	O
copper	B-chemical
(	I-chemical
I	I-chemical
)	E-chemical
-loaded	O
form	O
of	O
hCCSD1	S-GP
reported	O
here	O
contributes	O
further	O
to	O
characterization	O
of	O
the	O
copper-transfer	O
mechanism	O
to	O
hSOD1	S-GP
.	O
NMR	O
spectroscopy	O
was	O
also	O
used	O
to	O
examine	O
the	O
hSOD1	S-GP
mutants	O
C57A	S-GP
,	O
C146A	S-GP
,	O
and	O
C57A	S-GP
/	O
C146A	S-GP
,	O
which	O
are	O
unable	O
to	O
form	O
the	O
structurally	O
conserved	O
disulfide	S-chemical
bond	O
in	O
SOD1	S-GP
,	O
in	O
order	O
to	O
investigate	O
the	O
role	O
of	O
these	O
cysteines	S-chemical
during	O
hSOD1	S-GP
copper	O
acquisition	O
.	O
Together	O
,	O
the	O
information	O
on	O
both	O
hCCS	S-GP
and	O
hSOD1	S-GP
,	O
along	O
with	O
a	O
sequence	O
analysis	O
of	O
eukaryotic	O
CCSD1	S-GP
,	O
allows	O
us	O
to	O
propose	O
important	O
mechanistic	O
aspects	O
regarding	O
the	O
copper	S-chemical
-transfer	O
process	O
from	O
hCCS	S-GP
to	O
hSOD1	S-GP
.	O

Metformin	S-chemical
,	O
but	O
not	O
leptin	O
,	O
regulates	O
AMP-activated	B-GP
protein	I-GP
kinase	E-GP
in	O
pancreatic	O
islets	O
:	O
impact	O
on	O
glucose	S-chemical
-stimulated	O
insulin	S-GP
secretion	O
.	O
Metformin	S-chemical
,	O
a	O
drug	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
,	O
has	O
recently	O
been	O
shown	O
to	O
act	O
on	O
skeletal	O
muscle	O
and	O
liver	O
in	O
part	O
through	O
the	O
activation	O
of	O
AMP-activated	B-GP
protein	I-GP
kinase	E-GP
(	O
AMPK	S-GP
)	O
.	O
Whether	O
metformin	S-chemical
or	O
the	O
satiety	O
factor	O
leptin	O
,	O
which	O
also	O
stimulates	O
AMPK	S-GP
in	O
muscle	O
,	O
regulates	O
this	O
enzyme	O
in	O
pancreatic	O
islets	O
is	O
unknown	O
.	O
We	O
have	O
recently	O
shown	O
that	O
forced	O
increases	O
in	O
AMPK	S-GP
activity	O
inhibit	O
insulin	S-GP
secretion	O
from	O
MIN6	O
cells	O
(	O
da	O
Silva	O
Xavier	O
G	O
,	O
Leclerc	O
I	O
,	O
Varadi	O
A	O
,	O
Tsuboi	O
T	O
,	O
Moule	O
SK	O
,	O
and	O
Rutter	O
GA.	O
Biochem	O
J	O
371	O
:	O
761-774	O
,	O
2003	O
)	O
.	O
Here	O
,	O
we	O
explore	O
whether	O
1	O
)	O
glucose	S-chemical
,	O
metformin	S-chemical
,	O
or	O
leptin	O
regulates	O
AMPK	S-GP
activity	O
in	O
isolated	O
islets	O
from	O
rodent	O
and	O
human	O
and	O
2	O
)	O
whether	O
changes	O
in	O
AMPK	S-GP
activity	O
modulate	O
insulin	S-GP
secretion	O
from	O
human	O
islets	O
.	O
Increases	O
in	O
glucose	S-chemical
concentration	O
from	O
0	O
to	O
3	O
and	O
from	O
3	O
to	O
17	O
mM	O
inhibited	O
AMPK	S-GP
activity	O
in	O
primary	O
islets	O
from	O
mouse	O
,	O
rat	O
,	O
and	O
human	O
,	O
confirming	O
previous	O
findings	O
in	O
insulinoma	O
cells	O
.	O
Incubation	O
with	O
metformin	S-chemical
(	O
0.2-1	O
mM	O
)	O
activated	O
AMPK	S-GP
in	O
both	O
human	O
islets	O
and	O
MIN6	O
beta-cells	O
in	O
parallel	O
with	O
an	O
inhibition	O
of	O
insulin	S-GP
secretion	O
,	O
whereas	O
leptin	O
(	O
10-100	O
nM	O
)	O
was	O
without	O
effect	O
in	O
MIN6	O
cells	O
.	O
These	O
studies	O
demonstrate	O
that	O
AMPK	S-GP
activity	O
is	O
subject	O
to	O
regulation	O
by	O
both	O
glucose	S-chemical
and	O
metformin	S-chemical
in	O
pancreatic	O
islets	O
and	O
clonal	O
beta-cells	O
.	O
The	O
inhibitory	O
effects	O
of	O
metformin	S-chemical
on	O
insulin	S-GP
secretion	O
may	O
therefore	O
need	O
to	O
be	O
considered	O
with	O
respect	O
to	O
the	O
use	O
of	O
this	O
drug	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
.	O

Serotonin	B-GP
transporter	E-GP
polymorphisms	O
and	O
measures	O
of	O
impulsivity	O
,	O
aggression	O
,	O
and	O
sensation	O
seeking	O
among	O
African-American	O
cocaine	S-chemical
-dependent	O
individuals	O
.	O
Considerable	O
evidence	O
indicates	O
that	O
serotonergic	O
mechanisms	O
,	O
particularly	O
the	O
serotonin	B-GP
transporter	E-GP
(	O
5HTT	S-GP
)	O
,	O
may	O
mediate	O
central	O
effects	O
of	O
cocaine	S-chemical
and	O
may	O
also	O
be	O
involved	O
in	O
impulsive	O
and	O
aggressive	O
behavior	O
.	O
We	O
investigated	O
whether	O
polymorphisms	O
in	O
the	O
5HTT	S-GP
gene	O
were	O
related	O
to	O
traits	O
of	O
impulsivity	O
,	O
sensation	O
seeking	O
,	O
and	O
aggression	O
among	O
cocaine	S-chemical
abusers	O
.	O
Standardized	O
measures	O
of	O
these	O
personality	O
traits	O
were	O
obtained	O
in	O
a	O
sample	O
of	O
105	O
severely	O
affected	O
cocaine	S-chemical
-dependent	O
African-American	O
subjects	O
and	O
44	O
African-American	O
controls	O
.	O
Two	O
polymorphisms	O
of	O
the	O
5HTT	S-GP
gene	O
were	O
examined	O
involving	O
the	O
5	O
'	O
promoter	O
(	O
5HTTLPR	S-GP
)	O
region	O
and	O
a	O
17	O
base	O
pair	O
variable-number-tandem-repeat	S-GP
(	O
VNTR	S-GP
)	O
marker	O
among	O
cocaine	S-chemical
patients	O
.	O
No	O
significant	O
relationships	O
were	O
observed	O
between	O
polymorphic	O
variants	O
of	O
the	O
5HTTLPR	S-GP
and	O
VNTR	S-GP
regions	O
and	O
scores	O
on	O
any	O
of	O
the	O
trait	O
measures	O
.	O
Similarly	O
,	O
demographic	O
variables	O
and	O
measures	O
of	O
severity	O
of	O
substance	O
use	O
and	O
depression	O
were	O
unrelated	O
to	O
allele	O
frequencies	O
or	O
genotype	O
distributions	O
of	O
the	O
variants	O
among	O
cocaine	S-chemical
patients	O
.	O
As	O
expected	O
,	O
cocaine	S-chemical
patients	O
scored	O
significantly	O
higher	O
on	O
total	O
scores	O
of	O
impulsivity	O
,	O
aggression	O
,	O
and	O
sensation	O
seeking	O
compared	O
to	O
controls	O
.	O
The	O
findings	O
do	O
not	O
seem	O
to	O
support	O
an	O
association	O
between	O
these	O
polymorphisms	O
in	O
the	O
5HTT	S-GP
gene	O
and	O
impulsive-aggressive	O
traits	O
among	O
cocaine	S-chemical
-dependent	O
African-American	O
individuals	O
.	O

Anti-inflammatory	O
activity	O
of	O
patchouli	B-chemical
alcohol	E-chemical
in	O
RAW264.7	O
and	O
HT-29	O
cells	O
.	O
Patchouli	B-chemical
alcohol	E-chemical
(	O
PA	O
)	O
is	O
a	O
chemical	O
compound	O
extracted	O
from	O
patchouli	O
which	O
belongs	O
to	O
the	O
genus	O
Pogostemon	O
,	O
herb	O
of	O
mint	O
family	O
.	O
Recently	O
,	O
it	O
has	O
been	O
reported	O
that	O
PA	O
inhibits	O
the	O
production	O
of	O
inflammatory	O
mediators	O
.	O
However	O
,	O
the	O
biological	O
mechanisms	O
of	O
PA	O
for	O
anti-inflammatory	O
activities	O
have	O
not	O
been	O
studied	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
PA	O
decreases	O
the	O
production	O
of	O
inflammatory	O
mediators	O
through	O
downregulation	O
of	O
the	O
NF-κB	S-GP
and	O
ERK	S-GP
pathway	O
.	O
Our	O
data	O
indicated	O
that	O
PA	O
inhibits	O
the	O
over-expression	O
of	O
iNOS	S-GP
and	O
IL-6	S-GP
in	O
protein	O
and	O
mRNA	O
levels	O
in	O
LPS-stimulated	O
RAW264.7	O
and	O
TNF-α	S-GP
stimulated	O
HT-29	O
cells	O
.	O
PA	O
inhibited	O
IκB-α	S-GP
degradation	O
and	O
p65	S-GP
nuclear	O
translocation	O
,	O
and	O
subsequently	O
suppressed	O
transcriptional	O
activity	O
of	O
NF-κB	S-GP
in	O
LPS-stimulated	O
RAW264.7	O
and	O
TNF-α	S-GP
-stimulated	O
HT-29	O
cells	O
.	O
In	O
addition	O
,	O
PA	O
inhibited	O
LPS-	O
or	O
TNF-α	S-GP
-stimulated	O
ERK1/2	S-GP
activation	O
by	O
decreasing	O
phosphorylation	O
of	O
ERK1/2	S-GP
.	O
These	O
findings	O
suggest	O
that	O
PA	O
shows	O
anti-inflammatory	O
activities	O
through	O
suppressing	O
ERK	S-GP
-mediated	O
NF-κB	S-GP
pathway	O
in	O
mouse	O
macrophage	O
and	O
human	O
colorectal	O
cancer	O
cells	O
.	O

Triple	O
pharmacological	O
blockade	O
of	O
the	O
renin	S-GP
-	O
angiotensin	S-GP
-	O
aldosterone	S-chemical
system	O
in	O
nondiabetic	O
CKD	O
:	O
an	O
open-label	O
crossover	O
randomized	O
controlled	O
trial	O
.	O
BACKGROUND	O
:	O
Agents	O
inhibiting	O
the	O
renin	S-GP
-	O
angiotensin	S-GP
-	O
aldosterone	S-chemical
(	O
RAAS	O
)	O
system	O
have	O
an	O
important	O
role	O
in	O
slowing	O
the	O
progression	O
of	O
chronic	O
kidney	O
disease	O
.	O
We	O
evaluated	O
the	O
hypothesis	O
that	O
the	O
addition	O
of	O
an	O
aldosterone	B-GP
receptor	E-GP
antagonist	O
to	O
an	O
angiotensin-converting	B-GP
enzyme	E-GP
(	O
ACE	S-GP
)	O
inhibitor	O
and	O
angiotensin	B-GP
II	I-GP
type	I-GP
1	I-GP
(	I-GP
AT-1	I-GP
)	I-GP
receptor	E-GP
blocker	O
(	O
ARB	O
)	O
(	O
triple	O
RAAS	O
blockade	O
)	O
may	O
provide	O
an	O
additional	O
benefit	O
compared	O
with	O
an	O
ACE	S-GP
inhibitor	O
and	O
ARB	O
(	O
double	O
RAAS	O
blockade	O
)	O
.	O
DESIGN	O
:	O
Randomized	O
open	O
controlled	O
crossover	O
study	O
.	O
SETTING	O
&	O
PARTICIPANTS	O
:	O
18	O
whites	O
(	O
7	O
women	O
,	O
11	O
men	O
)	O
from	O
the	O
Outpatient	O
Department	O
of	O
Nephrology	O
with	O
chronic	O
nondiabetic	O
proteinuric	O
kidney	O
diseases	O
,	O
mean	O
age	O
42.4	O
+/-	O
1.9	O
years	O
(	O
SEM	O
)	O
.	O
INTERVENTIONS	O
:	O
In	O
the	O
8-week	O
run-in	O
period	O
,	O
all	O
participants	O
received	O
the	O
ACE	S-GP
inhibitor	O
cilazapril	S-chemical
(	O
5	O
mg	O
)	O
,	O
the	O
ARB	O
telmisarta	S-chemical
n	O
(	O
80	O
mg	O
)	O
,	O
and	O
the	O
diuretic	O
hydrochlorothiazide	S-chemical
(	O
12.5	O
mg	O
)	O
as	O
double	O
RAAS	O
blockade	O
to	O
achieve	O
the	O
target	O
blood	O
pressure	O
of	O
less	O
than	O
130/80	O
mm	O
Hg	O
.	O
Participants	O
were	O
then	O
randomly	O
assigned	O
to	O
2	O
treatment	O
sequences	O
,	O
either	O
the	O
addition	O
of	O
spironolactone	S-chemical
(	O
25	O
mg	O
)	O
(	O
triple	O
RAAS	O
blockade	O
)	O
through	O
8	O
weeks	O
followed	O
by	O
double	O
RAAS	O
blockade	O
through	O
8	O
weeks	O
(	O
sequence	O
1	O
)	O
or	O
double	O
RAAS	O
blockade	O
followed	O
by	O
triple	O
RAAS	O
blockade	O
(	O
sequence	O
2	O
)	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
24-hour	O
urine	O
protein	O
excretion	O
(	O
primary	O
end	O
point	O
)	O
and	O
markers	O
of	O
tubular	O
injury	O
and	O
fibrosis	O
(	O
secondary	O
end	O
points	O
)	O
.	O
Analysis	O
was	O
performed	O
using	O
analysis	O
of	O
variance	O
for	O
repeated	O
measurements	O
.	O
RESULTS	O
:	O
At	O
baseline	O
,	O
mean	O
serum	O
creatinine	O
level	O
was	O
1.16	O
+/-	O
0.09	O
mg/dL	O
(	O
103	O
+/-	O
8	O
micromol/L	O
)	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
was	O
107.8	O
mL/min	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
93	O
to	O
140.9	O
[	O
1.8	O
mL/s	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.55	O
to	O
2.35	O
;	O
Cockcroft-Gault	O
formula	O
)	O
,	O
and	O
24-hour	O
mean	O
proteinuria	O
was	O
0.97	O
+/-	O
0.18	O
g.	O
Mean	O
urine	O
protein	O
excretion	O
was	O
0.7	O
g/24	O
h	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0.48	O
to	O
0.92	O
)	O
less	O
after	O
triple	O
RAAS	O
blockade	O
than	O
after	O
double	O
RAAS	O
blockade	O
(	O
P	O
=	O
0.01	O
)	O
,	O
without	O
change	O
in	O
blood	O
pressure	O
.	O
Urine	O
excretion	O
of	O
N-acetyl-beta-d-glucosaminidase	S-GP
(	O
P	O
=	O
0.02	O
)	O
and	O
amino-terminal	O
propeptide	O
of	O
type	B-GP
III	I-GP
procollagen	E-GP
(	O
P	O
=	O
0.05	O
)	O
also	O
significantly	O
decreased	O
.	O
Potassium	S-chemical
levels	O
increased	O
significantly	O
after	O
triple	O
therapy	O
(	O
P	O
=	O
0.02	O
)	O
.	O
However	O
,	O
no	O
patient	O
was	O
withdrawn	O
because	O
of	O
adverse	O
effects	O
.	O
LIMITATIONS	O
:	O
Absence	O
of	O
blinding	O
,	O
small	O
sample	O
size	O
,	O
short	O
treatment	O
period	O
,	O
absence	O
of	O
histological	O
assessment	O
.	O
CONCLUSIONS	O
:	O
Administration	O
of	O
an	O
aldosterone	B-GP
receptor	E-GP
antagonist	O
in	O
addition	O
to	O
double	O
RAAS	O
blockade	O
with	O
an	O
ACE	S-GP
inhibitor	O
and	O
ARB	O
may	O
slow	O
the	O
progression	O
of	O
chronic	O
kidney	O
disease	O
.	O
Additional	O
studies	O
are	O
necessary	O
to	O
confirm	O
this	O
result	O
.	O

Identification	O
of	O
a	O
primary	O
target	O
of	O
thalidomide	S-chemical
teratogenicity	O
.	O
Half	O
a	O
century	O
ago	O
,	O
thalidomide	S-chemical
was	O
widely	O
prescribed	O
to	O
pregnant	O
women	O
as	O
a	O
sedative	O
but	O
was	O
found	O
to	O
be	O
teratogenic	O
,	O
causing	O
multiple	O
birth	O
defects	O
.	O
Today	O
,	O
thalidomide	S-chemical
is	O
still	O
used	O
in	O
the	O
treatment	O
of	O
leprosy	O
and	O
multiple	O
myeloma	O
,	O
although	O
how	O
it	O
causes	O
limb	O
malformation	O
and	O
other	O
developmental	O
defects	O
is	O
unknown	O
.	O
Here	O
,	O
we	O
identified	O
cereblon	S-GP
(	O
CRBN	S-GP
)	O
as	O
a	O
thalidomide-binding	B-GP
protein	E-GP
.	O
CRBN	S-GP
forms	O
an	O
E3	B-GP
ubiquitin	I-GP
ligase	I-GP
complex	E-GP
with	O
damaged	B-GP
DNA	I-GP
binding	I-GP
protein	I-GP
1	E-GP
(	O
DDB1	S-GP
)	O
and	O
Cul4A	S-GP
that	O
is	O
important	O
for	O
limb	O
outgrowth	O
and	O
expression	O
of	O
the	O
fibroblast	B-GP
growth	I-GP
factor	E-GP
Fgf8	S-GP
in	O
zebrafish	O
and	O
chicks	O
.	O
Thalidomide	S-chemical
initiates	O
its	O
teratogenic	O
effects	O
by	O
binding	O
to	O
CRBN	S-GP
and	O
inhibiting	O
the	O
associated	O
ubiquitin	B-GP
ligase	E-GP
activity	O
.	O
This	O
study	O
reveals	O
a	O
basis	O
for	O
thalidomide	S-chemical
teratogenicity	O
and	O
may	O
contribute	O
to	O
the	O
development	O
of	O
new	O
thalidomide	S-chemical
derivatives	O
without	O
teratogenic	O
activity	O
.	O

Switchable	O
Elastin-Like	B-GP
Polypeptides	E-GP
that	O
Respond	O
to	O
Chemical	O
Inducers	O
of	O
Dimerization	O
.	O
Elastin-like	B-GP
polypeptides	E-GP
(	O
ELPs	S-GP
)	O
are	O
protein	O
polymers	O
that	O
reversibly	O
phase	O
separate	O
in	O
response	O
to	O
increased	O
temperature	O
,	O
pressure	O
,	O
concentration	O
,	O
ionic	O
strength	O
,	O
and	O
molecular	O
weight	O
.	O
If	O
it	O
were	O
possible	O
to	O
engineer	O
their	O
phase	O
separation	O
to	O
respond	O
to	O
specific	O
molecular	O
substrates	O
,	O
ELP	S-GP
fusion	O
proteins	O
might	O
be	O
engineered	O
as	O
biosensors	O
,	O
smart	O
biomaterials	O
,	O
diagnostic	O
imaging	O
agents	O
,	O
and	O
targeted	O
therapies	O
.	O
What	O
has	O
been	O
lacking	O
is	O
a	O
strategy	O
to	O
design	O
ELPs	S-GP
to	O
respond	O
to	O
specific	O
substrates	O
.	O
To	O
address	O
this	O
deficiency	O
,	O
we	O
report	O
that	O
ELP	S-GP
fusion	O
proteins	O
phase	O
separate	O
in	O
response	O
to	O
chemical	O
inducers	O
of	O
dimerization	O
(	O
CID	O
)	O
.	O
The	O
rationale	O
is	O
that	O
ELP	S-GP
phase	O
separation	O
depends	O
on	O
molecular	O
weight	O
,	O
concentration	O
,	O
and	O
local	O
hydrophobicity	O
;	O
therefore	O
,	O
processes	O
that	O
affect	O
these	O
properties	O
,	O
including	O
noncovalent	O
dimerization	O
,	O
can	O
be	O
tuned	O
to	O
produce	O
isothermal	O
phase	O
separation	O
.	O
To	O
test	O
this	O
hypothesis	O
,	O
constructs	O
were	O
evaluated	O
consisting	O
of	O
an	O
immunophilin	S-GP
:	O
human	B-GP
FK-506	I-GP
binding	I-GP
protein	I-GP
12	E-GP
(	O
FKBP	S-GP
)	O
attached	O
to	O
an	O
ELP	S-GP
.	O
Under	O
stoichiometric	O
binding	O
of	O
a	O
CID	O
,	O
the	O
fusion	O
protein	O
homodimerizes	O
and	O
triggers	O
phase	O
separation	O
.	O
This	O
dimerization	O
is	O
reversible	O
upon	O
saturation	O
with	O
excess	O
CID	O
or	O
competitive	O
binding	O
of	O
a	O
small	O
lipophilic	O
macrolide	O
to	O
FKBP	O
.	O
By	O
modulating	O
the	O
ELP	S-GP
molecular	O
weight	O
,	O
phase	O
separation	O
was	O
tuned	O
for	O
isothermal	O
response	O
to	O
CID	O
at	O
physiological	O
ionic	O
strength	O
and	O
temperature	O
(	O
37	O
°C	O
)	O
.	O
To	O
interpret	O
the	O
relationship	O
between	O
transition	O
temperature	O
and	O
equilibrium	O
binding	O
constants	O
,	O
an	O
empirical	O
mathematical	O
model	O
was	O
employed	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
report	O
is	O
the	O
first	O
demonstration	O
of	O
reversible	O
ELP	S-GP
switching	O
in	O
response	O
to	O
controlled	O
dimerization	O
.	O
Due	O
to	O
its	O
simplicity	O
,	O
this	O
strategy	O
may	O
be	O
useful	O
to	O
design	O
ELP	S-GP
fusion	O
proteins	O
that	O
respond	O
to	O
specific	O
dimeric	O
biological	O
entities	O
.	O

Changes	O
in	O
gene	O
expression	O
associated	O
with	O
loss	O
of	O
function	O
of	O
the	O
NSDHL	S-GP
sterol	B-GP
dehydrogenase	E-GP
in	O
mouse	O
embryonic	O
fibroblasts	O
.	O
Seven	O
human	O
disorders	O
of	O
postsqualene	O
cholesterol	S-chemical
biosynthesis	O
have	O
been	O
described	O
.	O
One	O
of	O
these	O
,	O
congenital	O
hemidysplasia	O
with	O
ichthyosiform	O
nevus	O
and	O
limb	O
defects	O
(	O
CHILD	O
)	O
syndrome	O
,	O
results	O
from	O
mutations	O
in	O
the	O
X-linked	O
gene	O
NADH	B-GP
sterol	I-GP
dehydrogenase-like	E-GP
(	O
NSDHL	S-GP
)	O
encoding	O
a	O
sterol	B-GP
dehydrogenase	E-GP
.	O
A	O
series	O
of	O
mutant	O
alleles	O
of	O
the	O
murine	O
Nsdhl	S-GP
gene	O
are	O
carried	O
by	O
bare	O
patches	O
(	O
Bpa	O
)	O
mice	O
,	O
with	O
Bpa	O
(	O
1H	O
)	O
representing	O
a	O
null	O
allele	O
.	O
Heterozygous	O
Bpa	O
(	O
1H	O
)	O
females	O
display	O
skin	O
and	O
skeletal	O
abnormalities	O
in	O
a	O
distribution	O
reflecting	O
random	O
X	O
inactivation	O
,	O
whereas	O
hemizygous	O
male	O
embryos	O
die	O
before	O
embryonic	O
day	O
10.5	O
.	O
To	O
investigate	O
the	O
molecular	O
basis	O
of	O
defects	O
associated	O
with	O
perturbations	O
in	O
cholesterol	S-chemical
biosynthesis	O
,	O
microarray	O
analysis	O
was	O
performed	O
comparing	O
gene	O
expression	O
in	O
embryonic	O
fibroblasts	O
expressing	O
the	O
Bpa	O
(	O
1H	O
)	O
allele	O
versus	O
wild-type	O
(	O
wt	O
)	O
cells	O
.	O
Labeled	O
cDNAs	O
from	O
cells	O
grown	O
in	O
normal	O
serum	O
or	O
lipid-depleted	O
serum	O
(	O
LDS	O
)	O
were	O
hybridized	O
to	O
microarrays	O
containing	O
22,000	O
mouse	O
genes	O
.	O
Among	O
44	O
genes	O
that	O
showed	O
higher	O
expression	O
in	O
the	O
Bpa	O
(	O
1H	O
)	O
versus	O
wt	O
cells	O
grown	O
in	O
LDS	O
,	O
11	O
function	O
in	O
cholesterol	S-chemical
biosynthesis	O
,	O
7	O
are	O
involved	O
in	O
fatty	B-chemical
acid	E-chemical
synthesis	O
,	O
3	O
(	O
Srebp2	S-GP
,	O
Insig1	S-GP
,	O
and	O
Orf11	S-GP
)	O
encode	O
sterol	S-chemical
-regulatory	O
proteins	O
,	O
and	O
2	O
(	O
Ldlr	S-GP
and	O
StarD4	S-GP
)	O
are	O
lipid	O
transporters	O
.	O
Of	O
the	O
21	O
remaining	O
genes	O
,	O
16	O
are	O
known	O
genes	O
,	O
some	O
of	O
which	O
have	O
been	O
implicated	O
previously	O
in	O
cholesterol	S-chemical
homeostasis	O
or	O
lipid-mediated	O
signaling	O
,	O
and	O
5	O
are	O
uncharacterized	O
cDNA	O
clones	O
.	O

C677T	S-GP
polymorphism	O
of	O
the	O
methylenetetrahydrofolate	B-GP
reductase	E-GP
gene	O
does	O
not	O
affect	O
folic	B-chemical
acid	E-chemical
,	O
vitamin	B-chemical
B12	E-chemical
,	O
and	O
homocysteine	S-chemical
serum	O
levels	O
in	O
Turkish	O
children	O
with	O
neural	O
tube	O
defects	O
.	O
Association	O
between	O
neural	O
tube	O
defects	O
(	O
NTDs	O
)	O
and	O
C677T	S-GP
polymorphism	O
of	O
the	O
methylenetetrahydrofolate	B-GP
reductase	E-GP
(	O
MTHFR	S-GP
)	O
gene	O
was	O
suspected	O
,	O
because	O
the	O
MTHFR	S-GP
gene	O
codes	O
for	O
a	O
key	O
enzyme	O
in	O
folate	S-chemical
metabolism	O
.	O
Its	O
deficiency	O
usually	O
leads	O
to	O
significant	O
reductions	O
in	O
plasma	O
concentrations	O
of	O
folate	S-chemical
,	O
vitamin	B-chemical
B	I-chemical
(	I-chemical
12	I-chemical
)	E-chemical
and	O
methionine	S-chemical
,	O
whereas	O
homocysteine	S-chemical
levels	O
are	O
increased	O
.	O
We	O
examined	O
folate	S-chemical
,	O
vitamin	B-chemical
B	I-chemical
(	I-chemical
12	I-chemical
)	E-chemical
and	O
homocysteine	S-chemical
serum	O
concentrations	O
and	O
polymorphism	O
of	O
the	O
C677T	S-GP
MTHFR	S-GP
gene	O
in	O
Turkish	O
children	O
with	O
neural	O
tube	O
defects	O
.	O
Thirty-three	O
children	O
with	O
NTDs	O
,	O
26	O
mothers	O
and	O
48	O
healthy	O
individuals	O
were	O
studied	O
.	O
C677T	S-GP
MTHFR	S-GP
polymorphism	O
was	O
determined	O
by	O
melting	O
curve	O
analyses	O
(	O
LightCycler	O
)	O
.	O
The	O
levels	O
of	O
folate	S-chemical
,	O
vitamin	B-chemical
B	I-chemical
(	I-chemical
12	I-chemical
)	E-chemical
and	O
homocysteine	S-chemical
serum	O
concentrations	O
in	O
NTDs	O
were	O
evaluated	O
and	O
compared	O
,	O
along	O
with	O
information	O
concerning	O
alleles	O
of	O
the	O
MTHFR	S-GP
gene	O
.	O
C677T	S-GP
allele	O
frequencies	O
in	O
NTD	O
children	O
and	O
their	O
mothers	O
were	O
similar	O
to	O
those	O
found	O
in	O
controls	O
.	O
Serum	O
folate	S-chemical
and	O
vitamin	B-chemical
B	I-chemical
(	I-chemical
12	I-chemical
)	E-chemical
concentrations	O
were	O
significantly	O
higher	O
in	O
NTD	O
children	O
than	O
that	O
of	O
controls	O
.	O
Serum	O
homocysteine	S-chemical
concentrations	O
were	O
not	O
significantly	O
higher	O
in	O
NTD	O
children	O
and	O
mothers	O
.	O
We	O
concluded	O
that	O
C677T	S-GP
MTHFR	S-GP
gene	O
polymorphism	O
does	O
not	O
affect	O
folic	B-chemical
acid	E-chemical
,	O
vitamin	B-chemical
B	I-chemical
(	I-chemical
12	I-chemical
)	E-chemical
and	O
homocysteine	S-chemical
metabolism	O
in	O
Turkish	O
children	O
with	O
NTDs	O
.	O
C677T	S-GP
polymorphism	O
of	O
the	O
MTHFR	S-GP
gene	O
can	O
not	O
be	O
regarded	O
as	O
a	O
major	O
risk	O
factor	O
for	O
NTDs	O
in	O
Turkish	O
children	O
.	O

Clinical	O
,	O
biochemical	O
and	O
molecular	O
genetic	O
data	O
in	O
five	O
children	O
with	O
Gitelman	O
's	O
syndrome	O
.	O
Gitelman	O
's	O
variant	O
of	O
Bartter	O
's	O
syndrome	O
,	O
inherited	O
hypokalemic	O
alkalosis	O
,	O
is	O
caused	O
by	O
mutation	O
in	O
the	O
thiazide-sensitive	B-GP
NaCl	I-GP
co-transporter	E-GP
(	O
NCCT	S-GP
)	O
.	O
The	O
main	O
clinical	O
symptoms	O
are	O
:	O
muscular	O
weakness	O
,	O
carpopedal	O
spasm	O
,	O
constipation	O
and	O
short	O
stature	O
.	O
The	O
diagnosis	O
was	O
suspected	O
in	O
five	O
children	O
according	O
to	O
clinical	O
criteria	O
.	O
All	O
patients	O
exhibited	O
carpopedal	O
spasm	O
during	O
febrile	O
illness	O
,	O
three	O
patients	O
had	O
short	O
stature	O
.	O
Biochemical	O
features	O
were	O
:	O
metabolic	O
alkalosis	O
,	O
hypokalemia	O
,	O
hypomagnesemia	O
,	O
low	O
IGF-I	S-GP
levels	O
,	O
hyperkaliuria	O
,	O
hypernatriuria	O
,	O
hypocalciuria	O
and	O
normoprostaglandinuria	O
.	O
Three	O
patients	O
had	O
elevated	O
plasma	O
renin	S-GP
activity	O
and	O
hyperaldosteronism	O
.	O
Mutational	O
analysis	O
of	O
the	O
NCCT	S-GP
gene	O
confirmed	O
the	O
diagnosis	O
in	O
all	O
five	O
patients	O
.	O
Different	O
forms	O
of	O
therapy	O
,	O
potassium	S-chemical
and	O
magnesium	S-chemical
substitution	O
,	O
spironolactone	S-chemical
and	O
indomethacin	S-chemical
failed	O
to	O
fully	O
correct	O
hypokalemia	O
and	O
hypomagnesemia	O
,	O
but	O
markedly	O
improved	O
growth	O
velocity	O
and	O
normalized	O
IGF-I	S-GP
levels	O
in	O
the	O
three	O
patients	O
with	O
short	O
stature	O
.	O
During	O
therapy	O
,	O
clinical	O
symptoms	O
disappeared	O
.	O
We	O
conclude	O
that	O
Gitelman	O
's	O
syndrome	O
is	O
a	O
disorder	O
with	O
a	O
variable	O
symptom	O
profile	O
,	O
but	O
can	O
be	O
suspected	O
on	O
clinical	O
signs	O
already	O
in	O
early	O
childhood	O
.	O
The	O
early	O
diagnosis	O
is	O
essential	O
in	O
preventing	O
complications	O
.	O

The	O
accumulation	O
of	O
metal	O
(	O
Co	S-chemical
,	O
Cr	S-chemical
,	O
Cu	S-chemical
,	O
Mn	S-chemical
and	O
Zn	S-chemical
)	O
in	O
freshwater	O
Ulva	O
(	O
Chlorophyta	O
)	O
and	O
its	O
habitat	O
.	O
The	O
possibility	O
of	O
using	O
freshwater	O
Ulva	O
(	O
Chlorophyta	O
)	O
as	O
a	O
bioaccumulator	O
of	O
metals	O
(	O
Co	S-chemical
,	O
Cr	S-chemical
,	O
Cu	S-chemical
,	O
Mn	S-chemical
and	O
Zn	S-chemical
)	O
in	O
lake	O
and	O
river	O
water	O
was	O
examined	O
weekly	O
in	O
the	O
summer	O
of	O
2010	O
in	O
three	O
types	O
of	O
samples	O
:	O
the	O
water	O
,	O
the	O
sediment	O
and	O
the	O
thalli	O
of	O
Ulva	O
.	O
Samples	O
of	O
freshwater	O
Ulva	O
were	O
collected	O
from	O
two	O
aqueous	O
ecosystems	O
lie	O
250	O
km	O
away	O
from	O
the	O
basin	O
of	O
the	O
Baltic	O
Sea	O
and	O
53	O
km	O
from	O
each	O
other	O
.	O
A	O
flow	O
lake	O
located	O
in	O
the	O
centre	O
of	O
the	O
big	O
city	O
was	O
the	O
first	O
water	O
reservoir	O
(	O
ten	O
sites	O
)	O
and	O
second	O
,	O
the	O
suburban	O
river	O
(	O
six	O
sites	O
)	O
.	O
The	O
mean	O
metal	O
concentrations	O
in	O
the	O
Ulva	O
tissue	O
from	O
the	O
river	O
and	O
the	O
lake	O
decreased	O
in	O
the	O
following	O
order	O
:	O
Mn	S-chemical
>	O
Zn	S-chemical
>	O
Cr	S-chemical
>	O
Cu	S-chemical
>	O
Co	S-chemical
and	O
Mn	S-chemical
>	O
Cr	S-chemical
>	O
Zn	S-chemical
>	O
Cu	S-chemical
>	O
Co	S-chemical
,	O
respectively	O
.	O
Moreover	O
,	O
a	O
negative	O
and	O
statistically	O
significant	O
correlation	O
between	O
Mn	S-chemical
concentrations	O
in	O
the	O
Ulva	O
thalli	O
and	O
the	O
river	O
water	O
was	O
observed	O
.	O
Additionally	O
,	O
numerous	O
correlations	O
were	O
noted	O
between	O
the	O
different	O
concentrations	O
of	O
metals	O
within	O
the	O
Ulva	O
thalli	O
,	O
in	O
the	O
water	O
and	O
in	O
the	O
sediment	O
.	O
The	O
great	O
concentrations	O
of	O
Mn	S-chemical
and	O
Zn	S-chemical
and	O
the	O
smallest	O
of	O
Co	S-chemical
were	O
found	O
in	O
thalli	O
of	O
Ulva	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
the	O
ecosystem	O
from	O
which	O
samples	O
of	O
algal	O
thalli	O
originated	O
.	O
Freshwater	O
Ulva	O
populations	O
examined	O
in	O
this	O
study	O
were	O
clearly	O
characterized	O
a	O
dozen	O
or	O
so	O
times	O
by	O
the	O
higher	O
Mn	S-chemical
and	O
Cr	S-chemical
accumulation	O
than	O
taxa	O
from	O
that	O
genera	O
coming	O
from	O
sea	O
ecosystems	O
.	O
The	O
calculated	O
bioconcentration	O
factor	O
confirm	O
the	O
high	O
potential	O
for	O
freshwater	O
Ulva	O
to	O
be	O
a	O
bioaccumulator	O
of	O
trace	O
metals	O
in	O
freshwater	O
ecosystems	O
.	O

Aspirin	S-chemical
inhibits	O
mTOR	S-chemical
signaling	O
,	O
activates	O
AMP-activated	B-GP
protein	I-GP
kinase	E-GP
,	O
and	O
induces	O
autophagy	O
in	O
colorectal	O
cancer	O
cells	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
Aspirin	S-chemical
reduces	O
the	O
incidence	O
of	O
and	O
mortality	O
from	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
by	O
unknown	O
mechanisms	O
.	O
Cancer	O
cells	O
have	O
defects	O
in	O
signaling	O
via	O
the	O
mechanistic	B-GP
target	I-GP
of	I-GP
rapamycin	E-GP
(	O
mTOR	S-chemical
)	O
,	O
which	O
regulates	O
proliferation	O
.	O
We	O
investigated	O
whether	O
aspirin	S-chemical
affects	O
adenosine	B-GP
monophosphate-activated	I-GP
protein	I-GP
kinase	E-GP
(	O
AMPK	S-GP
)	O
and	O
mTOR	S-chemical
signaling	O
in	O
CRC	O
cells	O
.	O
METHODS	O
:	O
The	O
effects	O
of	O
aspirin	S-chemical
on	O
mTOR	S-chemical
signaling	O
,	O
the	O
ribosomal	B-GP
protein	I-GP
S6	E-GP
,	O
S6	B-GP
kinase	I-GP
1	E-GP
(	O
S6K1	S-GP
)	O
,	O
and	O
eukaryotic	B-GP
translation	I-GP
initiation	I-GP
factor	I-GP
4E	I-GP
binding	I-GP
protein	I-GP
1	E-GP
(	O
4E-BP1	S-GP
)	O
were	O
examined	O
in	O
CRC	O
cells	O
by	O
immunoblotting	O
.	O
Phosphorylation	O
of	O
AMPK	S-GP
was	O
measured	O
;	O
the	O
effects	O
of	O
loss	O
of	O
AMPKalpha	S-GP
on	O
the	O
aspirin	S-chemical
-induced	O
effects	O
of	O
mTOR	S-chemical
were	O
determined	O
using	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
in	O
CRC	O
cells	O
and	O
in	O
AMPK	B-GP
(	I-GP
alpha1/alpha2	E-GP
-/-	O
)	O
mouse	O
embryonic	O
fibroblasts	O
.	O
LC3	S-GP
and	O
ULK1	S-GP
were	O
used	O
as	O
markers	O
of	O
autophagy	O
.	O
We	O
analyzed	O
rectal	O
mucosa	O
samples	O
from	O
patients	O
given	O
600	O
mg	O
aspirin	S-chemical
,	O
once	O
daily	O
for	O
1	O
week	O
.	O
RESULTS	O
:	O
Aspirin	S-chemical
reduced	O
mTOR	S-chemical
signaling	O
in	O
CRC	O
cells	O
by	O
inhibiting	O
the	O
mTOR	S-chemical
effectors	O
S6K1	S-GP
and	O
4E-BP1	S-GP
.	O
Aspirin	S-chemical
changed	O
nucleotide	O
ratios	O
and	O
activated	O
AMPK	S-GP
in	O
CRC	O
cells	O
.	O
mTOR	S-GP
was	O
still	O
inhibited	O
by	O
aspirin	S-chemical
in	O
CRC	O
cells	O
after	O
siRNA	O
knockdown	O
of	O
AMPKalpha	S-GP
,	O
indicating	O
AMPK	S-GP
-dependent	O
and	O
AMPK	S-GP
-independent	O
mechanisms	O
of	O
aspirin	S-chemical
-induced	O
inhibition	O
of	O
mTOR	S-GP
.	O
Aspirin	S-chemical
induced	O
autophagy	O
,	O
a	O
feature	O
of	O
mTOR	S-GP
inhibition	O
.	O
Aspirin	S-chemical
and	O
metformin	S-chemical
(	O
an	O
activator	O
of	O
AMPK	S-GP
)	O
increased	O
inhibition	O
of	O
mTOR	S-chemical
and	O
Akt	S-GP
,	O
as	O
well	O
as	O
autophagy	O
in	O
CRC	O
cells	O
.	O
Rectal	O
mucosal	O
samples	O
from	O
patients	O
given	O
aspirin	S-chemical
had	O
reduced	O
phosphorylation	O
of	O
S6K1	S-GP
and	O
S6	S-GP
.	O
CONCLUSIONS	O
:	O
Aspirin	S-chemical
is	O
an	O
inhibitor	O
of	O
mTOR	S-chemical
and	O
an	O
activator	O
of	O
AMPK	S-GP
,	O
targeting	O
regulators	O
of	O
intracellular	O
energy	O
homeostasis	O
and	O
metabolism	O
.	O
These	O
could	O
contribute	O
to	O
its	O
protective	O
effects	O
against	O
development	O
of	O
CRC	O
.	O

Sulfasalazine	S-chemical
,	O
a	O
potent	O
suppressor	O
of	O
lymphoma	O
growth	O
by	O
inhibition	O
of	O
the	O
x	B-GP
(	I-GP
c	I-GP
)	I-GP
-	I-GP
cystine	I-GP
transporter	E-GP
:	O
a	O
new	O
action	O
for	O
an	O
old	O
drug	O
.	O
Although	O
cyst	B-chemical
(	I-chemical
e	I-chemical
)	I-chemical
ine	E-chemical
is	O
nutritionally	O
a	O
non-essential	B-chemical
amino	I-chemical
acid	E-chemical
,	O
lymphoid	O
cells	O
can	O
not	O
synthesize	O
it	O
,	O
rendering	O
their	O
growth	O
dependent	O
on	O
uptake	O
of	O
cyst	B-chemical
(	I-chemical
e	I-chemical
)	I-chemical
ine	E-chemical
from	O
their	O
microenvironment	O
.	O
Accordingly	O
,	O
we	O
previously	O
suggested	O
that	O
the	O
x	B-GP
(	I-GP
c	I-GP
)	I-GP
-	I-GP
plasma	I-GP
membrane	I-GP
cystine	I-GP
transporter	E-GP
provided	O
a	O
target	O
for	O
lymphoid	O
cancer	O
therapy	O
.	O
Its	O
inhibition	O
could	O
lead	O
to	O
cyst	B-chemical
(	I-chemical
e	I-chemical
)	I-chemical
ine	E-chemical
deficiency	O
in	O
lymphoma	O
cells	O
via	O
reduction	O
of	O
both	O
their	O
cystine	S-chemical
uptake	O
and	O
cysteine	S-chemical
supply	O
by	O
somatic	O
cells	O
.	O
In	O
this	O
study	O
,	O
using	O
rat	O
Nb2	O
lymphoma	O
cultures	O
,	O
drugs	O
were	O
screened	O
for	O
growth	O
arrest	O
based	O
on	O
x	B-GP
(	I-GP
c	I-GP
)	E-GP
-	O
inhibition	O
.	O
Sulfasalazine	S-chemical
was	O
fortuitously	O
found	O
to	O
be	O
a	O
novel	O
,	O
potent	O
inhibitor	O
of	O
the	O
x	B-GP
(	I-GP
c	I-GP
)	I-GP
-	I-GP
transporter	E-GP
.	O
It	O
showed	O
high	O
rat	O
lymphoma	O
growth-inhibitory	O
and	O
lytic	O
activity	O
in	O
vitro	O
(	O
IC50	O
=	O
0.16	O
mM	O
)	O
,	O
based	O
specifically	O
on	O
inhibition	O
of	O
x	B-GP
(	I-GP
c	I-GP
)	E-GP
--	O
mediated	O
cystine	S-chemical
uptake	O
,	O
in	O
contrast	O
to	O
its	O
colonic	O
metabolites	O
,	O
sulfapyridine	S-chemical
and	O
5-aminosalicylic	B-chemical
acid	E-chemical
.	O
Sulfasalazine	S-chemical
was	O
even	O
more	O
effective	O
against	O
human	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
DoHH2	O
)	O
cultures	O
.	O
In	O
rats	O
(	O
n	O
=	O
13	O
)	O
,	O
sulfasalazine	S-chemical
(	O
i.p	O
.	O
)	O
markedly	O
inhibited	O
growth	O
of	O
well-developed	O
,	O
rapidly	O
growing	O
rat	O
Nb2	O
lymphoma	O
transplants	O
without	O
apparent	O
side-effects	O
.	O
Reduced	O
,	O
macrophage-mediated	O
supply	O
of	O
cysteine	S-chemical
was	O
probably	O
involved	O
.	O
In	O
five	O
rats	O
,	O
90-100	O
%	O
tumor	O
growth	O
suppression	O
,	O
relative	O
to	O
controls	O
,	O
was	O
obtained	O
.	O
The	O
x	B-GP
(	I-GP
c	I-GP
)	I-GP
-	I-GP
cystine	I-GP
transporter	E-GP
represents	O
a	O
novel	O
target	O
for	O
sulfasalazine	S-chemical
-like	O
drugs	O
with	O
high	O
potential	O
for	O
application	O
in	O
therapy	O
of	O
lymphoblastic	O
and	O
other	O
malignancies	O
dependent	O
on	O
extracellular	O
cyst	B-chemical
(	I-chemical
e	I-chemical
)	I-chemical
ine	E-chemical
.	O

Manipulation	O
of	O
kinetic	O
profiles	O
in	O
2-aryl	B-chemical
propionic	I-chemical
acid	E-chemical
cyclooxygenase	S-GP
inhibitors	O
.	O
The	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
flurbiprofen	S-chemical
and	O
ibuprofen	S-chemical
were	O
modified	O
in	O
an	O
attempt	O
to	O
alter	O
the	O
kinetics	O
of	O
inhibitor	O
binding	O
by	O
COX-1	S-GP
.	O
Contrary	O
to	O
prior	O
predictions	O
,	O
a	O
halogen	S-chemical
substituent	O
is	O
not	O
sufficient	O
to	O
confer	O
slow	O
tight-binding	O
behavior	O
.	O
Conversion	O
of	O
the	O
carboxylate	S-chemical
moiety	O
of	O
flurbiprofen	S-chemical
to	O
an	O
ester	S-chemical
or	O
amide	S-chemical
abolishes	O
slow	O
tight-binding	O
behavior	O
,	O
regardless	O
of	O
halogenation	O
state	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
novel	O
flavin	S-chemical
-containing	O
spermine	B-GP
oxidase	E-GP
of	O
mammalian	O
cell	O
origin	O
.	O
During	O
polyamine	S-chemical
catabolism	O
,	O
spermine	S-chemical
and	O
spermidine	S-chemical
are	O
first	O
acetylated	O
by	O
spermidine/spermine	B-GP
N	I-GP
(	I-GP
1	I-GP
)	I-GP
-acetyltransferase	E-GP
(	O
SSAT	S-GP
)	O
and	O
subsequently	O
oxidized	O
by	O
polyamine	B-GP
oxidase	E-GP
(	O
PAO	S-GP
)	O
to	O
produce	O
spermidine	S-chemical
and	O
putrescine	S-chemical
,	O
respectively	O
.	O
In	O
attempting	O
to	O
clone	O
the	O
PAO	S-GP
involved	O
in	O
this	O
back-conversion	O
pathway	O
,	O
we	O
encountered	O
an	O
oxidase	S-GP
that	O
preferentially	O
cleaves	O
spermine	S-chemical
in	O
the	O
absence	O
of	O
prior	O
acetylation	O
by	O
SSAT	S-GP
.	O
A	O
BLAST	O
search	O
using	O
maize	B-GP
PAO	E-GP
sequences	O
identified	O
homologous	O
mammalian	O
cDNAs	O
derived	O
from	O
human	O
hepatoma	O
and	O
mouse	O
mammary	O
carcinoma	O
:	O
the	O
encoded	O
proteins	O
differed	O
by	O
20	O
amino	B-chemical
acids	E-chemical
.	O
When	O
either	O
cDNA	O
was	O
transiently	O
transfected	O
into	O
HEK-293	O
cells	O
,	O
intracellular	O
spermine	S-chemical
pools	O
decreased	O
by	O
75	O
%	O
while	O
spermidine	S-chemical
and	O
N	B-chemical
(	I-chemical
1	I-chemical
)	I-chemical
-acetylspermidine	E-chemical
pools	O
increased	O
,	O
suggesting	O
that	O
spermine	S-chemical
was	O
selectively	O
and	O
directly	O
oxidized	O
by	O
the	O
enzyme	O
.	O
Substrate	O
specificity	O
using	O
lysates	O
of	O
oxidase	S-GP
-transfected	O
HEK-293	O
cells	O
revealed	O
that	O
the	O
newly	O
identified	O
oxidase	S-GP
strongly	O
favoured	O
spermine	S-chemical
over	O
N	B-chemical
(	I-chemical
1	I-chemical
)	I-chemical
-acetylspermine	E-chemical
and	O
that	O
it	O
failed	O
to	O
act	O
on	O
N	B-chemical
(	I-chemical
1	I-chemical
)	I-chemical
-acetylspermidine	E-chemical
,	O
spermidine	S-chemical
or	O
the	O
preferred	O
PAO	S-GP
substrate	O
,	O
N	B-chemical
(	I-chemical
1	I-chemical
)	I-chemical
,	I-chemical
N	I-chemical
(	I-chemical
12	I-chemical
)	I-chemical
-diacetylspermine	E-chemical
.	O
The	O
PAO	S-GP
inhibitor	O
,	O
MDL-72,527	S-chemical
,	O
only	O
partially	O
blocked	O
oxidation	O
of	O
spermine	S-chemical
while	O
a	O
previously	O
reported	O
PAO	S-GP
substrate	O
,	O
N	B-chemical
(	I-chemical
1	I-chemical
)	I-chemical
-	I-chemical
(	I-chemical
n	I-chemical
-octanesulphonyl	I-chemical
)	I-chemical
spermine	E-chemical
,	O
potently	O
inhibited	O
the	O
reaction	O
.	O
Overall	O
,	O
the	O
data	O
indicate	O
that	O
the	O
enzyme	O
represents	O
a	O
novel	O
mammalian	B-GP
oxidase	E-GP
which	O
,	O
on	O
the	O
basis	O
of	O
substrate	O
specificity	O
,	O
we	O
have	O
designated	O
spermine	B-GP
oxidase	E-GP
in	O
order	O
to	O
distinguish	O
it	O
from	O
the	O
PAO	S-GP
involved	O
in	O
polyamine	S-chemical
back-conversion	O
.	O
The	O
identification	O
of	O
an	O
enzyme	O
capable	O
of	O
directly	O
oxidizing	O
spermine	S-chemical
to	O
spermidine	S-chemical
has	O
important	O
implications	O
for	O
understanding	O
polyamine	S-chemical
homoeostasis	O
and	O
for	O
interpreting	O
metabolic	O
and	O
cellular	O
responses	O
to	O
clinically	O
relevant	O
polyamine	O
analogues	O
and	O
inhibitors	O
.	O

Design	O
,	O
Synthesis	O
,	O
Biological	O
Evaluation	O
,	O
and	O
Docking	O
Studies	O
of	O
(	B-chemical
S	I-chemical
)	I-chemical
-Phenylalanine	E-chemical
Derivatives	O
with	O
a	O
2-Cyanopyrrolidine	S-chemical
Moiety	O
as	O
Potent	O
Dipeptidyl	B-GP
Peptidase	I-GP
4	E-GP
Inhibitors	O
.	O
A	O
novel	O
series	O
of	O
(	B-chemical
S	I-chemical
)	I-chemical
-phenylalanine	E-chemical
derivatives	O
with	O
a	O
2-cyanopyrrolidine	S-chemical
moiety	O
were	O
designed	O
and	O
synthesized	O
through	O
a	O
rational	O
drug	O
design	O
strategy	O
.	O
Biological	O
evaluation	O
revealed	O
that	O
most	O
tested	O
compounds	O
were	O
potent	O
dipeptidyl	B-GP
peptidase	I-GP
4	E-GP
(	O
DPP-4	S-GP
)	O
inhibitors	O
,	O
among	O
them	O
,	O
the	O
cyclopropyl-substituted	B-chemical
phenylalanine	E-chemical
derivative	O
11h	O
displayed	O
the	O
most	O
potent	O
DPP-4	S-GP
inhibitory	O
activity	O
with	O
an	O
IC50	O
value	O
of	O
0.247	O
μM	O
.	O
In	O
addition	O
,	O
molecular	O
docking	O
analysis	O
of	O
the	O
representative	O
compounds	O
11h	O
,	O
11k	O
,	O
and	O
15a	O
were	O
performed	O
,	O
which	O
not	O
only	O
revealed	O
the	O
impact	O
of	O
binding	O
modes	O
on	O
DPP-4	S-GP
inhibitory	O
activity	O
,	O
but	O
also	O
provided	O
additional	O
methodological	O
values	O
for	O
design	O
and	O
optimization	O
.	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
A/S	O
.	O

Investigation	O
of	O
astatine	B-chemical
(	I-chemical
III	I-chemical
)	E-chemical
hydrolyzed	O
species	O
:	O
experiments	O
and	O
relativistic	O
calculations	O
.	O
This	O
work	O
aims	O
to	O
resolve	O
some	O
controversies	O
about	O
astatine	B-chemical
(	I-chemical
III	I-chemical
)	I-chemical
hydroxide	E-chemical
species	O
present	O
in	O
oxidant	O
aqueous	O
solution	O
.	O
AtO	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
is	O
the	O
dominant	O
species	O
existing	O
under	O
oxidizing	O
and	O
acidic	O
pH	O
conditions	O
.	O
This	O
is	O
consistent	O
with	O
high-performance	O
ion-exchange	O
chromatography	O
data	O
showing	O
the	O
existence	O
of	O
one	O
species	O
holding	O
one	O
positive	O
charge	O
.	O
A	O
change	O
in	O
speciation	O
occurs	O
as	O
the	O
pH	O
changes	O
from	O
1	O
to	O
4	O
,	O
while	O
remaining	O
under	O
oxidizing	O
conditions	O
.	O
Dynamic	O
experiments	O
with	O
ion-exchange	O
resins	O
evidence	O
the	O
existence	O
of	O
a	O
neutral	O
species	O
witnessed	O
by	O
its	O
elution	O
in	O
the	O
void	O
volume	O
.	O
Batch-experiments	O
using	O
a	O
competition	O
method	O
show	O
the	O
exchange	O
of	O
one	O
proton	O
indicating	O
the	O
formation	O
of	O
the	O
AtO	B-chemical
(	I-chemical
OH	I-chemical
)	E-chemical
species	O
.	O
The	O
hydrolysis	O
thermodynamic	O
constant	O
,	O
extrapolated	O
to	O
zero	O
ionic	O
strength	O
,	O
was	O
determined	O
to	O
be	O
10	O
(	O
-1.9	O
)	O
.	O
This	O
value	O
is	O
supported	O
by	O
two-component	O
relativistic	O
quantum	O
calculations	O
and	O
therefore	O
allows	O
disclosing	O
unambiguously	O
the	O
structure	O
of	O
the	O
formed	O
species	O
.	O

A	O
dilated	O
cardiomyopathy	O
troponin	B-GP
C	E-GP
mutation	O
lowers	O
contractile	O
force	O
by	O
reducing	O
strong	O
myosin	S-GP
-	O
actin	S-GP
binding	O
.	O
In	O
this	O
study	O
we	O
explore	O
the	O
mechanisms	O
by	O
which	O
a	O
double	O
mutation	O
(	O
E59D	S-GP
/	O
D75Y	S-GP
)	O
in	O
cardiac	B-GP
troponin	I-GP
C	E-GP
(	O
CTnC	S-GP
)	O
associated	O
with	O
dilated	O
cardiomyopathy	O
reduces	O
the	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
-activated	O
maximal	O
tension	O
of	O
cardiac	O
muscle	O
.	O
Studying	O
the	O
single	O
mutants	O
(	O
i.e	O
.	O
E59D	S-GP
or	O
D75Y	S-GP
)	O
indicates	O
that	O
D75Y	S-GP
,	O
but	O
not	O
E59D	S-GP
,	O
causes	O
a	O
reduction	O
in	O
the	O
calcium	O
affinity	O
of	O
CTnC	S-GP
in	O
troponin	S-GP
complex	O
,	O
regulated	B-GP
thin	I-GP
filaments	E-GP
(	O
RTF	S-GP
)	O
,	O
and	O
the	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
sensitivity	O
of	O
contraction	O
and	O
ATPase	S-GP
in	O
cardiac	O
muscle	O
preparations	O
.	O
However	O
,	O
both	O
D75Y	S-GP
and	O
E59D	S-GP
are	O
required	O
to	O
reduce	O
the	O
actomyosin	S-GP
ATPase	S-GP
activity	O
and	O
maximal	O
force	O
in	O
muscle	O
fibers	O
,	O
indicating	O
that	O
E59D	S-GP
enhances	O
the	O
effects	O
of	O
D75Y	S-GP
.	O
Part	O
of	O
the	O
reduction	O
in	O
force/	O
ATPase	S-GP
may	O
be	O
due	O
to	O
a	O
defect	O
in	O
the	O
interactions	O
between	O
CTnC	S-GP
and	O
cardiac	B-GP
troponin	I-GP
T	E-GP
,	O
which	O
are	O
known	O
to	O
be	O
necessary	O
for	O
ATPase	S-GP
activation	O
.	O
An	O
additional	O
mechanism	O
for	O
the	O
reduction	O
in	O
force/	O
ATPase	S-GP
comes	O
from	O
measurements	O
of	O
the	O
binding	O
stoichiometry	O
of	O
myosin	B-GP
subfragment-1	E-GP
(	O
S-1	S-GP
)	O
to	O
the	O
RTF	S-GP
.	O
Using	O
wild	O
type	O
RTFs	S-GP
,	O
4.8	O
mol	O
S-1	S-GP
was	O
bound	O
per	O
mol	O
filament	O
(	O
seven	O
actins	O
)	O
,	O
whereas	O
with	O
E59D	S-GP
/	O
D75Y	S-GP
RTFs	S-GP
,	O
the	O
number	O
of	O
binding	O
sites	O
was	O
reduced	O
by	O
approximately	O
23	O
%	O
to	O
3.7	O
.	O
Altogether	O
,	O
these	O
results	O
suggest	O
that	O
the	O
reduction	O
in	O
force	O
and	O
ATPase	S-GP
activation	O
is	O
possibly	O
due	O
to	O
a	O
thin	O
filament	O
conformation	O
that	O
promotes	O
fewer	O
accessible	O
S-1-binding	B-GP
sites	E-GP
.	O
In	O
the	O
absence	O
of	O
any	O
family	O
segregation	O
data	O
,	O
the	O
functional	O
results	O
presented	O
here	O
support	O
the	O
concept	O
that	O
this	O
is	O
likely	O
a	O
dilated	O
cardiomyopathy-causing	O
mutation	O
.	O

Dominant	O
expression	O
of	O
mRNA	O
for	O
prostaglandin	B-GP
D	I-GP
synthase	E-GP
in	O
leptomeninges	O
,	O
choroid	O
plexus	O
,	O
and	O
oligodendrocytes	O
of	O
the	O
adult	O
rat	O
brain	O
.	O
Glutathione	S-chemical
-independent	O
prostaglandin	B-GP
D	I-GP
synthase	E-GP
[	O
prostaglandin-H2	B-GP
D-isomerase	E-GP
;	O
(	B-GP
5Z,13E	I-GP
)	I-GP
-	I-GP
(	I-GP
15S	I-GP
)	I-GP
-9	I-GP
alpha,11	I-GP
alpha-epidioxy-15-hydroxyprosta-5,13-dienoate	I-GP
D-isomerase	E-GP
,	O
EC	B-GP
5.3.99.2	E-GP
]	O
is	O
an	O
enzyme	O
responsible	O
for	O
biosynthesis	O
of	O
prostaglandin	B-chemical
D2	E-chemical
in	O
the	O
central	O
nervous	O
system	O
.	O
In	O
situ	O
hybridization	O
with	O
antisense	O
RNA	O
for	O
the	O
enzyme	O
indicated	O
that	O
mRNA	O
for	O
the	O
enzyme	O
was	O
predominantly	O
expressed	O
in	O
the	O
leptomeninges	O
,	O
choroid	O
plexus	O
,	O
and	O
oligodendrocytes	O
of	O
the	O
adult	O
rat	O
brain	O
.	O
The	O
findings	O
agree	O
with	O
those	O
obtained	O
by	O
immunohistochemical	O
staining	O
with	O
antibodies	O
against	O
the	O
enzyme	O
.	O
It	O
was	O
further	O
revealed	O
that	O
prostaglandin	B-GP
D	I-GP
synthase	E-GP
activity	O
was	O
considerably	O
greater	O
in	O
the	O
isolated	O
leptomeninges	O
(	O
14.2	O
nmol	O
per	O
min	O
per	O
mg	O
of	O
protein	O
)	O
and	O
choroid	O
plexus	O
(	O
7.0	O
nmol	O
per	O
min	O
per	O
mg	O
of	O
protein	O
)	O
than	O
the	O
activity	O
in	O
the	O
whole	O
brain	O
(	O
2.0	O
nmol	O
per	O
min	O
per	O
mg	O
of	O
protein	O
)	O
.	O
These	O
results	O
,	O
taken	O
together	O
,	O
indicate	O
that	O
the	O
enzyme	O
is	O
mainly	O
synthesized	O
and	O
located	O
in	O
the	O
leptomeninges	O
,	O
choroid	O
plexus	O
,	O
and	O
oligodendrocytes	O
in	O
the	O
brain	O
.	O

Non-front-fanged	O
colubroid	O
snakes	O
:	O
A	O
current	O
evidence-based	O
analysis	O
of	O
medical	O
significance	O
.	O
Non-front-fanged	O
colubroid	O
snakes	O
(	O
NFFC	O
;	O
formerly	O
and	O
artificially	O
taxonomically	O
assembled	O
as	O
``	O
colubrids	O
''	O
)	O
comprise	O
about	O
70	O
%	O
of	O
extant	O
snake	O
species	O
and	O
include	O
several	O
taxa	O
now	O
known	O
to	O
cause	O
lethal	O
or	O
life	O
threatening	O
envenoming	O
in	O
humans	O
.	O
Although	O
the	O
medical	O
risks	O
of	O
bites	O
by	O
only	O
a	O
handful	O
of	O
species	O
have	O
been	O
documented	O
,	O
a	O
growing	O
number	O
of	O
NFFC	O
are	O
implicated	O
in	O
medically	O
significant	O
bites	O
.	O
The	O
majority	O
of	O
these	O
snakes	O
have	O
oral	O
products	O
(	O
Duvernoy	O
's	O
secretions	O
,	O
or	O
venoms	O
)	O
with	O
unknown	O
biomedical	O
properties	O
and	O
their	O
potential	O
for	O
causing	O
harm	O
in	O
humans	O
is	O
unknown	O
.	O
Increasingly	O
,	O
multiple	O
NFFC	O
species	O
are	O
entering	O
the	O
commercial	O
snake	O
trade	O
posing	O
an	O
uncertain	O
risk	O
.	O
Published	O
case	O
reports	O
describing	O
NFFC	O
bites	O
were	O
assessed	O
for	O
evidence-based	O
value	O
,	O
clinical	O
detail	O
and	O
verified	O
species	O
identification	O
.	O
These	O
data	O
were	O
subjected	O
to	O
meta-analysis	O
and	O
a	O
hazard	O
index	O
was	O
generated	O
for	O
select	O
taxa	O
.	O
Cases	O
on	O
which	O
we	O
consulted	O
or	O
personally	O
treated	O
were	O
included	O
and	O
subjected	O
to	O
the	O
same	O
assessment	O
criteria	O
.	O
Cases	O
involving	O
approximately	O
120	O
species	O
met	O
the	O
selection	O
criteria	O
,	O
and	O
a	O
small	O
subset	O
designated	O
Hazard	O
Level	O
1	O
(	O
most	O
hazardous	O
)	O
,	O
contained	O
5	O
species	O
with	O
lethal	O
potential	O
.	O
Recommended	O
management	O
of	O
these	O
cases	O
included	O
antivenom	O
for	O
3	O
species	O
,	O
Dispholidus	O
typus	O
,	O
Rhabdophis	O
tiginis	O
,	O
Rhabdophis	O
subminiatus	O
,	O
whereas	O
others	O
in	O
this	O
subset	O
without	O
commercially	O
available	O
antivenoms	O
(	O
Thelotornis	O
spp	O
.	O
)	O
were	O
treated	O
with	O
plasma/erythrocyte	O
replacement	O
therapy	O
and	O
supportive	O
care	O
.	O
Heparin	O
,	O
antifibrinolytics	O
and/or	O
plasmapheresis/exchange	O
transfusion	O
have	O
been	O
used	O
in	O
the	O
management	O
of	O
some	O
Hazard	O
Level	O
1	O
envenomings	O
,	O
but	O
evidence-based	O
analysis	O
positively	O
contraindicates	O
the	O
use	O
of	O
any	O
of	O
these	O
interventions	O
.	O
Hazard	O
Level	O
2/3	O
species	O
were	O
involved	O
in	O
cases	O
containing	O
mixed	O
quality	O
data	O
that	O
implicated	O
these	O
taxa	O
(	O
e.g	O
.	O
Boiga	O
irregularis	O
,	O
Philodryas	O
olfersii	O
,	O
Malpolon	O
monspessulanus	O
)	O
with	O
bites	O
that	O
caused	O
rare	O
systemic	O
effects	O
.	O
Recommended	O
management	O
may	O
include	O
use	O
of	O
acetylcholinesterase	S-GP
inhibitors	O
(	O
e.g	O
.	O
neostigmine	S-chemical
)	O
and	O
wound	O
care	O
on	O
a	O
case-by-case	O
basis	O
.	O
Hazard	O
level	O
3	O
species	O
comprised	O
a	O
larger	O
group	O
capable	O
of	O
producing	O
significant	O
local	O
effects	O
only	O
,	O
often	O
associated	O
with	O
a	O
protracted	O
bite	O
(	O
eg	O
Heterodon	O
nasicus	O
,	O
Borikenophis	O
(	O
Alsophis	O
)	O
portoricensis	O
,	O
Platyceps	O
(	O
Coluber	O
)	O
rhodorachis	O
)	O
.	O
Management	O
is	O
restricted	O
to	O
wound	O
care	O
.	O
Bites	O
by	O
Hazard	O
level	O
4	O
species	O
comprised	O
the	O
majority	O
of	O
surveyed	O
taxa	O
and	O
these	O
showed	O
only	O
minor	O
effects	O
of	O
no	O
clinical	O
importance	O
.	O
This	O
study	O
has	O
produced	O
a	O
comprehensive	O
evidence-based	O
listing	O
of	O
NFFC	O
snakes	O
tabulated	O
against	O
medical	O
significance	O
of	O
bites	O
,	O
together	O
with	O
best-practice	O
management	O
recommendations	O
.	O
This	O
analysis	O
assumes	O
increasing	O
importance	O
,	O
as	O
there	O
is	O
growing	O
exposure	O
to	O
lesser-known	O
NFFC	O
snakes	O
,	O
particularly	O
in	O
captive	O
collections	O
that	O
may	O
uncover	O
further	O
species	O
of	O
significance	O
in	O
the	O
future	O
.	O
Careful	O
and	O
accurate	O
documentation	O
of	O
bites	O
by	O
verified	O
species	O
of	O
NFFC	O
snakes	O
is	O
required	O
to	O
increase	O
the	O
evidence	O
base	O
and	O
establish	O
the	O
best	O
medical	O
management	O
approach	O
for	O
each	O
species	O
.	O

Enhancing	O
macrocyclic	O
diterpenes	S-chemical
as	O
multidrug-resistance	O
reversers	O
:	O
structure-activity	O
studies	O
on	O
jolkinol	B-chemical
D	E-chemical
derivatives	O
.	O
The	O
phytochemical	O
study	O
of	O
Euphorbia	O
piscatoria	O
yielded	O
jolkinol	B-chemical
D	E-chemical
(	O
1	O
)	O
in	O
a	O
large	O
amount	O
,	O
whose	O
derivatization	O
gave	O
rise	O
to	O
12	O
ester	S-chemical
derivatives	O
(	O
2-13	O
)	O
and	O
hydrolysis	O
to	O
compound	O
14	O
.	O
The	O
in	O
vitro	O
modulation	O
of	O
P-gp	S-GP
of	O
compounds	O
1-14	O
was	O
evaluated	O
through	O
a	O
combination	O
of	O
transport	O
and	O
chemosensitivity	O
assays	O
,	O
using	O
the	O
L5178	O
mouse	O
T	O
lymphoma	O
cell	O
line	O
transfected	O
with	O
the	O
human	B-GP
MDR1	E-GP
gene	O
.	O
Apart	O
from	O
jolkinol	B-chemical
D	E-chemical
,	O
all	O
derivatives	O
(	O
2-14	O
)	O
showed	O
potential	O
as	O
MDR	O
reversal	O
agents	O
.	O
In	O
this	O
small	O
library	O
of	O
novel	O
bioactive	O
macrocyclic	O
lathyrane	B-chemical
diterpene	E-chemical
derivatives	O
,	O
designed	O
to	O
evaluate	O
structure-activity	O
relationships	O
essential	O
in	O
overcoming	O
multidrug	O
resistance	O
(	O
MDR	O
)	O
,	O
some	O
correlations	O
between	O
MDR	O
reversal	O
and	O
molecular	O
weight	O
,	O
accessible	O
solvent	O
areas	O
,	O
and	O
octanol	S-chemical
/water	O
partition	O
coefficient	O
were	O
identified	O
that	O
can	O
contribute	O
to	O
the	O
development	O
of	O
new	O
selective	O
P-gp	S-GP
reversal	O
agents	O
.	O

The	O
(	B-chemical
R	I-chemical
)	I-chemical
-omeprazole	E-chemical
hydroxylation	O
index	O
reflects	O
CYP2C19	S-GP
activity	O
in	O
healthy	O
Japanese	O
volunteers	O
.	O
PURPOSE	O
:	O
Omeprazole	S-chemical
has	O
(	O
R	O
)	O
-	O
and	O
(	O
S	O
)	O
-enantiomers	O
,	O
which	O
exhibit	O
different	O
pharmacokinetics	O
(	O
PK	O
)	O
among	O
patients	O
with	O
cytochrome	B-GP
P450	I-GP
(	I-GP
CYP	I-GP
)	I-GP
2C19	E-GP
genotype	O
groups	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
1-point	O
,	O
4-h	O
postdose	O
(	B-chemical
R	I-chemical
)	I-chemical
-omeprazole	E-chemical
hydroxylation	O
index	O
(	O
HI	O
)	O
of	O
racemic	B-chemical
omeprazole	E-chemical
reflects	O
the	O
three	O
CYP2C19	S-GP
genotype	O
groups	O
in	O
Japanese	O
individuals	O
.	O
METHODS	O
:	O
Ninety	O
healthy	O
Japanese	O
individuals	O
were	O
enrolled	O
and	O
classified	O
into	O
the	O
three	O
different	O
CYP2C19	S-GP
genotype	O
groups	O
:	O
homozygous	O
extensive	O
metabolizers	O
(	O
hmEMs	O
;	O
n	O
=	O
34	O
)	O
,	O
heterozygous	O
EMs	O
(	O
htEMs	O
;	O
n	O
=	O
44	O
)	O
,	O
and	O
poor	O
metabolizers	O
(	O
PMs	O
;	O
n	O
=	O
12	O
)	O
.	O
Blood	O
samples	O
were	O
drawn	O
4	O
h	O
after	O
the	O
intake	O
of	O
an	O
oral	O
dose	O
of	O
omeprazole	S-chemical
40	O
mg	O
,	O
and	O
plasma	O
levels	O
of	O
omeprazole	S-chemical
and	O
its	O
metabolites	O
were	O
analyzed	O
by	O
high-performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
using	O
a	O
chiral	O
column	O
.	O
RESULTS	O
:	O
Mean	O
plasma	O
concentrations	O
of	O
(	B-chemical
R	I-chemical
)	I-chemical
-	I-chemical
and	I-chemical
(	I-chemical
S	I-chemical
)	I-chemical
-omeprazole	E-chemical
in	O
PMs	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
hmEMs	O
and	O
htEMs	O
,	O
and	O
similar	O
results	O
were	O
obtained	O
in	O
the	O
case	O
of	O
omeprazole	B-chemical
sulfone	E-chemical
.	O
Additionally	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
plasma	O
concentrations	O
of	O
(	B-chemical
R	I-chemical
)	I-chemical
-5-hydroxyomeprazole	E-chemical
among	O
CYP2C19	S-GP
genotype	O
groups	O
,	O
whereas	O
no	O
significant	O
differences	O
were	O
observed	O
in	O
that	O
of	O
(	B-chemical
S	I-chemical
)	I-chemical
-5-hydroxyomeprazole	E-chemical
.	O
Similarly	O
,	O
(	B-chemical
R	I-chemical
)	I-chemical
-omeprazole	E-chemical
HI	O
in	O
hmEMs	O
,	O
htEMs	O
,	O
and	O
PMs	O
were	O
5.6	O
,	O
3.1	O
,	O
and	O
0.3	O
,	O
respectively	O
,	O
which	O
were	O
significantly	O
different	O
,	O
but	O
no	O
significant	O
difference	O
was	O
present	O
in	O
the	O
(	B-chemical
S	I-chemical
)	I-chemical
-omeprazole	E-chemical
HI	O
.	O
CONCLUSION	O
:	O
Our	O
findings	O
demonstrate	O
that	O
(	B-chemical
R	I-chemical
)	I-chemical
-omeprazole	E-chemical
HI	O
correlated	O
better	O
with	O
CYP2C19	S-GP
genotype	O
groups	O
than	O
racemic-omeprazole	S-chemical
HI	O
,	O
and	O
these	O
results	O
may	O
be	O
useful	O
for	O
classification	O
among	O
patients	O
in	O
CYP2C19	S-GP
genotype	O
groups	O
prior	O
to	O
omeprazole	O
treatment	O
.	O

Differential	O
regulation	O
of	O
Arabidopsis	B-GP
plastid	E-GP
gene	O
expression	O
and	O
RNA	O
editing	O
in	O
non-photosynthetic	O
tissues	O
.	O
RNA	O
editing	O
is	O
one	O
of	O
the	O
post-transcriptional	O
processes	O
that	O
commonly	O
occur	O
in	O
plant	B-GP
plastids	E-GP
and	O
mitochondria	O
.	O
In	O
Arabidopsis	O
,	O
34	O
C-to-U	O
RNA	O
editing	O
events	O
,	O
affecting	O
transcripts	O
of	O
18	O
plastid	S-GP
genes	O
,	O
have	O
been	O
identified	O
.	O
Here	O
,	O
we	O
examined	O
the	O
editing	O
and	O
expression	O
of	O
these	O
transcripts	O
in	O
different	O
organs	O
,	O
and	O
in	O
green	O
and	O
non-green	O
seedlings	O
(	O
etiolated	O
,	O
cia5-2	O
,	O
ispF	O
and	O
ispG	O
albino	O
mutants	O
,	O
lincomycin	S-chemical
-	O
,	O
and	O
norflurazon	S-chemical
-treated	O
)	O
.	O
The	O
editing	O
efficiency	O
of	O
Arabidopsis	B-GP
plastid	E-GP
transcripts	O
varies	O
from	O
site	O
to	O
site	O
,	O
and	O
may	O
be	O
specifically	O
regulated	O
in	O
different	O
tissues	O
.	O
Steady	O
state	O
levels	O
of	O
plastid	S-GP
transcripts	O
are	O
low	O
or	O
undetectable	O
in	O
etiolated	O
seedlings	O
,	O
but	O
most	O
editing	O
sites	O
are	O
edited	O
with	O
efficiencies	O
similar	O
to	O
those	O
observed	O
in	O
green	O
seedlings	O
.	O
By	O
contrast	O
,	O
the	O
editing	O
of	O
some	O
sites	O
is	O
completely	O
lost	O
or	O
significantly	O
reduced	O
in	O
other	O
non-green	O
tissues	O
;	O
for	O
instance	O
,	O
the	O
editing	O
of	O
ndhB-149	S-GP
,	O
ndhB-1255	S-GP
,	O
and	O
ndhD-2	S-GP
is	O
completely	O
lost	O
in	O
roots	O
and	O
in	O
lincomycin	S-chemical
-treated	O
seedlings	O
.	O
The	O
editing	O
of	O
ndhD-2	S-GP
is	O
also	O
completely	O
lost	O
in	O
albino	O
mutants	O
and	O
norflurazon	S-chemical
-treated	O
seedlings	O
.	O
However	O
,	O
matK-640	O
is	O
completely	O
edited	O
,	O
and	O
accD-794	S-GP
,	O
atpF-92	S-GP
,	O
psbE-214	S-GP
,	O
psbF-77	S-GP
,	O
psbZ-50	S-GP
,	O
and	O
rps14-50	S-GP
are	O
completely	O
or	O
highly	O
edited	O
in	O
both	O
green	O
and	O
non-green	O
tissues	O
.	O
In	O
addition	O
,	O
the	O
expression	O
of	O
nucleus-encoded	O
RNA	B-GP
polymerase	E-GP
dependent	O
transcripts	O
is	O
specifically	O
induced	O
by	O
lincomycin	S-chemical
,	O
and	O
the	O
splicing	O
of	O
ndhB	S-GP
transcripts	O
is	O
significantly	O
reduced	O
in	O
the	O
albino	O
mutants	O
and	O
inhibitor-treated	O
seedlings	O
.	O
Our	O
results	O
indicate	O
that	O
plastid	S-GP
gene	O
expression	O
,	O
and	O
the	O
splicing	O
and	O
editing	O
of	O
plastid	S-GP
transcripts	O
are	O
specifically	O
and	O
differentially	O
regulated	O
in	O
various	O
types	O
of	O
non-green	O
tissues	O
.	O

Anabolic	O
effects	O
of	O
clenbuterol	S-chemical
on	O
skeletal	O
muscle	O
are	O
mediated	O
by	O
beta	B-GP
2-adrenoceptor	E-GP
activation	O
.	O
The	O
potent	O
anabolic	O
effects	O
of	O
the	O
beta	B-GP
2-adrenoceptor	E-GP
agonist	O
clenbuterol	S-chemical
on	O
skeletal	O
muscle	O
have	O
been	O
reported	O
to	O
be	O
independent	O
of	O
actions	O
on	O
beta-adrenoceptors	S-GP
.	O
In	O
the	O
present	O
study	O
clenbuterol	S-chemical
,	O
presented	O
to	O
rats	O
in	O
the	O
diet	O
(	O
4	O
mg/kg	O
)	O
,	O
caused	O
significant	O
increases	O
in	O
gastrocnemius	O
muscle	O
mass	O
,	O
protein	O
,	O
and	O
RNA	O
content	O
and	O
a	O
decrease	O
in	O
epididymal	O
fat	O
pad	O
mass	O
.	O
These	O
effects	O
were	O
not	O
mimicked	O
by	O
oral	O
administration	O
of	O
the	O
beta	B-GP
2-adrenoceptor	E-GP
agonist	O
salbutamol	S-chemical
even	O
at	O
high	O
dose	O
(	O
52	O
mg/kg	O
diet	O
)	O
,	O
and	O
the	O
effects	O
of	O
clenbuterol	S-chemical
were	O
not	O
inhibited	O
by	O
addition	O
of	O
DL-propranolol	S-chemical
(	O
200	O
mg/kg	O
diet	O
)	O
.	O
However	O
,	O
the	O
selective	O
beta	O
2-antagonist	O
ICI-118,551	S-chemical
(	O
200	O
mg/kg	O
diet	O
)	O
reversed	O
the	O
anabolic	O
effects	O
of	O
clenbuterol	S-chemical
,	O
and	O
a	O
high	O
dose	O
of	O
DL-propranolol	S-chemical
(	O
1,000	O
mg/kg	O
diet	O
)	O
also	O
inhibited	O
these	O
actions	O
of	O
clenbuterol	S-chemical
.	O
Furthermore	O
,	O
continuous	O
infusion	O
of	O
salbutamol	S-chemical
(	O
1.15	O
mg.kg	O
body	O
wt-1.day-1	O
)	O
via	O
miniosmotic	O
pumps	O
did	O
cause	O
significant	O
increases	O
in	O
muscle	O
mass	O
,	O
protein	O
,	O
and	O
RNA	O
content	O
.	O
These	O
results	O
indicate	O
that	O
the	O
anabolic	O
effects	O
of	O
clenbuterol	S-chemical
are	O
dependent	O
on	O
interaction	O
with	O
the	O
beta	B-GP
2-adrenoceptor	E-GP
.	O
However	O
,	O
a	O
long	O
duration	O
of	O
action	O
appears	O
to	O
be	O
required	O
to	O
induce	O
the	O
anabolic	O
effects	O
of	O
beta	O
2-agonists	O
.	O

The	O
antitussive	O
activity	O
of	O
delta-opioid	B-GP
receptor	E-GP
stimulation	O
in	O
guinea	O
pigs	O
.	O
In	O
this	O
study	O
,	O
the	O
activity	O
of	O
the	O
delta-opioid	B-GP
receptor	E-GP
subtype-selective	O
agonist	O
,	O
SB	B-chemical
227122	E-chemical
,	O
was	O
investigated	O
in	O
a	O
guinea	O
pig	O
model	O
of	O
citric	B-chemical
acid	E-chemical
-induced	O
cough	O
.	O
Parenteral	O
administration	O
of	O
selective	O
agonists	O
of	O
the	O
delta-opioid	B-GP
receptor	E-GP
(	O
SB	B-chemical
227122	E-chemical
)	O
,	O
mu-opioid	B-GP
receptor	E-GP
(	O
codeine	S-chemical
and	O
hydrocodone	S-chemical
)	O
,	O
and	O
kappa-opioid	B-GP
receptor	E-GP
(	O
BRL	B-chemical
52974	E-chemical
)	O
produced	O
dose-related	O
inhibition	O
of	O
citric	B-chemical
acid	E-chemical
-induced	O
cough	O
with	O
ED	O
(	O
50	O
)	O
values	O
of	O
7.3	O
,	O
5.2	O
,	O
5.1	O
,	O
and	O
5.3	O
mg/kg	O
,	O
respectively	O
.	O
The	O
nonselective	O
opioid	B-GP
receptor	E-GP
antagonist	O
,	O
naloxone	S-chemical
(	O
3	O
mg/kg	O
,	O
i.m	O
.	O
)	O
,	O
attenuated	O
the	O
antitussive	O
effects	O
of	O
codeine	S-chemical
or	O
SB	B-chemical
227122	E-chemical
,	O
indicating	O
that	O
the	O
antitussive	O
activity	O
of	O
both	O
compounds	O
is	O
opioid	B-GP
receptor	E-GP
-mediated	O
.	O
The	O
delta-receptor	S-GP
antagonist	O
,	O
SB	B-chemical
244525	E-chemical
(	O
10	O
mg/kg	O
,	O
i.p	O
.	O
)	O
,	O
inhibited	O
the	O
antitussive	O
effect	O
of	O
SB	B-chemical
227122	E-chemical
(	O
20	O
mg/kg	O
,	O
i.p.	O
)	O
.	O
In	O
contrast	O
,	O
combined	O
pretreatment	O
with	O
beta-funaltrexamine	S-chemical
(	O
mu-receptor	S-GP
antagonist	O
;	O
20	O
mg/kg	O
,	O
s.c.	O
)	O
and	O
norbinaltorphimine	S-chemical
(	O
kappa-receptor	S-GP
antagonist	O
;	O
20	O
mg/kg	O
,	O
s.c.	O
)	O
,	O
at	O
doses	O
that	O
inhibited	O
the	O
antitussive	O
activity	O
of	O
mu-	B-GP
and	I-GP
kappa-receptor	E-GP
agonists	O
,	O
respectively	O
,	O
was	O
without	O
effect	O
on	O
the	O
antitussive	O
response	O
of	O
SB	B-chemical
227122	E-chemical
(	O
20	O
mg/kg	O
,	O
i.p.	O
)	O
.	O
The	O
sigma-receptor	S-GP
antagonist	O
rimcazole	S-chemical
(	O
3	O
mg/kg	O
,	O
i.p	O
.	O
)	O
inhibited	O
the	O
antitussive	O
effect	O
of	O
dextromethorphan	S-chemical
(	O
30	O
mg/kg	O
,	O
i.p	O
.	O
)	O
,	O
a	O
sigma-receptor	O
agonist	O
,	O
but	O
not	O
that	O
of	O
SB	B-chemical
227122	E-chemical
.	O
These	O
studies	O
provide	O
compelling	O
evidence	O
that	O
the	O
antitussive	O
effects	O
of	O
SB	B-chemical
227122	E-chemical
in	O
this	O
guinea	O
pig	O
cough	O
model	O
are	O
mediated	O
by	O
agonist	O
activity	O
at	O
the	O
delta-opioid	B-GP
receptor	E-GP
.	O

Management	O
of	O
psoriasis	O
:	O
the	O
position	O
of	O
retinoid	S-chemical
drugs	O
.	O
Oral	O
synthetic	O
retinoids	S-chemical
have	O
been	O
established	O
as	O
effective	O
systemic	O
therapy	O
for	O
psoriasis	O
since	O
their	O
introduction	O
for	O
clinical	O
use	O
in	O
the	O
1970s	O
;	O
a	O
compound	O
for	O
topical	O
use	O
,	O
tazarotene	S-chemical
has	O
been	O
recently	O
marketed	O
.	O
Despite	O
the	O
demonstrated	O
clinical	O
success	O
of	O
retinoid	S-chemical
therapy	O
in	O
psoriasis	O
,	O
its	O
mechanism	O
of	O
action	O
has	O
not	O
been	O
fully	O
elucidated	O
,	O
and	O
investigators	O
are	O
confronted	O
with	O
two	O
paradoxes	O
.	O
One	O
is	O
that	O
the	O
binding	O
of	O
retinoids	S-chemical
to	O
nuclear	O
retinoic	B-GP
acid	I-GP
receptors	E-GP
(	O
RARs	S-GP
)	O
does	O
not	O
match	O
their	O
therapeutic	O
efficacy	O
:	O
acitretin	S-chemical
activates	O
the	O
three	O
receptor	O
subtypes	O
,	O
RAR-alpha	B-GP
,	I-GP
-beta	I-GP
and	I-GP
-gamma	E-GP
,	O
without	O
measurable	O
receptor	O
binding	O
,	O
whereas	O
tazarotene	S-chemical
preferentially	O
binds	O
to	O
and	O
activates	O
RAR-beta	B-GP
and	I-GP
-gamma	E-GP
in	O
preference	O
to	O
RAR-alpha	S-GP
.	O
The	O
other	O
is	O
that	O
there	O
is	O
already	O
increased	O
formation	O
of	O
retinoic	B-chemical
acid	E-chemical
in	O
the	O
psoriatic	O
lesion	O
.	O
Answering	O
these	O
questions	O
should	O
result	O
in	O
better	O
use	O
of	O
these	O
drugs	O
in	O
the	O
treatment	O
of	O
psoriasis	O
.	O
Oral	O
administration	O
of	O
acitretin	S-chemical
remains	O
one	O
of	O
the	O
first	O
therapeutic	O
choices	O
for	O
severe	O
psoriasis	O
,	O
particularly	O
in	O
association	O
with	O
ultraviolet	O
light	O
therapy	O
,	O
of	O
which	O
it	O
may	O
decrease	O
the	O
carcinogenic	O
risk	O
.	O
Topical	O
tazarotene	S-chemical
is	O
suitable	O
for	O
moderate	O
plaque	O
psoriasis	O
.	O
Its	O
efficacy	O
and	O
tolerability	O
can	O
be	O
enhanced	O
by	O
the	O
addition	O
of	O
topical	O
corticosteroids	S-chemical
;	O
its	O
irritative	O
potential	O
is	O
counterbalanced	O
by	O
a	O
sustained	O
therapeutic	O
effect	O
after	O
the	O
treatment	O
is	O
stopped	O
.	O

Nebulized	O
arformoterol	S-chemical
in	O
patients	O
with	O
COPD	O
:	O
a	O
12-week	O
,	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
double-dummy	O
,	O
placebo-	O
and	O
active-controlled	O
trial	O
.	O
OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
and	O
tolerability	O
of	O
nebulized	O
arformoterol	B-chemical
tartrate	E-chemical
(	O
a	O
selective	O
,	O
long-acting	O
beta	B-GP
(	I-GP
2	I-GP
)	I-GP
-adrenergic	E-GP
agonist	O
that	O
is	O
the	O
[	B-chemical
R	I-chemical
,	I-chemical
R	I-chemical
]	I-chemical
isomer	I-chemical
of	I-chemical
formoterol	E-chemical
)	O
and	O
salmeterol	B-chemical
xinafoate	E-chemical
versus	O
placebo	O
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O
METHODS	O
:	O
This	O
12-week	O
,	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
double-dummy	O
,	O
placebo-	O
and	O
active-controlled	O
trial	O
was	O
conducted	O
at	O
60	O
centers	O
across	O
the	O
United	O
States	O
.	O
Male	O
and	O
female	O
patients	O
aged	O
>	O
or=35	O
years	O
with	O
physician-diagnosed	O
COPD	O
received	O
arformoterol	S-chemical
(	O
15	O
microg	O
BID	O
,	O
25	O
microg	O
BID	O
,	O
or	O
50	O
microg	O
QD	O
via	O
nebulizer	O
)	O
,	O
salmeterol	S-chemical
(	O
42	O
microg	O
BID	O
via	O
metered	O
dose	O
inhaler	O
)	O
,	O
or	O
placebo	O
.	O
Pulmonary	O
function	O
was	O
assessed	O
by	O
spirometry	O
;	O
dyspnea	O
,	O
by	O
the	O
Transitional	O
Dyspnea	O
Index	O
(	O
TDI	O
)	O
;	O
and	O
health	O
status	O
,	O
by	O
the	O
St.	O
George	O
's	O
Respiratory	O
Questionnaire	O
(	O
SGRQ	O
)	O
.	O
Adverse	O
events	O
(	O
AEs	O
)	O
were	O
assessed	O
by	O
site	O
personnel	O
at	O
all	O
clinic	O
visits	O
(	O
screening	O
,	O
first	O
dose	O
at	O
week	O
0	O
,	O
and	O
at	O
weeks	O
3	O
,	O
6	O
,	O
9	O
,	O
12	O
,	O
and	O
follow-up	O
)	O
.	O
COPD	O
exacerbations	O
were	O
defined	O
as	O
worsening	O
respiratory	O
status	O
requiring	O
a	O
change	O
in	O
medication	O
or	O
an	O
unscheduled	O
provider	O
visit	O
.	O
RESULTS	O
:	O
A	O
total	O
of	O
717	O
patients	O
received	O
study	O
medication	O
.	O
The	O
demographic	O
composition	O
of	O
all	O
treatment	O
arms	O
was	O
similar	O
.	O
The	O
mean	O
age	O
was	O
62.9	O
years	O
,	O
58	O
%	O
were	O
men	O
,	O
and	O
mean	O
baseline	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV	O
(	O
1	O
)	O
)	O
was	O
1.2	O
L	O
(	O
41	O
%	O
predicted	O
)	O
.	O
Mean	O
improvement	O
in	O
trough	O
FEV	O
(	O
1	O
)	O
over	O
12	O
weeks	O
was	O
significantly	O
greater	O
with	O
all	O
3	O
arformoterol	S-chemical
doses	O
(	O
15	O
microg	O
BID	O
,	O
+16.9	O
%	O
;	O
25	O
microg	O
BID	O
,	O
+18.9	O
%	O
;	O
50	O
microg	O
QD	O
,	O
+14.9	O
%	O
)	O
and	O
for	O
salmeterol	S-chemical
(	O
+17.4	O
%	O
)	O
relative	O
to	O
placebo	O
(	O
+6.0	O
%	O
;	O
P	O
<	O
0.001	O
)	O
.	O
There	O
were	O
significantly	O
greater	O
improvements	O
in	O
the	O
mean	O
percentage	O
change	O
in	O
FEV	O
(	O
1	O
)	O
AUC	O
(	O
0-12h	O
)	O
from	O
the	O
predose	O
value	O
over	O
12	O
weeks	O
(	O
15	O
microg	O
BID	O
,	O
12.7	O
%	O
,	O
25	O
microg	O
BID	O
,	O
13.9	O
%	O
,	O
50	O
microg	O
QD	O
,	O
18.9	O
%	O
;	O
salmeterol	S-chemical
,	O
9.8	O
%	O
)	O
versus	O
placebo	O
(	O
2.7	O
%	O
;	O
P	O
<	O
or=	O
0.001	O
)	O
;	O
all	O
doses	O
of	O
arformoterol	O
were	O
statistically	O
different	O
from	O
salmeterol	O
for	O
this	O
end	O
point	O
(	O
P	O
<	O
or=	O
0.024	O
)	O
.	O
At	O
week	O
12	O
,	O
TDI	O
focal	O
scores	O
were	O
significantly	O
greater	O
with	O
all	O
arformoterol	O
doses	O
compared	O
with	O
placebo	O
(	O
mean	O
[	O
95	O
%	O
CI	O
]	O
:	O
15	O
microg	O
BID	O
,	O
0.97	O
[	O
0.25-1.69	O
]	O
;	O
25	O
microg	O
BID	O
,	O
1.08	O
[	O
0.3-1.86	O
]	O
;	O
50	O
microg	O
QD	O
,	O
1.04	O
[	O
0.32-1.771	O
)	O
,	O
suggesting	O
treatment-associated	O
improvement	O
in	O
dyspnea	O
,	O
however	O
,	O
the	O
difference	O
between	O
salmeterol	O
and	O
placebo	O
was	O
not	O
statistically	O
significant	O
(	O
0.36	O
[	O
-0.40	O
to	O
1.12	O
]	O
)	O
.	O
Improvements	O
in	O
health	O
status	O
,	O
as	O
measured	O
using	O
SGRQ	O
total	O
scores	O
,	O
were	O
-2.6	O
to	O
-3.6	O
U	O
in	O
the	O
arformoterol	O
groups	O
,	O
-4.4	O
U	O
for	O
salmeterol	O
,	O
and	O
-1.2	O
U	O
for	O
placebo	O
;	O
95	O
%	O
CI	O
of	O
differences	O
versus	O
placebo	O
suggested	O
significant	O
improvement	O
for	O
the	O
arformoterol	O
25	O
microg	O
BID	O
and	O
salmeterol	O
groups	O
.	O
There	O
was	O
a	O
similar	O
frequency	O
of	O
AEs	O
and	O
COPD	O
exacerbations	O
across	O
all	O
groups	O
,	O
including	O
placebo	O
.	O
CONCLUSIONS	O
:	O
In	O
this	O
trial	O
,	O
patients	O
with	O
moderate	O
to	O
severe	O
COPD	O
administered	O
nebulized	O
arformoterol	O
over	O
12	O
weeks	O
were	O
observed	O
to	O
have	O
significant	O
and	O
sustained	O
improvements	O
in	O
airway	O
function	O
and	O
dyspnea	O
compared	O
with	O
placebo	O
.	O
The	O
results	O
also	O
suggest	O
that	O
all	O
doses	O
of	O
arformoterol	O
,	O
including	O
the	O
lowest	O
dose	O
(	O
15	O
microg	O
BID	O
)	O
,	O
were	O
effective	O
.	O
Overall	O
,	O
nebulized	O
arformoterol	O
was	O
well	O
tolerated	O
.	O

Derivatives	O
of	O
Dictyostelium	O
discoideum	O
differentiation-inducing	O
factor-3	O
suppress	O
the	O
activities	O
of	O
Trypanosoma	O
cruzi	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Chagas	O
disease	O
(	O
human	O
American	O
trypanosomiasis	O
)	O
,	O
which	O
is	O
caused	O
by	O
the	O
protozoan	O
parasite	O
Trypanosoma	O
cruzi	O
,	O
is	O
responsible	O
for	O
numerous	O
deaths	O
each	O
year	O
;	O
however	O
,	O
established	O
treatments	O
for	O
the	O
disease	O
are	O
limited	O
.	O
Differentiation-inducing	O
factor-1	O
(	O
DIF-1	O
)	O
and	O
DIF-3	O
are	O
chlorinated	O
alkylphenones	S-chemical
originally	O
found	O
in	O
the	O
cellular	O
slime	O
mold	O
Dictyostelium	O
discoideum	O
that	O
have	O
been	O
shown	O
to	O
possess	O
pharmacological	O
activities	O
.	O
Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
DIF-3	O
derivatives	O
on	O
the	O
infection	O
rate	O
and	O
growth	O
of	O
T.	O
cruzi	O
by	O
using	O
an	O
in	O
vitro	O
assay	O
system	O
utilizing	O
host	O
human	O
fibrosarcoma	O
HT1080	O
cells	O
.	O
Certain	O
DIF-3	O
derivatives	O
,	O
such	O
as	O
butoxy	S-chemical
-DIF-3	O
(	O
Bu-DIF-3	O
)	O
,	O
at	O
micro-molar	O
levels	O
strongly	O
suppressed	O
both	O
the	O
infection	O
rate	O
and	O
growth	O
of	O
T.	O
cruzi	O
in	O
HT1080	O
cells	O
and	O
exhibited	O
little	O
toxicity	O
for	O
HT1080	O
cells	O
.	O
For	O
example	O
,	O
the	O
IC50	O
of	O
DIF-3	O
and	O
Bu-DIF-3	O
versus	O
the	O
growth	O
of	O
T.	O
cruzi	O
in	O
HT1080	O
cells	O
were	O
3.95	O
and	O
0.72μM	O
,	O
respectively	O
,	O
and	O
the	O
LD50	O
of	O
the	O
two	O
compounds	O
versus	O
HT1080	O
cells	O
were	O
both	O
greater	O
than	O
100μM	O
.	O
We	O
also	O
examined	O
the	O
effects	O
of	O
DIF-3	O
and	O
Bu-DIF-3	O
on	O
T.	O
cruzi	O
activity	O
in	O
C57BL/6	O
mice	O
.	O
Intraperitoneally	O
administered	O
Bu-DIF-3	O
(	O
50mg/kg	O
)	O
significantly	O
suppressed	O
the	O
number	O
of	O
trypomastigotes	O
in	O
blood	O
with	O
no	O
apparent	O
adverse	O
effects	O
.	O
These	O
results	O
strongly	O
suggest	O
that	O
DIF-3	O
derivatives	O
could	O
be	O
new	O
lead	O
compounds	O
in	O
the	O
development	O
of	O
anti-trypanosomiasis	O
drugs	O
.	O

The	O
broad-spectrum	O
anti-emetic	O
activity	O
of	O
AS-8112	S-chemical
,	O
a	O
novel	O
dopamine	B-GP
D2	I-GP
,	I-GP
D3	E-GP
and	O
5-HT3	B-GP
receptors	E-GP
antagonist	O
.	O
The	O
anti-emetic	O
and	O
pharmacological	O
profile	O
of	O
AS-8112	S-chemical
(	O
(	B-chemical
R	I-chemical
)	I-chemical
-5-bromo-N-	I-chemical
(	I-chemical
1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl	I-chemical
)	I-chemical
-2-methoxy-6-methy	I-chemical
lamino-3-pyridinecarboxamide.2	I-chemical
fumarate	E-chemical
)	O
,	O
a	O
novel	O
and	O
potent	O
dopamine	B-GP
D2	I-GP
,	I-GP
D3	E-GP
and	O
5-hydroxytryptamine-3	B-GP
(	I-GP
5-HT3	I-GP
)	I-GP
receptors	E-GP
ligand	O
,	O
was	O
investigated	O
in	O
the	O
present	O
study	O
.	O
In	O
guinea-pig	O
isolated	O
colon	O
,	O
AS-8112	S-chemical
produced	O
a	O
rightward	O
shift	O
of	O
the	O
concentration-response	O
curves	O
of	O
2-methyl-5HT	S-chemical
,	O
a	O
5-HT3	B-GP
receptor	E-GP
agonist	O
(	O
pA2	O
value	O
of	O
7.04	O
)	O
.	O
Other	O
5-HT3	B-GP
receptor	E-GP
antagonists	O
also	O
produced	O
such	O
a	O
shift	O
in	O
the	O
following	O
antagonistic-potency	O
order	O
:	O
granisetron	S-chemical
>	O
ondansetron	S-chemical
=	O
AS-8112	S-chemical
>	O
>	O
metoclopramide	S-chemical
.	O
In	O
mice	O
,	O
AS-8112	S-chemical
(	O
1.0	O
-	O
3.0	O
mg	O
kg	O
(	O
-1	O
)	O
s.c.	O
)	O
potently	O
inhibited	O
hypothermia	O
induced	O
by	O
the	O
dopamine	B-GP
D3	I-GP
receptor	E-GP
agonist	O
;	O
R	B-chemical
(	I-chemical
+	I-chemical
)	I-chemical
-7-OH-DPAT	E-chemical
(	O
R	B-chemical
(	I-chemical
+	I-chemical
)	I-chemical
-7-hydroxy-2-	I-chemical
(	I-chemical
N	I-chemical
,	I-chemical
N-di-n-propylamino	I-chemical
)	I-chemical
tetraline	E-chemical
)	O
(	O
0.3	O
mg	O
kg	O
(	O
-1	O
)	O
s.c.	O
)	O
.	O
Domperidone	S-chemical
and	O
haloperidol	S-chemical
,	O
which	O
have	O
affinity	O
for	O
dopamine	B-GP
D3	I-GP
receptor	E-GP
,	O
also	O
inhibited	O
R	B-chemical
(	I-chemical
+	I-chemical
)	I-chemical
-7-OH-DPAT	E-chemical
-induced	O
hypothermia	O
.	O
In	O
ferrets	O
or	O
dogs	O
,	O
AS-8112	S-chemical
dose-dependently	O
inhibited	O
emesis	O
induced	O
by	O
R	B-chemical
(	I-chemical
+	I-chemical
)	I-chemical
-7-OH-DPAT	E-chemical
,	O
apomorphine	S-chemical
,	O
morphine	S-chemical
or	O
cisplatin	S-chemical
with	O
ID50	O
values	O
of	O
2.22	O
microg	O
kg	O
(	O
-1	O
)	O
s.c.	O
,	O
10.5	O
microg	O
kg	O
(	O
-1	O
)	O
s.c.	O
,	O
14.2	O
microg	O
kg	O
(	O
-1	O
)	O
i.v	O
.	O
and	O
17.6	O
microg	O
kg	O
(	O
-1	O
)	O
i.v.	O
,	O
respectively	O
.	O
Moreover	O
,	O
oral	O
administration	O
of	O
AS-8112	S-chemical
significantly	O
inhibited	O
emesis	O
induced	O
by	O
these	O
emetogens	O
.	O
AS-8112	S-chemical
(	O
0.3	O
mg	O
kg	O
(	O
-1	O
)	O
i.v	O
.	O
)	O
significantly	O
inhibited	O
emesis	O
induced	O
by	O
cyclophosphamide	S-chemical
and	O
doxorubicin	S-chemical
.	O
In	O
conclusion	O
,	O
AS-8112	S-chemical
is	O
a	O
potent	O
dopamine	B-GP
D2	I-GP
,	I-GP
D3	E-GP
and	O
5-HT3	B-GP
receptors	E-GP
antagonist	O
,	O
and	O
a	O
novel	O
anti-emetic	O
agent	O
with	O
a	O
broad-spectrum	O
of	O
anti-emetic	O
activity	O
.	O
These	O
results	O
suggest	O
that	O
this	O
compound	O
is	O
worthy	O
of	O
clinical	O
investigation	O
.	O

Synthesis	O
and	O
in-silico	O
studies	O
of	O
some	O
diaryltriazole	S-chemical
derivatives	O
as	O
potential	O
cyclooxygenase	S-GP
inhibitors	O
.	O
The	O
synthesis	O
of	O
several	O
4-phenyl-5-pyridin-4-yl-2,3-dihydro-3H-1,2,4-triazole-3-thiones	S-chemical
possessing	O
N-2	O
Mannich	B-chemical
bases	E-chemical
or	O
S-alkyl	S-chemical
substituents	O
,	O
is	O
reported	O
.	O
Several	O
of	O
them	O
exhibited	O
a	O
low	O
nanomolar	O
COX	S-GP
enzyme	O
inhibition	O
activity	O
.	O
Most	O
of	O
the	O
compounds	O
showed	O
inhibition	O
of	O
edema	O
was	O
similar	O
to	O
that	O
evoked	O
by	O
celocoxib	S-chemical
in	O
animal	O
model	O
.	O
Molecular	O
docking	O
studies	O
of	O
the	O
compounds	O
into	O
the	O
binding	O
sites	O
of	O
COX-1	S-GP
and	O
COX-2	S-GP
allowed	O
us	O
to	O
shed	O
light	O
on	O
the	O
binding	O
mode	O
of	O
these	O
novel	O
COX	S-GP
inhibitors	O
.	O

Analysis	O
of	O
NMDA	B-GP
receptors	E-GP
in	O
the	O
human	O
spinal	O
cord	O
.	O
NMDA	B-GP
receptors	E-GP
in	O
postmortem	O
human	O
spinal	O
cord	O
were	O
analyzed	O
using	O
[	B-chemical
3H	I-chemical
]	I-chemical
MK-801	E-chemical
ligand	O
binding	O
and	O
immunoblotting	O
with	O
NMDA	B-GP
receptor	E-GP
subunit-specific	O
antibodies	O
.	O
The	O
average	O
KD	O
for	O
[	B-chemical
3H	I-chemical
]	I-chemical
MK-801	E-chemical
binding	O
was	O
1.77	O
nM	O
with	O
a	O
Bmax	O
of	O
0.103	O
pmol/mg	O
.	O
The	O
EC50	O
for	O
stimulation	O
of	O
-	O
3H-MK-801	S-chemical
binding	O
with	O
L-glutamate	S-chemical
was	O
0.34	O
microM	O
.	O
None	O
of	O
these	O
parameters	O
were	O
affected	O
by	O
postmortem	O
intervals	O
up	O
to	O
72	O
h.	O
Immunoblotting	O
of	O
native	O
NMDA	B-GP
receptors	E-GP
showed	O
that	O
NR1	S-GP
,	O
NR2A	S-GP
,	O
NR2C	S-GP
,	O
and	O
NR2D	S-GP
subunits	O
could	O
all	O
be	O
found	O
in	O
the	O
human	O
spinal	O
cord	O
of	O
which	O
NR1	S-GP
was	O
preferentially	O
located	O
to	O
the	O
dorsal	O
half	O
.	O
Immunoprecipitation	O
of	O
solubilized	O
receptors	O
revealed	O
that	O
NR1	S-GP
,	O
NR2C	S-GP
,	O
and	O
NR2D	S-GP
subunits	O
coprecipitated	O
with	O
the	O
NR2A	S-GP
subunit	O
,	O
indicating	O
that	O
native	O
human	O
spinal	O
cord	O
NMDA	B-GP
receptors	E-GP
are	O
heteroligimeric	B-GP
receptors	E-GP
assembled	O
by	O
at	O
least	O
three	O
different	O
receptor	O
subunits	O
.	O
These	O
results	O
provide	O
a	O
basis	O
for	O
the	O
development	O
of	O
drugs	O
selectively	O
aimed	O
at	O
spinal	O
cord	O
NMDA	B-GP
receptors	E-GP
for	O
the	O
future	O
treatment	O
of	O
spinal	O
cord	O
disorders	O
.	O

Presynaptic	O
CaMKIIα	S-GP
modulates	O
dopamine	B-GP
D3	I-GP
receptor	E-GP
activation	O
in	O
striatonigral	O
terminals	O
of	O
the	O
rat	O
brain	O
in	O
a	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
dependent	O
manner	O
.	O
CaMKIIα	S-GP
is	O
expressed	O
at	O
high	O
density	O
in	O
the	O
nucleus	O
accumbens	O
where	O
it	O
binds	O
to	O
postsynaptic	O
D3	B-GP
receptors	E-GP
inhibiting	O
their	O
effects	O
.	O
In	O
striatonigral	O
projections	O
,	O
activation	O
of	O
presynaptic	O
D3	B-GP
receptors	E-GP
potentiates	O
D1	B-GP
receptor	E-GP
-induced	O
stimulation	O
of	O
cAMP	O
production	O
and	O
GABA	O
release	O
.	O
In	O
this	O
study	O
we	O
examined	O
whether	O
the	O
presynaptic	O
effects	O
of	O
D3	B-GP
receptor	E-GP
stimulation	O
in	O
the	O
substantia	O
nigra	O
reticulata	O
(	O
SNr	O
)	O
are	O
modulated	O
by	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
activation	O
of	O
CaMKIIα	S-GP
.	O
In	O
SNr	O
synaptosomes	O
two	O
procedures	O
that	O
increase	O
cytoplasmic	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
,	O
ionomycin	S-chemical
and	O
K	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-depolarization	O
,	O
blocked	O
the	O
additional	O
stimulation	O
of	O
cAMP	S-chemical
accumulation	O
produced	O
by	O
coactivating	O
D3	B-GP
and	I-GP
D1	I-GP
dopamine	I-GP
receptors	E-GP
.	O
The	O
selective	O
CaMKIIα	S-GP
inhibitor	O
KN-62	S-chemical
reversed	O
the	O
blockade	O
produced	O
by	O
ionomycin	S-chemical
and	O
K	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-depolarization	O
.	O
Incubation	O
in	O
either	O
Ca	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
-free	O
solutions	O
or	O
with	O
the	O
selective	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
blocker	O
nifedipine	S-chemical
,	O
also	O
reversed	O
the	O
blocking	O
effects	O
of	O
K	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-depolarization	O
.	O
Immunoblot	O
studies	O
showed	O
that	O
K	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-depolarization	O
increased	O
CaMKIIα	S-GP
phosphorylation	O
in	O
a	O
KN-62	S-chemical
sensitive	O
manner	O
and	O
promoted	O
CaMKIIα	S-GP
binding	O
to	O
D3	B-GP
receptors	E-GP
.	O
In	O
K	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-depolarized	O
tissues	O
,	O
D3	B-GP
receptors	E-GP
potentiated	O
D1	B-GP
receptor	E-GP
-induced	O
stimulation	O
of	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
GABA	E-chemical
release	O
only	O
when	O
CaMKIIα	S-GP
was	O
blocked	O
with	O
KN-62	S-chemical
.	O
In	O
the	O
presence	O
of	O
this	O
inhibitor	O
,	O
the	O
selective	O
D3	S-GP
agonist	O
PD	B-chemical
128,907	E-chemical
reduced	O
the	O
ED50	O
for	O
the	O
D1	S-GP
agonist	O
SKF	B-chemical
38393	E-chemical
from	O
56	O
to	O
4	O
nM	O
.	O
KN-62	S-chemical
also	O
enhanced	O
the	O
effects	O
of	O
dopamine	S-chemical
on	O
depolarization	O
induced	O
[	B-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
GABA	E-chemical
release	O
.	O
KN-62	S-chemical
changed	O
ED50	O
for	O
dopamine	S-chemical
from	O
584	O
to	O
56	O
nM	O
.	O
KN-62	S-chemical
did	O
not	O
affect	O
D1	B-GP
and	I-GP
D4	I-GP
receptor	E-GP
responses	O
.	O
These	O
experiments	O
show	O
that	O
in	O
striatonigral	O
projections	O
,	O
CaMKIIα	S-GP
inhibits	O
the	O
action	O
of	O
D3	B-GP
receptors	E-GP
in	O
a	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
dependent	O
manner	O
blocking	O
their	O
modulatory	O
effects	O
on	O
GABA	S-chemical
release	O
.	O
These	O
findings	O
suggest	O
a	O
mechanism	O
through	O
which	O
the	O
frequency	O
of	O
action	O
potential	O
discharge	O
in	O
presynaptic	O
terminals	O
regulates	O
dopamine	S-chemical
effects	O
.	O

Sodium	B-GP
channel	E-GP
blockers	O
identify	O
risk	O
for	O
sudden	O
death	O
in	O
patients	O
with	O
ST-segment	O
elevation	O
and	O
right	O
bundle	O
branch	O
block	O
but	O
structurally	O
normal	O
hearts	O
.	O
BACKGROUND	O
:	O
A	O
mutation	O
in	O
the	O
cardiac	B-GP
sodium	I-GP
channel	E-GP
gene	O
(	O
SCN5A	S-GP
)	O
has	O
been	O
described	O
in	O
patients	O
with	O
the	O
syndrome	O
of	O
right	O
bundle	O
branch	O
block	O
,	O
ST-segment	O
elevation	O
in	O
leads	O
V1	O
to	O
V3	O
,	O
and	O
sudden	O
death	O
(	O
Brugada	O
syndrome	O
)	O
.	O
These	O
electrocardiographic	O
manifestations	O
are	O
transient	O
in	O
many	O
patients	O
with	O
the	O
syndrome	O
.	O
The	O
present	O
study	O
examined	O
arrhythmic	O
risk	O
in	O
patients	O
with	O
overt	O
and	O
concealed	O
forms	O
of	O
the	O
disease	O
and	O
the	O
effectiveness	O
of	O
sodium	B-GP
channel	E-GP
blockers	O
to	O
unmask	O
the	O
syndrome	O
and	O
,	O
thus	O
,	O
identify	O
patients	O
at	O
risk	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
The	O
effect	O
of	O
intravenous	O
ajmaline	S-chemical
(	O
1	O
mg/kg	O
)	O
,	O
procainamide	S-chemical
(	O
10	O
mg/kg	O
)	O
,	O
or	O
flecainide	S-chemical
(	O
2	O
mg/kg	O
)	O
on	O
the	O
ECG	O
was	O
studied	O
in	O
34	O
patients	O
with	O
the	O
syndrome	O
and	O
transient	O
normalization	O
of	O
the	O
ECG	O
(	O
group	O
A	O
)	O
,	O
11	O
members	O
of	O
3	O
families	O
in	O
whom	O
a	O
SCN5A	S-GP
mutation	O
was	O
associated	O
with	O
the	O
syndrome	O
and	O
8	O
members	O
in	O
whom	O
it	O
was	O
not	O
(	O
group	O
B	O
)	O
,	O
and	O
53	O
control	O
subjects	O
(	O
group	O
C	O
)	O
.	O
Ajmaline	S-chemical
,	O
procainamide	S-chemical
,	O
or	O
flecainide	S-chemical
administration	O
resulted	O
in	O
ST-segment	O
elevation	O
and	O
right	O
bundle	O
branch	O
block	O
in	O
all	O
patients	O
in	O
group	O
A	O
and	O
in	O
all	O
11	O
patients	O
with	O
the	O
mutation	O
in	O
group	O
B	O
.	O
A	O
similar	O
pattern	O
could	O
not	O
be	O
elicited	O
in	O
the	O
8	O
patients	O
in	O
group	O
B	O
who	O
lacked	O
the	O
mutation	O
or	O
in	O
any	O
person	O
in	O
group	O
C.	O
The	O
follow-up	O
period	O
(	O
37+/-33	O
months	O
)	O
revealed	O
no	O
differences	O
in	O
the	O
incidence	O
of	O
arrhythmia	O
between	O
the	O
34	O
patients	O
in	O
whom	O
the	O
phenotypic	O
manifestation	O
of	O
the	O
syndrome	O
was	O
transient	O
and	O
the	O
24	O
patients	O
in	O
whom	O
it	O
was	O
persistent	O
(	O
log-rank	O
,	O
0.639	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
data	O
demonstrated	O
a	O
similar	O
incidence	O
of	O
potentially	O
lethal	O
arrhythmias	O
in	O
patients	O
displaying	O
transient	O
versus	O
persistent	O
ST-segment	O
elevation	O
and	O
right	O
bundle	O
branch	O
block	O
,	O
as	O
well	O
as	O
the	O
effectiveness	O
of	O
sodium	B-GP
channel	E-GP
blockers	O
to	O
unmask	O
the	O
syndrome	O
and	O
,	O
thus	O
,	O
identify	O
patients	O
at	O
risk	O
.	O

Inhibition	O
by	O
pentosan	O
polysulfate	O
(	O
PPS	O
)	O
of	O
heparin-binding	B-GP
growth	I-GP
factors	E-GP
released	O
from	O
tumor	O
cells	O
and	O
blockage	O
by	O
PPS	O
of	O
tumor	O
growth	O
in	O
animals	O
.	O
BACKGROUND	O
:	O
In	O
a	O
proliferating	O
tumor	O
,	O
locally	O
secreted	O
polypeptide	O
growth	O
factors	O
,	O
which	O
have	O
autocrine	O
and	O
paracrine	O
functions	O
,	O
induce	O
vascularization	O
essential	O
for	O
tumor	O
growth	O
and	O
metastasis	O
.	O
These	O
growth	O
factors	O
may	O
serve	O
as	O
targets	O
for	O
tumor	O
therapy	O
.	O
We	O
have	O
shown	O
that	O
the	O
heparinoid	O
pentosan	O
polysulfate	O
(	O
PPS	O
)	O
can	O
block	O
growth	O
of	O
subcutaneous	O
human	O
tumor	O
xenografts	O
in	O
nude	O
mice	O
and	O
angiogenesis	O
induced	O
by	O
the	O
heparin-binding	O
,	O
Kaposi	B-GP
's	I-GP
sarcoma-derived	I-GP
fibroblast	I-GP
growth	I-GP
factor	E-GP
(	O
K-FGF	S-GP
)	O
.	O
PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
PPS	O
might	O
also	O
interfere	O
with	O
stimulation	O
of	O
endothelial	O
cells	O
by	O
other	O
growth	O
factors	O
released	O
from	O
tumor	O
cells	O
and	O
whether	O
the	O
promising	O
antitumor	O
effects	O
of	O
PPS	O
extend	O
to	O
other	O
human	O
tumor	O
cell	O
lines	O
.	O
We	O
studied	O
the	O
effects	O
of	O
PPS	O
on	O
stimulation	O
by	O
heparin-binding	B-GP
growth	I-GP
factors	E-GP
released	O
from	O
seven	O
human	O
tumor	O
cell	O
lines	O
in	O
vitro	O
and	O
on	O
tumors	O
growing	O
from	O
these	O
cell	O
lines	O
in	O
athymic	O
nude	O
mice	O
.	O
METHODS	O
:	O
Seven	O
human	O
cell	O
lines	O
established	O
from	O
breast	O
,	O
prostate	O
,	O
epidermoid	O
,	O
and	O
lung	O
carcinomas	O
and	O
rhabdomyosarcoma	O
were	O
used	O
in	O
in	O
vivo	O
as	O
well	O
as	O
in	O
vitro	O
studies	O
of	O
the	O
effects	O
of	O
PPS	O
.	O
We	O
also	O
studied	O
in	O
vitro	O
the	O
effects	O
of	O
PPS	O
on	O
growth	O
factor-induced	O
colony	O
formation	O
of	O
normal	O
rat	O
kidney	O
fibroblasts	O
and	O
human	O
adrenal	O
carcinoma	O
cells	O
.	O
RESULTS	O
:	O
The	O
tumor	O
cell	O
lines	O
released	O
growth	O
factors	O
into	O
their	O
media	O
that	O
stimulated	O
growth	O
of	O
endothelial	O
and	O
epithelial	O
cells	O
as	O
well	O
as	O
fibroblasts	O
.	O
Heparin-affinity	O
chromatography	O
showed	O
that	O
heparin-binding	B-GP
growth	I-GP
factors	E-GP
contributed	O
substantially	O
to	O
this	O
paracrine	O
activity	O
and	O
that	O
PPS	O
inhibited	O
this	O
stimulus	O
.	O
Six	O
of	O
the	O
seven	O
tumor	O
cell	O
lines	O
were	O
resistant	O
to	O
PPS	O
in	O
soft-agar	O
cloning	O
assays	O
and	O
hence	O
did	O
not	O
appear	O
to	O
depend	O
on	O
autocrine	O
stimulation	O
by	O
the	O
heparin-binding	B-GP
growth	I-GP
factors	E-GP
.	O
In	O
contrast	O
to	O
this	O
in	O
vitro	O
resistance	O
,	O
subcutaneous	O
growth	O
of	O
tumors	O
from	O
all	O
cell	O
lines	O
in	O
athymic	O
nude	O
mice	O
was	O
inhibited	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
daily	O
intraperitoneal	O
injections	O
of	O
PPS	O
.	O
CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
heparin-binding	B-GP
growth	I-GP
factors	E-GP
contribute	O
substantially	O
to	O
tumor	O
growth	O
in	O
vivo	O
and	O
that	O
PPS	O
acts	O
by	O
blocking	O
the	O
paracrine	O
effects	O
of	O
heparin-binding	B-GP
growth	I-GP
factors	E-GP
released	O
from	O
the	O
tumor	O
cells	O
.	O
IMPLICATION	O
:	O
PPS	O
could	O
become	O
a	O
novel	O
treatment	O
tool	O
targeting	O
tumor	O
growth	O
factors	O
.	O

Correlations	O
between	O
serotonin	S-chemical
level	O
and	O
single-cell	O
firing	O
in	O
the	O
rat	O
's	O
nucleus	O
raphe	O
magnus	O
.	O
The	O
relation	O
between	O
serotonin	S-chemical
release	O
and	O
electrical	O
activity	O
was	O
examined	O
in	O
the	O
nucleus	O
raphe	O
magnus	O
of	O
rats	O
anesthetized	O
with	O
pentobarbital	S-chemical
.	O
Serotonin	S-chemical
levels	O
were	O
monitored	O
through	O
a	O
carbon	S-chemical
-fiber	O
microelectrode	O
by	O
fast	O
cyclic	O
voltammetry	O
(	O
usually	O
at	O
1	O
Hz	O
)	O
.	O
Single-cell	O
firing	O
was	O
recorded	O
through	O
the	O
same	O
microelectrode	O
,	O
except	O
during	O
the	O
voltammetry	O
waveform	O
and	O
associated	O
electrical	O
artifact	O
(	O
totaling	O
about	O
30	O
ms	O
)	O
.	O
Multi-barrel	O
micropipettes	O
incorporating	O
the	O
voltammetry	O
electrode	O
were	O
used	O
for	O
iontophoresis	O
of	O
drugs	O
.	O
Cells	O
were	O
inhibited	O
,	O
excited	O
or	O
unaffected	O
by	O
noxious	O
mechanical	O
skin	O
stimulation	O
.	O
These	O
were	O
respectively	O
designated	O
as	O
off	O
(	O
M	O
)	O
cells	O
,	O
on	O
(	O
M	O
)	O
cells	O
and	O
neutral	O
(	O
M	O
)	O
cells	O
,	O
M	O
denoting	O
mechanical	O
.	O
During	O
3	O
min	O
of	O
pinching	O
,	O
serotonin	S-chemical
slowly	O
rose	O
near	O
seven	O
of	O
14	O
on	O
(	O
M	O
)	O
cells	O
and	O
26	O
of	O
46	O
off	O
(	O
M	O
)	O
cells	O
;	O
it	O
fell	O
near	O
two	O
off	O
(	O
M	O
)	O
cells	O
;	O
it	O
was	O
unchanged	O
near	O
all	O
other	O
cells	O
,	O
including	O
six	O
neutral	O
(	O
M	O
)	O
cells	O
.	O
On	O
a	O
finer	O
spatiotemporal	O
scale	O
,	O
near	O
four	O
of	O
seven	O
on	O
(	O
M	O
)	O
cells	O
,	O
10	O
of	O
14	O
off	O
(	O
M	O
)	O
cells	O
and	O
0	O
of	O
four	O
neutral	O
(	O
M	O
)	O
cells	O
,	O
average	O
serotonin	S-chemical
levels	O
fell	O
significantly	O
within	O
+/-	O
100	O
ms	O
of	O
spontaneous	O
spikes	O
.	O
Lower	O
serotonin	S-chemical
may	O
have	O
caused	O
the	O
higher	O
spike	O
probability	O
;	O
the	O
converse	O
is	O
theoretically	O
unlikely	O
,	O
since	O
delays	O
between	O
release	O
and	O
detection	O
are	O
estimated	O
to	O
exceed	O
100	O
ms	O
.	O
Increased	O
serotonin	S-chemical
and	O
decreased	O
firing	O
were	O
always	O
seen	O
following	O
iontophoresis	O
or	O
intravenous	O
injection	O
(	O
1	O
mg/kg	O
)	O
of	O
the	O
serotonin	S-chemical
re-uptake	O
inhibitor	O
clomipramine	S-chemical
(	O
n	O
=	O
7	O
)	O
.	O
Iontophoresis	O
of	O
+/-	B-chemical
propranolol	E-chemical
,	O
whose	O
serotonergic	O
actions	O
include	O
antagonism	O
and	O
partial	O
agonism	O
at	O
5-HT1	S-GP
receptors	O
,	O
also	O
increased	O
serotonin	S-chemical
and	O
decreased	O
firing	O
(	O
n=4	O
)	O
.	O
Methiothepin	S-chemical
(	O
intravenous	O
,	O
1	O
mg/kg	O
)	O
,	O
whose	O
serotonergic	O
actions	O
include	O
5-HT1	S-GP
and	O
5-HT2	S-GP
antagonism	O
,	O
typically	O
raised	O
serotonin	S-chemical
levels	O
(	O
four	O
of	O
five	O
cells	O
)	O
and	O
always	O
blocked	O
inhibition	O
by	O
clomipramine	S-chemical
(	O
n	O
=	O
3	O
)	O
.	O
Iontophoresis	O
of	O
glutamate	S-chemical
always	O
lowered	O
serotonin	S-chemical
and	O
increased	O
firing	O
(	O
n	O
=	O
4	O
)	O
.	O
Since	O
serotonin	S-chemical
levels	O
and	O
firing	O
were	O
usually	O
inversely	O
correlated	O
,	O
except	O
near	O
on	O
(	O
M	O
)	O
cells	O
during	O
pinch	O
,	O
we	O
propose	O
that	O
serotonin	S-chemical
is	O
released	O
from	O
terminals	O
of	O
incoming	O
nociceptive	O
afferents	O
.	O
Prior	O
neuroanatomical	O
knowledge	O
favors	O
a	O
midbrain	O
origin	O
for	O
these	O
afferents	O
,	O
while	O
some	O
of	O
the	O
drug	O
findings	O
suggest	O
that	O
their	O
terminals	O
possess	O
inhibitory	O
serotonergic	O
autoreceptors	O
,	O
possibly	O
of	O
5-HT1b	S-GP
subtype	O
.	O
The	O
released	O
serotonin	S-chemical
could	O
contribute	O
to	O
the	O
inhibition	O
of	O
off	O
(	O
M	O
)	O
cells	O
and	O
excitation	O
of	O
on	O
(	O
M	O
)	O
cells	O
by	O
noxious	O
stimulation	O
,	O
since	O
inhibitory	O
5-HT1a	S-GP
receptors	O
and	O
excitatory	O
5-HT2	S-GP
receptors	O
,	O
respectively	O
,	O
have	O
previously	O
been	O
shown	O
to	O
dominate	O
their	O
serotonergic	O
responses	O
.	O

Epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
autocrine	O
signaling	O
in	O
RIE-1	O
cells	O
transformed	O
by	O
the	O
Ras	S-GP
oncogene	O
enhances	O
radiation	O
resistance	O
.	O
Oncogenic	O
forms	O
of	O
the	O
small	O
GTPase	S-GP
Ras	S-GP
increase	O
the	O
resistance	O
of	O
cells	O
to	O
killing	O
by	O
ionizing	O
radiation	O
(	O
IR	O
)	O
.	O
Although	O
not	O
all	O
of	O
the	O
signaling	O
pathways	O
for	O
radioresistance	O
are	O
well	O
defined	O
,	O
it	O
is	O
now	O
clear	O
that	O
Ras	S-GP
-dependent	O
signaling	O
pathways	O
involved	O
in	O
radioresistance	O
include	O
those	O
mediated	O
by	O
phosphatidylinositol	B-GP
3'-kinase	E-GP
(	O
PI3-K	S-GP
)	O
and	O
Raf	S-GP
.	O
Nevertheless	O
,	O
PI3-K	S-GP
and	O
Raf	S-GP
together	O
are	O
not	O
sufficient	O
to	O
reconstitute	O
all	O
of	O
the	O
resistance	O
conferred	O
by	O
Ras	S-GP
,	O
indicating	O
that	O
other	O
effectors	O
must	O
also	O
contribute	O
.	O
We	O
show	O
here	O
that	O
Ras	S-GP
-driven	O
autocrine	O
signaling	O
through	O
the	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	E-GP
(	O
EGFR	S-GP
)	O
also	O
contributes	O
to	O
radioresistance	O
in	O
Ras	S-GP
-transformed	O
cells	O
.	O
Conditioned	O
media	O
(	O
CM	O
)	O
collected	O
from	O
RIE-1	O
rat	O
intestinal	O
epithelial	O
cells	O
expressing	O
oncogenic	O
Ras	S-GP
increased	O
the	O
survival	O
of	O
irradiated	O
cells	O
.	O
Ras	S-GP
-CM	O
contains	O
elevated	O
levels	O
of	O
the	O
EGFR	S-GP
ligand	O
transforming	B-GP
growth	I-GP
factor	I-GP
alpha	E-GP
(	O
TGF-alpha	S-GP
)	O
.	O
Both	O
Ras	S-GP
-CM	O
and	O
TGF-alpha	S-GP
stimulated	O
EGFR	S-GP
phosphorylation	O
,	O
and	O
exogenous	O
TGF-alpha	S-GP
mimicked	O
the	O
effects	O
of	O
Ras	S-GP
-CM	O
to	O
increase	O
radioresistance	O
.	O
Blocking	O
EGFR	S-GP
signaling	O
with	O
the	O
EGFR	S-GP
/	O
HER-2	S-GP
kinase	O
inhibitor	O
(	O
KI	O
)	O
GW572016	S-chemical
decreased	O
the	O
postradiation	O
survival	O
of	O
irradiated	O
Ras	S-GP
-transformed	O
cells	O
and	O
normal	O
cells	O
but	O
had	O
no	O
effect	O
on	O
the	O
survival	O
of	O
unirradiated	O
cells	O
.	O
Ras	S-GP
-CM	O
and	O
TGF-alpha	S-GP
also	O
increase	O
PI3-K	S-GP
activity	O
downstream	O
of	O
the	O
EGFR	S-GP
and	O
increase	O
postradiation	O
survival	O
,	O
both	O
of	O
which	O
are	O
abrogated	O
by	O
GW572016	S-chemical
.	O
Thus	O
,	O
Ras	S-GP
utilizes	O
autocrine	O
signaling	O
through	O
EGFR	S-GP
to	O
increase	O
radioresistance	O
,	O
and	O
the	O
EGFR	S-GP
KI	O
GW572016	S-chemical
acts	O
as	O
a	O
radiosensitizer	O
.	O
The	O
observation	O
that	O
Ras	S-GP
-transformed	O
cells	O
can	O
be	O
sensitized	O
to	O
killing	O
by	O
ionizing	O
radiation	O
with	O
GW572016	S-chemical
demonstrates	O
that	O
EGFR	S-GP
KIs	O
could	O
potentially	O
be	O
used	O
to	O
radiosensitize	O
tumors	O
in	O
which	O
radioresistance	O
is	O
dependent	O
on	O
Ras	S-GP
-driven	O
autocrine	O
signaling	O
through	O
EGFR	S-GP
.	O

Biochemistry	O
of	O
cyclooxygenase	B-GP
(	I-GP
COX	I-GP
)	I-GP
-2	E-GP
inhibitors	O
and	O
molecular	O
pathology	O
of	O
COX-2	S-GP
in	O
neoplasia	O
.	O
Several	O
types	O
of	O
human	O
tumors	O
overexpress	O
cyclooxygenase	B-GP
(	I-GP
COX	I-GP
)	I-GP
-2	E-GP
but	O
not	O
COX-1	S-GP
,	O
and	O
gene	O
knockout	O
transfection	O
experiments	O
demonstrate	O
a	O
central	O
role	O
of	O
COX-2	S-GP
in	O
experimental	O
tumorigenesis	O
.	O
COX-2	S-GP
produces	O
prostaglandins	S-chemical
that	O
inhibit	O
apoptosis	O
and	O
stimulate	O
angiogenesis	O
and	O
invasiveness	O
.	O
Selective	O
COX-2	S-GP
inhibitors	O
reduce	O
prostaglandin	S-chemical
synthesis	O
,	O
restore	O
apoptosis	O
,	O
and	O
inhibit	O
cancer	O
cell	O
proliferation	O
.	O
In	O
animal	O
studies	O
they	O
limit	O
carcinogen-induced	O
tumorigenesis	O
.	O
In	O
contrast	O
,	O
aspirin	S-chemical
-like	O
nonselective	O
NSAIDs	O
such	O
as	O
sulindac	S-chemical
and	O
indomethacin	S-chemical
inhibit	O
not	O
only	O
the	O
enzymatic	O
action	O
of	O
the	O
highly	O
inducible	O
,	O
proinflammatory	O
COX-2	S-GP
but	O
the	O
constitutively	O
expressed	O
,	O
cytoprotective	O
COX-1	S-GP
as	O
well	O
.	O
Consequently	O
,	O
nonselective	O
NSAIDs	O
can	O
cause	O
platelet	O
dysfunction	O
,	O
gastrointestinal	O
ulceration	O
,	O
and	O
kidney	O
damage	O
.	O
For	O
that	O
reason	O
,	O
selective	O
inhibition	O
of	O
COX-2	S-GP
to	O
treat	O
neoplastic	O
proliferation	O
is	O
preferable	O
to	O
nonselective	O
inhibition	O
.	O
Selective	O
COX-2	S-GP
inhibitors	O
,	O
such	O
as	O
meloxicam	S-chemical
,	O
celecoxib	S-chemical
(	O
SC-58635	S-chemical
)	O
,	O
and	O
rofecoxib	S-chemical
(	O
MK-0966	S-chemical
)	O
,	O
are	O
NSAIDs	O
that	O
have	O
been	O
modified	O
chemically	O
to	O
preferentially	O
inhibit	O
COX-2	S-GP
but	O
not	O
COX-1	S-GP
.	O
For	O
instance	O
,	O
meloxicam	S-chemical
inhibits	O
the	O
growth	O
of	O
cultured	O
colon	O
cancer	O
cells	O
(	O
HCA-7	O
and	O
Moser-S	O
)	O
that	O
express	O
COX-2	S-GP
but	O
has	O
no	O
effect	O
on	O
HCT-116	O
tumor	O
cells	O
that	O
do	O
not	O
express	O
COX-2	S-GP
.	O
NS-398	S-chemical
induces	O
apoptosis	O
in	O
COX-2	S-GP
expressing	O
LNCaP	O
prostate	O
cancer	O
cells	O
and	O
,	O
surprisingly	O
,	O
in	O
colon	O
cancer	O
S/KS	O
cells	O
that	O
does	O
not	O
express	O
COX-2	S-GP
.	O
This	O
effect	O
may	O
due	O
to	O
induction	O
of	O
apoptosis	O
through	O
uncoupling	O
of	O
oxidative	O
phosphorylation	O
and	O
down-regulation	O
of	O
Bcl-2	S-GP
,	O
as	O
has	O
been	O
demonstrated	O
for	O
some	O
nonselective	O
NSAIDs	O
,	O
for	O
instance	O
,	O
flurbiprofen	S-chemical
.	O
COX-2	S-GP
mRNA	O
and	O
COX-2	S-GP
protein	O
is	O
constitutively	O
expressed	O
in	O
the	O
kidney	O
,	O
brain	O
,	O
spinal	O
cord	O
,	O
and	O
ductus	O
deferens	O
,	O
and	O
in	O
the	O
uterus	O
during	O
implantation	O
.	O
In	O
addition	O
,	O
COX-2	S-GP
is	O
constitutively	O
and	O
dominantly	O
expressed	O
in	O
the	O
pancreatic	O
islet	O
cells	O
.	O
These	O
findings	O
might	O
somewhat	O
limit	O
the	O
use	O
of	O
presently	O
available	O
selective	O
COX-2	S-GP
inhibitors	O
in	O
cancer	O
prevention	O
but	O
will	O
probably	O
not	O
deter	O
their	O
successful	O
application	O
for	O
the	O
treatment	O
of	O
human	O
cancers	O
.	O

Synergistic	O
enhancement	O
of	O
cancer	O
therapy	O
using	O
a	O
combination	O
of	O
heat	B-GP
shock	I-GP
protein	E-GP
targeted	O
HPMA	S-chemical
copolymer-drug	O
conjugates	O
and	O
gold	O
nanorod	O
induced	O
hyperthermia	O
.	O
In	O
the	O
field	O
of	O
nanomedicine	O
,	O
selective	O
delivery	O
to	O
cancer	O
cells	O
is	O
a	O
common	O
goal	O
,	O
where	O
active	O
targeting	O
strategies	O
are	O
often	O
employed	O
to	O
increase	O
tumor	O
accumulation	O
.	O
In	O
this	O
study	O
,	O
tumor	O
hyperthermia	O
was	O
utilized	O
as	O
a	O
means	O
to	O
increase	O
the	O
active	O
delivery	O
of	O
heat	B-GP
shock	I-GP
protein	E-GP
(	O
HSP	S-GP
)	O
targeted	O
N-	B-chemical
(	I-chemical
2-hydroxypropyl	I-chemical
)	I-chemical
methacrylamide	E-chemical
(	O
HPMA	S-chemical
)	O
copolymer-drug	O
conjugates	O
.	O
Following	O
hyperthermia	O
,	O
induced	O
expression	O
of	O
cell	O
surface	O
heat	B-GP
shock	I-GP
protein	E-GP
(	O
HSP	S-GP
)	O
glucose	B-GP
regulated	I-GP
protein	I-GP
78kDa	E-GP
(	O
GRP78	S-GP
)	O
was	O
utilized	O
for	O
targeted	O
drug	O
therapy	O
.	O
Conjugates	O
bearing	O
the	O
anticancer	O
agents	O
aminohexylgeldanamycin	S-chemical
(	O
AHGDM	S-chemical
)	O
,	O
docetaxel	S-chemical
(	O
DOC	S-chemical
)	O
,	O
or	O
cisplatin	S-chemical
and	O
the	O
GRP78	S-GP
targeting	O
peptide	O
WDLAWMFRLPVG	O
were	O
synthesized	O
and	O
characterized	O
.	O
Binding	O
to	O
cell	O
surface	O
expressed	O
heat	B-GP
shock	I-GP
protein	E-GP
GRP78	S-GP
on	O
the	O
surface	O
of	O
human	O
prostate	O
cancer	O
DU145	O
cells	O
was	O
evaluated	O
.	O
HSP	S-GP
targeted	O
AHGDM	S-chemical
and	O
DOC	S-chemical
conjugates	O
demonstrated	O
active	O
binding	O
comparable	O
to	O
native	O
targeting	O
peptide	O
.	O
They	O
were	O
then	O
assessed	O
in	O
vitro	O
for	O
the	O
ability	O
to	O
synergistically	O
induce	O
cytotoxicity	O
in	O
combination	O
with	O
moderate	O
hyperthermia	O
(	O
43°C	O
,	O
30min	O
)	O
.	O
HSP	S-GP
targeted	O
DOC	S-chemical
conjugates	O
exhibited	O
high	O
potency	O
against	O
DU145	O
cells	O
with	O
an	O
IC50	O
of	O
2.4nM	O
.	O
HSP	S-GP
targeted	O
AHGDM	S-chemical
and	O
DOC	S-chemical
conjugates	O
demonstrated	O
synergistic	O
effects	O
in	O
combination	O
with	O
hyperthermia	O
with	O
combination	O
index	O
values	O
of	O
0.65	O
and	O
0.45	O
respectively	O
.	O
Based	O
on	O
these	O
results	O
,	O
HSP	S-GP
targeted	O
DOC	S-chemical
conjugates	O
were	O
selected	O
for	O
in	O
vivo	O
evaluation	O
.	O
In	O
DU145	O
tumor	O
bearing	O
mice	O
,	O
a	O
single	O
treatment	O
of	O
tumor	O
hyperthermia	O
,	O
induced	O
via	O
gold	O
nanorod	O
mediated	O
plasmonic	O
photothermal	O
therapy	O
,	O
and	O
intravenous	O
administration	O
of	O
HSP	S-GP
targeted	O
HPMA	S-chemical
copolymer-	O
docetaxel	S-chemical
at	O
10mg/kg	O
resulted	O
in	O
maintained	O
tumor	O
regression	O
for	O
a	O
period	O
of	O
30days	O
.	O
These	O
results	O
demonstrate	O
the	O
potential	O
for	O
tumor	O
hyperthermia	O
to	O
increase	O
the	O
delivery	O
of	O
HSP	S-GP
targeted	O
macromolecular	O
chemotherapeutics	O
.	O

Multiple	O
rat	B-GP
brain	I-GP
calpastatin	E-GP
forms	O
are	O
produced	O
by	O
distinct	O
starting	O
points	O
and	O
alternative	O
splicing	O
of	O
the	O
N	S-chemical
-terminal	O
exons	O
.	O
5'-RACE	O
was	O
performed	O
on	O
rat	B-GP
brain	I-GP
calpastatin	E-GP
mRNA	O
and	O
two	O
new	O
translation	O
initiation	O
ATG	O
's	O
were	O
found	O
.	O
The	O
first	O
one	O
is	O
upstream	O
of	O
the	O
previously	O
designed	O
initiation	O
translation	O
site	O
localized	O
in	O
the	O
rat	B-GP
calpastatin	I-GP
L-domain	E-GP
.	O
The	O
deduced	O
protein	O
sequence	O
of	O
this	O
region	O
is	O
highly	O
homologous	O
to	O
the	O
XL-domain	S-GP
of	O
calpastatin	B-GP
type	I-GP
I	E-GP
in	O
other	O
species	O
.	O
The	O
other	O
ATG	O
has	O
not	O
previously	O
been	O
reported	O
and	O
is	O
localized	O
in	O
exon	O
8	O
,	O
thus	O
originating	O
a	O
calpastatin	S-GP
isoform	O
constituted	O
only	O
by	O
four	O
repetitive	O
inhibitory	O
units	O
without	O
the	O
XL-L-domains	S-GP
.	O
Transcripts	O
from	O
the	O
rat	B-GP
brain	I-GP
calpastatin	E-GP
gene	O
are	O
also	O
subjected	O
to	O
multiple	O
splicing	O
events	O
involving	O
exons	O
4	O
,	O
6	O
,	O
8	O
in	O
different	O
combinations	O
.	O
A	O
series	O
of	O
recombinant	O
calpastatin	S-GP
forms	O
was	O
produced	O
that	O
differed	O
in	O
the	O
exons	O
present	O
in	O
the	O
L-domain	S-GP
,	O
and	O
all	O
the	O
variants	O
showed	O
comparable	O
inhibitory	O
efficiency	O
against	O
calpain	S-GP
.	O
It	O
was	O
concluded	O
that	O
the	O
presence	O
of	O
the	O
XL-domain	S-GP
in	O
these	O
isoforms	O
is	O
not	O
relevant	O
for	O
the	O
formation	O
of	O
the	O
calpain	S-GP
/	O
calpastatin	S-GP
complex	O
in	O
the	O
absence	O
of	O
calcium	S-chemical
,	O
that	O
is	O
the	O
interaction	O
of	O
calpastatin	S-GP
with	O
inactive	O
calpain	S-GP
.	O
Using	O
exon-specific	O
antisera	O
,	O
specific	O
calpastatin	S-GP
protein	O
isoforms	O
containing	O
the	O
XL-domain	S-GP
have	O
been	O
detected	O
in	O
rat	O
brain	O
homogenates	O
.	O

Hydrogen	B-chemical
sulfide	E-chemical
,	O
the	O
next	O
potent	O
preventive	O
and	O
therapeutic	O
agent	O
in	O
aging	O
and	O
age-associated	O
diseases	O
.	O
Hydrogen	B-chemical
sulfide	E-chemical
(	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
)	O
is	O
the	O
third	O
endogenous	O
signaling	O
gasotransmitter	O
,	O
following	O
nitric	B-chemical
oxide	E-chemical
and	O
carbon	B-chemical
monoxide	E-chemical
.	O
It	O
is	O
physiologically	O
generated	O
by	O
cystathionine-γ-lyase	S-GP
,	O
cystathionine-β-synthase	S-GP
,	O
and	O
3-mercaptopyruvate	B-GP
sulfurtransferase	E-GP
.	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
has	O
been	O
gaining	O
increasing	O
attention	O
as	O
an	O
important	O
endogenous	O
signaling	O
molecule	O
because	O
of	O
its	O
significant	O
effects	O
on	O
the	O
cardiovascular	O
and	O
nervous	O
systems	O
.	O
Substantial	O
evidence	O
shows	O
that	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
is	O
involved	O
in	O
aging	O
by	O
inhibiting	O
free-radical	O
reactions	O
,	O
activating	O
SIRT1	S-GP
,	O
and	O
probably	O
interacting	O
with	O
the	O
age-related	O
gene	O
Klotho	S-GP
.	O
Moreover	O
,	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
has	O
been	O
shown	O
to	O
have	O
therapeutic	O
potential	O
in	O
age-associated	O
diseases	O
.	O
This	O
article	O
provides	O
an	O
overview	O
of	O
the	O
physiological	O
functions	O
and	O
effects	O
of	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
in	O
aging	O
and	O
age-associated	O
diseases	O
,	O
and	O
proposes	O
the	O
potential	O
health	O
and	O
therapeutic	O
benefits	O
of	O
H	B-chemical
(	I-chemical
2	I-chemical
)	I-chemical
S	E-chemical
.	O

Differential	O
expression	O
of	O
glycans	O
in	O
the	O
hippocampus	O
of	O
rats	O
trained	O
on	O
an	O
inhibitory	O
learning	O
paradigm	O
.	O
The	O
glycan	O
chains	O
of	O
glycoconjugates	O
play	O
important	O
roles	O
in	O
cell-cell	O
and	O
cell-matrix	O
interactions	O
.	O
In	O
the	O
CNS	O
,	O
previous	O
studies	O
on	O
learning	O
and	O
memory	O
suggest	O
the	O
importance	O
of	O
oligosaccharides	O
attached	O
to	O
glycoconjugates	O
in	O
the	O
modulation	O
of	O
synaptic	O
connections	O
.	O
We	O
studied	O
the	O
hippocampal	O
glycan	O
distribution	O
of	O
rats	O
subject	O
to	O
an	O
inhibitory	O
avoidance	O
task	O
.	O
The	O
expression	O
of	O
glycans	O
was	O
examined	O
by	O
lectin	S-GP
-histochemistry	O
using	O
Vicia	B-GP
villosa	I-GP
lectin	E-GP
(	O
VVL	S-GP
)	O
for	O
terminal	O
alpha/beta	B-chemical
N-acetylgalactosamine	E-chemical
(	O
alpha/beta	B-chemical
GalNAc	E-chemical
)	O
;	O
Galanthus	B-GP
nivalus	I-GP
lectin	E-GP
(	O
GNL	S-GP
)	O
for	O
terminal	O
mannose	B-chemical
alpha-1,3	E-chemical
(	O
Man	B-chemical
alpha-1,3	E-chemical
)	O
;	O
Peanut	B-GP
agglutinin	E-GP
(	O
PNA	S-GP
)	O
for	O
galactose	B-chemical
beta-1,3N-acetylgalactosamine	E-chemical
(	O
Gal	B-chemical
beta-1,3	I-chemical
GalNAc	E-chemical
)	O
;	O
Erythrina	B-GP
cristagalli	I-GP
lectin	E-GP
(	O
ECL	S-GP
)	O
for	O
galactose	B-chemical
beta-1,4	I-chemical
N-acetylglucosamine	E-chemical
(	O
Gal	B-chemical
beta-1,4	I-chemical
GlcNAc	E-chemical
)	O
;	O
Sambucus	B-GP
nigra	I-GP
lectin	E-GP
(	O
SNA	S-GP
)	O
for	O
sialic	B-chemical
acid	I-chemical
alpha-2.6	I-chemical
galactose	E-chemical
(	O
SA	B-chemical
alpha-2,6	I-chemical
Gal	E-chemical
)	O
;	O
Maackia	B-GP
amurensis	I-GP
lectin	I-GP
II	E-GP
(	O
MAL	B-GP
II	E-GP
)	O
for	O
sialic	B-chemical
acid	I-chemical
alpha-2,3	E-chemical
(	O
SA	B-chemical
alpha-2,3	E-chemical
)	O
;	O
Wheat	B-GP
germ	I-GP
agglutinin	E-GP
(	O
WGA	S-GP
)	O
for	O
terminal	O
N-acetylglucosamine	S-chemical
with/	O
without	O
sialic	B-chemical
acid	E-chemical
(	O
GlcNAc	S-chemical
wo	O
SA	S-chemical
)	O
;	O
succynilated	O
WGA	O
(	O
sWGA	O
)	O
for	O
terminal	O
N-acetylglucosamine	S-chemical
without	O
sialic	B-chemical
acid	E-chemical
(	O
terminal	O
GlcNAc	S-chemical
without	O
SA	S-chemical
)	O
;	O
Griffonia	B-GP
simplicifolia	I-GP
lectin	I-GP
II	E-GP
(	O
GSL	B-GP
II	E-GP
)	O
for	O
terminal	O
alpha/beta	B-chemical
N-acetylglucosamine	E-chemical
(	O
alpha/beta	B-chemical
GlcNAc	E-chemical
terminal	O
)	O
;	O
and	O
Lotus	B-GP
tetragonolobus	I-GP
lectin	E-GP
(	O
LTL	S-GP
)	O
alpha-fucose	S-chemical
.	O
Two	O
groups	O
of	O
10	O
animals	O
were	O
examined	O
:	O
non-trained	O
(	O
Control	O
)	O
and	O
Trained	O
rats	O
.	O
ECL	S-GP
,	O
sWGA	S-GP
and	O
GSL	B-GP
II	E-GP
were	O
negative	O
for	O
both	O
groups	O
in	O
all	O
the	O
hippocampal	O
subfields	O
studied	O
.	O
For	O
both	O
groups	O
,	O
VVL	O
was	O
negative	O
in	O
CA4	O
and	O
granular	O
cells	O
of	O
the	O
Dentate	O
Gyrus	O
(	O
DG	O
)	O
and	O
LTL	O
was	O
negative	O
in	O
the	O
CA4	O
subfield	O
.	O
Expression	O
of	O
alpha/beta	O
GalNAc	S-chemical
,	O
alpha-fucose	S-chemical
and	O
GlcNAc	S-chemical
in	O
other	O
hippocampal	O
subflields	O
was	O
positive	O
,	O
with	O
no	O
differences	O
between	O
groups	O
.	O
However	O
,	O
expression	O
of	O
Man	B-chemical
alpha-1,3	E-chemical
was	O
significantly	O
higher	O
in	O
the	O
CA1	O
,	O
CA2	O
,	O
CA3	O
,	O
and	O
CA4	O
subfields	O
in	O
the	O
Trained	O
group	O
.	O
On	O
the	O
other	O
hand	O
,	O
expression	O
of	O
Gal	B-chemical
beta-1,3	I-chemical
GalNAc	E-chemical
was	O
significantly	O
low	O
in	O
CA4	O
and	O
DG	O
in	O
the	O
Trained	O
group	O
.	O
In	O
conclusion	O
,	O
the	O
results	O
here	O
presented	O
indicate	O
that	O
the	O
exposure	O
of	O
rats	O
to	O
an	O
associative	O
behavioral	O
paradigm	O
related	O
to	O
declarative	O
memory	O
,	O
involves	O
some	O
regulatory	O
mechanism/s	O
for	O
the	O
differential	O
patterns	O
of	O
glycan	O
expression	O
.	O

Remethylation	O
defects	O
:	O
guidelines	O
for	O
clinical	O
diagnosis	O
and	O
treatment	O
.	O
The	O
main	O
remethylation	O
defects	O
include	O
disorders	O
which	O
all	O
have	O
defective	O
methionine	S-chemical
synthesis	O
in	O
common	O
.	O
Methylenetetrahydrofolate	B-GP
reductase	E-GP
deficiency	O
impairs	O
methyltetrahydrofolate	S-chemical
synthesis	O
,	O
defects	O
in	O
cytosolic	O
reduction	O
of	O
hydroxocobalamin	S-chemical
(	O
CblC/D	O
)	O
impair	O
the	O
synthesis	O
of	O
both	O
methyl	S-chemical
-	O
and	O
adenosyl	B-chemical
cobalamin	E-chemical
and	O
deficiencies	O
of	O
methionine	B-GP
synthase	E-GP
(	O
CblE/G	O
)	O
are	O
associated	O
with	O
defective	O
methyl	B-chemical
cobalamin	E-chemical
synthesis	O
.	O
The	O
clinical	O
presentation	O
is	O
characterized	O
by	O
acute	O
neurological	O
distress	O
in	O
early	O
infancy	O
.	O
In	O
childhood	O
,	O
patients	O
present	O
with	O
progressive	O
encephalopathy	O
with	O
an	O
end-stage	O
which	O
has	O
many	O
signs	O
in	O
common	O
with	O
the	O
adult	O
onset	O
form	O
.	O
In	O
fact	O
,	O
both	O
have	O
more	O
or	O
less	O
severe	O
signs	O
of	O
subacute	O
degeneration	O
of	O
the	O
cord	O
.	O
Cobalamin	S-chemical
defective	O
patients	O
must	O
be	O
treated	O
with	O
parenteral	O
supplementation	O
of	O
hydroxocobalamin	S-chemical
(	O
1-2	O
mg	O
per	O
dose	O
)	O
.	O
Some	O
methylenetetrahydrofolate	S-chemical
patients	O
could	O
be	O
folate	S-chemical
responsive	O
and	O
must	O
have	O
a	O
high-dosage	O
folate	O
trial	O
.	O
In	O
addition	O
,	O
oral	O
betaine	S-chemical
supplementation	O
(	O
2-9	O
g	O
per	O
day	O
depending	O
on	O
age	O
)	O
appears	O
an	O
effective	O
means	O
to	O
prevent	O
further	O
neurological	O
deterioration	O
.	O

Structural	O
basis	O
of	O
inhibition	O
of	O
the	O
human	B-GP
NAD+-dependent	I-GP
deacetylase	I-GP
SIRT5	E-GP
by	O
suramin	S-chemical
.	O
Sirtuins	O
are	O
NAD	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
-dependent	O
protein	O
deacetylases	O
and	O
are	O
emerging	O
as	O
molecular	O
targets	O
for	O
the	O
development	O
of	O
pharmaceuticals	O
to	O
treat	O
human	O
metabolic	O
and	O
neurological	O
diseases	O
and	O
cancer	O
.	O
To	O
date	O
,	O
several	O
sirtuin	S-GP
inhibitors	O
and	O
activators	O
have	O
been	O
identified	O
,	O
but	O
the	O
structural	O
mechanisms	O
of	O
how	O
these	O
compounds	O
modulate	O
sirtuin	S-GP
activity	O
have	O
not	O
yet	O
been	O
determined	O
.	O
We	O
identified	O
suramin	S-chemical
as	O
a	O
compound	O
that	O
binds	O
to	O
human	B-GP
SIRT5	E-GP
and	O
showed	O
that	O
it	O
inhibits	O
SIRT5	B-GP
NAD	I-GP
(	I-GP
+	I-GP
)	I-GP
-dependent	I-GP
deacetylase	E-GP
activity	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
22	O
microM	O
.	O
To	O
provide	O
insights	O
into	O
how	O
sirtuin	O
function	O
is	O
altered	O
by	O
inhibitors	O
,	O
we	O
determined	O
two	O
crystal	O
structures	O
of	O
SIRT5	S-GP
,	O
one	O
in	O
complex	O
with	O
ADP	S-chemical
-ribose	O
,	O
the	O
other	O
bound	O
to	O
suramin	S-chemical
.	O
Our	O
structural	O
studies	O
provide	O
a	O
view	O
of	O
a	O
synthetic	O
inhibitory	O
compound	O
in	O
a	O
sirtuin	S-GP
active	O
site	O
revealing	O
that	O
suramin	S-chemical
binds	O
into	O
the	O
NAD	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
,	O
the	O
product	O
,	O
and	O
the	O
substrate-binding	O
site	O
.	O
Finally	O
,	O
our	O
structures	O
may	O
enable	O
the	O
rational	O
design	O
of	O
more	O
potent	O
inhibitors	O
.	O

Synthesis	O
,	O
radiosynthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
carbon-11	B-chemical
labeled	I-chemical
2beta-carbomethoxy-3beta-	I-chemical
(	I-chemical
3'-	I-chemical
(	I-chemical
(	I-chemical
Z	I-chemical
)	I-chemical
-2-haloethenyl	I-chemical
)	I-chemical
phenyl	I-chemical
)	I-chemical
nortropanes	E-chemical
:	O
candidate	O
radioligands	O
for	O
in	O
vivo	O
imaging	O
of	O
the	O
serotonin	S-chemical

Severe	O
impairment	O
of	O
salivation	O
in	O
Na+/K+/2Cl-	B-GP
cotransporter	E-GP
(	O
NKCC1	S-GP
)	O
-deficient	O
mice	O
.	O
The	O
salivary	O
fluid	O
secretory	O
mechanism	O
is	O
thought	O
to	O
require	O
Na	B-GP
(	I-GP
+	I-GP
)	I-GP
/K	I-GP
(	I-GP
+	I-GP
)	I-GP
/2Cl	I-GP
(	I-GP
-	I-GP
)	I-GP
cotransporter	E-GP
-mediated	O
Cl	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
uptake	O
.	O
To	O
directly	O
test	O
this	O
possibility	O
we	O
studied	O
the	O
in	O
vivo	O
and	O
in	O
vitro	O
functioning	O
of	O
acinar	O
cells	O
from	O
the	O
parotid	O
glands	O
of	O
mice	O
with	O
targeted	O
disruption	O
of	O
Na	B-GP
(	I-GP
+	I-GP
)	I-GP
/K	I-GP
(	I-GP
+	I-GP
)	I-GP
/2Cl	I-GP
(	I-GP
-	I-GP
)	I-GP
cotransporter	I-GP
isoform	I-GP
1	E-GP
(	O
Nkcc1	S-GP
)	O
,	O
the	O
gene	O
encoding	O
the	O
salivary	O
Na	B-GP
(	I-GP
+	I-GP
)	I-GP
/K	I-GP
(	I-GP
+	I-GP
)	I-GP
/2Cl	I-GP
(	I-GP
-	I-GP
)	I-GP
cotransporter	E-GP
.	O
In	O
wild-type	O
mice	O
NKCC1	S-GP
was	O
localized	O
to	O
the	O
basolateral	O
membranes	O
of	O
parotid	O
acinar	O
cells	O
,	O
whereas	O
expression	O
was	O
not	O
detected	O
in	O
duct	O
cells	O
.	O
The	O
lack	O
of	O
functional	O
NKCC1	S-GP
resulted	O
in	O
a	O
dramatic	O
reduction	O
(	O
>	O
60	O
%	O
)	O
in	O
the	O
volume	O
of	O
saliva	O
secreted	O
in	O
response	O
to	O
a	O
muscarinic	O
agonist	O
,	O
the	O
primary	O
in	O
situ	O
salivation	O
signal	O
.	O
Consistent	O
with	O
defective	O
Cl	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
uptake	O
,	O
a	O
loss	O
of	O
bumetanide	S-chemical
-sensitive	O
Cl	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
influx	O
was	O
observed	O
in	O
parotid	O
acinar	O
cells	O
from	O
mice	O
lacking	O
NKCC1	S-GP
.	O
Cl	B-GP
(	I-GP
-	I-GP
)	I-GP
/	I-GP
HCO	I-GP
(	I-GP
3	I-GP
)	I-GP
(	I-GP
-	I-GP
)	I-GP
exchanger	E-GP
activity	O
was	O
increased	O
in	O
parotid	O
acinar	O
cells	O
isolated	O
from	O
knockout	O
mice	O
suggesting	O
that	O
the	O
residual	O
saliva	O
secreted	O
by	O
mice	O
lacking	O
NKCC1	S-GP
is	O
associated	O
with	O
anion	O
exchanger-dependent	O
Cl	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
uptake	O
.	O
Indeed	O
,	O
expression	O
of	O
the	O
Cl	B-GP
(	I-GP
-	I-GP
)	I-GP
/	I-GP
HCO	I-GP
(	I-GP
3	I-GP
)	I-GP
(	I-GP
-	I-GP
)	I-GP
exchanger	E-GP
AE2	S-GP
was	O
enhanced	O
suggesting	O
that	O
this	O
transporter	O
compensates	O
for	O
the	O
loss	O
of	O
functional	O
Na	B-GP
(	I-GP
+	I-GP
)	I-GP
/K	I-GP
(	I-GP
+	I-GP
)	I-GP
/2Cl	I-GP
(	I-GP
-	I-GP
)	I-GP
cotransporter	E-GP
.	O
Furthermore	O
,	O
the	O
ability	O
of	O
the	O
parotid	O
gland	O
to	O
conserve	O
NaCl	S-chemical
was	O
abolished	O
in	O
NKCC1	S-GP
-deficient	O
mice	O
.	O
This	O
deficit	O
was	O
not	O
associated	O
with	O
changes	O
in	O
the	O
morphology	O
of	O
the	O
ducts	O
,	O
but	O
transcript	O
levels	O
for	O
the	O
alpha-	O
,	O
beta-	O
,	O
and	O
gamma-subunits	O
of	O
the	O
epithelial	O
Na	B-chemical
(	I-chemical
+	I-chemical
)	E-chemical
channel	O
were	O
reduced	O
.	O
These	O
data	O
directly	O
demonstrate	O
that	O
NKCC1	S-GP
is	O
the	O
major	O
Cl	B-chemical
(	I-chemical
-	I-chemical
)	E-chemical
uptake	O
mechanism	O
across	O
the	O
basolateral	O
membrane	O
of	O
acinar	O
cells	O
and	O
is	O
critical	O
for	O
driving	O
saliva	O
secretion	O
in	O
vivo	O
.	O

Binding	O
of	O
(	B-chemical
-	I-chemical
)	I-chemical
-	I-chemical
[	I-chemical
3H	I-chemical
]	I-chemical
-CGP12177	E-chemical
at	O
two	O
sites	O
in	O
recombinant	O
human	B-GP
beta	I-GP
1-adrenoceptors	E-GP
and	O
interaction	O
with	O
beta-blockers	O
.	O
To	O
verify	O
the	O
hypothesis	O
that	O
the	O
non-conventional	O
partial	O
agonist	O
(	B-chemical
-	I-chemical
)	I-chemical
-CGP12177	E-chemical
binds	O
at	O
two	O
beta	B-GP
(	I-GP
1	I-GP
)	I-GP
-adrenoceptor	E-GP
sites	O
,	O
human	B-GP
beta	I-GP
(	I-GP
1	I-GP
)	I-GP
-adrenoceptors	E-GP
,	O
expressed	O
in	O
CHO	O
cells	O
,	O
were	O
labelled	O
with	O
(	B-chemical
-	I-chemical
)	I-chemical
-	I-chemical
[	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
-CGP12177	E-chemical
.	O
We	O
compared	O
the	O
binding	O
affinity	O
and	O
antagonist	O
potency	O
of	O
12	O
clinically	O
used	O
beta-blockers	O
against	O
the	O
cyclic	B-chemical
AMP	E-chemical
-enhancing	O
effects	O
of	O
(	B-chemical
-	I-chemical
)	I-chemical
-isoprenaline	E-chemical
and	O
(	B-chemical
-	I-chemical
)	I-chemical
-CGP12177	E-chemical
.	O
(	B-chemical
-	I-chemical
)	I-chemical
-	I-chemical
[	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
-CGP12177	E-chemical
bound	O
to	O
a	O
high	O
affinity	O
site	O
(	O
H	O
;	O
K	O
(	O
H	O
)	O
=0.47	O
nM	O
)	O
and	O
low	O
affinity	O
site	O
(	O
L	O
)	O
;	O
K	O
(	O
L	O
)	O
=235	O
nM	O
)	O
.	O
(	B-chemical
-	I-chemical
)	I-chemical
-	I-chemical
[	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
-CGP12177	E-chemical
dissociated	O
from	O
the	O
beta	B-GP
(	I-GP
1	I-GP
)	I-GP
-adrenoceptors	E-GP
with	O
a	O
fast	O
component	O
(	O
k	O
(	O
off	O
)	O
=0.45	O
min	O
(	O
-1	O
)	O
)	O
,	O
consistent	O
with	O
the	O
L-site	O
,	O
and	O
a	O
slow	O
component	O
(	O
k	O
(	O
off	O
)	O
=0.017-0.033	O
min	O
(	O
-1	O
)	O
)	O
,	O
consistent	O
with	O
the	O
H-site	O
.	O
(	B-chemical
-	I-chemical
)	I-chemical
-Isoprenaline	E-chemical
and	O
(	B-chemical
-	I-chemical
)	I-chemical
-CGP12177	E-chemical
caused	O
96-fold	O
and	O
12-fold	O
maximal	O
increases	O
in	O
cyclic	B-chemical
AMP	E-chemical
levels	O
with	O
-logEC	O
(	O
50	O
)	O
M	O
of	O
8.2	O
and	O
7.6	O
.	O
(	B-chemical
-	I-chemical
)	I-chemical
-CGP12177	E-chemical
antagonised	O
the	O
effects	O
of	O
(	B-chemical
-	I-chemical
)	I-chemical
-isoprenaline	E-chemical
with	O
a	O
pK	O
(	O
B	O
)	O
of	O
9.9	O
.	O
The	O
beta-blockers	O
antagonised	O
the	O
effects	O
of	O
(	B-chemical
-	I-chemical
)	I-chemical
-isoprenaline	E-chemical
more	O
than	O
the	O
effects	O
of	O
(	B-chemical
-	I-chemical
)	I-chemical
-CGP12177	E-chemical
with	O
potency	O
ratios	O
:	O
(	B-chemical
-	I-chemical
)	I-chemical
-atenolol	E-chemical
1,000	O
,	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-metropolol	E-chemical
676	O
,	O
(	B-chemical
-	I-chemical
)	I-chemical
-pindolol	E-chemical
631	O
,	O
(	B-chemical
-	I-chemical
)	I-chemical
-timolol	E-chemical
589	O
,	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-carvedilol	E-chemical
204	O
,	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-oxprenolol	E-chemical
138	O
,	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-sotalol	E-chemical
132	O
,	O
(	B-chemical
-	I-chemical
)	I-chemical
-propranolol	E-chemical
120	O
,	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-bisoprolol	E-chemical
95	O
,	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-alprenolol	E-chemical
81	O
,	O
(	B-chemical
+/-	I-chemical
)	I-chemical
-nadolol	E-chemical
68	O
and	O
(	B-chemical
-	I-chemical
)	I-chemical
-bupranolol	E-chemical
56	O
.	O
In	O
intact	O
cells	O
the	O
binding	O
constants	O
of	O
beta-blockers	O
,	O
estimated	O
from	O
competition	O
with	O
3-5	O
nM	O
(	B-chemical
-	I-chemical
)	I-chemical
-	I-chemical
[	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
-CGP12177	E-chemical
(	O
binding	O
to	O
the	O
H-site	O
)	O
,	O
correlated	O
with	O
the	O
corresponding	O
affinities	O
estimated	O
from	O
antagonism	O
of	O
the	O
(	B-chemical
-	I-chemical
)	I-chemical
-isoprenaline	E-chemical
effects	O
.	O
We	O
conclude	O
that	O
(	B-chemical
-	I-chemical
)	I-chemical
-	I-chemical
[	I-chemical
(	I-chemical
3	I-chemical
)	I-chemical
H	I-chemical
]	I-chemical
-CGP12177	E-chemical
binds	O
at	O
two	O
sites	O
in	O
the	O
recombinant	O
beta	B-GP
(	I-GP
1	I-GP
)	I-GP
-adrenoceptor	E-GP
.	O
(	B-chemical
-	I-chemical
)	I-chemical
-CGP12177	E-chemical
is	O
an	O
antagonist	O
of	O
catecholamine	S-chemical
effects	O
through	O
the	O
H-site	O
and	O
a	O
non-conventional	O
partial	O
agonist	O
through	O
the	O
L-site	O
.	O
beta-blockers	O
are	O
more	O
potent	O
antagonists	O
through	O
the	O
H-site	O
than	O
the	O
L-site	O
.	O

Pharmacokinetics	O
of	O
olmesartan	B-chemical
medoxomil	E-chemical
plus	O
hydrochlorothiazide	S-chemical
combination	O
in	O
healthy	O
subjects	O
.	O
BACKGROUND	O
:	O
Hypertension	O
treatment	O
guidelines	O
recommend	O
combination	O
therapy	O
with	O
diuretics	O
and	O
other	O
antihypertensive	O
agents	O
,	O
including	O
angiotensin	B-GP
II	I-GP
type	I-GP
1	I-GP
(	I-GP
AT1	I-GP
)	I-GP
receptor	E-GP
antagonists	O
.	O
This	O
trial	O
investigated	O
the	O
possibility	O
of	O
pharmacokinetic	O
interactions	O
between	O
the	O
AT1	B-GP
receptor	E-GP
antagonist	O
olmesartan	B-chemical
medoxomil	E-chemical
and	O
the	O
thiazide	S-chemical
diuretic	O
hydrochlorothiazide	S-chemical
in	O
healthy	O
subjects	O
.	O
METHODS	O
:	O
Twenty-four	O
healthy	O
normotensive	O
adult	O
male	O
subjects	O
underwent	O
three	O
consecutive	O
7-day	O
treatment	O
periods	O
(	O
A	O
,	O
B	O
and	O
C	O
,	O
respectively	O
)	O
during	O
which	O
they	O
were	O
randomised	O
to	O
receive	O
:	O
olmesartan	B-chemical
medoxomil	E-chemical
20	O
mg	O
once	O
daily	O
(	O
regimen	O
A	O
)	O
,	O
hydrochlorothiazide	S-chemical
25	O
mg	O
once	O
daily	O
(	O
regimen	O
B	O
)	O
,	O
or	O
olmesartan	B-chemical
medoxomil	E-chemical
20	O
mg	O
once	O
daily	O
plus	O
hydrochlorothiazide	S-chemical
25	O
mg	O
once	O
daily	O
(	O
regimen	O
C	O
)	O
.	O
Treatment	O
periods	O
were	O
separated	O
by	O
washouts	O
of	O
7-14	O
days	O
.	O
The	O
primary	O
pharmacokinetic	O
parameters	O
evaluated	O
were	O
:	O
the	O
area	O
under	O
the	O
plasma	O
concentration	O
versus	O
time	O
curve	O
at	O
steady	O
state	O
(	O
AUCss	O
,	O
tau	O
)	O
,	O
the	O
maximum	O
plasma	O
concentration	O
at	O
steady	O
state	O
(	O
Css	O
,	O
max	O
)	O
,	O
and	O
the	O
time	O
at	O
which	O
Css	O
,	O
max	O
occurred	O
(	O
tmax	O
)	O
.	O
RESULTS	O
:	O
Complete	O
data	O
sets	O
from	O
17	O
subjects	O
were	O
available	O
for	O
pharmacokinetic	O
analyses	O
.	O
Mean	O
concentration	O
versus	O
time	O
profiles	O
were	O
similar	O
for	O
monotherapy	O
and	O
combination	O
treatment	O
for	O
both	O
olmesartan	S-chemical
(	O
the	O
active	O
metabolite	O
of	O
olmesartan	B-chemical
medoxomil	E-chemical
)	O
and	O
hydrochlorothiazide	S-chemical
.	O
For	O
olmesartan	S-chemical
,	O
comparison	O
of	O
monotherapy	O
with	O
combination	O
therapy	O
showed	O
that	O
for	O
AUCss	O
,	O
tau	O
and	O
Css	O
,	O
max	O
point	O
estimates	O
were	O
close	O
to	O
unity	O
,	O
demonstrating	O
bioequivalence	O
.	O
For	O
hydrochlorothiazide	S-chemical
,	O
combination	O
therapy	O
resulted	O
in	O
decreases	O
in	O
AUCss	O
,	O
tau	O
and	O
Css	O
,	O
max	O
of	O
approximately	O
10	O
%	O
versus	O
monotherapy	O
;	O
nevertheless	O
,	O
since	O
90	O
%	O
CIs	O
were	O
within	O
the	O
acceptance	O
range	O
,	O
bioequivalence	O
was	O
proven	O
.	O
Median	O
tmax	O
values	O
for	O
olmesartan	S-chemical
and	O
hydrochlorothiazide	S-chemical
for	O
periods	O
A	O
,	O
B	O
and	O
C	O
were	O
identical	O
,	O
indicating	O
bioequivalence	O
.	O
Both	O
olmesartan	B-chemical
medoxomil	E-chemical
and	O
hydrochlorothiazide	S-chemical
were	O
well	O
tolerated	O
.	O
CONCLUSION	O
:	O
These	O
results	O
show	O
that	O
there	O
is	O
little	O
or	O
no	O
potential	O
for	O
a	O
clinically	O
relevant	O
pharmacokinetic	O
interaction	O
between	O
olmesartan	B-chemical
medoxomil	E-chemical
20	O
mg	O
and	O
hydrochlorothiazide	S-chemical
25	O
mg	O
,	O
and	O
therefore	O
dosage	O
adjustment	O
should	O
not	O
be	O
necessary	O
when	O
they	O
are	O
co-administered	O
.	O

PGE	B-chemical
(	I-chemical
1	I-chemical
)	E-chemical
stimulation	O
of	O
HEK293	O
cells	O
generates	O
multiple	O
contiguous	O
domains	O
with	O
different	O
[	O
cAMP	S-chemical
]	O
:	O
role	O
of	O
compartmentalized	O
phosphodiesterases	O
.	O
There	O
is	O
a	O
growing	O
appreciation	O
that	O
the	O
cyclic	B-chemical
adenosine	I-chemical
monophosphate	E-chemical
(	O
cAMP	S-chemical
)	O
-	O
protein	B-GP
kinase	I-GP
A	E-GP
(	O
PKA	S-GP
)	O
signaling	O
pathway	O
is	O
organized	O
to	O
form	O
transduction	O
units	O
that	O
function	O
to	O
deliver	O
specific	O
messages	O
.	O
Such	O
organization	O
results	O
in	O
the	O
local	O
activation	O
of	O
PKA	S-GP
subsets	O
through	O
the	O
generation	O
of	O
confined	O
intracellular	O
gradients	O
of	O
cAMP	S-chemical
,	O
but	O
the	O
mechanisms	O
responsible	O
for	O
limiting	O
the	O
diffusion	O
of	O
cAMP	S-chemical
largely	O
remain	O
to	O
be	O
clarified	O
.	O
In	O
this	O
study	O
,	O
by	O
performing	O
real-time	O
imaging	O
of	O
cAMP	S-chemical
,	O
we	O
show	O
that	O
prostaglandin	B-chemical
1	E-chemical
stimulation	O
generates	O
multiple	O
contiguous	O
,	O
intracellular	O
domains	O
with	O
different	O
cAMP	S-chemical
concentration	O
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O
By	O
using	O
pharmacological	O
and	O
genetic	O
manipulation	O
of	O
phosphodiesterases	S-GP
(	O
PDEs	S-GP
)	O
,	O
we	O
demonstrate	O
that	O
compartmentalized	O
PDE4B	S-GP
and	O
PDE4D	S-GP
are	O
responsible	O
for	O
selectively	O
modulating	O
the	O
concentration	O
of	O
cAMP	S-chemical
in	O
individual	O
subcellular	O
compartments	O
.	O
We	O
propose	O
a	O
model	O
whereby	O
compartmentalized	O
PDEs	S-GP
,	O
rather	O
than	O
representing	O
an	O
enzymatic	O
barrier	O
to	O
cAMP	S-chemical
diffusion	O
,	O
act	O
as	O
a	O
sink	O
to	O
drain	O
the	O
second	O
messenger	O
from	O
discrete	O
locations	O
,	O
resulting	O
in	O
multiple	O
and	O
simultaneous	O
domains	O
with	O
different	O
cAMP	S-chemical
concentrations	O
irrespective	O
of	O
their	O
distance	O
from	O
the	O
site	O
of	O
cAMP	S-chemical
synthesis	O
.	O

Benzoquinone	S-chemical
Reveals	O
a	O
Cysteine	S-chemical
-Dependent	O
Desensitization	O
Mechanism	O
of	O
TRPA1	S-GP
.	O
The	O
transient	B-GP
receptor	I-GP
potential	I-GP
ankyrin	I-GP
1	E-GP
(	O
TRPA1	B-GP
)	E-GP
nonselective	O
cation	B-GP
channel	E-GP
has	O
a	O
conserved	O
function	O
as	O
a	O
noxious	O
chemical	O
sensor	O
throughout	O
much	O
of	O
Metazoa	O
.	O
Electrophilic	O
chemicals	O
activate	O
both	O
insect	O
and	O
vertebrate	O
TRPA1	S-GP
via	O
covalent	O
modification	O
of	O
cysteine	S-chemical
residues	O
in	O
the	O
amino	S-chemical
-terminal	O
region	O
.	O
Although	O
naturally	O
occurring	O
electrophilic	O
plant	O
compounds	O
,	O
such	O
as	O
mustard	O
oil	O
and	O
cinnamaldehyde	S-chemical
,	O
are	O
TRPA1	S-GP
agonists	O
,	O
it	O
is	O
unknown	O
whether	O
arthropod-produced	O
electrophiles	O
activate	O
mammalian	B-GP
TRPA1	E-GP
.	O
We	O
characterized	O
the	O
effects	O
of	O
the	O
electrophilic	O
arthropod	O
defensive	O
compound	O
para-benzoquinone	S-chemical
(	O
pBQN	S-chemical
)	O
on	O
the	O
human	B-GP
TRPA1	E-GP
channel	O
.	O
We	O
used	O
whole-cell	O
recordings	O
of	O
human	O
embryonic	O
kidney	O
cells	O
heterologously	O
expressing	O
either	O
wild-type	O
TRPA1	S-GP
or	O
TRPA1	S-GP
with	O
three	O
serine	S-chemical
-substituted	O
cysteines	S-chemical
crucial	O
for	O
electrophile	O
activation	O
(	O
C621S	S-GP
,	O
C641S	S-GP
,	O
C665S	S-GP
)	O
.	O
We	O
found	O
that	O
pBQN	S-chemical
activates	O
TRPA1	S-GP
starting	O
at	O
10	O
nM	O
and	O
peaking	O
at	O
300	O
nM	O
;	O
higher	O
concentrations	O
caused	O
rapid	O
activation	O
followed	O
by	O
a	O
fast	O
decline	O
.	O
Activation	O
by	O
pBQN	S-chemical
required	O
reactivity	O
with	O
cysteine	S-chemical
residues	O
,	O
but	O
ones	O
that	O
are	O
distinct	O
from	O
those	O
previously	O
reported	O
to	O
be	O
the	O
key	O
targets	O
of	O
electrophiles	O
.	O
The	O
current	O
reduction	O
we	O
found	O
at	O
higher	O
pBQN	S-chemical
concentrations	O
was	O
a	O
cysteine-dependent	O
desensitization	O
of	O
TRPA1	S-GP
,	O
and	O
did	O
not	O
require	O
prior	O
activation	O
.	O
The	O
cysteines	S-chemical
required	O
for	O
desensitization	O
are	O
not	O
accessible	O
to	O
all	O
electrophiles	O
as	O
iodoacetamide	S-chemical
and	O
internally	O
applied	O
2-	B-chemical
(	I-chemical
trimethylammonium	I-chemical
)	I-chemical
ethyl	I-chemical
methanesulfonate	E-chemical
failed	O
to	O
cause	O
desensitization	O
(	O
despite	O
large	O
activation	O
)	O
.	O
Interestingly	O
,	O
following	O
pBQN	S-chemical
desensitization	O
,	O
wild-type	O
TRPA1	S-GP
had	O
dramatically	O
reduced	O
response	O
to	O
the	O
nonelectrophile	O
agonist	O
carvacrol	S-chemical
,	O
whereas	O
the	O
triple	O
cysteine	S-chemical
mutant	O
TRPA1	S-GP
retained	O
its	O
full	O
response	O
.	O
Our	O
results	O
suggest	O
that	O
modification	O
of	O
multiple	O
cysteine	S-chemical
residues	O
by	O
electrophilic	O
compounds	O
can	O
generate	O
both	O
activation	O
and	O
desensitization	O
of	O
the	O
TRPA1	S-GP
channel	O
.	O

Analgesia	O
and	O
COX-2	S-GP
inhibition	O
.	O
While	O
non-	O
steroidal	S-chemical
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
the	O
mainstay	O
of	O
therapy	O
for	O
the	O
management	O
of	O
acute	O
pain	O
and	O
rheumatoid	O
arthritis	O
,	O
toxicity	O
associated	O
with	O
chronic	O
administration	O
limits	O
their	O
benefit-to-risk	O
relationship	O
in	O
many	O
patients	O
.	O
A	O
series	O
of	O
studies	O
is	O
reviewed	O
that	O
assesses	O
the	O
relationship	O
between	O
cytokines	S-GP
released	O
at	O
the	O
site	O
of	O
tissue	O
injury	O
and	O
NSAID	O
analgesia	O
,	O
and	O
the	O
in	O
vivo	O
selectivity	O
of	O
a	O
selective	O
cyclooxygenase	B-GP
(	I-GP
COX	I-GP
)	I-GP
-2	E-GP
inhibitor	O
(	O
celecoxib	S-chemical
)	O
in	O
comparison	O
to	O
a	O
dual	O
COX-1	S-GP
/	O
COX-2	S-GP
inhibitor	O
(	O
ketorolac	S-chemical
)	O
.	O
Three	O
replicate	O
studies	O
in	O
the	O
oral	O
surgery	O
model	O
of	O
acute	O
pain	O
used	O
submucosal	O
microdialysis	O
sample	O
collection	O
for	O
the	O
measurement	O
of	O
prostaglandin	B-chemical
E2	E-chemical
(	O
PGE2	S-chemical
;	O
a	O
product	O
of	O
both	O
COX-1	S-GP
and	O
COX-2	S-GP
)	O
and	O
thromboxane	B-chemical
B2	E-chemical
(	O
as	O
a	O
biomarker	O
for	O
COX-1	S-GP
activity	O
)	O
with	O
parallel	O
assessments	O
of	O
pain	O
.	O
The	O
time	O
course	O
of	O
PGE2	S-chemical
production	O
was	O
consistent	O
with	O
early	O
release	O
due	O
to	O
COX-1	S-GP
activity	O
followed	O
by	O
increased	O
production	O
2-3	O
hours	O
after	O
surgery	O
,	O
consistent	O
with	O
COX-2	S-GP
expression	O
.	O
Ketorolac	S-chemical
30	O
mg	O
at	O
pain	O
onset	O
suppressed	O
both	O
pain	O
and	O
peripheral	O
PGE2	S-chemical
levels	O
.	O
Ketorolac	S-chemical
1	O
mg	O
either	O
at	O
the	O
site	O
of	O
injury	O
or	O
intramuscularly	O
also	O
produced	O
analgesia	O
but	O
without	O
any	O
effect	O
on	O
peripheral	O
PGE2	S-chemical
levels	O
.	O
Celecoxib	S-chemical
selectively	O
suppressed	O
PGE2	S-chemical
but	O
not	O
TxB2	S-chemical
at	O
time	O
points	O
consistent	O
with	O
COX-2	S-GP
activity	O
,	O
while	O
producing	O
analgesia	O
.	O
These	O
studies	O
demonstrate	O
the	O
ability	O
to	O
assess	O
the	O
time	O
course	O
and	O
selective	O
effects	O
of	O
COX-2	S-GP
inhibitors	O
in	O
vivo	O
and	O
suggest	O
that	O
suppression	O
of	O
COX-2	S-GP
mediated	O
PGE2	S-chemical
is	O
temporally	O
related	O
to	O
NSAID	O
analgesia	O
.	O

Porcine	O
TLR8	S-GP
and	O
TLR7	S-GP
are	O
both	O
activated	O
by	O
a	O
selective	O
TLR7	S-GP
ligand	O
,	O
imiquimod	S-chemical
.	O
Toll-like	B-GP
receptors	E-GP
(	O
TLRs	S-GP
)	O
are	O
a	O
family	O
of	O
highly	O
conserved	O
germline-encoded	O
pattern-recognition	B-GP
receptors	E-GP
(	O
PRR	S-GP
)	O
,	O
which	O
are	O
utilized	O
by	O
the	O
innate	O
immune	O
system	O
to	O
recognize	O
microbial	O
components	O
,	O
known	O
as	O
pathogen-associated	O
molecular	O
patterns	O
(	O
PAMP	O
)	O
.	O
We	O
cloned	O
and	O
characterized	O
porcine	O
TLR7	S-GP
and	O
TLR8	S-GP
genes	O
from	O
pig	O
lymph	O
node	O
tissue	O
.	O
Sequence	O
analysis	O
showed	O
that	O
the	O
aa	O
sequence	O
identities	O
of	O
porcine	B-GP
TLR7	E-GP
with	O
human	B-GP
,	I-GP
mouse	I-GP
and	I-GP
bovine	I-GP
TLR7	E-GP
are	O
85	O
,	O
78	O
and	O
90	O
%	O
,	O
respectively	O
,	O
whereas	O
porcine	B-GP
TLR8	E-GP
aa	O
sequence	O
identities	O
with	O
human	B-GP
,	I-GP
mouse	I-GP
and	I-GP
bovine	I-GP
TLR8	E-GP
are	O
73	O
,	O
69	O
and	O
79	O
%	O
,	O
respectively	O
.	O
Both	O
porcine	B-GP
TLR7	E-GP
and	O
TLR8	S-GP
proteins	O
were	O
expressed	O
in	O
cell	O
lines	O
and	O
were	O
N	S-chemical
-glycosylated	O
.	O
The	O
stimulatory	O
activity	O
of	O
TLR7	S-GP
and	O
TLR8	S-GP
ligands	O
to	O
porcine	B-GP
and	I-GP
human	I-GP
TLR7	E-GP
and	O
TLR8	S-GP
in	O
transiently	O
transfected	O
Cos-7	O
and	O
293T	O
cells	O
were	O
analyzed	O
using	O
a	O
NF-kappaB	S-GP
reporter	O
assay	O
.	O
Two	O
imidazoquinoline	S-chemical
molecules	O
,	O
imiquimod	S-chemical
and	O
gardiquimod	S-chemical
,	O
markedly	O
activated	O
both	O
porcine	B-GP
TLR7	E-GP
and	O
TLR8	S-GP
whereas	O
only	O
human	B-GP
TLR7	E-GP
,	O
but	O
not	O
TLR8	S-GP
,	O
was	O
activated	O
by	O
the	O
ligands	O
.	O
Therefore	O
,	O
receptor	O
specificity	O
for	O
porcine	B-GP
TLR8	E-GP
is	O
clearly	O
species	O
specific	O
.	O
We	O
further	O
showed	O
that	O
porcine	B-GP
TLR7	E-GP
and	O
TLR8	S-GP
are	O
located	O
intracellularly	O
and	O
are	O
mainly	O
within	O
the	O
endoplasmic	O
reticulum	O
.	O
Moreover	O
,	O
activation	O
of	O
transfected	O
cells	O
and	O
porcine	O
PBMC	O
by	O
TLR7	S-GP
ligands	O
was	O
inhibited	O
by	O
bafilomycin	B-chemical
A	I-chemical
(	I-chemical
1	I-chemical
)	E-chemical
indicating	O
the	O
requirement	O
of	O
endosomal/lysosomal	O
acidification	O
for	O
activation	O
of	O
the	O
receptors	O
.	O

Selective	O
inhibition	O
of	O
cyclooxygenase	B-GP
2	E-GP
spares	O
renal	O
function	O
and	O
prostaglandin	S-chemical
synthesis	O
in	O
cirrhotic	O
rats	O
with	O
ascites	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
The	O
critical	O
role	O
of	O
cyclooxygenase	S-GP
(	O
COX	S-GP
)	O
products	O
in	O
maintenance	O
of	O
renal	O
function	O
in	O
cirrhosis	O
with	O
ascites	O
discourages	O
the	O
use	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
in	O
this	O
disease	O
.	O
The	O
recent	O
development	O
of	O
selective	O
COX-2	S-GP
inhibitors	O
opens	O
new	O
avenues	O
for	O
the	O
use	O
of	O
these	O
compounds	O
in	O
decompensated	O
cirrhosis	O
.	O
The	O
current	O
study	O
evaluates	O
the	O
effects	O
of	O
a	O
selective	O
COX-2	S-GP
inhibitor	O
(	O
SC-236	S-chemical
)	O
on	O
renal	O
function	O
in	O
cirrhotic	O
rats	O
with	O
ascites	O
.	O
METHODS	O
:	O
In	O
protocol	O
1	O
,	O
urine	O
volume	O
,	O
urinary	O
excretion	O
of	O
sodium	S-chemical
and	O
prostaglandins	S-chemical
,	O
glomerular	O
filtration	O
rate	O
,	O
and	O
renal	O
plasma	O
flow	O
were	O
measured	O
before	O
and	O
after	O
administration	O
of	O
SC-236	S-chemical
(	O
n	O
=	O
12	O
)	O
or	O
ketorolac	S-chemical
(	O
n	O
=	O
10	O
)	O
to	O
rats	O
with	O
cirrhosis	O
.	O
Protocol	O
2	O
was	O
aimed	O
at	O
assessing	O
the	O
effects	O
of	O
COX	S-GP
inhibitors	O
on	O
renal	O
water	O
metabolism	O
in	O
28	O
cirrhotic	O
rats	O
.	O
RESULTS	O
:	O
Administration	O
of	O
SC-236	S-chemical
to	O
cirrhotic	O
animals	O
did	O
not	O
produce	O
significant	O
renal	O
effects	O
,	O
whereas	O
administration	O
of	O
the	O
nonselective	O
COX-1	S-GP
/	O
COX-2	S-GP
inhibitor	O
,	O
ketorolac	S-chemical
,	O
resulted	O
in	O
a	O
marked	O
reduction	O
in	O
urine	O
volume	O
,	O
urinary	O
excretion	O
of	O
prostaglandins	S-chemical
,	O
and	O
glomerular	O
filtration	O
rate	O
and	O
in	O
a	O
significant	O
impairment	O
in	O
renal	O
water	O
metabolism	O
.	O
CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
SC-236	S-chemical
does	O
not	O
significantly	O
impair	O
renal	O
function	O
in	O
rats	O
with	O
cirrhosis	O
.	O

Distinct	O
role	O
of	O
PYK2	S-GP
in	O
mediating	O
thromboxane	S-chemical
generation	O
downstream	O
of	O
both	O
G12/13	S-GP
and	O
integrin	B-GP
αiibβ	E-GP
in	O
platelets	O
.	O
Proline-rich	B-GP
tyrosine	I-GP
kinase	I-GP
2	E-GP
(	O
Pyk2	S-GP
)	O
is	O
activated	O
by	O
various	O
agonists	O
in	O
platelets	O
.	O
We	O
evaluated	O
the	O
signaling	O
mechanism	O
and	O
the	O
functional	O
role	O
of	O
Pyk2	S-GP
in	O
platelets	O
by	O
using	O
pharmacological	O
inhibitors	O
and	O
Pyk2	S-GP
-deficient	O
platelets	O
.	O
We	O
found	O
that	O
platelet	O
aggregation	O
and	O
secretion	O
in	O
response	O
to	O
2-MeSADP	S-chemical
and	O
AYPGKF	O
were	O
diminished	O
in	O
the	O
presence	O
of	O
Pyk2	S-GP
inhibitors	O
or	O
in	O
Pyk2	S-GP
-deficient	O
platelets	O
,	O
suggesting	O
that	O
Pyk2	S-GP
plays	O
a	O
positive	O
regulatory	O
role	O
in	O
platelet	O
functional	O
responses	O
.	O
It	O
has	O
been	O
shown	O
that	O
ADP	S-chemical
-	O
,	O
but	O
not	O
thrombin	S-GP
-	O
,	O
induced	O
thromboxane	S-chemical
(	O
TxA2	S-chemical
)	O
generation	O
depends	O
on	O
integrin	S-GP
signaling	O
.	O
Unlike	O
ADP	S-chemical
,	O
thrombin	S-GP
activates	O
G12/13	S-GP
pathways	O
,	O
and	O
G12/13	S-GP
pathways	O
can	O
substitute	O
for	O
integrin	S-GP
signaling	O
for	O
TxA2	S-chemical
generation	O
.	O
We	O
found	O
that	O
Pyk2	S-GP
was	O
activated	O
downstream	O
of	O
both	O
G12/13	S-GP
and	O
integrin	S-GP
-mediated	O
pathways	O
,	O
and	O
both	O
2-MeSADP	S-chemical
-	O
and	O
AYPGKF-induced	O
TxA2	S-chemical
generation	O
was	O
significantly	O
diminished	O
in	O
Pyk2	S-GP
-deficient	O
platelets	O
.	O
In	O
addition	O
,	O
TxA2	S-chemical
generation	O
induced	O
by	O
co-stimulation	O
of	O
Gi	S-GP
and	O
Gz	S-GP
pathways	O
,	O
which	O
is	O
dependent	O
on	O
integrin	S-GP
signaling	O
,	O
was	O
inhibited	O
by	O
blocking	O
Pyk2	S-GP
.	O
Furthermore	O
,	O
inhibition	O
of	O
2-MeSADP	S-chemical
-induced	O
TxA2	S-chemical
generation	O
by	O
fibrinogen	B-GP
receptor	E-GP
antagonist	O
was	O
not	O
rescued	O
by	O
co-stimulation	O
of	O
G12/13	S-GP
pathways	O
in	O
the	O
presence	O
of	O
Pyk2	S-GP
inhibitor	O
.	O
We	O
conclude	O
that	O
Pyk2	S-GP
is	O
a	O
common	O
signaling	O
effector	O
downstream	O
of	O
both	O
G12/13	S-GP
and	O
integrin	B-GP
αIIbβ3	E-GP
signaling	O
which	O
contributes	O
to	O
thromboxane	S-chemical
generation	O
.	O

Aminopropylindenes	S-chemical
derived	O
from	O
Grundmann	B-chemical
's	I-chemical
ketone	E-chemical
as	O
a	O
novel	O
chemotype	O
of	O
oxidosqualene	B-GP
cyclase	E-GP
inhibitors	O
.	O
A	O
series	O
of	O
aminopropylindenes	S-chemical
,	O
designed	O
as	O
mimics	O
of	O
a	O
cationic	O
high	O
energy	O
intermediate	O
in	O
the	O
oxidosqualene	B-GP
cyclase	I-GP
(	I-GP
1	I-GP
)	E-GP
(	O
OSC	S-GP
)	O
-mediated	O
cyclization	O
of	O
2,3-oxidosqualen	S-chemical
to	O
lanosterol	S-chemical
was	O
prepared	O
from	O
Grundmann	B-chemical
's	I-chemical
ketone	E-chemical
.	O
Screening	O
on	O
OSCs	S-GP
from	O
five	O
different	O
organisms	O
revealed	O
interesting	O
activities	O
and	O
selectivities	O
of	O
some	O
of	O
the	O
compounds	O
.	O
A	O
N	B-chemical
,	I-chemical
N-dimethylaminopropyl	E-chemical
derivative	O
showed	O
promising	O
inhibition	O
of	O
Trypanosoma	B-GP
cruzi	I-GP
OSC	E-GP
in	O
combination	O
with	O
low	O
cytotoxicity	O
,	O
and	O
showed	O
significant	O
reduction	O
of	O
cholesterol	S-chemical
biosynthesis	O
in	O
a	O
human	O
cell	O
line	O
.	O

Lipid	O
biomarkers	O
of	O
oxidative	O
stress	O
in	O
a	O
genetic	O
mouse	O
model	O
of	O
Smith-Lemli-Opitz	O
syndrome	O
.	O
7-Dehydrocholesterol	S-chemical
(	O
7-DHC	S-chemical
)	O
accumulates	O
in	O
tissues	O
and	O
fluids	O
of	O
patients	O
with	O
Smith-Lemli-Opitz	O
syndrome	O
(	O
SLOS	O
)	O
,	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
3β-hydroxysterol-Δ	B-GP
(	I-GP
7	I-GP
)	I-GP
-reductase	E-GP
(	O
DHCR7	S-GP
)	O
.	O
We	O
recently	O
reported	O
that	O
7-DHC	S-chemical
is	O
the	O
most	O
reactive	O
lipid	O
molecule	O
toward	O
free	O
radical	O
oxidation	O
(	O
lipid	O
peroxidation	O
)	O
and	O
14	O
oxysterols	S-chemical
have	O
been	O
identified	O
as	O
products	O
of	O
oxidation	O
of	O
7-DHC	S-chemical
in	O
solution	O
.	O
As	O
the	O
high	O
oxidizability	O
of	O
7-DHC	S-chemical
may	O
lead	O
to	O
systemic	O
oxidative	O
stress	O
in	O
SLOS	O
patients	O
,	O
we	O
report	O
here	O
lipid	O
biomarkers	O
of	O
oxidative	O
stress	O
in	O
a	O
Dhcr7	S-GP
-KO	O
mouse	O
model	O
of	O
SLOS	O
,	O
including	O
oxysterols	S-chemical
,	O
isoprostanes	S-chemical
(	O
IsoPs	S-chemical
)	O
,	O
and	O
neuroprostanes	S-chemical
(	O
NeuroPs	S-chemical
)	O
that	O
are	O
formed	O
from	O
the	O
oxidation	O
of	O
7-DHC	S-chemical
,	O
arachidonic	B-chemical
acid	E-chemical
and	O
docosahexaenoic	B-chemical
acid	E-chemical
,	O
respectively	O
.	O
In	O
addition	O
to	O
a	O
previously	O
described	O
oxysterol	S-chemical
,	O
3β,5α-dihydroxycholest-7-en-6-one	S-chemical
(	O
DHCEO	S-chemical
)	O
,	O
we	O
provide	O
evidence	O
for	O
the	O
chemical	O
structures	O
of	O
three	O
new	O
oxysterols	S-chemical
in	O
the	O
brain	O
and/or	O
liver	O
tissue	O
of	O
Dhcr7	S-GP
-KO	O
mice	O
,	O
two	O
of	O
which	O
were	O
quantified	O
.	O
We	O
find	O
that	O
levels	O
of	O
IsoPs	S-chemical
and	O
NeuroPs	S-chemical
are	O
also	O
elevated	O
in	O
brain	O
and/or	O
liver	O
tissues	O
of	O
Dhcr7	S-GP
-KO	O
mice	O
relative	O
to	O
matching	O
WT	O
mice	O
.	O
While	O
IsoPs	S-chemical
and	O
NeuroPs	S-chemical
have	O
been	O
established	O
as	O
a	O
reliable	O
measurement	O
of	O
lipid	O
peroxidation	O
and	O
oxidative	O
stress	O
in	O
vivo	O
,	O
we	O
show	O
that	O
in	O
this	O
genetic	O
SLOS	O
mouse	O
model	O
,	O
7-DHC	S-chemical
-derived	O
oxysterols	S-chemical
are	O
present	O
at	O
much	O
higher	O
levels	O
than	O
IsoPs	S-chemical
and	O
NeuroPs	S-chemical
and	O
thus	O
are	O
better	O
markers	O
of	O
lipid	O
oxidation	O
and	O
related	O
oxidative	O
stress	O
.	O

Decreased	O
histamine	B-GP
H1	I-GP
receptor	E-GP
binding	O
in	O
the	O
brain	O
of	O
depressed	O
patients	O
.	O
The	O
central	O
histamine	S-chemical
rgic	O
neuron	O
system	O
modulates	O
the	O
wakefulness	O
,	O
sleep-awake	O
cycle	O
,	O
appetite	O
control	O
,	O
learning	O
and	O
memory	O
,	O
and	O
emotion	O
.	O
Previous	O
studies	O
have	O
reported	O
changes	O
in	O
neuronal	O
histamine	O
release	O
and	O
its	O
metabolism	O
under	O
stress	O
conditions	O
in	O
the	O
mammalian	O
brain	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
,	O
using	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
and	O
[	B-chemical
(	I-chemical
11	I-chemical
)	I-chemical
C	I-chemical
]	I-chemical
-doxepin	E-chemical
,	O
whether	O
the	O
histaminergic	O
neuron	O
system	O
is	O
involved	O
in	O
human	O
depression	O
.	O
Cerebral	O
histamine	B-GP
H1	I-GP
receptor	E-GP
(	O
H	B-GP
(	I-GP
1	I-GP
)	I-GP
R	E-GP
)	O
binding	O
was	O
measured	O
in	O
10	O
patients	O
with	O
major	O
depression	O
and	O
in	O
10	O
normal	O
age-matched	O
subjects	O
using	O
PET	O
and	O
[	B-chemical
(	I-chemical
11	I-chemical
)	I-chemical
C	I-chemical
]	I-chemical
-doxepin	E-chemical
.	O
Data	O
were	O
calculated	O
by	O
a	O
graphical	O
analysis	O
on	O
voxel-by-voxel	O
and	O
ROI	O
(	O
region	O
of	O
interests	O
)	O
basis	O
.	O
Binding	O
potential	O
(	O
BP	O
)	O
values	O
for	O
[	B-chemical
(	I-chemical
11	I-chemical
)	I-chemical
C	I-chemical
]	I-chemical
-doxepin	E-chemical
binding	O
in	O
the	O
frontal	O
and	O
prefrontal	O
cortices	O
,	O
and	O
cingulate	O
gyrus	O
were	O
significantly	O
lower	O
in	O
the	O
depressed	O
patients	O
than	O
those	O
in	O
the	O
normal	O
control	O
subjects	O
.	O
There	O
was	O
no	O
area	O
of	O
the	O
brain	O
where	O
[	B-chemical
(	I-chemical
11	I-chemical
)	I-chemical
C	I-chemical
]	I-chemical
-doxepin	E-chemical
binding	O
was	O
significantly	O
higher	O
in	O
the	O
depressed	O
patients	O
than	O
in	O
the	O
controls	O
.	O
ROI-based	O
analysis	O
also	O
revealed	O
that	O
BP	O
values	O
for	O
[	B-chemical
(	I-chemical
11	I-chemical
)	I-chemical
C	I-chemical
]	I-chemical
-doxepin	E-chemical
binding	O
in	O
the	O
frontal	O
cortex	O
and	O
cingulate	O
gyrus	O
decreased	O
in	O
proportion	O
to	O
self-rating	O
depressive	O
scales	O
scores	O
.	O
The	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
depressed	O
patients	O
have	O
decreased	O
brain	O
H	B-GP
(	I-GP
1	I-GP
)	I-GP
R	E-GP
binding	O
and	O
that	O
this	O
decrease	O
correlates	O
with	O
the	O
severity	O
of	O
depression	O
symptoms	O
.	O
It	O
is	O
therefore	O
suggested	O
that	O
the	O
histaminergic	O
neuron	O
system	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
depression	O
and	O
that	O
its	O
modulation	O
may	O
prove	O
to	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
depression	O
.	O

Phytoestrogen	O
genistein	S-chemical
protects	O
against	O
endothelial	O
barrier	O
dysfunction	O
in	O
vascular	O
endothelial	O
cells	O
through	O
PKA	S-GP
-mediated	O
suppression	O
of	O
RhoA	S-GP
signaling	O
.	O
The	O
soy-derived	O
phytoestrogen	O
genistein	S-chemical
has	O
received	O
attention	O
for	O
its	O
potential	O
to	O
improve	O
vascular	O
function	O
,	O
but	O
its	O
mechanism	O
remains	O
unclear	O
.	O
Here	O
,	O
we	O
report	O
that	O
genistein	S-chemical
at	O
physiologically	O
relevant	O
concentrations	O
(	O
0.1-10	O
μM	O
)	O
significantly	O
inhibited	O
thrombin	S-GP
-induced	O
increase	O
in	O
endothelial	O
monolayer	O
permeability	O
.	O
Genistein	S-chemical
also	O
reduced	O
the	O
formation	O
of	O
stress	O
fibers	O
by	O
thrombin	S-GP
and	O
suppressed	O
thrombin	S-GP
-induced	O
phosphorylation	O
of	O
myosin	B-GP
light	I-GP
chain	E-GP
(	O
MLC	S-GP
)	O
on	O
Ser	S-chemical
(	O
19	O
)	O
/	O
Thr	S-chemical
(	O
18	O
)	O
in	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O
Genistein	S-chemical
had	O
no	O
effect	O
on	O
resting	O
intracellular	O
[	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
]	O
or	O
thrombin	S-GP
-induced	O
increase	O
in	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
mobilization	O
.	O
Addition	O
of	O
the	O
inhibitors	O
of	O
endothelial	B-GP
nitric	I-GP
oxide	I-GP
synthase	E-GP
or	O
estrogen	B-GP
receptor	E-GP
did	O
not	O
alter	O
the	O
protective	O
effect	O
of	O
genistein	S-chemical
.	O
RhoA	S-GP
is	O
a	O
small	O
GTPase	S-GP
that	O
plays	O
an	O
important	O
role	O
in	O
actin	S-GP
-	O
myosin	S-GP
contraction	O
and	O
endothelial	O
barrier	O
dysfunction	O
.	O
RhoA	S-GP
inhibitor	O
blocked	O
the	O
protective	O
effect	O
of	O
genistein	S-chemical
on	O
endothelial	O
permeability	O
and	O
also	O
ablated	O
thrombin	S-GP
-induced	O
MLC	S-GP
-phosphorylation	O
in	O
ECs	O
.	O
Inhibition	O
of	O
PKA	S-GP
significantly	O
attenuated	O
the	O
effect	O
of	O
genistein	S-chemical
on	O
thrombin	S-GP
-induced	O
EC	O
permeability	O
,	O
MLC	S-GP
phosphorylation	O
,	O
and	O
RhoA	S-GP
membrane	O
translocation	O
in	O
ECs	O
.	O
Furthermore	O
,	O
thrombin	S-GP
diminished	O
cAMP	S-chemical
production	O
in	O
ECs	O
,	O
which	O
were	O
prevented	O
by	O
treatment	O
with	O
genistein	S-chemical
.	O
These	O
findings	O
demonstrated	O
that	O
genistein	S-chemical
improves	O
thrombin	S-GP
-induced	O
endothelial	O
barrier	O
dysfunction	O
in	O
ECs	O
through	O
PKA	S-GP
-mediated	O
suppression	O
of	O
RhoA	S-GP
signaling	O
.	O

Pharmacodynamics	O
and	O
pharmacokinetics	O
of	O
phenylbutazone	S-chemical
in	O
calves	O
.	O
Phenylbutazone	S-chemical
(	O
PBZ	S-chemical
)	O
was	O
administered	O
to	O
six	O
calves	O
intravenously	O
(	O
i.v	O
.	O
)	O
and	O
orally	O
at	O
a	O
dose	O
rate	O
of	O
4.4	O
mg/kg	O
in	O
a	O
three-period	O
cross-over	O
study	O
incorporating	O
a	O
placebo	O
treatment	O
to	O
establish	O
its	O
pharmacokinetic	O
and	O
pharmacodynamic	O
properties	O
.	O
Extravascular	O
distribution	O
was	O
determined	O
by	O
measuring	O
penetration	O
into	O
tissue	O
chamber	O
fluid	O
in	O
the	O
absence	O
of	O
stimulation	O
(	O
transudate	O
)	O
and	O
after	O
stimulation	O
of	O
chamber	O
tissue	O
with	O
the	O
mild	O
irritant	O
carrageenan	O
(	O
exudate	O
)	O
.	O
PBZ	S-chemical
pharmacokinetics	O
after	O
i.v	O
.	O
dosage	O
was	O
characterized	O
by	O
slow	O
clearance	O
(	O
1.29	O
mL/kg/h	O
)	O
,	O
long-terminal	O
half-life	O
(	O
53.4	O
h	O
)	O
,	O
low	O
distribution	O
volume	O
(	O
0.09	O
L/kg	O
)	O
and	O
low	O
concentrations	O
in	O
plasma	O
of	O
the	O
metabolite	O
oxyphenbutazone	S-chemical
(	O
OPBZ	S-chemical
)	O
,	O
confirming	O
previously	O
published	O
data	O
for	O
adult	O
cattle	O
.	O
After	O
oral	O
dosage	O
bioavailability	O
(	O
F	O
)	O
was	O
66	O
%	O
.	O
Passage	O
into	O
exudate	O
was	O
slow	O
and	O
limited	O
,	O
and	O
penetration	O
into	O
transudate	O
was	O
even	O
slower	O
and	O
more	O
limited	O
;	O
area	O
under	O
curve	O
values	O
for	O
plasma	O
,	O
exudate	O
and	O
transudate	O
after	O
i.v	O
.	O
dosage	O
were	O
3604	O
,	O
1117	O
and	O
766	O
microg	O
h/mL	O
and	O
corresponding	O
values	O
after	O
oral	O
dosage	O
were	O
2435	O
,	O
647	O
and	O
486	O
microg	O
h/mL	O
.	O
These	O
concentrations	O
were	O
approximately	O
15-20	O
(	O
plasma	O
)	O
and	O
nine	O
(	O
exudate	O
)	O
times	O
greater	O
than	O
those	O
previously	O
reported	O
in	O
horses	O
(	O
receiving	O
the	O
same	O
dose	O
rate	O
of	O
PBZ	S-chemical
)	O
.	O
In	O
the	O
horse	O
,	O
the	O
lower	O
concentrations	O
had	O
produced	O
marked	O
inhibition	O
of	O
eicosanoid	O
synthesis	O
and	O
suppressed	O
the	O
inflammatory	O
response	O
.	O
The	O
higher	O
concentrations	O
in	O
calves	O
were	O
insufficient	O
to	O
inhibit	O
significantly	O
exudate	O
prostaglandin	B-chemical
E2	E-chemical
(	O
PGE2	S-chemical
)	O
,	O
leukotriene	B-chemical
B4	E-chemical
(	O
LTB4	S-chemical
)	O
and	O
beta-glucuronidase	S-GP
concentrations	O
and	O
exudate	O
leucocyte	O
numbers	O
,	O
serum	O
thromboxane	B-chemical
B2	E-chemical
(	O
TxB2	S-chemical
)	O
,	O
and	O
bradykinin	S-GP
-induced	O
skin	O
swelling	O
.	O
These	O
differences	O
from	O
the	O
horse	O
might	O
be	O
the	O
result	O
of	O
:	O
(	O
a	O
)	O
the	O
presence	O
in	O
equine	O
biological	O
fluids	O
of	O
higher	O
concentrations	O
than	O
in	O
calves	O
of	O
the	O
active	O
PBZ	S-chemical
metabolite	O
,	O
OPBZ	S-chemical
;	O
(	O
b	O
)	O
a	O
greater	O
degree	O
of	O
binding	O
of	O
PBZ	S-chemical
to	O
plasma	O
protein	O
in	O
calves	O
;	O
(	O
c	O
)	O
species	O
differences	O
in	O
the	O
sensitivity	O
to	O
PBZ	S-chemical
of	O
the	O
cyclo-oxygenase	S-GP
(	O
COX	S-GP
)	O
isoenzymes	O
,	O
COX-1	S-GP
and	O
COX-2	S-GP
or	O
;	O
(	O
d	O
)	O
a	O
combination	O
of	O
these	O
factors	O
.	O
To	O
achieve	O
clinical	O
efficacy	O
with	O
single	O
doses	O
of	O
PBZ	S-chemical
in	O
calves	O
,	O
higher	O
dosages	O
than	O
4.4	O
mg/kg	O
will	O
be	O
probably	O
required	O
.	O

Design	O
,	O
synthesis	O
and	O
structure-activity	O
relationship	O
of	O
new	O
arginine	B-chemical
vasopressin	E-chemical
analogues	O
containing	O
proline	S-chemical
derivatives	O
in	O
position	O
2	O
.	O
In	O
this	O
study	O
,	O
we	O
present	O
the	O
synthesis	O
and	O
pharmacological	O
properties	O
of	O
new	O
analogues	O
of	O
arginine	B-chemical
vasopressin	E-chemical
modified	O
in	O
the	O
N	S-chemical
-terminal	O
part	O
of	O
the	O
molecule	O
with	O
proline	S-chemical
derivatives	O
:	O
indoline-2-carboxylic	B-chemical
acid	E-chemical
(	O
Ica	S-chemical
)	O
and	O
(	B-chemical
2S,4R	I-chemical
)	I-chemical
-4-	I-chemical
(	I-chemical
naphthalene-2-ylmethyl	I-chemical
)	I-chemical
pyrrolidine-2-carboxylic	I-chemical
acid	E-chemical
.	O
All	O
the	O
peptides	O
were	O
tested	O
for	O
pressor	O
,	O
antidiuretic	O
and	O
in	O
vitro	O
uterotonic	O
activities	O
.	O
We	O
also	O
determined	O
their	O
binding	O
affinity	O
to	O
the	O
human	B-GP
oxytocin	I-GP
receptor	E-GP
.	O
The	O
Ica	S-chemical
(	O
2	O
)	O
substitution	O
resulted	O
in	O
two	O
moderately	O
potent	O
and	O
selective	O
antioxytocic	O
agents	O
:	O
[	B-chemical
Mpa	I-chemical
(	I-chemical
1	I-chemical
)	I-chemical
,	I-chemical
Ica	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
,	I-chemical
D-Arg	I-chemical
(	I-chemical
8	I-chemical
)	I-chemical
]	I-chemical
VP	E-chemical
and	O
[	B-chemical
Mpa	I-chemical
(	I-chemical
1	I-chemical
)	I-chemical
,	I-chemical
Ica	I-chemical
(	I-chemical
2	I-chemical
)	I-chemical
,	I-chemical
Val	I-chemical
(	I-chemical
4	I-chemical
)	I-chemical
,	I-chemical
D-Arg	I-chemical
(	I-chemical
8	I-chemical
)	I-chemical
]	I-chemical
VP	E-chemical
(	O
pA	O
(	O
2	O
)	O
=	O
7.09	O
and	O
7.50	O
,	O
respectively	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
peptides	O
modified	O
with	O
(	B-chemical
2S,4R	I-chemical
)	I-chemical
-4-	I-chemical
(	I-chemical
naphthalene-2-ylmethyl	I-chemical
)	I-chemical
pyrrolidine-2-carboxylic	I-chemical
acid	E-chemical
,	O
apart	O
from	O
their	O
moderate	O
antioxytocic	O
activity	O
,	O
turned	O
out	O
to	O
be	O
weak	O
antagonists	O
of	O
the	O
pressor	O
response	O
to	O
arginine	B-chemical
vasopressin	E-chemical
.	O
The	O
results	O
of	O
this	O
study	O
provide	O
useful	O
information	O
about	O
the	O
structure-activity	O
relationship	O
of	O
arginine	B-chemical
vasopressin	E-chemical
analogues	O
and	O
can	O
help	O
to	O
design	O
compounds	O
with	O
desired	O
biological	O
properties	O
.	O

Potency	O
switch	O
between	O
CHK1	S-GP
and	O
MK2	S-GP
:	O
Discovery	O
of	O
imidazo	B-chemical
[	I-chemical
1,2-a	I-chemical
]	I-chemical
pyrazine	E-chemical
-	O
and	O
imidazo	B-chemical
[	I-chemical
1,2-c	I-chemical
]	I-chemical
pyrimidine	E-chemical
-based	O
kinase	S-GP
inhibitors	O
.	O
Chemistry	O
has	O
been	O
developed	O
to	O
access	O
both	O
imidazo	B-chemical
[	I-chemical
1,2-a	I-chemical
]	I-chemical
pyrazines	E-chemical
and	O
imidazo	B-chemical
[	I-chemical
1,2-c	I-chemical
]	I-chemical
pyrimidines	E-chemical
.	O
Small	O
structural	O
modifications	O
in	O
both	O
series	O
led	O
to	O
a	O
switch	O
of	O
potency	O
between	O
two	O
kinases	S-GP
involved	O
in	O
mediating	O
cell	O
cycle	O
checkpoint	O
control	O
,	O
CHK1	S-GP
and	O
MK2	S-GP
.	O

The	O
COP9	B-GP
signalosome	E-GP
interacts	O
with	O
and	O
regulates	O
interferon	B-GP
regulatory	I-GP
factor	I-GP
5	I-GP
protein	E-GP
stability	O
.	O
The	O
transcription	O
factor	O
interferon	B-GP
regulatory	I-GP
factor	I-GP
5	E-GP
(	O
IRF5	S-GP
)	O
exerts	O
crucial	O
functions	O
in	O
the	O
regulation	O
of	O
host	O
immunity	O
against	O
extracellular	O
pathogens	O
,	O
DNA	O
damage-induced	O
apoptosis	O
,	O
death	B-GP
receptor	E-GP
signaling	O
,	O
and	O
macrophage	O
polarization	O
.	O
Tight	O
regulation	O
of	O
IRF5	S-GP
is	O
thus	O
warranted	O
for	O
an	O
efficient	O
response	O
toward	O
extracellular	O
stressors	O
and	O
for	O
limiting	O
autoimmune	O
and	O
inflammatory	O
responses	O
.	O
Here	O
we	O
report	O
that	O
the	O
COP9	B-GP
signalosome	E-GP
(	O
CSN	S-GP
)	O
,	O
a	O
general	O
modulator	O
of	O
diverse	O
cellular	O
and	O
developmental	O
processes	O
,	O
associates	O
constitutively	O
with	O
IRF5	S-GP
and	O
promotes	O
its	O
protein	O
stability	O
.	O
The	O
constitutive	O
CSN	S-GP
/	O
IRF5	S-GP
interaction	O
was	O
identified	O
using	O
proteomics	O
and	O
confirmed	O
by	O
endogenous	O
immunoprecipitations	O
.	O
The	O
CSN	S-GP
/	O
IRF5	S-GP
interaction	O
occurred	O
on	O
the	O
carboxyl	S-chemical
and	O
amino	S-chemical
termini	O
of	O
IRF5	S-GP
;	O
a	O
single	O
internal	O
deletion	O
from	O
amino	B-chemical
acids	E-chemical
455	O
to	O
466	O
(	O
Δ455-466	O
)	O
was	O
found	O
to	O
significantly	O
reduce	O
IRF5	S-GP
protein	O
stability	O
.	O
CSN	B-GP
subunit	I-GP
3	E-GP
(	O
CSN3	S-GP
)	O
was	O
identified	O
as	O
a	O
direct	O
interacting	O
partner	O
of	O
IRF5	S-GP
,	O
and	O
knockdown	O
of	O
this	O
subunit	O
with	O
small	O
interfering	O
RNAs	O
resulted	O
in	O
enhanced	O
degradation	O
.	O
Degradation	O
was	O
further	O
augmented	O
by	O
knockdown	O
of	O
CSN1	S-GP
and	O
CSN3	S-GP
together	O
.	O
The	O
ubiquitin	B-GP
E1	E-GP
inhibitor	O
UBEI-41	O
or	O
the	O
proteasome	S-GP
inhibitor	O
MG132	O
prevented	O
IRF5	S-GP
degradation	O
,	O
supporting	O
the	O
idea	O
that	O
its	O
stability	O
is	O
regulated	O
by	O
the	O
ubiquitin	S-GP
-	O
proteasome	S-GP
system	O
.	O
Importantly	O
,	O
activation	O
of	O
IRF5	S-GP
by	O
the	O
death	B-GP
receptor	E-GP
ligand	O
tumor	B-GP
necrosis	I-GP
factor-related	I-GP
apoptosis-inducing	I-GP
ligand	E-GP
(	O
TRAIL	S-GP
)	O
resulted	O
in	O
enhanced	O
degradation	O
via	O
loss	O
of	O
the	O
CSN	S-GP
/	O
IRF5	S-GP
interaction	O
.	O
This	O
study	O
defines	O
CSN	S-GP
to	O
be	O
a	O
new	O
interacting	O
partner	O
of	O
IRF5	S-GP
that	O
controls	O
its	O
stability	O
.	O

Structural	O
Characterization	O
of	O
an	O
LPA1	S-GP
Second	B-GP
Extracellular	I-GP
Loop	E-GP
Mimetic	O
with	O
a	O
Self-Assembling	O
Coiled-Coil	S-GP
Folding	O
Constraint	O
.	O
G	B-GP
protein-coupled	I-GP
receptor	E-GP
(	O
GPCR	S-GP
)	O
structures	O
are	O
of	O
interest	O
as	O
a	O
means	O
to	O
understand	O
biological	O
signal	O
transduction	O
and	O
as	O
tools	O
for	O
therapeutic	O
discovery	O
.	O
The	O
growing	O
number	O
of	O
GPCR	S-GP
crystal	O
structures	O
demonstrates	O
that	O
the	O
extracellular	B-GP
loops	E-GP
(	O
EL	S-GP
)	O
connecting	O
the	O
membrane-spanning	B-GP
helices	E-GP
show	O
tremendous	O
structural	O
variability	O
relative	O
to	O
the	O
more	O
structurally-conserved	O
seven	O
transmembrane	O
α-helical	B-GP
domains	E-GP
.	O
The	O
EL	S-GP
of	O
the	O
LPA	B-GP
(	I-GP
1	I-GP
)	E-GP
receptor	O
have	O
not	O
yet	O
been	O
conclusively	O
resolved	O
,	O
and	O
bear	O
limited	O
sequence	O
identity	O
to	O
known	O
structures	O
.	O
This	O
study	O
involved	O
development	O
of	O
a	O
peptide	O
to	O
characterize	O
the	O
intrinsic	O
structure	O
of	O
the	O
LPA	B-GP
(	I-GP
1	I-GP
)	E-GP
GPCR	S-GP
second	O
EL	S-GP
.	O
The	O
loop	O
was	O
embedded	O
between	O
two	O
helices	O
that	O
assemble	O
into	O
a	O
coiled-coil	S-GP
,	O
which	O
served	O
as	O
a	O
receptor-mimetic	O
folding	O
constraint	O
(	O
LPA	B-GP
(	I-GP
1	I-GP
)	E-GP
-CC-	O
EL2	S-GP
peptide	O
)	O
.	O
The	O
ensemble	O
of	O
structures	O
from	O
multi-dimensional	O
NMR	O
experiments	O
demonstrated	O
that	O
a	O
robust	O
coiled-coil	S-GP
formed	O
without	O
noticeable	O
deformation	O
due	O
to	O
the	O
EL2	S-GP
sequence	O
.	O
In	O
contrast	O
,	O
the	O
EL2	S-GP
sequence	O
showed	O
well-defined	O
structure	O
only	O
near	O
its	O
C	S-chemical
-terminal	O
residues	O
.	O
The	O
NMR	O
ensemble	O
was	O
combined	O
with	O
a	O
computational	O
model	O
of	O
the	O
LPA	B-GP
(	I-GP
1	I-GP
)	E-GP
receptor	O
that	O
had	O
previously	O
been	O
validated	O
.	O
The	O
resulting	O
hybrid	O
models	O
were	O
evaluated	O
using	O
docking	O
.	O
Nine	O
different	O
hybrid	O
models	O
interacted	O
with	O
LPA	S-chemical
18:1	O
as	O
expected	O
,	O
based	O
on	O
prior	O
mutagenesis	O
studies	O
,	O
and	O
one	O
was	O
additionally	O
consistent	O
with	O
antagonist	O
affinity	O
trends	O
.	O

A	O
new	O
concept	O
of	O
drug	O
delivery	O
for	O
acne	O
.	O
Adapalene	S-chemical
is	O
a	O
stable	O
naphthoic	B-chemical
acid	E-chemical
derivative	O
that	O
displays	O
a	O
strong	O
retinoid	S-chemical
agonist	O
pharmacology	O
.	O
This	O
drug	O
controls	O
cell	O
proliferation	O
and	O
differentiation	O
,	O
and	O
possesses	O
significant	O
anti-inflammatory	O
action	O
.	O
The	O
retinoid	S-chemical
action	O
of	O
adapalene	S-chemical
are	O
mediated	O
by	O
the	O
ligand-activated	B-GP
gene	I-GP
transcription	I-GP
factors	E-GP
retinoic	B-GP
acid	I-GP
receptors	E-GP
RAR	B-GP
beta	E-GP
and	O
RAR	B-GP
gamma	E-GP
.	O
We	O
describe	O
here	O
how	O
an	O
aqueous	O
gel	O
containing	O
adapalene	S-chemical
was	O
selected	O
for	O
the	O
topical	O
treatment	O
of	O
acne	O
.	O

Selective	O
separation	O
of	O
similarly	O
sized	O
proteins	O
with	O
tunable	O
nanoporous	O
block	O
copolymer	O
membranes	O
.	O
An	O
integral	O
asymmetric	O
membrane	O
was	O
fabricated	O
in	O
a	O
fast	O
and	O
one-step	O
process	O
by	O
combining	O
the	O
self-assembly	O
of	O
an	O
amphiphilic	O
block	O
copolymer	O
(	O
PS-b-P4VP	S-chemical
)	O
with	O
nonsolvent-induced	O
phase	O
separation	O
.	O
The	O
structure	O
was	O
found	O
to	O
be	O
composed	O
of	O
a	O
thin	O
layer	O
of	O
densely	O
packed	O
highly	O
ordered	O
cylindrical	O
channels	O
with	O
uniform	O
pore	O
sizes	O
perpendicular	O
to	O
the	O
surface	O
on	O
top	O
of	O
a	O
nonordered	O
sponge-like	O
layer	O
.	O
The	O
as-assembled	O
membrane	O
obtained	O
a	O
water	O
flux	O
of	O
more	O
than	O
3200	O
L	O
m	O
(	O
-2	O
)	O
h	O
(	O
-1	O
)	O
bar	O
(	O
-1	O
)	O
,	O
which	O
was	O
at	O
least	O
an	O
order	O
of	O
magnitude	O
higher	O
than	O
the	O
water	O
fluxes	O
of	O
commercially	O
available	O
membranes	O
with	O
comparable	O
pore	O
sizes	O
,	O
making	O
this	O
membrane	O
particularly	O
well	O
suited	O
to	O
size-selective	O
and	O
charge-based	O
separation	O
of	O
biomolecules	O
.	O
To	O
test	O
the	O
performance	O
of	O
the	O
membrane	O
,	O
we	O
conducted	O
diffusion	O
experiments	O
at	O
the	O
physiological	O
pH	O
of	O
7.4	O
using	O
bovine	B-GP
serum	I-GP
albumin	E-GP
(	O
BSA	S-GP
)	O
and	O
globulin-γ	S-GP
,	O
two	O
proteins	O
with	O
different	O
diameters	O
but	O
too	O
close	O
in	O
size	O
(	O
2-fold	O
difference	O
in	O
molecular	O
mass	O
)	O
to	O
be	O
efficiently	O
separated	O
via	O
conventional	O
dialysis	O
membrane	O
processes	O
.	O
The	O
diffusion	O
rate	O
differed	O
by	O
a	O
factor	O
of	O
87	O
,	O
the	O
highest	O
value	O
reported	O
to	O
date	O
.	O
We	O
also	O
analyzed	O
charge-based	O
diffusive	O
transport	O
and	O
separation	O
of	O
two	O
proteins	O
of	O
similar	O
molecular	O
weight	O
(	O
BSA	S-GP
and	O
bovine	B-GP
hemoglobin	E-GP
(	O
BHb	S-GP
)	O
)	O
through	O
the	O
membrane	O
as	O
a	O
function	O
of	O
external	O
pH	O
.	O
The	O
membrane	O
achieved	O
a	O
selectivity	O
of	O
about	O
10	O
at	O
pH	O
4.7	O
,	O
the	O
isoelectric	O
point	O
(	O
pI	O
)	O
of	O
BSA	S-GP
.	O
We	O
then	O
positively	O
charged	O
the	O
membrane	O
to	O
improve	O
the	O
separation	O
selectivity	O
.	O
With	O
the	O
modified	O
membrane	O
BSA	S-GP
was	O
completely	O
blocked	O
when	O
the	O
pH	O
was	O
7.0	O
,	O
the	O
pI	O
of	O
BHb	S-GP
,	O
while	O
BHb	S-GP
was	O
completely	O
blocked	O
at	O
pH	O
4.7	O
.	O
Our	O
results	O
demonstrate	O
the	O
potential	O
of	O
our	O
asymmetric	O
membrane	O
to	O
efficiently	O
separate	O
biological	O
substances/pharmaceuticals	O
in	O
bioscience	O
,	O
biotechnology	O
,	O
and	O
biomedicine	O
applications	O
.	O

Neuroprotective	O
effects	O
of	O
mercaptoethylleonurine	S-chemical
and	O
mercaptoethylguanidine	S-chemical
analogs	O
on	O
hydrogen	B-chemical
peroxide	E-chemical
-induced	O
apoptosis	O
in	O
human	O
neuronal	O
SH-SY5Y	O
cells	O
.	O
A	O
series	O
of	O
mercaptoethylleonurine	S-chemical
and	O
mercaptoethylguanidine	S-chemical
derivatives	O
were	O
designed	O
and	O
synthesized	O
.	O
Their	O
neuroprotective	O
effects	O
toward	O
H2O2	S-chemical
-induced	O
apoptosis	O
were	O
investigated	O
in	O
human	O
SH-SY5Y	O
cells	O
.	O
The	O
results	O
from	O
these	O
studies	O
identified	O
several	O
potent	O
compounds	O
,	O
with	O
compound	O
8k	O
emerging	O
as	O
the	O
most	O
effective	O
.	O
Further	O
investigation	O
demonstrated	O
that	O
8k	O
reduced	O
H2O2	S-chemical
-induced	O
activation	O
of	O
mitochondrial	O
apoptosis	O
by	O
inhibiting	O
the	O
expression	O
of	O
Bax	S-GP
and	O
elevating	O
the	O
expression	O
of	O
Bcl-2	S-GP
.	O
Moreover	O
,	O
the	O
molecular	O
mechanism	O
underlying	O
the	O
observed	O
neuroprotective	O
effects	O
of	O
8k	O
was	O
exerted	O
via	O
the	O
Akt	S-GP
and	O
JNK	S-GP
pathways	O
.	O
Compound	O
8k	O
can	O
be	O
a	O
lead	O
compound	O
for	O
further	O
discovery	O
of	O
neuroprotective	O
medicine	O
.	O

DNA	O
damage	O
and	O
homologous	O
recombination	O
signaling	O
induced	O
by	O
thymidylate	S-chemical
deprivation	O
.	O
DNA	O
damage	O
is	O
accepted	O
as	O
a	O
consequence	O
of	O
thymidylate	S-chemical
deprivation	O
induced	O
by	O
chemotherapeutic	O
inhibitors	O
of	O
thymidylate	B-GP
synthase	E-GP
(	O
TS	S-GP
)	O
,	O
but	O
the	O
types	O
of	O
damage	O
and	O
signaling	O
responses	O
remain	O
incompletely	O
understood	O
.	O
Thymidylate	S-chemical
deprivation	O
increases	O
dUTP	O
and	O
uracil	S-chemical
in	O
DNA	O
,	O
which	O
is	O
removed	O
by	O
base	O
excision	O
repair	O
(	O
BER	O
)	O
.	O
Because	O
BER	O
requires	O
a	O
synthesis	O
step	O
,	O
strand	O
break	O
intermediates	O
presumably	O
accumulate	O
.	O
Thymidylate	S-chemical
deprivation	O
also	O
induces	O
cell	O
cycle	O
arrest	O
during	O
replication	O
.	O
Homologous	O
recombination	O
(	O
HR	O
)	O
is	O
a	O
means	O
of	O
repairing	O
persistent	O
BER	O
intermediates	O
and	O
collapsed	O
replication	O
forks	O
.	O
There	O
are	O
also	O
intimate	O
links	O
between	O
HR	O
and	O
S-phase	O
checkpoint	O
pathways	O
.	O
In	O
this	O
study	O
,	O
the	O
goals	O
were	O
to	O
determine	O
the	O
involvement	O
of	O
HR-associated	O
proteins	O
and	O
DNA	O
damage	O
signaling	O
responses	O
to	O
thymidylate	S-chemical
deprivation	O
.	O
When	O
RAD51	S-GP
,	O
which	O
is	O
a	O
central	O
component	O
of	O
HR	O
,	O
was	O
depleted	O
by	O
siRNA	O
cells	O
were	O
sensitized	O
to	O
raltitrexed	S-chemical
(	O
RTX	S-chemical
)	O
,	O
which	O
specifically	O
inhibits	O
TS	S-GP
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
demonstration	O
in	O
mammalian	O
cells	O
that	O
depletion	O
of	O
RAD51	S-GP
causes	O
sensitivity	O
to	O
thymidylate	S-chemical
deprivation	O
.	O
Activation	O
of	O
DNA	O
damage	O
signaling	O
responses	O
was	O
examined	O
following	O
treatment	O
with	O
RTX	S-chemical
.	O
Phosphorylation	O
of	O
replication	B-GP
protein	I-GP
A	E-GP
(	O
RPA2	S-GP
subunit	O
)	O
and	O
formation	O
of	O
damage-induced	O
foci	O
were	O
strikingly	O
evident	O
following	O
IC	O
(	O
50	O
)	O
doses	O
of	O
RTX	S-chemical
.	O
Induction	O
was	O
much	O
more	O
striking	O
following	O
RTX	S-chemical
treatment	O
than	O
with	O
hydroxyurea	S-chemical
,	O
which	O
is	O
commonly	O
used	O
to	O
inhibit	O
replication	O
.	O
RTX	S-chemical
treatment	O
also	O
induced	O
foci	O
of	O
RAD51	S-GP
,	O
gamma-H2AX	S-GP
,	O
phospho-Chk1	S-GP
,	O
and	O
phospho-NBS1	S-GP
,	O
although	O
the	O
extent	O
of	O
co-localization	O
with	O
RPA2	S-GP
foci	O
varied	O
.	O
Collectively	O
,	O
the	O
results	O
suggest	O
that	O
HR	O
and	O
S-phase	O
checkpoint	O
signaling	O
processes	O
are	O
invoked	O
by	O
thymidylate	S-chemical
deprivation	O
and	O
influence	O
cellular	O
resistance	O
to	O
thymidylate	S-chemical
deprivation	O
.	O

Blockage	O
of	O
the	O
HERG	B-GP
human	I-GP
cardiac	I-GP
K+	I-GP
channel	E-GP
by	O
the	O
gastrointestinal	O
prokinetic	O
agent	O
cisapride	S-chemical
.	O
Cisapride	S-chemical
,	O
a	O
gastrointestinal	O
prokinetic	O
agent	O
,	O
is	O
known	O
to	O
cause	O
long	O
Q-T	O
syndrome	O
and	O
ventricular	O
arrhythmias	O
.	O
The	O
cellular	O
mechanism	O
is	O
not	O
known	O
.	O
The	O
human	B-GP
ether-a-go-go-related	I-GP
gene	E-GP
(	O
HERG	S-GP
)	O
,	O
which	O
encodes	O
the	O
rapidly	O
activating	O
delayed	O
rectifier	O
K+	S-chemical
current	O
and	O
is	O
important	O
in	O
cardiac	O
repolarization	O
,	O
may	O
serve	O
as	O
a	O
target	O
for	O
the	O
action	O
of	O
cisapride	S-chemical
.	O
We	O
tested	O
the	O
hypothesis	O
that	O
cisapride	S-chemical
blocks	O
HERG	S-GP
.	O
The	O
whole	O
cell	O
patch-clamp	O
recording	O
technique	O
was	O
used	O
to	O
study	O
HERG	S-GP
channels	O
stably	O
expressed	O
heterologously	O
in	O
HEK293	O
cells	O
.	O
Under	O
voltage-clamp	O
conditions	O
,	O
cisapride	S-chemical
block	O
of	O
HERG	S-GP
is	O
dose	O
dependent	O
with	O
a	O
half-maximal	O
inhibitory	O
concentration	O
of	O
6.5	O
nM	O
at	O
22	O
degrees	O
C	O
(	O
n	O
=	O
25	O
cells	O
)	O
.	O
Currents	O
rapidly	O
recovered	O
with	O
drug	O
washout	O
.	O
The	O
onset	O
of	O
block	O
by	O
cisapride	S-chemical
required	O
channel	O
activation	O
indicative	O
of	O
open	O
or	O
inactivated	O
state	O
blockage	O
.	O
Block	O
of	O
HERG	S-GP
with	O
cisapride	S-chemical
after	O
channel	O
activation	O
was	O
voltage	O
dependent	O
.	O
At	O
-20	O
mV	O
,	O
10	O
nM	O
cisapride	S-chemical
reduced	O
HERG	S-GP
tail-current	O
amplitude	O
by	O
5	O
%	O
,	O
whereas	O
,	O
at	O
+	O
20	O
mV	O
,	O
the	O
tail-current	O
amplitude	O
was	O
reduced	O
by	O
45	O
%	O
(	O
n	O
=	O
4	O
cells	O
)	O
.	O
At	O
-20	O
and	O
+	O
20	O
mV	O
,	O
100	O
nM	O
cisapride	S-chemical
reduced	O
tail-current	O
amplitude	O
by	O
66	O
and	O
90	O
%	O
,	O
respectively	O
.	O
We	O
conclude	O
that	O
cisapride	S-chemical
is	O
a	O
potent	O
blocker	O
of	O
HERG	S-GP
channels	O
expressed	O
in	O
HEK293	O
cells	O
.	O
This	O
effect	O
may	O
account	O
for	O
the	O
clinical	O
occurrence	O
of	O
Q-T	O
prolongation	O
and	O
ventricular	O
arrhythmias	O
observed	O
with	O
cisapride	S-chemical
.	O

Multilevel	O
regulation	O
of	O
2-cys	B-GP
peroxiredoxin	E-GP
reaction	O
cycle	O
by	O
s-nitrosylation	O
.	O
S-Nitrosothiols	S-chemical
(	O
SNOs	S-chemical
)	O
,	O
formed	O
by	O
nitric	B-chemical
oxide	E-chemical
(	O
NO	S-chemical
)	O
-mediated	O
S	S-chemical
-nitrosylation	O
,	O
and	O
hydrogen	B-chemical
peroxide	E-chemical
(	O
H2O2	S-chemical
)	O
,	O
a	O
prominent	O
reactive	O
oxygen	S-chemical
species	O
,	O
are	O
implicated	O
in	O
diverse	O
physiological	O
and	O
pathological	O
processes	O
.	O
Recent	O
research	O
has	O
shown	O
that	O
the	O
cellular	O
action	O
and	O
metabolism	O
of	O
SNOs	S-chemical
and	O
H2O2	S-chemical
involve	O
overlapping	O
,	O
thiol	S-chemical
-based	O
mechanisms	O
,	O
but	O
how	O
these	O
reactive	O
species	O
may	O
affect	O
each	O
other	O
's	O
fate	O
and	O
function	O
is	O
not	O
well	O
understood	O
.	O
In	O
this	O
study	O
we	O
investigated	O
how	O
NO	S-chemical
/	O
SNO	S-chemical
may	O
affect	O
the	O
redox	O
cycle	O
of	O
mammalian	B-GP
peroxiredoxin-1	E-GP
(	O
Prx1	S-GP
)	O
,	O
a	O
representative	O
of	O
the	O
2-Cys	B-GP
Prxs	E-GP
,	O
a	O
group	O
of	O
thioredoxin	S-GP
(	O
Trx	S-GP
)	O
-dependent	O
peroxidases	S-GP
.	O
We	O
found	O
that	O
,	O
both	O
in	O
a	O
cell-free	O
system	O
and	O
in	O
cells	O
,	O
NO	S-chemical
/	O
SNO	S-chemical
donors	O
such	O
as	O
S-nitrosocysteine	S-chemical
and	O
S-nitrosoglutathione	S-chemical
readily	O
induced	O
the	O
S	S-chemical
-nitrosylation	O
of	O
Prx1	S-GP
,	O
causing	O
structural	O
and	O
functional	O
alterations	O
.	O
In	O
particular	O
,	O
nitrosylation	O
promoted	O
disulfide	S-chemical
formation	O
involving	O
the	O
pair	O
of	O
catalytic	O
cysteines	S-chemical
(	O
Cys	S-chemical
-52	O
and	O
Cys	S-chemical
-173	O
)	O
and	O
disrupted	O
the	O
oligomeric	O
structure	O
of	O
Prx1	S-GP
,	O
leading	O
to	O
loss	O
of	O
peroxidase	S-GP
activity	O
.	O
A	O
highly	O
potent	O
inhibition	O
of	O
the	O
peroxidase	S-GP
catalytic	O
reaction	O
by	O
NO	S-chemical
/	O
SNO	S-chemical
was	O
seen	O
in	O
assays	O
employing	O
the	O
coupled	O
Prx	S-GP
-	O
Trx	S-GP
system	O
.	O
In	O
this	O
setting	O
,	O
S-nitrosocysteine	S-chemical
(	O
10	O
μm	O
)	O
effectively	O
blocked	O
the	O
Trx	S-GP
-mediated	O
regeneration	O
of	O
oxidized	B-GP
Prx1	E-GP
.	O
This	O
effect	O
appeared	O
to	O
be	O
due	O
to	O
both	O
competition	O
between	O
S-nitrosocysteine	S-chemical
and	O
Prx1	S-GP
for	O
the	O
Trx	S-GP
system	O
and	O
direct	O
modulation	O
by	O
S-nitrosocysteine	S-chemical
of	O
Trx	B-GP
reductase	E-GP
activity	O
.	O
Our	O
findings	O
that	O
NO	S-chemical
/	O
SNO	S-chemical
target	O
both	O
Prx	S-GP
and	O
Trx	B-GP
reductase	E-GP
may	O
have	O
implications	O
for	O
understanding	O
the	O
impact	O
of	O
nitrosylation	O
on	O
cellular	O
redox	O
homeostasis	O
.	O

Selective	O
cyclooxygenase-2	S-GP
(	O
COX-2	S-GP
)	O
inhibitors	O
and	O
breast	O
cancer	O
risk	O
.	O
BACKGROUND	O
:	O
Recent	O
epidemiologic	O
and	O
laboratory	O
studies	O
have	O
suggested	O
that	O
non-	O
steroidal	S-chemical
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
may	O
reduce	O
the	O
risk	O
of	O
breast	O
cancer	O
through	O
inhibition	O
of	O
cyclooxygenase-2	S-GP
(	O
COX-2	S-GP
)	O
.	O
METHODS	O
:	O
We	O
conducted	O
a	O
case-control	O
study	O
to	O
measure	O
the	O
association	O
between	O
selective	O
cox-2	S-GP
inhibitors	O
,	O
particularly	O
celecoxib	S-chemical
,	O
rofecoxib	S-chemical
,	O
valdecoxib	S-chemical
and	O
non-specific	O
NSAID	O
subgroups	O
,	O
and	O
breast	O
cancer	O
risk	O
.	O
Between	O
2003	O
and	O
2006	O
,	O
a	O
total	O
of	O
18,368	O
incident	O
breast	O
cancer	O
cases	O
were	O
identified	O
in	O
the	O
Ingenix/Lab	O
Rx	O
insurance	O
database	O
,	O
which	O
contains	O
clinical	O
encounter	O
and	O
drug	O
prescription	O
data	O
.	O
Four	O
controls	O
per	O
case	O
were	O
randomly	O
selected	O
,	O
matched	O
on	O
age	O
and	O
time	O
in	O
database	O
.	O
Odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
estimated	O
using	O
conditional	O
logistic	O
regression	O
.	O
RESULTS	O
:	O
Breast	O
cancer	O
risk	O
was	O
inversely	O
associated	O
with	O
both	O
non-specific	O
NSAID	O
and	O
selective	O
COX-2	S-GP
inhibitor	O
use	O
.	O
Greater	O
than	O
12	O
months	O
'	O
duration	O
of	O
use	O
of	O
Celecoxib	S-chemical
at	O
a	O
standard	O
dose	O
(	O
200mg/day	O
)	O
was	O
associated	O
with	O
a	O
16	O
%	O
decrease	O
in	O
breast	O
cancer	O
risk	O
(	O
OR=0.84	O
,	O
95	O
%	O
CI=0.73	O
,	O
0.97	O
)	O
.	O
We	O
observed	O
the	O
greatest	O
risk	O
reduction	O
in	O
association	O
with	O
>	O
2	O
years	O
of	O
rofecoxib	S-chemical
exposure	O
(	O
OR=0.54	O
,	O
95	O
%	O
CI=0.37	O
,	O
0.80	O
)	O
.	O
Acetaminophen	S-chemical
,	O
a	O
compound	O
with	O
less	O
biological	O
plausibility	O
for	O
chemoprevention	O
,	O
showed	O
no	O
significant	O
association	O
with	O
the	O
risk	O
of	O
developing	O
breast	O
cancer	O
.	O
CONCLUSION	O
:	O
Consistent	O
with	O
animal	O
models	O
and	O
laboratory	O
investigations	O
,	O
higher	O
doses	O
of	O
selective	O
COX-2	S-GP
inhibitors	O
were	O
more	O
protective	O
against	O
breast	O
cancer	O
than	O
non-specific	O
NSAIDs	O
.	O
With	O
exposure	O
to	O
rofecoxib	S-chemical
,	O
a	O
selective	O
COX-2	S-GP
inhibitor	O
,	O
breast	O
cancer	O
risk	O
reduction	O
was	O
appreciable	O
(	O
46	O
%	O
)	O
,	O
suggesting	O
a	O
possible	O
role	O
for	O
selective	O
COX-2	S-GP
inhibitors	O
in	O
breast	O
cancer	O
prophylaxis	O
.	O

Multiple	O
enzyme	O
inhibitions	O
by	O
histamine	B-GP
H3	I-GP
receptor	E-GP
antagonists	O
as	O
potential	O
procognitive	O
agents	O
.	O
Novel	O
highly	O
affine	O
histamine	B-GP
H3	I-GP
receptor	E-GP
ligands	O
with	O
additional	O
inhibitory	O
effects	O
on	O
the	O
main	O
histamine	S-chemical
metabolizing	O
enzyme	O
in	O
the	O
brain	O
,	O
N-methyltransferase	S-GP
,	O
chemically	O
show	O
structural	O
elements	O
of	O
the	O
acetylcholinesterase	S-GP
inhibitor	O
tacrine	S-chemical
.	O
H3	B-GP
receptor	E-GP
antagonism	O
,	O
inhibition	O
of	O
metabolisation	O
of	O
neuronal	O
histamine	S-chemical
as	O
well	O
as	O
inhibition	O
of	O
hydrolysis	O
of	O
acetylcholine	S-chemical
are	O
each	O
one	O
believed	O
to	O
improve	O
reduced	O
cognitive	O
functions	O
,	O
which	O
is	O
useful	O
for	O
symptomatic	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
.	O
Some	O
of	O
the	O
new	O
compounds	O
proved	O
in	O
a	O
slightly	O
modified	O
colorimetric	O
Ellmann	O
's	O
assay	O
to	O
be	O
potent	O
inhibitors	O
of	O
acetylcholinesterase	S-GP
and	O
of	O
butyrylcholinesterase	S-GP
which	O
is	O
another	O
catalytic	O
enzyme	O
hydrolysing	O
acetylcholine	S-chemical
.	O
Some	O
compounds	O
with	O
(	O
sub	O
)	O
nanomolar	O
activities	O
on	O
the	O
histamine	S-chemical
-related	O
targets	O
are	O
also	O
active	O
in	O
the	O
nanomolar	O
concentration	O
range	O
on	O
both	O
cholinesterase	S-GP
targets	O
being	O
5-	O
to	O
40-times	O
more	O
potent	O
than	O
tacrine	S-chemical
.	O
Preliminary	O
structure-activity	O
relationships	O
could	O
already	O
be	O
drawn	O
from	O
the	O
small	O
number	O
of	O
compounds	O
.	O
The	O
compounds	O
acting	O
as	O
hybrid	O
drugs	O
simultaneously	O
on	O
four	O
different	O
targets	O
to	O
enhance	O
cognitive	O
functions	O
via	O
different	O
pathways	O
are	O
promising	O
lead	O
structures	O
for	O
a	O
new	O
approach	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
.	O

The	O
synaptic	B-GP
vesicle	I-GP
protein	I-GP
SV2A	E-GP
is	O
the	O
binding	O
site	O
for	O
the	O
antiepileptic	O
drug	O
levetiracetam	S-chemical
.	O
Here	O
,	O
we	O
show	O
that	O
the	O
synaptic	B-GP
vesicle	I-GP
protein	I-GP
SV2A	E-GP
is	O
the	O
brain	O
binding	O
site	O
of	O
levetiracetam	S-chemical
(	O
LEV	S-chemical
)	O
,	O
a	O
new	O
antiepileptic	O
drug	O
with	O
a	O
unique	O
activity	O
profile	O
in	O
animal	O
models	O
of	O
seizure	O
and	O
epilepsy	O
.	O
The	O
LEV	S-chemical
-binding	O
site	O
is	O
enriched	O
in	O
synaptic	O
vesicles	O
,	O
and	O
photoaffinity	O
labeling	O
of	O
purified	O
synaptic	O
vesicles	O
confirms	O
that	O
it	O
has	O
an	O
apparent	O
molecular	O
mass	O
of	O
approximately	O
90	O
kDa	O
.	O
Brain	O
membranes	O
and	O
purified	O
synaptic	O
vesicles	O
from	O
mice	O
lacking	O
SV2A	S-GP
do	O
not	O
bind	O
a	O
tritiated	O
LEV	S-chemical
derivative	O
,	O
indicating	O
that	O
SV2A	S-GP
is	O
necessary	O
for	O
LEV	S-chemical
binding	O
.	O
LEV	S-chemical
and	O
related	O
compounds	O
bind	O
to	O
SV2A	S-GP
expressed	O
in	O
fibroblasts	O
,	O
indicating	O
that	O
SV2A	S-GP
is	O
sufficient	O
for	O
LEV	S-chemical
binding	O
.	O
No	O
binding	O
was	O
observed	O
to	O
the	O
related	O
isoforms	O
SV2B	S-GP
and	O
SV2C	S-GP
.	O
Furthermore	O
,	O
there	O
is	O
a	O
high	O
degree	O
of	O
correlation	O
between	O
binding	O
affinities	O
of	O
a	O
series	O
of	O
LEV	S-chemical
derivatives	O
to	O
SV2A	S-GP
in	O
fibroblasts	O
and	O
to	O
the	O
LEV	S-chemical
-binding	O
site	O
in	O
brain	O
.	O
Finally	O
,	O
there	O
is	O
a	O
strong	O
correlation	O
between	O
the	O
affinity	O
of	O
a	O
compound	O
for	O
SV2A	S-GP
and	O
its	O
ability	O
to	O
protect	O
against	O
seizures	O
in	O
an	O
audiogenic	O
mouse	O
animal	O
model	O
of	O
epilepsy	O
.	O
These	O
experimental	O
results	O
suggest	O
that	O
SV2A	S-GP
is	O
the	O
binding	O
site	O
of	O
LEV	S-chemical
in	O
the	O
brain	O
and	O
that	O
LEV	S-chemical
acts	O
by	O
modulating	O
the	O
function	O
of	O
SV2A	S-GP
,	O
supporting	O
previous	O
indications	O
that	O
LEV	S-chemical
possesses	O
a	O
mechanism	O
of	O
action	O
distinct	O
from	O
that	O
of	O
other	O
antiepileptic	O
drugs	O
.	O
Further	O
,	O
these	O
results	O
indicate	O
that	O
proteins	O
involved	O
in	O
vesicle	O
exocytosis	O
,	O
and	O
SV2	S-GP
in	O
particular	O
,	O
are	O
promising	O
targets	O
for	O
the	O
development	O
of	O
new	O
CNS	O
drug	O
therapies	O
.	O

Heparin-binding	O
exosite	O
of	O
factor	B-GP
Xa	E-GP
.	O
Recent	O
studies	O
have	O
indicated	O
that	O
the	O
basic	O
residues	O
Arg	S-chemical
(	O
93	O
)	O
,	O
Lys	S-chemical
(	O
96	O
)	O
,	O
Arg	S-chemical
(	O
125	O
)	O
,	O
Arg	S-chemical
(	O
165	O
)	O
,	O
Lys	S-chemical
(	O
169	O
)	O
,	O
Lys	S-chemical
(	O
236	O
)	O
,	O
and	O
Arg	S-chemical
(	O
240	O
)	O
(	O
chymotrypsin	S-GP
numbering	O
)	O
constitute	O
an	O
exosite	O
in	O
the	O
catalytic	O
domain	O
of	O
factor	B-GP
Xa	E-GP
that	O
can	O
effectively	O
bind	O
heparin	O
only	O
if	O
the	O
acidic	O
N-terminal	B-GP
Gla	I-GP
domain	E-GP
of	O
the	O
proteinase	S-GP
was	O
neutralized	O
by	O
physiological	O
levels	O
of	O
calcium	S-chemical
.	O
Binding	O
of	O
a	O
full-length	O
heparin	O
chain	O
to	O
this	O
site	O
of	O
factor	B-GP
Xa	E-GP
in	O
the	O
presence	O
of	O
calcium	S-chemical
makes	O
a	O
significant	O
contribution	O
to	O
acceleration	O
of	O
the	O
proteinase	S-GP
inhibition	O
by	O
antithrombin	S-GP
through	O
a	O
ternary	O
complex	O
bridging	O
or	O
template	O
mechanism	O
.	O
Moreover	O
,	O
certain	O
basic	O
residues	O
of	O
this	O
site	O
,	O
particularly	O
Arg	S-chemical
(	O
165	O
)	O
and	O
Lys	S-chemical
(	O
169	O
)	O
,	O
play	O
a	O
key	O
role	O
in	O
factor	B-GP
Va	E-GP
and/or	O
prothrombin	S-GP
recognition	O
by	O
factor	B-GP
Xa	E-GP
in	O
the	O
prothrombinase	O
complex	O
.	O
This	O
article	O
reviews	O
recent	O
structural	O
,	O
mutagenesis	O
and	O
kinetic	O
data	O
that	O
lead	O
to	O
identification	O
of	O
this	O
exosite	O
and	O
discusses	O
how	O
the	O
binding	O
of	O
protein	O
or	O
polysaccharide	O
cofactors	O
to	O
this	O
site	O
of	O
factor	B-GP
Xa	E-GP
can	O
modulate	O
the	O
specificity	O
and	O
physiological	O
function	O
of	O
this	O
key	O
coagulant	O
enzyme	O
in	O
plasma	O
.	O

Angiotensin	B-GP
AT1	I-GP
receptor	E-GP
antagonist	O
losartan	S-chemical
and	O
the	O
defence	O
reaction	O
in	O
the	O
anaesthetised	O
rat	O
.	O
Effect	O
on	O
the	O
carotid	O
chemoreflex	O
.	O
Modulation	O
at	O
the	O
level	O
of	O
the	O
nucleus	O
tractus	O
solitarii	O
(	O
NTS	O
)	O
appears	O
to	O
be	O
an	O
effective	O
way	O
of	O
controlling	O
cardiovascular	O
reflexes	O
.	O
Angiotensin	B-chemical
II	E-chemical
acting	O
on	O
angiotensin	B-GP
AT1	I-GP
receptors	E-GP
at	O
the	O
central	O
nervous	O
system	O
appears	O
to	O
have	O
an	O
important	O
role	O
in	O
these	O
modulatory	O
processes	O
.	O
The	O
hypothalamic	O
defence	O
area	O
(	O
HDA	O
)	O
is	O
a	O
potential	O
source	O
of	O
descending	O
fibres	O
containing	O
angiotensin	B-chemical
II	E-chemical
that	O
innervate	O
the	O
NTS	O
.	O
We	O
investigated	O
the	O
effect	O
of	O
AT1	B-GP
receptor	E-GP
blockade	O
in	O
the	O
NTS	O
on	O
the	O
response	O
to	O
stimulation	O
of	O
HDA	O
in	O
anaesthetised	O
rats	O
treated	O
with	O
the	O
neuromuscular	O
blocking	O
agent	O
pancuronium	B-chemical
bromide	E-chemical
.	O
The	O
characteristic	O
increase	O
in	O
heart	O
rate	O
,	O
blood	O
pressure	O
and	O
phrenic	O
nerve	O
activity	O
evoked	O
by	O
electrical	O
stimulation	O
of	O
HDA	O
is	O
decreased	O
by	O
the	O
microinjection	O
of	O
the	O
AT1	B-GP
receptor	E-GP
antagonist	O
losartan	O
into	O
the	O
NTS	O
and	O
the	O
cardiovascular	O
response	O
to	O
carotid	O
body	O
chemical	O
stimulation	O
is	O
also	O
reduced	O
.	O
These	O
results	O
support	O
the	O
hypothesis	O
that	O
AT1	B-GP
receptors	E-GP
in	O
the	O
NTS	O
play	O
a	O
role	O
in	O
the	O
modulation	O
of	O
cardiovascular	O
reflexes	O
,	O
and	O
modify	O
the	O
influence	O
exerted	O
on	O
the	O
processing	O
of	O
these	O
reflexes	O
by	O
other	O
areas	O
of	O
the	O
central	O
nervous	O
system	O
.	O

A	O
pilot	O
study	O
of	O
IL-1	S-GP
inhibition	O
by	O
anakinra	O
in	O
acute	O
gout	O
.	O
Monosodium	B-chemical
urate	E-chemical
crystals	O
stimulate	O
monocytes	O
and	O
macrophages	O
to	O
release	O
IL-1beta	S-GP
through	O
the	O
NALP3	S-GP
component	O
of	O
the	O
inflammasome	O
.	O
The	O
effectiveness	O
of	O
IL-1	S-GP
inhibition	O
in	O
hereditary	O
autoinflammatory	O
syndromes	O
with	O
mutations	O
in	O
the	O
NALP3	S-GP
protein	O
suggested	O
that	O
IL-1	S-GP
inhibition	O
might	O
also	O
be	O
effective	O
in	O
relieving	O
the	O
inflammatory	O
manifestations	O
of	O
acute	O
gout	O
.	O
The	O
effectiveness	O
of	O
IL-1	S-GP
inhibition	O
was	O
first	O
evaluated	O
in	O
a	O
mouse	O
model	O
of	O
monosodium	B-chemical
urate	E-chemical
crystal-induced	O
inflammation	O
.	O
IL-1	S-GP
inhibition	O
prevented	O
peritoneal	O
neutrophil	O
accumulation	O
but	O
TNF	S-GP
blockade	O
had	O
no	O
effect	O
.	O
Based	O
on	O
these	O
findings	O
,	O
we	O
performed	O
a	O
pilot	O
,	O
open-labeled	O
study	O
(	O
trial	O
registration	O
number	O
ISRCTN10862635	O
)	O
in	O
10	O
patients	O
with	O
gout	O
who	O
could	O
not	O
tolerate	O
or	O
had	O
failed	O
standard	O
antiinflammatory	O
therapies	O
.	O
All	O
patients	O
received	O
100	O
mg	O
anakinra	O
daily	O
for	O
3	O
days	O
.	O
All	O
10	O
patients	O
with	O
acute	O
gout	O
responded	O
rapidly	O
to	O
anakinra	O
.	O
No	O
adverse	O
effects	O
were	O
observed	O
.	O
IL-1	S-GP
blockade	O
appears	O
to	O
be	O
an	O
effective	O
therapy	O
for	O
acute	O
gouty	O
arthritis	O
.	O
The	O
clinical	O
findings	O
need	O
to	O
be	O
confirmed	O
in	O
a	O
controlled	O
study	O
.	O

T-Cells	O
from	O
HLA-B*57:01	S-GP
+	O
Human	O
Subjects	O
Are	O
Activated	O
with	O
Abacavir	S-chemical
through	O
Two	O
Independent	O
Pathways	O
and	O
Induce	O
Cell	O
Death	O
by	O
Multiple	O
Mechanisms	O
.	O
Susceptibility	O
to	O
abacavir	O
hypersensitivity	O
has	O
been	O
attributed	O
to	O
possession	O
of	O
the	O
specific	O
human	B-GP
leukocyte	I-GP
antigen	I-GP
allele	I-GP
HLA-B*57:01	E-GP
.	O
HLA-B*57:01	S-GP
-restricted	O
activation	O
of	O
CD8+	O
T-cells	O
provides	O
a	O
link	O
between	O
the	O
genetic	O
association	O
and	O
the	O
iatrogenic	O
disease	O
.	O
The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
characterize	O
the	O
functionality	O
of	O
drug-responsive	O
CD8+	O
T-cell	O
clones	O
generated	O
from	O
HLA-B*57:01	S-GP
+	O
drug-naive	O
subjects	O
and	O
to	O
explore	O
the	O
relationship	O
between	O
abacavir	S-chemical
accumulation	O
in	O
antigen	O
presenting	O
cells	O
and	O
the	O
T-cell	O
response	O
.	O
Seventy-four	O
CD8+	O
clones	O
expressing	O
different	O
Vβ	B-GP
receptors	E-GP
were	O
shown	O
to	O
proliferate	O
and	O
kill	O
target	O
cells	O
via	O
different	O
mechanisms	O
when	O
exposed	O
to	O
abacavir	S-chemical
.	O
Certain	O
clones	O
were	O
activated	O
with	O
abacavir	S-chemical
in	O
the	O
absence	O
of	O
antigen	O
presenting	O
cells	O
.	O
Analysis	O
of	O
the	O
remaining	O
clones	O
revealed	O
two	O
pathways	O
of	O
drug-dependent	O
T-cell	O
activation	O
.	O
Overnight	O
incubation	O
of	O
antigen	O
presenting	O
cells	O
with	O
abacavir	S-chemical
,	O
followed	O
by	O
repeated	O
washing	O
to	O
remove	O
soluble	O
drug	O
,	O
activated	O
approximately	O
50	O
%	O
of	O
the	O
clones	O
,	O
and	O
the	O
response	O
was	O
blocked	O
by	O
glutaraldehyde	S-chemical
fixation	O
.	O
In	O
contrast	O
,	O
a	O
1	O
h	O
antigen	O
presenting	O
cell	O
pulse	O
did	O
not	O
activate	O
any	O
of	O
the	O
clones	O
.	O
Accumulation	O
of	O
abacavir	S-chemical
in	O
antigen	O
presenting	O
cells	O
was	O
rapid	O
(	O
less	O
than	O
1	O
h	O
)	O
,	O
and	O
the	O
intracellular	O
concentrations	O
were	O
maintained	O
for	O
16	O
h.	O
However	O
,	O
intracellular	O
abacavir	S-chemical
was	O
not	O
detectable	O
by	O
mass	O
spectrometry	O
after	O
pulsing	O
.	O
These	O
data	O
suggest	O
that	O
T-cells	O
can	O
be	O
activated	O
by	O
abacavir	S-chemical
through	O
a	O
direct	O
interaction	O
with	O
surface	O
and	O
intracellular	O
major	B-GP
histocompatibility	I-GP
complex	E-GP
(	O
MHC	S-GP
)	O
molecules	O
.	O
With	O
the	O
former	O
,	O
abacavir	S-chemical
seemingly	O
participates	O
in	O
the	O
MHC	S-GP
T-cell	B-GP
receptor	E-GP
binding	O
interaction	O
.	O
In	O
contrast	O
,	O
the	O
latter	O
pathway	O
likely	O
involves	O
MHC	S-GP
binding	O
peptides	O
displayed	O
as	O
a	O
consequence	O
of	O
abacavir	S-chemical
exposure	O
,	O
but	O
not	O
abacavir	S-chemical
itself	O
.	O

Sulfonylureas	S-chemical
and	O
glinides	S-chemical
exhibit	O
peroxisome	B-GP
proliferator-activated	I-GP
receptor	I-GP
gamma	E-GP
activity	O
:	O
a	O
combined	O
virtual	O
screening	O
and	O
biological	O
assay	O
approach	O
.	O
Most	O
drugs	O
currently	O
employed	O
in	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
either	O
target	O
the	O
sulfonylurea	B-GP
receptor	E-GP
stimulating	O
insulin	S-GP
release	O
(	O
sulfonylureas	S-chemical
,	O
glinides	S-chemical
)	O
,	O
or	O
target	O
the	O
peroxisome	B-GP
proliferator-activated	I-GP
receptor	E-GP
(	O
PPARgamma	S-GP
)	O
improving	O
insulin	S-GP
resistance	O
(	O
thiazolidinediones	S-chemical
)	O
.	O
Our	O
work	O
shows	O
that	O
sulfonylureas	S-chemical
and	O
glinides	S-chemical
additionally	O
bind	O
to	O
PPARgamma	S-GP
and	O
exhibit	O
PPARgamma	S-GP
agonistic	O
activity	O
.	O
This	O
activity	O
was	O
predicted	O
in	O
silico	O
by	O
virtual	O
screening	O
and	O
confirmed	O
in	O
vitro	O
in	O
a	O
binding	O
assay	O
,	O
a	O
transactivation	O
assay	O
,	O
and	O
by	O
measuring	O
the	O
expression	O
of	O
PPARgamma	S-GP
target	O
genes	O
.	O
Among	O
the	O
measured	O
compounds	O
,	O
gliquidone	S-chemical
and	O
glipizide	S-chemical
(	O
two	O
sulfonylureas	S-chemical
)	O
,	O
as	O
well	O
as	O
nateglinide	S-chemical
(	O
a	O
glinide	S-chemical
)	O
,	O
exhibit	O
PPARgamma	S-GP
agonistic	O
activity	O
at	O
concentrations	O
comparable	O
with	O
those	O
reached	O
under	O
pharmacological	O
treatment	O
.	O
The	O
most	O
active	O
of	O
these	O
compounds	O
,	O
gliquidone	S-chemical
,	O
is	O
shown	O
to	O
be	O
as	O
potent	O
as	O
pioglitazone	S-chemical
at	O
inducing	O
PPARgamma	S-GP
target	O
gene	O
expression	O
.	O
This	O
dual	O
mode	O
of	O
action	O
of	O
sulfonylureas	S-chemical
and	O
glinides	S-chemical
may	O
open	O
new	O
perspectives	O
for	O
the	O
molecular	O
pharmacology	O
of	O
antidiabetic	O
drugs	O
,	O
because	O
it	O
provides	O
evidence	O
that	O
drugs	O
can	O
be	O
designed	O
that	O
target	O
both	O
the	O
sulfonylurea	B-GP
receptor	E-GP
and	O
PPARgamma	S-GP
.	O
Targeting	O
both	O
receptors	O
could	O
increase	O
pancreatic	O
insulin	S-GP
secretion	O
and	O
improve	O
insulin	S-GP
resistance	O
.	O
Glinides	S-chemical
,	O
sulfonylureas	S-chemical
,	O
and	O
other	O
acidified	B-chemical
sulfonamides	E-chemical
may	O
be	O
promising	O
leads	O
in	O
the	O
development	O
of	O
new	O
PPARgamma	S-GP
agonists	O
.	O
In	O
addition	O
,	O
we	O
provide	O
a	O
unified	O
concept	O
of	O
the	O
PPARgamma	S-GP
binding	O
ability	O
of	O
seemingly	O
disparate	O
compound	O
classes	O
.	O

Evaluation	O
of	O
body	O
weight	O
,	O
insulin	S-GP
resistance	O
,	O
leptin	S-GP
and	O
adiponectin	S-GP
levels	O
in	O
premenopausal	O
women	O
with	O
hyperprolactinemia	O
.	O
The	O
effects	O
of	O
hyperprolactinemia	O
on	O
metabolic	O
parameters	O
are	O
not	O
clear	O
and	O
a	O
few	O
data	O
evaluating	O
adiponectin	S-GP
levels	O
in	O
prolactinoma	O
and	O
idiopathic	O
hyperprolactinemia	O
exist	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
hyperprolactinemia	O
on	O
body	O
weight	O
,	O
insulin	O
resistance	O
,	O
beta	O
cell	O
function	O
,	O
and	O
leptin	S-GP
and	O
adiponectin	S-GP
levels	O
in	O
premenopausal	O
women	O
with	O
hyperprolactinemia	O
.	O
Forty	O
premenopausal	O
women	O
with	O
prolactinoma	O
or	O
idiopathic	O
hyperprolactinemia	O
were	O
compared	O
to	O
41	O
age-matched	O
healthy	O
premenopausal	O
women	O
with	O
regard	O
to	O
body	O
weight	O
,	O
body	O
mass	O
index	O
,	O
waist	O
and	O
hip	O
circumferences	O
,	O
waist	O
to	O
hip	O
ratio	O
,	O
fasting	O
plasma	O
glucose	S-chemical
,	O
insulin	S-GP
levels	O
,	O
insulin	S-GP
resistance	O
measured	O
by	O
homeostasis	O
model	O
assessment	O
(	O
HOMA	O
)	O
-	O
insulin	S-GP
resistance	O
index	O
,	O
beta	O
cell	O
function	O
measured	O
by	O
HOMA-β	O
index	O
,	O
leptin	S-GP
and	O
adiponectin	S-GP
levels	O
.	O
Plasma	O
insulin	S-GP
levels	O
and	O
HOMA	O
indexes	O
(	O
both	O
insulin	S-GP
resistance	O
and	O
beta	O
indexes	O
)	O
were	O
significantly	O
higher	O
in	O
hyper	O
prolactin	S-GP
emic	O
women	O
.	O
The	O
other	O
parameters	O
were	O
similar	O
between	O
both	O
groups	O
.	O
There	O
was	O
a	O
positive	O
correlation	O
between	O
prolactin	O
levels	O
and	O
fasting	O
plasma	O
glucose	S-chemical
in	O
hyper	O
prolactin	S-GP
emic	O
women	O
.	O
The	O
results	O
of	O
this	O
study	O
showed	O
that	O
high	O
prolactin	O
levels	O
may	O
be	O
associated	O
with	O
hyper	O
insulin	S-GP
emia	O
and	O
insulin	O
resistance	O
in	O
premenopausal	O
women	O
.	O
This	O
effect	O
seems	O
to	O
be	O
independent	O
of	O
body	O
weight	O
,	O
leptin	S-GP
and	O
adiponectin	S-GP
levels	O
.	O
High	O
prolactin	S-GP
levels	O
may	O
directly	O
stimulate	O
insulin	S-GP
secretion	O
from	O
pancreas	O
and	O
directly	O
cause	O
hepatic	O
and	O
whole-body	O
insulin	S-GP
resistance	O
.	O

Activation	O
of	O
cytoprotective	O
prostaglandin	B-GP
synthase-1	E-GP
by	O
minoxidil	S-chemical
as	O
a	O
possible	O
explanation	O
for	O
its	O
hair	O
growth-stimulating	O
effect	O
.	O
Data	O
from	O
the	O
literature	O
indicate	O
that	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
such	O
as	O
indomethacin	S-chemical
,	O
naproxen	S-chemical
,	O
piroxicam	S-chemical
,	O
or	O
ibuprofen	S-chemical
,	O
induce	O
hair	O
loss	O
in	O
vivo	O
.	O
These	O
NSAIDs	O
are	O
well-known	O
inhibitors	O
of	O
both	O
the	O
cytoprotective	O
isoform	O
of	O
prostaglandin	B-GP
endoperoxide	I-GP
synthase-1	E-GP
(	O
PGHS-1	S-GP
)	O
and	O
of	O
the	O
inducible	O
form	O
(	O
PGHS-2	S-GP
)	O
.	O
By	O
immunohistochemical	O
staining	O
,	O
we	O
found	O
that	O
PGHS-1	S-GP
is	O
the	O
main	O
isoform	O
present	O
in	O
the	O
dermal	O
papilla	O
from	O
normal	O
human	O
hair	O
follicle	O
(	O
either	O
anagen	O
or	O
catagen	O
)	O
,	O
whereas	O
PGHS-2	S-GP
was	O
only	O
faintly	O
and	O
exclusively	O
expressed	O
in	O
anagen	O
dermal	O
papilla	O
.	O
Thus	O
,	O
PGHS-1	S-GP
might	O
be	O
the	O
primary	O
target	O
of	O
the	O
hair	O
growth-inhibitory	O
effects	O
of	O
NSAIDs	O
.	O
We	O
thus	O
speculated	O
that	O
activation	O
of	O
PGHS-1	S-GP
might	O
be	O
a	O
mechanism	O
by	O
which	O
minoxidil	S-chemical
(	O
2,4-diamino-6-piperidinopyrimidine-3-oxyde	S-chemical
)	O
stimulates	O
hair	O
growth	O
in	O
vivo	O
.	O
We	O
demonstrate	O
here	O
that	O
minoxidil	S-chemical
is	O
a	O
potent	O
activator	O
of	O
purified	O
PGHS-1	S-GP
(	O
AC50	O
=	O
80	O
microM	O
)	O
,	O
as	O
assayed	O
by	O
oxygen	S-chemical
consumption	O
and	O
PGE2	O
production	O
.	O
This	O
activation	O
was	O
also	O
evidenced	O
by	O
increased	O
PGE2	O
production	O
by	O
BALB/c	O
3T3	O
fibroblasts	O
and	O
by	O
human	O
dermal	O
papilla	O
fibroblasts	O
in	O
culture	O
.	O
Our	O
findings	O
suggest	O
that	O
minoxidil	S-chemical
and	O
its	O
derivatives	O
may	O
have	O
a	O
cytoprotective	O
activity	O
in	O
vivo	O
and	O
that	O
more	O
potent	O
second-generation	O
hair	O
growth-promoting	O
drugs	O
might	O
be	O
designed	O
,	O
based	O
on	O
this	O
mechanism	O
.	O

Structure	O
prediction	O
of	O
binary	O
pernitride	S-chemical
MN2	S-chemical
compounds	O
(	O
M=	O
Ca	S-chemical
,	O
Sr	S-chemical
,	O
Ba	S-chemical
,	O
La	S-chemical
,	O
and	O
Ti	S-chemical
)	O
.	O
Metal-pernitride	S-chemical
compounds	O
belong	O
to	O
a	O
class	O
of	O
chemical	O
systems	O
in	O
which	O
both	O
the	O
complex	O
ions	O
and	O
the	O
non-bonding	O
electrons	O
may	O
play	O
roles	O
in	O
the	O
formation	O
of	O
their	O
modified	O
crystalline	O
structures	O
.	O
To	O
investigate	O
this	O
issue	O
,	O
the	O
energy	O
landscapes	O
of	O
pernitrides	S-chemical
of	O
metals	O
with	O
different	O
maximum	O
valence	O
(	O
M=	O
Ca	S-chemical
,	O
Sr	S-chemical
,	O
Ba	S-chemical
,	O
La	S-chemical
,	O
and	O
Ti	S-chemical
)	O
were	O
globally	O
explored	O
on	O
the	O
ab	O
initio	O
level	O
at	O
standard	O
and	O
high	O
pressures	O
,	O
thereby	O
yielding	O
possible	O
(	O
meta	O
)	O
stable	O
modifications	O
in	O
these	O
systems	O
together	O
with	O
information	O
on	O
how	O
the	O
landscape	O
changed	O
as	O
function	O
of	O
the	O
valence	O
of	O
the	O
metal	O
cation	O
.	O
For	O
all	O
of	O
the	O
systems	O
in	O
which	O
no	O
compounds	O
had	O
been	O
synthesized	O
so	O
far	O
,	O
we	O
predicted	O
the	O
existence	O
of	O
kinetically	O
stable	O
modifications	O
that	O
should	O
,	O
in	O
principle	O
,	O
be	O
experimentally	O
accessible	O
.	O
In	O
particular	O
,	O
TiN2	S-chemical
should	O
crystallize	O
in	O
a	O
new	O
structure	O
type	O
,	O
TiN2	S-chemical
-I	O
.	O

Population	O
pharmacokinetics	O
of	O
atorvastatin	S-chemical
and	O
its	O
active	O
metabolites	O
in	O
children	O
and	O
adolescents	O
with	O
heterozygous	O
familial	O
hypercholesterolemia	O
:	O
selective	O
use	O
of	O
informative	O
prior	O
distributions	O
from	O
adults	O
.	O
The	O
population	O
pharmacokinetics	O
(	O
PPK	O
)	O
of	O
atorvastatin	S-chemical
and	O
its	O
principal	O
active	O
metabolite	O
,	O
o-hydroxyatorvastatin	S-chemical
,	O
were	O
described	O
in	O
6-17	O
years	O
old	O
pediatric	O
hypercholesterolemia	O
patients	O
with	O
a	O
2-compartment	O
model	O
for	O
both	O
parent	O
and	O
metabolite	O
.	O
Informative	O
prior	O
distributions	O
on	O
selected	O
parameters	O
,	O
based	O
on	O
adult	O
data	O
,	O
were	O
required	O
to	O
stabilize	O
the	O
model	O
and	O
were	O
implemented	O
using	O
a	O
Bayesian	O
penalty	O
term	O
on	O
the	O
likelihood	O
function	O
in	O
the	O
nonlinear	O
mixed	O
effects	O
model	O
(	O
NONMEM	O
VI	O
with	O
PRIOR	O
)	O
.	O
Concentrations	O
below	O
the	O
limit	O
of	O
quantitation	O
were	O
treated	O
as	O
censored	O
data	O
using	O
a	O
conditional	O
likelihood	O
function	O
.	O
Atorvastatin	S-chemical
apparent	O
oral	O
clearance	O
(	O
CL/F	O
)	O
was	O
described	O
as	O
a	O
function	O
of	O
body	O
weight	O
using	O
an	O
allometric	O
equation	O
.	O
Based	O
on	O
the	O
final	O
model	O
,	O
the	O
typical	O
CL/F	O
estimates	O
for	O
a	O
Tanner	O
Stage	O
1	O
patient	O
(	O
35	O
kg	O
weight	O
)	O
and	O
Tanner	O
Stage	O
≥2	O
(	O
50	O
kg	O
weight	O
)	O
,	O
would	O
be	O
553	O
and	O
543	O
L/hour	O
,	O
respectively	O
.	O
When	O
scaled	O
allometrically	O
,	O
CL/F	O
was	O
similar	O
to	O
values	O
reported	O
for	O
adults	O
.	O
Variability	O
in	O
atorvastatin	S-chemical
PK	O
was	O
primarily	O
affected	O
by	O
weight	O
.	O

Chemical	O
assessment	O
and	O
antioxidant	O
capacity	O
of	O
pepper	O
(	O
Capsicum	O
annuum	O
L.	O
)	O
seeds	O
.	O
Capsicum	O
annuum	O
L.	O
is	O
reported	O
to	O
be	O
the	O
most	O
widely	O
cultivated	O
species	O
.	O
Recently	O
,	O
waste	O
of	O
vegetable	O
processing	O
,	O
like	O
seeds	O
,	O
has	O
been	O
the	O
subject	O
of	O
many	O
studies	O
as	O
an	O
attempt	O
to	O
find	O
new	O
,	O
alternative	O
and	O
cheap	O
resources	O
of	O
bioactive	O
compounds	O
with	O
application	O
in	O
several	O
industries	O
.	O
Despite	O
their	O
chemical	O
,	O
biological	O
and	O
ecological	O
importance	O
,	O
C.	O
annuum	O
seeds	O
are	O
still	O
poorly	O
studied	O
.	O
To	O
improve	O
the	O
knowledge	O
on	O
the	O
metabolic	O
profile	O
of	O
this	O
matrix	O
,	O
a	O
targeted	O
metabolite	O
analysis	O
was	O
performed	O
in	O
``	O
sweet	O
Italian	O
''	O
and	O
``	O
Reus	O
long	O
pairal	O
''	O
pepper	O
seeds	O
.	O
Sterols	S-chemical
,	O
triterpenes	S-chemical
,	O
organic	O
acids	O
,	O
fatty	B-chemical
acids	E-chemical
and	O
volatile	O
compounds	O
were	O
determined	O
by	O
different	O
chromatographic	O
methods	O
.	O
The	O
antioxidant	O
activity	O
was	O
assessed	O
against	O
DPPH	B-chemical
(	I-chemical
·	I-chemical
)	E-chemical
,	O
superoxide	S-chemical
and	O
nitric	B-chemical
oxide	E-chemical
radicals	O
.	O
A	O
concentration-dependent	O
activity	O
was	O
noticed	O
against	O
all	O
radicals	O
.	O
Acetylcholinesterase	S-GP
inhibitory	O
capacity	O
was	O
also	O
evaluated	O
,	O
but	O
no	O
effect	O
was	O
found	O
.	O
Data	O
provide	O
evidence	O
of	O
great	O
similarities	O
between	O
``	O
sweet	O
Italian	O
''	O
and	O
``	O
Reus	O
long	O
pairal	O
''	O
pepper	O
seeds	O
.	O
The	O
present	O
study	O
indicates	O
that	O
C.	O
annuum	O
seeds	O
are	O
a	O
potential	O
source	O
of	O
valuable	O
bioactive	O
compounds	O
that	O
could	O
be	O
used	O
in	O
food	O
industry	O
.	O

Alpha	B-GP
1-adrenoceptor	E-GP
subtypes	O
mediating	O
the	O
regulation	O
and	O
modulation	O
of	O
Ca2+	S-chemical
sensitization	O
in	O
rabbit	O
thoracic	O
aorta	O
.	O
Norepinephrine	S-chemical
(	O
10	O
microM	O
)	O
,	O
methoxamine	S-chemical
(	O
100	O
microM	O
)	O
and	O
clonidine	S-chemical
(	O
100	O
microM	O
)	O
with	O
guanosine	B-chemical
5'-triphosphate	E-chemical
(	O
GTP	O
,	O
50	O
microM	O
)	O
or	O
guanosine	B-chemical
5'-O-	I-chemical
(	I-chemical
3-thiotriphosphate	I-chemical
)	E-chemical
(	O
GTP	B-chemical
gamma-S	E-chemical
,	O
10	O
microM	O
)	O
all	O
significantly	O
enhanced	O
the	O
contraction	O
induced	O
by	O
0.3	O
microM	O
Ca2+	S-chemical
(	O
pCa6.5	O
)	O
in	O
beta-escin-skinned	O
smooth	O
muscle	O
of	O
rabbit	O
thoracic	O
aorta	O
.	O
The	O
enhancement	O
of	O
Ca2+	S-chemical
contraction	O
produced	O
by	O
norepinephrine	S-chemical
was	O
greater	O
than	O
that	O
produced	O
by	O
methoxamine	S-chemical
or	O
clonidine	S-chemical
.	O
In	O
beta-escin-skinned	O
strips	O
of	O
chloroethylclonidine	S-chemical
-pretreated	O
smooth	O
muscle	O
,	O
the	O
enhancement	O
of	O
Ca2+	S-chemical
contraction	O
produced	O
by	O
norepinephrine	S-chemical
was	O
significantly	O
decreased	O
,	O
whereas	O
the	O
amplitude	O
was	O
the	O
same	O
as	O
that	O
produced	O
by	O
methoxamine	S-chemical
or	O
clonidine	S-chemical
;	O
this	O
enhancement	O
was	O
inhibited	O
by	O
the	O
selective	O
alpha	B-GP
1A-adrenoceptor	E-GP
antagonist	O
WB	B-chemical
4101	E-chemical
(	O
100	O
nM	O
)	O
.	O
The	O
enhancement	O
of	O
Ca2+	S-chemical
contraction	O
produced	O
by	O
methoxamine	S-chemical
and	O
clonidine	S-chemical
was	O
not	O
affected	O
by	O
chloroethylclonidine	S-chemical
pretreatment	O
.	O
The	O
effects	O
of	O
methoxamine	S-chemical
,	O
clonidine	S-chemical
and	O
norepinephrine	S-chemical
in	O
the	O
chloroethylclonidine	S-chemical
-pretreated	O
tissue	O
were	O
all	O
inhibited	O
by	O
guanosine	B-chemical
5'-O-	I-chemical
(	I-chemical
2-thiodiphosphate	I-chemical
)	E-chemical
(	O
GDP	B-chemical
beta-S	E-chemical
,	O
1	O
mM	O
)	O
and	O
1-	B-chemical
(	I-chemical
5-isoquinolinylsulfonyl	I-chemical
)	I-chemical
-methylpiperazine	E-chemical
(	O
H-7	O
,	O
20	O
microM	O
)	O
.	O
Furthermore	O
,	O
the	O
phosphorylation	O
of	O
myosin	B-GP
light	I-GP
chain	E-GP
produced	O
by	O
norepinephrine	S-chemical
was	O
greater	O
than	O
that	O
produced	O
by	O
clonidine	S-chemical
.	O
These	O
results	O
suggest	O
that	O
both	O
alpha	B-GP
1-adrenoceptor	I-GP
subtypes	I-GP
(	I-GP
alpha	I-GP
1A	I-GP
and	I-GP
alpha	I-GP
1B	E-GP
)	O
increase	O
the	O
Ca2+	S-chemical
sensitivity	O
of	O
contractile	O
elements	O
,	O
and	O
that	O
the	O
Ca2+	S-chemical
sensitization	O
produced	O
by	O
alpha	B-GP
1A-subtype	I-GP
receptors	E-GP
is	O
mediated	O
through	O
G-protein	S-GP
and	O
protein	B-GP
kinase	I-GP
C	E-GP
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
contraction	O
of	O
smooth	O
muscle	O
of	O
rabbit	O
thoracic	O
aorta	O
.	O

The	O
scintigraphic	O
evaluation	O
and	O
genetic	O
correlation	O
of	O
joint	O
involvements	O
in	O
pediatric	O
patients	O
with	O
familial	O
Mediterranean	O
fever	O
.	O
Purpose	O
:	O
We	O
aimed	O
to	O
evaluate	O
the	O
articular	O
involvements	O
in	O
pediatric	O
patients	O
with	O
familial	O
Mediterranean	O
fever	O
(	O
FMF	O
)	O
with	O
joint	O
symptoms	O
by	O
bone	O
scintigraphy	O
and	O
to	O
correlate	O
the	O
involved	O
joints	O
with	O
the	O
gene	O
mutations	O
.	O
Materials	O
and	O
methods	O
:	O
A	O
total	O
of	O
41	O
newly	O
diagnosed	O
patients	O
in	O
pediatric	O
age	O
group	O
(	O
28	O
girls	O
and	O
13	O
boys	O
;	O
mean	O
age	O
9.14	O
±	O
2.91	O
years	O
)	O
with	O
joint	O
involvement	O
symptoms	O
were	O
included	O
in	O
this	O
study	O
.	O
Scintigraphic	O
images	O
were	O
obtained	O
at	O
5th	O
min	O
(	O
blood	O
pool	O
or	O
early	O
phase	O
)	O
and	O
starting	O
at	O
3	O
h	O
(	O
late	O
phase	O
)	O
after	O
(	O
after	O
tracer	O
injection	O
)	O
intravenous	O
administration	O
of	O
technetium-99m	S-chemical
(	O
99mTc	S-chemical
)	O
-	O
methylendiphosphonate	S-chemical
(	O
MDP	S-chemical
)	O
.	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
leukocytes	O
using	O
standard	O
salting	O
out	O
procedure	O
.	O
The	O
sequencing	O
data	O
were	O
analyzed	O
.	O
Results	O
:	O
Of	O
the	O
41	O
patients	O
,	O
arthritis	O
was	O
found	O
in	O
21	O
(	O
51.2	O
%	O
)	O
patients	O
.	O
Of	O
the	O
21	O
patients	O
,	O
there	O
was	O
single	O
joint	O
involvement	O
in	O
15	O
(	O
71.4	O
%	O
)	O
patients	O
and	O
multiple	O
joint	O
involvement	O
in	O
six	O
(	O
28.6	O
%	O
)	O
patients	O
.	O
The	O
mean	O
age	O
of	O
patients	O
with	O
joint	O
involvement	O
(	O
8	O
±	O
2.3	O
years	O
)	O
were	O
considerably	O
lower	O
than	O
the	O
patients	O
without	O
joint	O
involvement	O
(	O
10.35	O
±	O
3.04	O
years	O
)	O
,	O
and	O
this	O
was	O
statistically	O
significant	O
(	O
p	O
=	O
0.008	O
)	O
.	O
The	O
most	O
commonly	O
involved	O
joints	O
were	O
ankles	O
and	O
knees	O
.	O
Multiple	O
joint	O
involvements	O
were	O
most	O
frequently	O
observed	O
in	O
the	O
M694V	S-GP
and	O
M694I	S-GP
gene	O
mutations	O
(	O
16.7	O
%	O
)	O
.	O
Conclusions	O
:	O
We	O
use	O
and	O
recommend	O
the	O
bone	O
scintigraphy	O
in	O
patients	O
with	O
FMF	O
to	O
determine	O
the	O
presence	O
and	O
distribution	O
of	O
arthritis	O
,	O
since	O
bone	O
scintigraphy	O
is	O
inexpensive	O
,	O
noninvasive	O
,	O
easy-to-use	O
,	O
and	O
also	O
is	O
more	O
sensitive	O
in	O
the	O
diagnosis	O
and	O
distribution	O
of	O
arthritis	O
than	O
conventional	O
radiological	O
methods	O
and	O
clinical	O
examination	O
.	O

In	O
vitro	O
permeability	O
analysis	O
,	O
pharmacokinetic	O
and	O
brain	O
distribution	O
study	O
in	O
mice	O
of	O
imperatorin	S-chemical
,	O
isoimperatorin	S-chemical
and	O
cnidilin	S-chemical
in	O
Radix	O
Angelicae	O
Dahuricae	O
.	O
Coumarins	S-chemical
are	O
important	O
constituents	O
of	O
Radix	O
Angelicae	O
Dahuricae	O
,	O
a	O
well-known	O
traditional	O
Chinese	O
medicine	O
possess	O
several	O
known	O
bioactivities	O
with	O
potentials	O
in	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
diseases	O
.	O
By	O
using	O
an	O
HPLC-MS/MS	O
method	O
,	O
we	O
analyzed	O
the	O
in	O
vivo	O
plasma	O
and	O
brain	O
pharmacokinetics	O
of	O
three	O
ingredients	O
of	O
coumarins	S-chemical
,	O
including	O
imperatorin	S-chemical
,	O
isoimperatorin	S-chemical
and	O
cnidilin	S-chemical
in	O
mice	O
after	O
oral	O
administration	O
of	O
Dahuricae	O
extract	O
at	O
doses	O
of	O
800mg/kg	O
.	O
The	O
biosamples	O
were	O
prepared	O
using	O
acetonitrile	S-chemical
precipitation	O
and	O
the	O
separation	O
was	O
achieved	O
on	O
an	O
XDB-C18	O
column	O
by	O
gradient	O
elution	O
.	O
The	O
BBB	O
permeability	O
and	O
P-gp	S-GP
-mediated	O
efflux	O
were	O
further	O
examined	O
in	O
Madin	O
Canine	O
kidney	O
cells	O
transfected	O
with	O
full	O
length	O
cDNA	O
for	O
human	B-GP
multidrug	I-GP
resistance	I-GP
gene1	E-GP
(	O
MDCKII-	O
MDR1	S-GP
)	O
.	O
Our	O
results	O
demonstrate	O
that	O
the	O
method	O
has	O
excellent	O
and	O
satisfactory	O
selectivity	O
,	O
sensitivity	O
,	O
linearity	O
,	O
precision	O
,	O
and	O
accuracy	O
for	O
simultaneous	O
determination	O
of	O
imperatorin	S-chemical
,	O
isoimperatorin	S-chemical
and	O
cnidilin	S-chemical
.	O
The	O
pharmacokinetics	O
parameters	O
were	O
determined	O
by	O
using	O
noncompartmental	O
analyses	O
,	O
including	O
the	O
AUC	O
(	O
0-t	O
)	O
in	O
plasma	O
(	O
1695.22	O
,	O
1326.45	O
and	O
636.98mg*h/L	O
)	O
,	O
the	O
AUC	O
(	O
0-t	O
)	O
in	O
brain	O
(	O
1812.35	O
,	O
2125.17	O
and	O
1145.83ng*h/g	O
)	O
as	O
well	O
as	O
the	O
T1/2	O
in	O
plasma	O
(	O
0.66	O
,	O
0.82	O
,	O
0.97h	O
)	O
and	O
brain	O
(	O
0.96	O
,	O
1.1	O
,	O
0.99h	O
)	O
for	O
imperatorin	S-chemical
,	O
isoimperatorin	S-chemical
and	O
cnidilin	S-chemical
,	O
respectively	O
,	O
suggesting	O
that	O
the	O
three	O
coumarins	S-chemical
could	O
easily	O
pass	O
through	O
the	O
BBB	O
in	O
vivo	O
.	O
In	O
the	O
in	O
vitro	O
model	O
we	O
observed	O
high	O
permeability	O
of	O
imperatorin	S-chemical
and	O
isoimperatorin	S-chemical
with	O
the	O
P-gp	S-GP
-mediated	O
efflux	O
ratios	O
of	O
0.53	O
and	O
0.06	O
,	O
as	O
well	O
as	O
medium	O
permeability	O
of	O
cnidilin	S-chemical
with	O
0.82	O
.	O
All	O
data	O
suggest	O
that	O
these	O
three	O
coumarins	S-chemical
have	O
high	O
BBB	O
permeability	O
and	O
have	O
pharmacokinetic	O
potentials	O
for	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
diseases	O
.	O

Intrauterine	O
pressure	O
,	O
ischemia	O
markers	O
,	O
and	O
experienced	O
pain	O
during	O
administration	O
of	O
a	O
vasopressin	B-GP
V1a	I-GP
receptor	E-GP
antagonist	O
in	O
spontaneous	O
and	O
vasopressin	S-chemical
-induced	O
dysmenorrhea	O
.	O
BACKGROUND	O
:	O
A	O
model	O
to	O
study	O
the	O
effect	O
of	O
vasopressin	B-GP
V1a	E-GP
antagonist	O
in	O
dysmenorrhea	O
.	O
METHODS	O
:	O
A	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
,	O
cross-over	O
trial	O
was	O
performed	O
.	O
Eight	O
patients	O
with	O
primary	O
dysmenorrhea	O
and	O
eight	O
tuballigated	O
,	O
healthy	O
subjects	O
participated	O
on	O
days	O
1-2	O
of	O
two	O
consecutive	O
menstruations	O
.	O
At	O
each	O
menstruation	O
a	O
bolus	O
injection	O
of	O
10	O
pmol/kg	O
of	O
vasopressin	S-GP
was	O
administered	O
before	O
and	O
during	O
infusion	O
of	O
either	O
300	O
microg/min	O
of	O
atosiban	S-chemical
or	O
placebo	O
.	O
Intrauterine	O
pressure	O
was	O
measured	O
as	O
area	O
under	O
the	O
curve	O
throughout	O
the	O
experiments	O
.	O
Ischemia	O
markers	O
in	O
plasma	O
and	O
pain	O
recorded	O
by	O
a	O
visual	O
analog	O
scale	O
were	O
measured	O
before	O
and	O
after	O
each	O
vasopressin	S-chemical
injection	O
as	O
well	O
as	O
before	O
and	O
after	O
the	O
start	O
of	O
either	O
atosiban	S-chemical
or	O
placebo	O
infusion	O
.	O
RESULTS	O
:	O
Vasopressin	S-chemical
injections	O
elevated	O
area	O
under	O
the	O
curve	O
in	O
both	O
healthy	O
volunteers	O
and	O
dysmenorrhea	O
subjects	O
.	O
The	O
vasopressin	S-chemical
-induced	O
rise	O
in	O
area	O
under	O
the	O
curve	O
was	O
lower	O
during	O
atosiban	S-chemical
administration	O
than	O
during	O
infusion	O
of	O
placebo	O
in	O
both	O
groups	O
.	O
None	O
of	O
the	O
ischemia	O
markers	O
differed	O
between	O
or	O
within	O
groups	O
at	O
vasopressin	S-chemical
injections	O
or	O
atosiban	S-chemical
/placebo	O
infusions	O
.	O
In	O
subjects	O
with	O
dysmenorrhea	O
the	O
increase	O
in	O
pain	O
following	O
the	O
administration	O
of	O
vasopressin	S-GP
was	O
significantly	O
lower	O
during	O
atosiban	S-chemical
than	O
during	O
placebo	O
infusion	O
.	O
Healthy	O
volunteers	O
experienced	O
only	O
slight	O
discomfort	O
after	O
the	O
vasopressin	S-GP
injections	O
.	O
CONCLUSIONS	O
:	O
Atosiban	S-chemical
reduces	O
vasopressin	S-GP
-induced	O
intrauterine	O
pressure	O
in	O
both	O
healthy	O
volunteers	O
and	O
dysmenorrheics	O
,	O
and	O
reported	O
pain	O
in	O
subjects	O
with	O
dysmenorrhea	O
.	O
The	O
ischemia	O
markers	O
are	O
not	O
a	O
useful	O
biomarker	O
index	O
in	O
women	O
with	O
dysmenorrhea	O
.	O
The	O
dysmenorrhea	O
pain	O
evoked	O
by	O
vasopressin	S-GP
correlated	O
poorly	O
with	O
area	O
under	O
the	O
curve	O
,	O
which	O
may	O
suggest	O
that	O
the	O
effect	O
is	O
mediated	O
by	O
more	O
than	O
one	O
V1a-like	B-GP
receptor	E-GP
.	O
We	O
conclude	O
that	O
this	O
model	O
with	O
recordings	O
in	O
healthy	O
women	O
is	O
useful	O
in	O
the	O
evaluation	O
of	O
drug	O
candidates	O
for	O
primary	O
dysmenorrhea	O
.	O

Profluorogenic	O
reductase	O
substrate	O
for	O
rapid	O
,	O
selective	O
,	O
and	O
sensitive	O
visualization	O
and	O
detection	O
of	O
human	O
cancer	O
cells	O
that	O
overexpress	O
NQO1	S-GP
.	O
Achieving	O
the	O
vision	O
of	O
identifying	O
and	O
quantifying	O
cancer-related	O
events	O
and	O
targets	O
for	O
future	O
personalized	O
oncology	O
is	O
predicated	O
on	O
the	O
existence	O
of	O
synthetically	O
accessible	O
and	O
economically	O
viable	O
probe	O
molecules	O
fully	O
able	O
to	O
report	O
the	O
presence	O
of	O
these	O
events	O
and	O
targets	O
in	O
a	O
rapid	O
and	O
highly	O
selective	O
and	O
sensitive	O
fashion	O
.	O
Delineated	O
here	O
are	O
the	O
design	O
and	O
evaluation	O
of	O
a	O
newly	O
synthesized	O
turn-on	O
probe	O
whose	O
intense	O
fluorescent	O
reporter	O
signature	O
is	O
revealed	O
only	O
through	O
probe	O
activation	O
by	O
a	O
specific	O
intracellular	O
enzyme	O
present	O
in	O
tumor	O
cells	O
of	O
multiple	O
origins	O
.	O
Quenching	O
of	O
molecular	O
probe	O
fluorescence	O
is	O
achieved	O
through	O
unique	O
photoinduced	O
electron	O
transfer	O
between	O
the	O
naphthalimide	S-chemical
dye	O
reporter	O
and	O
a	O
covalently	O
attached	O
,	O
quinone	S-chemical
-based	O
enzyme	O
substrate	O
.	O
Fluorescence	O
of	O
the	O
reporter	O
dye	O
is	O
turned	O
on	O
by	O
rapid	O
removal	O
of	O
the	O
quinone	S-chemical
quencher	O
,	O
an	O
event	O
that	O
immediately	O
occurs	O
only	O
after	O
highly	O
selective	O
,	O
two-electron	O
reduction	O
of	O
the	O
sterically	O
and	O
conformationally	O
restricted	O
quinone	S-chemical
substrate	O
by	O
the	O
cancer-associated	O
human	B-GP
NAD	I-GP
(	I-GP
P	I-GP
)	I-GP
H	I-GP
:	I-GP
quinone	I-GP
oxidoreductase	I-GP
isozyme	I-GP
1	E-GP
(	O
hNQO1	S-GP
)	O
.	O
Successes	O
of	O
the	O
approach	O
include	O
rapid	O
differentiation	O
of	O
NQO1	S-GP
-expressing	O
and	O
-nonexpressing	O
cancer	O
cell	O
lines	O
via	O
the	O
unaided	O
eye	O
,	O
flow	O
cytometry	O
,	O
fluorescence	O
imaging	O
,	O
and	O
two-photon	O
microscopy	O
.	O
The	O
potential	O
for	O
use	O
of	O
the	O
turn-on	O
probe	O
in	O
longer-term	O
cellular	O
studies	O
is	O
indicated	O
by	O
its	O
lack	O
of	O
influence	O
on	O
cell	O
viability	O
and	O
its	O
in	O
vitro	O
stability	O
.	O

Beta-adrenoceptor	S-GP
-mediated	O
inhibition	O
of	O
IFN-gamma	S-GP
,	O
IL-3	S-GP
,	O
and	O
GM-CSF	S-GP
mRNA	O
accumulation	O
in	O
activated	O
human	O
T	O
lymphocytes	O
is	O
solely	O
mediated	O
by	O
the	O
beta2-adrenoceptor	S-GP
subtype	O
.	O
Cytokine	S-GP
gene	O
expression	O
in	O
T	O
lymphocytes	O
is	O
a	O
strictly	O
regulated	O
process	O
,	O
involving	O
both	O
stimulatory	O
and	O
inhibitory	O
signals	O
.	O
beta-Adrenoceptor	S-GP
(	O
betaAR	S-GP
)	O
agonists	O
are	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
asthma	O
and	O
are	O
able	O
to	O
induce	O
an	O
inhibitory	O
signal	O
on	O
immunological	O
responses	O
after	O
binding	O
to	O
their	O
specific	O
receptors	O
.	O
In	O
this	O
study	O
,	O
the	O
characterization	O
of	O
betaAR	S-GP
subtype	O
(	O
s	O
)	O
(	O
beta1	O
,	O
beta2	O
,	O
and	O
beta3	O
)	O
involved	O
in	O
the	O
regulation	O
of	O
interleukin	B-GP
(	I-GP
IL	I-GP
)	I-GP
-3	E-GP
,	O
IL-4	S-GP
,	O
granulocyte-macrophage	B-GP
colony-stimulating	I-GP
factor	E-GP
(	O
GM-CSF	S-GP
)	O
,	O
and	O
interferon-gamma	S-GP
(	O
IFN-gamma	S-GP
)	O
mRNA	O
accumulation	O
was	O
studied	O
by	O
using	O
various	O
betaAR	S-GP
agonists	O
and	O
antagonists	O
.	O
Concanavalin	B-GP
A	E-GP
(	O
Con	B-GP
A	E-GP
)	O
-induced	O
IFN-gamma	S-GP
,	O
GM-CSF	S-GP
,	O
and	O
IL-3	S-GP
mRNAs	O
are	O
dose-dependently	O
inhibited	O
by	O
the	O
nonselective	O
betaAR	S-GP
agonist	O
isoproterenol	S-chemical
and	O
by	O
the	O
selective	O
beta2AR	S-GP
agonist	O
fenoterol	S-chemical
.	O
IL-4	S-GP
mRNA	O
accumulation	O
was	O
not	O
susceptible	O
to	O
betaAR	S-GP
stimulation	O
.	O
The	O
observed	O
inhibition	O
on	O
IFN-gamma	S-GP
,	O
GM-CSF	S-GP
,	O
and	O
IL-3	S-GP
mRNA	O
was	O
blocked	O
by	O
the	O
selective	O
beta2AR	S-GP
antagonist	O
ICI	B-chemical
118,551	E-chemical
(	O
10	O
(	O
-6	O
)	O
M	O
)	O
and	O
by	O
timolol	S-chemical
(	O
10	O
(	O
-6	O
)	O
M	O
)	O
,	O
a	O
nonselective	O
antagonist	O
.	O
The	O
selective	O
beta1AR	S-GP
antagonist	O
atenolol	S-chemical
(	O
0.3	O
x	O
10	O
(	O
-6	O
)	O
M	O
)	O
did	O
not	O
have	O
any	O
effect	O
.	O
Secretion	O
of	O
GM-CSF	S-GP
protein	O
in	O
the	O
presence	O
of	O
increasing	O
concentrations	O
of	O
isoproterenol	S-chemical
followed	O
a	O
similar	O
pattern	O
as	O
observed	O
for	O
GM-CSF	S-GP
mRNA	O
.	O
In	O
addition	O
,	O
the	O
betaAR	S-GP
-mediated	O
inhibition	O
of	O
IFN-gamma	S-GP
,	O
GM-CSF	S-GP
,	O
and	O
IL-3	S-GP
mRNA	O
accumulation	O
and	O
GM-CSF	S-GP
protein	O
secretion	O
were	O
related	O
to	O
the	O
accumulation	O
of	O
intracellular	O
cyclic	B-chemical
adenosine	I-chemical
monophosphate	E-chemical
(	O
cAMP	S-chemical
)	O
levels	O
.	O
Although	O
beta3AR	S-GP
mRNA	O
was	O
detectable	O
in	O
Con	B-GP
A	E-GP
-activated	O
T	O
lymphocytes	O
,	O
we	O
could	O
not	O
demonstrate	O
a	O
functional	O
activity	O
in	O
the	O
regulation	O
of	O
cytokine	S-GP
expression	O
:	O
the	O
beta3AR	S-GP
agonist	O
BRL	B-chemical
37344	E-chemical
had	O
no	O
effect	O
on	O
the	O
accumulation	O
of	O
the	O
studied	O
cytokine	S-GP
mRNAs	O
,	O
and	O
did	O
not	O
significantly	O
affect	O
cellular	O
cAMP	S-chemical
levels	O
.	O
These	O
data	O
demonstrate	O
that	O
beta-agonist-induced	O
inhibition	O
of	O
IFN-gamma	S-GP
,	O
GM-CSF	S-GP
,	O
and	O
IL-3	S-GP
mRNA	O
accumulation	O
is	O
solely	O
mediated	O
by	O
beta2-adrenoceptors	S-GP
.	O

Crystal	O
structure	O
of	O
pyridoxal	B-GP
kinase	E-GP
in	O
complex	O
with	O
roscovitine	S-chemical
and	O
derivatives	O
.	O
Pyridoxal	B-GP
kinase	E-GP
(	O
PDXK	S-GP
)	O
catalyzes	O
the	O
phosphorylation	O
of	O
pyridoxal	S-chemical
,	O
pyridoxamine	S-chemical
,	O
and	O
pyridoxine	S-chemical
in	O
the	O
presence	O
of	O
ATP	S-chemical
and	O
Zn2+	S-chemical
.	O
This	O
constitutes	O
an	O
essential	O
step	O
in	O
the	O
synthesis	O
of	O
pyridoxal	B-chemical
5'-phosphate	E-chemical
(	O
PLP	S-chemical
)	O
,	O
the	O
active	O
form	O
of	O
vitamin	B-chemical
B6	E-chemical
,	O
a	O
cofactor	O
for	O
over	O
140	O
enzymes	O
.	O
(	B-chemical
R	I-chemical
)	I-chemical
-Roscovitine	E-chemical
(	O
CYC202	S-chemical
,	O
Seliciclib	S-chemical
)	O
is	O
a	O
relatively	O
selective	O
inhibitor	O
of	O
cyclin-dependent	B-GP
kinases	E-GP
(	O
CDKs	S-GP
)	O
,	O
currently	O
evaluated	O
for	O
the	O
treatment	O
of	O
cancers	O
,	O
neurodegenerative	O
disorders	O
,	O
renal	O
diseases	O
,	O
and	O
several	O
viral	O
infections	O
.	O
Affinity	O
chromatography	O
investigations	O
have	O
shown	O
that	O
(	B-chemical
R	I-chemical
)	I-chemical
-roscovitine	E-chemical
also	O
interacts	O
with	O
PDXK	S-GP
.	O
To	O
understand	O
this	O
interaction	O
,	O
we	O
determined	O
the	O
crystal	O
structure	O
of	O
PDXK	S-GP
in	O
complex	O
with	O
(	B-chemical
R	I-chemical
)	I-chemical
-roscovitine	E-chemical
,	O
N6-methyl-	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
-roscovitine	E-chemical
,	O
and	O
O6-	B-chemical
(	I-chemical
R	I-chemical
)	I-chemical
-roscovitine	E-chemical
,	O
the	O
two	O
latter	O
derivatives	O
being	O
designed	O
to	O
bind	O
to	O
PDXK	S-GP
but	O
not	O
to	O
CDKs	S-GP
.	O
Structural	O
analysis	O
revealed	O
that	O
these	O
three	O
roscovitines	S-chemical
bind	O
similarly	O
in	O
the	O
pyridoxal	S-chemical
-binding	O
site	O
of	O
PDXK	S-GP
rather	O
than	O
in	O
the	O
anticipated	O
ATP	S-chemical
-binding	O
site	O
.	O
The	O
pyridoxal	S-chemical
pocket	O
has	O
thus	O
an	O
unexpected	O
ability	O
to	O
accommodate	O
molecules	O
different	O
from	O
and	O
larger	O
than	O
pyridoxal	S-chemical
.	O
This	O
work	O
provides	O
detailed	O
structural	O
information	O
on	O
the	O
interactions	O
between	O
PDXK	S-GP
and	O
roscovitine	S-chemical
and	O
analogs	O
.	O
It	O
could	O
also	O
aid	O
in	O
the	O
design	O
of	O
roscovitine	S-chemical
derivatives	O
displaying	O
strict	O
selectivity	O
for	O
either	O
PDXK	S-GP
or	O
CDKs	S-GP
.	O

Phase	O
stability	O
and	O
elastic	O
properties	O
of	O
chromium	B-chemical
borides	E-chemical
with	O
various	O
stoichiometries	O
.	O
Phase	O
stability	O
is	O
important	O
to	O
the	O
application	O
of	O
materials	O
.	O
By	O
first-principles	O
calculations	O
,	O
we	O
establish	O
the	O
phase	O
stability	O
of	O
chromium	B-chemical
borides	E-chemical
with	O
various	O
stoichiometries	O
.	O
Moreover	O
,	O
the	O
phases	O
of	O
CrB3	S-chemical
and	O
CrB4	S-chemical
have	O
been	O
predicted	O
by	O
using	O
a	O
newly	O
developed	O
particle	O
swarm	O
optimization	O
(	O
PSO	O
)	O
algorithm	O
.	O
Formation	O
enthalpy-pressure	O
diagrams	O
reveal	O
that	O
the	O
MoB	S-chemical
-type	O
structure	O
is	O
more	O
energetically	O
favorable	O
than	O
the	O
TiI	S-chemical
-type	O
structure	O
for	O
CrB	S-chemical
.	O
For	O
CrB2	S-chemical
,	O
the	O
WB2	S-chemical
-type	O
structure	O
is	O
preferred	O
at	O
zero	O
pressure	O
.	O
The	O
predicted	O
new	O
phase	O
of	O
CrB3	S-chemical
belongs	O
to	O
the	O
hexagonal	O
P-6m2	O
space	O
group	O
and	O
it	O
transforms	O
into	O
an	O
orthorhombic	O
phase	O
as	O
the	O
pressure	O
exceeds	O
93	O
GPa	O
.	O
The	O
predicted	O
CrB4	S-chemical
(	O
space	O
group	O
:	O
Pnnm	O
)	O
phase	O
is	O
more	O
energetically	O
favorable	O
than	O
the	O
previously	O
proposed	O
Immm	O
structure	O
.	O
The	O
mechanical	O
and	O
thermodynamic	O
stabilities	O
of	O
predicted	O
CrB3	S-chemical
and	O
CrB4	S-chemical
are	O
verified	O
by	O
the	O
calculated	O
elastic	O
constants	O
and	O
formation	O
enthalpies	O
.	O
The	O
full	O
phonon	O
dispersion	O
calculations	O
confirm	O
the	O
dynamic	O
stability	O
of	O
WB2	S-chemical
-type	O
CrB2	S-chemical
and	O
predicted	O
CrB3	S-chemical
.	O
The	O
large	O
shear	O
moduli	O
,	O
large	O
Young	O
's	O
moduli	O
,	O
low	O
Poisson	O
ratios	O
,	O
and	O
low	O
bulk	O
and	O
shear	O
modulus	O
ratios	O
of	O
CrB4	S-chemical
PSC	O
and	O
CrB4	S-chemical
PSD	O
indicate	O
that	O
they	O
are	O
potential	O
hard	O
materials	O
.	O
Analyses	O
of	O
Debye	O
temperature	O
,	O
electronic	O
localization	O
function	O
,	O
and	O
electronic	O
structure	O
provide	O
further	O
understanding	O
of	O
the	O
chemical	O
and	O
physical	O
properties	O
of	O
these	O
borides	O
.	O

Pharmacological	O
evidence	O
of	O
functional	O
inhibitory	O
metabotrophic	B-GP
glutamate	I-GP
receptors	E-GP
on	O
mouse	O
arousal-related	O
cholinergic	O
laterodorsal	O
tegmental	O
neurons	O
.	O
Cholinergic	O
neurons	O
of	O
the	O
pontine	O
laterodorsal	O
tegmentum	O
(	O
LDT	O
)	O
are	O
importantly	O
involved	O
in	O
neurobiological	O
mechanisms	O
governing	O
states	O
of	O
arousal	O
such	O
as	O
sleep	O
and	O
wakefulness	O
as	O
well	O
as	O
other	O
appetitive	O
behaviors	O
,	O
such	O
as	O
drug-seeking	O
.	O
Accordingly	O
,	O
mechanisms	O
controlling	O
their	O
excitability	O
are	O
important	O
to	O
elucidate	O
if	O
we	O
are	O
to	O
understand	O
how	O
these	O
LDT	O
neurons	O
generate	O
arousal	O
states	O
.	O
Glutamate	S-chemical
mediates	O
the	O
vast	O
majority	O
of	O
excitatory	O
synaptic	O
transmission	O
in	O
the	O
vertebrate	O
CNS	O
and	O
while	O
presence	O
of	O
glutamate	S-chemical
input	O
in	O
the	O
LDT	O
has	O
been	O
shown	O
and	O
ionotropic	O
responses	O
to	O
glutamate	S-chemical
have	O
been	O
reported	O
in	O
the	O
LDT	O
,	O
characterization	O
of	O
metabotropic	O
responses	O
is	O
lacking	O
.	O
Therefore	O
,	O
electrophysiological	O
responses	O
and	O
changes	O
in	O
levels	O
of	O
intracellular	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
in	O
mouse	O
cholinergic	O
LDT	O
neurons	O
following	O
application	O
of	O
specific	O
mGluR	S-GP
agonists	O
and	O
antagonists	O
were	O
examined	O
.	O
Unexpectedly	O
,	O
both	O
the	O
mGluR	B-GP
(	I-GP
5	I-GP
)	E-GP
specific	O
agonist	O
,	O
CHPG	S-chemical
,	O
and	O
the	O
group	B-GP
II	I-GP
mGluR	E-GP
(	O
mGlu	B-GP
(	I-GP
2/3	I-GP
)	E-GP
)	O
agonist	O
,	O
LY379268	S-chemical
(	O
LY	O
)	O
,	O
induced	O
a	O
TTX	S-chemical
-insensitive	O
outward	O
current/hyperpolarization	O
.	O
Both	O
outward	O
currents	O
were	O
significantly	O
reduced	O
by	O
the	O
mGluR	S-GP
antagonist	O
MCPG	S-chemical
and	O
the	O
CHPG	S-chemical
-induced	O
current	O
was	O
blocked	O
by	O
the	O
specific	O
mGluR	B-GP
(	I-GP
5	I-GP
)	E-GP
antagonist	O
MTEP	S-chemical
.	O
Concurrent	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
imaging	O
revealed	O
that	O
while	O
CHPG	S-chemical
actions	O
did	O
include	O
release	O
of	O
Ca	B-chemical
(	I-chemical
2+	I-chemical
)	E-chemical
from	O
CPA	S-chemical
/	O
thapsigargin	S-chemical
-sensitive	O
intracellular	O
stores	O
,	O
actions	O
of	O
LY	O
did	O
not	O
.	O
Both	O
CHPG	S-chemical
-	O
and	O
LY-induced	O
outward	O
currents	O
were	O
mediated	O
by	O
a	O
TEA	S-chemical
-sensitive	O
potassium	S-chemical
conductance	O
.	O
The	O
large-conductance	O
,	O
Ca	B-GP
(	I-GP
2+	I-GP
)	I-GP
-dependent	I-GP
potassium	I-GP
(	I-GP
BK	I-GP
)	I-GP
channel	E-GP
blocker	O
,	O
iberiotoxin	O
,	O
attenuated	O
CHPG	S-chemical
actions	O
.	O
Consistent	O
with	O
actions	O
on	O
the	O
BK	O
conductance	O
,	O
CHPG	S-chemical
enhanced	O
the	O
amplitude	O
of	O
the	O
fast	O
component	O
of	O
the	O
after	O
hyperpolarizing	O
potential	O
,	O
concurrent	O
with	O
a	O
reduction	O
in	O
the	O
firing	O
rate	O
.	O
We	O
conclude	O
that	O
stimulation	O
of	O
mGluR	B-GP
(	I-GP
5	I-GP
)	E-GP
and	O
group	O
II	O
(	O
mGluR	B-GP
(	I-GP
2/3	I-GP
)	E-GP
)	O
elicits	O
postsynaptically-mediated	O
outward	O
currents/hyperpolarizations	O
in	O
cholinergic	O
LDT	O
neurons	O
.	O
Effects	O
of	O
glutamatergic	O
input	O
would	O
be	O
,	O
thus	O
,	O
expected	O
not	O
only	O
to	O
be	O
excitation	O
via	O
stimulation	O
of	O
ionotropic	B-GP
glutamate	I-GP
receptors	E-GP
and	O
mGluR	B-GP
(	I-GP
1	I-GP
)	E-GP
,	O
but	O
also	O
inhibition	O
via	O
actions	O
at	O
mGluR	B-GP
(	I-GP
5	I-GP
)	E-GP
and	O
mGluR	B-GP
(	I-GP
2/3	I-GP
)	E-GP
on	O
these	O
neurons	O
.	O
As	O
these	O
two	O
processes	O
counteract	O
each	O
other	O
,	O
these	O
surprising	O
findings	O
necessitate	O
revision	O
of	O
predictions	O
regarding	O
the	O
net	O
level	O
of	O
excitation	O
generated	O
by	O
glutamate	S-chemical
input	O
to	O
cholinergic	O
LDT	O
cells	O
and	O
,	O
by	O
extension	O
,	O
the	O
functional	O
outcome	O
of	O
glutamate	S-chemical
transmission	O
on	O
processes	O
which	O
these	O
neurons	O
regulate	O
.	O
This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Metabotropic	B-GP
Glutamate	I-GP
Receptors	E-GP
'	O
.	O

Synthesis	O
of	O
C17-	O
OH	S-chemical
-north	O
unit	O
of	O
ritterazine	B-chemical
G	E-chemical
via	O
``	O
Red-Ox	O
''	O
modifications	O
of	O
hecogenin	B-chemical
acetate	E-chemical
.	O
The	O
C17-	O
OH	S-chemical
-north	O
unit	O
of	O
ritterazine	B-chemical
G	E-chemical
was	O
prepared	O
in	O
13	O
steps	O
from	O
hecogenin	B-chemical
acetate	E-chemical
.	O
This	O
synthesis	O
features	O
a	O
highly	O
efficient	O
and	O
stereoselective	O
introduction	O
of	O
the	O
C17-	O
OH	S-chemical
via	O
E-ring	O
cleavage/F-ring	O
formation	O
,	O
D-ring	O
oxidation	O
,	O
and	O
F-ring	O
cleavage/E-ring	O
formation	O
.	O

Bone	B-GP
Morphogenetic	I-GP
Protein-7	E-GP
inhibits	O
silica	S-chemical
-induced	O
pulmonary	O
fibrosis	O
in	O
rats	O
.	O
Bone	B-GP
morphogenetic	I-GP
protein-7	E-GP
(	O
BMP-7	S-GP
)	O
has	O
been	O
shown	O
to	O
inhibit	O
liver	O
and	O
renal	O
fibrosis	O
in	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
.	O
There	O
is	O
no	O
study	O
to	O
investigate	O
BMP-7	S-GP
's	O
role	O
in	O
the	O
development	O
of	O
pulmonary	O
fibrosis	O
induced	O
by	O
silica	S-chemical
.	O
In	O
the	O
current	O
study	O
,	O
we	O
used	O
the	O
rat	O
model	O
to	O
explore	O
the	O
potential	O
antifibrotic	O
role	O
of	O
BMP-7	S-GP
and	O
its	O
underlying	O
mechanism	O
in	O
silica	S-chemical
-induced	O
pulmonary	O
fibrosis	O
.	O
Sixty	O
Wistar	O
rats	O
were	O
randomly	O
assigned	O
into	O
three	O
groups	O
.	O
Control	O
group	O
received	O
saline	O
,	O
silica	S-chemical
group	O
received	O
silica	S-chemical
and	O
BMP-7	S-GP
treated	O
group	O
received	O
silica	S-chemical
and	O
BMP-7	S-GP
.	O
BMP-7	S-GP
was	O
administered	O
to	O
silica	S-chemical
-treated	O
rats	O
intraperitoneally	O
at	O
a	O
dose	O
of	O
300μg/kg/injection	O
from	O
day	O
8	O
to	O
day	O
30	O
every	O
other	O
day	O
.	O
After	O
the	O
animals	O
were	O
sacrificed	O
on	O
day	O
15	O
and	O
30	O
,	O
hydroxyproline	S-chemical
levels	O
,	O
the	O
protein	O
expressions	O
of	O
BMP	S-GP
/	O
Smad	S-GP
and	O
TGF-β	S-GP
/	O
Smad	S-GP
signaling	O
,	O
and	O
histopathology	O
in	O
lung	O
tissues	O
were	O
analyzed	O
.	O
The	O
hydroxyproline	S-chemical
contents	O
in	O
BMP-7	S-GP
treated	O
groups	O
were	O
significantly	O
lower	O
than	O
the	O
silica	S-chemical
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O
Histopathological	O
results	O
showed	O
BMP-7	S-GP
could	O
reduce	O
the	O
progression	O
of	O
silica	S-chemical
induced	O
fibrosis	O
.	O
Furthermore	O
,	O
the	O
expression	O
of	O
p-Smad1/5/8	S-GP
,	O
a	O
marker	O
of	O
BMP	S-GP
/	O
Smad	S-GP
signaling	O
,	O
was	O
significantly	O
up-regulated	O
in	O
BMP-7	S-GP
treated	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
compared	O
with	O
the	O
silica	S-chemical
groups	O
.	O
On	O
the	O
contrary	O
,	O
the	O
expression	O
of	O
p-Smad2/3	S-GP
,	O
a	O
marker	O
for	O
TGF-β	S-GP
/	O
Smad	S-GP
signaling	O
,	O
reduced	O
significantly	O
in	O
BMP-7	S-GP
-treated	O
groups	O
compared	O
with	O
silica	S-chemical
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O
In	O
conclusion	O
,	O
the	O
pulmonary	O
fibrosis	O
induced	O
by	O
silica	S-chemical
in	O
rats	O
was	O
significantly	O
reduced	O
with	O
the	O
therapeutic	O
treatment	O
of	O
BMP-7	S-GP
.	O
The	O
antifibrotic	O
effect	O
of	O
BMP-7	S-GP
could	O
be	O
related	O
to	O
the	O
activation	O
of	O
BMP	S-GP
/	O
Smad	S-GP
signaling	O
and	O
inhibition	O
of	O
TGF-β	S-GP
/	O
Smad	S-GP
pathways	O
.	O

Role	O
of	O
oestrogen	B-GP
receptors	E-GP
on	O
the	O
modulation	O
of	O
NADPH-diaphorase	S-GP
-positive	O
cell	O
number	O
in	O
supraoptic	O
and	O
paraventricular	O
nuclei	O
of	O
ovariectomised	O
female	O
rats	O
.	O
Modulation	O
of	O
the	O
nitric	B-chemical
oxide	E-chemical
producing	O
system	O
(	O
demonstrated	O
via	O
the	O
NADPH-diaphorase	S-GP
histochemical	O
reaction	O
)	O
by	O
oestradiol	S-chemical
has	O
been	O
established	O
in	O
several	O
structures	O
of	O
the	O
rat	O
brain	O
.	O
The	O
present	O
study	O
aimed	O
to	O
explore	O
the	O
possible	O
regulation	O
of	O
NADPH-diaphorase	S-GP
activity	O
by	O
oestradiol	S-chemical
in	O
neurones	O
of	O
the	O
supraoptic	O
(	O
SON	O
)	O
and	O
paraventricular	O
(	O
PVN	O
)	O
nuclei	O
and	O
the	O
role	O
of	O
oestrogen	B-GP
receptors	E-GP
(	O
ERα	S-GP
and	O
ERβ	S-GP
)	O
in	O
this	O
regulation	O
.	O
Adult	O
ovariectomised	O
rats	O
were	O
divided	O
into	O
six	O
groups	O
and	O
injected	O
either	O
with	O
vehicle	O
or	O
a	O
single	O
dose	O
of	O
oestradiol	S-chemical
,	O
a	O
selective	O
ERα	S-GP
agonist-	O
PPT	S-chemical
[	O
4,4',4″-	B-chemical
(	I-chemical
4-propyl-	I-chemical
[	I-chemical
1H	I-chemical
]	I-chemical
-pyrazole-1,3,5-triyl	I-chemical
)	I-chemical
trisphenol	E-chemical
]	O
,	O
a	O
selective	O
ERβ	S-GP
agonist-	O
DPN	S-chemical
[	O
2,3-bis	B-chemical
(	I-chemical
4-hydroxyphenyl	I-chemical
)	I-chemical
-propionitrile	E-chemical
]	O
,	O
a	O
selective	O
ERα	S-GP
antagonist-	O
MPP	S-chemical
[	O
1,3-bis	B-chemical
(	I-chemical
4-hydroxyphenyl	I-chemical
)	I-chemical
-4-methyl-5-	I-chemical
[	I-chemical
4-	I-chemical
(	I-chemical
2-piperidinylethoxy	I-chemical
)	I-chemical
phenol	E-chemical
]	O
-	O
1H-pyrazole	B-chemical
dihydrochloride	E-chemical
]	O
or	O
a	O
selective	O
ERβ	S-GP
antagonist-	O
PHTPP	S-chemical
(	O
4-	B-chemical
[	I-chemical
2-phenyl-5,7-bis	I-chemical
(	I-chemical
trifluoromethyl	I-chemical
)	I-chemical
pyrazolo	I-chemical
[	I-chemical
1,5-a	I-chemical
]	I-chemical
pyrimidin-3-yl	I-chemical
]	I-chemical
phenol	E-chemical
)	O
.	O
The	O
number	O
of	O
NADPH-diaphorase	S-GP
positive	O
elements	O
in	O
the	O
SON	O
and	O
the	O
PVN	O
was	O
modulated	O
by	O
both	O
ERs	S-GP
but	O
,	O
depending	O
on	O
the	O
nucleus	O
,	O
ERα	S-GP
and	O
ERβ	S-GP
ligands	O
induced	O
different	O
effects	O
.	O
These	O
results	O
suggest	O
that	O
the	O
regulation	O
of	O
nitrergic	O
system	O
by	O
ERs	S-GP
may	O
play	O
a	O
role	O
in	O
the	O
control	O
of	O
oestrogen	S-chemical
-dependent	O
physiological	O
mechanisms	O
regulated	O
by	O
the	O
SON	O
and	O
the	O
PVN	O
.	O

Estradiol	S-chemical
replacement	O
enhances	O
cocaine	S-chemical
-stimulated	O
locomotion	O
in	O
female	O
C57BL/6	O
mice	O
through	O
estrogen	B-GP
receptor	I-GP
alpha	E-GP
.	O
Psychostimulant	O
effects	O
are	O
enhanced	O
by	O
ovarian	O
hormones	O
in	O
women	O
and	O
female	O
rodents	O
.	O
Estradiol	S-chemical
increases	O
behavioral	O
responses	O
to	O
psychostimulants	O
in	O
women	O
and	O
female	O
rats	O
,	O
although	O
the	O
underlying	O
mechanism	O
is	O
unknown	O
.	O
This	O
study	O
utilized	O
mice	O
to	O
investigate	O
the	O
time	O
frame	O
and	O
receptor	O
mediation	O
of	O
estradiol	S-chemical
's	O
enhancement	O
of	O
cocaine	S-chemical
-induced	O
behavior	O
as	O
mice	O
enable	O
parallel	O
use	O
of	O
genetic	O
,	O
surgical	O
and	O
pharmacological	O
methods	O
.	O
The	O
spontaneous	O
behavior	O
of	O
Sham	O
and	O
Ovariectomized	O
(	O
Ovx	O
)	O
female	O
wildtype	O
(	O
WT	O
)	O
mice	O
was	O
determined	O
during	O
habituation	O
to	O
a	O
novel	O
environment	O
and	O
after	O
cocaine	S-chemical
administration	O
.	O
Ovx	O
mice	O
were	O
replaced	O
with	O
vehicle	O
(	O
sesame	O
oil	O
)	O
or	O
17β-estradiol	S-chemical
(	O
E2	O
)	O
for	O
2	O
days	O
or	O
30	O
min	O
prior	O
to	O
a	O
cocaine	S-chemical
challenge	O
to	O
investigate	O
the	O
time	O
course	O
of	O
E2	O
's	O
effects	O
.	O
To	O
examine	O
receptor	O
mediation	O
of	O
estradiol	S-chemical
effects	O
,	O
Ovx	O
mice	O
replaced	O
for	O
2	O
days	O
with	O
either	O
the	O
ERα	S-GP
-selective	O
agonist	O
PPT	S-chemical
or	O
the	O
ERβ	S-GP
-selective	O
agonist	O
DPN	S-chemical
were	O
compared	O
to	O
Sham	O
mice	O
,	O
and	O
mice	O
lacking	O
either	O
ERα	S-GP
(	O
αER	S-GP
KO	O
)	O
or	O
ERβ	S-GP
(	O
βER	S-GP
KO	O
)	O
were	O
compared	O
to	O
WT	O
littermates	O
.	O
Ovx	O
mice	O
exhibited	O
fewer	O
ambulations	O
during	O
habituation	O
than	O
Sham	O
females	O
.	O
Cocaine	S-chemical
-induced	O
increases	O
in	O
behavioral	O
ratings	O
were	O
greater	O
in	O
Sham	O
than	O
in	O
Ovx	O
mice	O
.	O
Two	O
days	O
but	O
not	O
30	O
min	O
of	O
E2	O
replacement	O
in	O
Ovx	O
mice	O
increased	O
cocaine	S-chemical
responses	O
to	O
Sham	O
levels	O
.	O
PPT	S-chemical
replacement	O
also	O
increased	O
the	O
cocaine	S-chemical
response	O
relative	O
to	O
vehicle-	O
or	O
DPN	S-chemical
-	O
treated	O
Ovx	O
mice	O
.	O
αER	S-GP
KO	O
mice	O
displayed	O
modestly	O
attenuated	O
behavioral	O
responses	O
to	O
novelty	O
and	O
cocaine	S-chemical
compared	O
to	O
αWT	O
littermates	O
,	O
but	O
no	O
behavioral	O
differences	O
were	O
found	O
between	O
βER	S-GP
KO	O
and	O
βWT	O
mice	O
.	O
These	O
results	O
suggest	O
that	O
E2	O
enhances	O
cocaine	S-chemical
-stimulated	O
locomotion	O
in	O
mice	O
predominantly	O
through	O
ERα	S-GP
.	O

Genetic	O
polymorphism	O
and	O
activities	O
of	O
human	B-GP
lung	I-GP
alcohol	I-GP
and	I-GP
aldehyde	I-GP
dehydrogenases	E-GP
:	O
implications	O
for	O
ethanol	S-chemical
metabolism	O
and	O
cytotoxicity	O
.	O
Alcohol	B-GP
dehydrogenase	E-GP
(	O
ADH	S-GP
)	O
and	O
aldehyde	B-GP
dehydrogenase	E-GP
(	O
ALDH	S-GP
)	O
exhibit	O
genetic	O
polymorphism	O
and	O
tissue	O
specificity	O
.	O
ADH	S-GP
and	O
ALDH	S-GP
isozyme	O
phenotypes	O
from	O
39	O
surgical	O
Chinese	O
lung	O
specimens	O
were	O
identified	O
by	O
agarose	O
isoelectric	O
focusing	O
.	O
The	O
identity	O
of	O
the	O
lung	O
beta-ADHs	S-GP
was	O
further	O
demonstrated	O
by	O
their	O
characteristic	O
pH-activity	O
profiles	O
for	O
ethanol	S-chemical
oxidation	O
,	O
Km	O
values	O
for	O
NAD	O
and	O
ethanol	S-chemical
,	O
and	O
inhibition	O
by	O
4-methylpyrazole	S-chemical
or	O
1,10-phenanthroline	S-chemical
.	O
The	O
beta	O
2	O
allele	O
,	O
coding	O
for	O
beta	O
2	O
polypeptide	S-chemical
,	O
was	O
found	O
to	O
be	O
predominant	O
in	O
the	O
lung	O
specimens	O
studied	O
.	O
The	O
ADH	S-GP
activities	O
in	O
the	O
lungs	O
with	O
the	O
homozygous	O
phenotype	O
ADH2	B-GP
2-2	E-GP
(	O
exhibiting	O
beta	O
2	O
beta	O
2	O
)	O
and	O
ADH2	B-GP
1-1	E-GP
(	O
exhibiting	O
beta	O
1	O
beta	O
1	O
)	O
and	O
the	O
heterozygous	O
phenotype	O
ADH2	B-GP
2-1	E-GP
(	O
exhibiting	O
beta	O
2	O
beta	O
2	O
,	O
beta	O
2	O
beta	O
1	O
,	O
and	O
beta	O
1	O
beta	O
1	O
)	O
were	O
determined	O
to	O
be	O
999	O
+/-	O
77	O
,	O
48	O
+/-	O
17	O
,	O
and	O
494	O
+/-	O
61	O
nmol/min/g	O
tissue	O
,	O
respectively	O
.	O
Fifty-one	O
percent	O
of	O
the	O
specimens	O
studied	O
lacked	O
the	O
ALDH2	S-GP
activity	O
band	O
on	O
the	O
isoelectric	O
focusing	O
gels	O
.	O
The	O
activities	O
in	O
the	O
lung	O
tissues	O
with	O
the	O
ALDH2	S-GP
-active	O
phenotype	O
and	O
the	O
inactive	O
phenotype	O
were	O
determined	O
to	O
be	O
30	O
+/-	O
3	O
and	O
17	O
+/-	O
1	O
nmol/min/g	O
tissue	O
,	O
respectively	O
.	O
These	O
findings	O
indicate	O
that	O
human	O
pulmonary	O
ethanol	S-chemical
-metabolizing	O
activities	O
differ	O
significantly	O
with	O
respect	O
to	O
genetic	O
polymorphism	O
at	O
both	O
the	O
ADH2	S-GP
and	O
the	O
ALDH2	S-GP
loci	O
.	O
The	O
results	O
suggest	O
that	O
individuals	O
with	O
high	O
Vmax	O
beta	B-GP
2-ADH	E-GP
and	O
deficient	O
in	O
low-Km	O
mitochondrial	O
ALDH2	S-GP
,	O
accounting	O
for	O
approximately	O
45	O
%	O
of	O
the	O
Chinese	O
population	O
,	O
may	O
end	O
up	O
with	O
acetaldehyde	S-chemical
accumulation	O
during	O
alcohol	S-chemical
consumption	O
,	O
rendering	O
them	O
vulnerable	O
to	O
tissue	O
injury	O
caused	O
by	O
this	O
highly	O
reactive	O
and	O
toxic	O
metabolite	O
.	O

Induction	O
of	O
xenobiotic	B-GP
receptors	E-GP
,	O
transporters	O
,	O
and	O
drug	O
metabolizing	O
enzymes	O
by	O
oxycodone	S-chemical
.	O
Perturbations	O
of	O
the	O
expression	O
of	O
transporters	O
and	O
drug-metabolizing	O
enzymes	O
(	O
DMEs	O
)	O
by	O
opioids	O
can	O
be	O
the	O
locus	O
of	O
deleterious	O
drug-drug	O
interactions	O
(	O
DDIs	O
)	O
.	O
Many	O
transporters	O
and	O
DMEs	O
are	O
regulated	O
by	O
xenobiotic	B-GP
receptors	E-GP
[	O
XRs	S-GP
;	O
e.g.	O
,	O
pregnane	B-GP
X	I-GP
receptor	E-GP
(	O
PXR	S-GP
)	O
,	O
constitutive	B-GP
androstane	I-GP
receptor	E-GP
(	O
CAR	S-GP
)	O
,	O
and	O
Aryl	B-GP
hydrocarbon	I-GP
receptor	E-GP
(	O
AhR	S-GP
)	O
]	O
;	O
however	O
,	O
there	O
is	O
a	O
paucity	O
of	O
information	O
regarding	O
the	O
influence	O
of	O
opioids	O
on	O
XRs	S-GP
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
influence	O
of	O
oxycodone	S-chemical
administration	O
(	O
15	O
mg/kg	O
intraperitoneally	O
twice	O
daily	O
for	O
8	O
days	O
)	O
on	O
liver	O
expression	O
of	O
XRs	S-GP
,	O
transporters	O
,	O
and	O
DMEs	O
in	O
rats	O
.	O
Microarray	O
,	O
quantitative	O
real-time	O
polymerase	O
chain	O
reaction	O
and	O
immunoblotting	O
analyses	O
were	O
used	O
to	O
identify	O
significantly	O
regulated	O
genes	O
.	O
Three	O
XRs	S-GP
(	O
e.g.	O
,	O
PXR	S-GP
,	O
CAR	S-GP
,	O
and	O
AhR	S-GP
)	O
,	O
27	O
transporters	O
(	O
e.g.	O
,	O
ABCB1	S-GP
and	O
SLC22A8	S-GP
)	O
,	O
and	O
19	O
DMEs	O
(	O
e.g.	O
,	O
CYP2B2	S-GP
and	O
CYP3A1	S-GP
)	O
were	O
regulated	O
(	O
P	O
<	O
0.05	O
)	O
with	O
fold	O
changes	O
ranging	O
from	O
-46.3	O
to	O
17.1	O
.	O
Using	O
MetaCore	O
(	O
computational	O
platform	O
)	O
,	O
we	O
identified	O
a	O
unique	O
gene-network	O
of	O
transporters	O
and	O
DMEs	O
assembled	O
around	O
PXR	S-GP
,	O
CAR	S-GP
,	O
and	O
AhR	S-GP
.	O
Therefore	O
,	O
a	O
series	O
of	O
transactivation/translocation	O
assays	O
were	O
conducted	O
to	O
determine	O
whether	O
the	O
observed	O
changes	O
of	O
transporters/DMEs	O
are	O
mediated	O
by	O
direct	O
activation	O
of	O
PXR	S-GP
,	O
CAR	S-GP
,	O
or	O
AhR	S-GP
by	O
oxycodone	S-chemical
or	O
its	O
major	O
metabolites	O
(	O
noroxycodone	S-chemical
and	O
oxymorphone	S-chemical
)	O
.	O
Neither	O
oxycodone	S-chemical
nor	O
its	O
metabolites	O
activated	O
PXR	S-GP
,	O
CAR	S-GP
,	O
or	O
AhR	S-GP
.	O
Taken	O
together	O
,	O
these	O
findings	O
identify	O
a	O
signature	O
hepatic	O
gene-network	O
associated	O
with	O
repeated	O
oxycodone	S-chemical
administration	O
in	O
rats	O
and	O
demonstrate	O
that	O
oxycodone	S-chemical
alters	O
the	O
expression	O
of	O
many	O
transporters	O
and	O
DMEs	O
(	O
without	O
direct	O
activation	O
of	O
PXR	S-GP
,	O
CAR	S-GP
,	O
and	O
AhR	S-GP
)	O
,	O
which	O
could	O
lead	O
to	O
undesirable	O
DDIs	O
after	O
coadministration	O
of	O
substrates	O
of	O
these	O
transporters/DMEs	O
with	O
oxycodone	S-chemical
.	O

Discovery	O
of	O
4-phenyl-2-phenylaminopyridine	S-chemical
based	O
TNIK	S-GP
inhibitors	O
.	O
A	O
series	O
of	O
compounds	O
based	O
on	O
a	O
4-phenyl-2-phenylaminopyridine	S-chemical
scaffold	O
that	O
are	O
potent	O
and	O
selective	O
inhibitors	O
of	O
Traf2-	B-GP
and	I-GP
Nck-interacting	I-GP
kinase	E-GP
(	O
TNIK	S-GP
)	O
activity	O
are	O
described	O
.	O
These	O
compounds	O
were	O
used	O
as	O
tools	O
to	O
test	O
the	O
importance	O
of	O
TNIK	S-GP
kinase	S-GP
activity	O
in	O
signaling	O
and	O
proliferation	O
in	O
Wnt	S-GP
-activated	O
colorectal	O
cancer	O
cells	O
.	O
The	O
results	O
indicate	O
that	O
pharmacological	O
inhibition	O
of	O
TNIK	S-GP
kinase	S-GP
activity	O
has	O
minimal	O
effects	O
on	O
either	O
Wnt	S-GP
/	O
TCF4	S-GP
/	O
β-catenin	S-GP
-driven	O
transcription	O
or	O
viability	O
.	O
The	O
findings	O
suggest	O
that	O
the	O
kinase	S-GP
activity	O
of	O
TNIK	S-GP
may	O
be	O
less	O
important	O
to	O
Wnt	S-GP
signaling	O
than	O
other	O
aspects	O
of	O
TNIK	S-GP
function	O
,	O
such	O
as	O
its	O
putative	O
role	O
in	O
stabilizing	O
the	O
TCF4	S-GP
/	O
β-catenin	S-GP
transcriptional	O
complex	O
.	O

Tyrosine	B-GP
kinase	E-GP
blockers	O
:	O
new	O
hope	O
for	O
successful	O
cancer	O
therapy	O
.	O
Tyrosine	B-GP
kinases	E-GP
(	O
TKs	S-GP
)	O
are	O
attractive	O
targets	O
for	O
cancer	O
therapy	O
,	O
as	O
quite	O
often	O
their	O
abnormal	O
signaling	O
has	O
been	O
linked	O
with	O
tumor	O
development	O
and	O
growth	O
.	O
Constitutive	O
activated	O
TKs	S-GP
stimulate	O
multiple	O
signaling	O
pathways	O
responsible	O
for	O
DNA	O
repair	O
,	O
apoptosis	O
,	O
and	O
cell	O
proliferation	O
.	O
During	O
the	O
last	O
few	O
years	O
,	O
thorough	O
analysis	O
of	O
the	O
mechanism	O
underlying	O
tyrosine	B-GP
kinase	E-GP
's	O
activity	O
led	O
to	O
novel	O
cancer	O
therapy	O
using	O
TKs	S-GP
blockers	O
.	O
These	O
drugs	O
are	O
remarkably	O
effective	O
in	O
the	O
treatment	O
of	O
various	O
human	O
tumors	O
including	O
head	O
and	O
neck	O
,	O
gastric	O
,	O
prostate	O
and	O
breast	O
cancer	O
and	O
leukemias	O
.	O
The	O
most	O
successful	O
example	O
of	O
kinase	S-GP
blockers	O
is	O
Imatinib	S-chemical
(	O
Imatinib	B-chemical
mesylate	E-chemical
,	O
Gleevec	S-chemical
,	O
STI571	S-chemical
)	O
,	O
the	O
inhibitor	O
of	O
Bcr	S-GP
/	O
Abl	S-GP
oncoprotein	O
,	O
which	O
has	O
become	O
a	O
first-line	O
therapy	O
for	O
chronic	O
myelogenous	O
leukemia	O
.	O
The	O
introduction	O
of	O
STI571	S-chemical
for	O
the	O
treatment	O
of	O
leukemia	O
in	O
clinical	O
oncology	O
has	O
had	O
a	O
dramatic	O
impact	O
on	O
how	O
this	O
disease	O
is	O
currently	O
managed	O
.	O
Others	O
kinase	O
inhibitors	O
used	O
recently	O
in	O
cancer	O
therapy	O
include	O
Dasatinib	S-chemical
(	O
BMS-354825	S-chemical
)	O
specific	O
for	O
ABL	S-GP
non-receptor	B-GP
cytoplasmic	I-GP
kinase	E-GP
,	O
Gefitinib	S-chemical
(	O
Iressa	S-chemical
)	O
,	O
Erlotinib	S-chemical
(	O
OSI-774	S-chemical
,	O
Tarceva	S-chemical
)	O
and	O
Sunitinib	S-chemical
(	O
SU	B-chemical
11248	E-chemical
,	O
Sutent	S-chemical
)	O
specific	O
for	O
VEGF	B-GP
receptor	E-GP
kinase	S-GP
,	O
AMN107	S-chemical
(	O
Nilotinib	S-chemical
)	O
and	O
INNO-406	S-chemical
(	O
NS-187	S-chemical
)	O
specific	O
for	O
c-KIT	S-GP
kinase	O
.	O
The	O
following	O
TK	S-GP
blockers	O
for	O
treatment	O
of	O
various	O
human	O
tumors	O
are	O
in	O
clinical	O
development	O
:	O
Lapatinib	S-chemical
(	O
Lapatinib	B-chemical
ditosylate	E-chemical
,	O
Tykerb	S-chemical
,	O
GW-572016	S-chemical
)	O
,	O
Canertinib	S-chemical
(	O
CI-1033	S-chemical
)	O
,	O
Zactima	S-chemical
(	O
ZD6474	S-chemical
)	O
,	O
Vatalanib	S-chemical
(	O
PTK787	S-chemical
/	O
ZK	B-chemical
222584	E-chemical
)	O
,	O
Sorafenib	S-chemical
(	O
Bay	B-chemical
43-9006	E-chemical
,	O
Nexavar	S-chemical
)	O
,	O
and	O
Leflunomide	S-chemical
(	O
SU101	S-chemical
,	O
Arava	S-chemical
)	O
.	O
Herein	O
,	O
we	O
discuss	O
the	O
chemistry	O
,	O
biological	O
activity	O
and	O
clinical	O
potential	O
of	O
new	O
drugs	O
with	O
tyrosine	B-GP
kinase	E-GP
blockers	O
for	O
cancer	O
treatment	O
.	O

Endothelial	O
cell	O
response	O
to	O
(	O
co	O
)	O
polymer	O
nanoparticles	O
depending	O
on	O
the	O
inflammatory	O
environment	O
and	O
comonomer	O
ratio	O
.	O
Endothelial	O
cells	O
lining	O
the	O
lumen	O
of	O
blood	O
vessels	O
serve	O
as	O
a	O
physiological	O
barrier	O
controlling	O
nanoparticle	O
movement	O
from	O
the	O
vasculature	O
into	O
the	O
tissue	O
.	O
For	O
exploring	O
the	O
effect	O
of	O
polymer	O
hydrophilicity	O
on	O
nanoparticle	O
interactions	O
with	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
in	O
vitro	O
,	O
a	O
series	O
of	O
monomodal	O
poly	B-chemical
[	I-chemical
acrylonitrile-co-	I-chemical
(	I-chemical
N-vinylpyrrolidone	I-chemical
)	I-chemical
]	E-chemical
model	O
nanoparticles	O
with	O
increasing	O
hydrophilicity	O
as	O
related	O
to	O
their	O
increasing	O
content	O
(	O
0-30mol.	O
%	O
)	O
of	O
N-vinylpyrrolidone	S-chemical
(	O
NVP	S-chemical
)	O
were	O
synthesized	O
by	O
miniemulsion	O
polymerization	O
.	O
Nanoparticles	O
with	O
a	O
low	O
NVP	S-chemical
content	O
were	O
rapidly	O
endocytized	O
into	O
all	O
cells	O
independent	O
from	O
the	O
particle	O
dose	O
with	O
toxic	O
effects	O
only	O
observed	O
at	O
high	O
particle	O
concentrations	O
,	O
while	O
only	O
10-30	O
%	O
of	O
the	O
cells	O
incorporated	O
particles	O
with	O
⩾20mol.	O
%	O
NVP	S-chemical
.	O
Since	O
pathologies	O
are	O
often	O
related	O
to	O
inflammation	O
,	O
an	O
inflammatory	O
HUVEC	O
culture	O
condition	O
with	O
IL-1β	S-GP
stimulation	O
has	O
been	O
introduced	O
and	O
suggested	O
to	O
be	O
widely	O
applied	O
for	O
studying	O
nanocarriers	O
,	O
since	O
cellular	O
uptake	O
in	O
this	O
assay	O
was	O
clearly	O
increased	O
for	O
NVP	S-chemical
contents	O
⩾20mol.	O
%	O
.	O
Importantly	O
,	O
the	O
secretion	O
of	O
functional	O
biological	O
mediators	O
by	O
HUVEC	O
was	O
not	O
relevantly	O
influenced	O
by	O
the	O
nanoparticles	O
for	O
both	O
homeostatic	O
and	O
inflammatory	O
conditions	O
.	O
These	O
findings	O
may	O
motivate	O
concepts	O
for	O
nanocarriers	O
specifically	O
targeted	O
to	O
pathologic	O
regions	O
.	O
Additionally	O
,	O
rapidly	O
endocytized	O
RhodaminB	S-chemical
loaded	O
particles	O
with	O
low	O
NVP	S-chemical
content	O
may	O
be	O
explored	O
for	O
cell	O
labeling	O
and	O
tracking	O
.	O

Synthesis	O
of	O
novel	O
estrogen	B-GP
receptor	E-GP
antagonists	O
using	O
metal-catalyzed	O
coupling	O
reactions	O
and	O
characterization	O
of	O
their	O
biological	O
activity	O
.	O
Estrogen	B-GP
receptor	E-GP
(	O
ER	S-GP
)	O
antagonists	O
are	O
valuable	O
in	O
the	O
treatment	O
of	O
ER	S-GP
-positive	O
human	O
breast	O
cancer	O
.	O
In	O
this	O
study	O
,	O
we	O
designed	O
and	O
synthesized	O
nine	O
new	O
derivatives	O
of	O
17β-estradiol	S-chemical
(	O
E2	O
)	O
with	O
a	O
bulky	O
side	O
chain	O
attached	O
to	O
its	O
C-7α	O
position	O
,	O
and	O
determined	O
their	O
ER	S-GP
antagonistic	O
activity	O
using	O
in	O
vitro	O
bioassays	O
.	O
Four	O
of	O
the	O
derivatives	O
showed	O
a	O
strong	O
inhibition	O
of	O
ERα	S-GP
transactivation	O
activity	O
in	O
a	O
luciferase	O
reporter	O
assay	O
and	O
blocked	O
ERα	S-GP
interactions	O
with	O
coactivators	O
.	O
Similarly	O
,	O
these	O
derivatives	O
also	O
strongly	O
inhibited	O
the	O
growth	O
of	O
the	O
ERα	S-GP
-positive	O
human	O
breast	O
cancer	O
cells	O
.	O
Computational	O
docking	O
analysis	O
was	O
conducted	O
to	O
model	O
the	O
interaction	O
of	O
these	O
antagonists	O
with	O
the	O
human	B-GP
ERα	E-GP
and	O
showed	O
that	O
they	O
could	O
tightly	O
bind	O
to	O
the	O
ERα	S-GP
in	O
a	O
manner	O
similar	O
to	O
that	O
of	O
ICI-182,780	S-chemical
,	O
a	O
pure	O
ER	S-GP
antagonist	O
.	O
These	O
results	O
provide	O
an	O
example	O
that	O
attachment	O
of	O
a	O
bulky	O
side	O
chain	O
to	O
the	O
C-7α	O
position	O
of	O
E2	O
can	O
produce	O
ER	S-GP
antagonists	O
with	O
ER	S-GP
affinity	O
comparable	O
to	O
that	O
of	O
ICI-182,780	S-chemical
.	O

Seizures	O
and	O
enhanced	O
cortical	O
GABAergic	O
inhibition	O
in	O
two	O
mouse	O
models	O
of	O
human	O
autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
.	O
Selected	O
mutations	O
in	O
the	O
human	B-GP
alpha4	I-GP
or	I-GP
beta2	I-GP
neuronal	I-GP
nicotinic	I-GP
acetylcholine	I-GP
receptor	E-GP
subunit	O
genes	O
cosegregate	O
with	O
a	O
partial	O
epilepsy	O
syndrome	O
known	O
as	O
autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
(	O
ADNFLE	O
)	O
.	O
To	O
examine	O
possible	O
mechanisms	O
underlying	O
this	O
inherited	O
epilepsy	O
,	O
we	O
engineered	O
two	O
ADNFLE	O
mutations	O
(	O
Chrna4	S-GP
(	O
S252F	S-GP
)	O
and	O
Chrna4	S-GP
(	O
+L264	O
)	O
)	O
in	O
mice	O
.	O
Heterozygous	O
ADNFLE	O
mutant	O
mice	O
show	O
persistent	O
,	O
abnormal	O
cortical	O
electroencephalograms	O
with	O
prominent	O
delta	O
and	O
theta	O
frequencies	O
,	O
exhibit	O
frequent	O
spontaneous	O
seizures	O
,	O
and	O
show	O
an	O
increased	O
sensitivity	O
to	O
the	O
proconvulsant	O
action	O
of	O
nicotine	S-chemical
.	O
Relative	O
to	O
WT	O
,	O
electrophysiological	O
recordings	O
from	O
ADNFLE	O
mouse	O
layer	O
II/III	O
cortical	O
pyramidal	O
cells	O
reveal	O
a	O
>	O
20-fold	O
increase	O
in	O
nicotine	S-chemical
-evoked	O
inhibitory	O
postsynaptic	O
currents	O
with	O
no	O
effect	O
on	O
excitatory	O
postsynaptic	O
currents	O
.	O
i.p	O
.	O
injection	O
of	O
a	O
subthreshold	O
dose	O
of	O
picrotoxin	S-chemical
,	O
a	O
use-dependent	O
gamma-aminobutyric	B-GP
acid	I-GP
receptor	E-GP
antagonist	O
,	O
reduces	O
cortical	O
electroencephalogram	O
delta	O
power	O
and	O
transiently	O
inhibits	O
spontaneous	O
seizure	O
activity	O
in	O
ADNFLE	O
mutant	O
mice	O
.	O
Our	O
studies	O
suggest	O
that	O
the	O
mechanism	O
underlying	O
ADNFLE	O
seizures	O
may	O
involve	O
inhibitory	O
synchronization	O
of	O
cortical	O
networks	O
via	O
activation	O
of	O
mutant	O
alpha4-containing	B-GP
nicotinic	I-GP
acetylcholine	I-GP
receptors	E-GP
located	O
on	O
the	O
presynaptic	O
terminals	O
and	O
somatodendritic	O
compartments	O
of	O
cortical	O
GABAergic	O
interneurons	O
.	O

Stabilisation	O
of	O
amorphous	O
drugs	O
under	O
high	O
humidity	O
using	O
pharmaceutical	O
thin	O
films	O
.	O
In	O
this	O
study	O
,	O
the	O
stabilization	O
effects	O
of	O
three	O
polymers	O
on	O
four	O
model	O
drugs	O
(	O
felodipine	S-chemical
,	O
fenofibrate	S-chemical
,	O
carbamazepine	S-chemical
,	O
and	O
celecoxib	S-chemical
)	O
under	O
saturated	O
humidity	O
were	O
investigated	O
.	O
Three	O
different	O
types	O
of	O
thin	O
films	O
(	O
solid	O
dispersions	O
,	O
drug	O
films	O
with	O
a	O
polymer	O
film	O
coating	O
and	O
drug	O
films	O
laid	O
on	O
top	O
of	O
polymer	O
coated	O
surfaces	O
)	O
were	O
prepared	O
and	O
compared	O
with	O
films	O
containing	O
the	O
drug	O
alone	O
.	O
ATR-FTIR	O
spectroscopy	O
,	O
polarised	O
light	O
microscopy	O
(	O
PLM	O
)	O
,	O
scanning	O
electron	O
microscopy	O
(	O
SEM	O
)	O
and	O
nano-thermal	O
analysis	O
(	O
nano-TA	O
)	O
were	O
performed	O
on	O
the	O
model	O
systems	O
after	O
storage	O
under	O
saturated	O
humidity	O
.	O
The	O
recrystallisation	O
tendency	O
of	O
the	O
drug	O
in	O
the	O
drug	O
containing	O
thin	O
films	O
was	O
found	O
to	O
be	O
strongly	O
related	O
to	O
the	O
intrinsic	O
crystallization	O
tendency	O
of	O
the	O
drug	O
film	O
alone	O
and	O
the	O
strength	O
of	O
drug-polymer	O
interactions	O
.	O
Additionally	O
,	O
under	O
high	O
humidity	O
,	O
the	O
glass	O
transition	O
temperature	O
of	O
the	O
polymer	O
is	O
no	O
longer	O
an	O
indicator	O
of	O
its	O
drug	O
stabilization	O
capability	O
.	O
Instead	O
,	O
it	O
is	O
the	O
hygroscobicity	O
of	O
the	O
polymer	O
that	O
appears	O
to	O
be	O
the	O
most	O
important	O
parameter	O
.	O
Amongst	O
the	O
polymers	O
tested	O
in	O
this	O
study	O
,	O
EUDRAGIT	B-chemical
E	I-chemical
PO	E-chemical
was	O
found	O
to	O
have	O
the	O
greatest	O
inhibitory	O
effect	O
on	O
crystallization	O
,	O
whilst	O
PVP	B-chemical
K30	E-chemical
was	O
found	O
to	O
have	O
the	O
least	O
protective	O
effect	O
;	O
presumably	O
because	O
of	O
its	O
hygroscopic	O
nature	O
.	O

Electrophysiological	O
properties	O
of	O
mouse	O
horizontal	O
cell	O
GABAA	B-GP
receptors	E-GP
.	O
GABA	S-chemical
-induced	O
currents	O
have	O
been	O
characterized	O
in	O
isolated	O
horizontal	O
cells	O
from	O
lower	O
vertebrates	O
but	O
not	O
in	O
mammalian	O
horizontal	O
cells	O
.	O
Therefore	O
horizontal	O
cells	O
were	O
isolated	O
after	O
enzymatical	O
and	O
mechanical	O
dissociation	O
of	O
the	O
adult	O
mouse	O
retina	O
and	O
visually	O
identified	O
.	O
We	O
recorded	O
from	O
horizontal	O
cell	O
bodies	O
using	O
the	O
whole	O
cell	O
and	O
outside-out	O
configuration	O
of	O
the	O
patch-clamp	O
technique	O
.	O
Extracellular	O
application	O
of	O
GABA	S-chemical
induced	O
inward	O
currents	O
carried	O
by	O
chloride	S-chemical
ions	O
.	O
GABA	S-chemical
-evoked	O
currents	O
were	O
completely	O
and	O
reversibly	O
blocked	O
by	O
the	O
competitive	O
GABAA	B-GP
receptor	E-GP
antagonist	O
bicuculline	S-chemical
(	O
IC50	O
=	O
1.7	O
microM	O
)	O
,	O
indicating	O
expression	O
of	O
GABAA	S-GP
but	O
not	O
GABAC	B-GP
receptors	E-GP
.	O
Their	O
affinity	O
for	O
GABA	S-chemical
was	O
moderate	O
(	O
EC50	O
=	O
30	O
microM	O
)	O
,	O
and	O
the	O
Hill	O
coefficient	O
was	O
1.3	O
,	O
corresponding	O
to	O
two	O
GABA	B-GP
binding	I-GP
sites	E-GP
.	O
GABA	S-chemical
responses	O
were	O
partially	O
reduced	O
by	O
picrotoxin	S-chemical
with	O
differential	O
effects	O
on	O
peak	O
and	O
steady-state	O
current	O
values	O
.	O
Zinc	S-chemical
blocked	O
the	O
GABA	S-chemical
response	O
with	O
an	O
IC50	O
value	O
of	O
7.3	O
microM	O
in	O
a	O
noncompetitive	O
manner	O
.	O
Furthermore	O
,	O
GABA	B-GP
receptors	E-GP
of	O
horizontal	O
cells	O
were	O
modulated	O
by	O
extracellular	O
application	O
of	O
diazepam	S-chemical
,	O
zolpidem	S-chemical
,	O
methyl	B-chemical
6,7-dimethoxy-4-ethyl-beta-carboxylate	E-chemical
,	O
pentobarbital	S-chemical
,	O
and	O
alphaxalone	S-chemical
,	O
thus	O
showing	O
typical	O
pharmacological	O
properties	O
of	O
CNS	O
GABAA	B-GP
receptors	E-GP
.	O
GABA	S-chemical
-evoked	O
single-channel	O
currents	O
were	O
characterized	O
by	O
a	O
main	O
conductance	O
state	O
of	O
29.8	O
pS	O
and	O
two	O
subconductance	O
states	O
(	O
20.2	O
and	O
10.8	O
pS	O
,	O
respectively	O
)	O
.	O
Kinetic	O
analysis	O
of	O
single-channel	O
events	O
within	O
bursts	O
revealed	O
similar	O
mean	O
open	O
and	O
closed	O
times	O
for	O
the	O
main	O
conductance	O
and	O
the	O
20.2-pS	O
subconductance	O
state	O
,	O
resulting	O
in	O
open	O
probabilities	O
of	O
44.6	O
and	O
42.7	O
%	O
,	O
respectively	O
.	O
The	O
ratio	O
of	O
open	O
to	O
closed	O
times	O
,	O
however	O
,	O
was	O
significantly	O
different	O
for	O
the	O
10.8-pS	O
subconductance	O
state	O
with	O
an	O
open	O
probability	O
of	O
57.2	O
%	O
.	O

Asenapine	S-chemical
:	O
a	O
novel	O
psychopharmacologic	O
agent	O
with	O
a	O
unique	O
human	O
receptor	O
signature	O
.	O
Asenapine	S-chemical
is	O
a	O
novel	O
psychopharmacologic	O
agent	O
under	O
development	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
and	O
bipolar	O
disorder	O
.	O
We	O
determined	O
and	O
compared	O
the	O
human	O
receptor	O
binding	O
affinities	O
and	O
functional	O
characteristics	O
of	O
asenapine	S-chemical
and	O
several	O
antipsychotic	O
drugs	O
.	O
Compounds	O
were	O
tested	O
under	O
comparable	O
assay	O
conditions	O
using	O
cloned	O
human	O
receptors	O
.	O
In	O
comparison	O
with	O
the	O
antipsychotics	O
,	O
asenapine	O
showed	O
high	O
affinity	O
and	O
a	O
different	O
rank	O
order	O
of	O
binding	O
affinities	O
(	O
pKi	O
)	O
for	O
serotonin	B-GP
receptors	E-GP
(	O
5-HT1A	S-GP
[	O
8.6	O
]	O
,	O
5-HT1B	S-GP
[	O
8.4	O
]	O
,	O
5-HT2A	S-GP
[	O
10.2	O
]	O
,	O
5-HT2B	S-GP
[	O
9.8	O
]	O
,	O
5-HT2C	S-GP
[	O
10.5	O
]	O
,	O
5-HT5	S-GP
[	O
8.8	O
]	O
,	O
5-HT6	S-GP
[	O
9.6	O
]	O
and	O
5-HT7	S-GP
[	O
9.9	O
]	O
)	O
,	O
adrenoceptors	B-GP
(	I-GP
alpha1	E-GP
[	O
8.9	O
]	O
,	O
alpha2A	S-GP
[	O
8.9	O
]	O
,	O
alpha2B	S-GP
[	O
9.5	O
]	O
and	O
alpha2C	S-GP
[	O
8.9	O
]	O
)	O
,	O
dopamine	B-GP
receptors	I-GP
(	I-GP
D1	E-GP
[	O
8.9	O
]	O
,	O
D2	S-GP
[	O
8.9	O
]	O
,	O
D3	S-GP
[	O
9.4	O
]	O
and	O
D4	S-GP
[	O
9.0	O
]	O
)	O
and	O
histamine	B-GP
receptors	I-GP
(	I-GP
H1	E-GP
[	O
9.0	O
]	O
and	O
H2	S-GP
[	O
8.2	O
]	O
)	O
.	O
It	O
had	O
much	O
lower	O
affinity	O
(	O
pKi	O
<	O
or=5	O
)	O
for	O
muscarinic	O
receptors	O
and	O
was	O
the	O
only	O
agent	O
with	O
affinity	O
for	O
H2	O
receptors	O
.	O
Relative	O
to	O
its	O
D2	O
receptor	O
affinity	O
,	O
asenapine	O
had	O
a	O
higher	O
affinity	O
for	O
5-HT2C	O
,	O
5-HT2A	O
,	O
5-HT2B	O
,	O
5-HT7	O
,	O
5-HT6	O
,	O
alpha2B	O
and	O
D3	O
receptors	O
,	O
suggesting	O
stronger	O
engagement	O
of	O
these	O
targets	O
at	O
therapeutic	O
doses	O
.	O
Asenapine	O
behaved	O
as	O
a	O
potent	O
antagonist	O
(	O
pKB	O
)	O
at	O
5-HT1A	O
(	O
7.4	O
)	O
,	O
5-HT1B	O
(	O
8.1	O
)	O
,	O
5-HT2A	O
(	O
9.0	O
)	O
,	O
5-HT2B	O
(	O
9.3	O
)	O
,	O
5-HT2C	O
(	O
9.0	O
)	O
,	O
5-HT6	O
(	O
8.0	O
)	O
,	O
5-HT7	O
(	O
8.5	O
)	O
,	O
D2	O
(	O
9.1	O
)	O
,	O
D3	O
(	O
9.1	O
)	O
,	O
alpha2A	O
(	O
7.3	O
)	O
,	O
alpha2B	O
(	O
8.3	O
)	O
,	O
alpha2C	O
(	O
6.8	O
)	O
and	O
H1	O
(	O
8.4	O
)	O
receptors	O
.	O
These	O
functional	O
effects	O
differed	O
from	O
those	O
of	O
risperidone	O
(	O
pKB	O
<	O
5	O
for	O
5-HT6	O
)	O
and	O
olanzapine	O
(	O
pKB	O
<	O
5	O
for	O
5-HT1A	O
and	O
alpha2	O
)	O
.	O
Our	O
results	O
indicate	O
that	O
asenapine	O
has	O
a	O
unique	O
human	O
receptor	O
signature	O
,	O
with	O
binding	O
affinity	O
and	O
antagonistic	O
properties	O
that	O
differ	O
appreciably	O
from	O
those	O
of	O
antipsychotic	O
drugs	O
.	O

Enhancement	O
of	O
radiosensitivity	O
by	O
topoisomerase	B-GP
II	E-GP
inhibitor	O
,	O
amrubicin	S-chemical
and	O
amrubicinol	S-chemical
,	O
in	O
human	O
lung	O
adenocarcinoma	O
A549	O
cells	O
and	O
kinetics	O
of	O
apoptosis	O
and	O
necrosis	O
induction	O
.	O
The	O
effects	O
of	O
amrubicin	S-chemical
(	O
AMR	S-chemical
)	O
and	O
its	O
active	O
metabolite	O
,	O
amrubicinol	S-chemical
(	O
AMROH	S-chemical
)	O
,	O
on	O
the	O
sensitivity	O
of	O
human	O
lung	O
adenocarcinoma	O
A549	O
cells	O
to	O
ionizing	O
radiation	O
were	O
investigated	O
in	O
vitro	O
.	O
Further	O
,	O
the	O
kinetics	O
of	O
apoptosis	O
and	O
necrosis	O
induction	O
were	O
also	O
analyzed	O
.	O
The	O
cytocidal	O
effects	O
of	O
X-ray	O
irradiation	O
on	O
A549	O
cells	O
resulted	O
in	O
a	O
low	O
level	O
of	O
radiosensitivity	O
with	O
a	O
D0	O
value	O
of	O
12	O
Gy	O
.	O
The	O
slopes	O
of	O
the	O
survival	O
curves	O
in	O
the	O
exponential	O
phase	O
were	O
plotted	O
on	O
semilogarithmic	O
paper	O
for	O
radiation	O
combined	O
with	O
AMR	S-chemical
(	O
2.5	O
microg/ml	O
)	O
and	O
AMROH	S-chemical
(	O
0.02	O
microg/ml	O
)	O
treatment	O
,	O
and	O
were	O
shown	O
to	O
be	O
approximately	O
parallel	O
to	O
treatment	O
with	O
irradiation	O
alone	O
.	O
The	O
initial	O
shoulder-shape	O
portion	O
of	O
the	O
survival	O
curve	O
for	O
radiation	O
alone	O
,	O
indicating	O
the	O
repair	O
of	O
sublethal	O
damage	O
,	O
was	O
reduced	O
as	O
compared	O
to	O
that	O
for	O
sequential	O
combined	O
treatment	O
with	O
AMR	S-chemical
or	O
AMROH	S-chemical
.	O
Sequential	O
treatments	O
with	O
AMR	S-chemical
or	O
AMROH	S-chemical
prior	O
to	O
ionizing	O
radiation	O
resulted	O
in	O
an	O
additive	O
radio-enhancement	O
effect	O
that	O
reduced	O
not	O
only	O
survival	O
,	O
but	O
also	O
the	O
shoulder	O
width	O
.	O
Fractionated	O
irradiation	O
with	O
2	O
Gy	O
per	O
fraction	O
of	O
A549	O
cells	O
was	O
carried	O
out	O
in	O
vitro	O
similar	O
to	O
that	O
commonly	O
performed	O
in	O
clinical	O
radiotherapy	O
and	O
the	O
radio-resistance	O
of	O
the	O
cells	O
was	O
shown	O
to	O
be	O
inhibited	O
by	O
AMR	S-chemical
and	O
AMROH	S-chemical
.	O
Similar	O
to	O
AMR	S-chemical
and	O
AMROH	S-chemical
,	O
adriamycin	S-chemical
and	O
etoposide	S-chemical
(	O
VP-16	S-chemical
)	O
are	O
DNA	B-GP
topoisomerase	I-GP
II	E-GP
inhibitors	O
.	O
The	O
effects	O
of	O
these	O
4	O
agents	O
on	O
cells	O
that	O
received	O
X-ray	O
irradiation	O
were	O
compared	O
and	O
all	O
of	O
the	O
agents	O
exhibited	O
comparable	O
radio-enhancement	O
effects	O
.	O
The	O
induction	O
of	O
apoptosis	O
was	O
investigated	O
at	O
48	O
and	O
72	O
h	O
after	O
administration	O
of	O
AMROH	S-chemical
,	O
radiation	O
or	O
combined	O
treatment	O
,	O
and	O
apoptosis	O
was	O
not	O
significantly	O
induced	O
after	O
any	O
of	O
the	O
treatments	O
.	O
We	O
also	O
examined	O
the	O
induction	O
of	O
necrosis	O
,	O
and	O
found	O
that	O
the	O
incidence	O
of	O
necrosis	O
following	O
combined	O
treatment	O
was	O
approximately	O
2	O
times	O
higher	O
than	O
that	O
with	O
either	O
of	O
the	O
single	O
treatments	O
.	O

Neuronal	O
expression	O
of	O
glucosylceramide	B-GP
synthase	E-GP
in	O
central	O
nervous	O
system	O
regulates	O
body	O
weight	O
and	O
energy	O
homeostasis	O
.	O
Hypothalamic	O
neurons	O
are	O
main	O
regulators	O
of	O
energy	O
homeostasis	O
.	O
Neuronal	O
function	O
essentially	O
depends	O
on	O
plasma	O
membrane-located	O
gangliosides	O
.	O
The	O
present	O
work	O
demonstrates	O
that	O
hypothalamic	O
integration	O
of	O
metabolic	O
signals	O
requires	O
neuronal	O
expression	O
of	O
glucosylceramide	B-GP
synthase	E-GP
(	O
GCS	S-GP
;	O
UDP-glucose	B-GP
:	I-GP
ceramide	I-GP
glucosyltransferase	E-GP
)	O
.	O
As	O
a	O
major	O
mechanism	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
metabolic	O
control	O
,	O
we	O
demonstrate	O
that	O
GCS	S-GP
-derived	O
gangliosides	O
interacting	O
with	O
leptin	B-GP
receptors	E-GP
(	O
ObR	S-GP
)	O
in	O
the	O
neuronal	O
membrane	O
modulate	O
leptin	S-GP
-stimulated	O
formation	O
of	O
signaling	O
metabolites	O
in	O
hypothalamic	O
neurons	O
.	O
Furthermore	O
,	O
ganglioside-depleted	O
hypothalamic	O
neurons	O
fail	O
to	O
adapt	O
their	O
activity	O
(	O
c-Fos	S-GP
)	O
in	O
response	O
to	O
alterations	O
in	O
peripheral	O
energy	O
signals	O
.	O
Consequently	O
,	O
mice	O
with	O
inducible	O
forebrain	O
neuron-specific	O
deletion	O
of	O
the	O
UDP-glucose	B-GP
:	I-GP
ceramide	I-GP
glucosyltransferase	E-GP
gene	O
(	O
Ugcg	S-GP
)	O
display	O
obesity	O
,	O
hypothermia	O
,	O
and	O
lower	O
sympathetic	O
activity	O
.	O
Recombinant	O
adeno-associated	O
virus	O
(	O
rAAV	O
)	O
-mediated	O
Ugcg	S-GP
delivery	O
to	O
the	O
arcuate	O
nucleus	O
(	O
Arc	O
)	O
significantly	O
ameliorated	O
obesity	O
,	O
specifying	O
gangliosides	O
as	O
seminal	O
components	O
for	O
hypothalamic	O
regulation	O
of	O
body	O
energy	O
homeostasis	O
.	O

Reduction	O
of	O
oral	O
ethanol	S-chemical
self-administration	O
in	O
rats	O
by	O
monoamine	B-GP
oxidase	E-GP
inhibitors	O
.	O
Evidence	O
for	O
a	O
role	O
of	O
dopamine	S-chemical
and	O
serotonin	S-chemical
in	O
the	O
control	O
of	O
ethanol	S-chemical
intake	O
in	O
animals	O
suggests	O
that	O
monoamine	B-GP
oxidase	E-GP
(	O
MAO	S-GP
)	O
inhibitors	O
,	O
which	O
increase	O
the	O
synaptic	O
availability	O
of	O
serotonin	S-chemical
and	O
dopamine	S-chemical
by	O
blocking	O
their	O
metabolism	O
,	O
might	O
have	O
efficacy	O
in	O
the	O
treatment	O
of	O
alcohol	S-chemical
dependence	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
,	O
therefore	O
,	O
to	O
evaluate	O
several	O
MAO	S-GP
inhibitors	O
for	O
their	O
capacity	O
to	O
affect	O
ethanol	S-chemical
self-administration	O
in	O
rats	O
trained	O
to	O
self-administer	O
ethanol	S-chemical
(	O
10	O
%	O
v/v	O
)	O
orally	O
in	O
a	O
free-choice	O
two-lever	O
operant	O
task	O
.	O
The	O
nonselective	O
and	O
irreversible	O
MAO	S-GP
inhibitors	O
,	O
phenelzine	S-chemical
(	O
3-10	O
mg/kg	O
)	O
,	O
tranylcypromine	S-chemical
(	O
1-3	O
mg/kg	O
)	O
,	O
and	O
nialamide	S-chemical
(	O
30	O
mg/kg	O
)	O
,	O
decreased	O
rates	O
of	O
responding	O
maintained	O
by	O
ethanol	S-chemical
reinforcement	O
.	O
The	O
reversible	O
MAO-A	S-GP
inhibitor	O
,	O
befloxatone	S-chemical
(	O
0.3-3	O
mg/kg	O
)	O
,	O
and	O
the	O
irreversible	O
MAO-A	S-GP
inhibitor	O
,	O
clorgyline	S-chemical
(	O
10-30	O
mg/kg	O
)	O
,	O
also	O
reduced	O
ethanol	S-chemical
self-administration	O
.	O
However	O
,	O
befloxatone	S-chemical
-induced	O
effects	O
leveled	O
off	O
at	O
a	O
50	O
%	O
decrease	O
.	O
The	O
irreversible	O
MAO-B	S-GP
inhibitors	O
,	O
pargyline	S-chemical
(	O
30	O
mg/kg	O
)	O
and	O
l-deprenyl	S-chemical
(	O
3-10	O
mg/kg	O
)	O
also	O
decreased	O
responding	O
maintained	O
by	O
ethanol	S-chemical
reinforcement	O
;	O
these	O
results	O
are	O
consistent	O
with	O
previous	O
findings	O
that	O
both	O
drugs	O
decreased	O
ethanol	S-chemical
intake	O
in	O
mice	O
.	O
In	O
conclusion	O
,	O
the	O
present	O
results	O
showing	O
that	O
several	O
MAO	S-GP
inhibitors	O
decreased	O
ethanol	S-chemical
self-administration	O
in	O
rats	O
are	O
consistent	O
with	O
previous	O
findings	O
that	O
synaptic	O
levels	O
of	O
serotonin	S-chemical
and	O
dopamine	S-chemical
play	O
a	O
critical	O
role	O
in	O
the	O
control	O
of	O
ethanol	S-chemical
self-administration	O
.	O

Mutation	O
of	O
Gly721	O
alters	O
DNA	B-GP
topoisomerase	I-GP
I	E-GP
active	O
site	O
architecture	O
and	O
sensitivity	O
to	O
camptothecin	S-chemical
.	O
DNA	B-GP
topoisomerase	I-GP
I	E-GP
(	O
Top1p	S-GP
)	O
catalyzes	O
the	O
relaxation	O
of	O
supercoiled	O
DNA	O
via	O
a	O
concerted	O
mechanism	O
of	O
DNA	O
strand	O
cleavage	O
and	O
religation	O
.	O
Top1p	S-GP
is	O
the	O
cellular	O
target	O
of	O
the	O
anti-cancer	O
drug	O
camptothecin	S-chemical
(	O
CPT	S-chemical
)	O
,	O
which	O
reversibly	O
stabilizes	O
a	O
covalent	O
enzyme-DNA	O
intermediate	O
.	O
Top1p	S-GP
clamps	O
around	O
duplex	O
DNA	O
,	O
wherein	O
the	O
core	O
and	O
C	S-chemical
-terminal	O
domains	O
are	O
connected	O
by	O
extended	O
alpha-helices	S-GP
(	O
linker	B-GP
domain	E-GP
)	O
,	O
which	O
position	O
the	O
active	O
site	O
Tyr	S-chemical
of	O
the	O
C	S-chemical
-terminal	O
domain	O
within	O
the	O
catalytic	O
pocket	O
.	O
The	O
physical	O
connection	O
of	O
the	O
linker	O
with	O
the	O
Top1p	S-GP
clamp	O
as	O
well	O
as	O
linker	O
flexibility	O
affect	O
enzyme	O
sensitivity	O
to	O
CPT	S-chemical
.	O
Crystallographic	O
data	O
reveal	O
that	O
a	O
conserved	O
Gly	S-chemical
residue	O
(	O
located	O
at	O
the	O
juncture	O
between	O
the	O
linker	O
and	O
C	S-chemical
-terminal	O
domains	O
)	O
is	O
at	O
one	O
end	O
of	O
a	O
short	O
alpha-helix	S-GP
,	O
which	O
extends	O
to	O
the	O
active	O
site	O
Tyr	S-chemical
covalently	O
linked	O
to	O
the	O
DNA	O
.	O
In	O
the	O
presence	O
of	O
drug	O
,	O
the	O
linker	O
is	O
rigid	O
and	O
this	O
alpha-helix	S-GP
extends	O
to	O
include	O
Gly	S-chemical
and	O
the	O
preceding	O
Leu	S-chemical
.	O
We	O
report	O
that	O
mutation	O
of	O
this	O
conserved	O
Gly	S-chemical
in	O
yeast	B-GP
Top1p	E-GP
alters	O
enzyme	O
sensitivity	O
to	O
CPT	S-chemical
.	O
Mutating	O
Gly	S-chemical
to	O
Asp	S-chemical
,	O
Glu	S-chemical
,	O
Asn	S-chemical
,	O
Gln	S-chemical
,	O
Leu	S-chemical
,	O
or	O
Ala	S-chemical
enhanced	O
enzyme	O
CPT	S-chemical
sensitivity	O
,	O
with	O
the	O
acidic	O
residues	O
inducing	O
the	O
greatest	O
increase	O
in	O
drug	O
sensitivity	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
By	O
contrast	O
,	O
Val	S-chemical
or	O
Phe	S-chemical
substituents	O
rendered	O
the	O
enzyme	O
CPT	S-chemical
-resistant	O
.	O
Mutation-induced	O
alterations	O
in	O
enzyme	O
architecture	O
preceding	O
the	O
active	O
site	O
Tyr	S-chemical
suggest	O
these	O
structural	O
transitions	O
modulate	O
enzyme	O
sensitivity	O
to	O
CPT	S-chemical
,	O
while	O
enhancing	O
the	O
rate	O
of	O
DNA	O
cleavage	O
.	O
We	O
postulate	O
that	O
this	O
conserved	O
Gly	S-chemical
residue	O
provides	O
a	O
flexible	O
hinge	O
within	O
the	O
Top1p	S-GP
catalytic	O
pocket	O
to	O
facilitate	O
linker	O
dynamics	O
and	O
the	O
structural	O
alterations	O
that	O
accompany	O
drug	O
binding	O
of	O
the	O
covalent	O
enzyme-DNA	O
intermediate	O
.	O

Leydig	O
cell	O
hyperplasia	O
and	O
Leydig	O
cell	O
tumour	O
in	O
postmenopausal	O
women	O
:	O
report	O
of	O
two	O
cases	O
.	O
Leydig	O
cell	O
hyperplasia	O
and	O
Leydig	O
cell	O
tumours	O
of	O
the	O
ovary	O
are	O
rare	O
.	O
We	O
present	O
two	O
cases	O
in	O
which	O
patients	O
had	O
increased	O
blood	O
levels	O
of	O
testosterone	S-chemical
and	O
frank	O
hirsutism	O
.	O
Imaging	O
showed	O
minimal	O
abnormalities	O
.	O
After	O
adrenal	O
disease	O
had	O
been	O
ruled	O
out	O
,	O
they	O
underwent	O
a	O
bilateral	O
oophorectomy	O
.	O
One	O
case	O
showed	O
a	O
Leydig	O
cell	O
hyperplasia	O
,	O
the	O
other	O
a	O
Leydig	O
cell	O
tumour	O
.	O
An	O
androgen	S-chemical
producing	O
tumour	O
should	O
be	O
excluded	O
in	O
every	O
woman	O
with	O
evidence	O
of	O
hirsutism	O
or	O
frank	O
virilization	O
and	O
markedly	O
elevated	O
testosterone	S-chemical
levels	O
.	O
Adrenal	O
disease	O
with	O
androgen	S-chemical
hypersecretion	O
can	O
be	O
suspected	O
by	O
detailed	O
clinical	O
,	O
laboratory	O
and	O
radiologic	O
imaging	O
.	O
Although	O
DHEAS	S-chemical
has	O
a	O
good	O
sensitivity	O
in	O
the	O
detection	O
of	O
adrenal	O
origin	O
of	O
hyperandrogenism	O
(	O
and	O
hence	O
a	O
good	O
negative	O
predictive	O
value	O
)	O
it	O
is	O
not	O
specific	O
(	O
specificity	O
ranging	O
from	O
85	O
to	O
98	O
%	O
)	O
.	O
Imaging	O
of	O
the	O
ovaries	O
can	O
be	O
helpful	O
but	O
does	O
not	O
rule	O
out	O
ovarian	O
disease	O
if	O
normal	O
.	O
Indeed	O
,	O
diffuse	O
stromal	O
Leydig	O
cell	O
hyperplasia	O
and	O
Leydig	O
cell	O
tumours	O
(	O
usually	O
small	O
)	O
may	O
escape	O
imaging	O
and	O
in	O
some	O
cases	O
diagnosis	O
can	O
only	O
be	O
made	O
on	O
pathology	O
.	O
As	O
these	O
clinical	O
entities	O
represent	O
a	O
diagnostic	O
and	O
therapeutic	O
challenge	O
,	O
oophorectomy	O
should	O
be	O
considered	O
in	O
postmenopausal	O
women	O
with	O
hirsutism	O
and	O
elevated	O
testosterone	S-chemical
levels	O
,	O
after	O
the	O
exclusion	O
of	O
adrenal	O
causes	O
.	O
The	O
procedure	O
is	O
relatively	O
safe	O
and	O
effective	O
.	O
Follow-up	O
remains	O
indicated	O
.	O

Cloning	O
,	O
Characterization	O
,	O
and	O
Sulfonamide	S-chemical
and	O
Thiol	S-chemical
Inhibition	O
Studies	O
of	O
an	O
α-Carbonic	B-GP
Anhydrase	E-GP
from	O
Trypanosoma	O
cruzi	O
,	O
the	O
Causative	O
Agent	O
of	O
Chagas	O
Disease	O
.	O
An	O
α-carbonic	B-GP
anhydrase	E-GP
(	O
CA	S-GP
,	O
EC	B-GP
4.2.1.1	E-GP
)	O
has	O
been	O
identified	O
,	O
cloned	O
,	O
and	O
characterized	O
from	O
the	O
unicellular	O
protozoan	O
Trypanosoma	O
cruzi	O
,	O
the	O
causative	O
agent	O
of	O
Chagas	O
disease	O
.	O
The	O
enzyme	O
(	O
TcCA	S-GP
)	O
has	O
a	O
very	O
high	O
catalytic	O
activity	O
for	O
the	O
CO	B-chemical
(	I-chemical
2	I-chemical
)	E-chemical
hydration	O
reaction	O
,	O
being	O
similar	O
kinetically	O
to	O
the	O
human	O
(	O
h	O
)	O
isoform	O
hCA	B-GP
II	E-GP
,	O
although	O
it	O
is	O
devoid	O
of	O
the	O
His	S-chemical
64	O
proton	O
shuttle	O
.	O
A	O
large	O
number	O
of	O
aromatic/heterocyclic	B-chemical
sulfonamides	E-chemical
and	O
some	O
5-mercapto-1,3,4-thiadiazoles	S-chemical
were	O
investigated	O
as	O
TcCA	S-GP
inhibitors	O
.	O
The	O
aromatic	B-chemical
sulfonamides	E-chemical
were	O
weak	O
inhibitors	O
(	O
K	O
(	O
I	O
)	O
values	O
of	O
192	O
nM	O
to	O
84	O
μM	O
)	O
,	O
whereas	O
some	O
heterocyclic	O
compounds	O
inhibited	O
the	O
enzyme	O
with	O
K	O
(	O
I	O
)	O
values	O
in	O
the	O
range	O
61.6-93.6	O
nM	O
.	O
The	O
thiols	S-chemical
were	O
the	O
most	O
potent	O
in	O
vitro	O
inhibitors	O
(	O
K	O
(	O
I	O
)	O
values	O
of	O
21.1-79.0	O
nM	O
)	O
,	O
and	O
some	O
of	O
them	O
also	O
inhibited	O
the	O
epimastigotes	O
growth	O
of	O
two	O
T.	O
cruzi	O
strains	O
in	O
vivo	O
.	O

